,id,ticker,title,category,content,date,provider,url,article_id
197516,419032,JNJ,Better Coronavirus Play  Johnson   Johnson vs  Novavax,news,"Fears about the coronavirus outbreak that first hit China are increasing  There have been more than 20 000 confirmed cases of the virus and 425 deaths in just over one month 
But several drugmakers are racing to develop vaccines and antiviral drugs to fight the outbreak  Two companies at the forefront of these efforts are Johnson   Johnson  NYSE JNJ  and Novavax  NASDAQ NVAX   Which of these stocks is the better choice for investors 

The case for Johnson   Johnson
Johnson   Johnson announced on Jan  29 that it s launching what the company calls  a multipronged response  to the threat presented by the 2019 nCoV coronavirus that s been making headlines  J J s primary focus is to use its AdVac viral vector and PER C6 cell line technology to develop a vaccine for 2019 nCoV 
This appears to be a smart step  Both AdVac and PER C6 were used to create J J s experimental Ebola vaccine  Even though the vaccine isn t approved yet  it s already being used in the Democratic Republic of the Congo and in Rwanda as part of those countries  campaigns to prevent the spread of Ebola  In addition  J J used these two technologies to develop its experimental vaccines targeting HIV  respiratory syncytial virus  RSV   and Zika 
While J J works as quickly as possible to develop a coronavirus vaccine  the company has donated bottles of its HIV drug darunavir cobicistat  which is marketed under the brand name Prezcobix  to Chinese researchers investigating potential ways to treat the virus  Some anecdotal findings have suggested that HIV drugs could help patients with another coronavirus    severe acute respiratory syndrome  SARS  
As a huge drugmaker  Johnson   Johnson also has a lot of drugs that are already on the market or in its pipeline  including quite a few antiviral drugs  The company plans to conduct research to see if previously tested drugs could potentially help patients fight the latest coronavirus strain 
Even if J J s efforts are successful in addressing the coronavirus scare  though  sales of any one drug or vaccine would likely only amount to a drop in the bucket for the healthcare giant  But that underscores the appeal of buying J J stock  The company offers a way to obtain diversification across the healthcare spectrum because of its multibillion dollar business segments in consumer health  medical devices  and pharmaceuticals 
The case for Novavax
Novavax  on the other hand  would almost certainly see its shares skyrocket if it successfully develops a coronavirus vaccine  The biotech stock has already been one of the biggest winners among coronavirus focused drugmakers  with its shares up over 60  year to date 
Developing vaccines is Novavax s specialty  The company s lead product is a nanoparticle based vaccine for the flu  Novavax should report results from a late stage study of this vaccine later in the first quarter of 2020  Its pipeline also includes three other experimental vaccines in clinical testing 
Novavax has already developed vaccines targeting other types of coronavirus    SARS and Middle East respiratory syndrome  However  neither vaccine has won regulatory approval 
Gregory Glenn  Novavax s head of research and development  told Bloomberg that the company is  working very hard  on a coronavirus vaccine  However  he also acknowledged in another interview that it s not a quick process to develop a vaccine  win regulatory approval  and get to market 
Novavax has experienced some setbacks with its vaccine programs  The biotech s RSV vaccine ResVax failed in two different late stage clinical studies  But past failures don t mean that future successes aren t possible  Novavax could emerge as a big winner with its experimental coronavirus vaccine or with its NanoFlu flu vaccine 
Better pick
If you re looking for the stock that would deliver the biggest returns if it s successful in developing a coronavirus vaccine or treatment  the answer is easy  Novavax  But that doesn t necessarily make Novavax the better pick over Johnson   Johnson  Why  There s no guarantee that Novavax will be successful with its coronavirus program 
For that matter  there s no guarantee that J J will be successful with its coronavirus efforts  either  However  failure on this front simply won t matter that much to the investing case for J J 
It s entirely possible that the current coronavirus worries will fade away  just as worries about the avian flu  Ebola  SARS  and other viruses aren t as great as they once were  Instead of buying a stock based only on the prospects for developing a coronavirus vaccine or therapy  the smarter approach is to buy a stock based on the prospects that it will deliver solid long term gains 
Novavax might be able to generate tremendous gains in the future  However  the biotech s fortunes hinge largely on how NanoFlu performs in clinical testing  J J s gains probably won t be jaw dropping  but they should be more reliable  My view is that the stability and financial strength that J J provides makes it the better choice for long term investors ",2020-02-05,The Motley Fool,https://invst.ly/prcz0,2076560
197517,419033,JNJ,Drugmakers see long road ahead in coronavirus vaccine race,news,"By Carl O Donnell and Michael Erman
 Reuters    Drugmakers racing to find a vaccine or effective treatment for the deadly new coronavirus in China cautioned that they have a long way to go 
That runs counter to reports of a supposed  breakthrough  that on Wednesday boosted financial markets and spurred optimism not necessarily backed by reality 
At least a dozen drugmakers are working on vaccines or antivirals and other treatments to help those infected with the fast spreading contagion 
Investment costs for vaccines could run as high as  800 million in a process that  even if accelerated  will likely take more than a year until approval  according to executives from companies involved in the effort 
 It will take at least 12 to 18 months  which means in the acute situation we are in now   at least in China   that will not create a benefit   said Thomas Breuer  chief medical officer of GlaxoSmithKline s  L GSK  vaccine unit  GSK is working with developers by providing a technology that could make their vaccines more potent 
The virus  which emerged in December in China  has killed nearly 500 people and shows no sign of abating  with thousands of new cases reported each day  mostly in central China s Hubei province  But its spread to some 27 countries and regions has caused global alarm 
To be sure  companies developing treatments for patients who are already sick may be able to get a drug approved faster than a vaccine that would be given to healthy people  Even so  logistical and regulatory challenges remain  according to two executives at  Gilead Sciences Inc   O GILD   which is working on an experimental antiviral treatment 
 There is a distinction there between a therapeutic and a vaccine  Having said that  I think it is true that this won t be super fast and it will involve us investing at risk right now   said Gilead Chief Medical Officer Merdad Parsey 
Clinical trials for treatments can be smaller and of shorter duration than for vaccines  Parsey acknowledged 
Challenges in making sure therapies are effective and then scaling up production still remain  Gilead has only a limited supply of its remdesivir  which will be tested against the coronavirus after previously failing in trials as a treatment for Ebola 
 LOOKING FOR A MAGIC BULLET 
Dr  Thomas Frieden  who was director of the U S  Centers for Disease Control and Prevention during the also deadly MERS outbreak  said the benefit of antiviral treatments for such emergencies in the past has been modest 
What worked with MERS and SARS  for example  was better infection control in healthcare facilities  he said of two other types of coronaviruses that also caused global alarm 
 It doesn t mean we shouldn t try  but we re often looking for a magic bullet and the bright shiny object  Sometimes we need to just have the basics   Frieden said 
A Chinese TV report on Wednesday said that a research team at Zhejiang University had found an effective drug for the virus  while researchers in the UK told Sky News separately they had made a  significant breakthrough  in finding a vaccine 
Reuters could not independently verify the reports  but several traders cited them for sharp upticks in global stock markets 
 There are no known effective therapeutics against this 2019 nCoV   said World Health Organization spokesman Tarik Jasarevic  using the current designation for the new coronavirus  when asked about reports of  drug breakthroughs  
Health officials in the United States and China have set ambitious goals for getting a vaccine to initial human testing within the next few months 
Newer vaccine platforms  such as one developed by  Moderna  Inc  O MRNA   allow scientists to create a potential vaccine in record time just based on knowing the genetic code of the novel coronavirus  With the genetic code in hand  scientists can start vaccine development without needing a sample of the virus 
Anthony Fauci  director of the U S  National Institutes of Allergy and Infectious Diseases  which is using Moderna s platform  said the agency is on the fastest pace ever to develop a vaccine candidate 
He hopes to have a vaccine available for initial safety testing within two and a half to three months from the time scientists determined the genetic sequence of the virus 
 Novavax  Inc  O NVAX  research chief Gregory Glenn told Reuters his company has taken vaccines from discovery to clinical testing in 90 days and believes it could do something similar for the new coronavirus 
But to move vaccine candidates from the lab to widespread use in patients involves a number of hurdles  according to health experts and executives for drugmakers working on coronavirus vaccines and treatments 
In addition to scaling up manufacturing capacity and building distribution networks  there are regulatory hurdles such as conducting large clinical trials to make sure a vaccine not only confers immunity to the virus but is safe for use in the general population 
 The earliest you could even know if it s going to work is a year   Fauci said 
Whether even a highly effective vaccine will prove profitable for companies is another big question 
 The outbreak could be abating by the time a vaccine is deemed safe   Karen Andersen  who follows biotech companies for Morningstar  said in a research note 
The Coalition for Epidemic Preparedness Innovations  CEPI  has raised around  800 million from donors to aid in preventing pandemic diseases and has allocated some of those funds to biotechs  including  Inovio Pharmaceuticals Inc   O INO   Moderna Inc  O MRNA  and CureVac  which are working on coronavirus vaccines 
 We stepped into this with no economic expectation   said Paul Stoffels  Johnson   Johnson s  N JNJ  chief scientific officer   We ll see whether in the end it gives a reward  ",2020-02-05,Reuters,https://www.investing.com/news/stock-market-news/drugmakers-see-long-road-ahead-in-coronavirus-vaccine-race-2077438,2077438
197518,419034,JNJ,Johnson   Johnson told to pay  750M in New Jersey talc case,news,"A New Jersey jury today ordered Johnson   Johnson  NYSE JNJ  to pay  750M in punitive damages to four plaintiffs who claimed their use of the company s talc based products caused a rare cancer 
Citing state law  the judge presiding over the trial said she would reduce the punitive award to  186 5M  or  5x the  37 3M in compensatory damages awarded by a separate jury in the first phase of the case last year 
J J said it will appeal the verdicts in both phases of the trial  citing  numerous legal errors that subjected the jury to irrelevant information and prevented them from hearing meaningful evidence  
J J CEO Alex Gorsky had testified in court vouching for the safety of the company s Baby Powder and another talc based powder ",2020-02-06,Seeking Alpha,https://invst.ly/ps655,2078634
197519,419035,JNJ,Jury orders Johnson   Johnson to pay  750 million in New Jersey talc case,news,"By Lisa Girion and Michael Erman  Reuters    Johnson   Johnson  NYSE JNJ  was ordered on Thursday by a New Jersey state jury to pay punitive damages of  750 million to four plaintiffs who allege that the company s Baby Powder caused their cancer  a ruling that will be reduced to around  185 million because of state laws  according to a lawyer for the plaintiffs and the company  During an earlier phase of the trial  a different jury held J J liable for the plaintiffs  cancers and awarded them  37 2 million in compensation   Under New Jersey law  punitive damages are capped at 5 times the amount of compensatory damages  according to plaintiffs lawyer Chris Placitella   J J said in a statement it would quickly appeal both phases of the trial  citing  numerous legal errors that subjected the jury to irrelevant information and prevented them from hearing meaningful evidence   The verdict came after J J Chief Executive Alex Gorsky testified last month for the first time in a jury trial over allegations that the company s Baby Powder causes cancer    We believe the jury was speaking directly to Alex Gorsky   plaintiffs lawyer Placitella said   J J faces more than 16 000 lawsuits alleging it sold powders contaminated with asbestos and failed to warn users  It also faces a federal criminal investigation into how forthright it has been about the products  safety  J J denies that its talc causes cancer  saying numerous studies and tests by regulators worldwide have shown its talc to be safe and asbestos free  On Dec  14  2018  Reuters published a story that showed J J had failed to disclose that small amounts of asbestos  a known carcinogen  had sometimes been found in its talc over several decades  After the report was published  a selloff wiped more than  40 billion off the company s market value  
At the time  J J dismissed the Reuters  report as  an absurd conspiracy theory  ",2020-02-06,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-ordered-to-pay-750-million-in-new-jersey-talc-case-lawyer-2078441,2078441
197520,419036,JNJ,Johnson   Johnson Hit With  750 Million Fine Over Baby Powder Legal Case,news,"On Thursday afternoon  news broke that a New Jersey state jury had ordered Johnson   Johnson  NYSE JNJ  to pay  750 million in punitive damages to four plaintiffs  The jury had concluded that the company s baby powder product had contained carcinogenic substances and the company hadn t properly informed consumers about the risk  
Johnson   Johnson faces over 16 800 lawsuits concerning its talc products  which are alleged to have contained carcinogenic substances that directly lead to ovarian cancer and rare cancers such as mesothelioma  Although the pharmaceutical giant has denied that any of its products contained carcinogens  a separate jury ordered Johnson   Johnson to pay  37 3 million in compensatory damages during the first phase of this same case back in 2019 

While the jury ordered the company to pay  750 million to the four individuals  presiding judge Ana C  Viscomi stated that she would reduce the fine to just  186 5 million  Under state law  punitive damages can t be more than five times the amount of compensatory damages fined 
A growing number of legal defeats
Johnson s Baby Powder is one of the company s most recognizable products  with an extensive history that goes back to 1894  The trial also marked the first time in which Johnson   Johnson s CEO  Alex Gorsky  testified in the courtroom over the safety of the company s Baby Powder product 
In recent years  the company has been on the receiving end of a number of significant fines  Back in 2018  a separate lawsuit regarding the company s talc products resulted in Johnson   Johnson being forced to pay  4 7 billion to 22 women who claimed to have contracted ovarian cancer through those products ",2020-02-06,The Motley Fool,https://invst.ly/ps7uf,2078747
197521,419037,JNJ,Breaking  J J to Pay  750M in Baby Powder Case,news,"Investing com   Dow component Johnson   Johnson  NYSE JNJ  was ordered Friday to pay  750 million in a civil case charging its Johnson s Baby Powder contained asbestos 
A jury in New Jersey ordered J J to pay the punitive damages to four cancer patients 
The jury agreed J J acted  maliciously or in wonton disregard  of safety risks  the plaintiffs  lawyers said in a press release 

Shares of Johnson   Johnson  NYSE JNJ  fell 1  in afternoon trading ",2020-02-07,Investing.com,https://www.investing.com/news/stock-market-news/breaking-jj-to-pay-750m-in-baby-powder-case-2079470,2079470
197522,419038,JNJ,Johnson   Johnson Submits FDA Application for Multiple Myeloma Drug,news,"Johnson   Johnson  NYSE JNJ  subsidiary Janssen announced on Monday that it had filed a supplemental Biologics License Application  sBLA  to the U S  Food and Drug Administration  FDA  for its multiple myeloma drug Darzalex  also known as daratumumab  
Strong results from the company s phase 3 Candor study showed that J J s Darzalex in combination with two other drugs from Amgen  Kyprolis and dexamethasone  helped reduce the chance of cancer progression or death than Amgen s two drugs without Darzalex  Johnson   Johnson s new application will seek to expand the drug s approval to be used alongside Kyprolis and dexamethasone specifically for multiple myeloma patients who have failed to respond to traditional therapy  also known as refractory or relapsed multiple myeloma  

Janssen Research   Development Vice President Dr  Craig Tendler went on to say that most patients with multiple myeloma end up seeing the condition return  hence the importance of there being multiple different treatment options available  Darzalex was first approved by the FDA back in November 2015  and since then has received a variety of additional approvals from the healthcare agency  usually regarding dosing regimens or its use as part of a new drug combination 
The multiple myeloma market
Multiple myeloma is a type of blood and bone marrow cancer in which the body produces abnormal blood cells  specifically white blood cells known as plasma cells  These abnormal cells begin to accumulate in the bone marrow  crowding out the healthy functioning blood cells 
Estimates project that the global market for multiple myeloma treatments could reach as high as  50 5 billion annually by 2025  which represents a compounded annual growth rate of 13 3  over the next five years ",2020-02-11,The Motley Fool,https://invst.ly/ptie7,2081195
197523,419039,JNJ,Johnson   Johnson Is Racing Against Time to Develop the First Coronavirus Vaccine,news,"Over the past several weeks  there s nothing that has monopolized the news quite so much as the terrifying and deadly coronavirus  The illness has claimed over 1 000 lives at the time of this writing and has infected just over 43 000 individuals worldwide  
At the end of January  the World Health Organization  WHO  declared the virus a global emergency  On February 2  the U S  Department of State raised its travel advisory for China to a Level Four  A Level Four advisory is the highest warning issued and indicates that Americans should not under any circumstances travel to a country due to the extreme peril involved  

In the wake of the coronavirus pandemic that has already swept across Asia  Europe  North America  and the Middle East  big pharma companies including Gilead Sciences  NASDAQ GILD   Novavax  NASDAQ NVAX   and Johnson   Johnson  NYSE JNJ  have been scrambling to respond  
Johnson   Johnson is going head to head with these companies and others to be the first to develop the coronavirus vaccine and it looks like the company is well on its way to achieving its goal  If Johnson   Johnson succeeds in creating the coronavirus vaccine  this may not only save countless lives but also mean billions of dollars of revenue for the company that would see investor holdings soar  
Here s the latest investor update to start off the new week 
Combining forces with subsidiary Janssen Pharmaceuticals 
Johnson   Johnson has declared that it is combining forces with its Belgium based subsidiary Janssen Pharmaceuticals to create a preventative coronavirus vaccine  The companies will also be teaming up with outside laboratories to assess prospective antiviral drug solutions  
Johnson   Johnson s Chief Scientific Officer and Vice Chairman of the Executive Committee  Dr  Paul Stoffels stated   We are collaborating with regulators  healthcare organizations  institutions and communities worldwide to help ensure our research platforms  existing science and outbreak expertise can be maximized to stem this public health threat  
The collaboration of Johnson   Johnson with Janssen could speed up the vaccine development timeline by leaps and bounds and on a far larger scale  Janssen s AdVac platform will play a key role in this new development phase  The platform has already proven successful in the company s formulation of clinical candidates to treat HIV as well as an experimental Ebola drug that has been implemented in parts of Africa  including Rwanda  
The competition is steep  but Johnson   Johnson is coming from a position of strength
Investors have been more than a little concerned since the outbreak of the coronavirus  as indicated by the increased volatility in the stock market of late  With so many contenders rushing to break out the coronavirus vaccine  many investors are wondering just where they should be putting their cash  
It s no secret that Johnson   Johnson isn t alone in the race to get the first coronavirus vaccine from the lab to the consumer populace  Novavax previously developed vaccines for a few variations of the coronavirus  including SARS  While none of these vaccines have been approved by the FDA  this definitely puts Novavax ahead of the curve  and the company s shares have been soaring accordingly 
Gilead Sciences is another major player going neck in neck with Johnson   Johnson  The company s Ebola drug  Remdesivir  which has yet to receive regulatory approval  is now officially being tested by China to treat coronavirus patients  But only time will tell whether the drug has any efficacy to treat the coronavirus  
Johnson   Johnson has also gifted a drug for China to use in its research efforts  the company s HIV medication Prezcobix  A recent statement released by Johnson   Johnson stated the following   The company has a long standing commitment to fight emerging epidemics  We stand ready to support global efforts where it may make a difference   We have established technologies and facilities that enable us to create  test and scale up production for potentially transformational vaccines  Our experience in helping to address epidemics  coupled with our expertise in respiratory illnesses  uniquely positions us to address the latest coronavirus outbreak  
Johnson   Johnson s new collaboration with Janssen Pharmaceuticals is an unprecedented move to push the coronavirus vaccine development timeline forward  It s clear that the competition is steep  but there s no reason to think that Johnson   Johnson isn t up to the task to lead the pack in rolling out the coronavirus vaccine 
Johnson   Johnson is unequivocally coming from a position of strength  The company had a fantastic year earnings wise  with sales totaling roughly  20 billion per quarter over the trailing twelve months  Its profit margin exceeded 18  in 2019  and sales are projected to grow by as much as 5  in 2020  
Johnson   Johnson s diversified business model continues to make it a profitable buy for long term investors regardless of whether it wins the coronavirus vaccine race or not  However  if the company does become one of the first to release a coronavirus vaccine  as it very likely may  Johnson   Johson s financial future may look very bright indeed ",2020-02-11,The Motley Fool,https://invst.ly/ptxe2,2082222
197536,419052,JNJ,J J enters coronavirus fray with planned vaccine,news,"In what it calls a  multi pronged  response to the coronavirus outbreak  Johnson   Johnson  NYSE JNJ  announces that unit Janssen Pharmaceutical Companies has initiated activities to develop a vaccine against 2019 nCoV  the virus causing the current contagion 
The vaccine program will leverage Janssen s AdVac and PER C6 technologies that provide the ability to rapidly upscale production  the same technologies behind its vaccines for Ebola  Zika  RSV and HIV  
The company s efforts will include a review of known pathways in coronavirus pathophysiology to determine if previously tested drugs can help patients survive infection and reduce the severity of disease in non lethal cases 
It has also donated 300 boxes of HIV med Prezcobix  darunavir cobicistat  to the Shanghai Public Health Clinical Center and Zhongnan Hospital of Wuhan University for use in research to support efforts in finding a solution against 2019 nCoV  An additional 50 boxes have been provided to the Chinese Center for Disease Control and Prevention for laboratory based investigations  drug screening for antiviral properties against 2019 nCoV  ",2020-01-29,Seeking Alpha,https://invst.ly/pof1d,2070551
197537,419053,JNJ,Johnson   Johnson Joins the Hunt for a Coronavirus Vaccine,news,"Biopharmaceutical giant Johnson   Johnson  NYSE JNJ  is mobilizing dozens of scientists to research the genetic code of the Wuhan coronavirus in hopes of developing a vaccine that can stem its spread  If the company is successful on that front  it will be able to leverage its massive global manufacturing capacity to produce hundreds of millions of vaccine doses for use worldwide 

The rapid spread of the coronavirus has prompted a slate of biopharma companies to begin researching vaccines  but Johnson   Johnson is the biggest to enter the fray  With global annual sales of over  82 billion  it can deploy significant resources in support of its efforts  As of Wednesday morning  the number of confirmed coronavirus cases had topped 6 150  and it had caused at least 132 deaths 
In the short term  Johnson   Johnson s plan includes evaluating existing antiviral medications to see if they re effective against coronavirus  Longer term  the company will bring to bear technologies previously used to develop and manufacture a Zika vaccine and an investigational Ebola vaccine that is currently being used in Rwanda and the Democratic Republic of the Congo  
Johnson   Johnson s antiviral treatments for HIV could offer the best chance for people who are already infected with coronavirus  So far  J J has donated 300 boxes of Prezcobix  an HIV medication containing the active ingredients darunavir and cobicistat  to the Shanghai Public Health Clinical Center and Zhongnan Hospital of Wuhan University for evaluation  It also donated 50 boxes to the Chinese Center for Disease Control and Prevention for research purposes  In 2019  Prezcobix sales exceeded  2 1 billion worldwide ",2020-01-29,The Motley Fool,https://invst.ly/pohrt,2070772
197538,419054,JNJ,In a Mixed Quarter  Johnson   Johnson Shows Off Its Greatest Strength,news,"Johnson   Johnson  NYSE JNJ  is the largest healthcare company in the world  but that hasn t stopped the pharma giant from encountering headwinds  It is currently involved in a slew of legal challenges  including lawsuits by consumers claiming that the company s talcum powder  which allegedly contained asbestos  caused their cancer  In October 2019  Johnson   Johnson lost a lawsuit and was ordered to pay  37 2 million in punitive damages to four plaintiffs  
Given its recent troubles  the company had a chance to ease investors  fears when it released its earnings report on Jan  22  And although Johnson   Johnson failed to knock it out of the park  the company performed well enough to prevent a sell off  In particular  it showed off its greatest strength  diversification  

Johnson   Johnson s fourth quarter results
During the fourth quarter  net sales were  20 8 billion  an unimpressive 1 7  increase year over year and below the consensus analyst estimate  But the company s  4 billion net earnings grew by 31 8  versus the year ago period  and its  1 88 adjusted earnings per share came in slightly ahead of the consensus analyst estimates 
Johnson   Johnson s medical devices segment posted revenue of  6 63 billion  a 0 5  year over year decrease  Meanwhile  the company s consumer segment  which sells over the counter medical products  posted revenue of  3 57 billion  0 9  higher than the prior year quarter  
The pharmaceuticals segment generated  10 5 billion in sales  3 5  higher than the year ago period  Johnson   Johnson has been dealing with declining sales of several of its key pharmaceutical products  The rheumatoid arthritis drug Remicade reported  1 billion in sales  down from  1 2 billion in the prior year quarter  Also  the prostate cancer medicine Zytiga  which has been facing competition from biosimilars  generated  677 million in sales  a 13 8  year over year decline  
Fortunately  Johnson   Johnson s portfolio of pharmaceutical drugs is rich and diverse  and other products performed well enough to offset the declining sales of some of its top products  Sales of the cancer drug Imbruvica increased by 24 5  to  875 million  and revenue from Darzalex  for blood cancer multiple myeloma  increased by 42 1  to  830 million  Sales of immunology drugs Stelara and Tremfya grew by 17 7  and 53 9   respectively  
There was more good news for some of Johnson   Johnson s top pharmaceutical products  During the fourth quarter  Darzalex was approved in Europe for the treatment of multiple myeloma for certain patients  And the Food and Drug Administration recently approved Stelara for the treatment of moderately to severely active ulcerative colitis  a chronic inflammatory disease that affects about 910 000 patients in the U S  With these two approvals  sales of Darzalex and Stelara will likely keep growing  
More approvals on the way 
In addition to its rich portfolio of products  Johnson   Johnson boasts a rich pipeline  and the company likely has more approvals on the way  During the fourth quarter  it submitted a marketing authorization application to the European Medicines Agency  EMA  for a vaccine regimen for the prevention of ebola virus disease  The company also submitted an application to the EMA for Tremfya as a treatment for active psoriatic arthritis  
Johnson   Johnson s other regulatory submissions during the fourth quarter included Spravato as a treatment for major depressive disorder in Europe  and Imbruvica as a treatment for active chronic lymphocytic leukemia  in combination with another drug called rituximab that treats certain cancers   
The company s late stage pipeline also includes more than a dozen new products  or existing products seeking new indications  
Should you buy  
Johnson   Johnson is an excellent option for investors looking for companies with the versatility to handle a market downturn  It has a hand in three different segments within the healthcare industry  and the pharmaceutical segment is diversified as well  On the other hand  Johnson   Johnson probably won t outperform the market  
Over the past five years  the company s shares climbed by 46 15   whereas the S P 500 is up by 61 43  over the same period  In other words  whether you should buy shares of Johnson   Johnson depends on your priorities and investing style  Conservative investors will likely love it  whereas growth oriented investors might have to look elsewhere ",2020-01-31,The Motley Fool,https://invst.ly/ppgrc,2073018
197539,419055,JNJ,Johnson   Johnson Ordered to Pay  344 Million for Deceptively Marketing Pelvic Mesh Product,news,"Johnson   Johnson  NYSE JNJ  was hit with a  344 million fine by a California state court for deceptively marketing regarding its pelvic mesh products  This ruling brought together thousands of separate  individual lawsuits of patients who claimed that the surgically implanted meshes eroded within their bodies and caused significant harm  
Pelvis meshes  also referred to as transvaginal meshes  are a type of woven synthetic netting that s implanted inside the vagina for women whose pelvic organs  which include the bladder  uterus  cervix  rectum  and vagina  have begun to sag  While these meshes are supposed to help support the pelvic organs  patients involved in the lawsuit claim that Johnson   Johnson didn t provide information about many of the potential risks  These include chronic pain in the pelvic area as well as problems urinating and defecating 

 Johnson   Johnson intentionally concealed the risks of its pelvic mesh implant devices   said Attorney General Xavier Becerra in light of the ruling   Johnson   Johnson knew the danger of its mesh products but put profits ahead of the health of millions of women  
Further details
Johnson   Johnson apparently sold over 470 000 pelvic mesh products across the country between 2008 and 2014  with at least 30 000 of them sold in California  Although the healthcare giant has stated that it plans to appeal the decision  a process that will take years  it questionable whether Johnson   Johnson will end up succeeding in this effort 
Back in October  the company ended up settling a separate collection of lawsuits  agreeing to pay  117 million to resolve all claims of deceptively marketing its mesh products  However  the settlement only resolved claims in 41 states and the District of Columbia  with California  West Virginia  Kentucky  and Mississippi lawsuits remaining unaffected ",2020-01-31,The Motley Fool,https://invst.ly/ppm4b,2073495
197540,419056,JNJ,Johnson   Johnson Keeps Growing Despite Ongoing Legal Woes,news,"Johnson   Johnson  NYSE JNJ  released its fourth quarter earnings on Jan  22  The results were mixed  with earnings per share of  1 88  which came in above analyst expectations of  1 87 despite its top line of  20 74 billion missing Wall Street s estimates of  20 8 billion  The stock was initially down around 2  on the results but it has since climbed back up   
But let s take a closer look at J J s final report for fiscal 2019 to see whether the healthcare stock is still a good buy 
Strong growth continues  but so does legal trouble
For the full fiscal year  J J s total revenue was up just 0 6   going from  81 6 billion to  82 1 billion  But the company s largest segment  pharmaceuticals  was also its best with sales growth of 3 6   Multiple drugs grew by double digits this past year  
It s an impressive performance given the adversity the company has faced in recent years relating to its products  Thousands of people have sued the company over claims J J s baby powder products caused them to develop cancer  In 2018  a jury ordered J J to pay  4 7 billion to 22 women who developed ovarian cancer from the products  Then in 2019  a judge in Oklahoma ordered the healthcare giant to pay  572 million as a result of its role in the state s opioid crisis  Later that year  the company incurred a hefty fine of  8 billion in punitive damages for side effects related to its Risperdal drug which is used to treat mood disorders  including schizophrenia due to claims it caused patients to develop gynecomastia  or the growth of breasts in males   J J appealed the fine and a judge reduced it to  6 8 million  but it s yet another product that has put a black mark on the company s image  
Thanks to its diversification  J J has plenty of products that are doing well for the company  Stelara  in particular  continues to be a great performer  The drug  which treats Crohn s disease  generated  6 3 billion in sales in fiscal 2019 at a growth rate of 23 4   Darzalex  which treats myeloma  a form of blood cancer  also saw tremendous growth of nearly 50   With sales of  3 billion worldwide  it has the potential to be a key contributor to the company s pharmaceutical sales if it keeps growing at this clip  

And even though the company s medical device revenue was down 3 8  overall  that was mainly due to U S  sales  which were down 3 5   International medical device sales declined by 4 1   but without the impact of foreign exchange  that revenue would have been just 0 1  lower than in the prior year 
What was surprising is that in the consumer segment J J s sales were up 1 4  in the U S  in 2019  However  revenue from its baby care products declined by 14 2  year over year in the U S  and by 8 6  in international markets   Overall  the company s consumer segment did well internationally where sales were down 0 4   but had it not been for foreign exchange  revenue would have increased by 4 2  
J J expects its growth to continue in 2020 with guidance indicating adjusted diluted earnings per share growth between 3 1  and 4 8   The company also forecasts reported sales to rise between 4  and 5  this year  
18  profit margin intact despite litigation expenses
J J s earnings of  15 1 billion for the year were down 1 2  from 2018  but they were still more than 18  of the company s top line  An 18  profit margin is very strong  especially given that the company incurred more than  5 billion in litigation expenses during the year by fighting and settling lawsuits  
The strong bottom line is a testament to the company s resilient and diverse product base  which allows it to produce healthy profits in the face of adversity 
Why J J is still a good long term investment
What the company s year end results showed is just how well diversified J J is and how powerful a brand it still is  Although the company is struggling in the U S  market  that isn t the case internationally  where it continues to grow and perform well  
J J still faces many challenges relating to baby products and there s a lot of uncertainty about its role in the opioid epidemic  In January  Washington announced it was the latest state to sue J J in relation to the opioid crisis and more states could decide to do the same  However  despite the risks involved  the company still has many good products valued by consumers  And as long as it continues innovating and developing quality products  it ll remain a solid healthcare stock to buy and hold for many years 
Over the past five years  J J s stock has risen 47   Although it underperformed the S P s returns of 57  during that time  it s still a good investment once you factor in its dividend  A Dividend Aristocrat  J J has rewarded long term investors  increasing its payouts for more than 50 years in a row  Currently  the stock pays a dividend yield of 2 5   which is well above the S P 500 average of 1 85  
There s undoubtedly some risk involved in holding shares of J J  but with the company generating more than  80 billion in sales and an impressive bottom line  it s a calculated one that can more than pay off in the long run  Trading at a forward price to earnings ratio of 15  J J s stock is a good option for value investors as well as dividend investors who are looking for a steady stream of dividend income ",2020-02-01,The Motley Fool,https://invst.ly/pprpy,2073685
197552,419068,JNJ,J J scientific officer  pretty confident  they can create coronavirus vaccine as outbreak widens,news,Johnson   Johnson s chief scientific officer said he believes the drugmaker can create a vaccine in the coming months to fight against the fast spreading coronavirus But Dr  Paul Stoffels said it could take up to a year to bring it to market Stoffels said that J J needed to start from scratch on this vaccine  much like how it operated in the Zika outbreak ,2020-01-27,CNBC,https://invst.ly/pndbw,2068294
197553,419069,JNJ,Expanded use of J J s Stelara OK d in Canada,news,Health Canada has approved Johnson   Johnson  NYSE JNJ  unit Janssen Pharmaceutical Companies  Stelara  ustekinumab  for the treatment of adult patients with moderately to severely active ulcerative colitis ,2020-01-27,Seeking Alpha,https://invst.ly/pndtj,2068330
197554,419070,JNJ,J J Snack Foods EPS misses by  0 13  beats on revenue,news,"J J Snack Foods  NASDAQ JJSF   Q1 GAAP EPS of  0 89 misses by  0 13 
Revenue of  282 89M   4 2  Y Y  beats by  2 49M 
Shares  1 95  
Press Release",2020-01-27,Seeking Alpha,https://invst.ly/pnkbn,2068809
197555,419071,JNJ,J J Snack Foods Corp  JJSF  Q1 2020 Earnings Call Transcript,news,"J J Snack Foods Corp  NASDAQ JJSF Q1 2020 Earnings CallJan 28  2020  10 00 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorWelcome to the J J Snack Foods First Quarter Earnings Conference Call  My name is Paulette  and I will be your operator for today s call   Operator Instructions I will now turn the call over to Gerry Shreiber  you may begin Gerald B  Shreiber    Chairman  President and Chief Executive OfficerThank you  Paulette  Good morning everybody  and welcome to our conference call for our first quarter  Let me begin by introducing who is in the room with me Dennis Moore  our Chief Financial Officer  Bob Radano  our Chief Operations Officer  Bob Pape  our Vice President of Sales  Jerry Law  Senior Vice President of Operations  Marjorie Shreiber Roshkoff  our legal representative  and Bo Powell  Sales Manager for our Food Service  Did I get everybody Let me begin  The forward looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ from those projected in the forward looking statements  You are cautioned not to place undue reliance on these forward looking statements  which reflect management s analysis only as of the date hereof  We undertake no obligation to publicly revise or update these forward looking statements to reflect events or circumstances that arise after the date hereof Results of operations  Net sales increased 4  for the quarter  which include sales from the acquisition of a ICEE Distributor in October 2019  without that sales increased 3   Food Service  sales to Food Service customers increased 2  for the quarter  Our sales increase was due to increased sales of soft pretzels  up 2   churros up 8   funnel cake products up 25  and bakery sales up 2  Frozen juice bars and ices sales were down 6  and handheld sales were down 18   Sales to restaurant chains were up this quarter  while sales to schools were down  Operating income in our Food Service segment increased to  18 034 000 from  17 697 000 last year  primarily because of higher volume and improved operations at our Hill   Valley plant in the Midwest Retail Supermarkets  Sales of products to retail supermarkets were down 6  for the quarter  Soft pretzel sales were down 4  for the quarter  Sales of frozen juice bars and Italian ices were down 8   Handheld sales were down 15  and bakery sales including biscuits were down 11  Operating income in our retail supermarkets segment was essentially the same as last year  as the benefit of price increase implemented a year ago offset the impact of slightly lower volume  We expect to see volumes at least stabilizing and improving in the second quarter Frozen Beverages  which include ICEE  SLUSH PUPPIE  ARCTIC BLAST brands  Frozen beverage and related product sales were up 16  in the quarter  and beverage related sales were up 13   Without the sale of ICEE Distributors  an acquisition in the first quarter from the  Indecipherable  Van Group  overall sales were up 12  and beverage related sales were up 4   Service revenue for others was up 13   Machine revenue was  12 million  up from  8 9 million last year Operating income in our Frozen Beverage Group decreased  I m sorry to  1 452 000 from  2 174 000 in the quarter  primarily because of relocation costs and    cost and expenses related to the ICEE headquarters move to Tennessee  Approximately  1 million this quarter and estimated to be about  800 000 in our second quarter in connection with the relocation of ICEE headquarters In October  we purchased the asset of ICEE Distributors  the  Indecipherable  Van Group  which does business in Arkansas  Louisiana and Texas with annual sales of approximately  13 million  Consolidated  Gross profit as a percentage of sales was 27 52  in the three month period this year  down from 28 30     28 3  last year  Gross profit percentage decreased because of lower unit volume in the snack side of our business  generally higher costs and unfavorable product mix changes Total operating expense as a percentage of sales was 19 9  in the quarter  down from last year s 20 2   The decrease was due primarily to lower distribution costs in connection with freight Capital spending and cash flow  Our cash and investment securities balance of  306 million was down  37 million from our September year end  primarily because of the purchase of the ICEE Distributor  We continue to look for acquisitions  as a use of our cash   116 million of our investments are in corporate bonds with a purchase price yield to maturity of 2 8  Our capital spending was  18 million in the quarter  as we continue to invest in plant efficiencies and growing our businesses  We estimate our spending for the year to be about  60 million  as we continue to invest in our manufacturing plants and the ICEE business  Cash dividend of  0 575 a share was declared by our Board of Directors and paid on January 7th  This was a 15  increase from the previous dividend We did not buy back any shares of our stock during the quarter  Our investment income this year was  746 000 more than last year  because we recognized  1 027 000 of unrealized investment losses in last year s quarter  Last year we had a tax benefit of  900 000 related to the Tax Cuts and Job Act  which benefited last year s EPS by  0 05 a share Thank you for your continued interest  and we look forward to continuing our growth and success  Well  that concludes my upfront comments Questions and Answers OperatorThank you  We will now begin the question and answer session   Operating Instructions  And our first question comes from Rob Dickerson  Please go ahead Rob Dickerson    Jefferies    AnalystGreat  Super  Thank you so much Gerald B  Shreiber    Chairman  President and Chief Executive OfficerGood morning  Rob Rob Dickerson    Jefferies    AnalystGood morning  How are you Gerald B  Shreiber    Chairman  President and Chief Executive OfficerI m good  I think you just did a recent report on us or   Rob Dickerson    Jefferies    AnalystI did  We    Jefferies is a firm and my team just recently initiated on a number of food companies and you happen to be in that group  So look forward to working with you going forward Gerald B  Shreiber    Chairman  President and Chief Executive OfficerWe appreciate your research  and we re going to make you a hero Rob Dickerson    Jefferies    AnalystI always love hearing that  Not everyone thinks  I am  So I guess look    couple of questions I have all I think fairly basic hopefully  I guess the first one is just on the Supermarket division  you stated there was a little lost distribution there driven maybe by some of the higher prices  and then you re stating hopefully things stabilize in Q2  If you could just provide a little color as to kind of how that happens and I guess one  do you always like lose distribution when you take prices up  right because that doesn t always happen  It sounds like that was happened a little bit here   Gerald B  Shreiber    Chairman  President and Chief Executive OfficerThat will stabilize  We haven t lost any    we certainly haven t lost any share  And we still dominate that with our products in that category Rob Dickerson    Jefferies    AnalystOkay  So but    and when you think Q2 going forward  it sounds like maybe there was a little bit of distribution loss  but things seem to be OK  And as long as the kind of velocities are OK that you don t expect more distribution loss  it sounds like things should get better Gerald B  Shreiber    Chairman  President and Chief Executive OfficerI mean  we don t expect any more distribution loss  and we expect that recovery to start as we have our new products going in for the summer selling season  This is generally the time when we see the quarter resets  We ve been selling our Pretzel Bites and Auntie Anne s  We ve seen good placements for  So we expect the    that we ve bottomed out Rob Dickerson    Jefferies    AnalystOkay  All right  That s great  And then in terms of the Frozen Beverage segment just maybe a couple of questions  One  I guess just on the top line  Did great in the quarter  decent growth even on organic basis  which is always nice to see  As we think forward though for the rest of the year  we all know the compares get a little bit more difficult  machine sales seemed to be advantaged  let s call it in the back half of last year  Is there    when you look forward for the rest of the year  could there be some deceleration in that business not because the overall base is doing terribly  but just more so because you had a great back half of  19  That s the first question Gerald B  Shreiber    Chairman  President and Chief Executive OfficerWell  we had another good quarter in our Frozen Beverage Group  which is led by our ICEE brand  but that was complemented to some degree by the acquisition  one of the last remaining independent ICEE Distributors  We don t expect that to have a major impact on the year  but it s significant to note that  that added some  35 million or so for the quarter  ICEE Group  which include SLUSH PUPPIE and ARCTIC BLAST continues to perform or outperform And Dan Fachner is on the call  I am going to let him comment on the rest of the year  And Dan  rest assured  I ll kill you if we don t have a great year Dan Fachner    President of the ICEE Company SubsidiaryThank you  Gerry  Yes  Rob  it was really a good quarter for us for sure  Top line was great  I don t know that I would anticipate the top line being at that rate through the rest of the year  We are up against some good equipment sales  as we get deeper into the year  and I think those will taper down some and our increases will be more normalized in that probably 4  range or so  And then we will  as I said  we ll be fighting some really good equipment sales  as we get later into the year Rob Dickerson    Jefferies    AnalystOkay  fair  Good answer Gerald B  Shreiber    Chairman  President and Chief Executive OfficerDan is President of our ICEE Group and I didn t introduce him at the beginning of the meeting  but he s in California  no I am sorry  he is in Tennessee now participating in the call Rob Dickerson    Jefferies    AnalystOkay  That s great  It s a very unique business  which is    continues to perform well  So good job  And   Gerald B  Shreiber    Chairman  President and Chief Executive OfficerMore you  Speech Overlap Rob Dickerson    Jefferies    AnalystYes  It s a uniquely positive  In terms of the    just kind of the margin progression  where delta we saw in Q1 both gross and operating  the gross margin was down a little bit more than operating margin  but then you call out some of the incremental expenses for the Frozen Beverage headquarter move  I was just trying to kind of understand  it seems like from my kind of either distant perspective that maybe the gross margin was a little pressured more because of that kind of near term distribution pressure in retail along with maybe some product mix shift  not necessarily expenses flowing through from the headquarter move  which I would think would be   Dennis G  Moore    Chief Financial OfficerHi  and it s Dennis  Rob I think essentially  you are correct  I think the lower volume at our manufacturing plants  which is the snack food side of the business being down will always    almost always have a negative impact on your margins simply because you ve less volume flowing through  And costs for the most part go up from year to year  payroll costs go up  insurance costs go up that you ve higher costs and lower volumes  So that was the biggest component of why the margin    the gross margin dropped Rob Dickerson    Jefferies    AnalystOkay  But like    so if    but then it s    if there is a little Q1 pressure given  you have retail distribution  but then that picks up back in Q2  and hopefully that gross margin decline is not    it does not continue to decline at an increasing rate going forward  it would seem if volumes stabilize Dennis G  Moore    Chief Financial OfficerWe d expect this to improve  as volume improves Rob Dickerson    Jefferies    AnalystOkay  perfect  And then lastly for me  Keep it quick  Just balance sheet capital structure  you don t have any debt when I started looking at your company  it s always fastening when you see a company with zero debt   Speech Overlap  Yes  right  You ve cash  you ve free cash flow generation and cash flow balance sheet  dividend growth is obviously helped    is healthy what you stated on the call upfront Just in terms of kind of the go forward think internally strategically is this a    continue to look for great companies that can complement our business to acquire or is it more hey  if our cash builds and yes  we might think about continuing to increase the dividend at a high rate  I m just basically trying to figure out where your head is right now in terms of cash allocation if that cash continues to build Gerald B  Shreiber    Chairman  President and Chief Executive OfficerWell  I think we increased the dividend by 15  in the last quarter  which is a healthy  healthy increase Rob Dickerson    Jefferies    AnalystYes Gerald B  Shreiber    Chairman  President and Chief Executive OfficerWe will continue to operate our business in a strong dynamic manner  and we expect to  perhaps  we re still looking for acquisitions  They have to be right  They have to be a right fit  Notwithstanding our balance sheet of cash and liquidity  we re not going to let it burn a hole in our pocket  We will   Rob Dickerson    Jefferies    AnalystOkay  fair Gerald B  Shreiber    Chairman  President and Chief Executive OfficerOkay Rob Dickerson    Jefferies    AnalystYes  Makes complete sense  I will    thank you so much  I really appreciate your time  and I m happy to pass it on Gerald B  Shreiber    Chairman  President and Chief Executive OfficerWhere are you located at  Are you in New York  Connecticut Rob Dickerson    Jefferies    AnalystI m in New York City  Big Apple Gerald B  Shreiber    Chairman  President and Chief Executive OfficerOkay  Well  you re close enough that someday  you can come down and visit us Rob Dickerson    Jefferies    AnalystYes  that s the plan  That is the definite plan  I look forward to seeing you Gerald B  Shreiber    Chairman  President and Chief Executive OfficerMake your plans through Dennis  and when you re here  I m looking forward to meeting you Rob Dickerson    Jefferies    AnalystSounds great  I ve    likewise  Thank you Operator Operator Instructions  And our next question comes from Jon Andersen  Please go ahead Gerald B  Shreiber    Chairman  President and Chief Executive OfficerGood morning  Jon  How are you Jon Andersen    William Blair    AnalystGood morning  everybody  I m doing well  Hope you re all well Gerald B  Shreiber    Chairman  President and Chief Executive OfficerWe are Jon Andersen    William Blair    AnalystTerrific  Well  maybe I ll start with a question on the top line on sales  I m thinking more as we look to the second quarter  I m trying to understand if there are any    anything we should pay particular attention to  I think last year  there were some new items that you may have shipped  I think maybe in Q2 that might have    there might have been some pipeline benefit and there may have been some movement of some of your business with some co packers that we haven t lapped yet  So if you could talk a little bit  I don t know Dennis  maybe you have some more of the detail around that just so that we can think through how the top line might progress  as we move through the year  Thanks Dennis G  Moore    Chief Financial OfficerYes  I think in the second quarter  you re right  we did last year  we had the Burger King limited time offer program  which generated roughly  3 million of sales in the quarter  which we don t have this year  And then throughout last year  as Dan had mentioned  our machine sales were relatively    yes  relatively high  compared to what they normally are  and we would probably expect a drop off in those sales  the balance of the year  maybe in    as much as say  10 million  So that is going the other way  But on the other hand  there are some positives that perhaps Gerry walk and talk about Gerald B  Shreiber    Chairman  President and Chief Executive OfficerYes  We have a group of new items rolling in the Food Service  We have our new fries rolling out  We have a new funnel cake product rolling out  We have a group of savory crackers  We feel good about schools rolling forward  which has been a headwind for us in the first quarter  Retail  the resets are going to be great for us we think  We ve refreshed our LUIGI S packaging  which we feel like we re going to get a bump out of  We have a more robust  We have  I guess more comprehensive marketing program going forward in the next couple of quarters  So we re doing a lot around the business to get at the top line to move Jon Andersen    William Blair    AnalystAnd on the retail side  did you mentioned Gerry earlier something around Auntie Anne s that you re doing that s been well received  ahead of the resets Gerald B  Shreiber    Chairman  President and Chief Executive OfficerWe acquired Auntie Anne s about the    almost two years ago and it s been a good acquisition for us  although was a competitor to us in the soft pretzel category and supermarkets  now it s complementary product to our SUPERPRETZEL  So we expect to benefit from that this year and beyond Dennis G  Moore    Chief Financial OfficerYes  It continues to grow  There s a lot of white space for Auntie Anne s  and we continue to push that out there  And we have a new Minute Maid novelty rolling out or Minute Maid sticks this year  which we expect benefit from Jon Andersen    William Blair    AnalystSo those    net net couple of headwinds  but you ve got a good    it sounds like a strong pipeline that s going to start working its way into the business over the course of the next quarter or two Dennis G  Moore    Chief Financial OfficerYes  and  Speech Overlap  And other thing I didn t mentioned with regards to Frozen Beverages is that there will be an offset  a positive offset  which comes from the acquisition that would be  11 million of sales or so of the balance of the year Jon Andersen    William Blair    AnalystIs that from the ICEE    the acquisition of the   Gerald B  Shreiber    Chairman  President and Chief Executive OfficerWe acquired the    one of the very  very last independent ICEE Distributors this past quarter  Their sales were in the  35 million to  40 million range Dennis G  Moore    Chief Financial OfficerNo  no  Their sales were roughly  30 million Gerald B  Shreiber    Chairman  President and Chief Executive OfficerI m sorry  right Dennis G  Moore    Chief Financial Officer 11 million  Indecipherable Gerald B  Shreiber    Chairman  President and Chief Executive OfficerBut we expect that will continue and that will be a positive overall halo for the business  not only in the areas that we acquired it  but elsewhere Jon Andersen    William Blair    AnalystOkay  Are there    you said it s one of the last  how many are left and do you plan to pursue that  Is there something important about having all of them Gerald B  Shreiber    Chairman  President and Chief Executive OfficerWe re in almost regular communication with them  They kind of look to us as the leader to set the profile and whatnot  So there is no doubt that one day  they will be included in our Group  It s only a matter of when Jon Andersen    William Blair    AnalystOkay  And then the other question I had was on the relo costs in the quarter  So there were  1 million of relocation costs in the quarter  another  800 000 in the second quarter  Where do those show up in Q1 in the P L  and where would we expect them to show up in Q2  Will they split across cost of goods and operating expense  Or they are heavily    more heavily weighted in one or the other Dennis G  Moore    Chief Financial OfficerMore heavily weighted in operating expenses Jon Andersen    William Blair    AnalystOkay  Great  Thanks  Thanks very much guys  And look forward to seeing the new products on the shelf going forward Gerald B  Shreiber    Chairman  President and Chief Executive OfficerOkay  And incidentally  you covered the relocation  but we thought long and hard about the exodus from California for all the right reasons and we think it s going to work out very well for us in the long run Jon Andersen    William Blair    AnalystWell  maybe I should ask about that  And then  so presumably there is some kind of return on this    the cost or investment that you re making  right now  What are the benefits from making that move  because you re not moving manufacturing  right  you re just moving the kind of the administrative headquarters Gerald B  Shreiber    Chairman  President and Chief Executive OfficerAdministrative Dennis G  Moore    Chief Financial OfficerYes  This is Dennis again  Most of the benefit comes from    the hard dollar benefits comes from what our lease costs would have increased in California  if we had stayed there  So even our costs are going to be  we may save a  1 million a year going forward compared to what our costs  where are you  you really don t see most of that  because our costs would have gone up in California close to that number maybe  700 000 or so because we would be having higher lease costs  once the lease we re in now or had been in expires Jon Andersen    William Blair    AnalystOkay  I see cost avoidance then  Okay  Okay  Thanks  everybody  Thanks for the help and the color  Talk soon OperatorOur next question comes from Ryan Bell  Please go ahead Gerald B  Shreiber    Chairman  President and Chief Executive OfficerGood morning  Ryan  This is Gerry Shreiber Ryan Bell    Consumer Edge    AnalystHey  Gerry  Would you be able to walk through the performance of some of your recent innovations   Gerald B  Shreiber    Chairman  President and Chief Executive OfficerRyan  are you there Ryan Bell    Consumer Edge    AnalystYeah  I m here  Can you hear me now Gerald B  Shreiber    Chairman  President and Chief Executive OfficerYes  it s better  but it s not real clear yet Ryan Bell    Consumer Edge    AnalystOkay  Could you walk us through    of some of your recent innovations from your press release  it looks like the Food Service innovation is coming along well  And can you talk about the recent progress you ve been making into c stores Gerald B  Shreiber    Chairman  President and Chief Executive OfficerSure  A couple of years ago  we ve laid out a determined effort and plans to increase our sales in c stores  and there are roughly    there is tens of thousands of c stores  We have gotten both our pretzel products and some of our ICEE products and our juice bar products and good distribution and now that we re in there  we re going to be methodically  Technical Issues   So that is part of the consumer  Technical Issues   Many years ago  if you walked into a convenience store  you might get a hot dog  you might get a drink  now there are soft pretzels there  there is the ICEE Group  Technical Issues  Ryan Bell    Consumer Edge    AnalystGreat  And if I m looking at IRI traction or trends through your December quarter  it looks like they were a little bit healthier than what you reported in the quarter  Is there anything that you could talk about that would help to explain that dislocation Robert J  Pape    Senior Vice President of SalesHi  this is Bob Pape  Mostly  Technical Issues  consumers to the new retail pricing  and we feel that  that is starting to recover  And as a result  the takeaway numbers continue to improve Ryan Bell    Consumer Edge    AnalystOkay  great  Thank you  That s it from me OperatorAnd we are showing no further questions Gerald B  Shreiber    Chairman  President and Chief Executive OfficerAll right  I want to thank everybody for their participation in this call  and we look forward to all of you in our next quarter s call  which will be approximately three months or so from now  Have a good day  Thank you Operator Operator Closing Remarks Duration  27 minutesCall participants Gerald B  Shreiber    Chairman  President and Chief Executive OfficerDan Fachner    President of the ICEE Company SubsidiaryDennis G  Moore    Chief Financial OfficerRobert J  Pape    Senior Vice President of SalesRob Dickerson    Jefferies    AnalystJon Andersen    William Blair    AnalystRyan Bell    Consumer Edge    Analyst
More JJSF analysis
All earnings call transcripts",2020-01-28,The Motley Fool,https://invst.ly/po10-,2069770
197556,419072,JNJ,Johnson   Johnson s Nasal Spray Rejected in England Over Cost Effectiveness,news,"One of Britain s top healthcare agencies  the National Institute for Health and Care Excellence  NICE   announced on Tuesday that the group had decided to reject Johnson   Johnson s  NYSE JNJ  depression nasal spray Spravato due to questions regarding its efficacy as well as cost effectiveness  
NICE is responsible for determining whether a drug gets included in Britain s National Healthcare System  NHS   and for the past while has come down hard on drug candidates over the question of cost effectiveness  Although this is a blow to Johnson   Johnson  the decision isn t necessarily final as of this moment  NICE s initial conclusion is open to comment from Johnson   Johnson until Feb  18  and an appraisal committee meeting is expected to take place soon 

 Estimates of the costs of providing the clinical service for esketamine were highly uncertain  as are the costs of repeated courses of the drug   said Meindert Boysen  director of NICE s center for health technology evaluation  
Spravato s cost effectiveness and efficacy
This isn t the first time that JNJ s Spravato was criticized for its cost  Back in May 2019  the Institute for Clinical and Economic Review  a healthcare cost watchdog  criticized the company for supposedly overpricing the nasal spray  Spravato can cost up to  6 785 for the first month of a patient s dosing schedule 
Although Spravato has done well in five separate phase 3 trials  NICE argued that the nasal spray doesn t have enough data when pitted against  all relevant comparators   This includes treatments such as electroconvulsive therapy as well as various antidepressant antipsychotic medications  The agency also mentioned that they were unsure about whether any improvements in symptoms would remain even after patients stopped taking Spravato ",2020-01-28,The Motley Fool,https://invst.ly/po2af,2069853
197569,419085,JNJ,Genmab earns  150M Darzalex milestone from JJ,news,"Triggered by the achievement of  3B in global Darzalex  daratumumab  sales in 2019  Genmab A S  NASDAQ GMAB  earns a  150M milestone payment from Johnson   Johnson  NYSE JNJ  unit Janssen Biotech 
It also earns royalties on net sales under the exclusive license agreement 
Shares up 2  premarket on light volume ",2020-01-22,Seeking Alpha,https://invst.ly/plcjv,2064889
197570,419086,JNJ,Johnson   Johnson s Fourth Quarter Results Leave Wall Street With Mixed Emotions,news,"Johnson   Johnson  NYSE JNJ  kicked off another earnings season with fourth quarter results that missed analysts  consensus estimates on the top line  but contained enough positive surprises to keep the stock from plunging 
The world s largest healthcare company reported revenue of  20 75 billion  which was  80 million less than the average Wall Street estimate  The bottom line was a different story  Adjusted earnings of  1 88 per share surpassed expectations by one penny 

On the way down
Questions about how much asbestos makes it into talcum powder continued to pressure Johnson   Johnson s consumer goods segment  Sales of its baby care products fell 11  from the prior year period to  421 million 
The company s pharmaceutical segment is still responsible for a slight majority of total revenue despite declining sales of Remicade  Biosimilar competition for the aging anti inflammatory injection pushed fourth quarter sales down by 16 4  year over year to  1 0 billion 
Similarly  J J s blockbuster prostate cancer treatment  Zytiga has been facing generic competition since late 2018 that pushed its fourth quarter sales 13 8  lower to  677 million 
Going up
J J was able to report total fourth quarter revenue that rose 1 7  because a handful of newer products have compensated for the declines of Zytiga and Remicade 
Sales of Stelara    a treatment for psoriasis  Crohn s disease  and ulcerative colitis    surged 17 7  year over year to  1 7 billion  Sales of the company s more recently launched psoriasis injection  Tremfya  rocketed 53 9  higher to  270 million 
Younger drug launches in J J s oncology segment also stepped up their performance in the fourth quarter  Combined sales of blood cancer treatments Darzalex and Imbruvica rose 32 5  to  1 7 billion ",2020-01-22,The Motley Fool,https://invst.ly/plhbz,2065265
197571,419087,JNJ,Johnson   Johnson  JNJ  Q4 2019 Earnings Call Transcript,news,"Johnson   Johnson  NYSE JNJ Q4 2019 Earnings CallJan 22  2020  8 00 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorGood morning  Welcome to Johnson   Johnson s Fourth Quarter 2019 Earnings Conference Call   Operator Instructions  This call is being recorded  If anyone has any objections  you may disconnect at this time  Operator Instructions  I would now like to turn the conference call over to Johnson   Johnson  You may begin Christopher DelOrefice    Vice President of Investor RelationsGood morning  This is Chris DelOrefice  Vice President of Investor Relations for Johnson   Johnson  Welcome to our Company s review of business results for the fourth quarter and full year of 2019 Joining me on today s call are Alex Gorsky  Chairman of the Board of Directors and Chief Executive Officer and Joe Wolk  Executive Vice President  Chief Financial Officer A few logistics before we get into the details  This review is being made available via webcast  accessible through the Investor Relations section of the Johnson   Johnson website at investor jnj com  where you can also find additional materials  including today s presentation and associated schedules Please note that today s presentation includes forward looking statements  We encourage you to review this cautionary statement regarding such statements included in today s presentation as well as the Company s Form 10 K which identifies certain factors that may cause the Company s actual results to differ materially from those projected Our SEC filings  including our 2018 Form 10 K and our most recent 10 Q along with reconciliations of the non GAAP financial measures utilized for today s discussion to the most comparable GAAP measures are also available at investor jnj com Several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies  This slide acknowledges those relationships Moving to today s agenda  I will review the fourth quarter sales and P L results for the corporation and the three business segments  Alex will then provide some perspective on our overall results and business highlights for the year  Joe will conclude by providing insights about our cash position  capital allocation deployment and our guidance for 2020  The remaining time will be available for your questions  We anticipate the webcast will last up to 90 minutes Worldwide sales were  20 7 billion for the fourth quarter of 2019  an increase of 1 7  versus the fourth quarter of 2018  Operational sales growth  which excludes the effect of translational currency increased 2 6  as currency had a negative impact of 0 9 points In the U S   sales increased 1 4   In regions outside the U S   our reported growth was 2 1   Operational sales growth outside the U S  was 4  with currency negatively impacting our reported OUS results by 1 9 points Excluding the net impact of acquisitions and divestitures  adjusted operational sales growth was 3 4  worldwide  2 7  in the U S  and 4 1  outside the U S For the full year 2019  consolidated sales were  82 1 billion  an increase of 0 6  compared to the full year of 2018  Operationally  full year sales grew 2 8  with currency having a negative impact of 2 2 points Sales growth in the U S  was 0 5   In regions outside the U S   our reported growth was 0 7   Operational sales growth outside the U S  increased by 5 3  with currency negatively impacting our reported OUS results by 4 6 points  Excluding the net impact of acquisitions and divestitures  adjusted operational sales growth was 4 5  worldwide  2 3  in the U S  and 6 7  outside the U S Turning now to earnings  For the quarter  net earnings were  4 billion and diluted earnings per share was  1 50 versus diluted earnings per share of  1 12 a year ago  Excluding after tax intangible asset amortization expense and special items for both periods  adjusted net earnings for the quarter were  5 billion and adjusted diluted earnings per share was  1 88  representing decreases of 6 4  and 4 6  respectively compared to the fourth quarter of 2018 On an operational basis  adjusted diluted earnings per share declined 3   Regarding the full year  2019 net earnings were  15 1 billion and diluted earnings per share was  5 63  2019 adjusted net earnings were  23 3 billion and adjusted diluted earnings per share was  8 68  up 4 5  and 6 1  respectively versus full year 2018  On an operational basis  adjusted diluted earnings per share grew 8 8  Beginning with Consumer  I will now comment on business segment sales performance for the fourth quarter  highlighting items that build upon the slide you have in front of you  Unless otherwise stated  percentages quoted represent the operational sales change in comparison to the fourth quarter of 2018 and therefore exclude the impact of currency translation While not part of the prepared remarks for today s call  we have provided additional commentary on our website for the full year 2019 sales by segment to assist you in updating your models Worldwide Consumer segment sales totaled  3 6 billion  growing 2 1   Excluding the net impact of acquisitions and divestitures  adjusted operational sales growth was 1 4  with growth in the U S  of 1 6  due primarily to strong performance in our OTC franchise  Growth outside of the U S  was 1 3  Over the counter medicines grew globally almost 5  operationally and on an adjusted basis  In the U S   OTC growth was around 10  and is growing share in multiple products such as Adult TYLENOL driven by rapid release gels  PEPCID and ZARBEE s  However U S  growth was aided by about 200 basis points of stocking due to incremental distribution and trade promotion programs The Beauty franchise grew 4 3  or just under 1  when adjusted to exclude the impact of the acquisition of DR  CI LABO and the ROC divestiture  NEUTROGENA delivered strong performance globally with growth of 4  outside the U S   driven by anti aging and cleansing innovation in EMEA as well as hand and body moisture category strength in the Asia Pacific region  In the U S   share and market growth were largely offset by lapping of prior year new product pipeline builds and higher 2019 trade investment in NEUTROGENA Concluding the Consumer segment  Baby Care declined 9 3  globally or negative 7  when adjusted to exclude the impact of the Baby Center divestiture  This decline was primarily due to continued competitive pressures as well as comparisons to prior year relaunch activities  most notably in the United States Moving on to our Pharmaceutical segment  worldwide Pharmaceutical sales of  10 5 billion grew 4 4   enabled by double digit growth in nine key products  The segment delivered a seventh consecutive quarter above  10 billion in revenue  Sales grew in the U S  about 4  and increased outside the U S  by almost 5   Generic competition for ZYTIGA negatively impacted our worldwide and U S  growth by about 180 basis points and 310 basis points respectively Our strong portfolio of products and commercial capabilities has enabled us to deliver global growth at above market levels  despite significant biosimilar and generic headwinds  Our oncology portfolio delivered another strong quarter with worldwide growth of over 10   DARZALEX continued its strong performance growing about  Phonetic  45  globally  The U S  grew almost 38  with strong growth across all lines of therapy  driven by the new frontline indication for the multiple myeloma transplant Ineligible population The continued strong growth outside the U S  is driven by increased penetration and share gains  IMBRUVICA grew over 26  globally  driven largely by market share gains and strong market growth  primarily in the chronic lymphocytic leukemia indication in the U S   along with strong uptake outside the U S In the U S   based on third quarter data  IMBRUVICA gained above 7 points of market share in CLL Line 1 therapy  Worldwide ZYTIGA growth declined by about 13  with declines of almost 45  in the U S  due to generic competition  which was partially offset by continued strong growth of almost 13  outside the U S We continue to be pleased with the launch progress of ERLEADA  which generated global sales of  116 million in Q4 and  332 million for the full year  primarily in the United States  We continue to grow market share in non metastatic castration resistant prostate cancer  gaining over two points in the U S  this quarter Sales in the U S  reflects the first full quarter for the approved indication for patients with metastatic castration sensitive prostate cancer  We are also pleased with the launch progress in EMEA where ERLEADA is now available in 12 countries  Our immunology therapeutic area delivered global sales growth of just over 6   driven by strong double digit performance of STELARA and TREMFYA Sales growth was partially offset by continued erosion of REMICADE of about 16  due to increased discounts and modest share loss in the U S  to alternative mechanisms of action and biosimilars  STELARA growth of almost 19  was primarily driven by the Crohn s disease indication where market share has increased by 6 points in the U S  versus the fourth quarter of 2018  In October  we received U S  FDA approval of STELARA for the treatment of adults with moderately to severely active ulcerative colitis SIMPONI    SIMPONI ARIA delivered sales growth of 7 6   driven by strong market growth and SIMPONI ARIA share gains in the U S  TREMFYA grew over 55  and achieved an 8 3  share of the psoriasis market in the U S   which is up about 2 points from the fourth quarter of 2018 In neuroscience  our Paliperidone long acting portfolio performed well growing 15  with higher market share driven by increased new patient starts and strong persistency  In addition  we continue to progress the launch of SPRAVATO  Patient demand continues to build and the unmet need remains very high  New patient starts continue to steadily increase each month  with over 3 500 patients being treated to date Further  we are pleased to report that in December SPRAVATO was approved in Europe for adults with treatment resistant major depressive disorder In infectious diseases  our portfolio grew 9 6  led by strong growth of SYMTUZA and JULUCA for HIV  partially offset by cannibalization and increased generic competition in other products  In our cardiovascular metabolism and other product portfolio  we did experience declining sales of 9 5   primarily driven by declines in INVOKANA and biosimilar competition for PROCRIT XARELTO was flat with volume increases offset by rebates  primarily due to an increase in the legislative rate for the donut hole from 50  to 70  along with higher Medicare and donut hole utilization  In our total pulmonary hypertension portfolio  sales declined 6 2  as a result of a distributor model change in the U S  to realize efficiencies by leveraging our distribution capabilities  This change negatively impacted sales growth by about 800 basis points with sales growth of 2   when adjusting for this one time impact We continue to see strong share growth for OPSUMIT and UPTRAVI and when adjusting for the one time distributor model impact  their worldwide sales were about 10  and 30  respectively  Portfolio growth was also impacted by declining sales in TRACLEER as a result of continued generic competition I ll now turn your attention to the Medical Devices segment  Worldwide Medical Devices sales were  6 6 billion growing 0 2   Excluding the net impact of acquisitions and divestitures  primarily the divestiture of ASP  adjusted operational sales growth was 2 7  worldwide One time items negatively impacted growth in the quarter by about 70 basis points  largely related to a bleed down of the forward buying in Q3  in Japan  ahead of the consumption tax change  which primarily impacted our Vision business  The majority of this has sold through in Q4 with the remainder expected to occur in Q1  2020 Additionally  on a year on year basis  we are pleased to report the Medical Devices has accelerated underlying sales growth worldwide by 130 basis points with the second half of 2019 delivering 4  growth  Interventional solutions grew over 13  globally  led by continued strength in our electrophysiology business achieving about 14  growth worldwide and almost 16  for the year  continuing its trend of double digit growth for the 11th consecutive year Growth was strong in all regions driven by our newer product offerings in ablation and advanced catheters contributing to atrial fibrillation procedural market growth  Additionally  our Cerenovus business delivered its sixth straight quarter of double digit growth  driven by strong market growth and new product innovation  including EMBOTRAP for the treatment of ischemic stroke Vision grew 0 9  or 3  when adjusting for the negative impact of the Japan consumption tax forward buy I mentioned earlier  Growth was primarily driven by contact lenses which grew 2 6  globally or 5  adjusted for the bleed of the Japan consumption tax forward buy  led by double digit growth of daily disposables in the OASYS family For the year  contact lens grew almost 5  which we expect to be in line with the overall market  representing the fourth consecutive year the contact lens has grown at or above the market  In surgical vision  we saw continued strong OUS growth in the cataract business due to above market performance in IOLs  primarily in Asia Pacific This was offset by weak U S  performance due to competitive pressures and lower market growth in refractive surgery  We continue to see positive momentum in orthopaedics  delivering growth for the quarter of 1 2   On an annual basis  each major platform accelerated versus the prior year and adjusted growth for this franchise improved by 180 basis points This progress reflects the continued execution of our innovation and commercial strategies aimed to improve performance  Hips grew 4 2  driven by our leadership position in the anterior approach  continued strong demand of our primary stem ACTIS and enabling technologies such as the KINCISE surgical automated system and JointPoint navigation system Knees growth was 1 4  in the quarter  driven by strong performance of new innovation such as ATTUNE Revision  ATTUNE S plus I mean the ATTUNE Cementless rotating platform which launched at the end of Q3  OUS growth of 3 2  was led by Asia Pacific  Additionally  the United States returned to growth this quarter Trauma growth of 2 5  globally was driven by market growth supported by strong adoption of newer innovation  such as our Femoral Neck System  Spine declined 5 8  with the U S  being the primary driver  partially due to not repeating a time Q4 2018 favorable pricing related true up  which negatively impacted global growth by 250 basis points Excluding this impact  performance for the quarter was in line with the full year  While we lost share in the quarter  we continue to see positive uptake of newer products and are pleased with the strong start of our newly launched SYMPHONY surgical system for use in posterior cervical spine procedures Pricing pressure continue to impact all categories in orthopedics  U S  pure price in spine declined about 3  after adjusting for last year s pricing related true up  Trauma price was consistent with the Q3 decline of 2   Price in hips and knees both improved compared to Q3 at negative 1  and flat respectively Moving to the results for the surgery business  advanced surgery delivered global growth of over 3  led by bio surgery growth of about 4  with growth in all regions led by Asia Pacific share gains and market growth  However  growth in the quarter was tempered as SURGIFLO continued to ramp back up in the United States Energy and Endocutters grew approximately 3  and 2  respectively with OUS growth driven by share gains and new products in the Asia Pacific region  partially offset by competitive pressure in the United States Wound closure grew over 2  driven by continued strong market growth in China as well as share gains in conventional and barbed sutures  As expected  selling days had an immaterial impact on our global growth rates in the fourth quarter  In 2020  selling days will negatively impact Q1 Medical Devices growth by over 50 basis points  with the majority being offset in Q2 I will now provide some commentary on our earnings for the year  Please direct your attention to the box section at the bottom of the schedule  You will see we have provided our earnings adjusted to exclude intangible amortization expense and special items As reported this morning  our adjusted EPS of  8 68 reflects reported growth of 6 1  and operational growth of 8 8   exceeding the high end of both our reported an operational adjusted EPS guidance range from October  driven by our strong performance Consistent with our guidance  we did see a slight decline in adjusted pre tax operating margins of 30 basis points  driven by investment in digital surgery and medical devices Moving to the next slide  our full year 2019 adjusted income before tax for the Enterprise improved 170 basis points versus 2018  Looking at the adjusted pre tax income by segment  Medical Devices at 35 4  is higher than the previous year  primarily due to increased divestiture gains in 2019  partially offset by an increase in investments in digital surgery Pharmaceutical margins declined by 200 basis points to 40   driven by reduced divestiture gains and higher cost of products sold due to the negative impact of currency  Consumer margins improved by 90 basis points to 21 4   driven by planned prioritization and spending reductions  partially offset by reduced divestiture gains in 2018 Now  regarding our consolidated statement of earnings for the fourth quarter of 2019  please direct your attention to the boxed section of the schedule  As referenced in the table of non GAAP measures  the 2019 fourth quarter net earnings are adjusted to exclude intangible asset amortization expense and special items of  1 billion on an after tax basis  primarily driven by intangible amortization of  1 billion  Excluding the impact of those items  our adjusted earnings per share is  1 88  a decrease of 4 6  versus the fourth quarter 2018  Adjusted EPS on a constant currency basis was  1 91  down 3  versus fourth quarter 2018 I like to now highlight a few noteworthy items that have changed on the statement of earnings compared to the same quarter last year  Cost of products sold delevered slightly primarily driven by an increase in amortization expense  partially offset by favorable segment mix Selling  marketing and administrative margins for the quarter improved as a result of planned prioritization in the Consumer business and favorable segment mix  partially offset by increased investment in the Medical Devices business  R D investment was consistent year over year with slightly lower milestone payments in the Pharmaceutical business  offset by increased investment in digital solutions in the Medical Device business Net interest expense was lower by  50 million  primarily driven by the positive effect of net investment hedging arrangements  partially offset by reduced interest income resulting from lower rates of interest earned on cash balances  The change in the other income and expense line was primarily driven by lower litigation expense  higher unrealized gains on securities  partially offset by lower gains from divestitures Regarding taxes in the quarter  our effective tax rate was 4 9  compared to the fourth quarter of 2018 tax rate of 2 6   The current quarter includes an estimated tax expense for the transition provisions of Swiss tax reform  partially offset by reorganization of certain foreign subsidiaries and additional impacts of recently issued regulations associated with U S  tax reform  We encourage you to reference our 10 K for further details on this and other specific tax matters  Excluding special items  the effective tax rate was 10 7   relatively consistent with the same period last year  which was 11 1  Now looking at adjusted income before tax  In the fourth quarter of 2019  our adjusted income before tax for the enterprise as a percentage of sales decreased from 29 6  to 27 1  in the fourth quarter of 2019  primarily driven by the impact of divestiture gains in Q4 of last year The following are the main drivers of adjusted income before tax by segment  Medical Devices declined by 830 basis points  driven by the LifeScan divestiture gain reported in Q4 2018  as well as an increased investment in robotics and digital solutions in 2019  Consumer margins declined by 280 basis points  primarily driven by the divestiture of ROC in Q4 2018  The slight increase in Pharmaceutical margins of 30 basis points was primarily driven by reduced milestone payments  That concludes the sales and P L highlights for Johnson   Johnson s fourth quarter 2019 For your reference  here is a slide summarizing notable developments occurring in the fourth quarter  some of which were mentioned in my comments  I m now pleased to turn the call over to Alex Gorsky Alex Gorsky    Chairman  Board of Directors and Chief Executive OfficerThank you  Chris  And thanks to all of you for joining us today  We re very pleased to be highlighting our fourth quarter and full year performance  We delivered strong revenue and earnings growth in 2019  exceeding the financial performance metrics that we set at the beginning of the year  Now we accomplished this while also making strategic investments that advance the pipeline of opportunities and innovation across all three of our business segments  and as we faced a variety of challenges from debates about the healthcare system in our country to uncertainty with global trade to today s litigious environment to name a few  Now I m very proud that despite the challenges  we still remain focused and delivered on Our Credo commitments and responsibilities to our patients  employees  communities and shareholders  ultimately driving our purpose to advance health for humanity  And I m confident that we are well positioned to build on this momentum and solid foundation as we move into 2020 and beyond We remain focused on the long term  a mindset we ve maintained for more than a century  a mindset that is directly linked to our focused execution  our relentless pursuit of innovation  our talented and passionate people  our culture of caring for the world and unwavering focus on value creation for all our stakeholders In fact  I m proud to highlight that 2019 marked our 36th consecutive year of adjusted operational earnings growth for Johnson   Johnson  Now this performance is indicative of the strength of our broad based business and we remain focused on driving the next generation of innovation across our entire portfolio in new markets  in markets where we have greater opportunity to compete and in the markets where we lead  which include our 26 platforms that each deliver  1 billion or more in sales annually In Pharmaceuticals  our strong track record of success continued again in 2019 as our Pharma segment outpaced the market  growing operationally 5 8   which more than offset the loss of exclusivity due to biosimilar competition and generic erosion as well as new competitive entrants and other market pressures Now  it s important to note that our robust growth can be attributed to volume not price  And our sales growth is a reflection of the increased number of patients we re reaching with our transformational medicines for unmet needs  This strong growth  not only enabled us to deliver life saving and life changing medicines to people around the globe  but it also enabled us to become the third largest pharmaceutical company in the world  retain our Number 1 leadership position in the U S  and be recognized as the Number 1 pharmaceutical company on Fortune magazine s annual Most Admired Companies list  Our pharma investments in R D continue to fuel exceptional growth as well  We achieved double digit growth for 10 key products and delivered strong performance across all regions  including in both developed and emerging markets We re very proud and excited that we gained approval and launched two new transformational medicines  SPRAVATO for treatment resistant depression and BALVERSA for metastatic urothelial cancer  We also continue to maximize the value in our market brands  submitting numerous filings and receiving approvals for line extensions for key brands  including STELARA  DARZALEX and ERLEADA  many with peak sales potential that is greater than  500 million  And we continue to expand our portfolio of strategic licensing and acquisition of new assets and platforms  including cusatuzumab from Argenx  an investigational antibody for the treatment of acute myeloid leukemia and high risk myelodysplastic syndromes  a gene regulation platform from MeiraGTx and bermekimab from XBiotech Inc   an anti IL 1 alpha in Phase II development to treat atopic dermatitis and hidradenitis suppurativa With this industry leading pipeline  our commercial capabilities and robust R D productivity  I m confident that we are well positioned to continue delivering sustained long term above market growth in 2020 and beyond  Now  2019 marked a year of significant transformation for the Consumer Health business  We reestablished our brand and purpose and made strategic decisions that over time will accelerate growth  reduce complexity and improve operating margins  Fueled by science based professionally endorsed brands and strong consumer insights  we placed a concerted focus throughout 2019 on establishing a clear plan and path to achieve benchmark profitability in 2020  And this segment is already well on its way  delivering 90 basis points of adjusted pre tax margin improvement for the year Additionally  we successfully integrated the acquisitions of Zarbee s  Inc   a leader in naturally based over the counter remedies and the Dr Ci Labo line of dermocosmetic skin care products  strengthening our position in these higher growth categories  Our U S  Consumer business continues to grow above the market and our priority areas of beauty and OTC delivered solid operational growth for the year I m also pleased to share that Medical Devices accelerated growth again in 2019  As a result of our relentless focus on execution  innovation and portfolio management  our underlying growth was just under 4   Now improved performance was driven by electrophysiology  achieving its 11th consecutive year of double digit growth  contact lens  which delivered growth at or above the market for the fourth straight year  energy and endocutters businesses growing mid single digits and improved performance in orthopedics with each major platform accelerating compared to 2018 During the year  we also fortified our commitment and accelerated our entry into one of the fastest growing healthcare categories and exciting transformative fields of medicine  digital surgery  Consistent with our historical pioneering spirit in medical devices  we are focused on the next frontier of surgery  The acquisition of Auris Health  Inc   a developer of robotic technologies currently in lung cancer accelerated our entry into robotics as part of a digital surgery ecosystem designed to make medical intervention smarter  less invasive and more personalized to elevate the standard of care Additionally  just last month  we announced an agreement to acquire the remaining stake in Verb Surgical to further strengthen our ecosystem  And we also successfully launched critical products across each franchise throughout 2019  including  the ATTUNE Cementless knee system  our first of its kind ACUVUE OASYS contact lens with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY  The industry s first powered circular stapler ECHELON and the VIZIGO steerable sheath in our market leading electrophysiology business Our team continues to focus on improving our cadence of innovation as well as our portfolio optimization  which included the completion of the Advanced Sterilization products divestiture and the execution of more than 50 acquisitions or strategic partnerships that we expect will further augment our future growth We are committed to building upon this momentum in 2020 and I m pleased to share that we will be hosting our Medical Device Business Review Day on May 13th to highlight the strategies that we believe will drive further growth and provide additional insights into the team s plans in digital surgery Looking ahead  across all three business segments  we know we ve got more work to do  but we are committed to continuing to deliver above market growth in our Pharmaceutical business  broadening the reach of our Consumer business and meeting the full potential of our Medical Devices business And one of the most critical factors in achieving the goals of all of our business strategies is sustaining our investment in innovation  Once again in 2019  we achieved record levels of investment  investing more than  11 billion in research and development  And across all industries  we remain one of the top 10 global companies that invest at the highest levels in R D and innovation Across Johnson   Johnson  we recognize the powerful impact that technology  innovation and health breakthroughs have in creating meaningful change in people s lives and establishing a competitive differentiation within the industry Now  I would be remiss if I did not acknowledge that all of these many accomplishments would not have been possible without the efforts  passion and engagement of our approximately 132 000 global Johnson   Johnson colleagues who continue to demonstrate a commitment to delivering healthcare solutions that benefit patients  consumers and communities around the world Our purpose driven  Credo based culture puts patients and people first  and this is certainly true in the way we think about our employees and work to consistently cultivate the world s best  healthiest and most engaged workforce  The fact that our Johnson   Johnson colleagues are truly the driving force behind our successful performance and in fulfilling our purpose is something that we never  never take for granted and always celebrate We share the common objective of always making the health and well being of the patients and consumers who use our products every day our number one priority and it has been this way for the last 134 years  We are on the front lines of developing medicines and revolutionary products that are literally saving people s lives  and we re working to prevent cancer  offer less invasive surgeries and to end Ebola and HIV  This is what the world expects of us and this is what our global workforce is united around  committed to and prepared to do  Now  putting the needs of those we serve first also means protecting our shared environment in natural resources  We know that human health is directly linked to the health of the planet  Healthy people and communities go hand in hand with a healthy environment  This is why we are committed to reducing the environmental footprint of our operations  products and supply chain with 2020 targets to reduce carbon emissions by 20  and procure 35  of electricity from renewable resources Looking over the long term  we are optimizing our operations to improve water and energy efficiency while focusing on sustainable design and reduction in product packaging as well  all with the goal of delivering better health for people everywhere So now I d like to close where I began  In spite of the numerous industry challenges we faced throughout 2019  I m very pleased that we remain focused on meeting the needs of patients and consumers globally  delivering value to all of our stakeholders  innovating  driving growth  and achieving solid performance  Our sustainable business model is built for the long term and provides us with increased confidence about our business  our strategic direction and the healthcare industry in what may sometimes feel like uncertain times  You have our unwavering commitment that we will hold ourselves accountable to fulfill all of Our Credo responsibilities  where we always keep the patient at the center of everything we do and also ensure the continued long term success of Johnson   Johnson We have an incredible opportunity to play a leading role in defining and driving the future of healthcare and putting it within the reach of everyone everywhere  This is why we are so very excited and confident about 2020 and beyond  I look forward to addressing your questions during the upcoming Q A  but I ll now turn it over to Joe  who will provide additional details about our results and guidance for 2020 Thank you  Joe Joseph J  Wolk    Executive Vice President  Chief Financial OfficerThank you  Alex  Hello  everyone  We appreciate you joining today s call  I will be providing additional context around our 2019 performance  including our year end cash position and the capital allocation actions that we executed throughout the year  and then conclude with our guidance for 2020  As Alex and Chris mentioned  we delivered solid fourth quarter results  which capped a strong year of performance for Johnson   Johnson  Our full year results reflect a continued commitment to our long term strategic objectives  Throughout the quarter and the year  we maintained our focus on delivering life saving and life changing products to patients and consumers across the globe  Heading into 2020  we are confident in our overall strategy and ability to drive results across the enterprise that will yield strong shareholder returns  Our solid results during the year generated strong cash flow  our highest level ever of free cash flow of nearly  20 billion With respect to our cash position  at the end of 2019  we had approximately  8 4 billion of net debt  consisting of approximately  19 3 billion of cash and marketable securities and approximately  27 7 billion of debt  Although we don t provide cash flow guidance  for transparency as we come off a record year of free cash flow generation  we do expect a decline in 2020 of approximately 10  as we are planning for a payment related to the agreement in principle to settle opioid litigation  as previously disclosed In 2019  we executed on all four elements of our capital allocation strategy  Our first objective within that framework is to invest in growth opportunities to solidify and advance our current business  Delivering transformative healthcare solutions and creating access is the top priority for Johnson   Johnson  And  as Alex mentioned  we invested more than  11 billion in R D during 2019 As investors in Johnson   Johnson know  delivering a competitive and increasing dividend is a capital allocation priority for us  In 2019  we returned almost  10 billion to investors  which is approximately 50  of our free cash flow  increasing the quarterly dividend by 5 6   Once we ve satisfied our dividend objectives  we seek M A opportunities where our capabilities can create compelling value During the year  we completed a number of strategic acquisitions totaling almost  6 billion to further strengthen our portfolio which Alex outlined earlier in the call  Finally  after executing on these three important capital allocation priorities  we consider other prudent ways to return value to shareholders  such as the  5 billion share repurchase program we began in December of 2018 and concluded in the third quarter of 2019 Let s move the discussion to guidance and information to assist your financial modeling for the year ahead  I ll begin with some qualitative comments that we considered in our outlook  First  our projected sales growth includes the benefit of an additional two to three shipping days associated with a 53rd week in our 2020 fiscal calendar  This will be partially offset by a SKU rationalization program in our Consumer segment As part of our efforts to further improve profitability in 2020  the consumer segment will continue to invest in platforms where we have differentiated brands with the greatest potential  Therefore  we plan to rationalize approximately 10  of the SKUs across the global portfolio  translating to a negative impact on 2020 topline growth of slightly over 100 basis points for the segment  This program will be primarily focused outside the U S  with a larger impact coming in the second half of the year in the baby and beauty franchises  considering both the additional shipping days associated with a 53rd fiscal week and the consumer SKU rationalization program  The net impact is approximately 50 basis points to 100 basis points of benefit to the company s sales growth outlook  Specific to each segment  our adjusted sales guidance also assumes continued above market performance in our Pharmaceutical segment  driven by continued strong growth from key products such as DARZALEX  IMBRUVICA  TREMFYA  STELARA and ERLEADA due to increased penetration and new indications Continued acceleration of sales growth in Medical Devices generated by recent launches and improved execution  And in the Consumer Health business  we will continue to grow above the market in the U S  while executing the SKU rationalization program to position the segment for benchmark profitability  Given these factors  we expect adjusted operational sales growth for the full year of between 5  and 6  or 5 5  at the midpoint  The adjusted operational sales growth of 5  to 6  is on a constant currency basis  reflecting how we manage our business performance  Considering a negative impact from net acquisitions and divestitures  which we estimate at 50 basis points  we are comfortable with your models reflecting operational sales growth in the range of 4 5  to 5 5  or  85 8 billion to  86 6 billion As you know  we do not predict the impact of currency movements  but utilizing the euro spot rate relative to the U S  dollar as of last week at 1 11  there is an estimated negative impact of foreign currency translation of approximately 50 basis points  resulting in an estimated reported sales growth between 4  and 5  compared to 2019 or  85 4 billion to  86 2 billion Let s now discuss earnings per share  As you can see on your screen  here s a slide depicting the components and assumptions included in our 2020 EPS guidance  Using the sales growth guidance I just referenced provides approximately  0 40 growth to EPS  The next column is based on expected operating margin improvement of approximately 100 basis points  which translates to an incremental  0 25 of contribution net of continued investments across our segments  Operating margin improvement will be primarily driven by continued efforts to improve manufacturing capabilities  optimize sales marketing and administrative expenses  and the consumer SKU rationalization just discussed This results in strong adjusted operational EPS growth for the core business of  0 65 or 7 5  versus the prior year  Offsetting those two operating components is the anticipated reduced level of other income of approximately  0 30 compared to 2019  You may recall that we benefited from a large divestiture gain from the sale of our Advanced Sterilization Products business in the second quarter of 2019 The final element to this EPS waterfall chart is the 2020 benefit we will have from the share repurchase program completed in 2019 which adds  0 05 to EPS compared to 2019  resulting in an adjusted operational EPS of  9 08 at the midpoint or a growth rate of 4 6   While not predicting the impact of currency movements using recent exchange rates  our reported adjusted EPS would be negatively impacted by approximately  0 05 per share  resulting in adjusted reported earnings per share of  9 03 at the midpoint  reflecting growth of approximately 4  Continuing with EPS guidance  this slide provides a summary of additional P L items to better provide insight into our full year 2020 guidance  As referenced earlier  for 2020 we are expecting our adjusted pre tax operating margin to improve by approximately 100 basis points  while still prioritizing investment in our business that accelerates and further strengthens our pipeline of new products for the long term Although we are continuously evaluating external value creating opportunities for purposes of your models  we currently assume no major acquisitions or other major uses of cash and are therefore comfortable with your modeling net interest expense between zero and  100 million As a reminder  other income and expense is the line on the P L where we record royalty income as well as gains and losses related to the items such as litigation  investments by our Johnson   Johnson development corporation  divestitures  asset sales  and write offs We would be comfortable with your models for 2020 reflecting net other income and expense  excluding special items  as net income ranging from  1 5 billion to  1 7 billion  This is lower than 2019 as we had elevated levels of divestiture gains and we do not expect an event of that magnitude in 2020 Moving on to taxes  Our effective tax rate guidance for 2020  excluding special items  is approximately 17 5  to 18 5  were higher than where we ended 2019  driven by expected changes in the mix of global earnings and miscellaneous one time benefits not expected to reoccur in 2020 Considering all these factors  we are comfortable with adjusted EPS guidance in a range of  9 00 to  9 15 per share on a constant currency basis  reflecting operational or constant currency growth of approximately 3 7  to 5 4  Again  while not predicting the impact of currency movements  but to provide some insight on the potential impact on EPS using exchange rates from last week  our reported adjusted EPS would be negatively impacted by approximately  0 05 per share  Therefore  our estimate for 2020 reported adjusted EPS is between a range of  8 95 to  9 10 per share or  9 03 per share at the midpoint As a final comment  our guidance assumes no formal share repurchase program at this time  I wanted to provide this reminder since the last time I looked  Street estimates utilized an average share count which is significantly lower than what we are assuming for our 2020 guidance We estimate the average diluted shares outstanding to be largely in line with the fourth quarter 2019 share count or 2 67 billion shares  Although we do not provide quarterly guidance  there are a few factors for you to consider in your models beyond the selling day fluctuations Chris mentioned in his remarks for Medical Device For sales  you can expect the fourth quarter of 2020 to have the benefit of the additional shipping days  partially offset by the Consumer SKU rationalization program that we are projecting throughout the year but more pronounced in the back half  With respect to earnings  the first quarter of 2019 included an equity gain related to the consumer acquisition of DR  CI LABO  and the second quarter of 2019 included the gain associated with the ASP divestiture in medical devices We don t anticipate similar events for other income and expense in the first half of 2020  but would expect elevated levels of other income aligned to today s guidance in the second half of 2020  Lastly  based on today s spot rates  currency will have a more negative impact in the first half of 2020 That concludes prepared remarks of our financial summary of 2019 results and 2020 guidance  Our 2019 results reinforce our confidence in our broad based business as we head into 2020 and we look forward to delivering continued value on behalf of all stakeholders As Alex mentioned  we will be hosting our Medical Device Business Review Day on May 13th and I look forward to seeing all of you in person at this exciting event  which will be held in New York City this year For your planning purposes and based on investment community feedback  please note that we will be highlighting our Consumer segment at consumer focused events such as notable CPG conferences this year  A special thank you to our Johnson   Johnson associates around the world for their tireless efforts and commitment who make the results we have attained possible and the outlook so bright I will now turn the call back to Chris to begin the Q AChristopher DelOrefice    Vice President of Investor RelationsThank you  Joe  We will now move to the Q A portion of the webcast  Operator  can you please provide instructions for those on the line wishing to ask a question Questions and Answers OperatorYes  thank you   Operator Instructions  Your first question comes from Chris Schott with JPMorgan Chris Schott    JPMorgan    AnalystGreat  thanks very much for the questions  The first was just on Pharma  can you just elaborate a little bit more on your expectations for growth in 2020  I guess specifically  what are you expecting in terms of patent expirations headwinds for this year  And can you also elaborate on the competitive dynamics you re expecting for both TREMFYA and STELARA in psoriasis with the launch of Skyrizi  Thanks so much Christopher DelOrefice    Vice President of Investor RelationsHey  good morning  Chris  and thanks for the question  Thanks for joining us today  So with Pharmaceuticals  as I mentioned in some of my prepared remarks  we do expect continued growth above the market  I think as we would have sat here last year  we expected a bigger impact in 2019 from the loss of exclusivity and generic and biosimilar competition to our products and to our teams credit  based on the data  the safety  the efficacy  the familiarity of the products and comfortability for physicians and patients  those products were able to retain that business a little bit longer We would expect that to bleed into 2020 and    but we still do even with that  I ll call a neutralized headwinds  It s not a tailwind per se  but I ll call it a neutralized headwind compared to 2019  I think we do certainly expect that the portfolio of products will continue to outperform the general market of pharmaceuticals in general Alex Gorsky    Chairman  Board of Directors and Chief Executive OfficerHey Chris  this is Alex  Just to add one comment on to that  look  we re extremely proud overall of the performance of our Pharmaceutical Group  but particularly our immunology group within Pharma  If you    if you just step back a moment and look over the past several years at    first of all  the way that they were able to manage the biosimilar impact with REMICADE  while simultaneously launching multiple new indications for compounds like STELARA launching TREMFYA To note that TREMFYA 55  growth in the quarter  STELARA had 19  growth  And frankly also  it s the clinical development and the competitive differentiation with TREMFYA  for example  having comparative trials not only versus our own compounds but also against Humira and Cosentyx And I think what s really important is that in areas that these products are used  it s not only the short term results  but it s particularly important for the long term results So many patients on psoriasis will shift from product to product and are suffering from this condition for a long time  And having in excess of 48 months  worth of duration and treatment effect by a compound like TREMFYA  I think really helps explain its uptake and continued confidence and use by physicians and patients in the marketplace So and we combine that with the penetration rate of probably somewhere in the 30  to 40  rate in this overall category  we think that there is still a lot of unmet need We think that there is still a lot of opportunity with these compounds and that doesn t even include some of the additional clinical development programs that we re having in areas such as GI as well for these  where particularly for a compound like STELARA  we re seeing great impact  We think that there is a lot of opportunity ahead Chris Schott    JPMorgan    AnalystGreat  thanks for that  Maybe one other really quick one here  Other income   1 5 billion to  1 7 billion  I think that s still a bit above your historic levels of other income  I know this number can be a bit lumpy  but should we think about this type of level as a new norm or can we think about that number of declining further  as we look beyond 2020  Thanks Joseph J  Wolk    Executive Vice President  Chief Financial OfficerYeah  Chris  thanks for the question  I would say it s certainly down from what we experienced in 2019  And I would expect not to provide any insight into 2021 just yet  but I would expect that number to come further down as we look out  So as you see this year  we re improving our operating margins by nearly a 100 basis points to offset some of the effect that we had the benefit of in 2019  And I think we ll continue to do that But to be truthful  we continually look and manage our portfolio in a very rigorous fashion  making sure that we re the best owners of the assets that we have and that works both ways  So we look to complement our portfolio  but we ll also look to take underperforming businesses and create value for shareholders in other ways Chris Schott    JPMorgan    AnalystThank you Christopher DelOrefice    Vice President of Investor RelationsChris  thanks for your questions  Next question please OperatorYour next question comes from Larry Biegelsen with Wells Fargo Larry Biegelsen    Wells Fargo    AnalystGood morning  thanks for taking the question  Just one on the extra week and one of the litigation  Joe  can you talk about the impact of the extra week in 2020  In 2015  it was about 4  in Q4  1  for the full year and neutral to EPS  Does it impact U S  more than international  Does it impact some businesses more than other  I heard your comments on Consumer but I m thinking more about Pharma and Med Tech  And I had one follow up Joseph J  Wolk    Executive Vice President  Chief Financial OfficerYes  So Larry  with respect to the fiscal 53rd week that translates to about two to three shipping days  I would say that s pretty much the norm for the Medical Device and Pharmaceutical units that you ve asked about  It s a little bit less in Consumer in terms of impact  because it doesn t impact stocking during the holiday season  So    and you re absolutely correct  we had the same assumptions around EPS  It s pretty much neutral because you still have a full week of expenses without really the benefit of a full week of sales Larry Biegelsen    Wells Fargo    AnalystThanks for that  And Alex  just one on litigation  Just  what s the latest on the opioid litigation  the latest on the  4 billion settlement you had previously announced  Any important dates and milestones we should think about  And just lastly on talc  when do you expect the decision from the Daubert hearing  Thanks for taking the questions Joseph J  Wolk    Executive Vice President  Chief Financial OfficerHey Larry  this is Joe  I ll take that  Thanks for the questions  With respect to the opioid settlement  an agreement in principle that was announced shortly after our Q3 earnings where we set aside  4 billion  we continue to work with the Negotiating Committee of the State Attorney Generals to finalize the agreement in principle  We remain  I would say  cautiously optimistic that that s progressing very well We re highly engaged to the extent we can be to finalize that agreement in principle  and we hope to hear more over the coming months from the lead negotiators representing not just the states  but as you know the counties and municipalities With respect to talc and the Daubert litigation  we are awaiting Judge Wolfson s verdict in that  Again  as you know  that s an evidentiary standards hearing  So we ll be able to make sure that there is great clarity and certainty as to the type of scientific evidence that needs to be presented As you know and you probably saw in the Journal of American Medical Association article published just a few weeks ago  probably one of the most comprehensive reports evaluating all studies from independent sources found no link between talc and cancer  So we think that s  again  another independent source and we think those facts  those    that data  that scientific research will bear out in the end  Thank you Larry Biegelsen    Wells Fargo    AnalystGreat  thanks Christopher DelOrefice    Vice President of Investor RelationsThanks  Larry  Rob  Next question please OperatorYour next question is from David Lewis with Morgan Stanley David Lewis    Morgan Stanley    AnalystGreat  Just a couple of questions this morning  Joe  just one clarification and one qualitative on revenue  So the 5  to 6  operational guidance for 2020  the way to think about that is that includes about 50 basis points to 100 basis points of the net effect of selling days adjusted for the consumers SKUs Joseph J  Wolk    Executive Vice President  Chief Financial OfficerThat s exactly right  David David Lewis    Morgan Stanley    AnalystOkay  And just a follow up on revenue  and one more quick one after that  Just qualitatively Joe  can you sort of help us understand 2020  how you see it framing up from a Pharmaceutical  Consumer and Medical Device business  and historically  you ve given us a sense of sort of which businesses are likely to accelerate and which businesses are sort of more stable  So across Pharma  MD and Consumer  how do you see sort of the qualitative parameters driving the 2020 guide Joseph J  Wolk    Executive Vice President  Chief Financial OfficerYeah  thanks for the question  David  So we have    I think right now  it is across all three of our businesses  If you look at Pharmaceuticals  we will continue to accelerate growth  I would say we ll be above market  It s probably not as robust as we would have thought this time last year  again because we were able to retain some of the business that was subject to generic and biosimilar competition But again  very healthy growth above market and we ll be looking to complement the portfolio certainly with advancing our pipeline  We ve got a couple of things that are    hopefully will be filed this year around Ponesimod for multiple sclerosis We hope to gain approval on the DARZALEX subcutaneous formulation  which is a tremendous benefit for patients and we ll see the continued uptake of BALVERSA and SPRAVATO In medical Devices  we re very pleased and just to put it into some context for the analyst community here  In 2017  we grew 1 6   In 2017    2018  I m sorry  we grew 2 7  and now we re up to 3 9  and we re not done  So we re going to continue to accelerate growth  be toward that in the middle of the market range that we believe is on the horizon for 2020 and that s before we have the opportunity to launch what we think will be a very differentiated offering around digital robotic surgery In Consumer  again  as Alex mentioned in some of his remarks  we have focused on profitability there  We focused putting investment behind our stronghold categories of skin health and self care  so that would be TYLENOL and MOTRIN for self care  AVEENO and NEUTROGENA for skin health  Those brands continue to do extremely well  I would suspect we grow more in line with the market for that category  except for the SKU rationalization where we ll be looking to de prioritize some less productive brands  Okay David Lewis    Morgan Stanley    AnalystAnd Joe    and then just  Joe  just one quick question  follow up on margins  In some of the years you ve had sort of other income headwinds  you ve been able to offset it with more significant SG A gains driving margins  You re talking about a 100 basis points of margin expansion into 2020  Medical Devices with the JV  Phonetic  agreement continues to track well  Are there just spending dynamics or more visibility on sort of 100 basis points of underlying margin expansion in 2020 headwinds and tailwinds we should be thinking about  Thanks so much Joseph J  Wolk    Executive Vice President  Chief Financial OfficerYeah  I don t know Chris  if you want to add something Christopher DelOrefice    Vice President of Investor RelationsI just wanted to amplify in Consumer just examples of that TYLENOL and NEUTROGENA for the full year this past year  NEUTROGENA at 6  growth TYLENOL 9  growth  just to build on what you were sharing on consumer Joseph J  Wolk    Executive Vice President  Chief Financial OfficerRight  OK  Thanks  Chris  With respect to margin expansion  David  I think we would look to certainly manufacturing capabilities and improving our productivity there  I would point to the consumer SKU rationalization  the design behind that is specifically to improve profitability and then we ll continue to look at other opportunities for enabling functions across finance  HR  information technology and procurement to get savings  So we think we re in pretty good shape to deliver that for 2020 Christopher DelOrefice    Vice President of Investor RelationsGreat  Thanks  David  Appreciate the questions  Rob  Next question please OperatorYour next question comes from Kristen Stewart with Barclays Kristen Stewart    Barclays    AnalystHi  thanks for taking my question  Just one clarification  The extra week with the SKU rationalization  it s a net impact overall  it s 50 to a 100 to the top line  is that correct Joseph J  Wolk    Executive Vice President  Chief Financial OfficerThat s correct  Kristen Kristen Stewart    Barclays    AnalystOkay  perfect  Just want to clarify that  And then just a big picture  I guess  question  Just on portfolio and capital allocation  I know you had mentioned just in terms of models need to take into consideration with the share count  no further share repurchase activity  you guys are in a pretty good position  Obviously from a share    I m sorry  cash flow perspective  generating  20 billion this year  it sounds like your expectation is to pay out the opioid settlement  but I guess  why not get more aggressive from a share repurchase perspective  Just how should we think about capital allocation going forward Alex Gorsky    Chairman  Board of Directors and Chief Executive OfficerHey Kristen  this is Alex  Thank you very much for the question  And look  we re really proud of our strong performance across our businesses  and frankly  as it relates to our capital allocation model this year and we re very confident in it going forward  As we mentioned in the results earlier  if you think about the free cash flow spin off that we had in 2019  I think it s indicative of not only great discipline across our various lines and you see the P L in front of you So overall  it was quite healthy  But it s also important to note that we did that in the context of also continuing to invest in more than 11 acquisitions  about six licensing agreements where we invested almost  7 5 billion just in the course of the year  So  as we talked about in the past  we ll continue to invest in our brands and in research and development at an appropriate rate If you go back over the last four years  I think if you add the numbers up in R D  we ve invested more than  45 billion during that timeframe  and we think that based upon the number of new product launches in our Pharma Medical Device business and our Consumer business that we ve gotten a good return on that  We ve continued to keep a healthy dividend at the same time  We realize how important that is During that same timeframe  four years  it s a pretty similar number to our R D  It s about  40 billion to  45 billion  And of course  after that  we always take a look at value creating acquisitions  And again  during that same timeframe  I think the number comes to about  50 billion that we ve invested Over the past year of note was  you might say  the additional investment that we made in Auris and we think combining that with the later buyout that we did with the Verb  with Verb and Verily is the right thing  If you think ahead in Medical Devices  there are probably few things that are going to represent a more secular shift in that domain than the shift into digital and robotic surgery  And bringing those together we think creates a very exciting opportunity for us But we also continue to do value creating tuck in opportunities as well in our Pharmaceutical businesses  We just talked about the end of the year  we brought in two really exciting compounds bermekimab in particular in both AS as well as other conditions  We think it represents a great opportunity and it s certainly in an area where we ve got a lot of capability and a lot of expertise And finally  we talk about share repurchases  And I think we ve demonstrated over the last four or five years that we ll certainly employee share repurchases when we think that we re undervalued particularly in a significant way  And again  I think an outcome of the way that we manage our overall P L  it means that we can do these things simultaneously  It s not necessarily in order and we continue to    we expect to continue that strategy going forward Kristen Stewart    Barclays    AnalystOkay  great  Phonetic  Joseph J  Wolk    Executive Vice President  Chief Financial OfficerYeah  Kristen  Just a quick comment and thanks for noticing the comments around share count  I have to tip my hat and complement the investment community because when we go through the consensus P L  the income in terms of absolute dollars was almost spot on  It was the yearly close in fact  and then really the disconnect came in the form of share count where the average share count used in consensus was about 14 million shares less  which translates to about  0 05 or  0 06 So we thought we were very much in line with what consensus expectations were  and while we don t provide guidance assuming any share repurchase that s not currently authorized  It seems that a few analysts may have made that assumption Kristen Stewart    Barclays    AnalystOkay  perfect  Thank so much Christopher DelOrefice    Vice President of Investor RelationsGreat  thank you Kristen  Rob  next question please OperatorNext question is from the line of Josh Jennings with Cowen Josh Jennings    Cowen   Company    AnalystHi  good morning  Thanks for taking the questions  First is on robotics  and you clearly have put a stake in the ground and with investments pursuing leadership in digital surgery ecosystem  I just wanted to see if    and I understand we re going to get a big update at the Med Device day in May  but if you could whet our appetite at all today just give any updates on progress in the Auris launch  the timelines for Orthotaxy  and then any indications that you see where robotics is not in play today that could come into play over the next three to five years within your portfolio And then  second question is just for Joe and Alex  I guess it s just on  you know the other income line has been a focus  I think the concerns are where that could fall off next year or in the out years and you talk about your process for portfolio review and then pruning I mean the underperforming assets or assets don t fit under your roof If you could just talk about that process and how regiment it is  Is there a formula  Is there 1  of the portfolio that gets pruned every year or is it just strategic and opportunistic annually  Thanks for taking the questions and I apologize for the background noise Alex Gorsky    Chairman  Board of Directors and Chief Executive OfficerHey Josh  thank you very much for the question  And look  I am really glad that you mentioned robotics and digital in terms of an entire platform for us because of course that s exactly what it is  And let s start first with our acquisition of Auris Health  And overall what we would say  it s off to a great start where we couldn t be more thrilled to have the robotics pioneer and former CEO Fred Moll and his team at J J The Monarch Platform is off to a very good start  It s going to play a critical role in our lung cancer initiative  And when you just look at the science and the technology and what it can do with the distal parts of the lung and what it brings in terms of potentially ablation leveraging it with our NeuWave technology And even longer term  having the potential to dispense oncolytic viruses in treating cancer in very new and unique ways is exciting  Physicians can perform more than 2000 bronchoscopy procedures with the Monarch Platform and we re really pleased with what we re seeing with it Second  you saw our announcement on Verb and we think combining Auris and Verb really helps ensure that we have a very strong role in the next generation of the digital surgery platform and ongoing development  Our teams are working now together in a really comprehensive way  We do look     sorry for that feedback  But we do look at this as a platform that is something that will be in place for the next several decades  Therefore  it s really important that we step through this in the right way And what I would say is  the early results from the collaboration and the partnership that we re seeing between these teams is very encouraging and that s why we re excited to give you this preview that Joe mentioned on May 13th in New York because we think it will provide very clear  transparent kind of tangible evidence of not only the machines  but also the digital platform component of this as well Next  we re really excited about the progress that s being made with VELYS in our orthopedics robotics platform as well  It s an exciting technology  We think that it s going to offer a portable low cost system that s easy to use  will improve accuracy  It also is a nice combination to ensure if the surgeon remains intimately involved  And if we look at the training and technical support  it s something that will be easily coordinated between ORs and surgeon So we re progressing toward a mid year 2020 regulatory submission for this  So really if you just step back and you think about what we have going with Auris and Monarch  if you think about the plans now that we have in place with VELYS in orthopaedics  and then longer term  as we bring out that next generation of digital and robotics platform more broadly across surgery  we re very excited about it Joseph J  Wolk    Executive Vice President  Chief Financial OfficerAnd  Josh  to address your question regarding the management of our portfolio  so I would say it s rigorous  it s not formulaic though  So we meet as a management team and executive committee monthly on what additions or deletions from our portfolio makes sense  And that    and makes sense probably should be defined in terms of we have aspirations in all the markets we play in to be either number one or number two in that space with the promise of bringing better solutions in that space to patients and consumers across the globe We have plans in place for all of our businesses to do that  But after a period of time when those plans don t come to fruition  we ll assess other alternatives  I would say under Alex s leadership  we ve gotten very disciplined in this this rigor and that s proved to be pretty productive  I think  in terms of how we ve been able to take underperforming businesses  turn that into gains and reinvest back in businesses in areas that we think we ve got a differentiated right to win Christopher DelOrefice    Vice President of Investor RelationsThanks Josh  Appreciate the questions  Rob  Next question please OperatorYour next question is from Matt Miksic with Credit Suisse Matt Miksic    Credit Suisse    AnalystHi  thanks for taking the question  So  I just had one follow up on one of your business lines in Med Devices  In orthopedics clearly  it looks like you were able to deliver a pretty solid improvement in knees in the U S  and just was wondering if you d be willing to offer any color on the spine growth within the sort spine and other category  I think which parts of that were    what are the drivers of the decline  And then I had one follow up if I could for Alex on digital health Alex Gorsky    Chairman  Board of Directors and Chief Executive OfficerSo  thanks for the question  Matt  Good to speak with you  So  we are very proud of the Knees performance  If you look  that was declining business in 2018  We ve had almost a two point improvement there  So the team has done a very nice job We have ATTUNE  both the primary as well as the Revision platform available for patients  We ve also made an entry into the Cementless side of the business  which as you know  is the fastest growing piece of that business  And  as Alex mentioned  we look forward to what VELYS could do on the horizon With respect to spine  I think you have to take into account the impact of 2018 U S  rebate adjustment which impacted comparative growth  about 250 basis points  If you look at the growth in the U S   it was probably about half of the decline of what you saw based on that comparison  We continue to see pretty good growth outside the U S   specifically in Asia Pacific  I don t know Chris  if there is any other commentary in spine other   Christopher DelOrefice    Vice President of Investor RelationsYeah  Matt  I would just say  if you adjust for that  I would say the business has stabilized at low single digit declines  Where we re seeing success is where we have new innovation in particular in degenerative spine with our 3D Cage and our VIPER PRIME systems  I think the next level of improvements will come from SYMPHONY System in posterior cervical which was launched later this year  So we really didn t get that benefit in this year at all and we ll expect to see that continued improvement through next year and beyond Matt Miksic    Credit Suisse    AnalystThat s great  And then just a follow up  Appreciate the update and overview on the robotic surgery strategy  Alex  But I guess one of the things that we ve noticed is just how quickly    and I realize it s sort of a buzzwordy term and we see it in a lot of magazines  but artificial intelligence in digital health  for whatever reason implementation and you know innovation  but it seems to be moving perhaps the fastest of the categories of digital surgery and digital health Just wondering    one of your competitors has partnered with a smaller innovator in that space around stroke  I m sure you re watching it  I m sure you re making investments and looking at it  Just curious if you could give us an update or a preview  perhaps of which you ll talk about in the spring Alex Gorsky    Chairman  Board of Directors and Chief Executive OfficerSure  Thanks again for the question  Matt  Look I    there are a few areas across our different innovation or technology platforms that are not being touched by some of this new technology  whether it s AI whether it s ML  whether it s digital  whether it s the cloud  I mean if you think about just our Pharmaceutical portfolio  for example  and you talk to Paul Stoffels or Mathai Mammen or Bill Hait  I think what they would tell you is one of the most important areas supporting that is our data sciences capabilities and the insights that we can gain from reviewing these large datasets and coming and developing much better insights frankly is helping    lead us to a much faster and more productive identification of new targets And it certainly is helping us when we apply those same skills and capabilities of the clinical development programs as you work with hospitals and large medical systems and you can review medical health records  for example  in a much more detailed way in terms of patient selection and tracking through development  So we re certainly excited about there As it relates to Medical Devices  we ve been  I think  very consistent in sharing our thinking that again this next generation is certainly about the robotics component that helps facilitate perhaps having more consistency in an exact procedure  perhaps getting into a tighter space  having better access  But we think longer term  the digital AI component of that in terms of helping preoperatively in developing a very detailed plan even being applied intraoperatively in terms of additional guidance systems And by the way  then that can be    not only to help a surgeon get to a particular area but it could also be to help him or her stay away from areas that may and could cause a problem  And so    and then of course  how that information can be utilized by large healthcare systems to really ensure that they ve got the most effective and efficient and value added healthcare delivery program is in place  we think will be more important than ever So hence our reason for partnering with Verb and Verily and Alphabet in building those capabilities and again it s something that more broadly across Johnson   Johnson we re spending a lot of time thinking about how all those capabilities are going to become more and more a part of our    of our doing business of our doing research and development across each one of our sectors Christopher DelOrefice    Vice President of Investor RelationsThanks  Matt  Appreciate the questions Matt Miksic    Credit Suisse    AnalystThank you Christopher DelOrefice    Vice President of Investor RelationsRob  Next question please OperatorYour next question is from Danielle Antalffy with SVB Leerink Danielle Antalffy    SVB Leerink    AnalystHey  good morning guys  Thanks so much for taking the question  Just wanted to talk a little bit more about Medical Devices  specifically you guys saw a pretty strong sales growth acceleration on an operational adjusted basis this year  How do we think about the next year  I know Ashley has said in the past  it s not linear quarterly  But I suspect we should be looking for another uptick  Can you help talk about that and what specifically will be the drivers in 2020 of that Alex Gorsky    Chairman  Board of Directors and Chief Executive OfficerSure Danielle  thank you very much for the question  Look we re  again  we re really proud of the progress that Ashley and her team has made over the last several years  Joe took you through the improvement from 2017 to  18 to 2019 and we certainly expect that trajectory to continue in the coming years  If I just kind of zero down for a moment though on 2019  we saw first half growth of about 3 8  and we saw growth in the second half at 4   And while there is a bit of lumpiness in the quarters  consistent with Ashley s comments and look we re still taking a look at Q4  We think that the timing of the holidays and a few other things  I think you always have to be careful what you attribute But if you just look at the number of days  between some of those we think that that could potentially have had an impact  but it really doesn t change the overall trend of accelerated growth in second half versus first half  Now if we look at our business  it s really being driven by a number of factors  In our surgery business  what you re seeing is strong performance in areas like electrophysiology  another 14  growth in this quarter with great new technology  We expect a continuous launch in the coming year as well with new products You also saw good performance in our Energy business  so just about 3  growth and biosurgery coming in at about 4  growth  We think one of the growth drivers  frankly is just overcoming our supply issue in 2020 that probably cut our biosurgery growth rate and half  especially in the latter part of the year  So we think once we work our way through that that s going to be a growth driver for us Our circular stapler launch is also going well  We re going to lap the recall as well that we had in the past year  So we think those are definitely drivers in our core surgery business  If we look at orthopaedics  here too we ve seen the steady cadence of improvement  Our knee business ATTUNE  the launch of the Cementless  the Revision is going very well  And you think about it  we ve turn that from being down almost 0 5  to 1  to growing at 1 4  in this quarter  which again shows physicians increasing confidence in that platform and we re starting to see an uptick again in ATTUNE primaries  And so we re really pleased to see that And then  of course our Hip performance coming in at over 4   Strong trauma at about 2 5   We think is pretty consistent with the market  Chris addressed some of the issues in spine and how we see that moving forward  And then of course there s Vision Care and I think what we see in Vision Care is fundamentally strong performance in contact lens  You saw about 3  growth overall in our contact lens business  But what s important to note there is we had 9  growth in the United States So the transition lens  the astig lens  daily disposables continue to go well  Frankly  we ve been disappointed in some of our surgical performance  particularly in the U S  We ve got plans in place to address that  If you look at the ongoing rollout that we re going to have with the TECNIS and the Symphony and the synergy  we re very optimistic that it s going to make us more competitive  not only in the astig area  but really across that entire platform So we re confident that that s going to lead to continued growth trends as we go through 2020 and certainly setting ourselves up for even continued growth beyond that as well Danielle Antalffy    SVB Leerink    AnalystThank you so much Christopher DelOrefice    Vice President of Investor RelationsThanks Danielle  Appreciate it  Rob  next question please OperatorThe next question is from Terence Flynn with Goldman Sachs Terence Flynn    Goldman Sachs    AnalystHi  good morning  Thanks for taking the questions  Maybe just two from me  You guys presented additional data at ASH from your BCMA CAR T program in myeloma and recently got breakthrough designation  are planning to file for approval later this year  I would love your initial thoughts on overcoming some of the hurdles faced by other CAR T drugs  And longer term where you see this drug playing a role in the treatment paradigm The second question relates to the FDA announcement of a meeting next month on testing methods for asbestos and talc  I was just wondering if the company is participating and then what you think the key issues are that are going to be discussed there  Thank you Alex Gorsky    Chairman  Board of Directors and Chief Executive OfficerSure Terence  thank you very much  Let me take the first one regarding the CAR T data at ASH  As I m sure you saw when we released the data we were very excited when we saw those results  And again here too  I think it s maybe important to just step back and think about the steps that our team has taken over the last several years regarding CAR T therapy And when you look at the different development programs that are out there  how we were able to support or source this from Legend  The way that we were able to accelerate the development timelines  the ongoing great work that our supply chain is doing as well to ensure that we ve got the strong integrity of that supply chain  the dependability that s put in place  We re really proud of the progress they made I think the results that we shared at ASH demonstrate our increasing confidence  And by the way  we think this is great news for patients  particularly those who have failed multiple other treatment lines in a very difficult to treat condition like multiple myeloma  And as we think about it going forward  look we think that this is truly an opportunity to transform the way patients are treated in this space  We ve got a lot of confidence in our reimbursement teams  I think we demonstrated in other areas that we can work with payers in a very collaborative way We re also innovative  not only in the products that we re bringing  but frankly in the reimbursement programs that we introduced as well  And we intend to work just that way with payers and providers  both in the United States  but also abroad ultimately to make sure that this therapy is available for patients  they can get access to it and that it s not only as effective as the data that you    that we saw at ASH  but it s also cost effective to the overall healthcare system  Joe  did you want to   Joseph J  Wolk    Executive Vice President  Chief Financial OfficerSure  And Terence  with respect to the meeting  I believe it s next month  February 4th  regarding testing methods around talc  We certainly welcome any discussion around the safety and efficacy of the product  specifically  We will not be active participants at that meeting  However  I can say that our current internal testing methods exceed that of current FDA standards for cosmetic talc Terence Flynn    Goldman Sachs    AnalystGreatChristopher DelOrefice    Vice President of Investor RelationsThank you  Terence  Appreciate the questions  Rob  we have time for one last question OperatorYes  that last question will be coming from Louise Chen with Cantor Fitzgerald Louise Chen    Cantor Fitzgerald    AnalystHi  thanks for taking my questions here  So my first question for you is  what your view on M A is this year and what areas you re most interested in  Is it Pharma  Consumer or Devices or all the above  And then my second question is  how optimistic are you regarding a universal settlement for opioids  Thank you Joseph J  Wolk    Executive Vice President  Chief Financial OfficerOkay  Let me take the first part of that  Louise  Thank a lot for the question  Look  I think we demonstrated in 2019  as I mentioned earlier  that we remained active really across all three areas  I think we did 11 acquisitions  six licensing agreements and putting more than  7 billion worth of capital to work  We have continued  I think  our pattern of tuck in acquisitions where we get new technologies as you saw that we did with both XBiotech and other opportunities in our Pharmaceutical business We would expect to continue that  We also did a    had a fair amount of activity in our Medical Device Group led by Auris that we did earlier in the year  And then  in our consumer group of course that was led by DR  CI LABO which also gave us a great toehold  you might say  into the premium beauty segment  particularly in Asia  but with plans to expand that into the United States So we ll be looking across all three of our segments  But we would expect there to be an ongoing cadence of M A activity in those different areas Alex Gorsky    Chairman  Board of Directors and Chief Executive OfficerAnd Louise  with respect to the opioid settlement  So we continue to work with the Negotiating Committee of the State Attorney General s to finalize the agreement in principle  I would say  we remain optimistic and confident that the agreement is moving forward  but certainly can t predict when that agreement in principle will be finalized  So we ll continue to monitor that  engage as needed and hopefully come to a resolution Christopher DelOrefice    Vice President of Investor RelationsThanks Louise  appreciate it  And thanks to everyone for your questions and continued interest in our Company  Apologies to those we couldn t get to because of time but don t hesitate to reach out to the Investor Relations team as needed I ll now turn the call back to Alex just for some closing comments Alex Gorsky    Chairman  Board of Directors and Chief Executive OfficerWell  thank you everybody for your ongoing support across 2019  As we mentioned earlier  we re very proud of our strong performance  but we re even more excited and more confident about what the prospects hold for 2020 and beyond I think we had a chance to review a lot of the opportunities that lie in front of us and we look forward to continuing to keep you updated throughout the year as we progress through our plan  So thank you very much everybody and have a great day Operator Operator Closing Remarks Duration  89 minutesCall participants Christopher DelOrefice    Vice President of Investor RelationsAlex Gorsky    Chairman  Board of Directors and Chief Executive OfficerJoseph J  Wolk    Executive Vice President  Chief Financial OfficerChris Schott    JPMorgan    AnalystLarry Biegelsen    Wells Fargo    AnalystDavid Lewis    Morgan Stanley    AnalystKristen Stewart    Barclays    AnalystJosh Jennings    Cowen   Company    AnalystMatt Miksic    Credit Suisse    AnalystDanielle Antalffy    SVB Leerink    AnalystTerence Flynn    Goldman Sachs    AnalystLouise Chen    Cantor Fitzgerald    Analyst
More JNJ analysis
All earnings call transcripts",2020-01-22,The Motley Fool,https://invst.ly/pljr4,2065440
197572,419088,JNJ,Better Buy  AbbVie vs  Johnson   Johnson,news,"AbbVie  NYSE ABBV  and Johnson   Johnson  NYSE JNJ  are two of the largest pharmaceutical companies in the world  However  big doesn t mean buy  and both of these juggernauts currently face headwinds that may scare many investors away  AbbVie is dealing with Humira s declining international sales caused by competition from biosimilars in Europe 
Johnson   Johnson is facing thousands of different product liability lawsuits  New Mexico just filed a lawsuit against Johnson   Johnson alleging that the company s claims about the safety of its baby powder were misleading  In October  Johnson   Johnson settled a lawsuit for  10 million with two Ohio counties that removed the company from the first federal lawsuit against opioid manufacturers  In addition to mounting legal troubles  Johnson   Johnson s competitive advantage is under pressure 
With that said  these pharma giants are hardly dead in the water  and there are several good reasons to consider purchasing shares of each  But which of the two should you buy today  Let s dig in a little deeper and find out  
The case for AbbVie
Despite Humira s declining prospects in Europe  the drug is still racking up strong    and growing    sales in the U S  During the third quarter  U S  sales of Humira were  3 9 billion  a 9 6  increase year over year  In other words  Humira is still contributing significantly to AbbVie s top line  and according to the research firm EvaluatePharma  Humira will remain the top selling drug in the world until 2024  In the meantime  AbbVie can look for other products to replace its crown jewel 

The company boasts several drugs with fast growing sales  Most notably  cancer drugs Imbruvica and Venclexta have combined sales for the third quarter of  1 5 billion  a 38  increase compared to the prior year quarter  Further  Humira made a big move last year when it acquired Allergan  NYSE AGN  in a cash and stock deal valued at  63 billion 
This acquisition will help AbbVie become a leader in the medical aesthetic market and further diversify its product line  Finally  AbbVie is a great dividend stock  The company offers a dividend yield of 5 3   and its quarterly dividend payout has increased by 141  over the past five years  For all those reasons  AbbVie still looks like an attractive stock 
The case for Johnson   Johnson
One of the most attractive features Johnson   Johnson offers investors is its diversification across several business lines within the healthcare sector  There s the company s pharmaceutical business  which boasts several products with blistering sales growth  For instance  Johnson   Johnson s plaque psoriasis drug Stelara recorded sales of  1 7 billion during the third quarter  30  higher than the same quarter the prior year  Also  sales of Tremfya  a treatment for moderate to severe psoriasis  were  290 million  representing a 69  year over year increase  
While sales of many of the company s drugs are declining    such as Remicade  which saw its sales for the third quarter decline by 17 6  year over year to  1 1 billion    Johnson   Johnson has enough products to pick up the slack  Revenue from Johnson   Johnson s pharmaceuticals segment during the third quarter was  10 9 billion  a 5 1  year over year increase  Johnson   Johnson s pharmaceutical segment generates the bulk of its revenue  about 52  during the third quarter   but the company also has its consumer and medical devices segments to fall back on 
During the third quarter  revenue from Johnson   Johnson s consumer business  which offers over the counter medical products  was  3 5 billion and increased by 1 6   while its medical devices segment recorded a revenue figure of  6 4 billion  a 3 1  year over year decrease 
Johnson   Johnson is also a dream come true for income seeking investors  The company offers a 2 6  dividend yield and has raised its dividends every year for 57 years in a row  Johnson   Johnson will likely remain a top player in the healthcare sector for many years to come  Given its diversified business and its secure dividends  the company is worth serious consideration  
Profitability and valuation 
During the third quarter  AbbVie posted net earnings of  1 9 billion  a 31 4  decrease year over year  the company also recorded an earnings per share  EPS  of  1 26  down from  1 81 compared to the year ago period  By comparison  Johnson   Johnson s net earnings were  1 8 billion  a 55 4  decrease compared to the prior year quarter  and its EPS was  0 66  down by 54  year over year  
With both companies posting less than stellar bottom lines  let s turn to their respective price to earnings  PE  and price to earnings growth  PEG  ratios  In this department  AbbVie s 9 27 forward P E  and its 2 72 PEG compares favorably to Johnson   Johnson s 16 41 forward P E and 2 91 PEG  
The verdict 
Johnson   Johnson s shares rose by 13  last year  which isn t outstanding considering the S P 500 gained almost 30  during 2019  but it is still better than AbbVie s stock  which slid by 3 96   
I think Johnson   Johnson is a better buy today  and here s why  Johnson   Johnson isn t likely to produce double digits top line growth routinely  but the company s diversified business is a major strength that can help keep the company afloat even in times of economic downturns  Also  Johnson   Johnson s dividend is one of the most secure out there 
While the company is facing some legal issues  this is nothing new for Johnson   Johson which has faced scores of lawsuits before  and the company has always managed to come out of them in one piece  In other words  Johnson   Johnson s current wave of lawsuits is unlikely to make a serious dent in the company s long term thesis  if past history is any indication  
By contrast  AbbVie s acquisition of Allergan has yet to close  and there s still some uncertainty as to how this move will affect the company s financial performance in the future  With its top selling product gradually losing more and more steam over the next few years  AbbVie has yet to show that other products will fill Humira s shoes definitively  With its future still being a bit murky  I think AbbVie loses this matchup ",2020-01-24,The Motley Fool,https://invst.ly/pmfom,2067209
197585,419101,JNJ,Day Ahead  Top 3 Things to Watch for Jan  22,news,"By Kim Khan 
Investing com   Here are three things that could rock markets tomorrow 
1  J J Weighs in With Results
Dow component Johnson   Johnson  NYSE JNJ  will report earnings ahead of trading tomorrow 
On average  analysts are predicting quarterly earnings of  1 87 per share on revenue of about  20 8 billion  according to forecasts compiled by Investing com 
But with all the litigation the pharma company is facing  even a robust quarter is unlikely to produce a sustainable rally in J J  NYSE JNJ  stock  which has substantially trailed the broader market this year   Investing com analyst Haris Anwar said 
  Barclays    LON BARC  upgraded J J stock last month to overweight from equal weight with an increased price target of  173 per share 
The analyst noted that fundamentals are positive and that the consensus outlook was achievable 
2  Existing Home Sales Seen Rising
Housing data headlines the economic calendar tomorrow with the latest figures on prices and existing home sales 
The National Association of Realtors reports on December sales of existing homes at 10 00 AM ET  15 00 GMT  
Sales are expected to come in at an annual rate of 5 43 million for last month  up from 5 35 million in November  according to economists  forecasts compiled by Investing com 
Before that  at 9 00 AM ET  the Office of Federal Housing Enterprise Oversight reports on November house prices 
Its house price index is forecast to have risen 0 2  for the month 
3  Market Will Continue Watching Health Scare
Along with the numbers  investors would do well to keep an eye out for any news on the Wuhan coronavirus 
Wall Street looked to be shaking off concerns in early trading  despite weakness in sectors like airlines and gaming  But the report of the first confirmed case of the disease in the U S  sent shares into the red right away  resulting in a down day for the major indexes 
A man who traveled back from Wuhan  a city of 11 million people  to Washington state was confirmed to have the infection Monday afternoon after being hospitalized last week 
The disease is believed to be spread from person to person and could hurt both U S  and Chinese economies 
But the S P 500 Consumer Discretionary sector  the companies most likely struggle if an outbreak were to happen  ended the day down just 0 17  
Also outside of the earnings and economic calendars  there will be another day of headlines from the World Economic Forum in Davos  Trade is likely in focus again  although neither President Donald Trump s speech nor his meeting with European Commission President Ursula von der Leyen generated much market movement ",2020-01-21,Investing.com,https://www.investing.com/news/stock-market-news/day-ahead-top-3-things-to-watch-for-jan-22-2064393,2064393
197586,419102,JNJ,J J Raises Underlying Guidance After Strong Q4  but Legal Risks Linger,news,"Investing com   Johnson   Johnson  NYSE JNJ  raised its guidance for underlying earnings and revenue after a strong fourth quarter on Wednesday but was unable to stop reported earnings slumping due to costs related to opioid  and talc related lawsuits 
The company announced fourth quarter adjusted earnings of  1 88 a share for the quarter  1c ahead of forecasts  but reported earnings tumbled by 54  to only 66c  Revenue also fell short of forecasts slightly at  20 75 billion 

EPS were down from  1 97 a year ago  while revenue edged up from  20 39 billion  
The company now expects underlying earnings of a range between  8 62 and  8 67 for 2019  up from a range of  8 53  8 63 previously  Chief executive Alex Gorsky pointed to  underlying growth in Pharmaceuticals and Medical Devices  as well as continued optimization in our Consumer business  as the reasons 
However  J J warned that it can t give forecasts for GAAP line items such as net profit because it is  unable to predict with reasonable certainty the ultimate outcome of legal proceedings  unusual gains and losses  acquisition related expenses and purchase accounting fair value adjustments without unreasonable effort  

The outlook still threatens to be a drag on its performance in 2020  according to Investing com analyst Haris Anwar 
 It s tough for investors to focus on J J s fundamentals when the company is facing thousands of lawsuits in the U S  over product safety and marketing practices for a range of products including baby powder and opioids   Anwar said   In addition to these legal issues  there is a good amount of political uncertainty related to the U S  presidential election that makes healthcare stocks a risky trade in 2020  

J J  NYSE JNJ  stock hit a new record high on Tuesday and finished up 2 3  for the year to date 
J J follows other major Healthcare sector earnings this monthOn October 31  2019  Novocure Ltd reported third quarter EPS of  0 02 on revenue of  92 06M  was in comparison with a forecasts for EPS of   0 04 on revenue of  86 94M 
ABIOMED earnings beat analysts  expectations on January 13  with third quarter EPS of  1 09 on revenue of  221 6M  Investing com analysts forecast EPS of  1 07 on revenue of  226 67M
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2020-01-22,Investing.com,https://www.investing.com/news/stock-market-news/jj-raises-underlying-guidance-after-strong-q4-but-legal-risks-linger-2064709,2064709
197587,419103,JNJ,JNJ EPS up 34  in Q4,news,"Johnson   Johnson  JNJ  Q4 results  Revenues   20 747M   1 7    Consumer   3 567M   0 9    Pharmaceutical   10 548M   3 5    Medical Devices   6 632M   0 5   
Net Income   4 010M   31 8    EPS   1 50   33 9    non GAAP Net Income   5 027M   6 4    non GAAP EPS   1 88   4 6   
Key Product Sales  Remicade   1 035M   16 4    Simponi Simponi Aria   515M   6 6    Stelara   1 700M   17 7    Tremfya   270M   53 9    Darzalex   830M   42 1    Xarelto   609M   0 4    Zytiga   677M   13 8    Imbruvica   875M   24 5    Velcade   115M   54 6    Invega Sustennn Xeplion Trinza Trevicta   871M   14 2    Edurant rilpivirine   222M   15 2    Prezista Prezcobix Rezolsta Symtuza   544M   9 9    Procrit Eprex   183M   17 0    Opsumit   326M   1 0    Uptravi   208M   14 8    Invokana Invokamet   177M   22 2   
2020 Guidance  Revenues   85 4B   86 2B  Non GAAP EPS   8 95   9 10 
Shares are down 1  premarket ",2020-01-22,Seeking Alpha,https://invst.ly/plb5n,2064779
197588,419104,JNJ,Why Johnson   Johnson Stock Is Not Reacting More Positively to Earnings,news,"Johnson   Johnson  NYSE  JNJ  reported fourth quarter 2019 results before markets opened Wednesday  The health care giant reported quarterly adjusted diluted earnings per share  EPS  of  1 88 on revenue of  20 75 billion  In the same period a year ago  it reported EPS of  1 97 on revenue of  20 39 billion  Fourth quarter results also compare to the consensus estimates for EPS of  1 87 on revenue of  20 8 billion For the full fiscal year  the company reported EPS of  8 68 on revenues of  82 06 billion  compared to 2018 EPS of  8 18 and revenues of  81 58 billion  Analysts had forecast  8 67 in EPS and revenues of  82 12 billion For fiscal year 2020  Johnson   Johnson guided revenues in a range of  85 4 billion to  86 2 billion  a year over year increase in the range of 4  to 5   EPS is forecast in a range of  8 95 to  9 10  a rise of 3 1  to 4 8  year over year  Analysts had estimated EPS of  9 10 and sales of  85 48 billion div connatix margin bottom  1 5em   div connatix img  margin  unset  Adjusted for currency fluctuations  the company s quarterly worldwide sales dipped by 0 9  year over year  with sales in its consumer segment down by 2  internationally  Pharmaceutical sales for the quarter rose by 3 9  in the United States and 2 9  internationally  Foreign currency adjustments lowered international revenues by 2 2  year over year and the entire segment slipped by 0 9  compared to the fourth quarter of 2018 Total full year revenues  adjusted for currency differences  were down 4 6  internationally and 2 2  overall  International consumer products sales dipped by 2 7   pharmaceuticals sales slipped by 5 1  and medical device sales fell by 4  CEO Alex Gorsky said We delivered strong underlying sales and earnings growth in 2019  driven by the strength of our Pharmaceutical business  accelerating performance in our Medical Devices business and improved profitability in our Consumer business  As we enter into 2020 and this next decade  our strategic investments focused on advancing our pipelines and driving innovation across our entire product portfolio  position us well to deliver long term sustainable growth and value to our shareholders Narrowly beating estimates for earnings and revenues is rarely bullish to investors  In Johnson   Johnson s case  the narrow beats turned into misses when adjusted for currency differences  The company s 2020 guidance put the consensus analyst estimate for EPS at the top end of the company s range and the revenue estimate at the bottom of the consensus range  That s weak  Or it is cagey  managing expectations for the year ahead  Either way  it s not enough for investors Shares traded down about 0 1  in Wednesday s premarket  at  149 06 in a 52 week range of  125 00 to  150 17  The high was posted Tuesday  The consensus 12 month price target on the stock is  157 20  Johnson   Johnson offers a dividend yield of 2 55   at Tuesday s closing price  


				ALSO READ  10 Top Tech Stocks for 2020 Score Major Analyst Upgrades Ahead of Earnings				


By Paul Ausick",2020-01-22,247wallst,https://invst.ly/plbnu,2064813
197589,419105,JNJ,J J forecasts weak annual profit  misses revenue estimates,news," Reuters    Johnson   Johnson  NYSE JNJ  on Wednesday forecast full year profit largely below expectations  after posting a rare miss on quarterly revenue as sales of some of its major drugs fell short of Wall Street expectations  Shares of the healthcare giant  which were trading at a record high prior to the results  fell about 1 5  to  147 in premarket trading  J J s pharmaceuticals unit  which makes up half of the overall sales and produces blockbuster drugs such as Imbruvica and Stelara  has powered much of the company s recent growth even as it works to improve the performance of its medical device and consumer health units  However  intense competition for some off patent drugs such as prostate cancer drug Zytiga  coupled with pressure on prescription drug prices in the United States  has weighed on revenue at the top earning unit  Revenue at the pharma unit  which also makes antidepressant Spravato and plaque psoriasis drug Tremfya  rose 3 5  to  10 55 billion in the fourth quarter  but missed the average estimate of  10 63 billion  according to two analysts polled by Refinitiv  Sales of psoriasis drug Stelara rose 17 7  to  1 70 billion  missing Credit Suisse s estimate of  1 79 billion  Cancer drug Imbruvica s sales rose 24 5  to  875 million  although they missed the brokerage s estimate of  907 million  Medical device sales fell to  6 63 billion from  6 67 billion  also missing the average estimate of  6 69 billion according to Refinitiv data  The company said it expects full year 2020 adjusted earnings per share in the range  8 95 to  9 10  with the top end of the range meeting analysts  average estimate  Litigation expenses fell to  264 million in the fourth quarter  from  1 29 billion a year ago  J J s net earnings rose to  4 01 billion  or  1 50 per share  in the quarter  from  3 04 billion  or  1 12 per share  a year earlier  Excluding items  it earned  1 88 per share  beating the average analyst estimate by a cent  according to IBES data from Refinitiv  
Total sales rose 1 7  to  20 75 billion  below the average estimate of  20 80 billion  That was the company s first revenue miss in at least eight quarters ",2020-01-22,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-quarterly-profit-jumps-32-2064711,2064711
197600,419116,JNJ,Johnson   Johnson Seeks Expanded Use in Europe for Depression Nasal Spray,news,"Johnson   Johnson s  NYSE JNJ  subsidiary Janssen announced that it s seeking to expand the use of its depression nasal spray  Spravato  as a short term treatment to be used alongside conventional oral antidepressants 
Spravato  which was already approved last month in Europe as a depression treatment  targets patients with treatment resistance depression who have failed to see improvements in their symptoms through other methods  It can also treat patients who have major depressive disorder and who are experiencing suicidal ideation with intent    the demographic for which it is seeking approval for in Europe 

Janssen s submission is backed by two phase 3 clinical studies   Aspire I and Aspire II   which both showed impressive results in reducing depression symptoms while handily outperforming a placebo nasal spray  One trial found that around 70  of patients responded well to Spravato  with a 50  reduction in symptom severity  In addition to being a fast acting treatment  with depression symptoms subsiding as quickly as four hours after the first dose  Spravato is well tolerated by patients as well  The most common side effects were dizziness  headaches  and nausea 
Further details about Spravato
Spravato   also known as esketamine   is a modified form of ketamine  While used illegally as a hallucinogen  ketamine can be used to induce anesthesia in patients  Johnson   Johnson has high expectations for the nasal spray  which carries a price tag of  6 785 for the first month of a patient s dosing schedule 
The pharmaceutical drug first received approval from the U S  Food and Drug Administration in March 2019  and Janssen is now awaiting a response for a supplemental New Drug Application filed for Spravato in October ",2020-01-15,The Motley Fool,https://invst.ly/pihsx,2060403
197601,419117,JNJ,Johnson   Johnson Gets Punitive Damages in Risperdal Case Reduced to  6 8 Million,news,"Healthcare giant Johnson   Johnson  NYSE JNJ  got good news on Friday when a Philadelphia judge drastically reduced the  8 billion punitive damage verdict the company was initially ordered to pay in October down to just  6 8 million 
The original fine was awarded by a jury to a plaintiff who experienced unwanted side effects from the company s Risperdal medication  which is used to treat people with schizophrenia  bipolar disorder  and it also helps people with autism  The plaintiff in the case  Nicholas Murray  began taking the medication as a child to treat behaviors related to autism  but the drug caused the young man to grow breasts    a condition called gynecomastia 
The punitive damages were in addition to a  680 000 compensatory award the plaintiff would receive  Johnson   Johnson challenged the ruling  and today it learned of the reduction to the punitive fees 

Just one of many problems for J J
Friday s ruling offers some much needed positivity for Johnson   Johnson  as it has been under pressure for the past few years from product liability litigation  
Some consumers alleged the company s baby powder products led them to develop ovarian cancer  There have also been problems relating to vaginal mesh products in Australia  where the company lost a case last year  Oklahoma came after J J for its role in the opioid crisis and a judge ruled the company would be fined  572 million  which was reduced to  465 million in November 
Amid all these controversies  Johnson   Johnson s stock rose a modest 13  in 2019  well below what was a fantastic year for the markets that saw the S P 500 climb 30   Despite Friday s positive result  the healthcare stock was up less than 1  ",2020-01-17,The Motley Fool,https://invst.ly/pjgcn,2062355
197602,419118,JNJ,Judge slashes  8 billion Risperdal award against Johnson   Johnson to  6 8 million,news,"By Jonathan Stempel  Reuters    A Pennsylvania judge on Friday slashed to  6 8 million from  8 billion a punitive damages award against Johnson   Johnson  NYSE JNJ  to a man who said it failed to warn that boys using its antipsychotic drug Risperdal could grow breasts  Judge Kenneth Powell of the Philadelphia Court of Common Pleas reduced the payout that a jury awarded Oct  8 to the plaintiff Nicholas Murray  a Maryland resident  No reason was given for the reduction  which was disclosed in court records  Lawyers for Murray have said the punitive damages award was the first in thousands of lawsuits against Johnson   Johnson s Janssen Pharmaceuticals unit over Risperdal  Murray claimed he had been prescribed the drug in 2003  when he was 9  to treat symptoms related to autism  He had previously been awarded  680 000 in compensatory damages  Both sides pledged to appeal   The ruling is wrong  and  provides essentially no punishment for the worst of the worst of corporate misconduct   Murray s lawyer Thomas Kline said in an email   We believe that when the merits are reviewed that the  8 billion will be reinstated   Johnson   Johnson said that while Powell  appropriately reduced the excessive punitive damages award   he wrongly excluded evidence that Risperdal s label  clearly and appropriately  outlined the risks of use  The U S  Food and Drug Administration approved Risperdal in 1993 to treat schizophrenia and bipolar mania in adults  and in 2006 for irritability associated with autism in children  Plaintiffs suing over the drug have said Johnson   Johnson concealed the link between Risperdal and excessive growth of female breast tissue in boys  known as gynecomastia  While doctors may prescribe many drugs as they see fit  including for off label uses  Murray said Johnson   Johnson should have warned his doctors about Risperdal s side effects  Johnson   Johnson said in October it faced lawsuits by 13 600 people over Risperdal  The New Brunswick  New Jersey based company agreed separately in 2013 to pay  2 2 billion to settle U S  criminal and civil probes into its marketing of Risperdal and two other drugs  
In late afternoon trading  Johnson   Johnson shares were up 74 cents at  148 94 ",2020-01-17,Reuters,https://www.investing.com/news/stock-market-news/judge-slashes-8-billion-risperdal-award-against-johnson--johnson-to-68-million-2062365,2062365
197603,419119,JNJ,First FANG stock report  home sales  J J earnings  3 things to watch for on Wednesday,news,Here are the most important things to know about Wednesday before you hit the door ,2020-01-21,CNBC,https://invst.ly/pkzzd,2064263
197614,419130,JNJ,Is Johnson   Johnson Stock a Buy ,news,"Johnson   Johnson  NYSE JNJ  didn t have a great year in 2019  Sure  the stock was up 13   However  that wasn t even half the gain that the S P 500 index delivered last year  J J was bogged down by opioid related litigation  more worries that its talc based products contain asbestos  and anemic growth 
But it s not a good idea to base an opinion about any stock on one problematic year  especially the stock of a company that s been in business for more than 130 years  Is Johnson   Johnson stock a buy now  The answer  It depends 

So so growth
Investors who prefer strong growth probably won t be attracted to Johnson   Johnson  Wall Street analysts project the company s earnings will grow by an average of less than 6  annually over the next five years  Growth oriented investors can certainly find quality stocks that deliver much higher growth than that 
One problem for J J is the continued decline in sales for Remicade  It wasn t too long ago that the immunology drug ranked as the company s top selling product  With biosimilar rivals on the market  though  J J can t depend on its former star  But Remicade isn t the only problem spot  Sales for cancer drug Zytiga are also sinking  Several other drugs in J J s lineup aren t performing very well  including diabetes drug Invokana 
On a positive note  the company still claims multiple big winners  Sales growth for immunology drugs Stelara  Simponi  and Tremfya are offsetting the tanking sales for Remicade  J J s cancer drugs Imbruvica  which it comarkets with AbbVie  and Darzalex continue to enjoy strong momentum  The company also has another potential blockbuster of the future that s just getting started with depression drug Spravato 
Johnson   Johnson s pharmaceutical segment remains its biggest source of growth  but what about its other segments  The company s consumer unit is at best treading water  However  net of the negative impact of divestitures  J J s medical device segment is delivering modest revenue growth  Still  the overall story for the company is likely to be only so so growth over the next several years 
A reasonable valuation
Bargain hunters probably won t jump up and down over Johnson   Johnson s valuation  but some might think that the stock is priced at a relatively attractive level  Shares currently trade at 16 times expected earnings  That s well below J J s historical price to earnings  P E  level 
On the other hand  Johnson   Johnson s valuation doesn t look as attractive when compared to some of its peers  Merck  for example  has considerably better growth prospects than J J does but its forward earnings multiple is only a little higher 
My view is that Johnson   Johnson claims a reasonable valuation at current levels  But without the promise of great growth  a reasonable valuation might not be enough to justify the stock as a buy 
The main reason to buy J J
However  there is one reason that I think does make Johnson   Johnson stock a buy  its dividend  Growth investors and value investors might turn up their noses at the stock  but income seeking investors should really like J J 
Investors buy dividend stocks because they want steady and reliable dividend payouts  Johnson   Johnson s dividend currently yields 2 6   but what s even more appealing is the company s track record  J J has increased its dividend for 57 consecutive years 
If you re looking for income  that s the kind of history you like to see  It also helps that J J is well diversified across the healthcare space and operates more than 260 different businesses  This gives the company a broad revenue base that allows it to keep those dividends flowing    and growing ",2020-01-05,The Motley Fool,https://invst.ly/pdt94,2052532
197615,419131,JNJ,Why Johnson   Johnson Will Survive its Latest Litigation Wave,news,"Johnson   Johnson  NYSE JNJ  has long been plagued with lawsuits alleging its talcum products contain the cancer causing substance asbestos  Unluckily for Johnson   Johnson  these allegations are a series in a long line of legal troubles  Just in October 2019  Johnson   Johnson was directed to pay  8 billion in damages to plaintiffs for pressuring medical providers to prescribe Risperdal to patients  
At the time of this article  Johnson   Johnson is embroiled in a stream of over 16 000 asbestos related legal actions filed by enraged consumers  The stakes were raised even higher when just two days into the New Year  the state of New Mexico filed a civil claim against Johnson   Johnson for allegedly deceiving users regarding the safety of its talc products  This is one of the first times ever that an asbestos lawsuit has been filed by a state  rather than a person  against a pharmaceutical manufacturer  

Needless to stay  the steady stream of lawsuits pummeling Johnson   Johnson has some investors concerned  But  Johnson and Johnson has seen considerably positive returns over the past year  Here s why Johnson   Johnson will likely be able to weather this storm in the months ahead  
Johnson   Johnson showed healthy earnings growth in the third quarter
In Johnson   Johnson s Q3 report  released in October 2019  the company showed a strong year to year revenue boost of 1 9  with sales totaling more than  20 billion  Factoring out certain currency irregularities  the company experienced an operational growth rate of 3 2 percent on a year over year basis  Earnings per share also exceeded analyst s projections in Q3  with an adjusted value of  2 12  
A company s cash flow is also an excellent measurement of the valuation and risk attached to a particular stock  At the close of the Q3  Johnson   Johnson had produced a year to date free cash flow of just under  20 billion  Both Johnson   Johnson s earnings report and cash flow are indicative of the company s strong overall financial health  
Johnson   Johnson will release its Q4 earnings on January 22  at which point stockholders should take a close look to assess whether its operations continue to forecast positive performance and guidance in the new year  
Johnson   Johnson s global footprint continues to expand 
Despite the fact that the lion s share of Johnson   Johnson s sales is U S  based  the company continues to expand its worldwide footprint  Its Q3 report announced that consumer product earnings increased by 3 3  year over year  with worldwide revenue growth of 3 2  
The company s pharmaceutical sector grew by a monumental 6 4   with one of the most notable contenders being the plaque psoriasis drug Tremfya  In the final week of December  China put its stamp of approval on imports of Tremfya into the country  which will almost certainly lead to a healthy spike in Johnson   Johnson s gross sales and net income  
It s tough to beat Johnson   Johnson s dividend payout
One of the primary reasons Johnson   Johnson stock has been so attractive to investors in the past is its excellent dividends  The current 2 65  dividend rate is certainly less than other stocks on the market  but Johnson   Johnson s consistent pattern of increasing its dividend payout year to year is more than a little attractive to long term investors  
For example  if you were to invest  20 000 in Johnson   Johnson stock today  you d receive  530 annually in dividends  Assuming Johnson   Johnson continues its long standing pattern of annually increasing its dividends  that figure would only grow  
Even amid growing consumer claims  Johnson   Johnson has paid out  9 8 billion of its nearly  20 billion in free cash flow over the past year  All things considered  it appears that litigation likely won t impact investor dividends anytime soon 
The bottom line
Despite the fact that Johnson   Johnson has been slapped with over 100 000 lawsuits in recent years  its overall growth has been steady  albeit slow  A huge factor in Johnson   Johnson s resilience despite an eroding moat has been its clear diversification strategy  With its hands in everything from medical devices to pharmaceutical products  Johnson   Johnson has weathered many a legal storm in its time and come through relatively unscathed 
I m not saying investors should disregard the potential impact that future lawsuits could have on the company s top and bottom line    but for now  alarmism seems premature ",2020-01-14,The Motley Fool,https://invst.ly/pi30n,2059598
197616,419132,JNJ,Better Buy  Johnson   Johnson vs  Merck,news,"Johnson   Johnson  NYSE JNJ  and Merck   Co   NYSE MRK  are two heavyweights in the pharmaceutical sector  Both companies generate billions in sales and profits and have developed many successful drugs over the years 
However  both underperformed in 2019  Merck s 19  return last year was well above the 13  that Johnson   Johnson produced for its investors  but shares of both companies still fell well shy of the 30  return enjoyed by the S P 500 
Deciding which stock is the better buy today is no easy task  Both offer investors some great opportunities in healthcare  and there s not a whole lot separating the two  Let s take a closer look at the two stocks to see which one has the edge today 
Is J J worth the risk 
By looking at its financials  J J looks to be a solid stock  Sales of  20 billion in each of the last four quarters  accompanied with profits of at least  3 billion during that time  make the stock appear to be a very good buy  The company has even achieved modest growth in its most recent quarter  with sales climbing by 1 9    
Its global reach and wide range of products and services that cover consumer  pharmaceutical  and medical devices  make the stock an appealing option for long term investors as it offers a lot of diversification 

The problem with investing in J J is the danger the stock faces from a legal perspective 
It s already faced multiple lawsuits  with its talc powder issue being one of its more high profile concerns today  In November  the company lost a lawsuit relating to its vaginal mesh products in Australia  Oklahoma also went after J J for the company s role in opioid related deaths in the state   and it won  It sets a troubling precedent for the company  should other states follow suit 
Overall  the stock has good fundamentals today  and it s in a good position to handle these lawsuits with  18 billion in cash on its books and the company continuing to generate positive free cash flow  However  if the fines and lawsuits keep coming  it could put in a dent in not only the company s cash but its image as well 
Merck is a safer option  but it may not be diversified enough
Merck also has strong financials   without the same risks that J J is facing today 
Over the past four quarters  its numbers are a bit more modest  with profits ranging from  1 8 billion to  2 9 billion  and revenue typically hovering around  11 billion to  12 billion  However  it s also avoided the bad press that J J has endured over the years  which could make it a much safer and more predictable investment 
The company got some great news this month from the Food and Drug Administration  FDA  after it approved Keytruda for use in a specific type of bladder cancer for patients who have not had success with other treatment options 
Keytruda is already an important part of Merck s sales  as the cancer fighting drug also treats patients with other types of cancers as well 
In the company s third quarter results released in October  Keytruda s sales were up 63  from the prior year quarter  reaching  3 1 billion  The  1 2 billion increase in the drug s sales from a year ago was the main driver behind the company s overall improvement  as Merck s top line increased by just  1 6 billion during the quarter 
As valuable as Keytruda is  the danger for Merck is that it may be too dependent on this one blockbuster 
Why Merck is the better buy
There s not a lot separating these two stocks  While Merck may be smaller than J J  it s by no means worse for it 
Both stocks have good numbers and both trade at a forward price to earnings ratio of 16  Merck offers slightly better value when factoring in analyst expectations of growth  as its PEG ratio of 1 7 is lower than J J s  which comes in at 2 9  
Merck also offers a slightly higher dividend yield of 2 7   versus the 2 6  that J J pays  While J J has a stronger track record when it comes to increasing dividend payments and is a Dividend Aristocrat  that s not enough to tip the scales in its favor 
Overall  with a slight advantage in valuation and fewer risks facing the company  Merck is the better healthcare stock for investors today ",2020-01-15,The Motley Fool,https://invst.ly/piaxr,2059866
197626,419142,JNJ,Johnson   Johnson says new tests show no asbestos in Johnson s Baby Powder,news,"By Sanjana Shivdas and Carl O Donnell  Reuters    Johnson   Johnson  NYSE JNJ  said on Tuesday that recent tests showed that Johnson s Baby Powder was free of asbestos  after U S  Food and Drug Administration investigations reported trace amounts of the material in the product earlier this year  A total of 155 tests were conducted by two different third party labs using four different testing methods on samples from the same bottle tested by the FDA s contracted lab  the company said  The tests are the latest effort by J J to prove the safety of its widely used consumer product after the test by the FDA prompted J J to undertake a nationwide recall of one lot of Johnson s Baby Powder in October  The FDA was not immediately available for comment  However  in response to an October announcement from J J that a smaller number of independent tests also found no asbestos  the regulatory agency said it stood by its findings  The different test outcomes could have resulted from the fact that contaminants are not uniformly dispersed throughout talc and there is no standard test for asbestos in talc  FDA officials told Reuters in October  Tests conducted by the third party labs showed asbestos was not present in the single bottle that the FDA s contracted lab had tested  nor was it present in retained samples of the finished lot from which the bottle was produced  the company said on Tuesday  The company said its investigation concluded that the most probable root causes for the FDA s reported results were either test sample contamination or analyst error at the lab  or both  In October  J J recalled around 33 000 bottles of baby powder in the United States after the FDA said it had found trace amounts of asbestos in samples taken from a bottle purchased online  The voluntary recall was limited to one lot of Johnson s Baby Powder produced and shipped in the United States in 2018  the company said at the time  That move marked the first time the company recalled its baby powder for possible asbestos contamination  and the first time U S  regulators have announced a finding of asbestos in the product  Asbestos is a known carcinogen that has been linked to deadly mesothelioma  The recall was the latest blow to the more than 130 year old U S  healthcare conglomerate that is facing thousands of lawsuits over a variety of products  including baby powder  opioids  medical devices and the antipsychotic Risperdal  
J J faces more than 15 000 lawsuits from consumers claiming its talc products  including Johnson s Baby Powder  caused their cancer ",2019-12-03,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-confirms-no-asbestos-in-johnsons-baby-powder-2033108,2033108
197627,419143,JNJ,Pulmatrix up 49  premarket on J J deal,news,"Thinly traded nano cap Pulmatrix  NASDAQ PULM  is up 49  premarket on robust volume in reaction to its license and development deal with Johnson   Johnson s  NYSE JNJ  Lung Cancer Initiative for a lineup of narrow spectrum kinase inhibitors 
Lead candidate is RV1162 PUR1800  based on PULM s iSPERSE dry powder technology which enhances the efficacy of inhaled therapeutics 
Under the terms of the agreement  PULM will receive  7 2M upfront  a  2M milestone upon the completion of a Phase 1b study evaluating RV1162 PUR1800 in chronic obstructive pulmonary disease  COPD  patients  up to  91M in additional milestones if the Lung Cancer Initiative exercises its option to develop the kinase inhibitors and royalties on net sales ",2020-01-02,Seeking Alpha,https://invst.ly/pccsz,2051190
197628,419144,JNJ,The Phil Flynn Energy Report  February 4  2020,opinion,"No Pandemic Yet 
The World Health Organization  WHO  says that there is no pandemic when it comes to the coronavirus  There may be no pandemic in global stock markets as well  Stocks are soaring back and oil is finding support on a Bloomberg report of a phone call between Russian President Vladimir Putin and Saudi King Salman bin Abdulaziz discussing the global energy market on Mond
ay evening  The Kremlin said in a statement  both leaders confirmed   readiness to continue cooperation within OPEC    it said  The kingdom also endorsed the call according to Bloomberg raising expectations that those two co conspirators are getting ready to shock and awe the oil market 
There is a Reuters report that Russian Energy Minister Alexander Novak said on Tuesday that he could not say for sure if it were time to tighten oil output curbs amid an outbreak of a new coronavirus and slump in oil prices  Three OPEC  sources and an industry source familiar with the discussions told Reuters on Monday that OPEC  were considering cutting their oil output by a further 500 000 barrels per day  bpd  due to the impact on oil demand from the coronavirus   I can t tell you about concrete proposals    It is important now to evaluate the situation and evaluate the right forecasts  There are lots of uncertainties  maybe those are panic attacks   Novak told reporters 
Iran is also on board  Reuters is reporting that Iranian Oil Minister Bijan Zanganeh said on Monday that   the spread of China s new coronavirus had hit oil demand and called for an effort to stabilize oil prices   Iran s official news agency IRNA reported 
Reuters is reporting that   An OPEC  technical committee meeting on Tuesday to assess the impact on global oil demand and economic growth of the outbreak of the coronavirus has invited China s envoy to the United Nations in Vienna to attend  OPEC  sources told Reuters  Wang Qun will address the Joint Technical Committee  JTC   which is tasked with advising the Organization of the Petroleum Exporting Countries and its allies led by Russia  known as OPEC   on market fundamentals  The JTC is holding an extraordinary meeting at 1200 GMT in Vienna to study different scenarios for whether deeper cuts or an extension to a current output reduction deal is needed  sources said  It will continue meeting on Wednesday and take the outbreak of the SARS virus as an example to assess the potential impact of the coronavirus on demand  and OPEC  source said 
Add to that  massive Chinese stimulus and a better than expected U S  Manufacturing number is setting the stage for the post coronavirus economic bump 
The hit to demand is historically substantial  it is a far cry from the 3 million barrels a day that was predicted by one source  Reuters is reporting a more modest number and more in line with my expectations  Reuters wrote   The global economic slowdown in the wake of China s coronavirus outbreak is set to reduce global oil demand in 2020 by up to 0 5   BP s  NYSE BP  Chief Financial Officer Brian Gilvary said on Tuesday  The drop in industrial activity and flight cancellations have so far hit oil demand by around 200 000 to 300 000 barrels per day  bpd   Gilvary told Reuters  after  BP   LON BP  reported its fourth quarter results  For the whole year  the slowdown will reduce consumption by 300 000 to 500 000 bpd  roughly 0 5  of global demand  according to Gilvary  The impact in China has been more pronounced  reducing demand by around 1 million bpd  he added 
It also possible that a vaccine for the Coronavirus might be right around the corner  Bloomberg News reported that   Remdesivir  a new antiviral drug by Gilead Sciences  NASDAQ GILD  aimed at infectious diseases such Ebola and SARS  will be tested by a medical team from Beijing based China Japan Friendship Hospital for efficacy in treating the deadly new strain of coronavirus  a hospital spokeswoman told Bloomberg News Monday  
The Washington Examiner reports that roughly   10 pharmaceutical companies have coronavirus treatments or vaccine projects in the works  including Johnson   Johnson  NYSE JNJ  and Inovio Pharmaceuticals  NASDAQ INO   Still  it may take months before the drugs are approved 
It might be time to start looking at a seasonal bottom in RBOB  U S  demand should soar  We get the API today ",2020-02-04,Phil Flynn,https://www.investing.com/analysis/the-phil-flynn-energy-report-february-4-2020-200504367,200504367
197629,419145,JNJ,Merck  MRK  Beats On Q4 Earnings  Plans Women Health Spin Off ,opinion,Merck   Co   Inc    NYSE MRK   reported fourth quarter 2019 adjusted earnings of  1 16 per share  which beat the Zacks Consensus Estimate of  1 14  Earnings rose 12  year over year Including acquisition  and divestiture related costs  restructuring costs and certain other items  earnings per share were 92 cents  up 33  year over year Revenues rose 8  year over year  9  excluding currency impact  to  11 9 billion  which missed the Zacks Consensus Estimate of  12 1 billion Along with the earnings release  Merck announced that it will spin off products from its Women s Health unit  legacy drugs  including Zetia and Vytorin  and biosimilar products into a new publicly traded company Quarter in DetailThe Pharmaceutical segment generated revenues of  10 53 billion  up 7   up 8  excluding Fx impact  year over year as higher sales in oncology and hospital business were offset by lower vaccines and diabetes sales  As in the previous quarters  loss of exclusivity  LOE  for several drugs also hurt the top line In October  Merck borrowed doses of Gardasil vaccine from U S  Centers for Disease Control and Prevention s  CDC  stockpile to support routine vaccinations in the United States  and to free up some manufacturing capacity to make doses for ex U S  markets  The stockpile borrowing hurt fourth quarter sales by approximately  120 million Keytruda  the largest product in Merck s portfolio  generated sales of  3 1 billion in the quarter  up 45  year over year  Sales were driven by the launch of new indications globally  Keytruda sales are gaining particularly from continued strong momentum in first line lung cancer indication and launch in newer indications namely renal cell carcinoma and adjuvant melanoma  However  sales of Keytruda fell short of the Zacks Consensus Estimate of  3 2 billion In the fourth quarter  Keytruda gained approvals in China for two non small cell lung cancer indications and in Europe for first line head neck cancer  Last month  Keytruda was approved by the FDA to treat patients with high risk non muscle invasive bladder cancer  NMIBC   unresponsive to Bacillus Calmette Guerin  BCG    a therapy widely used in the management of bladder cancer Alliance revenues from Lynparza and Lenvima also boosted oncology sales in the quarter Lynparza alliance revenues were  132 million in the quarter compared with  123 million in the previous quarter  Lenvima alliance revenues were  124 million compared with  109 million in the previous quarter Merck has a deal with Swiss pharma giant AstraZeneca   NYSE AZN   to co develop and commercialize PARP inhibitor Lynparza and a similar one with Japan s Eisai for tyrosine kinase inhibitor  Lenvima In the hospital specialty portfolio  Bridion  sugammadex  Injection generated sales of  313 million in the quarter  up 22  year over year  driven by strong demand in the United States In vaccines  Gardasil Gardasil 9 sales declined 17  year over year to  693 million hurt by the stockpile borrowing discussed above  Gardasil Gardasil 9 sales fell significantly below the Zacks Consensus Estimate of  979 million  Excluding the impact of stockpile borrowing  Gardasil Gardasil 9 sales rose 15  in the quarter Proquad  M M R II and Varivax vaccines recorded combined sales of  481 million  up 6  year over year  Pneumovax 23 and Rotateq vaccines rose 4  to  334 million and 21  to  227 million  respectively Pharmaceutical sales were hurt by generic competition for blockbuster drug  Remicade in Merck s marketing territories in Europe and loss of U S  market exclusivity for Noxafil  Emend  Cubicin  Zetia and Vytorin  Also  a generic version of NuvaRing was launched in the United States  which hurt sales of the drug in the quarter Remicade sales declined 27  year over year to  89 million in the quarter  Please note that Merck markets Remicade in partnership with J J   NYSE JNJ   Zetia and Vytorin recorded sales of  146 million and  54 million  down 9  and 35   respectively from the year ago quarter due to LOE for both drugs Januvia Janumet  diabetes  franchise sales declined 3  year over year to  1 42 billion due to continued pricing pressure in the United States  Sales of Isentress declined 20  to  223 million Merck s Animal Health segment generated revenues of  1 12 billion  up 8   up 10  excluding Fx impact  from the year ago quarter  driven by higher sales of its livestock products  particularly products added from the acquisition of Antelliq Margin DiscussionAdjusted gross margin was 72 6   down 240 basis points from the year ago quarter due to unfavorable manufacturing variances and the negative impact of pricing pressure Selling  general and administrative  SG A  expenses were  2 8 billion in the reported quarter  up 8  year over year driven by higher administrative and promotion costs  partially offset by favorable impact of foreign exchange movement  Research and development  R D  spend rose 12  to  2 4 billion in the quarter due to ongoing clinical studies and cost related to early drug development 2019 ResultsFull year 2019 sales rose 11  to  46 84 billion  missing the Zacks Consensus Estimate of  47 0 billion  However  sales were within the guided range of  46 5 billion    47 billion Adjusted earnings of  5 19 per share beat Zacks Consensus Estimate of  5 16 and came ahead of the guided range of  5 12  5 17  Earnings rose 20  year over year Issues 2020 OutlookMerck expects revenues to be in the range of  48 8 billion    50 3 billion including a negative currency impact of less than 1   The Zacks Consensus Estimate stands at  49 8 billion Adjusted earnings are expected to be in the range of  5 62  5 77  including a negative currency impact of approximately 1 5   The Zacks Consensus Estimate is pegged at  5 54 The company expects adjusted operating expenses to increase year over year at low single digit rate Merck had stated last year that it expects revenues in 2020 to be hurt by increased pricing pressure  moderated growth rates for Gardasil and potential generic erosion of Noxafil and NuvaRing Details of Spin OffMerck expects the spin off to help it achieve more than  1 5 billion in operating efficiencies by 2024 by reducing its manufacturing footprint for pharmaceutical drugs by 25   Accordingly  Merck expects to achieve operating margins greater than 40  in 2024  The new company is expected to comprise Merck s total revenue of approximately  6 5 billion in 2020  Moreover  Merck expects to receive  8 billion to  9 billion through a special tax free dividend from the spin off  The transaction is expected to be completed by the first half of 2021 Our TakeMerck s fourth quarter results were mixed as the company beat estimates for earnings but missed the same for sales  Keytruda continued its robust performance on strong demand trends and label expansions  Gardasil Gardasil 9 sales  however  disappointed in the quarterIn a surprising move  the company revealed plans to spin off its women s healthcare unit  biosimilar drugs and legacy products to allow it to focus on its core areas  oncology  vaccines  hospital and animal health  Shares were down 2 3  in pre market trading Merck s shares have risen 14 2  in the past year compared with 11 7  increase for the    Zacks RankMerck currently carries a Zacks Rank  3  Hold   A better ranked large cap pharma stock is Sanofi   NASDAQ SNY   with a Zacks Rank  2  Buy   You can see  Sanofi s earnings estimates have increased 1 2  for 2020 over the past 60 days Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 8 stocks to watch  The report is only available for a limited time ,2020-02-04,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-beats-on-q4-earnings-plans-women-health-spin-off-200504776,200504776
197630,419146,JNJ,Can Humira Cancer Drugs Help AbbVie  ABBV  Beat Q4 Earnings ,opinion,AbbVie  Inc    NYSE ABBV   flagship product  Humira sales decelerated in the first three quarters of 2019 given the launch of biosimilars in international markets  especially Europe  The drug is approved for several inflammatory indications and generates more than half of the company s revenues  The declining trend in international Humira sales is likely to have continued in the fourth quarter  However  the drugs sales in the United States are likely to have remained strong in the to be reported quarter AbbVie s shares have risen 5 8  in the past year  underperforming the  s increase of 10 7    The Zacks Consensus Estimate for Humira stands at  4 88 billion  The Zacks Consensus Estimate for U S  sales is pegged at  3 92 billion while that for international sales is  959 million Sales of its key oncology medicine  Imbruvica are likely to have been driven by increased adoption rates in the approved indications  especially front line chronic lymphocytic leukemia   CLL    The drug is marketed in partnership with J J   NYSE JNJ   globally  The Zacks Consensus Estimate for the drug is pegged at  1 29 billion Sales of another leukemia drug  Venclexta  were strong in the first nine months of 2019 driven by continued uptake in the broad relapsed refractory CLL setting and the recently approved indications for first line CLL and AML  The trend most likely continued in the fourth quarter  AbbVie markets Venclexta in partnership with Roche   OTC RHHBY    The Zacks Consensus Estimate for the drug is pegged at  245 million Sales of other drugs like Duodopa  Creon  Synthroid  Synagis and Lupron must have increased in the quarter However  AbbVie s new HCV drug  Mavyret recorded a decline in the first three quarters of 2019  primarily due to lower patient volumes in certain international markets and competitive dynamics in the United States  We do not expect to see an improvement in the fourth quarter results  The Zacks Consensus Estimate for the HCV segment  mainly comprising Mavyret  stands at  667 million Overall  in the fourth quarter  higher sales of Humira in the United States  and Imbruvica and Venclexta are likely to have made up for lower sales of Humira in international markets  AbbVie is set to acquire Botox maker Allergan   NYSE AGN   in a cash and stock deal for  63 billion  The deal  if it gets all necessary approvals  is expected to close in early 2020   Last week  Allergan and AbbVie announced a definitive agreement to divest Allergan s mid stage candidate brazikumab and marketed medicine  Zenpep to AstraZeneca and Nestle  respectively in connection with the pending merger  An update is expected on the conference call   Read More   AbbVie Inc  Price and Consensus   Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 8 stocks to watch  The report is only available for a limited time  ,2020-02-04,Zacks Investment Research,https://www.investing.com/analysis/can-humiracancer-drugs-help-abbvie-abbv-beat-q4-earnings-200504825,200504825
197631,419147,JNJ,Regeneron Expands Agreement To Develop Coronavirus Therapy,opinion,Regeneron Pharmaceuticals  Inc    NASDAQ REGN   announced that it has entered into an expanded agreement with the U S  Department of Health and Human Services   HHS    Per the new agreement  the company will develop treatment for coronavirus named 2019 nCoV  recently found in China Shares of Regeneron increased 4 4  on Feb 4 following the announcement  However  the company s shares have declined 12 4  in the past year compared with the  s decrease of 7 2  The World Health Organization recently declared the coronavirus outbreak a global public health emergency  as the viral infection has spread to more than 20 countries  While the coronavirus has infected more than 20 000 people in China with death toll crossing 400  isolated cases have been reported in other countries Regeneron will use its proprietary  rapid response technology   VelociSuite   to develop a promising antibody candidate to tackle the outbreak  The company and HHS entered into an agreement in 2017 to develop a portfolio of antibodies targeting up to 10 pathogens that pose significant risk to public health  including the Influenza virus and 2019 nCoV  The company is also developing a treatment for Ebola  REGN EB3  in collaboration with HHS  Biomedical Advanced Research and Development Authority   BARDA   Authorities across countries  especially China and the United States  are initiating preventive measures to contain the risk of infection  Authorities in China have recommended AbbVie s   NYSE ABBV   HIV drug  kaletra  as a treatment for the 2019 nCoV infection  Per a Bloomberg   the U S  Centers for Disease Control and Prevention is trying to get an emergency approval for a test to diagnose 2019 nCoV  which may be used in hospitals across the United States for faster remedies  Several restrictions are in place to decelerate the spread of 2019 nCoV infection  including travel ban to and fro from China Meanwhile  several pharma companies have shown interest in developing a vaccine for the coronavirus including    NYSE JNJ   and Gilead   NASDAQ GILD    Stocks of several small biotechs have surged following the announcement of their  to develop a 2019 nCoV vaccine  including Moderna  Novovax  Inovio Pharmaceuticals and   However  we note that the development process will take time and the coronavirus infection may stop like SARS  This may negatively impact the shares of these biotechs as several of these planned therapies may not get effectively monetized  SARS  caused by another coronavirus  was found in 2003 but no infection was diagnosed beyond 2004  Moreover  another Bloomberg  stated that investors are developing short interest in some of these small biotechs following the initial hype Regeneron Pharmaceuticals  Inc  Price   Zacks RankRegeneron currently carries a Zacks Rank  3  Hold  You can see  Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 8 stocks to watch  The report is only available for a limited time ,2020-02-04,Zacks Investment Research,https://www.investing.com/analysis/regeneron-expands-agreement-to-develop-coronavirus-therapy-200504862,200504862
197632,419148,JNJ,Can Biotech ETFs Continue To Soar In 2020 ,opinion," 1 20    Who Could Benefit From A Coronavirus Treatment  5 45    What Should Investors Expect From Biotech In 2020  10 50    Will The FDA Approve Biogen s New Alzheimer s Drug  15 00    New and Exciting Cancer Treatments 22 15    CRISPR  Is 2020 The Year For Gene Therapy  32 40    Merck s Product Spin Off In this episode of ETF Spotlight  I speak with Brad Loncar  biotech expert and CEO of Loncar Investments 
Biotech stocks soared in 2019  particularly in the fourth quarter  thanks in part to very strong M A activity in the space  Per   life sciences M A activity  driven by pharmaceutical buyers  totaled an unprecedented  357 billion in 2019  as of November 30   topping the 2014 record 
Looking at the longer term   the SPDR S P Biotech  NYSE XBI  ETF  was one of the best performing ETFs of the past decade  What lies ahead in 2020 
Coronavirus has already killed about 565 people  mostly in China  and infected more than 28 000 people across 25 countries  Gilead   NASDAQ GILD   is reported to be working with the Chinese authorities to conduct a clinical trial of the drug remdesivir in patients infected with the coronavirus  Johnson   Johnson   NYSE JNJ   and GlaxoSmithKline   NYSE GSK   are also working on vaccines 
Some small and mid sized biotech companies Moderna   NASDAQ MRNA   Novavax   NASDAQ NVAX   NanoViricides   NYSE NNVC   have said they are working on new treatments for the virus and their shares have been quite volatile  Should investors look at them 
Will FDA approve Biogen s potentially game changing Alzheimer s drug this year  The drug reportedly showed slower declines in study patients  cognitive abilities 
The cancer death rate in the US declined 2 2  from 2016 to 2017  the largest single year decrease ever recorded  according to the latest  from the American Cancer Society  mainly due to great improvements in survival rates for lung cancer and melanoma 
Major drug makers like Roche   OTC RHHBY   and Bristol Meyers   NYSE BMY   are spending billions of dollars to gain an edge in the  123 billion global cancer drugs market  which is among the industry s biggest and fastest growing  per WSJ 
What are the key things to watch in cancer treatments like immunotherapy for 2020 
Spending on gene therapies is projected to grow  by the end of 2024  Brad thinks 2020 could be a big year for gene therapy 
Crispr is the best known gene editing technology  The Chinese scientist who created the world s first genetically modified babies  using the Crispr Cas9 editing technique  was sentenced to three years in prison recently  Tune into the podcast to learn more 
Please visit  to learn more about the immunotherapy and China biopharma indexes  Make sure to be on the lookout for the next edition of the ETF Spotlight  If you have any comments or questions  please email 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week  
More Stock News  This Is Bigger than the iPhone                    It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ",2020-02-06,Zacks Investment Research,https://www.investing.com/analysis/can-biotech-etfs-continue-to-soar-in-2020-200505473,200505473
197633,419149,JNJ, No QE  Vaccine For Coronavirus s Threat To Markets,opinion,"Last week  I asked the question of whether the  correction was over  To wit 

 On a very short term basis  there is a potential for a reflexive bounce  If your  investment duration   or rather your  investment holding period  is very short  there may be a  trading  opportunity for you  

Well  that bounce came hard and fast during the first half of the week  as the S P 500 rebounded off the 50 dma to set new highs on Thursday  






The Good NewsAs noted  the market bounced firmly off the 50 dma and rallied back to new highs on Thursday  While Friday saw a bit of retracement  which isn t surprising given the torrid move early in the week  the  virus correction  was recovered  Importantly  the  buy signal   in the lower panel  was close to registering a  sell signal   The sharp early week rally kept that signal from triggering  which would have confirmed the  sell signal  in the top panel  Historically  when both  sell signals  are triggered  deeper corrections have tended to follow 
The Not So Good NewsPreviously  we discussed that we had taken profits out of portfolios as we were expecting between a 3 5  correction to allow for a better entry point to add equity exposure  While the  virus correction  did encompass a correction of 3   it was too shallow to reverse the rather extreme extension of the market  The rally this past week has reversed the corrective process  and returned the markets to 3 standard deviations above the 200 dma  Furthermore  all daily  weekly  and monthly conditions have returned to more extreme overbought levels as well 






Of course  the reason for the rally was more liquidity from the Federal Reserve  

While the economic impact from the virus is likely to be substantial  traders looked past economic realities  They focused instead on more liquidity being pumped into the markets by both the Fed  and the PBOC  Peoples Bank of China  

 The PBOC decided that instead of unwinding the large liquidity provision  they would double down on it  and that they did in size  The last four weeks have seen China supply over CNY2 trillion  net   into its financial system   something we have never seen anything like before     Zerohedge







But  as I stated  it wasn t just the PBOC  but also the Federal Reserve dumping tremendous amounts of liquidity into the markets which only had one place to go  equities 






While the Fed continues to deny current liquidity interventions are indeed  QE   they have been clearly concerned about the potential of global instability impacting the U S  In their most recent report to Congress  the  coronavirus  made its appearance as the latest threat to the global economic instability  
Do NOT dismiss that last sentence lightly  
Since last October  the Fed has been injecting the financial system with massive quantities of liquidity to fix  short term funding needs   Each time they have tried to slow the rates of funding  the market has declined  so they extended the facility  Initially  the facility was for October tax payments  Then it was extended for the  year end  turn  Then it was extended for April  tax payments   The  coronavirus  will be the next reason to extend the program into June 

Just in case you missed our previous report on this issue  the importance is that this type of funding has not occurred to such a magnitude outside of a financial crisis 






The question you should be asking is   exactly what is going on  
Dollar RallyCurrently  the flood of liquidity has been pulling foreign capital back into U S  Dollars  While the U S  dollar had previously started to breakdown heading into year end  which gave a boost to commodities and oil  Unfortunately  that breakdown has been reversed 
This past week  our analysis warned of the potential for a continued dollar rally  The importance of this rally is that a stronger U S  Dollar is not friendly to commodities  international  and emerging market exposure 






While there has been a good bit of excitement over the last couple of weeks of improving economic data points  it will likely be short lived  Given these data points are both  sentiment surveys  and  lagging  in nature  what they captured was the uptick in commodities seen at the end of 2019 as the dollar weakened on  trade deal  hopes 






What has yet to be captured is the subsequent reversion in the major  economically sensitive  components  While the markets have rallied on news of more liquidity  the impact from the  coronavirus  has only yet started to be felt economically  Even if the virus was cured today  the economic impact will continue to be felt over the rest of this year 
Importantly  the impact on China will be substantially greater  which will undermine any potential positive to the U S  from the  trade deal   That impact will result not only in the form of weaker economic growth in China  but globally as well due to the interlinked supply chains  This is going to manifest itself in weaker earnings and corporate profits  which will continue to make elevated asset prices harder to justify  
As shown in the long term chart below  despite the short term correction  which is barely noticeable  the market remains extremely extended  overbought  and pushing into the top of its long term trading range 
Furthermore  the put call ratio  which warned of the previous correction is once again pushing extreme levels rarely seen from a historical perspective 






The rally this past week serves as a stern reminder that market participants are trained to respond to  Pavlov s Bell   
For the time being  investors have gotten away with overpaying for value  ignoring risk  and chasing yield  Eventually  the party ends  and it always ends in the most brutal of fashions 
This is why it s important to have a process and adhere to it 
Trust The Process







There were quite a few questions about why we were buying into our portfolios this week 
The short answer is  

 Because that is what our process required us to do   
To understand the process  we have to go back  

 With bond yields plummeting this past week  our bond exposures have gotten extremely stretched  The sell off in the market  combined with the  risk off  rotation to bonds  sets the market up for a reflexive bounce  The duration and magnitude of that bounce will be critical as to our next steps in positioning   
A few weeks ago  Shawn Langlois at MarketWatch picked up our article discussing why we were selling positions in our portfolio  To wit 

 Specifically  Roberts raised cash by selling off shares of Apple  NASDAQ AAPL   Microsoft  NASDAQ MSFT   United Healthcare  Johnson   Johnson  NYSE JNJ   and Micron  NASDAQ MU   and scaling back overweight holdings in various ETF sector plays  such as the Technology Select Sector SPDR  and the Health Care Select Sector  
While at the time  it seemed like a wrong move  a couple of weeks later  the market sold off  The benefit was the extra cash  and reduced exposure  help limit the downside draw to about 1 3rd of the market decline  
Then  last week  things changed 
Chart updated through Friday






As noted  the market had gotten oversold on a short term basis  which brought the risk reward measures back into better alignment  This is where our process required we add equity exposure back into portfolios  

 The  bullish bias  is not dead as of yet  and investors will be quick to try and  write off  the impact of the  virus   After a decade of  macro events  not stopping the bullish charge  the belief the market is  bulletproof  has become so deeply ingrained into investor mentality it won t be dislodged until it is far too late to matter  
In the ETF Model  we added Financials  XLF  and increased our stake in HealthCare  XLV  with both of those sectors having gotten oversold and bouncing off their respective 50 dma s In the EQUITY Model  we added JP Morgan  JPM  and  Pfizer   NYSE PFE  while increasing our stakes in Abbvie  ABBV   United Healthcare  UNH   and Alerian MLP  AMLP   Importantly  this rebalancing of risk did not dramatically increase our equity exposure  This is because  as noted above  the longer term technical outlook remains  cautious  
Yes  we realize we are very late cycle  we also know that with the Fed  and global Central Banks  still intervening  we must give deference to the  bullish bias   At the moment  the bullish bias remains  and functioned as we predicted last week 
We have no certainty about when  or what will trigger the next bear market  
What we do know is that such an event will likely be far more brutal than most realize due to years of excess risk taking  leverage  and demographics  
However  this is what our process is designed to handle 
The portfolio is managed for risk by adjusting the level of equity exposure relative to market dynamics  return outlooks  and technical deviations from long term means The allocation is managed for risk by balancing positions for relative performance to our benchmark The positions are managed for risk by Employing trailing stop lossesRegularly rebalancing positions back to target weights  taking profits Cutting laggards which aren t performing as expectedMonitoring relative performance and participation
Importantly  notice that everything the process covers is the management against the  risk  of loss  
If we manage against the risk of capital loss  we can safely participate with markets as they rise  When something eventually does goes wrong  the process will systematically close out positions  protecting our investment capital  until that process is complete  Then the process reverses to rebuild exposure when risk reward dynamics are greatly improved  
As long as the process is followed  risk can be controlled  Where the majority of investors go wrong  is by not having a process 
 Hoping  markets will continue higher indefinitely  is not a process 
As we concluded last week 

 We won t know for sure until after the fact  This is why we manage risk in the short term  Managing risk allows us to navigate the  twists and turns  of the market without careening off the cliff  ",2020-02-09,Lance Roberts,https://www.investing.com/analysis/no-qe-vaccine-for-coronaviruss-threat-to-markets-200505881,200505881
197634,419150,JNJ,J J Files Application For Darzalex Label Expansion With FDA,opinion,"Johnson   Johnson s   NYSE JNJ   subsidiary  Janssen  announced that it has submitted a supplemental biologics license application  sBLA  to the FDA for the label expansion of its multiple myeloma drug  Darzalex  daratumumab   The sBLA is seeking label expansion of Darzalex in combination with Amgen s   NASDAQ AMGN   Kyprolis  carfilzomib  and dexamethasone as second to fourth line treatment option for patients with relapsed refractory multiple myeloma  r rMM  Darazalex is already marketed in the United States as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy  The drug is already approved in several combination regimens for the treatment of different multiple myeloma indications as well as in different treatment settings The sBLA was supported by data from the phase III CANDOR study  In the study  treatment with the three drug Darzalex combo  DKd  led to a reduction in the risk of progression or death by 37  in patients with r rMM The randomized  open label CANDOR study was initiated by Amgen as part of its collaboration agreement with Janssenwhich is also co funding the study along with Amgen Shares of J J have gained 13 2  in the past year compared with the  s increase of 12 5  Currently  Darzalex is approved for only intravenous administration  Meanwhile  J J has developed a subcutaneous formulation of Darzalex using Halozyme s   NASDAQ HALO   ENHANZE drug delivery technology  The company submitted a BLA in July last year seeking approval for the new formulation of Darzalex  A potential approval to subcutaneous formulation may boost sales of the drug as it is likely to make administration of the drug easier Darzalex is a key drug in J J s portfolio  Sales of the drug rose 48  year over year to  3 billion in 2019 Meanwhile  Darzalex is being evaluated in a comprehensive clinical development program across a range of treatment settings in multiple myeloma  such as in frontline and relapsed settings  These include combination studies with other cancer drugs like Roche Holding  SIX ROG  AG s   OTC RHHBY   Tecentriq and Bristol Myers  Opdivo Johnson   Johnson Price
    Zacks RankJ J currently carries a Zacks Rank  3  Hold  You can see  Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020 Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ",2020-02-11,Zacks Investment Research,https://www.investing.com/analysis/jj-files-application-for-darzalex-label-expansion-with-fda-200506451,200506451
197647,419163,JNJ,Oklahoma judge reduces Johnson   Johnson opioid payout to  465 million,news,"By Nate Raymond and Jonathan Stempel  Reuters    An Oklahoma judge on Friday said Johnson   Johnson  NYSE JNJ  must pay that state  465 million for fueling the opioid epidemic through the deceptive marketing of painkillers  down from his original award of  572 million  The decision by Cleveland County District Judge Thad Balkman in Norman  Oklahoma  came in the first case to go to trial out of 2 700 nationally by states  counties and cities seeking to hold drug companies responsible for the deadly epidemic  Balkman reduced the amount he had awarded in August by  107 million after agreeing with New Brunswick  New Jersey based J J that he had made a math error  J J said it will appeal  and that the award and finding of liability were  neither supported by the facts nor the law   A spokesman for Oklahoma Attorney General Mike Hunter said that office is reviewing the decision and will formally respond within the next few days  Opioids were involved in almost 400 000 overdose deaths from 1999 to 2017  according to the U S  Centers for Disease Control and Prevention  Following a non jury trial  Balkman ruled in August that Oklahoma had proven that J J engaged in misleading marketing about the benefits of painkillers  and that their addictive risks caused a public nuisance in the form of the opioid crisis  Hunter had sought to have J J pay  17 billion to help fund addiction treatment and other services to repair damage from the opioid epidemic over the next 30 years  Balkman  however  awarded only enough money for one year of programs  saying Oklahoma failed to support its claims regarding the need to abate the epidemic in future years  Following the August ruling  Oklahoma asked Balkman for permission to return to his courtroom annually to prove those costs  but Balkman on Friday maintained his prior ruling  J J  meanwhile  argued that it deserved a  355 million credit  reflecting pre trial settlements by the drugmakers Purdue Pharma LP and Teva Pharmaceutical Industries  NYSE TEVA  Ltd  Balkman concluded on Friday that state law did not allow such credits  Last month  J J and four other companies proposed a  48 billion settlement framework to resolve all of the opioid cases they face  with J J paying  4 billion  Lawyers for the local governments have opposed the proposal  
If approved  the settlement would let J J resolve some of the thousands of product liability lawsuits it faces  The company also faces litigation over whether its baby powder causes cancer  a claim it denies ",2019-11-15,Reuters,https://www.investing.com/news/stock-market-news/oklahoma-judge-reduces-johnson--johnson-payout-in-opioid-case-to-465-million-2021821,2021821
197648,419164,JNJ,Sanofi weighing options for consumer healthcare unit  sources,news,By Arno Schuetze and Matthias Blamont FRANKFURT PARIS  Reuters    Sanofi  PA SASY  is considering a joint venture or outright sale among options for its consumer healthcare unit  sources told Reuters  as the French drugmaker prepares to present a new strategic plan next month  An initial public offering  IPO  of the unit  which could be worth around  30 billion according to two sources familiar with the matter  is also on the cards  Sources cautioned that no final decision had been made   Recently appointed chief executive Paul Hudson  who took the job on Sept  1  plans to meet investors for a capital markets day in Cambridge  Massachusetts  on Dec  10   Analysts have speculated in recent weeks over a possible divestment or spin off of Sanofi s consumer healthcare arm  whose revenue grew by 3  at constant exchange rates last year to 4 7 billion euros   5 21 billion   arguing proceeds would enable the group to invest more in internal research   Sanofi is looking at various options  joint venture  initial public offering  sale       They are talking to investments banks about options but have not taken a decision   one of the sources said  The source added that forming a consumer healthcare joint venture with one of its large peers would allow it to benefit from cost cuts and later reap a higher valuation in a possible IPO or sale further down the line   Shares in Sanofi were up 1 45  at 84 08 euros at 1030 GMT  after Bloomberg earlier reported that the company was studying options for the consumer unit   A Sanofi spokesman had no comment  Hudson said last month he and his teams would study the performances of every Sanofi division to decide where to invest   Prioritization will become increasingly important going forward   Hudson told reporters in October   The reality in business is that some things are more important than others and we have to understand where we must win   Sanofi swapped its animal health unit with Boehringer Ingelheim for the German company s consumer healthcare operations in a  20 billion deal closed in 2017  Britain s GlaxoSmithKline  L GSK   in turn  has created the market leader after agreeing to combine its consumer healthcare unit with that of U S  Pfizer   N PFE  last year  The joint venture will be spun off and separately listed  Analysts at Bernstein Research said in a September note that there was significant opportunity for consolidation because the top 10 players in consumer health only have a combined 23  market share between them  The GSK joint venture has a global market share of 3 5   with Johnson   Johnson  N JNJ   Bayer  DE BAYGn  and Sanofi as close competitors ,2019-11-21,Reuters,https://www.investing.com/news/stock-market-news/sanofi-weighing-options-for-consumer-healthcare-unit-sources-2025168,2025168
197649,419165,JNJ,AstraZeneca shares rise on early U S  approval for leukemia drug,news,"FRANKFURT  Reuters    AstraZeneca  L AZN  shares rose 2 7  on Friday after the British drugmaker won earlier than expected U S  regulatory approval for a leukemia drug  in a challenge to rival AbbVie  N ABBV  
AstraZeneca said late on Thursday that the U S  Food and Drug Administration  FDA  had given its go ahead for the company s Calquence drug to treat chronic lymphocytic leukemia  CLL   one of the most common types of leukemia in adults 
The drug was approved under a new speedy review program in collaboration with drug watchdogs in Canada and Australia  and was also approved to treat small lymphocytic lymphoma  a similar disease 
That will pit the AstraZeneca drug against AbbVie and Johnson   Johnson s  N JNJ  established CLL treatment Imbruvica 
The FDA s green light  which analysts at brokerage Bryan Garnier said came at record speed  adds momentum to Astra s growing cancer drug business with brands including Tagrisso and Imfinzi 
 Physicians are used to Imbruvica and we do not expect a rapid and massive shift towards Calquence but we do see it progressively taking market share from the leader   Bryan Garnier analysts said  adding that FDA tests had showed Calquence performed well in terms of side effects 
Astra shares were up 2 1  at 1415 GMT  outperforming a 0 7  gain in the STOXX Europe 600 Health Care  SXDP  index 
Astra shares have risen 28  this year  boosted by revenue growth from new drugs 
Average analyst forecasts point to 2024 Calquence sales of almost  1 5 billion  up from a projected  160 million this year  according to Refinitiv data 
Abbvie and J J chalked up 2018 Imbruvica revenues of  3 6 billion and  2 6 billion  respectively 
Calquence had previously been approved for the relatively smaller group of mantle cell lymphoma  MCL  patients that had received prior therapy ",2019-11-22,Reuters,https://www.investing.com/news/stock-market-news/astrazeneca-shares-rise-on-early-us-approval-for-leukemia-drug-2026279,2026279
197650,419166,JNJ,J J  JNJ  Plans To Develop Vaccine For New Coronavirus ,opinion,"Johnson   Johnson   NYSE JNJ   announced its interest in developing a vaccine with multi pronged approach to address the current novel coronavirus  2019 nCoV  outbreak  The company has initiated the process to identify compounds with antiviral activity against 2019 nCoV and develop a vaccine candidate 
The company will use Janssen s technologies  which will help it to rapidly upscale production of the optimal vaccine candidate  These technologies have already been used to develop vaccine candidates for other virus caused infections namely Ebola  HIV and for respiratory syncytial virus  a common respiratory virus  The company will also review previously tested medicines for coronavirus infections like SARS and MERS to determine their efficacy in preventing the 2019 nCoV infection 
Moreover  the company is also donating its HIV medication  Prezcobix  to several China based entities engaged in developing a 2019 nCoV vaccine  Prezcobix includes a protease inhibitor   PI   as its component and PI has shown favorable clinical response against SARS 
Meanwhile  several other large and small pharma companies are working on developing a vaccine for fighting the coronavirus outbreak  A Bloomberg  stated that AbbVie s   NYSE ABBV   HIV drug  Kaletra  has been recommended for treating 2019 nCoV infection by a Chinese authority  The drug has previous history of clinical response against SARS 
Moreover  Gilead   NASDAQ GILD   is planning to develop its failed Ebola vaccine as a 2019 nCoV vaccine  per a CNBC   Smaller biotechs like Moderna   NASDAQ MRNA   and Inovio Pharmaceuticals have received grant from CEPI  a public private nonprofit organization  to develop a similar vaccine 
The 2019 nCOV infection is spreading rapidly in China with latest data showing nearly 6 000 infections and almost 130 deaths  With several large cap pharma companies showing interest and promising to provide support to fight the infection  development of vaccines may be accelerated 
However  we note that development of an effective vaccine may take some time as clinical studies are required to test its efficacy in humans  Meanwhile  stocks of some small biotechs  which had rallied last week on the coronavirus news  declined on Jan 29 following J J s interest  Entry of large cap players with significant funds and strong expertise may impact the potential of small biotechs 
J J s stock has risen 13 1  in the past year compared with an increase of 12 1  recorded by the  

 
In a separate press release  J J announced that the European Commission   EC   has granted marketing authorization to its new prostate cancer drug Erleada for an expanded patient population 
With the latest approval  Erleada will be available in Europe to treat patients with metastatic hormone sensitive prostate cancer  also known as metastatic castration sensitive prostate cancer  in combination with androgen deprivation therapy Erleada is already approved in the EU for the treatment of men with non metastatic castration resistant prostate cancer
A similar label expansion for the drug was  by the FDA in September 2019 Johnson   Johnson Price
 

    
Zacks Rank
J J currently has a Zacks Rank  3  Hold   You can see  
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  50    83  and  164  in as little as 2 months  The stocks in this report could perform even better ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-plans-to-develop-vaccine-for-new-coronavirus-200503417,200503417
197651,419167,JNJ,The Wining Sector   Its Top Stocks In Virus Infected January  ,opinion,"The first month of 2020 was moderate for Wall Street despite a host of negative events globally  starting from the Middle East tension to the coronavirus outbreak  Global growth worries also resurfaced in the month 
Still  Wall Street stayed resilient apart from some occasional dips  The S P 500  the Dow Jones and the Nasdaq advanced about 1 6   1 1  and 3 6   respectively  in the past one month  as of Jan 30  2020  
Most of the top performing stocks of the month were from the biotech sector  Let s delve a little deeper into the winning sector in the virus tormented January that showered gains on investors 
Inside the Headline Events in January 
The key U S  indexes  spectacular 2019 rally faltered to start 2020 as the U S  Iran row triggered concerns of a war  While the event kept the market edgy at the start of January  the signing of the mini U S  China trade deal offered some support in mid month only to witness IMF s downbeat projections about global growth 
To make matters worse  the report of the SARS  severe acute respiratory syndrome  like coronavirus outbreak hit the market in late January  China s coronavirus has so far taken about  
The World Health Organization  WHO  termed the outbreak a global emergency  All these events sparked a safe haven rally  dragging down benchmark U S  treasury yields to as low as 1 57  on Jan 30 
Biotech Rallies 
The coronavirus event did have a reason to give a boost to the biotech space  After all  healthcare and biotech stocks should do well on the growing need for the formulation of vaccines to fight the virus and higher demand for hygiene related products 
Apart from coronavirus  the general trend of the sector also aided the space as the biotech area has been thriving with positive drug data  FDA approval and plenty of mergers and acquisitions  So far this year  FDA has approved three drugs compared with no approval in Jan 2019  and one approval each in Jan 2018  Jan 2017 and Jan 2016 
Below we highlight a few biotech stocks that were clear winners in the past four weeks  as of Jan 30  2020  
Trillium Therapeutics Inc    NASDAQ TRIL     Up 330 1 
The company is a clinical stage immuno oncology company developing innovative therapies for the treatment of cancer The stock belongs to a favorable Zacks industry   Medical   Drugs    placed at the top 44  of 250  industries  
Miragen Therapeutics Inc     Up 252 2 
Miragen Therapeutics  Inc  is a biopharmaceutical company  It develops microRNA biology  oligonucleotide chemistry  drugs and therapies for cancer  pathologic fibrosis  neuro inflammatory and cardiovascular diseases  The company  for Cobomarsen in Adult T Cell Leukemia on Jan 30  which led the stock to rise by 20 7  on the day  The stock belongs to a favorable Zacks industry   biomedical and genetics    top 29   
Co Diagnostics Inc    NASDAQ CODX     Up 222 8 
Co Diagnostics Inc  is a molecular diagnostics company  The company is a clear beneficiary of the virus threat as it   The new screening can test several patients at a time  The stock hails from the favorable Zacks industry  top 29   
Pulmatrix Inc    NASDAQ PULM     Up 111 6 
It is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease  The company joined forces with Johnson   Johnson   NYSE JNJ    at the start of the month 
At month end  the company s PUR1900   Pulmazole   received the  from the FDA  The proprietary product is an inhaled itraconazole antifungal candidate being developed to treat allergic bronchopulmonary aspergillosis  ABPA  in patients with asthma 
Vaxart Inc    NASDAQ VXRT     Up 105 7 
Vaxart  Inc  is a clinical stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform  Its development programs are oral tablet vaccines designed to protect against norovirus  seasonal influenza and respiratory syncytial virus  as well as a therapeutic vaccine for human papillomavirus 
Due to its development profile  the coronavirus case made the stock a winner  This is especially true given the fact that VXRT stock was heavily shorted in recent times  So  the latest virus threat worked wonders for Vaxart  The stock comes from a favorable Zacks industry  top 44   
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ",2020-01-31,Zacks Investment Research,https://www.investing.com/analysis/the-wining-sector--its-top-stocks-in-virusinfected-january-200503490,200503490
197652,419168,JNJ,Vaxart  VXRT  To Make Vaccines To Check Coronavirus  Stock Up,opinion,Shares of Vaxart  Inc    NASDAQ VXRT   soared 72 1  after the company announced that it has initiated a program to develop vaccine candidates for fighting the new coronavirus infection  The new vaccine candidate will be based on the company s proprietary oral vaccine platform  VAAST Additionally  the stock was up 22 4  in pre market trading on Monday  However  shares of Vaxart have plunged 42 4  in the past year compared with the  decrease of 4 5  Coronavirus is commonly found in animals  causing several diseases like diarrhea and upper respiratory problem  However  in humans  this virus results in mild to moderate illness including common cold  Seven different types of coronavirus have been discovered so far including the recent one in China  It has been named 2019 Novel Coronavirus  2019 nCoV  by the CDC Vaxart recently published results from an influenza challenge study  which demonstrated that its oral tablet vaccine primarily protects through mucosal immunity  which is a potential key factor when targeting mucosal pathogens  such as this new coronavirus Per the press release  Vaxart plans to develop vaccine candidates based on the published genome of the 2019 nCoV and evaluate the same in preclinical studies for the ability to generate both mucosal and systemic immune responses Meanwhile  several other large and small pharma companies are working on developing a vaccine to fight the coronavirus outbreak  Last week  pharma giant Johnson   Johnson   NYSE JNJ   announced its interest in developing a vaccine with multi pronged approach to address the current novel coronavirus  2019 nCoV  outbreak  The company initiated the process to identify compounds with antiviral activity against 2019 nCoV and develop a vaccine candidate Moreover  a Bloomberg  reported that AbbVie s   NYSE ABBV   HIV drug Kaletra is recommended for treating 2019 nCoV infection by a Chinese authority  The drug has a history of clinical response against SARS Additionally  smaller biotechs like Inovio Pharmaceuticals   NASDAQ INO   and Moderna  Inc  received grants from CEPI  a public private nonprofit organization  to develop a vaccine for the 2019 nCoV infection This rapidly spreading virus in China with its  from the World Health Organization  claims more than 14 000 infected cases and almost 304 deaths in the country  With several companies showing interest and promising to provide support to fight the infection  development of vaccines may be accelerated Zacks RankVaxart currently has a Zacks Rank  3  Hold   You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2020-02-02,Zacks Investment Research,https://www.investing.com/analysis/vaxart-vxrt-to-make-vaccines-to-check-coronavirus-stock-up-200504019,200504019
197653,419169,JNJ,Merck  MRK  To Report Q4 Earnings  Is A Beat In The Offing ,opinion,"Merck   Co   Inc    NYSE MRK   is set to report fourth quarter and full year 2019 results on Feb 5  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 20 8  Merck s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The four quarter positive earnings surprise was 12 51   on average Merck   Co   Inc  Price and EPS Surprise
 

   Merck s shares have risen 11 1  in the past year compared with 10 2  increase for the   Factors to ConsiderMerck s new products like cancer drug Keytruda  Gardasil vaccine and Bridion injection are likely to have driven the top line in the to be reported quarter backed by strong demand trends  Alliance revenues from Lynparza and Lenvima may have contributed to higher oncology sales  Please note that Merck markets Lynparza in partnership with AstraZeneca   NYSE AZN    Strong performance in international markets  especially China  is likely to have driven the top line further However  the top line is expected to reflect the impact of loss of exclusivity for some products  biosimilar competition for Remicade in Merck s marketing territories and competitive pressure for the diabetes franchise  Januvia Janumet  and currency headwinds Merck markets Remicade in partnership with J J   NYSE JNJ   Keytruda sales might have been driven by continued strong momentum in first line lung cancer indication and launch in newer indications  namely renal cell carcinoma and adjuvant melanoma In the fourth quarter  Keytruda gained approvals in China for two non small cell lung cancer indications and in Europe for first line head neck cancer  The Zacks Consensus Estimate for Keytruda s sales is  3 22 billion Strong demand in most markets has been driving sales of Bridion  sugammadex  Injection   a trend that most likely continued in the fourth quarter  The Zacks Consensus Estimate for Bridion is  294 million Higher demand in China  Europe and the United States is likely to have benefited Gardasil sales in the fourth quarter  In October  Merck borrowed doses of Gardasil from CDC stockpile to support routine vaccinations in the United States  and to free up some manufacturing capacity to make doses for ex U S  markets  At the third quarter conference call  the company said that the stockpile borrowing is expected to hurt fourth quarter sales by approximately  120 million The Zacks Consensus Estimate for Gardasil is  979 million Animal health franchise is expected to have done well in the fourth quarter  driven by higher sales of its companion animal and livestock products In December  the FDA granted approval to Merck s investigational vaccine for Ebola virus disease  Ervebo Ervebo was approved in Europe in November  We expect management to discuss the vaccine s commercialization plans at the fourth quarter conference call Key Q4 Developments
In the fourth quarter  Merck announced a definitive deal to buy Massachusetts based ArQule for  20 per share in cash for an approximate total equity value of  2 7 billion  The buyout was closed in January  The acquisition is expected to strengthen Merck s oncology pipeline with the addition of some strategic assets  most notably  ARQ 531  ArQule s novel  oral Bruton s tyrosine kinase inhibitor  ARQ 531 is currently being evaluated in a phase II dose expansion study for the treatment of B cell malignancies Earnings WhispersOur proven model predicts an earnings beat for Merck this time around because it has the right combination of two key ingredients  A stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate of  1 15 and the Zacks Consensus Estimate of  1 14  is  1 05   You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Merck has a Zacks Rank  3 Another Stock to Consider Another large drug biotech stock that has the right combination of elements to beat on earnings this time around is Gilead Sciences   NASDAQ GILD    It has an Earnings ESP of  1 55  and a Zacks Rank  3  The company is scheduled to release results on Feb 4  You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2020-02-03,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-to-report-q4-earnings-is-a-beat-in-the-offing-200503882,200503882
197654,419170,JNJ,AbbVie  ABBV  To Report Q4 Earnings  What s In The Cards ,opinion,AbbVie  Inc    NYSE ABBV   is set to report fourth quarter and full year 2019 results on Feb 7  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 1 75  AbbVie s shares have risen 3 2  in the past year  underperforming the  s increase of 10  The company s earnings performance has been mixed  Its earnings beat expectations in three of the last four quarters  with the positive surprise being 1 71   on average AbbVie Inc  Price and EPS Surprise   Factors to ConsiderThe company expects fourth quarter earnings between  2 17 and  2 19 per share  It predicts operational sales growth to be approximately 5  Although U S  sales of AbbVie s flagship product  Humira  are likely to have increased in the quarter  international sales might have declined significantly due to the impact of biosimilars in Europe  The Zacks Consensus Estimate for Humira stands at  4 88 billion Also  sales of key oncology drugs  Imbruvica and Venclexta  are likely to have jumped  supporting the top line  AbbVie markets Imbruvica in partnership with J J   NYSE JNJ   and Venclexta in partnership with Roche  The Zacks Consensus Estimate for Imbruvica and Venclexta is  1 29 billion and  245 billion  respectively  However  AbbVie s new HCV drug  Mavyret  recorded a decline in the first three quarters of 2019 primarily due to lower patient volumes in certain international markets and competitive dynamics in the U S  The trend is expected to have continued in the fourth quarter  In 2019  AbbVie gained FDA approval for two immunology drugs  Skyrizi  risankizumab  for plaque psoriasis in April 2019 and Rinvoq  upadacitinib  for moderate to severe rheumatoid arthritis in August 2019  In the third quarter conference call  the company noted that both Skyrizi and Rinvoq are off to an impressive start  Rinvoq was approved in the EU in December 2019  Investors will be keen to know the sales numbers of both these new drugs at the fourth quarter conference call Recent Key DevelopmentsAbbVie is set to acquire Botox maker Allergan   NYSE AGN   in a cash and stock deal for  63 billion  The deal  if it gets all necessary approvals  is expected to close in early 2020   Last week  Allergan   AbbVie announced a definitive agreement to divest the former s mid stage candidate  and marketed medicine  Zenpep to AstraZeneca and Nestle  respectively in connection with the pending merger  An update is expected at the conference call Earnings WhispersOur proven model does not conclusively predict earnings beat for AbbVie this time around  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But that is not the case here Earnings ESP  Its Earnings ESP is  0 08   The Zacks Consensus Estimate is pegged at  2 20  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AbbVie carries a Zacks Rank  4  Sell  Stock to Consider A large drug stock that has the right combination of elements to beat on earnings this time around is Merck   NYSE MRK    It has an Earnings ESP of  1 05  and a Zacks Rank  3  The company is scheduled to release results on Feb 5  You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 7  per year  So be sure to give these hand picked 7 your immediate attention   ,2020-02-03,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-to-report-q4-earnings-whats-in-the-cards-200504363,200504363
197668,419184,JNJ,Walmart  CVS and Rite Aid pull 22 ounce J J baby powder off shelves,news,"By Manojna Maddipatla and Nivedita Balu  Reuters    Three major U S  retailers  including Walmart  NYSE WMT   are removing all 22 ounce bottles of Johnson   Johnson s baby powder from their stores  following the healthcare conglomerate s recall last week of some bottles due to possible asbestos contamination  CVS Health Corp  NYSE CVS  said on Thursday it would remove the bottles from its online store as well  out of caution and to prevent customer confusion  The pharmacy chain said all other sizes of the talc would remain on its shelves  Rite Aid had informed its stores to pull all 22 ounce bottles of Johnson s Baby Powder from shelves on Oct  18 and store them in a secure location  company spokesman Chris Savarese said   Additionally  we ve applied a point of sale system block for this product to prevent it from being sold   Late Thursday  CNBC reported  that Walmart  the world s largest retailer  had also removed and blocked all of the recalled baby powder  The company did not respond to a Reuters request for comment  J J  NYSE JNJ   which is facing thousands of lawsuits over a variety of products  said last week it was recalling around 33 000 bottles of baby powder in the United States after U S  health regulators found trace amounts of asbestos in samples taken from a bottle purchased online  The move marked the first time J J recalled its iconic baby powder for possible asbestos contamination  and the first time U S  regulators announced a finding of asbestos in the product  Asbestos is a known carcinogen that has been linked to deadly mesothelioma  The voluntary recall was limited to one lot of Johnson s Baby Powder produced and shipped in the United States in 2018  J J had said  The company added that testing by the U S  Food and Drug Administration as recently as a month ago found no asbestos in their talc   It s not important at all in terms of the dollar figure to either CVS or J J  What it tells you is that retailers are being extra cautious with how they are dealing with J J s voluntary recall   Jefferies healthcare analyst Jared Holz said  Commenting on CVS s move  J J spokesman Ernie Knewitz said   It s temporary     They are doing it storewide because they don t have the resources to go through at the store level and check all the SKUs  stock keeping units   check all the lot numbers   Other retailers are expected to remove the product from their shelves as they want to avoid liability  said Eric Schiffer  chief executive officer of private equity firm Patriarch Organization   It wouldn t surprise me to see Amazon  NASDAQ AMZN  and other online retailers do the same   he added  J J has known for decades that asbestos lurked in its talc  Reuters reported last year  Internal company records  trial testimony and other evidence show that from at least 1971 to the early 2000s  the company s raw talc and finished powders sometimes tested positive for small amounts of asbestos  Company executives  mine managers  scientists  doctors and lawyers fretted over the problem and how to address it  while failing to disclose it to regulators or the public  Reuters found  
J J has repeatedly said that its talc products are safe  and that decades of studies have shown them to be asbestos free and that they do not cause cancer ",2019-10-24,Reuters,https://www.investing.com/news/stock-market-news/cvs-pulls-out-22-ounce-jj-baby-powder-from-stores-2003629,2003629
197669,419185,JNJ,J J says new tests find no asbestos in same baby powder bottle that sparked recall,news,"By Carl O Donnell and Lisa Girion  Reuters    Johnson   Johnson  NYSE JNJ  said on Tuesday that 15 new tests found no asbestos in a bottle of baby powder that the U S  Food and Drug Administration says tested positive for trace amounts of asbestos  a finding the agency stands by  The tests are the latest effort by J J to prove the safety of its widely used consumer product after a test by the FDA prompted J J to undertake a nationwide recall of one lot of its Johnson s Baby Powder  FDA officials  in an interview with Reuters  said the agency continues to support the company s voluntary recall    They would say the product is free of asbestos based on their testing  and we would say the opposite for that sample   said Steve Musser  deputy director for scientific operations in the FDA s Center for Food Safety and Nutrition   Earlier this month  J J recalled around 33 000 bottles of baby powder in the United States after the FDA found trace amounts of asbestos in samples taken from a bottle purchased online   Rigorous and third party testing confirms there is no asbestos in Johnson s Baby Powder  We stand by the safety of our product   J J said in a statement  The company did not immediately respond to a request for additional comment on the FDA standing by its test result   The different test outcomes could have resulted from the fact that contaminants are not uniformly dispersed throughout talc and there is no standard test for asbestos in talc  FDA officials said   The voluntary recall was limited to one lot of Johnson s Baby Powder produced and shipped in the United States in 2018  the company said at the time   That move marked the first time the company recalled its iconic baby powder for possible asbestos contamination  and the first time U S  regulators have announced a finding of asbestos in the product  Asbestos is a known carcinogen that has been linked to deadly mesothelioma  J J will not reverse the recall of those 22 ounce containers  but its baby powder remains available to consumers in stores  a company spokesman told Reuters   The recall had been the latest blow to the more than 130 year old U S  healthcare conglomerate that is facing thousands of lawsuits over a variety of products  including baby powder  opioids  medical devices and the antipsychotic Risperdal  J J faces more than 15 000 lawsuits from consumers claiming its talc products  including Johnson s Baby Powder  caused their cancer  
 This version corrects spelling of powder in headline ",2019-10-29,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-says-new-tests-find-no-asbestos-in-fdatested-baby-powder-2006944,2006944
197670,419186,JNJ,Exclusive  J J s own expert  working for FDA  found asbestos in Baby Powder,news,"By Chad Terhune and Lisa Girion  Reuters    Ever since Johnson   Johnson  NYSE JNJ  disclosed this month that a government test had turned up asbestos in its Baby Powder  the company has attacked the validity of the result  On Tuesday  for example  J J announced that other labs it hired ultimately found no asbestos in samples from the bottle tested by the U S  Food and Drug Administration or from the same production lot  In challenging the FDA s finding  however  the healthcare giant is casting doubt on one of its own experts  The private Maryland lab that found asbestos in Baby Powder under a contract with the FDA is run by a paid expert witness for J J  Andreas Saldivar  laboratory director of AMA Analytical Services Inc  has served as a litigation expert on several occasions for J J since 2017 in its defense against plaintiffs  claims that asbestos in talc caused their cancers  He testified in a May 2018 deposition that testing he did in 2010 for the FDA showed no evidence of asbestos in Johnson s Baby Powder  helping to bolster the company s argument that its iconic brand is safe  Saldivar s lab began testing cosmetic talc products for the FDA again this year  and in September it found asbestos in an unmarked sample that the FDA later identified as Johnson s Baby Powder   I have never heard of anything like this   said Richard Ausness  a University of Kentucky law professor who specializes in product liability  referring to Saldivar s dual roles   This is bad news for J J  The plaintiffs are clearly going to say this lab director worked for J J for years  and he found asbestos so there must be asbestos there   J J s challenge now is to discredit the single test result as erroneous without undermining the reputation and track record of its expert witness  Ausness said   J J could try to frame it as not so much this lab director is unreliable or incompetent  but false positives do happen and additional tests are called for   Ausness said  The company appeared to do just that on Tuesday  saying testing done by other laboratories J J hired had found no asbestos in the same bottle of Baby Powder tested by Saldivar for the FDA  nor in the lot of Baby Powder recalled as a result of Saldivar s finding  In an interview with Reuters on Tuesday  FDA officials said they stood by the AMA lab and its results  They also said they were not surprised by J J s findings because contaminants are not uniformly dispersed throughout talc and different testing methods can yield varying results  The company  would say the product is free of asbestos based on their testing  and we would say the opposite for that sample   said Steve Musser  deputy director for scientific operations in FDA s Center for Food Safety and Applied Nutrition  Plaintiffs  attorneys said Saldivar s finding for the FDA could be detrimental to J J s defense in court  The company faces lawsuits from more than 16 000 people alleging that asbestos in its powders caused cancer  The impact was immediate in one courtroom  Hours after J J disclosed the FDA s asbestos finding on Oct  18  a plaintiff s lawyer  Nate Finch  asked an Indianapolis judge to let him tell the jury about it in a trial involving a 71 year old woman who alleged that Baby Powder contributed to her cancer  J J s lawyers opposed the request  arguing that the information could prejudice the jury against the company  but the judge granted Finch s request  Days later  Finch told the judge his client had come to a confidential resolution with J J  a trial transcript shows  Finch told Reuters he could not comment on the resolution  J J did not respond to questions about the Indianapolis case  The company declined to comment on Saldivar s role in the FDA testing  or on how it might affect the company s legal strategy going forward   Saldivar declined to comment  NO SAFE LEVELS In a June deposition  Saldivar said J J lawyers had retained him in 2017 as a company expert in  maybe 20 or 30  cases  His firm bills  200 to  350 an hour for his services  he testified  Under the FDA contract  his lab found asbestos fibers in the Baby Powder sample on Sept  7  according to the lab s report  J J said it was notified of the finding by FDA officials on Oct  16  prompting the company to recall 33 000 bottles  out of an abundance of caution   In response  some major U S  retailers have said they are removing all 22 ounce bottles of Johnson s baby powder from their shelves   At the same time  the company has expressed suspicions about the finding  saying it had launched its own investigation  to determine the integrity of the tested sample  and the validity of the test results   On Friday  the FDA posted online Saldivar s 16 page report to the agency on the analysis of J J Baby Powder  In samples weighing less than a gram  the lab said it found six chrysotile asbestos fibers  Given that the samples were extremely small  the asbestos could amount to millions of fibers per gram  testing experts told Reuters  While most people exposed to asbestos never develop cancer  for some  even small amounts are enough to trigger the disease years later  Just how small hasn t been established  The World Health Organization and other health authorities recognize no safe level of exposure to asbestos  a known carcinogen   Since there are no known safe levels of asbestos  the FDA has asked manufacturers to voluntarily recall their products when fibers consistent with asbestos are found in them   the agency said this month  Several juries over the past two years have concluded that Baby Powder exposures caused cancer and have awarded plaintiffs more than  5 billion  Other juries have sided with J J  and some cases have settled   JUST NOT CORRECT  The FDA has never before announced that government testing found asbestos in J J s Baby Powder  Since the early 1970s  J J has pushed back hard on reports of asbestos in its talc by outside scientists  plaintiffs  experts and  on several occasions  by its own testing labs  In an Oct  3 deposition in a New York lawsuit  J J Chief Executive Alex Gorsky dismissed the findings of asbestos over the years  saying  they were later shown to be inaccurate  incomplete and just not correct   Attacking Saldivar s finding  some legal experts told Reuters  could hurt the company s ability to use him as a witness in lawsuits and undercut its broader message to jurors and consumers  That message boils down to  Trust our experts  But a product liability defense lawyer who helped organize a recent talc litigation symposium said the impact on pending cases could be limited because asbestos related cancers are known to take decades to develop  The FDA s new finding  would be difficult to tie  to cancers allegedly caused by long ago exposures  said Edward Ulloa  a Los Angeles based lawyer who does not represent J J  The FDA findings are  essentially anecdotal   Ulloa said   specific to that product and that particular sample   In its Tuesday announcement  J J said that one of the labs it hired initially found asbestos in three samples of Baby Powder  but the lab determined that a portable air conditioner running when the samples were prepared was contaminated with asbestos  Subsequent tests in a different room found no asbestos  the company said  NO EXPERIENCE  NO ASBESTOS In 2010  when the AMA lab tested 34 talc products for the FDA  including Johnson s Baby Powder  the lab had no experience looking for asbestos fibers in talc milled for powders and cosmetics  Saldivar testified in several depositions that the lab s work had previously focused on determining the amount of asbestos in old building products  such as vinyl flooring  AMA made fast work of the 2010 FDA job  lab records reviewed by Reuters show  His lab examined 102 samples  three from each product  in a single day  using a method called transmission electron microscopy  TEM   That works out to less than five minutes per sample  assuming an eight hour shift with no breaks  Experts who have found asbestos in milled talc powders told Reuters they require anywhere from a half hour to a day per sample using TEM  and litigation records show they often look at more talc per sample than Saldivar has testified is the practice at AMA  In a deposition earlier this year  Saldivar acknowledged that he looked at less talc per sample than others in the field and that looking at more talc  would raise your analytical sensitivity    the ability to find any contamination  But he said he believed that his methods were sufficient  After the AMA lab found no asbestos in 2010  the FDA cautioned against reading too much into the results   not because of the sensitivity of the test but because so few products were tested  Though the agency has described the testing as using the  most sensitive techniques available   it said the results  do not prove that most or all talc or talc containing cosmetic products currently marketed in the United States are likely to be free of asbestos contamination   When J J s lawyers approached Saldivar a few years ago about serving as an expert and testing Baby Powder  they  wanted me to follow my protocols that I used on my FDA testing  in 2010  Saldivar testified in May 2018  In June  he testified that his lab had never found any asbestos in talc samples  including Baby Powder  that it had tested for J J and other manufacturer defendants  The testing by Saldivar s lab for the FDA this year was a different story  
 This positive test turns up the heat on J J   said Nora Freeman Engstrom  a Stanford University law professor who studies complex litigation   And their expert lit the match  ",2019-10-30,Reuters,https://www.investing.com/news/stock-market-news/exclusive-jjs-own-expert-working-for-fda-found-asbestos-in-baby-powder-2007445,2007445
197671,419187,JNJ,Johnson   Johnson  JNJ  Q4 Earnings Beat Estimates,opinion,"Johnson   Johnson  NYSE JNJ  came out with quarterly earnings of  1 88 per share  beating the Zacks Consensus Estimate of  1 86 per share  This compares to earnings of  1 97 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 1 08   A quarter ago  it was expected that this world s biggest maker of health care products would post earnings of  2 per share when it actually produced earnings of  2 12  delivering a surprise of 6  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Johnson   Johnson  which belongs to the Zacks Large Cap Pharmaceuticals industry  posted revenues of  20 75 billion for the quarter ended December 2019  missing the Zacks Consensus Estimate by 0 21   This compares to year ago revenues of  20 39 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Johnson   Johnson shares have added about 2 3  since the beginning of the year versus the S P 500 s gain of 2 8  
What s Next for Johnson   Johnson 
While Johnson   Johnson has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Johnson   Johnson was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 32 on  20 60 billion in revenues for the coming quarter and  9 08 on  85 56 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Large Cap Pharmaceuticals is currently in the top 21  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-01-22,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-q4-earnings-beat-estimates-200500521,200500521
197672,419188,JNJ,Davos Diverts Attention From BoC Decision And Earnings,opinion,"It s a mixed bag across Europe on Wednesday  with much of the headlines coming from Davos where Trump delivered his keynote speech yesterday 






It s always interesting to hear the views of some of the world s most influential people at these events but so far  as many expected  it s having little impact on the markets  It was interesting to hear the President once again blaming the Fed for the slower economy and Dow not being another 10 000 points higher  something I expect we ll hear repeated over and over again this year 
Fear around the spread of coronavirus is not yet having any real impact on markets outside of China but with reports of cases appearing outside the country  that may change  It s difficult to say at this stage how much and quickly it will spread but everyone is clearly very alert to the prospect of this becoming a much greater problem 

While much of the headlines will continue to come from Davos today  it is worth noting that another batch of companies will report on the fourth quarter today including Johnson   Johnson  NYSE JNJ   The Bank of Canada will also announce its interest rate decision  although no change is expected today or for the rest of the year  in fact  That could change though and the statement and press conference will tell us if any shift on the committee is happening 
Path of least resistance lower for gold
Gold s rally on Tuesday didn t last long  a further sign that we re likely trading at the upper end of its range at the moment  The spike earlier this year was driven by increased geopolitical risk and even then  it struggled to break  1 600  The path of least resistance may  therefore  be below  although for now  it is clinging onto the hard fought gains of the last couple of weeks 
Gold Daily Chart






Oil testing  64 after failing at  66
Brent oil prices are pulling back again today  after running quickly low on fuel on the run up to  66  Heightened middle east risk earlier this year saw it briefly top  70 but that was quickly sold into  affirming its place as a major level of resistance  We ve struggled to get close since and  66 now appears to represent a ceiling  The next level of interest is now  64  where price found support in the aftermath of the events in Iran and Iraq 
Brent Daily Chart






Economic Calendar",2020-01-22,Craig Erlam,https://www.investing.com/analysis/davos-diverts-attention-from-boc-decision-and-earnings-200500457,200500457
197673,419189,JNJ,Pharma Stock Roundup  J J s Mixed Q4  Roche   Novartis  New Drugs Approval In EU,opinion,"This week marked the beginning of the fourth quarter 2019 earnings season with J J   NYSE JNJ   announcing mixed results  The European Commission granted approval to two new drugs  Roche s   OTC RHHBY   lymphoma drug  Polivy and Novartis    NYSE NVS   Mayzent for secondary progressive multiple sclerosis  SPMS  Recap of the Week s Most Important Stories J J s Mixed Fourth Quarter Earnings  J J s fourth quarter results were mixed as it beat estimates for  but missed the same for sales  J J s Pharma segment performed above market despite currency headwinds and the impact of biosimilar and generic competition on sales of some key drugs like Remicade and Zytiga  Its 2020 financial guidance was quite lukewarm  Adjusted earnings per share in 2020 are expected in the range of  8 95    9 10  Revenues are expected in the range of  85 4  86 2 billion  indicating year over year growth of 4  5  EU Approvals to Novartis   Roche s New Drugs  The European Commission granted conditional marketing approval to Roche s lymphoma drug    polatuzumab vedotin piiq   The drug has been approved in combination with bendamustine plus MabThera for the treatment of adults with relapsed or refractory  R R  diffuse large B cell lymphoma  DLBCL  who are not candidates for a hematopoietic stem cell transplant  The drug was approved by the FDA in June last year  two months ahead of schedule The regulatory agency also approved Novartis    siponimod   a next generation  selective sphingosine 1 phosphate receptor modulator for adult patients with SPMS with active disease  The drug was approved by the FDA in March last year for a similar indication EU Approval for Expanded Use of J J s Stelara   Darzalex  The European Commission also granted approval for expanded use of J J s blockbuster medicines  Darzalex and Stelara  The regulatory agency approved use of Darzalex in combination with Velcade  bortezomib   thalidomide and dexamethasone  VTd   in newly diagnosed  transplant eligible multiple myeloma patient population  The approval was based on data from a phase III CASSIOPEIA study The EC also approved expanded use of Stelara for the treatment of pediatric patients  ages 6 11  with moderate to severe plaque psoriasis  Stelara is also under review with the FDA for pediatric patients  Stelara is already marked for adolescents and adults with moderate to severe plaque psoriasis  Stelara is also marketed to treat adults with active psoriatic arthritis and moderate to severe Crohn s disease Meanwhile  J J also submitted type II variation application to the European Medicines Agency  EMA   seeking expanded use of Imbruvica in combination with Roche s Rituxan for patients with previously untreated chronic lymphocytic leukemia  CLL  FDA Updates on AstraZeneca s Cancer Drugs  AstraZeneca   NYSE AZN   and Merck   NYSE MRK    announced that the FDA has granted priority review to a supplemental new drug application  seeking label expansion approval of in men with metastatic castration resistant prostate cancer who have a mutation in their homologous recombination repair genes  The disease of these men had progressed on prior treatment with new hormonal agent treatments like Zytiga and Xtandi  making it difficult to treat  The FDA s decision is expected in the second quarter of 2020  The designation was granted based on results from the phase III PROfound study The regulatory agency also granted Orphan Drug Designation to AstraZeneca s PD L1 inhibitor Imfinzi and tremelimumab  an anti CTLA4 antibody  for the treatment of hepatocellular carcinoma  HCC   the most common type of liver cancer  A phase III HIMALAYA study is presently testing Imfinzi monotherapy and Imfinzi plus tremelimumab in first line advanced HCC setting The FDA accepted and granted priority review to Glaxo s   NYSE GSK   BLA  seeking approval for the 2 5 mg dose of in patients with heavily pre treated multiple myeloma   The BLA was based on data from the pivotal DREAMM 2 study  which enrolled heavily pre treated patients who had actively progressing multiple myeloma that had worsened despite current standard of care Roche s SMA Candidate Meets Primary Goal in Study  Roche announced positive data from part 2 of the pivotal FIREFISH study  evaluating its pipeline candidate  in infants with type 1 spinal muscular atrophy  SMA   The study met its primary endpoint which was the proportion of infants sitting without support for at least five seconds at 12 months of treatment  assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition  BSID III   The data showed that risdiplam led to statistically significant and medically meaningful motor milestone improvement in the aforesaid infant patient population Meanwhile  risdiplam is under priority review with the FDA for the treatment of patients aged 2 25 years with type 2 or 3 SMA  A decision from the regulatory body is expected on May 24  2020 Meanwhile  a phase III study evaluating Roche s Tecentriq for adjuvant  after surgery  monotherapy treatment of patients with muscle invasive urothelial cancer did not meet its primary endpoint of disease free survival  DFS  The NYSE ARCA Pharmaceutical Index declined 0 5  in the last four trading sessions Large Cap Pharmaceuticals Industry 5YR   ReturnHere is how the seven major stocks performed in the last four trading sessions   
 
 
 
 
Last week  Glaxo recorded the maximum gain  1 4   while Merck declined the most  2 9   In the past six months  Bristol Myers has risen the most  47 2   while Pfizer   NYSE PFE   lost the maximum  4 6    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for fourth quarter 2019 results of Pfizer  Novartis  Roche and Lilly and regular pipeline and regulatory updates next week Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020 Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ",2020-01-23,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-jjs-mixed-q4-roche--novartis-new-drugs-approval-in-eu-200501383,200501383
197674,419190,JNJ,J J Snack Foods  JJSF  Q1 Earnings Lag Estimates,opinion,"J J  NYSE JNJ  Snack Foods  JJSF  came out with quarterly earnings of  0 89 per share  missing the Zacks Consensus Estimate of  1 01 per share  This compares to earnings of  0 88 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of  11 88   A quarter ago  it was expected that this drink and snack maker would post earnings of  1 42 per share when it actually produced earnings of  1 36  delivering a surprise of  4 23  
Over the last four quarters  the company has surpassed consensus EPS estimates two times 
J J Snack Foods  which belongs to the Zacks Food   Miscellaneous industry  posted revenues of  282 90 million for the quarter ended December 2019  surpassing the Zacks Consensus Estimate by 0 98   This compares to year ago revenues of  271 61 million  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
J J Snack Foods shares have added about 1 2  since the beginning of the year versus the S P 500 s gain of 2  
What s Next for J J Snack Foods 
While J J Snack Foods has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for J J Snack Foods was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 13 on  284 85 million in revenues for the coming quarter and  5 25 on  1 22 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Food   Miscellaneous is currently in the top 29  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/jj-snack-foods-jjsf-q1-earnings-lag-estimates-200501967,200501967
197688,419204,JNJ,J J recalls 33 000 bottles of baby powder as FDA finds asbestos in sample,news,"By Julie Steenhuysen and Lisa Girion  Reuters    Johnson   Johnson  NYSE JNJ  said on Friday it is recalling around 33 000 bottles of baby powder in the United States after U S  health regulators found trace amounts of asbestos in samples taken from a bottle purchased online  J J shares fell more than 6  to close at  127 70  The move marks the first time the company has recalled its iconic baby powder for possible asbestos contamination  and the first time U S  regulators have announced a finding of asbestos in the product  Asbestos is a known carcinogen that has been linked to deadly mesothelioma  The recall is the latest blow to the more than 130 year old U S  healthcare conglomerate that is facing thousands of lawsuits over a variety of products  including baby powder  opioids  medical devices and the antipsychotic Risperdal  A jury last week ordered the company to pay  8 billion to a plaintiff in a case claiming J J downplayed the risks of Risperdal  That award is not expected to stand  the company and legal experts have said   J J faces more than 15 000 lawsuits from consumers claiming its talc products  including Johnson s Baby Powder  caused their cancer  On a conference call with reporters on Friday  Dr  Susan Nicholson  head of Women s Health in the company s medical safety organization  called the asbestos finding  extremely unusual   adding that it was  inconsistent with our testing to date   The voluntary recall announced on Friday is limited to one lot of Johnson s Baby Powder produced and shipped in the United States in 2018  the company said  J J in a news release said that testing by the U S  Food and Drug Administration as recently as a month ago found no asbestos in their talc  The FDA said in a statement that the latest sampling took place during its testing for asbestos in talc containing cosmetics that it began reporting this year  A second Johnson s Baby Powder sample from a different lot tested negative for asbestos  the agency said  The FDA said it stands by the quality of its testing and results and recommended consumers stop using the product if it comes from the affected lot  J J said on the conference call that it received a report from the FDA on Oct  17 alerting the company about the asbestos finding  It said it has started an investigation and is reviewing manufacturing records and collecting data on the distribution of the lot to determine where the product was shipped  J J added that it is working with the FDA to determine the integrity of the tested sample as well as the validity of test results  THOROUGH INVESTIGATION NEEDED The type of asbestos discovered by FDA testing has not been found in the mine where the company sources its talc  J J s Nicholson said  She described it as an environmental contaminant most commonly found in building materials and industrial applications  J J said it was too early to confirm whether cross contamination of the sample had caused a false positive  whether the sample was taken from a bottle with an intact seal or whether the it was prepared in a controlled environment  It added that it could not confirm whether the tested product was authentic or counterfeit   It is so critical that we perform a thorough investigation of the sample to determine the source of contamination   Nicholson said  Since 2003  talc in Johnson s Baby Powder sold in the United States has come from China through supplier Imerys Talc America  a unit of Paris based Imerys SA and a co defendant in much of the talc litigation  Imerys and J J said the Chinese talc is safe   J J has known for decades that asbestos lurked in its talc  Reuters reported last year  Internal company records  trial testimony and other evidence show that from at least 1971 to the early 2000s  the company s raw talc and finished powders sometimes tested positive for small amounts of asbestos  Company executives  mine managers  scientists  doctors and lawyers fretted over the problem and how to address it  while failing to disclose it to regulators or the public  Reuters found  J J has repeatedly said that its talc products are safe  and that decades of studies have shown them to be asbestos free and that they do not cause cancer  The FDA test indicated the presence of no greater than 0 00002  of chrysotile asbestos in the tested sample  J J said  The World Health Organization and other authorities recognize no safe level of exposure to asbestos  While most people exposed never develop cancer  for some  even small amounts of asbestos are enough to trigger the disease years later  Thousands of the lawsuits against J J have been consolidated before a New Jersey federal judge  who is currently weighing company motions to disqualify plaintiffs  expert witnesses  including the head of an asbestos testing lab who has testified in earlier trials that he found the contaminant in J J powders  Leigh O Dell  one of the lead plaintiff attorneys  on Friday said the recall  vindicates the position we ve been taking for months    Wells Fargo   NYSE WFC  analyst Larry Biegelsen said in a research note that the recall could encourage additional lawsuits and prompt the company to pursue a broader settlement  Jefferies healthcare strategist Jared Holz said J J has already lost close to  10 billion in market value due to the talc issue over the past year  He said further downside to J J stock is likely to be limited because legal concerns over talc are well known and have already taken a toll on the share price   This is one single bottle within one lot with barely a trace here   he said  J J said in February that it had received subpoenas from the U S  Justice Department and the Securities and Exchange Commission for documents related to the asbestos contamination allegations  A Bloomberg report  which Reuters has confirmed  said those inquiries include a criminal grand jury investigation into how forthright J J has been in its statements about the safety of its powders  
While talc products make up less than 1  of J J sales expected by analysts to reach  82 billion in 2019  the New Jersey based healthcare products maker considers its Baby Powder to be an essential facet of a carefully tended image as a caring company   Reporting and writing by Julie Steenhuysen in Chicago  additional reporting by Lisa Girion and Chad Terhune in Los Angeles  Caroline Humer in New York  Tamara Mathias and Ankur Banerjee in Bengaluru and Daniel Levine in San Francisco  Editing by Bill Berkrot ",2019-10-18,Reuters,https://www.investing.com/news/stock-market-news/jj-to-recall-single-lot-of-baby-powder-as-fda-finds-traces-of-asbestos-1999110,1999110
197689,419205,JNJ,J J slashes third quarter profit by  3 billion over proposed opioid deal,news," Reuters    Johnson   Johnson  N JNJ  on Wednesday lowered its previously reported third quarter profit by  3 billion to account for a proposed opioid settlement payment  A framework settlement  announced on Monday  was hammered out by some drugmakers and distributors and attorneys general in North Carolina  Pennsylvania  Tennessee and Texas  The proposed deal will need broad support among all the state attorneys general and local governments that have sued the companies over the opioid crisis  J J  which is facing thousands of lawsuits over a variety of products  lowered its reported profit to  1 8 billion  or 66 cents per share  from  4 8 billion  or  1 81 per share  and said there was no impact to its adjusted earnings numbers  The company said it could not predict when or if the opioid deal would be finalized    J J  has to disclose it now   and take the accounting hit  Later they can come back and adjust the impact on an actual payment settlement on their goodwill when the actual cost of the settlement comes into focus   Brian Quinn at Boston College Law School said  Reuters reported last week citing sources that drug distributors McKesson Corp  N MCK   AmerisourceBergen Corp  N ABC  and  Cardinal Health   N CAH  have offered to pay  18 billion in cash over 18 years  while drugmaker Johnson   Johnson  N JNJ  would pay  4 billion in cash  
The drug industry faces roughly 2 600 lawsuits brought by state and local governments  hospitals and other entities seeking to hold drugmakers and distributors responsible for the toll of opioid abuse ",2019-10-23,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-says-proposed-opioid-settlement-to-lower-reported-third-quarter-profit-by-3-billion-2002704,2002704
197690,419206,JNJ,JNJ Stock Pattern Suggests Uptrend Is Almost Over,opinion,"Despite its top quality  Johnson   Johnson didn t fully participate in the post 2009 bull market  Johnson   Johnson  NYSE JNJ  stock is up 224  since the bottom of the Financial Crisis  while the Dow Jones added 354  in the same period 
However  JNJ stock climbed to a new all time high last week in a breakout that makes the bulls very excited about the future  But are they right to feel optimistic  That is the question we hope to answer with the help of the  and the chart below 






JNJ s weekly chart reveals the entire price structure from the 2009 bottom at  46 25  As you can see  it is a textbook   labeled I II III IV V  It unfolded within the parallel lines of a trend channel and the sub waves of wave III are also visible 
The market apparently took the guideline of alternation into account  too  Wave II was a sharp plunge  while wave IV moved sideways in a   Triangles precede the final wave of the larger sequence  If this count is correct  the current rally must be wave V 
The theory postulates that a three wave correction in the other direction follows every impulse  For JNJ stock  this means we can expect a bearish reversal once wave V is over  The anticipated retracement has the potential to erase the entire fifth wave 
A decline back to the  of wave IV or even lower is very likely   110 a share seems like a reasonable target in the next couple of years  The risk reward ratio doesn t look very favorable to the bulls with the stock around  150 ",2020-01-21,EWM Interactive,https://www.investing.com/analysis/jnj-stock-pattern-suggests-uptrend-is-almost-over-200500187,200500187
197691,419207,JNJ,J J s  JNJ  Q4 Earnings Surpass Estimates  Sales Fall Short,opinion,"Johnson   Johnson s   NYSE JNJ   fourth quarter 2019 earnings came in at  1 88 per share  which beat the Zacks Consensus Estimate of  1 86  Earnings  however  declined 4 6  from the year ago period Adjusted earnings exclude after tax intangible amortization expense and some special items  Including these items  J J reported fourth quarter earnings of  1 50 per share  up 33 9  from the year ago quarter Sales of the drug and consumer products giant came in at  20 75 billion  which missed the Zacks Consensus Estimate of  20 79 billion  Sales rose 1 7  from the year ago quarter  reflecting an operational increase of 2 6   which offset an unfavorable currency impact of 0 9  Organically  excluding the impact of acquisitions and divestitures  sales increased 3 4  on an operational basis  less than 5 2  increase seen in the previous quarter Sales declined sequentially in Pharmaceutical and Medical Devices segments on an organic basis but improved slightly in the Consumer unit Fourth quarter sales rose 1 4  in the domestic market to  10 77 billion and 2 1  in international markets to  9 97 billion  However  international sales reflected 4  operational growth  which was offset by 1 9  negative currency impact  Excluding the impact of all acquisitions and divestitures  on an adjusted operational basis  international sales rose 4 1  in the quarter Segment DetailsPharmaceutical segment sales rose 3 5  year over year to  10 55 billion  reflecting 4 4  operational growth  which was offset by 0 9  negative currency impact  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 4 5   declining from 6 4  increase in the previous quarter The sales increase was led by the company s oncology drugs Imbruvica and Darzalex as well as psoriasis treatment  Stelara Worldwide sales of J J s oncology drugs rose 9 1  in the quarter to  2 72 billion  Other core products like Stelara  Simponi Simponi Aria and Invega Sustenna also contributed to growth  However  sales of new immunology medicine  Tremfya  disappointed in the quarter  Moreover  sales of some other key drugs like Xarelto were soft in the quarter  Sales of others like Zytiga  Remicade  Tracleer  Procrit Eprex declined due to the impact of generic biosimilar competition Darzalex sales rose 42 1  year over year to  830 million in the quarter  Stelara sales rose 17 7  to  1 7 billion in the quarter  Imbruvica sales rose 24 5  to  875 million in the quarter  Please note that J J markets Imbruvica in partnership with AbbVie  Inc    NYSE ABBV    Invega Sustenna sales rose 14 2  to  871 million in the quarter Simponi Simponi Aria sales rose 6 6  to  515 million in the quarter  Newly launched Tremfya recorded sales of  270 million in the quarter compared with  290 million in the third quarter Zytiga sales declined 13 8  to  677 million in the quarter  Sales of Invokana Invokamet declined 22 2  to  177 million  Xarelto sales rose 0 4  in the quarter to  609 million  Sales of Procrit Eprex declined 17  to  183 million in the quarter  Sales of Remicade were down 16 4  in the quarter to  1 04 billion  Please note that J J markets Remicade in partnership with Merck   NYSE MRK   In the quarter  J J recorded pulmonary arterial hypertension revenues of  623 million  down 6 7  year over year  Strong demand for Uptravi and Opsumit was offset by a decline in Tracleer sales  We remind investors that Teva Pharmaceutical Industries Limited   NYSE TEVA   launched a generic version of Tracleer in the United States in June 2019 Medical Devices segment sales came in at  6 63 billion  down 0 5  from the year ago period  reflecting an operational increase of 0 2  and negative currency movement of 0 7  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 2 7   less than 5 3  in the previous quarter The Consumer segment recorded revenues of  3 57 billion in the reported quarter  up 0 9  year over year  On an operational basis  Consumer segment sales increased 2 1   partially offset by unfavorable foreign currency movement of 1 2  Excluding the impact of acquisitions and divestitures  adjusted operational sales growth was 1 4  worldwide  a slight improvement from 1 3  in the previous quarter 2019 ResultsFull year 2019 sales rose 0 6  to  82 06 billion  missing the Zacks Consensus Estimate of  82 17 billion  However  sales were within the guided range of  81 8  82 3 billionAdjusted earnings for 2019 were  8 68 per share  above the Zacks Consensus Estimate of  8 67 and up 6 1  year over year  Earnings were slightly more than the guided range of  8 62    8 67 per share 2020 Guidance J J announced guidance for 2020 Adjusted earnings per share in 2020 are expected in the range of  8 95    9 10  The Zacks Consensus Estimate stands at  9 08 per share  The guidance range indicates growth of 3 1  4 8   On an operational  constant currency basis  adjusted earnings per share are expected to grow in the range of 3 7  5 4   Revenues are expected in the range of  85 4  86 2 billion  indicating year over year growth of 4  5   The Zacks Consensus Estimate stands at  85 56 billion  Operational constant currency sales growth is expected to be in the range of 4 5  5 5   Adjusted operational sales growth   excluding currency impact  acquisitions divestitures  is expected to be in the range of 5  to 6  Our TakeJ J fourth quarter results were mixed as it beat estimates for earnings but missed the same for sales  Its 2020 financial guidance was also quite lukewarm  Shares were down around 1 7  in pre market trading  The stock has returned 15 9  in the past year compared with an increase of 14 7  recorded by the   J J s Pharma segment sales continued to be hurt by the impact of biosimilar and generic competition on sales of some key drugs like Remicade  Tracleer and Zytiga Meanwhile  J J also faces a slew of lawsuits  which allege personal injuries to patients caused by the use of its medicines  mainly its talc and opioid products  These lawsuits have resulted in uncertainty lately  Nevertheless  J J had said in the past that it expects its sales and earnings growth to accelerate in 2020  supported by above market performance of its Pharmaceuticals unit as well as continued improvement in the Medical Devices segment  It also plans to improve the profitability of its Consumer unit while continuing to optimize its portfolio for competitive growth  J J is also making rapid progress with its pipeline line extensions with several pivotal data readouts and regulatory milestones expected in 2020  It gained FDA approval for two new drugs in 2019  Balversa and SpravatoJ J currently has a Zacks Rank  2  Buy   You can see   Johnson   Johnson Price  Consensus and EPS Surprise
    
Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ",2020-01-21,Zacks Investment Research,https://www.investing.com/analysis/jjs-jnj-q4-earnings-surpass-estimates-sales-fall-short-200500623,200500623
197704,419220,JNJ,Johnson   Johnson agrees to pay about  117 million to settle U S  states  mesh probe,news," Reuters    Johnson   Johnson  NYSE JNJ  has agreed to pay nearly  117 million to resolve allegations that it deceptively marketed transvaginal surgical mesh devices  U S  state attorneys general said on Thursday  The settlement resolves a multistate investigation that found J J violated consumer protection laws by misrepresenting the safety and effectiveness of its devices and failing to sufficiently disclose risks associated with their use  the attorneys general said  Thousands of women have sued the company and its Ethicon unit alleging that they were injured by its pelvic mesh devices  which are used to treat bladder issues and pelvic organ prolapse  in which organs shift from their normal positions  The settlement resolves claims with 41 states and the District of Columbia   The deal does not cover lawsuits over J J s mesh marketing by four states  California  West Virginia  Kentucky and Mississippi  which remain pending   A trial in California s case concluded in September  though a decision has not yet been issued  The state of Washington settled a similar case in April for  9 9 million  J J in a statement on Thursday said the settlement contains no admission of liability or misconduct on the part of Ethicon  Earlier this year  the U S  Food and Drug Administration ordered makers of all implants to immediately stop their sale and distribution amid claims that they caused pain  perforations  urinary problems  bleeding and other serious injuries  J J in 2012 stopped selling mesh implants for pelvic organ prolapse  though it continues to market devices for use in treating incontinence  J J shares have been under pressure this year  widely underperforming the S P healthcare sector  as the company faces tens of thousands of lawsuits alleging deceptive marketing and harm from side effects caused by its products  including baby powder  opioid drugs and medical devices  On Wednesday  two people familiar with the matter told Reuters the company would pay  4 billion in cash to resolve lawsuits seeking to hold it responsible for partly fueling the U S  opioid crisis  
Last week  a jury hit J J with  8 billion in punitive damages for a case involving its anti psychotic drug Risperdal  highlighting the risks an all or nothing legal strategy could have ",2019-10-17,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-agrees-to-pay-about-117-million-to-settle-vaginal-mesh-litigation-1998402,1998402
197717,419233,JNJ,Massive jury award against J J highlights risks of its legal strategy,news,"By Carl O Donnell and Tom Hals  Reuters    A jury award that hit Johnson   Johnson  N JNJ  with  8 billion in punitive damages for a case involving its anti psychotic drug Risperdal highlights the risks of the drugmaker s all or nothing legal strategy  several legal experts told Reuters on Wednesday   The jury in a Philadelphia court awarded the  8 billion to a man who previously won  680 000 over his claims that it failed to warn that young men using Risperdal could grow breasts  J J called the sum  grossly disproportionate with the initial compensatory award  and said it was confident it would be overturned  Legal experts agreed that the penalty was likely to be slashed  But the verdict  which helped drive J J s shares down 2  on Wednesday  is an example of how public outrage at the pharmaceutical industry for high drug prices has contributed to harsher verdicts against drugmakers accused of wrongdoing in recent years  legal experts said  Outsized penalties awarded by some juries highlight risks in a longstanding strategy by drugmakers such as J J of taking their chances at trial rather then settle product liability lawsuits brought by patients   Every pharmaceutical company needs to seriously consider if they want to litigate to verdict in the present environment  but with the settlement demands so incredibly high it s not always clear what their alternative is   said Barry Thompson  a partner at Baker McKenzie law firm who was not involved in the case  Drugmakers often prefer to litigate rather than settle in hopes of protecting their brands and discouraging future patient lawsuits  Thompson said  Companies also may use a series of early trial verdicts to gauge the size of any settlement it might eventually offer  as Merck   Co  N MRK  did with its withdrawn Vioxx arthritis pain drug when facing thousands of lawsuits by patients who claimed harm from the drug   A 2003 U S  Supreme Court decision suggests that the upper limit of a fair punitive penalty in the Risperdal case would be about  6 million based on the earlier compensatory award   J J could still get a favorable ruling on appeal that would give the company leverage in dealing with the remaining cases  said Benjamin McMichael  a professor at the Alabama School of Law who has researched punitive damage awards   With such a large punitive damages award at issue  appellate courts may be more willing to come down hard on the plaintiffs   McMichael said  J J faces more than 13 000 lawsuits tied to Risperdal alleging that it caused a condition called gynecomastia in boys  in which breast tissue becomes enlarged  The company is also facing lawsuits involving its baby powder  opioids  medical devices and other products   We re operating within a very litigious environment  and we must at times be willing to go to trial when the science  facts and law are on our side   J J spokesman Ernie Knewitz said in an email   We also have to remain open to resolving cases through settlement when and where that s appropriate to do  We have a proven track record of being able to successfully and appropriately manage this balance   Knewitz added  The company has had its share of legal wins  losses and settlements  An Oklahoma judge in August ordered J J to pay  572 1 million to that state for its part in fueling the opioid crisis by deceptively marketing addictive painkillers  although the sum was substantially less than investors had expected  Johnson   Johnson has said it plans to appeal the ruling   Earlier this month  the company agreed to pay  20 4 million to settle claims by two Ohio counties  avoiding a federal opioid trial  
In 2013  J J paid more than  2 2 billion to resolve civil and criminal investigations by the U S  Department of Justice into its marketing of Risperdal and other drugs ",2019-10-09,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-hit-as-jury-awards-excessive-8-billion-in-damages-1993905,1993905
197718,419234,JNJ,J J Earnings  Revenue Beat in Q3,news,"Investing com   J J  NYSE JNJ  reported third quarter earnings and revenue that beat analysts  expectations on Tuesday 
The firm reported earnings per share of  2 12 on revenue of  20 73B  Analysts polled by Investing com forecast EPS of  2 on revenue of  20 1B  That compared to EPS of  2 05 on revenue of  20 35B in the same period a year earlier  The company had reported EPS of  2 58 on revenue of  20 56B in the previous quarter 
J J follows other major Healthcare sector earnings this monthOn October 8  Helen of Troy Ltd reported second quarter EPS of  2 24 on revenue of  414M  compared to forecasts of EPS of  1 88 on revenue of  391 86M 
Neogen earnings missed analysts  expectations on September 24  with first quarter EPS of  0 28 on revenue of  101 42M  Investing com analysts expected EPS of  0 3 on revenue of  105 16M
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-10-15,Investing.com,https://www.investing.com/news/stock-market-news/jj-earnings-revenue-beat-in-q3-1996338,1996338
197719,419235,JNJ,Prescription drugs boost drives J J forecasts higher  shares rise,news," Reuters    Johnson   Johnson  N JNJ  boosted its profit forecast for the year on Tuesday after posting better than expected quarterly earnings on stronger prescription sales of its psoriasis treatment Stelara and cancer drug Imbruvica  Shares of the company  which makes products ranging from prescription drugs to consumer goods such as Band Aids  rose 2  to  133 48 in premarket trading   J J shares have been under pressure this year  widely underperforming the S P healthcare sector  SPXHC   as the company faces more than 13 000 lawsuits tied to antipsychotic drug Risperdal as well as a range of lawsuits involving its baby powder  opioids  medical devices and other products   J J did not report litigation expenses for the third quarter and its legal costs over the nine month period remained at  832 million  as was reported at the end of the second quarter  JP Morgan analyst Chris Schott said litigation risk remains a clear overhang on the shares  but added that the results will likely be well received and continue to believe that analysts  estimates remain too low   J J s pharmaceuticals business has in recent years cushioned the impact of relatively slow growth in its other medical device and consumer units even as some of the company s older drugs face competition from cheaper versions  Much of the growth has come from newer treatments such as Stelara  which reported a near 30  growth in sales to about  1 7 billion  Sales from cancer treatment Imbruvica rose about 31  to  921 million in the quarter   The company on Tuesday said it now expects full year adjusted earnings per share in the range  8 62 to  8 67  from its prior forecast of  8 53 to  8 63  Analysts were expecting  8 60 per share  Net earnings rose to  4 83 billion  or  1 81 per share  in the quarter  from  3 93 billion  or  1 44 per share  a year earlier   Excluding items  the company earned  2 12 per share  beating analysts  expectations of  2 01 per share  according to IBES data from Refinitiv   Total sales rose 1 9  to  20 73 billion  above the average analysts  estimate of  20 07 billion  
Pharmaceutical unit sales rose 5 1  to  10 88 billion  above analysts estimates of  10 28 billion  according to a Refinitiv poll of three analysts ",2019-10-15,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-posts-23-rise-in-thirdquarter-profit-1996345,1996345
197720,419236,JNJ,Johnson   Johnson  JNJ  Expected To Beat Earnings Estimates  What To Know Ahead Of Q4 Release,opinion,"Johnson   Johnson  NYSE JNJ  is expected to deliver a year over year decline in earnings on higher revenues when it reports results for the quarter ended December 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The earnings report  which is expected to be released on January 22  2020  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This world s biggest maker of health care products is expected to post quarterly earnings of  1 87 per share in its upcoming report  which represents a year over year change of  5 1  
Revenues are expected to be  20 79 billion  up 2  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 2 81  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Johnson   Johnson 
For Johnson   Johnson  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 77  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination indicates that Johnson   Johnson will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Johnson   Johnson would post earnings of  2 per share when it actually produced earnings of  2 12  delivering a surprise of  6  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Johnson   Johnson appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2020-01-15,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release-200499046,200499046
197721,419237,JNJ,Will J J  JNJ  Roll Out Pharma Q4 Earnings With A Beat ,opinion,"We expect Johnson   Johnson   NYSE JNJ   to beat expectations when it reports fourth quarter 2019 results on Jan 22  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 6  The healthcare bellwether s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The company has a four quarter positive earnings surprise of 4 27   on average Johnson   Johnson Price and EPS Surprise   J J s stock has risen 13 4  in the past year  compared to an increase of 14 3  for the  
  Factors to ConsiderJ J s Pharma segment has been putting up an above market performance despite currency headwinds and the impact of biosimilar and generic competition on sales of some key drugs like Zytiga  Remicade  Procrit Eprex  Please note that J J markets Remicade in partnership with Merck   NYSE MRK    The positive trend is expected to have continued in the fourth quarter J J s oncology drugs  Imbruvica and Darzalex as well as psoriasis treatment  Stelara are likely to have driven sales growth in the fourth quarter  The FDA granted approval to Stelara for a new indication   moderately to severely active ulcerative colitis in October 2019  which is likely to have contributed to the drug s sales in the fourth quarter  The Zacks Consensus Estimate for Imbruvica  Darzalex and Stelara is pegged at  895 million   769 million and  1 71 billion  respectivelyOther core products like Simponi Simponi Aria and Invega Sustenna and new drugs like immunology medicine Tremfya and prostate cancer drug Erleada are also likely to have contributed to growth  However  generic biosimilar headwinds might reflect on the Pharma unit s sales Meanwhile  sales of J J s some other drugs like Invokana Invokamet and Xarelto were soft in the three quarters reported so far  Xarelto s sales declined as prescription growth was offset by increased discounts and rebates  We do not expect much improvement in fourth  quarter sales of these drugsSales in J J s Medical Devices unit improved in the third quarter  In the Consumer Unit  sales declined sequentially as growth in beauty and over the counter products due to innovation was offset by lower baby care products due to prior year re launch activities  It remains to be seen if third quarter Consumer unit sales have improved The Zacks Consensus Estimate for J J s Pharmaceuticals  Consumer and Medical Device segments is  10 47 billion   3 59 billion and  6 75 billion  respectively On the third quarter conference call  J J had said that R D costs could be higher in the fourth quarter due to potentially increased investment in the pipeline  Moreover  fourth quarter 2018 earnings had benefited from  800 million of adjusted other income primarily due to the LifeScan divestiture which was missing in the fourth quarter of 2019 On the investor call  management is likely to face questions about talc and opioid litigation issues J J faces more than 16 000 lawsuits for its talc based products  primarily its baby powders  The lawsuits allege that its talc products contain asbestos  which caused many women to develop ovarian cancerIn early October  J J announced a voluntary recall of one lot of its Johnson s The recall was initiated following tests done by the FDA  which revealed traces of asbestos in samples from one bottle purchased online  In early December  J J announced that a total of  were conducted by two different third party labs on the same bottle of Johnson s Baby Powder that was previously tested by the FDA  The tests found no asbestos J J also faces thousands of other lawsuits related to abuse of its opioid based drugs  These lawsuits claim that J J is one of the several companies whose opioid based drugs were responsible for fueling the state s opioid epidemic Earnings WhispersOur proven model shows that J J is likely to beat estimates this quarter because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for a likely positive surprise Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate of  1 88 and the Zacks Consensus Estimate of  1 87  is  0 77   You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  J J has a Zacks Rank  2 Other Stocks to ConsiderHere are some other large drug biotech stocks that have the right combination of elements to beat on earnings this time around Regeneron Pharmaceuticals   NASDAQ REGN   with an Earnings ESP of  2 20  and a Zacks Rank  3  The company is scheduled to release results on Feb 6  You can see  Novartis   NYSE NVS   has an Earnings ESP of  4 35  and a Zacks Rank  3  The company is scheduled to release results on Jan 29 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2020-01-16,Zacks Investment Research,https://www.investing.com/analysis/will-jj-jnj-roll-out-pharma-q4-earnings-with-a-beat-200499576,200499576
197722,419238,JNJ,Is Johnson   Johnson  JNJ  A Good Pick For Value Investors ,opinion,"Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Johnson   Johnson  Inc    NYSE JNJ   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Johnson   Johnson has a trailing twelve months PE ratio of 16 90  as you can see in the chart below 
This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 20 57  If we focus on the stock s long term PE trend  the current level puts Johnson   Johnson s current PE ratio slightly below its midpoint  which is 17 12  over the past five years 
Further  the stock s PE compares favorably with the Zacks Medical sector s trailing twelve months PE ratio  which stands at 23 48  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers 
 We should also point out that Johnson   Johnson has a forward PE ratio  price relative to this year s earnings  of just 16 18  so it is fair to say that a slightly more value oriented path may be ahead for Johnson   Johnson s stock in the near term too P CF RatioAn often overlooked ratio that can still be a great indicator of value is the price cash flow metric  This ratio doesn t take amortization and depreciation into account  so can give a more accurate picture of the financial health in a business  This is a preferred metric to some valuation investors because cash flows are  a  generally less prone to manipulation by the company s management and  b  are less affected by variation in accounting policies between different companies The ratio is generally applied to find out whether a company s stock is overpriced or underpriced with reference to its cash flows generation potential compared with its competitors  However  it is not commonly used for cross industry comparison  as the average price to cash flow ratio varies from industry to industry In this case  Johnson   Johnson s P CF ratio of 17 01 is lower than the Zacks Large Cap Pharmaceuticals industry average of 19 35  which indicates that the stock is somewhat undervalued in this respect 
Broad Value OutlookIn aggregate  Johnson   Johnson currently has a Value Style Score of B  putting it into the top 20  of all stocks we cover from this look  This makes JNJ a solid choice for value investors What About the Stock Overall Though Johnson   Johnson might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of C and a Momentum score of B  This gives JNJ a VGM score or its overarching fundamental grade of B   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been encouraging  The current quarter has seen one estimate go higher in the past thirty days compared to none lower  while the current year estimate has seen a similar trend in the same time period This has had a noticeable impact on the consensus estimate  as the current quarter consensus estimate has inched up 0 5  in the past one month  while the current year estimate has nudged up 0 1   You can see the consensus estimate trend and recent price action for the stock in the chart below Johnson   Johnson Price and Consensus
    This somewhat favorable trend is why the stock has just a Zacks Rank  2  Buy  and why we are looking for better performance from the company in the near term Bottom LineJohnson   Johnson is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Boasting a strong industry rank  top 21  out of more than 250 industries  and a solid Zacks Rank  the company deserves attention right now  In fact  over the past one year  the sector has clearly underperformed the broader market  as you can see below So  value investors might want to wait for industry trend to turn favorable in this name first  but once that happens  this stock could be a compelling pick 
7 Best Stocks for the Next 30 Days
Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  
Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2020-01-16,Zacks Investment Research,https://www.investing.com/analysis/is-johnson--johnson-jnj-a-good-pick-for-value-investors-200499669,200499669
197736,419252,JNJ,Jury says J J must pay  8 billion in case over male breast growth linked to Risperdal,news,"By Brendan Pierson and Nate Raymond NEW YORK  Reuters    Johnson   Johnson  NYSE JNJ  must pay  8 billion in punitive damages to a man who previously won  680 000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could grow breasts  a Philadelphia jury said on Tuesday  The Philadelphia Court of Common Pleas jury s verdict in favor of Nicholas Murray came in the first case in which a Pennsylvania jury had been able to consider awarding punitive damages in one of thousands of Risperdal cases pending in the state   This jury  as have other juries in other litigations  once again imposed punitive damages on a corporation that valued profits over safety and profits over patients   Murray s lawyers  Tom Kline and Jason Itkin  said in a joint statement   Johnson   Johnson and  subsidiary  Janssen chose billions over children   J J said the award was  grossly disproportionate with the initial compensatory award in this case  and the company is confident it will be overturned   It added that the jury in the case had not been allowed to hear evidence of Risperdal s benefits  Professor Carl Tobias of the University of Richmond School of Law said he expects the punitive damages to be lowered on appeal  citing a U S  Supreme Court decision which found that  few awards exceeding a single digit ratio between punitive and compensatory damages  to a significant degree  will satisfy due process   Tobias said the verdict was about sending a message   A jury  if it s outrageous enough conduct  will award a big number and let the lawyers and judges work it out   he said  Tobias added that the verdict could be a sign that J J will face more large damages awards in other Risperdal cases   The kind of evidence in this trial may persuade another jury or judge to do something similar   he said  Murray  like other male plaintiffs in the mass tort litigation over Risperdal  alleges that he developed breasts after being prescribed the medicine when he was a minor  The U S  Food and Drug Administration approved the drug in late 1993 for treating schizophrenia and episodes of bipolar mania in adults  Plaintiffs claim that J J failed to warn of the risk of gynecomastia  the development of enlarged breasts in males  associated with Risperdal  which they say the company marketed for unapproved uses with children  In his lawsuit  Murray  now 26  alleged that he developed breasts after his doctors began prescribing him Risperdal off label in 2003 after a psychologist diagnosed him with autism spectrum disorder  Doctors are allowed to prescribe medicines as they see fit  while companies are only allowed to promote their drugs for approved uses   A jury in 2015 awarded Murray  1 75 million after finding J J was negligent in failing to warn of the risk of gynecomastia  A state appeals court upheld the verdict in February 2018 but reduced it to  680 000  Plaintiffs in the mass tort litigation had been barred from seeking punitive damages since 2014  when a state court judge ruled that the law of New Jersey  which prohibits punitive damages and is J J s home state  should be applied globally to the cases  
But a Pennsylvania Superior Court ruling in 2018 cleared the way for punitive damages awards  holding that the law of each plaintiff s state should instead apply ",2019-10-08,Reuters,https://www.investing.com/news/stock-market-news/jj-must-pay-8-billion-in-case-over-male-breast-growth-linked-to-risperdal-jury-1993611,1993611
197737,419253,JNJ,Top 5 Things to Know in the Market on Wednesday,news,"Investing com    Hopes for a limited trade deal spark a modest bounce in stocks  while Turkey gets ready to invade Syria and the Federal Reserve prepares to release the minutes from its last policy meeting  Here s what you need to know in financial markets on Wednesday  9th October 
1  Trade hope springs eternal
China remains open to a partial trade deal with the U S   despite a spate of interventions over the last couple of days that had seemed to banish any hope of meaningful progress  according to Bloomberg 
China would accept a limited deal as long as no more tariffs are imposed by President Donald Trump  including two rounds of higher duties set to take effect this month and in December  it cited an official as saying  In return  Beijing would offer to buy more U S  agricultural products  albeit without conceding anything major on issues like subsidies for state owned firms 
The offshore Chinese yuan strengthened to an intraday high of 7 1348 to the dollar on the news  but further gains will depend on whether the U S  signals greater willingness to accept a narrow deal in the short term  President Donald Trump said at the weekend the prospect didn t interest him 
2  Stocks set to open higher
The choppy week for U S  stock markets looks set to continue  with major indices poised to regain around two thirds of Tuesday s losses at the opening   mostly on the back of the positive noises from China 
By 6 AM ET  Dow futures were indicated up 201 points or 0 8   while S P 500 Futures were up 27 points or 0 9  and Nasdaq 100 Futures were up 1 1  
It s a quiet day for earnings and economic data  although the Federal Reserve will release the minutes of its latest policy meeting at 2 PM ET  1800 GMT  
Yields on U S  Treasury bonds were a fraction higher as the appetite for risk returned  The 2 Year yield rose two basis points to 1 44   while the 10 Year rose by the same to 1 56    
3  Johnson   Johnson  NYSE JNJ  hit with  8 billion Risperdal verdict  Levi s beats expectations
Johnson   Johnson  NYSE JNJ  was ordered by a Philadelphia jury to pay a Maryland man  8 billion because its antipsychotic drug Risperdal caused him to grow enlarged breasts 
It was the biggest award to date among the 13 000 suits that J J faces over Risperdal  While it s unlikely to be upheld on appeal  it s a new source of legal risk for a company that has already had to pay heavily for issues relating to its opioid drugs and its talc baby powder   The shares fell 1 5  in after hours trading on the news 
Also in focus  Levi Strauss  NYSE LEVI  shares may be due a pop at opening after the company beat expectations with its third quarter earnings after the bell on Tuesday 
4  Turkish troops enter Syria
Turkish forces and Syrian rebel allies are set to cross the border into Syria  shortly   newswires quoted a Turkish official as saying  in an operation that could open a new chapter in Syria s ruinous eight year old war 
The move has put pressure on the Turkish lira  with traders mindful that President Donald Trump threatened to  obliterate the Turkish economy  in his  great and unmatched wisdom  if the country s forces attacked Syrian Kurds  which had enjoyed the protection of the U S  until this week  when Trump announced he would pull U S  forces out of the country 
The lira  which weakened to within touching distance of a three month low on Tuesday  edged lower again on Wednesday 
5  Crude inventories data due
The U S  government will release its weekly update on U S  oil supplies at 10 30 AM ET  An increase of 1 4 million barrels in crude inventories is expected by analysts 
Last week s surprisingly strong increase of 3 1 million barrels had refocused the market on the issue of weakening global demand as the world economy slows down  A further warning may be on the cards today  given that the American Petroleum Institute s data  released Tuesday  showed a 4 1 million barrel increase in stocks 
By 6 AM ET  revived hopes for a U S  China trade deal had helped U S  crude futures recoup the losses they suffered on the API data  WTI Futures were at  53 16 a barrel  up 1 0  on the day  while Brent futures were up 1 0  at  58 80 ",2019-10-09,Investing.com,https://www.investing.com/news/economy/top-5-things-to-know-in-the-market-on-wednesday-1993775,1993775
197738,419254,JNJ,Why Johnson   Johnson  JNJ  Could Beat Earnings Estimates Again,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Johnson   Johnson  NYSE JNJ   which belongs to the Zacks Large Cap Pharmaceuticals industry 
This world s biggest maker of health care products has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 6 31  
For the last reported quarter  Johnson   Johnson came out with earnings of  2 12 per share versus the Zacks Consensus Estimate of  2 per share  representing a surprise of 6   For the previous quarter  the company was expected to post earnings of  2 42 per share and it actually produced earnings of  2 58 per share  delivering a surprise of 6 61  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for Johnson   Johnson  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Johnson   Johnson currently has an Earnings ESP of  0 77   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  2  Buy  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on January 22  2020 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  though this is not the only reason why their shares gain  Additionally  some stocks may remain stable even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2020-01-13,Zacks Investment Research,https://www.investing.com/analysis/why-johnson--johnson-jnj-could-beat-earnings-estimates-again-200498408,200498408
197753,419269,JNJ,Bayer hires former J J executive for more pharma deals,news,"FRANKFURT  Reuters    Bayer  DE BAYGn  said it hired Johnson   Johnson  N JNJ  executive Marianne De Backer to manage acquisitions and licensing deals at its drugs unit  as the German drugmaker turns to outside sources to boost its development pipeline 
De Backer will take the role of Head of Business Development   Licensing at Bayer s pharmaceuticals division  joining from rival J J  where she lead business development activities across different therapeutic areas and regions 
Based in Berkeley  California  the Belgian national will have a more senior role than her predecessor  reporting directly to the head of pharmaceuticals  Stefan Oelrich  and taking a seat on the division s Executive Committee 
Bayer said last year it would lean more strongly on external firms and institutions for a better drug development pipeline  which most analysts regard as too thin to make up for an expected decline in revenues from its two pharma bestsellers from about 2024 
Bayer has recently agreed deals to sell a stake in a chemical park operator  consumer health brands Dr  Scholl s and Coppertone  as well as its animal health unit in a bid to reduce the debt burden from its  63 billion takeover of  Monsanto   NYSE MON  ",2019-09-03,Reuters,https://www.investing.com/news/stock-market-news/bayer-hires-former-jj-executive-for-more-pharma-deals-1968942,1968942
197754,419270,JNJ,Will J J Be Able To Overcome Its Legal Troubles In 2020 ,opinion,"Johnson and Johnson   NYSE JNJ   has the most diversified revenue stream among large cap pharma companies  The company s portfolio comprises several blockbuster drugs approved for a broad range of diseases as well as medical devices and consumer products However  with such a diverse revenue stream  the company also faces several legal issues across its verticals  Although the company posted strong quarterly sales and profits  raised sales guidance thrice and saw rapid pipeline progress  it witnessed share price  during the year due to its ongoing litigations J J faces a slew of lawsuits  which allege personal injuries to patients caused by the use of its medicines  mainly its talc and opioid products  These lawsuits have resulted in uncertainty Talc LitigationsThe lawsuits allege that the company s talc based products  primarily its baby powders  contain asbestos  which may cause ovarian cancer  There are more than 16 000 lawsuits pending related to these products  In 2018  J J was ordered by a Missouri court to pay  4 7 billion in damages to 22 women who made such allegations  However  the company has appealed against the decision  Earlier this month  the company provided  from 155 tests on its talc based products conducted by two different third party labs  The test results showed no trace of asbestos in the products  However  the company s pending litigations related to its talc based products will continue to remain an overhang in 2020 Opioid LitigationsApart from talc based products  the company has been in the news in 2019 for its alleged involvement in opioid based drug abuse in the United States in the past two decades along with Teva Pharmaceuticals   NYSE TEVA    Mallinckrodt   NYSE MNK   and Endo International   NASDAQ ENDP    The company has been named in more than 2 500 lawsuits filed by various state and local governments in the United States related to the marketing of its opioid drugs including Duragesic  Nucynta and Nucynta ER In August  J J was  by a district court in Oklahoma to pay  572 million to the state in connection with a lawsuit filed by the latter  In October  J J  with two counties of Ohio for  10 million plus other cost reimbursements  in connection with the multi district opioid case in Ohio  The company is planning to enter an agreement with several state attorney generals in attempt to resolve all pending opioid litigations for  4 billion  A criminal investigation was  last month by federal prosecutors in Brooklyn on opioid manufacturers and distributors Other LawsuitsJ J faces more than 13 000 similar lawsuits alleging that use of its antipsychotic drug  Risperdal causes enlargement of breast tissues in boys  a condition called gynecomastia  The company has been  to pay  8 billion in punitive damages related to Risperdal use in October  The company is also facing several other injury claims and patent litigations against several of its products ConclusionWe expect volatility in J J s share price to subside and start an uptrend going forward in 2020 as the litigation issues are already priced in its stock now  Although 2019 was a volatile year for J J  it still managed to outperform its broader  industry in the past year  Moreover  the company s sound cash resources are expected to help it absorb any costs related to legal issues   J J s anticipated growth in 2020 is also backed by its strong fundamentals  The company registered sales growth across all its divisions in the first nine months of 2019  Sales growth is expected to continue as the company has been raising its guidance every quarter this year  The company expects its Pharmaceutical unit to deliver above market growth in 2020 on the back of strong performance of its core products including Imbruvica  Darzalex  Stelara and others   It is also developing several of its marketed drugs for new indications or treatment settings  J J announced promising data from several pivotal studies and made rapid progress with its pipeline and line extensions in 2019  J J gained FDA approval for two new drugs and line extensions for several drugs in 2019  These approvals are likely to drive sales in 2020 as well The company is also working on turning around its Medical Devices business by developing innovative products  expanding global presence and implementing novel commercial models  Sales in the segment improved in 2017 and 2018 from 2016 levels  J J is optimistic that this segment will deliver above market growth by 2020 driven by innovation  strategic partnerships  portfolio management and new business models Johnson   Johnson Price
    J J currently carries a Zacks Rank  2  Buy   You can see  Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 top tickers for the entirety of 2020 These 10 are painstakingly hand picked from over 4 000 companies covered by the Zacks Rank  They are our primary picks to buy and hold ",2019-12-29,Zacks Investment Research,https://www.investing.com/analysis/will-jj-be-able-to-overcome-its-legal-troubles-in-2020-200495437,200495437
197755,419271,JNJ,Pacira s  PCRX  Exparel Meets Key Goals In C Section Study,opinion,Pacira BioSciences  Inc    NASDAQ PCRX   announced that the phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section  C section  achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours  P 0 001  The study also achieved the key secondary endpoint with Exparel demonstrating statistical significance for reduction in the incidence and severity of itching through 72 hours following surgery Per the company  169 patients undergoing elective C section in the study were randomized to receive either 150 mcg morphine spinal anesthesia   standard of care postoperative pain regimen  50 mcg morphine spinal anesthesia plus Exparel transversus abdominis plane  TAP  field block or an opioid free spinal anesthesia   Exparel TAP block Notably  in the EXPAREL arms  patients were administered with a protocol defined postoperative pain management regimen comprising ketorolac  acetaminophen and ibuprofen  Importantly  the Exparel TAP block demonstrated superiority over morphine spinal based standard of care Shares of Pacira have rallied 11 3  in the past year compared with the  rise of 0 3  We remind investors that in January 2019  Pacira announced that its phase IV study on Exparel  which evaluated patients undergoing Cesarean section  C section   met the primary endpoint with a statistically significant decrease in total postsurgical opioid consumption throughout 72 hours The CHOICE study is a follow up on this study  which is designed to evaluate a completely opioid free arm with Exparel including opioid free spinal anesthesia Exparel is a liposome injection of bupivacaine  indicated for single dose administration into the surgical site to produce postsurgical analgesia Exparel revenues grew 23  year over year during the first nine months of 2019  Continued adoption of the drug for TAP and infiltration procedures for abdominal plus genitourinary surgeries should boost its sales going forward  The company is currently looking for partners to expand the medicine s geographical footprint In June 2019  the European Medicines Agency accepted the marketing authorization application for Exparel to treat postsurgical analgesia  An opinion from the Committee for Medicinal Products for Human Use is expected in the second half of 2020 Notably  Pacira has partnership with Johnson   Johnson   NYSE JNJ   wherein the latter continues to support the uptake of Exparel through its world class educational programs and orthopedic procedural solutions for the former Zacks Rank   Stocks to ConsiderPacira currently carries a Zacks Rank  3  Hold   Better ranked stocks in the same sector include Dermira  Inc    NASDAQ DERM   and Verrica Pharmaceuticals Inc    NASDAQ VRCA    both sporting a Zacks Rank  1  Strong Buy   You can see  Dermira s loss per share estimates have narrowed 1 2  for 2020 over the past 60 days  The stock has skyrocketed 108 3  in the past year Verrica Pharmaceuticals  loss per share estimates have narrowed 4 4  for 2020 over the past 60 days  The stock has jumped 26 7  in the past year The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2020-01-07,Zacks Investment Research,https://www.investing.com/analysis/paciras-pcrx-exparel-meets-key-goals-in-csection-study-200497285,200497285
197770,419286,JNJ,New look board for drugmaker Boehringer Ingelheim,news,"FRANKFURT  Reuters    German drugmaker Boehringer Ingelheim will enter next year with a new look executive board after the retirement of two of its top executives and another of the positions on the six person executive board becoming redundant 
Allan Hillgrove  head of pharmaceuticals and biopharma and a company veteran of 37 years  will retire at the end of the year and will be replaced by Carine Brouillon  who joined unlisted Boehringer from Johnson   Johnson  N JNJ  in 2018 
The head of Boehringer s animal health unit  Joachim Hasenmaier  will also retire at the end of the year  to be succeeded by Jean Scheftsik de Szolnok  currently head of Boehringer s French business 
Boehringer became the world s second largest animal health company when it acquired Sanofi s  PA SASY  Merial business in 2017 but it is set to drop a place in the ranking when Elanco  N ELAN  wraps up its agreed purchase of Bayer s  DE BAYGn  veterinary drugs business next year 
Boehringer added that head of personnel Andreas Neumann would quit at the end of September because responsibilities for human resources will be shared by Chief Executive Hubertus von Baumbach and finance chief Michael Schmelmer 
A company spokesman declined to comment whether the departures were connected or coincidental ",2019-08-26,Reuters,https://www.investing.com/news/stock-market-news/newlook-board-for-drugmaker-boehringer-ingelheim-1963524,1963524
197771,419287,JNJ,Why Is Halozyme Therapeutics  HALO  Up 6 1  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Halozyme Therapeutics  HALO   Shares have added about 6 1  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Halozyme Therapeutics due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Halozyme Earnings   Revenues Miss Estimates in Q3Halozyme Therapeutics reported third quarter 2019 loss of 17 cents per share  wider than the Zacks Consensus Estimate of a loss of 12 cents  The company had reported loss of 19 cents in the year ago quarter Total revenues increased 80 5  year over year to  46 2 million  driven by higher product sales  partially offset by lower royalties  However  the top line missed the Zacks Consensus Estimate of  58 82 million Quarter in DetailHalozyme s top line comprises product sales  royalties and revenues under collaborative agreements Royalty revenues were  16 6 million in the third quarter  down 11 2  from the year ago quarter  The decline was due to lower sales of Roche s breast cancer drug  Herceptin SC  which was partially offset by higher sales of Roche s Rituxan Hycela and Takeda s  TAK  HyQvia  These drugs are developed using Halozyme s ENHANZE drug delivery technology Product sales  solely from the sale of bulk rHuPH20 to collaborators using the ENHANZE platform for drug development  increased 365  to  29 2 million in the third quarter  The significant increase was primarily attributable to sales of  20 1 million to Janssen  a subsidiary of J J  NYSE JNJ  Revenues under collaborative agreements were  0 4 million compared with  0 6 million in the prior year quarter Research and development expenses declined 14 1  to  30 5 million primarily due to lower expenses related to clinical studies  as the company progressed toward the completion of HALO 301 study on its lead pipeline candidate  PEGPH20  However  the study was discontinued in November following failure to meet primary endpoint General and administrative expenses were up 20 8  to  18 million in the reported quarter primarily due to costs related to commercialization initiatives to support oncology operations 2019 GuidanceHalozyme lowered its revenue guidance for 2019 to  195  205 million from  205  215 million mentioned earlier  The guidance was lowered due to delay in the initiation of a planned phase III study on a partnered candidate  partially offset by new unplanned target nomination  These activities generate revenues for the company either through product sales or milestone payments  It also lowered its guidance for royalty revenues to  67  69 million from  72  74 million stated previously The company maintained its expectation for year end cash  cash equivalents and marketable securities of  220  230 million  It increased the outlook for operating expenses to  255 265 million from previously mentioned  215 225 million  The increase was led by anticipated one time restructuring costs of  25  27 million  which will be incurred in the fourth quarter 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended downward during the past month  The consensus estimate has shifted  43 75  due to these changes 
VGM Scores
Currently  Halozyme Therapeutics has a poor Growth Score of F  however its Momentum Score is doing a bit better with a D  Charting a somewhat similar path  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Halozyme Therapeutics has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-11,Zacks Investment Research,https://www.investing.com/analysis/why-is-halozyme-therapeutics-halo-up-61-since-last-earnings-report-200492188,200492188
197772,419288,JNJ,Pacira s Late Stage Study On Exparel Label Expansion Positive ,opinion,Pacira BioSciences Inc    NASDAQ PCRX   announced positive results from its phase III PLAY study of Exparel administered as a single dose infiltration in pediatric patients undergoing spinal or cardiac surgeries  The study enrolled 98 patients to evaluate the pharmacokinetics and safety of the drug in two patient groups   aged 12 years to less than 17 years and 6 years to less than 12 years According to the guidance provided by the FDA  the primary objectives of the PLAY study were to evaluate the pharmacokinetics and safety of Exparel  The overall findings of the study were consistent with the pharmacokinetic and safety profiles for adult patients  with no safety concerns identified at a dose of 4 mg kg  The full study results will be submitted for publication in the peer reviewed medical literature later this year These results will provide the foundation for the company s supplemental new drug application  sNDA  in the first half of 2020 seeking expansion of the Exparel label to include children aged six years or above  The pediatric program has been designed in consultation with FDA with a second phase III registration study of Exparel administered as a nerve block in the pediatric setting which is expected to start in 2020 If approved  the drug will be the only local anesthetic approved for use in children However  the stock has gained 6 7  so far this year compared with the  s growth of 11 8  We would like to remind investors that Exparel is a liposome injection of bupivacaine  which is indicated for a single dose administration into the surgical site to produce postsurgical analgesia in the United States  In April 2018  the FDA also approved the expansion of the Exparel label to include administration via nerve block for prolonged regional analgesia  With this nod  the drug became the first long acting  single dose nerve block available for patients undergoing upper extremity surgeries  such as total shoulder arthroplasty or rotator cuff repair Notably  Pacira has a co promotion agreement with DePuy Synthes  part of the Johnson   Johnson   NYSE JNJ    family of companies  to market and promote the use of Exparel for orthopedic procedures in the U S  market  Pacira Pharmaceuticals  Inc  Price    Zacks Rank   Stocks to ConsiderPacira is a Zacks Rank  3  Hold  stock  currently A few better ranked stocks in the medical drugs sector are Ironwood Pharmaceuticals Inc    NASDAQ IRWD   and Jounce Therapeutics Inc    NASDAQ JNCE    both sporting a Zacks Rank  1  Strong Buy   You can see  Ironwood s earnings per share estimates have increased from 55 cents to 78 cents for 2020 in the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters by 135 01   on average   Jounce Therapeutics  earnings per share estimates have increased from  1 64 to  1 92 for 2019 in the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters by 27 10   on average 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops   Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-12-17,Zacks Investment Research,https://www.investing.com/analysis/paciras-latestage-study-on-exparel-label-expansion-positive-200493500,200493500
197773,419289,JNJ,GlaxoSmithKline s Long Acting HIV Regimen Gets CRL From FDA,opinion,GlaxoSmithKline plc s   NYSE GSK   HIV subsidiary  ViiV Healthcare  and partner J J   NYSE JNJ   received a complete response letter  CRL  from the FDA for its investigational long acting injectable regimen of cabotegravir and J J s Edurant  rilpivirine  for the treatment of HIV 1 infection in virologically suppressed adults Glaxo said the CRL was related to to chemistry  manufacturing and controls  CMC  and there were no reported safety issues related to CMC ViiV Healthcare had filed the NDA for the long acting regimen in April which was granted priority review by the FDA in July ViiV Healthcare is an HIV company  majorly owned by Glaxo and Pfizer   NYSE PFE    So far this year  Glaxo s shares have rallied 23 8  compared with the  s 11 9  growth HIV is a key therapeutic area for Glaxo  with successful dolutegravir based regimens   Tivicay  Triumeq and Juluca   in its portfolio  In April  ViiV Healthcare obtained FDA approval for a single tablet  two drug regimen Dovato for the treatment of na ve HIV 1 adults  ViiV Healthcare focuses on advancing HIV care by exploring new treatment paradigms  two drug regimens   modalities  long acting injectables  and mechanisms of actions  including maturation inhibitors and broadly neutralizing antibodies   Other than the long acting  injectable  two drug regimen of cabotegravir and rilpivirine  Glaxo has fostemsavir in its HIV pipeline  developed to treat heavily pretreated HIV patients  An NDA for fostemsavir was filed in December Other key players in the HIV market are Gilead   NASDAQ GILD    Merck  AbbVie  NYSE ABBV  and J J Glaxo currently carries a Zacks Rank  2  Buy   You can see   GlaxoSmithKline plc Price    Just Released  Zacks  7 Best Stocks for Today Experts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year  These 7 were selected because of their superior potential for immediate breakout ,2019-12-22,Zacks Investment Research,https://www.investing.com/analysis/glaxosmithklines-longacting-hiv-regimen-gets-crl-from-fda-200494395,200494395
197785,419301,JNJ,J J says FTC probing efforts to protect arthritis drug Remicade,news,"WASHINGTON  Reuters    The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug  Remicade  violated antitrust laws  the company said in a regulatory filing on Monday  Shares of the company traded marginally down at  132 47  after having closed up 1 7  on Monday   https     J J  NYSE JNJ  said that the FTC had issued a  civil investigative demand   or CID  the equivalent of a subpoena to determine if the contracting practices were legal   Pfizer  Inc  NYSE PFE  filed a lawsuit against J J in 2017  saying its rival s contracts with health insurers for blockbuster rheumatoid arthritis drug  Remicade  were anticompetitive and aimed at blocking sales of Pfizer s biosimilar called Inflectra  Pfizer said in the lawsuit that J J had contracted with many insurers to give discounts in exchange for giving preference to Remicade  and to only pay for Inflectra in cases where Remicade proved to be ineffective  Inflectra was approved in 2016 while Remicade went on the market in 1998  Remicade is an infused treatment for chronic autoimmune disorders and costs about  4 000 per dose  or  26 000 a year  Pfizer said in the lawsuit  J J has denied any wrongdoing and is fighting the Pfizer lawsuit  Pfizer said in a statement that it had received a CID in June    As Pfizer s complaint alleges  J J s unlawful conduct is designed to prevent Inflectra from being able to compete on its primary point of differentiation   price  Today  Inflectra has an average selling price  ASP  that is more than 22  lower than Remicade   the company said in a statement   Despite these facts  J J has not lost substantial volume or share of sales   counter to what should occur in a competitive market   Biosimilars are intended to be lower cost alternatives to expensive biotech medicines  But since they are made from living cells and it is not possible to make an exact copy of the branded medicine  they are not automatically substituted for the existing branded drug the way a generic drug would be  
The drugs treat ailments like rheumatoid arthritis  Crohn s disease and ulcerative colitis ",2019-07-29,Reuters,https://www.investing.com/news/stock-market-news/jj-says-ftc-probing-efforts-to-protect-arthritis-drug-remicade-1938159,1938159
197786,419302,JNJ,Glaxo Files NDA For Fostemsavir For Heavily Pre Treated HIV,opinion,GlaxoSmithKline plc s   NYSE GSK   HIV subsidiary ViiV Healthcare announced that it has submitted a new drug application  NDA  to the FDA for its pipeline candidate fostemsavir for heavily treatment experienced adult patients with HIV The candidate is being developed for use in combination with other antiretroviral agents in heavily pre treated HIV patients  who are unable to form a suppressive regimen due to resistance  intolerance or safety considerations The NDA filing was based on data from the pivotal phase III BRIGHTE study  In July 2019  Glaxo presented week 96 data from the same study at the International AIDS Society Conference on HIV Science held in Mexico City The results showed that treatment with fostemsavir led to improvement in virologic suppression and immunologic response in such patients ViiV Healthcare is an HIV company  majorly owned by Glaxo and Pfizer   NYSE PFE    The company plans to submit regulatory applications for fostemsavir in Europe during the coming months Shares of Glaxo have rallied 18 3  so far this year  outperforming the  increase of 7  Meanwhile  Glaxo s long acting  injectable two drug HIV regimen of cabotegravir plus J J s   NYSE JNJ   Edurant  rilpivirine  is under priority review in the United States with decision expected on Dec 29  2019 from the FDA  The candidate is also under review in Europe Moreover  in April  Glaxo gained FDA approval for Dovato  a single tablet regimen of Tivicay  dolutegravir    lamivudine for treatment na ve HIV patients  Later  it was also approved in the EU in July  The new HIV medicine is off to a strong start in both the United States and the EU We remind investors that HIV is a key therapeutic area for Glaxo with successful dolutegravir based regimens  namely Tivicay  Triumeq and Juluca in its portfolio  HIV sales totaled  3 6 billion in the first nine months of 2019  Upon potential approval  new medicines should further boost sales of the HIV franchise Other key players in the HIV market are Gilead   NASDAQ GILD    Merck  AbbVie  NYSE ABBV  and J J Zacks RankGlaxo currently carries a Zacks Rank  2  Buy   You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2019-12-05,Zacks Investment Research,https://www.investing.com/analysis/glaxo-files-nda-for-fostemsavir-for-heavily-pretreated-hiv-200490657,200490657
197787,419303,JNJ,Pharma Stock Roundup  FDA Updates For RHHBY  AZN  MRK  No Asbestos In Talc Says JNJ,opinion,"This week  the FDA granted approval to Roche s   OTC RHHBY   cancer immunotherapy Tecentriq for expanded use in lung cancer  It also granted priority review status to AstraZeneca   NYSE AZN     Merck s   NYSE MRK   applications looking for label expansion approvals of their PD L1 inhibitors Imfinzi and Keytruda  respectively  Meanwhile  J J   NYSE JNJ   said that two third party labs conducted 155 tests on samples of its baby powders  All these tests confirmed that the talc does not contain asbestos  a known carcinogen Recap of the Week s Most Important Stories FDA Grants Priority Review to AstraZeneca   Merck s Supplemental Applications  AstraZeneca s supplemental biologics license application  sBLA  looking for approval of  for the first line treatment of extensive stage small cell lung cancer was accepted and granted priority by the FDA  With the FDA granting priority review designation  a decision is expected in the first quarter of 2020  The sBLA was based on positive results from the phase III CASPIAN study The regulatory agency granted the same prestigious designation to Merck s supplemental new drug application  sNDA  seeking approval of  for a form of bladder cancer  The sNDA was based on data from the phase II KEYNOTE 057 study  Meanwhile  FDA s Oncologic Drugs Advisory Committee  ODAC  is due to discuss this sNDA at its December 17 meeting  With the FDA granting priority review  Merck expects a decision in January 2020 Meanwhile  Glaxo s   NYSE GSK   HIV subsidiary  ViiV Healthcare submitted a NDA to the FDA seeking approval for its investigational candidate fostemsavir for heavily treatment experienced patients with HIV J J s Tests Say Baby Powder is Free of Asbestos  J J s investigation conducted on the same bottle of Johnson s Baby Powder that was previously tested by the FDA found no   which allegedly caused many women to develop ovarian cancer  In early October  J J announced a voluntary recall of one lot of its Johnson s Baby Powder   The recall was initiated following tests done by the FDA  which revealed traces of asbestos in samples from one bottle purchased online  J J said that a total of 155 tests were conducted by two different third party labs in the same bottle which FDA s contracted lab  Analytical Services  Inc   AMA   had tested as well as samples from the same lot that was recalled and three lots each manufactured before and after the recall  All these tests also confirmed that the talc does not contain asbestos FDA Approval for Expanded Use of Roche s Tecentriq  Roche s cancer immunotherapy  was also approved by the FDA in combination with Celgene s Abraxane and carboplatin for the first line treatment of patients suffering metastatic non squamous non small cell lung cancer without EGFR or ALK genomic tumour aberrations  The approval was based on results from the phase III IMpower133 study  Tecentriq was approved for the same indication in the EU in September Bristol Myers Orencia Gets FDA s Breakthrough Therapy for GvHD  The FDA granted Breakthrough Therapy status to Bristol Myers  BMY  arthritis drug  for a new indication  The prestigious designation is for the prevention of moderate to severe acute graft versus host disease  a potentially life threatening complication after stem cell transplant Meanwhile  Bristol Myers and partner Acceleron Pharma announced that an FDA advisory committee will review its sBLA seeking label expansion of newly approved rare blood disorder drug   in myelodysplastic syndromes  MDS   The FDA s Oncologic Drugs Advisory Committee will do so at its meeting on Dec 18   The sBLA is under review with the FDA with a decision expected on Apr 4  2020   Reblozyl  which was added to Bristol Myers  portfolio with the recent acquisition of Celgene  NASDAQ CELG   was approved by the FDA last month for the treatment of anemia in adult patients with beta thalassemia who require regular RBC transfusions AstraZeneca Merck s Lynparza Approved in China for First Line Ovarian Cancer   AstraZeneca Merck announced that Lynparza was approved in China for first line maintenance treatment of BRCA mutated advanced ovarian cancer  With the approval  it became the only PARP inhibitor approved in this setting in China  It was approved in the United States and EU for the indication in late 2018 and June 2019  respectively  The regulatory filing was based on data from the phase III SOLO 1 study AstraZeneca announced an agreement to sell rights to  and Seroquel XR  a treatment for schizophrenia and bipolar disease in United States and Canadato Cheplapharm Arzneimittel GmbH  AstraZeneca has lost exclusivity for these medicines in these two countries  For the divestiture  AstraZeneca will get an upfront payment of  35million plus future sales contingent payments of up to  6 million  In October  AstraZeneca also sold rights to Seroquel and Seroquel XRin Europe and Russia to Cheplapharm  The transactions are part of the company s efforts to focus on its three main therapy areas of Oncology  Cardiovascular  Renal   Metabolism and Respiratory The NYSE ARCA Pharmaceutical Index was almost flat in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 Here is how the seven major stocks performed in the last five trading sessions Last week  Bristol Myers rose the most  3 5   while AstraZeneca declined the most  2 4   In the past six months  Bristol Myers has risen the most  27 6   while Pfizer   NYSE PFE   lost the maximum  11 3    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ",2019-12-05,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-fda-updates-for-rhhby-azn-mrk-no-asbestos-in-talc-says-jnj-200490686,200490686
197788,419304,JNJ,Geron  GERN  Up 2 4  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Geron  GERN   Shares have added about 2 4  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Geron due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Geron Q3 Earnings Beat EstimatesGeron incurred a loss of 8 cents per share in third quarter 2019  narrower than the Zacks Consensus Estimate of a loss of 14 cents  In the year ago quarter  the company had incurred a loss of 3 cents per share Quarterly revenues were  0 13 million  slightly beating the Zacks Consensus Estimate of  0 1 million  Notably  the top line comprised royalty and license fee revenues received under various non imetelstat license agreements  In the year ago quarter  revenues totaled  0 17 million  The top line declined as the number of active license agreements fell due to the expiry of patents of Geron s underlying technology R D expenses were  11 1 million compared with  2 7 million in the year ago quarter  Transition costs  including resuming sponsorship of imetelstat clinical studies from J J  NYSE JNJ   costs related to the start up of phase III portion of the IMerge study and expansion of development team  resulted in significantly higher R D expenses General and administrative expenses rose 16 3  to  5 million  reflecting legal costs related to patent litigations and recruitment expenses for additional headcounts Geron ended the third quarter with  159 3 million in cash and investments compared with  162 3 million at the end of the second quarter 2019 Guidance MaintainedGeron reiterated the outlook for 2019  The company expects operating expenses of  80  85 million for the year  This includes one time costs of  20  25 million related to activities for transition of imetelstat from Janssen to Geron  and purchase of material for the phase III portion of IMerge study 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended downward during the past month  The consensus estimate has shifted  30  due to these changes 
VGM Scores
At this time  Geron has a poor Growth Score of F  however its Momentum Score is doing a bit better with a D  Charting a somewhat similar path  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Notably  Geron has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-05,Zacks Investment Research,https://www.investing.com/analysis/geron-gern-up-24-since-last-earnings-report-can-it-continue-200490803,200490803
197802,419318,JNJ,Oklahoma  J J to wrap up first trial over opioid crisis,news,"By Heide Brandes NORMAN  Okla   Reuters    Lawyers for the state of Oklahoma on Monday compared Johnson   Johnson  N JNJ  to a drug cartel leader as they sought to hold the drugmaker responsible for fueling the U S  opioid epidemic in the first trial to result from lawsuits over the crisis  Lawyers for the state  including Attorney General Mike Hunter  told a judge in Norman  Oklahoma that J J s  greed  led the drugmaker to carry out a years long marketing effort that caused  utter confusion  about the addictive painkillers  risks  Brad Beckworth  a lawyer for the state  said J J knew opioids were harmful  yet minimized the risk of addiction in their marketing  resulting in a surge in overdose deaths as doctors overprescribed the drugs and they flooded the state   They didn t get here from a Mexican cartel   Beckworth said   They got here from the pharmaceutical cartel  and the kingpin of them all is Johnson   Johnson   The state urged Judge Thad Balkman  who presided over the nonjury trial for six weeks  to find J J liable for creating a public nuisance and force it to pay up to  17 billion over 30 years to address the epidemic  Larry Ottaway  J J s attorney  countered its products  which had included the painkillers Duragesic and Nucynta  were minimally used in Oklahoma and that trial testimony showed doctors were not misled about the drugs  risks before prescribing them  He said New Brunswick  New Jersey based J J strictly adhered to regulations governing opioids  which served a legitimate purpose  and called Oklahoma s multi billion dollar demand  untenable    Only a company that believes its innocence would come in and defend itself against a state  but we take the challenge on because we believe we are right   Ottaway said in his closing argument  Balkman said he would rule after receiving briefs from both sides  due July 31  The case is one of around 2 000 actions by state and local governments accusing drug manufacturers of contributing to the opioid epidemic  Opioids were linked to a record 47 600 overdose deaths in 2017  according to the U S  Centers for Disease Control and Prevention  The Oklahoma case is being closely watched by plaintiffs in other opioid lawsuits  particularly in 1 900 cases pending before a federal judge in Ohio who has been pushing for a settlement ahead of an October trial  
Purdue and Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  were originally also defendants in the case  Purdue reached a  270 million settlement with Oklahoma in March and Teva settled for  85 million in May  Both deny wrongdoing ",2019-07-15,Reuters,https://www.investing.com/news/stock-market-news/oklahoma-jj-to-wrap-up-first-trial-over-opioid-crisis-1923401,1923401
197803,419319,JNJ,Johnson   Johnson Lifts Sales Guidance After Q2 Earnings Beat ,news,"Investing com   Johnson   Johnson  NYSE JNJ  lifted its annual sales outlook for the year after reporting second quarter earnings that beat consensus on the top and bottom line 
The company reported earnings per share of  2 58 on revenue of  20 56 billion   That represented a 1 6  increase in sales in constant currencies  Earrnings were supported by a  2 billion pretax gain on the sale of part of the company s medical devices business  Analysts polled by Investing com forecast EPS of  2 44 on revenue of  20 29 billion 
J J shares trimmed earlier gains after the release and by 7 21 AM ET  11 21 GMT   they were up 0 4  at  135 20 in premarket trade  having stood at  135 84 before the news 
The company raised its guidance for full year sales to between 3 2  and 3 7  in constant currencies  up from a previous range around 3   It left its earnings guidance unchanged 
The shares remain under a cloud of lingering uncertainty while J J seeks to settle thousands of lawsuits   14 000 according to media estimates   that claim its talcum powder caused ovarian cancer 
The company itself admitted in Tuesday s release that it was  unable to predict with reasonable certainty the ultimate outcome of legal proceedings  
Last Friday  the shares fell more than 4  after Bloomberg reported that the U S  Justice Department is investigating whether the company had hidden knowledge of the product s possible risks from the public 
A grand jury in Washington is examining documents that could help shed light onto what the company may have known about any carcinogens in its products  the report said  citing unnamed sources 
Investing com analyst Haris Anwar warned ahead of the release that the litigation could continue to pressure the stock for some time  although he was confident that the company has the  company has the resources to fight these claims  thanks to its wide moat and massive cash generation capabilities  
J J follows other major healthcare sector earnings this month
 On June 18  Bayer AG PK reported second quarter EPS of  0 71 on revenue of  14 5B  compared to forecasts of EPS of  0 69 on revenue of  14 17B 
Helen of Troy Ltd earnings beat analysts  expectations on July 9  with first quarter EPS of  2 06 on revenue of  376 34M  Investing com analysts expected EPS of  1 69 on revenue of  351 54M
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-07-16,Investing.com,https://www.investing.com/news/stock-market-news/jj-earnings-revenue-beat-in-q2-1924589,1924589
197804,419320,JNJ,Johnson   Johnson beats profit estimates on pharma strength  raises sales outlook,news," Reuters    Johnson   Johnson  N JNJ  hiked its full year operational sales forecast as strong demand for its cancer drugs Darzalex and Imbruvica helped it beat estimates for second quarter profit on Tuesday 
Overall strength in J J s pharmaceuticals unit  bolstered by recent approvals for new treatments such as its cancer drug Erleada also helped drive its earnings beat 
Pharmaceutical sales rose 1 7  to  10 53 billion  above analysts  estimates of  10 27 billion  according to three analysts polled by Refinitiv 
The company raised its operational sales forecast for 2019 to  82 4 billion to  83 2 billion  from a prior range of  82 billion to  82 8 billion 
The diversified healthcare company  the first major U S  drugmaker to report second quarter results  said net earnings rose to  5 61 billion  or  2 08 per share  from  3 95 billion  or  1 45 per share  a year earlier 
Excluding items  the company earned  2 58 per share  beating analysts  expectations for  2 46 per share  according to IBES data from Refinitiv 
The company reported a quarterly litigation expense of  409 million  down from  703 million a year earlier 
Sales fell 1 3  to  20 56 billion but came in ahead of estimates for  20 29 billion ",2019-07-16,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-quarterly-profit-jumps-418-1924611,1924611
197805,419321,JNJ,Geron  GERN  Stock Surges 40  YTD  What s Driving The Rally ,opinion,"Geron Corporation s   NASDAQ GERN   shares have surged 40  so far this year compared with the  s growth of 5 2   riding on the progress of its sole pipeline candidate  imetelstat Imetelstat is being evaluated as a treatment for hematologic myeloid malignancies like myelofibrosis   MF   in a phase II IMbark study and myelodysplastic syndromes   MDS   in a phase III IMerge study Notably  both studies are being conducted by Geron  following the termination of the collaboration related to imetelstat development by Johnson   Johnson   NYSE JNJ   last year  The candidate enjoys an Orphan Drug designation for both indications Pipeline ProgressGeron is progressing well with the development of imetelstat  In August  the company initiated the phase III IMerge study and dosed the first patient in October  IMerge is a two part phase II III study evaluating imetelstat in lower risk MDS patients  Previously reported data from the phase II portion of the study showed that patients treated with imetelstat achieved meaningful and durable transfusion independence  as well as potential disease modifying activity  The positive data along with the dosage and dosing schedule from the phase II portion formed the basis of the phase III study Meanwhile  Geron also added new leaders to its development team with vast experience in oncology and drug development to support the progress of imetelstat The company plans to conduct the end of phase II meeting related to the IMbark study in the first quarter of 2020  A decision on the late stage development of imetelstat in MF will be provided after this meeting  In September  the FDA granted Fast Track designation to the candidate as a treatment for primary or relapsed refractory MF  This is likely to facilitate frequent interactions with the FDA for the company to discuss the drug s development plan Although Geron s operating expenses are set to increase due to the cost of imetelstat s development following the termination of the collaboration with J J  it has sufficient funds to start the phase III portion of the IMerge studies However  dependence on a single pipeline candidate is a concern  Any hiccups in the development of imetelstat may hurt Geron s stock significantly  Meanwhile  a regulatory application for Acceleron Pharma   NASDAQ XLRN   luspatercept is under review with the FDA seeking approval as treatment for MDS  A decision from the FDA is expected in April 2020  A potential approval to luspatercept for treating MDS is likely to hurt prospects for imetelstat  Aprea Therapeutics   NASDAQ APRE   is also developing a late stage candidate as treatment for MDS Geron Corporation Price
    Zacks RankGeron currently carries a Zacks Rank  3  Hold  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ",2019-11-28,Zacks Investment Research,https://www.investing.com/analysis/geron-gern-stock-surges-40-ytd-whats-driving-the-rally-200488964,200488964
197806,419322,JNJ,AbbVie  ABBV  Up 10 3  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for AbbVie  ABBV   Shares have added about 10 3  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is AbbVie due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  AbbVie Beats on Q3 Earnings   SalesThird quarter 2019 earnings of  2 33 per share beat the Zacks Consensus Estimate of  2 29 and came in higher than the company s guided range of  2 28  2 30  Earnings rose 8 9  year over year The adjusted earnings excluded a net charge of 56 cents per share related to the impairment of intangible assets acquired as part of the Stemcentrx acquisition Revenues of  8 48 billion surpassed the Zacks Consensus Estimate of  8 41 billion  Sales rose 3  on a reported basis  Excluding currency headwinds  operational revenues increased 3 5   backed by higher sales of several products  which offset the impact of international biosimilar competition for Humira  Revenues were also slightly ahead of the guidance of being approximately  8 4 billionQuarter in DetailsHumira sales declined 3 7   3 2  on an operational basis  to  4 94 billion as higher U S  sales were offset by decline in international markets Sales in the United States increased 9 6  to  3 89 billion  higher than the guidance of approximately 8  growth  driven by strong demand trends  Humira sales in ex U S  markets were down 31 8  on an operational basis and 33 5  on a reported basis to  1 05 billion  However  international sales were slightly higher than the expectation of being approximately  1 billion International sales were severely impacted by the launch of several direct biosimilar drugs in Europe and other international markets  On the call  the company said that biosimilar trends and dynamics were in line with management expectations AbbVie s oncology hematology  including Imbruvica and Venclexta  sales surged 38 5  on an operational basis to  1 5 billion in the quarter  driven by strong growth of both Imbruvica and Venclexta Third quarter net revenues from Imbruvica were  1 26 billion  up 29 3  year over year  slightly higher than the guidance of approximately  1 2 billion  U S  sales of Imbruvica grossed  1 04 billion  up 28 3  from the year ago figure  primarily driven by continued uptake in the front line CLL segment  AbbVie logged  215 million of international profit sharing with J J  NYSE JNJ   up 34 5  year over year Venclexta brought in revenues of  221 million  up more than 100  year over year driven by continued uptake in the broad relapsed refractory CLL setting and the recently approved indications for first line CLL and AML HCV products  including Viekira and Mavyret  recorded sales of  698 million  down 19   down 18 6  on an operational basis  year over year on lower sales of Mavyret as well as Viekira  In the United States  HCV revenues declined 17  to  368 million  International HCV revenues declined 20 4  on an operational basis to  330 million Mavyret sales totaled  695 million in the quarter  down 17 1   down 16 7  on an operational basis  year over year due to a decline in the United States as well as international markets  International sales of Mavyret declined 16 4  in the third quarter on an operational basis due to lower treated patient volumes in some markets  U S sales were down 17  year over year due to increased competition in management Medicaid segment Other products that delivered an encouraging performance include Duodopa  It recorded revenue growth of 14 4  on an operational basis to  117 million  Creon and Synthroid generate sales only from U S  markets  Creon witnessed an increase of 11 2  in revenues to  265 million  Sales of Synthroid grew 2 3  to  197 million  Synagis and Lupron sales increased 35 4  to  132 million and 8 2  to  230 million  respectively  on an operational basis during the quarter Drugs that recorded sales decline include Androgel  Kaletra and Sevoflurane  which fell 61 1   13 9  and 0 9   respectively on an operational basis during the quarter Newly launched drug Orilissa recorded sales of  27 million  entirely from the U S  market versus  19 million in the previous quarter  The sales ramp up of the drug has been slower than expected New immunology drugs Skyrizi and Rinvoq registered sales of  91 million and  14 million  respectively Per the company  both Skyrizi and Rinvoq are off to an impressive start On the call  the company said that Skyrizi is witnessing strong prescription volume  Through the first six months of launch  more than 9 000 patients were treated with the drug including both new patients  and switching patients  Following the solid launch progress  management raised its full year expectations for the drug  for the second time this year  Management expects Skyrizi s full year global sales of approximately  275 million  up from the prior expectation of approximately  250 million Regarding Rinvoq  on the call  the company said that the early uptake trends were encouraging and the medicine is currently covering approximately 6  of in play RA patients Margins RiseAdjusted gross margin rose 30 bps to 82  in the quarter  Adjusted gross margin included a 140 bps benefit due to low Humira royalties owed  Adjusted SG A expenses were almost flat year over year at  1 6 billion  R D expenses were  1 23 billion in the third quarter due to greater investments in the pipeline  Adjusted operating margin was 48 4  of sales in the reported quarter  up120 bps year over year Dividend IncreaseThe company announced a 10 3  increase in its quarterly cash dividend from  1 07 per share to  1 82 per share beginning February 2020 2019 GuidanceAbbVie raised the lower end of its guidance for adjusted EPS to the range of  8 90  8 92 from the previous guidance of  8 82  8 92 for 2019  The earnings guidance indicates a year over year increase of 12 6  at the mid pointRevenues are expected to grow approximately 2 5  on an operational basis in 2019 versus prior growth expectation of approximately 2   Currency headwinds are expected to hurt 2019 revenues by approximately 1   same as the previous expectation In 2019  U S  Humira sales are expected to rise approximately 8 5   previously 8    International Humira sales are expected to be approximately  4 3 billion  down approximately 28  The company expects Imbruvica sales of approximately  4 7 billion  up from prior expectations of  4 6 billion  U S  sales of Imbruvica are expected to rise approximately 28   previously 27    Venclexta sales are expected to be approximately  775 million  Global HCV sales are expected to approach  3 0 billion  versus prior expectation of  3 1 billion Adjusted gross margin is expected to approach 82 5  of sales in 2019  slightly lower than the prior expectation of 83   Operating margin is expected to be just above 47   an increase of roughly 250 basis points year over year  While R D is expected to be approximately 15 5  of sales  SG A is expected to be approximately 20 5  of salesFourth Quarter 2019 OutlookFourth quarter earnings are expected between  2 17 and  2 19 per share  Operational sales growth is expected to be approximately 5   
How Have Estimates Been Moving Since Then 
It turns out  estimates revision have trended upward during the past month 
VGM Scores
Currently  AbbVie has a strong Growth Score of A  though it is lagging a bit on the Momentum Score front with a B  Following the exact same course  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of this revision looks promising  Notably  AbbVie has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-11-30,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-up-103-since-last-earnings-report-can-it-continue-200489107,200489107
197822,419338,JNJ,StockBeat   J J Falls as Justice Department Launches Probe Into Talc Cancer Claims,news,"Investing com   Johnson   Johnson plunged Friday as the Justice Department reportedly launched a criminal investigation into whether the company lied about the possible cancer risks of its talcum powder  
A grand jury in Washington is examining documents related to what company officials knew about any carcinogens in their products  Bloomberg reported  Johnson   Johnson  NYSE JNJ  fell nearly 5   That was enough to subtract 46 points from the Dow on an otherwise bullish day 
The company said in a statement that it is cooperating with the previously announced DOJ investigation and that there are no new developments  It also reiterated its previous denials of wrongdoing 
With Johnson   Johnson  NYSE JNJ  already facing more than 13 000 talc related lawsuits nationwide  the Justice Department probe will do little to ease investor fears the healthcare conglomerate could be on the hook to pay out hefty settlements to claimants  resulting in massive liabilities   
Last month  a California jury ruled in favor of a plaintiff who claimed her use of the company s talc powder caused a rare cancer  In May  the company was ordered to pay out  300 million in punitive damages to women who also claimed the company s talc powder caused asbestos linked cancer 
Reuters said last year that an examination of internal company memos and other documents found the Johnson   Johnson was aware of the presence of asbestos in its products from as early as 1971 but failed to disclose that fact to regulators or to the general public 
The company called the Reuters report  one sided  false and inflammatory  and has continually denied its Baby Powder talc causes cancer  stressing that numerous studies and tests by regulators worldwide have shown that it is safe 
While Baby Powder only makes up a small portion of total revenue  it is a core brand 
Johnson and Johnson is up about 4  this year  The company is set to report quarterly performance on July 16 ",2019-07-12,Investing.com,https://www.investing.com/news/forex-news/stockbeat--jnj-falls-as-justice-department-launches-probe-into-talc-cancer-claims-1922458,1922458
197823,419339,JNJ,Johnson   Johnson faces criminal probe related to baby powder  Bloomberg,news," Reuters    The U S  Justice Department is pursuing a criminal probe into whether Johnson   Johnson  NYSE JNJ  lied about potential cancer risks of its talcum powder and has convened a grand jury in Washington  Bloomberg reported on Friday  citing people with knowledge of the matter  The Bloomberg report said the grand jury was looking into documents related to what company officials knew about any carcinogens in their products     J J disclosed in its annual report in February that it had received subpoenas from the Justice Department and Securities and Exchange Commission related to the ongoing baby powder litigation but did not give more details  The company said in a statement emailed to Reuters on Friday that there had been no new developments in the matter   As we previously disclosed in our February 2019 SEC filing  we have received a subpoena from the U S  Department of Justice  We are fully cooperating with the DOJ investigation   spokesman Ernie Knewitz said in an emailed statement   The Justice Department declined to comment  Shares of the company fell 5  to  133 02 following the report  Johnson   Johnson faces lawsuits involving over 14 000 plaintiffs who allege use of its talc products  including Baby Powder  caused cancer  
A Reuters report on Dec  14 revealed that Johnson   Johnson knew for decades that small amounts of asbestos  a known carcinogen  had been occasionally found in its talc and powder products  according to tests from the 1970s to the early 2000s   information it did not disclose to regulators or the public    ",2019-07-12,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-faces-criminal-probe-related-to-baby-powder-bloomberg-1922393,1922393
197824,419340,JNJ,Halozyme  HALO  Earnings   Revenues Miss Estimates In Q3,opinion,"Halozyme Therapeutics  Inc    NASDAQ HALO    reported third quarter 2019 loss of 17 cents per share  wider than the Zacks Consensus Estimate of a loss of 12 cents  The company had reported loss of 19 cents in the year ago quarter Total revenues increased 80 5  year over year to  46 2 million  driven by higher product sales  partially offset by lower royalties  However  the top line missed the Zacks Consensus Estimate of  58 82 million Shares of Halozyme were down 4 6  in after market trading on Nov 12  following the earnings release  However  the stock has gained 14 6  so far this year compared with the  s 1 2  growth   Quarterly HighlightsHalozyme s top line comprises product sales  royalties and revenues under collaborative agreements Royalty revenues were  16 6 million in the third quarter  down 11 2  from the year ago quarter  The decline was due to lower sales of Roche s   OTC RHHBY   breast cancer drug  Herceptin SC  which was partially offset by higher sales of Roche s Rituxan Hycela and Takeda s   NYSE TAK   HyQvia  These drugs are developed using Halozyme s ENHANZE drug delivery technology Product sales  solely from the sale of bulk rHuPH20 to collaborators using the ENHANZE platform for drug development  increased 365  to  29 2 million in the third quarter  The significant increase was primarily attributable to sales of  20 1 million to Janssen  a subsidiary of J J   NYSE JNJ   Revenues under collaborative agreements were  0 4 million compared with  0 6 million in the prior year quarter Research and development expenses declined 14 1  to  30 5 million primarily due to lower expenses related to clinical studies  as the company progressed toward the completion of HALO 301 study on its lead pipeline candidate  PEGPH20 General and administrative expenses were up 20 8  to  18 million in the reported quarter primarily due to costs related to commercialization initiatives to support oncology operations Business DevelopmentsIn November  Halozyme announced that the phase III study  evaluating a combination regimen of PEGPH20 as a first line treatment for metastatic pancreas cancer  failed to meet the primary end point of overall survival In October 2019  Halozyme s partner Roche nominated one new undisclosed target for evaluation in clinical study  utilizing the ENHANZE technology  This triggered a  10 million milestone payment to Halozyme In September 2019  Roche successfully completed the phase III FeDeriCa study  which evaluated a fixed dose combination of Perjeta and Herceptin for subcutaneous administration  using Halozyme s ENHANZE drug delivery technology  for treating HER2 positive breast cancer In August 2019  Roche initiated a phase I study to evaluate Ocrevus  utilizing the ENHANZE technology in patients with multiple sclerosis In October 2019  Halozyme s another partner Bristol Myers Squibb  NYSE BMY  initiated a phase I study to evaluate relatlimab in combination with Opdivo  utilizing the ENHANZE technology Restructuring InitiativesEarlier this month  Halozyme announced strategic actions as part of its restructuring plan to focus on its ENHANZE drug delivery technology and close oncology operations  These initiatives were planned following the failure of its lead pipeline candidate PEGPH20 in late stage pancreatic cancer study The company will halt all clinical developmental activities related to PEGPH20 and oncology operations  As part of the plan  it will reduce headcount by 55  or 160 employees The restructuring and cost saving efforts are likely to generate savings of  130  140 million in 2020  Halozyme is anticipating a decline in operating expenses  excluding cost of goods sold  of  65  75 million for 2020  most likely driven by lower research   development expenses  following the discontinuation of the PEGPH20 development  The company expects to reach sustainable profitability by the second quarter of 2020  It also authorized the initiation of a share repurchase program worth  350 million to be completed over the next three years 2019 GuidanceHalozyme lowered its revenue guidance for 2019 to  195  205 million from  205  215 million mentioned earlier  The guidance was lowered due to delay in the initiation of a planned phase III study on a partnered candidate  partially offset by new unplanned target nomination  These activities generate revenues for the company either through product sales or milestone payments  It also lowered its guidance for Royalty revenues to  67  69 million from  72  74 million stated previously The company maintained its expectation for year end cash  cash equivalents and marketable securities of  220  230 million  It increased the outlook for operating expenses to  255 265 million from previously mentioned  215 225 million  The increase was led by anticipated one time restructuring costs of  25  27 million  which will be incurred in the fourth quarter Halozyme Therapeutics  Inc  Price  Consensus and EPS Surprise
    Zacks RankHalozyme currently carries a Zacks Rank  2  Buy   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-11-12,Zacks Investment Research,https://www.investing.com/analysis/halozyme-halo-earnings--revenues-miss-estimates-in-q3-200485038,200485038
197825,419341,JNJ,Why Is Johnson   Johnson  JNJ  Down 2 9  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Johnson   Johnson  NYSE JNJ   Shares have lost about 2 9  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Johnson   Johnson due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  J J Q3 Earnings and Sales Beat EstimatesJ J beat third quarter estimates for both earnings and sales and raised its financial outlook for the year Third quarter adjusted earnings came in at  2 12 per share  which beat the Zacks Consensus Estimate of  2 00 and increased 3 4  from the year ago period Adjusted earnings exclude after tax intangible amortization expense and some special items  Including these items  J J reported third quarter earnings of  1 81 per share  up 25 7  from the year ago quarter Sales of  20 73 billion beat the Zacks Consensus Estimate of  20 08 billion  Sales rose 1 9  from the year ago quarter  reflecting an operational increase of 3 2   which offset an unfavorable currency impact of 1 3   Organically  excluding the impact of acquisitions and divestitures  sales increased 5 2  on an operational basis  higher than 3 7  increase seen in the previous quarter Sales rose in all the three segments on an organic basis  It accelerated in the Medical Device and Pharma units but decelerated in the Consumer unit on a sequential basis Third quarter sales rose 1 2  in the domestic market to  10 79 billion and 2 6  in international markets to  9 94 billion  However  international sales reflected 5 4  operational growth  which was offset by 2 8  negative currency impact  Excluding the impact of all acquisitions and divestitures  on an adjusted operational basis  international sales rose 7 3  in the quarter Segment DetailsThe Pharma segment performed above market despite currency headwinds and the impact of biosimilar and generic competition on sales of some key drugs like Remicade and Zytiga At the call  the company said that it is seeing about  2 billion of incremental negative impact from biosimilar and generics which was lower than its guided range of being around  3 billion  This may have contributed to the above market sales growth in the Pharma unit Pharmaceutical segment sales rose 5 1  year over year to  10 88 billion  reflecting 6 4  operational growth  which was offset by 1 3  negative currency impact  Sales in the domestic market rose 4  to  6 34 billion  International sales grew 6 8  to  4 54 billion  operational increase of 10 0    Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 6 4   improving from 4 4  increase in the previous quarter  The sales increase was led by the company s oncology drugs Imbruvica and Darzalex as well as psoriasis treatment  Stelara Worldwide sales of J J s oncology drugs rose 6 7  in the quarter to  2 76 billion  Other core products like Stelara  Simponi Simponi Aria and Invega Sustenna and new immunology medicines like Tremfya also contributed to growth  However  sales of some other key drugs like Xarelto were soft in the quarter  Sales of others like Zytiga  Remicade  Procrit Eprex declined due to the impact of generic biosimilar competition Imbruvica sales rose 30 6  to  921 million in the quarter driven by market share gains and strong market growth primarily in the CLL indication in the United States and solid uptake in the European  Asia Pacific  and Latin America markets Darzalex sales rose 53 5  year over year to  765 million in the quarter  In the United States  market growth and market share gains across all lines of therapy drove sales  In outside U S  markets  increased penetration and share gains drove sales growth Stelara sales rose 29 6  to  1 7 billion in the quarter driven primarily by the Crohn s disease indication PAH revenues of  654 million declined 0 3  year over year as strong demand for Uptravi and Opsumit was partially offset by a decline in Tracleer sales  which were hurt by continued generic competition in Europe and recent generic launch in the United States Simponi Simponi Aria sales rose 9 6  to  586 million in the quarter  Prezista sales rose 3 7  to  508 million in the quarter   Invega portfolio s sales rose 13 7  to  851 million Tremfya recorded sales of  290 million in the quarter compared with  235 million in the second quarter  J J said that the product is seeing strong demand trends with the drug capturing 8 1  share of the psoriasis market in the United States  up 2 5 points from the year ago quarter J J is encouraged by the early sales uptake of new drug Erleada in the United States as well as launch progress in Europe  J J said that Erleada gained almost 3 points of market share in the United States Regarding Spravato  which was approved and launched in the first quarter  J J said that the drug is off to a strong start and patient demand is strong Zytiga sales declined 22 7  to  741 million in the quarter as growth outside the United States was offset by sales decline in the United States due to generic competition  Sales of Procrit Eprex declined 22 4  to  198 million in the quarter due to biosimilar competition Xarelto sales were almost flat in the quarter at  613 million as prescription growth was offset by increased discounts and rebates  Sales of Invokana Invokamet declined 5 8  to  179 million Sales of Remicade were down 17 6  in the quarter to  1 14 billion due to increased discounts and share loss to biosimilars in the United States  While U S  sales declined 24 1   U S  exports went down 12   Remicade sales rose 2 5  in international markets Medical Devices segment sales came in at  6 38 billion  down 3 1  from the year ago period  reflecting an operational decrease of 2  and negative currency movement of 1 1  Excluding the impact of all acquisitions and divestitures primarily the divestitures of LifeScan and ASP  on an operational basis  worldwide sales increased 5 3   better than 3 2  in the previous quarter  Sales in the quarter benefitted by around 80 basis points due to some forward buying ahead of the consumption tax change in Japan in the Vision business Operational growth was driven by continued strong performance of the electrophysiology business in Interventional Solutions  international energy products in Advanced Surgery and contact lenses in Vision  which partially offset softer growth in the orthopedics portfolio due to pricing pressure  However  J J s orthopedics portfolio is showing improving trends supported by innovations and execution of commercial strategies  In orthopedics portfolio  while sales of knees  hips and trauma products rose  sales of spine products declined due to loss of market share Domestic market sales declined 4 4  year over year to  3 06 billion  International market sales decreased 1 9  year over year to  3 33 billion  On an operational basis  international sales increased 0 3  The Consumer segment recorded revenues of  3 47 billion in the reported quarter  up 1 6  year over year  On an operational basis  Consumer segment sales increased 3 3   partially offset by unfavorable foreign currency movement of 1 7  Excluding the impact of acquisitions and divestitures  adjusted operational sales growth was 1 3  worldwide  a deceleration from 2 3  the previous quarter  Growth in beauty and over the counter products due to innovation was offset by lower baby care products due to prior year re launch activities  Sales in the domestic market rose 1 7  from the year ago period to  1 39 billion  Meanwhile  the international segment rose 1 4  to  2 08 billion  An operational increase of 4 3  was offset by negative currency impact of 2 9  in the quarter 2019 GuidanceJ J raised its full year earnings and sales view on strong third quarter results Adjusted earnings per share in 2019 are expected in the range of  8 62    8 67  up from the prior range of  8 53    8 63  The guidance range indicates growth of 5 4 6   previously 4 3 5 5    On an operational  constant currency basis  adjusted earnings per share are expected to grow in the range of 8 1   8 7   up from the prior expectation of 6 7 7 9    Revenues are expected in the range of  81 8  82 3 billion  up from the previous range of  80 8  81 6 billion  including currency impact  Currency impact is expected to negatively hurt sales by 230 basis points  higher than the  previous estimate of 200 basis points  Operational constant currency sales growth is expected to be in the range of 2 5  better than 1 expected previously  Adjusted operational sales growth   excluding currency impact  acquisitions divestitures  is expected to be in the range of 4 5  to 5   higher than 3 2  to 3 7  expected previously J J expects higher R D costs in the fourth quarter due to potentially increased investment in the pipeline  Fourth quarter earnings in 2018 had benefited from  800 million of adjusted other income primarily due to the LifeScan divestiture  which would not be reported in the fourth quarter of 2019 Also the full year tax rate guidance was tightened from 17 5    18 5  to 18    18 5  Preliminary 2020 OutlookJ J expects its Pharmaceutical business to continue to deliver growth above market in 2020 while the sale momentum in its Medical Device unit will continue  It also plans to improve the profitability of its Consumer unit while continuing to optimize its portfolio for competitive growth Update on Talc Opioid LitigationsIn relation to the Philadelphia jury verdict  Joseph Wolk  the company s chief financial officer said that J J is confident that it will be overturned and the amount will be significantly reduced  Regarding  the talc litigations  he said that plaintiff s attorneys have developed big business with class action lawsuits like these  He said that J J will continue the product  which the company knows is safe and does not cause cancer  With respect to opioids  it took two divergent approaches  In Oklahoma  it could not find a reasonable settlement approach and decided to fight it by appealing  In Ohio  the company saw a reasonable amount in proportion to other companies that were involved as defendants  So  it decided to enter into a settlement under appropriate terms 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in estimates review 
VGM Scores
At this time  Johnson   Johnson has a nice Growth Score of B  a grade with the same score on the momentum front  Following the exact same course  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Johnson   Johnson has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-11-13,Zacks Investment Research,https://www.investing.com/analysis/why-is-johnson--johnson-jnj-down-29-since-last-earnings-report-200485324,200485324
197835,419351,JNJ,Exclusive  Sanofi poised to appoint Novartis  Hudson as CEO,news,"By Matthias Blamont PARIS  Reuters    Sanofi  PA SASY  is poised to appoint Paul Hudson  a top executive with Switzerland s Novartis  to become the French drugmaker s next CEO from Sept  1  a source familiar with the decision told Reuters on Thursday  Current Sanofi SA CEO Olivier Brandicourt will leave the company to retire  said the source  who asked not to be named because of the sensitivity of the matter   Hudson has been chosen because of his reputation  He is known as a solid manager and has an expertise in digital relating to pharmaceuticals   the source said  A spokeswoman with Sanofi had no comment   Officials at Novartis AG could not be reached for comment  Reuters had reported on March 18 Sanofi was working to find a successor to Brandicourt  Hudson  born in 1967 according to Novartis  website  has been CEO of Novartis Pharmaceuticals unit since 2016  He is a member of Novartis  executive committee   According to his corporate biography  Hudson joined Novartis from AstraZeneca Plc where he held several senior positions in Japan and the United States  Back in March  sources had told Reuters talks over the future of Sanofi s management were intensifying  The group has an age limit of 65 for its CEO and Brandicourt will be 65 in February 2021  Brandicourt was hired in 2015 to help revive the fortunes of France s biggest drugmaker and has been actively reshaping the business since  Under his tenure  the company swapped its animal health unit to Boehringer Ingelheim in exchange for the German firm s consumer healthcare operations in a  20 billion deal  It has also sold its European generics arm for 1 9 billion euros   2 14 billion  to private equity firm Advent International  New launches such as eczema treatment Dupixent  cost cutting and new priorities setting in research and development have also enabled Sanofi to return to profits in the second half of last year after a series of disappointing quarters due to falling diabetes sales   Brandicourt s teams  however  failed to land two strategic acquisitions  losing out on buying California based cancer specialist Medivation to  Pfizer   NYSE PFE  in 2016  and failing to snatch up Swiss biotech company Actelion  which was bought by Johnson   Johnson  NYSE JNJ  in 2017   But Sanofi regained some momentum last year with the purchase of Belgian biotech company Ablynx for 3 9 billion euros  That followed the acquisition of U S  hemophilia specialist Bioverativ for  11 6 billion  its biggest deal for seven years  Brandicourt said he hoped the two transactions will help Sanofi build a strong franchise in rare blood disorders  In February  the U S  Food and Drug Administration approved Ablynx s most promising asset  the experimental drug caplacizumab for treating the blood disease acquired thrombotic thrombocytopenic purpura  
Sanofi has made rare diseases a top priority since it bought Massachusetts biotech firm Genzyme in 2011 ",2019-06-06,Reuters,https://www.investing.com/news/stock-market-news/exclusive-french-drugmaker-sanofi-poised-to-appoint-novartis-paul-hudson-as-next-ceo-1891071,1891071
197836,419352,JNJ,Drugmaker Sanofi appoints Novartis  Hudson as CEO,news,By Matthias Blamont PARIS  Reuters    Sanofi  PA SASY  has appointed Novartis executive Paul Hudson to replace CEO Olivier Brandicourt who will retire in September  France s biggest drugmaker said on Friday  Hudson will take over on Sept  1  Sanofi said  confirming a Reuters report published on Thursday and marking the latest transfer of a Novartis executive to a competitor  UK born Hudson  51  has been CEO of the Novartis Pharmaceuticals  one of the Swiss company s three main divisions  since 2016  Earlier  he worked at Schering Plough and AstraZeneca   Novartis named Marie France Tschudin  president of Novartis unit Advanced Accelerator Applications  AAA   to replace Hudson with immediate effect   Hudson has been chosen because of his reputation  He is known as a solid manager and has digital expertise relating to pharmaceuticals   a Sanofi source said on Thursday  Brandicourt was hired in 2015 to help to revive the fortunes of Sanofi and has been actively reshaping the business  Under his tenure  the company swapped its animal health unit with Boehringer Ingelheim for the German company s consumer healthcare operations in a  20 billion deal  Sanofi also sold its European generics arm for 1 9 billion euros   2 1 billion  to private equity firm Advent International  New launches such as eczema treatment Dupixent  cost cutting measures and new priorities in research and development enabled Sanofi to return to profit in the second half of last year after a series of disappointing quarters  Brandicourt s teams  however  failed to land two strategic acquisitions  losing out to  Pfizer   NYSE PFE  on buying California based cancer specialist Medivation in 2016 and failing to acquire Swiss biotech company Actelion  which was bought by Johnson   Johnson  NYSE JNJ  in 2017  NEW MEDICINES At Novartis  Tschudin takes over a main drugs business with  35 billion in annual sales and a stable of medicines including newly approved  2 1 million per patient gene therapy Zolgensma  the world s most expensive one time therapy  for children with spinal muscular atrophy  Hudson s departure follows the exit of Samit Hirawat  head of oncology drug development  who is to become chief medical officer at Bristol Myers Squibb  NYSE BMY  in a move announced on Wednesday  Novartis is being watched for how successfully it can roll out Zolgensma as well as several other new medicines including Mayzent in a crowded multiple sclerosis field  Tschudin  a Swiss citizen who speaks six languages  joined Novartis in 2017 after working at Celgene  NASDAQ CELG  where she ran its Hematology Oncology business for Europe  Middle East and Africa  Answering to Chief Executive Vas Narasimhan  Tschudin s brief will be continuing the Swiss drugmakers  push into cell and gene therapy for rare diseases  while also building out a diverse portfolio of medicines for heart disease  immunology  liver disease  neuroscience and respiratory ailments   Marie France has a strong record of accomplishments in driving commercial excellence and a culture of inclusiveness and integrity   Narasimhan said ,2019-06-07,Reuters,https://www.investing.com/news/stock-market-news/sanofi-appoints-paul-hudson-as-ceo-to-replace-retiring-brandicourt-1891236,1891236
197837,419353,JNJ,GSK offers concessions to address EU concerns over Pfizer deal,news,"BRUSSELS  Reuters    GlaxoSmithKline has offered concessions to address EU antitrust concerns over its planned joint venture with Pfizer s consumer health business  the European Commission said on Thursday  The EU competition enforcer will decide by July 10 whether to accept the proposal  demand more or open a full scale investigation  according to a filing on its site  
GSK announced the deal in December last year  a move which will put it ahead of rivals Johnson   Johnson  NYSE JNJ   Bayer  DE BAYGN  and Sanofi  PA SASY  ",2019-06-20,Reuters,https://www.investing.com/news/stock-market-news/gsk-offers-concessions-to-address-eu-concerns-over-pfizer-deal-1902661,1902661
197838,419354,JNJ,Oklahoma judge approves Teva s  85 million opioid settlement,news,By Nate Raymond  Reuters    An Oklahoma judge on Monday approved a revised  85 million settlement with Teva Pharmaceutical Industries  NYSE TEVA  Ltd resolving claims by the state s attorney general that the drugmaker helped fuel the U S  opioid epidemic  The decision by Cleveland County District Judge Thad Balkman in Norman  Oklahoma came after the state s attorney general  governor and top lawmakers resolved a dispute over how the money should be deposited and spent   Oklahoma Attorney General Mike Hunter struck an initial settlement with Teva on May 26  just days before the Israel based drugmaker was set to face trial alongside Johnson   Johnson  NYSE JNJ   which is continuing to fight the case  The settlement resolved claims that Teva and other drugmakers helped cause the epidemic by marketing opioids as safe and effective for everyday pain while downplaying their addictive qualities  The case is one of around 2 000 by state and local governments seeking to hold drugmakers responsible for an epidemic the U S  Centers for Disease Control and Prevention says led to a record 47 600 opioid related overdose deaths in 2017  Teva s deal came just days before the Israel based drugmaker was set to face trial in the case  and two days after Oklahoma Governor Kevin Stitt signed a bill into law that required funds recovered in lawsuits by the state to be deposited into the state s treasury  The law followed criticism by state legislators that money from an earlier   270 million settlement in the case with Purdue Pharma LP in March was not deposited in the state s coffers for lawmakers to determine its use  Instead  nearly  200 million of that March settlement went toward creating an addiction treatment and research center at Oklahoma State University  Under Teva s initial settlement  the  85 million was to be deposited into a court controlled account pending the outcome of J J s trial  Hunter s office argued Teva s settlement should be combined with any money J J must pay to help remedy  or abate  what the state says is a public nuisance that will cost  17 5 billion to remedy over 30 years  J J denies the allegations  But Stitt and Republican leaders of the state s legislature argued any funds should be deposited directly with the state s treasury  Under the revised accord  money from Teva s settlement would be deposited in a fund with the state and only be used to address the opioid epidemic  subjected to future legislation  according to court papers  Teva did not admit wrongdoing ,2019-06-24,Reuters,https://www.investing.com/news/stock-market-news/oklahoma-judge-approves-tevas-85-million-opioid-settlement-1906089,1906089
197839,419355,JNJ,Fate of opioid litigation hinges on government  police power ,news,"By Mike Spector and Nate Raymond NEW YORK BOSTON  Reuters    The fate of thousands of lawsuits seeking to hold drugmakers responsible for fueling the U S  opioid epidemic hinges in part on a thorny legal question  Can a company use a bankruptcy to stop lawsuits from cities and states   U S  Bankruptcy Judge Kevin Gross is expected in July to decide whether to halt more than 160 active lawsuits brought by state attorneys general  cities and counties against opioid manufacturer Insys Therapeutics Inc  When it filed for Chapter 11 protection in Delaware earlier this month  Insys requested the cases be paused   A bankruptcy filing would normally halt active litigation immediately  giving a company such as Insys time to reorganize and preserve money that would otherwise be spent fighting the cases   But a longstanding exception in U S  bankruptcy law can keep the lawsuits alive if they are enforcing government officials   police or regulatory power   The exception holds that government actions seeking to enforce laws related to matters such as public health and safety are not automatically stopped by a company s bankruptcy filing as other lawsuits are   State and local officials are suing Insys and other drugmakers in an attempt to address harm from an opioid crisis that has killed nearly 400 000 people between 1999 and 2017  More than half these deaths resulted from prescription painkillers  according to the U S  Centers for Disease Control and Prevention   For a graphic  click   Criminal enterprises   should not be permitted to shield themselves from the consequences of their misconduct by running to bankruptcy court and obtaining the equivalent of a stay that allows them to evade justice   said Minnesota Attorney General Keith Ellison and Maryland Attorney General Brian Frosh in a Tuesday legal filing opposing Insys s request to halt lawsuits   The opioid crisis  is a national public health emergency   they said in the filing  which other state attorneys general supported  including those in New York  New Jersey and Arizona   The interests of the public therefore are served by allowing these police powers actions of the states to continue unfettered by the injunctions that Insys seeks   A spokesman for Insys  which faces trials in Maryland and Minnesota beginning in August  declined to comment beyond the company s court filings   Insys already had reached a  225 million settlement before filing for bankruptcy with the U S  Justice Department  admitting to illegal conduct in resolving claims that it bribed doctors to write prescriptions  including medically unnecessary ones  for a fentanyl spray called Subsys designed to treat cancer pain  The Chandler  Arizona based company still faces  overall  more than 1 000 lawsuits raising similar allegations of deception and fraud in marketing its opioids  The misconduct occurred under a prior management team that has since  entirely turned over  and Insys is now committed to lawful marketing practices  the company said in court papers  Insys contends in bankruptcy court filings that Judge Gross should halt the lawsuits against it regardless of any exceptions  lest the company drain limited financial resources fighting cases on multiple fronts   Allowing the cases to continue would leave less money for creditors  including the very government officials seeking to hold it to account  Insys contends  adding that its request is not an attempt to escape liability   It had less than  40 million in the bank when filing for bankruptcy and predicts spending up to  9 million through December to continue fighting lawsuits  according to court papers  The judge s ruling is expected to influence whether another opioid manufacturer facing 2 000 lawsuits   OxyContin maker Purdue Pharma LP   decides to file for bankruptcy protection  according to a person familiar with the matter and legal experts  A Purdue spokesman declined to comment   A ruling allowing the Insys litigation to proceed could discourage Purdue from seeking bankruptcy protection  while pausing the cases might signal that Chapter 11 bankruptcy proceedings are a viable way to halt lawsuits and take advantage of breathing room to reach a broader settlement with plaintiffs  according to the person familiar with the matter and several legal experts  Insys lawyers are attempting to persuade government officials to agree to voluntarily halt their cases  according to a bankruptcy court filing  Insys is nearing a deal that would effectively halt some of those legal claims against the drugmaker that are consolidated in an Ohio federal court  said Paul Hanly  a lead lawyer for plaintiffs in the opioid litigation  An Insys spokesman declined to comment on the potential agreement   Insys has some legal precedent backing its approach  In 2017  a bankruptcy judge sided with Takata Corp when temporarily halting lawsuits brought by Hawaii  New Mexico and the U S  Virgin Islands against the Japanese supplier of automobile airbags that exploded  finding that allowing the litigation to continue threatened the company s reorganization  That would have harmed creditors  including those seeking to hold Takata accountable for widespread deaths and injuries  the judge ruled  The ruling allowed Takata to focus on completing a sale to a rival  creating a combined company called Joyson Safety Systems  A Joyson representative declined to comment  The Minnesota and Maryland attorneys general argued in their legal filing on Tuesday that Insys has not demonstrated the kind of exceptional circumstances present in the Takata case   an unprecedented automotive recall   that warranted halting government lawsuits  While the outcome in the Insys case is not critical for opioid manufacturers with stronger balance sheets that face lawsuits  such as Johnson   Johnson  NYSE JNJ   it holds significance for the likes of OxyContin maker Purdue  according to several legal experts  In March  Reuters reported that Purdue was exploring filing for bankruptcy protection to address lawsuits alleging it pushed prescription painkillers while downplaying their abuse and overdose risks  according to people familiar with the matter  Purdue s CEO later confirmed the company was considering a bankruptcy filing   
The company has denied allegations it contributed to the opioid crisis  pointing to the U S  Food and Drug Administration approving labels on its drugs carrying warnings about risk and abuse associated with treating pain ",2019-06-26,Reuters,https://www.investing.com/news/stock-market-news/fate-of-opioid-litigation-hinges-on-government-police-power-1907828,1907828
197840,419356,JNJ,J J Snack Foods  JJSF  Q4 Earnings Miss Estimates,opinion,"J J  NYSE JNJ  Snack Foods  JJSF  came out with quarterly earnings of  1 36 per share  missing the Zacks Consensus Estimate of  1 42 per share  This compares to earnings of  1 22 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of  4 23   A quarter ago  it was expected that this drink and snack maker would post earnings of  1 54 per share when it actually produced earnings of  1 63  delivering a surprise of 5 84  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
J J Snack Foods  which belongs to the Zacks Food   Miscellaneous industry  posted revenues of  311 87 million for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 0 46   This compares to year ago revenues of  300 72 million  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
J J Snack Foods shares have added about 31 6  since the beginning of the year versus the S P 500 s gain of 22 7  
What s Next for J J Snack Foods 
While J J Snack Foods has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for J J Snack Foods was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 99 on  282 million in revenues for the coming quarter and  5 30 on  1 22 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Food   Miscellaneous is currently in the bottom 42  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-11-07,Zacks Investment Research,https://www.investing.com/analysis/jj-snack-foods-jjsf-q4-earnings-miss-estimates-200483651,200483651
197841,419357,JNJ,Pacira s  PCRX  Q3 Earnings Top Estimates  Revenues Rise Y Y,opinion,Pacira BioSciences  Inc    NASDAQ PCRX   reported third quarter 2019 earnings of 48 cents per share  surpassing the Zacks Consensus Estimate of 34 cents and also the year ago bottom line of 31 cents Total revenues also increased 25  year over year to  104 7 million from the year earlier number of  83 4 million  Meanwhile  revenues were almost in line with the Zacks Consensus Estimate of  105 million Shares of Pacira were up almost 2 5  following earnings announcement on Thursday  However  the stock has lost 0 9  so far this year against the increase of 3 7  Quarter in DetailPacira s top line mainly comprises product revenues  other product sales and royalty revenues Expare bupivacaine liposome injectable suspension sales came in at  101 7  rising 23  year over year  Also  the same inched up 1 9  sequentially  Exparel is a liposome injection of bupivacaine  which is indicated for single dose administration into the surgical site to produce postsurgical analgesia Newly added product iovera system generated sales of  2 6 million in the reported quarter  reflecting an increase of 30  sequentially We remind investors that in April 2019  Pacira acquired the privately held MyoScience  Inc  following which the former added the latter s iovera system to its portfolio  which is highly complementary to Exparel as a non opioid therapy  Moreover  upon the closing of the acquisition  Pacira changed its corporate name to Pacira BioSciences  Inc Royalty revenues came in at  0 33 million in the reported quarter  down 55  year over year Research and development  R D  expenses  excluding stock based compensation  surged 36 9  to  18 9 million Selling  general and administrative  SG A  expenses  excluding stock based compensation  increased 13 3  to  43 4 million in the reported quarter 2019 OutlookPacira provided its guidance for Exparel sales in 2019 and expects the same in the  400  410 million range  This is intact with the last reported quarter s estimate iovera net product sales are expected in the range of  8   10 million  unchanged from the previous quarter s projection Adjusted R D expenses are expected in the band of  60  70 million while adjusted SG A expense is anticipated with  180  190 million  Both are unaltered from the previous guidance Recent DevelopmentsIn September 2019  Pacira completed enrollment in the phase III study on Exparel for treating pediatric patients aged from six to less than 17 years  The subjects are undergoing spinal or cardiac surgeries  Results from this study will support a supplemental new drug application for Exparel in the United States regarding its label expansion to include children aged six years and above We remind investors that in June 2019  the European Medicines Agency  EMA  accepted Pacira s marketing authorization application  MAA  seeking an approval of Exparel  bupivacaine liposome injectable suspension  as a medicine for postsurgical analgesia  The company expects an opinion from the Committee for Medicinal Products for Human Use  CHMP  in the second half of 2020 Pacira is advancing Exparel in phase IV studies to expand the drug s utilization in areas like cesarean section  spine and hip fracture  On the conference call  management stated that it plans to complete enrollment in the phase IV opioid free C section study known as CHOICE with top line data expected in January 2020 Pacira has partnership with Johnson   Johnson   NYSE JNJ   wherein the latter continues to support the uptake of Exparel with the help of its world class educational programs and orthopedic procedural solutions for the former Pacira BioSciences  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stocks to ConsiderPacira currently carries a Zacks Rank  3  Hold   Better ranked stocks in the same sector include Trillium Therapeutics Inc    NASDAQ TRIL   and Portola Pharmaceuticals  Inc    NASDAQ PTLA    While Trillium sports a Zacks Rank  1  Strong Buy   Portola has a Zacks Rank  2  Buy   You can see  Trillium s loss per share estimates have been narrowed 1 5  for 2019 and 38 5  for 2020 over the past 60 days Portola s loss per share estimates have been narrowed 1 6  for 2019 and 8 2  for 2020 over the past 60 days  The stock has rallied 45 4  year to date Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-11-07,Zacks Investment Research,https://www.investing.com/analysis/paciras-pcrx-q3-earnings-top-estimates-revenues-rise-yy-200484014,200484014
197853,419369,JNJ,Oklahoma takes on drugmakers J J  Teva in landmark opioid trial,news,"By Nate Raymond  Reuters    Gail Box vividly remembers the day in May 2011 when she first learned her 22 year old son Austin  a University of Oklahoma linebacker  was abusing opioid painkillers  It was the day he died of an overdose  In a few months he had gone from taking pills prescribed for a back injury to illicitly obtaining more of the addictive drugs from acquaintances   We did not know he was abusing   she said   At that time  there was a lot of over prescribing  and I think people in his life were able to get him opioids   The question of why painkillers flooded into Oklahoma and the rest of the country will be the a central issue in a trial beginning Tuesday in Norman  Oklahoma  pitting the state against two drugmakers it accuses of fueling the epidemic  Johnson   Johnson  NYSE JNJ  and Teva Pharmaceutical Industries  NYSE TEVA  Ltd  Oklahoma Attorney General Mike Hunter s  17 billion lawsuit is the first to go to trial of more than 2 000 actions by state and local governments accusing opioid manufacturers of contributing to an epidemic linked to a record 47 600 overdose deaths in 2017  according to the U S  Centers for Disease Control and Prevention  The state will seek to convince Cleveland County District Judge Thad Balkman to find that the companies created a public nuisance by using deceptive marking that downplayed their drugs  addictive risks while overstating their benefits  Balkman will rule following the trial  which will last eight weeks  The state resolved related claims against OxyContin maker Purdue Pharma LP in March for  270 million  J J and Teva deny wrongdoing  arguing the state lacks evidence linking any marketing they did to doctors writing unwarranted opioid prescriptions  They also argue that even if they falsely marketed their products  the state cannot prove they caused the opioid epidemic given the role doctors  patients  pharmacists and drug dealers played in it   The FDA approved labels for these prescription pain medications provide clear information about their risks and benefits   New Brunswick  New Jersey based J J said in a statement   The allegations made against our company are baseless and unsubstantiated   Israeli drugmaker Teva in a statement said it has in no way contributed to opioid abuse in Oklahoma and will vigorously defend itself  In the wake of Purdue s March settlement with Oklahoma  the state dropped many of its claims against the other two defendants and shifted its focus primarily to J J  which it claims  acted as the kingpin behind this public health emergency  The state claims J J and Teva deceptively marketed opioids with Purdue by retaining prominent doctors to give talks advocating use of opioids to treat chronic rather than short term pain  It also says the companies funded groups that purported to be independent and these groups in turn promoted the misrepresentations  The state claims J J even marketed painkillers to children  It says the company  which formerly marketed the painkillers Duragesic and Nucynta  also grew and imported the raw materials to make the drugs  MEMORIES OF TOBACCO SETTLEMENT The Oklahoma case is being closely watched by plaintiffs in other opioid cases  particularly some 1 850 mostly municipal and state governments that have sued the same drugmakers in federal court in Ohio  The judge in that litigation is pushing the parties to reach a settlement agreement ahead of a scheduled October trial  Some plaintiffs  lawyers have compared the opioid cases to litigation by states against the tobacco industry that led to a  246 billion settlement in 1998   Paul Hanly  a lead lawyer for the plaintiffs in the Ohio litigation  said the Oklahoma trial could have major implications for a nationwide settlement   We will have an opportunity to see how these theories play out   he said   Anyone who cares about public health issues should care about how the industry  or a portion of the industry  fares in this case   Box said she believes  greed  in the pharmaceutical industry caused the epidemic  Box  whose husband  Craig  will testify  said she hopes any money the state recovers can be used to fund treatment and research to fight opioid addiction  
 Those are the things I m hoping come out of this   she said   Because at least myself and other families who lost loved ones  nothing is going bring them back  ",2019-05-24,Reuters,https://www.investing.com/news/stock-market-news/oklahoma-takes-on-drugmakers-jj-teva-in-landmark-opioid-trial-1878557,1878557
197854,419370,JNJ,Teva Pharm to pay Oklahoma  85 million to settle opioid claims,news,"BOSTON JERUSALEM  Reuters    Teva Pharmaceutical Industries  NYSE TEVA  Ltd said on Sunday it had agreed to pay an  85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that it and other drugmakers helped fuel the U S  opioid epidemic  Teva  the world s largest generic drugmaker  said the settlement  does not establish any wrongdoing on the part of the company  and denied contributing to opioid abuse in Oklahoma  Claims against Teva focused on the branded opioid products Actiq and Fentora as well as generic painkillers it produced  The trial against Israel based Teva  along with Johnson   Johnson  NYSE JNJ   was set to begin on Tuesday  The lawsuit alleged the companies  marketing of the painkiller was to blame for the opioid epidemic  In a statement  Janssen Pharmaceuticals Inc  a J J subsidiary  said it had acted responsibly and was ready for trial  It said it disagreed with what it called Oklahoma s  overly expansive theories  of public nuisance law  and said they should not apply in this situation   At the same time  as with all litigation  if an appropriate resolution is possible that avoids the expense and uncertainty of a trial  we are always open to that option   the company said in a statement  Oklahoma Attorney General Mike Hunter has alleged that J J and Teva  along with OxyContin maker Purdue Pharma LP  carried out deceptive marking campaigns that downplayed opioids  addictive risks while overstating their benefits  The state also alleges the companies  actions created an oversupply of painkillers and a public nuisance that will cost  12 7 billion to  17 5 billion to remedy  Oklahoma resolved its claims against Purdue Pharma LP in March for  270 million  The Oklahoma case is being closely watched by plaintiffs in other opioid cases  particularly some 1 850 mostly municipal and state governments that have sued the same drugmakers in the federal court in Ohio   Teva is pleased to put the Oklahoma case behind it and remains prepared to vigorously defend claims against the company  including the upcoming federal court trial in Cleveland where the majority of the cases are pending   the company said  Attorney General Hunter s office said in a statement the money would be used to address the opioid crisis in Oklahoma and that the J J case is still scheduled to go to trial on Tuesday before Cleveland County District Judge Thad Balkman  
 Nearly all Oklahomans have been negatively impacted by this deadly crisis and we look forward to Tuesday  where we will prove our case against Johnson   Johnson and its subsidiaries   Hunter said in a statement ",2019-05-26,Reuters,https://www.investing.com/news/stock-market-news/oklahoma-reaches-85-million-settlement-with-teva-pharmaceuticals-ahead-of-trial-1879134,1879134
197855,419371,JNJ,Oklahoma  Johnson   Johnson face off in first opioid crisis trial,news,"By Nate Raymond  Reuters    Drugmaker Johnson   Johnson  NYSE JNJ  is set to face trial in a multibillion dollar lawsuit by the state of Oklahoma aimed at pinning the blame for the opioid epidemic on its painkiller marketing  Lawyers for the state and J J are scheduled to appear on Tuesday in a state court in Norman  Oklahoma  to deliver their opening statements at the start of the first trial to result from more than 2 000 similar lawsuits against opioid manufacturers nationally  The lawsuits by state and local governments seek to hold the J J and other companies responsible for a drug abuse epidemic that the U S  Centers for Disease Control and Prevention says led to a record 47 600 opioid related overdose deaths in 2017  Oklahoma Attorney General Mike Hunter alleges J J  along with OxyContin maker Purdue Pharma LP and Teva Pharmaceutical Industries  NYSE TEVA  Ltd  carried out deceptive marking campaigns that downplayed opioids  addictive risks while overstating their benefits  Hunter alleges J J  which marketed the painkillers Duragesic and Nucynta  was  the kingpin behind this public health emergency   growing and importing the raw materials other drugmakers used for their products  The state claims the companies  actions created an oversupply of painkillers and a public nuisance that will cost  12 7 billion to  17 5 billion to remedy  Oklahoma resolved its claims against Purdue in March for  270 million and against Teva on Sunday for  85 million  leaving only J J as a defendant in the nonjury trial before Cleveland County District Judge Thad Balkman    We believe our evidence is persuasive and compelling with regard to their legal responsibility for thousands of deaths and hundreds of thousands of addictions in the state   Hunter said  J J denies wrongdoing  arguing that its marketing efforts were proper and that the state cannot prove it caused the opioid epidemic given the role doctors  patients  pharmacists and drug dealers played   We acted responsibly in providing FDA approved pain medications  and we are ready for trial   J J said in a statement on Sunday  But J J also said it was open to an  an appropriate resolution  that would avoid the expense and uncertainty of a trial  The case is being closely watched by plaintiffs in other opioid lawsuits  particularly the 1 850 cases consolidated before a federal judge in Ohio  who has been pushing for a settlement agreement ahead of an October trial  
Some plaintiffs  lawyers have compared the opioid cases to litigation by states against the tobacco industry that led to a  246 billion settlement in 1998 ",2019-05-28,Reuters,https://www.investing.com/news/stock-market-news/oklahoma-johnson--johnson-face-off-in-first-opioid-crisis-trial-1880081,1880081
197856,419372,JNJ,Overdose victim s father testifies in Oklahoma opioid trial of JJ,news,"By Nate Raymond  Reuters    The father of a university football player who died of a drug overdose provided emotional testimony about the personal cost of the nationwide opioid epidemic on Wednesday during the second day of trial in a lawsuit by the state of Oklahoma accusing drugmaker Johnson   Johnson  NYSE JNJ  of fueling the crisis  The testimony in a state court in Norman  Oklahoma  came during the first trial to result from more than 2 000 similar lawsuits against pharmaceutical manufacturers nationally seeking to hold them responsible for the opioid abuse crisis  Those cases by state and local governments seek to hold the companies responsible for a drug abuse epidemic that the U S  Centers for Disease Control and Prevention says led to a record 47 600 opioid related overdose deaths in 2017  Craig Box  an Oklahoma attorney  testified that he never suspected his son Austin was abusing prescription painkillers until after he was discovered unconscious at a friend s house in 2011 and was taken to a hospital  Holding back tears  Box said he only learned after the death of the 22 year old University of Oklahoma linebacker  who had a herniated disk the year before  that his son had once been prescribed opioids and must have turned to the streets to get more   We had no idea about the prevalence of these drugs and the dangers of these drugs   he said during testimony streamed online by Courtroom View Network  Box was called as a witness to support claims by Oklahoma Attorney General Mike Hunter that J J helped cause the epidemic by marketing opioids as safe and effective for everyday pain while downplaying their addictive qualities  Hunter alleges that deceptive marketing campaigns carried out by J J  along with OxyContin maker Purdue Pharma LP and Teva Pharmaceutical Industries  NYSE TEVA  Ltd  led to an oversupply of addictive painkillers in the state  Oklahoma resolved its claims against Purdue in March for  270 million and against Teva on Sunday for  85 million  leaving J J as the only defendant in the nonjury trial before Cleveland County District Judge Thad Balkman  J J denies wrongdoing  arguing that its marketing efforts were proper and that the state cannot prove it caused the opioid epidemic given the role doctors  patients  pharmacists and drug dealers played  
The state claims that J J s actions created an oversupply of painkillers and a public nuisance that will cost  12 7 billion to  17 5 billion to remedy over the next 20 to 30 years ",2019-05-29,Reuters,https://www.investing.com/news/stock-market-news/overdose-victims-father-testifies-in-oklahoma-opioid-trial-of-jj-1881890,1881890
197857,419373,JNJ,Exclusive  Canada told drugmakers it would limit scope of some new price rules,news,By Allison Martell TORONTO  Reuters    The Canadian government has assured the pharmaceutical industry that new features of its plan to cut drug costs would apply only to new medicines  Health Canada said  offering some relief to drugmakers even as other regulations could still lower prices of medicines already on the market  Drugmakers have argued that new regulations should only apply to newly approved drugs  The Health Canada clarification comes after draft rules published in 2017 sowed confusion over how the government would implement its plan  The new features of the government s proposed regulations  which would take into account cost effectiveness of medicines and their likely impact on government budgets  would be limited to new drugs  Health Canada told Innovative Medicines Canada  IMC  and BIOTECanada  the patented drug industry s main lobby groups  in a letter dated April 8  2019  It added that other parts of the same draft regulation  changing the list of countries Canadian officials use as a basis for comparison when setting maximum prices  would apply to all drugs   Health Canada described the contents of the letter in response to questions  but Reuters has not seen the letter  Canada  like governments around the world  is grappling with the rising cost of drugs  particularly expensive new specialty medicines for cancer and rare diseases  A new national prescription drug program is one of Prime Minister Justin Trudeau s key promises ahead of an October federal election  making tackling prices a priority    The overall intent of the regulatory proposal is prospective application to new drugs   Health Canada said in a statement   There is some scope for this information to affect the prices of drugs already in the marketplace   it added  The department acknowledged that as originally written  the draft regulation would have involved all prescription drugs  new and old  but said that is not its intention  Global drugmakers have campaigned against the Canadian plan  which would change the way a little known federal agency called the Patented Medicine Prices Review Board decides whether high drug prices are legal  Canada s patented drug prices are among the highest in the world  PLAN DELAYED The regulations  originally expected to go into effect in January  were delayed so the government could spend more time reviewing comments  The plan could still be softened or even scrapped  But earlier this month  Minister of Health Ginette Petitpas Taylor said final regulations would be ready soon  IMC  whose members include Merck   Co  Johnson   Johnson  NYSE JNJ    Pfizer  Inc  NYSE PFE  and others  was not satisfied by assurances in the letter   We remain concerned that changes to the group of comparator countries and other aspects of the amendments may be applied to both new and existing products   the organization said in a statement  Applying any new rules to already marketed drugs would create  significant uncertainty  for companies whose business planning is based on existing prices  it added  The industry has said it believes the reforms duplicate processes that already exist  and could hurt Canadians  access to new drugs as well as spending on research and development   We remain committed to working with the government to find alternative solutions that balance the need for more affordable medicines with a competitive regulatory environment for health research   IMC said  Health Canada described the letter as  re confirming  details it had stated publicly before  Asked where those details had been disclosed  a spokesman pointed to a cost benefit analysis cited in the 2017 draft regulations  and an expert review of that analysis that was not made public until Reuters reported on it in February  Patented drug sales in Canada were C 16 8 billion   12 4 billion  in 2017  according to government data  The original cost benefit analysis estimated the new regulations would cost drugmakers C 8 6 billion   6 4 billion  over 10 years  As an alternative to the proposed changes  drugmakers offered to voluntarily give up C 8 6 billion in revenue over the same period  Reuters reported in February  Exactly how much the new rules will reduce prices depends on implementation details that have not yet been decided  Lower prices in Canada could have a ripple effect on drugmakers  most lucrative market   the United States   given recent proposals there to lower medical costs for U S  consumers   The United States is mulling basing drug prices paid under its government Medicare health program on the cost of medicines in other countries  including Canada  And some U S  lawmakers and states are looking into allowing importation of less expensive prescription drugs from Canada ,2019-05-29,Reuters,https://www.investing.com/news/stock-market-news/exclusive-canada-told-drugmakers-it-would-limit-scope-of-some-new-price-rules-1882088,1882088
197858,419374,JNJ,These 21 Safe Funds Pay Monthly  Never Go Down,opinion," Brett  give me some bond funds with big yields  And it d be great if their prices never went down  
My money manager friend was chasing the holy grail of retirement income  He wanted safe payouts from bonds to balance his clients  stock exposure 
 How about the Artisan High Income Fund Investor Shares   I replied   It pays a steady 6  or so  And it never goes down  
Up  Up  Up With Barely a Blip




 The only problem is that it doesn t quite have double digit yearly return potential  And that s prevented me from recommending it to my Contrarian Income Report subscribers  
Our CIR portfolio has returned 11 7  per year since inception  Adding ARTFX to the mix would drag our retirement boat lower 
I prefer price upside alongside my dividends  And for big gains we must consider closed end funds  CEFs   which are bought and sold with less efficiency than blue chip stocks and ETFs 
The dividend dictionary is filled with the latter  We know Johnson   Johnson  NYSE JNJ  for its century old dividend and the SPDR  Bloomberg  Barclays   LON BARC  High Yield Bond ETF  NYSE JNK  because its ticker spells  junk   But few turn the page to the underrated PIMCO Dynamic Credit Income Fund  NYSE PCI  
This is a shame because PCI pays a generous 8 3  today while JNJ yields just 3  and JNK pays 5 6   It s doubly ironic because PCI has more than doubled the returns of its two better known  competitors  
PCI Pays More  Goes Up Faster Than JNJ and JNK




PCI s payout is safe but its price is subject to market whims  As a CEF  the fund has a fixed amount of shares  like an individual stock   This means its price can swing up and down  like an individual stock   Over the long haul this  volatility  works in our favor as patient investors  but it can cause indigestion for folks who watch their tickers daily  or worse  hourly  
The Hare Won  As Long As You Didn t Sell 




And I get it some of you just do check your stock quotes every day  and that s just how it s always going to be  Or you may have plenty of potential action packed into the rest of the portfolio  whether it s dividend growth or cryptocurrencies or weed stocks  I m not judging  and you just want anchors that can help steady the ship and pay you every month no matter what happens 
A bond CEF is a great addition to a  no withdrawal  portfolio  or an account in which you are comfortable letting prices do what they will while you collect your monthly and quarterly payouts  But bond CEF prices are going to fluctuate day to day  while ARTFX is a distribution rock 
Want more bond rocks  Let s dig  Here are 11 more funds that  like ARTFX  meet the following strict criteria 
First  they pay 5  or better  While we re not looking for moonshots  we are looking for meaningful yield 
Second  they ve returned 4 5  or better annualized over the last five years  This means these funds have at least  returned their yields   They re not tapping their own portfolios  or net asset values  NAVs  to pay us 
And finally  their  betas  are in the basement at 0 2 or below  This is the measure of how much the stock swings relative to the broader market  If the S P 500 moved 10 points  we d expect these prices to only move a point or two at most 
The 12 Safest Bond Mutual Funds That Actually Pay




The 12 funds above are all mutual funds  a tribute to the value that an active manager can add in Bondland  Now I know that some investors prefer ETFs  either by choice or by necessity  This is doable but we must widen our strike zone a bit to allow for lower yields and yearly returns 
The 8 Safest Bond ETFs That Actually Pay




As we discussed with ARTFX  I don t anticipate I ll ever formally recommend one of these funds in CIR  Their total returns are unlikely to clear my high single digit yearly hurdle  However  they are good ideas for anyone looking to tie down their portfolio during any market turbulence  These 5  and 6  yields are about as steady as they come 
The Best Bond Funds  CEFs for 8 5  Yields and 78  Returns 
I prefer CEFs to mutual funds and ETFs because 
They yield more  andThey can go up in price more quickly In fact  CEFs flash a crystal clear buy signal when a big price rise is coming  You ll find it in the discount to NAV  which is the percentage by which the fund s market price trails the market value of all the assets in its portfolio  known as the net asset value  or NAV  
This makes our plan simple  wait for the discount to sink below its normal level and make our move  Then we ll keep rolling our dividend cash into that fund until its discount closes  or swings to a premium  
This is exactly what happened when we bought the PIMCO Dynamic Credit and Mortgage Fund  PCI  in my Contrarian Income Report service in May 2016  Not only did we collect the fund s generous dividend  but we won two more ways over the three years we ve held PCI because its 
NAV increased  orange line below   and  Its discount window tightened as its price  blue line  caught up with and eventually surpassed its NAV 2 Ways to Win for 78  Total Returns




We ve earned 78  total returns from PCI  thanks to the dividends we ve collected  the NAV gains we ve enjoyed and the discount window closing entirely and flipping to a premium 
For much of PCI s run  I ve had a  buy  rating on the fund when this  twofer  potential remained in place  making it a perfect destination for both reinvested dividends and new cash my members had available to invest 
For a period of time  though  PCI has cruised along as a  hold  for us  This happened after its price rallied so furiously that its discount window closed 
When this happens  it makes sense to bank our PCI dividends  or  redirect  them to our other Contrarian Income Report buys  and wait for our next buying opportunity 
That s what happened with PCI  Its discount window opened again in the late 2018 selloff   on October 5  to be precise   when its market price fell below my  23 50 buy up to level  Investors who got in then picked up a nice 14  total return  nearly three times the market s gain 
Buy Window Opens  Gains  and Dividends  Ensue




As you can see in the orange line above  your typical S P 500 investor didn t come anywhere close to those returns in that time 
Yours Now  My Next 8    Monthly  Income Buys 
As you can probably guess from the chart above  PCI is trading at a massive premium to NAV now  so I ve switched it back to a hold 
But it s only a matter of time before our buy window slides open again and we can put more cash into this amazing 8 7  yielder 
When you take a no risk trial to Contrarian Income Report  you ll be the first to know when the time is right 
Meantime  if you re looking for some stout monthly high yielders to buy NOW  fear not  I ve got you covered there  too 
Those would be the stocks  high yield REITs and CEFs in my powerful     With just  500K invested  this dynamic collection of investments will hand you a rock solid  40 000 a year income stream  That s easily enough for most folks to retire on 
The best part is you won t have to go back to  lumpy  quarterly payouts to do it  Thanks to this breakthrough portfolio s reliable monthly dividends  you can look forward to the steady drip of  3 333 in income  month in and month out on your  500K  give or take a couple hundred bucks 
Full details on these stalwart income plays are   You ll discover 
An 8 1  payer that s set to rake in huge profits from an artificially depressed sector The brainchild of one of the top fund managers on the planet that s giving out a generous 9 1  yield And a rock steady 6 9  dividend trading at a massive discount to NAV Don t miss your chance to start tapping this retirement changing dividend stream while you can still get in at a bargain 
Disclosure  Brett Owens and Michael Foster are contrarian income investors who look for undervalued stocks funds across the U S  markets  Click here to learn how to profit from their strategies in the latest report   7 Great Dividend Growth Stocks for a Secure Retirement  ",2019-10-30,Brett Owens,https://www.investing.com/analysis/these-21-safe-funds-pay-monthly-never-go-down-200479921,200479921
197874,419390,JNJ,Congo Ebola death toll nears 1 000  expected to spread  WHO,news,"GENEVA  Reuters    The World Health Organization said on Friday it feared continued  intense transmission  of Ebola virus in the Democratic Republic of Congo  where deaths from a nine month old epidemic is 994 and expected to exceed 1 000 within hours  The WHO plans to introduce an unlicensed new Ebola vaccine made by Johnson   Johnson  NYSE JNJ   in addition to a Merck vaccine already being used  as  another tool in the toolbox   Dr  Michael Ryan  Executive Director of the WHO Health Emergencies Programme  told a news briefing in Geneva  
But security incidents continue to plague the response to the outbreak  including a would be assault on a facility on Thursday  slowing vaccination and daily checks on some 12 000 people potentially exposed to the virus  he said ",2019-05-03,Reuters,https://www.investing.com/news/world-news/congo-ebola-death-toll-nears-1000-expected-to-spread-who-1855701,1855701
197875,419391,JNJ,J J agrees to pay about  1 billion to resolve hip implant lawsuits  Bloomberg,news, Reuters    Johnson   Johnson  NYSE JNJ  agreed to pay about  1 billion to resolve the bulk of lawsuits claiming the company sold defective metal on metal hip implants that ultimately had to be removed  Bloomberg reported on Tuesday  citing people with knowledge of the matter  The agreement resolves over 95 percent of the 6 000 cases in which surgeons extracted the company s Pinnacle implants because they left patients unable to walk and in pain  according to the report  The  1 billion total includes an earlier settlement for more than  400 million and there are still about 4 500 pending suits by patients with artificial hips that were not made totally of metal or haven t been surgically removed  Bloomberg added   In February  Reuters reported J J s DePuy Orthopedics unit  which made the products  was in settlement talks to resolve most individual lawsuits alleging the company s metal on metal Pinnacle hip implants were defective and caused severe injuries  The implants were said to cause a build up of metal ions in the blood  causing groin pain  allergic reactions  bone erosion and tissue death   In 2013  DePuy ceased selling the metal on metal Pinnacle devices after the U S  Food and Drug Administration strengthened its artificial hip regulations  The Pinnacle system continues to be sold with other material combinations  Texas based plaintiff lawyer Mark Lanier  one of the main attorneys for the consumers  declined to comment   Johnson   Johnson did not immediately respond to Reuters  request for comment ,2019-05-07,Reuters,https://www.investing.com/news/stock-market-news/jj-agrees-to-pay-about-1-billion-to-resolve-hip-implant-lawsuits-bloomberg-1859229,1859229
197876,419392,JNJ,Why Is Jabil  JBL  Up 2 4  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Jabil  JBL   Shares have added about 2 4  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Jabil due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Jabil Q4 Earnings Beat Estimates  Revenues Up Y YJabil reported fourth quarter fiscal 2019 earnings of 88 cents per share  which beat the Zacks Consensus Estimate by a couple of cents and improved 25 7  year over year The earnings figure was within management s guided range of 76 96 cents per share on a non GAAP basis  Jabil incurred a one time charge of  6 2 million due to a distressed customer in the networking space Moreover  the company exchanged  50 million of iQor preferred stock associated with its divestiture of the aftermarket services business in 2014  The exchange resulted in a one time net non cash charge of  29 6 million Revenues increased 13 9  year over year to  6 57 billion  which was within management s guided range of  6 3  6 9 billion  However  the figure lagged the Zacks Consensus Estimate of  6 61 billion Quarter DetailsElectronics Manufacturing Services  EMS  revenues accounted for 63  of total revenues and increased 23  year over year to  4 billion  driven by strength in cloud  5G wireless  energy and automotive end markets Diversified Manufacturing Services  DMS  revenues accounted for 37  of total revenues and improved 2  year over year to  2 4 billion  The year over year growth was driven by robust performance in the healthcare business Gross margin  on a GAAP basis  contracted 10 basis points  bps  year over year to 7 5  Core EBITDA margin contracted 20 bps on a year over year basis to 6 6  Operating expenses on a GAAP basis contracted 30 bps on a year over year basis to 5 9   While selling  general and administrative  SG A  expenses shrank 30 bps to 4 2   research   development  R D  expenses as a percentage of revenues were flat at 0 2  Non GAAP core operating margin expanded 10 bps on a year over year basis to 3 7   which is within Jabil s guided range of 3 4 4  EMS core margin was 4 3   primarily due to the soft capital equipment space and costs associated with the ramping up of new business awards DMS core margin expanded 20 bps on a year over year basis to 2 9   driven by improved business mix supported by Jabil s diversification efforts Manufacturing Footprint Optimization EffortsJabil stated that overcapacity in the mobility business hurt DMS margins in fiscal 2019 The company is taking steps to optimize its manufacturing footprint  It plans to reduce capacity that will help it efficiently utilize fixed assets and normalize the cost structure Moreover  for fiscal 2021  Jabil expects market share growth to boost unit volumes  The ongoing automation efforts and manufacturing process improvements will result in an optimized footprint Non core expenses associated with Jabil s optimization activities are estimated to be  85 million  The company s optimization efforts will primarily be related to its manufacturing footprint in China Balance Sheet   Cash FlowAs of Aug 31  cash and cash equivalents were  1 16 billion compared with  694 million at the end of the previous quarter Core return on invested capital for was 21 3  in the reported quarter  The company exited the quarter with total debt to core EBITDA of approximately 1 5 times In the quarter  cash flow from operations was  1 1 billion In fiscal 2019  Jabil returned almost  400 million through buybacks and dividends  Moreover  its board of directors authorized a share repurchase program of up to  600 million as part of a two year capital allocation framework GuidanceFor first quarter fiscal 2020  Jabil expects total revenues between  6 65 billion and  7 35 billion DMS revenues are forecasted to be  3 1 billion  up roughly 3  year over year  EMS revenues are forecasted to be  3 9 billion  up nearly 11  year over year Core operating income is estimated to be  235  285 million  with core operating margin of 3 4 4   The company s core earnings are expected between 82 cents and  1 04 per share on a non GAAP basis For fiscal 2020  revenues are expected to be  26 billion  Moreover  revenues associated with the Johnson   Johnson  NYSE JNJ  Medical Devices Companies collaboration are still expected between  800 million and  1 billion Notably  the company is on track to complete the Wave 3 part of the transition by the end of this month Core operating income is expected to be  960 million  with core operating margin of 3 7  For DMS segment  revenues are expected to be  10 billion  up low single digits  Jabil expects core operating margin to expand 10 bps primarily due to revenue mix shift from Mobility Edge Devices and Lifestyle to Healthcare   Packaging end markets Further  EMS segment revenues are expected to be  16 million  up 4   Proliferation of autonomous driving   electric vehicles  roll out of 5G infrastructure and strong growth in cloud are expected to drive segment revenues Jabil expects 40 bps of core margin expansion in the EMS segment for fiscal 2020 The company s core earnings are expected to be  3 45 per share on a non GAAP basis Adjusted free cash flow is expected to be more than  500 million For fiscal 2021  revenues are expected to be  27 billion  Core operating income is expected to be  1 08 billion  with core operating margin of 4  The company s core earnings are expected to be  4 per share on a non GAAP basis Further  adjusted free cash flow is expected to be more than  600 million 
How Have Estimates Been Moving Since Then 
Estimates review followed a flat path over the past two months  The consensus estimate has shifted  16 23  due to these changes 
VGM Scores
At this time  Jabil has a great Growth Score of A  though it is lagging a lot on the Momentum Score front with a D  However  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Jabil has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-10-23,Zacks Investment Research,https://www.investing.com/analysis/why-is-jabil-jbl-up-24-since-last-earnings-report-200477482,200477482
197877,419393,JNJ,Lannett  LCI  To Report Q1 Earnings  What s In The Cards ,opinion,"Investors focus is likely to be on the performance of Lannett Company  Inc  s   NYSE LCI   anti psychosis and cardiovascular drugs when it reports fiscal first quarter 2020 results Lannett s shares have rallied 147 2  so far this year compared with the  s increase of 0 5  Factors at PlayLannett s generic product launches since 2018 have driven net sales and the trend most likely continued in the soon to be reported quarter  In fact  anti psychosis and cardiovascular drugs in the company s generic portfolio witnessed strong sales growth in the fiscal fourth quarter of 2019  We expect this trend to have continued in the fiscal first quarter of 2020 The Zacks Consensus Estimates for sales of anti psychosis and cardiovascular drugs stands at  18 million and  25 million  respectively In May and June  the company launched generic versions of two major attention deficit hyperactivity disorder drugs namely J J s   NYSE JNJ   Concerta and Teva Pharmaceutical s   NYSE TEVA   Adderall  Launch of these two generic drugs along with a generic version of Aspirin are likely to have resulted in significant sales for Lannett Restructuring initiatives and reduction in outstanding loans is likely to have benefited Lannett s bottom line in the first quarter of 2020  However  continued launches and research activities might have driven operating expenses higher Earnings WhispersOur proven model does not conclusively predict an earnings beat for Lannett in this reporting cycle  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But that is not the case here as you will see below Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate is  1 64    You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Lannett sports a Zacks Rank  1 Lannett Co Inc Price and Consensus
    A Stock That Warrants a LookHere is a biotech stock that you may want to consider  as our model shows that it has the right combination of elements to post an earnings beat in its upcoming release Incyte Corporation   NASDAQ INCY   has an Earnings ESP of  1 15  and a Zacks Rank  1  The company is scheduled to release third quarter results on Oct 29  You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/lannett-lci-to-report-q1-earnings-whats-in-the-cards-200478420,200478420
197878,419394,JNJ,Imbruvica To Offset Humira Woes In AbbVie  ABBV  Q3 Earnings ,opinion,AbbVie Inc s   NYSE ABBV   flagship product  Humira  has witnessed declining sales in the past couple of quarters given the launch of biosimilars in international markets  especially Europe  The drug is approved for several inflammatory indications and generates more than half of the company s revenues  Loss of exclusivity in Europe has led to the launch of multiple biosimilar drugs by other pharma companies since October last year  These launches significantly dented international sales in the first half of 2019 and the trend is likely to have continued in the third quarter  However  the drug is well protected from competition in the United States till mid 2023 by patents The company expects U S  Humira sales to increase 8  in the soon to be reported quarter  The company estimates international sales to be  1 billion  The drug had brought in sales of  1 58 billion in the year ago quarter from international markets  The Zacks Consensus Estimate for third quarter Humira sales is pegged at  4 9 billion  The Zacks Consensus Estimate for U S  sales is pegged at  3 9 billion and for international sales stand at  1 02 billion In April  the company s inflammation portfolio was strengthened with the approval of Skyrizi for treating moderate to severe plaque psoriasis in the United States and Europe  Sales of the drug were better than management s expectations in the second quarter  Strong launch uptake is expected to have continued in the third quarter as well Its key oncology medicine  Imbruvica has shown impressive adoption in the approved indications  especially front line chronic lymphocytic leukemia   CLL    The drug is approved for use as a monotherapy or in combination for front line CLL  The drug is the only preferred regimen under the NCCN guidelines for this indication  The drug is marketed in partnership with J J   NYSE JNJ    globally  J J on its third quarter earnings call reported impressive sales of the drug AbbVie expects Imbruvica sales to be approximately  1 2 billion in the third quarter  The Zacks Consensus Estimate for the drug is also pegged at  1 2 billion Sales of another leukemia drug  Venclexta  have shown strong trend in the first half of 2019 with sales more than doubling year over year on the back of label expansion in additional indications  In May  the drug was approved in combination with Roche s   OTC RHHBY   Gazyva as first line treatment for CLL patients  which might have brought additional sales in third quarter  The Zacks Consensus Estimate for the drug is pegged at  208 millionOther drugs  namely Duodopa and Creon  are also likely to have continued their strong performance in the soon to be reported quarter  The respective Zacks Consensus Estimate for Duodopa and Creon sales is pegged at  117 million and  265 million AbbVie s new HCV drug  sales of Mavyret were down in the first half of 2019 due to decline in international market share and pricing  Moreover  sales in the U S  markets also suffered in the second quarter  The trend is likely to have continued in the third quarter  The Zacks Consensus Estimate for the HCV segment  mainly comprising of Mavyret  stands at  762 million   Read more  AbbVie s stock has declined 17  this year so far  against the increase of 0 9  recorded by the  AbbVie currently carries a Zacks Rank  2  Buy   You can see  AbbVie Inc  Price and Consensus   Upcoming ReleaseIncyte Corporation   NASDAQ INCY   is set to report third quarter results on Oct 29  The company has an  of  1 15  and a Zacks Rank  1  You can also uncover the best stocks to buy or sell before they re reported with our  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-10-27,Zacks Investment Research,https://www.investing.com/analysis/imbruvica-to-offset-humira-woes-in-abbvie-abbv-q3-earnings-200478964,200478964
197879,419395,JNJ,Merck  MRK  Beats On Q3 Earnings   Sales  Raises  19 View,opinion,"Merck   Co   Inc    NYSE MRK   reported third quarter 2019 adjusted earnings of  1 51 per share  which beat the Zacks Consensus Estimate of  1 25  Earnings rose 27  year over year on a reported basis as well as excluding the impact of currency Including acquisition  and divestiture related costs  restructuring costs and certain other items  earnings per share were 74 cents compared with 73 cents in the year ago quarter Revenues for the quarter rose 15  year over year to  12 4 billion  beating the Zacks Consensus Estimate of  11 7 billion  Currency movement negatively impacted revenues by 1   Excluding currency impact  sales rose 16  year over year Strength in cancer drugs  especially Keytruda  and Gardasil vaccine and a strong performance in international markets  especially China  offset headwinds from loss of exclusivity   LOE   for some products including Zetia and Vytorin  and competitive pressure for Janumia and Janumet  Sales in China surged 84   90  excluding Fx impact  from the year ago period Quarter in DetailThe Pharmaceutical segment generated revenues of  11 1 billion  up 15   up 16  excluding Fx impact  year over year as higher sales in oncology and vaccines were offset by lower sales in virology  As in the previous quarters  LOE for several drugs hurt the top line Keytruda  the largest product in Merck s portfolio  generated sales of  3 1 billion in the quarter  up around 18  sequentially and 62  year over year  Sales were driven by the launch of new indications globally  Keytruda sales are gaining particularly from strong momentum in first line lung cancer indication and launch in newer indications namely renal cell carcinoma and adjuvant melanoma Keytruda is already approved for many types of cancers and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma and bladder cancer  In July  the FDA approved a label expansion of the drug to include patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus Alliance revenues from Lynparza and Lenvima also boosted oncology sales in the quarter Lynparza alliance revenues were  123 million in the quarter compared with  111 million in the previous quarter  Lenvima alliance revenues were  109 million compared with  97 million in the previous quarter Merck has a deal with Swiss pharma giant AstraZeneca   NYSE AZN   to co develop and commercialize PARP inhibitor Lynparza and a similar one with Japan s Eisai for tyrosine kinase inhibitor  Lenvima In the hospital specialty portfolio  Bridion  sugammadex  Injection generated sales of  284 million in the quarter  up 31  year over year  driven by strong demand in the United States In vaccines  Gardasil Gardasil 9 sales rose 46  year over year to  1 32 billion  gaining from ongoing commercial launch in China and strong growth in Europe  Favorable public sector buying patterns  and positive demand and pricing in the United States also boosted sales of the vaccine Proquad  M M R II and Varivax vaccines recorded combined sales of  623 million  up 19  year over year  Sales were driven by higher demand in Europe  favorable pricing in the United States and government orders from Latin America Pharmaceutical sales were hurt by generic competition for blockbuster drug  Remicade in Merck s marketing territories in Europe and loss of U S  market exclusivity for Invanz  Cubicin  Zetia and Vytorin Remicade sales declined 37 6  year over year to  101 million in the quarter  Please note that Merck markets Remicade in partnership with J J   NYSE JNJ   Zetia and Vytorin recorded sales of  147 million and  57 million  down 10 9  and 38   respectively from the year ago quarter due to LOE for both drugs  Adempas sales grew 13 8  to  107 million  Atozet sales were down 15 5  to  97 million  Strong growth in sales of Adempas and Atozet partially offset loss of sales in the cardiovascular segment  Please note that Adempas is commercialized in collaboration with Bayer   OTC BAYRY   Januvia Janumet  diabetes  franchise sales declined 12  year over year to  1 31 billion due to continued pricing pressure in the United States  which was partially offset by higher sales in ex U S  markets  Sales of Isentress declined 9  to  250 million Merck s Animal Health segment generated revenues of  1 12 billion  up 10   up 12  excluding Fx impact  from the year ago quarter  driven by higher sales of its companion animal products as well as livestock products  particularly products added from the acquisition of Antelliq Adjusted gross margin came in at 75 9   down 80 basis points from the year ago quarter driven primarily by higher amortization of certain expenses Selling  general and administrative  SG A  expenses were  2 6 billion in the reported quarter  up 5  year over year driven by higher administrative and promotion costs  partially offset by favorable impact of foreign exchange movement  Research and development  R D  spend rose 7  to  2 2 billion in the quarter due to ongoing clinical studies and cost related to early drug development 2019 Guidance UpMerck increased its earnings and sales guidance for 2019 Merck expects revenues to be in the range of  46 5 billion    47 billion versus the previous expectation of  45 2 billion    46 2 billion  The Zacks Consensus Estimate is pegged at  46 03 billion  Adjusted earnings are now expected to be in the range of  5 12  5 17  much higher than the previously guided range of  4 84  4 94  The Zacks Consensus Estimate is pegged at  4 91 per share  The revenue guidance includes approximately 2  negative impact of currency fluctuation The company maintained its expectation for adjusted operating expenses to increase year over year at mid single digit rate Our TakeMerck s third quarter results were strong as the company beat estimates for earnings as well as sales  It raised its earnings expectations for the year for the third consecutive quarter  Shares were up by more than 2 5  in pre market trading  Merck s shares have outperformed the industry so far this year  It has risen 7 5  in the said time frame while the industry recorded 1 6  increase Importantly  Keytruda continued its robust performance on strong demand trends and label expansions  Vaccine products also performed strongly and continue to be core growth drivers for Merck Going forward  growth of key products like Keytruda  Lynparza  Gardasil  Bridion and Animal Health should continue to make up for the headwinds from LOE  softness in the diabetes franchise  and competitive pressure on Zepatier and Zostavax Merck   Co   Inc  Price  Consensus and EPS Surprise
    Zacks RankMerck currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-10-28,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-beats-on-q3-earnings--sales-raises-19-view-200479702,200479702
197880,419396,JNJ,Bayer  BAYRY  Q3 Earnings Beat Estimates  Sales Rise Y Y,opinion,"Bayer AG  DE BAYGN  s   OTC BAYRY   third quarter 2019 core earnings per share of 32 cents per American Depositary Receipt   ADR   increased 1 8  year over year  The figure excludes earnings from discontinued operations  Core earnings per ADR also beat the Zacks Consensus Estimate of 29 cents Total sales in the quarter were approximately  10 94 billion  up 1 6  from  10 77 billion in the year ago quarter  The growth was driven by higher sales across segments namely Crop Science  Pharmaceuticals and Consumer Health divisions In August  the company entered into an agreement with Elanco to divest its Animal Health business  The company also agreed to sell its 60  stake in Germany based site services provider  Currenta  to a company controlled by Macquarie Infrastructure and Real Assets in the same month  Bayer reported these two businesses under discontinued operations in the third quarter of 2019 Shares of the company have risen 3 7  year to date compared with the  s increase of 1 6   All growth rates mentioned below are on a year over year basis  and after adjusting for currency and portfolio changes Quarter HighlightsThe company started reporting through three segments   Pharmaceuticals  Consumer Health and Crop Science   from the quarter under review In the reported quarter  Crop Science sales were  3 948 million  up 4 8  from the year ago quarter on the back of growth in Latin and North America  Business at this segment has grown well amid challenging market environment  While sales of Fungicides  Corn Seed   Traits and Soybean Seed   Traits were strong during the quarter  segment revenues were hurt by decline in sales of Vegetable Seeds and other Please note that lawsuits against the company s crop protection product  glyphosate  have increased during the quarter driven by higher advertising spend by the plaintiffs  However  the company believes it has meritorious defenses to fight these lawsuits Revenues at the Pharmaceuticals segment increased 5 9  to  4 504 million in the third quarter  Growth was backed by consistent strong performance of key products like Xarelto  Eylea  Avalox  Stivarga and Adempas  Strong growth momentum in China continued in this quarter  However  sales of Betaferon Betaseron  a multiple sclerosis treatment  decreased due to intense competition in the United States  Please note that blood thinner drug  Xarelto  was developed in collaboration with J J   NYSE JNJ    while Regeneron Pharmaceuticals   NASDAQ REGN   commercializes eye drug  Eylea  in collaboration with Bayer in ex U S  markets Consumer Health sales were up 3 7  year over year to  1 288 million in the third quarter  The business gained in Europe Middle East Africa   EMEA   and Latin America on currency and portfolio adjusted basis  The Pain   Cardio category delivered the strongest performance  with sales increasing 9   Sales were up in all categories  with Allergy   Cold up 6 4   except Digestive Health category  down 7 5   2019 Guidance The company updated its view for 2019 to exclude the sales and earnings contributions from Animal Health segment and Currenta  However  expected growth rates remained the same  Sales are expected to be  43 5 billion  previously  46 billion   increasing about 4  on currency and portfolio adjusted basis Core earnings per share are expected to rise to  6 35  previously  6 80  on a currency adjusted basis  The guidance takes into account a decline of  0 35 per share due to portfolio measures and  0 10 per share due to currency effects Bayer Aktiengesellschaft Price  Consensus and EPS Surprise
    Zacks Rank   Stock to ConsiderBayer currently carries a Zacks Rank  4  Sell  GlaxoSmithKline plc   NYSE GSK   is a better ranked pharma stock  carrying a Zacks Rank  2  Buy   You can see  Glaxo s earnings per share estimates have increased from  2 89 to  3 00 for 2019 and from  2 96 to  3 00 for 2020 in the past 60 days Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-29,Zacks Investment Research,https://www.investing.com/analysis/bayer-bayry-q3-earnings-beat-estimates-sales-rise-yy-200480172,200480172
197897,419413,JNJ,J J Earnings  Revenue Beat in Q1,news,"Investing com   J J  NYSE JNJ  reported first quarter earnings  that Beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  2 1 on revenue of  20 02B  Analysts polled by Investing com anticipated EPS of  2 04 on revenue of  19 62B  That compared to EPS of  2 06 on revenue of  20 01B in the same period a year earlier  The company had reported EPS of  1 97 on revenue of  20 39B in the previous quarter 

J J follows other major Healthcare sector earnings this month
 On March 18  Tilray reported first quarter EPS of   0 33 on revenue of  15 53M  compared to forecasts of EPS of   0 14 on revenue of  14 15M 
INC Research earnings Beat analysts  expectations on March 18  with first quarter EPS of  0 95 on revenue of  1 15B  Investing com analysts expected EPS of  0 81 on revenue of  1 15B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-04-16,Investing.com,https://www.investing.com/news/stock-market-news/jj-earnings-revenue-beat-in-q1-1837156,1837156
197898,419414,JNJ,Forex   U S  Dollar Flat as Investors Turn to Stocks,news,"Investing com   The greenback was flat as upbeat Chinese and European data eased investor concern over the global economy and investors flocked to equities after upbeat earnings 
The U S  dollar index  which measures the greenback s strength against a basket of six major currencies  rose 0 06  to 96 618 as of 11 17 AM ET  15 17 GMT  
Housing prices in China rose at the fastest pace since April 2017 in March  helping ease concerns over the slowing economy  while the German ZEW economic sentiment index jumped more than expected in April 
Upbeat earnings reports also shifted investor focus on U S  equities after better than expected earnings from Johnson   Johnson  NYSE JNJ  and others 
The dollar was down against the safe haven yen  with USD JPY slipping 0 08  to 111 98 
Elsewhere  sterling fell as Brexit talks stalled within the U K  government  opposition leader Jeremy Corbyn told The Guardian  The two sides have failed to agree on a customs union or workers rights and talks were halted due to the Conservative party wanting deregulation post Brexit 
 The government doesn t appear to be shifting the red lines because they ve got a big pressure in the Tory party that actually wants to turn this country into a deregulated low tax society which will do a deal with Trump  I don t want to do that   he said 
GBP USD fell 0 4  to 1 3048 
Elsewhere  USD CAD inched down 0 07  to 1 3352 and EUR USD slipped 0 1  to 1 1292 ",2019-04-16,Investing.com,https://www.investing.com/news/forex-news/forex--us-dollar-flat-as-investors-turn-to-stocks-1837529,1837529
197899,419415,JNJ,Pharmaceuticals drive J J to better than expected quarterly profit,news,By Manas Mishra and Saumya Joseph  Reuters    Johnson   Johnson  NYSE JNJ  on Tuesday reported a first quarter profit that exceeded Wall Street expectations on higher sales of its prescription medicines  including a double digit increase for its psoriasis treatment Stelara  even as the company faces fierce competition for some of its other important drugs  The U S  healthcare conglomerate said growth in its pharmaceuticals business was driven by volume rather than price hikes  and its shares rose more than 2 percent to  139 49  Sales of Stelara  which also treats Crohn s disease  jumped about 32 percent to  1 41 billion  fueling a 4 percent rise for the pharmaceutical business  which accounts for more than half of the company s total revenue  Double digit increases for cancer drugs Darzalex and Imbruvica also contributed to the earnings beat   We re really seeing the strength in pharma sales drive top and bottom line growth   said John Ham  associate advisor at New England Investment and Retirement Group  which owns J J shares   We think growth in pharma sales not only in Asia but also in the United States will be a driver for the company going forward   Excluding items  the company earned  2 10 per share  beating analysts  average estimates by 7 cents  according to IBES data from Refinitiv  J J also tightened its full year forecast for adjusted earnings to  8 53 to  8 63 per share from its prior range of  8 50 to  8 65  The company on a conference call said 800 sites have already been certified to treat patients with its new nasal spray depression treatment Spravato  which won U S  approval last month   We believe that we re off to a very  very strong start with Spravato and that is going to be an important growth driver for us   said Jennifer Taubert  head of J J s pharma unit  Sales of prostate cancer drug Zytiga  which is now facing competition from cheaper generic versions as well as from branded rival Xtandi from  Pfizer  Inc  NYSE PFE  and Astellas Pharma  fell 19 6 percent  But the company said it now sees the overall sales decline it expects due to competition from generics and biosimilars in 2019 coming in at the lower end of its prior  3 billion to  3 5 billion forecast   Overall sales increased slightly to  20 02 billion  topping analyst estimates of  19 61 billion  Sales from the medical device business fell 4 6 percent to  6 46 billion  edging past Wall Street estimates of  6 44 billion  Consumer health sales declined 2 4 percent to  3 32 billion  Net profit for the quarter fell 14 2 percent to  3 75 billion as the company recorded  423 million in litigation expenses ,2019-04-16,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-reports-firstquarter-sales-above-expectations-1837176,1837176
197912,419428,JNJ,Johnson   Johnson s baby shampoo samples fail Indian quality test  company rejects findings,news,"By Subrat Patnaik NEW DELHI  Reuters    Johnson   Johnson s baby shampoo samples failed quality tests conducted by the northwestern Indian state of Rajasthan  according to a public notice from the state s drugs watchdog  findings that were rejected by the U S  drugmaker  This comes just a few months after Indian authorities launched an investigation into J J s Baby Powder to see if it contains cancer causing asbestos  J J  NYSE JNJ  said in late February it had resumed production of baby talc after government tests found no asbestos in the product  The Rajasthan Drugs Control Organisation s notice dated March 5  said that the samples of J J s baby shampoo taken from two batches had failed the quality test as they contained  harmful ingredients   It did not elaborate  A J J spokeswoman said that the results it received from the watchdog indicated that formaldehyde had been discovered in the samples  Formaldehyde  used in making building materials  is a known carcinogen   We do not accept the interim results given to us  which mentioned samples to  contain harmful ingredients  identification positive for formaldehyde    she told Reuters    We unequivocally maintain that our products are safe and our assurance process is amongst the most rigorous in the world   the J J spokeswoman said  adding that the company has contested the interim test results of the government analysis that were based on  unknown and unspecified methods   The two batches of the baby shampoo tested are due to expire in September 2021 and were manufactured at the company s plant in the northern state of Himachal Pradesh  according to the watchdog s notice   We have confirmed to the Indian authorities that we do not add formaldehyde as an ingredient in our shampoo nor does Johnson s baby shampoo contain any ingredient that can release formaldehyde over time   the company spokeswoman said   The Rajasthan Drugs Control Organisation and India s Central Drugs Standard Control Organisation  CDSCO  were not immediately available to comment  The federal regulator and its counterparts in Indian states launched an investigation into J J s Baby Powder following a Reuters report in December that the firm knew for decades that cancer causing asbestos could be found in the product  J J has described the Reuters article as  one sided  false and inflammatory   
J J s Baby Powder is one of the most recognised foreign brands in the country  The company leads sales in the Indian baby and child toiletries market  according to market research provider Euromonitor ",2019-04-01,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnsons-baby-shampoo-samples-fail-indian-quality-test-company-rejects-findings-1823457,1823457
197913,419429,JNJ,U S   China key to GSK s consumer venture with Pfizer,news,"By Martinne Geller LONDON  Reuters    The United States and China will be key focuses for the consumer healthcare venture being formed by GlaxoSmithKline and  Pfizer   NYSE PFE   as the companies look to build on strong existing positions in those markets   GSK and Pfizer are on track to create the world s biggest consumer health business   with brands from Advil painkillers to Chapstick lip balm   by the second half of 2019  Brian McNamara  CEO of GSK Consumer Healthcare  told Reuters on Thursday   The venture  to be 68 percent owned by GSK  will become a stand alone company within three years of closing the deal  and McNamara will lead it   The U S  and China are really two of the key value drivers of the deal because it s where Pfizer has critical mass and a significant amount of their key brands   he said in an interview  noting the new entity will be the No 1 player in the United States and No 2 in China   U S  and China are must win markets   The consumer health sector  which spans vitamins  non prescription medicines and other drug store purchases  is buoyed by ageing populations  a growing interest in health  wellness and self care  and growing middle classes  It has slowed at times in recent years  due to emerging market fluctuations or weak flu seasons   The new  yet to be named company will have annual sales of 9 8 billion pounds   12 9 billion  and more than 7 percent of the global consumer health market  with brands also including Centrum vitamins and Sensodyne toothpaste   That puts it ahead of rivals Johnson   Johnson  NYSE JNJ   Bayer  DE BAYGN  and Sanofi  PA SASY   Pfizer s Centrum is already the leading multivitamin in China  while Caltrate is the No 2 calcium supplement in what is one of the world s most calcium deficient populations  McNamara said   He said vitamins  minerals and supplements  VMS  would be a major focus  alongside oral care and over the counter pain medicine  and respiratory treatments like cold and flu tablets    It gives us the presence globally but it really strengthens our China position   he said about VMS  GSK has said it is aiming to make divestments worth about 1 billion pounds   1 3 billion  in 2019 2020  but McNamara declined to comment on them   
GSK in December announced plans to separate into two companies   one for prescription drugs and vaccines  the other for over the counter products   after agreeing the deal with the consumer health business that Pfizer tried  and failed  to sell previously ",2019-04-04,Reuters,https://www.investing.com/news/stock-market-news/us-china-key-to-gsks-consumer-venture-with-pfizer-1827553,1827553
197914,419430,JNJ,Despite Chaotic Year  Johnson   Johnson s Data  Is Trending In The Right Direction,opinion,"Johnson   Johnson  NYSE JNJ  is having the best of times and the worst of times  As for the best of times  its third quarter earnings call showed the stock rebounding following a tumultuous last year  
But 2019 has been utter chaos for J J  First  it was the subject of a major controversy when Bloomberg revealed that the company s talc powder was linked to cancer  resulting in a criminal investigation into the company 
Then there was the time every drug company under the sun got sued for the opioid crisis  Or how about recently  the two completely different cases of a judge mishandling the amount of money in a lawsuit awarded in two different states  And who could forget this priceless moment  J J was ordered to pay a man  not a woman  billions for breast growth  The drug involved in that verdict was antipsychotic  by the way 
The wild  back and forth nature of all of these storylines has manifested itself in our Facebook  NASDAQ FB   Talking About  data  You could go so far as to pinpoint the spikes in social media buzz to each of the above hyperlinked headlines 





But back to the good news  Johnson   Johnson s data is trending in the right direction  at least for investors 





As you can see  the stock falls and rises with the global staff count  The same goes for the job listings data  which follows the same curve in stock price  At least everything is going up slightly now  24  since June 





In the future  don t spend upwards of  832 million a year to fight roughly 100 000  legal battles  Just don t do it 
About the Data  
Thinknum tracks companies using information they post online   jobs  social and web traffic  product sales and app ratings   and creates data sets that measure factors like hiring  revenue and foot traffic  Data sets may not be fully comprehensive  they only account for what is available on the web   but they can be used to gauge performance factors like staffing and sales ",2019-10-18,Thinknum,https://www.investing.com/analysis/despite-chaotic-year-johnson--johnsons-data--is-trending-in-the-right-direction-200474974,200474974
197926,419442,JNJ,Exclusive  Sanofi says working on CEO succession plan,news,"By Matthias Blamont PARIS  Reuters    Pharmaceuticals group Sanofi  PA SASY  is working on a plan to find a new CEO in agreement and consultation with current chief executive Olivier Brandicourt  a spokesman for the French drugmaker told Reuters on Monday  Sanofi has an age limit of 65 for its CEO  Brandicourt will be 65 in February 2021   It is the responsibility of any company s board of directors to consider and plan for the succession of its CEO and executive committee members by identifying the next set of future leaders   a spokesman told Reuters   With this perspective  the board has been considering this succession plan for some time now  in agreement and consultation with our CEO   he said  without elaborating on a specific time frame  Sources told Reuters talks over the future of the group s management had intensified in recent weeks  Sanofi is to hold an annual meeting next month during which shareholders will be asked to vote to renew the mandate of the board s chairman  Serge Weinberg   Brandicourt was hired in 2015 to help revive the fortunes of France s biggest drugmaker and has been actively reshaping the business  He was previously the head of Bayer s healthcare arm  Under his management  the company swapped its animal health unit to Boehringer Ingelheim in exchange for the German firm s consumer healthcare operations in a  20 billion deal  It has also sold its European generics arm for 1 9 billion euros   2 15 billion  to private equity firm Advent International  New launches such as eczema treatment Dupixent  cost cutting and new priorities setting in research and development have also enabled Sanofi to return to profits in the second half of last year after a series of disappointing quarters due to falling diabetes sales  Brandicourt s teams failed to land two strategic acquisitions  loosing out on buying California based cancer specialist Medivation to  Pfizer   NYSE PFE  in 2016  and failing to snatch up Swiss biotech company Actelion  which was bought by Johnson   Johnson  NYSE JNJ  in 2017  But the company regained momentum last year with the purchase of Belgian biotech company Ablynx for 3 9 billion euros  That followed the acquisition of U S  group Bioverativ for  11 6 billion  its biggest deal for seven years  Brandicourt hopes the two transactions will help Sanofi build a strong franchise in rare blood disorders  Last month  the U S  Food and Drug Administration approved Ablynx s most promising asset  the experimental drug caplacizumab for treating the blood disease Acquired Thrombotic Thrombocytopenic Purpura  
Sanofi has made rare diseases a top priority since it bought Massachusetts biotech firm Genzyme in 2011 ",2019-03-18,Reuters,https://www.investing.com/news/stock-market-news/exclusive-sanofi-says-working-at-hiring-a-new-ceo-1810633,1810633
197927,419443,JNJ,Bayer  J J settle U S  Xarelto litigation for  775 million,news,By Tina Bellon  Reuters     Bayer AG   DE BAYGN  and Johnson   Johnson  NYSE JNJ  have agreed to settle more than 25 000 U S  lawsuits over their blockbuster blood thinner Xarelto for a total of  775 million  court documents on Monday showed  The amount will be shared equally between the two companies that jointly developed the drug  Bayer and J J do not admit liability under the agreement  The settlement will resolve all pending U S  lawsuits over Xarelto  which plaintiffs claimed causes uncontrollable and irreversible bleeding leading to severe injuries and even death among thousands of plaintiffs   Plaintiffs accused the drugmakers of having failed to warn about the bleeding risks  claiming their injuries could have been prevented had doctors and patients been provided adequate information  Bayer in a statement on Monday said it continues to believe the claims are without merit   However  this favorable settlement allows the company to avoid the distraction and significant cost of continued litigation   the company said  J J in a statement said it continued to believe in the safety of Xarelto  but that the settlement was the right thing to do for patients and their doctors  Xarelto is Bayer s best selling drug  It contributed 3 6 billion euros   4 07 billion  in revenue to the German group s pharmaceutical business last year  Bayer on Monday said its share of the settlement amount will be partially offset by product liability insurance  Bayer jointly developed Xarelto with J J s Janssen Pharmaceuticals unit  which sells the blood clot preventer under a licensing agreement in the United States   J J reported 2018 Xarelto sales of  2 47 billion ,2019-03-25,Reuters,https://www.investing.com/news/stock-market-news/bayer-jj-settle-us-xarelto-litigation-for-775-million-1817138,1817138
197928,419444,JNJ,Oklahoma top court clears way for Purdue  J J  Teva to face opioid trial,news,"By Nate Raymond  Reuters    Oklahoma s top court on Monday declined to delay a landmark trial set for May in a multibillion dollar lawsuit accusing OxyContin maker Purdue Pharma LP and two other drugmakers of helping fuel an opioid abuse and overdose epidemic in the state  The Oklahoma Supreme Court s decision was a win for the state s attorney general  whose case is set to be the first to face trial of roughly 2 000 lawsuits nationally seeking to hold opioid manufacturers responsible for contributing to the epidemic  Oklahoma Attorney General Mike Hunter s 2017 lawsuit accuses Purdue  Johnson   Johnson  NYSE JNJ    Teva Pharmaceutical Industries  NYSE TEVA  Ltd of engaging in deceptive marketing that downplayed the risks of addiction associated with opioid pain drugs while overstating their benefits  The companies deny wrongdoing  They had sought to delay the May 28 trial to Sept  16  citing the need to review records the state belatedly turned over that could be critical to their defense  The state is seeking over  20 billion in damages  The trial delay bid came as Purdue  owned by members of the wealthy Sackler family  was exploring filing for Chapter 11 bankruptcy protection to address potential liabilities stemming from the lawsuits  people familiar with the matter have told Reuters  Purdue did not respond to a request for comment on Monday  After the trial judge declined on March 8 to delay the trial  Stamford  Connecticut based Purdue denied that his ruling would have any affect on whether it files for bankruptcy   We appreciate the quick action taken by the court and for not rewarding the defendants with more time for a problem of their own making   Hunter said in a statement  J J and Teva did not immediately respond to requests for comment  Opioids  including prescription painkillers  heroin and fentanyl  were involved in a record 47 600 overdose deaths in 2017  according to the U S  Centers for Disease Control and Prevention   The epidemic has prompted lawsuits by state and local governments accusing Purdue and other drugmakers of contributing to the crisis   
More than 1 600 lawsuits have been consolidated before a federal judge in Ohio  who has pushed for a settlement ahead of the trial before him in October  Other cases  including Oklahoma s  are pending in state courts ",2019-03-25,Reuters,https://www.investing.com/news/stock-market-news/oklahoma-top-court-clears-way-for-purdue-jj-teva-to-face-opioid-trial-1817538,1817538
197929,419445,JNJ,OxyContin maker Purdue reaches  270 million settlement in Oklahoma opioid case,news,"By Nate Raymond and Mike Spector  Reuters    OxyContin maker Purdue Pharma LP and members of the wealthy Sackler family that own the company reached a  270 million settlement to resolve a lawsuit brought by the state of Oklahoma accusing the drugmaker of fueling an opioid abuse epidemic  The settlement with Oklahoma Attorney General Mike Hunter  unveiled on Tuesday  was the first to result from a wave of recent lawsuits accusing Purdue of deceptively marketing painkillers that eventually helped create a deadly crisis sweeping the United States  Hunter s 2017 lawsuit was set to go to a jury in May in what would have been the first trial to result from roughly 2 000 lawsuits filed in federal and state courts nationwide against Purdue and other drugmakers Hunter accused Purdue  Johnson   Johnson  NYSE JNJ  and Teva Pharmaceutical Industries  NYSE TEVA  Ltd of deceptive marketing that played down the risks of addiction associated with opioid pain drugs while overstating their benefits  contributing to an epidemic  Opioids  including prescription painkillers  heroin and fentanyl  were involved in a record 47 600 overdose deaths in 2017 in the United States  according to the U S  Centers for Disease Control and Prevention  The companies deny wrongdoing  Purdue has argued that U S  Food and Drug Administration approved labels for its opioids carried warnings about the risk of abuse and misuse associated with them   Purdue s chief executive this month said the company was weighing filing for bankruptcy protection as an option to address potential liabilities from the lawsuits  a move that Reuters had reported earlier  Companies facing mounting litigation often consider a bankruptcy filing to halt lawsuits and negotiate with plaintiffs in one federal court proceeding   START OF THE DOMINOES FALLING   Avoiding the trial with a settlement relieves immediate pressure on Purdue to seek bankruptcy protection  said Alexandra Lahav  a professor at the University of Connecticut School of Law  While the company has not ruled out a bankruptcy filing  it now plans to focus attention on attempting a far reaching settlement with other plaintiffs pursuing similar cases  including state and local governments  a person familiar with Purdue s deliberations said   This may be the start of the dominoes falling for Purdue   Lahav said  Members of the Sackler family in a statement called allegations that they contributed to the opioid crisis  not accurate  and argued that Tuesday s agreement did not represent  a financial model for future settlement discussions   Purdue Chief Executive Craig Landau and members of the Sackler family expressed compassion for opioid victims and portrayed the settlement as furthering their commitment to combat the addiction crisis   Around 1 600 lawsuits are consolidated before a federal judge in Ohio  who has pushed for a settlement ahead of the first trial scheduled before him in October  Purdue will likely attempt to finalize any decisions related to a settlement and a bankruptcy filing before that court date  the source familiar with the company s deliberations said  Tuesday s settlement covers only Purdue  leaving claims pending against J J and Israel based Teva  The deal was announced a day after the Oklahoma Supreme Court rejected an effort by Purdue and its co defendants to delay the May 28 trial   Purdue s marketing efforts helped fuel the opioid epidemic and turn OxyContin into a top selling painkiller that by 2017 had generated an estimated  35 billion in sales since the product s release in 1996  according to the lawsuit  The state had been seeking more than  20 billion in damages  according to court papers  Under the terms of Tuesday s settlement  Purdue said it will contribute  102 5 million to help fund an addiction treatment center at Oklahoma State University  and donate  20 million worth of medications to support its treatment mission  The Sacklers  who were not named as defendants in Oklahoma s lawsuit  agreed to contribute  75 million toward the university center as well  Purdue said  Another  12 5 million will be made available to Oklahoma localities to help address the opioid epidemic in their communities  and another  60 million will go toward costs and legal fees stemming from the lawsuit  Purdue said  Lawyers for plaintiffs pursuing similar cases nationally against Purdue and other opioid manufacturers welcomed Tuesday s settlement as a breakthrough that could help secure other deals  
They have often compared the cases against Purdue to widespread lawsuits against the tobacco industry that resulted in a  246 billion settlement in 1998  Paul Hanly  a lead lawyer for the plaintiffs in the federal opioid litigation  said they are  hopeful that the Oklahoma settlement is the beginning of a good faith program on the part of Purdue to settle all of the nationwide litigation  ",2019-03-26,Reuters,https://www.investing.com/news/stock-market-news/oxycontin-maker-purdue-agrees-to-settle-oklahoma-opioid-case-source-1817792,1817792
197930,419446,JNJ,New Jersey jury finds J J not liable in talc cancer trial  company settles three other cases,news,"By Tina Bellon  Reuters    A New Jersey jury on Wednesday cleared Johnson   Johnson  NYSE JNJ  of liability in a lawsuit brought by a man who said that asbestos in the company s talcum powder products caused his mesothelioma  The jury delivered its unanimous verdict in Middlesex County Superior Court in New Brunswick  just miles from J J s headquarters  in the case of plaintiff Ricardo Rimondi  J J  which faces some 13 000 talc related lawsuits nationwide  denies that its talc causes cancer  saying numerous studies and tests by regulators worldwide have shown its talc to be safe and asbestos free  Johnson   Johnson on Wednesday also settled three other mesothelioma talc cases pending in state courts in California  Oklahoma and New York  Chris Panatier  a lawyer for the plaintiffs  told Reuters  Panatier declined to provide further details  citing confidentiality agreements  Addressing the settlements  J J in a statement said   there are one off situations where settlement is reasonable   J J said it stood by the safety of its talc and would continue to vigorously defend the safety of baby powder   We do not have any organized program to settle Johnson s Baby Powder cases  nor are we planning a settlement program   the company said   Referring to the Rimondi verdict  J J said the company s track record in the talc litigation underscored  the decades of clinical evidence and scientific studies by medical experts around the world  supporting the safety of Johnson s Baby Powder  J J shares  which had been down slightly  turned positive after the jury verdict was announced and closed up 13 cents at  138 70  Lawyers for the 58 year old Rimondi could not be reached for comment  Rimondi in 2016 was diagnosed with mesothelioma  a type of cancer that has been linked to asbestos exposure   He and his wife sued J J in 2017  They alleged that Rimondi s lifetime exposure to Johnson s Baby Powder and Shower to Shower  another powder product containing talc sold by J J in the past  caused his disease   The jury returned its verdict in favor of the company after just half an hour of deliberations  according to a livestream of the proceedings by Courtroom View Network  The healthcare conglomerate to date has faced 12 trials by plaintiffs claiming asbestos in talc caused their mesothelioma   J J has now been cleared of liability in four trials  with another five resulting in hung juries and mistrials  Three juries have found J J liable  awarding a total of  172 million in damages  J J is appealing those verdicts  The majority of the 13 000 talc lawsuits against the company involve ovarian cancer claims  Juries in those cases have hit the company with verdicts as high as  4 69 billion  Some of the ovarian cancer verdicts have been overturned on appeal on technical legal grounds  while the company s other appeals are still pending   It remains true that of all the talc related verdicts against Johnson   Johnson that have been through the appeals process  every one has been overturned   the company said in its statement on Wednesday   Plaintiffs  lawyers have more recently focused on arguing that asbestos contamination in talc caused ovarian cancer and mesothelioma  Reuters in December published a report detailing that the company knew that the talc in its raw and finished powders sometimes tested positive for small amounts of asbestos from the 1970s into the early 2000s   test results the company did not disclose to regulators or consumers  
J J denies the findings of the Reuters report  which it describes as inaccurate and misleading  In emphasizing the safety of its baby powder  the company says that repeated tests of the powder never found asbestos and that it has cooperated fully and openly with the U S  Food and Drug Administration and other global regulators ",2019-03-27,Reuters,https://www.investing.com/news/stock-market-news/new-jersey-jury-clears-jj-of-liability-in-latest-talc-cancer-trial-1819925,1819925
197931,419447,JNJ,Johnson   Johnson  JNJ  Surpasses Q3 Earnings And Revenue Estimates,opinion,"Johnson   Johnson  NYSE JNJ  came out with quarterly earnings of  2 12 per share  beating the Zacks Consensus Estimate of  2 per share  This compares to earnings of  2 05 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 6   A quarter ago  it was expected that this world s biggest maker of health care products would post earnings of  2 42 per share when it actually produced earnings of  2 58  delivering a surprise of 6 61  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Johnson   Johnson  which belongs to the Zacks Large Cap Pharmaceuticals industry  posted revenues of  20 73 billion for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 3 22   This compares to year ago revenues of  20 35 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Johnson   Johnson shares have added about 1 3  since the beginning of the year versus the S P 500 s gain of 18 3  
What s Next for Johnson   Johnson 
While Johnson   Johnson has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Johnson   Johnson was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 92 on  20 71 billion in revenues for the coming quarter and  8 59 on  81 46 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Large Cap Pharmaceuticals is currently in the top 40  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-15,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-surpasses-q3-earnings-and-revenue-estimates-200473673,200473673
197932,419448,JNJ,J J  JNJ  Beats Q3 Earnings   Sales  Shares Rise,opinion,"Johnson   Johnson   NYSE JNJ    the bellwether of healthcare companies  has a strong presence in the pharmaceutical  medical devices and consumer care markets across the world  This New Jersey based company is well known for its baby care products and brands like Tylenol in addition to drugs like Remicade and Imbruvica However  like many of its peers  JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment In this scenario  investor focus remains on late stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top and bottom line numbers J J s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The average positive earnings surprise over the last four quarters was 3 02 Currently  JNJ has a Zacks Rank  4  Sell   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  JNJ beat on third quarter earnings   the company reported EPS of  2 12 while our consensus called for EPS of  2 00 Revenues Beat  Revenues also beat expectations  J J posted revenues of  20 73 billion  compared to our consensus estimate of  20 08 billion Key Statistics  Pharmaceutical segment sales rose 5 1  year over year to  10 88 billion  reflecting 6 4  operational growth and 1 3  negative currency impact  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide pharmaceutical sales increased 6 4   improving from 4 4  increase in the previous quarter  The sales increase was led by the company s oncology drugs Imbruvica and Darzalex as well as psoriasis treatment  Stelara Ups 2019 Outlook  J J raised its full year earnings and sales outlook on continued strength of its business 2019 adjusted earnings per share are expected in the range of  8 62    8 67  up from prior range of  8 53    8 63  The guidance range indicates growth of 5 4 6 0   previously 4 3 5 5    Revenues are expected in the range of  81 8  82 3 billion  up from the previous range of  80 8  81 6 billion  including currency impact Stock Price Impact  Shares rose more than 2 0  in pre market trading Check back later for our full write up on this JNJ earnings report later Johnson   Johnson Price and Consensus
     
Today s Best Stocks from Zacks 
 Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-15,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-beats-q3-earnings--sales-shares-rise-200473464,200473464
197938,419454,JNJ,U S  senators tell drug company executives pricing is  morally repugnant ,news,By Yasmeen Abutaleb and Michael Erman WASHINGTON NEW YORK  Reuters    U S  senators called drug pricing practices  morally repugnant  and told drug company executives they do not want to hear them blame others for the high prices  taking an aggressive stance at a Senate hearing on the rising costs of prescription medicines   Senators took aim in particular at Abbvie Inc Chief Executive Richard Gonzalez and his company s rheumatoid arthritis drug Humira   the world s top selling prescription medicine  Executives from AstraZeneca PLC  Sanofi  PA SASY  SA   Pfizer  Inc  NYSE PFE   Merck   Co  Johnson   Johnson  NYSE JNJ  and Bristol Myers Squibb  NYSE BMY  Co also answered questions from members of the U S  Senate Finance Committee  The executives pointed to their companies  records of developing lifesaving medications  saying profits generated in the lucrative U S  market help them fund expensive research and development of future treatments    American research based companies are leading the next wave of biomedical innovation to help patients whose diseases cannot be adequately treated with today s medicines  We should work to ensure policies that support and reward these investments   said Bristol Myers CEO Giovanni Caforio  The executives also voiced support for plans to reform the industry wide system of rebates that pharmacy benefit managers  PBMs  and health insurers receive from drugmakers in exchange for preferential coverage of their medicines   In his opening statement  Senator Ron Wyden  the Finance Committee s top Democrat  tore into each company one by one for  profiteering and two faced scheming    Drugmakers behave as if patients and taxpayers are unlocked ATMs full of cash to be extracted  and their shareholders are the customers they value above all else   Wyden said   Senators from both parties targeted AbbVie s Gonzalez  with Wyden noting that the CEO s bonus was partially tied to Humira sales  which reached nearly  20 billion globally last year  Republican Senator John Cornyn criticized the company s web of more than 130 patents that protects Humira s exclusivity  The drug has a list price of more than  60 000 a year  nearly double what it was in 2014  according to Rx Savings Solutions  which helps health plans and employers seek lower cost prescription medicines    I support drug companies recovering a profit based on their research and development and development of innovative drugs  But at some point  that patent has to end  that exclusivity has to end  to be able to get it at a much cheaper cost   said Cornyn  the No  2 Senate Republican from Texas  Cornyn suggested that the powerful Senate Judiciary Committee should examine the U S  patent system under which drug companies protect the exclusivity of their medicines  Congress has already held several hearings on rising prescription drug prices in both the Democrat controlled House of Representatives and the Republican led Senate  but Tuesday s hearing is the first time drug company executives  most of them CEOs  will face lawmakers in more than two years  U S  President Donald Trump has said drugmakers are  getting away with murder   and his administration has made bringing down prescription medicine costs for U S  consumers a top priority  The U S  Department of Health and Human Services  HHS  last year rolled out a plan to lower drug prices and has introduced several modest proposals to curb medicine costs  but Democrats have said the Trump administration is not doing enough  HHS has proposed a rule to eliminate rebates for drugs paid for by Medicare and Medicaid  the government health insurance programs  Several drugmakers temporarily froze price increases last year after criticism from Trump  but they raised prices on more than 250 prescription drugs at the start of this year  albeit at lower levels than in years past ,2019-02-26,Reuters,https://www.investing.com/news/stock-market-news/drug-company-executives-to-testify-before-senate-1790870,1790870
197939,419455,JNJ,FDA finds asbestos in three Claire s cosmetics products,news,"By Chad Terhune  Reuters    The U S  Food and Drug Administration called on Congress to modernize rules for cosmetics safety on Tuesday after it issued an alert warning consumers not to use three cosmetics products sold by Claire s Stores Inc because they tested positive for asbestos  a known carcinogen  The FDA said it would work with Congress to update the regulatory framework that the agency has been operating under for more than 80 years for cosmetics  It said there are currently no legal requirements for any cosmetic manufacturer selling goods to American consumers to test their products for safety  In its safety alert  the FDA identified the products as Claire s eye shadows  contour palette and compact powder and cited the talc used in the products  Claire s disputed the FDA test results  saying they  show significant errors  and have  mischaracterized fibers in the products as asbestos   The retailer  which emerged from bankruptcy in October  said   There is no evidence that any products sold by Claire s are unsafe   However  out of an abundance of caution  it said it removed the three products in question from stores as well as  any remaining talc based cosmetic products   The FDA has come under intensifying pressure from lawmakers and consumer advocates to investigate possible asbestos contamination of talc following a report published by Reuters on Dec  14 about talc in Johnson   Johnson  NYSE JNJ  powders  The Reuters report detailed that J J knew that the talc in its raw and finished powders sometimes tested positive for small amounts of asbestos from the 1970s into the early 2000s  J J did not disclose its test results to regulators or consumers  The alleged presence of asbestos in talc products is at issue in thousands of lawsuits filed against J J  Last month  J J said it had received federal subpoenas for the first time related to the asbestos litigation and said it is cooperating with the inquiries  J J and its talc supplier  Imerys Talc America  have said numerous studies and tests by regulators worldwide have shown their talc to be safe and asbestos free  In response to the FDA s call on Tuesday for new rules  J J said it supports the agency s efforts to  reaffirm the safety of cosmetic talc products   The company said it has backed previous legislative efforts to modernize FDA s regulatory authority over cosmetics  J J also reiterated Tuesday that  for decades global independent laboratories and health authorities have tested Johnson s Baby Powder and have never found asbestos     SHIFT THE SAFETY PARADIGM  The FDA on Tuesday said it would investigate cosmetics manufacturers  sources for talc and what steps they take to test the raw material or their finished products  The agency did not name specific companies   We also want to know how many cosmetics products contain talc and whether manufacturers have received adverse event reports associated with talc containing products   the FDA said  In a joint statement on Tuesday  FDA Commissioner Scott Gottlieb  who separately announced his resignation  and the director of the agency s Center for Food Safety and Applied Nutrition  Susan Mayne  said federal rules have not keep pace with the cosmetic industry s substantial growth and a global supply chain   To significantly shift the safety paradigm of cosmetics in the U S   we would need to work with stakeholders  including Congress  to modernize the outdated regulatory framework that the FDA has been operating under for more than 80 years when it comes to cosmetics   they said in the statement  The FDA said the new rules for cosmetics manufacturers may require companies to report adverse events  provide access to consumer complaints during routine inspections and disclose known allergens on a product s label  In the meantime  U S  regulators are asking cosmetics firms to voluntarily register their products and a list of ingredients  including talc  with the FDA  Asbestos is a mineral often found near talc  a common ingredient in many cosmetics  and if steps are not taken to purify raw talc sufficiently the talc put in consumer products may be contaminated with asbestos  the FDA said  Talc may be used in cosmetics  for example  to prevent caking or to make facial makeup opaque  In 2017  the FDA said it became aware of reports of asbestos contamination in several cosmetics sold by Claire s and another retailer  Justice  which is owned by Ascena Retail Group Inc  The two retailers subsequently removed certain products  such as glitter creams  eye shadows and make up sets  The FDA then ordered independent tests and the results received in late February confirmed asbestos in three Claire s products and one from Justice  The Justice product had already been recalled from the market   In a statement on Tuesday  Justice said it  quickly and responsibly issued a voluntary recall in 2017 out of an abundance of caution   The FDA said Claire s had refused to comply with its request to recall the products that tested positive for asbestos  The FDA said it does not have the authority to mandate a recall  so it issued the safety alert   The United States Public Interest Research Group last May reported the health and safety regulator for the Netherlands ordered Claire s to remove several makeup products from Dutch shops after a study by U S  PIRG showed contamination with asbestos  Claire s in March 2018  in a statement  questioned the accuracy of asbestos testing by Dutch authorities  It said its own testing at independent laboratories in the European Union and the United States labs found that Claire s products were  compliant with all relevant cosmetic safety regulations    Claire s  based in the Chicago suburb of Hoffman Estates  operated 2 471 stores in North America and Europe as of August 2018   
The FDA said the warning pertains to  Claire s Eye Shadows   Batch No Lot No  08 17  Claire s Compact Powder   Batch No Lot No  07 15  and Claire s Contour Palette   Batch No Lot No  04 17 ",2019-03-05,Reuters,https://www.investing.com/news/stock-market-news/fda-finds-asbestos-in-three-products-sold-by-claires-1798432,1798432
197940,419456,JNJ,World s second man cleared of AIDS virus invigorates quest for cure,news,"By Kate Kelland and Julie Steenhuysen LONDON CHICAGO  Reuters    Scientific investigation into the world s second man cleared of the AIDS virus is zooming in on a gene and a treatment side effect  as newly enthused researchers strive to find a cure for the disease that has killed millions   Known as the  London Patient   the man had HIV and a type of blood cancer called Hodgkin s lymphoma  He responded successfully to a bone marrow transplant from a donor with rare genetic resistance to HIV infection  The transplant cleared the man s cancer and his HIV  but the resistant genes may not be the sole cause of his HIV remission   Since the pandemic began in the 1980s  more than 70 million people have been infected with HIV and about 35 million have died  most in Africa  Medical advances mean tests can detect HIV early  new drugs can control it  and there are ways to stop it spreading   but 37 million people still live with the virus  The London Patient s case gives fresh hope to scientists and pharmaceutical researchers who have spent decades looking for ways to end AIDS  HIV expert Sharon Lewin said two factors were probably at play in his success story  the genetic resistance and a transplant side effect that attacks immune cells   The new bone marrow is resistant to HIV  and also the new bone marrow is actively eliminating any HIV infected cells through something called  graft versus host  disease   said Lewin  co chair of the International AIDS Society s cure research advisory board and a researcher at Australia s Doherty Institute   The London Patient joins the first case of this kind  Timothy Ray Brown   or the  Berlin Patient    whose HIV was eradicated by a similar transplant treatment in 2007  It involved the destruction of his immune system and transplanted stem cells with a gene mutation called CCR5 that resists HIV  The AIDS virus uses CCR5 to enter cells  but if the gene is mutated  HIV cannot latch onto cells and infect them  This  graft versus host  effect is akin to a deadly battle of two immune systems  explained Steven Deeks  an HIV expert at the University of California  The incoming transplanted donor immune cells seek out and destroy all the host s immune cells   including those in which HIV can hide out  he said   The transplant resulted in the complete destruction of the old immune system and the construction of a new immune system in which the  HIV  virus can t replicate  because of the genetic mutation   That is the cure   Deeks told Reuters    LONG WAY TO GO  But such transplants are complex  expensive and highly risky to the patients  who would run a risk of dying in the process   So the key is that someone has to come up with a way to deliver  CCR5  gene editing capability to all the  immune system  T cells   and that s what people are working on right now   Deeks added  Teams in labs around the world  as well as drug companies including Gilead Sciences  NASDAQ GILD   Johnson   Johnson  NYSE JNJ  and GSK s ViiV Healthcare  have very early stage cure studies in the works  said Rowena Johnston  director of research at U S  AIDS research foundation amfAR    Companies dip their toes in and out of cure research   But the idea of looking for a cure involving bone marrow transplants to destroy and replace the immune systems of all those infected with HIV is a non starter   Many patients currently have good control of their disease with treatments such as Gilead s anti retroviral drug Biktarvy  which combines three HIV medicines in a single daily tablet    I d rather be on the single pill a day with very little toxicities than risk something as draconian as a transplant   said Anthony Fauci  director of the U S  National Institute of Allergy and Infectious Diseases  He and others said the London Patient s case does  however  underline that in this approach  two factors combined are crucial   the CCR5 genetic resistance  plus its delivery to all cells  including immune cells  Some research teams in the United States and elsewhere are developing gene editing techniques to edit CCR5 cells outside of the body and reintroduce the edited cells back to patients   Specialists said this method has its limits  because it only edits some cells and leaves native wild type cells untouched in the body where HIV can still hide  Other avenues are also being explored   Dan Barouch  a vaccine researcher at the Harvard affiliated Beth Israel Deaconess Medical Center in Boston  is working with Gilead to develop what s known as a  kick and kill  treatment  The idea is to use an initial drug to flush out HIV that is hiding from the immune system and then use standard antiretrovirals to kill the newly exposed virus  Animal studies have shown hope  but it has not yet been proven in people   All HIV cure approaches in general are in their infancy   he said in a telephone interview   
Rare cases of remission  such as the London and Berlin patients  provide a lot of enthusiasm and motivation  for research teams and show that a cure can be achieved  he said   but we still have a long way to go  ",2019-03-06,Reuters,https://www.investing.com/news/world-news/worlds-second-man-cleared-of-aids-virus-invigorates-quest-for-cure-1799449,1799449
197941,419457,JNJ,OxyContin maker Purdue Pharma loses bid to delay opioid epidemic trial,news,"By Nate Raymond  Reuters    OxyContin maker Purdue Pharma LP and two other drugmakers on Friday lost a bid to delay a landmark trial set for May in a multibillion dollar lawsuit by Oklahoma s attorney general accusing them of helping fuel an opioid abuse and overdose epidemic in the state  Cleveland County District Judge Thad Balkman s decision was a win for the state  even as one of the lawyers for the state said Purdue had  threatened  to file for bankruptcy rather than face the first trial to result from around 2 000 lawsuits nationally   This case needs to get to trial because people are dying every day   Reggie Whitten  the lawyer for the state  said during a hearing in Norman  Oklahoma  Reuters  citing people familiar with the matter  on Monday reported that Stamford  Connecticut based Purdue  owned by members of the wealthy Sackler family  was exploring filing for Chapter 11 bankruptcy protection  Doing so would allow it to address potential legal liabilities while halting the cases  Eric Pinker  Purdue s lawyer  made no mention of a potential bankruptcy while arguing that the May 28 trial in the lawsuit brought by Oklahoma Attorney General Mike Hunter against it  Johnson   Johnson  NYSE JNJ  and Teva Pharmaceutical Industries  NYSE TEVA  Ltd should be delayed  He said delaying the trial to Sept  16 was necessary because the state belatedly turned over 1 6 million pages of records critical to Purdue s defense   This case is not at a posture where it can fairly and fully go to trial in May of this year   Pinker said  But the judge said the drugmakers had not established the state s actions had prejudiced them  Purdue in a statement said it  categorically  denies that the ruling will affect whether it files for bankruptcy  Purdue said it was  looking at all of its options  but had made no decisions  Opioids  including prescription painkillers  heroin and fentanyl  were involved in a record 47 600 overdose deaths in 2017  according to the U S  Centers for Disease Control and Prevention  The epidemic has prompted lawsuits by state and local governments accusing Purdue and other drugmakers of contributing to the crisis through deceptive marketing that downplayed the risks of addictive opioids  The companies deny wrongdoing  noting their drugs carried warning labels and pointing to others factors behind the epidemic  
More than 1 600 lawsuits have been consolidated before a federal judge in Ohio  who has pushed for a settlement ahead of the trial before him in October  Other cases  including Oklahoma s  are pending in state courts ",2019-03-08,Reuters,https://www.investing.com/news/stock-market-news/oxycontin-maker-purdue-pharma-loses-bid-to-delay-opioid-epidemic-trial-1802623,1802623
197942,419458,JNJ,California jury awards  29 million to woman with cancer who used J J talc,news,By Tina Bellon  Reuters    A California jury on Wednesday awarded  29 million to a woman who said that asbestos in Johnson   Johnson s talcum powder based products caused her cancer   The verdict  in California Superior Court in Oakland  marks the latest defeat for the healthcare conglomerate facing more than 13 000 talc related lawsuits nationwide  J J  NYSE JNJ  said it would appeal  citing  serious procedural and evidentiary errors  in the course of the trial  saying lawyers for the woman had fundamentally failed to show its baby powder contains asbestos  The company did not provide further details of the alleged errors during the trial    We respect the legal process and reiterate that jury verdicts are not medical  scientific or regulatory conclusions about a product   J J said in a statement on Wednesday   The New Brunswick  New Jersey based company denies that its talc causes cancer  saying numerous studies and tests by regulators worldwide have shown that its talc is safe and asbestos free   The lawsuit was brought by Terry Leavitt  who said she used Johnson s Baby Powder and Shower to Shower   another powder containing talc sold by J J in the past   in the 1960s and 1970s and was diagnosed with mesothelioma in 2017  It was the first of more than a dozen J J talc cases scheduled for trial in 2019  The nine week trial began on Jan  7 and included testimony from nearly a dozen experts on both sides  The jury deliberated for two days before delivering its verdict  which was broadcast online by Courtroom View Network  Jurors found that J J s talc based products used by Leavitt were defective and that the company had failed to warn consumers of the health risks  awarding  29 4 million in damages to Leavitt and her husband  The jury declined to award punitive damages   Yet another jury has rejected J J s misleading claims that its talc was free of asbestos   said Moshe Maimon  a lawyer for Leavitt  in a statement on Wednesday   The internal J J documents that the jury saw  once more laid bare the shocking truth of decades of cover  up  deception and concealment by J J    Leavitt s was the first talc case to go to trial since Reuters on Dec  14 published a report detailing that J J knew that the talc in its raw and finished powders sometimes tested positive for small amounts of asbestos from the 1970s into the early 2000s   test results it did not disclose to regulators or consumers  Leavitt s trial originally included J J s talc supplier  Imerys Talc America  a unit of Imerys SE  as a co defendant  California Superior Court Judge Brad Seligman  who oversaw the trial  told jurors in February that the company was no longer part of the case after it filed for Chapter 11 bankruptcy protection under the weight of the talc litigation  which stayed lawsuits against it  While earlier talc lawsuits alleged talc itself causes ovarian cancer  plaintiffs  lawyers have more recently focused on arguing asbestos contamination in talc caused ovarian cancer and mesothelioma  a form of cancer linked to asbestos exposure  In 11 cases so far alleging asbestos contamination in talc  three have resulted in wins for plaintiffs  awarding damages as high as  4 69 billion in a July 2018 multi plaintiff ovarian cancer verdict  J J won three other cases and another five ended in hung juries  J J has appealed all of the plaintiff verdicts  and the company said it is confident the verdicts would be overturned on appeal    Read the documents that sparked the investigation    ,2019-03-14,Reuters,https://www.investing.com/news/stock-market-news/california-jury-orders-jj-to-pay-29-million-in-latest-talc-cancer-trial-1807024,1807024
197943,419459,JNJ,The Zacks Analyst Blog Highlights  Novartis  J J  Pfizer  Novo Nordisk And Glaxo,opinion,For Immediate ReleaseChicago  IL  October 14  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Novartis   NYSE NVS    J J   NYSE JNJ    Pfizer   NYSE PFE    Novo Nordisk   NYSE NVO   and Glaxo   NYSE GSK   Here are highlights from Friday s Analyst Blog Pharma Stock Roundup  NVS  NVO  GSK and MoreThis week  the FDA approved Novartis  potential blockbuster eye drug  Beovu  J J submitted a regulatory application seeking label expansion approval of its plaque psoriasis drug  Stelara for pediatric patients  Pfizer  Novo Nordisk and Glaxo announced licensing deals Recap of the Week s Most Important StoriesFDA Approves Novartis  New Eye Drug The FDA granted approval to Novartis  ophthalmology drug    brolucizumab  injection to treat wet age related macular degeneration  AMD   Novartis claims that this anti VEGF therapy offers greater fluid resolution as compared to Regeneron Bayer s market leading drug Eylea  The FDA approval was based on data from the phase III HAWK and HARRIER studies  in which Beovu demonstrated significant advantages over Eylea Meanwhile  Novartis announced data from the phase IIb dose finding study  which showed that more patients treated with its investigational monoclonal antibody  ligelizumab  were completely symptom free from chronic spontaneous urticaria compared to Xolair  300 mg   which Novartis markets together with Roche J J Files sBLA for Stelara in Adolescent Patients  J J submitted a supplemental Biologics License Application  sBLA  to the FDA  seeking approval of Stelara for the treatment of pediatric patients  6 to 11 years of age  with moderate to severe plaque psoriasis  Stelara is already marked for adolescents and adults with moderate to severe plaque psoriasis  Stelara is also marketed to treat adults with active psoriatic arthritis and moderate to severe Crohn s disease Meanwhile  a Philadelphia jury ordered J J to pay punitive damages of  8 billion to a man who claimed that the use of its antipsychotic drug  Risperdal caused him to develop breasts  The lawsuit filed by Nicholas Murray claimed that J J did not warn of the risk that young men using Risperdal can develop enlarged breasts  J J responded by saying that the award was  grossly disproportionate  and was confident that the jury verdict will be overturned in the court Pfizer  Glaxo and Novo Nordisk Sign New Deals Pfizer in licensed global rights to Akcea Therapeutics  investigational antisense therapy AKCEA ANGPTL3 LRx which is being evaluated in a phase II study as a treatment for patients with type II diabetes  hypertriglyceridemia and non alcoholic fatty liver disease  NAFLD    AKCEA ANGPTL3 LRx is designed to reduce the production of a protein in liver  Akcea is an affiliate of Ionis Pharmaceuticals and the companies will receive an upfront payment of  250 million from Pfizer  which will be split equally between the two companies  This apart  they will be entitled to milestone payments of up to  1 3 billion as well as royalties Novo Nordisk signed a three year research deal with bluebird bio to develop in vivo genome editing candidates for  and other severe genetic diseases  Per the deal  bluebird bio s new platform technology   mRNA based megaTAL technology   will be utilized to create a highly differentiated approach to treat severe genetic diseases  No financial terms of the deal were disclosed Glaxo also announced a five year collaboration with small biotech Lyell Immunopharma to develop next generation cancer cell therapies The NYSE ARCA Pharmaceutical Index rose 0 4  in the last five trading sessions Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-10-13,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-novartis-jj-pfizer-novo-nordisk-and-glaxo-200473195,200473195
197944,419460,JNJ,Q3 Results Begin  Can We Avoid An Earnings Recession ,opinion,Tuesday  October 15  2019 As we await news reports from companies reporting Q3 results this morning  we see the October Empire State Index   which had been expected out this morning   was released in error yesterday  with a headline of 4 0  This is better than the 2 0 expected  and between recent highs   24 3 in August 2018  and lows   8 6 in June 2019    Clearly  these results tend toward the more volatile  although interestingly  the estimates for this New York state production survey are almost always higher than the actual   though not for this month  This index looks to be bouncing off those recent lows  the end of the year will be key for this metric  JPMorgan Chase   NYSE JPM    a Zacks Rank  3  Hold  company  outperformed expectations on both top and bottom lines   2 68 per share versus  2 44 expected  Revenues came in at  29 3 billion  above the  28 4 billion analysts were looking for  Fixed Income  working off a relatively weak year over year comp  was up 25  in Q3 2019  while Credit Loss Provisions rose 60  from the year ago quarter  Shares at this hour in the pre market are up 1 9  on the news  and  7  year to date  JPMorgan has only come up short of earnings estimates once since Q1 2016   Johnson   Johnson   NYSE JNJ    a Zacks Rank  4  Sell  rated stock ahead of its earnings report  beat estimates on both top and bottom lines this morning   2 12 per share amounted to a 12 cent positive surprise  on sales of  20 73 billion which surpassed the  20 08 billion expected  Sales in its important Pharma space rose 5 1   J J raised earnings guidance for full year 2019   up 9 cents on the bottom end of the range and  4 cents on the top  to  8 67 per share  Shares are up 1 66  at this moment of pre market trading  coming up from its near lows year to date   These amount to just a sample of what we are about to see in the days and weeks ahead  Will Q3 bear out better than expected  or are we destined for an earnings recession  For a comprehensive view on the subject  check out this interview with Zacks Director of Research Sheraz Mian   Mark VickerySenior Editor  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-10-14,Zacks Investment Research,https://www.investing.com/analysis/q3-results-begin-can-we-avoid-an-earnings-recession-200473581,200473581
197945,419461,JNJ,Initial Q3 Results Are Better Than Expected,opinion,As we await news reports from companies reporting Q3 results this morning  we see the October Empire State Index   which had been expected out this morning   was released in error yesterday  with a headline of 4 0  This is better than the 2 0 expected  and between recent highs   24 3 in August 2018  and lows   8 6 in June 2019   Clearly  these results tend toward the more volatile  although interestingly  the estimates for this New York state production survey are almost always higher than the actual   though not for this month  This index looks to be bouncing off those recent lows  the end of the year will be key for this metric JPMorgan Chase     a Zacks Rank  3  Hold  company  outperformed expectations on both top and bottom lines   2 68 per share versus  2 44 expected  Revenues came in at  29 3 billion  above the  28 4 billion analysts were looking for  Fixed Income  working off a relatively weak year over year comp  was up 25  in Q3 2019  while Credit Loss Provisions rose 60  from the year ago quarter Shares at this hour in the pre market are up 1 9  on the news  and  7  year to date  JPMorgan has only come up short of earnings estimates once since Q1 2016  Johnson   Johnson  NYSE JNJ      a Zacks Rank  4  Sell  rated stock ahead of its earnings report  beat estimates on both top and bottom lines this morning   2 12 per share amounted to a 12 cent positive surprise  on sales of  20 73 billion which surpassed the  20 08 billion expected  Sales in its important Pharma space rose 5 1  J J raised earnings guidance for full year 2019   up 9 cents on the bottom end of the range and  4 cents on the top  to  8 67 per share  Shares are up 1 66  at this moment of pre market trading  coming up from its near lows year to date  These amount to just a sample of what we are about to see in the days and weeks ahead  Will Q3 bear out better than expected  or are we destined for an earnings recession  For a comprehensive view on the subject  check out this interview with Zacks Director of Research Sheraz Mian ,2019-10-14,Zacks Investment Research,https://www.investing.com/analysis/initial-q3-results-are-betterthanexpected-200473569,200473569
197946,419462,JNJ,J J  JNJ  Beats On Q3 Earnings As Sales Rise  Ups 2019 View,opinion,"Johnson   Johnson s   NYSE JNJ   third quarter 2019 earnings came in at  2 12 per share  which beat the Zacks Consensus Estimate of  2 00 and increased 3 4  from the year ago period Adjusted earnings exclude after tax intangible amortization expense and some special items  Including these items  J J reported third quarter earnings of  1 81 per share  up 25 7  from the year ago quarter Sales of the drug and consumer products giant came in at  20 73 billion  which beat the Zacks Consensus Estimate of  20 08 billion  Sales rose 1 9  from the year ago quarter  reflecting an operational increase of 3 2   which offset an unfavorable currency impact of 1 3  Organically  excluding the impact of acquisitions and divestitures  sales increased 5 2  on an operational basis  higher than 3 7  increase seen in the previous quarter Sales rose in all the three segments on an organic basis  It accelerated in the Medical Device and Pharma units but decelerated in the Consumer unit on a sequential basis mainly due to lower sales of baby care products Third quarter sales rose 1 2  in the domestic market to  10 79 billion and 2 6  in international markets to  9 94 billion  However  international sales reflected 5 4  operational growth  which was offset by 2 8  negative currency impact Segment DetailsPharmaceutical segment sales rose 5 1  year over year to  10 88 billion  reflecting 6 4  operational growth which was offset by 1 3  negative currency impact  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 6 4   improving from 4 4  increase in the previous quarter The sales increase was led by the company s oncology drugs  Imbruvica and Darzalex as well as psoriasis treatment  Stelara Worldwide sales of J J s oncology drugs rose 6 7  in the quarter to  2 76 billion  Other core products like Stelara  Simponi Simponi Aria and Invega Sustenna and new immunology medicines like Tremfya also contributed to growth  However  sales of some other key drugs like Xarelto were soft in the quarter  Sales of others like Zytiga  Remicade  Procrit Eprex declined due to the impact of generic biosimilar competition Darzalex sales rose 53 5  year over year to  765 million in the quarter  Stelara sales rose 29 6  to  1 7 billion in the quarter  Imbruvica sales rose 30 6  to  921 million in the quarter  Please note that J J markets Imbruvica in partnership with AbbVie  Inc    NYSE ABBV    Invega Sustenna sales rose 13 7  to  851 million in the quarter Simponi Simponi Aria sales rose 9 6  to  586 million in the quarter  Newly launched Tremfya recorded sales of  290 million in the quarter compared with  235 million in the second quarter Zytiga sales declined 22 7  to  741 million in the quarter as growth outside the United States was offset by sales decline in the United States due to generic competition Sales of Invokana Invokamet declined 5 8  to  179 million  Xarelto sales were almost flat in the quarter at  613 million  Sales of Procrit Eprex declined 22 4  to  198 million in the quarter  Sales of Remicade were down 17 6  in the quarter to  1 14 billion  Please note that J J markets Remicade in partnership with Merck   NYSE MRK   In the quarter  J J recorded pulmonary arterial hypertension revenues of  654 million  down 0 3  year over year  Strong demand for Uptravi and Opsumit was offset by a decline in Tracleer sales  We remind investors that Teva Pharmaceutical Industries Limited   NYSE TEVA   launched a generic version of Tracleer in the United States in June Medical Devices segment sales came in at  6 38 billion  down 3 1  from the year ago period  reflecting an operational decrease of 2 0  and negative currency movement of 1 1  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 5 3   better than 3 2  in the previous quarter The Consumer segment recorded revenues of  3 47 billion in the reported quarter  up 1 6  year over year  On an operational basis  Consumer segment sales increased 3 3   partially offset by unfavorable foreign currency movement of 1 7  Excluding the impact of acquisitions and divestitures  adjusted operational sales growth was 1 3  worldwide  a deceleration from 2 3  the previous quarter 2019 Guidance J J raised its full year earnings and sales view on strong third quarter results Adjusted earnings per share in 2019 are expected in the range of  8 62    8 67  up from the prior range of  8 53    8 63  The guidance range indicates growth of 5 4 6   previously 4 3 5 5    On an operational  constant currency basis  adjusted earnings per share are expected to grow in the range of 8 1   8 7   up from the prior expectation of 6 7 7 9   Revenues are expected in the range of  81 8  82 3 billion  up from the previous range of  80 8  81 6 billion  including currency impact Operational constant currency sales growth is expected to be in the range of 2 5  3   better than 1  2  expected previously  Adjusted operational sales growth   excluding currency impact  acquisitions divestitures  is expected to be in the range of 4 5  to 5   higher than 3 2  to 3 7  expected previously Our TakeJ J beat third quarter estimates for both earnings and sales and raised its financial outlook for the year  which pushed its shares up more than 2  in pre market trading  The stock has returned 1 3  this year so far against a decrease of 0 8  recorded by the   J J s Pharma segment recorded a surprising sales increase despite currency headwinds and the impact of biosimilar and generic competition on sales of some key drugs like Remicade and Zytiga In 2019  J J is witnessing significant generic biosimilar headwinds in the Pharma unit  However  the company expects its sales and earnings growth to accelerate in 2020  supported by contribution from new drugs like Tremfya  Erleada and Spravato and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug  Stelara  J J is also making rapid progress with its pipeline and line extensions However  J J faces a slew of lawsuits  which allege personal injuries to patients caused by the use of its medicines  mainly its talc and opioid products  J J faces more than 15 000 lawsuits for its talc based products  primarily its baby powders  The lawsuits allege that its talc products contain asbestos  which caused many women to develop ovarian cancer  It also faces thousands of other lawsuits related to abuse of its opioid based drugs  These lawsuits claim that J J is one of the several companies whose opioid based drugs were responsible for fueling the state s opioid epidemic  Earlier this month  J J settled with two counties of Ohio for  10 million plus other cost reimbursements  in connection with the multi district opioid case in OhioJ J also faces more than 13 000 lawsuits alleging that use of its antipsychotic drug  Risperdal causes enlargement of breast tissues in boys  Last week  a ordered J J to pay punitive damages of  8 billion to a man who claimed that the use of Risperdal caused him to develop gynecomastia  enlarged breasts  These lawsuits have raised uncertainty about the company  A group of analysts  however  believe J J is strong enough to handle the legal issues J J currently has a Zacks Rank  4  Sell  You can see   Johnson   Johnson Price  Consensus and EPS Surprise
    Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-14,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-beats-on-q3-earnings-as-sales-rise-ups-2019-view-200473625,200473625
197947,419463,JNJ,J J  JNJ  Gets FDA Approval For Xarelto Label Expansion,opinion,"Janssen  a subsidiary of Johnson   Johnson   NYSE JNJ    and partner Bayer  DE BAYGN  AG   OTC BAYRY   announced that the FDA has approved a label expansion of its blood thinner  Xarelto  rivaroxaban  With the latest label expansion  Xarelto can now be prescribed for prevention of venous thromboembolism   VTE   or blood clot  and VTE related death during hospitalization and post hospital discharge in acutely ill medical patients at risk for VTE and not at high risk of bleedingXarelto is already approved for a wide range of patient population for prevention and reduction in the risk of recurrence of VTE Shares of J J have increased 1 3  so far this year against the  s decrease of 0 8  The approval was based on data from a phase III program including MAGELLAN and MARINER studies  which evaluated Xarelto in patients with acute medical illnesses  Previously announced data from the MAGELLAN study showed that Xarelto was non inferior to Sanofi s   NASDAQ SNY   Lovenox  enoxaparin  in short term use  and superior in long term use compared to short term enoxaparin treatment followed by placebo Although data from the MARINER study did not meet its primary endpoint  Xarelto achieved positive benefit risk profile based on reduction in symptomatic VTE Per the press release  more than seven million people are hospitalized in the United States for acute medical illness  These patients have increased risk of blood clot during three months of discharge from hospitals  Several marketed anti coagulants are administered through injection and mainly during hospitalization  Xarelto  which is an orally administered anti coagulant  will provide a better treatment option for these patients and can be administered for a few days after discharge as well  Label expansion of Xarelto for use in hospitalized acutely ill medical patients is likely to create an incremental growth opportunity Meanwhile  J J continues to evaluate Xarelto in other patient population  In July  the company  that the drug has achieved similar low risk of recurrent VTE or blood clots and similar rates of bleeding compared to current standard anticoagulation therapy in pediatric patients in phase III EINSTEIN Jr study Another popular blood thinner  Eliquis  is marketed by Bristol Myers   NYSE BMY   in collaboration with Pfizer  NYSE PFE  Johnson   Johnson Price
    Zacks RankJ J currently carries a Zacks Rank  4  Sell  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-10-14,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-gets-fda-approval-for-xarelto-label-expansion-200473608,200473608
197955,419471,JNJ,At least four pharma CEOs to testify at Senate drug pricing hearing,news,"By Michael Erman NEW YORK  Reuters    Drugmakers  Pfizer  Inc  NYSE PFE   Bristol Myers Squibb  NYSE BMY  Co and Sanofi  PA SASY  SA said on Wednesday that their chief executives plan to testify at a Senate hearing on rising prescription drug prices later this month  They join Merck   Co CEO Ken Frazier  who said on Tuesday that he would testify at the Feb  26 hearing  Johnson   Johnson  NYSE JNJ  said on Wednesday that Jennifer Taubert  its head of global pharmaceuticals  would represent the healthcare conglomerate at the hearing   Republican Senator Chuck Grassley  chairman of the Senate Finance Committee  and Democratic Senator Ron Wyden  ranking member of the committee on Monday invited executives from seven pharmaceutical companies to testify at the hearing   The other companies invited to send executives are  AbbVie Inc   NYSE ABBV  and AstraZeneca Plc    Sanofi CEO Olivier Brandicourt currently serves as chairman of drug industry lobby group PhRMA  Bristol Myers CEO Giovanni Caforio is the group s chairman elect  Albert Bourla  who became Pfizer CEO last month  will represent the largest U S  drugmaker at the hearing   The United States  which leaves drug pricing to market competition  has higher prices than in other developed countries  where governments directly or indirectly control costs  That makes it by far the world s most lucrative market for manufacturers  Congress has been targeting the pharmaceutical industry over the rising cost of prescription drugs for U S  consumers  particularly since Democrats took over the House of Representatives in January  Drug pricing is also a top priority of the administration of President Donald Trump  who had made it a central issue of the 2016 presidential campaign  Drugmakers have slowed and limited U S  price increases as scrutiny on their practices has intensified over the past few years   
They nonetheless increased prices on hundreds of drugs in January  including a 6 2 percent increase on the world s top selling drug   AbbVie s rheumatoid arthritis treatment Humira   and hikes on insulin prices by Sanofi and  Novo Nordisk   CO NOVOb  ",2019-02-06,Reuters,https://www.investing.com/news/stock-market-news/at-least-four-pharma-ceos-to-testify-at-senate-drug-pricing-hearing-1771620,1771620
197956,419472,JNJ,J J becomes first drugmaker to add prices to television ads,news,"By Julie Steenhuysen CHICAGO  Reuters    Johnson   Johnson  NYSE JNJ  said on Thursday it will start adding the price of its medicines to television commercials by next month  becoming the first drugmaker to heed a call by U S  President Donald Trump for price transparency of drugs advertised directly to consumers on TV  The healthcare conglomerate said it will include both the list price of a product   the price before any rebates or discounts to insurers or pharmacy benefit managers   as well as potential out of pocket costs that patients will pay  The move  announced in a statement on J J s website  won swift praise from U S  Health and Human Services Secretary Alex Azar  Last May  Azar s office released a blueprint for reducing the cost of drug prices  which included a proposal to require disclosure of list prices in TV ads for drugs   We commend Johnson   Johnson for recognizing the value of informing consumers about list prices and for doing so voluntarily  We call on other manufacturers to follow their lead   Azar said in a statement  Trump made lowering the cost of prescription drugs for U S  consumers a central issue of the 2016 presidential campaign and emphasized it again in his State of the Union Address this week  Ads for the blood thinner Xarelto  J J s most widely prescribed medicine  will be the first television spot to include pricing information  the company said  The treatment used to prevent blood clots costs about  450 to  540 a month  Congress has increased its scrutiny of U S  drug pricing since Democrats took over control of the House of Representatives in January  while pressure is also coming from the Republican led Senate  
Republican Senator Chuck Grassley  chairman of the Senate Finance Committee  and Democratic Senator Ron Wyden  ranking member of the committee  on Monday invited executives from seven pharmaceutical companies  including J J  to testify at a Feb  26 hearing on rising drug prices ",2019-02-07,Reuters,https://www.investing.com/news/stock-market-news/jj-becomes-first-drugmaker-to-add-prices-to-television-ads-1772898,1772898
197957,419473,JNJ,FDA OKs split dosing regimen for J J s Darzalex,news,The FDA approves a split dosing regimen  over two consecutive days  for Johnson   Johnson  NYSE JNJ  unit Janssen Pharmaceutical s multiple myeloma med DARZALEX  daratumumab  The new regimen was approved in December 2018 in Europe and Canada Now read ,2019-02-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-splitdosing-regimen-for-jjs-darzalex-1777072,1777072
197958,419474,JNJ,Johnson   Johnson receives federal subpoenas related to baby powder litigation,news,"By Chris Kirkham  Reuters    Johnson   Johnson  NYSE JNJ  said Wednesday it has received subpoenas from the U S  Justice Department and the Securities and Exchange Commission  SEC  related to litigation involving alleged asbestos contamination in its signature Baby Powder product line  The company said it intends to  cooperate fully with these inquiries and will continue to defend the Company in the talc related litigation   The disclosure in Johnson   Johnson s annual report on Wednesday is the first time that the company disclosed it had received subpoenas from federal agencies regarding its talc powder products  The Justice Department declined to comment and the SEC did not immediately respond to requests for comment  A Reuters report on Dec  14 revealed that Johnson   Johnson knew for decades that small amounts of asbestos  a known carcinogen  had been occasionally found in its talc and powder products  according to tests from the 1970s to the early 2000s   information it did not disclose to regulators or the public   The Reuters article prompted a selloff in Johnson   Johnson shares  erasing about  40 billion from the company s market value in one day  and a public relations crisis as the healthcare conglomerate faced widespread questions about the possible health effects of one of its most iconic products   Johnson   Johnson said that the federal inquiries  are related to news reports that included inaccurate statements and also withheld crucial information  that had already been made public  The company added that  decades of independent tests by regulators and the world s leading labs prove Johnson   Johnson s baby powder is safe and asbestos free  and does not cause cancer   Johnson   Johnson faces lawsuits involving 13 000 plaintiffs who allege use of its talc products  including Baby Powder  caused cancer  
Last month  U S  Democratic Senator Patty Murray sent a letter to J J Chief Executive Alex Gorsky seeking documents and information related to testing of its talc products for the presence of carcinogens and  how it presented that information to regulators and consumers  ",2019-02-21,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-receives-federal-subpoenas-related-to-baby-powder-litigation-1785732,1785732
197959,419475,JNJ,Court ruling could help J J defeat St  Louis talc lawsuits,news,"By Tina Bellon NEW YORK  Reuters    A Missouri Supreme Court ruling on talc lawsuits could reduce the liability and number of large trials Johnson   Johnson  NYSE JNJ  faces over allegations its talc products  including baby powder  cause cancer  The ruling will likely offer some respite to the healthcare conglomerate as it deals with growing pressure over the safety of its talc products  some defense lawyers said  The company revealed in its annual report on Wednesday that it had received subpoenas from the U S  Justice Department and the Securities and Exchange Commission related to talc litigation  Some plaintiffs  lawyers  however  played down the impact of the ruling  It was a trial in St  Louis s 22nd Circuit Court  brought by 21 plaintiffs from outside of the city whose cases were joined to that of a single St  Louis resident  that in July produced a record  4 69 billion talc verdict against J J  The company is facing several more such lawsuits in St  Louis   However  Missouri s high court on Feb  13 ruled in a separate talc case that allowed a non resident to participate in joined cases was  a clear and direct violation  of state law barring the use of joinder   combining two or more cases   to allow courts to hear cases they otherwise could not   Most state courts can only hear cases involving plaintiffs or defendants from that state or alleging injuries occurring within their jurisdiction  The U S  Supreme Court strengthened those restrictions in a 2017 decision  But the St  Louis court had allowed out of state residents to continue to sue New Jersey based J J through liberal use of joinder  In the case that produced the July verdict  18 of the plaintiffs were from outside Missouri and three were from outside the city of St  Louis  Of the roughly 700 talc cases filed in St  Louis  only 40 involve Missouri residents  according to court filings   If the Feb  13 ruling closes off the St  Louis court to non resident claims  J J may have a stronger hand defending itself in smaller talc cases spread out among other  potentially less plaintiff friendly state and federal courts    There s no real way of reading this decision other than this court clearly saying you can t join claims if the injury did not occur in the venue   said Mark Cheffo  a New York based product liability defense lawyer not involved in talc litigation   J J in a statement said it was pleased with the decision   One claim that is properly before a court cannot provide a basis for drawing into a trial other claims that are not  We believe that decision is clearly correct  and we continue to believe that the science doesn t support plaintiffs  claims   the company said  declining further comment  IMPACT UNCLEAR Some plaintiffs  lawyers said the Feb  13 ruling was not as definitive as Cheffo suggests   If defendants are celebrating this ruling as the end of St  Louis mass tort  they have not read the entire Missouri case law   said Eric Holland  a St  Louis based plaintiff lawyer involved in the talc litigation  Holland pointed to a 2016 Missouri Supreme Court decision that upheld a  38 million verdict in a pharmaceutical product liability case the defendant claimed had been improperly joined  The court let the result stand  saying that even an improper joinder did not render the trial unfair to defendants  Though the 2016 ruling involved a case already decided  Holland and other plaintiffs  lawyers said they planned to argue its fairness analysis also applies to out of state talc claims in cases yet to go to trial  They said they would also argue joining the cases was the most efficient use of judicial resources  Defense lawyers said the Feb  13 decision would likely mean dismissal or severing of the out of state claims from four upcoming multi plaintiff cases scheduled for trial in St  Louis  Two of the cases were halted by the Missouri Supreme Court ahead of its ruling  Holland and other plaintiff lawyers said they would challenge J J requests to sever or dismiss talc cases by arguing the Feb  13 decision did not overrule the 2016 ruling  Cheffo said the 2016 ruling could make it harder for J J to overturn the July verdict and its record penalty because the company would have to prove the joinder led to an unfair trial   FORUM SHOPPING  BY OUT OF STATE PLAINTIFFS The St  Louis court has been a venue for more talc trials and has seen larger verdicts than any other jurisdiction  Outside of St  Louis  the only other significant talc verdicts against J J to date have come in lawsuits filed by individual plaintiffs in New Jersey and California  where the company is currently facing jury verdicts totaling  142 million   A Los Angeles jury delivered a  417 million talc verdict against J J in 2017  but the judge threw out the award weeks later as unsupported by the evidence  All talc verdicts against J J are on appeal  The St  Louis court has a history of issuing large punitive damages against companies and has often been criticized by business groups as allowing  forum shopping  by out of state plaintiffs   While J J faces some trials brought by individuals in other jurisdictions  the multi plaintiff St  Louis cases are the largest and have the most potential to produce additional billion dollar verdicts  Plaintiffs allege that the talc in Johnson s baby powder and other J J products causes ovarian cancer  or that asbestos contamination in the talc causes ovarian cancer and mesothelioma  Asbestos is a known carcinogen linked to mesothelioma  J J and its talc supplier  Imerys Talc America  a co defendant in the litigation  deny the allegations  saying numerous studies and tests by regulators worldwide have shown their talc to be safe and asbestos free  Reuters on Dec  14 published a report detailing that J J knew that the talc in its raw and finished powders sometimes tested positive for small amounts of asbestos from the 1970s into the early 2000s   test results it did not disclose to regulators or consumers      J J is currently facing roughly 13 000 lawsuits over talc  most of which have been consolidated in federal court in New Jersey  Many plaintiff s lawyers have fought to keep cases out of federal court  which they feel favors corporate defendants  Three juries have rejected claims that Baby Powder was tainted with asbestos or caused plaintiffs  mesothelioma  Five other juries have failed to reach verdicts  resulting in mistrials  
In a statement  Imerys Talc America said the Missouri ruling affirmed legal arguments it has made in litigation for the last four years  The company filed for Chapter 11 bankruptcy on Feb  13  saying it lacked the financial clout to defend against talc lawsuits ",2019-02-25,Reuters,https://www.investing.com/news/stock-market-news/court-ruling-could-help-jj-defeat-st-louis-talc-lawsuits-1789039,1789039
197960,419476,JNJ,Pharma stocks could see turbulence from U S  Senate drug price hearing,news,"By Lewis Krauskopf NEW YORK  Reuters    U S  healthcare stocks could face more turbulence on Tuesday  after a bumpy early 2019  as top executives from some of the largest pharmaceutical companies are expected to get grilled in the U S  Senate on the high cost of prescription drugs  The Senate Finance Committee hearing on drug pricing is likely to turn up the volume on the debate over healthcare costs  an issue looming as a potential negative for the sector s performance in the coming months  As the 2020 U S  presidential race heats up  drug companies could become political targets  causing unease for investors who hold the stocks  as was the case ahead of the last presidential election in 2016   I think the rhetoric is still going to be pretty harsh   said Jeff Jonas  a healthcare portfolio manager with Gabelli Funds   I don t think any actual policy is going to be implemented  but I think the rhetoric is going to be an overhang   Chief executives and other top officials are expected at Tuesday s hearing from  AbbVie Inc   NYSE ABBV   AstraZeneca Plc  Bristol Myers Squibb  NYSE BMY  Co  Johnson   Johnson  NYSE JNJ   Merck   Co Inc   Pfizer  Inc  NYSE PFE  and Sanofi  PA SASY  SA   We expect the hearing to be negative for the group  and continue to believe investors are under pricing the risks    Wells Fargo   NYSE WFC  analyst David Maris said in a research note  Kevin Gade  a portfolio manager at Bahl   Gaynor focusing on pharmaceutical and biotech stocks  said he expects the executives to point the finger for high drug prices elsewhere in the drug supply chain  such as at pharmacy benefit managers or insurance companies   I don t think pharma is going to be able to win them over   Gade said  adding that  you can only hope   that anything disastrous is avoided   So far this year  the S P 500 healthcare sector has climbed 7 percent against a nearly 12 percent gain for the overall S P 500  which is the benchmark index for large U S  companies  S P 500 pharmaceutical companies are up only 4 percent with S P 500 biotech companies overall up 4 8 percent  Investors said healthcare has underwhelmed this year largely because it was the best performing major S P 500 sector last year  as investors sought healthcare as a relative safe haven when the market became more volatile at the end of 2018   GRAPHIC  U S  health stocks lag in 2019     But they added that the political concerns also could be weighing on the group  Although Republicans control the Senate committee running Tuesday s hearing  drug pricing and the cost to U S  consumers is expected to get a fresh spotlight with Democrats having taken control of the House of Representatives in January  Nicholas Colas  co founder of DataTrek Research  last week recommended that investors underweight healthcare stocks in part because the companies  are in the sights of both Democrat and Republican lawmakers  an important point as the 2020 presidential campaign cycle gets under way   
 They are an easy target because the electorate really dislikes the American healthcare system   Colas said in a note ",2019-02-25,Reuters,https://www.investing.com/news/stock-market-news/pharma-stocks-could-see-turbulence-from-us-senate-drugprice-hearing-1789812,1789812
197961,419477,JNJ,Johnson   Johnson  JNJ  Stock Moves  0 99   What You Should Know,opinion,"In the latest trading session  Johnson   Johnson  NYSE JNJ  closed at  131 84  marking a  0 99  move from the previous day  This change was narrower than the S P 500 s 1 56  loss on the day  At the same time  the Dow lost 1 19   and the tech heavy Nasdaq lost 1 67  
Coming into today  shares of the world s biggest maker of health care products had gained 4 89  in the past month  In that same time  the Medical sector lost 3 6   while the S P 500 lost 1 22  
Wall Street will be looking for positivity from JNJ as it approaches its next earnings report date  This is expected to be October 15  2019  In that report  analysts expect JNJ to post earnings of  2 per share  This would mark a year over year decline of 2 44   Meanwhile  our latest consensus estimate is calling for revenue of  20 05 billion  down 1 45  from the prior year quarter 
For the full year  our Zacks Consensus Estimates are projecting earnings of  8 60 per share and revenue of  81 51 billion  which would represent changes of  5 13  and  0 09   respectively  from the prior year 
Investors should also note any recent changes to analyst estimates for JNJ  These revisions help to show the ever changing nature of near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate remained stagnant within the past month  JNJ currently has a Zacks Rank of  4  Sell  
Digging into valuation  JNJ currently has a Forward P E ratio of 15 49  For comparison  its industry has an average Forward P E of 14 44  which means JNJ is trading at a premium to the group 
We can also see that JNJ currently has a PEG ratio of 2 25  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2 11 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 35  putting it in the top 14  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-10-08,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-stock-moves-099-what-you-should-know-200471638,200471638
197962,419478,JNJ,J J Ordered By Philadelphia Jury To Pay  8B In Risperdal Case,opinion,Johnson   Johnson   NYSE JNJ   stock declined around 1 5  in after hours trading after a Philadelphia jury ordered it to pay  8 billion in punitive damages in a case related to its antipsychotic drug  Risperdal The lawsuit filed by Nicholas Murray claimed that J J did not warn of the risk that young men using Risperdal can develop enlarged breasts J J faces more than 13 000 similar lawsuits alleging that use of Risperdal causes enlargement of breast tissues in boys   a condition known as gynecomastia  The latest award is the largest in the pending Risperdal lawsuits  which have been primarily filed in state courts in Pennsylvania  California  and Missouri  Earlier  a compensatory damage award of  680 000 was paid to Murray in the same lawsuit J J responded by saying that the award was  grossly disproportionate  and was confident that the jury verdict will be overturned in the court  It said Risperdal s label clearly mentioned the risks associated with the use of the medicine  However  the jury did not hear evidence related to this J J s stock has risen 2 1  this year so far against a decrease of 0 6  recorded by the    J J faces a slew of lawsuits  which allege personal injuries to patients caused by the use of its medicines  mainly its talc and opioid products J J faces more than 15 000 lawsuits for its talc based products  primarily its baby powders  The lawsuits allege that its talc products contain asbestos  which caused many women to develop ovarian cancer  In August 2018  J J was ordered by a Missouri court to pay  4 7 billion in damages to 22 women who made such allegations  affirming a St  Louis court jury s verdict in July  J J intends to appeal the case In August 2019  J J was ordered by a district court in Oklahoma to pay  572 million to the state of Oklahoma in connection with a lawsuit filed by the latter  Last week  J J settled with two counties of Ohio for  10 million plus other cost reimbursements  in connection with the trial this month under the federal multidistrict litigation related to abuse of its opioid based drugs  Duragesic  Nucynta and Nucynta ER  All these lawsuits claim that J J is one of the several companies whose opioid based drugs were responsible for fueling the state s opioid epidemic J J currently has a Zacks Rank  3  Hold   Some better ranked large cap pharma stocks include AbbVie   NYSE ABBV    Sanofi   NASDAQ SNY   and Merck   NYSE MRK    all with a Zacks Rank  2  Buy   You can see  Shares of Sanofi have gained 3 6  this year so far  Earnings estimates for 2019 have risen 0 6  while that for 2020 have gone up by 1 4  over the past 90 days Merck s stock is up 9  this year so far  Its earnings estimates have risen 3 8  for 2019 and 1 9  for 2020 over the past 90 days AbbVie s earnings estimates for 2019 have risen 1 5  over the past 90 days Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-08,Zacks Investment Research,https://www.investing.com/analysis/jj-ordered-by-philadelphia-jury-to-pay-8b-in-risperdal-case-200471975,200471975
197963,419479,JNJ,Geron Starts Enrollment In Phase III MDS Study On Imetelstat,opinion,Geron Corporation   NASDAQ GERN   announced that it has started enrollment in the phase III IMerge study  evaluating its sole pipeline candidate  imetelstat  for treating hematologic myeloid malignancy  myelodysplastic syndromes   MDS   The phase III study will enroll a total of 170 patients from a targeted patient population with lower risk MDS and are naive to treatment with hypomethylating agents  HMAs  and lenalidomide as identified in the phase II portion Shares of Geron were up almost 1 4  in after hours trading on Oct 10  following the announcement  So far this year  the stock has gained 44  against the  s 8 9  decrease Myelodysplastic syndromes represent a group of diverse blood disorders  which develop as bone marrow cells fail to mature into healthy blood cells  This leads to requirement of blood or red blood cell transfusions in patients  However  serial transfusions can lead to iron overload  heart and kidney complications and may lead to shorter overall survival The primary endpoint of the IMerge study is the proportion of patients achieving transfusion independence over the eight weeks period of treatment duration IMerge study is a two part study comprised of phase II and phase III stages of development for imetelstat for treating lower risk MDS in transfusion dependent patients Data from the phase II portion of the IMerge study showed that imetelstat has the potential to achieve meaningful and durable transfusion independence  as well as potential disease modifying activity in MDS patients  Data presented in June demonstrated 8 week transfusion independence in 42  of patients and 24 week transfusion independence in 29  of patients  The median duration of transfusion independence was 85 9 weeks We remind investors that Geron had a collaboration with Janssen  a subsidiary of J J   NYSE JNJ    related to development of imetelstat  which was terminated by J J last year  Geron now holds the full responsibility for development of imetelstat  Meanwhile  another MDS candidate  luspatercept  is being developed by Acceleron Pharma   NASDAQ XLRN   and its partner Celgene   NASDAQ CELG   in a phase III study  which may pose competition for imetelstat Apart from MDS  the company is also developing imetelstat for another hematologic myeloid malignancy  myelofibrosis   MF    In December 2018  Geron presented updated median overall survival   OS   data from the higher dosage arm  9 4 mg kg  of the study  The candidate achieved median OS of 29 9 months  which suggests a meaningful survival outcome  The company is planning to conduct an end of phase II meeting with the FDA related to IMbark study in the first quarter of 2020 to discuss the path forward for the development of imetelstat in relapsed refractory MF Last month  the FDA granted Fast Track designation to imetelstat for treating MF  The designation was given for treating adult patients with intermediate 2 or high risk MF  whose disease has relapsed following treatment by a JAK inhibitor or is refractory to a JAK inhibitor  as well as patients with primary MF and MF developed after essential thrombocythemia or polycythemia vera Geron Corporation Price   Zacks RankGeron currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-10-10,Zacks Investment Research,https://www.investing.com/analysis/geron-starts-enrollment-in-phase-iii-mds-study-on-imetelstat-200472686,200472686
197968,419484,JNJ,U S  senator asks J J for documents on talc  baby powder safety,news," Reuters    U S  Democratic Senator Patty Murray sent a letter to Johnson   Johnson  NYSE JNJ  on Tuesday seeking information related to allegations in a Reuters Special Report that the healthcare company knew about the presence of asbestos in its talc based baby powder  The letter addressed to J J Chief Executive Alex Gorsky asks for documents and information related to testing of its talc products for the presence of carcinogens and  how it presented that information to regulators and consumers   Reuters on Dec  14 published a Special Report detailing that the company knew that the talc in its raw and finished powders sometimes tested positive for cancer causing asbestos from the 1970s into the early 2000s   test results the company did not disclose to regulators or consumers   While exposure to asbestos has been linked to mesothelioma  J J has repeatedly said that its talc products are safe  and that decades of studies have shown them to be asbestos free and that they do not cause cancer  J J spokesman Ernie Knewitz  in an emailed statement  acknowledged receiving the letter and said the company looks forward to sharing its response with the senator   As we have consistently stated  we firmly stand behind the safety and purity of our talc  which has been confirmed by thousands of independent tests by regulators worldwide  including the U S  FDA and many of the world s leading independent laboratories   the company statement said  Murray  the top Democrat on the Republican controlled Senate Committee on Health  Education  Labor and Pensions  referred to the Reuters report in her letter  It began   I am troubled by recent reports of an alleged decades long effort by Johnson   Johnson to potentially mislead regulators and consumers about the safety of one of its products  which may have resulted in long term harm for men  women  and children who used Johnson   Johnson baby powder   J J is facing more than 11 000 lawsuits alleging that use of its talc products  including baby powder  caused cancer   
Murray asked for documents to support the company s claim that its current talc products do not contain any level of asbestos  documents on the testing of its talc products and communications with the Food and Drug Administration about the safety of its baby powder dating from 1966 to present ",2019-01-29,Reuters,https://www.investing.com/news/stock-market-news/us-senator-asks-jj-for-documents-on-talc-baby-powder-safety-1761896,1761896
197969,419485,JNJ,TG Therapeutics up 7  premarket on positive TG 1101 TGR 1202 data,news,TG Therapeutics  NASDAQ TGTX  is up 7  premarket on light volume on the heels of data just published in The Lancet Haematology on triplet therapy TG 1101  TGR 1202 and AbbVie  NYSE ABBV  and J J s  NYSE JNJ  Imbruvica  ibrutinib  The results were generated from 46 patients with relapsed refractory B cell blood cancers  The overall response rate in 44 evaluable patients was 84   including a 100  response rate in 22 patients with chronic lymphocytic leukemia or small lymphocytic lymphoma  CLL SLL   36   n 8 22  of the CLL SLL patients were complete responders The response rate was 68   n 15 22  in patients with non Hodgkin lymphoma  NHL  and 100  in patients with marginal zone lymphoma  n 3  and mantle cell lymphoma  n 6  TG 1101 is an anti CD20 monoclonal antibody  TGR 1202 is a PI3K delta inhibitor  Ibrutinib is a Bruton s tyrosine kinase inhibitor Clinical development is ongoing Now read ,2019-01-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/tg-therapeutics-up-7-premarket-on-positive-tg1101tgr1202-data-1763210,1763210
197970,419486,JNJ,Exclusive  Sri Lanka halts imports of Johnson   Johnson Baby Powder pending asbestos tests,news,"COLOMBO  Reuters    Sri Lanka has halted imports of Johnson   Johnson  NYSE JNJ  Baby Powder until the company proves its product is free from cancer causing asbestos  two government officials and the product s local distributor told Reuters   Stocks of the product already in Sri Lanka can still be sold  but there will be no new imports of the talc  a popular healthcare product across Sri Lanka and much of Asia  until J J India  from where Sri Lanka imports the product  provides fresh test results   On Dec  14  Reuters reported that the U S  drugs and consumer products group knew for decades that asbestos lurked in its Baby Powder  leading to tests in several countries  including in India   The report was based on thousands of pages of company memos  internal reports  and other confidential documents  J J has described the Reuters story as  one sided  false  and inflammatory    Kamal Jayasinghe  chief executive of Sri Lanka s National Medicine Regulatory Authority  NMRA   which is part of the health ministry  said it had informed the distributor  A Baur   Co   that it would require further tests for it to continue importing the powder   We have held their re registration and informed the distributor to submit quality reports from an accredited laboratory to ensure there is no asbestos in their products   Jayasinghe told Reuters   The license for A Baur   Co to import the product expired in December  a second person at the NMRA said  Shalutha Perera  head of consumer for A Baur  told Reuters the firm has informed J J in India of the suspension of the licensing process   J J India directly handles all the regulatory matters   he said   Perera said the NMRA contacted A Baur in December regarding new asbestos testing   A spokeswoman for J J India declined to comment on the halt of shipments to Sri Lanka but said the company  is in full compliance with current Indian regulatory requirements for the manufacturing and testing of our talc    We are fully cooperating with the Indian government and are awaiting results from their testing   she added   
The spokeswoman said the product was routinely tested by both suppliers and independent labs to ensure it is free of asbestos ",2019-01-31,Reuters,https://www.investing.com/news/stock-market-news/exclusive-sri-lanka-halts-imports-of-johnson--johnson-baby-powder-pending-asbestos-tests-1764530,1764530
197971,419487,JNJ,Powerful Senate committee invites pharma executives to testify,news,WASHINGTON  Reuters    A powerful U S  Senate committee on Monday invited seven pharmaceutical companies to testify at a hearing later this month examining rising prescription drug prices  Republican Senator Chuck Grassley  chairman of the Senate Finance Committee  and Democratic Senator Ron Wyden  ranking member of the committee  invited executives from  AbbVie Inc   NYSE ABBV   AstraZeneca PLC  Bristol Myers Squibb  NYSE BMY  Co  Johnson   Johnson  NYSE JNJ   Merck   Co Inc   Pfizer  Inc  NYSE PFE  and Sanofi  PA SASY  SA   The U S  Congress has been intensifying scrutiny of the pharmaceutical industry as rising prescription drug prices consistently poll as a top voter concern  It is also a priority for the administration of President Donald Trump  who made it a central issue of the 2016 presidential campaign  The Senate Finance Committee held its first hearing on drug prices in January  when Grassley and Wyden noted that several drug companies declined an invitation to testify  Some of the companies were re invited on Monday  though the senators did not specify which ones  The Senate is controlled by Republicans and the House of Representatives is controlled by Democrats   The invitation follows a slew of actions by lawmakers to heighten scrutiny of the pharmaceutical industry  The House Oversight Committee also held a drug pricing hearing in January  and a handful of House Democrats have sent letters to drug companies asking for information on their pricing practices ,2019-02-04,Reuters,https://www.investing.com/news/politics-news/powerful-senate-committee-invites-pharma-executives-to-testify-1769042,1769042
197972,419488,JNJ,J J  plaintiffs  close  to deal on Pinnacle hip implant lawsuits  lawyer,news,"By Tina Bellon  Reuters    Johnson   Johnson s DePuy Orthopaedics unit is in settlement talks to resolve the bulk of individual lawsuits alleging the company s metal on metal Pinnacle hip implants were defective and caused severe injuries  a lawyer for the plaintiffs said on Monday  Texas based plaintiff lawyer Mark Lanier said lawyers for the consumers had talked to the company in recent days to reach an agreement to resolve the long running litigation that includes more than 10 000 cases   It s still not a done deal  but we re getting close   Lanier said  adding that plaintiffs hope to reach a final agreement by the end of the year  Lanier said it was uncertain at this point how many of the roughly 10 000 Pinnacle lawsuits would be subject to the settlement  He declined further comment  A spokeswoman for DePuy on Monday declined to comment  Bloomberg first reported on the settlement talks  In 2013  DePuy ceased selling the metal on metal Pinnacle devices after the U S  Food and Drug Administration strengthened its artificial hip regulations  The Pinnacle system continues to be sold with other material combinations  Metal on metal hip implants have come under scrutiny over allegations that the products cause a build up of metal ions in the blood  causing groin pain  allergic reactions  bone erosion and tissue death  J J  NYSE JNJ  denies those allegations  saying the company acted appropriately and responsibly in the development  testing and marketing of the devices  Last month  J J agreed to pay  120 million to resolve deceptive marketing claims by several U S  states over metal on metal hip implants  DePuy said the settlement involved no admission of liability or misconduct on the part of the companies  J J to date has faced several federal jury trials over the Pinnacle hip implants  It won the first case in 2014  but lost all subsequent trials  with verdicts ranging from  151 million to  540 million  J J has appealed those verdicts  
News of the settlement talks on Monday caused a federal judge overseeing an ongoing Pinnacle trial in Dallas to dismiss the jury in that case  Lanier said that case  involving five Texas plaintiffs  has not been settled yet ",2019-02-04,Reuters,https://www.investing.com/news/stock-market-news/jj-plaintiffs-close-to-deal-on-pinnacle-hip-implant-lawsuits-lawyer-1769069,1769069
197973,419489,JNJ,Merck CEO Frazier plans to testify at Senate drug pricing hearing,news," Reuters    U S  drugmaker Merck   Co Inc said on Tuesday that its Chief Executive Ken Frazier plans to testify at a Senate hearing later this month examining rising prescription drug prices  Republican Senator Chuck Grassley  chairman of the Senate Finance Committee  and Democratic Senator Ron Wyden  ranking member of the committee  on Monday invited executives from seven pharmaceutical companies  including Merck  to testify  The other companies are  AbbVie Inc   NYSE ABBV   AstraZeneca Plc   Bristol Myers Squibb  NYSE BMY  Co  Johnson   Johnson  NYSE JNJ    Pfizer  Inc  NYSE PFE  and Sanofi  PA SASY  SA   A spokesman from Senator Grassley s office said on Monday that two of the CEOs have agreed to testify so far  but did not specify from which companies   A Sanofi spokeswoman said the French drugmaker was reviewing Chief Executive Olivier Brandicourt s scheduling to determine if he can attend the hearing  Britain based AstraZeneca said it was reviewing the request and will respond to the committee  Pfizer  Bristol Myers  and J J did not immediately have a statement on the invitation to testify  while AbbVie did not respond to a request for comment  
Congress has been intensifying scrutiny of the pharmaceutical industry over the rising cost of prescription drugs for U S  consumers  which consistently polls as a top voter concern  It is also a top priority of the administration of President Donald Trump  who had made it a central issue of the 2016 presidential campaign ",2019-02-05,Reuters,https://www.investing.com/news/stock-market-news/merck-ceo-frazier-plans-to-testify-at-senate-drug-pricing-hearing-1769938,1769938
197974,419490,JNJ,The Zacks Analyst Blog Highlights  J J  AstraZeneca  Roche  Glaxo And Merck,opinion,For Immediate ReleaseChicago  IL   October 7  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  J J   NYSE JNJ    AstraZeneca   NYSE AZN    Roche   OTC RHHBY    Glaxo   NYSE GSK   and Merck   NYSE MRK   Here are highlights from Friday s Analyst Blog  Pharma Stock Roundup  JNJ  AZN  GSK and MoreThis week  J J settled with two counties of Ohio for  10 million related to the upcoming multidistrict litigation for opioid based drug abuse  The FDA issued a complete response letter to AstraZeneca s triple combo inhaler  PT010 while granting approval to Roche s Rituxan to treat pediatric patients two years and older with two rare blood vessel disorders  Meanwhile  almost all pharma bigwigs presented data from cancer studies at the European Society of Medical Oncology  ESMO  congress in Barcelona  Spain Recap of the Week s Most Important StoriesJNJ Settles With Ohio Counties in Multidistrict Opioid Trial  J J announced that it has entered into a settlement with two Ohio counties   Summit and Cuyahoga  in connection with the upcoming October 2019 trial under the federal multidistrict litigation related to abuse of its opioid based drugs  Duragesic  Nucynta and Nucynta ER  These lawsuits claim that J J is one of the several companies whose opioid based drugs were responsible for fueling the state s opioid epidemic J J has agreed to pay  10 million to resolve all claims pertaining to the scheduled trial  In addition  J J has agreed to reimburse the counties  legal costs of  5 million  J J stated that it has acted responsibly with its opioid products and the settlement is not an admission of liability  In August 2019  J J was ordered by a district court in Oklahoma to pay  572 million to the state of Oklahoma in connection with a lawsuit filed by the latter FDA Rejects AstraZeneca s Triple Combo COPD Inhaler  The FDA issued a CRL to AstraZeneca s triple combo inhaler  PT010  for chronic obstructive pulmonary disease  COPD   The NDA was based on data from the KRONOS study  AstraZeneca said that it will meet with the FDA to discuss the step forward including submitting data from another study   ETHOS   on PT010 for review  The ETHOS data was not included in the NDA as the study was incomplete at that time  PT010 was approved in Japan in June by the trade name of Breztri Aerosphere  to relieve symptoms of COPD  The candidate is also under review in the EU and China AstraZeneca also announced that it is divesting the global commercial rights  excluding China  Japan  the United States and Mexico  of its acid reflux medicine  Losec  omeprazole  and other medicines containing omeprazole to Germany s pharma company  Cheplapharm  Earlier  AstraZeneca had divested the commercial rights to Losec and other omeprazole medicines in the United States  Japan and Mexico The FDA approved a self administration option for AstraZeneca s respiratory biologic  Fasenra and a new delivery method   a pre filled  single use auto injector  the Fasenra pen  FDA Approval to Roche s Rituxan for Rare Blood Vessel Disorders  The FDA granted approval to Roche s Rituxan  in combination with glucocorticoids  to treat pediatric patients two years and older with two rare blood vessel disorders  granulomatosis with polyangiitis  GPA  or microscopic polyangiitis  MPA   This is Rituxan s first FDA approval for a pediatric indication  Rituxan is currently approved for the treatment of four autoimmune indicationsMeanwhile  Roche announced yet another extension of tender offer period for shares of Spark Therapeutics  This time  the offer period has been extended till Oct 30 as the U S  Federal Trade Commission and UK s Competition and Markets Authority continues to review Roche s pending acquisition of Spark J J   Glaxo Submit sNDA to FDA  J J submitted a supplemental new drug application  sNDA  to the FDA seeking label expansion of its antidepressant Spravato  esketamine  nasal spray in severely ill patient population  The sNDA was based on data from two phase III studies  ASPIRE I   II  which demonstrated a rapid reduction of depressive symptoms in adult patients with major depressive disorder who have active suicidal ideation with intent Glaxo also submitted a sNDA to the FDA  seeking label expansion of its triple combination inhaler Trelegy Ellipta for a new indication   uncontrolled asthma  At present  Trelegy Ellipta is approved to treat COPD FDA Grants Priority Review to Merck s NDAs for Antibacterial Medicine  The FDA accepted Merck s two regulatory applications  looking for approval of Dificid for the treatment of pediatric patients aged 6 months or older with Clostridium difficile infections  CDI   The first application is an NDA looking for approval of an oral suspension formulation of Dificid  which is presently available in tablet form  The second application is a sNDA looking for approval of Dificid tablets as well as the oral suspension for the pediatric patients  With the FDA granting priority review to both the applications  a decision is expected on Jan 24  2020 Meanwhile  Merck s Keytruda was granted approval in China  as a monotherapy  for first line treatment of certain patients with advanced non small cell lung cancer  NSCLC  whose tumors express PD L1  Keytruda is already approved in China in combination with chemotherapy in first line setting for NSCLC Meanwhile  a pivotal phase III study evaluating Merck s new combination antibacterial injection  Recarbrio  for another indication   hospital acquired and ventilator associated bacterial pneumonia  HABP VABP    met the primary endpoint  Recarbrio is a fixed combination of relebactam with imipenem cilastatin  Recarbrio was approved for the treatment of adults with complicated urinary tract infections and complicated intra abdominal bacterial infections caused by certain susceptible gram negative bacteria in JulyUpdate from ESMO  At Europe s biggest oncology conference  AstraZeneca and Glaxo presented detailed data from late stage studies evaluating their PARP inhibitors  Lynparza and Zejula  respectively  for a broader advanced ovarian cancer patient populationAstraZeneca and Merck s Lynpazra added to bevacizumab as a first line maintenance treatment reduced the risk of disease progression or death by 41  in women suffering from advanced ovarian cancer regardless of their biomarker status or surgical outcome  Glaxo s Zejula  niraparib   as monotherapy for maintenance therapy of women with first line ovarian cancer  cut the same risk by 38   irrespective of the biomarker status AstraZeneca also presented detailed data from the phase III PROfound study which evaluated Lynparza in men with metastatic castration resistant prostate cancer  mCRPC  who have a mutation in their homologous recombination repair  HRRm  genes   In the study  Lynparza doubled the time without radiographic disease progression in this advanced prostate cancer patient population Novartis  CDK4 6 inhibitor Kisqali in combination with fulvestrant achieved statistically significant improvement in overall survival  OS  with a 28  reduction in risk of death  per data presented from the phase III MONALEESA 3 study  This is the second study in which Kisqali has demonstrated positive OS in postmenopausal women with HR  HER2  advanced or metastatic breast cancer Lilly presented OS data from the phase III MONARCH 2 study  which evaluated Verzenio plus fulvestrant in HR   HER2  advanced breast cancer patients who experienced disease progression following endocrine therapy  The data showed that OS rate in Verzenio plus fulvestrant arm was 46 7 months while in the placebo plus fulvestrant arm  the same was 37 3 months   Verzenio plus fulvestrant is already approved for the above patient population on the basis of progression free survival data from the same study  Lilly will now look to get approval for OS data from the study to be included on the drug s label AstraZeneca presented new data from the phase III FLAURA study  which demonstrated the superior OS benefit of Tagrisso to standard of care medicines in patients with EGFR mutated non small cell lung cancer  NSCLC   Meanwhile  Merck and Bristol Myers presented data from label expansion studies on their respective PD L1 inhibitors  Keytruda and Opdivo  respectively  While Merck presented Keytruda data in triple negative breast cancer  Bristol Myers presented OS data from CheckMate  227 study  evaluating Opdivo plus low dose Yervoy in advanced non small cell lung cancer and five year survival data on Opdivo plus Yervoy in advanced melanoma Pfizer  NYSE PFE  presented detailed data from a phase III study evaluating a combination of Braftovi  Mektovi and cetuximab for the treatment of BRAFV600E mutant metastatic colorectal cancer  Braftovi plus Mektovi  which Pfizer acquired from its recent acquisition of Array BioPharma  was launched as a treatment for BRAF mutant melanoma  last year The NYSE ARCA Pharmaceutical Index declined 1 4  in the last five trading sessions Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-10-06,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-jj-astrazeneca-roche-glaxo-and-merck-200471212,200471212
197975,419491,JNJ,Earnings Preview  Johnson   Johnson  JNJ  Q3 Earnings Expected To Decline,opinion,"The market expects Johnson   Johnson  NYSE JNJ  to deliver a year over year decline in earnings on lower revenues when it reports results for the quarter ended September 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on October 15  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This world s biggest maker of health care products is expected to post quarterly earnings of  2 per share in its upcoming report  which represents a year over year change of  2 4  
Revenues are expected to be  20 05 billion  down 1 5  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Johnson   Johnson 
For Johnson   Johnson  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  4 
So  this combination makes it difficult to conclusively predict that Johnson   Johnson will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Johnson   Johnson would post earnings of  2 42 per share when it actually produced earnings of  2 58  delivering a surprise of  6 61  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Johnson   Johnson doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-07,Zacks Investment Research,https://www.investing.com/analysis/earnings-preview-johnson--johnson-jnj-q3-earnings-expected-to-decline-200471528,200471528
197981,419497,JNJ,J J Earnings  Revenue beat in Q4,news,"Investing com   J J  NYSE JNJ  reported fourth quarter earnings  that beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  1 97 on revenue of  20 39B  Analysts polled by Investing com forecast EPS of  1 95 on revenue of  20 2B  That compared to EPS of  1 74 on revenue of  20 2B in the same period a year earlier  The company had reported EPS of  2 05 on revenue of  20 35B in the previous quarter 
J J follows other major Healthcare sector earnings this month
 On October 25  2018  McKesson reported second quarter EPS of  3 6 on revenue of  53 08B  compared to forecasts of EPS of  3 28 on revenue of  53 56B 
Helen of Troy Ltd earnings beat analyst s expectations on January 8  with third quarter EPS of  2 4 on revenue of  431 08M  Investing com analysts expected EPS of  2 36 on revenue of  425 76M
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-01-22,Investing.com,https://www.investing.com/news/stock-market-news/jj-earnings-revenue-beat-in-q4-1753128,1753128
197982,419498,JNJ,Johnson   Johnson 2019 revenue forecast misses expectations,news,"By Manas Mishra  Reuters    Johnson   Johnson  NYSE JNJ  on Tuesday forecast 2019 sales that fell short of analysts  estimates as the healthcare conglomerate faces increasing competition for some of its older drugs  The company s prostate cancer drug Zytiga  an important growth driver  is expected to be pressured by generic competition  while sales of its rheumatoid arthritis drug Remicade has been slipping due to competition from cheaper biosimilar versions  The company said it expects full year sales in the range of  80 4 billion to  81 2 billion  compared with the average analyst estimate of  82 69 billion  according to IBES data from Refinitiv  In the fourth quarter  sales rose about 1 percent to  20 39 billion  topping the average Wall Street estimate of  20 20 billion  helped by double digit percentage growth in sales of Crohn s disease treatment Stelara and cancer drugs such as Darzalex and Imbruvica   Strength in the company s pharmaceuticals business also offset higher costs  In the quarter ended Dec  31  the company s litigation expense doubled to  1 29 billion  J J did not provide a specific reason for the surge in litigation costs and a spokesperson was not immediately available for comment  The healthcare company is facing more than 11 000 lawsuits over the safety of talc in its products  including baby powder  alleging that its use caused cancer  Reuters on Dec  14 published a special report detailing that the company knew for decades that cancer causing asbestos could be found in the product  J J has repeatedly defended the safety of its talc products  saying that decades of studies have shown them be asbestos free and that they do not cause cancer  Darzalex and Imbruvica sales saw a double digit rise in sales to  584 million and  703 million  respectively  in the fourth quarter  Sales of Stelara  also used to treat psoriasis  rose 33 6 percent to  1 44 billion  While J J has huge medical device and consumer health divisions  its pharmaceuticals unit has been its main growth driver in recent years  J P  Morgan analyst Chris Schott said the positive pharma outlook was tempered by ongoing growth challenges to the company s medical device and the ongoing talc litigation  The company posted net profit of  3 04 billion  or  1 12 per share  for the fourth quarter  compared with a loss of  10 71 billion  or  3 99 per share  a year earlier  when it recorded a  13 6 billion charge related to changes to the U S  tax law  Excluding items  the company earned  1 97 per share  beating analysts  average estimate of  1 95 per share  The company said it expected adjusted 2019 profit in the range of  8 50 per share to  8 65 per share  compared with analysts  expectation of  8 60 per share  
Shares of the company were down 1 percent at  129 35 in early trading ",2019-01-22,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-quarterly-sales-beat-expectations-1753157,1753157
197983,419499,JNJ,Johnson   Johnson eyeing surgical robotics firm Auris Health  Bloomberg,news," Reuters    Johnson   Johnson  NYSE JNJ  is pursuing an acquisition of surgical robotics firm Auris Health Inc  Bloomberg reported on Wednesday  citing people with knowledge of the matter  J J is seeking to purchase Auris at a premium to the valuation from its latest funding round that valued the company at  2 billion  Bloomberg reported   The final deal has not been reached and there is no certainty that the deliberations will lead to a sale of Auris  according to Bloomberg  
J J declined to comment while Auris could not be immediately reached for comment ",2019-01-23,Reuters,https://www.investing.com/news/technology-news/jj-eying-surgical-robotics-firm-auris-health-bloomberg-1754396,1754396
197984,419500,JNJ,AstraZeneca Merck s Lynparza Positive In Prostate Cancer Study,opinion,AstraZeneca plc   NYSE AZN   presented detailed data from a phase III study evaluating the company s and Merck s   NYSE MRK   PARP inhibitor  Lynparza  as a precision medicine for an advanced prostate cancer patient population  at the European Society of Medical Oncology  ESMO  congress in Barcelona  Spain The phase III PROfound study  n 387  evaluated Lynparza in men with metastatic castration resistant prostate cancer  mCRPC  who have a mutation in their homologous recombination repair  HRRm  genes  The disease of these men had progressed on prior treatment with new hormonal agent  NHA  treatments like J J s   NYSE JNJ   Zytiga and Pfizer   NYSE PFE   Astellas  Xtandi which makes it a difficult to treat disease Data from the study showed that Lynparza improved radiographic progression free survival  rPFS   or the time men with BRCA1 2  or ATM mutated mCRPC lived without disease progression or death  to a median of 7 4 months versus 3 6 months for those treated with Zytiga Xtandi  It thus met the primary endpoint of the study  Treatment with Lynparza reduced the risk of disease progression or death by 66  in such men  However  in the overall HRRm population  Lynparza reduced the risk of disease progression or death by 51   thereby meeting a key secondary endpoint  The clinical benefit seen in patients beyond just those with BRCA mutations was encouraging In August  the companies had announced top line data from the same study  Back then  the company had said the study met the primary endpoint of significantly increasing the time patients live without radiographic disease progression versus standard of care treatment As ESMO  AstraZeneca and Merck earlier presented detailed data from another late stage study evaluating Lynparza for a broader advanced ovarian cancer patient population    when added to bevacizumab  as a first line maintenance treatment  reduced the risk of disease progression or death by 41  in women suffering from advanced ovarian cancer regardless of their biomarker status or surgical outcome Shares of AstraZeneca have rallied 17 3  this year so far against the  s decrease of 0 6  Lynparza  presently marketed for advanced ovarian cancer and breast cancer  is also in different studies for a range of tumor types including prostate  pancreatic and gastric cancers as well as earlier line settings for ovarian and breast cancers Lynparza is part of AstraZeneca s strong oncology portfolio  Oncology sales now comprise around 35  of AstraZeneca s total product sales  surging 50  in 2018 and 58  in the first half of 2019  In the same period  Lynparza generated sales of  520 million  up 93  year over year Zacks Rank AstraZeneca currently carries a Zacks Rank  2  Buy   You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-09-30,Zacks Investment Research,https://www.investing.com/analysis/astrazenecamercks-lynparza-positive-in-prostate-cancer-study-200469521,200469521
197985,419501,JNJ,Geron s Imetelstat Gets Fast Track Status For Myelofibrosis,opinion,"Geron Corporation   NASDAQ GERN   announced that the FDA has granted Fast Track designation to its sole pipeline candidate  imetelstat  for treating a hematologic myeloid malignancy  myelofibrosis   MF    The designation was given for treating adult patients with intermediate 2 or high risk MF  whose disease has relapsed following treatment by a JAK inhibitor or is refractory to a JAK inhibitor  as well as patients with primary MF and MF developed after essential thrombocythemia or polycythemia vera  The company is evaluating imetelstat in a similar patient population in the phase II IMbark study The FDA grants Fast Track designation to help the development and faster review of drugs  which treat serious and unmet medical conditions  With this designation  the drug is expected to be granted priority review once the company files a new drug application Shares of Geron rallied 18 1  in after market trading on Sep 30  following the announcement  So far this year  the stock has gained 33  against the  s 6 2  decrease  Please note that in December 2018  Geron presented updated median overall survival   OS   data from the higher dosage arm  9 4 mg kg  of the study  The candidate achieved median OS of 29 9 months  which suggests a meaningful survival outcome  The company is planning to conduct an end of phase II meeting related to IMbark study in the first quarter of 2020 to discuss the path forward for the development of imetelstat in relapsed refractory MF Apart from MF  the company is evaluating imetelstat in a phase II III IMerge study as a treatment for another hematologic myeloid malignancy  myelodysplastic syndromes   MDS    Top line data from the phase II portion of the study is expected by the end of 2019  Preliminary data presented last year had shown that the benefit risk profile of imetelstat in treated patients  including the expansion arm  supports continued development in lower risk MDS indication  Based on this data  the company initiated the phase III portion of the IMerge study in August We remind investors that Geron had a collaboration with Janssen  a subsidiary of J J   NYSE JNJ    related to development of imetelstat  which was terminated by J J last year  Geron now holds the full responsibility for development of imetelstat  The company has added new leaders to its development team with vast experience in oncology and drug development to support the progress of imetelstat Another MDS candidate  luspatercept  is being developed by Acceleron Pharma   NASDAQ XLRN   and its partner Celgene   NASDAQ CELG   in a phase III study  which may pose competition for imetelstat Geron Corporation Price
    Zacks RankGeron currently carries a Zacks Rank  4  Sell  You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2019-09-30,Zacks Investment Research,https://www.investing.com/analysis/gerons-imetelstat-gets-fast-track-status-for-myelofibrosis-200469541,200469541
197986,419502,JNJ,Mallinckrodt Up On Settlement Agreement With Ohio Counties,opinion,Shares of Mallinckrodt plc   NYSE MNK   gained 7  after it announced the execution of a definitive settlement agreement with Cuyahoga and Summit Counties in Ohio concerning the lawsuits pending in multidistrict opioid litigation  MDL  in the U S  District Court for the Northern District of Ohio The settlement fully resolves the Track 1 Cases against all named Mallinckrodt entities that are currently scheduled to go to trial later in the month in the MDL  The Track 1 Cases assert various claims related to the opioid business operated by SpecGx LLC Per the terms  Mallinckrodt will pay a total sum of  24 million in cash and donate  6 million to the generic business  which includes addiction treatment products  The agreement also requires a  500 000 payment in two years in recognition of the counties  time and expenses Moreover  Mallinckrodt has agreed that the two plaintiff counties will receive the value  which would have been received under such a resolution in the event of a comprehensive resolution of government related opioid claims The resolution comes as a major relief for Mallinckrodt s shares  The shares have plunged 84 7  year to date compared with the  s decline of 7  due to pricing pressure in the generic segment and the rising menace of penalties regarding opioid litigations Mallinckrodt s shares depreciated after a Bloomberg report suggested that the company may file bankruptcy to limit its liabilities related to the pending opioid litigations  Per the report  the company hired restructuring advisers to explore options to avoid the MDL  Earlier  allegations against its lead drug Acthar s previous owner  Questcor  for conducting illegal sales and marketing activities related to the drug negatively impacted Mallinckrodt s shares Apart from Mallinckrodt  many pharma companies like Endo International   NASDAQ ENDP   and Teva Pharma   NYSE TEVA   are embroiled in multiple opioid litigations filed by several states  counties and political subdivisions in the United States regarding the abuse of opioid based drugs  The industry players are accused of faulty marketing practices  which downplayed addiction risks from these drugs and spurred their consumption instead Last month  Endo too executed a definitive settlement agreement with the County of Cuyahoga  Ohio  the County of Summit  Ohio  and certain related persons in connection with the lawsuits pending in the U S  District Court for the Northern District of Ohio Earlier  Johnson   Johnson   NYSE JNJ   received an unfavorable ruling in the court case filed by the state authorities of Oklahoma  pertaining to the abuse of its opioid based drugs Mallinckrodt currently carries a Zacks Rank  3  Hold   You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-10-01,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-up-on-settlement-agreement-with-ohio-counties-200469491,200469491
197993,419509,JNJ,AbbVie s Imbruvica flunks late stage pancreatic cancer study,news,A Phase 3 clinical trial  RESOLVE  evaluating AbbVie s  NYSE ABBV  IMBRUVICA  ibrutinib  plus chemo in patients with metastatic pancreatic cancer failed to achieve the primary endpoint  Specifically  the combination did not sufficiency separate from chemo   placebo as determined by progression free survival  PFS  or overall survival  OS  in a first line setting Complete results will be submitted for presentation at a future medical conference and or for publication Related ticker   NYSE JNJ Now read ,2019-01-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/abbvies-imbruvica-flunks-latestage-pancreatic-cancer-study-1751471,1751471
197994,419510,JNJ,Pharma Stock Roundup  FDA Approves Expanded Use Of MRK J J s Drugs   Other Updates,opinion,"The FDA was fairly active this week  granting approval for expanded use of Merck s   NYSE MRK   blockbuster PD L1 inhibitor  Keytruda and J J s   NYSE JNJ   new prostate cancer drug  Erleada  The regulatory agency granted Fast Track status to AstraZeneca s   NYSE AZN   diabetes medicine  Farxiga for heart failure and Breakthrough Therapy status to Roche s   OTC RHHBY   leukemia medicine  Gazyva for lupus nephritis Recap of the Week s Most Important StoriesFDA Approval to Merck s Keytruda Lenvima Combo for Endometrial Carcinoma  Merck gained FDA s accelerated approval for a combination of its cancer medicines  Keytruda and tyrosine kinase inhibitor   for the treatment of certain types of endometrial carcinoma  Merck has a deal with Japan s Eisai to co develop and commercialize Lenvima  both as a monotherapy as well as in combination with Keytruda  for several types of cancer  The latest approval is the first in the United States for a combination of Keytruda and Lenvima  The approval of Keytruda Lenvima for women whose endometrial cancer has progressed following prior systemic therapy and whose tumors are not MSI H or dMMR and who are not candidates for curative surgery or radiation  is an accelerated one  It is based on objective response rate and the duration of response data from KEYNOTE 146 study  The FDA also accepted Merck s biologics license application  BLA  for its investigational vaccine for Ebola Zaire disease  V920  Merck filed the BLA on a rolling basis  beginning in November last year  With the FDA granting priority review designation to the BLA  a decision is expected on Mar 14  2020  A regulatory application is also under review in the EU for V920 FDA Approval to J J s Erleada for New Indication  The FDA granted approval to J J s new prostate cancer drug for expanded use   for the treatment of patients with metastatic castration sensitive prostate cancer  Erleada is already marketed in the United States for the treatment of men with non metastatic castration resistant prostate cancer  The supplemental new drug application was based on data from the phase III TITAN study J J s subsidiary  Janssen announced submission of a supplemental biologics license application to the FDA  seeking approval to expand the label of its IL 23 inhibitor as a treatment for active psoriatic arthritis  The sBLA filing was based on data from the phase III DISCOVER 1 and 2 studies  J J expects to file a similar regulatory application in the EU by the end of this year FDA s Fast Track Status to AstraZeneca s Farxiga for Heart Failure   The FDA granted Fast Track designation to AstraZeneca s SGLT2 inhibitor   dapagliflozin  to reduce the risk of cardiovascular  CV  death  or the worsening of heart failure  in patients with heart failure with reduced ejection fraction and preserved ejection fraction  The status was granted based on data from the DAPA HF and DELIVER phase III outcomes studies  Last month  Farxiga was granted the prestigious for chronic kidney disease FDA s Breakthrough Therapy Status to Roche s Gazyva for Lupus Nephritis  The FDA granted Breakthrough Therapy status to Roche s leukemia medicine  for lupus nephritis  a serious kidney disorder  which is a complication of systemic lupus erythematosus  an autoimmune disease  The prestigious status was based on data from the phase II NOBILITY study  which showed that Gazyva  in combination with standard of care medicines  helped a higher number of lupus nephritis patients achieve a complete renal response than standard of care alone  Roche plans to begin enrolment in a phase III study on the indication in 2020 Novartis  Label Expansion Study on Cosentyx Meets Endpoints  Novartis    NYSE NVS   phase III PREVENT study evaluating its psoriasis drug    for its fourth indication  active non radiographic axial spondyloarthritis  nr axSpA   met its primary as well as all secondary endpoints  The study met its primary endpoint of ASAS40 at week 16  showing that patients treated with Cosentyx experienced significant and clinically meaningful reduction in disease activity versus placebo  Cosentyx is already approved in the United States and Europe for the treatment of moderate to severe plaque psoriasis  AS and psoriatic arthritis The NYSE ARCA Pharmaceutical Index rose 0 02  in the last five trading sessions 
 Large Cap Pharmaceuticals Industry 5YR   Return
  
 
Here is how the seven major stocks performed in the last five trading sessions Last week  while AstraZeneca rose the most  4    Pfizer   NYSE PFE   declined the most  2 1   In the past six months  AstraZeneca has been the biggest gainer  3 9   while Pfizer lost the most  13 7    See the last pharma stock roundup here  What s Next in the Pharma World Watch out for regular pipeline and regulatory updates next week Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ",2019-09-20,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-fda-approves-expanded-use-of-mrkjjs-drugs--other-updates-200466681,200466681
197995,419511,JNJ,Johnson   Johnson  JNJ  Stock Moves  0 14   What You Should Know,opinion,"In the latest trading session  Johnson   Johnson  NYSE JNJ  closed at  131 55  marking a  0 14  move from the previous day  This move was narrower than the S P 500 s daily loss of 0 84   At the same time  the Dow lost 0 53   and the tech heavy Nasdaq lost 1 47  
Prior to today s trading  shares of the world s biggest maker of health care products had gained 3 08  over the past month  This has outpaced the Medical sector s gain of 2 64  and lagged the S P 500 s gain of 5 2  in that time 
Wall Street will be looking for positivity from JNJ as it approaches its next earnings report date  This is expected to be October 15  2019  The company is expected to report EPS of  2  down 2 44  from the prior year quarter  Meanwhile  our latest consensus estimate is calling for revenue of  20 05 billion  down 1 45  from the prior year quarter 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  8 60 per share and revenue of  81 51 billion  These totals would mark changes of  5 13  and  0 09   respectively  from last year 
Investors might also notice recent changes to analyst estimates for JNJ  These revisions typically reflect the latest short term business trends  which can change frequently  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  The Zacks Consensus EPS estimate remained stagnant within the past month  JNJ currently has a Zacks Rank of  3  Hold  
Looking at its valuation  JNJ is holding a Forward P E ratio of 15 32  For comparison  its industry has an average Forward P E of 14 26  which means JNJ is trading at a premium to the group 
Investors should also note that JNJ has a PEG ratio of 2 23 right now  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 03 at yesterday s closing price 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 52  which puts it in the top 21  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow JNJ in the coming trading sessions  be sure to utilize Zacks com ",2019-09-24,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-stock-moves-014-what-you-should-know-200467680,200467680
197996,419512,JNJ,Looking For A Growth Stock  3 Reasons Why J J Snack Foods  JJSF  Is A Solid Choice,opinion,"Growth investors focus on stocks that are seeing above average financial growth  as this feature helps these securities garner the market s attention and deliver solid returns  But finding a growth stock that can live up to its true potential can be a tough task 
By their very nature  these stocks carry above average risk and volatility  Moreover  if a company s growth story is over or nearing its end  betting on it could lead to significant loss 
However  it s pretty easy to find cutting edge growth stocks with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
J J  NYSE JNJ  Snack Foods  JJSF  is one such stock that our proprietary system currently recommends  The company not only has a favorable Growth Score  but also carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy  
Here are three of the most important factors that make the stock of this drink and snack maker a great growth pick right now 
Earnings Growth
Earnings growth is arguably the most important factor  as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors  For growth investors  double digit earnings growth is highly preferable  as it is often perceived as an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for J J Snack Foods is 4 4   investors should actually focus on the projected growth  The company s EPS is expected to grow 23 4  this year  crushing the industry average  which calls for EPS growth of 5 7  
Impressive Asset Utilization Ratio
Asset utilization ratio    also known as sales to total assets  S TA  ratio    is often overlooked by investors  but it is an important indicator in growth investing  This metric exhibits how efficiently a firm is utilizing its assets to generate sales 
Right now  J J Snack Foods has an S TA ratio of 1 23  which means that the company gets  1 23 in sales for each dollar in assets  Comparing this to the industry average of 1 18  it can be said that the company is more efficient 
While the level of efficiency in generating sales matters a lot  so does the sales growth of a company  And J J Snack Foods is well positioned from a sales growth perspective too  The company s sales are expected to grow 3 7  this year versus the industry average of 0  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for J J Snack Foods  The Zacks Consensus Estimate for the current year has surged 0 7  over the past month 
Bottom Line
J J Snack Foods has not only earned a Growth Score of A based on a number of factors  including the ones discussed above  but it also carries a Zacks Rank  2 because of the positive earnings estimate revisions 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that J J Snack Foods is a potential outperformer and a solid choice for growth investors ",2019-09-24,Zacks Investment Research,https://www.investing.com/analysis/looking-for-a-growth-stock-3-reasons-why-jj-snack-foods-jjsf-is-a-solid-choice-200467500,200467500
197997,419513,JNJ,Mallinckrodt s StrataGraft Tissue Phase III Data Positive,opinion,Beleaguered Mallinckrodt plc   NYSE MNK   announced positive top line results from a late stage study on experimental StrataGraft regenerative tissue for the treatment of deep partial thickness thermal burns The pivotal  open label  controlled  randomized  multicenter phase III study in adults evaluated the efficacy and safety of a single application of StrataGraft tissue for the treatment of deep partial thickness thermal burns The study used an intra patient control  wherein two similar areas of burn injury on the same patient were randomly assigned to either standard of care  autograft  or StrataGraft treatment The study met both primary endpoints  Results showed that a significantly smaller area of burn wounds treated with StrataGraft tissue required autografting by three months as compared to treatment with only autograft  Additionally  results showed that the proportion of StrataGraft treated wounds that achieved durable wound closure at three months exceeded the pre defined threshold for statistical significance Results indicate that StrataGraft upon approval will provide an alternative treatment option to surgeons for deep partial thickness burns  Moreover  the safety profile of StrataGraft tissue was comparable to that of autograft The encouraging results cheered investors  Mallinckrodt intends to submit a Biologics License Application for the same to the FDA in the first half of 2020 Mallinckrodt s shares have plunged 84 4  year to date compared with the  s decline of 4 6  due to pricing pressure in the generic segment and the rising menace of penalties regarding opioid litigations  Earlier this month  Mallinckrodt s shares depreciated after a Bloomberg report suggested that the company may file bankruptcy to limit its liabilities related to the pending opioid litigations  Per the report  the company hired restructuring advisers to explore options to avoid the multidistrict litigation scheduled in October  Moreover  its high debt levels will make matters worse if a settlement is reached or a penalty is imposed by the court Thereafter  Mallinckrodt inked a definitive agreement to sell its wholly owned subsidiary  BioVectra Inc   to an affiliate of H I G  Capital for approximately  250 million to generate some free cash to deal with liabilities from the ongoing lawsuits The company also reached a settlement in principle with Cuyahoga and Summit Counties in Ohio  concerning lawsuits pending in multidistrict opioid litigations  The settlement will fully resolve the Track 1 cases against Mallinckrodt and subsidiaries that are scheduled to go on trial in October Earlier  allegations against its lead drug Acthar s previous owner  Questcor  for conducting illegal sales and marketing activities related to the drug negatively impacted Mallinckrodt s shares It remains to be seen how the company rises from the ashes and returns to the growth trajectory Apart from Mallinckrodt  many pharma companies like Endo International   NASDAQ ENDP   and Teva Pharma   NYSE TEVA   are embroiled in multiple opioid litigations filed by several states  counties and other political subdivisions in the United States regarding the abuse of opioid based drugs  The industry players are accused of faulty marketing practices  which downplayed addiction risks from these drugs and spurred their consumption instead  Earlier  Johnson   Johnson   NYSE JNJ   received an unfavorable ruling in the court case filed by the state authorities of Oklahoma pertaining to the abuse of its opioid based drugs Mallinckrodt currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-24,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodts-stratagraft-tissue-phase-iii-data-positive-200467495,200467495
198003,419519,JNJ,Johnson   Johnson declares  0 90 dividend,news,Johnson   Johnson  NYSE JNJ  declares  0 90 share quarterly dividend  in line with previous Forward yield 2 79 Payable March 12  for shareholders of record Feb  26  ex div Feb  25 See JNJ Dividend Scorecard  Yield Chart    Dividend Growth Now read ,2019-01-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/johnson--johnson-declares-090-dividend-1734946,1734946
198004,419520,JNJ,Prana Biotechnology  84  on raising US 31 4M,news,Prana Biotechnology  NASDAQ PRAN  has entered into a securities purchase agreement with Life Biosciences LLC to raise up to  A 44 5M   US 31 4M  Life Biosciences will initially invest US 7 5M   A 10 6M   with the agreement allowing Prana to raise an additional US 2M  A further amount of up to  US 21 9M   A 31M  would be invested by Life Biosciences and other investors on exercise of short term warrants being issued as part of the transaction The transaction involves an issue of  272M new fully paid ordinary shares in the capital of Prana  The Ordinary Shares would be issued at A 0 0390  3 9 cents  and the Warrants would have an exercise price of A 0 0450  4 5 cents  PRAN shares are up 84  premarket  Now read ,2019-01-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/prana-biotechnology-84-on-raising-us314m-1734938,1734938
198005,419521,JNJ,U S  drugmaker J J s India sales dip 3 percent in 2017 18  filing,news,NEW DELHI  Reuters    Johnson   Johnson s  N JNJ  sales in India dipped 3 percent in the year to March 2018  a regulatory filing showed on Thursday  as the U S  drugmaker grappled with the country s stringent medical device pricing policies  The company  currently mired in a controversy surrounding the safety of its baby talcum powder  reported overall sales of 58 28 billion rupees   829 million  in India for the year  its filing with the country s Ministry of Corporate Affairs shows  But its after tax profit for the period rose 18 percent to  98 million on other income  including foreign exchange gains  J J s medical device sales in India have been hit following the federal government s move in 2017 to cap prices of devices such as orthopedic knee implants to help poor patients   The restrictions were part of a broader push by India to end what it called  illegal profiteering  by companies  The company has recently been in the news after a Reuters investigation found J J knew for decades that cancer causing asbestos lurked in its baby powder   The report prompted drug inspectors across India to collect talc samples from J J facilities for testing   J J has said the Reuters article was  one sided  false and inflammatory   adding that its Baby Powder was  safe and asbestos free   J J s Baby Powder is one of the most recognized foreign brands in India  The company leads sales in the Indian baby and child toiletries market  which Euromonitor International estimates was worth  178 million last year  J J s consumer segment in India  which includes baby care products such as soap and talc  recorded sales of 31 billion rupees in the year to March 2018  marginally lower than the previous year  the company s India filing showed  Sales in its medical segment  which includes its orthopedic products  fell 7 percent to 19 6 billion rupees ,2019-01-03,Reuters,https://www.investing.com/news/stock-market-news/us-drugmaker-jjs-india-sales-dip-3-percent-in-201718-filing-1735781,1735781
198006,419522,JNJ,Latest trial in J J talc litigations gets under way in California,news,By Tina Bellon  Reuters    A California jury on Monday heard opening statements in the latest trial over allegations that Johnson   Johnson s talc based products  including the company s baby powder  were contaminated with asbestos and cause cancer  The lawsuit brought by Terry Leavitt in Alameda Superior Court in Oakland is the first of over a dozen J J  NYSE JNJ  talc cases scheduled for trial in 2019  The company is facing some 11 700 lawsuits over the safety of talc in its products  Leavitt s lawyer  Joseph Satterley  accused J J in his opening statement of knowingly selling a dangerous product  according to an online broadcast by Courtroom View Network   The evidence will show that J J knew about the asbestos risk and they continued to sell the product  giving consumers no opportunity to protect themselves   he said  A lawyer for co defendant Imerys Talc America  a unit of French Imerys SA  told the jury the evidence would show there is no asbestos in its talc and that Leavitt s disease was not caused by its product  A lawyer for J J will make his opening remarks on Tuesday   Our talc is safe and does not contain asbestos  For decades  Johnson   Johnson s Baby Powder has repeatedly been tested and been found not to contain asbestos   the company said in response to a request for comment on Monday  J J and Imerys have argued in court that decades of studies have shown their products to be safe and asbestos free  Leavitt s is the first talc case to go to trial since Reuters on Dec  14 published a special report detailing internal J J documents showing talc in the company s raw and finished powders sometimes tested positive for small amounts of asbestos from the 1970s into the early 2000s  The report prompted a stock selloff on fears of J J s liability  Shares on Monday closed at  127 01  14 percent below their Dec  13 value  While earlier talc lawsuits alleged talc itself causes ovarian cancer  plaintiffs  lawyers have more recently focused on arguing that asbestos contamination in talc caused mesothelioma  a form of cancer linked to asbestos exposure  Leavitt s case is being tried by the same team of lawyers  including Satterley  who in April 2018 won a  117 million award by a New Jersey jury for a man who blamed his mesothelioma on J J s cosmetic talc  That verdict is under appeal  In 11 cases so far alleging asbestos contamination in talc  three resulted in wins for plaintiffs  awarding damages as high as  4 69 billion in a July 2018 multi plaintiff ovarian cancer verdict  J J won three other cases and another five ended in hung juries  J J has appealed all of the plaintiff verdicts  and the company said it is confident the verdicts would be overturned on appeal  Leavitt was diagnosed with mesothelioma in 2017  She was born in the Philippines and claims she was exposed to J J cosmetic talc that originated from South Korea mines during the first two years of her life before her parents moved back to the United States in 1968  Satterley said on Monday  He said testing of Asian talc samples from the 1960s and 1970s by his own expert would show Korean mined talc tested positive for asbestos fibers  as has talc from U S  sources  J J in court filings in the Leavitt case said that fibers found in the Korean talc or any of its other cosmetic talc could not be classified as asbestos and referred to them as non asbestos forms that its experts say are harmless   Geologically  some asbestos can occur as  non asbestiform  rocks  Both forms often occur together and in talc deposits  The company in its Monday statement did not specifically address the allegations surrounding the South Korean mine ,2019-01-07,Reuters,https://www.investing.com/news/stock-market-news/latest-trial-in-jj-talc-litigations-gets-under-way-in-california-1740235,1740235
198007,419523,JNJ,J J raises U S  prices on around two dozen drugs,news,"By Michael Erman NEW YORK  Reuters    Johnson   Johnson  NYSE JNJ  raised U S  prices on around two dozen prescription drugs on Thursday  including the psoriasis treatment Stelara  prostate cancer drug Zytiga and blood thinner Xarelto  all among its top selling products  J J joined many other companies that raised U S  prices on hundreds of prescription medicines earlier this month  Most of the J J increases were between 6 percent and 7 percent  according to data from Rx Savings Solutions  which helps health plans and employers seek lower cost prescription medicines  The increases came on the same day that Democratic members of Congress introduced proposed legislation aimed at lowering the cost of prescription drugs for American consumers  J J said the average list price increase on its drugs will be 4 2 percent this year  However  it expects the net price it actually receives for its medicines to drop  That is because drugmakers negotiate rebates and discounts off the list price with payers in order to ensure patient access to their products  The company does not plan to raise prices on any more drugs this year  J J spokesman Ernie Knewitz said   Drugmakers kicked off 2019 with U S  price increases on more than 250 prescription medicines by Jan  2  That total has almost doubled  with pharmaceutical companies hiking prices on nearly 490 drugs by Jan  10  according to Rx Savings  This includes insulin price hikes of between 4 4 percent and 5 2 percent by Sanofi  PA SASY  and 4 9 percent by  Novo Nordisk   CO NOVOb   Sanofi said its increases were below the Centers for Medicare   Medicaid Services projections for medical inflation  and that it expects net prices to drop in 2019  Novo Nordisk said its raised list prices help offset increases in rebates to insurers and pharmacy benefit managers  With pressure from lawmakers and the administration of President Donald Trump intensifying  the pace of drug increases has been slower than last year  when drugmakers raised prices on around 650 drugs over the first 10 days of 2018   The United States  which leaves drug pricing to market competition  has higher prices than in other countries  where governments directly or indirectly control costs  That makes it by far the world s most lucrative market for manufacturers  
The U S  Department of Health and Human Services has proposed policy changes aimed at lowering drug prices and passing on more of the discounts negotiated by health insurers to patients  Those measures are not expected to provide relief to consumers in the short term  however  and fall short of giving government health agencies direct authority to negotiate or regulate drug prices ",2019-01-10,Reuters,https://www.investing.com/news/stock-market-news/jj-raises-us-prices-on-around-two-dozen-drugs-1744051,1744051
198008,419524,JNJ,Karyopharm Signs  150M Royalty Agreement To Support Xpovio,opinion,"Karyopharm Therapeutics Inc    NASDAQ KPTI   announced that it has entered into a royalty agreement for up to  150 million with private investment firm  HealthCare Royalty Partners  The deal was signed to support commercialization of its recently approved drug  Xpovio  selinexor   as well as its ongoing development Karyopharm will receive  75 million upfront at the close of the deal  anticipated this month  It is also eligible to receive regulatory and commercial milestone payments of up to  75 million  In return  HealthCare Royalty Partners will be eligible to receive tiered royalty in mid single digits on worldwide sales of Xpovio or any other future products Please note that Xpovio was  in July by the FDA as a treatment for relapsed or refractory multiple myeloma   RRMM   in patients who have received at least four prior therapies and are refractory to at least two proteasome inhibitors  at least two immunomodulatory agents  and an anti CD38 monoclonal antibody The company stated that the upfront  75 million along with its existing cash resources and future product sales will be sufficient to fund its operations through mid 2021 Shares of Karyopharm were up 7 4  on Sep 16  following the announcement  The company s shares have increased 26 5  year to date compared with the  s growth of 6 2  We note that Xpovio has received accelerated approval from the FDA for fifth or later line RRMM  which means that continued approval is contingent upon data from confirmatory study  Meanwhile  the drug is under review in Europe for a similar indication and a decision is expected by early 2020 Karyopharm is also developing the drug in combination with Takeda s   NYSE TAK   Velcade as a first to third line treatment option for patients with RRMM in a late stage study  The company is also evaluating the drug for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma  Last year  the company had announced positive top line data from a mid stage study evaluating Xpovio in this indication  The drug also enjoys Fast Track designation for this indication  The company is also developing the drug in combination with currently approved therapies for treating liposarcoma  recurrent gliomas and endometrial cancer Please note that although there are several drugs available for treating RRMM  Xpovio is unlikely to face significant competition as the targeted patient population includes patients who are resistant to several available drugs Meanwhile  in June  J J s   NYSE JNJ   Darzalex was approved in combination with Celgene s   NASDAQ CELG   Revlimid for treating first line multiple myeloma  Darzalex is also being developed for relapsed multiple myeloma Karyopharm Therapeutics Inc  Price
    Zacks RankKaryopharm currently has a Zacks Rank  2  Buy   You can see  5 Stocks Set to DoubleZacks experts released their picks to gain  100  or more in 2020  One is a famous cutting edge food company that is  hiding in plain sight   Swamped with competitors and ignored by Wall Street  its stock price floundered  Now  suddenly  it acquired a company that gives it an advantage none of its peers have ",2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/karyopharm-signs-150m-royalty-agreement-to-support-xpovio-200465360,200465360
198009,419525,JNJ,Novartis Announces New Data On Spondylitis Drug Cosentyx ,opinion,Swiss pharma giant Novartis AG   NYSE NVS   announced positive new data from the ongoing PREVENT study on spondylitis drug  Cosentyx  secukinumab  PREVENT is an ongoing two year randomized  double blind  placebo controlled phase III study  with a two year extension phase  investigating the efficacy and safety of Cosentyx in patients with active non radiographic axial spondyloarthritis  nr axSpA  The ongoing study met its primary endpoint at week 16 as the data showed a significant and clinically meaningful reduction in disease activity in patients treated with Cosentyx compared to those on placebo  The study also met all secondary endpoints  The data also demonstrated a favorable safety profile  consistent with previous clinical studies Notably  axial spondyloarthritis  axSpA  is a spectrum of long term inflammatory disease characterized by chronic inflammatory back pain   nr axSpA forms part of the axSpA spectrum and is characterized by chronic inflammatory back pain and symptoms such as nocturnal pain  morning stiffness and impaired quality of life  The spectrum includes ankylosing spondylitis  AS   in which joint damage is visible on x ray  and nr axSpA  in which joint damage is not visible on x ray Per estimates  approximately 1 7 million patients with nr axSpA are living in the European Union and the United States Cosentyx is the first and only fully human biologic that directly inhibits interleukin 17A  IL 17A   Novartis has already submitted its application to the European Medical Agency  EMA  for approval of the same in the nr axSpA indication  If approved  this will be the fourth indication  for which the drug will be approved in this region  The 52 week data from the PREVENT study are expected later in the year and should support a potential label expansion of the drug in the United States for this indication Novartis  shares have gained 0 5  in the year so far against the  s decline of 2 4  We remind investors that Cosentyx is already approved in the United States and Europe for the treatment of moderate to severe plaque psoriasis  AS and psoriatic arthritis  Sales of the drug came in at  1 6 billion in the first half of 2019 However  the drug faces stiff competition from the likes of Johnson   Johnson s   NYSE JNJ   Stelara and Tremfya  and AbbVie s   NYSE ABBV   Skyrizi in various indications Zacks Rank   Another Stock to ConsiderNovartis currently carries a Zacks Rank  2  Buy  Another well placed  large cap pharma stock is Bristol Myers Squibb Company   NYSE BMY    sporting a Zacks Rank  1  Strong Buy   You can see  Bristol Myers  earnings per share estimates have increased from  4 16 to  4 28 for 2019 and from  4 41 to  5 36 for 2020 in the past 60 days 5 Stocks Set to DoubleZacks experts released their picks to gain  100  or more in 2020  One is a famous cutting edge food company that is  hiding in plain sight   Swamped with competitors and ignored by Wall Street  its stock price floundered  Now  suddenly  it acquired a company that gives it an advantage none of its peers have ,2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/novartis-announces-new-data-on-spondylitis-drug-cosentyx-200465428,200465428
198010,419526,JNJ,Are You Looking For A High Growth Dividend Stock  Johnson   Johnson  JNJ  Could Be A Great Choice,opinion,"Whether it s through stocks  bonds  ETFs  or other types of securities  all investors love seeing their portfolios score big returns  But for income investors  generating consistent cash flow from each of your liquid investments is your primary focus 
Cash flow can come from bond interest  interest from other types of investments  and of course  dividends  A dividend is that coveted distribution of a company s earnings paid out to shareholders  and investors often view it by its dividend yield  a metric that measures the dividend as a percent of the current stock price  Many academic studies show that dividends make up large portions of long term returns  and in many cases  dividend contributions surpass one third of total returns 
Johnson   Johnson  NYSE JNJ  in Focus
Johnson   Johnson  JNJ  is headquartered in New Brunswick  and is in the Medical sector  The stock has seen a price change of 0 48  since the start of the year  Currently paying a dividend of  0 95 per share  the company has a dividend yield of 2 93   In comparison  the Large Cap Pharmaceuticals industry s yield is 2 78   while the S P 500 s yield is 1 88  
Looking at dividend growth  the company s current annualized dividend of  3 80 is up 7 3  from last year  Johnson   Johnson has increased its dividend 5 times on a year over year basis over the last 5 years for an average annual increase of 6 34   Future dividend growth will depend on earnings growth as well as payout ratio  which is the proportion of a company s annual earnings per share that it pays out as a dividend  Right now  Johnson   Johnson s payout ratio is 44   which means it paid out 44  of its trailing 12 month EPS as dividend 
Looking at this fiscal year  JNJ expects solid earnings growth  The Zacks Consensus Estimate for 2019 is  8 60 per share  with earnings expected to increase 5 13  from the year ago period 
Bottom Line
Investors like dividends for many reasons  they greatly improve stock investing profits  decrease overall portfolio risk  and carry tax advantages  among others  However  not all companies offer a quarterly payout 
For instance  it s a rare occurrence when a tech start up or big growth business offers their shareholders a dividend  It s more common to see larger companies with more established profits give out dividends  Income investors must be conscious of the fact that high yielding stocks tend to struggle during periods of rising interest rates  With that in mind  JNJ is a compelling investment opportunity  Not only is it a strong dividend play  but the stock currently sits at a Zacks Rank of 3  Hold  ",2019-09-17,Zacks Investment Research,https://www.investing.com/analysis/are-you-looking-for-a-highgrowth-dividend-stock-johnson--johnson-jnj-could-be-a-great-choice-200465724,200465724
198011,419527,JNJ,Trovagene s Onvansertib Shows Response In Phase Ib AML Study,opinion,"Trovagene  Inc    NASDAQ TROV   announced successful completion of a phase Ib dose escalation study evaluating its sole pipeline candidate  onvansertib  in combination with standard of care chemotherapy for treating acute myeloid leukemia   AML    The company also announced that it has initiated enrolment in the phase II portion for the candidate in a similar indication The phase Ib study evaluated onvansertib chemotherapy in treatment naive patients who are ineligible for induction therapy or whose disease has relapsed following prior treatment  The study identified the recommended phase II dose of onvansertib  Data from the dose escalation phase Ib showed that onvansertib in combination with decitabine met the study s primary endpoint of objective response rate in five out of 21 patients with difficult to treat relapsed refractory AML  Moreover  30  of the patients in the study were biomarker positive  Data also showed onvansertib plus chemotherapy was safe and well tolerated in patients  Detailed data from the study will be presented at the European Society for Medical Oncology on Sep 28 The phase II study will evaluate a combination of onvansertib and decitabine in previously not treated patients who are not eligible for induction therapy or in patients whose disease has relapsed following up to one prior regimen So far this year  Trovagene s shares have declined 47 3  compared with the  s decrease of 1 4   Apart from AML  the company is also developing onvansertib in combination with other drugs for treating metastatic castration resistant prostate cancer  mCRPC   metastatic colorectal cancer  mCRC  among others A phase II study is evaluating onvansertib in combination with J J s   NYSE JNJ   Zytiga or prednisone in patients with mCRPC  Another phase Ib II study is evaluating onvansertib in combination with Sanofi s   NASDAQ SNY   Zaltrap  Folfiri  and Roche s   OTC RHHBY   Avastin as a second line treatment for mCRC with a KRAS mutation  The company also has plans to develop onvansertib in combaintion with AbbVie s Venclexta for first line AML In May  Trovagene signed a research collaboration agreement with Nektar Therapeutics to evaluate a combination of onvansertib and Nketar s Onzeald BRAF and KRAS mutant colorectal cancer TrovaGene  Inc  Price
    Zacks RankTrovaGene currently carries a Zacks Rank  3  Hold   You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ",2019-09-19,Zacks Investment Research,https://www.investing.com/analysis/trovagenes-onvansertib-shows-response-in-phase-ib-aml-study-200466632,200466632
198015,419531,JNJ,Drugmaker GSK to split after striking Pfizer consumer health deal,news,"By Ben Hirschler LONDON  Reuters    GlaxoSmithKline plans to split into two businesses    one for prescription drugs and vaccines  the other for over the counter products    after forming a new joint venture with Pfizer s consumer health division  The revamp is the boldest move yet by GSK Chief Executive Emma Walmsley  who took over last year  It will lead to the creation of a consumer health giant with a market share of 7 3 percent  well ahead of its nearest rivals Johnson   Johnson  NYSE JNJ   Bayer  DE BAYGN  and Sanofi  PA SASY   all on around 4 percent  Walmsley has previously played down the idea of breaking up the group  something that a number of investors have called for over the years  On Wednesday  however  she announced that GSK and  Pfizer   NYSE PFE  would combine their consumer health businesses in a joint venture with sales of 9 8 billion pounds   12 7 billion   68 percent owned by the British company  in an all equity transaction   GSK said the deal laid the foundation for the creation of two new UK based global companies focused on pharma vaccines and consumer healthcare within three years of the transaction closing  For Pfizer  the deal resolves the issue of what to do with its consumer health division  which includes Advil painkillers and Centrum vitamins  after an abortive attempt to sell it outright earlier this year  GSK  whose consumer products include Sensodyne toothpaste and Panadol painkillers  had withdrawn from that earlier Pfizer auction process but Walmsley said the opportunity to strike an all equity deal cleared the way for the new agreement   It s something we ve been able to do quickly and quietly   she told reporters in a conference call   What this deal is all about is the opportunity to strengthen two businesses    a world leading consumer healthcare business and a new GSK that is focused on pharma and vaccines   CRYSTALLIZING VALUE Shareholders welcomed the news and the shares jumped 7 percent  with Jefferies analysts saying the future separation could crystallize value   The new joint venture with Pfizer is expected to generate total annual cost savings of 500 million pounds by 2022 for expected total cash costs of 900 million and non cash charges of 300 million  GSK plans divestments of some 1 billion pounds  Walmsley said there would be an inevitable impact on jobs but there was also an opportunity for cost savings in procurement and across the supply chain  The Pfizer deal is expected to boost adjusted earnings and free cashflow in the first full year after closing  which GSK anticipates will occur in the second half of 2019  Pfizer  which already has a long standing HIV medicines joint venture with GSK  said the transaction would be slightly accretive in each of the first three years after it closed  The consumer tie up follows a deal by GSK earlier this year to buy Novartis s stake in their consumer joint venture for  13 billion and comes as Walmsley tries to reshape Britain s biggest drugmaker  which has seen its shares move sideways for years  Earlier this month  she agreed to buy cancer drug specialist Tesaro for  5 1 billion to try to revitalize its pharmaceuticals business  a high priced acquisition that was poorly received by the market  GSK has lagged rivals in recent years in producing multibillion dollar blockbusters and it largely sat out a spate of dealmaking by rivals under previous CEO Andrew Witty  Seeking to reassure investors of its financial strength  GSK extended its guarantee on the dividend by stating it expected to pay unchanged dividends of 80 pence per share for 2019  
GSK was advised by Citi  J P  Morgan Cazenove and Greenhill  while Centerview  Guggenheim and  Morgan Stanley   NYSE MS  acted for Pfizer ",2018-12-19,Reuters,https://www.investing.com/news/stock-market-news/gsk-and-pfizer-to-combine-consumer-health-businesses-1725868,1725868
198016,419532,JNJ,J J says Indian drug regulators visited facilities  took talc samples,news,"By Rahul Singh  Aditya Kalra and Krishna N  Das NEW DELHI  Reuters    Indian drug authorities visited some of Johnson   Johnson s  N JNJ  facilities on Wednesday and took  tests and samples  of its talcum powder  the company said in a statement   The visits came as regulators in India launched an investigation into J J s Baby Powder following a Reuters report last Friday that the firm knew for decades that cancer causing asbestos could be found in the product  The company told Reuters in a statement that the facilities were visited by the Central Drugs Standard Control Organization  CDSCO  and some state based food and drug administrations  FDAs    Today  a few of our facilities were visited by the CDSCO and local FDA authorities and we are fully co operating with them by providing tests and samples   the J J statement said   The characterization of these visits as  raids  or  seizures  is incorrect as has been reported in some instances   it said   The tests have been conducted in the regular way that the FDA collects samples   J J added that the safety of its cosmetic talc was based on a long history of safe use and decades of research and clinical evidence by independent researchers and scientific review boards across the world  It also said Indian FDAs and the CDSCO have in the past confirmed that its products  comply with Indian standards and are free of asbestos   Quoting an industry source with knowledge of the matter  Reuters reported earlier in the day that drug inspectors had taken samples of Baby Powder from its Baddi factory in the northern Indian state of Himachal Pradesh  A source at the CDSCO said its officials lifted samples for testing from nine Indian cities   Mumbai  Chennai  Kolkata  Ahmedabad  Hyderabad  Bengaluru  Indore  Chandigarh and Ghaziabad  J J did not immediately specify how many manufacturing plants the company has in India   A CDSCO spokeswoman did not respond to a request for comment  Surendranath Sai  a regional drug officer in the southern state of Telangana  on Wednesday said he would instruct inspectors to collect samples there   On the basis of the news report  we are alerting staff to pick up samples  We will test them in a drug control lab here   said Sai   We will take action accordingly  Certainly we are worried because millions of babies may be affected   Earlier  the Times of India quoted an official source as saying 100 drug inspectors had been assigned to examine different manufacturing facilities  wholesalers and distributors linked to J J India  starting early on Wednesday  A health ministry spokeswoman declined to comment when contacted by Reuters  However  a senior official at the ministry said the report was worrying   We are concerned about it and will take action   the official told Reuters  declining to be identified due to the matter s sensitivity  The official did not elaborate on what kind of action the ministry could take  A Reuters examination of company memos  internal reports and other confidential documents  as well as deposition and trial testimony  showed that from at least 1971 to the early 2000s  J J s raw talc and finished powders sometimes tested positive for small amounts of asbestos   It also showed that company executives  mine managers  scientists  doctors and lawyers fretted over how to address the problem while failing to disclose it to regulators or the public  The documents also depicted successful efforts to influence U S  regulators  plans regarding limiting asbestos in cosmetic talc products and scientific research on talc s health effects  
J J said on Monday it planned to buy back up to  5 billion of its stock  after  40 billion was wiped from its market value following the Reuters report ",2018-12-19,Reuters,https://www.investing.com/news/stock-market-news/indian-drug-inspectors-seize-johnson--johnson-baby-powder-samples-source-1725904,1725904
198017,419533,JNJ,J J loses bid to have  4 7 billion talc verdict set aside  vows to appeal,news,"By Tina Bellon  Reuters    Johnson   Johnson  NYSE JNJ  failed to persuade a Missouri trial judge to set aside a July verdict awarding a record  4 69 billion to 22 women who blamed their ovarian cancer on asbestos in the company s Baby Powder and other talc products  The healthcare company faces thousands of lawsuits over the safety of talc in its Baby Powder  a fixture of its consumer products division that has been core to J J s reputation as a family friendly company   Read the Reuters investigation     The trial was the first in which plaintiffs claimed that asbestos fibers in J J s talc caused ovarian cancer  It relied on unsealed internal company documents detailing J J s alleged knowledge of asbestos contamination since at least the 1970s  The company  which says its Baby Powder does not contain asbestos and is safe  in a statement said the failed motion was merely a formal step required before appealing the verdict   The same judge has denied similar motions on prior verdicts in his court that were ultimately overturned by the appellate courts  We are confident this verdict will also be overturned on appeal   J J said  Judge Rex Burlison in the ruling on Wednesday said the jury s decision and the large award of punitive damages was justified based on J J s  particularly reprehensible conduct  as evidenced during trial  He denied the company s request to overturn the verdict  saying the women had presented sufficient evidence to support the jury s verdict   A jury in July awarded  550 million in compensatory damages and  4 14 billion in punitive damages  Reuters on Dec  14 published a special report detailing the company documents that sent J J shares tumbling  They have dropped more than 13 percent since Friday  wiping out more than  45 billion in the company s market value  Shares on Wednesday were off about 2 percent at  127 88  Mark Lanier  the women s lawyer during trial  in a statement said plaintiffs were pleased with Burlison s decision  DECADES LONG USE The women and their families said decades long use of baby powder and other cosmetic talc products caused their illness  They allege the company knew its talc was contaminated with asbestos since at least the 1970s but failed to warn consumers about the risks   While plaintiffs in the long running litigation in the past had claimed talc itself causes ovarian cancer  plaintiff lawyers in recent months shifted their claims to allege asbestos in the talc causes mesothelioma  a cancer closely linked to asbestos exposure  and ovarian cancer   J J denies that its talc products ever contained asbestos and says decades of studies and regulatory assessments show its talc to be safe  Missouri s appeals court has overturned two prior ovarian cancer talc verdicts against J J on technical legal grounds  saying the decisions could not stand following a 2017 U S  Supreme Court decision limiting where companies can be sued for personal injuries  The company in its September motion made a similar argument  telling Burlison that the women  the majority of whom were from out of state  had no right to sue in Missouri  J J also said Lanier during the trial  substituted proof and evidence with misleading and inflammatory graphics   including an image depicting J J pushing a woman off a cliff into ovarian cancer   But Burlison in his Wednesday ruling said the cases rightly belonged in Missouri court due to J J s connection to the state   
More than 9 700 talc lawsuits  the vast majority of those J J faces  allege asbestos laced cosmetic talc caused ovarian cancer  while a smaller number claim its use led to mesothelioma ",2018-12-19,Reuters,https://www.investing.com/news/stock-market-news/jj-loses-motion-to-overturn-47-billion-talc-verdict-1726625,1726625
198018,419534,JNJ,As Ebola threatens mega cities  vaccine stockpile needs grow,news,"By Kate Kelland LONDON  Dec 20  Reuters    Doubts are growing about whether the world s emergency stockpile of 300 000 Ebola vaccine doses is enough to control future epidemics as the deadly disease moves out of rural forest areas and into urban mega cities  Outbreak response experts at the World Health Organization  WHO  and at the vaccines alliance GAVI are already talking to the leading Ebola vaccine manufacturer  Merck  to reassess just how much larger global stocks need to be   We re actively engaged with the World Health Organization and with groups like GAVI  the U S  government and others to try to understand what will be an appropriate sized stockpile in the future   Merck s head of vaccines clinical research  Beth Ann Coller  said in a telephone interview  Supply of the Merck shot  which is currently being used to fight a large and spreading outbreak of Ebola in eastern Democratic Republic of Congo  is not a problem right now  according to the WHO s deputy director general of emergency preparedness and response  Peter Salama  But the nature of Ebola outbreaks is changing  he told Reuters  As the virus finds its way out of rural villages into populous urban settings  plans for how to contain it in future must change too   What I m concerned about is the medium  to long term stockpile  The figure of 300 000 was very much based on previous Ebola outbreaks where you never really had huge numbers of cases because they were in isolated  rural  populations  But now  we increasingly see Ebola in mega cities and towns     We need to view it now as an urban disease as well as a rural one   and therefore one requiring a different order of magnitude of preparations  including vaccines   he said  Merck s experimental Ebola vaccine  known as rVSV ZEBOV  is the furthest ahead in development  Another potential vaccine being developed by Johnson   Johnson  NYSE JNJ  could also eventually become part of the stockpile  global health officials say   Congo s two Ebola outbreaks this year illustrate the shifting nature of the threat  The first was relatively contained  infecting up to 54 people and killing 33 of them in an area of DRC s Equateur Province that is remote and sparsely populated   Several of the eight outbreaks before this one in Congo   including one in 2014 and another in 2017 both also in Equateur   were also quickly contained and limited in size   But this year s second outbreak in Congo   and the country s tenth since the virus was first identified there in 1976   is concentrated not in rural villages but in urban areas of the North Kivu and Ituri provinces   It has already infected more than 450 people  killed more than 270  and last month spread to Butembo  a densely populated city of about one million  This kind of prospect means global health emergency responders must  review our assumptions around Ebola   Salama said   If it were to take off in Butembo  or Goma  or  even worse  Kinshasa  we d be talking about a totally different issue in terms of     vaccine supplies required   Seth Berkley  chief executive of the GAVI vaccines alliance which has an agreement with Merck to ensure a current stockpile of 300 000 rVSV ZEBOV doses  told Reuters that around 40 000 doses had been used so far in the Congo outbreak   The emergency response is based on  ring vaccination  which aims to control an outbreak by identifying and offering the vaccine to contacts of anyone likely to be infected  This method uses relatively small numbers of vaccine doses and forms a human buffer of immunity to try to prevent spread of the disease  For now in Congo  Berkley said  there is no immediate need to boost the stockpile  But looking towards future inevitable outbreaks  the numbers would likely need to change   The challenge we would have   and this has been under discussion   is if we started to do community based vaccination in urban and semi urban areas  That s when the numbers would start to get quite big quite quickly   he told Reuters   Merck s shot has proven safe and effective in trials in West Africa but has yet to be approved for a license by U S  and European regulators  so is being used in the Congo outbreak under special emergency rules for experimental products  When it gets approval  which Coller hopes would be in 2019  it will be made at a newly built manufacturing plant in Germany  
Coller said Merck is not yet clear how many doses a year  or a month  the German facility could churn out once it is in production  but she stressed the company would  work collaboratively with the public health agencies to do our best to support their needs  ",2018-12-20,Reuters,https://www.investing.com/news/world-news/as-ebola-threatens-megacities-vaccine-stockpile-needs-grow-1727762,1727762
198019,419535,JNJ,Indian regulator orders Johnson   Johnson to stop using raw material to make Baby Powder in India  source,news,"By Rahul Singh and Krishna N  Das NEW DELHI  Reuters    India s drugs regulator has ordered Johnson   Johnson  N JNJ  to stop manufacturing its Baby Powder using raw materials in two of its Indian factories until test results prove they are free of asbestos  a senior official said on Thursday  The official at the Central Drugs Standard Control Organization  CDSCO   who declined to be named citing the sensitivity of the matter  said a written order had been sent to the U S  company telling it to stop using the  huge quantities  of raw materials stocked in its plants in northern and western India  Read the Reuters investigation  The company said on Wednesday that Indian drug authorities visited some of its facilities and took  tests and samples  of its talcum powder  It also said that the safety of its cosmetic talc was based on a long history of safe use and decades of research and clinical evidence by independent researchers and scientific review boards across the world  The visits came as the CDSCO and state based food and drug administrations launched an investigation into J J s Baby Powder following a Reuters report last Friday that the firm knew for decades that cancer causing asbestos could be found in the product  J J has described the Reuters article as  one sided  false and inflammatory   The company didn t immediately respond to requests for comment on Thursday  Asked if the order meant the company would have to stop producing its ubiquitous baby powder in India for now  the official at the drugs regulator said that was  the inference you have to take  at least as far as the stores of raw materials were concerned   We have told them until this investigation concludes  you should not use the raw material  Test results will take time   the official said   Testing for asbestos is not a routine procedure  It might be in traces  It will require us to develop a method and all those things   FAMILIAR BRAND J J s Baby Powder is one of the most recognised foreign brands in India along with Colgate toothpaste and Surf detergent   The company started selling its Baby Powder in India in 1948  just a year after the country won independence from the British  Presenting gift boxes containing the product and others aimed at newborns is almost a family ritual in this country of 1 3 billion people  28 percent of whom are aged between 0 14  The company also commands a strong retail distribution network through small pharmacies  larger stores and the internet  There is yet to be any significant signs of a backlash against J J products in India because of the scare  At eight pharmacies across India visited by Reuters reporters on Thursday  seven said J J remained the No  1 seller of powder for babies  That doesn t mean it isn t under pressure from local and international competitors who sell talc type powders  such as Bengaluru based Himalaya Herbals  and Italy s Artsana  which produces Chicco baby brands   And some individual consumers say they are now very wary of J J s Baby Powder   It is really very  very shocking   said Sitaram Beria  a chartered accountant in the eastern city of Bhubaneswar  He said he stopped applying J J powder on his six month old baby after hearing about the Reuters report over the weekend  J J leads sales in the Indian baby and child toiletries market  which market research provider Euromonitor estimates would be worth 12 5 billion rupees   178 million  this year  and forecasts will grow 84 percent to 23 billion rupees in 2022  Euromonitor did not give a breakdown for baby powder alone but said J J was the biggest player in the overall segment  followed by Mumbai based VVF Ltd  Artsana  Wipro of Bengaluru and Himalaya  Himalaya said in a statement that its herbs based baby care products  are exclusively promoted and recommended by over 40 000 doctors in the country  which is the greatest endorsement for us   while declining to provide any financial figures  The other companies could not be reached for comment  
  1   70 2600 Indian rupees ",2018-12-20,Reuters,https://www.investing.com/news/stock-market-news/indian-regulator-orders-johnson--johnson-to-stop-using-raw-material-to-make-baby-powder-in-india-source-1727775,1727775
198020,419536,JNJ,Two lawmakers question EPA on asbestos after Reuters report,news,WASHINGTON  Reuters    Two Democratic U S  lawmakers have called on the Environmental Protection Agency to answer questions about asbestos exposure after Reuters reported that documents showed Johnson   Johnson  NYSE JNJ  knew for decades of the mineral s presence in its popular baby powder  Whether asbestos in the talc supply in Johnson   Johnson s Baby Powder caused cancer has been the subject of litigation for years  The lawmakers  Senator Jeff Merkley and Representative Suzanne Bonamici  did not mention Johnson   Johnson by name but expressed  deep concern  about Friday s Reuters report  according to a copy of their letter dated Dec  19 and reviewed by Reuters  Read the Reuters investigation  In their letter  the two lawmakers asked the EPA how it was regulating potentially unsafe asbestos containing products  J J has disputed the Reuters report  calling it a  misrepresentation   The company says its talc is safe and has never contained asbestos  adding that decades of studies and regulatory assessments confirm the safety of its product  Representatives for the EPA did not be respond to an email or a telephone call seeking comment on the congressional letter  Asked about the lawmakers  letter  J J spokesman Ernie Knewitz declined to comment but said the Reuters report was  one sided  false and inflammatory   According to the Reuters report  documents as well as deposition and trial testimony showed that from at least 1971 to the early 2000s the company s raw talc and finished powders sometimes tested positive for small amounts of asbestos   Most internal J J asbestos test reports Reuters reviewed did not find asbestos  The company has defended its products in recent days with a series of full page newspaper advertisements and a television interview with its chief executive  Shares of the company have fallen about 12 5 percent since the Reuters report on Friday  Merkley and Bonamici also asked the EPA to detail what steps it was taking to help prevent vulnerable populations such as pregnant women and infants from being exposed to products containing asbestos  including other products with talc  a mineral  Although baby powder is subject to regulation under the Federal Food  Drug  and Cosmetic Act  other talc products sold to consumers would be within the purview of the Toxic Substances Control Act  TSCA  and thus the responsibility of the EPA  they wrote in the letter  Democratic U S  Senator Edward Markey separately called on the FDA to investigate the findings in the Reuters report in a letter on Friday  The FDA could not immediately be reached for comment   Asbestos is a known carcinogen  and one for which there is no controlled use or safe level of exposure   Merkley and Bonamici wrote   Fifty five countries have already banned asbestos  Unfortunately  the United States still permits the use of asbestos  ,2018-12-20,Reuters,https://www.investing.com/news/stock-market-news/two-lawmakers-question-epa-on-asbestos-after-reuters-report-1728372,1728372
198021,419537,JNJ,Exclusive  Bangladesh says to collect  test samples of Johnson   Johnson Baby Powder,news,By Serajul Quadir DHAKA  Reuters    Bangladesh will collect and test samples of Johnson   Johnson s  N JNJ  Baby Powder for asbestos in a couple of days  its main testing authority said on Friday  after a Reuters report last Friday that the firm knew for decades that cancer causing asbestos could be found in the product  The Bangladesh Standards and Testing Institution  BSTI   under the Industries Ministry  said it will either do the tests inside or outside the country  Read the Reuters investigation   We take this issue seriously and within a couple of days we will collect samples from the market       S M  Isahaque Ali  a director at the BSTI  told Reuters   He said Bangladesh wouldn t stop the Baby Powder from being marketed unless it discovers asbestos is present  J J has described the Reuters article as  one sided  false and inflammatory    J J spokespersons in India and Bangladesh could not be immediately reached for comment on the Bangladesh government move  J J said on Thursday that its talc is routinely tested by both suppliers and independent labs to ensure that it is free of asbestos  It told Reuters in a statement   All talc in India is sourced and exclusively sold in India and surrounding markets   including Sri Lanka  Bangladesh  Nepal  Bhutan  Maldives   and fully meets the regulatory standards of the Government of India  ,2018-12-21,Reuters,https://www.investing.com/news/stock-market-news/exclusive-bangladesh-says-to-collect-test-samples-of-johnson--johnson-baby-powder-1728505,1728505
198022,419538,JNJ,After damaging Reuters report  J J doubles down on talc safety message,news,"By Mike Spector and Lisa Girion NEW YORK LOS ANGELES  Reuters    Johnson   Johnson  NYSE JNJ  Inc s statement was unequivocal   The FDA has tested Johnson s talc since the  70s  Every single time it did not contain asbestos   the company said in a Dec  19 tweet  It followed by several days the publication of a Reuters investigation    that found the healthcare conglomerate knew for decades that the carcinogen lurked in its Baby Powder and other cosmetic talc products  The tweet  posted under the handle  JNJNews  didn t mention that the U S  Food and Drug Administration  FDA  found traces of asbestos in the company s Shower to Shower talc in 1973  as revealed in agency documents  reviewed by Reuters  And it is only one of dozens of tweets conveying a similar message about talc safety since the Reuters article appeared Dec  14  The Reuters article prompted a stock selloff that erased about  40 billion from J J s market value in one day and created a public relations crisis as the blue chip healthcare conglomerate faced widespread questions about the possible health effects of one of its most iconic products  To reassure investors and consumers  J J has tweeted  posted on Facebook  NASDAQ FB   run a series of full page newspaper ads across the United States  published a lengthy rebuttal to the Reuters investigation on its website and announced a  5 billion stock buyback  Chairman and Chief Executive Officer Alex Gorsky has appeared in a company video and on CNBC s  Mad Money  to reinforce the company s position  That position has been unwavering  J J insists that its Baby Powder is safe and has been asbestos free at least since regular testing began in the 1970s  The message doubles down on the stance the company has taken to defend against lawsuits in which about 11 700 plaintiffs allege that the J J talc they used in past decades caused their cancer  The company is pursuing this strategy despite the evidence that talc in its raw and finished powders sometimes tested positive for the carcinogen from the 1970s into the early 2000s   test results that the company didn t disclose to regulators or consumers  In response to a Reuters request for comment  the company said it is committed to defending the talc litigation   and that same  long term view is reflected in our ongoing communications that consistently point to the strong scientific evidence that our talc is and always has been safe   As for the 1973 Shower to Shower test  J J noted that the result didn t  reflect FDA s final determination about this sample  in a 1976 table summarizing the agency s early 1970s cosmetic talc testing  However  in that 1976 table  which Reuters examined  the FDA did not indicate any result  positive or negative  for the type of asbestos found in the Shower to Shower sample in 1973  Given the mass of litigation it faces  J J has little choice but to zealously dispute findings that its products sometimes contained traces of asbestos  said Eric Dezenhall  a crisis management consultant in Washington  D C   If your position in court is that the claims being made are false you can t just shrug your shoulders   he said  Soon after the Reuters article appeared  J J executives consulted crisis management experts  according to people familiar with the matter  Among the company s reasons for deciding to maintain its stance on absolute talc purity  these people said  was a conviction that a company known for putting health and safety first had the facts on its side  a litigation track record that included victories and mistrials  and the expectation that adverse verdicts will be overturned on appeal  THROUGH LAWYERS Many of J J s subsequent messages have mirrored the company s written responses to questions and findings Reuters presented to the company during its investigation  They deny that the company kept information from regulators and point to the many studies finding that talc is safe and doesn t cause cancer  Those earlier responses were composed by J J s outside litigators  led by Peter Bicks at Orrick  Herrington   Sutcliffe  and conveyed to Reuters by lawyers at a crisis management firm co founded by Lanny Davis  a lawyer who represented U S  President Bill Clinton in the 1990s and Michael Cohen  President Donald Trump s former attorney who has pleaded guilty to multiple criminal charges  Gorsky  in his appearance on  Mad Money   invoked J J s now legendary response to the Tylenol crisis as evidence that the company can be trusted to address any safety problems linked to its products  In 1982  J J moved decisively to pull all Tylenol from store shelves after seven people died from taking cyanide laced pills   I can t believe the company that took that dramatic of an action would allow a product that they felt in any way could be harmful to stay on the market   Gorsky told  Mad Money  host Jim Cramer   We unequivocally believe that our talc  our Baby Powder  does not contain asbestos   Citing the Tylenol recall provides  some reputational buffer   said Stephen A  Greyser  the Harvard Business School professor who wrote the first study of the company s handling of that crisis   But it is not a total protection  because it won t shield the company from a loss of trust if consumers or investors conclude the company hasn t been fully forthcoming in this case  he said  J J needs to guard against  reputational contagion   the risk that a loss of confidence in Baby Powder could bleed over into how consumers  shareholders and others view the company more broadly  Greyser added  The key difference between the two crises is that poisoned Tylenol presented a threat to consumers at the time  while the documented asbestos contamination of J J talc that Reuters investigated spanned from 1971 to the early 2000s  J J says that if it believed that Baby Powder today presented safety risks  it wouldn t hesitate to remove it from store shelves  given that the product accounts for less than 0 5  of annual revenue  The company joined its talc supplier  Imerys Talc America  a unit of Paris based Imerys SA  in requesting that a trial scheduled for January in St  Louis be delayed for  among other things  what they called  negative national and local news coverage  resulting from the Reuters investigation that would inevitably taint prospective jurors  The judge denied the motion  The same judge recently upheld a  4 69 billion jury award in a separate ovarian cancer case  which J J says it expects to be overturned on appeal  The judge said J J s promotion of a product that the evidence showed was contaminated with a known carcinogen was  particularly reprehensible   In an emailed statement  Imerys Talc America said it  is committed to the quality and safety of its products   and that rigorous research  overwhelmingly confirms that talc is safe  and no agency has asserted that talc causes cancer   UNDERMINED BY EVIDENCE Some of J J s messages in its recent campaign omit key details regarding findings on talc and  in certain instances  are undermined by other evidence  according to a Reuters review of the company s statements  The Dec  19 tweet claiming that the FDA s own tests never found asbestos in J J talc  for example  ignores an agency scientist s 1973 finding that a Shower to Shower sample contained asbestos fibers  according to a copy of an FDA report titled  Asbestos and Other Contaminants in Talc  and a deposition of a former J J head toxicologist  The FDA did not respond to questions for this article  citing a partial government shutdown  On CNBC  Gorsky said   We also not only used the best testing methodologies that were available  but we continued to improve them through the years   J J s testing methods do exceed the industry standard  But even so  as a geologist and frequent J J expert witness acknowledged in court this year  only a tiny fraction of the company s talc sold over the past 40 years has been tested using what is widely recognized as the best method to detect asbestos fibers  known as transmission electron microscopy  Plaintiffs  lawyers are already homing in on inconsistencies between J J s statements and other evidence regarding its talc  and they are planning to depose Gorsky in coming weeks   There is no flexibility in what they re saying   said Leigh O Dell  one of the lead lawyers representing plaintiffs in thousands of lawsuits against J J consolidated in a New Jersey federal court   Taking these statements on behalf of the company and pointing out to juries and judges the misrepresentations contained in those statements   I think you re going to see that in every case going forward  whether it s an ovarian cancer case or a mesothelioma case   One of J J s recent tweets criticized plaintiffs  lawyers   Far from a new theory or insight  plaintiffs  lawyers have resurrected a disproven argument about asbestos in our talc that dates to the 1970s   The Reuters investigation found that tests by J J s own contract labs and others periodically found small amounts of asbestos in talc from mines that supplied the mineral for Baby Powder as recently as the early 2000s  Some J J tweets and newspaper ads have adopted a question and answer format   What about the allegation you withheld safety information   the company said in a full page ad in USA Today the day after Christmas   It is false   the company said   All safety concerns are taken seriously  and we share all relevant information with regulators   Some Twitter users have responded to J J s tweets with praise and support  Others have referenced their relatives  longtime use of J J talc products and subsequent deaths from ovarian cancer   We re very sorry to hear this   J J responded to several Twitter users  expressing a desire to speak with them and offering a phone number to call  In response to another recent tweet in which J J said its talc doesn t contain asbestos  one Twitter user asked   Did it USED to   
 No   J J responded   For decades  J J s baby powder has repeatedly been tested for asbestos and found not to contain asbestos  ",2018-12-31,Reuters,https://www.investing.com/news/stock-market-news/after-damaging-reuters-report-jj-doubles-down-on-talc-safety-message-1734171,1734171
198023,419539,JNJ, Mallinckrodt To Divest Contract Manufacturing Unit  Stock Up,opinion,"Shares of the beleaguered generic maker  Mallinckrodt plc   NYSE MNK    gained 84 7  on Sep 10  after it announced plans to sell its contract manufacturing unit Investors cheered the move as the company will have some free cash to deal with liabilities from the ongoing lawsuits related to the misuse of opioid based drugs Mallinckrodt s shares have plunged so far this year due to pricing pressure in the generic segment and the rising menace of penalties regarding litigations Mallinckrodt public limited company Price
    Mallinckrodt inked a definitive agreement to sell its wholly owned subsidiary  BioVectra Inc   to an affiliate of H I G  Capital for approximately  250 million BioVectra is a contract development and manufacturing organization  CDMO   which provides global pharmaceutical and biotech companies with full service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients  APIs  The total payment includes a fixed consideration of  175 million  comprising an upfront payment of  135 million and a long term note of  40 million  and contingent payments of up to  75 million The transaction is expected to close in the fourth quarter of 2019 The decision to sell the CDMO comes at a crucial time for Mallinckrodt  which is striving hard to come out of various litigations related to opioid drugs The company recently reached a settlement in principle with Cuyahoga and Summit Counties in Ohio concerning lawsuits pending in multidistrict opioid litigation  MDL   The settlement will fully resolve the Track 1 cases against Mallinckrodt and subsidiaries that are scheduled to go on trial in October 2019 in the MDL  Per the terms  the company will pay  24 million in cash and donate  6 million to generic products  including addiction treatment products Last week  shares of Mallinckrodt plummeted after a Bloomberg report suggested that the company may file for bankruptcy to limit its liabilities related to the pending opioid litigations Per the report  Mallinckrodt hired restructuring advisers to explore options that could help avoid the multi district litigation scheduled in October  Moreover  its high debt levels will make matters worse if a settlement is reached or a penalty is imposed by the court  The company may also divest its generic business  which includes opioid drugs Apart from Mallinckrodt  many pharma companies like Endo International   NASDAQ ENDP   and Teva Pharma   NYSE TEVA   are embroiled in multiple opioid litigations filed by several states  counties and other political subdivisions in the United States regarding the abuse of opioid based drugs  The industry players are accused of faulty marketing practices  which downplayed addiction risks from these drugs and spurred their consumption instead Earlier  Johnson   Johnson   NYSE JNJ   received an unfavorable ruling in the court case filed by the state authorities of Oklahoma pertaining to the abuse of its opioid based drugs and was levied a fine of  572 million Mallinckrodt currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-09-11,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-to-divest-contract-manufacturing-unit-stock-up-200463804,200463804
198024,419540,JNJ,J J Files SBLA For Tremfya With FDA For Psoriatic Arthritis ,opinion,Johnson   Johnson   NYSE JNJ   submitted a supplemental biologics license application  sBLA  to the FDA  seeking approval to expand the label of itsIL 23 inhibitor Tremfya as a treatment for active psoriatic arthritis  PsA  The sBLA filing was based on data from the phase III DISCOVER 1 and 2 studies  which evaluated the safety and efficacy of Tremfya compared to placebo for treating adult patients with PsA In June  J J s subsidiary  Janssen had announced top line results from the studies  which evaluated Tremfya administered by subcutaneous injection  The studies met the primary endpoint of achieving American College of Rheumatology 20  improvement while the safety profile was consistent with the previous programs on Tremfya guselkumab J J expects to file a similar regulatory application with the European Medicines Agency by the end of this year J J s stock has risen 0 4  this year so far against a decrease of 1 9  recorded by the    Tremfya was first approved in the United States and the EU in 2017 for the treatment of moderate to severe plaque psoriasis and was off to a solid start after its launch The drug recorded sales of  452 million in the first half of 2019  If approved by the FDA for PsA  Tremfya will be the first IL 23 inhibitor to be approved to treat this complex inflammatory disease  which causes pain  stiffness and swelling in and around the joints  It will expand the drug s eligible patient population and should boost its sales Tremfya has proved its superiority over other drugs in the past  Last December  J J announced results from a head to head phase III ECLIPSE study  which compared Tremfya with Novartis    NYSE NVS   psoriasis drug  Cosentyx  secukinumab  Data from the study showed that after a 48 week treatment  84 5  of the patients treated with Tremfya achieved 90  improvement in disease symptoms as measured by the Psoriasis Area Severity Index in comparison to 70  achieved by Novartis  Cosentyx The drug is also being studied for various other indications including phase IIb III studies in Crohn s disease and ulcerative colitis and in a phase II study for hidradenitis suppurativa J J currently has a Zacks Rank  3  Hold   Some better ranked large cap pharma stocks include Roche Holding  SIX ROG  AG   OTC RHHBY   and Merck   NYSE MRK    both with a Zacks Rank  2  Buy   You can see  Shares of Roche have gained 10 8  this year so far  Earnings estimates for 2019 have risen 0 8  while that for 2020 have increased 2  over the past 60 days Merck s stock is up 7 3  this year so far  Its earnings estimates have risen 3 6  for 2019 and 1 3  for 2020 over the past 60 days 5 Stocks Set to DoubleZacks experts released their picks to gain  100  or more in 2020  One is a famous cutting edge food company that is  hiding in plain sight   Swamped with competitors and ignored by Wall Street  its stock price floundered  Now  suddenly  it acquired a company that gives it an advantage none of its peers have ,2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/jj-files-sbla-for-tremfya-with-fda-for-psoriatic-arthritis-200465364,200465364
198026,419542,JNJ,J J announces  5 billion share repurchase plan,news, Reuters    Johnson   Johnson  N JNJ  on Monday announced a share repurchase of up to  5 billion of its common stock  The repurchase plan has no time limit and may be suspended for periods or discontinued at any time  the company said in a statement ,2018-12-17,Reuters,https://www.investing.com/news/stock-market-news/jj-announces-5-billion-share-repurchase-plan-1724175,1724175
198027,419543,JNJ,J J announces  5 billion share buyback after shares extend losses,news," Reuters    Johnson   Johnson  NYSE JNJ  said on Monday it plans to buy back up to  5 billion of its stock  after a Reuters report on Friday that the company knew for decades that its Baby Powder contained cancer causing asbestos wiped about  40 billion from its market value   Shares of the company closed down 3 percent on Monday  extending a 10 percent fall on Friday after the report was published   They were up about 1 percent in extended trading following the announcement of the share buyback  The repurchase plan has no time limit and may be suspended for periods or discontinued at any time  the company said in a statement   J J knew about the presence of small amounts of asbestos in its products as early as 1971  a Reuters examination of company memos  internal reports and other confidential documents showed  The share repurchase was just the latest effort the healthcare conglomerate has made to boost investor confidence  In response to the report  the company said on Friday  any suggestion that Johnson   Johnson knew or hid information about the safety of talc is false   On Monday  J J took out a full page ad in the New York Times titled  Science  Not Sensationalism   saying it has scientific evidence its talc is safe and beneficial to use   If we had any reasons to believe our talc was unsafe  it would be off our shelves   the ad said  J J Chief Executive Alex Gorsky  in his first public statement since the Reuters story was published  is scheduled to appear on CNBC at 6 p m  EST  2300 GMT  on Monday    We unequivocally believe that our talc  our baby powder  does not contain asbestos   Gorsky said in a clip CNBC released ahead of the interview  He also touted the company s testing practices for determining whether the talc was safe   While J J has dominated the talc powder market for more than 100 years  the products contributed less than 0 5 percent of its  76 5 billion revenue last year  The company has large pharmaceutical and medical device portfolios in addition to its consumer products business   
J J shares were trading at  130 30 in after hours trading following a close at  129 14 on Monday ",2018-12-17,Reuters,https://www.investing.com/news/stock-market-news/jj-shares-extend-losses-company-defends-baby-powder-as-safe-1723767,1723767
198028,419544,JNJ,J J moves to limit impact of Reuters report on asbestos in Baby Powder,news,"By Mike Spector NEW YORK  Reuters    Johnson   Johnson  NYSE JNJ  on Monday scrambled to contain fallout from a Reuters report that the healthcare conglomerate knew for decades that cancer causing asbestos lurked in its Baby Powder  taking out full page newspaper ads defending its product and practices  and readying its chief executive for his first television interview since investors erased tens of billions of dollars from the company s market value  J J shares fell nearly 3 percent Monday  closing at  129 14 in New York Stock Exchange trading  That drop was on top of the 10 percent plunge that wiped out about  40 billion of the company s market capitalization following the Reuters report  Friday  J J also announced Monday that it would be repurchasing up to  5 billion of its common stock  Senator Edward Markey  a Massachusetts Democrat on the Environment and Public Works Committee  on Friday sent a letter to the head of the U S  Food and Drug Administration calling on the agency to investigate the findings in the Reuters report to determine whether J J misled regulators and whether its Baby Powder products threaten public health and safety  J J Chief Executive Alex Gorsky  in his first interview since the Reuters article was published  defended the company during an appearance on CNBC s  Mad Money  with host Jim Cramer on Monday night  J J knew for decades about the presence of small amounts of asbestos in its products dating back to as early as 1971  a Reuters examination of company memos  internal reports and other confidential documents showed  In response to the report  J J said on Friday that  any suggestion that Johnson   Johnson knew or hid information about the safety of talc is false   A Monday full page ad from J J    headlined  Science  Not sensationalism      ran in newspapers including The New York Times and The Wall Street Journal  The ad asserted that J J has scientific evidence its talc is safe and beneficial to use   If we had any reasons to believe our talc was unsafe  it would be off our shelves   the ad said  J J rebutted Reuters  report in a lengthy written critique of the article and a video from Gorsky  In the written critique  posted on the company s website   J J said Reuters omitted information it supplied to the news organization that demonstrated the healthcare conglomerate s Baby Powder is safe and does not cause cancer  that J J s baby powder has repeatedly been tested and found to be asbestos free  and that the company has cooperated with the U S  FDA and other regulators around the world to provide information requested over decades   Since tests for asbestos in talc were first developed  J J s Baby Powder has never contained asbestos   Gorsky said in the video   He added that regulators  have always found our talc to be asbestos free   A Reuters spokeswoman on Monday said the agency  stands by its reporting   Reuters  investigation found that while most tests in past decades found no asbestos in J J talc and talc products  tests on Baby Powder conducted by scientists at Mount Sinai Medical Center in 1971 and Rutgers University in 1991  as well as by labs for plaintiffs in cancer lawsuits  found small amounts of asbestos  In 1972  a University of Minnesota scientist found what he called  incontrovertible asbestos  in a sample of Shower to Shower  Other tests by J J s own contract labs and others periodically found small amounts of asbestos in talc from mines that supplied the mineral for Baby Powder and other cosmetic products into the early 2000s   The company did not report to the FDA three tests by three different labs from 1972 to 1975 that found asbestos in the company s talc  The Reuters story drew no conclusions about whether talc itself causes ovarian cancer  Asbestos  however  is a carcinogen  The World Health Organization s International Agency for Research on Cancer has listed asbestos contaminated talc as a carcinogen since 1987  Reuters also found that J J tested only a fraction of the talc powder it sold  The company never adopted a method for increasing the sensitivity of its tests that was recommended to the company by consultants in 1973 and in a published report in a peer review scientific journal in 1991  The ad J J ran in newspapers Monday also pointed to an online talc fact page the company created with  independent studies from leading universities  research from medical journals and third party opinions   That website has changed since early December  according to a Reuters review of online archives  The website  for instance  no longer contains a section headlined  Conclusions from Global Authorities  that as recently as Dec  5 listed organizations including the U S  FDA  the European Union and Health Canada as among entities that have  reviewed and analyzed all available data and concluded that the evidence is insufficient to link talc use to cancer   On Dec  14  the day Reuters published its report  that section of the website had been removed  It is not clear exactly when the online page changed  The Canadian government released a draft report this month that found a  consistent and statistically significant positive association  between talc exposure and ovarian cancer  The draft report also said that talc meets criteria to be deemed toxic  The draft report put forth proposed conclusions that are subject to a public comment period and confirmation in a so called final screening assessment  Health Canada said  If the conclusions are confirmed  Canadian officials will consider adding talc to a government list of toxic substances and implementing measures to prohibit or restrict use of talc in some cosmetics  non prescription drugs and natural health products  Health Canada said   A J J spokeswoman said the company removed the website section after the Canadian government issued the draft report   We chose to be conservative while that draft is under review   the spokeswoman said  
While J J has dominated the talc powder market for more than 100 years  the products contributed less than 0 5 percent of J J s  76 5 billion in revenue last year ",2018-12-18,Reuters,https://www.investing.com/news/stock-market-news/jj-moves-to-limit-impact-of-reuters-report-on-asbestos-in-baby-powder-1724271,1724271
198029,419545,JNJ,Indian regulator says Reuters report on J J baby powder  under consideration ,news,"By Rahul Singh and Krishna N  Das NEW DELHI  Reuters    India s federal drug regulator said on Tuesday a Reuters report that Johnson   Johnson  N JNJ  knew for decades that cancer causing asbestos lurked in its baby powder was  under consideration   A spokeswoman for the Central Drugs Standard Control Organization  CDSCO  told Reuters it was too early to say if a formal investigation would be launched into the baby powder that is ubiquitous in many Indian homes  a potential market of 1 3 billion people  K  Bangarurajan  a senior official at the CDSCO  told Reuters powder samples were tested earlier but nothing wrong was found in them   We tested samples in 2016  but no such thing was found in them   Bangarurajan said by phone   The samples were found to be complying with Indian standards   A J J spokesperson in India said it had not been contacted by the government since the Reuters story  J J said in a statement that the Reuters article  which was published on Friday   is one sided  false and inflammatory     Johnson   Johnson s baby powder is safe and asbestos free   it added   Studies of more than 100 000 men and women show that talc does not cause cancer or asbestos related disease  Thousands of independent tests by regulators and the world s leading labs prove our baby powder has never contained asbestos   the company said  A Reuters examination of many company memos  internal reports and other confidential documents  as well as deposition and trial testimony  showed that from at least 1971 to the early 2000s  the company s raw talc and finished powders sometimes tested positive for small amounts of asbestos  and that company executives  mine managers  scientists  doctors and lawyers fretted over the problem and how to address it while failing to disclose it to regulators or the public  The documents also depicted successful efforts to influence U S  regulators  plans to limit asbestos in cosmetic talc products and scientific research on the health effects of talc  Before the Reuters report  a small portion of the documents had been produced at trial and cited in media reports  Many were shielded from public view by court orders that allowed J J to turn over thousands of documents it designated as confidential  Much of their contents was reported by Reuters for the first time  
J J said on Monday it planned to buy back up to  5 billion of its stock  after the Reuters report wiped about  40 billion from its market value ",2018-12-18,Reuters,https://www.investing.com/news/stock-market-news/indian-regulator-says-reuters-report-on-jj-baby-powder-under-consideration-1724616,1724616
198030,419546,JNJ,Indian regulator  considering  inquiry into J J s baby powder,news,Reuters reports that India s Central Drugs Standard Control Organization is  considering  investigating whether Johnson   Johnson  JNJ  1 1   knew for many years that its baby powder contained asbestos  despite earlier tests that failed to find anything A spokesperson from the agency said it is premature to say if an inquiry will be launched Now read ,2018-12-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/indian-regulator-considering-inquiry-into-jjs-baby-powder-1725075,1725075
198031,419547,JNJ,Indian regulator to test samples of Johnson   Johnson baby powder  media,news,"NEW DELHI  Reuters    India s federal drug regulator will on Wednesday seize samples of Johnson   Johnson s  N JNJ  baby powder for testing  local media said  following a Reuters report that the company knew for decades that cancer causing asbestos lurked in the product  The Times of India quoted an official source as saying that a team of 100 drug inspectors had been assigned to examine different manufacturing facilities  wholesalers and distributors  starting early Wednesday   Samples of all brands of the powder will be collected and sent for testing   the unnamed official told the paper  The Mint business daily also quoted an unnamed official as saying that the drug inspectors would visit J J s manufacturing operations and draw samples for further investigation  On Tuesday  a spokeswoman for the Central Drugs Standard Control Organization  CDSCO  said the Reuters report was  under consideration  but that it was too early to say if a formal investigation would be launched into the baby powder that is ubiquitous in many Indian homes  a potential market of 1 3 billion people  The CDSCO spokeswoman did not immediately respond to a request for comment on Wednesday  An Indian health ministry spokeswoman declined to comment   J J in India did not have any immediate comment on the reports of sample seizures by Indian authorities  On Tuesday the company said in a statement that the Reuters article  which was published on Friday   is one sided  false and inflammatory    Johnson   Johnson s baby powder is safe and asbestos free   it added   Studies of more than 100 000 men and women show that talc does not cause cancer or asbestos related disease  Thousands of independent tests by regulators and the world s leading labs prove our baby powder has never contained asbestos   the company said  A Reuters examination of many company memos  internal reports and other confidential documents  as well as deposition and trial testimony  showed that from at least 1971 to the early 2000s  the company s raw talc and finished powders sometimes tested positive for small amounts of asbestos  and that company executives  mine managers  scientists  doctors and lawyers fretted over the problem and how to address it while failing to disclose it to regulators or the public  The documents also depicted successful efforts to influence U S  regulators  plans to limit asbestos in cosmetic talc products and scientific research on the health effects of talc  
J J said on Monday it planned to buy back up to  5 billion of its stock  after the Reuters report wiped about  40 billion from its market value ",2018-12-19,Reuters,https://www.investing.com/news/stock-market-news/indian-regulator-to-test-samples-of-jj-baby-powder-media-1725820,1725820
198032,419548,JNJ,Large U S  Stocks May Be Underestimating  Worldwide Manufacturing Recession,opinion,"Global manufacturing data have been exceedingly grim  One would be hard pressed to find a country in Europe  Asia or North America that is exporting products with little difficulty 
If the United States wishes to export products at a higher clip  we d require partners with the means to afford our products  Yet the U S  dollar s strength alongside foreign tariffs is impeding the process 





One might think that the dollar s strength would be helpful in importing products from other countries  At the moment  however  a wide range of imported goods have been tagged with tariffs that wind up costing end using consumers a whole lot more money 
For the most part  the U S  consumer has been strong and resilient  On the other hand  if we re not acquiring enough goods from places like the United Kingdom and Germany  it may adversely affect jobs stateside 





Consider the manufacturing recessions that are burgeoning in Europe   See the charts below   Readings below 50 represent contraction 





Notice that I have not even mentioned the elephant in the global room  China  The world s 2nd largest economy is not just our trading partner  but it is pivotal in nearly everything that transpires across the Asia Pacific region 
The fact that China s economy is now growing at its slowest pace in 27 years is downright devastating  One might even take notice that the last two times that Chinese GDP fell to these levels   2000 and 2008   the U S  experience significant economic downturns 





Importantly  the U S  manufacturing segment recently began contracting like the rest of the world   Some may dismiss the reality because we are a consumer oriented society  Others may point to the recessionary pressures in U S  manufacturing from 2013 and 2016  where broader based contraction did not come to pass 
There are differences  however  Throughout the early 2010s  the U S  engaged in  emergency  level stimulus with zero percent rate policy and quantitative easing  In a similar vein  nearly every major central bank in the world  double downed  on more quantitative easing stimulus  QE  in 2016  What s more  in 2016  fiscal stimulus via tax cut promises occurred alongside a Republican sweep of the branches of government 





Here in 2019  Congress is unlikely to authorize any fiscal packages prior to the 2020 election  As for monetary stimulus  dissent at the Federal Reserve would likely restrict voting members to a more subtle rate cutting trajectory   They d require more evidence of an industry wide recession that has spread beyond manufacturing before throwing in the towel and kick starting more QE 
Still  it is clear that the U S  manufacturing slowdown is adversely impacting the U S  economy at large  Take a look at the rather dramatic slide in S P 500 per share estimates in 2019 





An optimist might choose to look at the absolute levels of the S P 500  A mere 3  off of all time highs  Surely U S  stocks would be down much more than that if we were closing in on an industry wide recession beyond the manufacturing segment  Wouldn t they 
It is worth remembering that the S P 500 was only 5  off of its all time record at the time that the Great Recession began in December of 2007  It is also worth remembering that the experts in charge of identifying receptions were nearly 12 months late in declaring the Great Recession s reception  It was not until 12 1 2008 when NBER finally announced that a recession had started roughly one year earlier 





It is fair to say that we may be underestimating the impact of a worldwide slowdown on the U S  economy and U S  asset prices  Some will tell you that  17 trillion in negative interest rate bonds are not suggesting that something s awry  Others will dismiss the fact that every maturity on the U S  Treasury curve has inverted below the overnight lending rate 





Is the global bond market truly wrong  Or have U S  large cap stocks simply stayed late at a party that actually ended more than 19 months ago in January of 2018 
Credit spreads between Treasury bonds and corporate bonds tend to widen significantly before a full fledged recession  One has come to expect a widening of roughly 500 basis points  The reality that spreads remain tight and that a flight away from corporate bonds has yet to occur is a prominent positive for risk takers 





Still  a reversal could happen very quickly  Moreover  the bulk of data  including the resurgence of gold  is hinting at some amount of risk reduction 
For the bulk of my near retiree and retiree client base  we still maintain roughly 48  50  in equity  including assets like Vanguard Dividend Appreciation  NYSE VIG   iShares Minimum Volatility Global  NYSE ACWV   iShares U S  REIT  NYSE USRT  and Vanguard MegaCap  NYSE MGC   We also see value in a few individual companies like Johnson   Johnson  NYSE JNJ  
In the income space  we have a wide variety of preferreds  including Van Eck Preferred EX Financial  NYSE PFXF  and individual names like STANLEY BLACK   DECKER INC 5 75  PRF 2052   NYSE SWJ   We ve also held on to income mainstays such as iShares Core U S  Treasury  NYSE GOVT  as well as iShares Aaa A Rated Corporate Bond  NYSE QLTA   as well as cash equivalents like SPDR Bloomberg  Barclays   LON BARC  1 3 Month T Bill ETF  NYSE BIL  
Keep in mind  if we believed that we were early in the credit cycle  we would likely be looking for 65  growth 35  income as well as a much wider array of risk assets  However  the likelihood is that we are very late in the credit cycle  This means we are keenly aware of the potential for things to devolve  We would not hesitate to cut our allocation to stocks and other risks if our outlook called for greater portfolio protection 
Disclosure  Gary Gordon  MS  CFP is the president of Pacific Park Financial  Inc   a Registered Investment Adviser with the SEC  Gary Gordon  Pacific Park Financial  Inc  and or its clients June hold positions in the ETFs  mutual funds  and or any investment asset mentioned above  The commentary does not constitute individualized investment advice  The opinions offered herein are not personalized recommendations to buy  sell or hold securities  At times  issuers of exchange traded products compensate Pacific Park Financial  Inc  or its subsidiaries for advertising at the ETF Expert web site  ETF Expert content is created independently of any advertising relationships ",2019-09-05,Gary Gordon,https://www.investing.com/analysis/large-us-stocks-may-be-underestimating--worldwide-manufacturing-recession-200461659,200461659
198033,419549,JNJ,Mallinckrodt  MNK  To Resolve Opioid Cases With Ohio Counties,opinion,"Mallinckrodt plc   NYSE MNK   announced that it has reached a settlement in principle with Cuyahoga and Summit Counties in Ohio in connection with lawsuits pending in multidistrict opioid litigation  MDL  
The settlement will fully resolve the Track 1 Cases against Mallinckrodt and subsidiaries that are scheduled to go to trial in October 2019 in the MDL  Per the terms  Mallinckrodt will pay a total sum of  24 million in cash and donate  6 million in generic products including addiction treatment products 
Consequently  cases against all entities will be dismissed 
The resolution of the Track 1 Cases will provide Mallinckrodt with adequate time to resolve its pending opioid lawsuits 
Last week  shares of Mallinckrodt plummeted following a Bloomberg report that suggested its restructuring plans  It also stated that the company may file for bankruptcy to limit its liabilities related to the pending opioid litigations 
Per the report  Mallinckrodt hired restructuring advisers to explore options that could help avoid the multi district litigation scheduled in October  The company is mulling over insolvency if costs become unwieldy  Moreover  its high debt levels make matters worse as it is a prospective threat in case a settlement is reached or a penalty is slapped by the court  The company may also divest its generic business  which includes opioid drugs 
Mallinckrodt s shares have tanked 88 4  so far this year compared with the  s fall of 6 7  due to pricing pressure in the generic segment and the rising menace of penalties regarding litigations 

 
Apart from Mallinckrodt  many pharma companies like Endo International   NASDAQ ENDP   and Teva Pharma   NYSE TEVA   are embroiled in multiple opioid litigations filed by several states  counties and other political subdivisions in the United States in relation to the abuse of opioid based drugs  These industry players are accused of faulty marketing practices  which downplayed the risk of addiction from these drugs and boosted their consumption instead 
Earlier  Johnson   Johnson   NYSE JNJ   received an unfavorable ruling in the court case filed by the state authorities of Oklahoma pertaining to the abuse of its opioid based drugs  namely Duragesic  Nucynta and Nucynta ER  The Cleveland County District Court charged JNJ a fine of  572 million 
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-09-09,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-mnk-to-resolve-opioid-cases-with-ohio-counties-200463066,200463066
198034,419550,JNJ,Lexicon  LXRX  Settles With Sanofi For  260M  Shares Rally,opinion,"Lexicon Pharmaceuticals  Inc    NASDAQ LXRX   announced that it will regain re gain global rights to diabetes drug  Zynquista  sotagliflozin   and will receive  260 million from Sanofi   NASDAQ SNY   per the terms of a deal related to termination of their alliance for the product s development  The deal includes settlement of all related disputes with Sanofi  The termination of the alliance between the companies stands effective from Sep 9 The total amount includes  208 million in upfront payment and the rest of the amount will be paid by Sanofi over the next 12 months  This payment will significantly boost Lexicon s cash resources Shares of Lexicon surged 30 2  in after market trading on Sep 10  following the announcement  However  the company s shares have declined 74 1  so far this year compared with the  s decrease of 3 2    Please note that Lexicon and Sanofi had entered into the alliance four years ago for the development of Zynquista  a dual SGLT1 and SGLT2 inhibitor  for the treatment of patients with type I or type II diabetes  In July  Sanofi announced its decision to terminate the alliance following the announcement of top line data from three phase III studies evaluating Zynquista in type II diabetes in patients receiving metformin or with stage 3 chronic kidney disease   CKD   or stage 4 CKD Data from the studies showed Zynquista achieved statistically significant reduction in HbA1c  blood sugar  levels in patients on metformin and overall patient population in stage 3 CKD study  However  Zynquista failed to achieve reduction in HbA1c levels of statistical significance in patients with stage 3b or 4 CKD  However  Lexicon will continue to analyze data from these three studies Meanwhile  in April  Zynquista received approval for the treatment of type I diabetes in Europe  However  the FDA had  a complete response letter   CRL   to the new drug application seeking approval for Zynquista for a similar indication Although investors cheered the payment from Sanofi  the loss of a strong partner is likely to have an unfavorable impact on Lexicon going forward  Following the termination  Lexicon may face hiccups with the launch of Zynquista in Europe  which otherwise could have been smooth given strong presence of Sanofi in that market  The company is currently looking for partnerships for development  regulatory approval and commercialization of Zynquista We note that the diabetes segment is a competitive space  In March  AstraZeneca s   NYSE AZN   SGLT2 inhibitor  Forxiga  received approval in EU for type I diabetes  However  the drug has received CRL in the United States  Meanwhile  several companies are also developing SGLT2 inhibitor  like J J s   NYSE JNJ   Invokana and Eli Lilly s Jardiance  targeting type II diabetes Lexicon Pharmaceuticals  Inc  Price
    Zacks RankLexicon currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-09-10,Zacks Investment Research,https://www.investing.com/analysis/lexicon-lxrx-settles-with-sanofi-for-260m-shares-rally-200463689,200463689
198043,419559,JNJ,Special Report  J J knew for decades that asbestos lurked in its Baby Powder,news,By Lisa Girion LOS ANGELES  Reuters    Darlene Coker knew she was dying  She just wanted to know why  She knew that her cancer  mesothelioma  arose in the delicate membrane surrounding her lungs and other organs  She knew it was as rare as it was deadly  a signature of exposure to asbestos  And she knew it afflicted mostly men who inhaled asbestos dust in mines and industries such as shipbuilding that used the carcinogen before its risks were understood  Coker  52 years old  had raised two daughters and was running a massage school in Lumberton  a small town in eastern Texas  How had she been exposed to asbestos   She wanted answers   her daughter Cady Evans said  Fighting for every breath and in crippling pain  Coker hired Herschel Hobson  a personal injury lawyer  He homed in on a suspect  the Johnson s Baby Powder that Coker had used on her infant children and sprinkled on herself all her life  Hobson knew that talc and asbestos often occurred together in the earth  and that mined talc could be contaminated with the carcinogen  Coker sued Johnson   Johnson  NYSE JNJ   alleging that  poisonous talc  in the company s beloved product was her killer  J J denied the claim  Baby Powder was asbestos free  it said  As the case proceeded  J J was able to avoid handing over talc test results and other internal company records Hobson had requested to make the case against Baby Powder  Coker had no choice but to drop her lawsuit  Hobson said   When you are the plaintiff  you have the burden of proof   he said   We didn t have it   That was in 1999  Two decades later  the material Coker and her lawyer sought is emerging as J J has been compelled to share thousands of pages of company memos  internal reports and other confidential documents with lawyers for some of the 11 700 plaintiffs now claiming that the company s talc caused their cancers   including thousands of women with ovarian cancer  A Reuters examination of many of those documents  as well as deposition and trial testimony  shows that from at least 1971 to the early 2000s  the company s raw talc and finished powders sometimes tested positive for small amounts of asbestos  and that company executives  mine managers  scientists  doctors and lawyers fretted over the problem and how to address it while failing to disclose it to regulators or the public  The documents also depict successful efforts to influence U S  regulators  plans to limit asbestos in cosmetic talc products and scientific research on the health effects of talc  A small portion of the documents have been produced at trial and cited in media reports  Many were shielded from public view by court orders that allowed J J to turn over thousands of documents it designated as confidential  Much of their contents is reported here for the first time   RATHER HIGH  The earliest mentions of tainted J J talc that Reuters found come from 1957 and 1958 reports by a consulting lab  They describe contaminants in talc from J J s Italian supplier as fibrous and  acicular   or needle like  tremolite  That s one of the six minerals that in their naturally occurring fibrous form are classified as asbestos  At various times from then into the early 2000s  reports by scientists at J J  outside labs and J J s supplier yielded similar findings  The reports identify contaminants in talc and finished powder products as asbestos or describe them in terms typically applied to asbestos  such as  fiberform  and  rods   In 1976  as the U S  Food and Drug Administration  FDA  was weighing limits on asbestos in cosmetic talc products  J J assured the regulator that no asbestos was  detected in any sample  of talc produced between December 1972 and October 1973  It didn t tell the agency that at least three tests by three different labs from 1972 to 1975 had found asbestos in its talc   in one case at levels reported as  rather high   Most internal J J asbestos test reports Reuters reviewed do not find asbestos  However  while J J s testing methods improved over time  they have always had limitations that allow trace contaminants to go undetected   and only a tiny fraction of the company s talc is tested  The World Health Organization and other authorities recognize no safe level of exposure to asbestos  While most people exposed never develop cancer  for some  even small amounts of asbestos are enough to trigger the disease years later  Just how small hasn t been established  Many plaintiffs allege that the amounts they inhaled when they dusted themselves with tainted talcum powder were enough  The evidence of what J J knew has surfaced after people who suspected that talc caused their cancers hired lawyers experienced in the decades long deluge of litigation involving workers exposed to asbestos  Some of the lawyers knew from those earlier cases that talc producers tested for asbestos  and they began demanding J J s testing documentation  What J J produced in response to those demands has allowed plaintiffs  lawyers to refine their argument  The culprit wasn t necessarily talc itself  but also asbestos in the talc  That assertion  backed by decades of solid science showing that asbestos causes mesothelioma and is associated with ovarian and other cancers  has had mixed success in court  In two cases earlier this year   in New Jersey and California   juries awarded big sums to plaintiffs who  like Coker  blamed asbestos tainted J J talc products for their mesothelioma  A third verdict  in St  Louis  was a watershed  broadening J J s potential liability  The 22 plaintiffs were the first to succeed with a claim that asbestos tainted Baby Powder and Shower to Shower talc  a longtime brand the company sold in 2012  caused ovarian cancer  which is much more common than mesothelioma  The jury awarded them  4 69 billion in damages  Most of the talc cases have been brought by women with ovarian cancer who say they regularly used J J talc products as a perineal antiperspirant and deodorant  At the same time  at least three juries have rejected claims that Baby Powder was tainted with asbestos or caused plaintiffs  mesothelioma  Others have failed to reach verdicts  resulting in mistrials   JUNK  SCIENCE J J has said it will appeal the recent verdicts against it  It has maintained in public statements that its talc is safe  as shown for years by the best tests available  and that the information it has been required to divulge in recent litigation shows the care the company takes to ensure its products are asbestos free  It has blamed its losses on juror confusion   junk  science  unfair court rules and overzealous lawyers looking for a fresh pool of asbestos plaintiffs   Plaintiffs  attorneys out for personal financial gain are distorting historical documents and intentionally creating confusion in the courtroom and in the media   Ernie Knewitz  J J s vice president of global media relations  wrote in an emailed response to Reuters  findings   This is all a calculated attempt to distract from the fact that thousands of independent tests prove our talc does not contain asbestos or cause cancer  Any suggestion that Johnson   Johnson knew or hid information about the safety of talc is false   J J declined to comment further for this article  For more than two months  it turned down repeated requests for an interview with J J executives  On Dec  8  the company offered to make an expert available  It had not done so as of Thursday evening  The company referred all inquiries to its outside litigation counsel  Peter Bicks  In emailed responses  Bicks rejected Reuters  findings as  false and misleading    The scientific consensus is that the talc used in talc based body powders does not cause cancer  regardless of what is in that talc   Bicks wrote   This is true even if   and it does not   Johnson   Johnson s cosmetic talc had ever contained minute  undetectable amounts of asbestos   He dismissed tests cited in this article as  outlier  results  In court  J J lawyers have told jurors that company records showing that asbestos was detected in its talc referred to talc intended for industrial use  Other records  they have argued  referred to non asbestos forms of the same minerals that their experts say are harmless  J J has also argued that some tests picked up  background  asbestos   stray fibers that could have contaminated samples after floating into a mill or lab from a vehicle clutch or fraying insulation  The company has made some of the same arguments about lab tests conducted by experts hired by plaintiffs  One of those labs found asbestos in Shower to Shower talc from the 1990s  according to an Aug  11  2017  court report  Another lab found asbestos in more than half of multiple samples of Baby Powder from past decades   in bottles from plaintiffs  cupboards and acquired from eBay  NASDAQ EBAY   and even a 1978 bottle held in J J s corporate museum  The concentrations were great enough that users  would have  more likely than not  been exposed   the plaintiffs  lab report presented in several cases this year concluded  Matthew Sanchez  a geologist with consultants RJ Lee Group Inc and a frequent expert witness for J J  dismissed those findings in testimony in the St  Louis trial   I have not found asbestos in any of the current or modern  what I consider modern  Johnson   Johnson talc products   Sanchez told the jury  Sanchez did not return calls seeking comment  RJ Lee said it does not comment on the work it does for clients  Since 2003  talc in Baby Powder sold in the United States has come from China through supplier Imerys SA  a co defendant in most of the talc litigation  Both companies said the Chinese talc is safe  An Imerys spokesman said the Paris based company s tests  consistently show no asbestos  Talc s safe use has been confirmed by multiple regulatory and scientific bodies   J J  based in New Brunswick  New Jersey  has dominated the talc powder market for more than 100 years  its sales outpacing those of all competitors combined  according to Euromonitor International data  And while talc products contributed just  420 million to J J s  76 5 billion in revenue last year  Baby Powder is considered an essential facet of the healthcare products maker s carefully tended image as a caring company   a  sacred cow   as one 2003 internal email put it   When people really understand what s going on  I think it increases J J s exposure a thousand fold   said Mark Lanier  one of the lawyers for the women in the St  Louis case  The mounting controversy surrounding J J talc hasn t shaken investors  The share price is up about 6 percent so far this year  Talc cases make up fewer than 10 percent of all personal injury lawsuits pending against J J  based on the company s Aug  2 quarterly report  in which the company said it believed it had  strong grounds on appeal   J J Chairman and Chief Executive Officer Alex Gorsky has pledged to fight on  telling analysts in July   We remain confident that our products do not contain asbestos   Gorsky s comment  echoed in countless J J statements  misses a crucial point  Asbestos  like many environmental carcinogens  has a long latency period  Diagnosis usually comes years after initial exposure   20 years or longer for mesothelioma  J J talc products today may be safe  but the talc at issue in thousands of lawsuits was sold and used over the past 60 years   SAFETY FIRST  In 1886  Robert Wood Johnson enlisted his younger brothers in an eponymous startup built around the  Safety First  motto  Johnson s Baby Powder grew out of a line of medicated plasters  sticky rubber strips loaded with mustard and other home remedies  When customers complained of skin irritation  the brothers sent packets of talc  Soon  mothers began applying the talc to infants  diaper chafed skin  The Johnsons took note  They added a fragrance that would become one of the most recognizable in the world  sifted the talc into tin boxes and  in 1893  began selling it as Johnson s Baby Powder  In the late 1950s  J J discovered that talc from its chief source mine for the U S  market in the Italian Alps contained tremolite  That s one of six minerals   along with chrysotile  actinolite  amosite  anthophyllite and crocidolite   that occur in nature as crystalline fibers known as asbestos  a recognized carcinogen  Some of them  including tremolite  also occur as unremarkable  non asbestiform  rocks  Both forms often occur together and in talc deposits  J J s worry at the time was that contaminants made the company s powder abrasive  It sent tons of its Italian talc to a private lab in Columbus  Ohio  to find ways to improve the appearance  feel and purity of the powder by removing as much  grit  as possible  In a pair of reports from 1957 and 1958  the lab said the talc contained  from less than 1 percent to about 3 percent of contaminants   described as mostly fibrous and  acicular  tremolite  Most of the authors of these and other J J records cited in this article are dead  Sanchez  the RJ Lee geologist whose firm has agreed to provide him as a witness in up to 100 J J talc trials  has testified that tremolite found decades ago in the company s talc  from Italy and later Vermont  was not tremolite asbestos at all  Rather  he has said  it was  cleavage fragments  from non asbestiform tremolite  J J s original records don t always make that distinction  In terms of health risk  regulators since the early 1970s have treated small fiber shaped particles of both forms the same  The U S  Environmental Protection Agency  for example   makes no distinction between fibers and  comparable  cleavage fragments   agency officials wrote in a response to an RJ Lee report on an unrelated matter in 2006  the year before the firm hired Sanchez  The Occupational Safety and Health Administration  OSHA   though it dropped the non fibrous forms of the minerals from its definition of asbestos in 1992  nonetheless recommends that fiber shaped fragments indistinguishable from asbestos be counted in its exposure tests  And as the product safety director for J J s talc supplier acknowledged in a 2008 email to colleagues    I f a deposit contains  non asbestiform  tremolite  there is also asbestiform tremolite naturally present as well    THE LUNGS OF BABIES  In 1964  J J s Windsor Minerals Inc subsidiary bought a cluster of talc mines in Vermont  with names like Argonaut  Rainbow  Frostbite and Black Bear  By 1966  it was blasting and bulldozing white rock out of the Green Mountain state  J J used the milled powder in its cosmetic powders and sold a less refined grade to roofing  flooring and tire companies for use in manufacturing  Ten years after tremolite turned up in the Italian talc  it showed up in Vermont talc  too  In 1967  J J found traces of tremolite and another mineral that can occur as asbestos  according to a table attached to a Nov  1  1967  memo by William Ashton  the executive in charge of J J s talc supply for decades  J J continued to search for sources of clean talc  But in an April 9  1969  memo to a company doctor  Ashton said it was  normal  to find tremolite in many U S  talc deposits  He suggested J J rethink its approach   Historically  in our Company  Tremolite has been bad   Ashton wrote   How bad is Tremolite medically  and how much of it can safely be in a talc base we might develop   Since pulmonary disease  including cancer  appeared to be on the rise   it would seem to be prudent to limit any possible content of Tremolite   to an absolute minimum   came the reply from another physician executive days later  The doctor told Ashton that J J was receiving safety questions from pediatricians  Even Robert Wood Johnson II  the founder s son and then retired CEO  had expressed  concern over the possibility of the adverse effects on the lungs of babies or mothers   he wrote   We have replied   the doctor wrote  that  we would not regard the usage of our powders as presenting any hazard   Such assurances would be impossible  he added   if we do include Tremolite in more than unavoidable trace amounts   The memo is the earliest J J document reviewed by Reuters that discusses tremolite as more than a scratchy nuisance  The doctor urged Ashton to consult with company lawyers because  it is not inconceivable that we could become involved in litigation   NEVER  100  CLEAN  By the early 1970s  asbestos was widely recognized as the primary cause of mesothelioma among workers involved in producing it and in industries that used it in their products  Regulation was in the air  In 1972  President Richard Nixon s newly created OSHA issued its first rule  setting limits on workplace exposure to asbestos dust  By then  a team at Mount Sinai Medical Center led by pre eminent asbestos researcher Irving Selikoff had started looking at talcum powders as a possible solution to a puzzle  Why were tests of lung tissue taken post mortem from New Yorkers who never worked with asbestos finding signs of the mineral  Since talc deposits are often laced with asbestos  the scientists reasoned  perhaps talcum powders played a role  They shared their preliminary findings with New York City s environmental protection chief  Jerome Kretchmer  On June 29  1971  Kretchmer informed the Nixon administration and called a press conference to announce that two unidentified brands of cosmetic talc appeared to contain asbestos  The FDA opened an inquiry  J J issued a statement   Our fifty years of research knowledge in this area indicates that there is no asbestos contained in the powder manufactured by Johnson   Johnson   Later that year  another Mount Sinai researcher  mineralogist Arthur Langer  told J J in a letter that the team had found a  relatively small  amount of chrysotile asbestos in Baby Powder  Langer  Selikoff and Kretchmer ended up on a J J list of  antagonistic personalities  in a Nov  29  1972  memo  which described Selikoff as the leader of an  attack on talc    I suppose I was antagonistic   Langer told Reuters  Even so  in a subsequent test of J J powders in 1976  he didn t find asbestos   a result that Mount Sinai announced  Langer said he told J J lawyers who visited him last year that he stood by all of his findings  J J has not called him as a witness  Selikoff died in 1992  Kretchmer said he recently read that a jury had concluded that Baby Powder was contaminated with asbestos   I said to myself   How come it took so long     he said  In July 1971  meanwhile  J J sent a delegation of scientists to Washington to talk to the FDA officials looking into asbestos in talcum powders  According to an FDA account of the meeting  J J shared  evidence that their talc contains less than 1   if any  asbestos   Later that month  Wilson Nashed  one of the J J scientists who visited the FDA  said in a memo to the company s public relations department that J J s talc contained trace amounts of  fibrous minerals  tremolite actinolite     INCONTROVERTIBLE ASBESTOS  As the FDA continued to investigate asbestos in talc  J J sent powder samples to be tested at private and university labs  Though a private lab in Chicago found trace amounts of tremolite  it declared the amount  insignificant  and the samples  substantially free of asbestiform material   J J reported that finding to the FDA under a cover letter that said the  results clearly show  the samples tested  contain no chrysotile asbestos   J J s lawyer told Reuters the tremolite found in the samples was not asbestos  But J J s FDA submission left out University of Minnesota professor Thomas E  Hutchinson s finding of chrysotile in a Shower to Shower sample    incontrovertible asbestos   as he described it in a lab note  The FDA s own examinations found no asbestos in J J powder samples in the 1f970s  Those tests  however  did not use the most sensitive detection methods  An early test  for example  was incapable of detecting chrysotile fibers  as an FDA official recognized in a J J account of an Aug  11  1972  meeting with the agency   I understand that some samples will be passed even though they contain such fibers  but we are willing to live with it   By 1973  Tom Shelley  director of J J s Central Research Laboratories in New Jersey  was looking into acquiring patents on a process that a British mineralogist and J J consultant was developing to separate talc from tremolite   It is quite possible that eventually tremolite will be prohibited in all talc   Shelley wrote on Feb  20  1973  to a British colleague  Therefore  he added  the  process may well be valuable property to us   At the end of March  Shelley recognized the sensitivity of the plan in a memo sent to a J J lawyer in New Jersey   We will want to carefully consider the   patents re asbestos in talc  It s quite possible that we may wish to keep the whole thing confidential rather than allow it to be published in patent form and thus let the whole world know   J J did not obtain the patents  While Shelley was looking into the patents  J J research director DeWitt Petterson visited the company s Vermont mining operation   Occasionally  sub trace quantities of tremolite or actinolite are identifiable   he wrote in an April 1973 report on the visit   And these might be classified as asbestos fiber   J J should  protect our powder franchise  by eliminating as many tiny fibers that can be inhaled in airborne talc dust as possible  Petterson wrote  He warned  however  that  no final product will ever be made which will be totally free from respirable particles   Introducing a cornstarch version of Baby Powder  he noted   is obviously another answer   Bicks told Reuters that J J believes that the tremolite and actinolite Petterson cited were not asbestos  Cornstarch came up again in a March 5  1974  report in which Ashton  the J J talc supply chief  recommended that the company research that alternative  for defensive reasons  because  the thrust against talc has centered primarily on biological problems alleged to result from the inhalation of talc and related mineral particles    WE MAY HAVE PROBLEMS  A few months after Petterson s recognition that talc purity was a pipe dream  the FDA proposed a rule that talc used in drugs contain no more than 0 1 percent asbestos  While the agency s cosmetics division was considering similar action on talcum powders  it asked companies to suggest testing methods  At the time  J J s Baby Powder franchise was consuming 20 000 tons of Vermont talc a year  J J pressed the FDA to approve an X ray scanning technique that a company scientist said in an April 1973 memo allowed for  an automatic 1  tolerance for asbestos   That would mean talc with up to 10 times the FDA s proposed limit for asbestos in drugs could pass muster  The same scientist confided in an Oct  23  1973  note to a colleague that  depending on what test the FDA adopted for detecting asbestos in cosmetic talc   we may have problems   The best way to detect asbestos in talc was to concentrate the sample and then examine it through microscopes  the Colorado School of Mines Research Institute told J J in a Dec  27  1973  report  In a memo  a J J lab supervisor said the concentration technique  which the company s own researchers had earlier used to identify a  tremolite type  asbestos in Vermont talc  had one limitation   It may be too sensitive   In his email to Reuters  J J s lawyer said the lab supervisor s concern was that the test would result in  false positives   showing asbestos where there was none  J J also launched research to find out how much powder a baby was exposed to during a diapering and how much asbestos could be in that powder and remain within OSHA s new workplace exposure limits  Its researchers had strapped an air sampling device to a doll to take measurements while it was powdered  according to J J memos and the minutes of a Feb  19  1974  meeting of the Cosmetic Toiletry and Fragrance Association  CTFA   an industry group   It was calculated that even if talc were pure asbestos the levels of exposure of a baby during a normal powdering are far below the accepted tolerance limits   the minutes state  In a Sept  6  1974  letter  J J told the FDA that since  a substantial safety factor can be expected  with talc that contains 1 percent asbestos   methods capable of determining less than 1  asbestos in talc are not necessary to assure the safety of cosmetic talc   Not everyone at the FDA thought that basing a detection method on such a calculation was a good idea  One official called it  foolish   adding  according to a J J account of a February 1975 meeting   No mother was going to powder her baby with 1  of a known carcinogen irregardless of the large safety factor   PUSH FOR SELF REGULATION Having failed to persuade the FDA that up to 1 percent asbestos contamination was tolerable  J J began promoting self policing as an alternative to regulation  The centerpiece of this approach was a March 15  1976  package of letters from J J and other manufacturers that the CTFA gave to the agency to show that they had succeeded at eliminating asbestos from cosmetic talc   The attached letters demonstrate responsibility of industry in monitoring its talcs   the cover letter said   We are certain that the summary will give you assurance as to the freedom from contamination by asbestos for materials of cosmetic talc products   In its letter  J J said samples of talc produced between December 1972 and October 1973 were tested for asbestos  and none was detected  in any sample   J J didn t tell the FDA about a 1974 test by a professor at Dartmouth College in New Hampshire that turned up asbestos in talc from J J    fiberform  actinolite  as he put it  Nor did the company tell the FDA about a 1975 report from its longtime lab that found particles identified as  asbestos fibers  in five of 17 samples of talc from the chief source mine for Baby Powder   Some of them seem rather high   the private lab wrote in its cover letter  Bicks  the J J lawyer  said the contract lab s results were irrelevant because the talc was intended for industrial use  He said the company now believes that the actinolite the Dartmouth professor found  was not asbestiform   based on its interpretation of a photo in the original lab report  Just two months after the Dartmouth professor reported his findings  Windsor Minerals Research and Development Manager Vernon Zeitz wrote that chrysotile   fibrous anthophyllite  and other types of asbestos had been  found in association with the Hammondsville ore body    the Vermont deposit that supplied Baby Powder talc for more than two decades  Zeitz s May 1974 report on efforts to minimize asbestos in Vermont talc  strongly urged  the adoption of ways to protect  against what are currently considered to be materials presenting a severe health hazard and are potentially present in all talc ores in use at this time   Bicks said that Zeitz was not reporting on actual test results  The following year  Zeitz reported that based on weekly tests of talc samples over six months   it can be stated with a greater than 99 9  certainty that the ores and materials produced from the ores at all Windsor Mineral locations are free from asbestos or asbestiform minerals    MISREPRESENTATION BY OMISSION  J J s selective use of test results figured in a New Jersey judge s decision this year to affirm the first verdict against the company in a case claiming asbestos in J J products caused cancer   Providing the FDA favorable results showing no asbestos and withholding or failing to provide unfavorable results  which show asbestos  is a form of a misrepresentation by omission   Middlesex County Superior Court Judge Ana Viscomi said in her June ruling   J J respectfully disagrees with the Judge s comments   Bicks said   J J did not withhold any relevant testing from FDA   The FDA declined to comment on the ruling  Lacking consensus on testing methods  the FDA postponed action to limit asbestos in talc  Years later  it did set limits on asbestos in talc used in drugs  It has never limited asbestos in cosmetic talc or established a preferred method for detecting it  Instead  in 1976  a CTFA committee chaired by a J J executive drafted voluntary guidelines  establishing a form of X ray scanning with a 0 5 percent detection limit as the primary test  the method J J preferred  The method is not designed to detect the most commonly used type of asbestos  chrysotile  at all  The group said the more sensitive electron microscopy was impractical  The CTFA  which now does business as the Personal Care Products Council  declined to comment  X ray scanning is the primary method J J has used for decades  The company also periodically requires the more sensitive checks with electron microscopes  J J s lawyer said the company s tests exceed the trade association standard  and they do  He also said that today  J J s X ray scans can detect suspect minerals at levels as low as 0 1 percent of a sample  But the company never adopted the Colorado lab s 1973 recommendation that samples be concentrated before examination under a microscope  And the talc samples that were subjected to the most sensitive electron microscopy test were a tiny fraction of what was sold  For those and other reasons  J J couldn t guarantee its Baby Powder was asbestos free when plaintiffs used it  according to experts  including some who testified for plaintiffs  As early as 1976  Ashton  J J s longtime talc overseer  recognized as much in a memo to colleagues  He wrote that talc in general  if subjected to the most sensitive testing method  using concentrated samples   will be hard pressed in supporting purity claims   He described this sort of testing as both  sophisticated  and  disturbing    FREE OF HAZARD  By 1977  J J appeared to have tamped down concerns about the safety of talc  An internal August report on J J s  Defense of Talc Safety  campaign noted that independent authorities had deemed cosmetic talc products to be  free of hazard   It attributed  this growing opinion  to the dissemination to scientific and medical communities in the United States and Britain of  favorable data from the various J J sponsored studies   In 1984  FDA cosmetics chief and former J J employee Heinz Eiermann reiterated that view  He told the New York Times that the agency s investigation a decade earlier had prompted the industry to ensure that talc was asbestos free   So in subsequent analyses   he told the paper   we really could not identify asbestos or only on very rare occasions   Two years later  the FDA rejected a citizen request that cosmetic talc carry an asbestos warning label  saying that even if there were trace contamination  the use of talc powder during two years of normal diapering would not increase the risk of cancer  In 1980  J J began offering a cornstarch version of Baby Powder   to expand its customer base to people who prefer cornstarch  the company says  The persistence of the industry s view that cosmetic talc is asbestos free is why no studies have been conducted on the incidence of mesothelioma among users of the products  It s also partly why regulations that protect people in mines  mills  factories and schools from asbestos laden talc don t apply to babies and others exposed to cosmetic talc   even though Baby Powder talc has at times come from the same mines as talc sold for industrial use  J J says cosmetic talc is more thoroughly processed and thus purer than industrial talc  Until recently  the American Cancer Society  ACS  accepted the industry s position  saying on its website   All talcum products used in homes have been asbestos free since the 1970s   After receiving inquiries from Reuters  the ACS in early December revised its website to remove the assurance that cosmetic talcs are free of asbestos  Now  it says  quoting the industry s standards  that all cosmetic talc products in the United States  should be free from detectable amounts of asbestos   The revised ACS web page also notes that the World Health Organization s International Agency for Research on Cancer classifies talc that contains asbestos as  carcinogenic to humans   Despite the success of J J s efforts to promote the safety of its talc  the company s test lab found asbestos fibers in samples taken from the Vermont operation in 1984  1985 and 1986  Bicks said   The samples that we know of during this time period that contained a fiber or two of asbestos were not cosmetic talc samples   Then  in 1992  three years after J J sold its Vermont mines  the new owner  Cyprus Minerals  said in an internal report on  important environmental issues  in its talc reserves that there was  past tremolite  in the Hammondsville deposit  Hammondsville was the primary source of Baby Powder talc from 1966 until its shutdown in 1990  Bicks rejected the Cyprus report as hearsay  saying there is no original documentation to confirm it  Hammondsville mine records  according to a 1993 J J memo   were destroyed by the mine management staff just prior to the J J divestiture   Bicks said the destroyed documents did not include talc testing records  In 2002 and 2003  Vermont mine operators found chrysotile asbestos fibers on several occasions in talc produced for Baby Powder sold in Canada  In each case  a single fiber was recorded   a finding deemed  BDL    below detection limit  Bicks described the finding as  background asbestos  that did not come from any talc source  In 2009  the FDA  responding to growing public concern about talc  commissioned tests on 34 samples  including a bottle of J J Baby Powder and samples of Imerys talc from China  No asbestos was detected  FDA Commissioner Scott Gottlieb said the agency continues to receive a lot of questions about talc cosmetics   I recognize the concern   he told Reuters  He said the agency s policing of cosmetics in general   fewer than 30 people regulating a  vast  industry   was  a place where we think we can be doing more   Gottlieb said the FDA planned to host a public forum in early 2019 to  look at how we would develop standards for evaluating any potential risk   An agency spokeswoman said that would include examining  scientific test methods for assessment of asbestos    FISHING EXPEDITION  Before law school  Herschel Hobson worked at a rubber plant  There  his job included ensuring that asbestos in talc the workers were exposed to didn t exceed OSHA limits  That s why he zeroed in on Johnson s Baby Powder after he took on Darlene Coker as a client in 1997  The lawsuit Coker and her husband  Roy  filed that year against J J in Jefferson County District Court in Beaumont  Texas  is the earliest Reuters found alleging Baby Powder caused cancer  Hobson asked J J for any research it had into the health of its mine workers  talc production records from the mid 1940s through the 1980s  depositions from managers of three labs that tested talc for J J and any documents related to testing for fibrous or asbestiform materials  J J objected  Hobson s  fishing expedition  would not turn up any relevant evidence  it asserted in a May 6  1998  motion  In fact  among the thousands of documents Hobson s request could have turned up was a letter J J lawyers had received only weeks earlier from a Rutgers University geologist confirming that she had found asbestos in the company s Baby Powder  identified in her 1991 published study as tremolite  asbestos  needles  Hobson agreed to postpone his discovery demands until he got the pathology report on Coker s lung tissue  Before it came in  J J asked the judge to dismiss the case  arguing that Coker had  no evidence  Baby Powder caused mesothelioma  Ten days later  the pathology report landed  Coker s lung tissue contained tens of thousands of  long fibers  of four different types of asbestos  The findings were  consistent with exposure to talc containing chrysotile and tremolite contamination   the report concluded   The asbestos fibers found raise a new issue of fact   Hobson told the judge in a request for more time to file an opposition to J J s dismissal motion  The judge gave him more time but turned down his request to resume discovery  Without evidence from J J and no hope of ever getting any  Hobson advised Coker to drop the suit  Hobson is still practicing law in Nederland  Texas  When Reuters told him about the evidence that had emerged in recent litigation  he said   They knew what the problems were  and they hid it   J J s records would have made a  100  difference  in Coker s case  Had the information about asbestos in J J s talc come out earlier  he said   maybe there would have been 20 years less exposure  for other people  Bicks  the J J lawyer  said Coker dropped her case because  the discovery established that J J talc had nothing to do with Plaintiff s disease  and that asbestos exposure from a commercial or occupational setting was the likely cause   Coker never learned why she had mesothelioma  She did beat the odds  though  Most patients die within a year of diagnosis  Coker held on long enough to see her two grandchildren  She died in 2009  12 years after her diagnosis  at age 63  Coker s daughter Crystal Deckard was 5 when her sister  Cady  was born in 1971  Deckard remembers seeing the white bottle of Johnson s Baby Powder on the changing table where her mother diapered her new sister   When Mom was given this death sentence  she was the same age as I am right now   Deckard said   I have it in the back of my mind all the time  Could it happen to us  Me  My sister     Edited by Janet Roberts and John Blanton ,2018-12-14,Reuters,https://www.investing.com/news/stock-market-news/special-report-jj-knew-for-decades-that-asbestos-lurked-in-its-baby-powder-1721947,1721947
198044,419560,JNJ,J J shares nosedive on report it knew of asbestos in Baby Powder,news,"By Saumya Joseph  Reuters    Shares of Johnson   Johnson  N JNJ  fell 10 percent on Friday and were on track to post their biggest percentage drop in more than 16 years  after Reuters reported that the pharma major knew for decades that cancer causing asbestos lurked in its Baby Powder  The decline in shares erased about  40 billion from the company s market capitalization  with investors worrying about the impact of the report as it faces thousands of talc related lawsuits  The stock was the biggest drag on the broader Dow Jones Industrial Average  DJI  and S P 500  SPX  indexes and was among the most traded on U S  exchanges  About 28 million shares exchanged hands by 1830 GMT  more than three times its 25 day moving average  J J was found to have known about the presence of small amounts of asbestos in its products from as early as 1971  a Reuters examination of company memos  internal reports and other confidential documents showed  The report also said the company had commissioned and paid for studies conducted on its Baby Powder franchise and hired a ghostwriter to redraft the article that presented the findings in a journal  In response to the report  the company said  any suggestion that Johnson   Johnson knew or hid information about the safety of talc is false    This is all a calculated attempt to distract from the fact that thousands of independent tests prove our talc does not contain asbestos or cause cancer   Ernie Knewitz  J J s vice president of global media relations  wrote in an emailed response to the report  The company also said Baby Powder was asbestos free and added it would continue to defend the safety of its product  At least two Wall Street analysts said the stock appeared to be oversold on the news   In our opinion litigation overhangs are real  and we do not minimize the situation  but the stock pull back does seem over done to us   BMO Capital Markets analyst Joanne Wuensch said  J J  in 1976  had assured the U S  Food and Drug Administration that no asbestos was  detected in any sample  of talc produced between December 1972 and October 1973 when at least three tests by three different labs from 1972 to 1975 had found asbestos in its talc  The company has been battling more than 10 000 cases claiming its Baby Powder and Shower to Shower products cause ovarian cancer  The products have also been linked with mesothelioma  a rare and deadly form of cancer that affects the delicate tissue that lines body cavities    We believe it is highly unlikely the company s exposure to this talc issue will even come close to the  40 billion in lost market cap today   J P  Morgan analysts said  They added that talc was not an issue that would resolve quickly for J J and expect shares to trade at a lower multiple pending further clarity on the company s exposure to the issue  While J J has dominated the talc powder market for more than 100 years  the products contributed to a mere 0 5 percent of its revenue of  76 5 billion last year  Talc cases make up fewer than 10 percent of all personal injury lawsuits pending against the company  However  Baby Powder is considered essential to J J s image as a caring company   a  sacred cow   as one 2003 internal email put it  CFRA Research analyst Colin Sarcola said   We see today s news potentially impacting sales of everything from baby shampoo to prosthetic hips    Given these elevated risks  we no longer feel JNJ shares are attractive at recent prices   Sarcola added  
Shares were last down 8 percent at  135 85  also pulling down the broader S P 500 healthcare index  SPXHC  ",2018-12-14,Reuters,https://www.investing.com/news/stock-market-news/jj-shares-drop-on-report-company-knew-of-asbestos-in-baby-powder-1722043,1722043
198045,419561,JNJ,Why Is Geron  GERN  Up 21 7  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Geron  GERN   Shares have added about 21 7  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Geron due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Geron s Q2 Earnings   Sales Miss EstimatesGeron incurred a loss of 8 cents per share in second quarter 2019  wider than the Zacks Consensus Estimate of a loss of 6 cents  In the year ago quarter  the company had incurred a loss of 4 cents per share Quarterly revenues in the quarter came in at  0 1 million  which missed the Zacks Consensus Estimate of  0 2 million  Notably  the top line comprised royalty and license fee revenues received under various non imetelstat license agreements  In the year ago quarter  revenues totaled  0 21 million  Revenues decreased as the number of active license agreements declined due to expiry of patents of Geron s underlying technology Research and development  R D  expense were up 215  year over year to  10 1 million  Transition costs  including resuming sponsorship of imetelstat clinical studies from J J  NYSE JNJ   costs related to start up of phase III portion of the IMerge study  evaluating imetelstat in myelodysplastic syndromes  and expansion of development team  resulted in the significant increase in R D expenses General and administrative  G A  expenses rose 23 8  to  5 2 million  reflecting legal costs related to patent litigations and recruitment expenses for additional headcounts Geron ended the second quarter with  162 3 million in cash and investments compared with  170 million at the end of the first quarter 2019 GuidanceGeron anticipates its full year operating expense to be in the range of  80  85 million  This includes one time cost of  20  25 million related to activities for transition of imetelstat from Janssen to Geron and purchase of material for the phase III portion of IMerge study  Geron expects to end 2019 with approximately  100 million in cash and investments 
How Have Estimates Been Moving Since Then 
It turns out  estimates revision have trended downward during the past month  The consensus estimate has shifted  100  due to these changes 
VGM Scores
At this time  Geron has a poor Growth Score of F  however its Momentum Score is doing a bit better with a D  Charting a somewhat similar path  the stock was allocated a grade of F on the value side  putting it in the fifth quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  It s no surprise Geron has a Zacks Rank  4  Sell   We expect a below average return from the stock in the next few months ",2019-08-30,Zacks Investment Research,https://www.investing.com/analysis/why-is-geron-gern-up-217-since-last-earnings-report-200460540,200460540
198046,419562,JNJ,Here s Why Glaxo  GSK  Steadily Stays Ahead Of Its Industry ,opinion,So far this year  GlaxoSmithKline plc s   NYSE GSK   shares have outperformed the   The stock has risen 8 8  against a 1 4  decrease for its industry   Meanwhile  estimates for 2019 have inched up 1 4  in the past 30 days Its successful product launches  increasing focus in the oncology area  and positive pipeline and regulatory updates have all contributed to this upside New Products  Impressive Performance In 2017  Glaxo received approvals for its three key new drugs  namely Shingrix vaccine for shingles  which enjoys preferential recommendation from ACIP  Trelegy Ellipta  which provides three medicines in a single inhaler to treat COPD and Juluca  dolutegravir and rilpivirine   the first two drug regimen  once daily  single pill for HIV  All three products did well in 2018 and during the first half of 2019  particularly Shingrix Juluca has been developed by Glaxo HIV focused company ViiV Healthcare in partnership with Johnson   Johnson   NYSE JNJ   In fact  these new products coupled with the restructuring in the Consumer Health unit strengthened Glaxo s competitive position In June 2018  Glaxo bought Novartis    NYSE NVS   36 5  stake in their Consumer Healthcare joint venture  JV  for  13 billion   9 2 billion   In December 2018  Glaxo and Pfizer   NYSE PFE   announced an agreement  stating that both will merge their consumer healthcare units into a new joint venture  JV   Glaxo owns a controlling stake of 68  in the JV   The transaction closed on Aug 1  2019 Pipeline   Regulatory Successes Glaxo has made significant progress with its late stage pipeline  The company has had major positive data read outs on multiple new medicines in HIV  oncology  immuno inflammation and respiratory in 2019 so far with many other scheduled for the second half HIV is expected to be an important driver for Glaxo s Pharma business going forward  It had some positive developments in its HIV pipeline  In April this year  Glaxo gained an FDA approval for Dovato  a single tablet regimen of Tivicay  dolutegravir    lamivudine for treatment na ve HIV patients  Meanwhile  the same was approved in the EU in July  The new HIV medicine is off to a strong start Glaxo also announced positive data from both the FLAIR and ATLAS studies this year  evaluating cabotegravir plus rilpivirine in a long acting  once monthly HIV formulation  Glaxo believes that this long acting injectable HIV therapy will provide a highly differentiated treatment option for patients seeking a long lasting therapy for HIV  thereby freeing them of the burden of daily oral therapy  The cabotegravir plus rilpivirine long acting regimen was filed with the FDA and the European Commission with the former expected to convey its decision on the same come December Increasing Progress in OncologyGlaxo has made a significant progress in its oncology pipeline recently and now has 16 assets in development  double from 8 as of July 2018  This has been achieved through advancement of internal programs as well as targeted business development including the January 2019 acquisition of Tesaro and the February global alliance with Merck KGaA  to co develop bintrafusp alpha M7824  a promising new oncology medicine  Meanwhile  Glaxo now has a number of molecules with diverse mechanisms of action  offering an opportunity for many innovative cancer combinations  The company expects to launch three new cancer medicines in the next 18 months  Zejula  the ovarian cancer drug Glaxo acquired from the Tesaro buyout  was granted a priority review by the FDA in June for an expanded use in treatment of the late stage ovarian cancer  The regulatory body is expected to give its decision on Oct 24  Meanwhile  another regulatory application seeking a nod for ovarian cancer in first line maintenance setting is expected to be filed by 2019 end  The FDA approval for these expanded indications will make Zejula eligible to treat a larger patient population ConclusionGlaxo has its share of challenges in the form of stiff competition  genericization and pricing pressure on key drugs in the Pharma segment  Particularly  pricing pressure and competitive dynamics are hampering sales of Glaxo s respiratory products  Importantly  a generic version of its top selling drug Advair has been launched  which is significantly eroding the drug s sales  Also  competitive pressure on HIV drugs is on the rise  Nonetheless  higher sales of new products  pipeline success and accretive deals are expected to keep the stock afloat through the rest of the year Glaxo currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2019-09-02,Zacks Investment Research,https://www.investing.com/analysis/heres-why-glaxo-gsk-steadily-stays-ahead-of-its-industry-200460768,200460768
198047,419563,JNJ,Service Corporation Up 12  In A Year  Will Momentum Last ,opinion,Service Corporation International   NYSE SCI   is well positioned for growth  courtesy of its strong efforts and favorable demographic trends  These have been driving this funeral services company even amid hurdles like escalated costs and rising demand for cremations  Markedly  shares of the company have gained almost 12  in the past year against the  s decline of 10 2  Let s delve deeper and see if this Zacks Rank  3  Hold  company can sustain this solid momentum Factors Favoring Service CorporationService Corporation s growth efforts are mainly aimed at improving revenues  utilizing scale and deploying capital efficiently  Well  the company focuses on addressing the changing consumer needs and utilizing its robust scale to drive preneed sales  In fact  its second quarter 2019 comparable cemetery revenues inched up 0 7  year over year  mainly driven by growth in recognized preneed sales Further  Service Corporation is making technological advancements to better present its products and services to consumers  These factors along with the demographic landscape are tailwinds for the company s revenues  Markedly  Service Corporation is likely to continue gaining from the aging Baby Boomer population  which is fueling its preneed cemetery sales programs and likely to drive preneed and at need funeral results  Going ahead  the company plans to allocate about  195 million toward capital enhancements at existing facilities and cemetery development This apart  Service Corporation is committed toward pursuing buyouts for both its segments and building new funeral homes to generate greater returns  We note that buyouts are an integral part of the company s capital investment ventures  The company deployed  14 million during the second quarter toward acquisitions of real estate  It also invested an additional  10 million in building and expansion of funeral homes Hurdles Likely to be OffsetService Corporation has been witnessing a rise in the number of cremations as another option to the traditional funeral service  Well  the company s average revenues from cremations with service are usually lower compared to that for traditional burials  Hence  the persistence of such a trend is a threat to the company s overall performance Also  Service Corporation has been witnessing escalated interest expenses for a while now  In the second quarter of 2019  interest costs rose  2 8 million to  47 3 million due to higher interest rates on its floating rate debt  This also drove interest costs by  3 8 million in the first quarter to  47 4 million  We believe that persistent high costs may weigh on the company s bottom line in the near term Nonetheless  the aforementioned drivers are likely to help the company tide over these hurdles and keep its impressive show on Looking for Consumer Staples Stocks  Check These Carriage Services   NYSE CSV    with a Zacks Rank  2  Buy   has a long term EPS growth rate of 15   You can see MEDIFAST   NYSE MED    also with a Zacks Rank  2  has delivered positive earnings surprise in the trailing three quarters J J  NYSE JNJ  Snack Foods   NASDAQ JJSF    with a Zacks Rank  2  has an impressive earnings surprise record Legalizing THIS Could Be Even Bigger than MarijuanaAmericans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge ,2019-09-03,Zacks Investment Research,https://www.investing.com/analysis/service-corporation-up-12-in-a-year-will-momentum-last-200460986,200460986
198052,419568,JNJ,Janssen affiliate teams up with argenx to develop cancer candidate cusatuzumab,news,Cilag GmbH  an affiliate of Johnson   Johnson  JNJ  0 8   unit Janssen Pharmaceutical  inks a global collaboration and license agreement with argenx BVBA and argenx SE  ARGX  12 3   to develop and commercialize cusatuzumab  an anti CD70 SIMPLE Antibody  for a range of cancers  A Phase 1 2 trial is underway in patients with acute myeloid leukemia  AML  and high risk myelodysplastic syndromes  MDS   Under the terms of the deal  Janssen will pay  300M upfront  milestones and double digit royalties on net ex U S  sales  The companies will equally share costs and profits losses in the U S   Janssen will be responsible for global commercialization while argenx has the option to participate in commercialization in the U S  The transaction should close next quarter  Now read ,2018-12-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/janssen-affiliate-teams-up-with-argenx-to-develop-cancer-candidate-cusatuzumab-1708604,1708604
198053,419569,JNJ,J J unit to pay  360 million to U S  to resolve charity kickback probe,news,"By Nate Raymond BOSTON  Reuters    A unit of Johnson   Johnson  NYSE JNJ  will pay the U S  government  360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out of pocket drug costs  the Department of Justice said on Thursday  The settlement with Actelion Pharmaceuticals US Inc  which became a subsidiary of J J following a 2017 acquisition  was the largest so far to result from an industry wide probe into drugmakers  support of patient assistance charities  The government alleged Actelion from 2014 to 2015 used a charity as a conduit to improperly pay the co pay obligations of thousands of Medicare patients using its pulmonary artery hypertension treatments Tracleer  Ventavis  Veletri and Opsumit  That charity  Caring Voice Coalition  has stopped providing aid after the government in 2017 revoked its approval to do so because of concerns drugmakers had improper influence over it  Actelion did not admit wrongdoing  Caroline Pavis  a company spokeswoman  said in a statement the conduct pre dated New Brunswick  New Jersey based J J s acquisition of Actelion and that it was committed to following the law  Caring Voice Coalition had no immediate comment  Drug companies are prohibited from subsidizing co payments for patients enrolled in the Medicare government healthcare program for the elderly  But companies may donate to non profits providing co pay assistance as long as they are independent   Amid increased attention on rising drug prices in the United States  there has been concern that donations from drugmakers to patient assistance groups may be contributing to price inflation  A probe led by the U S  Attorney s Office for the District of Massachusetts has led to allegations that several drugmakers used these charitable foundations as a means to pay Medicare patients  co pays in violation of the Anti Kickback Statute   In Actelion s case  the government alleged it routinely obtained data from Caring Voice Coalition regarding the extent that patients it helped used its drugs  The company then used that information to budget for future payments to the charity  Caring Voice Coalition was at the center of an earlier   210 million settlement by United Therapeutics Corp in December 2017  which resolved claims the company improperly used the charity to cover co payments  Several other drugmakers have  since 2015  disclosed receiving subpoenas as a result of the investigation   Pfizer  Inc  NYSE PFE  in May resolved similar allegations involving a different charity for nearly  23 85 million  
Jazz Pharmaceuticals Plc and Lundbeck earlier this year disclosed they had reached agreements to resolve similar claims for  57 million and  52 6 million  respectively ",2018-12-06,Reuters,https://www.investing.com/news/stock-market-news/jj-unit-to-pay-360-million-to-us-to-resolve-charity-kickback-probe-1713486,1713486
198054,419570,JNJ,Geron  GERN  Stock Rises 40  In 2019 So Far  Here s Why,opinion,"Geron Corporation   NASDAQ GERN   shares have risen 40  so far this year against the  s decrease of 3   riding on the progress of its sole pipeline candidate  imetelstat  Imetelstat is being evaluated as a treatment for hematologic myeloid malignancies like myelofibrosis   MF   in a phase II IMbark study and myelodysplastic syndromes   MDS   in a phase II III IMerge study Notably  both the studies are being conducted by Geron  following the termination of the collaboration related to imetelstat development by Johnson   Johnson   NYSE JNJ   last year  The candidate enjoys orphan drug designation for both the indications Pipeline ProgressGeron is progressing well with the development of imetelstat  In May  the company completed the transfer of the sponsorship of the investigational new drug  related to imetelstat from Janssen  Geron now holds the full responsibility for the development of imetelstat Enrollment has been stopped in the phase II portion of IMerge study and the company anticipates top line data from it by the end of 2019  Preliminary data presented last year had shown that the benefit risk profile of imetelstat in treated patients  including the expansion arm  supports continued development in lower risk MDS indication  Based on this data  the company initiated the phase III portion of the IMerge study earlier this month Geron has also added new leaders to its development team with vast experience in oncology and drug development to support the progress of imetelstat Meanwhile  the company postponed the date of the end of phase II meeting related to IMbark study to the first quarter of 2020 from the third quarter of this year  The extended period is likely to be used for further analysis of data from the IMbark study  which may support the regulatory application seeking approval of imetelstat in relapsed refractory MF Although the company s operating expense is set to increase due to cost of imetelstat development following the termination of collaboration with J J  Geron has sufficient funds to start the phase III portion of IMerge studies However  dependence on a single pipeline candidate is a concern  Any hiccups in development of imetelstat may hurt Geron s stock significantly  Meanwhile  Acceleron Pharma   NASDAQ XLRN   and its partner Celgene s   NASDAQ CELG   luspatercept  which is being developed for MDS in a phase III study  may give competition to imetelstat Geron Corporation Price
    Zacks RankGeron currently carries a Zacks Rank  4  Sell  You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/geron-gern-stock-rises-40-in-2019-so-far-heres-why-200459927,200459927
198055,419571,JNJ,AbbVie Ends Rova T Program As 3rd Lung Cancer Study Fails,opinion,AbbVie  Inc    NYSE ABBV   announced that it is discontinuing development of its small cell lung cancer  SCLC  candidate rovalpituzumab tesirine or Rova T after failure of the third study  MERU The phase III MERU study was evaluating Rova T as a first line maintenance therapy for advanced SCLC  a difficult to treat lung cancer  compared to placebo  Interim data from the study demonstrated no survival benefit for patients treated with Rova T  The lack of survival benefit led the Independent Data Monitoring Committee  IDMC  to recommend termination of MERU AbbVie s stock has declined 28 2  this year so far compared with a decrease of 1 7  recorded by the    We remind investors that Rova T was added to AbbVie s portfolio  following the  5 8 billion acquisition of Stemcentrx in June 2016 In December 2018  AbbVie stopped enrollment in a pivotal phase III study   TAHOE  evaluating Rova T in second line SCLC on recommendation of IDMC  The study compared efficacy  safety and tolerability of Rova T versus topotecan  The IDMC recommendation to halt the study was based on shorter overall survival in the Rova T arm compared with the topotecan control arm In March 2018  Rova T fell short of expectations in a phase II TRINITY study evaluating it in third line or later SCLC  The failure of TRINITY and the halt on TAHOE had already raised skepticism on Rova T s potential and the success of MERU AbbVie had significant confidence in Rova T s potential when it bought Stemcentrx and believed the candidate had blockbuster potential  AbbVie had in the past guided peak sales for Rova T of  5 billion  The discontinuation of the candidate has now brought into question the viability of the Stemcentrx deal  Rova T was also being evaluated in an early stage eight arm  basket study  in neuroendocrine tumors Oncology is a key therapeutic area for AbbVie and the company believes that it will be its major growth driver over the next 10 years  Key drugs in its oncology portfolio include Imbruvica  currently approved for quite a few indications and marketed in partnership with J J   NYSE JNJ    and Venclyxto Venclexta  approved to treat chronic lymphocytic leukemia  CLL  and acute myeloid leukemia  AML  and marketed in partnership with Roche   OTC RHHBY   Several studies on Imbruvica are ongoing to evaluate the drug alone or in combination in different patient segments  AbbVie is also studying Venclyxto Venclexta to expand the label to address a broader relapsed refractory CLL patient population  expand into earlier lines of therapy  and broaden into other hematologic malignancies like multiple myeloma AML Despite the presence of successful medicines in its portfolio  AbbVie has had its shares of failure in cancer studies other than Rova T In May 2019  a phase III study evaluating depatuxizumab mafodotin  Depatux M  failed to show any survival benefit in patients with newly diagnosed glioblastoma  an aggressive form of brain cancer  As a result  AbbVie stopped enrollment in all ongoing Depatux M studies In March 2019  the FDA placed a partial clinical hold on all studies evaluating Venclexta for the treatment of multiple myeloma  The decision was taken after a higher proportion of deaths were observed in the Venclexta arm compared to the control arm of the ongoing phase III BELLINI study In April 2017  AbbVie announced that two phase III studies evaluating its PARP inhibitor  veliparib in combination with chemotherapy for squamous non small cell lung cancer and triple negative breast cancer failed to meet their primary endpoints  Based on the data  AbbVie discontinued development in these indications AbbVie currently carries a Zacks Rank  3  Hold   You can see A better ranked large cap pharma stock is Merck   Co    NYSE MRK    carrying a Zacks Rank  2  Buy   Shares of Merck have risen 13 5  this year so far  Earnings estimates for 2019 and 2020 have risen 3 2  and 1 3   respectively over the past 60 days Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-29,Zacks Investment Research,https://www.investing.com/analysis/abbvie-ends-rovat-program-as-3rd-lung-cancer-study-fails-200460314,200460314
198060,419576,JNJ,Zoetis Inc Earnings  Revenue beat in Q3,news,"Investing com    Zoetis Inc   NYSE ZTS  reported third quarter earnings  that beat analyst s expectations on Thursday and revenue that topped forecasts 
The firm reported earnings per share of  0 83 on revenue of  1 48B  Analysts polled by Investing com forecast EPS of  0 77 on revenue of  1 45B  That compared to EPS of  0 65 on revenue of  1 27B in the same period a year earlier  The company had reported EPS of  0 77 on revenue of  1 42B in the previous quarter 
For the year  Zoetis Inc shares are up 25 14   outperforming the S P 500 which is up 1 04  year to date 
Zoetis Inc follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 05B 
 Pfizer   NYSE PFE  earnings beat analyst s expectations on Tuesday  with third quarter EPS of  0 78 on revenue of  13 3B  Investing com analysts expected EPS of  0 75 on revenue of  13 55B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-11-01,Investing.com,https://www.investing.com/news/stock-market-news/zoetis-inc-earnings-revenue-beat-in-q3-1669639,1669639
198061,419577,JNJ,AbbVie Earnings  Revenue beat in Q3,news,"Investing com   AbbVie  NYSE ABBV  reported third quarter earnings  that beat analyst s expectations on Friday and revenue that topped forecasts 
The firm reported earnings per share of  2 14 on revenue of  8 24B  Analysts polled by Investing com expected EPS of  2 01 on revenue of  8 23B  That compared to EPS of  1 41 on revenue of  7 00B in the same period a year earlier  The company had reported EPS of  2 on revenue of  8 26B in the previous quarter 
For the year  AbbVie shares are down 17 06   under performing the S P 500 which is up 2 11  year to date 
AbbVie follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 05B 
 Pfizer   NYSE PFE  earnings beat analyst s expectations on Tuesday  with third quarter EPS of  0 78 on revenue of  13 3B  Investing com analysts expected EPS of  0 75 on revenue of  13 55B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-11-02,Investing.com,https://www.investing.com/news/stock-market-news/abbvie-earnings-revenue-beat-in-q3-1671747,1671747
198062,419578,JNJ,AbbVie lifts profit target after cancer drug powers third quarter beat,news," Reuters     AbbVie Inc   N ABBV  beat Wall Street estimates for third quarter profit and raised its earnings forecast for the year on Friday  driven by strong sales of blockbuster cancer medicine Imbruvica  Imbruvica  which the company markets with partner Johnson   Johnson  N JNJ   brought in  972 million in the third quarter  up 41 percent from a year earlier and above the average Wall Street estimate of  885 6 million  The drug has won nine FDA approvals to treat six diseases  most recently receiving the green light to treat a rare form of blood cancer in combination with Roche Holding AG s  S ROG  cancer drug Rituxan  In the quarter ended Sept  30  AbbVie s top selling drug Humira generated revenue of  5 12 billion  ahead of the  5 10 billion forecast by nine analysts polled by IBES Refinitiv  However  revenue from Hepatitis C medicine Mavyret disappointed  with the drug bringing in sales of  839 million  compared with the consensus estimate of  887 million  The U S  market for Hepatitis C has been steadily shrinking as the impact of the disease lessens  The Chicago based drugmaker raised its 2018 adjusted earnings per share forecast to between  7 90 and  7 92 from a prior range of  7 76 to  7 86  Analysts had forecast  7 88 per share  Net earnings jumped 68 4 percent to  2 75 billion  or  1 81 per share  Excluding items  AbbVie earned  2 14 per share  ahead of analysts  estimates of  2 02 per share  
Net revenue rose nearly 18 percent to  8 24 billion in the quarter  beating the average estimate of  8 23 billion helped by sales of its blood cancer treatments ",2018-11-02,Reuters,https://www.investing.com/news/stock-market-news/abbvie-lifts-profit-target-after-cancer-drug-powers-thirdquarter-beat-1671768,1671768
198063,419579,JNJ,Gene study reveals secrets of parasitic worms  possible treatments,news,By Kate Kelland LONDON  Reuters    The largest study to date of the genetic makeup of parasitic worms has found hundreds of new clues about how they invade the human body  evade its immune system and cause disease  The results point to potential de worming treatments to help fight some of the most neglected tropical diseases   including river blindness  schistosomiasis and hookworm disease   which affect around a billion people worldwide   Parasitic worms are some of our oldest foes and have evolved over millions of years to be expert manipulators of the human immune system   said Makedonka Mitreva of Washington University s McDonnell Genome Institute  who co led the work with colleagues from Britain s Wellcome Sanger Institute and Edinburgh University  She said the results of this study would lead to both a deeper knowledge of the biology of parasites and a better understanding of how human immune systems can be harnessed or controlled  Parasitic worm infections can last many years and can cause severe pain  physical disabilities  retarded development in children and social stigma linked to deformity   Current medicines to combat them   including drugs made by Sanofi  PA SASY   GSK and Johnson   Johnson  NYSE JNJ    can be moderately effective and are often donated by drugmakers or sold at cut down prices to those who need them  But the spectrum of drugs to treat worm infections is still limited  To try to improve the potential drug pipeline and to understand how worms invade and take up residence inside humans and other animals  the research team compared the genomes of 81 species of roundworms and flatworms  including 45 that had never previously had their genomes sequenced   The analysis found almost a million new genes that had not been seen before  belonging to thousands of new gene families  and identified many new potential drug targets and drugs    We focussed our search by looking at existing drugs for human illnesses   said the Sanger Institute s Avril Coghlan  who worked on the team  She said this offered a possible fast track route  to pinpointing existing drugs that could be repurposed for deworming   The study s findings were published in the journal Nature Genetics on Monday ,2018-11-05,Reuters,https://www.investing.com/news/general-news/gene-study-reveals-secrets-of-parasitic-worms-possible-treatments-1674284,1674284
198064,419580,JNJ,Jury clears J J of liability in California talc cancer case,news,"By Tina Bellon  Reuters    A California jury on Wednesday cleared Johnson   Johnson  N JNJ  of liability in a case involving a woman who alleged that the company s talc based products  including its baby powder  contain asbestos and caused her cancer  the company said  The jury in Humboldt County Superior Court in Eureka  California rejected claims by Carla Allen who said that her mesothelioma  a tissue cancer closely linked to asbestos exposure  was caused by the company s talc products  including Johnson s Baby Powder  J J denies the allegations  saying decades of scientific testing and regulatory approvals have shown its talc to be safe and asbestos free  Plaintiffs in the litigation allege that J J knew of asbestos fibers in its cosmetic talc and concealed risks associated with the products  The New Brunswick  New Jersey based company faces some 11 700 U S  talc lawsuits  according to an October regulatory filing  More than 9 700 of those cases involve claims over ovarian cancer  recent filings in New Jersey federal court  where most of the cases are consolidated  showed  The remaining plaintiffs allege asbestos in J J s talc caused them to develop mesothelioma  J J in a statement on Wednesday said it was pleased with the jury s decision in the case of Allen    While we deeply sympathize with anyone suffering from any form of cancer  the science and facts show that her disease was not caused by her use of our talcum based products   the company said  The California jury reached its decision following a roughly seven week long jury trial  court records showed  but further details were not immediately available  Lawyers for Allen did not immediately respond to a request for comment  J J has been fighting talc cancer lawsuits for several years  but the litigation shifted in recent months to include allegations of asbestos contamination   Plaintiffs now claim asbestos fibers in the products are causing both ovarian cancer and mesothelioma  J J to date has been cleared of liability in three mesothelioma cases  It has lost two mesothelioma cases in New Jersey and California  with juries awarding a total of  142 million in damages  Both cases are under appeal  Four additional mesothelioma cases resulted in a mistrial because jurors could not reach a verdict or because the plaintiff died  
In July  a Missouri jury hit J J with a massive  4 69 billion verdict in the first trial alleging asbestos contamination has caused ovarian cancer in 22 women  That decision is also under appeal ",2018-11-14,Reuters,https://www.investing.com/news/stock-market-news/jury-clears-jj-of-liability-in-california-talc-cancer-case-1688644,1688644
198065,419581,JNJ,New jury fails to reach verdict in J J South Carolina talc cancer trial,news,"By Tina Bellon  Reuters    A second South Carolina jury on Thursday failed to reach a verdict in the retrial of a case by a woman whose family said her long term use of Johnson   Johnson s  N JNJ  baby powder led to her death from asbestos related cancer  The case of Bertila Boyd Bostic  who died of a rare form of cancer in 2017 at the age of 30  is the latest in a series of trials in the United States that center around allegations that the company s talc based powder contains cancer causing asbestos  In May  a deadlocked jury at the Darlington County Court of Common Pleas in Charleston failed to reach a verdict in the first trial  J J  which denies the allegations  to date has lost two trials and won three in the litigation over whether Johnson s Baby Powder causes mesothelioma  a tissue cancer closely linked to asbestos exposure  Jury trials in another four mesothelioma cases have resulted in mistrials because jurors could not agree on a verdict or because the plaintiff died  J J  faced with some 11 700 U S  talc lawsuits  in a statement on Thursday said it believed the mistrials  as well as the verdicts clearing it of liability reflected the  diligent review  by juries in the cases   We look forward to a new trial to present our defense  which rests on decades of independent  non litigation driven scientific evaluations  none of which have found that Johnson s Baby Powder contains asbestos   the company said  Christopher Swett  a lawyer for Boyd Bostic s family  in a statement said plaintiffs were disappointed with Thursday s result  Swett said the trial court judge had urged the parties to consider a settlement  but that J J  refuses to be reasonable and take responsibility   The New Brunswick  New Jersey based company in the past has said that it was not considering to settle talc cases and currently is appealing all jury verdicts against it  Of the 11 700 talc lawsuits  more than 9 700 involve claims over ovarian cancer  recent filings in federal court in New Jersey  where most of the cases are consolidated  showed  The remaining plaintiffs allege asbestos in J J s talc caused them to develop mesothelioma  J J has been fighting talc cancer lawsuits for several years  but the litigation shifted in recent months to include allegations of asbestos contamination   
In July  a Missouri jury hit J J with a massive  4 69 billion verdict in the first trial alleging asbestos contamination has caused ovarian cancer in 22 women  That decision is under appeal ",2018-11-15,Reuters,https://www.investing.com/news/stock-market-news/new-jury-fails-to-reach-verdict-in-jj-south-carolina-talc-cancer-trial-1690910,1690910
198066,419582,JNJ,Glaxo Submits First Regulatory Application For Daprodustat,opinion,"GlaxoSmithKline plc   NYSE GSK   announced that it has submitted a new drug application for its pipeline candidate  daprodustat  an oral hypoxia inducible factor prolyl hydroxylase inhibitor  to Japanese regulatory authorities  The company is looking to get the candidate approved for the treatment of renal anemia associated with chronic kidney disease   CKD   This is the first regulatory application submission globally  seeking approval for daprodustat  The regulatory submission is based on data from three phase III studies conducted in Japan  which evaluated the candidate for the treatment of anemia in patients across the spectrum of CKD from stages 3 5  Data from these studies have shown that oral daprodustat met its primary endpoint of non inferiority to darbepoetin alfa IV injection as measured by mean hemoglobin levels over weeks 40 to 52 In April  Glaxo  a marketing deal with Kyowa Hakko Kirin Co   Ltd for commercialization of daprodustat in Japan following a potential approval  The press release states that there are approximately 3 5 million patients with anemia associated with renal disease in Japan  Successful commercialization is likely to boost Glaxo s future revenues Meanwhile  Glaxo is conducting a global clinical development program for daprodustat in a similar indication consisting of two late stage studies   ASCEND D and ASCEND ND  The studies are evaluating the candidate in CKD patients on dialysis and those not on dialysis  While enrollment has been completed in ASCED D study  it is currently ongoing in the other study Shares of Glaxo have increased 6 5  so far this year against the  s decline of 2 1  In a separate press release  ViiV Healthcare  Glaxo s HIV subsidiary  announced headline data from phase III ATLAS 2M study of its long acting  injectable two drug regimen of cabotegravir plus rilpivirine as a treatment for HIV patients  The study evaluated administration of the combo regimen every eight weeks  two months  compared to every four weeks  one month   Data from the study showed that administration of the combo every two months was non inferior to administration once every month Please note that rilpivirine has been developed by Janssen  a subsidiary of J J   NYSE JNJ    and is marketed under the tradename of Edurant for HIV 1 infection  ViiV Healthcare is a joint venture between Glaxo  Pfizer   NYSE PFE   and Shionogi Limited ViiV Healthcare has submitted regulatory applications in the United States and in Europe for once a month administration of cabotegravir plus rilpivirine regimen for the treatment of HIV 1 infection  In July  the FDA accepted the application under priority review with a decision expected in December 2019 Meanwhile  ViiV Healthcare also announced the start of the first ever study   CUSTOMIZE   to identify and evaluate approaches to implementing its once monthly injectable HIV treatment in the real world HIV is a key therapeutic area for Glaxo with successful dolutegravir based regimens  namely Tivicay  Triumeq and Juluca  in its portfolio  The company remains committed to bringing new treatment regimens for HIV patients GlaxoSmithKline plc Price
    Zacks Rank   Stock to ConsiderGlaxo currently carries a Zacks Rank  3  Hold   Merck   Co   Inc    NYSE MRK   is a better ranked stock in the large cap pharma sector  carrying a Zacks Rank  2  Buy   You can see  Merck s earnings estimates have been revised 3 2  upward for 2019 and 1 1  for 2020 in the past 30 days  The stock has rallied 13 7  so far this year It s Illegal in 42 States  But Investors Will Make Billions LegallyIn addition to the companies you read about above  today you get details on the newly legalized industry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year That s twice as much as they spend on marijuana  legally or otherwise Zacks special report revealing how investors can profit from this new opportunity  As more states legalize this activity  the industry could expand by as much as 15X  Zacks  has just released a Special Report revealing 5 top stocks to watch in this space ",2019-08-21,Zacks Investment Research,https://www.investing.com/analysis/glaxo-submits-first-regulatory-application-for-daprodustat-200457605,200457605
198067,419583,JNJ,Mallinckrodt  MNK  Stock Down 70 8  YTD On Numerous Lawsuits,opinion,Shares of Mallinckrodt plc   NYSE MNK   have plunged 70 8  year to date compared with the  s decline of 8 9   It has been a dismal year for this Dublin  Ireland based company  which develops  manufactures  markets and distributes branded and generic specialty pharmaceutical and biopharmaceutical products While the company beat on earnings in the recently reported second quarter  it is currently facing multiple challenges The company is currently under the scanner for the sale and marketing of opioid drugs  which contributed to the ongoing opioid epidemic in the United States  It is facing multiple lawsuits related to the same Earlier  allegations against its lead drug Acthar s previous owner  Questcor  for conducting illegal sales and marketing activities related to the drug negatively impacted Mallinckrodt s shares  Per the company  the original action was filed in 2012  prior to its ownership of Acthar Gel  and consisted of two complaints filed by former Questcor employees It reached an agreement in principle with the U S  Department of Justice  DOJ  regarding the Questcor litigation to resolve the previously disclosed government investigation of the drug s legacy sales and marketing activities  Mallinckrodt expects to pay  15 4 million related to legacy Questcor activities  per the civil False Claims Act settlement Earlier  shares of the company had plunged after it filed suit in federal district court against the U S  Department of Health and Human Services  HHS  and Centers for Medicare and Medicaid Services  CMS  to protect Medicaid patient access to Acthar  The lawsuit was filed against the agency s decision  which required Mallinckrodt to change the base date average manufacturer price  AMP  used to calculate Medicaid drug rebates for the drug  Per the company  the attempted reversal  which CMS seeks unlawfully to make retroactive  would substantially eliminate Medicaid net sales of Acthar In December 2018  the company announced that it intends to spin off the Specialty Generics business into a new company  However  based on current market conditions and developments  including increasing uncertainties regarding the opioid litigation  the company has shelved this plan for now  Mallinckrodt continues to evaluate a range of options for the separation of the Specialty Generics business The aforementioned factors have led to a significant decline in the share price  Nevertheless  there is some hope for Mallinckrodt as other companies like Endo International plc   NASDAQ ENDP   recently reached a settlement in principle with the County of Cuyahoga  Ohio  the County of Summit  Ohio  and certain related persons in connection with the pending lawsuits related to opioid medications  Bigwigs like Johnson   Johnson   NYSE JNJ   and generic maker Teva Pharmaceuticals   NYSE TEVA   are embroiled in similar lawsuits as well Mallinckrodt carries a Zacks Rank  3  Hold   You can see   It s Illegal in 42 States  But Investors Will Make Billions LegallyIn addition to the companies you read about above  today you get details on the newly legalized industry that s tapping into a  habit  that Americans spend an estimated  150 billion on every year That s twice as much as they spend on marijuana  legally or otherwise Zacks special report revealing how investors can profit from this new opportunity  As more states legalize this activity  the industry could expand by as much as 15X  Zacks  has just released a Special Report revealing 5 top stocks to watch in this space ,2019-08-22,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-mnk-stock-down-708-ytd-on-numerous-lawsuits-200457513,200457513
198068,419584,JNJ,AbbVie  ABBV  Down 1  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for AbbVie  ABBV   Shares have lost about 1  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is AbbVie due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  AbbVie Beats on Q2 Earnings   Sales  Raises EPS ViewSecond quarter 2019 earnings of  2 26 per share in the second quarter beat the Zacks Consensus Estimate of  2 21 and rose 13  year over year  Earnings per share were also better than the guided range of  2 20 to  2 22 Revenues of  8 26 billion beat the Zacks Consensus Estimate of  8 1 billion  Sales were flat on a reported basis  Excluding 1 5  unfavorable impact from foreign exchange rate fluctuations  operational revenues rose 1 5   backed by higher sales of several products  which offset the impact of international biosimilar competition for Humira  Revenues were also slightly ahead of the guidance of being above  8 1 billion Quarter in DetailsHumira sales declined 4 8   6 1  on an operational basis  to  4 87 billion Sales in the United States increased 7 7  to  3 79 billion  slightly higher than the guidance of approximately 7  growth  driven by strong demand trends  Humira sales in ex U S  markets were down 31  on an operational basis and 35 2  on a reported basis to  1 1 billion International sales were severely impacted by the launch of several direct biosimilar drugs in Europe and other international markets  On the call  the company said that biosimilar trends and dynamics were in line with management expectations AbbVie s oncology hematology  including Imbruvica and Venclexta  sales rose 39 1  on an operational basis to  1 27 billion in the quarter driven by strong growth of both Imbruvica and Venclexta  Second quarter net revenues from Imbruvica were  1 1 billion  slightly higher than the guidance of approximately  1 billion  Imbruvica sales rose 29 3  year over year  U S  sales of Imbruvica grossed  886 million  up 27 9  from the year ago figure  primarily driven by continued uptake in the frontline CLL segment  AbbVie logged  213 million of international profit sharing with J J  NYSE JNJ   up 35 9  year over year Venclexta brought in revenues of  169 million  up more than 100  year over year driven by continued uptake in the broad relapsed refractory CLL setting and the recently approved indications for first line CLL and AML HCV products  including Viekira and Mavyret  recorded sales of  784 million  down 19 4   down 17 1  on an operational basis  year over year on lower sales of Mavyret as well as Viekira  In the United States  HCV revenues declined 6 2  to  396 million  International HCV revenues declined 25 4  on an operational basis to  388 million Mavyret sales totaled  780 million in the quarter  down 6 9   down 14  on an operational basis  year over year due to a decline in the United States as well as international markets  International sales of Mavyret declined 20 4  in the second quarter due to lower treated patient volumes  U S sales were down 6  year over year Other products that delivered an encouraging performance include Duodopa  It recorded revenue growth of 11 3  on an operational basis and 5 3  on a reported basis  While Creon  which generates sales from U S  markets  witnessed an increase of 17 5  in revenues  sales of Synthroid grew 4 9  Drugs that recorded sales decline include Androgel  Synagis  Kaletra  Lupron and Sevoflurane  which fell 83   3 9   10 8   4 5  and 14 1   respectively  operationally  during the quarter Newly launched drug Orilissa recorded sales of  19 million in the quarter  which included  18 million in the United States  On the call  the company said that the sales ramp of the drug was slower than expected and halved its full year expectations for the drug  Orilissa sales are expected to be approximately  100 million in 2019  less than the prior expectation of  200 million Newly launched Skyrizi performed significantly above company expectations  contributing  48 million to sales in the second quarter  Management had expected a modest contribution from the drug in the second quarter  On the call  the company said that Skyrizi s is off to a strong start and the drug is witnessing strong prescription volume  Through the first 11 weeks of launch  approximately 3 750 patients were treated with the drug  Following the solid launch progress  management raised its full year expectations for the drug  Management expects Skyrizi s full year global sales of approximately  250 million  Earlier  management had guided that Skyrizi will contribute approximately  150 million of sales in the second half of 2019 Margins RiseAdjusted gross margin rose 220 bps to 82 7  in the quarter  Adjusted gross margin included a 290 bps benefit due to low Humira royalties owed  Adjusted SG A expenses decreased 1 4  to  1 62 billion  As a percentage of sales  SG A expenses declined 20 bps to 19 6  in the quarter  R D expenses rose 2 8  to  1 23 billion in the quarter due to greater investments in the pipeline  Adjusted operating margin was 48 2  of sales in the reported quarter  up 290 bps year over year 2019 GuidanceAbbVie raised its guidance for full year earnings and sales on a strong first half performance and a favorable outlook for the second half  Earnings are now expected in the range of  8 82  8 92  up from the previous guidance of  8 73  8 83 for 2019  The earnings guidance indicates a year over year increase of 12 1    previously 11   at the mid point Revenues are expected to grow approximately 2  on an operational basis in 2019 versus prior growth expectation of approximately 1   Currency headwinds are expected to hurt 2019 revenues by approximately 1   same as the previous expectation In 2019  U S  Humira sales are expected to rise approximately 8   The oncology hematology franchise is expected to record sales of approximately  5 3 billion including Imbruvica sales of approximately  4 6 billion  both representing an increase from 2018 levels  U S  sales of Imbruvica are expected to rise approximately 27   Global HCV sales are expected to approach  3 1 billion  indicating a year over year decline Adjusted gross margin is still expected to approach 83  of sales in 2019  Operating margin is expected to be just above 47   an increase of roughly 250 basis points year over year  While R D is expected to be approximately 15 5  of sales  SG A is expected to be approximately 20 5  of salesThird Quarter 2019 OutlookThird quarter earnings are expected between  2 28 and  2 30 per share  Revenues are estimated to be approximately  8 4 billion  Foreign exchange is expected to have a modest unfavorable impact on sales in the quarter While U S  Humira sales are expected to rise approximately 8   international Humira sales are expected to be approximately  1 billion  Imbruvica is expected to record sales of approximately  1 2 billion Adjusted operating margin is expected to be approximately 48  Discontinuing ABBV 8E12 in PSPOn the second quarter conference call  AbbVie announced the discontinuation of the phase II study of ABBV 8E12 in progressive supranuclear palsy  A futility analysis showed that the candidate failed to demonstrate the expected efficacy  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in estimates review 
VGM Scores
Currently  AbbVie has a nice Growth Score of B  however its Momentum Score is doing a bit better with an A  Following the exact same course  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision has been net zero  Notably  AbbVie has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-08-24,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-down-1-since-last-earnings-report-can-it-rebound-200458341,200458341
198069,419585,JNJ,Johnson   Johnson  A Long Term Buy Despite Near Term Fears,opinion,"It s safe to say that Johnson   Johnson  NYSE JNJ   has lagged the S P 500 considerably so far in 2019  The company is in the midst of facing financial and reputational damages due to litigation pertaining to both its talcum baby powder  which is alleged in thousands of lawsuits to have contained traces of asbestos  and its opioid drugs Nucynta and Duragesic  which the state of Oklahoma claims helped to fuel a major public health crisis 

The company s stock has justifiably suffered under the weight of these uncertainties  and JNJ has increasingly fallen out of favor with an investor community that had formerly regarded the company as having the most pristine of reputations  As a result  the stock is now trading negative on the year  falling behind both the S P index as well as its sector benchmark  Health Care Select Sector SPDR  NYSE XLV    in which it serves as the largest component 




But even with all of the uncertainty facing JNJ  it s clear that the market has been pricing in an extreme worst case scenario for the company  The stock has experienced several 10   corrections over the last year and a half  with each of them in some way having to do with the litigation concerns being faced by the company  From a peak market capitalization of  397 billion  the decline in JNJ reflects a loss in market cap of approximately  60 billion 





This seems quite overdone  given that Bloomberg s worst case estimate for potential talc settlements reaches  15 billion  and that the company seems to have a reasonable case against liability in the opioid case  Unlike peers Purdue Pharma and Teva Pharma Industries Ltd ADR  NYSE TEVA   which chose to settle against similar accusations by the state of Oklahoma  Johnson   Johnson  NYSE JNJ  has chosen to oppose the accusations head on  claiming that its opioid products represented a small fraction of total opioid sales in Oklahoma  It s hard to quantify how much total opioid lawsuit damages could cost for the company  while Oklahoma is demanding  17 billion to be paid over 30 years  there are also several other states looking into lawsuits of their own  However  even if JNJ were to lose its trial against the state of Oklahoma  the actual payout would likely be nowhere near the  17 billion demanded  due to the high likelihood of a reversal or reduction upon appeal 




On top of all this  the company already has a considerable cash reserve of over  14 billion  as well as a AAA credit rating that enables it to borrow money on more advantageous terms  as if the cost of borrowing money wasn t already cheap   All in all  this combination of a lagging stock price coupled with what seems to be better than feared fundamentals provides an opportunity for long term investors to build a position in JNJ at a discount 





A Strong Dividend At A Reasonable Valuation
Throughout the duration of JNJ s underperformance  the stock has experienced a steady increase in its dividend yield  Since the start of 2018 the stock s returns have essentially remained flat  yet company management has increased the quarterly dividend twice  first from  0 84 to  0 90 in mid 2018 and again from  0 90 to  0 95 in mid 2019 
Examining the stock s dividend yield history over the last three years  there have been four prior periods where JNJ s yield has fallen within the 2 8  2 9  range  December 2016  January 2017  June 2018  and December 2018  Each of these instances ended up representing a bottom for the stock  and the fact that JNJ s yield is once again trading within this range leads me to believe that another bottom could be in the cards 




Additionally  it should be noted that JNJ is experiencing somewhat of a valuation contraction  which I attribute to a combination of company specific litigation fears and industry wide regulation fears  The stock currently carries a P E ratio of 21 2  While this valuation may seem expensive at face value  it s not unreasonable for a blue chip company of JNJ s caliber  with exceptional diversification across the health care industry  a solid international presence  high quality management  and a consistent history of growth with regards to revenues  earnings  and dividends  And taking into consideration that JNJ has historically traded at a mid 20s multiple on earnings  one can reach the conclusion that the stock is cheap relative to past valuations 





Conclusion
Despite what I view as quality fundamentals for Johnson   Johnson  I would be wary of adding shares prior to Monday s upcoming opioid trial verdict  it s impossible to tell how JNJ will react to the news  and in an environment that s this volatile  the market isn t willing to show mercy to any stock with signs of weakness  But for investors seeking high quality exposure to the health care sector  Johnson   Johnson presents a strong long term buying opportunity  I believe that the litigation concerns around the company s talc and opioid products are real but overblown  and that investor panic has provided a chance to take advantage of an outsized dividend at a deflated valuation ",2019-08-25,Nima Abbaszadeh,https://www.investing.com/analysis/johnson--johnson-a-longterm-buy-despite-nearterm-fears-200458386,200458386
198070,419586,JNJ,Case Shiller Index Nudges Up,opinion,Again  here at the end of August  we mostly wait for a time of more populous economic data  in a week  we ll start seeing things like new jobs reports from the month of August  Until then  we sift through tea leaves until we can land on something new and concrete Which brings us to Norman  Oklahoma  where Johnson   Johnson   NYSE JNJ   has been ruled against in a major opioid epidemic landmark case  The pharma giant now owes  572 million  as per the judge in this case  which pits J J responsible for rampant opioid use beyond responsible levels  The other two companies originally named in the case   Teva   NYSE TEVA   and Purdue Pharma   had already settled for  85 million and  270 million  respectively However  shares are up roughly 1  in today s pre market for J J  as analysts following the trial and other newsworthy items amid the U S  opioid epidemic expected as much as a  17 billion charge to J J in the case  Wall Street had priced in  1 2 billion  So even though J J has been ruled to pay more than double Purdue s settlement   J J will no doubt be appealing this ruling   the dollar amount is still well below what many investors were fearing Not only J J  but other pharma companies that provide opiates for patients   Teva  Mallinckrodt   NYSE MNK    Endo International   NASDAQ ENDP     are all up 3  in today s pre market  That said  the Oklahoma case is but the tip of the iceberg  analysts now look toward a new trial in Ohio this October on opioid abuse and pharma companies  involvement in it  For that case  J J is already openly discussing settlement options Case Shiller Home Prices Up  but SlowerThe late read  from June    but deemed most accurate   on U S  home prices from the latest Case Shiller index showed home prices continuing to rise  but lower than in recent months  A headline of  3 1  annually is 20 basis points lower than the read for May  The 10 City index rose 1 8  while the 20 City was  2 1   both down from the 2 2  and 2 4  in the previous month  respectively Leading cities were some of the usual suspects  Phoenix led the way in June home pricing   5 8   followed by Las Vegas at 5 5  and Tampa at 4 7   Analysts cite hopefulness for future reads  with lower mortgage rates hopefully having spurred home prices in the later summer months  But  of course  we will need to wait a while to see if these expectations will have come to fruition ,2019-08-26,Zacks Investment Research,https://www.investing.com/analysis/caseshiller-index-nudges-up-200458973,200458973
198074,419590,JNJ,Merck Co Earnings beat  Revenue misses In Q3,news,"Investing com   Merck Co  NYSE MRK  reported third quarter earnings  that beat analyst s expectations on Thursday and revenue that fell short of forecasts 
The firm reported earnings per share of  1 19 on revenue of  0 73  Analysts polled by Investing com forecast EPS of  1 13 on revenue of  10 89B  That compared to EPS of  1 11 on revenue of  10 33B in the same period a year earlier  The company had reported EPS of  1 06 on revenue of  10 47B in the previous quarter 

For the year  Merck Co shares are up 24 65   outperforming the S P 500 which is down 1 03  year to date 
Merck Co follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 04B 
Novartis ADR earnings beat analyst s expectations on October 18  with third quarter EPS of  1 32 on revenue of  12 78B  Investing com analysts expected EPS of  1 31 on revenue of  12 98B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-25,Investing.com,https://www.investing.com/news/stock-market-news/merckco-earnings-beat-revenue-misses-in-q3-1659209,1659209
198075,419591,JNJ,Celgene Earnings  Revenue beat in Q3,news,"Investing com   Celgene  NASDAQ CELG  reported third quarter earnings  that beat analyst s expectations on Thursday and revenue that topped forecasts 
The firm reported earnings per share of  2 29 on revenue of  3 89B  Analysts polled by Investing com anticipated EPS of  2 23 on revenue of  3 84B  That compared to EPS of  1 91 on revenue of  3 29B in the same period a year earlier  The company had reported EPS of  2 16 on revenue of  3 81B in the previous quarter 
Celgene shares gained 1 06  to trade at  75 50 in pre market trade following the report 
For the year  Celgene shares are down 29 04   under performing the Nasdaq 100 which is up 5 56  year to date 
Celgene follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 04B 
Novartis ADR earnings beat analyst s expectations on October 18  with third quarter EPS of  1 32 on revenue of  12 78B  Investing com analysts expected EPS of  1 31 on revenue of  12 98B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-25,Investing.com,https://www.investing.com/news/stock-market-news/celgene-earnings-revenue-beat-in-q3-1659351,1659351
198076,419592,JNJ,Gilead Earnings  Revenue beat in Q3,news,"Investing com   Gilead reported third quarter earnings  that beat analyst s expectations on Thursday and revenue that topped forecasts 
The firm reported earnings per share of  1 84 on revenue of  5 6B  Analysts polled by Investing com forecast EPS of  1 62 on revenue of  5 37B  That compared to EPS of  2 27 on revenue of  6 51B in the same period a year earlier  The company had reported EPS of  1 91 on revenue of  5 65B in the previous quarter 
Gilead shares gained 1 43  to trade at  69 60 in after hours trade following the report 
For the year  Gilead shares are down 4 95   under performing the Nasdaq which is up 5 49  year to date 
Gilead follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 04B 
Novartis ADR earnings beat analyst s expectations on October 18  with third quarter EPS of  1 32 on revenue of  12 78B  Investing com analysts expected EPS of  1 31 on revenue of  12 98B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-25,Investing.com,https://www.investing.com/news/stock-market-news/gilead-earnings-revenue-beat-in-q3-1660372,1660372
198077,419593,JNJ,Stryker Earnings beat  Revenue misses In Q3,news,"Investing com   Stryker reported third quarter earnings  that beat analyst s expectations on Thursday and revenue that fell short of forecasts 
The firm reported earnings per share of  1 69 on revenue of  3 24B  Analysts polled by Investing com anticipated EPS of  1 68 on revenue of  3 26B  That compared to EPS of  1 52 on revenue of  3 01B in the same period a year earlier  The company had reported EPS of  1 76 on revenue of  3 32B in the previous quarter 
Stryker shares lost 2 58  to trade at  161 00 in after hours trade following the report 
For the year  Stryker shares are up 5 5   outperforming the S P 500 which is up 0 81  year to date 
Stryker follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 04B 
Novartis ADR earnings beat analyst s expectations on October 18  with third quarter EPS of  1 32 on revenue of  12 78B  Investing com analysts expected EPS of  1 31 on revenue of  12 98B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-25,Investing.com,https://www.investing.com/news/stock-market-news/stryker-earnings-beat-revenue-misses-in-q3-1660457,1660457
198078,419594,JNJ,Aetna Earnings  Revenue beat in Q3,news,"Investing com   Aetna  NYSE AET  reported third quarter earnings  that beat analyst s expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  2 96 on revenue of  15 48B  Analysts polled by Investing com anticipated EPS of  2 83 on revenue of  15 25B  That compared to EPS of  2 45 on revenue of  15B in the same period a year earlier  The company had reported EPS of  3 43 on revenue of  15 56B in the previous quarter 
For the year  Aetna shares are up 6 25   outperforming the S P 500 which is down 1 58  year to date 
Aetna follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 05B 
Novartis ADR earnings beat analyst s expectations on October 18  with third quarter EPS of  1 32 on revenue of  12 78B  Investing com analysts expected EPS of  1 3 on revenue of  12 94B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-30,Investing.com,https://www.investing.com/news/stock-market-news/aetna-earnings-revenue-beat-in-q3-1665306,1665306
198079,419595,JNJ,HCA Earnings  Revenue beat in Q3,news,"Investing com   HCA  NYSE HCA  reported third quarter earnings  that beat analyst s expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  2 16 on revenue of  11 45B  Analysts polled by Investing com anticipated EPS of  1 9 on revenue of  11 3B  That compared to EPS of  1 21 on revenue of  10 70B in the same period a year earlier  The company had reported EPS of  2 29 on revenue of  11 53B in the previous quarter 
For the year  HCA shares are up 9 23   outperforming the S P 500 which is down 1 58  year to date 
HCA follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 05B 
 Pfizer   NYSE PFE  earnings beat analyst s expectations on Tuesday  with third quarter EPS of  0 78 on revenue of  13 3B  Investing com analysts expected EPS of  0 75 on revenue of  13 55B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-30,Investing.com,https://www.investing.com/news/stock-market-news/hca-earnings-revenue-beat-in-q3-1665585,1665585
198080,419596,JNJ,J J s Tuberculosis Drug Gets FDA Nod For Adolescent Patients,opinion,Johnson   Johnson   NYSE JNJ   announced that the FDA has granted accelerated approval to its antimycobacterial tablets  Sirturo  bedaquiline  as a combination therapy to treat adolescents with pulmonary multidrug resistant tuberculosis  MDR TB  Sirturo is already marketed in combination with a background regimen for treating MDR TB in adults  Continued approval for the adolescent indication will be based on verification of data from confirmatory studies  A similar application is also under review in the EU The approval for Sirturo in adolescents patient group  12 to less than 18 years of age and weighing at least 30 kg  was based on a cohort of a J J phase II pediatric pharmacokinetic and safety study  C211  The other cohorts of the study are evaluating Sirturo in pediatric patients in different age groups  For the adolescent patient group  the formulation  100 mg tablet  and the dosing recommendation are the same as those approved for adults  Tuberculosis is a deadly infectious disease  which claimed the lives of 230 000 children in 2017  Though it is more common in adult patients  all age groups are at risk J J s stock has risen 2 3  this year so far against a decrease of 1 3  recorded by the    J J currently has a Zacks Rank  3  Hold   Some better ranked large cap pharma stocks are Roche Holding  SIX ROG  AG   OTC RHHBY    Sanofi   NASDAQ SNY   and Merck   NYSE MRK    While Roche sports a Zacks Rank  1  Strong Buy   Sanofi and Merck carry a Zacks Rank  2  Buy   You can see  Shares of Roche have gained 12 3  this year so far  Earnings estimates for 2019 have risen 0 8  while that for 2020 have increased 2  over the past 30 days Sanofi s earnings estimates have increased 0 3  and 0 9   respectively  for 2019 and 2020 over the past 30 days Merck s stock is up 11 9  this year so far  Its earnings estimates have risen almost 3  for 2019 and 1 7  for 2020 over the past 30 days Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-11,Zacks Investment Research,https://www.investing.com/analysis/jjs-tuberculosis-drug-gets-fda-nod-for-adolescent-patients-200454208,200454208
198081,419597,JNJ,3 Reasons Why Growth Investors Shouldn t Overlook J J Snack Foods  JJSF ,opinion,"Growth investors focus on stocks that are seeing above average financial growth  as this feature helps these securities garner the market s attention and deliver solid returns  But finding a great growth stock is not easy at all 
That s because  these stocks usually carry above average risk and volatility  In fact  betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss 
However  the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects  makes it pretty easy to find cutting edge growth stocks 
J J  NYSE JNJ  Snack Foods  JJSF  is on the list of such stocks currently recommended by our proprietary system  In addition to a favorable Growth Score  it carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy   returns are even better 
While there are numerous reasons why the stock of this drink and snack maker is a great growth pick right now  we have highlighted three of the most important factors below 
Earnings Growth
Earnings growth is arguably the most important factor  as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for J J Snack Foods is 4 4   investors should actually focus on the projected growth  The company s EPS is expected to grow 22 5  this year  crushing the industry average  which calls for EPS growth of 4 8  
Impressive Asset Utilization Ratio
Growth investors often overlook asset utilization ratio  also known as sales to total assets  S TA  ratio  but it is an important feature of a real growth stock  This metric shows how efficiently a firm is utilizing its assets to generate sales 
Right now  J J Snack Foods has an S TA ratio of 1 23  which means that the company gets  1 23 in sales for each dollar in assets  Comparing this to the industry average of 1 2  it can be said that the company is more efficient 
While the level of efficiency in generating sales matters a lot  so does the sales growth of a company  And J J Snack Foods looks attractive from a sales growth perspective as well  The company s sales are expected to grow 3 7  this year versus the industry average of 0  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for J J Snack Foods  The Zacks Consensus Estimate for the current year has surged 1  over the past month 
Bottom Line
J J Snack Foods has not only earned a Growth Score of A based on a number of factors  including the ones discussed above  but it also carries a Zacks Rank  2 because of the positive earnings estimate revisions 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that J J Snack Foods is a potential outperformer and a solid choice for growth investors ",2019-08-20,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-why-growth-investors-shouldnt-overlook-jj-snack-foods-jjsf-200456814,200456814
198086,419602,JNJ,Centene Earnings miss  Revenue beats In Q3,news,"Investing com   Centene reported third quarter earnings  that missed analyst s expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  0 09 on revenue of  16 18B  Analysts polled by Investing com expected EPS of  1 77 on revenue of  16 03B  That compared to EPS of  1 35 on revenue of  11 9B in the same period a year earlier  The company had reported EPS of  1 8 on revenue of  14 18B in the previous quarter 

For the year  Centene shares are up 40 33   outperforming the S P 500 which is up 2 69  year to date 
Centene follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 04B 
Novartis ADR earnings beat analyst s expectations on Thursday  with third quarter EPS of  1 32 on revenue of  12 78B  Investing com analysts expected EPS of  1 31 on revenue of  12 98B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-23,Investing.com,https://www.investing.com/news/stock-market-news/centene-earnings-miss-revenue-beats-in-q3-1655062,1655062
198087,419603,JNJ,Boston Scientific Earnings  Revenue miss in Q3,news,"Investing com   Boston Scientific  NYSE BSX  reported third quarter earnings  that missed analyst s expectations on Wednesday and revenue that fell short of forecasts 
The firm reported earnings per share of  0 31 on revenue of  2 39B  Analysts polled by Investing com expected EPS of  0 34 on revenue of  2 4B  That compared to EPS of  0 31 on revenue of  2 22B in the same period a year earlier  The company had reported EPS of  0 41 on revenue of  2 49B in the previous quarter 

For the year  Boston Scientific shares are up 44 47   outperforming the S P 500 which is up 2 12  year to date 
Boston Scientific follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 04B 
Novartis ADR earnings beat analyst s expectations on October 18  with third quarter EPS of  1 32 on revenue of  12 78B  Investing com analysts expected EPS of  1 31 on revenue of  12 98B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-24,Investing.com,https://www.investing.com/news/stock-market-news/boston-scientific-earnings-revenue-miss-in-q3-1657195,1657195
198088,419604,JNJ,Vertex Earnings  Revenue miss in Q3,news,"Investing com   Vertex reported third quarter earnings  that missed analyst s expectations on Wednesday and revenue that fell short of forecasts 
The firm reported earnings per share of  0 5 on revenue of  783M  Analysts polled by Investing com forecast EPS of  1 01 on revenue of  789 71M  That compared to EPS of  0 53 on revenue of  578 2M in the same period a year earlier  The company had reported EPS of  0 94 on revenue of  751 22M in the previous quarter 
Vertex shares lost 0 06  to trade at  163 00 in after hours trade following the report 
For the year  Vertex shares are up 8 73   outperforming the Nasdaq 100 which is up 5 56  year to date 
Vertex follows other major Healthcare sector earnings this month
 On October 16  J J  NYSE JNJ  reported third quarter EPS of  2 05 on revenue of  20 35B  compared to forecasts of EPS of  2 03 on revenue of  20 04B 
Novartis ADR earnings beat analyst s expectations on October 18  with third quarter EPS of  1 32 on revenue of  12 78B  Investing com analysts expected EPS of  1 31 on revenue of  12 98B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-24,Investing.com,https://www.investing.com/news/stock-market-news/vertex-earnings-revenue-miss-in-q3-1658417,1658417
198089,419605,JNJ,J J Snack Foods  JJSF  Beats Q3 Earnings And Revenue Estimates,opinion,"J J  NYSE JNJ  Snack Foods  JJSF  came out with quarterly earnings of  1 63 per share  beating the Zacks Consensus Estimate of  1 54 per share  This compares to earnings of  1 39 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 5 84   A quarter ago  it was expected that this drink and snack maker would post earnings of  1 02 per share when it actually produced earnings of  1 08  delivering a surprise of 5 88  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
J J Snack Foods  which belongs to the Zacks Food   Miscellaneous industry  posted revenues of  326 70 million for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 4 38   This compares to year ago revenues of  306 24 million  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
J J Snack Foods shares have added about 13 3  since the beginning of the year versus the S P 500 s gain of 20 7  
What s Next for J J Snack Foods 
While J J Snack Foods has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for J J Snack Foods was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 43 on  309 40 million in revenues for the coming quarter and  4 93 on  1 17 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Food   Miscellaneous is currently in the bottom 44  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-29,Zacks Investment Research,https://www.investing.com/analysis/jampj-snack-foods-jjsf-beats-q3-earnings-and-revenue-estimates-200446682,200446682
198090,419606,JNJ,Merck  MRK  Beats On Q2 Earnings   Sales  Raises  19 View,opinion,"Merck   Co   Inc    NYSE MRK   reported second quarter 2019 adjusted earnings of  1 30 per share  which beat the Zacks Consensus Estimate of  1 16  Earnings rose 23  year over year  up 25  excluding the impact of currency Including acquisition  and divestiture related costs  restructuring costs and certain other items  earnings per share were  1 03 compared with 63 cents in the year ago quarter Revenues for the quarter rose 12  year over year to  11 76 billion  beating the Zacks Consensus Estimate of  10 91 billion  Currency movement negatively impacted revenues by 3   Excluding currency impact  sales rose 15  year over year Strength in cancer drug  Keytruda  and Gardasil vaccine and a strong performance in international markets  especially China  offset headwinds from loss of exclusivity   LOE   for some products including Zetia and Vytorin  and competitive pressure for Janumia and Janumet  Sales in China surged 41   51  excluding Fx impact  from the year ago period Quarter in DetailThe Pharmaceutical segment generated revenues of  10 46 billion  up 13   up 17  excluding Fx impact  year over year as higher sales in oncology and vaccines were offset by lower sales in virology  As in the previous quarters  LOE for several drugs hurt the top line Keytruda  the largest product in Merck s portfolio  generated sales of  2 6 billion in the quarter  up around 15 9  sequentially and 58  year over year  Sales were driven by the launch of new indications globally  Keytruda sales are gaining particularly from strong momentum in first line lung cancer indication and launch in newer indications   renal cell carcinoma and adjuvant melanoma Keytruda is already approved for many types of cancers and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma and bladder cancer  In June  the FDA approved two label expansions of the drug    of head and neck squamous cell carcinoma and  in third line setting Alliance revenues from Lynparza and Lenvima also boosted oncology sales in the quarter Lynparza alliance revenues were  111 million in the quarter compared with  79 million in the previous quarter  Lenvima alliance revenues were  97 million compared with  74 million in the previous quarter Merck has a deal with Swiss pharma giant AstraZeneca   NYSE AZN   to co develop and commercialize PARP inhibitor Lynparza and a similar one with Japan s Eisai for tyrosine kinase inhibitor  Lenvima In the hospital specialty portfolio  Bridion  sugammadex  Injection generated sales of  278 million in the quarter  up 16  year over year  driven by strong demand in the United States In vaccines  Gardasil Gardasil 9 sales rose 46  year over year to  886 million  gaining from ongoing commercial launch in China and strong growth in Europe  Favorable public sector buying patterns  and positive demand and pricing in the United States also boosted sales of the vaccine Proquad  M M R II and Varivax vaccines recorded combined sales of  675 million  up 58  year over year  Sales were driven by higher demand in Europe  favorable pricing in the United States and government orders from Latin America Pharmaceutical sales were hurt by generic competition for blockbuster drug  Remicade in Merck s marketing territories in Europe and loss of U S  market exclusivity for Zetia and Vytorin Remicade sales declined 37 6  year over year to  98 million in the quarter  Please note that Merck markets Remicade in partnership with J J   NYSE JNJ   The Zetia Vytorin franchise recorded sales of  232 million  down 39 1  from the year ago quarter due to LOE for both Zetia and Vytorin  While Adempas sales grew 38 7  to  104 million  Atozet sales were down 8 9  to  92 million  Strong growth in Adempas  sales partially offset loss of sales in the cardiovascular segment  Please note that Adempas is commercialized in collaboration with Bayer   OTC BAYRY   Januvia Janumet  diabetes  franchise sales declined 6  year over year to  1 4 billion due to continued pricing pressure in the United States  which was completely offset by higher sales in ex U S  markets  Sales of Isentress declined 19  to  247 million Merck s Animal Health segment generated revenues of  1 12 billion  up 3   up 9  excluding Fx impact  from the year ago quarter  driven by higher sales of its companion animal products as well as livestock products  particularly products added from Antelliq acquisition Adjusted gross margin came in at 75 4   up 100 basis points from the year ago quarter driven primarily by favorable product mix Selling  general and administrative  SG A  expenses were  2 62 billion in the reported quarter  up 5 1  year over year driven by higher administrative and promotion costs  partially offset by favorable impact of foreign exchange movement  Research and development  R D  spend rose 13 3  to  2 18 billion in the quarter due to ongoing clinical studies and cost related to early drug development 2019 Guidance UpMerck increased its earnings and sales guidance for 2019 Merck expects revenues to be in the range of  45 2 billion    46 2 billion versus previous expectation of  43 9 billion    45 1 billion  The Zacks Consensus Estimate is pegged at  44 63 billion  Adjusted earnings are now expected to be in the range of  4 84  4 94  much higher than the previously guided range of  4 67  4 79  The Zacks Consensus Estimate is pegged at  4 74 per share  The revenue guidance includes a slightly more than 1  negative impact of currency fluctuation Adjusted operating expenses are expected to increase year over year at mid single digit rate Our TakeMerck s second quarter results were strong as the company beat estimates for earnings as well as sales  It raised its earnings expectations for the year for the second consecutive quarter  Shares were up by more than 3  in pre market trading  Merck s shares have outperformed the  so far this year  It has risen 7 9  in the said time frame while the industry recorded no movement Importantly  Keytruda continued its robust performance on strong demand trends and label expansions  Vaccine products also performed strongly and continue to be core growth drivers for Merck Going forward  growth of key products like Keytruda  Lynparza  Gardasil  Bridion and Animal Health should continue to make up for the headwinds from LOE  softness in the diabetes franchise  and competitive pressure on Zepatier and Zostavax Merck   Co   Inc  Price  Consensus and EPS Surprise
    Zacks RankMerck currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-07-30,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-beats-on-q2-earnings--sales-raises-19-view-200447351,200447351
198091,419607,JNJ,These 21 Safe Bond Funds Pay Up To 8 5  And Never Go Down,opinion,"The 8 Safest Bond ETFs That Actually Pay




As we discussed with ARTFX  I don t anticipate I ll ever formally recommend one of these funds in CIR  Their total returns are unlikely to clear my high single digit yearly hurdle  However  they are good ideas for anyone looking to tie down their portfolio during any market turbulence  These 5  and 6  yields are about as steady as they come 
The Best Bond Funds  CEFs for 8 5  Yields and 78  Returns 
I prefer CEFs to mutual funds and ETFs because 
They yield more  andThey can go up in price more quickly In fact  CEFs flash a crystal clear buy signal when a big price rise is coming  You ll find it in the discount to NAV  which is the percentage by which the fund s market price trails the market value of all the assets in its portfolio  known as the net asset value  or NAV  
This makes our plan simple  wait for the discount to sink below its normal level and make our move  Then we ll keep rolling our dividend cash into that fund until its discount closes  or swings to a premium  
This is exactly what happened when we bought the PIMCO Dynamic Credit and Mortgage Fund  PCI  in my Contrarian Income Report service in May 2016  Not only did we collect the fund s generous dividend  but we won two more ways over the three years we ve held PCI because its 
NAV increased  orange line below   and  Its discount window tightened as its price  blue line  caught up with and eventually surpassed its NAV 2 Ways to Win for 78  Total Returns




We ve earned 78  total returns from PCI  thanks to the dividends we ve collected  the NAV gains we ve enjoyed and the discount window closing entirely and flipping to a premium 
For much of PCI s run  I ve had a  buy  rating on the fund when this  twofer  potential remained in place  making it a perfect destination for both reinvested dividends and new cash my members had to invest 
For a period of time  though  PCI has cruised along as a  hold  for us  This happened after its price rallied so furiously that its discount window closed 
When this happens  it makes sense to bank our PCI dividends  or  redirect  them to our other Contrarian Income Report buys  and wait for our next buying opportunity 
That s what happened with PCI  Its discount window opened again in the late 2018 selloff on October 5  to be precise when its market price fell below my  23 50 buy up to level  Investors who got in then picked up a nice 14  total return  nearly three times the market s gain 
Buy Window Opens  Gains  and Dividends  Ensue




As you can see in the orange line above  your typical S P 500 investor didn t come anywhere close to those returns in that time 
Yours Now  My Next 8    Monthly  Income Buys 
As you can probably guess from the chart above  PCI is trading at a massive premium to NAV now  so I ve switched it back to a hold 
But it s only a matter of time before our buy window slides open again and we can put more cash into this amazing 8 7  yielder 
When you take a no risk trial to Contrarian Income Report  you ll be the first to know when the time is right 
Meantime  if you re looking for some stout monthly high yielders to buy NOW  fear not  I ve got you covered there  too 
Those would be the stocks  high yield REITs and CEFs in my powerful     With just  500K invested  this dynamic collection of investments will hand you a rock solid  40 000 a year income stream  That s easily enough for most folks to retire on 
The best part is you won t have to go back to  lumpy  quarterly payouts to do it  Thanks to this breakthrough portfolio s reliable monthly dividends  you can look forward to the steady drip of  3 333 in income  month in and month out on your  500K  give or take a couple hundred bucks 
Full details on these stalwart income plays are   You ll discover 
An 8 1  payer that s set to rake in huge profits from an artificially depressed sector The brainchild of one of the top fund managers on the planet that s giving out a generous 9 1  yield And a rock steady 6 9  dividend trading at a massive discount to NAV 
Disclosure  Brett Owens and Michael Foster are contrarian income investors who look for undervalued stocks funds across the U S  markets  Click here to learn how to profit from their strategies in the latest report   7 Great Dividend Growth Stocks for a Secure Retirement  
 Brett  give me some bond funds with big yields  And it d be great if their prices never went down  
My money manager friend was chasing the holy grail of retirement income  He wanted safe payouts from bonds to balance his clients  stock exposure 
 How about the Artisan High Income Investor Fund  ARTFX    I replied   It pays a steady 6  or so  And it never goes down  
Same S P Yearly Return  Less Heartburn




 The only problem is that it never goes up  either  And that s prevented me from recommending it to my Contrarian Income Report subscribers  
Our CIR portfolio holds eight bond funds today  versus ten stocks and stock funds   Our average annualized return on these eight open fixed income holdings is 11 2   which means adding ARTFX to the mix would drag our retirement boat lower 
I prefer price upside alongside my monthly bond payouts  And for big gains we must consider closed end funds  CEFs   which are bought and sold with less efficiency than ETFs and blue chip stocks 
Many investors buy Johnson   Johnson  NYSE JNJ  for its dividend and recall the SPDR Bloomberg  Barclays   LON BARC  High Yield Bond ETF  JNK   because its ticker spells  junk    but few know about PIMCO s Dynamic Credit and Mortgage Fund  PCI   This is ironic because PCI pays a generous 8 5  today while JNJ yields just 2 9  and JNK pays 5 5   It s doubly ironic because PCI has more than doubled the returns of its two better known  competitors  
PCI Pays More  Goes Up Faster Than JNJ and JNK




PCI s payout is safe but its price is subject to market whims  As a CEF  the fund has a fixed amount of shares  like an individual stock   This means its price can swing up and down  like an individual stock   Over the long haul this  volatility  works in our favor as patient investors  but it can cause indigestion for folks who watch their tickers daily  or worse  hourly  
The Hare Won  As Long As You Didn t Sell 




And I get it some of you just do check your stock quotes every day  and that s just how it s always going to be  Or you may have plenty of potential action packed into the rest of the portfolio  whether it s dividend growth or cryptocurrencies or weed stocks  I m not judging  and you just want anchors that can help steady the ship and pay you every month no matter what happens 
A bond CEF is a great addition to a  no withdrawal  portfolio  or an account in which you are comfortable letting prices do what they will while you collect your monthly and quarterly payouts  But bond CEF prices are going to fluctuate day to day  while ARTFX is the type of distribution rock that would make Bob Seger blush 
Want more bond rocks  Let s dig  Here are 11 more funds that  like ARTFX  meet the following strict criteria 
First  they pay 5  or better  While we re not looking for moonshots  we are looking for meaningful yield 
Second  they ve returned 4 5  or better over the last five years  This means these funds have at least  returned their yields   They re not tapping their own portfolios  or net asset values  NAVs  to pay us 
And finally  their  betas  are in the basement at 0 2 or below  This is the measure of how much the stock swings relative to the broader market  If the S P 500 moved 10 points  we d expect these prices to only move a point or two at most 
The 12 Safest Bond Mutual Funds That Actually Pay




The 12 funds above are all mutual funds  a tribute to the value that an active manager can add in Bondland  Now I know that some investors prefer ETFs  either by choice  they like the ease of buying and watching the TV commercials  or by necessity  their brokerage account requires a regular stock like ticker   This is doable but we must widen our strike zone a bit to allow for lower yields and yearly returns ",2019-07-31,Brett Owens,https://www.investing.com/analysis/these-21-safe-bond-funds-pay-up-to-85-and-never-go-down-200447803,200447803
198092,419608,JNJ,Looking For A Growth Stock  3 Reasons Why J J Snack Foods  JJSF  Is A Solid Choice,opinion,"Growth stocks are attractive to many investors  as above average financial growth helps these stocks easily grab the market s attention and produce exceptional returns  However  it isn t easy to find a great growth stock 
By their very nature  these stocks carry above average risk and volatility  Moreover  if a company s growth story is over or nearing its end  betting on it could lead to significant loss 
However  it s pretty easy to find cutting edge growth stocks with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
J J  NYSE JNJ  Snack Foods  JJSF  is one such stock that our proprietary system currently recommends  The company not only has a favorable Growth Score  but also carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy  
Here are three of the most important factors that make the stock of this drink and snack maker a great growth pick right now 
Earnings Growth
Earnings growth is arguably the most important factor  as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors  For growth investors  double digit earnings growth is highly preferable  as it is often perceived as an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for J J Snack Foods is 3 8   investors should actually focus on the projected growth  The company s EPS is expected to grow 22 5  this year  crushing the industry average  which calls for EPS growth of 5 4  
Impressive Asset Utilization Ratio
Growth investors often overlook asset utilization ratio  also known as sales to total assets  S TA  ratio  but it is an important feature of a real growth stock  This metric exhibits how efficiently a firm is utilizing its assets to generate sales 
Right now  J J Snack Foods has an S TA ratio of 1 23  which means that the company gets  1 23 in sales for each dollar in assets  Comparing this to the industry average of 1 2  it can be said that the company is more efficient 
While the level of efficiency in generating sales matters a lot  so does the sales growth of a company  And J J Snack Foods looks attractive from a sales growth perspective as well  The company s sales are expected to grow 2 8  this year versus the industry average of 0  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for J J Snack Foods  The Zacks Consensus Estimate for the current year has surged 1  over the past month 
Bottom Line
J J Snack Foods has not only earned a Growth Score of A based on a number of factors  including the ones discussed above  but it also carries a Zacks Rank  2 because of the positive earnings estimate revisions 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination positions J J Snack Foods well for outperformance  so growth investors may want to bet on it ",2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/looking-for-a-growth-stock-3-reasons-why-jampj-snack-foods-jjsf-is-a-solid-choice-200449038,200449038
198093,419609,JNJ,Geron  GERN  Stock Up Despite Q2 Earnings   Sales Miss,opinion,Geron Corporation   NASDAQ GERN   incurred a loss of 8 cents per share in second quarter 2019  wider than the Zacks Consensus Estimate of a loss of 6 cents  In the year ago quarter  the company had incurred a loss of 4 cents per share Quarterly revenues in the quarter came in at  0 1 million  which missed the Zacks Consensus Estimate of  0 2 million  Notably  the top line comprised royalty and license fee revenues received under various non imetelstat license agreements  In the year ago quarter  revenues totaled  0 21 million  Revenues declined as the number of active license agreements declined due to expiry of patents of Geron s underlying technology Research and development  R D  expense were up 215  year over year to  10 1 million  Transition costs  including resuming sponsorship of imetelstat clinical studies from J J   NYSE JNJ    costs related to start up of phase III portion of the IMerge study  evaluating imetelstat in myelodysplastic syndromes  and expansion of development team  resulted in the significant increase in R D expenses General and administrative  G A  expenses rose 23 8  to  5 2 million  reflecting legal costs related to patent litigations and recruitment expenses for additional headcounts Geron ended the second quarter with  162 3 million in cash and investments compared with  170 million at the end of the first quarter 2019 GuidanceGeron anticipates its full year operating expense to lie in the range of  80  85 million  This includes one time cost of  20  25 million related to activities for transition of imetelstat from Janssen to Geron and purchase of material for the phase III portion of IMerge study  Geron expects to end 2019 with approximately  100 million in cash and investments Pipeline UpdateFollowing the termination of the agreement with Janssen  a subsidiary of J J  in September 2018  Geron regained global development rights to imetelstat and decided to continue developing imetelstat independently  The transition activities  including ex U S  clinical and regulatory responsibilities  are expected to be completed in the third quarter Geron assumed sponsorship of the investigational new drug application for imetelstat in May this year  By August end  the company will initiate enrollment in the planned phase III portion of phase II III study  IMerge  in patients who have not received prior treatment with hypomethylating agents and lenalidomide  This may have led to the price rally of more than 5  in shares of Geron in after market trading on Aug 1  So far this year  the stock has gained 15  against the  s 0 4  decrease Another phase II study   IMbark   is evaluating the candidate in myelofibrosis  In December  Geron presented updated median overall survival   OS   data from the higher dosage arm  9 4 mg kg  of the study  The candidate achieved median OS of 29 9 months  which suggests a meaningful survival outcome  A decision on the path toward late stage development in myelofibrosis is expected to be announced by the third quarter of 2019 Geron Corporation Price  Consensus and EPS Surprise   Zacks Rank   Other Stocks to ConsiderGeron currently carries a Zacks Rank  2  Buy  A couple of top ranked biotech stocks include Axovant Sciences   NASDAQ AXGT   and Acorda Therapeutics   NASDAQ ACOR    both sporting a Zacks Rank  1  Strong Buy   You can see  Axovant s loss estimates have narrowed from  7 00 to  5 34 for 2019 and from  6 48 to  3 59 for 2020 over the past 60 days Acorda s loss estimates narrowed from  3 59 to  3 51 for 2019 and from  3 09 to  3 05 for 2020 over the past 60 days Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/geron-gern-stock-up-despite-q2-earnings--sales-miss-200450142,200450142
198096,419612,JNJ,J J Earnings  Revenue beat in Q3,news,"Investing com   J J  NYSE JNJ  reported third quarter earnings  that beat analyst s expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  2 05 on revenue of  20 35B  Analysts polled by Investing com anticipated EPS of  2 03 on revenue of  20 04B  That compared to EPS of  1 9 on revenue of  19 65B in the same period a year earlier The company had reported EPS of  2 1 on revenue of  20 83B in the previous quarter 
For the year  J J shares are down 4 09   under performing the S P 500 which is up 2 5  year to date 
J J follows other major Healthcare sector earnings this month
On September 27  Cantel Medical reported fourth quarter EPS of  0 62 on revenue of  228 85M  compared to forecasts of EPS of  0 58 on revenue of  225 98M 
Neogen earnings matched analyst s expectations on September 25  with first quarter EPS of  0 29 on revenue of  99 63M  Investing com analysts expected EPS of  0 29 on revenue of  104 57M
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2018-10-16,Investing.com,https://www.investing.com/news/stock-market-news/jj-earnings-revenue-beat-in-q3-1645662,1645662
198097,419613,JNJ,Johnson   Johnson profit beats  lifts forecast on cancer drug demand,news," Reuters    Johnson   Johnson  N JNJ  on Tuesday reported quarterly profit above estimates and raised its full year forecast  as demand for its cancer drugs Zytiga and Imbruvica helped offset decline in sales of blockbuster drug  Remicade   J J said it now expects adjusted 2018 earnings per share to be in the range of  8 13 and  8 18  up from its previous range of  8 07 to  8 17   Sales of rheumatoid arthritis treatment Remicade fell 16 3 percent to  1 38 billion in the quarter as pressure from biosimilars intensified  Analysts had expected revenue of  1 36 billion  according to  Barclays   LON BARC   As Remicade faces increased competition and the company s consumer and medical health businesses come under pressure  J J has been inking deals and spending more on its drug pipeline to beef up sales   The healthcare conglomerate s net earnings rose to  3 93 billion  or  1 44 per share  in the third quarter  from  3 76 billion  or  1 37 per share  a year earlier  Excluding items  the company earned  2 05 per share  Analysts on average expected  2 03 per share  according to I B E S data from Refinitiv   
Sales rose 3 6 percent to  20 35 billion  above analysts  average estimate of  20 05 billion ",2018-10-16,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-profit-beats-lifts-forecast-on-cancer-drug-demand-1645806,1645806
198098,419614,JNJ,J J Snack Foods  JJSF  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"The market expects J J  NYSE JNJ  Snack Foods  JJSF  to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended June 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on July 29  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This drink and snack maker is expected to post quarterly earnings of  1 54 per share in its upcoming report  which represents a year over year change of  10 8  
Revenues are expected to be  313 million  up 2 2  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for J J Snack Foods 
For J J Snack Foods  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that J J Snack Foods will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that J J Snack Foods would post earnings of  1 02 per share when it actually produced earnings of  1 08  delivering a surprise of  5 88  
Over the last four quarters  the company has beaten consensus EPS estimates two times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
J J Snack Foods doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-21,Zacks Investment Research,https://www.investing.com/analysis/jj-snack-foods-jjsf-reports-next-week-wall-street-expects-earnings-growth-200442580,200442580
198099,419615,JNJ,Will Humira   Other Drugs Drive AbbVie s  ABBV  Q2 Earnings ,opinion,AbbVie Inc s   NYSE ABBV   flagship product  Humira  has been witnessing strong sales despite the launch of competing drugs with new mechanisms of action  The drug is approved for several inflammatory indications and generates more than half of the company s revenues  The drug is well protected from competition in the United States till mid 2023 by patents  However  loss of exclusivity in Europe has led to the launch of multiple biosimilar drugs by other pharma companies since October last year  These launches have significantly dented international sales in the past couple of quarters and are expected to do the same in the soon to be reported quarter U S  Humira sales are expected to rise 7  in the soon to be reported quarter  The company estimates international sales to be  1 billion  The drug had brought in sales of  1 67 billion in the year ago quarter  The Zacks Consensus Estimate for second quarter Humira sales is pegged at  4 82 billion In April  the company s inflammation portfolio was strengthened with the approval of Skyrizi for treating moderate to severe plaque psoriasis in the United States and Europe  However  the impact of the drug on the top line is expected to be modest in the second quarter Its key oncology medicine  Imbruvica has shown impressive adoption in the approved indications  especially front line chronic lymphocytic leukemia   CLL    The drug is approved for use as a monotherapy or in combination for front line CLL  The drug is the only preferred regimen under the NCCN guidelines for this indication  The drug is marketed in partnership with J J   NYSE JNJ    globally  J J on its second quarter earnings call reported impressive sales of the drug AbbVie expects Imbruvica to record sales of approximately  1 1 billion in the second quarter  The Zacks Consensus Estimate for the drug is pegged at  1 09 billion for the soon to be reported quarter Sales of another leukemia drug  Venclexta  doubled year over year in the first quarter on the back of continued progress in the relapsed refractory CLL indication  Label extension of the drug in acute myeloid leukemia also boosted sales  The growth trend is expected to continue in the soon to be reported quarter  In May  the drug was approved in combination with Roche s   OTC RHHBY   Gazyva as first line treatment for CLL patients  which may add to second quarter revenues Other drugs  namely Duodopa and Creon  are also likely to continue their strong performance in the soon to be reported quarter  The Zacks Consensus Estimate for Duodopa and Creon sales is pegged at  120 million and  245 million  respectively AbbVie s new HCV drug  Mavyret recorded a decline in the first quarter due to decline in international market share and pricing  However  growth in the U S  markets was strong  It remains to be seen how the drug performs in international markets this time around   Read more   AbbVie s stock has depreciated 26 2  this year so far  compared with a decline of 1 2  recorded by the  AbbVie currently carries a Zacks Rank  2  Buy   You can see  Upcoming ReleaseBristol Myers Squibb   NYSE BMY   is set to report second quarter results on Jul 25  The company has an  of  0 28  and a Zacks Rank  3  You can also uncover the best stocks to buy or sell before they re reported with our  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-23,Zacks Investment Research,https://www.investing.com/analysis/will-humira--other-drugs-drive-abbvies-abbv-q2-earnings-200443017,200443017
198100,419616,JNJ,Social Media Earnings  Facebook And Twitter Prepare To Share,opinion,"Earnings are in full swing this week and technology investors who hold any of the nation s major social media companies are likely preparing for a hectic few days  Facebook  NASDAQ FB  and Twitter  NYSE TWTR   two platforms on which millions of investors and non investors alike share their memories  gripes and sometimes everyday mundane doings through posts and tweets  are opening their books this week 
Both social media giants reported double digit revenue growth in Q1 as their active users numbers climbed  helping to rev up advertising dollars  FB is at the top of the mountain in both users and ad revenue  and TWTR looks to be holding its own  but on a smaller scale 
Have the companies been able to keep up the momentum in Q2  If their stock prices are any indication  it appears investors at least are keeping the faith  FB has been among the top tech guns elevating the S P 500 s  SPX  climbs to fresh peaks   FB stock represents 1 9  of the index and is up some 50  since the beginning of the year  TWTR s path has been a bit wobbly  but it has still managed to clock about a 28  increase 
Analysts watching FB say they will be looking for solid upticks in all the numbers and updates on a potential  5 billion fine for FB from the Federal Trade Commission  For TWTR  analysts may be looking at how TWTR says it s monitoring those who violate the site s community standards rules 
There s a lot of focus on potential regulatory issues  and a key thing to consider is that companies under a government shadow might see less of a potential bullish response if their earnings beat  Even if FB and TWTR have killer earnings  the fact that they re in the cross hairs could limit gains for their stocks 
That dynamic arguably played out last week when Johnson   Johnson  NYSE JNJ  the subject of a Justice Department probe didn t get much lift despite an impressive earnings performance across the entire company 
FB s Regulatory Fines
FB is expected to move the conversation  away from putting out privacy fires and back toward innovation   Barclays  LON BARC  analyst Ross Sandler told MarketWatch  He said he will be looking for signs  for example  that advertisers are beginning to embrace FB s  Stories  format an Instagram copycat layout launched last September as a means of stepping up engagement between users and advertisers 
There are also a number of issues investors might be interested in hearing updates about  a few of which are tied to regulatory issues that some investors and analysts point out could be good for FB 
Every time FB announces that it s settled with a government here or abroad  the stock gets a boost  Josh Brown  chief executive of Ritholtz Wealth Management said on CNBC   The Street loves when there s finality to those things   he said 
Here s a short list of issues analysts have said they will be listening to on FB s conference call 
Updates on its  1 billion acquisition of Instagram in 2012 and its  19 billion acquisition of WhatsApp in 2014  both drivers of new users across diverse age groups 
What other mergers and acquisition FB might be toying with as it builds its user empire  FB typically acquires apps and companies that are outside its main offerings and tend to be attractive to a broad range of age groups  what McKinsey calls  programmatic M A   FB has acquired 72 companies since August 2005  according to Techwyse com  at a cost of  23 36 billion 
Libra  the new cryptocurrency it s launching that looks to be facing a barrage of headwinds from a nearly every commercial and political corner of the world  Mixing internet services with banking on a social media platform appears to be helping stir the controversy  But FB has said cryptocurrency could be the next best thing to the gold standard  Stay tuned 
That expected  5 billion fine that FB is said to have settled with the Federal Trade but has not been officially announced publicly  While  5 billion is a big chunk of change from nearly anyone s pocketbook  investors should remember that FB already took a  3 billion charge in Q1 in anticipation of a multi billion dollar hit 
And if that doesn t do it for you  think back to FB s 2018 results  Net income of  22 11 billion on  55 84 billion in revenue  And then there was its record breaking Q1 of  15 1 billion in revenue 
Plus  the markets embraced the stock when the rumored  5 billion figure hit the headlines  reaching a fresh peak since the start of the year  possibly because it could signal that the end was near  It barely flinched when Libra was announced and the backlash began  possibly supporting Brown s theory  The stock is up some 50  since the beginning of the year 
Analysts polled by FactSet expect Facebook to report Q2 earnings per share of  1 87  up nearly 7  from the year ago result of  1 74 a share  and revenue of  16 5 billion  which would represent a 25  increase from  13 23 billion 
FB reports Wednesday  July 24 after the bell with a conference call at 5 p m  ET 
FB Options Activity
The options market has priced in an expected share price move of about 5 9  in either direction around the earnings release  according to the Market Maker Move  indicator on the thinkorswim  platform 
Volume in both puts and calls have been elevated  Puts have been most active at the 192 5 and 195 strikes  and calls have seen higher volume at the 205 through 210 strikes  The implied volatility sits at the 45th percentile as of Tuesday morning 
Note  Call options represent the right  but not the obligation  to buy the underlying security at a predetermined price over a set period of time  Put options represent the right  but not the obligation  to sell the underlying security at a predetermined price over a set period of time 
TWTR s Got a New Look
The pot is not nearly as full at TWTR  but investors might want to hear more about the short messaging app s tests to make conversation threads easier to follow  TWTR last week unveiled its latest plan to achieve that by using icons instead of labels in replies 
Will this help  Some would argue the platform s interface isn t that complicated to begin with 
Twitter also rolled out a new design with  a refreshed and updated website that s faster  easier to navigate and more personalized   according to the company s release  Techies appear to have mixed feelings about it  The customization options look like they re a hit  but some critics say they don t like all the sidebar additions on the left  Change is never easy 
Some investors might want to know what those outages earlier in the month were all about  At the time  TWTR said the shutdown was due to an  internal configuration change   but didn t explain exactly what that meant and what might be the likelihood of it happening again 
And finally  TWTR said in late June that it was adding disclaimers to world leaders  tweets that break the firm s community standards if they are in the public interest 
How might TWTR determine where to draw the line between  public interest  and misinformation   This is not about perceived bias but about providing more clarity if our rules have been broken   a Twitter spokesperson told CNN Business 
TWTR is expected to report per share earnings of  0 18 a 5 9  increase over the year ago period on revenue of  829 million which would be a 16 6  lift from the year ago period 
Twitter s earnings are expected to be released on Friday  July 26  ahead of the market s open 
TWTR Options Activity
The options market has priced in an expected share price move of about 9 4  in either direction around the earnings release  according to the Market Maker Move  indicator on the thinkorswim  platform 
Call activity has been relatively light  but heaviest at the 37 5 and 39 strikes  Put volume has been heavier overall  with the highest concentration at the 35 strike  The implied volatility sits at the 41st percentile 
Good Trading
Disclaimer  TD Ameritrade  commentary for educational purposes only  Member SIPC  Options involve risks and are not suitable for all investors  Please read Characteristics and Risks of Standardized Options ",2019-07-24,JJ Kinahan,https://www.investing.com/analysis/social-media-earnings-facebook-and-twitter-prepare-to-share-200443626,200443626
198101,419617,JNJ,Why Johnson   Johnson  JNJ  Is A Great Dividend Stock Right Now,opinion,"Getting big returns from financial portfolios  whether through stocks  bonds  ETFs  other securities  or a combination of all  is an investor s dream  However  when you re an income investor  your primary focus is generating consistent cash flow from each of your liquid investments 
While cash flow can come from bond interest or interest from other types of investments  income investors hone in on dividends  A dividend is the distribution of a company s earnings paid out to shareholders  it s often viewed by its dividend yield  a metric that measures a dividend as a percent of the current stock price  Many academic studies show that dividends make up large portions of long term returns  and in many cases  dividend contributions surpass one third of total returns 
Johnson   Johnson  NYSE JNJ  in Focus
Headquartered in New Brunswick  Johnson   Johnson  JNJ  is a Medical stock that has seen a price change of 0 57  so far this year  The world s biggest maker of health care products is paying out a dividend of  0 95 per share at the moment  with a dividend yield of 2 93  compared to the Large Cap Pharmaceuticals industry s yield of 3 09  and the S P 500 s yield of 1 86  
Looking at dividend growth  the company s current annualized dividend of  3 80 is up 7 3  from last year  Over the last 5 years  Johnson   Johnson has increased its dividend 5 times on a year over year basis for an average annual increase of 6 34   Any future dividend growth will depend on both earnings growth and the company s payout ratio  a payout ratio is the proportion of a firm s annual earnings per share that it pays out as a dividend  Johnson   Johnson s current payout ratio is 44   This means it paid out 44  of its trailing 12 month EPS as dividend 
Earnings growth looks solid for JNJ for this fiscal year  The Zacks Consensus Estimate for 2019 is  8 60 per share  with earnings expected to increase 5 13  from the year ago period 
Bottom Line
Investors like dividends for many reasons  they greatly improve stock investing profits  decrease overall portfolio risk  and carry tax advantages  among others  It s important to keep in mind that not all companies provide a quarterly payout 
For instance  it s a rare occurrence when a tech start up or big growth business offers their shareholders a dividend  It s more common to see larger companies with more established profits give out dividends  Income investors must be conscious of the fact that high yielding stocks tend to struggle during periods of rising interest rates  With that in mind  JNJ is a compelling investment opportunity  Not only is it a strong dividend play  but the stock currently sits at a Zacks Rank of 3  Hold  ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/why-johnson--johnson-jnj-is-a-great-dividend-stock-right-now-200444739,200444739
198106,419622,JNJ,FDA OKs revised labeling for ViiV Healthcare HIV meds to include risk of birth defects,news,The FDA has signed off on new labeling for ViiV Healthcare s HIV meds TIVICAY  dolutegravir   TRIUMEQ  abacavir  dolutegravir and lamivudine  and JULUCA  dolutegravir  rilpivirine  to include information on the risk of neural tube defects  birth defects of the brain  spine or spinal cord   Pregnant women or women who plan to become pregnant should avoid taking the medications ViiV is the HIV focused joint venture between  Pfizer   NYSE PFE   GlaxoSmithKline  NYSE GSK  and Shionogi  OTCPK SGIOY  OTCPK SGIOF  Report received via email update Now read ,2018-09-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-revised-labeling-for-viiv-healthcare-hiv-meds-to-include-risk-of-birth-defects-1601281,1601281
198107,419623,JNJ,J J to work with India on compensation for recalled hip implants,news,"By Aditya Kalra MUMBAI  Reuters    Johnson   Johnson  NYSE JNJ   J J  said it would work with the Indian government to compensate patients who had suffered from hip implants that were recalled by the U S  healthcare firm eight years ago after data showed high failure rates  This follows last week s recommendation from a government panel that J J pay at least 2 million rupees   27 812  to each patient for the faulty ASR hip implant  The federal government has asked states to help patients get relief soon  About 93 000 people worldwide received ASR implants which were recalled in 2010  The Indian panel said in its report that about 4 700 of those people were in India  Given the recent committee report   we are seeking to work with the Indian government to develop an appropriate process for providing further support and compensation for patients in need   a J J spokeswoman said in a statement to Reuters  adding the firm was committed to support all ASR patients in India  Sushobhan Dasgupta  a senior J J executive in India  has  however  told Indian newspaper Mint that the company  will not pay people who had an ASR implant if they are doing well   The company is not okay with the methodology used by the Indian panel  Dasgupta told the paper in an interview  published on Friday  The report has  factual inaccuracies  and  the conclusions could also be inaccurate   he added  In 2013  J J agreed to pay  nearly  2 5 billion to settle thousands of lawsuits from patients in the United States who said they were injured by the implants  In India  the company paid  2 million to patients for repeat surgeries and about  250 000 in related diagnostic costs under its ASR reimbursement program  but the government panel has criticized J J for offering no compensation  Metal hip implant systems such as ASR were designed to be more durable than a traditional metal on plastic  ball and socket design  But many Indian patients suffered adverse reactions to the implant  the panel said  J J entered the Indian market in 1947 when it started selling its now ubiquitous baby powder  It has in recent years faced issues such as price caps on medical devices  
  1   71 9100 Indian rupees ",2018-09-07,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-says-to-work-on-india-compensation-for-recalled-hip-implants-1601589,1601589
198108,419624,JNJ,J J s Stelara succeeds in chronic bowel disease study,news," Reuters    Johnson   Johnson  NYSE JNJ  said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late stage trial  Two doses of Stelara  already approved for psoriasis  psoriatic arthritis and Crohn s disease  was tested in 961 patients with moderate to severe ulcerative colitis  UC  who had failed prior therapy  Both 6 mg kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients  compared with those on placebo  after eight weeks  the company said  The treatment and the placebo arms reported similar proportion of side effects  with one patient on the 6 mg kg dose dying following excessive bleeding  J J said  The patient had no prior history of high blood pressure or cirrhosis  the drugmaker said   More than half of UC patients have not experienced remission with currently available treatment options   the study s lead investigator Bruce Sands said  Stelara  which brought in sales of  1 34 billion in the second quarter of 2018  is also being tested in autoimmune disease lupus  Ulcerative colitis  which affects about 38 000 people in the United States annually  is a chronic condition causing abdominal pain  intestinal ulcers  bloody diarrhea and weight loss  Current treatments include  Pfizer   NYSE PFE  Inc s Xelijanz  an oral treatment for adults patients with moderate to severe UC  and Merck   Co s Renflexis  
 This story has been refilled to correct the dosage to 130 mg  not 130 mg kg in paragraph 3 ",2018-10-10,Reuters,https://www.investing.com/news/general-news/jjs-stelara-succeeds-in-chronic-bowel-disease-study-1636846,1636846
198109,419625,JNJ,Jury clears J J of liability in New Jersey talc cancer case,news,"By Tina Bellon  Reuters    A New Jersey jury on Thursday cleared Johnson   Johnson  NYSE JNJ  of liability in a case involving a woman who alleged that the company s talc based products  including its baby powder  contain asbestos and caused her cancer  After less than a day of deliberations  the jury in New Brunswick  New Jersey rejected claims by Rosalind Henry and her husband  who had alleged that Henry s mesothelioma  a cancer associated with asbestos exposure  was caused by the company s talc products  J J is facing some 10 600 liability lawsuits across the United States over its talc products  most involving claims that they caused ovarian cancer  and that the company knew of and concealed risks associated with the products  The company  which is based just a few miles from the courtroom where the latest case took place  said it was pleased with the unanimous jury verdict   We have deep sympathy for anyone diagnosed with any form of cancer and appreciate that people are looking for answers  However  Johnson s baby powder is not the cause of this disease   the company said in a statement  It said decades of scientific testing by academic institutions and regulators have shown its talc to be safe and free of asbestos  A lawyer for Henry did not immediately return a request for comment  During trial  Henry s lawyers said J J had known for decades about asbestos fibers in its talc  but hid the evidence from regulators and consumers  J J has been fighting talc cancer lawsuits for several years  but the litigation shifted in recent months to include allegations of asbestos contamination   Plaintiffs now claim asbestos fibers in the products are causing both ovarian cancer and mesothelioma  In April  J J lost the first trial over such allegations when a jury in New Jersey awarded  117 million to a man suffering from mesothelioma and his wife  It lost another trial in May  when a California jury awarded  25 7 million to a woman diagnosed with mesothelioma  Both decisions are under appeal  Since then  the company has had four mistrials in similar cases because jurors could not reach a verdict or because the plaintiff died  
In July  a Missouri jury hit J J with a massive  4 69 billion verdict in the first trial alleging asbestos contamination has caused ovarian cancer in 22 women  That decision is also under appeal ",2018-10-11,Reuters,https://www.investing.com/news/stock-market-news/jury-clears-jj-of-liability-in-new-jersey-talc-cancer-case-1641186,1641186
198110,419626,JNJ,Why Is Jabil  JBL  Up 1  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Jabil  JBL   Shares have added about 1  in that time frame  underperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Jabil due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Jabil s Q3 Results Benefit From Strong EMS PerformanceJabil reported third quarter fiscal 2019 earnings of 57 cents per share  which beat the Zacks Consensus Estimate by a penny and rallied 23 9  year over year Revenues increased 12 8  year over year to  6 14 billion that outpaced the Zacks Consensus Estimate of  6 billion Moreover  during the quarter  Jabil completed Wave 1 and Wave 2 phases related to the previously announced collaboration with Johnson   Johnson  NYSE JNJ  Medical Devices Companies  JJMDC    Quarter DetailsElectronics Manufacturing Services  EMS  revenues accounted for 65  of total revenues and increased 26  year over year to  4 billion  driven by strength in cloud  point of sale  5G and wireless  and industrial end markets Diversified Manufacturing Services  DMS  revenues accounted for 37  of revenues and decreased 6  year over year to  2 1 billion  primarily due to weak demand for mobility  which is part of Mechanics and Edge Devices   Accessories end markets Gross margin on a GAAP basis contracted 10 basis points  bps  year over year to 7 2  Core EBITDA margin contracted 20 bps on a year over year basis to 6 1  Operating expenses on a GAAP basis declined 30 bps to 4 9   While selling  general and administrative  SG A  expenses shrank 20 bps to 4 5   research   development  R D  expenses as percentage of revenues were flat at 0 2  Non GAAP core operating margin expanded 30 bps to 3  EMS core margin declined 100 bps on a year over year basis to 3 3   primarily due to softness in the capital equipment space and costs associated with the ramping up of new business awards However  DMS core margin improved 130 bps on a year over year basis to 2 6   driven by improved business mix well supported by Jabil s diversification efforts Balance Sheet   Cash FlowJabil exited the quarter with cash and cash equivalents of  694 million compared with  749 1 million in the previous quarter In the quarter  cash flow from operations was  5 million  while free cash outflow was  225 million GuidanceFor fourth quarter fiscal 2019  Jabil expects total revenues between  6 3 billion and  6 9 billion  Revenues are expected to grow almost 14  year over year at mid point DMS revenues are forecasted to be  2 5 billion  up roughly 4  year over year  EMS revenues are forecasted to be  4 1 billion  up nearly 22  year over year Core operating income is estimated to be  215  275 million  with core operating margin of 3 4  The company s core earnings are expected to be 76 96 cents per share on a non GAAP basis For fiscal 2019  revenues are expected to be  25 3 billion  Core operating income is expected to be  875 million  up 14  year over year Adjusted free cash flow is expected around  400 million  up 60  year over year For DMS segment  revenues are expected to be  9 9 billion  Jabil expects core operating margin to be 3 9  and EBITDA of  890 million Further  EMS segment revenues are expected to be  15 4 million  The company expects core operating margin to be 3 2  and EBITDA of  760 million Moreover  for fiscal 2020  revenues associated with the J J collaboration are expected between  800 million and  1 billion 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  The consensus estimate has shifted  6 8  due to these changes 
VGM Scores
At this time  Jabil has a nice Growth Score of B  though it is lagging a lot on the Momentum Score front with an F  However  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of this revision looks promising  Notably  Jabil has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/why-is-jabil-jbl-up-1-since-last-earnings-report-200441273,200441273
198116,419632,JNJ,Missouri judge affirms  4 69 billion talc verdict  J J vows to appeal,news,"By Tina Bellon  Reuters    A Missouri trial court judge has affirmed the massive  4 69 billion verdict against Johnson   Johnson  N JNJ  in a case involving 22 women and their families who alleged the company s talc based products  including its baby powder  contain asbestos and caused them to develop ovarian cancer  J J in a statement on Wednesday said it would continue to pursue all available appellate remedies  The company  which denies the allegations and says its talc is safe  previously said it was confident the verdict would be overturned on appeal  In a series of orders on Tuesday evening  Judge Rex Burlison of the Circuit Court of the City of St  Louis affirmed the jury s July 12 decision in favor of the women  six of whom have died   The Court finds there is no just reason for delay and hereby certifies this judgment as final for purposes of appeal   Burlison wrote in the judgments  Defendants in civil cases can generally file so called post trial motions  asking the trial court judge to reduce a verdict or set it aside entirely  but J J did not file such motions  It can now take up the cases with a Missouri appeals court  The jury found the company s talc based products had caused the women s cancer  awarding  550 million in compensatory damages and  4 14 billion in punitive damages to all plaintiffs  Mark Lanier  a lawyer for the women  in a statement on Wednesday said he was confident the judgment would be upheld on appeal   We hope this judgment will compel Johnson   Johnson to take responsible  effective action in acknowledging the inherent dangers of the use of talc  and specifically the use of Johnson s Baby Powder and similar products   Lanier said  The verdict was the largest to date arising from lawsuits alleging products like J J s Baby Powder cause cancer  The company faces some 10 600 cases nationwide over talc  according to an August regulatory filing  J J has called the five week St  Louis trial  fundamentally unfair  and its Chief Executive Alex Gorsky has expressed confidence the jury decision will be overturned on appeal  
J J has been successful at having other talc verdicts in Missouri thrown out on appeal  A lawyer for the company told Reuters J J would focus on jurisdictional arguments and put forth its case that scientific studies overwhelmingly show talc itself is safe and the company s talc based products never contained asbestos ",2018-08-22,Reuters,https://www.investing.com/news/stock-market-news/missouri-judge-affirms-469-billion-talc-verdict-jj-vows-to-appeal-1583648,1583648
198117,419633,JNJ,Missouri judge affirms  4 69B verdict against J J in talc case  appeal planned,news,A Missouri trial court judge has affirmed the  4 69B verdict against Johnson   Johnson  JNJ  0 5   in a product liability case involving 22 women and their families who claim the company s baby powder caused their ovarian cancer The company continues to deny the allegations and vows to appeal  Thousands of lawsuits remain to be adjudicated Now read ,2018-08-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/missouri-judge-affirms-469b-verdict-against-jj-in-talc-case-appeal-planned-1583672,1583672
198118,419634,JNJ,Indian panel wants Johnson   Johnson to pay compensation over recalled implants,news,"By Aditya Kalra NEW DELHI  Reuters    A government panel has recommended that Johnson   Johnson  NYSE JNJ   J J  pay compensation of at least  28 500 to each Indian patient who suffered from artificial hip implants the U S  healthcare firm recalled eight years ago  The ASR hip implants were recalled in 2010  after data suggested they failed at a higher than expected rate  In 2013  the firm agreed to pay nearly  2 5 billion to settle thousands of lawsuits from those in the United States who said they were injured by the implants     In India  J J paid  2 million to patients for repeat surgeries and about  250 000 in related diagnostic costs under its ASR reimbursement program  but the panel criticized the company for offering no compensation   The fact remains that no compensation ever has been made by the firm in India to any patient   the panel said in a 118 page report released late on Tuesday   The panel was set up by the federal health ministry  which has said it is reviewing the report  In a statement  J J said its unit did not have access to data on patients who received implants because of patient confidentiality regulations  but it had given  top priority  to supporting ASR patients   The company has always put the health and safety of ASR patients first in everything we do   it said  About 93 000 people worldwide received ASR implants  the panel said  about 4 700 of them in India   Metal hip implant systems such as ASR were designed to be more durable than a traditional metal on plastic ball and socket design  But many Indian patients suffered adverse reactions from the implant  the panel said  It also criticized J J for being  evasive  in sharing information on ASR s design with it  Only in 2015  five years after the ASR recall  did the company run newspaper notices in India about the move    This  shows the negligent behavior of the firm to reach out to the affected patients   the panel said  calling for periodic advertisements to raise patient awareness about the implants  J J denied the panel s assessment  saying its unit had not been evasive and had  fully cooperated with the expert committee in their investigation   The panel findings  first reported by Indian media last week  have sparked a public relations crisis for the U S  based company  which has also faced criticism from patient rights activists  
J J  has the responsibility to track patients  make them aware of the adverse effects and compensate them   said Oommen C  Kurian  a health researcher at the New Delhi based Observer Research Foundation ",2018-08-29,Reuters,https://www.investing.com/news/stock-market-news/indian-panel-wants-johnson--johnson-to-pay-compensation-over-recalled-implants-1590450,1590450
198119,419635,JNJ,Bull Signal Sounds For Johnson   Johnson Stock Before Earnings,opinion,"Johnson   Johnson  NYSE JNJ  and the state of Oklahoma are set to wrap up a trial today in a case that accused the pharmaceutical firm of being a  kingpin  in the opioid epidemic by downplaying the addictive risks of painkillers  The company s legal troubles are far from over  however  with Bloomberg reporting last week the U S  Justice Department is investigating the company s knowledge of carcinogens in its baby powder    news that sent the Dow stock plummeting 
JNJ is inching higher today  up 0 6  at  135 13  but has barely put a dent in the damage caused by last Friday s 4 1  plummet  Looking more broadly  JNJ has experienced a choppy year on the charts  with a late June attempt to close last December s dramatic bear gap capped at the  145 region  On the other hand  the equity has managed a 4 6  year to date gain  and is up 7 2  year over year 
This recent drop may have created a short term buying opportunity  if history is any indicator  During its pullback  JNJ retreated to its 320 day moving average  According to data from Schaeffer s Senior Quantitative Analyst Rocky White  in the five other times the equity pulled back to this trendline in the last couple years  it was higher 21 days later 60  of the time  and averaged a one month return of 3 84   A similar move would put JNJ right near Thursday s pre bear gap levels at  140 

Johnson   Johnson s earnings report  which is slated for release tomorrow morning  could determine the stock s direction  too  JNJ has clocked a positive earnings reaction following five of the last eight reports  including a 3 5  swing higher this time last year  This time around  the options market is pricing in a 3 3  swing for tomorrow s session  slightly higher than the 2 3  post earnings move it s averaged in the past two years 
Expanding on activity in the options pits  it looks like traders are ramping up their bullish bets before tomorrow s unveiling  Currently  over 25 000 calls have crossed the threshold so far today  three times what is typically seen at this point  The October 140 call is seeing most of this action  followed by the July 136 call  with positions being opened at both 
Split analyst sentiment could sway JNJ stock  too  with seven  buy  or better ratings compared to five  hold  ratings on the table  The consensus 12 month target price of  149 17  however  sits in territory the equity has yet to reach ",2019-07-16,Schaeffer's Investment Research,https://www.investing.com/analysis/bull-signal-sounds-for-johnson--johnson-stock-before-earnings-200439992,200439992
198120,419636,JNJ,Monday Market Momentum Continues,opinion,"And we keep going higher 
The S P is now up 15  for the year and 25  off the December lows and 10  off the June lows  so it s been quite a year for the senior index  Citigroup  NYSE C  kicked off earnings season this morning with a decent report but tomorrow things begin to get serious and it will be a jam packed couple of weeks as July 4th cost us a week so we re a bit behind in our reporting already 
Income at C is up 7  from last year at  4 5Bn for the quarter  which is  1 95 share vs  1 85 expected but revenues were only in line at  18 5Bn so we re not likely to get a very enthusiastic reaction with the stock already at  72  we are long C with a 2021 target of  75 in our LTP   There aren t many bank stocks we like but C is one of them so no surprise here  Wells Fargo  NYSE WFC  tomorrow will be much more interesing and Johnson   Johnson  NYSE JNJ  also reports in the morning and we ll see what they set aside for their talcum powder scandal 


These are probably the most fun earnings to play but it s early in the season and we have little to go on though we are already long on Skechers  SKX  and Cliffs  CLF  though SKX passed our  27 target long agao and we re just waiting to get paid as the spread is netting just  11 025 out of a potential  16 000 so it still has  4 975  45   left to gain between now and Jan 17th  2020 even though it s  20  in the money   aren t options fun 

So  as a brand new trade  you can take this spread and make up to 45  from scratch  Of course  we netted in originally for a  1 680 credit and we re making almost 10x more than that if SKX finishes the cycle over  27   now THAT is what I call fun  SKX is at the top of their trading range and hopefully they pull back a bit on earnings so we can add them to the OOP  though we ll come up with something that makes more than 45    so dull  
Our favorite kinds of earnings plays are to pick up stocks other peope are throwing away for the wrong reasons but  as I noted above  early in the season we re more worried about playing defense with our existing positions  rather than chasing after new ones unless there s a particularly amazing bargain to be had  like BBBY last week  

Getting back to Cleveland Cliffs  CLF   I can t believe they are still down in the dumps and I m tempted to add more ahead of their earnings on Friday as Iron Ore pricing has shot up and CLF has the advantage of being a US producer in the trade wars yet the stock is languising around  10 50  which is  on track  for our 2021  12 target but our spread has only gained  1 100 and it s a potential  8 000 spread that s currently net  1 500 so another  6 500  433   potential to gain so  even if you missed our original  400 entry last month   433  upside in 18 months doesn t suck 

Here s how ridiculously cheap CLF is   10 50 is just under  3Bn in market cap yet last year CLF had  1 1Bn in profit though  475M of that was a tax credit so call it  625M but they ll pay taxes on that this year so we ll call it net profits of  500M for  3Bn and the p e is 6x at  10 50 but Iron Ore prices have gone up 50  since the start of the year and that can have a tremendous impact on earnings yet estimates for CLF have barely budged  0 57 expected Fri vs 0 55 last year   so I m expecting a nice beat and raised guidance 
We ll see what joys the earnings season can bring us and we have a ton of Fed speak on tap with 7 speeches just tomorrow and one today  one Thursday and two Friday  all surrounding the Fed s Beige Book Report on Wednesday  We have the Empire State Manufacturing this mornng  Retail Sales and Industrial Production tomorrow  the Philly Fed Thursday and Consumer Sentiment on Friday   along with about 200 earnings reports this week ",2019-07-16,Phoenix Capital Research,https://www.investing.com/analysis/monday-market-momentum-continues-200440001,200440001
198121,419637,JNJ,Johnson   Johnson  JNJ  Tops Q2 Earnings And Revenue Estimates,opinion,"Johnson   Johnson  NYSE JNJ  came out with quarterly earnings of  2 58 per share  beating the Zacks Consensus Estimate of  2 42 per share  This compares to earnings of  2 10 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 6 61   A quarter ago  it was expected that this world s biggest maker of health care products would post earnings of  2 03 per share when it actually produced earnings of  2 10  delivering a surprise of 3 45  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Johnson   Johnson  which belongs to the Zacks Large Cap Pharmaceuticals industry  posted revenues of  20 56 billion for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 1 17   This compares to year ago revenues of  20 83 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Johnson   Johnson shares have added about 4 4  since the beginning of the year versus the S P 500 s gain of 20 2  
What s Next for Johnson   Johnson 
While Johnson   Johnson has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Johnson   Johnson was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 06 on  20 10 billion in revenues for the coming quarter and  8 60 on  81 28 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Large Cap Pharmaceuticals is currently in the top 11  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-16,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-tops-q2-earnings-and-revenue-estimates-200440106,200440106
198126,419642,JNJ,Long acting injection a shot in the arm for GSK s HIV business,news,"By Ben Hirschler LONDON  Reuters    A long acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus  lifting prospects for the British drugmaker s key HIV business  GSK s majority owned ViiV Healthcare unit said on Wednesday the experimental two drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three drug oral regimen  after 48 weeks of a clinical trial  The result from the big Phase III study is a boost for GSK s goal of developing dual therapies that are easier to tolerate than conventional triple ones  and shares in GSK rose more than 1 percent  It follows recent positive data from combining two oral drugs  GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences  NASDAQ GILD   the U S  drugmaker that dominates the  26 billion a year HIV market   Gilead currently has a market share of around 52 percent against GSK s 22 percent  but Deborah Waterhouse  who heads the British drugmaker s HIV unit  says she hopes to overtake her U S  rival by the mid 2020s  That is a bold ambition  since many analysts have been expecting GSK to lose market share to Gilead s new triple drug Biktarvy  rather than see it gain ground  Liberum analyst Roger Franklin  who rates GSK a  buy   believes the company s dual drug strategy has been under appreciated by the market   Whilst duals will likely be a slow burn as resistance data is collected and the regimen gains credence among physicians  the prospects are much improved now versus a year ago   he said   GSK is betting that a shift to using two drugs rather than three will boost its sales by offering patients a therapy with greater convenience and fewer toxic side effects  In certain cases  depending on the drugs used  two drug regimens will also be significantly cheaper  Still  some doctors worry that using just two drugs to keep the AIDS virus at bay might risk drug resistance because HIV will only have to evade two drugs rather than three  That is certainly the view at Gilead  which is sticking with three  In the case of the cabotegravir and rilpivirine monthly injection  GSK said drug resistance results in the latest study were consistent with data from earlier smaller trials  It did not go into further details but said full results would be presented at an upcoming scientific meeting  ViiV Chief Scientific and Medical Officer John Pottage argued the novel injection offered an alternative long term treatment for patients   If approved  this regimen would give people living with HIV one month between each dose of antiretroviral therapy  changing HIV treatment from 365 dosing days per year  to just 12   he said  
Results from a second trial of cabotegravir and rilpivirine are expected later this year  Rilpivirine was developed by Johnson   Johnson  NYSE JNJ  and GSK is working with the U S  drugmaker on the new injection regimen ",2018-08-15,Reuters,https://www.investing.com/news/stock-market-news/longacting-injection-a-shot-in-the-arm-for-gsks-hiv-business-1574752,1574752
198127,419643,JNJ,Trump administration proposes production quota cuts for six opioids,news,WASHINGTON NEW YORK  Reuters    The Trump administration on Thursday proposed that U S  drugmakers cut production quotas of the six most abused opioids by 10 percent next year to fight a nationwide addiction crisis  In a statement  the U S  Justice Department and Drug Enforcement Administration  DEA  said the proposed cut would be in keeping with President Donald Trump s effort to cut opioid prescription fills by one third within three years  Trump on Thursday also pressed U S  Attorney General Jeff Sessions to sue drug manufacturers over the opioid crisis   I d like to bring a federal lawsuit against those companies   Trump said during a meeting of his Cabinet at the White House  He did not name the companies  Addiction to opioids   mainly prescription painkillers  heroin and fentanyl   is a growing U S  problem  especially in rural areas  According to the Centers for Disease Control and Prevention  opioids were involved in more than 49 000 deaths in the country last year  The Justice Department and the DEA said they are proposing to cut production quotas for oxycodone  hydrocodone  oxymorphone  hydromorphone  morphine  and fentanyl by 7 percent to 15 percent  depending on the compound  in 2019   Hundreds of lawsuits have been filed by states  counties and cities against opioid manufacturers including Purdue Pharmaceuticals LP  Endo International Plc  O ENDP    Mallinckrodt  Plc  N MNK  and Johnson   Johnson  N JNJ  seeking to hold them responsible for contributing to the epidemic  Those companies were not immediately available for comment  In March  Trump unveiled a plan to get tough on opioids  including cutting opioid prescriptions by changing federal programs  funding for other initiatives and stiffer sentencing laws for drug dealers   He also suggested the death penalty for dealers  a proposal that has gained little support from drug abuse and judicial experts ,2018-08-16,Reuters,https://www.investing.com/news/politics-news/trump-administration-seeks-cuts-in-production-of-abused-opioids-1577203,1577203
198128,419644,JNJ,Exclusive  OxyContin maker Purdue taps financial restructuring adviser   sources,news,"By Jessica DiNapoli and Nate Raymond NEW YORK BOSTON  Reuters    OxyContin maker Purdue Pharma LP has tapped law firm Davis Polk   Wardwell LLP for financial restructuring advice  as its potential liabilities swell with a wave of lawsuits over the opioid addiction epidemic sweeping the United States  people familiar with the matter said on Thursday   Purdue and other opioid manufacturers  including Endo International Plc and Johnson   Johnson  NYSE JNJ   have been fighting hundreds of lawsuits filed by U S  states  counties and cities accusing the drugmakers of pushing addictive painkillers through deceptive marketing   U S  President Donald Trump said on Thursday that he would like to bring a federal lawsuit against the companies over the opioid crisis  According to the U S  Centers for Disease Control and Prevention  opioids were involved in more than 49 000 deaths in the United States last year  The sources that disclosed the appointment of Davis Polk asked not to be identified because the matter is confidential   Purdue is preparing for a bright future that includes diversification into non opioid products   Purdue told Reuters in a statement  The privately held company said that it retains firms with a variety of expertise but declines to discuss publicly who those firms are and the reasons for which they are retained Davis Polk did not immediately respond to a request for comment  Purdue has been participating in settlement talks with lawyers for the plaintiffs  who have often compared the cases to the litigation by states against the tobacco industry that led to a  246 billion settlement in 1998  The lawsuits have accused Purdue of deceiving doctors and patients and of misrepresenting the risks of addiction and death associated with the prolonged use of its prescription opioids  The company has denied the allegations  At least 27 states and Puerto Rico have sued Purdue  New York became the latest state to sue Purdue  in a lawsuit filed on Tuesday alleging that the company sought to boost profits at the cost of lives  The drugmaker  which is owned by the Sackler family  announced in June that it had laid off 350 employees including the remainder of its sales force  which had been reduced in February when Purdue said it would stop sending representatives to doctors  offices to discuss the pain medications  The company currently has 550 employees and has focused its efforts on developing medications for sleep disorders and cancer   
In July  Steve Miller  a restructuring veteran who recently retired as chief executive of automotive supplier International Automotive Components Group and is the author of  The Turnaround Kid   joined Purdue s board as the chairman ",2018-08-16,Reuters,https://www.investing.com/news/stock-market-news/exclusive-oxycontin-maker-purdue-taps-financial-restructuring-adviser--sources-1577703,1577703
198129,419645,JNJ,J J Earnings  No News Is Good News Until Cancer Claims Are Settled,opinion,"  Reports Q2 2019 results on Tuesday  July 16  before market open  Revenue Expectation   20 29 billion  EPS Expectation   2 44
For Johnson   Johnson  NYSE JNJ  investors no news is good news until the world s largest maker of both consumer and pharmaceutical health care products finds a way to settle thousands of lawsuits claiming its talcum powder caused ovarian cancer 
There are so many of these cases 14 000 according to media estimates that the issue threatens enormous financial and reputational risks to the multinational pharmaceutical company  The stock plunged more than 4  on Friday after reports the U S  Justice Department is investigating whether the company has withheld from the public the possible cancerous risks of its talcum powder 
The criminal probe coincides with a regulatory investigation and civil claims by thousands of cancer patients that J J s Baby Powder talc was responsible for their illness  Now  a grand jury in Washington is examining documents that could help shed light onto what officials from the company may have known about any carcinogens in its products  a Bloomberg report said citing unnamed sources 
These developments and ongoing litigations in multiple jurisdictions have kept JNJ shares under pressure since December last year  despite some positive news on the earnings front  Trading at  134 29 at Friday s close  J J stock is up just 5 5  this year  underperforming the S P 500  which surged more than 20  in the same period 

For the quarter that ended on June 30  the company is expected to earn  2 44 a share on sales of  20 9 billion  according to analysts  consensus estimate  Though baby powder accounts for only a tiny fraction of J J s annual revenue  it s been a core brand for the company for more than a century as well as a big drag on the company s financial health amid uncertainty about the amount it may need to set aside for out of court settlements 
The company has said it has set aside money for legal costs related to talc claims but hasn t specified the amount  According to Bloomberg estimates civil settlements could cost J J as much as  15 billion overall  The company  however  maintains that it has no liability because its products are safe 
J J Earnings Strength
Keeping the lawsuits related risk aside  J J has consistently proven that its product portfolio is strong enough to produce hefty cash flows for investors  In the first quarter  the company s fast growing pharmaceutical unit was key to offsetting its weaker consumer and medical device lines 
J J s drug business is now the largest of the company s three main segments  with Q1 sales growing 4 1  to  10 2 billion helped by psoriasis drug Stelara  sales of which were up 32  to  1 4 billion 
Another bright spot was the launch of nasal spray Spravato  a close chemical cousin of the anaesthetic ketamine that works quickly to alleviate symptoms of depression  The rollout is  off to a very  very strong start   Jennifer Taubert  head of the group s pharmaceutical unit  told investors on a conference call 
Bottom Line
J J stock could remain under pressure for some time and it s hard to see it hitting a bottom anytime soon  At the same time  we continue to believe that the company has the resources to fight these claims  thanks to its wide moat and massive cash generation capabilities  But the question is  when should investors focus on the company s core earnings and start ignoring litigation related risks 
In our view  it all depends on how consistently J J performs on the earnings front and whether it shows its future outlook is improving  The Q2 earnings report coming out tomorrow should give some clarity ",2019-07-15,Haris Anwar/Investing.com,https://www.investing.com/analysis/jj-earnings-no-news-is-good-news-until-cancer-claims-are-settled-200439549,200439549
198133,419649,JNJ,Women who sued J J declare victory after  4 69 billion talc verdict,news,"By Tina Bellon NEW YORK  Reuters    A woman who claimed her cancer was caused by using Johnson   Johnson s baby powder for decades said she believes justice was served after a jury found the company should pay her and 21 other women  4 69 billion in damages  A St  Louis jury on July 12 concluded that J J s talc based products contained asbestos  causing the 22 women  six of whom have died  to develop ovarian cancer  J J Chief Executive Alex Gorsky earlier this week expressed confidence that the jury decision will be overturned on appeal   Justice has been served  regardless of the ultimate outcome  Toni Roberts  62  told Reuters in a telephone interview   We have made a difference  We have alerted the public   said Roberts of Philadelphia  who was diagnosed with ovarian cancer in 2014   New Jersey based J J  which is battling some 9 000 talc product liability cases  has consistently denied that the products cause cancer and says they never contained asbestos  The St  Louis trial was the first to allege asbestos contaminated talc caused ovarian cancer  J J has successfully overturned prior verdicts in the talc litigation  A company lawyer told Reuters J J would argue on appeal that the case was based on flawed science  and that it should not have been heard in Missouri because many of the defendants were from out of state  A 2017 U S  Supreme Court decision severely restricted state courts  jurisdiction over injury lawsuits brought by non residents against out of state companies  One of the women in the Missouri case  Krystal Kim  from West Chester  Pennsylvania  told Reuters she had been using J J baby powder several times a day since she was 10  The now 53 year old Kim said she put the powder on bed sheets  carpets  her hair  face and body and even on her dog  Kim said she put her faith in the brand because of its promise of purity   They call it baby powder to make it seem innocuous   she said   Kim and Roberts said J J should take its talc based powder off the market or add a warning label  J J has said those steps were unnecessary  citing scientific tests concluding talc does not cause cancer or contain asbestos  During the trial  the company s lawyer  Peter Bicks  said J J had deep compassion for the women  but that the company was not to blame for their diseases  
 Just because something terrible happened doesn t mean that Johnson   Johnson  NYSE JNJ  had anything to do with it   Bicks said ",2018-07-19,Reuters,https://www.investing.com/news/stock-market-news/women-who-sued-jj-declare-victory-after-469-billion-talc-verdict-1537379,1537379
198134,419650,JNJ,Special Report  Biotech incubator taps investors through in house brokerage,news,By Elizabeth Dilts  Benjamin Lesser  Carl O Donnell and Michael Erman NEW YORK  Reuters    Last August  National Securities Corp analyst Jonathan Aschoff was bullish on  Avenue Therapeutics Inc   O ATXI   a fledgling biotechnology company with no revenue and one drug in clinical trials  In a research note posted on National s website  he rated the newly listed stock a  buy  and predicted that the share price would more than double in a year   Graphic  National Securities note on Avenue Therapeutics     Nearly a year later  Avenue shares are down 36 percent  at about  4  A few months earlier  Aschoff had waxed equally optimistic about another biotech venture   Checkpoint Therapeutics  Inc  O CKPT   with several cancer drugs in various stages of development  He predicted the share price would rise from  10 75 to  18 in a year  It is now around  2 60   Graphic  National Securities note on Checkpoint Therapeutics     Then in September  he recommended  Mustang Bio  Inc  O MBIO   which is working on a drug to treat brain cancer  He forecast a 12 month increase in the share price from around  12 to  21  That stock is now at  6 62   Graphic  National Securities note on Mustang Bio     What Aschoff did not mention in any of these bullish notes  His employer  National Securities  is owned by the same company that controls Avenue  Checkpoint and Mustang  That company is Fortress Biotech Inc  N FBIO   the brainchild of longtime biotech entrepreneurs Dr Lindsay Rosenwald and Michael Weiss  In September 2016  Fortress acquired a controlling stake in National Securities  parent   National Holdings  Corp  O NHLD   The deal solidified an unusual relationship that dates to 2010  when Rosenwald and Weiss  through an investment fund they control  invested  3 million in National Holdings  Owning National gives Fortress an in house underwriter and a private sales force of about 700 brokers   nearly a third of whom have been flagged by regulators   to help it raise money for its stable of nine ventures that are developing new drugs or treatments  If this setup seems like a conflict of interest  that s because it is one  National brokers are required under U S  regulations to ensure that they promote investments deemed appropriate for their clients   the same clients to whom they are marketing securities in their parent company s ventures in biotech  a notoriously high risk sector   I ve never seen a firm that needs to raise a lot of capital acquire a brokerage for that purpose   said Benjamin Edwards  an associate professor of securities law at the University of Nevada  Las Vegas  echoing nearly a dozen other experts in corporate finance and securities law whom Reuters interviewed for this article  Since coming under Fortress s umbrella  National brokers  with an assist from analysts like Aschoff  have helped raise at least  240 million from thousands of individual investors across the United States to fund Fortress or its related biotech companies  according to data from National  And U S  Securities and Exchange Commission  SEC  filings show that Fortress related deals are in the works to raise as much as an additional  125 million  OUT IN THE OPEN While Aschoff did not disclose the relationship in the analyst notes  National discloses the conflict of interest in prospectuses for securities offerings it underwrites for Fortress  in keeping with U S  regulations  The Financial Industry Regulatory Authority  FINRA   the watchdog funded by the industry it monitors  approved National s application for ownership change when Fortress acquired it  as required under U S  regulations  FINRA declined to answer questions about the deal  saying it does not discuss specific firms  The SEC did not respond to requests for comment  The agency asked Avenue for greater disclosure of its connection to National in the lead up to the biotech firm s initial public offering last year  but ultimately allowed it to raise money through the investment firm  filings show  Still   na ve investors may not even know the connection  Most small investors don t read the prospectus   said Roni Michaely  a professor of finance at Cornell University   If you are selling your own company  you want to sell it at the highest possible price  This is a situation that is very troublesome    Personally  I wouldn t touch  the offerings  with a 9 foot pole   In an interview with Reuters  Weiss  executive vice chairman of Fortress  said   We over disclose  We tell everything  We are the most honest management team ever to walk through this biotech business   Weiss served as chairman of the National Holdings board from shortly after Fortress acquired a controlling stake in the company until he resigned in June   A National executive acknowledged on Dec  4  2017  that Aschoff s research notes did not disclose the relationships between Fortress and its cash raising subsidiaries on one hand and National on the other  In an email Weiss forwarded to Reuters  the executive said National republished the notes in September last year to correct the omission  However  the notes as they appeared on National s website in December did not contain such company specific disclosures  The notes have since been removed from the site  National on June 5 this year denied that the notes ever lacked proper disclosure  pointing to nonspecific boilerplate language in them that says   One or more directors  officers  and or employees of NSC  National Securities Corp  and its affiliated companies  or independent contractors affiliated with NSC may be a director of the issuer of the securities mentioned herein   Even with that general disclosure   it does not eliminate the conflict of interest   said Michael McMillan  director of ethics education at the CFA Institute   In most cases  a firm will suspend analyst coverage of a company if a potential conflict of interest arises between the firm and the covered company  McMillan said  Fortress s ownership of National  he said  raises questions about the ability of its analysts to remain independent and objective  On May 15  more than a year and a half after Fortress acquired its controlling interest in National   and as Reuters continued to make inquiries about the relationship   National posted on its website a page titled  Meet our Majority Shareholder  Fortress Biotech    In a section on potential conflicts of interest  National says it and Fortress  have built a unique model that inherently aligns Fortress  business objectives with the financial interest of National s clients   The company says it is  proud  of the Fortress affiliated deals it has handled since the acquisition  It notes that those are a fraction of the total of  2 835 billion in deals National has closed during the same period  BROKERS WITH A PAST In June 2017  Reuters reported  that 35 percent of National s brokers   more than three times the industry average   had a history of regulatory run ins  legal disputes or personal financial difficulties that must be disclosed to investors under FINRA rules  based on a Reuters analysis of the regulator s data  A fresh analysis encompassing disclosures from 2000 through June 2018 found that the proportion still hovered at 30 percent  National executives said the Reuters analysis did not adequately reflect efforts to implement  a new culture at National    an effort that has included removing 298 brokers since shortly after Fortress bought the company  National also questioned the value of including regulatory disclosures from more than a decade ago  and it pointed out that the firm itself hasn t been hit with any regulatory sanctions since 2015   We ve worked so hard at changing the culture   said Michael Mullen  National Holdings  chief executive officer and a longtime business associate of Rosenwald  In 2002  FINRA accused analyst Aschoff of falsely claiming to be a medical doctor to obtain inside information about a drug development program at an unidentified publicly traded company  Aschoff  working for B  Riley FBR Inc at the time  agreed to a  10 000 fine and a two week suspension without admitting or denying wrongdoing  In a statement provided by National  Aschoff acknowledged the incident and declined to comment on it further  A former National broker told Reuters he learned he was raising money for the National parent s biotech ventures only after several months of recruiting investors for Mustang Bio  When he asked his supervisor about potential conflicts  he said   I was told to stop asking questions and get back to dialing   Weiss said he found  it hard to believe that there is a broker at National who   did not read anything in the prospectus that says that Fortress has a majority interest in National   He said National brokers recruited mostly accredited investors   individuals who under U S  law meet certain minimum wealth requirements   for Fortress deals  National brokers  Weiss said  sell Fortress deals because the investments make money for brokers and clients alike  UNUSUAL STRUCTURES For outside investors  Fortress s ventures not only carry the typical risks of a long shot biotech bet  they also come with unique conditions that can put outsiders at a disadvantage relative to the parent company  For one thing  the upside potential for outside investors is damped by covenants between Fortress and its offshoots that favor Fortress with equity awards over time  Fortress also treats the cost of acquiring drug development rights as debt owed by its startups  and that debt is repaid from money raised from sales of the startups  shares  Fortress ventures have paid at least  5 million under such arrangements across two deals  SEC filings show  The amounts may seem small  biotech analysts and investors said  but they allow Fortress to shift costs onto outside investors   It s a very sweet deal for Fortress   said Erik Gordon  a professor at University of Michigan s Ross School of Business   I think someone could see it as either very smart or very tricky   Weiss and Rosenwald acknowledged the unusual nature of the equity awards  but said that by pricing stock offerings at low valuations  they mitigate the impact of the dilution  In addition  they said  many investors don t plan to hold the stock long enough for the dilution to hit them very hard  Rosenwald and Weiss together owned 30 5 percent of Fortress as of March 31  For the past three years combined  each was paid  1 6 million in Fortress related compensation and  5 6 million in stock awards  according to SEC filings  As for National  its investment banking revenue surged more than 25 percent to  44 6 million in fiscal 2017 from a year earlier  thanks in part to fees from Fortress related offerings  according to a Reuters review of SEC filings  And National s brokerage operation collects commissions on Fortress related shares sold to investors   Retail investors need more protections than institutional investors   and the complex structures of Fortress deals  do the opposite of that   said Les Funtleyder  a portfolio manager at E Squared Capital Management   That s compounded by the fact that biotech  because it s so risky  isn t really appropriate for retail investors to begin with   In an interview  Rosenwald argued that  if anybody thinks that Fortress is getting too good of a deal from the  subsidiary  companies   then you can go out and buy Fortress stock   Those shares are down 35 percent  at  2 25  since April 2015  when publicly listed Coronado Biosciences  a failed venture  was renamed Fortress and became an incubator for Rosenwald and Weiss biotech ventures  The structure of Fortress s deals  Rosenwald said  doesn t eliminate all risk for the parent company and its executives  Fortress covers overhead costs for its ventures  he noted  including office space  management  human resources and legal advice  amounting to millions of dollars a year  Some of that  however  is repaid to Fortress through fees charged to each company  Fortress said it holds  30 million in direct investments in the ventures  and Rosenwald is an Avenue investor  However  the biggest risk for Fortress  is reputational   Rosenwald said   You re allowed to fail in biotech  If they all fail  that s horrible   EASING PAIN Failure is common in biotech  Lead times are long  Startups burn through cash and usually have no revenue  Treatments that show early promise can blow up in late stage trials  Nine times out of 10  according to a 2016 study by a group of biotech industry organizations  ventures do not achieve the ultimate goal  U S  Food and Drug Administration approval of a new drug or therapy  But while payoff is rare  it can be huge  That s why the sector typically attracts venture capital funds and other  smart money  investors who are willing to take on more risk than most  Over the past two decades  Rosenwald and Weiss have  together and separately  launched more than 50 separate biotech firms  Most of their ventures have conformed to the industry norm  failing to receive FDA approval  They ve had rare successes  too  such as Cougar Biotechnology Inc  which was developing prostate cancer drug Zytiga when Johnson   Johnson  NYSE JNJ  bought the company for  1 billion in 2009  The purchase price represented a 16 percent premium to the company s market value at the time  Zytiga received FDA approval in 2011  Whether a venture succeeds or fails  Fortress has found a way to boost the benefit and trim the risk for itself relative to the retail investors who help fund its ventures  That innovation was on display recently with Avenue Therapeutics  In 2015  Fortress  then still known as Coronado Biosciences  created Avenue to develop for the U S  market an intravenous formulation of the synthetic opioid Tramadol to treat pain in patients after surgery  The drug is already sold worldwide in oral form  and outside the United States for intravenous use  Avenue  with no revenue and only the one drug in its pipeline  went public last summer  Fortress hired Oppenheimer   Co as lead underwriter for the IPO   a role that includes conducting due diligence on the deal and the issuing company  In an unusual move  two thirds of the Avenue shares offered were allotted to National   The deal from the beginning was designed to be a National led transaction for our clients   Weiss said   We hired Oppenheimer   to satisfy the regulatory requirements   Oppenheimer declined to comment  The IPO raised nearly  38 million  That was already much less than the  50 million Fortress had initially hoped to raise  according to SEC filings  Avenue soon afterward paid out  6 6 million  or 17 percent of the IPO proceeds  More than  3 million went to cover Fortress s debt from buying the rights to IV Tramadol  The rest repaid a line of credit that Fortress had provided to Avenue  With that debt repaid  outside investors are now bearing most of the cost of developing IV Tramadol and carrying the most risk if Avenue fails  Typically  biotech companies hold little debt  if any  when going public so that shareholders are protected from undue risk if the company struggles to bring its product to market  several biotech investors told Reuters  For Fortress  debt is part of the formula   We are using debt as Fortress s balance sheet grows  We prefer not to   Rosenwald said   We will probably stop using debt soon   Further  the founders agreement between Fortress and Avenue gives the parent company the equivalent of 2 5 percent of Avenue s outstanding shares each year  plus additional shares equal to 2 5 percent of any equity or debt financing  That provision would benefit Fortress  relative to outside investors  should Avenue succeed and the shares take off  Over  say  15 years  the annual transfer alone would dilute the value of outside investors  holdings in Avenue by nearly a third  Rosenwald told Reuters that over such a 15 year span  he and Weiss would  add so much value to these companies that the little bit that keeps us interested financially will be a decimal point   Avenue s Tramadol formulation is now in late stage clinical trials  and the company expects to apply for FDA approval by the end of 2019   I have never seen a structure like this one before   said Funtleyder  the E Squared portfolio manager   We would need a really good reason to participate in something like that and probably wouldn t on principle because there are so many other investments that don t have this kind of baggage   The founders agreement also calls for Avenue to send Fortress 4 5 percent of net sales each year  if Avenue begins producing revenue  The annual 2 5 percent equity transfer is contained in the founders agreements between Fortress and nine ventures  according to SEC filings  One of them is Checkpoint Therapeutics  whose shares began trading on Nasdaq last June  just after Aschoff published his  buy  recommendation  Another is Mustang Bio  whose shares began trading on Nasdaq in August last year  Mustang is in the early stages of developing several immunotherapy products to treat cancer  In a July 2017 appearance on the Fox TV network morning show  Fox   Friends   Rosenwald and Mustang s CEO talked about the potential of one of those drugs to help U S  Senator John McCain  who had recently been diagnosed with a lethal brain cancer   It s early clinical trials   Rosenwald said during the broadcast   We have to prove the effectiveness   A year ago  National completed a private placement of Mustang shares  raising  95 million  according to SEC filings  National s fee came to 10 percent  or  9 5 million  An additional  2 million paid Fortress s debt from licensing fees  Caelum Biosciences  another company with the same founders agreement  is in the early stages of developing a treatment for a rare immune system disorder called amyloidosis  National raised  9 9 million for the company through the sale of convertible notes to around 170 investors  earning nearly  1 million in commissions  SEC filings show  ALL IN THE FAMILY In 1987  Rosenwald  who holds a medical degree from Temple University  started working at D H  Blair   Co  a Wall Street boiler room that a New York state judge likened to a criminal enterprise and that was led for decades by Rosenwald s father in law  J  Morton  Morty  Davis  In 2000  several executives and employees were charged in New York state court with 173 counts of securities fraud  among other violations  Two years later  the firm and three officers  including two of Rosenwald s brothers in law  pleaded guilty to and were convicted of three counts of violating state securities law   One brother in law served time in prison  the other got probation   Neither Rosenwald nor Davis was charged  Rosenwald had already left to launch his own small brokerage  Paramount BioCapital  in 1991  he said  Weiss came on board in 1994  Paramount functioned much as National does now  raising money for Rosenwald startups in biotech  In 2009  FINRA records show  the regulator determined that in two deals for Rosenwald controlled biotech companies  Paramount had failed to meet the requirement that it hire an independent underwriter  to protect investors from purchasing shares at an unfair price   FINRA also found that Paramount had failed to obtain approval to issue initial public offerings  Paramount paid a fine of  20 000  without admitting wrongdoing  Rosenwald said that the people involved  are no longer working with us   and that the violations were  minor technical infractions  not worth fighting  The following year  Opus Point Partners  an investment fund controlled by Rosenwald and Weiss  invested  3 million in National  Opus and National then formed OPN Capital Markets  a boutique investment bank focused on the healthcare industry  Rosenwald shuttered Paramount  National took up where Paramount left off  handling a private placement and later serving as co lead underwriter for the IPO of Ventrus BioSciences  a Rosenwald venture that was developing treatments for gastrointestinal ailments  A month after the December 2010 IPO  National analyst Jason Kolbert published a research report with an enthusiastic  buy  recommendation   Bet the horse  bet the jockey   he wrote  The report did not disclose the connection between National  Rosenwald and Ventrus  Kolbert did not respond to requests for comment  Representatives for National and Fortress pointed out that the note included boilerplate language stating   One or more directors  officers  and or employees of NSC and its affiliated companies  or independent contractors affiliated with NSC may be a director of the issuer of the securities mentioned herein   Ventrus raised  65 million through the private placement  IPO and several follow on offerings  Over the next two years  Ventrus s stock rose from a  6 initial offering price to as high as  21 as investors awaited news on the hemorrhoid ointment  the anal fissure cream and the incontinence gel the company was developing  As underwriter  National   including its many brokers with FINRA flags   was key to promoting the shares  In one case Reuters found  17 separate purchases of Ventrus stock were among 38 unauthorized trades a National broker made on a single client s account between May 24 and July 26  2012  according to the complaint filed by FINRA  The broker  Glenn McDowell  was permanently barred from the securities business  National fired McDowell in January 2013  Reuters was unable to locate McDowell  On June 25  2012  Ventrus announced that it would abandon development of what had been its most promising product   the hemorrhoid ointment   after it failed its final clinical trial  The share price plunged more than 50 percent in a day  In February 2014  the anal fissure cream failed a key clinical trial  and the stock plunged 63 percent  A few months later  Ventrus merged with Assembly Biosciences  a small biotech with no ties to Fortress  Though Rosenwald said he  lost millions  on Ventrus  he  Weiss and other National executives described Ventrus as a success because investors who got out of the stock at the right time made a profit   Edited by Brian Thevenot  Lauren Tara LaCapra and John Blanton  OLUSECON Reuters US Online Report Economy 20180802T130754 0000,2018-08-02,Reuters,https://www.investing.com/news/stock-market-news/special-report-biotech-incubator-taps-investors-through-inhouse-brokerage-1557520,1557520
198135,419651,JNJ,Can Johnson   Johnson  JNJ  Keep The Earnings Surprise Streak Alive ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  Johnson   Johnson  NYSE JNJ   which belongs to the Zacks Large Cap Pharmaceuticals industry  could be a great candidate to consider 
This world s biggest maker of health care products has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 2 24  
For the last reported quarter  Johnson   Johnson came out with earnings of  2 10 per share versus the Zacks Consensus Estimate of  2 03 per share  representing a surprise of 3 45   For the previous quarter  the company was expected to post earnings of  1 95 per share and it actually produced earnings of  1 97 per share  delivering a surprise of 1 03  
Price and EPS Surprise

With this earnings history in mind  recent estimates have been moving higher for Johnson   Johnson  In fact  the Zacks Earnings ESP  Expected Surprise Prediction  for the company is positive  which is a great sign of an earnings beat  especially when you combine this metric with its nice Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Johnson   Johnson currently has an Earnings ESP of  2 54   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  3  Hold  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on July 16  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-07-08,Zacks Investment Research,https://www.investing.com/analysis/can-johnson--johnson-jnj-keep-the-earnings-surprise-streak-alive-200438158,200438158
198136,419652,JNJ,Why Earnings Season Could Be Great For Johnson   Johnson  JNJ  ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Johnson   Johnson   NYSE JNJ   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Johnson   Johnson is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for JNJ in this report In fact  the Most Accurate Estimate for the current quarter is currently at  2 48 per share for JNJ  compared to a broader Zacks Consensus Estimate of  2 42 per share  This suggests that analysts have very recently bumped up their estimates for JNJ  giving the stock a Zacks Earnings ESP of  2 54  heading into earnings season Johnson   Johnson Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that JNJ has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Johnson   Johnson  and that a beat might be in the cards for the upcoming report  The Hottest Tech Mega Trend of All        Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/why-earnings-season-could-be-great-for-johnson--johnson-jnj-200439337,200439337
198137,419653,JNJ,Pharma Stock Roundup  Pipeline   Regulatory Updates By MRK  GSK  SNY,opinion,"This week was relatively quiet for the pharma sector ahead of a string of earnings releases toward the end of this month  Glaxo   NYSE GSK   provided pipeline and regulatory updates on a couple of its two drug HIV regimens  The FDA accepted Merck s   NYSE MRK   regulatory application looking for a more flexible dosing option for its blockbuster PD L1 inhibitor Keytruda and Sanofi s   NASDAQ SNY   biologics license application  BLA  for multiple myeloma candidate isatuximab Recap of the Week s Most Important StoriesHIV Update From Glaxo  Glaxo s phase III evaluating the antiviral efficacy and safety of switching to its newly approved two drug HIV regimen  Dovato in HIV 1 infected patients who are virally suppressed and stable on a three drug TAF based regimen  met the primary endpoint  Dovato  a single tablet regimen of Tivicay  dolutegravir    lamivudine for treatment na ve HIV patients  was approved in the United States in April and in the EU in July   The 48 week data from the study demonstrated that Dovato was non inferior in maintaining viral suppression in such patients to the three drug TAF based regimen  This suggests that such patients can maintain viral suppression if they switch from the three drug regimen to the two drug regimen  thereby reducing their pill burden Glaxo also said that the regulatory application for its long acting  injectable two drug regimen of cabotegravir plus rilpivirine was granted by the FDA in June  With this  a decision is expected on Dec 29  2019   ViiV Healthcare also announced the start of the first ever study   CUSTOMIZE   to identify and evaluate approaches to implementing its once monthly injectable HIV treatment in the real world  This approach can be different and an improvement from the controlled setting of a clinical study FDA Accepts Sanofi s Isatuximab BLA  Sanofi  PA SASY  announced that the FDA has accepted its biologics license application  BLA  for  for review  Sanofi is looking for approval of isatuximab  its anti CD38 monoclonal antibody  for the treatment of patients with relapsed refractory multiple myeloma  RRMM    The FDA is expected to give its decision on the BLA on Apr 30  2020 FDA Accepts Merck s sBLA for Six Week Dosing Option of Keytruda  The FDA accepted Merck s supplemental BLAs looking for approval of a  of Keytruda for melanoma and multiple other indications  The new recommended dose will provide greater flexibility than the currently approved dose of 200 mg every three weeks  The FDA will give its decision on Feb 18  2020 Update From Haemophilia Conference  A few big pharma companies presented data from studies on their haemophilia candidates at the International Society on Thrombosis and Haemostasis  ISTH  held in Melbourne  Australia At ISTH  Novo Nordisk   NYSE NVO   presented data from the main phase  24 weeks  of two phase II studies on its   The data demonstrated concizumab s potential as a safe and efficacious subcutaneous prophylaxis treatment for the prevention of bleeding episodes in patients with haemophilia A  explorer5  and haemophilia A B with inhibitors   Sangamo Therapeutics and its partner Pfizer  Inc    NYSE PFE   presented promising   evaluating their gene therapy candidate   SB 525   in patients with severe hemophilia A Roche   OTC RHHBY   presented a for Hemlibra across multiple pivotal studies in haemophilia A patients  New analyses from phase III HAVEN studies demonstrated the long term safety  efficacy and quality of life benefit of Hemlibra in people with haemophilia A with and without factor VIII inhibitors  First data from the phase IIIb STASEY study reinforced the safety profile of Hemlibra seen in pivotal HAVEN 1 study Bayer  DE BAYGN  and J J   NYSE JNJ   presented results from the   which showed a strong efficacy and safety profile of Xarelto  rivaroxaban  in children with venous thromboembolism  VTE  The NYSE ARCA Pharmaceutical Index declined 3 1  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return 
Here is how the seven major stocks performed in the last five trading sessions  AstraZeneca recorded the highest rally  6 7   while Lilly declined the most  6 0   In the past six months  AstraZeneca has been the biggest gainer  13 8   while Bristol Myers declined the most  7 2    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for J J s second quarter earnings and regular pipeline and regulatory updates next week The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2019-07-12,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-pipeline--regulatory-updates-by-mrk-gsk-sny-200439225,200439225
198144,419660,JNJ,Johnson   Johnson quarterly profit beats on higher pharma unit sales,news, Reuters    Johnson   Johnson  N JNJ  on Tuesday topped analysts  estimates for quarterly profit and revenue  driven by higher sales of rare disease treatments from its acquisition of Actelion and cancer drugs Zytiga and Darzalex  Sales across the company s three main units rose  with the pharmaceutical business surging nearly 20 percent to  10 35 billion  accounting for almost half of total sales in the second quarter   The company s shares were volatile in premarket trading  recovering from an initial drop to trade up 1 4 percent at  126 46  J J has vowed to appeal a Missouri jury verdict that earlier this month ordered the company to pay a record  4 69 billion to 22 women  who had claimed their cancer was caused by J J talc products   The company is facing about 9 000 lawsuits alleging that its talc based products  including its baby powder  caused ovarian cancer and mesothelioma  a rare cancer linked to asbestos  The company has denied that the products contain asbestos or cause cancer of any kind  Net earnings rose to  3 95 billion  or  1 45 per share  in the second quarter  from  3 83 billion  or  1 40 per share  a year earlier  Excluding items  the company reported a profit of  2 10 per share  beating analysts  average estimate of  2 07  Total sales rose to  20 83 billion from  18 84 billion a year ago  above analysts  estimates of  20 39 billion   International revenue for J J rose 11 8 percent in the reported quarter  and accounted for nearly half of its total sales   The healthcare conglomerate said it expects full year sales of  80 5 billion to  81 3 billion  compared with a prior estimate of  81 0 billion to  81 8 billion  The company cited a strengthening dollar for the trim  Analysts had expected full year profit of  8 12 per share and sales of  81 47 billion  according to Thomson Reuters I B E S   J J said it now expects adjusted earnings of  8 07 to  8 17 per share  compared with an earlier forecast of  8 00  8 20 per share ,2018-07-17,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnsons-quarterly-profit-rises-33-percent-1532590,1532590
198145,419661,JNJ,J J s Rising Pharmaceutical Sales Hurt by Strong U S  Dollar,news," Bloomberg     Johnson   Johnson  NYSE JNJ  recorded 20 percent growth in its drug unit in the second quarter  but the company is trimming its forecast for the year as a strong dollar hampers its growth 
The U S  medical conglomerate said in a statement Tuesday that it was cutting its full year revenue projection to  80 5 billion to  81 3 billion  from  81 billion to  81 8 billion  and narrowing its adjusted earnings forecast 
The shares were up 0 6 percent to  125 40 in trading before the markets opened in New York  reversing earlier losses 
J J is based in New Brunswick  New Jersey  but generates about half its sales overseas  It s one of the first major U S  multinationals to report earnings after President Donald Trump began implementing a round of tariffs and threatening others  which has rattled markets 
Those changes in the markets appear to have affected J J  Three months ago  the company said exchange rates would give it a 4 2 percent boost to sales  this quarter it cut that estimate to 1 9 percent 
Currency trends could weigh on other large drugmakers as well  said Vamil Divan  an analyst with  Credit Suisse   SIX CSGN  Group AG 
 This was a key driver of the company lowering full year sales guidance and sets a potentially cautious tone for earnings season for the U S  pharma space  especially those with greater ex US exposure   Divan said in a note 
Since April 16  the day before J J s last quarterly report  the U S  dollar is up 5 4 percent against a basket of 10 major global currencies  Trade and monetary policy tensions between nations can have a stark impact on currency markets 
J J Chief Financial Officer Joseph Wolk  who took over the role this month  said the company hadn t been hurt by specific tariffs    although products in its consumer unit are most vulnerable
 It s really not attributable to the trade war at all   Wolk said   It s simply the macro effect of a stronger dollar  
The currency shifts have also affected J J s drug unit  which has grown quickly through deals and new products to become the company s biggest  The unit s benefit from exchange rates fell to 2 3 percent in the second quarter  compared to 4 3 percent in the prior period 
Wolk also said the company will continue to defend itself in the legal saga surrounding its talc products  Last week  a jury ordered the company to pay  4 69 billion to women who claimed asbestos in the products caused them to develop ovarian cancer  the six largest product defect verdict in U S  history 
 We believe the science is overwhelmingly on our side   Wolk said  The company has said it will appeal the judgment 
 Updates with CFO comment in sixth paragraph  ",2018-07-17,Bloomberg,https://www.investing.com/news/stock-market-news/jjs-rising-pharmaceutical-sales-hurt-by-strong-us-dollar-1533152,1533152
198146,419662,JNJ,J J s Darzalex Gets FDA Nod For First Line Multiple Myeloma,opinion,"Johnson   Johnson   NYSE JNJ   announced that its subsidiary  Janssen  has received approval from the FDA for label expansion of its blockbuster drug  Darzalex 
The latest approval is for Darzalex in combination with Celgene s   NASDAQ CELG   Revlimid  lenalidomide  and dexamethasone  Rd  to treat newly diagnosed multiple myeloma   MM   patients ineligible for autologous stem cell transplant   ASCT   
A combination of Darzalex  Takeda s   NYSE TAK   Velcade  bortezomib   melphalan and prednisone is already approved for transplant ineligible MM patients in the first line setting  The recent approval is Darzalex s sixth FDA approved indication in multiple myeloma and the second for newly diagnosed patients 
In March  J J  a regulatory application seeking approval of a similar Darzalex combination for a similar indication in Europe  The company is also  for approval of Darzalex in combination with Velcade  thalidomide and dexamethasone  VTd  in patients with newly diagnosed MM who are eligible for ASCT 
J J s stock has risen 9  this year so far compared with an increase of 1 9  recorded by the  
The approval was based on data from the phase III MAIA study  which showed that at a median follow up of 28 months  the addition of Darzalex to Rd significantly reduced the risk of disease progression or death by 44  in such patients compared to treatment with Rd alone  While progression free survival   PFS   for patients who received Rd alone was 31 9 months  the median PFS for Darzalex plus Rd arm was not reached  The regulatory application was reviewed by the FDA under the Real Time Oncology Review pilot program  which ensures a more efficient review process 
Darzalex has been generating strong sales and is a key contributor to J J s top line  The drug generated sales of  629 million in the first quarter of 2019  representing year over year growth of nearly 45 5  
Meanwhile  Darzalex is being evaluated in a comprehensive clinical development program across a range of treatment settings in multiple myeloma  such as in frontline and relapsed settings 
These include combination studies with other cancer drugs like Roche Holding  SIX ROG  AG s   OTC RHHBY   Tecentriq  Bristol Myers  Opdivo and Amgen s Kyprolis Johnson   Johnson Price
 

   Zacks Rank
J J currently has a Zacks Rank  3  Hold   You can see  
Will you retire a millionaire 
One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-28,Zacks Investment Research,https://www.investing.com/analysis/jjs-darzalex-gets-fda-nod-for-firstline-multiple-myeloma-200435767,200435767
198147,419663,JNJ,Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status,opinion,"Arcturus Therapeutics   NASDAQ ARCT   announced that the FDA has granted an orphan drug designation to its pipeline candidate  ARCT 810  for the treatment of ornithine transcarbamylase deficiency   OTCD    an inherited metabolic disorder  OTCD is the most common urea cycle disorder  which impacts an individual s ability to remove toxic waste products from the body ARCT 810 is a RNA based pre clinical candidate  which has been designed using the company s proprietary LUNAR lipid mediated delivery platform  The company is planning to submit an investigational new drug application to the FDA in early 2020 to initiate clinical study on ARCT 810 Notably  the orphan drug designation is granted to drugs capable of treating rare diseases that affect less than 200 000 people in the United States  The designation also makes a company entitled to certain other benefits including tax credits related to clinical trial expenses and exemption from the FDA user fee The status makes ARCT 810 eligible for seven years of marketing exclusivity in the United States Apart from OTCD  the company has collaborated with Cystic Fibrosis Foundation for developing RNA based therapy to treat cystic fibrosis Arcturus  shares have rallied 108 4  so far this year compared with the  s increase of 5 4  Multiple pharma biotechs have signed collaborations with Arcturus to use its RNA based technology to develop treatments that target different indications Last month  the company expanded its existing collaboration with Ultragenyx Pharmaceutical   NASDAQ RARE   to discover and develop mRNA  DNA and siRNA therapeutics for up to 12 rare disease targets  Pursuant to the agreement  Ultragenx will pay  30 million of upfront payments to Arcturus  including  6 million cash for collaboration agreement amendment and  24 million equity investment at  10 per share  Arcturus is also entitled to preclinical  clinical  regulatory and sales milestone payments for each product developed under the collaboration  With the agreement  Ultragenyx is now Arcturus  largest shareholder  Ultragenyx has an option to purchase an additional 600 000 shares of Arcturus  common stock at  16 per share Arcturus has an agreement with Takeda Pharmaceutical   NYSE TAK   for the development of therapies targeting nonalcoholic steatohepatitis and with J J   NYSE JNJ   for the treatment of hepatitis B The company completed the change of its domicile from Israel to Delaware last month Arcturus Therapeutics Holdings Inc  Price
    Zacks RankArcturus currently carries a Zacks Rank  3  Hold  You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-06-30,Zacks Investment Research,https://www.investing.com/analysis/arcturus-metabolic-disorder-candidate-gets-orphan-drug-status-200436114,200436114
198148,419664,JNJ,Karyopharm Gets Accelerated FDA Approval For Myeloma Drug,opinion,Shares of Karyopharm Therapeutics Inc     NASDAQ KPTI    rallied 36  after the FDA granted accelerated approval to oral Xpovio  selinexor  in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma  RRMM   who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors  at least two immunomodulatory agents  and an anti CD38 monoclonal antibody Selinexor is the first FDA approved medication for this indication  Shares of the company have increased 111  year to date compared with the  s growth of 11 8  The approval was supported by data from the phase IIb STORM study in patients with RRMM  In the study 122 patients were treated with selinexor 80 mg in combination with dexamethasone 20 mg on days 1 and 3 of every week  A pre specified subgroup analysis of 83 patients  whose disease was refractory to prior treatments  showed that the benefit risk ratio was greater in the more heavily pretreated population than the overall trial population  The overall response rate  which served as the basis for Xpovio s accelerated approval  was 25 3  in this subgroup  The subgroup included 1 stringent complete response  no complete responses  4 very good partial responses and 16 partial responses  The median time to first response for these patients was 4 weeks and the median duration of response was 3 8 months  per the data Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory study  The ongoing  randomized phase III BOSTON trial evaluating Xpovio in combination with Velcade  bortezomib  and low dose dexamethasone will serve as the confirmatory study Karyopharm expects Xpovio to become commercially available in the United States on or before Jul 10  2019   A Marketing Authorization Application for the drug is also currently under review by the European Medicines Agency We remind investors that last month  Johnson   Johnson   NYSE JNJ   announced that its subsidiary Janssen received approval from the FDA for label expansion of its blockbuster drug  Darzalex  to treat newly diagnosed multiple myeloma   MM   patients  who are ineligible for autologous stem cell transplant   ASCT    The approval is for Darzalex in combination with Celgene s   NASDAQ CELG   Revlimid  lenalidomide  and dexamethasone  Rd   The drug is being evaluated in a comprehensive clinical development program across a range of treatment settings in multiple myeloma  such as frontline and relapsed settings These include combination studies with other cancer drugs like Roche Holding  SIX ROG  AG s   OTC RHHBY   Tecentriq  Bristol Myers  Opdivo and Amgen s Kyprolis Karyopharm Therapeutics Inc  Price   Zacks RankKaryopharm currently has a Zacks Rank  3  Hold   You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-03,Zacks Investment Research,https://www.investing.com/analysis/karyopharm-gets-accelerated-fda-approval-for-myeloma-drug-200437045,200437045
198154,419670,JNJ,Jury orders J J to pay  4 7 billion in Missouri asbestos cancer case,news,"By Tina Bellon  Reuters    A Missouri jury on Thursday ordered Johnson   Johnson  N JNJ  to pay a record  4 69 billion to 22 women who alleged the company s talc based products  including its baby powder  contain asbestos and caused them to develop ovarian cancer  The verdict is the largest J J has faced to date over allegations that its talc based products cause cancer   The company is battling some 9 000 talc cases  J J denies both that its talc products cause cancer and that they ever contained asbestos  It says decades of studies show its talc to be safe and has successfully overturned previous talc verdicts on technical legal grounds   Thursday s massive verdict  handed down in the Circuit Court of the City of St  Louis  was comprised of  550 million in compensatory damages and  4 14 billion in punitive damages  according to an online broadcast of the trial by Courtroom View Network   J J in a statement called the trial  fundamentally unfair  and said it would appeal the decision   J J shares fell  1 31  or 1 percent  to  126 45 in after hours trading following the punitive damages award  They had risen  1 52 during regular trading  The jury s decision followed more than five weeks of testimony by nearly a dozen experts on both sides   The women and their families said decades long use of Baby Powder and other cosmetic talc products caused their diseases  They allege the company knew its talc was contaminated with asbestos since at least the 1970s but failed to warn consumers about the risks   Johnson   Johnson is deeply disappointed in the verdict  which was the product of a fundamentally unfair process   the company said in a statement  The company said it remained confident that its products do not contain asbestos or cause cancer   Every verdict against Johnson   Johnson in this court that has gone through the appeals process has been reversed and the multiple errors present in this trial were worse than those in the prior trials which have been reversed   J J added  saying that it would pursue all available appellate remedies  J J has successfully overturned talc verdicts in the past  with appeals courts pointing to a 2017 decision by the U S  Supreme Court that limits where personal injury lawsuits can be filed   Of the 22 women in the St  Louis trial  17 were from outside Missouri  a state generally regarded as friendly towards plaintiffs  The practice of combining plaintiffs in such jurisdictions  commonly criticized as  forum shopping  by defendants  will be challenged on appeal  Mark Lanier  the lawyer for the women  in a statement following the verdict called on J J to pull its talc products from the market  before causing further anguish  harm  and death from a terrible disease    If J J insists on continuing to sell talc  they should mark it with a serious warning   Lanier said  The majority of the lawsuits that J J faces involve claims that talc itself caused ovarian cancer  but a smaller number of cases allege that contaminated talc caused mesothelioma  a tissue cancer closely linked to asbestos exposure  The cases that went to trial in St  Louis effectively combine those claims by alleging asbestos contaminated talc caused ovarian cancer  Previous talc trials have produced verdicts as large as  417 million  But that 2017 verdict by a California jury  as well as other verdicts in Missouri  was overturned on appeal  and challenges to at least another five verdicts are pending  The U S  Food and Drug Administration commissioned a study of various talc samples from 2009 to 2010  including of J J s Baby Powder  No asbestos was found in any of the talc samples  the agency said   But Lanier during the trial told jurors that the agency and other laboratories and J J have used flawed testing methods that did not allow for the proper detection of asbestos fibers  Talc  the world s softest rock  is a mineral closely linked to asbestos and the two substances can appear in close proximity in the earth   
Plaintiffs claim the two can become intermingled in the mining process  making it impossible to remove the carcinogenic substance  J J denies those allegations  saying rigorous testing and purification processes ensure its talc is clean ",2018-07-12,Reuters,https://www.investing.com/news/stock-market-news/jury-orders-jj-to-pay-550-million-in-missouri-asbestos-cancer-case-1528211,1528211
198155,419671,JNJ,J J vows to overturn  4 7 billion talc verdict but experts see hurdles,news,"By Tina Bellon NEW YORK  Reuters    Johnson   Johnson  NYSE JNJ  has vowed to appeal a  4 7 billion verdict awarded to 22 women who claim asbestos contaminated talc in the company s products gave them ovarian cancer by arguing the plaintiffs  science was flawed and the case should not have been heard in Missouri  But several legal experts said that even though J J has been successful in winning appeals of other talc cases in Missouri  it will face a challenging road in appealing the verdict handed down on Thursday in the Circuit Court of the City of St  Louis  John Beisner  a lawyer for Johnson   Johnson  said   One of the hardest things will be prioritizing what to appeal first   He described to Reuters the company s jurisdictional and scientific arguments for overturning Thursday s verdict  In a statement responding to the verdict  J J reiterated its position that its products never contained asbestos and were not carcinogenic   Thursday s verdict is the largest to date arising from lawsuits alleging talc based products like J J s baby powder have caused cancer  The jury reached its decision in less than a day  following five weeks of expert testimony from both sides  The stakes are potentially high for J J  which is facing 9 000 cases nationwide over talc  The company has had previous success in overturning large verdicts in talc cases as well as others alleging harm from its products  But several legal experts said Missouri courts  including at the appellate and supreme court level  were historically plaintiff friendly and could prove unreceptive to J J s arguments   J J has strong arguments  but unless they get to certify this case to the U S  Supreme Court  which are very long odds  this decision is likely to stand   said Lars Noah  a law professor at the University of Florida  He said he expected J J would go through the appeals process but would ultimately wind up settling the case  Beisner said he was not aware of any interest in settlement   Our attention will remain focused on the appeals from this and the other trials awaiting review   Beisner said jurisdiction will be one major basis for J J to appeal Thursday s verdict  Most of the 22 plaintiffs were not Missouri residents  and he said they should not have been allowed to sue New Jersey based Johnson   Johnson in St  Louis under a recent U S  Supreme Court decision that severely restricted state courts  jurisdiction over injury lawsuits brought by non residents against out of state companies  J J seized on that decision to successfully overturn previous talc verdicts in Missouri  Mark Lanier  the plaintiffs  lawyer who won Thursday s verdict  said he was ready for that argument  Lanier said his team amassed  hundreds of pages of evidence  showing lobbying efforts and baby powder focus groups J J conducted in the state  He also spotlighted the claim by 15 of his non resident clients that they used a specific short lived J J talc based product manufactured by Missouri based contractor   I hope they focus their appeal on jurisdiction because I m confident we ll win that   Lanier said  He did say that he expects the punitive damages award to be halved during the appeals process due to a Missouri state law that caps such damages  but is confident the verdict would stand overall  The  4 69 billion in total damages includes  550 million in compensatory damages and  4 14 billion in punitive damages  Elizabeth Burch  a law professor at the University of Georgia  said that even under the new Supreme Court guidance  the women s claim that they used the specific product  if true  provided  a pretty strong link to Missouri   At trial J J had unsuccessfully sought to cast doubt on the 15 women s claims to have used the same product that was only available for a few months  depicting it as a ruse designed to bypass the jurisdiction issue  Beisner said J J would make the same argument on appeal  Along with jurisdictional arguments  Beisner said the company would continue to put forth its case that scientific studies overwhelmingly show talc itself is safe and the company s talc based products never contained asbestos    None of plaintiffs  experts were able to put forward a valid theory and there is simply no science to support what they call asbestos in the product   said Beisner  J J says decades of testing by laboratories and independent agencies  including a study by the U S  Food and Drug Administration  support its position  The company said plaintiffs  tests showing asbestos contamination were  junk science   But Lanier argued that it was the agencies and labs cited by J J that used flawed testing methods that failed to detect asbestos  Noah said Missouri judges have historically applied a lower standard than federal court for admitting scientific evidence  Last year the state passed a law requiring its courts to adopt the federal standard  but he said state courts would be interpreting that requirement for years to come  
 Missouri judges aren t going to suddenly change their tune   Noah said ",2018-07-13,Reuters,https://www.investing.com/news/stock-market-news/jj-vows-to-overturn-47-billion-talc-verdict-but-experts-see-hurdles-1529628,1529628
198156,419672,JNJ,Arbutus Gets Clearance To Initiate Hepatitis Study  Stock Up,opinion,"Arbutus Biopharma Corporation   NASDAQ ABUS   received regulatory clearance to initiate a phase Ia Ib study to evaluate its hepatitis B virus   HBV   candidate  AB 729 Shares of Arbutus surged 37 2  on Jun 20 following the announcement  presumably due to earlier than expected study initiation  However  the company s shares have decreased 41  so far this year against the  s rise of 5 5   Please note that a regulatory authority had requested the company last month to complete three  and six month toxicology studies on AB 729 before initiating the aforementioned study  This was likely to delay the initiation of the early stage clinical study on the candidate  However  the company submitted a revised protocol for the study and received a go ahead from the authority  The company is planning to start the study soon The phase Ia Ib study is a single and multiple dose clinical study  which will evaluate subcutaneous administration of AB 729 in healthy volunteers followed by patients with chronic hepatitis B infection  The candidate is an RNAi agent  which inhibits HBV replication and reduces HBsAg antigen production  Reduction in HBsAg antigen levels are believed to be a pre requisite for activating the body s immune system to respond to the virus The company has another early stage HBV candidate  AB 506  an oral capsid inhibitor  in its pipeline  Top line data from an interim analysis of the phase Ia Ib study evaluating AB 506 is expected in July 2019  The company is also planning to initiate a dose finding phase IIa study on the candidate in the second half of this year  It is also planning to evaluate a combination AB 729 and AB 506 in clinical study in HBV patients  The company anticipates the combination therapy could result in profound inhibition of HBV replication and reduction in HBsAg antigen levels In the fourth quarter of 2018  the company discontinued development of another RNAi candidate  AB 1467  which was being evaluated in a mid stage study in combination with Gilead s   NASDAQ GILD   Viread  tenofovir  and PEG IFN in HBV patients  The company discontinued the development of AB 1467 to focus on AB 729 as the latter has the potential to achieve more durable HBsAg reduction  The company also has several pre clinical candidates targeting HBV in its portfolio  A clinical study on newly discovered oral RNA destabilizer  AB 452  is expected in early 2020 Arbutus is also focused on strengthening its senior management by appointing executives with experience at large pharma companies  Earlier this week  the company announced the appointment of William H  Collier as the president and chief executive officer  Collier has more than 30 years of experience in the pharmaceutical industry  Prior to joining Arbutus  he served as the president of ViiV Healthcare North America  ViiV Healthcare is a joint venture between Glaxo   NYSE GSK   and Pfizer   NYSE PFE    Last year  the company had appointed Gaston Picchio as its chief development officer  who held several high level management positions at Janssen  a subsidiary of Johnson   Johnson  NYSE JNJ  The HBV segment is competitive with several large pharma companies showing interest in developing treatments  There are also multiple therapies approved for the disease  Rapid pipeline progress and management should help the company survive in a competitive environment Arbutus Biopharma Corporation Price
    Zacks RankArbutus currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-06-20,Zacks Investment Research,https://www.investing.com/analysis/arbutus-gets-clearance-to-initiate-hepatitis-study-stock-up-200433790,200433790
198160,419676,JNJ,Missouri appeals court tosses  55 million J J talc powder verdict,news,"By Tina Bellon  Reuters    A Missouri appeals court on Friday threw out a  55 million verdict against Johnson   Johnson  NYSE JNJ  in a lawsuit by a woman who claimed she developed ovarian cancer after using talc based products  including J J s baby powder  citing a U S  Supreme court ruling on where such cases can be brought  South Dakota resident Gloria Ristesund had been awarded  5 million in compensatory damages and  50 million in punitive damages in the 2016 verdict   She alleged that her decades long use of J J talc based products for feminine hygiene caused her cancer  and that the company had failed to warn consumers about the risks  J J denied the allegations  saying decades of testing have shown its cosmetic talc based products to be safe  The healthcare conglomerate is battling some 9 000 cases claiming its talc based products cause ovarian cancer and  in some cases  mesothelioma  a rare cancer closely linked to asbestos exposure  amid allegations the products were contaminated with asbestos fibers  J J has said its talc products do not contain asbestos or cause any form of cancer  The unanimous three judge panel of the Missouri Court of Appeals in the Eastern District  in overturning the verdict  did not rule on the merits of the allegations  The judges instead said the verdict could not stand following a 2017 U S  Supreme Court decision that limits where companies can be sued for personal injuries  The high court ruled that state courts cannot hear claims against companies that are not based in the state or when the alleged injuries did not occur there  J J is based in New Jersey and Ristesund exclusively purchased and used the company s talc products in South Dakota and Minnesota  according to court records  J J  in a statement  said it was extremely pleased with the court s decision to recognize that the trial should have never occurred  Ristesund s case was one of more than 60 related talc lawsuits consolidated in Missouri state court  where juries have a reputation for issuing high paying verdicts  But only one of those cases involved a woman from Missouri  leading many of the cases to be tossed on jurisdictional grounds  
During the appeals process  Ristesund asked the court for permission to present additional evidence tying J J to Missouri  The judges on Friday rejected her request  saying she had ample opportunity to present such evidence over the past two years ",2018-06-29,Reuters,https://www.investing.com/news/stock-market-news/missouri-appeals-court-tosses-55-million-jj-talcpowder-verdict-1513742,1513742
198161,419677,JNJ,Is J J Snack Foods  JJSF  A Solid Growth Stock  3 Reasons To Think   Yes  ,opinion,"Growth stocks are attractive to many investors  as above average financial growth helps these stocks easily grab the market s attention and produce exceptional returns  But finding a great growth stock is not easy at all 
By their very nature  these stocks carry above average risk and volatility  Moreover  if a company s growth story is over or nearing its end  betting on it could lead to significant loss 
However  the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects  makes it pretty easy to find cutting edge growth stocks 
J J  NYSE JNJ  Snack Foods  JJSF  is on the list of such stocks currently recommended by our proprietary system  In addition to a favorable Growth Score  it carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy   returns are even better 
Here are three of the most important factors that make the stock of this drink and snack maker a great growth pick right now 
Earnings Growth
Arguably nothing is more important than earnings growth  as surging profit levels is what most investors are after  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for J J Snack Foods is 3 8   investors should actually focus on the projected growth  The company s EPS is expected to grow 21 3  this year  crushing the industry average  which calls for EPS growth of 6  
Impressive Asset Utilization Ratio
Growth investors often overlook asset utilization ratio  also known as sales to total assets  S TA  ratio  but it is an important feature of a real growth stock  This metric exhibits how efficiently a firm is utilizing its assets to generate sales 
Right now  J J Snack Foods has an S TA ratio of 1 24  which means that the company gets  1 24 in sales for each dollar in assets  Comparing this to the industry average of 1 2  it can be said that the company is more efficient 
In addition to efficiency in generating sales  sales growth plays an important role  And J J Snack Foods looks attractive from a sales growth perspective as well  The company s sales are expected to grow 2 8  this year versus the industry average of 0 2  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
The current year earnings estimates for J J Snack Foods have been revising upward  The Zacks Consensus Estimate for the current year has surged 1  over the past month 
Bottom Line
J J Snack Foods has not only earned a Growth Score of A based on a number of factors  including the ones discussed above  but it also carries a Zacks Rank  2 because of the positive earnings estimate revisions 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that J J Snack Foods is a potential outperformer and a solid choice for growth investors ",2019-06-07,Zacks Investment Research,https://www.investing.com/analysis/is-jj-snack-foods-jjsf-a-solid-growth-stock-3-reasons-to-think--yes--200429527,200429527
198167,419683,JNJ,U S  jury fails to reach verdict in latest J J talc trial,news,By Tina Bellon NEW YORK  Reuters    A South Carolina jury on Friday could not agree on a verdict in a case of a woman whose family said her long term use of Johnson   Johnson s Baby Powder led to her death from asbestos related cancer  resulting in a mistrial  The case of Bertila Boyd Bostic  who died of a rare form of cancer in 2017 at the age of 30  is the latest in a series of trials in the United States that center around allegations that the company s talc based powder contained asbestos   We re disappointed the jury did not reach a unanimous verdict for Johnson   Johnson  NYSE JNJ    the company said in a statement emailed to Reuters   The talc in Johnson s Baby Powder does not contain asbestos  which is supported by more than 50 years of independent  non litigation driven scientific evaluations    Asbestos is a known carcinogen linked to mesothelioma  the type of cancer Boyd Bostic had been diagnosed with at the age of 29  After two weeks of trial  the jury in the Darlington County Court of Common Pleas said it could not decide whether J J was responsible for the disease  Under South Carolina law  a jury has to make a unanimous decision  Christopher Swett  a lawyer for the family of Boyd Bostic  said in a statement that the plaintiffs would retry the case at the earliest opportunity   We continue to believe that the daily use of baby powder on Bertila from birth led to her death   Swett said  The case also named as a defendant the U S  unit of talc supplier Imerys SA  as well as a local unit of Rite Aid  one of the largest U S  drugstore chains  which allegedly sold the baby powder used by the woman  Gwen Myers  a spokeswoman for Imerys Talc America  said   We remain confident that talc does not cause cancer  Imerys follows all FDA and other regulatory guidelines and utilizes rigorous testing to ensure that our talc meets the highest quality standards  We continue to stand by the safety of our product   Rite Aid did not immediately respond to a request for comment  J J is battling some 9 000 cases claiming its talc products cause ovarian cancer  but litigants have recently focused on claims based on alleged asbestos contamination  A California jury on Thursday awarded  25 7 million in damages to a woman and her husband over allegations that the company s baby powder had caused her mesothelioma  A New Jersey court jury in April ordered J J and Imerys Talc America to pay  117 million to a man who alleged he developed mesothelioma due to asbestos exposure from talc based products   The company won the only other asbestos related trial in November  when a Los Angeles Superior Court jury ruled in its favor ,2018-05-25,Reuters,https://www.investing.com/news/stock-market-news/us-jury-fails-to-reach-verdict-in-latest-jj-talc-trial-over-asbestos-claims-1463996,1463996
198168,419684,JNJ,Investors ready to resuscitate Johnson   Johnson s ailing stock,news,"By Lewis Krauskopf NEW YORK  Reuters    Johnson   Johnson  N JNJ  shareholders have endured a painful year amid worries about prospects for its many businesses  but investors capitalizing on the stock s relatively cheap valuation may be set to apply a Band Aid to the declines  Shares of J J  the largest U S  healthcare company by market value  had slumped 11 2 percent this year as of Friday s close  although recent gains may indicate the start of a rebound  The stock s year to date decline compares to more than 2 percent gains for both the S P 500 healthcare sector  SPXHC  and the blue chip Dow Jones Industrial Average  DJI   of which J J is a member   If J J ends the year with its current 11 2 percent decline  2018 will be the worst calendar year performance in 25 years for the stock  a bellwether for the healthcare sector and one traditionally considered a safe haven investment during periods of market uncertainty  The diversified company  whose products include Band Aid bandages  Tylenol pain reliever  replacement knees and cancer and immunology medicines  faces concerns in all three of its main segments   pharmaceuticals  medical devices and consumer   But the stock s swoon makes it look particularly cheap  based on its price to earnings ratio of 14 8 times forward earnings estimates  which is enticing investors  along with the stock s above market dividend yield of 2 9 percent   We are much more upbeat about J J today than we were six months ago   said David Katz  chief investment officer at Matrix Asset Advisors in New York  as the stock traded just above  120 a share    We definitely think it s an attractive investment opportunity   Katz said  J J shares are up more than 3 percent in June  following five straight months of declines  the stock s longest such losing streak in over a decade  J J s pharmaceuticals segment  roughly half of company revenue  saw sales jump by 19 percent in the first quarter  But concerns about generic drug competition eroding sales of prostate cancer medicine Zytiga  a standout in the first quarter  and rheumatoid arthritis drug Remicade have investors leery about the segment s future performance  Pharmaceuticals has been the strongest segment of J J s businesses  but  the ability to sustain an above average growth rate has been a question   said Dean Dillard  senior research analyst at USAA Investments in San Antonio  J J s medical devices segment including its orthopedics business has been losing market share  said Jeff Jonas  a portfolio manager focusing on healthcare for Gabelli   Co   Performance in J J s consumer segment has been  pretty lackluster for a few quarters   Jonas said  The division also may be subject to weak investor sentiment in general for consumer brand companies  amid fierce competition and other concerns   There is concern around all three of the businesses   Jonas said   GRAPHIC  J J shares in 2018  A stock in need of Tylenol      J J shares may also be suffering from concerns about scrutiny over prescription drug costs that are undermining pharmaceutical shares broadly   Sentiment remains fairly negative for the group  so that by and large does not help Johnson   Johnson   said Kevin Gade  a portfolio analyst  who follows pharmaceutical stocks at Bahl   Gaynor Investment Counsel in Cincinnati  VALUATION ATTRACTIVE The stock s recent valuation at 14 8 times earnings estimates for the next 12 months is its lowest since late 2015 and well below its five year average of 16 5 times  according to Thomson Reuters Datastream  J J is also trading at a nearly 10 percent discount to the S P 500  SPX   compared to the slight premium it has held over the benchmark index on average over the past five years  Also appealing  investors said  is J J s dividend yield of 2 9 percent compared to 1 9 percent for the S P 500  as well as the company s track record of consistently raising it  Aside from paying its dividend  some investors want J J to use its cash for a stock buyback or for an acquisition to improve its growth prospects   J J is  capable of doing 10  5 billion transactions  We don t have to do a  50 billion transaction   Chief Financial Officer Dominic Caruso told an investor conference last week  J J s broad healthcare portfolio  which offers products that people will require even in economic down times  helps position it as a safe haven stock in the event of market volatility or an increasingly uncertain economy   
 If and when the economy sees negative growth   Gade said   relative to the market  Johnson   Johnson is the type of company and business model an investor would want to hold  ",2018-06-11,Reuters,https://www.investing.com/news/stock-market-news/investors-ready-to-resuscitate-johnson--johnsons-ailing-stock-1488498,1488498
198169,419685,JNJ,Why Is Geron  GERN  Down 22  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Geron  GERN   Shares have lost about 22  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Geron due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Geron s Q1 Earnings Beat  Revenues MissGeron incurred a loss of 5 cents per share in first quarter 2019  narrower than the Zacks Consensus Estimate of a loss of 6 cents  In the year ago quarter  the company had incurred a loss of 4 cents per share Quarterly revenues during the quarter came in at  0 06 million  which missed the Zacks Consensus Estimate of  0 21 million  Revenues comprised royalty and license fee revenues received under various non imetelstat license agreements  Revenues in the year ago quarter were  0 32 million  Revenues declined as active license agreements reduced due to expiry of patents of Geron s underlying technology Research and development  R D  expense increased 145  year over year to  5 9 million  Following the termination of collaboration with Janssen  a subsidiary of J J  NYSE JNJ  for imetelstat development  Geron bore full development cost that was earlier shared equally with Janssen  This led to a significant increase in R D expenses General and administrative  G A  expenses rose 3 6  to  5 5 million  reflecting recruitment expenses for new board members Geron ended the quarter with  170 million in cash and investments compared with  182 million at the end of the fourth quarter 2019 GuidanceGeron increased its guidance for operating expenses to the range of  80  85 million in 2019 from the previously guided range of  65  70 million  This will include  20 million to  25 million in one time costs related to transition of imetestat and transfer of investigational new drug  IND  sponsorship from Janssen to Geron among others  Geron is also planning to expand its development team for imtelstat
How Have Estimates Been Moving Since Then 
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions 
VGM Scores
At this time  Geron has a poor Growth Score of F  however its Momentum Score is doing a lot better with a B  However  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Geron has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-31,Zacks Investment Research,https://www.investing.com/analysis/why-is-geron-gern-down-22-since-last-earnings-report-200427467,200427467
198170,419686,JNJ,Johnson   Johnson  Best In Class Dividend Growth Stock ,opinion,"Johnson   Johnson  NYSE JNJ  has raised its dividend for 57 consecutive years and thus it is a Dividend King  Thanks to the strength of its brands and its solid growth trajectory  it has always been a slow moving stock  However  the stock has been facing a series of litigation issues since December and hence it has entered a remarkably volatile period  As a result  it has shed 6  in the last week and is now trading 12  lower off its peak  in December  The big question is whether the stock has become a bargain 
Business overview
Johnson   Johnson is an outstanding company  It has grown its operational earnings for 35 consecutive years and its dividend for 57 years in a row  The company has 26 brands platforms that generate more than  1 billion in annual sales  with 14 of them generating more than  2 billion in annual sales 
Source  Investor Presentation
Johnson   Johnson generates approximately 70  of its sales from the Nr 1 or 2 position  It is also the Nr 5 in the U S  and Nr 8 globally in R D investment  Thanks to this leading position  it currently generates about 25  of its sales from products that were introduced in the last five years  This is an impressive accomplishment for a mature company that has a market capitalization of  348 billion  which reassures investors that management never rests on its laurels  instead  it continuously tries to keep the company in its enviable  multi decade growth trajectory 
Growth prospects
Johnson   Johnson is well known for its consumer products but the main growth driver of the company is its pharmaceutical segment  which generates about half of the total revenues  The consumer segment has stumbled in the last two years  as it has become very easy to launch a new product online and market it at a minimum cost via social media  This is reflected in the performance of this division  which grew its revenue by only 2  last year  Moreover  the medical device segment grew its revenue by only 1  last year whereas the pharmaceutical segment achieved 12  revenue growth  A similar trend was observed in the first quarter of this year as well 
It is thus evident that Johnson   Johnson relies primarily on its pharmaceutical business to keep growing its earnings at a meaningful pace  Indeed this segment has exciting growth prospects ahead  In the first quarter  it posted 8  revenue growth mostly thanks to strong uptake of Stelara in Crohn s disease and market share gain of Darzalex in the U S   Europe  Japan and Latin America  as well as strong momentum of Imbruvica  These brands will continue to drive growth in the upcoming years thanks to increased penetration 
Moreover  Johnson   Johnson expects up to 10 major launches over the next three years  Each of these launches is expected to generate more than  1 billion in annual revenues  Furthermore  the acquisition of Actellion  which cost  30 billion  is likely to provide another source of growth  Thanks to all these growth drivers  management expects to grow the operational earnings per share by 5 7  7 6  this year and will continue growing them at a significant rate in the upcoming years 
Dividend
Johnson   Johnson has raised its dividend for 57 consecutive years and thus it is a dividend king  It has been able to achieve such an impressive dividend growth streak thanks to its consistent earnings growth record  The company has grown its operational earnings for 35 consecutive years  These growth streaks are impressive  particularly given the intense competition in the pharmaceutical business and the shocks in the cash flows that are sometimes caused by the expiration of patents 
Moreover  the company has a low dividend payout ratio  which stands at 42   and a pristine balance sheet  Given also its promising growth prospects  Johnson   Johnson is likely to continue raising its dividend for several more years  Therefore  investors can purchase the stock at its current 2 9  dividend yield and rest assured that the dividend will keep rising for the foreseeable future 
Original post",2019-06-04,Modest Money,https://www.investing.com/analysis/johnson--johnson-bestinclass-dividend-growth-stock-200428047,200428047
198171,419687,JNJ,Theravance Bio  TBPH  Down 27 7  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Theravance Biopharma  TBPH   Shares have lost about 27 7  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Theravance Bio due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Theravance Q1 Loss Widens  Revenues Miss EstimatesTheravance Biopharma incurred a loss of  1 32 per share in first quarter 2019  wider than the Zacks Consensus Estimate of a loss of  1 18 as well as the year ago loss of  1 22 Total revenues of  5 3 million in the quarter significantly missed the Zacks Consensus Estimate of  16 45 million  Moreover  revenues dropped 36 1  year over year due to no product sales in the quarter Quarterly DetailsLast November  Theravance completed the sale of its only marketed drug  Vibativ  to Cumberland Pharmaceuticals  As a result  the company was not able to generate any revenues from product sales in the first quarter of 2019 The entire revenues comprised collaboration revenues from partner Johnson   Johnson  NYSE JNJ  for the joint development of Theravance s pan Janus kinase inhibitor  TD 1473  to treat inflammatory intestinal diseases  Collaboration revenues were  4 6 million in the year earlier quarter Research and development expenses were  53 8 million  up 12 8  from the year ago quarter  primarily due to higher costs to support key programs and higher employee related expenses Selling  general   administrative expenses inched up 2  to  25 2 million due to increased collaboration expenses related to the launch activities of Yupelri 2019 OutlookFor 2019  Theravance anticipates operating loss excluding non cash share based compensation to be  210  230 million  unchanged from the previously issued guidance 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
Currently  Theravance Bio has a poor Growth Score of F  however its Momentum Score is doing a lot better with a C  However  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of this revision indicates a downward shift  Notably  Theravance Bio has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-06-05,Zacks Investment Research,https://www.investing.com/analysis/theravance-bio-tbph-down-277-since-last-earnings-report-can-it-rebound-200429127,200429127
198172,419688,JNJ,Celgene   Acceleron s BLA For Luspatercept Accepted By FDA,opinion,"Celgene Corporation   NASDAQ CELG   announced that the FDA has accepted its Biologics License Application  BLA  for pipeline candidate  luspatercept 
Luspatercept  an investigational erythroid maturation agent  is being developed for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes  MDS  associated anemia  who have ring sideroblasts and require red blood cell  RBC  transfusions  and for those with beta thalassemia associated anemia  who require RBC transfusions 
The candidate is being developed in collaboration with clinical stage biopharmaceutical partner  Acceleron Pharma Inc    NASDAQ XLRN   
The FDA has granted Priority Review to the BLA for the treatment of beta thalassemia and set a target action date of Dec 4  2019  In addition  the FDA has also set a PDUFA date of Apr 4  2020  for the evaluation of the MDS indication 
The application was submitted on the basis of data from phase III studies  MEDALIST and BELIEVE  which evaluated the ability of luspatercept to effectively treat the anemia associated with MDS and beta thalassemia  respectively 
The Marketing Authorization Application for the same is under review in the EU  The candidate is also being evaluated in the phase III COMMANDS trial in ESA na ve  lower risk MDS patients  the BEYOND phase II trial for non transfusion dependent beta thalassemia and a phase II trial in myelofibrosis 
Celgene also announced encouraging data from the TRANSCEND CLL 004 and TRANSCEND NHL 001 trials at the American Society of Clinical Oncology  ASCO  annual meeting in Chicago in patients with relapsed refractory  R R  chronic lymphocytic leukemia or small lymphocytic lymphoma  CLL SLL   These trials evaluated anti CD19 chimeric antigen receptor  CAR  T cell therapy  lisocabtagene maraleucel  liso cel  JCAR017  
The data included safety and efficacy findings from 23 patients  who received liso cel infusion at one of two dose levels   50   106 or 100   106 total CAR positive T cells   following lymphodepleting chemotherapy  All patients were previously treated with Johnson   Johnson s   NYSE JNJ   Imbruvica  The best overall response rate was 82   with 46  of patients achieving complete remission with or without complete blood count recovery  CR CRi  
Shares of Celgene have surged 49 2  year to date compared with the  s growth of 0 9  

 
The company has a robust pipeline  Celgene  which is set to be acquired by Bristol Myers Squibb Company   NYSE BMY    is focused on the next cycle of innovation with five late stage candidates   ozanimod  fedratinib  luspatercept  liso cel and bb2121  It also plans to evaluate fedratinib in combination with luspatercept 
Per the terms of the acquisition  Celgene shareholders will receive  50 plus one share of Bristol Myers and one tradeable Contingent Value Right  which will entitle the holder to receive a cash payment of  9 00 upon the achievement of FDA approval of three candidates  ozanimod  liso cel and bb2121  within the specified time periods 
Zacks Rank
Celgene currently carries a Zacks Rank  2  Buy   You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-06-06,Zacks Investment Research,https://www.investing.com/analysis/celgene--accelerons-bla-for-luspatercept-accepted-by-fda-200429345,200429345
198176,419692,JNJ,J J defends itself in trial over baby powder asbestos claims,news,By Tina Bellon  Reuters    A trial for a lawsuit alleging that Johnson   Johnson  NYSE JNJ  Baby Powder was responsible for the death of a woman due to her exposure to cancer causing asbestos began in South Carolina on Monday in the latest case against the healthcare conglomerate and a supplier over their talc based products  J J said that its widely used baby powder never contained asbestos  a known carcinogen linked to mesothelioma  The case also names as a defendant a local unit of Rite Aid  one of the largest U S  drugstore chains  which allegedly sold the baby powder used by the woman  The case marked the first time a drugstore was involved in a talcum powder liability trial and a lawyer for the company  Sarah Johnston  said there was no reason for Rite Aid to be part of the suit  In opening statements  a lawyer for the family of Bertila Boyd Bostic  who died of a rare form of cancer in 2017 at the age of 30  told a jury in the Darlington County Court of Common Pleas that J J had known for decades that its baby powder contained asbestos   J J and its supplier  a unit of Imerys SA  deny the allegations  and their lawyers said their talc product did not cause any form of cancer  according to an online broadcast of the trial by Courtroom View Network   The case is one of several in recent months that alleged asbestos in talc products caused mesothelioma   A New Jersey state court jury in April ordered J J and Imerys to pay  117 million to a man who alleged he developed mesothelioma due to asbestos exposure from J J Baby Powder  An appeal is pending  J J has also been battling some 6 000 cases claiming its baby powder caused ovarian cancer  Boyd Bostic used baby powder nearly all her life  her family s lawyer  Christopher Swett  said on Monday  In 2016  she was diagnosed with pericardial mesothelioma  an extremely rare form of cancer that develops in the lining around the heart   J J s choices are why we re here   Swett said  He accused the company of concealing knowledge of asbestos contamination since the 1970s and choosing not to warn consumers of the risks  Bruce Bishop  a lawyer for J J  said there was no evidence in Boyd Bostic s medical records that her mesothelioma was in any way related to asbestos exposure   Michael Brown  another J J lawyer  said millions of people had used Johnson   Johnson Baby Powder without developing any diseases   And that s because it does not contain asbestos   he said ,2018-05-14,Reuters,https://www.investing.com/news/stock-market-news/jj-defends-itself-in-trial-over-baby-powder-asbestos-claims-1446751,1446751
198177,419693,JNJ,FDA names drugmakers potentially acting to delay cheap generics,news,"By Michael Erman  Reuters    The U S  Food and Drug Administration on Thursday listed a number of drugmakers it said could be improperly blocking access to their medicines in order to delay generic competition  But many of the companies immediately pushed back  saying the FDA list of drugmakers may be out of date and that some of the drugs included on it already have generic competitors  The FDA said the list contained all of the inquiries about drugs it had received from generic drugmakers since 2005  It said companies generally do not inform it if they have made samples available after a generic developer has reached out to the agency   Releasing the list of drugmakers  which includes  Celgene Corp   O CELG   Johnson   Johnson  N JNJ   Gilead Sciences  O GILD  and  Novartis  AG  S NOVN   is part of the Trump administration s efforts to pressure companies to lower drug prices  Last week  U S  President Donald Trump unveiled a  blueprint  aimed at doing that  but critics have said the proposals did not do nearly enough to substantially decrease the cost of drugs for consumers  Shares of drugmakers rose on Friday after Trump s speech  The agency said companies on the list may be using FDA safety regulations and other tactics to deny access to their medicines from generic drugmakers hoping to copy them  Generic drugmakers may not be able to develop alternatives without access to samples of branded products they intend to copy  the FDA said   I want to be very clear  a path to securing samples of brand drugs for the purpose of generic drug development should always be available   FDA Commissioner Scott Gottlieb said in a statement   Gottlieb  who has made faster approvals of cheaper generic medicines a priority  said this should be true even in cases where there is limited access to drugs for safety reasons  The FDA is notifying the Federal Trade Commission  which can investigate anti competitive acts  of cases where drugmakers may be blocking access to their products if there is no safety reason  Gottlieb added   The FDA said it had also heard of some drugmakers adopting tactics to make it hard for generic companies to purchase branded drugs even at a fair value in the open market  Industry lobby group Pharmaceutical Research and Manufacturers of America  PhRMA  said it was concerned that the FDA list lacks context and conflates a number of issues    It is important to differentiate between those products for which FDA has received complaints as opposed to those products for which it has received a request for a safety determination letter   PhRMA said  Celgene  for example  argued that the three of its products on the FDA list all carry risk of significant side effects  including severe birth defects   These therapies are subjected to rigorous safety controls that have been developed by the company and approved by the FDA   Celgene said in a statement  It noted that two of the three drugs already have generic versions licensed to enter the market in coming years  including multiple myeloma treatment Revlimid  by far the company s biggest selling product  A number of other companies said the drugs in question already had generic competition  Roche  S ROG   which was listed for acne drug Accutane  said it stopped making or selling the drug in the United States in 2009  RBC Capital Markets analyst Brian Abrahams said in a research note that the effect of the FDA s list will likely be limited  
 Though such efforts maintain the public concern about biopharma s role in high drug prices and potentially anti competitive practices  other than creating negative optics for these companies we see minimal impact such a list will have on actual generic risk   he said ",2018-05-17,Reuters,https://www.investing.com/news/stock-market-news/fda-names-drugmakers-potentially-acting-to-delay-cheap-generics-1452198,1452198
198178,419694,JNJ,3 Reasons Growth Investors Will Love J J Snack Foods  JJSF ,opinion,"Growth stocks are attractive to many investors  as above average financial growth helps these stocks easily grab the market s attention and produce exceptional returns  But finding a growth stock that can live up to its true potential can be a tough task 
In addition to volatility  these stocks carry above average risk by their very nature  Also  one could end up losing from a stock whose growth story is actually over or nearing its end 
However  it s pretty easy to find cutting edge growth stocks with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
J J  NYSE JNJ  Snack Foods  JJSF  is one such stock that our proprietary system currently recommends  The company not only has a favorable Growth Score  but also carries a top Zacks Rank 
Studies have shown that stocks with the best growth features consistently outperform the market  And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy   returns are even better 
While there are numerous reasons why the stock of this drink and snack maker is a great growth pick right now  we have highlighted three of the most important factors below 
Earnings Growth
Earnings growth is arguably the most important factor  as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for J J Snack Foods is 3 8   investors should actually focus on the projected growth  The company s EPS is expected to grow 21 3  this year  crushing the industry average  which calls for EPS growth of 4 5  
Impressive Asset Utilization Ratio
Asset utilization ratio    also known as sales to total assets  S TA  ratio    is often overlooked by investors  but it is an important indicator in growth investing  This metric exhibits how efficiently a firm is utilizing its assets to generate sales 
Right now  J J Snack Foods has an S TA ratio of 1 24  which means that the company gets  1 24 in sales for each dollar in assets  Comparing this to the industry average of 1 2  it can be said that the company is more efficient 
In addition to efficiency in generating sales  sales growth plays an important role  And J J Snack Foods looks attractive from a sales growth perspective as well  The company s sales are expected to grow 2 8  this year versus the industry average of 0  
Promising Earnings Estimate Revisions
Beyond the metrics outlined above  investors should consider the trend in earnings estimate revisions  A positive trend is a plus here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
The current year earnings estimates for J J Snack Foods have been revising upward  The Zacks Consensus Estimate for the current year has surged 1  over the past month 
Bottom Line
While the overall earnings estimate revisions have made J J Snack Foods a Zacks Rank  2 stock  it has earned itself a Growth Score of B based on a number of factors  including the ones discussed above 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination positions J J Snack Foods well for outperformance  so growth investors may want to bet on it ",2019-05-22,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-growth-investors-will-love-jj-snack-foods-jjsf-200423909,200423909
198179,419695,JNJ,Why Is AbbVie  ABBV  Up 0 9  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for AbbVie  ABBV   Shares have added about 0 9  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is AbbVie due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  AbbVie Beats on Q1 Earnings   Sales  Raises EPS ViewFirst quarter 2019 earnings of  2 14 per share beat the Zacks Consensus Estimate of  2 06  Earnings rose 14 4  year over year driven by higher sales and operating margins  Earnings per share were also better than the guided range of  2 05 and  2 07 Revenues of  7 83 billion beat the Zacks Consensus Estimate of  7 75 billion  Sales decreased 1 3  on a reported basis  Excluding a 1 7  unfavorable impact from foreign exchange rate fluctuations  operational revenues rose 0 4  backed by higher sales of several products  which offset the impact of international biosimilar competition  Revenues were higher than the guided figure of approximately  7 7 billion Quarter in DetailsHumira sales declined 5 6   3 8  on an operational basis  to  4 4 billion Sales in the United States increased 7 1  to  3 22 billion  in line with the guidance  driven by strong demand trends  Humira sales in ex U S  markets were down 23  on an operational basis and 27 9  on a reported basis to  1 23 billionInternational sales were severely impacted by the launch of several direct biosimilar drugs in Europe and other international markets  On the call  the company said that biosimilar trends and dynamics were in line with management expectations In the U S  market  Humira sales are expected to rise approximately 7  in 2019  which is less than growth of 10  in 2018 due to lighter price contribution for the year  In 2019  international Humira sales are expected to decline approximately 30  on an operational basis AbbVie s oncology hematology  including Imbruvica and Venclexta  sales rose 43 2  to  1 17 billion in the quarter driven by strong growth of both Imbruvica and Venclexta  First quarter net revenues from Imbruvica were  1 02 billion  in line with the guidance  up 34  year over year  U S  sales of Imbruvica grossed  829 million  up 32 8  from the year ago figure primarily driven by continued uptake in the frontline CLL segment  AbbVie logged  193 million of international profit sharing with J J  NYSE JNJ   up 39 6  year over year Venclexta  brought in revenues of  151 million  up more than 100  year over year driven by continued uptake in the second line plus setting following approval in the broad relapsed refractory CLL segment  MURANO study  last year and the recent launch in first line AML In 2019  Imbruvica global revenues are expected to approach  4 4 billion with sales in the United States growing approximately 21   Venclexta sales are expected to be approximately  725 million  Total global oncology hematology sales are expected to be approximately  5 1 billion HCV products  including Viekira and Mavyret  recorded sales of  815 million  down 11 3   down 9 1  on an operational basis  year over year on lower sales of Mavyret as well as Viekira  In the United States  HCV revenues rose 17 3  to  403 million reflecting market share gains Mavyret accounted for  790 million in the quarter  down 6 9   down 4 9  on an operational basis  year over year In 2019  global HCV sales are expected to be higher than  3 3 billion with roughly flat performance in the United States and international sales of approximately  1 7 billion Other products that delivered an impressive performance include Duodopa  It recorded revenue growth of 14 4  on an operational basis and 8 3  on a reported basis  While Creon  which generates sales from U S  markets  witnessed an increase of 8 6  in revenues  sales of Kaletra grew 10 9  and 6 9  on operational and reported basis  respectively Drugs that recorded sales decline include Androgel  Synagis and Sevoflurane  which fell 42 9   7  and 8 5   respectively  operationally  during the quarter Margins RiseAdjusted gross margin rose 310 bps to 83 3  in the quarter  Adjusted gross margin includes a 280 bps benefit due to low Humira royalties owed  Adjusted SG A expenses decreased 6 4  to  1 56 billion  However  as a percentage of sales  SG A expenses declined 100 bps to 20  in the quarter  R D expenses rose almost 1  to  1 2 billion in the first quarter due to greater investments in the pipeline  Adjusted operating margin was 48 1  of sales in the reported quarter  up 400 bps year over year 2019 GuidanceAbbVie raised its guidance for adjusted EPS based on a strong first quarter performance and strong business momentum  Earnings are now expected in the range of  8 73  8 83  up from the previous guidance of  8 65  8 75 for 2019  The earnings guidance indicates a year over year increase of 11  at the mid point Revenues are expected to grow approximately 1  on an operational basis in 2019  Currency headwinds are expected to hurt 2019 revenues by approximately 1   compared to less than 1  expected previously In 2019  AbbVie expects roughly  2 billion of erosion related to international biosimilar competition to Humira  In addition  it expects a  400 million headwind from generic competition to AndroGel in 2019  Also  costs to support expected launches of five new products and line extensions should put pressure on margins  However  these new products will be at early stages of their launch trajectory in 2019 and will not be a significant offset to international biosimilar impact  However  AbbVie believes the products will grow over the next few years and provide significant offset to the 2023 U S  biosimilar event In 2019  AbbVie believes that the loss of international Humira revenues will be made up for by U S  Humira and hematological oncology franchise growth Adjusted gross margin is expected to approach 83  of sales in 2019  up from 82 5  expected previously Operating margin is expected to be just above 47   an increase of roughly 250 basis points year over year  Previously  the operating margin was expected to be just above 46 5   representing an increase of 200 bps While R D is expected to be approximately 15 5  of sales  SG A is expected to be approximately 20 5  of salesSecond Quarter 2019 OutlookSecond quarter earnings are expected between  2 20 and  2 22 per share  Revenues are estimated to be above  8 1 billion  Foreign exchange is expected to have approximately 1 5  unfavorable impact on sales in the quarter While U S  Humira sales are expected to rise approximately 7   international Humira sales are expected to be approximately  1 billion  Imbruvica is expected to record sales of approximately  1 1 billion Adjusted operating margin is expected to be similar to the first quarter level of 48 1   which is higher than the full year expectation of just above 47   This is because the company expects higher spending related to new product launches in the second half  In the second quarter  sales contribution from Skyrizi is expected to be modest  Skyrizi is expected to contribute approximately  150 million of sales in the second half of 2019  Orilissa sales are expected to be approximately  200 million in 2019  
How Have Estimates Been Moving Since Then 
Fresh estimates followed an upward path over the past two months 
VGM Scores
At this time  AbbVie has a nice Growth Score of B  though it is lagging a lot on the Momentum Score front with an F  However  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
AbbVie has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-05-24,Zacks Investment Research,https://www.investing.com/analysis/why-is-abbvie-abbv-up-09-since-last-earnings-report-200425141,200425141
198180,419696,JNJ,J J Stock Up This Year So Far  Will The Momentum Continue ,opinion,Johnson   Johnson   NYSE JNJ   stock has risen 7 6  this year so far compared with an increase of 0 8  recorded by the    This marks a decent recovery from a decline of 7 3  last year on allegations that its talc products contain asbestos  which causes users to develop ovarian cancer  J J s earnings estimates for 2019 have gone up from  8 58 to  8 60 in the past 60 days  This New Brunswick  NJ based pharma giant has a Zacks Rank  3  Hold    You can see  The better performance this year so far has been supported by a series of positive news including promising data from several pivotal studies and rapid progress with its pipeline and line extensions  The positive trend is likely to continue through the rest of the year J J has already gained FDA approval for two new drugs in 2019   Spravato  esketamine  for treatment resistant depression and Balversa  erdafitinib  for metastatic urothelial cancer  J J believes that both Spravato and Balversa have the potential for more than  1 billion of peak revenues Among line extensions  a key FDA approval was that of its blockbuster cancer drug Imbruvica in combination with Roche s   OTC RHHBY   Gazyva  obinutuzumab  for the first line treatment of patients with chronic lymphocytic leukemia small lymphocytic lymphoma  CLL SLL   Please note that J J markets Imbruvica in partnership with AbbVie  Inc    NYSE ABBV   In February  J J announced a definitive agreement to acquire Auris Health  Inc   a privately held developer of robotic technologies focused on lung cancer  for approximately  3 4 billion in cash  Auris Health s robotic platform will expand J J s digital surgery portfolio  J J closed the Auris Health acquisition on Apr 1  J J also announced a new gene therapy with MeiraGTx to develop gene therapy programs for inherited retinal diseases  IRD  Recently  at a meeting with industry analysts  J J gave a rather bullish outlook for its Janssen pharmaceutical unit  It expects the segment to deliver above market growth through 2023  J J expects to launch or file for approval of more than 10 new products with blockbuster potential between 2019 and 2023  The company is targeting more than 40 line extensions of existing and new drugs through 2023  10 of which have more than half a billion dollars of opportunity Management is optimistic about the Pharmaceuticals unit as key cancer drugs like Imbruvica and Darzalex and immunology drug  Stelara are likely to witness sales uptake and line extensions  Meanwhile  new products launched in late 2017 2018  Tremfya for plaque psoriasis and Erleada for prostate cancer  should perform well  However  this year  J J is expected to witness significant generic biosimilar headwinds in the Pharma unit  Continued biosimilar competition for Remicade and Procrit and generic competition for Velcade  Tracleer and Zytiga in the United States will hurt revenues by  3 billion in 2019 Nevertheless  J J s sales and earnings growth is expected to accelerate in 2020 supported by contribution from new drugs like Tremfya  Erleada and Spravato and successful label expansion of Imbruvica  Darzalex and Stelara  Please note that J J markets Remicade in partnership with Merck   NYSE MRK   Meanwhile  the Medical Devices segment is expected to continue to improve driven by improved execution and product introductions  Also  share buybacks and restructuring initiatives should provide bottom line support With several pivotal data readouts and regulatory milestones expected in the rest of the year  the bullish run of the stock is likely to continue Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-05-27,Zacks Investment Research,https://www.investing.com/analysis/jj-stock-up-this-year-so-far-will-the-momentum-continue-200425627,200425627
198181,419697,JNJ,Geron Stock Up More Than 50  In 2019 So Far  Here s Why,opinion,"Geron Corporation   NASDAQ GERN   shares have risen 55  so far this year compared with the  s increase of 2 1   riding on the development of its sole pipeline candidate  imetelstat Imetelstat is being evaluated as a treatment for hematologic myeloid malignancies like myelofibrosis   MF   in a phase II IMbark study and myelodysplastic syndromes   MDS   in a phase II III IMerge study Notably  both the studies are being conducted by Geron  following the termination of the collaboration related to imetelstat development by Johnson   Johnson   NYSE JNJ    The candidate enjoys orphan drug designation for both the indications Pipeline ProgressGeron is progressing well with the development of imetelstat  Earlier this month  the company completed the transfer of the sponsorship of the investigational new drug   IND   related to imetelstat from Janssen  Geron now holds the full responsibility for the development of imetelstat Enrollment has been stopped in the phase II portion of IMerge study and the company anticipates top line data from it by the end of 2019  Preliminary data presented last year had shown that the benefit risk profile of imetelstat in treated patients  including the expansion arm  supports continued development in lower risk MDS indication  Based on this data  the company expects to initiate the phase III portion of the IMerge study in mid 2019 Geron has also added new leaders to its development team with vast experience in oncology and drug development to support the progress of imetelstat Meanwhile  the company postponed the date of the end of phase II meeting related to IMbark study to the first quarter of 2020 from the third quarter of this year  The extended period is likely to be used for further analysis of data from the IMbark study  which may support the regulatory application seeking approval of imetelstat in relapsed refractory MF However  operating expense is set to increase as Geron will bear all costs of imetelstat development following the termination of collaboration with J J  Geron has sufficient funds to start the phase III portion of IMerge studies  However  it may face difficulties with the progress of the study  if the company fails to raise funds or find a suitable partner for funding the continuation of the study Moreover  the single pipeline candidate is also a concern  Any hiccups in development may lead to share price decline  Meanwhile  Acceleron Pharma Inc    NASDAQ XLRN   and its partner Celgene Corporation s   NASDAQ CELG   luspatercept  which is being developed for MDS in a phase III study  may give competition to imetelstat Geron Corporation Price
    Zacks RankGeron currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-05-27,Zacks Investment Research,https://www.investing.com/analysis/geron-stock-up-more-than-50-in-2019-so-far-heres-why-200425684,200425684
198185,419701,JNJ,Why Is Johnson   Johnson  JNJ  Down 1 2  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Johnson   Johnson  NYSE JNJ   Shares have lost about 1 2  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Johnson   Johnson due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  J J Beats on Q1 Earnings  Ups 2019 Sales Growth ViewJ J beat estimates for both earnings and sales in the first quarter of 2019  First quarter 2019 earnings came in at  2 10 per share  which surpassed the Zacks Consensus Estimate of  2 03 and increased 1 9  from the year ago period driven by higher revenues and other income Adjusted earnings exclude after tax intangible amortization expense and some special items  Including these items  J J reported first quarter earnings of  1 39 per share  down 13 1  from the year ago quarter Sales came in at  20 02 billion  which beat the Zacks Consensus Estimate of  19 63 billion  Sales increased 0 1  from the year ago quarter  reflecting an operational increase of 3 9  and an unfavorable currency impact of 3 8  Organically  excluding the impact of acquisitions and divestitures  sales increased 5 5  on an operational basis  better than 5 3  increase seen in the previous quarter  Continued strong sales performance in the Pharmaceutical segment and continued improvement in Medical Devices unit offset a softer performance in the Consumer unit First quarter sales grew 1 8  in the domestic market to  10 13 billion but declined 1 7  in international markets to  9 89 billion  reflecting 6  operational growth and 7 7  negative currency impact Segment DetailsJ J s Pharma segment delivered an above market performance globally despite currency headwinds and the impact of biosimilar and generic competition on sales of some key drugs like Remicade and Zytiga Pharmaceutical segment sales rose 4 1  year over year to  10 24 billion  reflecting 7 9  operational growth and 3 8  negative currency impact as sales rose in both domestic and international markets  Sales in the domestic market rose 4 3  to  5 58 billion  International sales grew 3 9  to  4 66 billion  operational increase of 12 2    Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 7 9   better than 7 2  in the previous quarter Organic sales growth in the Pharma segment  benefited by approximately 200 bps of pricing adjustments in the prior period The strong performance was led by the company s oncology drug Darzalex as well as psoriasis treatment  Stelara Worldwide sales of J J s cancer drugs like Imbruvica and Darzalex rose 9  in the quarter to  2 52 billion  Other core products like Stelara  Simponi Simponi Aria and Invega Sustenna and new immunology medicines like Tremfya also contributed to growth  However  sales of some other key drugs like Xarelto and Invokana declined in the quarter  Sales of Zytiga declined sharply due to the impact of generic competition in the United States Imbruvica sales rose 33 5  to  784 million in the quarter driven by market share gains and strong market growth across multiple indications in the United States and strong uptake in the European and Asia Pacific markets Darzalex sales rose 45 5  to  629 million in the quarter  In United States  market growth and market share gains drove sales  In outside U S  markets  increased penetration and share gains drove sales growth Stelara sales rose 32 4  to  1 41 billion in the quarter driven primarily by the Crohn s disease indication PAH revenues of  656 million rose 12 1  year over year as strong demand for Uptravi and Opsumit was partially offset by a decline in Tracleer sales  which were hurt by increased use of Opsumit as well as generic competition in Europe Simponi Simponi Aria sales recovered in the quarter  rising 1  to  524 million in the quarter  Prezista sales rose 9 5  to  523 million in the quarter Newly launched Tremfya recorded sales of  217 million in the quarter compared with  175 million in the fourth quarter  J J said that the product is seeing strong demand trends with more than 31 000 patients now on therapy and the drug capturing 6 9  share of the psoriasis market in the United States  up 4 points from the previous quarter Regarding Spravato  which was approved and launched in the first quarter  J J said that the drug is off to a very strong start and could prove to be an important growth driver for the company Zytiga sales declined 19 6  to  679 million in the quarter as growth outside the United States was offset by sales decline in the United States due to generic competition Sales of Procrit Eprex declined 18  to  226 million in the quarter Xarelto sales declined 6 3  in the quarter to  542 million as prescription growth was offset by increased discounts and rebates The October 2018 FDA approval of Xarelto for a new 2 5 milligram vascular dose for the CAD PAD indication significantly expands the drug s eligible patient population  which can improve sales of the drug in the future quarters  Regarding this label expansion  management said on the call that it has seen positive response to the 2 5 milligram vascular dose and it could be a significant contributor to Xarelto s sales in the future quarters  Also  if J J s sNDA to include data from MARINER and MAGELLAN studies on Xarelto s label is approved and launched in 2019  it will create an incremental growth opportunity Sales of Invokana Invokamet declined 18 4  to  202 million Sales of Remicade were down 20 6  in the quarter to  1 10 billion due to increased discounts and share loss to biosimilars  While U S  sales declined 15 5   U S  exports went down 46 4   Remicade sales rose 23 6  in international markets Medical Devices segment sales came in at  6 46 billion  down 4 6  from the year ago period  It included an operational decrease of 1  and negative currency movement of 3 6  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 4 3   better than 3 3  in the previous quarter Operational growth was driven by continued strong performance in Interventional Solutions  Advanced Surgery and Vision  which partially offset softer growth in the orthopedics portfolio due to pricing pressure  However  J J s orthopedics portfolio is showing improving trends and has delivered five straight quarters of sequential improvement Domestic market sales declined 1 6  year over year to  3 11 billion  International market sales decreased 7 1   operational decrease of 0 3   year over year to  3 35 billion The Consumer segment recorded revenues of  3 32 billion in the reported quarter  down 2 4  year over year  On an operational basis  Consumer segment sales increased 2 2   which was offset by unfavorable foreign currency movement of 4 6  Excluding the impact of acquisitions and divestitures  adjusted operational sales growth was 0 7  worldwide  a significant deceleration from 3 8  the previous quarter Growth in beauty and over the counter products was offset by lower baby care sales in the United StatesSofter end markets also hurt the performance of the Consumer segment   On the call  the company said that overall market growth in its categories slowed to slightly more than 1  in the quarter Sales in the domestic market rose 0 2  from the year ago period to  1 44 billion  Meanwhile  the international segment recorded a decline of 4 2  to  1 88 billion  An operational increase of 3 7  was offset by negative currency impact 7 9  in the quarter 2019 OutlookDespite  increased negative impact of translational currency  J J raised its adjusted sales and earnings growth forecast for 2019 based on strong first quarter performance J J tightened its 2019 adjusted earnings per share guidance from a range of  8 50    8 65 to  8 53    8 63  The guidance range  however  indicates a growth rate of 4 3    5 5   higher than 3 9    5 8  expected previously  Currency is expected to negatively impact EPS by 20 cents per share higher than 5 cents expected previously On an operational  constant currency basis  adjusted earnings per share are expected to grow in the range of 6 7    7 9  versus 5 7    7 6  expected previously   Revenues are still expected in the range of  80 4 to  81 2 billion  including currency impact Operational constant currency sales growth is expected to be in the range of 0 5    1 5   better than 0  to 1  expected previously  Adjusted operational sales growth   excluding currency impact  acquisitions divestitures  is expected to be in the range of 2 5  to 3 5   higher than 2  to 3  expected previously In 2019  J J is expected to witness significant generic biosimilar headwinds in the Pharma unit  Continued biosimilar competition for Remicade and Procrit and generic competition for Velcade  Tracleer and Zytiga in the United States will hurt revenues by  3 billion in 2019  However  J J s sales and earnings growth is expected to accelerate in 2020 supported by contribution from new drugs like Tremfya  Erleada and Spravato and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug  Stelara Meanwhile  the Medical Devices segment is expected to continue to improve driven by improved execution and new product introductions Second Quarter OutlookSales in the second quarter are expected to be hurt by divestiture of minimal Advanced Sterilization Products unit  currency headwinds  difficult comparison from a strong sales performance in the second quarter of 2018  potentially accelerated generic erosion of Zytiga and biosimilar erosion of Procrit in the United States from the first quarter 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
Currently  Johnson   Johnson has a strong Growth Score of A  though it is lagging a bit on the Momentum Score front with a B  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of this revision looks promising  Notably  Johnson   Johnson has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-15,Zacks Investment Research,https://www.investing.com/analysis/why-is-johnson--johnson-jnj-down-12-since-last-earnings-report-200422158,200422158
198186,419702,JNJ,AbbVie s Brain Cancer Candidate Fails In Phase III Study,opinion,AbbVie  Inc    NYSE ABBV   announced that a late stage study evaluating its pipeline candidate  depatuxizumab mafodotin  Depatux M  failed to show any survival benefit in patients with newly diagnosed glioblastoma  an aggressive form of brain cancer The phase III INTELLANCE 1 study  conducted in collaboration with the RTOG Foundation  did not meet the primary endpoint of overall survival at the interim analysis  The Independent Data Monitoring Committee  IDMC  recommended that the study be stopped due to lack of survival benefit in patients treated with Depatux M compared with placebo when added to the standard regimen of radiation and temozolomide  Enrolment has been stopped in all ongoing Depatux M studies AbbVie s stock has declined 13 8  this year so far compared with a decrease of 1 1  recorded by the    Oncology is a key therapeutic area for AbbVie and the company believes that it will be its major growth driver over the next 10 years  Key drugs in its oncology portfolio are Imbruvica  currently approved for quite a few indications and marketed in partnership with J J   NYSE JNJ    and Venclyxto Venclexta  approved to treat chronic lymphocytic leukemia  CLL  and marketed in partnership with Roche   OTC RHHBY   Several studies on Imbruvica are ongoing to evaluate the drug alone or in combination in different patient segments AbbVie is also studying Venclyxto Venclexta to expand the label to address the broader relapsed refractory CLL patient population  expand into earlier lines of therapy  and broaden into other hematologic malignancies like multiple myeloma and acute myeloid leukemia  AML  Despite the presence of successful medicines in its portfolio  AbbVie has had its shares of failure in cancer studies  In March  the FDA placed a partial clinical hold on all studies evaluating Venclexta for the treatment of multiple myeloma  The decision was taken after a higher proportion of deaths was observed in the Venclexta arm compared to the control arm of the study in the ongoing phase III BELLINI study Last year  AbbVie s rovalpituzumab tesirine or Rova T fell short of expectations in a phase II TRINITY study evaluating it in third line or later small cell lung cancer  SCLC   Rova T was added to AbbVie s portfolio following the  5 8 billion acquisition of Stemcentrx in June 2016 AbbVie said it will not seek accelerated approval of Rova T in the third line setting after consulting with the FDA  In December  AbbVie stopped enrolment in a pivotal phase III study   TAHOE   evaluating Rova T in second line small cell lung cancer  SCLC   The failure of TRINITY and the halt on TAHOE have raised skepticism on Rova T s potential and brought into question the viability of the Stemcentrx deal AbbVie currently carries a Zacks Rank  2  Buy  Another top ranked large cap pharma stock is Merck   Co   Inc    NYSE MRK    which has a Zacks Rank  2  You can see  Shares of Merck have gained 3  so far this year while estimates for 2019 and 2020 have risen 1 5  and 0 8   respectively  over the past 30 days  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-05-19,Zacks Investment Research,https://www.investing.com/analysis/abbvies-brain-cancer-candidate-fails-in-phase-iii-study-200423050,200423050
198195,419711,JNJ,J J Baby Powder litigation takes new focus with asbestos claims,news,By Tina Bellon NEW YORK  Reuters    A  117 million verdict against Johnson   Johnson  NYSE JNJ  and a supplier in favor of a man who said his asbestos related cancer was caused by long term use of J J s Baby Powder could open a new front for thousands of cases claiming the widely used product caused cancer  legal experts and plaintiffs lawyers said  J J has been battling some 6 000 cases claiming its baby powder and Shower to Shower products cause ovarian cancer  The  117 million verdict by a New Jersey jury last week  however  involved a different form of cancer that is clearly linked to asbestos  Plaintiffs lawyers claim that internal J J documents seen in that trial show that baby powder had been contaminated with asbestos  They now plan to use the documents in upcoming ovarian cancer trials to allege that the asbestos contamination also caused that form of cancer  J J and Imerys Talc America  a unit of Imerys SA  have vowed to appeal the New Jersey verdict and deny asbestos has ever been present in their products or that their talc can cause any form of cancer  The case of Stephen Lanzo  a New Jersey resident who claimed he developed mesothelioma after using baby powder since his birth in 1972  was the first time a jury saw the internal J J documents which plaintiffs claim show that J J knew since the 1970s that the talc in its baby powder was contaminated by asbestos during the mining process  J J says the documents present no such evidence  but merely show the company s caution  Peter Bicks  a lawyer leading J J s talc asbestos defense  said that in the early 1970s  the company was looking at how it could potentially remove asbestos from talc if the two became intermingled in the mining process  He says no contamination was ever found  citing decades of testing by independent laboratories and scientists  Bicks called the claims of a link between talc and asbestos  junk science    Mesothelioma  a rare and deadly form of cancer closely associated with exposure to asbestos  affects the delicate tissue that lines body cavities  While the link between asbestos and mesothelioma is sufficiently established  scientists are divided on whether asbestos exposure can cause ovarian cancer  Some studies have shown an association between the two  while other studies have found no such link  Elizabeth Burch  holder of the Charles H  Kirbo Chair of Law at the University of Georgia  said it remained an open question whether talc contained asbestos and that each case would turn on the facts   But J J  which had  76 5 billion in sales in 2017  gives the plaintiffs  bar an enticing new target  said Nathan Schachtman  a lecturer at Columbia University who used to defend asbestos cases  Some 3 000 people are diagnosed with mesothelioma each year  according to the American Cancer Society  a number that Howard Erichson  a law professor at Fordham University who specializes in mass tort litigation  called significant from a legal standpoint   But the roughly 22 000 women who were diagnosed with ovarian cancer last year  according to the National Cancer Institute  provide lawyers with a potentially much larger pool of plaintiffs to tap    This is just the tip of the iceberg   said Mark Lanier  one of the lawyers representing consumers  who said plaintiffs would file thousands of additional mesothelioma and ovarian cancer cases  New Jersey based J J in a statement after the Lanzo verdict said plaintiffs  attorneys had shifted their strategy to focus on asbestos after a series of losses at trial and in court rulings over previous allegations that the talc itself causes cancer  Of the six ovarian cancer trials to date  juries found J J liable five times  but a Missouri appellate court threw out the first verdict and a California judge tossed another  Appeals of the other cases are pending  J J in November also won the first trial over allegations that its talc contained asbestos and caused a woman s mesothelioma  Plaintiffs lawyers say the jury in that case did not see the documents presented during the Lanzo trial  But Erichson said the widespread use of J J s consumer products generally make the company an attractive litigation target   Baby powder is as ubiquitous a product you can think of and there are lots of people who can testify they ve been exposed to it   he said ,2018-04-16,Reuters,https://www.investing.com/news/stock-market-news/jj-baby-powder-litigation-takes-new-focus-with-asbestos-claims-1395602,1395602
198196,419712,JNJ,J J raises sales forecast but keeps profit outlook unchanged  shares drop,news," Reuters    Johnson   Johnson  N JNJ  raised its sales forecast for the year on Tuesday but kept its outlook for full year profit unchanged  disappointing investors and sending its shares down 1 6 percent   The healthcare conglomerate  whose stock had climbed about 3 percent over the previous six days  reported better than expected profit in the first quarter  helped by strong demand for its cancer treatments  J J said it was not revising its earnings forecast higher for the year because certain divestments it previously expected to make this year might be pushed into 2019   I m definitely surprised by the stock reaction   said Gabelli Funds portfolio manager Jeff Jonas   There was some expectation that they would raise EPS guidance this quarter just because foreign exchange has gotten better and the business did do pretty well   Shares were down  1 99 at  129 63 in late morning trading on the New York Stock Exchange  Quarterly sales of its cancer treatments surged 45 percent to  2 31 billion  accounting for nearly a quarter of its pharmaceutical unit s revenue  The company s blockbuster rheumatoid arthritis drug Remicade has come under pressure from cheaper copies  pushing the company to focus on newer treatments such as cancer drugs  Remicade s first quarter sales fell 16 9 percent to  1 39 billion  The company said it plans to streamline its global supply chain and expects pretax savings of  600 million to  800 million by 2022  J J said it would boost capital expenditure by 15 percent in the United States  bringing the total to  30 billion over the next four years as it reinvests a windfall from U S  tax reforms  For the full year  J J raised its sales forecast to a range of  81 0 billion to  81 8 billion  from  80 6 billion to  81 4 billion estimated previously  Sales at J J s consumer products unit  which makes Band Aids  Neutrogena beauty products and Tylenol  rose 5 3 percent to  3 40 billion  Net earnings fell to  4 37 billion  or  1 60 per share  in the latest quarter  from  4 42 billion  or  1 61 per share  a year earlier  Excluding items  the company earned  2 06 per share  Analysts on average were expecting earnings of  2 02 per share  according to Thomson Reuters I B E S  
Total sales jumped 12 6 percent to  20 01 billion  beating analysts  estimates of  19 46 billion ",2018-04-17,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-quarterly-sales-rise-126-percent-1398114,1398114
198197,419713,JNJ,The Zacks Analyst Blog Highlights  Merck  Pfizer  AbbVie  Sanofi And Glaxo,opinion,"For Immediate Release
Chicago  IL   May 6  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Merck   NYSE MRK    Pfizer   NYSE PFE    AbbVie   NYSE ABBV    Sanofi   NASDAQ SNY   and Glaxo   NYSE GSK   
Here are highlights from Friday s Analyst Blog  
Pharma Stock Roundup  MRK  LLY  PFE   More
 This week was a relatively busy one for the pharma sector  marked by earnings of bigwigs like Merck and Pfizer  Meanwhile  the European Commission granted approval to AbbVie s new plaque psoriasis drug Skyrizi  risankizumab  and Sanofi Lexicon Pharmaceuticals  dual SGLT1 and SGLT2 inhibitor  Zynquista  sotagliflozin   The Committee for Medicinal Products for Human Use   CHMP   of the European Medicines Agency  EMA  recommended marketing approval for several drugs 
Recap of the Week s Most Important Stories
Q1 Earnings Update  Pfizer  Glaxo and Merck beat estimates for first quarter earnings and sales  Pfizer raised the mid point of its earnings expectations for 2019 by a penny and confirmed its previous outlook for full year sales  Merck raised its expectations for both earnings and sales for the year while Glaxo maintained its previous earnings guidance for 2019 
EU Approval to Sanofi   AbbVie Drugs  The European Commission granted approval to AbbVie s Skyrizi  risankizumab  for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy  Skyrizi was approved in the United States in late April and is expected to be launched this month  It was approved in Japan in March 
Lexicon Pharmaceuticals and partner Sanofi announced that the European Commission granted approval to their dual SGLT1 and SGLT2 inhibitor  Zynquista  sotagliflozin   in combination with insulin  for the treatment of type I diabetes in adult patients  In March  the FDA had issued a complete response letter   CRL   to the new drug application   NDA   seeking approval for Zynquista 
CHMP Gives Positive Opinion to Several Drugs  AstraZeneca Merck s PARP inhibitor Lynparza gained a positive CHMP opinion  recommending expanded approval for first line maintenance treatment of BRCA mutated advanced ovarian cancer  It is already approved in the United States for the indication  The CHMP also gave nod to Novo Nordisk s Esperoct  turoctocog alfa pegol  N8 GP  for the treatment of haemophilia A  The drug was approved by the FDA in February this year  Glaxo also gained positive CHMP opinion for its once daily  single tablet two drug regimen  2DR   Dovato for the treatment of newly diagnosed adults with HIV 1 infection  Dovato is a fixed dose combination of Tivicay  dolutegravir   50 mg  in combination with lamivudine  300 mg  and was approved by the FDA last month   Pfizer s new PARP inhibitor  Talzenna also gained a positive opinion from the CHMP for inherited  germline  BRCA mutated advanced breast cancer 
The final decision by the European Union on these products is expected in the coming months 
Glaxo J J File NDA for Long Acting Two Drug HIV Regimen  Glaxo s HIV subsidiary  ViiV Healthcare and partner J J  NYSE JNJ  filed a NDA looking for approval of long acting  two drug regimen of ViiV Healthcare s cabotegravir and Janssen s Edurant  rilpivirine   The companies are seeking approval for the two drug monthly regimen for the treatment of HIV 1 infected adults who had maintained viral suppression and who are not resistant to cabotegravir or rilpivirine  The approval was based on data from the phase III ATLAS study  which showed that the two drug regimen  injected once a month  had similar efficacy to a standard of care  daily  oral three drug regimen at week 48 
Glaxo and its partner Innoviva s phase III study  CAPTAIN  evaluating their triple combination once daily single inhaler Trelegy Ellipta versus Relvar Breo Ellipta for a new indication  uncontrolled asthma   met the primary endpoint  Data from the study showed that treatment with Trelegy Ellipta led to statistically significant improvement in lung function in such patients  thereby meeting the study s primary endpoint  At present  Trelegy Ellipta is approved to treat chronic obstructive pulmonary disease 
Bayer  DE BAYGN  Gets FDA s Priority Review for Prostate Cancer Candidate  Bayer s new drug application looking for approval of its prostate cancer candidate  darolutamide was accepted and granted priority review by the FDA  In February 2019  Bayer completed the rolling submission of the NDA for darolutamide to the FDA  The submission is based on data from the phase III ARAMIS study in men with non metastatic castration resistant prostate cancer  nmCRPC   Regulatory applications are also under review in Europe and Japan 
Media Contact
Zacks Investment Research
800 767 3771 ext  9339
 
 
Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2019-05-05,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-merck-pfizer-abbvie-sanofi-and-glaxo-200417285,200417285
198198,419714,JNJ,Geron s  GERN  Q1 Earnings Beat  Revenues Miss  Stock Up,opinion,"Geron Corporation   NASDAQ GERN   incurred a loss of 5 cents per share in first quarter 2019  narrower than the Zacks Consensus Estimate of a loss of 6 cents  In the year ago quarter  the company had incurred a loss of 4 cents per share Quarterly revenues during the quarter came in at  0 06 million  which missed the Zacks Consensus Estimate of  0 21 million  Revenues comprised royalty and license fee revenues received under various non imetelstat license agreements  Revenues in the year ago quarter were  0 32 million  Revenues declined as of active license agreements reduced due to expiry of patents of Geron s underlying technology Shares were up 1 7  in after market trading on May 3  So far this year  shares of Geron have rallied 80  compared with the  s 5 1  increase Research and development  R D  expense increased 145  year over year to  5 9 million  Following the termination of collaboration with Janssen  a subsidiary of J J   NYSE JNJ    for imetelstat development  Geron bore full development cost that was earlier shared equally with Janssen  This led to a significant increase in R D expenses General and administrative  G A  expenses rose 3 6  to  5 5 million  reflecting recruitment expenses for new board members Geron ended the quarter with  170 million in cash and investments compared with  182 million at the end of the fourth quarter Pipeline UpdateFollowing the termination of the agreement with Janssen in September 2018  Geron regained global development rights to imetelstat and decided to continue developing imetelstat independently Geron is expected to assume sponsorship of the investigational new drug   IND   application for imetelstat by the end of the second quarter  The company will be able to initiate enrollment in the planned phase III portion of phase II III study  IMerge  evaluating imetelstat in myelodysplastic syndromes   MDS   following the transfer of IND Another phase II study   IMbark   is evaluating the candidate in myelofibrosis  In December  Geron presented updated median overall survival   OS   data from the higher dosage arm  9 4 mg kg  of the study  The candidate achieved median OS of 29 9 months  which suggests a meaningful survival outcome  A decision on the path toward late stage development in myelofibrosis is expected to be announced by the third quarter of 2019 Geron Corporation Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderGeron currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the pharmaceutical sector include Editas Medicine  Inc    NASDAQ EDIT   and Alder BioPharmaceuticals  Inc    NASDAQ ALDR    both carrying a Zacks Rank  2  Buy   You can see  Editas  loss estimates narrowed from  2 74 to  2 68 for 2019 and from  3 05 to  3 01 for 2020 over the past 60 days Alder s loss estimates narrowed from  4 59 to  4 47 for 2019 and from  3 24 to  3 20 for 2020 over the past 60 days Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-05-05,Zacks Investment Research,https://www.investing.com/analysis/gerons-gern-q1-earnings-beat-revenues-miss-stock-up-200417409,200417409
198199,419715,JNJ,4 Trade Ideas For Johnson   Johnson,opinion,"Johnson   Johnson  NYSE JNJ    JNJ  was consolidating under resistance for 2 months before breaking out to the upside last week  This gives a target to 154  The RSI is rising and bullish with the MACD moving higher and positive  There is resistance at 143 25 and 144 60 the 147 and 148 70  Support lower comes at 140 25 and 138 then 136 85 and 135  Short interest is low under 1   The stock pays a 2 7  dividend and will trade ex dividend beginning May 24th  The company is expected to report earnings next on July 16th 
The May options see the biggest open interest on the put side at the 135 strike with size also at 140 and 132  On the call side  it is biggest at 145 then 140 and 143  In the June chain the open interest on the put side is spread from 105 to 135  But on the call side it is very big and focused at 145  The July options  covering the next earnings report  are building open interest and see it spread from 110 to 135 on the put side  It builds from 135 to a peak at 145 then tails to 160 on the call side 
Johnson   Johnson  Ticker   JNJ

4 Trade Ideas
Buy the stock now  over 140 25  with a stop at 139 
Buy the stock now  over 140 25  and add a June 140 135 Put Spread   1 35  while selling the July 150 Calls  90 cents  
Buy the May July 145 Call Calendar   2 00  and sell the May 135 Puts  20 cents  
Buy the July 135 145 bull Risk Reversal  60 cents  
Elsewhere look for Gold to continue lower in its pullback while Crude Oil joins it as it turns lower  The US Dollar Index is also reversing lower while US Treasuries reverse to the upside  The Shanghai Composite ended its short week pulling back but Emerging Markets are now poised to reverse back higher 
Volatility looks to remain at very low levels keeping the bias higher for the equity index ETF s SPY  NYSE SPY   IWM and QQQ  Their charts all look strong on the weekly timeframe  On the daily timeframe  it does looks like the QQQ is ready to consolidate while the IWM takes the lead  with the SPY driving higher as well  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2019-05-06,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-for-johnson--johnson-bonus-idea-200417196,200417196
198209,419725,JNJ,Sailing s Barcelona World Race abandoned over Catalan uncertainty,news,MADRID  Reuters    Organizers of sailing s Barcelona World Race said on Thursday they were suspending the 2018 19 event due to political unrest in the Spanish region of Catalonia which had hit sponsorship  An illegal referendum and declaration of independence by Catalan politicians in October prompted Spanish courts to jail or seek the arrest of participants and regular mass protests across the industrialized region   Political instability has made it difficult to guarantee delivering the event to the standards a round the world race deserves   the Barcelona Ocean Sailing Foundation said  The 10 year old regatta  which is held every four years  is a two crew round the world yacht race of some 26 000 nautical miles  48 152 kilometers  starting and finishing in the Catalan capital of Barcelona  with a stop over in Sydney   The clash between the northeast region  which produces around a fifth of Spain s economic output  and the government in Madrid has led thousands of companies based in Catalonia to relocate their legal headquarters to other parts of Spain    A sporting event of this scale requires significant private sponsorship  which is its only source of funding   they said  adding that they had found the political climate had prevented them from ensuring a reliable sponsorship process  Sponsors of the last Barcelona World Race in 2014 15  which was won by Bernard Stamm of Switzerland and Jean Le Cam of France  included Estrella Damn   Renault   PA RENA  and Johnson   Johnson  NYSE JNJ   The board of trustees for the Barcelona World Race includes the Barcelona City Council  the Barcelona Chamber of Commerce  Port of Barcelona and the Barcelona Trade Fair  The organizers said they were beginning talks with the IMOCA class association  with the aim to secure a future edition of the Barcelona World Race in 2022 2023  ,2018-03-29,Reuters,https://www.investing.com/news/general-news/sailings-barcelona-world-race-abandoned-over-catalan-uncertainty-1369467,1369467
198210,419726,JNJ,Pfizer in talks with P G for consumer health unit sale  CNBC,news," Reuters     Pfizer  Inc  NYSE PFE  is in talks with Procter   Gamble Co for a sale of the largest U S  drugmaker s consumer health business  CNBC reported on Tuesday  citing sources  The companies were far apart on a price for the business and Pfizer is considering other options  including a joint venture with other drugmakers  the report said   Pfizer said it is evaluating potential strategic options for the unit and expects to make a decision in 2018   GlaxoSmithKline  Reckitt Benckiser and Johnson   Johnson  NYSE JNJ  have all exited from the bidding process  endangering an auction Pfizer hoped would bring in as much as  20 billion  
P G said it declined to comment ",2018-04-03,Reuters,https://www.investing.com/news/stock-market-news/pfizer-in-talks-with-pg-for-consumer-health-unit-sale-cnbc-1375693,1375693
198211,419727,JNJ,Here Are The Key Takeaways From J J s Q1 Earnings Report,opinion,Johnson   Johnson   NYSE JNJ   kick started the earnings season for the pharma players  The company s share price has risen 1 5  since it reported better than expected first quarter 2019 results on Apr 16  Let s delve into some of the key aspects of this pharma giant s first quarter results The stock has rallied 7 3  this year so far compared with an increase of 0 3  recorded by the    The Quarter in a GistThe drug and consumer giant beat estimates for both earnings and sales in the quarter  Higher sales of its drugs led to the impressive top line performance  J J also raised its 2019 expectations for organic sales growth Higher revenues and other income led the company to post earnings of  2 10 per share in the first quarter of the year  up 1 9  from the year ago period Sales came in at  20 02 billion  Organically  excluding the impact of acquisitions and divestitures  sales increased 5 5  on an operational basis  better than 5 3  increase seen in the previous quarter  Continued strong sales performance in the Pharmaceutical segment and continued improvement in Medical Devices unit offset a softer performance in the Consumer unit Other than the top and bottom line numbers  J J s chief financial officer Joe Wolk  also discussed J J s outlook for 2019  The segment leaders discussed the performance of their respective segments Pharma Segment Impresses  Pharma segment performed well despite currency headwinds and the impact of biosimilar and generic competition on sales of some key drugs like Remicade and Zytiga  Excluding the impact of all acquisitions and divestitures  on an operational basis  organic sales increased 7 9   better than 7 2  in the previous quarter  Strong performance of oncology drugs Darzalex and Imbruvica and psoriasis treatment  Stelara and solid commercial execution related to product launches  such as that of Tremfya and Erleada  and line extensions contributed to growth  Please note that J J markets Imbruvica in partnership with AbbVie  Inc    NYSE ABBV   and Remicade with Merck   NYSE MRK   Consumer Segment Soft  Consumer segment revenues of  3 32 billion declined year over year  Excluding the impact of acquisitions and divestitures  adjusted operational sales growth was 0 7  worldwide  a significant deceleration from 3 8  the previous quarter  Growth in beauty and over the counter products was offset by lower baby care sales in the United States  Broad end market softness also hurt the performance of the Consumer segment  Also  allegations that its talc baby powders contain asbestos  which causes users to develop ovarian cancer  continue to be an overhang on the stock Better Expectations for 2019 Than Before  In spite of increased negative impact of translational currency  J J raised its adjusted sales and earnings growth forecast for 2019 based on strong first quarter performance  Overall  management appeared quite confident about the balance of 2019 compared with the time of announcing fourth quarter 2018 results in January In 2019  J J is expected to witness significant generic biosimilar headwinds in the Pharma unit  Continued biosimilar competition for Remicade and Procrit and generic competition for Velcade  Tracleer and Zytiga in the United States will hurt revenues by  3 billion in 2019  Several generic versions of Zytiga have already entered the market while a biosimilar version of Procrit was launched by Pfizer   NYSE PFE   in NovemberHowever  contribution from new drugs like Tremfya  Erleada and Spravato and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug  Stelara should provide top line support  Meanwhile  share buybacks and restructuring initiatives should provide bottom line support Moreover  growth in the Medical Devices segment is expected to continue to improve driven by better execution and product introductions Second Quarter Headwinds  Sales in the second quarter are expected to be hurt by divestiture of minimal Advanced Sterilization Products unit  currency headwinds  difficult year over year comparison  potentially accelerated generic erosion of Zytiga and biosimilar erosion of Procrit in the United States from the first quarter J J currently has a Zacks Rank  3  Hold   You can see   Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-17,Zacks Investment Research,https://www.investing.com/analysis/here-are-the-key-takeaways-from-jjs-q1-earnings-report-200408515,200408515
198212,419728,JNJ,Merck  MRK  Beats On Q1 Earnings   Sales As Keytruda Shines,opinion,Merck   Co   Inc    NYSE MRK   reported first quarter 2019 adjusted earnings of  1 22 per share  which beat the Zacks Consensus Estimate of  1 05  Earnings rose 16  year over year  up 18  excluding the impact of currency Including acquisition  and divestiture related costs  restructuring costs and certain other items  earnings per share were  1 12 against a loss of 27 cents in the year ago quarter Revenues for the quarter rose 8  year over year to  10 8 billion  beating the Zacks Consensus Estimate of  10 32 billion  Currency movement negatively impacted revenues by 3   Excluding currency impact  sales rose 11  year over year Strength in cancer drug  Keytruda  and Gardasil vaccine and strong performance in international markets  especially China  offset headwinds from loss of exclusivity   LOE   for some products including Zetia and Vytorin  and competitive pressure for Janumia and Janumet  Sales in China surged 58   67  excluding Fx impact  from the year ago period Quarter in DetailThe Pharmaceutical segment generated revenues of  9 66 billion  up 8   up 12  excluding Fx impact  year over year as higher sales in oncology and vaccines were offset by lower sales in virology  As in the previous quarters  loss of market exclusivity for several drugs hurt the top line Keytruda  the largest product in Merck s portfolio  generated sales of  2 27 billion in the quarter  up around 5 6  sequentially and 55  year over year  Sales were driven by the launch of new indications globally  Keytruda sales are gaining particularly from strong momentum in first line lung cancer indication as it is the only anti PD 1 approved in first line setting Keytruda is already approved for many types of cancers and treatment settings including lung cancer  melanoma  head and neck cancer  classical Hodgkin s lymphoma and bladder cancer  Alliance revenues from Lynparza and Lenvima also boosted oncology sales in the quarter Lynparza alliance revenues were  79 million in the quarter compared with  62 million in the previous quarter  Lenvima alliance revenues were  74 million compared with  71 million in the previous quarter Merck has a deal with Swiss pharma giant AstraZeneca   NYSE AZN   to co develop and commercialize PARP inhibitor Lynparza and a similar one with Japan s Eisai for tyrosine kinase inhibitor Lenvima In the hospital specialty portfolio  Bridion  sugammadex  Injection generated sales of  255 million in the quarter  up 25  year over year  driven by strong demand  Bridion was launched in China in the third quarter  which may have boosted sales this quarter In vaccines  Gardasil Gardasil 9 sales rose 31  year over year to  838 million  gaining from ongoing commercial launch in China and strong growth in Europe  partially offset by lower sales in the United States Proquad  M M R II and Varivax vaccines recorded combined sales of  496 million  up 30  year over year Pharmaceutical sales were hurt by generic competition for blockbuster drug  Remicade in Merck s marketing territories in Europe and loss of U S  market exclusivity for Zetia and Vytorin Remicade sales declined 26  year over year to  123 million in the quarter  Please note that Merck markets Remicade in partnership with J J   NYSE JNJ   The Zetia Vytorin franchise recorded sales of  238 million  down 50  from the year ago quarter due to loss of exclusivity for both Zetia and Vytorin  However  Adempas and Atozet posted strong growth  partially offsetting loss of sales in the cardiovascular segment  While Adempas sales grew 33  to  90 million  Atozet sales were up 29  to  94 million  Please note that Adempas is commercialized in collaboration with Bayer   OTC BAYRY   Januvia Janumet  diabetes  franchise sales declined 5  year over year to  1 35 billion due to continued pricing pressure  Sales of Isentress declined 9  to  255 million Merck s Animal Health segment generated revenues of  1 03 billion  down 4   up 3  excluding Fx impact  from the year ago quarter  driven by higher sales of its companion animal products as well as livestock products  particularly swine and poultry products Adjusted gross margin came in at 75 9   up 20 basis points  bps  from the year ago quarter driven primarily by favorable product mix  which offset unfavorable effects of pricing pressure Selling  general and administrative  SG A  expenses were  2 43 billion in the reported quarter  down 2 9  year over year  Research and development  R D  spend rose 9 4  to  1 96 billion in the quarter due to ongoing clinical studies and cost related to early drug development 2019 GuidanceMerck revised its earnings and sales guidance for 2019 Merck expects revenues to be in the range of  43 9 billion    45 1 billion  previously  43 2 billion    44 7 billion   The Zacks Consensus Estimate is pegged at  44 31 billion  Adjusted earnings are expected to be in the range of  4 67  4 79  previously  4 57  4 72   The Zacks Consensus Estimate is pegged at  4 65 per share  While the revenue guidance includes a slightly more than 1  negative impact of currency fluctuation  the earnings guidance includes a slightly positive impact Adjusted operating expenses are expected to increase year over year at a low  to mid single digit rate Our TakeMerck s first quarter results were strong as the company beat estimates for earnings as well as sales  It raised its earnings expectations for the year  which pushed up shares by more than 1  in pre market trading  Merck s shares have outperformed the  so far this year  It has risen 0 5  in the said time frame against a 1  decrease for the industry Importantly  Keytruda continued its robust performance on strong demand trends  Vaccine products also performed strongly and continue to be core growth drivers for Merck Going forward  growth from key products like Keytruda  Lynparza  Gardasil  Bridion and Animal Health should make up for headwinds from LOEs  softness in the diabetes franchise  and competitive pressure on Zepatier and Zostavax Merck   Co   Inc  Price  Consensus and EPS Surprise    Zacks RankMerck currently carries a Zacks Rank  3  Hold   You can see  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-beats-on-q1-earnings--sales-as-keytruda-shines-200412898,200412898
198213,419729,JNJ,Why Johnson   Johnson  JNJ  Is A Top Dividend Stock For Your Portfolio,opinion,"All investors love getting big returns from their portfolio  whether it s through stocks  bonds  ETFs  or other types of securities  But when you re an income investor  your primary focus is generating consistent cash flow from each of your liquid investments 
While cash flow can come from bond interest or interest from other types of investments  income investors hone in on dividends  A dividend is the distribution of a company s earnings paid out to shareholders  it s often viewed by its dividend yield  a metric that measures a dividend as a percent of the current stock price  Many academic studies show that dividends account for significant portions of long term returns  with dividend contributions exceeding one third of total returns in many cases 
Johnson   Johnson  NYSE JNJ  in Focus
Johnson   Johnson  JNJ  is headquartered in New Brunswick  and is in the Medical sector  The stock has seen a price change of 10  since the start of the year  Currently paying a dividend of  0 9 per share  the company has a dividend yield of 2 54   In comparison  the Large Cap Pharmaceuticals industry s yield is 2 98   while the S P 500 s yield is 1 88  
In terms of dividend growth  the company s current annualized dividend of  3 60 is up 1 7  from last year  Over the last 5 years  Johnson   Johnson has increased its dividend 5 times on a year over year basis for an average annual increase of 6 11   Looking ahead  future dividend growth will be dependent on earnings growth and payout ratio  which is the proportion of a company s annual earnings per share that it pays out as a dividend  Johnson   Johnson s current payout ratio is 44   This means it paid out 44  of its trailing 12 month EPS as dividend 
JNJ is expecting earnings to expand this fiscal year as well  The Zacks Consensus Estimate for 2019 is  8 60 per share  which represents a year over year growth rate of 5 13  
Bottom Line
Investors like dividends for many reasons  they greatly improve stock investing profits  decrease overall portfolio risk  and carry tax advantages  among others  It s important to keep in mind that not all companies provide a quarterly payout 
High growth firms or tech start ups  for example  rarely provide their shareholders a dividend  while larger  more established companies that have more secure profits are often seen as the best dividend options  Income investors have to be mindful of the fact that high yielding stocks tend to struggle during periods of rising interest rates  With that in mind  JNJ is a compelling investment opportunity  Not only is it a strong dividend play  but the stock currently sits at a Zacks Rank of 3  Hold  ",2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/why-johnson--johnson-jnj-is-a-top-dividend-stock-for-your-portfolio-200415595,200415595
198223,419739,JNJ,Johnson   Johnson s Invokana lowers risk of CV death or hospitalization in T2D,news,A new analysis from the CANVAS study showed patients with type 2 diabetes  T2D  treated with Johnson   Johnson  JNJ  0 6   unit Janssen Pharmaceuticals  INVOKANA  canagliflozin  experienced significantly less risk of cardiovascular  CV  death or hospitalization for heart failure  HHF   The data were presented at the American College of Cardiology Annual Scientific Session   Expo in Orlando  FL Treatment with INVOKANA reduced the risk of CV death or HHF by 22   fatal or hospitalized heart failure by 30  and HHF alone by 33   In patients with prior history of heart failure  the risk of CV death or HHF was reduced 39   The risk reduction in patients without previous heart failure was 13  The company s U S  marketing application seeking approval for a MACE  major cardiovascular events  reduction claim is currently under FDA review Now read ,2018-03-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/johnson--johnsons-invokana-lowers-risk-of-cv-death-or-hospitalization-in-t2d-1337277,1337277
198224,419740,JNJ,Teva rebuffs EU pay for delay charge at hearing,news,"BRUSSELS  Reuters    Israeli drugmaker Teva  TA TEVA  rebuffed EU antitrust charges of making an illegal deal with rival Cephalon to delay selling a cheaper generic version of the latter s sleep disorder drug at a hearing on Tuesday  The European Commission charged the company with the pay for delay drug deal in July last year  after hitting Denmark s Lundbeck  CO LUN   U S  giant Johnson   Johnson  N JNJ  and French drugmaker Servier over similar practices in recent years   Teva has responded to the statement of objections robustly  and has attended the oral hearing today   the company said in a statement  referring to the EU charge sheet   We do not believe that Cephalon and Teva entered into any anti competitive behavior   it said   Senior officials from the Commission and national competition agencies as well as rivals and consumer groups typically attend these closed hearings while companies try to reinforce their arguments   Teva  the world s biggest generic drugmaker  reached the deal with Cephalon as part of a settlement to end a lawsuit over alleged infringement of the latter s patents on the blockbuster drug  Teva subsequently acquired Cephalon in 2011  
The EU competition watchdog said the deal may have pushed up prices of the drug modafinil  It can penalize companies up to 10 percent of their global turnover for breaching EU rules ",2018-03-13,Reuters,https://www.investing.com/news/stock-market-news/teva-rebuffs-eu-payfordelay-charge-at-hearing-1339783,1339783
198225,419741,JNJ,Johnson   Johnson nears diabetes device exit with  2 1 billion LifeScan sale,news,"By Arjun Panchadar  Reuters    Johnson   Johnson  N JNJ  said on Friday it was offered about  2 1 billion for its LifeScan Inc unit  which makes blood glucose monitoring products  by private equity firm Platinum Equity  another step towards exiting the diabetes device market  Platinum has given J J until mid June to accept the offer to allow for consultations with overseas workers  Sales at J J s diabetes device business  which also includes Animas Corp and Calibra Medical Inc  have been falling since 2012 in a highly competitive market and the company said last January that it was evaluating options for the units  J J said in October it would shut down Animas  which makes insulin pumps  after failing to find a buyer  J J spokeswoman Donna Lorenson said the strategic review of the Calibra division  which sells wearable insulin pumps  is ongoing   LifeScan  which has headquarters in Chesterbrook  Pennsylvania  and Zug  Switzerland  sells personal blood glucose meters  testing strips  and testing systems  More than 20 million people in 90 countries use its products  Platinum Equity said in a press release that it is currently consulting with works councils that represent employees  The offer could be finalized by mid June  unless it is extended  and a deal is anticipated to close by the end of 2018   The company has 2 400 employees  largely in Europe  China and the United States  Lorenson said  ANALYSTS SAY PRICE OK The price for LifeScan  which generated revenue of about  1 5 billion in 2017  was disappointing but fair since the unit had weighed on J J s growth for some time  Atlantic Equities analyst Steve Chesney said   Obviously expectations were for a higher valuation based on earlier reports  but probably closer to reality given the state of the business   Chesney said   Reuters had reported in January that Chinese buyers were interested in paying  3 billion to  4 billion for the companies  Cowen analyst Joshua Jennings said in a research note that the LifeScan valuation was reasonable given that the business was declining and facing continued pricing pressure  J J said it factored the transaction into the 2018 earnings forecast it gave in January  
J J shares fell 0 4 percent  or 56 cents  to  132 50 in morning trading ",2018-03-16,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-says-offered-21-billion-for-lifescan-diabetes-unit-1345587,1345587
198226,419742,JNJ,Geron up 35  premarket on rosier outlook for imetelstat,news,Geron  NASDAQ GERN  is up 35  premarket on modest volume in apparent reaction to its update on a mid stage study assessing imetelstat in treatment resistant patients with lower risk myelodysplastic syndromes  MDS   It reported the progress in the study  called IMerge  in its Q4 results announcement after the close on Friday  March 16 IMerge involves red blood cell transfusion dependent MDS patients who have not responded to treatment with an erythropoiesis stimulating agent  Last month  licensee Janssen Research   Development  NYSE JNJ  completed the enrollment of 20 additional patients in the expanded Part 1 of the trial from a subset of subjects who were responding to treatment with imetestat Another Phase 2  IMbark  in patients with intermediate 2 or high risk myelofibrosis who have not responded to treatment with a JAK inhibitor  is ongoing  At month 19  median overall survival  OS  has not been reached in either dosing arm  Based on the rate of deaths in the study  the assessment of OS should begin by late Q2  An extension phase is being planned After the completion of the primary analysis of IMbark  Janssen will notify the company if it plans to continue development  expected by late Q3 Previously  Geron down 13  in early trading on extended timeline for imetelstat study  risk that Janssen will bail  Aug  1  2017 Now read ,2018-03-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/geron-up-35-premarket-on-rosier-outlook-for-imetelstat-1347845,1347845
198227,419743,JNJ,J J  JNJ  Beats On Q1 Earnings  Ups 2019 Sales Growth View,opinion,"Johnson   Johnson s   NYSE JNJ   first quarter 2019 earnings came in at  2 10 per share  which beat the Zacks Consensus Estimate of  2 03 and increased 1 9  from the year ago period Adjusted earnings exclude after tax intangible amortization expense and some special items  Including these items  J J reported first quarter earnings of  1 39 per share  down 13 1  from the year ago quarter Sales of the drug and consumer products giant came in at  20 02 billion  which beat the Zacks Consensus Estimate of  19 63 billion  Sales increased 0 1  from the year ago quarter  reflecting an operational increase of 3 9  and an unfavorable currency impact of 3 8  Organically  excluding the impact of acquisitions and divestitures  sales increased 5 5  on an operational basis  better than 5 3  increase seen in the previous quarter  Continued strong sales performance in the Pharmaceutical segment and continued improvement in Medical Devices unit offset a softer performance in the Consumer unit First quarter sales grew 1 8  in the domestic market to  10 13 billion but declined 1 7  in international markets to  9 89 billion  reflecting 6  operational growth and 7 7  negative currency impact Segment DetailsPharmaceutical segment sales rose 4 1  year over year to  10 24 billion  reflecting 7 9  operational growth and 3 8  negative currency impact as sales rose in both domestic and international markets  Sales in the domestic market rose 4 3  to  5 58 billion  International sales grew 3 9  to  4 66 billion  operational increase of 12 2    Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 7 9   better than 7 2  in the previous quarter The strong performance was led by the company s oncology drug Darzalex as well as psoriasis treatment  Stelara Worldwide sales of J J s cancer drugs like Imbruvica and Darzalex rose 9  in the quarter to  2 52 billion  Other core products like Stelara  Simponi Simponi Aria and Invega Sustenna and new immunology medicine like Tremfya also contributed to growth  However  sales of some other key drugs like Xarelto declined in the quarter  Sales of Zytiga declined sharply due to the impact of generic competition in the United States Darzalex sales rose 45 5  to  629 million in the quarter  Stelara sales rose 32 4  to  1 41 billion in the quarter  Imbruvica sales rose 33 5  to  784 million in the quarter  Please note that J J markets Imbruvica in partnership with AbbVie  Inc    NYSE ABBV    Invega Sustenna sales rose 13 5  to  790 million in the quarter In the quarter  J J recorded pulmonary arterial hypertension  PAH  revenues of  656 million  up 12 1  year over year  Strong demand for Uptravi and Opsumit was partially offset by the expected decline of Tracleer outside the United States due to generic competition Simponi Simponi Aria sales recovered in the quarter  rising 1  to  524 million in the quarter  Newly launched Tremfya recorded sales of  217 million in the quarter compared with  175 million in the fourth quarter Zytiga sales declined 19 6  to  679 million in the quarter  Several generic versions of key prostate cancer drug Zytiga have entered the market  J J received an unfavorable ruling in district court cases related to generic versions of Zytiga  which opened doors for an earlier than expected generic launch in late 2018 Sales of Invokana Invokamet declined 18 4  to  202 million  Xarelto sales declined 6 3  in the quarter to  542 million Sales of Procrit Eprex declined 18  to  226 million in the quarter  We remind investors that a biosimilar version of Procrit was launched by Pfizer   NYSE PFE   in November 2018 Sales of Remicade were down 20 6  in the quarter to  1 10 billion due to increased discounts and share loss to biosimilars   While U S  sales declined 15 5   U S  exports went down 46 4   Remicade sales rose 23 6  in international markets  Please note that J J markets Remicade in partnership with Merck   NYSE MRK   Medical Devices segment sales came in at  6 46 billion  down 4 6  from the year ago period  It included an operational decrease of 1  and negative currency movement of 3 6  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 4 3   better than 3 3  in the previous quarter Operational growth was driven by continued strong performance in Interventional Solutions  Advanced Surgery  General Surgery and Vision  which partially offset a decline in the orthopedics portfolio Domestic market sales declined 1 6  year over year to  3 11 billion  International market sales decreased 7 1   operational decrease of 0 3   year over year to  3 35 billion The Consumer segment recorded revenues of  3 32 billion in the reported quarter  down 2 4  year over year  On an operational basis  Consumer segment sales increased 2 2   which was offset by unfavorable foreign currency movement of 4 6  Excluding the impact of acquisitions and divestitures  adjusted operational sales growth was 0 7  worldwide  a significant deceleration from 3 8  the previous quarter Growth in beauty  analgesics  digestive health products and international anti smoking aids and over the counter products was offset by lower baby care sales in the United States despite the re launch of the baby care brand Sales in the domestic market rose 0 2  from the year ago period to  1 44 billion  Meanwhile  the international segment recorded a decline of 4 2  to  1 88 billion  An operational increase of 3 7  was offset by negative currency impact 7 9  in the quarter Higher Growth Expectations for 2019 J J tightened its 2019 adjusted earnings per share guidance from a range of  8 50    8 65 to  8 53    8 63  The guidance range  however  reflects a growth rate of 4 3    5 5   higher than 3 9    5 8  expected previously  On an operational  constant currency basis  adjusted earnings per share are expected to grow in the range of 6 7    7 9  versus 5 7    7 6  expected previously  Revenues are still expected in the range of  80 4 to  81 2 billion  including currency impact Operational constant currency sales growth is expected to be in the range of 0 5    1 5   better than 0  to 1  expected previously  Adjusted operational sales growth   excluding currency impact  acquisitions divestitures  is expected to be in the range of 2 5  to 3 5   higher than 2  to 3  expected previously Our TakeJ J beat estimates for both earnings and sales in the first quarter of 2019  J J s Pharma segment continued to perform well despite currency headwinds and the impact of biosimilar and generic competition on sales of some key drugs like Remicade and Zytiga J J also raised its adjusted sales and earnings growth forecast for the year on continued strength of its business  pushing its shares up 1  in pre market trading The stock has increased 5 8  this year so far against a decrease of 0 1  recorded by the    In 2019  J J is expected to witness significant generic biosimilar headwinds in the Pharma unit  However  J J s sales and earnings growth is expected to accelerate in 2020 supported by drug launches  successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug  Stelara  J J is also making rapid progress with its pipeline and line extensions This year J J has already gained FDA approval for two new drugs   nasal spray Spravato  esketamine  for treatment resistant depression  TRD  and Balversa  erdafitinib  for metastatic urothelial cancer in patients with certain FGFR genetic alterations  J J believes that both Spravato and Balversa have the potential for more than  1 billion of peak revenues  Johnson   Johnson Price  Consensus and EPS Surprise
  
   J J currently has a Zacks Rank  2  Buy   You can see   Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire ",2019-04-15,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-beats-on-q1-earnings-ups-2019-sales-growth-view-200407280,200407280
198228,419744,JNJ,Axsome s AXS 05 Meets Goal In Phase II Study  Shares Up,opinion,Axsome Therapeutics  Inc    NASDAQ AXSM   announced that a phase II study  evaluating its pipeline candidate   AXS 05   for smoking cessation treatment  met the prespecified primary endpoint of significantly curbing the habit of daily smoking as compared to GlaxoSmithKline s   NYSE GSK   active comparator  Wellbutrin  bupropion  Shares of Axsome were up 6 3  following this news on Monday  In fact  the stock has skyrocketed 407 5  so far this year  outperforming its increase of 8 6  This study was conducted at the Duke Center for Smoking Cessation under a research collaboration between Axsome and Duke University This double blind phase II program evaluated 58 adult smokers  who were treated with AXS 05  45 mg  or Wellbutrin  105 mg  over a 3 week period  Data from the study showed that patients who received AXS 05  demonstrated 25  greater reduction in the average number of cigarettes smoked per day in comparison to Wellbutrin Axsome is focused on developing AXS 05 as a smoking cessation treatment as smoking is widely considered the leading cause for preventable deaths and affects about 40 million adults in the United States  The candidate is a novel  oral  investigational N methyl D aspartate  NMDA  receptor antagonist with multimodal activity This apart  Axsome is evaluating AXS 05 in a phase III study for treating resistant depression  TRD  and in a phase II III investigation for addressing agitation associated with Alzheimer s disease  The candidate is also developed for major depressive disorder  MDD  Notably  late last month  the FDA granted a Breakthrough Therapy designation to AXS 05 for the treatment of MDD  This status was supported by positive results from the phase II ASCEND probe  in which 80 patients with a confirmed moderate to severe MDD were treated with AXS 05 or the active comparator  Wellbutrin We would like to remind investors that in March 2019  the FDA approved Johnson   Johnson s   NYSE JNJ   nasal spray  Spravato  esketamine   for treatment resistant depression  TRD  in adults but with a boxed warning  This nasal spray has been approved for use in conjunction with an oral antidepressant in patients suffering MDD  who have not benefited from multiple standard treatments Zacks Rank   Key PickAxsome currently carries a Zacks Rank  4  Sell  A better ranked stock in the healthcare sector is PDL BioPharma  Inc    NASDAQ PDLI    which sports a Zacks Rank  1  Strong Buy   You can see  PDL BioPharma s earnings estimates have been revised 100  upward for 2019 and 30  for 2020 over the past 60 days  The stock has surged 31  year to date Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-04-15,Zacks Investment Research,https://www.investing.com/analysis/axsomes-axs05-meets-goal-in-phase-ii-study-shares-up-200407276,200407276
198229,419745,JNJ,Potential Post Earnings Sentiment Shift On JNJ Stock,opinion,"Shares of pharmaceutical giant Johnson   Johnson  NYSE JNJ  are slightly higher  last seen up 0 1  at  136 16  Traders are gearing up for first quarter earnings  which are slated for before the market opens  tomorrow  April 16  Below we will take a look at how JNJ has been faring on the charts  and see what the options market is pricing in for its post earnings moves 
Johnson   Johnson stock has been moving higher his calendar year  and despite its late December pullback  has rallied to or above the historically support  135 mark  While the 160 day moving average has been a line of resistance for the shares since its late 2018 dip  it also has performed as support in the past    as recently as mid August  Year to date  JNJ is up 5  

Moving onto JNJ s earnings history  the blue chip has closed higher the day after reporting in half of its past eight earnings  including a 3 5  surge last July  Over the past two years  the shares have swung an average of 2 6  the day after earnings  regardless of direction  This time around  the options market is pricing in a nearly double  4 6  swing for tomorrow s trading 
Digging deeper  the security s Schaeffer s put call open interest ratio  SOIR  of 1 20 sits in the 89th percentile of its annual range  In other words  this suggests a larger than usual put skew among near term options traders  Analyst attention also remains bearish  setting up potential post earnings bull notes ",2019-04-16,Schaeffer's Investment Research,https://www.investing.com/analysis/potential-for-postearnings-sentiment-shift-on-jnj-stock-200406999,200406999
198230,419746,JNJ,Johnson   Johnson  JNJ  Q1 Earnings And Revenues Top Estimates,opinion,"Johnson   Johnson  NYSE JNJ  came out with quarterly earnings of  2 10 per share  beating the Zacks Consensus Estimate of  2 03 per share  This compares to earnings of  2 06 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 45   A quarter ago  it was expected that this world s biggest maker of health care products would post earnings of  1 95 per share when it actually produced earnings of  1 97  delivering a surprise of 1 03  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Johnson   Johnson  which belongs to the Zacks Large Cap Pharmaceuticals industry  posted revenues of  20 02 billion for the quarter ended March 2019  surpassing the Zacks Consensus Estimate by 2 01   This compares to year ago revenues of  20 01 billion  The company has topped consensus revenue estimates four times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Johnson   Johnson shares have added about 5 8  since the beginning of the year versus the S P 500 s gain of 15 9  
What s Next for Johnson   Johnson 
While Johnson   Johnson has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Johnson   Johnson was favorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  2  Buy  for the stock  So  the shares are expected to outperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 38 on  20 45 billion in revenues for the coming quarter and  8 58 on  81 18 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Large Cap Pharmaceuticals is currently in the top 24  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-04-16,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-q1-earnings-and-revenues-top-estimates-200407088,200407088
198231,419747,JNJ,JNJ Beats  Ups Sales Growth View  Healthcare ETFs In Focus,opinion,Johnson   Johnson  NYSE JNJ  set the ball rolling for pharma earnings when it reported first quarter results on Apr 16  before the opening bell  The world s biggest maker of health care products continued its long streak of earnings beat and also outpaced revenue estimates  Though it raised the guidance for full year sales growth  it tightened the earnings per share forecast Earnings per share came in at  2 10  7 cents ahead of the Zacks Consensus Estimate and 1 9  higher than the year ago quarter  Revenues inched up 3 9  year over year to  20 02 billion and edged past the Zacks Consensus Estimate of  19 63 billion  The robust results were driven by higher sales of its prescription medicines  including a double digit increase for its psoriasis treatment  Stelara  as well as cancer drugs Darzalex and Imbruvica  read    For 2019  Johnson   Johnson raised its guidance for sales growth to 2 5  3 5  from 2  3  but narrowed its earnings per share guidance range to  8 53  8 63 from  8 50  8 65  The company s drug continued to face pricing pressure from generics and biosimilars  In particular  the company s prostate cancer drug  Zytiga  an important growth driver  is facing competition from cheaper generic versions as well as from branded rival  Xtandi developed by Pfizer Inc  NYSE PFE  and Astellas Pharma  Sales of its rheumatoid arthritis drug Remicade have also been falling due to competition from cheaper biosimilar versions The midpoint of the new earnings per share guidance is in line  with the current Zacks Consensus Estimate of  8 58 Market ImpactShares of JNJ were up 1 1  at the close of session  Currently  the stock has a Zacks Rank  3  Hold  and has a VGM Score of B  Additionally  Johnson   Johnson belongs to a top ranked Zacks industry Rank    As a result  investors should closely watch the movement of the stock and keep a close eye on ETFs having double digit allocation to this diversified drug maker  Below we have highlighted them  see    iShares U S  Pharmaceuticals ETF This ETF provides exposure to 45 companies that manufacture prescription or over the counter drugs or vaccines by tracking the Dow Jones U S  Select Pharmaceuticals Index  Of these  Johnson and Johnson takes the second spot  accounting for 21 3  share  The product has  369 3 million in AUM and charges 43 bps in fees and expenses  Volume is lower as it exchanges about 16 000 shares a day  The fund has a Zacks ETF Rank  3  Hold  with a High risk outlook Health Care Select Sector SPDR Fund The most popular health care ETF  XLV follows the Health Care Select Sector Index  This fund manages nearly  18 4 billion in its asset base and trades in heavy volume of around 11 4 million shares  Expense ratio comes in at 0 13   In total  the fund holds 62 securities in its basket  with JNJ taking the top spot at 10 7  of the assets  Pharma accounts for 32 6  share from a sector look  while health care equipment and supplies  health care providers and services  and biotech have double digit exposure each  It has a Zacks ETF Rank  1  Strong Buy  with a Medium risk outlook iShares U S  Healthcare ETF This fund offers exposure to 129 securities by tracking the Dow Jones U S  Health Care Index  Here again  Johnson   Johnson dominates the fund s returns with 9 9  of the total assets  In terms of industrial exposure  pharma takes the top spot at 31 1   followed by health care equipment  22 7   and biotech  18 8    The product has amassed nearly  2 2 billion in its asset base and charges 43 bps in annual fees  It trades in a good volume of around 144 000 shares a day and has a Zacks ETF Rank  1 with a Medium risk outlook  read    iShares Evolved U S  Innovative Healthcare ETF This actively managed ETF employs data science techniques to identify companies with exposure to the innovative health care sector  Holding 201 stocks in its basket  JNJ is the top firm with 10  allocation  The product has accumulated  5 1 million in its asset base and trades in a meager volume of 2 000 shares per day on average  It charges 18 bps in annual fees Vanguard Health Care ETF   AX VHT  This ETF tracks the MSCI US Investable Market Health Care 25 50 Index and holds 361 stocks in its basket  Of these  Johnson   Johnson occupies the top position with 9 3  allocation  Pharma takes the largest share at 30   while health care equipment and biotech round off the top three spots  VHT is also one of the popular and liquid ETFs with AUM of  9 1 billion and average daily volume of about 318 000 shares  It charges 10 bps in annual fees and has a Zacks ETF Rank  1 with a Medium risk outlook  read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-04-16,Zacks Investment Research,https://www.investing.com/analysis/jnj-beats-ups-sales-growth-view-healthcare-etfs-in-focus-200407679,200407679
198236,419752,JNJ,FDA OKs Johnson   Johnson s apalutamide for prostate cancer,news,Under Priority Review status  the FDA approves Johnson   Johnson  JNJ  0 4   unit Janssen Pharmaceuticals  ERLEADA  apalutamide  for the treatment of non metastatic castration resistant prostate cancer Apalutamide is a next generation oral androgen receptor inhibitor that blocks the action of testosterone in prostate cancer cells and works by preventing androgen from binding to the receptor Previously  Janssen s prostate cancer candidate apalutamide granted accelerated review in U S   Dec  21  2017 Now read ,2018-02-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-johnson--johnsons-apalutamide-for-prostate-cancer-1247837,1247837
198237,419753,JNJ,Looking For A Growth Stock  3 Reasons Why Johnson   Johnson  JNJ  Is A Solid Choice,opinion,"Growth stocks are attractive to many investors  as above average financial growth helps these stocks easily grab the market s attention and produce exceptional returns  But finding a great growth stock is not easy at all 
That s because  these stocks usually carry above average risk and volatility  In fact  betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss 
However  the task of finding cutting edge growth stocks is made easy with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
Johnson   Johnson  NYSE JNJ  is one such stock that our proprietary system currently recommends  The company not only has a favorable Growth Score  but also carries a top Zacks Rank 
Research shows that stocks carrying the best growth features consistently beat the market  And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy   returns are even better 
Here are three of the most important factors that make the stock of this world s biggest maker of health care products a great growth pick right now 
Earnings Growth
Earnings growth is arguably the most important factor  as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors  And for growth investors  double digit earnings growth is definitely preferable  and often an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Johnson   Johnson is 7 8   investors should actually focus on the projected growth  The company s EPS is expected to grow 4 9  this year  crushing the industry average  which calls for EPS growth of 0 7  
Cash Flow Growth
Cash is the lifeblood of any business  but higher than average cash flow growth is more beneficial and important for growth oriented companies than for mature companies  That s because  high cash accumulation enables these companies to undertake new projects without raising expensive outside funds 
Right now  year over year cash flow growth for Johnson   Johnson is 13 9   which is higher than many of its peers  In fact  the rate compares to the industry average of 10 2  
While investors should actually consider the current cash flow growth  it s worth taking a look at the historical rate too for putting the current reading into proper perspective  The company s annualized cash flow growth rate has been 7 9  over the past 3 5 years versus the industry average of 3 3  
Promising Earnings Estimate Revisions
Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions  A positive trend is of course favorable here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for Johnson   Johnson  The Zacks Consensus Estimate for the current year has surged 0 1  over the past month 
Bottom Line
Johnson   Johnson has not only earned a Growth Score of B based on a number of factors  including the ones discussed above  but it also carries a Zacks Rank  2 because of the positive earnings estimate revisions 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Johnson   Johnson is a potential outperformer and a solid choice for growth investors ",2019-04-12,Zacks Investment Research,https://www.investing.com/analysis/looking-for-a-growth-stock-3-reasons-why-johnson--johnson-jnj-is-a-solid-choice-200406327,200406327
198238,419754,JNJ,Jabil  JBL  Up 10 5  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Jabil  JBL   Shares have added about 10 5  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Jabil due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Jabil s Q2 Results Benefit From Strong EMS PerformanceJabil reported second quarter fiscal 2019 earnings of 64 cents per share  which beat the Zacks Consensus Estimate by three cents but decreased 3  year over year Revenues increased 14 4  year over year to  6 07 billion that outpaced the Zacks Consensus Estimate of almost  6 billion At the end of the second quarter  new business award wins for fiscal 2019 are roughly  2 40 billion  Both healthcare and 5G wireless wins are up  50 million since fiscal 2018 end  Cloud is up 30 40  since the beginning of the fiscal year and automotive business wins met management s target Moreover  during the quarter  Jabil transitioned the first two sites from Johnson   Johnson  NYSE JNJ  Medical Devices Companies  JJMDC  as part of the previously announced strategic collaboration between the companies Quarter DetailsElectronics Manufacturing Services  EMS  revenues  63  of total revenues  surged 33  year over year to  3 billion  driven by strength in retail  industrial  5G and cloud end markets Diversified Manufacturing Services  DMS  revenues  37  of revenues  decreased 7  year over year to  2 3 billion  primarily due to weak demand for mobility  which is part of Mechanics and Edge Devices   Accessories end markets  Gross margin on a GAAP basis remained unchanged year over year at 7 5  Operating expenses on a GAAP basis declined 10 basis points  bps  to 5   Selling  general and administrative  SG A  and research   development  R D  expenses as percentage of revenues remained flat at 4 7  and 0 2   respectively Moreover  Jabil incurred  13 million of acquisition and integration related expenses Non GAAP core operating margin contacted 20 bps to 3 1  EMS core margin declined 100 bps on a year over year basis to 2 3   primarily due to softness in the capital equipment space and costs associated with the ramping up of new business awards  However  DMS core margin improved 110 bps on a year over year basis to 4 5  Balance Sheet   Cash FlowJabil exited the quarter with cash and cash equivalents of  749 1 million compared with  804 4 million in the previous quarter In the quarter  cash flow from operations was  199 million  while free cash flow was  28 million Jabil bought approximately 6 million shares at average price of  24 35 per share  thereby fully utilizing its  350 million repurchase authorization GuidanceFor third quarter fiscal 2019  Jabil expects total revenues between  5 7 billion and  6 3 billion  Revenues are expected to grow almost 10  year over year DMS revenues are forecasted to be  2 billion  down roughly 12  year over year  EMS revenues are forecasted to be  4 billion  up nearly 27  year over year Core operating income is estimated to be  150  200 million  The company s core earnings are expected to be 47 67 cents per share on a non GAAP basis Jabil is focusing on end markets and product diversification  Management s target is that  no product or product family should be greater than 5  of operating income or cash flows in any fiscal year   The diversification will increase reliability of the company s earnings and revenues For fiscal 2019  cloud end market revenues are expected to be more than  1 billion For fiscal 2019  Jabil expects earnings of almost  3 per share on revenues of  25 billion  Adjusted free cash flow is expected around  400 million  up 60  year over year For DMS segment  Jabil expects core margin to be 3 7   up 20 bps despite an anticipated revenue decline of  10 billion  The anticipated strength in healthcare is expected to make up for mobility weakness Further  EMS segment is expected to benefit from robust performance of 5G wireless and cloud  while an anticipated decline in enterprise sales is a concern  Continued weakness in semiconductor capital equipment business is expected to hurt EMS margins by 20 bps despite  15 billion higher revenues Moreover  for fiscal 2020  revenues associated with the J J collaboration are expected between  800 million and  1 billion 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  8 33  due to these changes 
VGM Scores
At this time  Jabil has an average Growth Score of C  though it is lagging a bit on the Momentum Score front with a D  However  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Notably  Jabil has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-04-12,Zacks Investment Research,https://www.investing.com/analysis/jabil-jbl-up-105-since-last-earnings-report-can-it-continue-200406490,200406490
198239,419755,JNJ,J J  JNJ  Tops Q1 Earnings  Pharma Segment Drives Sales ,opinion,"Johnson   Johnson   NYSE JNJ    the bellwether of healthcare companies  has a strong presence in the pharmaceutical  medical devices and consumer care markets across the world  This New Jersey based company is well known for its baby care products and brands like Tylenol in addition to drugs like Remicade and Imbruvica However  like many of its peers  JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment In this scenario  investor focus remains on late stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top and bottom line numbers J J s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The average positive earnings surprise over the last four quarters is 1 61  Estimates for 2020 have gone down slightly in the past seven days Currently  JNJ has a Zacks Rank  2  Buy   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  JNJ beat on first quarter earnings   the company reported EPS of  2 10 while our consensus called for EPS of  2 03 Revenues Beat  Revenues also beat expectations  Johnson   Johnson posted revenues of  20 02 billion  compared to our consensus estimate of  19 63 billion Key Statistics  Pharmaceutical segment sales rose 4 1  year over year to  10 24 billion  reflecting 7 9  operational growth  The strong performance was led by the company s oncology drug Darzalex as well as psoriasis treatment  Stelara Issues 2019 Outlook  J J raised its adjusted sales and earnings growth forecast for the year on continued strength of its business J J tightened its 2019 adjusted earnings per share guidance from a range of  8 50    8 65 to  8 53    8 63  The guidance range  however  reflects a growth rate of 4 3   5 5   higher than 3 9    5 8  previously  The Zacks Consensus Estimate for EPS for 2019 was  8 58 Revenues are still expected in the range of  80 4 to  81 2 billion  including currency impact  The Zacks Consensus Estimate for revenues of  81 18 billion Adjusted operational sales growth   excluding currency impact  acquisitions divestitures  is expected to be in the range of 2 5  to 3 5   higher than 2  to 3  expected previously Stock Price Impact  Shares rose 1 9  in pre market trading  Johnson   Johnson Price and Consensus
     
Check back later for our full write up on this JNJ earnings report later Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire ",2019-04-15,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-tops-q1-earnings-pharma-segment-drives-sales-200407163,200407163
198240,419756,JNJ,Johnson   Johnson  JNJ  Is A Top Dividend Stock Right Now  Should You Buy ,opinion,"All investors love getting big returns from their portfolio  whether it s through stocks  bonds  ETFs  or other types of securities  But for income investors  generating consistent cash flow from each of your liquid investments is your primary focus 
Cash flow can come from bond interest  interest from other types of investments  and of course  dividends  A dividend is that coveted distribution of a company s earnings paid out to shareholders  and investors often view it by its dividend yield  a metric that measures the dividend as a percent of the current stock price  Many academic studies show that dividends account for significant portions of long term returns  with dividend contributions exceeding one third of total returns in many cases 
Johnson   Johnson  NYSE JNJ  in Focus
Johnson   Johnson  JNJ  is headquartered in New Brunswick  and is in the Medical sector  The stock has seen a price change of 5 79  since the start of the year  The world s biggest maker of health care products is paying out a dividend of  0 9 per share at the moment  with a dividend yield of 2 64  compared to the Large Cap Pharmaceuticals industry s yield of 2 91  and the S P 500 s yield of 1 9  
Taking a look at the company s dividend growth  its current annualized dividend of  3 60 is up 1 7  from last year  Over the last 5 years  Johnson   Johnson has increased its dividend 5 times on a year over year basis for an average annual increase of 6 11   Any future dividend growth will depend on both earnings growth and the company s payout ratio  a payout ratio is the proportion of a firm s annual earnings per share that it pays out as a dividend  Johnson   Johnson s current payout ratio is 44   This means it paid out 44  of its trailing 12 month EPS as dividend 
Looking at this fiscal year  JNJ expects solid earnings growth  The Zacks Consensus Estimate for 2019 is  8 58 per share  representing a year over year earnings growth rate of 4 89  
Bottom Line
Investors like dividends for many reasons  they greatly improve stock investing profits  decrease overall portfolio risk  and carry tax advantages  among others  However  not all companies offer a quarterly payout 
Big  established firms that have more secure profits are often seen as the best dividend options  but it s fairly uncommon to see high growth businesses or tech start ups offer their stockholders a dividend  Income investors have to be mindful of the fact that high yielding stocks tend to struggle during periods of rising interest rates  With that in mind  JNJ presents a compelling investment opportunity  it s not only an attractive dividend play  but the stock also boasts a strong Zacks Rank of  2  Buy  ",2019-04-15,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-is-a-top-dividend-stock-right-now-should-you-buy-200407141,200407141
198248,419764,JNJ,Och Ziff hedge fund rebounds but succession  other issues linger,news,By Lawrence Delevingne NEW YORK  Reuters    Och Ziff Capital Management Group LLC rode bets on Asian stocks and U S  corporate mergers to strong returns in 2017   its best showing in years   but remained challenged by succession planning  declining assets and a stagnant stock price   Its flagship hedge fund  the OZ Master Fund Ltd  gained an estimated 10 4 percent net of fees in 2017  according to a letter sent to investors this week seen by Reuters  That was better than its historical average of 8 86 percent  its highest return since 2013  and above the benchmark HFRI asset weighted composite gain of 6 52 percent  The performance  according to the letter  was driven by Asian shares such as  Alibaba   NYSE BABA  Group Holding Inc  JD com Inc and Nintendo Co  T 7974   and mergers and acquisitions like pharmaceuticals business Actelion Ltd  which was bought by Johnson   Johnson  NYSE JNJ  in June  and Aetna  NYSE AET  Inc s proposed merger with CVS Health Corp  NYSE CVS    The New York hedge fund firm  which goes by  Oz Management   also made money on U S  corporate and structured credit and lost on U S  stocks and convertible and derivative arbitrage  the letter said  A spokesman for Oz declined to comment   The strong performance comes amid a stalled succession plan for Daniel Och  the firm s billionaire founder and chief executive officer   Oz sent a letter to investors on Dec  23 saying that it was  not the right time  to promote co Chief Investment Officer James  Jimmy  Levin to CEO  It added that Och and the firm s board of directors hoped that the 34 year old Levin  Och s longtime prot g  and heir apparent  would remain as co CIO  David Windreich is the other co CIO  The December letter was previously reported by the Wall Street Journal and Bloomberg  The Oz communication to clients this week added that  we hope to come back to you in the near future to present the  succession  plan   Och  through a spokesman  and Levin did not immediately respond to requests for comment  One of the few publicly traded hedge fund managers  Oz s stock price and assets have also not rebounded alongside its performance   Shares have languished around  4 or below since early 2016 and fell to  2 37 on Friday from around  3 20 a year ago  The issue is not new  Oz went public in November 2007 at  32 a share   The firm managed  31 9 billion as of Jan  1  according to the new letter  down from  47 5 billion at the end of 2014 and  37 9 billion at the end of 2016  according to public filings ,2018-01-26,Reuters,https://www.investing.com/news/stock-market-news/ochziff-hedge-fund-rebounds-but-succession-other-issues-linger-1158917,1158917
198249,419765,JNJ,Sanofi beats Novo to buy Ablynx for  4 8 billion in biotech M A boom,news,"By Matthias Blamont and Ben Hirschler PARIS LONDON  Reuters    French drugmaker Sanofi  PA SASY  has agreed to buy Belgian biotech company Ablynx for 3 9 billion euros   4 8 billion   beating  Novo Nordisk   CO NOVOb  and marking its second big deal this month after buying Bioverativ  The transaction is a further sign of accelerating merger and acquisition  M A  activity in the global biotech sector and comes after Ablynx rejected a 2 6 billion euro offer from Denmark s Novo Nordisk  Sanofi said on Monday it would pay 45 euros per share in cash for Ablynx  a premium of 21 percent over its closing price on Friday  and more than double the price before Novo went public with its initial bid  Novo Nordisk conceded defeat  saying it could not justify the knock out price being paid by Sanofi for Ablynx  which is developing a prized experimental drug for a rare blood disorder  This month has seen a spike in multibillion dollar deals in biotech  with U S  based Celgene  NASDAQ CELG  paying  9 billion for cancer specialist Juno Therapeutics  and several experts predicting a bumper year for M A  Total biotech M A so far this month now stands at  26 3 billion  or more than 80 percent of the value of all deals in 2016 and far ahead of any comparable January tally in over a decade  according to Thomson Reuters data  Such deals are being driven by the need for large drugmakers to tap the promising new medicines being developed by smaller rivals to help revive flagging growth  Last week  Sanofi agreed to buy U S  haemophilia specialist Bioverativ for  11 6 billion  its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases  Sanofi Chief Executive Officer Olivier Brandicourt said the deals expanded the French company s late stage pipeline and strengthened its line up of treatments for rare blood disorders   but did not necessarily mark the end of its M A ambitions   We have a strong balance sheet  We generate significant cash flow  We are going to look at opportunities on a case by case basis   he told reporters   We also identified CHC  consumer healthcare  previously as an area where we want to sustain a leadership position and therefore you can expect us to evaluate opportunities   Both  Pfizer   NYSE PFE  and Merck  NYSE MRK  KGaA are currently looking to divest consumer health businesses  Sanofi  which expects the cost of debt to finance the deal to be around 1 percent  said Ablynx would boost long term shareholder value  while being neutral for business earnings per share in 2018 and 2019   The Belgian group specializes in the research of novel drugs based on so called nanobodies found in the immune systems of llamas and alpacas  for which it partners with several of the world s largest pharmaceutical companies  EXPERIMENTAL DRUG  Sanofi is already one of Ablynx s big pharma partners  after striking a deal in July 2017 to find new treatments for inflammatory diseases  By buying the company outright it will now get access to Ablynx s most promising asset  the experimental drug caplacizumab for treating the blood disease acquired thrombotic thrombocytopenic purpura  Brandicourt said caplacizumab would complement Sanofi s line up of blood products  following the acquisition of Bioverativ and an earlier deal to obtain global rights for fitusiran from Alnylam  Sanofi will be able to use its existing infrastructure and the recently acquired platform from Bioverativ to help to commercialize caplacizumab  It will also benefit from some of the other drugs Ablynx is working on  such as an infant anti viral treatment  that would not have fitted within Novo Nordisk  Berenberg analysts said Ablynx was a good fit but they estimated the deal would generate no more than a 4 percent return on invested capital  assuming caplacizumab sales of around 400 million euros by 2023  Ablynx itself has forecast peak caplacizumab sales of 1 2 billion euros  but Sanofi said it was too early to comment  The rare blood drug was also the main attraction for Novo Nordisk  The Danish group has sat out previous rounds of M A in the drugs sector to focus on its core diabetes business but it now needs to find new products for its struggling smaller biopharmaceutical unit  where Ablynx would have been a good fit  That remains a challenge for CEO Lars Fruergaard Jorgensen  who took over a year ago  and has previously stated that Novo Nordisk needs external innovation to broaden its product line up  Chief Financial Officer Jesper Brandgaard told Reuters Novo Nordisk would continue to hunt for promising assets to boost its blood products business  Shares in Sanofi were little changed  with pricing considerations offset by relief that Sanofi was finally taking action to improve its drugs portfolio  following its past failure to land big deals  Sanofi lost out on buying California based cancer specialist Medivation to Pfizer in 2016  and also missed acquiring Swiss biotech company Actelion  which was bought by Johnson   Johnson  NYSE JNJ  last year   Morgan Stanley   NYSE MS  and Lazard advised Sanofi on the deal while JP Morgan advised Ablynx  
  1   0 8055 euros ",2018-01-29,Reuters,https://www.investing.com/news/stock-market-news/frances-sanofi-buys-ablynx-for-48-billion-in-biotech-ma-boom-1163587,1163587
198250,419766,JNJ,J J  JNJ  To Kick start Pharma Q1 Earnings  What s In Store ,opinion,"Johnson   Johnson   NYSE JNJ   will report first quarter 2019 results on Apr 6  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 1 03  J J s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The average positive earnings surprise over the last four quarters is 1 61 Johnson   Johnson Price and EPS Surprise
    J J s stock has risen 5 1  this year so far compared with an increase of 3 9  recorded by the  
  Factors to ConsiderJ J s sales growth accelerated in 2018 backed by above market sales growth in the Pharmaceutical segment and improved performance of the Medical Devices unit  However  on the fourth quarter conference call  J J said that 2019 sales are likely to be hurt by generic biosimilar headwinds in the Pharma unit The strong performance of the Pharmaceuticals segment was driven by its oncology portfolio  a trend expected to remain unchanged in the first quarter of 2019  J J s cancer drugs like Imbruvica and Darzalex should continue to perform well  In the first quarter  J J gained line extension approvals for a split dosing regimen of Darzalex in the United States and EU and for Imbruvica in the United States in combination with Roche s   OTC RHHBY   Gazyva  obinutuzumab  for the treatment of first line chronic lymphocytic leukemia small lymphocytic lymphoma  CLL SLL   The label expansions will contribute to these drugs  sales in the quarter Other core products like Stelara and Invega Sustenna should also contribute to growth  However  sales of some other key drugs like Simponi Simponi Aria and Xarelto declined in the fourth quarter  It remains to be seen if these drugs  sales improve in the first quarter  The FDA approval of Xarelto for a new 2 5 milligram vascular dose for the CAD PAD indication in October has significantly expanded the drug s eligible patient population  which may improve sales of the drug in the first quarter Also  new drugs like Erleada and Tremfya should perform well  Regarding newly launched Tremfya  J J said on the Q4 call that the product is seeing strong demand trends and has captured 6 6  share of the psoriasis market in the United States In the pulmonary arterial hypertension  PAH category  strong demand for Uptravi and Opsumit is likely to be partially offset by a decline in Tracleer due to increased use of Opsumit as well as generic competition in Europe Continued biosimilar competition for Remicade and Procrit and generic competition for Velcade  Tracleer and Zytiga in the United States are expected to hurt revenues in 2019  Other than that  pricing pressure will continue to hurt salesSeveral generic versions of key prostate cancer drug Zytiga have entered the market  J J received an unfavorable ruling in district court cases related to generic versions of Zytiga  which opened doors for an earlier than expected generic launch in 2018  Sales of Zytiga slowed down significantly in the fourth quarter due to the impact of generic competition in the United States  a negative trend expected to continue in the first quarter While the Consumer unit will grow slightly above the market in 2019 supported by innovation and improved go to market models  the Medical Devices segment is expected to improve driven by better execution and product introductions The Zacks Consensus Estimate for J J s Pharmaceuticals  Consumer and Medical Device segments is  9 8 billion   3 4 billion and  6 4 billion  respectively Investor focus on the call will be on the launch plans for J J s newly approved nasal spray Spravato  esketamine  for treatment resistant depression  TRD  in adults  Spravato was approved by the FDA last month Earnings WhispersOur proven model does not conclusively show that J J is likely to beat on earnings this quarter  This is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  Its Earnings ESP is  2 52  as the Most Accurate Estimate stands at  1 99 per share while the Zacks Consensus Estimate is pegged higher at  2 04  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  J J s Zacks Rank  2 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some large drug stocks that have the right combination of elements to beat on earnings this time around AbbVie  Inc    NYSE ABBV   with an Earnings ESP of  0 89  and a Zacks Rank  3  The company is expected to release results on Apr 25  You can see  AstraZeneca  plc   NYSE AZN   has an Earnings ESP of  9 52  and a Zacks Rank  2  The company is expected to release results on Apr 26 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-09,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-to-kickstart-pharma-q1-earnings-whats-in-store-200405586,200405586
198251,419767,JNJ,5 Stocks To Prepare For A Global Economic Slowdown,opinion,On Apr 9  the International Monetary Fund  IMF  reduced its growth forecast for the year once again  The international lending body believes economic headwinds including monetary tightening by the Federal Reserve and trade conflicts could derail global growth in the months ahead The IMF also cited industrial production data and surveys of purchasing managers to justify its projection for slower global growth in 2019  Meanwhile  even as China implements stimulus measures to boost its flagging economy  the situation in Eurozone remains worrying With a lurking global economic slowdown  it makes sense to fortify your portfolio for such conditions  In such an event  demand for products and services generated by utilities  consumer staples and medical companies remain invariant  Investing in stocks from these sectors looks like a smart option IMF Cuts Global Growth ProjectionsOn Tuesday  the IMF reduced its forecast for global economic growth for the third time in six months  The international lending body now believes that global growth will clock in at 3 3  for 2019  0 2  lower than the estimate released in January  However  its projection for 2020 remained flat at 3 6  A major headwind for the global economy is the lingering trade war between the United States and China  The IMF thinks that the inability to come to an agreement and the resultant tariff barriers would result in  higher costs of imported intermediate and capital goods and higher final goods prices for consumers  And despite the Federal Reserve s recent attempts to step away from its earlier hawkish standpoint  the IMF thinks a change in the monetary stance of central banks could also imperil global growth  The IMF thinks that market expectations for the federal funds rate is well below the Fed s projections According to the global lender  this is likely to  result in higher US interest rates  renewed dollar appreciation  and tighter financial conditions  for emerging economies with large volumes of debt Global Stimulus Needed  Eurozone VulnerableSpeaking at a news conference in Washington on Tuesday  IMF chief economist Gita Gopinath said that this was a  delicate moment for the global economy   The IMF believes that coordinated global stimulus measures would be needed to cushion the impact of a sharp downturn  Gopinath added that a dovish monetary approach would also be needed to counter the slowdown According to the IMF  most of the global economy s likely troubles this year will originate from problems in developed economies  including leading members of the EU  Apart from the impact of an inevitable Brexit  other factors are impeding growth in the region The outlook for Germany  the Eurozone s economic powerhouse  has softened because of sluggish demand for exports and a decline in consumer spending  Tougher emission standards are also likely to weigh on sales of cars produced in the country Our ChoicesThe IMF s decision to cut global growth projections is likely to rattle investors across the world  The risks it lays out while justifying this reduction are very real and likely to weigh on the pace of economic expansion in the near term Investing in stocks whose demand remains invariant even during an all encompassing slowdown looks prudent at this time  Picking utilities  consumer staples and medical stocks for your portfolio would be a good option  However  picking winning stocks may prove to be difficult This is where our  comes in  Here V stands for Value  G for Growth and M for Momentum and the score is a weighted combination of these three scores  Such a score allows you to eliminate the negative aspects of stocks and select winners  However  it is important to keep in mind that each Style Score will carry a different weight while arriving at a VGM Score  We have narrowed down our search to the following stocks based on a good Zacks Rank and VGM Score Unilever  LON ULVR  PLC   NYSE UL   is engaged in manufacturing of branded and packaged consumer goods  including food  detergents and personal care product on a global basis Unilever has a Zacks Rank  1  Strong Buy  and VGM Score of A  The company has expected earnings growth of 2 5  for the current year  The Zacks Consensus Estimate for the current year has improved by 6  over the past 30 days Medifast  Inc    NYSE MED   is a leading manufacturer and distributor of clinically proven healthy living and nutritional products Medifast has a VGM Score of B  The company has expected earnings growth of 41 1  for the current year  The stock has a Zacks Rank  1  You can see  Molina Healthcare  Inc    NYSE MOH   is a multi state managed care organization participating exclusively in government sponsored health care programs Molina Healthcare has a Zacks Rank  2  Buy  and VGM Score of A  The Zacks Consensus Estimate for the current year has improved by 6 5  over the past 60 days Johnson and Johnson  Inc    NYSE JNJ   focuses on the development  manufacturing  and marketing of pharmaceutical  medical and consumer related healthcare products  Johnson and Johnson has a Zacks Rank  2 and VGM Score of B  The company has expected earnings growth of 4 9  for the current year  The Zacks Consensus Estimate for the current year has improved by 0 1  over the past 30 days MYR Group Inc    NASDAQ MYRG   is a holding company of leading specialty contractors serving the electrical infrastructure market throughout the United States and Canada MYR Group has a Zacks Rank  2 and VGM Score of B  The company has expected earnings growth of 24 9  for the current year Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-04-10,Zacks Investment Research,https://www.investing.com/analysis/5-stocks-to-prepare-for-a-global-economic-slowdown-200405434,200405434
198252,419768,JNJ,Novartis To Market Rizmoic Through Sandoz  Spins Off Alcon,opinion,"Novartis AG s   NYSE NVS  generic arm  Sandoz  signed an agreement with Japanese pharmaceutical company  Shionogi   Co Ltd  for commercialization of Rizmoic in the key European markets of Germany  the U K  and the Netherlands  plus right of first refusal for certain other European markets 
Rizmoic  a once daily 200 microgram oral tablet discovered and developed by Shionogi  was approved in the EU on Feb 22  2019  The drug is approved to treat opioid induced constipation  OIC  in adult patients previously treated with a laxative 
We note that Sandoz has a strong presence in the European market for anti pain therapeutics 
Per the agreement  Sandoz will be responsible for commercializing Rizmoic in Germany  the U K  and the Netherlands  while Shionogi will manufacture and develop the drug 
We note that Sandoz is currently facing competitive pressure in the United States  In September 2018  Novartis agreed to sell selected portions of its Sandoz U S  portfolio  specifically the Sandoz U S  dermatology business and the U S  oral solids portfolio  The divestiture is in accordance with Sandoz s strategy of focusing on complex generics  value added medicines and biosimilars to achieve sustainable and profitable growth in the United States in the long run  The transaction will be completed in 2019 
Earlier  Novartis completed the spin off of the eye care devices business  Alcon  through a dividend in kind distribution to holders of Novartis shares and ADRs  American Depositary Receipts   with each holder receiving 1 Alcon share for every 5 Novartis shares or ADRs held on Apr 8  2019  at the close of business  Shares of Alcon have commenced trading under the symbol  ALC  on the SIX Swiss Exchange  SIX  
We remind investors that Novartis decided to spin off its ophthalmology unit to better focus on its legacy pharma business  with a financial profile closer to its pharmaceutical industry peers  The company also sold its stake in consumer healthcare joint venture to GlaxoSmithKline   NYSE GSK   for  13 billion 
Shares of the company have gained 14 9  in the past six months compared with the  s 5 9  growth 

 
Last year was a transformative one for Novartis  as it restructured its business to become a core drug focused company  powered by data and digital technologies  The company acquired U S  based clinical stage gene therapy company  AveXis  Inc in 2018  Novartis also acquired Endocyte to expand expertise in radiopharmaceuticals  We expect more acquisitions in the coming months  as the company looks to further restructure its business 
Novartis intends to raise its annual dividend from CHF 2 85 per share  The company also plans to complete its previously announced share buyback of  5 billion in 2019 
Zacks Rank   Stocks to Consider
Novartis currently carries a Zacks Rank  5  Strong Sell  
A couple of better ranked stocks in the same space are Johnson   Johnson   NYSE JNJ   and Bayer  DE BAYGN  AG   OTC BAYRY    Both stocks carry a Zacks Rank  2  Buy   You can see see  
Johnson   Johnson s earnings per share estimates have increased from  9 20 to  9 21 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters at an average of 1 61  
Bayer s earnings per share estimates have increased from  1 92 to  1 95 for 2019 over the past 60 days 
Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-04-11,Zacks Investment Research,https://www.investing.com/analysis/novartis-to-market-rizmoic-through-sandoz-spins-off-alcon-200406102,200406102
198261,419777,JNJ,Zymeworks and vTv Therapeutics join biotech breakouts,news,Zymeworks  ZYME  19 9   and vTv Therapeutics  VTVT  26 7    both thinly traded  are showing healthy breakouts on 3x and 6x surges in volume  respectively No particular company specific news accounts for the action  but biotechs in general are heading north  The SPDR S P Biotech  MX XBI  ETF  XBI  2 2    for example  has rallied over 9  since Thursday Zymeworks  lead candidate is ZW25  in Phase 1 development for HER2  cancers  It has collaboration deals with Celgene  NASDAQ CELG   Daiichi Sankyo  Johnson   Johnson  NYSE JNJ   Eli Lilly and Merck  NYSE MRK  Vtv Therapeutics  lead candidate is azeliragon  TTP488   in Phase 3 development for Alzheimer s disease Now read ,2018-01-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/zymeworks-and-vtv-therapeutics-join-biotech-breakouts-1141551,1141551
198262,419778,JNJ,Roche Extends Offer Period For Spark Therapeutics Acquisition,opinion,Roche Holding  SIX ROG  AG   OTC RHHBY   withdrew its Premerger Notification and Report Form in connection with the pending acquisition of Spark Therapeutics  Inc    NASDAQ ONCE   We remind investors that Roche entered into an agreement to acquireSpark Therapeutics in February 2019 for  114 50 per share in an all cash transaction  This price represented a premium of about 122  to Spark Therapeutics  closing price on Feb 22  2019  The total value of the deal was  4 8 billion  Roche received only 29 4  of the shares of Spark Therapeutics in a tender offer and failed to get the majority of outstanding Spark Therapeutics  stock   With the withdrawal and refiling of the above mentioned documents  Roche is extending the offer period of its previously announced tender offer for Spark Therapeutics The offer that was previously scheduled to expire on Apr 3  2019  will now expire on May 2  2019  All terms and conditions of the offer shall remain unchanged during the extended periodShares of Roche have rallied 25 4  in the past year compared with the  s growth of 16 7  The company offered  acquire Spark Therapeutics to gain access to some hemophilia products  which will broaden its drug development pipeline  Post completion of the probable buyout  Roche will get access to Spark Therapeutics  novel gene therapy  SPK 8011for the treatment of hemophilia A  which is expected to enter phase III in 2019  Spark Therapeutics also has SPK 8016 in a phase I II study  which is aimed at addressing the hemophilia A inhibitor population  Roche already sells Hemlibra for the treatment of hemophilia A  With the acquisition  the company will also get to add Luxturna to its portfolio  Luxturna is a one time gene therapy product indicated for the treatment of patients with confirmed biallelic RPE65 mutation associated retinal dystrophy  The drug is currently marketed in the United States by Spark Therapeutics and elsewhere by Novartis   NYSE NVS    Roche Holding AG Price    Zacks Rank   A Stock to ConsiderRoche currently carries a Zacks Rank  3  Hold   Another better ranked stock from the same space is Johnson   Johnson   NYSE JNJ    carrying a Zacks Rank  2  Buy   You can see  Johnson   Johnson s earnings per share estimates have increased from  9 20 to  9 21 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters at an average of 1 61  Is Your Investment Advisor Fumbling Your Financial Future  See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-04-02,Zacks Investment Research,https://www.investing.com/analysis/roche-extends-offer-period-for-spark-therapeutics-acquisition-200403651,200403651
198263,419779,JNJ,J J Stock On An Uptrend This Year So Far  More Room To Run ,opinion,Johnson   Johnson   NYSE JNJ   stock has risen 5 5  this year so far compared with an increase of 3 7  recorded by the    This marks a decent recovery from a decline of 7 3  last year on allegations that its talc products contain asbestos  which causes users to develop ovarian cancer  J J s earnings estimates for 2019 have gone up 0 1  in the past 30 days  This New Brunswick  NJ based pharma giant has a Zacks Rank  2  Buy   You can see  What s Driving the Shares The better performance this year so far has been supported by a series of positive news including promising data from several pivotal studies and rapid progress with its pipeline and line extensions  The positive trend is likely to continue through the rest of the year Importantly  this month  J J gained FDA approval for a key pipeline candidate   its nasal spray  Spravato  esketamine  for treatment resistant depression  TRD  in adults  With the approval  Spravato  which is thought to work differently from currently approved therapies  will be the first new medicine in 30 years to treat depression  a difficult to treat mental disease   It has been seen that while most antidepressants take a couple of weeks or months to show effects  Spravato works in hours Among line extensions  a key FDA approval was that of its blockbuster cancer drug Imbruvica in combination with Roche s   OTC RHHBY   Gazyva  obinutuzumab  for the first line treatment of patients with chronic lymphocytic leukemia small lymphocytic lymphoma  CLL SLL   Please note that J J markets Imbruvica in partnership with AbbVie  Inc    NYSE ABBV   In February  J J announced a definitive agreement to acquire Auris Health  Inc   a privately held developer of robotic technologies focused on lung cancer  for approximately  3 4 billion in cash  Auris Health s robotic platform will expand J J s digital surgery portfolio  J J also announced a new gene therapy with MeiraGTx to develop gene therapy programs for inherited retinal diseases  IRD Factors Likely to Support the Rally AheadWith several pivotal data readouts and regulatory milestones expected in the rest of the year  the bullish run of the stock is likely to continue Importantly  J J expects FDA decision in another key pipeline candidate  erdafitinib this year as a regulatory application seeking approval for metastatic urothelial cancer is under review in the United States  J J believes that both Spravato and erdafitinib have the potential for more than  1 billion of peak revenues  J J could also get approval in United States as well as EU for its key drug Stelara for a new indication   moderately to severely active ulcerative colitis this year Management is optimistic about the Pharmaceuticals unit as key cancer drugs like Imbruvica and Darzalex and immunology drug  Stelara are likely to witness sales uptake and line extensions  Meanwhile  new products launched in late 2017 2018  Tremfya for plaque psoriasis and Erleada for prostate cancer  should perform well  However  continued biosimilar competition for Remicade and Procrit and generic competition for Velcade  Tracleer and Zytiga in the United States are expected to hurt revenues by  3 billion in 2019  Please note that J J markets Remicade in partnership with Merck   NYSE MRK    Other than that  pricing pressure will continue to hurt sales  Nonetheless J J is confident that its sales and earnings growth will accelerate in 2020 supported by drug launches and successful label expansion of Imbruvica  Darzalex and Stelara While the Consumer unit will grow slightly above the market in 2019 supported by innovation and improved go to market models  the Medical Devices segment is expected to be driven by improved execution and new product introductions  Meanwhile  share buybacks and restructuring initiatives should provide bottom line support Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-04-07,Zacks Investment Research,https://www.investing.com/analysis/jj-stock-on-an-uptrend-this-year-so-far-more-room-to-run-200404816,200404816
198264,419780,JNJ,Aeglea  AGLE  Reports New Positive Data For Pegzilarginase,opinion,Aeglea BioTherapeutics  Inc    NASDAQ AGLE   announced new positive phase I II data for pegzilarginase in patients with Arginase 1 Deficiency  ARG1 D   a rare genetic disease  The data showed that pegzilarginase is highly effective in sustainably lowering plasma arginine  which is the primary endpoint in Aeglea s single  global pivotal phase III PEACE study  Plasma arginine reduction was statistically significant  p 0 001  at eight weeks  with sustained control through longer term dosing Further  the new data showed that the marked improvement in plasma arginine control is accompanied by clinically meaningful responses in mobility and adaptive behavior  which are secondary endpoints in the PEACE trial  The treatment was generally well tolerated  Hypersensitivity reactions were infrequent  manageable with standard measures  and did not lead to treatment discontinuation Aeglea expects to begin the single  global pivotal phase III PEACE trial in ARG1 D in the second quarter of 2019 Shares of the company have increased 17 1  in the past year compared with the  s growth of 12 1  The company is evaluating pegzilarginase in two ongoing clinical studies   one phase I study for the treatment of advanced solid tumors  and a phase I II combination study of pegzilarginase and Merck s   NYSE MRK   anti PD 1 therapy  Keytruda  pembrolizumab  for the treatment of patients with small cell lung cancer  SCLC   After receiving the maximum tolerated dose in the phase Ib combination study  the company advanced pegzilarginase to phase II in December 2018 and dosed the first patient  The company expects to report topline data from open label phase II study in the first half of 2020 Zacks Rank   Stock to ConsiderAeglea currently carries a Zacks Rank  3  Hold   Some better ranked stocks worth considering are Johnson   Johnson   NYSE JNJ   and Bayer  DE BAYGN  AG   OTC BAYRY    each carrying a Zacks Rank  2  Buy   You can see  Johnson   Johnson s earnings per share estimates have increased from  9 20 to  9 21 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters at an average of 1 61  Bayer s earnings per share estimates have increased from  1 92 to  1 95 for 2019 over the past 60 days Is Your Investment Advisor Fumbling Your Financial Future  See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-04-07,Zacks Investment Research,https://www.investing.com/analysis/aeglea-agle-reports-new-positive-data-for-pegzilarginase-200404793,200404793
198265,419781,JNJ,Earnings Preview  Johnson   Johnson  JNJ  Q1 Earnings Expected To Decline,opinion,"Wall Street expects a year over year decline in earnings on lower revenues when Johnson   Johnson  NYSE JNJ  reports results for the quarter ended March 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on April 16  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This world s biggest maker of health care products is expected to post quarterly earnings of  2 04 per share in its upcoming report  which represents a year over year change of  1  
Revenues are expected to be  19 63 billion  down 1 9  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 2 53  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Johnson   Johnson 
For Johnson   Johnson  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  2 52  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination makes it difficult to conclusively predict that Johnson   Johnson will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Johnson   Johnson would post earnings of  1 95 per share when it actually produced earnings of  1 97  delivering a surprise of  1 03  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Johnson   Johnson doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-08,Zacks Investment Research,https://www.investing.com/analysis/earnings-preview-johnson--johnson-jnj-q1-earnings-expected-to-decline-200405140,200405140
198266,419782,JNJ,Johnson   Johnson  An Ideal DRIP Stock,opinion,"Investors that take advantage of a DRIP  Dividend Reinvestment Plan  get access to direct purchases of a company s stock  funded by the dividend payments they are receiving  This happens automatically and is seamless to the investor 
There are many stocks that offer DRIPs to investors  but some of them require the stockholder to pay a fee to use the DRIP  Obviously  that is a negative for the investor as these fees eat into returns over time  The good news is that there are companies that offer no fee DRIPs  which help investors build their wealth more quickly when used with high quality  dividend paying companies 
Dividend Aristocrats are the perfect subset of stocks to examine for DRIP investors as they are among the best of the best in terms of dividend stocks  They have at least 25 year track records of growing dividends and are members of the S P 500 index  One Dividend Aristocrat that offers investors a no fee DRIP is Johnson   Johnson  NYSE JNJ   We see it as among the best DRIP stocks 
Business Overview And Recent Events
Johnson   Johnson is a diversified health care company that provides a wide variety of common use and specialized medical products around the world  The company derives about half of its revenue from pharmaceuticals  about a third from medical devices  and the balance from general consumer products  Johnson   Johnson was founded in 1886 and today  it employs 125 000 people around the world  The stock has a current market capitalization of more than  360 billion 
The company has an impressive slate of dominant products in their respective categories 

Source  Earnings presentation  page 22
In fact  the company has 26 different product families that each produces at least a billion dollars in annual revenue  including 12 that have at least  2 billion in annual revenue 
Johnson   Johnson reported full year earnings on January 22  2019  and results looked quite good  Earnings per share rose 12  year over year to  8 18  The revenue growth came in at 7  for 2018 thanks to broad gains across its segments 
The largest segment  pharmaceuticals  grew its top line by 12 4  in 2018 thanks mostly due to strong organic growth  Worldwide sales for this segment rose 8 4  without the benefit of acquisitions and divestitures  completing another year of strong performance from the company s core business  Oncology and immunology drugs were the big winners and drove a strong performance for the segment as a whole 
Medical devices showed much lower growth rates throughout 2018 and finished the year with a 1 5  worldwide sales gain  Excluding acquisitions and divestitures  that number rose to 2 6  as strength in interventional solutions  surgery  and vision was offset by weakness in diabetes care and orthopedics 
Finally  the consumer products segment saw 2018 growth of 1 8  on the top line  which was 3 2  excluding acquisitions and divestitures  The company suffered mightily in its wound care business  which declined by more than 13  in 2018  However  beauty care showed strength  as did OTC  which sells highly recognizable products like Tylenol and Zyrtec 
In total  2018 represented another year of strong growth that also highlighted the benefits Johnson   Johnson accrues from its deep and wide portfolio of health care products  Johnson   Johnson is present in an enormous variety of segments and product families and over time  this diversification has produced good results for shareholders 
Management expects earnings per share to come in around  8 58 for 2019  representing prospective growth of about 5  over last year 
Based upon this midpoint of earnings guidance  Johnson   Johnson trades today at a price to earnings multiple of 15 9  which is nearly exactly in line with our estimate of fair value at 15 8 times earnings  This is based upon the company s own historical price to earnings multiples and given the rate of growth earnings should experience this year  we see it as a reasonable valuation  Given that the current valuation and our estimate of fair value are essentially the same  we see no impact to total returns from the valuation in the coming years 
In total  we forecast total returns of about 9  for Johnson   Johnson annually in the coming years  Returns will accrue from a combination of earnings growth  which we see at 6  annually  and the dividend yield  which is currently 2 6   As mentioned  we see no change from the valuation 
Dividend Growth And DRIP Stocks
Johnson   Johnson s latest dividend declaration was for 90 cents  marking the fourth quarter of dividends in that amount  The annualized payout of  3 60 is good for a 2 6  yield today as the share price has rallied in recent weeks  Johnson   Johnson normally raises its dividend in April for May distribution  so we d expect to see an announcement of a higher payout in the coming weeks 
When investors elect to use the DRIP feature offered by Johnson   Johnson  the compounding effect of the dividend on one s wealth becomes even more profound  If an investor bought shares today at the 2 6  yield and elected into the DRIP  that investor would automatically receive the 2 6  yield in additional shares each quarter as the dividend is paid  The second year  assuming a flat share price and no change in the payout  the investor would receive dividends on 102 6  of their original investment  compounding the impact of the dividend 
Johnson   Johnson also continues to grow its payout   averaging more than 6  annual growth in the past decade   which creates a double compounding effect from the DRIP 
Over the course of many years  this impact can be enormous as the investor s yield on cost grows over time  Finding high quality dividend names with long track records of dividend growth   and no fee DRIPs   is one of the best ways to build dividend stock wealth over time 
We see Johnson   Johnson as a high quality stock that has a deep and wide product portfolio that affords it strong earnings growth potential  With the stock right at fair value and the yield at 2 6    a number that should be higher in a few weeks thanks to an anticipated dividend raise   we see Johnson   Johnson as offering attractive returns for dividend investors  When combined with the fact that the company offers a no fee DRIP  we believe it is a terrific opportunity for investors to build their wealth over time 
Original post",2019-04-09,Modest Money,https://www.investing.com/analysis/johnson--johnson-an-ideal-drip-stock-200404916,200404916
198267,419783,JNJ,Johnson   Johnson  JNJ  Stock Moves  0 47   What You Should Know,opinion,"In the latest trading session  Johnson   Johnson  NYSE JNJ  closed at  135 50  marking a  0 47  move from the previous day  This change was narrower than the S P 500 s daily loss of 0 61   Elsewhere  the Dow lost 0 72   while the tech heavy Nasdaq lost 0 56  
Coming into today  shares of the world s biggest maker of health care products had lost 1 75  in the past month  In that same time  the Medical sector gained 2 13   while the S P 500 gained 5 68  
Investors will be hoping for strength from JNJ as it approaches its next earnings release  which is expected to be April 16  2019  The company is expected to report EPS of  2 04  down 0 97  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  19 63 billion  down 1 91  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  8 58 per share and revenue of  81 18 billion  which would represent changes of  4 89  and  0 49   respectively  from the prior year 
Investors might also notice recent changes to analyst estimates for JNJ  These recent revisions tend to reflect the evolving nature of short term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  The Zacks Consensus EPS estimate has moved 0 09  higher within the past month  JNJ is holding a Zacks Rank of  2  Buy  right now 
Looking at its valuation  JNJ is holding a Forward P E ratio of 15 87  This valuation marks a premium compared to its industry s average Forward P E of 15 4 
Investors should also note that JNJ has a PEG ratio of 2 08 right now  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2 13 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 67  putting it in the top 27  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-04-09,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-stock-moves-047-what-you-should-know-200405305,200405305
198268,419784,JNJ,Glaxo s Dovato Gets FDA Nod For Treatment Naive HIV Patients,opinion,GlaxoSmithKline plc s   NYSE GSK   HIV subsidiary  ViiV Healthcare announced that the FDA has granted approval to a new once daily  single tablet two drug regimen  2DR   Dovato for the treatment of newly diagnosed adults with HIV 1 infection Dovato is a fixed dose combination of Glaxo s successful HIV drug Tivicay dolutegravir  50 mg  in combination with lamivudine  300 mg   The submission is based on the global GEMINI 1   2 studies that evaluated the two drug regimen in treatment na ve HIV patients who have not received prior antiviral therapy compared to a three drug regimen of dolutegravir plus tenofovir alafenamide fumarate and emtricitabine  The new drug application  NDA  for this single tablet regimen was filed in October last year  using a priority review voucher At week 48  the studies demonstrated that the dolutegravir and lamivudine regimen was non inferior to the standard three drug regimen  This means a two drug HIV regimen can control HIV in treatment na ve patients as effectively as a three drug regimen  thereby exposing these newly diagnosed patients to fewer drugs at the start of treatment   A similar application is under review in the EU ViiV Healthcare is an HIV company majorly owned by Glaxo and Pfizer   NYSE PFE    It markets another two drug  once daily  single pill for HIV  Juluca  which is a combination of Tivicay and J J s   NYSE JNJ   Edurant  rilpivirine   Juluca was approved in the United States in late 2017 and in the EU in mid 2018 for HIV patients that have received prior treatment So far this year  Glaxo s shares have outperformed the   rising 9 1  compared with 3 6  increase for the industry   HIV is a key therapeutic area for Glaxo with successful dolutegravir based regimens  Tivicay  Triumeq and Juluca in its portfolio  HIV sales totaled  4 7 billion in 2018 with dolutegravir based regimens generating  4 4 billion driven by increased market share ViiV Healthcare is focused on advancing HIV care by exploring new treatment paradigms  two drug regimens   new modalities  long acting injectables  and new mechanisms of actions  including maturation inhibitors and broadly neutralising antibodies   Key candidates in late stage development include a long acting  injectable two drug regimen of cabotegravir and rilpivirine and fostemsavir in heavily pre treated HIVpatients  New drug applications for both these candidates are expected to be filed this year Other key players in the HIV market are Gilead   NASDAQ GILD    Merck  AbbVie  NYSE ABBV  and J J Glaxo currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-04-09,Zacks Investment Research,https://www.investing.com/analysis/glaxos-dovato-gets-fda-nod-for-treatmentnaive-hiv-patients-200405038,200405038
198280,419796,JNJ,Johnson   Johnson Beats on Q4 Earnings,news,"Investing com   Johnson   Johnson  NYSE JNJ  saw shares move slightly higher in pre market trade on Tuesday after reporting fourth quarter earnings that beat consensus 
Specifically  the Dow component reported fourth quarter adjusted earnings per share  EPS  of  1 74  compared to expectations of  1 72 
Revenue at the healthcare giant grew 11 5  from the same period a year before to  20 2 billion  coming in ahead of estimates for  20 07 billion 
 Johnson   Johnson delivered strong adjusted earnings per share growth of 8 5  and total shareholder return of greater than 24  in 2017  driven by the robust performance of our Pharmaceutical business  while continuing to make investments in acquisitions  innovation and strategic partnerships to accelerate growth in each of our businesses   the company s chairman and chief executive officer Alex Gorsky said in the release 
 As we enter 2018 and look beyond  we are experiencing an incredible pace of change in health care  Johnson   Johnson is uniquely positioned to lead during this dynamic era and deliver innovative solutions for patients and consumers that drive sustainable  long term growth   he added 
Gorsky also indicated that the firm was pleased with the recent overhaul to U S  tax legislation which will enable the company to  invest in innovation at higher levels to help address the most challenging unmet medical needs facing health care today  
Following the release  shares  NYSE JNJ  were up 1 17  to  149 88  compared to Monday s closing price of  148 14 ",2018-01-23,Investing.com,https://www.investing.com/news/stock-market-news/johnson--johnson-beats-on-q4-earnings-1138090,1138090
198281,419797,JNJ,Johnson   Johnson Q4 revenues up 12   non GAAP EPS up 10   updates guidance,news,Johnson   Johnson  JNJ  0 5   Q4 results  Revenues   20 195M   11 5    Consumer   3 540M   3 1    Pharmaceutical   9 681M   17 6    Medical Devices   6 974M   8 3   Net Income   4 777M   9 5    Non GAAP EPS   1 74   10 1   Sales by Business  Baby Care   490M   0 6    Beauty   1 110M   4 4    Oral Care   393M   1 0    Women s Health   262M   0 8    Immunology   3 086M   5 1    Infectious Diseases   800M   5 1    Neuroscience   1 524M   3 7    Oncology   2 039M   39 5    Cardiovascular   Metabolism   Other   1 622M   1 2   Key Product Sales  REMICADE   1 466M   9 7    SIMPONI   SIMPONI ARIA   490M   15 0    STELARA   1 081M   23 0    DARZALEX   371M   85 5    XARELTO   710M   18 7    ZYTIGA   755M   45 5   2018 Guidance  Revenues   80 6B    81 4B  Non GAAP EPS   8 00    8 20 Shares are up 2  premarket on light volume Now read ,2018-01-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/johnson--johnson-q4-revenues-up-12-nongaap-eps-up-10-updates-guidance-1138334,1138334
198282,419798,JNJ,FQ2 beat propels ResMed  up 14 ,news,ResMed  RMD  14 3   is up in early trading on 30  higher volume after posting better than expected fiscal Q2 results yesterday after the close Consensus view for calendar Q1  fiscal Q3  is EPS of  0 77 on revenues of  563M Previously  ResMed FQ2 revenues up 13   EPS down 87   cash flow up 5   Jan  22 Previously  ResMed beats by  0 22  beats on revenue  Jan  22 Now read ,2018-01-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/fq2-beat-propels-resmed-up-14-1139925,1139925
198283,419799,JNJ,AstraZeneca  AZN  Signs  6 9B Cancer Deal With Daiichi Sankyo,opinion,"AstraZeneca plc    NYSE AZN   announced that it has acquired joint development and commercialization rights to a promising cancer candidate from Daiichi Sankyo  The deal requires the British drug giant to pay as much as  6 9 billion to the Japan based drug maker 
Per the deal  the companies will develop and commercialize Daiichi Sankyo s proprietary antibody drug conjugate  ADC  trastuzumab deruxtecan  which they claim has the potential to redefine the standard of care in cancer treatment  This is because targeted cancer medicines like ADC s deliver chemotherapy selectively to cancer cells and reduce systemic exposure unlike conventional chemotherapy medicines 
Trastuzumab deruxtecan is being developed in HER2 expressing cancers including five pivotal late stage studies for HER2 expressing breast and gastric cancers and mid stage studies for HER2 expressing advanced colorectal cancer and metastatic non squamous HER2 overexpressing or HER2 mutated NSCLC  The first regulatory application for trastuzumab deruxtecan is expected to be filed in the second half of 2019 for advanced or refractory breast cancer 
The candidate enjoys FDA s Breakthrough Therapy status for HER2 positive metastatic breast cancer in patients who have been previously treated with Roche s   OTC RHHBY   breast cancer medicines Herceptin  trastuzumab  and Perjeta  pertuzumab  and witnessed disease progression after trastuzumab emtansine 
For the deal  AstraZeneca will make an upfront payment of  1 35 billion while being entitled to make contingent payments  comprising regulatory and sales related milestone fees of up to  5 55 billion
Daiichi  however  retained exclusive rights to the drug in Japan  The companies will equally share development and commercialization costs  AstraZeneca informed that it will fund the transaction partly through a share issue of up to  3 5 billion  
The deal further strengthens AstraZeneca s oncology pipeline  AstraZeneca is aggressively working on strengthening its oncology product portfolio and has several candidates in its pipeline  Oncology sales now comprise around 29  of total product sales for AstraZeneca and rose 50  in 2018  Key new and successful cancer drugs in its pipeline are Imfinzi  Lynparza and Tagrisso 
AstraZeneca s shares were down 5  in pre market trading on Friday probably as investors found the deal costly  Nonetheless  AstraZeneca s stock has rallied 13 1  this year so far  outperforming the rise of 4 4  

 
AstraZeneca currently carries a Zacks Rank  3  Hold   Some better ranked large cap drug stocks are Johnson   Johnson   NYSE JNJ   and Bayer   OTC BAYRY    Both the companies carry a Zacks Rank  2  Buy   You can see  
J J s shares have risen 7 6  this year so far  a decent recovery from the decline last year  Its earnings estimates for 2019 have gone up 0 1  in the past 30 days  Though Bayer s shares have declined 9 8  this year  its earnings estimates have increased 2 1  for 2019 over the past 60 days 
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-29,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-azn-signs-69b-cancer-deal-with-daiichi-sankyo-200402385,200402385
198284,419800,JNJ,AstraZeneca s Selumetinib Gets Breakthrough Therapy Status,opinion,"AstraZeneca Inc    NYSE AZN   announced that the FDA has granted Breakthrough Therapy designation  BTD  to its investigational MEK 1 2 inhibitor  selumetinib for the treatment of neurofibromatosis type 1  NF1  related plexiform neurofibromas  PN   an incurable genetic condition that affects newborns 
The Breakthrough Therapy designation is granted to speed up the development and review of drugs that target serious or life threatening conditions  AstraZeneca is developing selumetinib in partnership with Merck   Co  Inc    NYSE MRK    AstraZeneca and Merck entered into a co development and co commercialization agreement for selumetinib in 2017 
Shares of AstraZeneca have increased 20 5  year to date compared with the  s growth of 20  

 
The BTD was supported by phase II results from the SPRINT study  testing selumetinib as an oral monotherapy in pediatric patients aged three years or older with inoperable NF1 related PN  Results from the study have shown that selumetinib shrank tumors in children and young adults with NF1 and may improve symptoms such as pain and reduced mobility that result from tumors called  which develop in many people with  
In the study  36 of the 50 patients  72   had a partial response to selumetinib  which means the tumor volume shrank at least 20   Selumetinib was granted Orphan Drug designation for the treatment of NF1 by the FDA in February 2018 and the European Medicines Agency in August 2018  It is being developed as a monotherapy and in combination with other treatments in ongoing studies 
AstraZeneca boasts a strong late stage oncology pipeline  Other than Selumetinib  the company s oncology portfolio includes savolitinib  kidney cancer   which is also in late stage development  An interesting candidate in the company s immuno oncology pipeline is Imfinzi  durvalumab   which is being evaluated for multiple cancers  either alone or in combination with other regimens  Imfinzi is presently marketed in the United States for second line advanced bladder and early stage lung cancer  NSCLC  
Lynparza  also marketed in partnership with Merck for advanced ovarian and breast cancers  is being evaluated in different studies for a range of tumor types  including prostate and pancreatic cancers  and earlier line settings for ovarian cancer  Tagrisso is also being evaluated in earlier line settings for lung cancer AstraZeneca PLC Price
    
Zacks Rank   Stocks to Consider
AstraZeneca is currently a Zacks Rank  3  Hold  stock 
Some better ranked stocks from the same space are Johnson   Johnson   NYSE JNJ   and Roche Holding  SIX ROG  AG   OTC RHHBY    each carrying a Zacks Rank  2  Buy   You can see  
Johnson   Johnson s earnings per share estimates have increased from  9 20 to  9 21 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 1 61  
Roche s earnings per share estimates have increased from  2 30 to  2 35 for 2019 and from  2 34 to  2 37 for 2020 over the past 90 days 
Zacks  Top 10 Stocks for 2019 
In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year 
From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  
This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-selumetinib-gets-breakthrough-therapy-status-200402828,200402828
198285,419801,JNJ,Company News For Apr 2  2019,opinion,Johnson   Johnson s   NYSE JNJ   shares fell 0 6  after its baby shampoo samples failed quality tests in India and were rejected by regulatorscomScore  Inc  s   NASDAQ SCOR   shares dipped 29 7  after CEO Bryan Wiener resigned from the companyShares of Village Farms International  Inc   gained 9 4  after the company announced that its 50  joint venture for cannabis production has commenced operationsShares of TG Therapeutics  Inc    NASDAQ TGTX   rose 0 6  after the company announced positive results from interim trial data for the evaluation of Umbralisib,2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-apr-2-2019-200403072,200403072
198286,419802,JNJ,Novartis Gets Approval For Psoriasis Drug Cosentyx In China ,opinion,Novartis AG   NYSE NVS   announced today that the China Health Authority NMPA approved its blockbuster psoriasis drug  Cosentyx Cosentyx  a first in class interleukin 17A  IL 17A  inhibitor  is the first biologic approved in China for moderate to severe plaque psoriasis in adult patients  who are candidates for systemic therapy or phototherapy A phase III study conducted in China showed that nine out of 10 patients  who received Cosentyx  300mg on an every four week dosing regimen after loading   achieved clear or almost clear skin after 16 weeks More than 6 million patients are living with mild  moderate or severe forms of psoriasis in China  Hence  there is huge scope for growth Approval of the drug in additional geographies should further boost sales  Sales of the drug came in at  2 8 billion in 2018  up 37  from 2017 Concurrently  AveXis  a Novartis company  announced that it signed an agreement to purchase an advanced biologics therapy manufacturing campus in Longmont  CO The agreement will enhance AveXis  production capacity  as it prepares to launch Zolgensma  an investigational gene therapy awaiting global regulatory approvals for the treatment of spinal muscular atrophy  SMA  Type 1 and future gene therapy treatments in development In December 2018  the FDA accepted the company s Biologics License Application for Zolgensma in SMA Type 1 patients  The drug was earlier granted Breakthrough Therapy designation and Priority Review status by the FDA  with regulatory action anticipated in May 2019  Additionally  the drug is anticipated to receive approval in Japan and the European Union later this year Shares of the company have gained 11 7  in the past six months compared with the  s 3 3  growth  Last year was a transformative one for Novartis  as it restructured business to become a core drug focused company  powered by data and digital technologies  Novartis acquired AveXis  Inc  a U S  based clinical stage gene therapy company  in 2018  The company also acquired Endocyte to expand expertise in radiopharmaceuticals  We expect more acquisitions in the coming months  as the company looks to further restructure its business Approval of new drugs and label expansion of existing drugs bode well for Novartis  as it looks to streamline its business In September 2018  Novartis agreed to sell selected portions of its Sandoz U S  portfolio  specifically the Sandoz U S  dermatology business and the U S  oral solids portfolio  The divestiture is in accordance with Sandoz s strategy of focusing on complex generics  value added medicines and biosimilars to achieve sustainable and profitable growth in the United States in the long run  The transaction will be completed in 2019  Novartis also sold its stake in consumer healthcare joint venture to GlaxoSmithKline   NYSE GSK   for  13 billion Zacks Rank   Stocks to ConsiderNovartis currently carries a Zacks Rank  4  Sell   A couple of better ranked stocks in the same space are Johnson   Johnson   NYSE JNJ   and Roche   OTC RHHBY    Both stocks carry a Zacks Rank  2  Buy   You can see  Johnson   Johnson s earnings per share estimates have increased from  9 20 to  9 21 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters at an average of 1 61  Roche s earnings per share estimates have increased from  2 32 to  2 35 for 2019 in the past 60 days Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-04-01,Zacks Investment Research,https://www.investing.com/analysis/novartis-gets-approval-for-psoriasis-drug-cosentyx-in-china-200403172,200403172
198299,419815,JNJ,Bayer  J J win reversal of  28 million verdict in Xarelto lawsuit,news,"By Nate Raymond and Tina Bellon  Reuters    A Pennsylvania state court judge on Tuesday overturned a  27 8 million jury award to an Indiana couple who accused  Bayer AG   DE BAYGn  and Johnson   Johnson  N JNJ  of failing to warn of internal bleeding risks of their drug Xarelto  the companies said  Judge Michael Erdos  in the Philadelphia County Court of Common Pleas  ruled following a hearing on the drugmakers  motion to reverse the December verdict  which was their first trial loss in litigation over the blood thinner  the companies said  J J s Janssen Pharmaceuticals Inc unit and Bayer  which jointly developed Xarelto  in separate statements welcomed the decision and said they will continue to defend against the allegations in related litigation   Bayer stands behind the safety and efficacy of Xarelto and will continue to vigorously defend it   Bayer said in a statement  The verdict came in a lawsuit by Lynn Hartman  who was prescribed Xarelto to prevent strokes as a result of atrial fibrillation  an irregular heartbeat  Hartman said that she took the drug for approximately one year and in June 2014 was hospitalized with severe gastrointestinal bleeding  which she blamed on Xarelto  She has since recovered  Hartman and her husband sued the drugmakers in 2015  A jury in December awarded  1 8 million in compensatory damages and  26 million in punitive damages  The lawsuit was one of around 21 400 that J J says are pending in federal and state courts blaming injuries on Xarelto  The trial was the first to result from roughly 1 400 Xarelto cases pending in the Philadelphia court   Michael Weinkowitz  a lawyer for the couple  said the decision related to a  very narrow issue related to Mrs  Hartman s prescribing physician   He said he looked forward to trying the next series of Xarelto related cases in Philadelphia  The U S  Food and Drug Administration approved Xarelto in 2011  It is prescribed for people with atrial fibrillation  a common heart rhythm disorder  and to treat and reduce the risk of deep vein thrombosis and pulmonary embolisms   But plaintiffs contend Xarelto was unreasonably dangerous and that J J and Bayer failed to warn patients about a serious risk of uncontrollable  irreversible bleeding in emergencies  Bayer and J J contend Xarelto s label adequately warns of bleeding risks  
Federal juries have cleared the companies of liability in three previous trials  The latest verdict in the federal litigation came in August in the case of a Mississippi woman ",2018-01-10,Reuters,https://www.investing.com/news/stock-market-news/bayer-jj-win-reversal-of-28-million-verdict-in-xarelto-lawsuit-1085024,1085024
198300,419816,JNJ,Johnson   Johnson  JNJ  Dips More Than Broader Markets  What You Should Know,opinion,"Johnson   Johnson  NYSE JNJ  closed at  136 61 in the latest trading session  marking a  0 22  move from the prior day  This change lagged the S P 500 s 0 08  loss on the day  Elsewhere  the Dow gained 0 06   while the tech heavy Nasdaq lost 0 07  
Prior to today s trading  shares of the world s biggest maker of health care products had gained 1 1  over the past month  This has outpaced the Medical sector s loss of 0 22  and the S P 500 s gain of 0 52  in that time 
Wall Street will be looking for positivity from JNJ as it approaches its next earnings report date  This is expected to be April 16  2019  In that report  analysts expect JNJ to post earnings of  2 07 per share  This would mark year over year growth of 0 49   Meanwhile  our latest consensus estimate is calling for revenue of  19 67 billion  down 1 7  from the prior year quarter 
For the full year  our Zacks Consensus Estimates are projecting earnings of  8 57 per share and revenue of  81 25 billion  which would represent changes of  4 77  and  0 4   respectively  from the prior year 
Any recent changes to analyst estimates for JNJ should also be noted by investors  These recent revisions tend to reflect the evolving nature of short term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate remained stagnant within the past month  JNJ is currently a Zacks Rank  3  Hold  
Investors should also note JNJ s current valuation metrics  including its Forward P E ratio of 15 97  This valuation marks a premium compared to its industry s average Forward P E of 15 3 
Investors should also note that JNJ has a PEG ratio of 2 1 right now  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2 13 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 158  putting it in the bottom 39  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-03-25,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-dips-more-than-broader-markets-what-you-should-know-200400853,200400853
198301,419817,JNJ,Bayer   JNJ Settle Numerous Xarelto Lawsuits For  775 Million,opinion,"Bayer AG  DE BAYGN    OTC BAYRY   and Johnson   Johnson s   NYSE JNJ   subsidiary  Janssen Pharmaceuticals Inc  announced that they have reached a  775 million settlement to resolve litigation filed by patients who suffered a bleeding injury after taking the blood thinner  Xarelto 
The settlement will virtuallyresolve approximately 25 000 Xarelto claims in the United States  Notably  plaintiffs claimed that the drug caused uncontrollable and irreversible bleeding  leading to severe injuries and even death among thousands of patients 
The settlement amount will be shared equally between the two companies  It is expected that Bayer s share will be partially offset by product liability insurance 
Shares of Bayer have declined 41 4  in the past year  against the  s growth of 17 1  
 

 
Plaintiffs accused the drug makers of having failed to warn about the bleeding risks  claiming that their injuries could have been prevented had doctors and patients been provided with adequate information 
In addition to addressing lawsuits  the agreement resolves newly filed claims that meet certain criteria  These include plaintiffs who had retained a lawyer to investigate Xarelto related personal injury claims before Mar 11  2019  register their claim by Mar 28  2019  and file a civil action by Apr 4  2019  Individuals involved in these lawsuits are required to contact their personal attorneys to address eligibility questions 
Payments will be substantially reduced for any claimant whose first Xarelto prescription was on or after Dec 1  2015  and or whose first alleged injury from Xarelto occurred on or after Mar 1  2016 
The companies had so far won all six trials over Xarelto s alleged bleeding risk 
We remind investors that Xarelto is approved by the FDA to treat people with atrial fibrillation  a common heart rhythm disorder that increases the risk of stroke  The drug is used to treat and reduce the risk of deep vein thrombosis and pulmonary embolisms  It is also used to reduce the risk of serious heart problems  heart attack and stroke in patients with coronary artery disease Bayer Aktiengesellschaft Price
   Zacks Rank and Other Stocks to Consider
Bayer currently carries a Zacks Rank  2  Buy  
Some other top ranked stocks from the same space are AstraZeneca Plc    NYSE AZN   and Roche Holding  SIX ROG  AG   OTC RHHBY    each carrying a Zacks Rank  2  You can see  
AstraZeneca s earnings per share estimates have increased from  1 74 to  1 79 for 2019 and from  2 14 to  2 20 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 106 40  
Roche s earnings per share estimates have increased from  2 31 to  2 35 for 2019 and from  2 34 to  2 37 for 2020 over the past 90 days 
Is Your Investment Advisor Fumbling Your Financial Future  
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-26,Zacks Investment Research,https://www.investing.com/analysis/bayer--jnj-settle-numerous-xarelto-lawsuits-for-775-million-200401229,200401229
198302,419818,JNJ,J J Files SBLA For Darzalex In Expanded Myeloma Patient Group,opinion,Johnson   Johnson   NYSE JNJ   filed a supplemental biologics license application  sBLA  with the FDA to get approval for Darzalex combination therapy for an expanded patient population With the sBLA filing  J J is looking for approval of Darzalex in combination with its  proteasome inhibitor  Velcade  bortezomib   thalidomide and dexamethasone  VTd   in patients with newly diagnosed multiple myeloma   MM   who are eligible for autologous stem cell transplant  ASCT   The filing was based on data from a phase III CASSIOPEIA study Please note that Darzalex is already approved for use in combination with Velcade  melphalan and prednisone  VMP  for newly diagnosed MM patients who are ineligible for ASCT  The FDA approval for the transplant ineligible patient population was received in May last year  This is the first filing for a Darzalex combination treatment regimen in the frontline setting for transplant eligible MM patients Earlier this month  J J had filed a sBLA looking for approval of Darzalex in combination with the standard of care treatment regimen   Celgene s   NASDAQ CELG   Revlimid  lenalidomide  and dexamethasone  Rd  in newly diagnosed MM patients who are ineligible for ASCT  This sBLA filing was based on data from a phase III MAIA study J J s stock has risen 7 4  this year so far compared with an increase of 3 7  recorded by the    Darzalex is approved as a monotherapy treatment for MM patients who have received at least three prior lines of therapy as well as in combination treatment with other MM drugs like Revlimid  Pomalyst and Velcade in different treatment settings Darzalex has been generating strong sales and is a key contributor to J J s top line  The drug generated sales of  2 03 billion in 2018  representing year over year growth of more than 63  Meanwhile  Darzalex is being evaluated in a comprehensive clinical development program across a range of treatment settings in multiple myeloma  such as in frontline and relapsed settings These include combination studies with other cancer drugs like Roche Holding  SIX ROG  AG s   OTC RHHBY   atezolizumab  Bristol Myers Squibb Company s   NYSE BMY   Opdivo  and Amgen s Kyprolis J J currently has a Zacks Rank  2  Buy   You can see   Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-03-26,Zacks Investment Research,https://www.investing.com/analysis/jj-files-sbla-for-darzalex-in-expanded-myeloma-patient-group-200401510,200401510
198303,419819,JNJ,3 Reasons Why Johnson   Johnson  JNJ  Is A Great Growth Stock,opinion,"Growth investors focus on stocks that are seeing above average financial growth  as this feature helps these securities garner the market s attention and deliver solid returns  But finding a growth stock that can live up to its true potential can be a tough task 
In addition to volatility  these stocks carry above average risk by their very nature  Also  one could end up losing from a stock whose growth story is actually over or nearing its end 
However  it s pretty easy to find cutting edge growth stocks with the help of the Zacks Growth Style Score  part of the Zacks Style Scores system   which looks beyond the traditional growth attributes to analyze a company s real growth prospects 
Our proprietary system currently recommends Johnson   Johnson  NYSE JNJ  as one such stock  This company not only has a favorable Growth Score  but also carries a top Zacks Rank 
Research shows that stocks carrying the best growth features consistently beat the market  And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank  1  Strong Buy  or 2  Buy   returns are even better 
Here are three of the most important factors that make the stock of this world s biggest maker of health care products a great growth pick right now 
Earnings Growth
Earnings growth is arguably the most important factor  as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors  For growth investors  double digit earnings growth is highly preferable  as it is often perceived as an indication of strong prospects  and stock price gains  for the company under consideration 
While the historical EPS growth rate for Johnson   Johnson is 7 8   investors should actually focus on the projected growth  The company s EPS is expected to grow 4 9  this year  crushing the industry average  which calls for EPS growth of 1 6  
Cash Flow Growth
While cash is the lifeblood of any business  higher than average cash flow growth is more important and beneficial for growth oriented companies than for mature companies  That s because  growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds 
Right now  year over year cash flow growth for Johnson   Johnson is 13 9   which is higher than many of its peers  In fact  the rate compares to the industry average of 10 2  
While investors should actually consider the current cash flow growth  it s worth taking a look at the historical rate too for putting the current reading into proper perspective  The company s annualized cash flow growth rate has been 7 9  over the past 3 5 years versus the industry average of 3 3  
Promising Earnings Estimate Revisions
Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions  A positive trend is of course favorable here  Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near term stock price movements 
There have been upward revisions in current year earnings estimates for Johnson   Johnson  The Zacks Consensus Estimate for the current year has surged 0 1  over the past month 
Bottom Line
While the overall earnings estimate revisions have made Johnson   Johnson a Zacks Rank  2 stock  it has earned itself a Growth Score of B based on a number of factors  including the ones discussed above 
You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
This combination indicates that Johnson   Johnson is a potential outperformer and a solid choice for growth investors ",2019-03-27,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-why-johnson--johnson-jnj-is-a-great-growth-stock-200401488,200401488
198304,419820,JNJ,This Is Why Johnson   Johnson  JNJ  Is A Great Dividend Stock,opinion,"All investors love getting big returns from their portfolio  whether it s through stocks  bonds  ETFs  or other types of securities  But for income investors  generating consistent cash flow from each of your liquid investments is your primary focus 
Cash flow can come from bond interest  interest from other types of investments  and of course  dividends  A dividend is the distribution of a company s earnings paid out to shareholders  it s often viewed by its dividend yield  a metric that measures a dividend as a percent of the current stock price  Many academic studies show that dividends make up large portions of long term returns  and in many cases  dividend contributions surpass one third of total returns 
Johnson   Johnson  NYSE JNJ  in Focus
Headquartered in New Brunswick  Johnson   Johnson  JNJ  is a Medical stock that has seen a price change of 7 48  so far this year  The world s biggest maker of health care products is paying out a dividend of  0 9 per share at the moment  with a dividend yield of 2 6  compared to the Large Cap Pharmaceuticals industry s yield of 2 7  and the S P 500 s yield of 1 98  
Taking a look at the company s dividend growth  its current annualized dividend of  3 60 is up 1 7  from last year  In the past five year period  Johnson   Johnson has increased its dividend 5 times on a year over year basis for an average annual increase of 6 40   Looking ahead  future dividend growth will be dependent on earnings growth and payout ratio  which is the proportion of a company s annual earnings per share that it pays out as a dividend  Right now  Johnson   Johnson s payout ratio is 44   which means it paid out 44  of its trailing 12 month EPS as dividend 
Looking at this fiscal year  JNJ expects solid earnings growth  The Zacks Consensus Estimate for 2019 is  8 58 per share  which represents a year over year growth rate of 4 89  
Bottom Line
From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages  investors like dividends for a variety of different reasons  It s important to keep in mind that not all companies provide a quarterly payout 
For instance  it s a rare occurrence when a tech start up or big growth business offers their shareholders a dividend  It s more common to see larger companies with more established profits give out dividends  Income investors must be conscious of the fact that high yielding stocks tend to struggle during periods of rising interest rates  With that in mind  JNJ presents a compelling investment opportunity  it s not only an attractive dividend play  but the stock also boasts a strong Zacks Rank of  2  Buy  ",2019-03-27,Zacks Investment Research,https://www.investing.com/analysis/this-is-why-johnson--johnson-jnj-is-a-great-dividend-stock-200401876,200401876
198305,419821,JNJ,Why Is Theravance Bio  TBPH  Down 7 9  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Theravance Biopharma  TBPH   Shares have lost about 7 9  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Theravance Bio due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Theravance Q4 Loss Narrows  Revenues Beat EstimatesTheravance Biopharma incurred a loss of 92 cents per share in fourth quarter 2018  narrower than the Zacks Consensus Estimate of a loss of  1 12 and the year ago loss of  1 64 Total revenues in the quarter skyrocketed 248 5  year over year to  15 7 million  mainly on the back of an upfront payment received from J J  NYSE JNJ  in relation to a joint development agreement for Theravance s pan Janus kinase inhibitor  TD 1473  Moreover  the top line surpassed the Zacks Consensus Estimate of  12 3 million Quarterly DetailsVibativ generated U S  revenues of  2 4 million in the fourth quarter  down 41 5  from the year ago period s figure  Revenues from collaborations  primarily related to the collaboration with J J for TD 1473  were  10 million compared with  0 39 million in the year earlier quarter  Profit sharing revenues related to Yupelri was  3 3 million in the quarter Research and development expenses were  52 3 million  up 2 3  from the year ago quarter  primarily due to higher costs to support key programs Selling  general   administrative expenses decreased 13 5  to  25 5 million  due to lower expenses regarding share based compensation 2019 OutlookFor 2019  Theravance anticipates operating loss  excluding non cash share based compensation  to be  210  230 million 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates flatlined during the past month  The consensus estimate has shifted  6 4  due to these changes 
VGM Scores
Currently  Theravance Bio has a subpar Growth Score of D  however its Momentum Score is doing a lot better with a B  However  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Theravance Bio has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-03-27,Zacks Investment Research,https://www.investing.com/analysis/why-is-theravance-bio-tbph-down-79-since-last-earnings-report-200401810,200401810
198306,419822,JNJ,AstraZeneca s Forxiga Gets Nod In Japan For Type I Diabetes,opinion,AstraZeneca plc    NYSE AZN   announced that the Japanese regulatory authority has granted marketing approval to its SGLT2 inhibitor Forxiga for a new indication   as an oral adjunct treatment to insulin in adults with type Idiabetes With this approval from the Japanese Ministry of Health  Labour and Welfare  MHLW   Forxigacan now be prescribed to type Idiabetespatients whose glucose levels are not adequately controlled with insulin alone  The approval is based on data from the phase III DEPICT study and a special study conducted in Japanese patients Data from the study showed that both the 5mg and 10mg doses of Forxiga led to significant and clinically meaningful reductions from baseline in average blood glucose levels HbA1c  primary endpoint   weight and total daily insulin dose  secondary endpoints  at 24 weeks Please note that Forxiga was approved for type I diabetes in Europe last week and is under review in the United States for the same indication with a decision expected in the second half of 2019  Forxiga is known by the name of Farxiga in United States  Farxiga Forxiga is already approved as both monotherapy and combination therapy to improve glycemic control  with additional benefits of weight loss and blood pressure reduction  as an adjunct to diet and exercise in adults with type II diabetes Talking about type I diabetes drugs  the FDA recently issued a complete response letter to Lexicon Pharmaceuticals  Inc  s   NASDAQ LXRX   new drug application seeking approval of its lead pipeline candidate  Zynquista  sotagliflozin   Zynquista is a dual SGLT1 and SGLT2 inhibitor evaluated in combination with insulin for type I diabetes in adult patients  Lexicon is developing the candidate in collaboration with Sanofi   NASDAQ SNY   AstraZeneca s stock has rallied 12 3  this year so far  outperforming the  rise of 4 9    Farxiga Forxiga  a key driver of AstraZeneca s top line  recorded sales of almost  1 4 billion in 2018  representing growth of 30   Farxiga  one of the many successful new drugs in AstraZeneca s portfolio enjoys volume market share leadership globally The approval for the type I diabetes indication expands the drugs  eligible patient population  which should improve sales in the future quarters Other SGLT2 inhibitors available in the market are Johnson   Johnson s  NYSE JNJ   Invokana and Lilly s Jardiance  Synjardy  a fixed dose combination of Jardiance and metformin  and Glyxambi a fixed dose combination of Jardiance and Tradjenta  AstraZeneca currently carries a Zacks Rank  3  Hold   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-03-27,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-forxiga-gets-nod-in-japan-for-type-i-diabetes-200401992,200401992
198310,419826,JNJ,France fines J J 25 million euros over painkiller patch,news,PARIS  Reuters    France s competition authority fined U S  healthcare group Johnson   Johnson  NYSE JNJ  25 million euros   29 6 million  on Wednesday after it ruled the company had deliberately slowed market access to generic copies of its painkiller Durogesic  Durogesic is sold as a skin patch to control ongoing moderate to severe pain and is often prescribed in cancer cases  It contains fentanyl  an opioid which  if misused  can lead to death by overdose  The French Autorite de la Concurrence said J J s Janssen had  repeatedly intervened  to block the approval processes in France of Durogesic s generic copies and disparaged them when in contact with doctors and other healthcare professionals  The company disputed the finding    We firmly object to the statements contained in the competition authority s release and to its assessments   a spokeswoman for J J said in an emailed statement  adding that the company was studying its options  The case was brought to the watchdog by German firm Ratiopharm  later acquired by Israel s Teva pharmaceuticals  after Durogesic lost its patent in 2005  In 2013  France s Sanofi  PA SASY  was ordered to pay 40 6 million euros for disparaging generic competition to its Plavix blood thinner ,2017-12-20,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-fined-25-million-euros-by-french-competition-watchdog-1012589,1012589
198311,419827,JNJ, 11 billion biotech binge fuels forecasts of 2018 M A surge,news,"By Ben Hirschler LONDON  Reuters    An  11 billion burst of biotech bids in just four days has fueled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals  Separate reports on Monday by consultancy EY and law firm Baker McKenzie both predict a significant rise in mergers and acquisitions  M A  this year  helped by U S  tax changes that may lift big companies  appetite for deals  Celgene s  O CELG  up to  7 billion agreed takeover of Impact Biomedicines  Novo Nordisk s  CO NOVOb   3 1 billion offer for  Ablynx   BR ABLX  and Takeda Pharmaceutical s  T 4502  plan to buy TiGenix  BR G9U  for  630 million have already got 2018 off to a flying start  This follows a relatively subdued 2017  when total life sciences M A totaled around  200 billion  dominated by Johnson   Johnson s  N JNJ   30 billion purchase of Actelion and Gilead s  O GILD   12 billion acquisition of Kite  EY is confident this year s deal value will exceed  200 billion  given companies  increased financial firepower and balance sheet strength  There is also substantial pent up demand  with 60 percent of life sciences executives surveyed in October 2017 planning to actively pursue M A in the next 12 months  compared with 46 percent in April  Baker McKenzie  meanwhile  predicts global healthcare M A could rise 50 percent in 2018  with North America accounting for well over half of transactions  Driving the demand is the increasingly pivotal role of biotech firms in discovering the drugs of tomorrow   I believe you will see a higher proportion of innovation at an industry level    and also at  Novo Nordisk     coming from external resources   Novo s Chief Financial Officer Jesper Brandgaard told Reuters   Ablynx is an example of strong technology development occurring in a smaller biotech setting  with considerable speed and a lack of some of the bureaucracy you can get at large pharma companies   NICHE DISEASES U S  drug approvals hit a 21 year high in 2017  with 46 novel medicines winning a green light and a growing share of new products coming from younger biotech companies  For large drugmakers  as well as big biotech businesses like Gilead and Celgene  small and innovative upstarts are now a vital source of experimental drugs with which to top up in house development pipelines  Pricing pressures on established medicines for conditions like diabetes and respiratory disorders  as well as patent expiries on yesterday s blockbusters  are driving big players into niche disease areas where biotech groups often excel  according to Edison analyst and former fund manager Andy Smith   The pressures at big pharma look to be increasing and 90 percent of prescriptions in the U S  are now for generics  so that pushes companies to look at cutting edge therapies and it takes them straight into the biotech wheelhouse   he said  Whether 2018 will turn out to be a golden year for biotech M A remains to be seen  but investors like event driven hedge fund Case Equity Partners have high hopes for the drugs sector  following recent implementation of U S  tax changes   U S  companies with lots of cash trapped overseas can now put capital to work in the global M A market more easily  We hence expect 2018 to be immensely active with multiple competitive auctions at significant premia   the fund said in a an end of year letter  Although bankers say the U S  tax overhaul and particularly a lower tax rate for the repatriation of cash held offshore has so far had limited impact on deal negotiations  they believe companies may decide to allocate more cash to M A in 2018  
The M A outlook is likely to be a hot topic at the annual JP Morgan Healthcare Conference starting on Monday in San Francisco  when many biotech deals and alliances are often announced ",2018-01-08,Reuters,https://www.investing.com/news/stock-market-news/11-billion-biotech-binge-fuels-forecasts-of-2018-ma-surge-1076012,1076012
198312,419828,JNJ,J J Seeks Approval For Darzalex In Expanded Patient Group,opinion,Johnson   Johnson   NYSE JNJ   filed a supplemental biologics license application  sBLA  with the FDA to get approval for Darzalex combination therapy for an expanded patient population With the sBLA filing  J J is looking for approval of Darzalex in combination with the standard of care treatment regimen   Celgene s   NASDAQ CELG   Revlimid  lenalidomide  and dexamethasone  Rd    in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant  ASCT   The filing was based on data from a phase III MAIA study Please note that Darzalex is already approved for use in combination with Takeda s Velcade  melphalan and prednisone  VMP  for newly diagnosed multiple myeloma in patients who are ineligible for ASCT  The FDA approval for this patient population was received in May last year Previous data from the MAIA study showed that at a median follow up of 28 months  the addition of Darzalex to Rd significantly reduced the risk of disease progression or death by 44  in such patients compared to treatment with Rd alone  While progression free survival  PFS  for patients who received Rd alone was 31 9 months  the median PFS for Darzalex plus Rd arm was not reached  The study is being reviewed by the FDA under the Real Time Oncology Review  RTOR  pilot program  which ensures a more efficient review process J J s stock has risen 6 9  this year so far compared with an increase of 3 5  recorded by the   Darzalex has been generating strong sales and is a key contributor to J J s top line  The drug generated sales of  2 03 billion in 2018  representing year over year growth of more than 63  Meanwhile  Darzalex is being evaluated in a comprehensive clinical development program across a range of treatment settings in multiple myeloma  such as in frontline and relapsed settings These include combination studies with other cancer drugs like Roche Holding  SIX ROG  AG s   OTC RHHBY   atezolizumab  Bristol Myers Squibb Company   NYSE BMY   Opdivo  and Amgen s Kyprolis J J currently has a Zacks Rank  3  Hold   You can see   Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-03-15,Zacks Investment Research,https://www.investing.com/analysis/jj-seeks-approval-for-darzalex-in-expanded-patient-group-200397991,200397991
198313,419829,JNJ,Johnson   Johnson  JNJ  Stock Sinks As Market Gains  What You Should Know,opinion,"Johnson   Johnson  NYSE JNJ  closed at  137 35 in the latest trading session  marking a  0 19  move from the prior day  This move lagged the S P 500 s daily gain of 0 37   Meanwhile  the Dow gained 0 25   and the Nasdaq  a tech heavy index  added 0 34  
Prior to today s trading  shares of the world s biggest maker of health care products had gained 2 45  over the past month  This has outpaced the Medical sector s gain of 1 34  and the S P 500 s gain of 1 83  in that time 
Wall Street will be looking for positivity from JNJ as it approaches its next earnings report date  The company is expected to report EPS of  2 08  up 0 97  from the prior year quarter  Meanwhile  our latest consensus estimate is calling for revenue of  19 67 billion  down 1 67  from the prior year quarter 
For the full year  our Zacks Consensus Estimates are projecting earnings of  8 57 per share and revenue of  81 23 billion  which would represent changes of  4 77  and  0 43   respectively  from the prior year 
Any recent changes to analyst estimates for JNJ should also be noted by investors  These revisions help to show the ever changing nature of near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Our research shows that these estimate changes are directly correlated with near term stock prices  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 03  lower  JNJ is currently sporting a Zacks Rank of  3  Hold  
Digging into valuation  JNJ currently has a Forward P E ratio of 16 05  This represents a premium compared to its industry s average Forward P E of 15 27 
It is also worth noting that JNJ currently has a PEG ratio of 2 11  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 14 at yesterday s closing price 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 100  which puts it in the top 40  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-03-18,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-stock-sinks-as-market-gains-what-you-should-know-200398852,200398852
198314,419830,JNJ,AbbVie s Venclexta Multiple Myeloma Studies Put On Hold By FDA,opinion,AbbVie  Inc    NYSE ABBV    announced that the FDA has placed a partial clinical hold on all studies evaluating its leukemia drug  Venclexta  venetoclax  for the treatment of multiple myeloma  The decision was taken after  in the ongoing phase III BELLINI study  a higher proportion of deaths were observed in the Venclexta arm compared to the control arm of the study Following the observation  it has been instructed that until the data is further analyzed  no new patients should be enrolled in any studies of Venclexta for multiple myeloma  Meanwhile  those who are already enrolled in multiple myeloma studies and receiving benefit from Venclexta have been instructed to continue with treatment after consulting their doctorVenclexta is presently approved for other cancer types like newly diagnose chronic lymphocytic leukemia  CLL  and second line treatment of certain acute myeloid leukemia  AML  patients  The clinical hold does not impact any of the approved indications for Venclexta  It is presently not approved to treat multiple myeloma The BELLINI study is evaluating the safety and efficacy of Venclexta plus Takeda s Velcade  bortezomib  and dexamethasone in patients with relapsed or refractory multiple myeloma who are considered sensitive or na ve to proteasome inhibitors and have received one to three prior lines of therapy  The combination is being compared to treatment with Velcade  dexamethasone and placebo AbbVie s stock has declined 12 3  this year so far against an increase of 3 7  recorded by the    Venclexta is jointly marketed by AbbVie and Roche s   OTC RHHBY   pharma arm  Genentech in the United States and by AbbVie outside the United States  Venclexta is marketed by the trade name of Venclyxto in the EU For AbbVie  Venclexta brought in revenues of  344 million in 2018  up more than 100  year over year driven by uptake in the second line plus setting following approval in the United States as well as EU in the broad relapsed refractory CLL segment  MURANO study  in 2018  Venclexta is a key drug in AbbVie s oncology portfolio AbbVie is studying Venclyxto Venclexta to expand the label to address the broader relapsed refractory CLL patient population  expand into earlier lines of therapy  and broaden into other hematologic malignancies like multiple myeloma and AML  As mentioned above  regulatory applications seeking approval for Venclexta plus Rituxan for relapse refractory CLL  based on MURANO study data  were approved in the United States and in the EU in 2018 Data from the phase III MURANO study of Venclexta plus Rituxan in relapse refractory CLL showed that the combination led to a profound improvement in progression free survival compared to Teva s   NYSE TEVA   Treanda plus Rituxan  In November 2018  AbbVie gained FDA approval for Venclexta in first line AML  Label expansion for these indications has expanded the patient population of Venclexta significantly  However  pipeline setbacks like the clinical hold on the multiple myeloma studies will hurt the growth prospects of this important oncology drug Another important cancer drug in AbbVie s portfolio is Imbruvica  which it markets in partnership with J J   NYSE JNJ    Imbruvica  currently approved for quite a few indications  has multi billion dollar potential  AbbVie is exploring the potential to expand Imbruvica s label into solid tumors and autoimmune diseases  Several studies on Imbruvica are ongoing to evaluate the drug alone or in combination in different patient segments  AbbVie expects Imbruvica peak sales of more than  7 billion and revenues of about  5 billion in 2020 AbbVie currently carries a Zacks Rank  3  Hold   You can see This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-03-19,Zacks Investment Research,https://www.investing.com/analysis/abbvies-venclexta-multiple-myeloma-studies-put-on-hold-by-fda-200399499,200399499
198315,419831,JNJ,J J Files Application For Darzalex Label Expansion In Europe,opinion,"Johnson   Johnson   NYSE JNJ   announced that it has filed a type II variation application to the European Medicines Agency  EMA   seeking an approval for the label expansion of Darzalex  daratumumab  as a combination therapy for an expanded patient population 
J J is looking for a nod with respect to Darzalex in combination with Celgene s   NASDAQ CELG   Revlimid  lenalidomide  and dexamethasone  Rd  for treating the newly diagnosed multiple myeloma  MM  patients  who are ineligible for autologous stem cell transplant  ASCT   The filing was based on data from a phase III MAIA study 
Results from the program showed that at a median follow up of 28 months  Darzalex plus Rd significantly reduced the risk of disease progression or death by 44  in such patients compared with patients treated with Rd alone  Though the median progression free survival  PFS  for Darzalex plus Rd arm was not reached  the PFS was 31 9 months for patients  who received only Rd In Europe  Darzalex is already approved for use in combination with bortezomib  melphalan and prednisone  VMP  for the newly diagnosed MM in adult patients  who are ineligible for ASCT 
 Shares of J J have risen 6 1  so far this year  outperforming the increase of 3 7  
Earlier in March  J J filed a supplemental biologics license application  sBLA  with the FDA to get an approval for Darzalex for the same patient population in the given combo regimen  The investigation is being reviewed by the FDA under the Real Time Oncology Review  RTOR  pilot program  which ensures a more efficient assessment process 
In February 2019  J J announced that the FDA granted an approval to a split dosing regimen of Darzalex  With this nod  Darzalex s label is updated in the United States to allow prescribing the medicine by splitting the first infusion of Darzalex over two consecutive days  Approval for this split dosing option is likely to improve the administration profile of the medicine 
Notably  Darzalex generated sales of  2 03 billion in 2018  representing a surge of more than 63  year over year  The drug remains a key contributor to J J s top line Meanwhile  Darzalex is being evaluated in a comprehensive clinical development program across a range of treatment settings in MM  such as in frontline and relapsed settings  These include combination studies with other cancer drugs like Roche s   OTC RHHBY   atezolizumab  Bristol Myers    NYSE BMY   Opdivo  and Amgen s Kyprolis Zacks RankJ J currently has a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-24,Zacks Investment Research,https://www.investing.com/analysis/jj-files-application-for-darzalex-label-expansion-in-europe-200400751,200400751
198316,419832,JNJ,Jury orders Bayer  J J to pay  28 million in Xarelto lawsuit,news,"By Tina Bellon  Reuters    A Philadelphia state court jury on Tuesday ordered  Bayer AG   DE BAYGN  and Johnson   Johnson  NYSE JNJ  to pay  27 8 million to an Indiana couple over the drugmakers  failure to warn of internal bleeding risks from their blood thinner Xarelto  The jury slapped the companies  which jointly developed the blockbuster drug  with  1 8 million in compensatory and  26 million in punitive damages  according to the couple s lawyer   The verdict marks the first trial loss in litigation over Xarelto  Bayer and J J have won three previous cases in federal court  Bayer in a statement said it believed there was no basis for the verdict  including the punitive damages award  and said it was going to appeal the verdict  Janssen  J J s pharmaceutical subsidiary  in a statement also said it was going to appeal the verdict  adding that it contradicted years of scientific data and repeated confirmations of Xarelto s safety by the U S  Food and Drug Administration   Xarelto is the worst in class of the new blood thinners   Michael Weinkowitz  the couple s lawyer  said in a statement   The serious health complications suffered by thousands of patients could have been avoided if physicians were properly instructed about the risks   Lynn Hartman and her husband had sued the drugmakers in 2015   Hartman was prescribed Xarelto to prevent strokes as a result of atrial fibrillation  an irregular heartbeat  She took the drug for approximately one year and in June 2014 was hospitalized with severe gastrointestinal bleeding  which she blamed on Xarelto  She has since recovered   The trial was the first of roughly 1 400 Xarelto cases pending in the Philadelphia court  More than 18 500 cases are pending in federal court  where they are consolidated in a multidistrict litigation at the U S  District Court for the Eastern District of Louisiana  Federal juries have cleared the companies of liability in three previous trials  The latest verdict in the federal litigation came down in August in the case of a Mississippi woman  Xarelto is Bayer s best selling drug and in 2016 contributed 2 9 billion euros   3 41 billion  in revenues to the German group s pharmaceutical business  J J in 2016 reported  2 2 billion in revenues from Xarelto  
The U S  Food and Drug Administration approved Xarelto in 2011  The drug is prescribed for people with atrial fibrillation and to treat and reduce the risk of deep vein thrombosis and pulmonary embolisms ",2017-12-05,Reuters,https://www.investing.com/news/stock-market-news/jury-orders-bayer-jj-to-pay-29-million-in-xarelto-lawsuit-955944,955944
198317,419833,JNJ,Sanofi investors hungry for drug progress and deal news,news,"By Matthias Blamont PARIS  Reuters    Sanofi  PA SASY  still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes  investors told Reuters  The French drugmaker holds an  innovation day  on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine  Already irked by the lack of a large acquisition since Olivier Brandicourt was appointed as chief executive in 2015  some investors are losing patience that has been stretched for months  Shares in Sanofi are trading close to a 10 month low and are down more than 4 percent this year after a 2 2 percent decline last year  Over the past five years they have lagged the sector  rising about 3 percent against a 49 percent gain for the STOXX Europe 600 Healthcare index  SXDP    Nothing is happening in terms of business development and there is very little news in the pipeline  What just happened with dengue is negative and shocking   said Rudi Van Den Eynde  of asset management firm Candriam   DENGVAXIA BLOW  The Philippines suspended a national immunization program last week after Sanofi s recent findings that its Dengvaxia vaccine could  in some cases  increase the risk of severe dengue in recipients not previously infected by the virus  Manila launched an investigation and halted the sale of the medication  Once touted out as a potential  1 billion a year blockbuster product  Dengvaxia s initial sales last year were only 55 million euros   65 million  and industry analysts have been dialing back expectations  The Dengvaxia blow follows two other snags at Sanofi Pasteur  the group s vaccines unit  The division ended the development of an experimental vaccine for clostridium difficile infection this month and pulled out of a Zika vaccine program with the U S  military this summer  PRESSURE AHEAD Last month Sanofi said that currency adjusted sales at its diabetes franchise were likely to have shrunk by 6 8 percent a year between 2015 and 2018 after third quarter results below expectations  It had previously forecast a 4 8 percent drop owing to persistent pricing pressure in the United States  the world s largest healthcare market  where its blockbuster insulin drug Lantus has lost its patent    What is frustrating is that we constantly feel Sanofi is one step behind the competition   another London based investor said  asking not to be named   We are not expecting anything magical during the innovation day  Management is likely to talk at length about its monoclonal antibody candidate in multiple myeloma  isatuximab  but  Genmab   CO GEN  and Johnson   Johnson  J J   N JNJ  already have a drug on the market  Darzalex  that sells well   NO CHEAP TARGETS  Sanofi has said several times this year that it has felt no urge to engage in a large acquisition and that investors were lauding its financial discipline  The group has  however  failed to land major deals after losing California based cancer specialist Medivation to  Pfizer   N PFE  in 2016 and Swiss biotech company Actelion to U S  drugmaker J J in January   Looking back  Sanofi would maybe have overpayed for Medivation  In that regard  their discipline is healthy  yet we see that the company is struggling at laying out a strategy and getting us excited   Moneta Asset Management s Gregoire Uettwiller said  Moneta and Candriam are both long term investors with small stakes in Sanofi of around 0 1 percent  Reuters data shows  Candriam s Van Den Eynde  meanwhile  says Sanofi needs to shed its qualms about splashing out on a big deal    Once you see that your pipeline is not paying off  you cannot be naive  you must engage in M A   Van Den Eynde said  
 Hiding behind the fact that targets are expensive is not doing it  In the modern world  no interesting firm will be available at low valuations  ",2017-12-12,Reuters,https://www.investing.com/news/stock-market-news/sanofi-investors-hungry-for-drug-progress-and-deal-news-981047,981047
198318,419834,JNJ,Tonix Pharmaceuticals completes positive pre IND meeting with FDA for TNX 102 SL  shares ahead 15  premarket,news,Tonix Pharmaceuticals  NASDAQ TNXP  announces that it recently held a pre Investigational New Drug  IND  meeting with the FDA to discuss its proposed development of TNX 102 SL for bedtime use for the treatment of agitation in Alzheimer s disease  AAD  TNX 102 SL IND for AAD is expected to be submitted in Q1 2018  TNX 102 SL is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride which provides rapid transmucosal absorption Shares are up 15  premarket on light volume  Now read ,2017-12-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/tonix-pharmaceuticals-completes-positive-preind-meeting-with-fda-for-tnx102-sl-shares-ahead-15-premarket-981401,981401
198319,419835,JNJ,Geron s  GERN  Q4 Loss In Line  Revenues Beat  Stock Up,opinion,"Geron Corporation   NASDAQ GERN   incurred an adjusted loss of 5 cents  excluding settlement gains and change in equity fair value  per share in fourth quarter 2018  in line with the Zacks Consensus Estimate as well as the year ago quarter loss Quarterly revenues nearly doubled from the year ago quarter number to  0 38 million  which outpaced the Zacks Consensus Estimate of  0 22 million  Revenues comprised royalty and license fee revenues received under various non imetelstat license agreements Shares were up 1 4  in after market trading on Mar 7  So far this year  shares of Geron have gained 43  compared with the  s 11 1  rally Research and development  R D  expense more than doubled to  5 1 million  Following the termination of collaboration with Janssen  a subsidiary of J J   NYSE JNJ    for imetelstat development  Geron bears full development cost that was earlier shared equally with Janssen  This led to the significant increase in R D expenses On the flip side  general and administrative  G A  expenses fell 10 9  to  4 9 million due to lower personnel related expenses  partially offset by higher consulting and legal expenses Geron ended the quarter with  182 million in cash and investments compared with  184 8 million at the end of the third quarter Full Year ResultsGeron s yearly revenues remained flat year over year at  1 1 million in 2018  The company incurred an adjusted loss of 16 cents per share  narrower than the year ago loss of 18 cents per share Pipeline UpdateFollowing the termination of the agreement with Janssen in September 2018  Geron regained global development rights to imetelstat and decided to continue developing imetelstat independently  The transfer of rights to imetelstat from Janssen to Geron will be complete in the third quarter of 2019 Currently  Geron is developing imetelstat as treatment for myelofibrosis and myelodysplastic syndromes  MDS  A phase II study   IMbark   is evaluating the candidate in myelofibrosis  In December  Geron presented updated median overall survival   OS   data from the higher dosage arm  9 4 mg kg  of the study  The candidate achieved median OS of 29 9 months  which suggests a meaningful survival outcome  A decision on the path toward late stage development in myelofibrosis is expected to be announced by the third quarter of 2019 Also  a phase II III study  IMerge  is evaluating imetelstat in MDS  Geron remains confident about the potential of the candidate in the MDS indication based on supportive data from initial and expansion arms of phase II portion of IMerge study  The company expects to start enrollment in the phase III portion of the study by mid 2019 2019 GuidanceGeron announced that it expects operating expenses to be in the range of  65  70 million in 2019  This will include few one time costs related to transition of imetestat and transfer of investigational new drug   IND   sponsorship from Janssen to Geron among others  The significant increase in estimated operating expenses is also due to the fact that Geron is planning to expand its development team for imtelstat Our TakeWith the termination of the agreement with Janssen  Geron lost a strong and experienced partner as well as its major source of funds  Although the cash resources  as of 2018 end  will be sufficient to initiate the phase III portion of the IMerge study in MDS but it is not enough to support the continuation of the study  Meanwhile  operating expenses are increasing as J J shared half of the imetelstat development costs in the past We expect that the company might face serious difficulties if it is unable to find new avenues for funds like new partnerships or share sale Geron Corporation Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderGeron currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the pharmaceutical sector include Celgene Corporation   NASDAQ CELG   and Genomic Health  Inc    NASDAQ GHDX    While Celgene sports a Zacks Rank  1  Strong Buy   Genomic Health carries a Zacks Rank  2  Buy   You can see  Celgene s earnings estimates have been revised 7 8  upward for 2019 and 4 7  for 2020 over the past 60 days  The stock has rallied almost 33 7  so far this year Genomic Health s earnings estimates have moved north 21 1  for 2019 and 4 5  for 2020 over the past 60 days  The stock has gained 14 1  so far this year Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-07,Zacks Investment Research,https://www.investing.com/analysis/gerons-gern-q4-loss-in-line-revenues-beat-stock-up-200395909,200395909
198320,419836,JNJ,Bayer Submits Application In EU For Prostate Cancer Drug,opinion,Bayer AG  DE BAYGN    OTC BAYRY   submitted a marketing authorization application  MAA  to the European Medicines Agency  EMA  for darolutamide for the treatment of patients with non metastatic castration resistant prostate cancer  nmCRPC   The submission is based on data from the phase III ARAMIS study in men with nmCRPC showing a statistically significant improvement in metastasis free survival  MFS  for darolutamide plus androgen deprivation therapy  ADT   Darolutamide plus ADT has shown a favorable safety profile compared to placebo plus ADT Shares of Bayer have declined 34 3  in the past year against the  s growth of 9 6  In February 2019  Bayer completed the rolling submission of a new drug application  NDA  for darolutamide to the FDA  The company has also submitted an application for marketing authorization to the Ministry of Health  Labor and Welfare  MHLW  in Japan for darolutamide for the treatment of patients with castration resistant prostate cancer  CRPC   Bayer is also in discussions with other health authorities regarding submissions Bayer has been granted Fast Track designation by the FDA for darolutamide in men with nmCRPC  The compound is being developed jointly by Bayer and Orion Corporation  a globally operating Finnish pharmaceutical company  We note that another company  Johnson   Johnson s   NYSE JNJ   Erleada was approved in EU in January 2019 for the treatment of nmCRPC who are at high risk of developing metastatic disease  It is presently marketed in the United States for the same indication  Bayer Aktiengesellschaft Price    Zacks Rank and Other Key PicksBayer currently carries a Zacks Rank  2  Buy  Some other top ranked stocks from the same space are AstraZeneca Plc    NYSE AZN   and BioDelivery Bristol Myers Squibb Company   NYSE BMY    each carrying a Zacks Rank  2  You can see  AstraZeneca s earnings per share estimates have increased from  1 76 to  1 79 for 2019 and from  1 99 to  2 19 for 2020 in the past 90 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 106 40  Bristol Myers  earnings per share estimates have increased from  4 12 to  4 16 for 2019 and from  4 36 to  4 64 for 2020 over the past 90 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 14 26  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year  Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-03-11,Zacks Investment Research,https://www.investing.com/analysis/bayer-submits-application-in-eu-for-prostate-cancer-drug-200396537,200396537
198323,419839,JNJ,Exclusive  Carlyle explores sale or IPO of Ortho Clinical Diagnostics   sources,news,"By Greg Roumeliotis and Carl O Donnell  Reuters    Private equity firm  Carlyle Group   NASDAQ CG  LP is exploring a sale or initial public offering of Ortho Clinical Diagnostics Inc  a U S  diagnostics company that could be valued at more than  7 billion  including debt  people familiar with the matter said  A divestment of Ortho Clinical Diagnostics  which Carlyle acquired from Johnson   Johnson  NYSE JNJ  in 2014 for  4 billion  would show how buyout firms can turn unloved businesses of major corporations into lucrative investments within a few years  Carlyle has hired investment banks to run a sale process for Ortho Clinical  the sources said this week  Carlyle may also pursue an IPO of the company if the offers it receives do not meet valuation expectations  the sources added  The sources asked not to be identified because the deliberations are confidential   Carlyle declined to comment  Ortho Clinical Diagnostics did not respond to a request for comment  Headquartered in Raritan  New Jersey  Ortho Clinical produces in vitro diagnostics equipment and associated assays and reagents  It generates about  1 7 billion in annual revenue and employs about 4 300 people worldwide  according to its website  Ortho Clinical has incurred significant expenses in the last three years to find its footing as a standalone company  These implementation and restructuring costs are expected to taper off by the end of the year  as it severs most of its ties with Johnson   Johnson  according to credit ratings agency Moody s Investors Service Inc  The company sells its products in more than 125 countries  but has potential to grow in emerging markets  according to Moody s  Any deal for Ortho Clinical would likely come in the first half of 2018  making it one of the first major Carlyle portfolio companies to be divested under the leadership of Glenn Youngkin and Kewsong Lee  who are set to become co chief executive officers of Carlyle in January  taking over the reins from founders David Rubenstein  William Conway and Daniel D Aniello  
Carlyle has a long track record of investing in healthcare companies and has been seeking to cash out on some of them this year  In April  Carlyle agreed to sell down part of its 60 percent stake in U S  clinical trials firm Pharmaceutical Product Development LLC at a  9 05 billion corporate valuation ",2017-11-10,Reuters,https://www.investing.com/news/stock-market-news/exclusive-carlyle-explores-sale-or-ipo-of-orthoclinical-diagnostics--sources-841737,841737
198324,419840,JNJ,Loxo selloff  knee jerk  reaction   JMP,news,JMP analyst Michael King says investors  bearish reaction to Loxo Oncology s  LOXO  5 1   collaboration with Bayer  DE BAYGN   which could pay out as much as  1 55B  is misguided since a buyout is still possible  He cites AbbVie s 2015 takeout of Pharmacyclics despite its Imbruvica deal with Johnson   Johnson  NYSE JNJ  as an example Source  BloombergPreviously  Loxo teams up with Bayer to develop TRK inhibitors  shares up 6  premarket  Nov  14 Now read ,2017-11-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/loxo-selloff-knee-jerk-reaction--jmp-857456,857456
198325,419841,JNJ,Genmab earns  25M milestone from Janssen s first Darzalex sale in Japan,news,Johnson   Johnson  JNJ  0 1   unit Janssen Biotech has booked the first commercial sale of multiple myeloma med DARZALEX  daratumumab  in Japan  approved in September The sale triggers a  25M milestone payment to licensor Genmab A S  OTCPK GNMSF  0 8   Genmab updates its 2017 guidance  MDKK   Revenue  2 110   2 310 from 1 950   2 150  Operating income  1 060   1 260 from 900   1 100 The companies inked a global license and development deal for daratumumab in August 2012 Previously  Janssen files Darzalex marketing application in Japan for multiple myeloma   10M milestone due Genmab  Dec  20  2016 Now read ,2017-11-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/genmab-earns-25m-milestone-from-janssens-first-darzalex-sale-in-japan-860080,860080
198326,419842,JNJ,Johnson   Johnson wins California lawsuit claiming asbestos in talc caused cancer,news,"By Nate Raymond  Reuters    A California jury on Thursday ruled in favor of Johnson   Johnson  NYSE JNJ  in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company s talc based products including J J s Baby Powder  The Los Angeles Superior Court jury s verdict came in the first trial centering on claims that J J s talc products contained asbestos  J J is separately battling thousands of cases claiming those products can also cause ovarian cancer  The verdict came in a lawsuit by Tina Herford  who said she developed mesothelioma after using J J talcum powder products that her lawyers claimed contained asbestos  Reuters watched the verdict through an online broadcast by Courtroom View Network  The jury also found in favor of talc supplier Imerys Talc  J J in a statement welcomed the verdict  J J said it believed that setbacks dealt to individuals pursuing ovarian cancer cases had  forced plaintiff attorneys to pivot to yet another baseless theory    Johnson s Baby Powder has been around since 1894 and it does not contain asbestos or cause mesothelioma or ovarian cancer   J J said  Chris Panatier  Herford s lawyer  in an email cautioned against reading too much into a single verdict   It is a matter of time before juries begin holding them to account   he said  The verdict came as a federal jury  separately  ordered J J to pay  247 million to six patients who said they were injured by defective Pinnacle hip implants  Mesothelioma is a deadly form of cancer closely associated with exposure to asbestos  It affects the delicate tissue that lines body cavities  most often around the lungs  but also in the abdomen and elsewhere   Herford s lawyers contended that internal J J documents showed the New Jersey based company for decades was aware of the presence of asbestos in the talc that was used in its products but kept selling them anyway  J J faces lawsuits by around 5 500 plaintiffs nationally asserting talc related claims  largely based on claims it failed to warn women about the risk of developing ovarian cancer from the products  In five trials in Missouri involving ovarian cancer lawsuits  juries found J J liable four times and awarded the plaintiffs  307 million  In California  a jury awarded a now deceased woman  417 million  But in October  J J scored major victories when a Missouri appellate court threw out the first verdict there for  72 million and a California judge tossed the  417 million verdict  
The case is Herford et al v  AT T  NYSE T  Corp et al  Los Angeles Superior Court  No  BC646315 ",2017-11-16,Reuters,https://www.investing.com/news/stock-market-news/johnson--johnson-wins-california-lawsuit-claiming-asbestos-in-talc-caused-cancer-873910,873910
198327,419843,JNJ,Perrigo  PRGO  Q4 Earnings Miss  Sales Beat  Stock Down,opinion,Perrigo Company plc   NYSE PRGO   reported fourth quarter 2018 adjusted earnings of 97 cents per share  which missed the Zacks Consensus Estimate of 98 cents  The bottom line also decreased 24 2  year over year Net sales declined 6 9  year over year to  1 2 billion but outpaced the Zacks Consensus Estimate of  1 18 billion  The year over year decline was mainly due to lower sales volume in the Prescription segment  Sales of  51 million from new products were partially offset by a loss of  16 million in sales of from discontinued products Shares of Perrigo were down 4 6  in pre market trading on Feb 28  possibly due to lowered earnings and revenue guidance for 2018  Also  the stock has declined 40 8  in a year s time Segment DiscussionPerrigo reports under three segments  Consumer Health Care Americas   CHCA    Consumer Healthcare International   CHCI   and Prescription Pharmaceuticals   RX   CHCA   CHCA net sales in the fourth quarter of 2018 came in at  617 million  down 4 1  year over year  Strong performance of smoking cessation and analgesics was more than offset by lower net sales in the animal health business and nutrition categories  The new product sales of  10 million were completely offset by the lost sales from discontinued products  Excluding animal health category  sales decreased 1 9  organically CHCI  CHCI segment reported net sales of  356 million  down 4 9  from the year ago period  On a constant currency basis  the metric decreased 0 5   Excluding the sales of  2 million from the exited Russian and unprofitable distribution businesses in 2017 and unfavorable foreign currency movements of  10 million  net sales remained almost flat   Net sales of diagnostics and analgesics categories and new product sales of  10 million were mostly offset by lower sales in lifestyle and cough cold category  The company lost sales of  2 million from discontinued products RX   This segment s net sales declined 14 9  to  222 million on a reported basis as well as on a constant currency basis  The downside can be attributed to several industry based factors including pricing pressure and supply constraints for few products While new product sales of  22 million contributed to the top line  the company lost sales of  4 million from discontinued products 2018 ResultsPerrigo recorded full year sales of  4 7 billion  down 4 3  on a year over year basis  The reported figure included new product sales of  170 million  partially offset by discontinued products of  66 million  Currency movements resulted in a loss of  34 million in sales  The company s adjusted loss for the period was  4 55 per share  lower than the year ago loss of  4 93 per share The company has announced that it will provide an update on portfolio reconfiguration and cost savings plans among others as well as its guidance for 2019 at the Investor Day presentation to be held on May 9  2019 Our TakePerrigo s revenues and margins have been under pressure in 2018 mainly due to the challenges faced by its Rx segment  This is likely to continue in 2019  However  the company s plan to divest the Rx segment will help it to better capitalize on differentiated generic pharmaceutical products and focus on expanding its leading consumer business  Perrigo also expects sales to increase in 2019 at its CHCI segment Meanwhile  the company is focusing on switching of prescription drugs to over the counter   OTC   brands and expanding store brand solution to drive growth at the Consumer Healthcare Americas segment  In the second half of 2018  the company received the FDA approval for a stored brand OTC equivalent of Johnson   Johnson s   NYSE JNJ   multi symptom relief drug  Imodium  and also entered into an agreement with Merck   NYSE MRK   to gain exclusive rights to the OTC version of the latter s allergy drug   Nasonex nasal spray These apart  the Irish High Court has granted a leave to Perrigo for judicial review of the   The company has already appealed against the tax assessment before the Tax Appeals Commission  which has been stayed till judicial review is resolved  A win for the company will save almost  1 9 billion Zacks Rank   Stock to ConsiderPerrigo currently carries a Zacks Rank  4  Sell  Celgene Corporation   NASDAQ CELG   is a better ranked stock in the biotech sector  sporting a Zacks Rank  1  Strong Buy   You can see  Celgene s earnings estimates have been revised 5 3  upward for 2019 and 9 2  for 2020 over the past 60 days  The stock has rallied almost 42  so far this year  In a year s time  shares of the company have gained 42  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-27,Zacks Investment Research,https://www.investing.com/analysis/perrigo-prgo-q4-earnings-miss-sales-beat-stock-down-200393530,200393530
198328,419844,JNJ,Pharma Stock Roundup  Roche To Buy ONCE  Lawmakers Grill CEOs Over High Drug Prices,opinion,"The drug price battle took center stage this week as executives from several big pharma companies including Pfizer   NYSE PFE    Sanofi   NASDAQ SNY    J J   NYSE JNJ    AbbVie   NYSE ABBV   and others were grilled by senators regarding high drug prices  Senators emphasized that the United States has some of the highest drug prices in the world and the companies need to make changes in drug pricing before the government imposes regulations  They blamed the American patent system for the high prices of drugs as it gives these companies a lot of monopoly protection  In other news  Roche   OTC RHHBY   announced a definitive agreement to buy gene therapy company Spark Therapeutics  Inc    NASDAQ ONCE   for approximately  4 3 billion while Bristol Myers   NYSE BMY    Celgene s  74 billion merger deal ran into trouble Recap of the Week s Most Important HeadlinesRoche s Acquisition of Spark Therapeutics for  4 3B  Roche announced a  Philadelphia  PA based gene therapy company Spark Therapeutics in an all cash deal for  114 50 per share  at a significant premium of 122   The total deal value stands at approximately  4 3 billion  Spark Therapeutics has one marketed gene therapy  Luxturna  approved for the treatment of a rare genetic retinal disease that causes blindness Spark Therapeutics is developing gene therapies for other genetic diseases  including SPK 8011  for haemophilia A  which is expected to enter late stage development in 2019 and SPK 9001 for haemophilia B  which is already in later stage development  The deal will build Roche s haemophilia portfolio that includes Hemlibra  approved for haemophilia A Roche also gained FDA approval for Herceptin Hylecta   a subcutaneous formulation of Herceptin   for the treatment of certain HER2 positive breast cancers  Herceptin Hylecta is a combination of Roche s Herceptin  trastuzumab  and Halozyme Therapeutics  Enhanz drug delivery technology Bristol Myers Celgene Merger Deal Faces Shareholder Opposition  Activist investors  Starboard and Wellington Management voiced their opposition to Bristol Myers  proposed acquisition of Celgene  NASDAQ CELG  for  74 billion  Starboard criticized Bristol Myers management team as the company s stock has performed poorly over the years  The activist investors feel the deal is too risky and expensive and Bristol Myers should instead consider selling itself   The transaction is expected to close in the third quarter of 2019 AbbVie Signs Parkinson s Disease Deal with Voyager   AbbVie announced  Therapeutics to develop potential vectorized antibodies to target a protein called alpha synuclein  which has been linked to Parkinson s disease  PD   Voyager is entitled to receive  65 million upfront from AbbVie and up to  245 million in preclinical and phase I option payments  Meanwhile  Voyager will also be entitled to potential development  regulatory  and commercial milestone payments of up to  728 million and royalties on future sales Novartis In Licenses Rights to TQJ230  Novartis exercised its  and commercialization rights to investigational  RNA targeting candidate TQJ230 from Ionis Pharmaceuticals  TQJ230 is being developed to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein a   Lp a      a lipoprotein that travels through the blood  Novartis is now solely responsible for the global development and commercialization of TQJ230  which was until now being co developed with Ionis  subsidiary  Akcea AstraZeneca Merck s Lynparza Meets Endpoint in Pancreatic Cancer Study  AstraZeneca and Merck s PARP inhibitor  in a late stage study  evaluating it as first line maintenance treatment in germline BRCA mutated metastatic pancreatic cancer  Data from the POLO study showed that treatment with Lynparza led to a statistically significant and clinically meaningful improvement in the primary endpoint of progression free survival  Lynparza is presently approved for multiple indications in advanced ovarian cancer and metastatic breast cancer  It became the first PARP inhibitor to show positive data in a study in germline BRCA mutated metastatic pancreatic cancer AstraZeneca s phase III THEMIS study on Brilinta met the primary endpoint showing that the blood thinner plus aspirin led to a statistically significant reduction in cardiovascular events in patients with type II diabetes with coronary artery disease  CAD  who have not experienced any prior heart attack or stroke Meanwhile  FDA approved label expansions of AstraZeneca s medicines  Farxiga and Xigduo XR  Farxiga metformin HCl extended release  for patients with type II diabetes and moderate renal impairment FDA Approves Expanded Label for Sanofi s Soliqua   The FDA also approved an expanded indication for Sanofi s once daily single pre filled injection for type II diabetes  Soliqua  While Soliqua was previously approved as an add on to diet and exercise in type II diabetes patients who are uncontrolled on long acting insulin or lixisenatide  it is now approved for patients uncontrolled on oral antidiabetic medicines  Soliqua is a combination of Lantus  basal insulin glargine 100 Units mL  and GLP 1 receptor agonist  Lyxumia Bayer  DE BAYGN  Earnings Decline  Revenues Rise in Q4  Bayer AG s fourth quarter 2018 year over year while revenues rose 28 7   in euros  The Crop Science and Pharmaceuticals divisions registered higher sales year on year while sales of Consumer Health unit declined year over year  In 2019  Bayer expects sales to be more than  46 billion  corresponding to an increase of about 4  on a currency  and portfolio adjusted basis  Core earnings per share are expected to rise to about  6 80 on a currency adjusted basis The NYSE ARCA Pharmaceutical Index rose 1 4  in the last five trading sessions  Large Cap Pharmaceuticals Industry 5YR   Return
  
Here is how the seven major stocks performed in the last five trading sessions  In the last five trading sessions  all the stocks were in the green except Glaxo  which declined 0 2   AstraZeneca recorded the highest gain of 4 8  In the past six months  Lilly has been the biggest gainer  18 9   while Bristol Myers declined the most  15 9    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for pipeline and regulatory updates next week This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-02-28,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-roche-to-buy-once-lawmakers-grill-ceos-over-high-drug-prices-200393948,200393948
198329,419845,JNJ,Pacira  PCRX  Q4 Earnings And Revenues Surpass Estimates,opinion,Pacira Pharmaceuticals  Inc    NASDAQ PCRX   delivered fourth quarter 2018 earnings of 47 cents per share  surpassing the Zacks Consensus Estimate of 25 cents and also the year ago bottom line of 38 cents Revenues increased 20  year over year to  95 1 million  beating the Zacks Consensus Estimate of  94 4 million as well as the year earlier number of  79 1 million  Exparel sales came in at  94 4 million for the fourth quarter of 2018  rising 20  year over year  Exparel sales rose 14 8  sequentially Shares of Pacira were up almost 3 8  following its earnings release on Feb 28  2018  However  the stock has dipped 2  so far this year against the  increase of 15  Quarter in DetailPacira s top line comprises product revenues  other product sales plus royalty revenues  Royalty revenues came in at  0 4 million in the reported quarter  up 77 8  year over year Research and development  R D  expenses  excluding stock based compensation  surged 47 7  to  13 million Selling  general and administrative  SG A  expenses  excluding stock based compensation  increased 16 2  to  38 7 million in the reported quarter Full Year ResultsFor the full year  Pacira generated revenues of  337 3 million  reflecting an increase of 18  on a year over year basis  Exparel sales were  331 1 million in 2018  up 17  year over year Recent DevelopmentsLast January  Pacira announced that its phase IV study on Exparel  which evaluated patients undergoing Cesarean section  C section   met the primary endpoint with a statistically significant decrease in total postsurgical opioid consumption all through 72 hours  The drug also achieved a statistical importance for pain reduction Notably  last December  Pacira announced new data regarding the use of Exparel as an incorporating transversus abdominis plane  TAP  block to manage postsurgical pain following cesarean section  C section  procedures  This new finding showed that patients  who received Exparel experienced a substantial reduction in opioid consumption and pain intensity plus significantly improved discharge  and postanesthesia care unit  PACU  ready times  functional recovery as well as lowered the length of stay  LOS  Additionally  Pacira released new results last November on the use of Exparel following total knee arthroplasty  TKA   The latest findings proved that patients  administered with Exparel saw a considerable reduction in opioid use  their hospital length of stay  LOS  and the total hospitalization costs compared with TKA patients  who did not resort to Exparel regime We would like to remind investors that Pacira has partnership with Johnson   Johnson   NYSE JNJ    On fourth quarter conference call  the company stated that J J continues to support the uptake of Exparel via the latter s world class educational programs and orthopedic procedural solutions for Pacira Pacira is also developing Exparel for its use in pain management pertaining to various other surgeries and is also expanding its label to address complications in pediatric patient population 2019 OutlookPacira raised its guidance for Exparel sales in 2019 and expects the same in the  400  410 million range  The previous view was in the band of  325  330 million The company s R D expenses  excluding stock based compensation  might be within  60  70 million while SG A expenses  excluding stock based compensation  are anticipated in the  165  175 million range  Both are increased from the last reported quarter s projection levels Pacira Pharmaceuticals  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stocks to ConsiderPacira currently carries a Zacks Rank  3  Hold   Better ranked stocks in the same sector include Taro Pharmaceutical Industries Ltd    NYSE TARO   and Corbus Pharmaceuticals Holdings  Inc    NASDAQ CRBP    both sporting a Zacks Rank  1  Strong Buy   You can see  Taro Pharmaceutical s earnings estimates have been revised 7 7  upward for 2019 over the past 60 days  The stock has rallied 23 4  so far this year Corbus Pharmaceuticals  loss per share estimates have been narrowed 8 2  for 2019 over the past 60 days  The stock has gained 7 9  so far this year Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-03-03,Zacks Investment Research,https://www.investing.com/analysis/pacira-pcrx-q4-earnings-and-revenues-surpass-estimates-200394402,200394402
198330,419846,JNJ,The Zacks Analyst Blog Highlights  Facebook  Johnson   Johnson  JPMorgan  Sun Life And Evergy,opinion,For Immediate ReleaseChicago  IL  March 4  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Facebook   NASDAQ FB    Johnson   Johnson   NYSE JNJ    JPMorgan   NYSE JPM    Sun Life Financial   TO SLF   and Evergy Inc    NYSE EVRG   Here are highlights from Friday s Analyst Blog Top Stock Reports for Facebook  J J and JPMorganThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Facebook  Johnson   Johnson and JPMorgan  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Buy rankedFacebook s shares have gained  23 2  year to date  outperforming the S P 500 s increase of  11 1  during the same period  The Zacks analyst thinks Facebook will benefit from solid mobile ad revenues driven by robust performance of Instagram Stories and an expanding user base in 2019 Further  the company s plan to introduce commerce in Instagram is expected to be a major growth driver  The growing appeal of the company s Workplace platform  which now has two million paid users  is another key catalyst  Additionally  the company s plan to integrate messaging apps   WhatsApp  Instagram  and Messenger   will boost user experience by making the services more secure through end to end encryption However  continued mix shift toward Stories is expected to hurt ARPU  Further  increasing regulatory headwinds is a concern  Facebook is also likely to face record fines from Federal Trade Commission  FTC  over security failures including the Cambridge Analytica scandal  You can   Shares of Johnson   Johnson have gained  7 4  in the past year  outperforming the S P 500 s increase of  4  over the same period  J J s sales growth accelerated in 2018 backed by above market sales growth in the Pharmaceutical segment and improving performance in Medical Devices unit J J s guidance for 2019 sales growth was below expectations due to Pharma generic biosimilar headwinds  which will hurt sales by  3 billion  The Zacks analyst thinks J J sales and earnings growth will accelerate in 2020 supported by drug launches  successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug  Stelara  J J is also making rapid progress with its pipeline and line extensions  Meanwhile  share buybacks and restructuring initiatives should provide bottom line support Headwinds like biosimilar generic competition and pricing pressure remain  Allegations that its talc products contain asbestos  which causes users to develop ovarian cancer  have been an overhang on the stock price  You can   JPMorgan s shares have underperformed the S P 500 over the past six months   9 4  vs   3 9    However  JPMorgan has an impressive earnings surprise history  having surpassed expectations in three of the trailing four quarters The Zacks analyst thinks expansion into new markets by opening branches  focus on strengthening credit card business  higher rates and improving loan balance will continue supporting its profitability  Management targets to achieve return on tangible equity of 17  over the medium term  Further  the company s enhanced capital deployment actions reflect strong liquidity position However  dismal mortgage banking performance  owing to lower origination volume and refinancing activities  remains a major concern  The company s significant dependence on capital markets revenues is another cause for worry  These are expected to hurt the bank s fee income growth to an extent  You can   Other noteworthy reports we are featuring today include Sun Life Financial and Evergy Inc This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-03-03,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-facebook-johnson--johnson-jpmorgan-sun-life-and-evergy-200394400,200394400
198337,419853,JNJ,AbbVie s risankizumab beats Humira and Stelara in late stage psoriasis studies  investors unmoved  shares down 5 ,news,Results from three Phase 3 clinical trials showed AbbVie s  ABBV  4 9   IL 23 inhibitor risankizumab to be more effective than HUMIRA  adalimumab  and J J s  NYSE JNJ  STELARA  ustekinumab  in patients with moderate to severe plaque psoriasis All three trials met the co primary endpoints of at least a 90  improvement in symptoms  PASI 90  and a score of clear almost clear as measured by a scale called sPGA at week 16 compared to placebo or HUMIRA At one year  56  and 60  of patients treated with risankizumab achieved total skin clearance  PASI 100  compared to 21  and 30  for STELARA Development is ongoing Now read ,2017-10-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/abbvies-risankizumab-beats-humira-and-stelara-in-latestage-psoriasis-studies-investors-unmoved-shares-down-5-548461,548461
198338,419854,JNJ,Johnson   Johnson s Stelara successful in mid stage lupus study,news,Johnson   Johnson  NYSE JNJ  unit Janssen Research   Development LLC announces positive results from a Phase 2 clinical trial assessing STELARA  ustekinumab  in patients with active systemic lupus erythematosus  SLE   The data are being presented at the 2017 ACR ARHP Annual Meeting in San Diego  CA The study med the primary endpoint of demonstrating a statistically significantly higher proportion of patients in the treatment group experiencing improvements in lupus disease activity at week 24 compared to placebo  60  vs  31   p 0 0046  The company plans to advance development into Phase 3 Lupus is a chronic inflammatory autoimmune disorder that can affect a range of organs and body systems Ustekinumab  an IL 12 and IL 23 antagonist  is currently approved in the U S  to treat plaque psoriasis  psoriatic arthritis and Crohn s disease Now read ,2017-11-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/johnson--johnsons-stelara-successful-in-midstage-lupus-study-764452,764452
198339,419855,JNJ,Johnson   Johnson to advance Tremfya into Phase 3 for psoriatic arthritis,news,Longer term results from a Phase 2 clinical trial evaluating Johnson   Johnson s  NYSE JNJ  TREMFYA  guselkumab  for the treatment of active psoriatic arthritis  PA  showed more that 70  of treated patients achieved at least a 20  improvement  ACR 20  in symptoms at week 56  The data were presented at the ACR ARHP Annual Meeting in San Diego Initial results showed 58  of treated patients achieved ACR 20 at week 24 compared to 18 4  for placebo  p 0 001   the primary endpoint The company has launched two Phase 3 trials  DISCOVER 1  patients with active PA who may have been previously treated with anti tumor necrosis factor alpha therapies  and DISCOVER 2  biologic therapy naive patients  Previously  FDA OKs J J s guselkumab for plaque psoriasis  July 13 Now read ,2017-11-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/johnson--johnson-to-advance-tremfya-into-phase-3-for-psoriatic-arthritis-839490,839490
198340,419856,JNJ,Johnson   Johnson  JNJ  Outpaces Stock Market Gains  What You Should Know,opinion,"Johnson   Johnson  NYSE JNJ  closed at  136 35 in the latest trading session  marking a  0 49  move from the prior day  The stock outpaced the S P 500 s daily gain of 0 18   At the same time  the Dow added 0 24   and the tech heavy Nasdaq gained 0 03  
Coming into today  shares of the world s biggest maker of health care products had gained 5 35  in the past month  In that same time  the Medical sector gained 3   while the S P 500 gained 4 28  
JNJ will be looking to display strength as it nears its next earnings release  On that day  JNJ is projected to report earnings of  2 09 per share  which would represent year over year growth of 1 46   Our most recent consensus estimate is calling for quarterly revenue of  19 67 billion  down 1 67  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  8 57 per share and revenue of  81 23 billion  which would represent changes of  4 77  and  0 43   respectively  from the prior year 
Investors might also notice recent changes to analyst estimates for JNJ  Recent revisions tend to reflect the latest near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 75  lower within the past month  JNJ is currently sporting a Zacks Rank of  3  Hold  
Investors should also note JNJ s current valuation metrics  including its Forward P E ratio of 15 83  Its industry sports an average Forward P E of 15 28  so we one might conclude that JNJ is trading at a premium comparatively 
Meanwhile  JNJ s PEG ratio is currently 2 17  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 07 at yesterday s closing price 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 172  putting it in the bottom 33  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-02-20,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-outpaces-stock-market-gains-what-you-should-know-200390438,200390438
198341,419857,JNJ,Why Is Johnson   Johnson  JNJ  Up 5 9  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Johnson   Johnson  NYSE JNJ   Shares have added about 5 9  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Johnson   Johnson due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  J J Q4 Earnings Beat  Issues 2019 OutlookJ J s fourth quarter 2018 earnings came in at  1 97 per share  which beat the Zacks Consensus Estimate of  1 95 and increased 13 2  from the year ago period driven by higher revenues and lower tax rate Adjusted earnings excluded after tax intangible amortization expense and some special items  Including these items  J J reported fourth quarter earnings of  1 12 per share against loss of  3 99 per share in the year ago quarter Sales came in at  20 39 billion  beating the Zacks Consensus Estimate of  20 1 billion  Sales increased 1  from the year ago quarter  reflecting an operational increase of 3 3  and an unfavorable currency impact of 2 3  Organically  excluding the impact of acquisitions and divestitures  sales increased 5 3  on an operational basis  less than 6 1  increase seen in the previous quarter  Continued above market growth in the Pharmaceutical segment and continued improvement in Medical Devices unit offset a softer performance in the Consumer unit Fourth quarter sales grew 1 5  in the domestic market to  10 63 billion and 0 4  in international markets to  9 77 billion  reflecting 5 1  operational growth and 4 7  negative currency impact Segment DetailsJ J s Pharma segment continued to perform well despite the impact of biosimilars on Remicade sales Pharmaceutical segment sales rose 5 3  year over year to  10 19 billion  reflecting 7 2  operational growth and 1 9  negative currency impact as sales rose in both domestic and international markets  Sales in the domestic market rose 2 8  to  5 94 billion  International sales grew 8 9  to  4 25 billion  operational increase of 13 7    Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 7 2   less than 8 2  in the previous quarter primarily due to lower sales of Zytiga and Xarelto The strong performance was led by the company s oncology portfolio  Worldwide sales of J J s cancer drugs rose 22 1  in the quarter J J s cancer drugs like Imbruvica and Darzalex continued to perform well  Core products like Stelara and Invega Sustenna also contributed to growth  However  sales of some other key drugs like Simponi Simponi Aria and Xarelto declined in the quarter  Sales of Zytiga slowed down significantly from the previous quarter due to the impact of generic competition in the United States Imbruvica sales rose 34 7  to  703 million in the quarter driven by market share gains and strong market growth across multiple indications in the United States and strong uptake in the European and Asia Pacific markets Darzalex sales rose 57 4  to  584 million in the quarter  In United States  market growth and market share gains drove sales  In outside U S  markets  increased penetration and share gains drove sales growth Stelara sales rose 33 6  to  1 44 billion in the quarter  Stelara witnessed strong uptake in its new indication for Crohn s disease  experiencing share gains in the quarter  Invega Sustenna sales rose 10 1  to  763 million in the quarter Zytiga sales rose 4 1  to  786 million in the quarter as growth outside the United States was offset by sales decline in the United States due to generic competition Simponi Simponi Aria sales declined 1 6  to  482 million in the quarter  Sales of Procrit Eprex declined 4 7  to  221 million in the quarter In the quarter  J J recorded pulmonary arterial hypertension  PAH  revenues of  667 million  up 9 3  year over year  Strong demand for Uptravi and Opsumit supported by share gains and overall market growth was partially offset by decline in Tracleer due to increased use of Opsumit as well as generic competition in Europe Sales of Invokana Invokamet declined 14 6  to  228 million due to higher managed care discounting and market share decline due to competitive pressure Xarelto sales declined 14 4  in the quarter to  608 million as prescription growth was offset by increased discounts and rebates  The October FDA approval of Xarelto for a new 2 5 milligram vascular dose for the CAD PAD indication significantly expands the drug s eligible patient population  which can improve sales of the drug in the future quarters  Regarding this label expansion  management said on the call that the initial customer response has been positive Sales of Remicade were down 15 6  in the quarter to  1 24 billion due to increased discounts and share loss to biosimilars   While U S  sales declined 21 4   U S  exports went down 21 7   Remicade sales rose 9 7  in international markets Regarding newly launched Tremfya  J J said that the product is seeing strong demand trends with more than 28 000 patients now on therapy and the drug capturing 6 6  share of the psoriasis market in the United States which is up almost 1 point from the previous quarter  Tremfya recorded sales of  175 million in the quarter compared with  171 million in the third quarter Medical Devices segment sales came in at  6 67 billion  down 4 4  from the year ago period  It included an operational decrease of 2 2  and a negative currency movement of 2 2  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 3 3   better than 2 9  in the previous quarter Operational growth was driven by continued strong performance in Interventional Solutions  Advanced Surgery  General Surgery and Vision  which partially offset a decline in the orthopedics portfolio Domestic market sales declined 3  year over year to  3 2 billion  International market sales decreased 5 6   operational decrease of 1 4   year over year to  3 45 billion The Consumer segment recorded revenues of  3 54 billion in the reported quarter  almost flat year over year  Moreover  on an operational basis  Consumer segment sales increased 3 3   which was offset by unfavorable foreign currency movement of 3 4  Excluding the impact of acquisitions and divestitures  adjusted operational sales growth was 3 8  worldwide  a significant deceleration from 6 1  the previous quarter Growth in beauty  oral care and over the counter products was offset by lower baby care sales in the United States despite the baby care brand re launch Sales in the domestic market rose 7 3  from the year ago period to  1 48 billion  Meanwhile  the international segment recorded a decline of 4 8  to  2 06 billion  The operational increase of 0 8  was offset by negative currency impact of 5 6  in the quarter 2018 ResultsFull year 2018 sales rose 6 7  to  81 58 billion  beating the Zacks Consensus Estimate of  81 36 billion and came ahead of the guided range of  81 to  81 4 billionAdjusted earnings for 2018 were  8 18 per share  exceeding the Zacks Consensus Estimate of  8 16 and up 12 1  year over year  Earnings were at the higher end of the guided range of  8 13    8 18 per share 2019 OutlookJ J s guidance for 2019 sales growth was below expectations J J expects 2019 adjusted earnings per share in the range of  8 50    8 65  The guidance range reflects an operational constant currency growth rate between 5 7  and 7 6  Revenues are expected in the range of  80 4 to  81 2 billion  including currency impact  Currency fluctuations are expected to unfavorably impact sales by approximately 1 5  with Fix headwinds being more pronounced in the first half Operational constant currency sales growth is expected to be in the range of 0  to 1   Acquisitions and divestitures are expected to hurt sales growth by about 2  Adjusted operational sales growth   excluding FX  acquisitions divestitures  is expected to be in the range of 2  to 3   which marks a deceleration from 5 5  in 2018 In 2019  J J expects that the Pharmaceutical unit will deliver growth despite significant impacts from biosimilar and generic competition for some of its drugs In Pharmaceuticals  management is optimistic that key drugs like Darzalex  Imbruvica and Stelara should witness continued uptake and line extensions and new drugs like Erleada and Tremfya should perform well  However  continued biosimilar competition for Remicade and Procrit and generic competition for Velcade  Tracleer and Zytiga in the U S  will hurt revenues by  3 billion in 2019  Other than that  pricing pressure will continue to hurt sales While the Consumer unit will grow slightly above the market in 2019 supported by innovation and improved go to market models  the Medical Devices segment is expected to continue to improve driven by improved execution and new product introductions Adjusted pre tax operating margin is expected to improve slightly in 2019 Adjusted tax rate is guided in the range of 17   18  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
Currently  Johnson   Johnson has an average Growth Score of C  though it is lagging a bit on the Momentum Score front with a D  However  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending upward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Johnson   Johnson has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-02-20,Zacks Investment Research,https://www.investing.com/analysis/why-is-johnson--johnson-jnj-up-59-since-last-earnings-report-200390746,200390746
198342,419858,JNJ,Why Is AbbVie  ABBV  Down 6 8  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for AbbVie  ABBV   Shares have lost about 6 8  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is AbbVie due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  AbbVie Q4 Earnings   Sales Miss  Humira Ex U S  Sales DeclineFourth quarter 2018 earnings of  1 90 per share missed the Zacks Consensus Estimate of  1 92  Earnings rose 28 4  year over year driven by higher sales  share repurchases and lower tax  Earnings per share were within the guided range of  1 89 and  1 91 In the quarter  AbbVie recorded an impairment charge of  2 75 per share on assets from the 2016 acquisition of Stemcentrx due to recent Rova T clinical setbacks  Including this charge  loss per share was  1 23 per share against earnings per share of 3 cents in the year ago quarter Revenues of  8 31 billion missed the Zacks Consensus Estimate of  8 36 billion  Sales rose 7 3  on a reported basis  Excluding a 1  unfavorable impact from foreign exchange rate fluctuations  operational revenues rose 8 3  backed by higher sales of Humira in U S  market and its hematological oncology products  Imbruvica and Venclexta  Operational revenue growth was better than the expectation of approximately 7  Quarter in DetailsHumira sales rose 0 5   1 4  on an operational basis  to  4 9 billion Sales in the United States increased 9 1  to  3 6 billion driven by strong prescription volume growth and favorable pricing  Humira sales in the ex U S  markets were down 14 8  on an operational basis and 17 5  on reported basis to  4 92 billion International sales were severely impacted by the launch of several direct biosimilar drugs in Europe and other international markets  On the call  the company said that biosimilar competitors are giving more aggressive discounts than AbbVie anticipated  which severely hurt international sales In the U S  market  Humira sales are expected to rise approximately 7  in 2019  which is less than growth of 10  in 2018 due to lighter price contribution for the year  In 2019  international Humira sales are expected to decline approximately 30  on an operational basis  a sharper decline that previous expectation of a range of 26 27  AbbVie s oncology hematology  including Imbruvica and Venclexta  sales rose 50 2  to  1 13 billion in the quarter  Fourth quarter net revenues from Imbruvica were  1 billion  up 42  year over year  U S  sales of Imbruvica grossed  839 million  up 43 2  from the year ago figure primarily driven by continued uptake in the frontline CLL segment  AbbVie logged  167 million of international profit sharing with J J  NYSE JNJ   up 36 4  year over year Venclexta brought in revenues of  124 million  up more than 100  year over year driven by uptake in the second line plus setting following approval in the broad relapsed refractory CLL segment  MURANO study  in June In 2019  Imbruvica global revenues are expected to approach  4 4 billion with sales in the United States growing approximately 21   Venclexta sales are expected to be approximately  725 million  Total global oncology hematology sales are expected to be approximately  5 1 billion HCV products  including Viekira and Mavyret  recorded sales of  862 million  up 69 3  year over year  on the back of strong demand for Mavyret  which was launched in the second half of 2017 Mavyret alone accounted for  819 million in the quarter  up more than 100  year over year driven by rapid uptake  On the call  the company said that Mavyret continue to command roughly 50  market share globally In 2019  global HCV sales are expected to be higher than  3 3 billion with roughly flat performance in the United States and international sales of approximately  1 7 billion Other products that performed well include Lupron   236 million  up 5 3  year over year   Creon   261 million  up 11 4    Duodopa   113 million  up 14   and Synthroid   209 million  up 2    Sales of Synagis  AndroGel  Sevoflurane and Kaletra declined in the quarter Regarding  newly launched Orilissa  AbbVie said the early launch was impressive with demand expected to ramp up given recent increased formulary access  which stands at approximately 70   Orilissa sales are expected to be approximately  200 million in 2019 Margins RiseAdjusted gross margin rose 80 bps to 79 8  in the quarter  Adjusted SG A expenses increased 9 2  to  1 8 billion  As a percentage of sales  SG A expenses rose 30 bps to 21 6  in the quarter  R D expenses rose 3 1  to  1 37 billion in the quarter due to greater investments in the pipeline  Adjusted operating margin was 41 7  of sales in the reported quarter  up 100 bps year over year Both gross and operating margins declined sequentially in the quarter 2018 ResultsEarnings per share were  7 91 for full year 2018  up 41 3  year over year and within the guided range of  7 90  7 92 Full year 2018 revenues were  32 73 billion  up 16  year over year  Revenues were in line with management s expectation of approaching  32 7 billion  Revenues were up 15 2  on an operational basis  in line with expectations 2019 GuidanceAbbVie expects adjusted EPS to be in the range of  8 65  8 75 for 2019  The earnings guidance indicates a year over year increase of 10  at the mid point Revenues are expected to grow approximately 1  on an operational basis in 2019  Currency headwinds are expected to hurt 2019 revenues by less than 1  In 2019  AbbVie expects roughly  2 billion of erosion related to international biosimilar competition to Humira  In addition  it expects a  400 million headwind from generic competition to AndroGel in 2019  Also  costs to support expected launches of five new products and line extensions should put pressure on margins  However  these new products will be at early stages of their launch trajectory in 2019 and will not be a significant offset to international biosimilar impact  However  AbbVie believes the products will grow over the next few years and provide significant offset to the 2023 U S  biosimilar event In 2019  AbbVie believes that the loss of international Humira revenues will be made up for by U S  Humira and hematological oncology franchise growth Adjusted gross margin is expected to be above 82 5  of sales in 2019  While  R D is expected to be approximately 15 5  of sales  SG A is expected to be approximately 20 5  of salesOperating margin is expected to be just above 46 5   an increase of roughly 200 basis points year over year On the fourth quarter call  the company said it is not contemplating any large M A deal First Quarter 2019 OutlookFirst quarter earnings are expected between  2 05 and  2 07 per share  Revenues are estimated to be approximately  7 7 billion  Foreign exchange is expected to have approximately 2  unfavorable impact on sales in the quarter While U S  Humira sales are expected to be approximately  3 2 billion  international Humira sales are expected to be approximately  1 2 billion  Imbruvica is expected to record sales of approximately  1 billion While adjusted gross margin ratio is expected to be in line with full year guidance of 82 5   costs are expected to be higher in the first quarter relative to the full year due to the timing of the spending 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates flatlined during the past month 
VGM Scores
Currently  AbbVie has a great Growth Score of A  though it is lagging a lot on the Momentum Score front with a D  However  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
AbbVie has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-02-23,Zacks Investment Research,https://www.investing.com/analysis/why-is-abbvie-abbv-down-68-since-last-earnings-report-200391916,200391916
198343,419859,JNJ,AbbVie Extends Deal With Voyager To Make Parkinson s Drugs ,opinion,AbbVie  Inc    NYSE ABBV   announced an expansion of its global strategic collaboration and option agreement with small biotech Voyager Therapeutics  Inc    NASDAQ VYGR   to develop potential gene therapies for Parkinson s disease  PD  and other synucleinopathies Per the deal  Voyager will develop vectorized antibodies targeting pathological species of alpha synuclein  An abnormal accumulation of misfolded alpha synuclein protein eventually leads to the formation of protein deposits and progressive neurodegeneration in patients with PD and other synucleinopathies Per the deal  Voyager will develop vectorized antibodies in preclinical stage  after which AbbVie has an option to in license the vectorized alpha synuclein antibody program for further clinical development Voyager is entitled to receive  65 million upfront from AbbVie and up to  245 million in preclinical and phase I option payments  Meanwhile  Voyager will also be entitled to potential development  regulatory  and commercial milestone payments of up to  728 million and royalties on future sales Last year  AbbVie signed a collaboration with Voyager to develop potential new treatments for Alzheimer s disease and other tau related neurodegenerative diseases Shares of Voyager were up almost 23  on announcement of the deal with AbbVie AbbVie has always been actively pursuing partnership deals and collaborations for candidates across several therapeutic areas including oncology  immunology  neuroscience  and infectious diseases  Some partners include Roche   OTC RHHBY    J J   NYSE JNJ   and Boehringer Ingelheim among others  We believe the company will continue pursuing deals like the one with Voyager to grow its pipeline AbbVie currently carries a Zacks Rank  3  Hold   You can see This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-02-24,Zacks Investment Research,https://www.investing.com/analysis/abbvie-extends-deal-with-voyager-to-make-parkinsons-drugs-200392091,200392091
198348,419864,JNJ,Johnson   Johnson gets court reversal of verdict over talc cancer risks,news,"Johnson   Johnson  NYSE JNJ  today won a reversal of a  72M verdict that had favored the family of a woman whose death from ovarian cancer they claimed was caused by her use of the company s talc based products 
A Missouri Court of Appeals said that given a recent U S  Supreme Court decision that limited where injury lawsuits could be filed  the case over the Alabama resident s death should not have been tried in St  Louis 
JNJ faces lawsuits by 4 800 plaintiffs nationally asserting similar claims over its talc based products  with many in Missouri  where the February 2016 verdict for the family was the first of four jury awards totaling  307M  and in California  where in August a jury awarded a woman  417M 
Now read ",2017-10-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/johnson--johnson-gets-court-reversal-of-verdict-over-talc-cancer-risks-543120,543120
198349,419865,JNJ,Premarket analyst action   healthcare,news,Krystal Biotech   Pending KRYS  initiated with Buy rating and  23  137  upside  price target by Ladenburg Thalmann Immuron  NASDAQ IMRN  initiated with Buy rating and  15  178  upside  price target by H C  Wainwright T2 Biosystems  NASDAQ TTOO  initiated with Buy rating and  8  90  upside  by H C  Wainwright Johnson   Johnson  NYSE JNJ  price target raised to  165  17  upside  from  150 by Leerink  Price target raised to  142  1  upside  by Stifel Source  BloombergNow read ,2017-10-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-543426,543426
198350,419866,JNJ,FDA OKs expanded uses for J J s Simponi Aria,news,The FDA approves Johnson   Johnson  NYSE JNJ  unit Janssen Biotech s SIMPONI ARIA  golimumab  for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis The product was first approved in the U S  in July 2013 for rheumatoid arthritis SIMPONI ARIA is a fully human anti tumor necrosis factor therapy administered via 30 minute infusion Now read ,2017-10-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-expanded-uses-for-jjs-simponi-aria-545180,545180
198351,419867,JNJ,California judge tosses  417 million talc cancer verdict against Johnson   Johnson,news,"By Tina Bellon and Nate Raymond  Reuters    A California judge on Friday threw out a  417 million verdict against Johnson   Johnson  N JNJ  in a lawsuit by a woman who claimed she developed ovarian cancer after using its talc based products like Johnson s Baby Powder for feminine hygiene  The ruling by Los Angeles Superior Court Judge Maren Nelson marked the latest setback facing women and family members who accuse J J of not adequately warning consumers about the cancer risks of its talc based products   The decision followed a jury s decision in August to hit J J with the largest verdict to date in the litigation  awarding California resident Eva Echeverria  70 million in compensatory damages and  347 million in punitive damages  Nelson on Friday reversed the jury verdict and granted J J s request for a new trial  Nelson said the August trial was underpinned by errors and insufficient evidence on both sides  culminating in excessive damages  Mark Robinson  who represented the woman in her lawsuit  in a statement said he would file an appeal immediately   We will continue to fight on behalf of all women who have been impacted by this dangerous product   he said  J J in a statement said it was pleased with the verdict  adding that it will continue to defend itself in additional trials  The judge added that there also had been misconduct of the jury during the trial   J J said declarations by two jurors after the trial showed that three members of the 12 person jury who voted against finding the company liable were improperly excluded from determining damages  J J says it faces lawsuits by 4 800 plaintiffs nationally asserting talc related claims  Many of those cases are in California  where Echeverria s case was the first to go to trial  and in Missouri  where J J has faced five trials  The Missouri litigation led to four verdicts against J J in which juries issued verdicts totaling  307 million  The company has only won one trial  But the Missouri cases  which have largely been brought by out of state plaintiffs  have faced jurisdictional questions after the Supreme Court issued a ruling in June that limited where personal injury lawsuits could be filed   
On Tuesday  a Missouri appellate court threw out a  72 million verdict by a jury in February 2016 to the family of a deceased Alabama woman after ruling the case should not have been tried in St  Louis ",2017-10-21,Reuters,https://www.investing.com/news/stock-market-news/california-judge-tosses-417-million-talc-cancer-verdict-against-johnson--johnson-545226,545226
198352,419868,JNJ,UniQure readies 5M share stock offering,news,UniQure  NASDAQ QURE  launches a public offering of 5M shares of common stock  Underwriters over allotment will be an additional 750K shares  Price and terms have yet to be released Shares are down a fraction after hours Now read ,2017-10-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/uniqure-readies-5mshare-stock-offering-546094,546094
198353,419869,JNJ,Roche Halts Two Late Stage Studies On Alzheimer s Candidate,opinion,"Roche Holding  SIX ROG  AG   OTC RHHBY   announced that it is discontinuing two phase III studies on the investigational anti beta amyloid molecule  crenezumab in people with early  prodromal to mild  sporadic Alzheimer s disease  AD   The company made this decision based on the results from a pre planned interim analysis that indicated that crenezumab was unlikely to meet the primary endpoint of change from baseline in Clinical Dementia Rating Sum of Boxes  CDR SB  Score 
The interim analysis was conducted by the Independent Data Monitoring Committee  IDMC   The two late stage studies   CREAD 1 and CREAD 2   were evaluating the efficacy and safety of crenezumab in 1 500 early AD patients with confirmed evidence of cerebral beta amyloid pathology  CSF or amyloid PET   These studies used doses four times higher than that in the phase II studies 
Roche stated that an Alzheimer s Prevention Initiative  API  study of crenezumab in familial Alzheimer s disease will continue  and so will late stage GRADUATE studies with gantenerumab and mid stage TAURIEL study with the anti tau molecule  RG6100 
Crenezumab is being developed by Roche in collaboration with Swiss biotechnology company  AC Immune SA   NASDAQ ACIU    Shares of AC Immune went down about 34 6  in pre market  following the news  Shares of Roche have increased 7 4  in the past year  against the  s decline of 1 2  

 
Alzheimer s  a fatal illness that causes progressive decline in memory  has always been a highly challenging area  with not much progress being made in spite of significant investments  both funds and resources   Several companies have failed to develop safe and effective treatment options for this deadly brain disease 
Lilly has had its share of failures in AD  In June 2018 Lilly discontinued two late stage studies on its AD candidate lanabecestat on the recommendation of the IDMC 
Among other companies  in May 2018  J J   NYSE JNJ   halted the development of atabecestat  its investigational BACE inhibitor  which was being developed for pre clinical stage Alzheimer s disease  due to safety concerns 
In February 2018  Merck   NYSE MRK   discontinued the second late stage study evaluating its BACE inhibitor verubecestat for the treatment of prodromal Alzheimer s disease  as its success was unlikely 
Despite the setbacks  companies continue to invest heavily in developing Alzheimer s disease treatments  given the high commercial potential in the market  Success in this area means huge returns  The market has immense commercial potential  and companies coming out with new treatments could rake in billions of dollars 
Roche currently carries a Zacks Rank  3  Hold  You can see   
Roche Holding AG Price

    
Zacks  Top 10 Stocks for 2019 
In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year 
From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  
This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-01-30,Zacks Investment Research,https://www.investing.com/analysis/roche-halts-two-latestage-studies-on-alzheimers-candidate-200381513,200381513
198359,419875,JNJ,New cancer drugs help Johnson   Johnson top profit estimates,news,"By Akankshita Mukhopadhyay and Michael Erman  Reuters    Johnson   Johnson  NYSE JNJ  posted better than expected third quarter earnings  raising its full year forecast due to growth from new cancer drugs and high margin treatments picked up in its  30 billion acquisition of Actelion earlier this year  Shares of J J  part of the Dow Jones Industrial Average  rose 3 4 percent to  140 79 on Tuesday   The shares have traded at or near record levels for much of the year  Guggenheim Securities analyst Tony Butler said the stock has historically done well when its high margin pharmaceuticals business is the main driver of growth  rather than its consumer segment  Sales at J J s pharmaceuticals segment rose 15 4 percent to  9 7 billion in the third quarter  Around half of that growth came from the Actelion deal  Higher demand for J J s blood cancer drugs  Darzalex and Imbruvica  and Actelion s rare diseases treatments are expected to boost earnings going forward  The two cancer drugs should continue to capture market share  Guggenheim Securities  Butler said   The oncology business is doing exceptionally well   he said   It s really hard to figure out where that stops for both Darzalex and Imbruvica   Still  sales of J J s diabetes drug  Invokana  slipped around 10 percent from the second quarter  The company this year was required to add new warnings about the risk of foot and leg amputations and also has had to contend with competition from Eli Lilly and Co s Jardiance   Its rheumatoid arthritis drug  Remicade  also had weaker sales in the quarter  J J said adjusted earnings  excluding one time items  rose 13 percent to  1 90 per share  Analysts on average were expecting an adjusted profit of  1 80 per share   according to Thomson Reuters I B E S  Sales at J J s consumer products segment  which makes Band Aids  Neutrogena beauty products and Tylenol  rose 2 9 percent to  3 4 billion  The company s net earnings fell to  3 76 billion  or  1 37 per share  in the quarter from  4 27 billion  or  1 53 per share  a year earlier  The company said it was hurt by amortization and deal related expenses   J J raised its 2017 profit forecast to  7 25 to  7 30 per share  from its previous forecast of  7 12 to  7 22 per share  It now expects revenue of  76 1 billion to  76 5 billion for the year  Johnson   Johnson has six drug manufacturing facilities on Puerto Rico  which was hit by Hurricane Maria last month  It said that while they are all running again  it cannot rule out intermittent shortages of some of its drugs  
Also on Tuesday  the company won the reversal of a  72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company s talc based products like Johnson s Baby Powder ",2017-10-17,Reuters,https://www.investing.com/news/stock-market-news/jj-reports-119-percent-fall-in-quarterly-profit-542636,542636
198360,419876,JNJ,Johnson   Johnson  JNJ  Gains As Market Dips  What You Should Know,opinion,"Johnson   Johnson  NYSE JNJ  closed at  128 99 in the latest trading session  marking a  0 59  move from the prior day  The stock outpaced the S P 500 s daily loss of 0 79   Elsewhere  the Dow lost 0 85   while the tech heavy Nasdaq lost 1 11  
Heading into today  shares of the world s biggest maker of health care products had gained 0 64  over the past month  lagging the Medical sector s gain of 9 42  and the S P 500 s gain of 13 44  in that time 
Wall Street will be looking for positivity from JNJ as it approaches its next earnings report date  This is expected to be April 16  2019  In that report  analysts expect JNJ to post earnings of  2 09 per share  This would mark year over year growth of 1 46   Meanwhile  our latest consensus estimate is calling for revenue of  19 67 billion  down 1 67  from the prior year quarter 
For the full year  our Zacks Consensus Estimates are projecting earnings of  8 59 per share and revenue of  81 23 billion  which would represent changes of  5 01  and  0 43   respectively  from the prior year 
Any recent changes to analyst estimates for JNJ should also be noted by investors  These recent revisions tend to reflect the evolving nature of short term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 88  lower within the past month  JNJ currently has a Zacks Rank of  3  Hold  
In terms of valuation  JNJ is currently trading at a Forward P E ratio of 14 93  This represents a premium compared to its industry s average Forward P E of 14 04 
Meanwhile  JNJ s PEG ratio is currently 2 04  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  JNJ s industry had an average PEG ratio of 1 91 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 77  which puts it in the top 31  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow JNJ in the coming trading sessions  be sure to utilize Zacks com ",2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-gains-as-market-dips-what-you-should-know-200380260,200380260
198362,419878,JNJ,FDA OKs Johnson   Johnson s Stelara for psoriatic patients as young as 12 years,news,The FDA approves the use of Johnson   Johnson unit  NYSE JNJ  Janssen Biotech s STELARA  ustekinumab  to treat adolescents as young as 12 years old with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy STELARA was first approved in the U S  in September 2009 for adults with moderate to severe plaque psoriasis  It was subsequently approved for adults with psoriatic arthritis in September 2013 and adults with moderately to severely active Crohn s disease in September 2016 Now read ,2017-10-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-johnson--johnsons-stelara-for-psoriatic-patients-as-young-as-12-years-541466,541466
198363,419879,JNJ,Is A Beat In Store For AbbVie  ABBV  This Earnings Season ,opinion,"We expect AbbVie Inc    NYSE ABBV   to beat expectations when it reports fourth quarter 2018 results on Jan 25  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 6 47  Shares of AbbVie have declined 0 8  in the past six months against the  s increase of 5 8  Notably  AbbVie s earnings history is quite impressive with the pharmaceuticals company outpacing estimates in all the last four quarters with the average beat being 3 54  Let s see how things are shaping up for the company this quarter Factors to ConsiderAbbVie expects earnings per share for the quarter to be in the range of  1 89 and  1 91  Revenues are expected to be driven by operational growth of 7   However  currency movement is likely to have an unfavorable impact of less than 1   The Zacks Consensus Estimate for earnings and revenue stands at  1 91 per share and  8 38 billion  respectively AbbVie s flagship product  Humira  which is approved for several inflammatory indications  has witnessed strong demand trends despite the launch of drugs with new mechanisms of action and competition from indirect biosimilars  U S  sales were above expectation in the third quarter and in the soon to be reported quarter a similar performance is likely  However  international sales are likely to have an unfavorable impact as several biosimilar versions of the drug were launched in Europe in October  U S  Humira sales are expected to be  13 7 billion in 2018 while the company reduced its guidance for international sales from  6 4 billion to  6 3 billion  The Zacks Consensus Estimate for fourth quarter Humira sales is pegged at  5 billion The company also has a strong oncology portfolio  New drug Imbruvica has shown impressive adoption in the approved indications  especially front line chronic lymphocytic leukemia  AbbVie continues to develop the drug in several indications  There were several positive data readouts during the quarter  Earlier this week  the company s partner  Johnson   Johnson   NYSE JNJ   reported earnings  Sales of Imbruvica confirm the growth trend in the fourth quarter Label expansion of Imbruvica in combination with Roche Biogen s Rituxan for treating Waldenstr m s macroglobulinemia in August is likely to boost sales this quarter  In 2018  the company expects Imbruvica global revenues to exceed  3 5 billion with sales in the United States likely to cross  2 9 billion  The Zacks Consensus Estimate for the drug is pegged at  967 million in the soon to be reported quarter Other drugs  namely Duodopa and Creon  are also likely to continue their year to date strong performance in the soon to be reported quarter  The Zacks Consensus Estimate for Duodopa and Creon sales is  113 million and  246 million  respectively Sales of another leukemia drug  Venclexta  is also growing rapidly on the back of label expansion in second line plus setting for CLL patients and doubled year over year in the third quarter  In September  the drug s label was expanded to include CLL patients with minimal residual disease  broadening the eligible patient population in the fourth quarter  However  impact on sales remains to be seen In November  the drug received approval for newly diagnosed acute myeloid leukaemia  AML  patients aged 75 years or older or those ineligible for intensive induction chemotherapy in the United States  In October  the drug was approved in combination with Roche s Rituxan for treating CLL in second or later line setting in Europe AbbVie s hepatitis C virus   HCV   segment also showed impressive growth on the back of better than expected uptake of Mavyret despite stiff competition  Mavyret has become a major growth driver for AbbVie within a short time of its launch and commanded roughly 50  market share globally at the end of the third quarter  We expect the positive trend to continue this quarter  However  Viekira may continue to see declining sales  affected by intense pricing and competitive pressure in the HCV market  Full year HCV global sales are estimated to be  3 5 billion  up nearly 2 7 times from 2017 The company may continue to see higher operating expense due to ongoing clinical studies and launch of new drugs and label expansions Why a Likely Positive Surprise Our proven model indicates that AbbVie is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate   1 97  and the Zacks Consensus Estimate   1 91   stands at  2 65   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AbbVie has a Zacks Rank  3  The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat Conversely  we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions AbbVie Inc  Price and EPS Surprise
    Other Stocks That Warrant a LookHere are some biotech stocks that you may also want to consider  as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases Exact Sciences Corporation   NASDAQ EXAS   has an Earnings ESP of  17 7  and a Zacks Rank  2  The company is expected to release fourth quarter results on Feb 28  You can see  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   has an Earnings ESP of  6 12  and a Zacks Rank  3  The company is expected to release fourth quarter results on Feb 14 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-01-22,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-abbvie-abbv-this-earnings-season-200378317,200378317
198364,419880,JNJ,JNJ Beats  Offers Bleak Outlook  Health Care ETFs In Focus,opinion,The Q4 earnings season has commenced and Johnson   Johnson   NYSE JNJ   was the first drug company to report on Jan 22  before the opening bell  The world s biggest maker of health care products continued its long streak of earnings beat and outpaced the estimate on the revenue front  However  it offered a downbeat outlook for 2019 Earnings per share came in at  1 97  a couple of cents ahead of the Zacks Consensus Estimate and 13 2  higher than the year ago quarter  Revenues inched up 1  year over year to  20 39 billion and edged past the Zacks Consensus Estimate of  20 1 billion  Robust results were driven by double digit growth in sales of Crohn s disease treatment Stelara and cancer drugs such as Darzalex and Imbruvica Johnson   Johnson expects its sales growth to slow down this year due to pricing pressures and generic drug competition for its pharmaceutical division  This is especially true as the company s prostate cancer drug Zytiga  an important growth driver  is expected to be pressured by generic competition while sales of its rheumatoid arthritis drug Remicade have been slipping due to competition from cheaper biosimilar versions  read    As a result  revenues are expected in the range of  80 4  81 2 billion  reflecting year over year growth of 0 0 1 0  while earnings per share will likely range between  8 50 and  8 65  reflecting growth of 5 7 7 6   The midpoints of the guidance are well below the Zacks Consensus Estimate of  82 61 billion for revenues and  8 64 for earnings Market ImpactShares of JNJ were down 1 5  at the close of session  Currently  the stock has a Zacks Rank  3  Hold  and VGM Score of B  Additionally  Johnson   Johnson belongs to a top ranked Zacks industry Rank   As a result  investors should closely watch the movement of the stock and keep a close eye on ETFs having double digit allocation to this diversified drug maker  Below we have highlighted them  see    iShares U S  Pharmaceuticals ETF This ETF provides exposure to 47 companies that manufacture prescription or over the counter drugs or vaccines by tracking the Dow Jones U S  Select Pharmaceuticals Index  Of these  Johnson and Johnson takes the top spot  accounting for 11 1  share  The product has  391 6 million in AUM and charges 43 bps in fees and expenses  Volume is lower as it exchanges about 20 000 shares a day  The fund has a Zacks ETF Rank  2  Buy  with a High risk outlook Health Care Select Sector SPDR Fund The most popular health care ETF  XLV follows the Health Care Select Sector Index  This fund manages nearly  18 6 billion in its asset base and trades in heavy volume of around 10 7 million shares  Expense ratio comes in at 0 13   In total  the fund holds 62 securities in its basket  with JNJ taking the top spot at 10 3  of the assets  Pharma accounts for 32 4  share from a sector look  while health care equipment and supplies  health care providers and services  and biotech have double digit exposure each  It has a Zacks ETF Rank  1  Strong Buy  with a Medium risk outlook  read    iShares U S  Healthcare ETF This fund offers exposure to 128 securities by tracking the Dow Jones U S  Health Care Index  Here again  Johnson   Johnson dominates the fund s returns with 9 5  of total assets  In terms of industrial exposure  pharma takes the top spot at 30 7   followed by health care equipment  21 2   and biotech  20 1    The product has amassed nearly  2 5 billion in its asset base  while charges 43 bps in annual fees  It trades in a good volume of around 128 000 shares a day and has a Zacks ETF Rank  2 with a Medium risk outlook iShares Evolved U S  Innovative Healthcare ETF This actively managed ETF employs data science techniques to identify companies with exposure to the innovative health care sector  Holding 203 stocks in its basket  JNJ is the top firm with 9 6  allocation  The product has accumulated  5 1 million in its asset base and trades in a meager volume of 1 500 shares per day on average  It charges 18 bps in annual fees  read    Vanguard Health Care ETF   AX VHT  This ETF tracks the MSCI US Investable Market Health Care 25 50 Index and holds 359 stocks in its basket  Of these  Johnson   Johnson occupies the top position with 9 2  allocation  Pharma takes the largest share at 30 7   while health care equipment and biotech round off the top three spots  VHT is also one of the popular and liquid ETFs with AUM of  8 9 billion and average daily volume of about 300 000 shares  It charges 10 bps in annual fees and has a Zacks ETF Rank  1 with a Medium risk outlook Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-01-22,Zacks Investment Research,https://www.investing.com/analysis/jnj-beats-offers-bleak-outlook-health-care-etfs-in-focus-200378529,200378529
198365,419881,JNJ,On Trade And Growth Concerns Safe Haven Assets Rally,opinion,"Risk aversion has been the dominating direction this week  It first started with China s GDP growing at slowest pace since 1990  then we saw cuts to the global outlook by the IMF  followed by concerns from Chinese President Xi over a  black swan  or  gray rhino  event  today earnings mostly missed and lastly the U S  reportedly turned down latest Chinese offer  that story was later refuted  but doubts still grew that a deal could be reached by the March 1st deadline 
Japanese Yen
The Japanese yen has rallied against most of its major trading partners as markets can t seem to shrug off global growth concerns and the resumption of tough trade talk from the U S  The news that the Trump administration scrapped this week s preparatory trade talks with two Chinese vice ministers was later refuted by White House Adviser Larry Kudlow  Even though the story was refuted  it should be expected to start to see the U S  show a tougher stance as we near the trade truce deadline  Throughout the stages of negotiations of trade talks  the U S  consistently provides dissatisfaction once we get closer to pivotal deadlines to enhance their negotiation stance  The issue of forced technology transfers and structural reforms to the Chinese economy are unlikely to see major progress by the March 
British Pound
The British pound  rallied against all of its major trading partners as expectations are still high that we will not see a no deal Brexit and that today s wage data raised expectations for the BOE to deliver a hike by the fall  Today s wage data rose to the highest pace since 2008 and it could help deliver higher inflation  Current expectations are that we could see a 65  chance the BOE raise rates at the November meeting  earlier in the month the markets were pricing a rate hike at the first meeting in 2020  a day before Governor Carney s term ends 

Stocks
U S  stocks returned from a 3 day weekend and delivered the worst drop in three weeks as trade tensions ramp up and earning season continues to deliver softer outlooks  The trade war escalation could continue to weigh on technology  energy and multinational businesses  Earlier this morning  poor outlooks and guidance from Haliburton and Johnson   Johnson  NYSE JNJ  kept the narrative negative 

Commodities
Commodities got crushed across the board  except for gold  The story behind the broad based selling is an easy one  falling demand  China growth falling to a near three decade low  the IMF slashing global growth forecasts and many large early reporters this earning season have expressed concern with their outlooks  U S  shale production continues to surge and pushing refiners to the highest pace in 15 years  Record stocks of fuel keep the gasoline glut in focus 

Original post",2019-01-22,Ed Moya,https://www.investing.com/analysis/safe-haven-assets-remain-bid-on-trade-and-growth-concerns-200378126,200378126
198370,419886,JNJ,For Johnson   Johnson  Lawsuits  Not Earnings  Are The Pain Point ,opinion,"Reports Q4 2018 results onTuesday  January 22  before the market open
Revenue Expectation   20 17 billion
EPS Expectation   1 95
Even if Johnson   Johnson  NYSE JNJ   the world s largest maker of both consumer and pharmaceutical health care products  delivers a blowout quarter when they report Tuesday  investors might still not be delighted  A massive beat won t overshadow the biggest worry currently stalking stakeholders  the outcome of litigation brought by nearly 12 000 plaintiffs over the company s baby powder and other talc products  The complainants allege that asbestos in those Johnson   Johnson products caused their ovarian cancer 
The company paid a steep price during 2018 because of these claims  In July  a jury ordered J J to pay  4 69 billion to 22 women who blamed the talc based product for their ovarian cancer  The prospect of similar judgments increased after Reuters published a story last month alleging that the company had known for years that its talcum powder contained  small amounts of asbestos   and had kept that knowledge a secret 

The news abruptly ended an impressive rally in JNJ stock  causing it to plunge from a near record high of almost  149 in December  wiping out  45 billion in the company s market value  Currently trading at  131  JNJ shares have barely recovered since the stumble 
Though the July verdict was appealed  the company lost the motion in mid December  Still  Johnson   Johnson plans to continue seeking a reversal of the motion via additional appeals  Going forward  the question no one can answer at this juncture is how will all this be resolved 
For mega cap consumer companies such as JNJ  reputation is paramount  Without addressing the argument that JNJ says it has strong scientific research backing its case that its talc does not contain asbestos  the problem we see is that the company has a mixed track record in this battle 
Juries in states including Missouri  California and New Jersey have handed down more than  5 billion in total awards to plaintiffs since suits started going to trial in 2016  However  some of those verdicts have been thrown out by judges  J J has appealed or won verdicts in other cases while still others were declared mistrials  To date Johnson   Johnson has only settled in one case 
Estimates put the possible damage to JNJ as a result of these claims at as high as  20 billion  That s a colossal amount  Even if that number were to be cut in half  it means the company will lose its income for the next two quarters  assuming it continues to produce around  4 billion in net quarterly profit 
Bottom Line
We believe Johnson   Johnson will continue to fight these claims  Given the large number of cases involved  the company will find it hard to settle  If the situation persists well into 2019  it will continue to be a major weight on J J s share price 
In our view  now is not the time to call a bottom on JNJ shares despite the company s excellent moat  Even its attractive 2 79  dividend yield and stellar history of raising its payout for 55 years in a row isn t enough to make the stock a buy right now  For investors  the prudent strategy is to stay on the sidelines and monitor how the situation evolves  at least into the summer ",2019-01-21,Haris Anwar/Investing.com,https://www.investing.com/analysis/for-johnson--johnson-baby-powder-lawsuits-hurt-more-than-earnings-----reports-t-200377460,200377460
198371,419887,JNJ,J J  JNJ  Beats Estimates For Earnings   Sales In Q4,opinion,"Johnson   Johnson   NYSE JNJ    the bellwether of healthcare companies  has a strong presence in the pharmaceutical  medical devices and consumer care markets across the world  This New Jersey based company is well known for its baby care products and brands like Tylenol in addition to drugs like Remicade and Concerta However  like many of its peers  JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment  Recently  allegations that its talc baby powders contain asbestos which causes the users to develop ovarian cancer have been an overhang on the stock s price In this scenario  investor focus remains on late stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top and bottom line numbers J J s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The average positive earnings surprise over the last four quarters is 1 65   Estimates for 2019 have gone up slightly over the past 7 days Currently  JNJ has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  JNJ beat on fourth quarter earnings   the company reported EPS of  1 97 while our consensus called for EPS of  1 95 Revenues Beat  Revenues also beat expectations  Johnson   Johnson posted revenues of  20 39 billion  compared to our consensus estimate of  20 1 billion Key Statistics  Pharmaceutical segment sales rose 5 3  year over year to  10 19 billion  reflecting 7 2  operational growth and 1 9  negative currency impact as sales rose in both domestic and international markets Issues 2019 Outlook  J J issued earnings and sales guidance for 2019 J J expects 2019 adjusted earnings per share in the range of  8 50    8 65  The guidance range reflects an operational growth rate between 5 7  and 7 6   The Zacks Consensus Estimate for EPS for 2019 was  8 64 Revenues are expected in the range of  80 4 to  81 2 billion which fell short of the Zacks Consensus Estimate for revenues of  82 61 billion The sales guidance reflected operational constant currency sales growth in the range of 0  to 1   Organically  excluding the impact of acquisitions and divestitures  sales growth is expected to be in the range of 2  to 3  on an operational basis Stock Price Impact  Shares rose 0 6  in pre market trading Check back later for our full write up on this JNJ earnings report later  Johnson   Johnson Price and Consensus
    Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-beats-estimates-for-earnings--sales-in-q4-200377964,200377964
198377,419893,JNJ,Janssen bails on duvortuxizumab development deal with MacroGenics after neurotoxicity observed in early stage study,news,Thinly traded MacroGenics  NASDAQ MGNX  is poised for a down day after its announcement that Janssen Biotech  NYSE JNJ  is terminating their collaboration and licence agreement for CD19 x CD3 DART molecule duvortuxizumab  Janssen made the decision after a number of patients in a Phase 1 dose escalation study developed treatment related neurotoxicity similar to what has been observed with other CD19 targeting T cell therapies Janssen is still on board with the second DART molecule licensed from MacroGenics  MGD015  JNJ 9383   The first in human study should commence in 2018 CEO Scott Koenig  M D   Ph D   says   While this decision is disappointing  MacroGenics and its strategic partner  Janssen  continue to be fully committed to the DART platform and our ongoing collaboration on MGD015  Duvortuxizumab s neurotoxicity profile is a CD19 targeting issue and has not been observed in our other DART clinical programs  Given our large portfolio of product candidates currently being pursued  it is unlikely that we will continue development of this molecule at this time  Previously  MacroGenics inks collaboration with Janssen to develop DART based cancer med  shares up 17   May 18  2016 Now read ,2017-09-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/janssen-bails-on-duvortuxizumab-development-deal-with-macrogenics-after-neurotoxicity-observed-in-earlystage-study-524726,524726
198378,419894,JNJ,J J  JNJ  To Commence Pharma Q4 Earnings  What To Expect,opinion,"Johnson   Johnson   NYSE JNJ    a healthcare bellwether  will report fourth quarter and full year 2018 results on Jan 22  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 0 99  J J s performance has been pretty impressive  with the company exceeding earnings expectations in all the trailing four quarters  The average positive earnings surprise over the last four quarters is 1 65  Johnson   Johnson Price and EPS Surprise
    
 The stock has depreciated 12 7  in the past year compared with a decrease of 0 9  recorded by the  
  Factors to ConsiderJ J s sales growth has accelerated in the past few quarters backed by continued above market growth in the Pharmaceutical segment and improved organic sales growth in the Medical Devices and the Consumer segments  In fact  J J raised its full year organic sales growth expectations thrice in 2018 J J s strong performance in pharmaceuticals segment is being led by its oncology portfolio  a trend expected to remain unchanged in the fourth quarter  Core products like Imbruvica  Darzalex Stelara  Zytiga  Simponi Simponi Aria and Invega Sustenna should contribute to growth  Though sales of another key drug  Xarelto declined in the third quarter  the situation is expected to improve in this time around  A new 2 5 milligram vascular dose of Xarelto for the CAD PAD indication was approved by the FDA in October 2018  which significantly expanded the drug s eligible patient population  This is expected to drive sales of the drug in the fourth quarter and in 2019 In the pulmonary arterial hypertension  PAH  category  strong demand for Uptravi and Opsumit will be partially offset by an expected decline in Tracleer outside the United States due to generic competition Meanwhile  biosimilar competition is expected persist  hurting key arthritis drug Remicade outside the United States  Please note that J J markets Remicade in partnership with MerckRegarding newly launched Tremfya  J J  on its third quarter call  noted strong demand for the product  The drug captured 5 8  share of the psoriasis market in the United States We expect the drug to generate higher sales in the fourth quarter than the previous quarters On the same call  J J had said that while the Consumer and Medical Device businesses should continue to improve in the fourth quarter  the Pharmaceuticals segment might see slower growth  The Pharmaceuticals segment is likely to face difficult comparisons in fourth quarter  which coupled with expected biosimilar and generic competition to Tracleer and Procrit in late 2018  may put pressure on the segment s growth  Though the generic version of Tracleer was not launched in 2018  a biosimilar of Procrit was launched by Pfizer   NYSE PFE   in November The Zacks Consensus Estimate for J J s Pharmaceuticals  Consumer and Medical Device segments is  9 87 billion   3 57 billion and  6 72 billion  respectively Higher R D costs and investments for product launches will continue to hurt profits We expect management to be flooded with questions related to how the company plans to come out clean from the recent allegations by a Reuters article  which claimed that the company knew for decades that its baby powders contained asbestos J J is fighting thousands of lawsuits alleging that its talc baby powders contain asbestos  which causes users to develop ovarian cancer  J J  in a statement  called the reports by Reuters  one sided  false  and inflammatory   J J said that independent tests by regulators  academic institutions and leading labs have proven that its talc based products never contained asbestos Earnings WhispersOur proven model does not conclusively show that J J is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Earnings ESP  Its Earnings ESP is 0 00  as both the Most Accurate Estimate as well as the Zacks Consensus Estimate is pegged at  1 95  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  J J s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some drug biotech stocks that have the right combination of elements to beat on earnings this time around Ultragenyx Pharmaceutical Inc    NASDAQ RARE   with an Earnings ESP of  28 71  and a Zacks Rank  3  The company is expected to release results on Feb 19  You can see  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   has an Earnings ESP of  10 67  and a Zacks Rank  3  The company is expected to release results on Feb 14 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2019-01-16,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-to-commence-pharma-q4-earnings-what-to-expect-200376626,200376626
198379,419895,JNJ,J J Snack Foods  JJSF  Earnings Expected To Grow  Should You Buy ,opinion,"J J  NYSE JNJ  Snack Foods  JJSF  is expected to deliver a year over year increase in earnings on higher revenues when it reports results for the quarter ended December 2018  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on January 28  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This drink and snack maker is expected to post quarterly earnings of  0 87 per share in its upcoming report  which represents a year over year change of  11 5  
Revenues are expected to be  270 45 million  up 2  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for J J Snack Foods 
For J J Snack Foods  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that J J Snack Foods will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that J J Snack Foods would post earnings of  1 32 per share when it actually produced earnings of  1 22  delivering a surprise of  7 58  
The company has not been able to beat consensus EPS estimates in any of the last four quarters 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
J J Snack Foods doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-20,Zacks Investment Research,https://www.investing.com/analysis/jj-snack-foods-jjsf-earnings-expected-to-grow-should-you-buy-200377674,200377674
198380,419896,JNJ,AbbVie s Imbruvica Fails In Phase III Pancreatic Cancer Study,opinion,"AbbVie Inc    NYSE ABBV   announced that a combination regimen of its blockbuster cancer drug  Imbruvica  ibrutinib   failed in a phase III study  evaluating it for the treatment of metastatic pancreatic adenocarcinoma  one of the most aggressive and deadliest forms of cancer  The study was unable to meet its primary endpoint of improving progression free survival  PFS  or overall survival  OS  benefit amid the given patient population 
The phase III RESOLVE study investigated the efficacy of Imbruvica in combination with chemotherapy agents nab paclitaxel and gemcitabine compared with placebo in combination with these chemotherapy agents for first line treatment of patients suffering metastatic pancreatic cancer  The study did not show a statistically significant PFS or OS benefit in the Imbruvica combo arm as compared to the placebo one 
Complete data from the study will be submitted for presentation at a future medical conference 
Shares of AbbVie have declined 16  in the past year  wider than the  dip of 0 8  

 
Notably  Imbruvica has been jointly developed and marketed by AbbVie and Janssen Biotech  a unit of Johnson   Johnson   NYSE JNJ   
Currently approved for nine cancer indications  Imbruvica has multi billion dollar potential and AbbVie is exploring the potential to expand Imbruvica s label into solid tumors and autoimmune diseases 
In the first nine months of 2018  Imbruvica generated sales of  2 58 billion  reflecting a surge of 38 7  year over year  AbbVie expects Imbruvica s peak sales to be more than  7 billion and revenues of about  5 billion in 2020  However  study failure like that of RESOLVE will cause a hindrance to AbbVie J J s expansion plans for Imbruvica 
Another important cancer drug in AbbVie s oncology portfolio is Venclexta  Regulatory applications seeking an approval for Venclexta plus Roche s   OTC RHHBY   Rituxan for relapse refractory chronic lymphocytic leukemia  based on MURANO study data  were lent with a nod in the United States  last June and in the EU  last October  Visibly  label expansion for this indication has increased the patient population for Venclexta significantly  which will further boost its commercial potential 
Also  last November  AbbVie gained an FDA approval for Venclexta for first line acute myeloid leukemia  AML  while outcomes from the phase III program on multiple myeloma are awaited in the first half of 2019  AbbVie Roche also plans to soon file for approving Venclexta  Gazyva in first line CLL setting 
Zacks Rank   Another Key Pick
AbbVie currently carries a Zacks Rank  2  Buy   Another top ranked stock in large cap pharma sector is H Lundbeck A S   OTC HLUYY    which sports a Zacks Rank  1  Strong Buy   You can see  
H Lundbeck s earnings estimates have moved 5 2  north for 2019 over the past 60 days 
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-21,Zacks Investment Research,https://www.investing.com/analysis/abbvies-imbruvica-fails-in-phase-iii-pancreatic-cancer-study-200377745,200377745
198382,419898,JNJ,J J ordered to pay  417 million in trial over talc cancer risks,news,"By Nate Raymond  Reuters    A California jury on Monday ordered Johnson   Johnson  NYSE JNJ  to pay  417 million to a woman who claimed she developed ovarian cancer after using the company s talc based products like Johnson s Baby Powder for feminine hygiene  The Los Angeles Superior Court jury s verdict in favor of California resident Eva Echeverria was the largest yet in lawsuits alleging J J failed to adequately warn consumers about the cancer risks of its talc based products   We are grateful for the jury s verdict on this matter and that Eva Echeverria was able to have her day in court   Mark Robinson  her lawyer  said in a statement  The verdict included  70 million in compensatory damages and  347 million in punitive damages  It was a major setback for J J  which faces 4 800 similar claims nationally and has been hit with over  300 million in verdicts by juries in Missouri   We will appeal today s verdict because we are guided by the science  which supports the safety of Johnson s Baby Powder   J J said  Echeverria s lawsuit was the first out of hundreds of California talc cases to go to trial  The 63 year old claimed she developed terminal ovarian cancer after decades of using J J s products  Her lawyers argued J J encouraged women to use its products despite knowing of studies linking ovarian cancer to genital talc use  J J s lawyers countered that studies and federal agencies have not found that talc products are carcinogenic  The trial follows five prior ones in Missouri state court  where many lawsuits are pending  J J lost four of those trials and  along with a talc supplier  has been hit with  307 million in verdicts  Before Monday  the largest verdict was for  110 million  The Missouri cases  which have largely been brought by out of state plaintiffs  have faced jurisdictional questions after the U S  Supreme Court issued a ruling in June that limited where personal injury lawsuits can be filed  In a decision in a case involving Bristol Myers Squibb Co  the Supreme Court said state courts cannot hear claims against companies that are not based in the state when the alleged injuries did not occur there  The ruling prompted a St  Louis judge  at New Jersey based J J s urging  to declare a mistrial in the talc case already underway  The judge has nonetheless left the door open for the plaintiffs to argue they still have jurisdiction based on a Missouri based bottler J J used to package its products  
The case is Echeverria et al v  Johnson   Johnson  Los Angeles Superior Court  No  BC628228 ",2017-08-21,Reuters,https://www.investing.com/news/stock-market-news/jampj-ordered-to-pay-417-million-in-trial-over-talc-cancer-risks-520756,520756
198383,419899,JNJ, Johnson   Johnson to pay  417 million in latest cancer lawsuit,news,"Investing com  Johnson   Johnson  NYSE JNJ will have to pay  417 million to a woman who claims that the company s baby powder caused her ovarian cancer following a jury verdict in California  The company says it plans to appeal   but this is not the first time that the courts have ruled that Johnson   Johnson s baby powder has caused cancer 
According to the consumersafety org  numerous studies over the past several decades have found a connection between talcum powder and ovarian cancer 
Investors were unphased about this latest suit  Shares closed Monday s session fractionally higher ",2017-08-21,Investing.com,https://www.investing.com/news/stock-market-news/johnson--johnson-to-pay-417-million-in-latest-cancer-lawsuit-520815,520815
198384,419900,JNJ,Massive California verdict expands J J s talc battlefield,news,"By Tina Bellon NEW YORK  Reuters    A massive California verdict in a lawsuit alleging Johnson   Johnson s  N JNJ  talc based products cause cancer has opened a new front in the litigation  upending the company s hopes that the cases were only gaining traction in Missouri  legal experts said  The  417 million award by California jury to a California resident suggested so called forum shopping  in which parties seek to file cases in whichever jurisdictions seem most favorable  may not be the main problem facing J J as it wrestles with some 4 800 outstanding talc lawsuits  J J  which denies any link between talc and cancer  said in a statement it would appeal Monday s verdict but declined further comment  That verdict was more than the sum of all the previous talc awards  which totaled  307 million and were meted out by juries in the same state court in St  Louis  Missouri  in cases filed by out of state residents  A fourth of talc lawsuits nationally were brought in St  Louis after the first large verdicts there  J J has cast the St  Louis court as overly plaintiff friendly and has focused on getting the cases brought by out of state plaintiffs dismissed   This has very much been about forum shopping   Howard Erichson  a professor at Fordham School of Law  said about the talc trials   The fact that there has been a big verdict in California is definitely interesting   Monday s verdict in Los Angeles Superior Court came in a case involving a 63 year old woman who claimed she developed ovarian cancer from using Johnson s Baby Powder for feminine hygiene since childhood   Corporations have long fought against plaintiffs filing lawsuits in courts favorable to them  and a U S  Supreme Court ruling in June delivered them a big victory  holding that state courts cannot hear claims against companies not based in the state when the alleged injury did not occur there   J J appeared to be an immediate beneficiary of that ruling  which a St  Louis judge cited in declaring a mistrial in a talc case involving two out of state women   The company also said it believed the Supreme Court decision required the reversal of the four St  Louis verdicts   But legal experts said the verdict in the California case  in which venue was not an issue  could shift the focus back to the evidence  J J shares did not react to the verdict  The company has so far not announced a litigation reserve for talc cases and analysts have said they would not be concerned until that happened   The first talc award against J J was handed down in St  Louis state court in February 2016  with the jury ordering J J to pay  72 million   The company prevailed in only one of the four talc trials that followed in the same court  with the other verdicts ranging from  55 million to  110 million  The company has decried the St  Louis court for allowing plaintiffs to present expert testimony linking talc products with cancer that the company contends is speculative and scientifically unsound  It has appeals pending on those grounds   J J has contrasted the Missouri court s stance to a New Jersey state court ruling in September 2016 that disqualified plaintiffs  experts  leading to the dismissal of two talc cases  The plaintiffs  appeal of that ruling is pending  The Los Angeles judge allowed the testimony of some of the same plaintiffs  experts as in St  Louis   The California jury seemed to react similarly to the evidence  said Diane Lifton  a defense lawyer not involved in the talc case   Something clearly inflamed the jury again   she said  Nathan Schachtman  a product liability defense lawyer  said the California verdict showed that  venue issues aside  the evidence against J J was compelling   
 I think it s a tough case for the defense   he said ",2017-08-23,Reuters,https://www.investing.com/news/stock-market-news/massive-california-verdict-expands-jampjs-talc-battlefield-521292,521292
198385,419901,JNJ, 417M California verdict in J J baby powder case suggests forum shopping   legal experts  shares down 1 ,news,"Legal experts say the recent  417M awarded to a woman in a California district court against Johnson   Johnson  JNJ  1   suggests forum shopping  meaning plaintiffs seek to file cases in favorable jurisdictions 
The award  the largest to date by far  opens a new front in the litigation  The company hoped to confine the baby powder lawsuits to Missouri  where a St  Louis district court was hearing a number of the cases  A total of  307M has been awarded there to date 
Companies have long fought the practice  a stance backed by a June ruling by the U S  Supreme Court stating that state courts should not hear claims against out of state firms when the alleged injury did not occur there  A St  Louis judge subsequently declared a mistrial in a talc case involving two out of state women 
J J maintains that the Supreme Court ruling requires the reversal of the four unfavorable St  Louis verdicts 
The Los Angeles judge allowed the testimony of some of the St  Louis plaintiffs  experts 
The company faces  4 800 lawsuits claiming the use of its baby powder led to ovarian cancer 
Previously  J   J on the hook for  417M in California talcum powder case  Aug  21 
Now read ",2017-08-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/417m-california-verdict-in-jj-baby-powder-case-suggests-forumshopping--legal-experts-shares-down-1-521570,521570
198386,419902,JNJ,Florida set to carry out execution with drug not previously used in lethal injections,news,By Bernie Woodall FT  LAUDERDALE  Fla   Reuters    Florida is scheduled on Thursday to put to death an inmate by lethal injection that includes a drug never before used in a U S  execution  Mark James Asay  53  would be the first Florida inmate executed since January 2016  when the U S  Supreme Court ruled the state s death penalty process was unconstitutional because it gave powers to judges that should be reserved for juries  Asay would also be the first white man executed for killing a black man in Florida since the state revived its death penalty in 1979  according to the Death Penalty Information Center  In dissenting from a Florida Supreme Court ruling earlier this month denying a stay of execution  Justice Barbara Pariente wrote that Asay was being treated as  the proverbial guinea pig  for the untested death penalty drug  etomidate  which she said would violate the constitutional protection against cruel and unusual punishment  The court s majority cited a U S  Supreme Court decision from two years ago that said that since the death penalty is constitutional  there must be a way to carry out executions and that eliminating all pain during them was not workable  Florida  along with other states  had to find a replacement for drugs that became unavailable when drugmakers stopped distributing them because of their stands against the death penalty  In Florida  etomidate replaced midazolam  which  Pfizer  Inc  NYSE PFE  stopped making last year to keep it from being used in executions  Etomidate  an anesthesia invented in Belgium in the 1960s by Janssen  now a division of privately held U S  based Johnson   Johnson  NYSE JNJ   is off patent and more readily available than midazolam and produced by others as a generic drug  Janssen stopped making the drug last year  after never selling it in the United States   We do not condone the use of our medicines in lethal injections for capital punishment   Janssen said in an emailed statement  Marty McClain  Asay s attorney  told Reuters on Wednesday that etomidate  which would be part of a three drug lethal injection protocol  causes pain before it takes hold and could cause involuntary body movements that make it difficult for corrections personnel  to know when the guy is unconscious   Asay was sentenced to death in 1988 for the killing of two men in Jacksonville a year earlier   He shot Robert Lee Booker in the belly after an argument in which he used a racial slur against him  according to court records  He killed Robert McDowell by shooting him multiple times in the chest  Asay said later he believed McDowell had cheated him out of  10  Booker was black and McDowell was white  Since it resumed capital punishment in 1979  Florida has executed 90 men and two women  Florida Governor Rick Scott signed a death warrant for Asay in January 2016  Days later  the U S  Supreme Court ruled it should be juries  not judges  who decide whether aggravating factors determine if a defendant is eligible for execution  Florida lawmakers rewrote the state s capital punishment law this year to require that juries be unanimous when recommending the death penalty ,2017-08-24,Reuters,https://www.investing.com/news/world-news/florida-set-to-carry-out-execution-with-drug-not-previously-used-in-lethal-injections-521887,521887
198387,419903,JNJ,J J s Darzalex extends progression free survival in late state multiple myeloma study over Velcade MP alone,news,Preliminary results from a Phase 3 clinical trial  ALCYONE  assessing Johnson   Johnson unit  JNJ  0 3   Janssen Biotech s DARZALEX  daratumumab   in combination with Takeda s VELCADE  bortezomib  and melphalan prednisone  in treatment naive multiple myeloma patients showed a statistically valid increase in progression free survival  PFS  compared to Velcade and melphalan prednisone  VMP  alone The pre planned interim analysis showed the addition of DARZALEX reduced the risk of cancer progression or death by 50   Median PFS in the DARZALEX group has not been reached  Median PFS in patients treated with VMP alone was estimated to be 18 1 months The Independent Data Monitoring Committee has recommended that the data be unblinded  All participants will continue to be followed for safety and overall survival  The data will be submitted for presentation at a future medical conference and for publication Janssen licensed daratumumab from Genmab A S  OTCPK GNMSF  OTCPK GMXAY  in 2012 Genmab maintains its 2017 guidance Now read ,2017-08-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/jjs-darzalex-extends-progressionfree-survival-in-latestate-multiple-myeloma-study-over-velcademp-alone-522040,522040
198388,419904,JNJ,AbbVie  ABBV  Inks Immunotherapy Deal With Private Biotech,opinion,"AbbVie   NYSE ABBV   and Tizona Therapeutics  Inc    Tizona    entered into a strategic collaboration to develop and commercialize CD39 targeted therapeutics  including pre clinical candidate TTX 030  Per the agreement  Tizona received an upfront payment of  105 million for the exclusive option to license the CD39 program while also buying an equity stake in the company 
CD39 is the enzyme  which helps in converting immune stimulatory extracellular ATP to immune suppressive adenosine in the tumor microenvironment  TME   Inhibition of CD39 with TTX 030 represents a unique way to target this pathway  Preclinical research shows that inhibiting CD39 may be helpful in restoring and bolstering immune responses against tumors 
Share price of AbbVie has declined 9 8  in the past year  against the  s growth of 3 3  

 
Tizona will take care of clinical development until the completion of phase Ib studies  after which AbbVie will have an exclusive option to conduct global development and commercial activities  Tizona has retained the option to co develop and market the candidate in the United States and is also entitled to future development  commercial milestone payments and tiered royalties on net sales 
An investigational new drug application for TTX 030 has been accepted by the FDA  Initiation of clinical studies with TTX 030 is targeted in the first quarter of 2019 
AbbVie has been actively pursuing partnership deals and collaborations for candidates across several therapeutic areas  including oncology  immunology  neuroscience and infectious diseases  Some of AbbVie s partners include Roche   OTC RHHBY    J J   NYSE JNJ    Bristol Myers   NYSE BMY   and Boehringer Ingelheim  among others  We believe the company will continue pursuing such deals to enhance its pipeline AbbVie Inc  Price

   Zacks Rank 
AbbVie currently carries a Zacks Rank  3  Hold   You can see  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-01-04,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-inks-immunotherapy-deal-with-private-biotech-200373054,200373054
198389,419905,JNJ,Johnson   Johnson  JNJ  Stock Sinks As Market Gains  What You Should Know,opinion,"Johnson   Johnson  NYSE JNJ  closed the most recent trading day at  128 93  moving  0 79  from the previous trading session  This change lagged the S P 500 s 0 48  gain on the day  Elsewhere  the Dow gained 0 53   while the tech heavy Nasdaq added 0 8  
Prior to today s trading  shares of the world s biggest maker of health care products had lost 11 29  over the past month  This has lagged the Medical sector s loss of 3 81  and the S P 500 s loss of 2 09  in that time 
Investors will be hoping for strength from JNJ as it approaches its next earnings release  which is expected to be January 22  2019  On that day  JNJ is projected to report earnings of  1 95 per share  which would represent year over year growth of 12 07   Meanwhile  our latest consensus estimate is calling for revenue of  20 11 billion  down 0 42  from the prior year quarter 
Any recent changes to analyst estimates for JNJ should also be noted by investors  These revisions help to show the ever changing nature of near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 13  lower within the past month  JNJ currently has a Zacks Rank of  4  Sell  
Looking at its valuation  JNJ is holding a Forward P E ratio of 15 03  This represents a premium compared to its industry s average Forward P E of 14 6 
Also  we should mention that JNJ has a PEG ratio of 1 92  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  JNJ s industry had an average PEG ratio of 1 91 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 60  putting it in the top 24  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
You can find more information on all of these metrics  and much more  on Zacks com ",2019-01-09,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-stock-sinks-as-market-gains-what-you-should-know-200374217,200374217
198390,419906,JNJ,Johnson   Johnson  JNJ  Earnings Expected To Grow  Should You Buy ,opinion,"The market expects Johnson   Johnson  NYSE JNJ  to deliver a year over year increase in earnings on lower revenues when it reports results for the quarter ended December 2018  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on January 22  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This world s biggest maker of health care products is expected to post quarterly earnings of  1 95 per share in its upcoming report  which represents a year over year change of  12 1  
Revenues are expected to be  20 11 billion  down 0 4  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 96  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Johnson   Johnson 
For Johnson   Johnson  the Most Accurate Estimate is the same as the Zacks Consensus Estimate  suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate  This has resulted in an Earnings ESP of 0  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Johnson   Johnson will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Johnson   Johnson would post earnings of  2 03 per share when it actually produced earnings of  2 05  delivering a surprise of  0 99  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Johnson   Johnson doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-14,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-earnings-expected-to-grow-should-you-buy-200375742,200375742
198391,419907,JNJ,Johnson   Johnson  JNJ  Gains But Lags Market  What You Should Know,opinion,"In the latest trading session  Johnson   Johnson  NYSE JNJ  closed at  129 36  marking a  0 84  move from the previous day  This move lagged the S P 500 s daily gain of 1 07   At the same time  the Dow added 0 65   and the tech heavy Nasdaq gained 1 71  
Prior to today s trading  shares of the world s biggest maker of health care products had lost 0 67  over the past month  This has was narrower than the Medical sector s loss of 2 4  and lagged the S P 500 s loss of 0 58  in that time 
JNJ will be looking to display strength as it nears its next earnings release  which is expected to be January 22  2019  The company is expected to report EPS of  1 95  up 12 07  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  20 11 billion  down 0 42  from the year ago period 
It is also important to note the recent changes to analyst estimates for JNJ  These recent revisions tend to reflect the evolving nature of short term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 3  lower  JNJ is holding a Zacks Rank of  3  Hold  right now 
Investors should also note JNJ s current valuation metrics  including its Forward P E ratio of 14 87  Its industry sports an average Forward P E of 14 41  so we one might conclude that JNJ is trading at a premium comparatively 
It is also worth noting that JNJ currently has a PEG ratio of 1 9  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1 9 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 29  putting it in the top 12  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-01-15,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-gains-but-lags-market-what-you-should-know-200375846,200375846
198392,419908,JNJ,Despite Recent Rally  Pharma Giant Continues To Struggle  Here s The Trade,opinion,"I ve been following Johnson   Johnson  NYSE JNJ   which plunged last month on news that the company could still have issues regarding its popular baby powder product  On December 13  2018  the shares traded as high as  148 58 a share  On December 24  JNJ traded as low as  121 before finding a near term bottom with the major stock market indexes  Today the stock is trading at  128 42 a share  So while it has certainly bounced higher  JNJ has not come close to its December 13 high  In fact  the stock is now signaling weak relative strength  Traders should note that the issue is still trading below its important 200 day moving average  which is actually a sign of weakness 
Watch This Support
If the stock breaks below its key  121 support level it will trigger another sell signal  Johnson   Johnson s next major support level lies around the  113 area  Right now  JNJ is hanging in there  but this is a stock that I will be watching closely ",2019-01-16,Nicholas Santiago,https://www.investing.com/analysis/despite-recent-rally-pharma-giant-continues-to-struggle-heres-the-trade-200376269,200376269
198397,419913,JNJ,Johnson   Johnson  JNJ  Stock Moves  1 59   What You Should Know,opinion,"Johnson   Johnson  NYSE JNJ  closed at  125 72 in the latest trading session  marking a  1 59  move from the prior day  This move was narrower than the S P 500 s daily loss of 2 48   Elsewhere  the Dow lost 2 83   while the tech heavy Nasdaq lost 3 04  
Prior to today s trading  shares of the world s biggest maker of health care products had lost 12 52  over the past month  This has lagged the Medical sector s loss of 9 67  and the S P 500 s loss of 8 82  in that time 
Wall Street will be looking for positivity from JNJ as it approaches its next earnings report date  This is expected to be January 22  2019  In that report  analysts expect JNJ to post earnings of  1 95 per share  This would mark year over year growth of 12 07   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  20 11 billion  down 0 42  from the year ago period 
It is also important to note the recent changes to analyst estimates for JNJ  These revisions typically reflect the latest short term business trends  which can change frequently  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Our research shows that these estimate changes are directly correlated with near term stock prices  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 08  lower  JNJ is holding a Zacks Rank of  4  Sell  right now 
Digging into valuation  JNJ currently has a Forward P E ratio of 14 77  This represents a premium compared to its industry s average Forward P E of 14 44 
We can also see that JNJ currently has a PEG ratio of 1 88  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1 88 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 160  putting it in the bottom 37  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-01-03,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-stock-moves-159-what-you-should-know-200372721,200372721
198400,419916,JNJ,Novavax to host RSV F vaccine update July 24  shares ahead 8  premarket,news,Novavax   NASDAQ NVAX  is up 8  premarket on light volume on the heels of its announcement that  on July 24  it will release top line data from its Phase 2 clinical trial assessing its RSV F Vaccine in older adults  additional data from its prior Phase 2 and Phase 3 studies in older adults and data from its Phase 3 study in infants via maternal immunization  The conference call will begin at 4 30 pm ET Now read ,2017-07-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/novavax-to-host-rsv-f-vaccine-update-july-24;-shares-ahead-8-premarket-506737,506737
198401,419917,JNJ,Johnson   Johnson raises 2017 profit forecast after second quarter earnings beat,news,"By Divya Grover  Reuters    Johnson   Johnson  N JNJ  on Tuesday raised its full year profit forecast and reported better than expected quarterly earnings  helped by strong demand for its newer products such as cancer drug Darzalex  J J is banking on newer pharmaceutical products to reaccelerate growth and to counter slowing demand for some of the company s key products  including its top selling Remicade treatment and diabetes drug Invokana   We are optimistic that the investments we are making will accelerate our sales growth in the second half of this year   Chief Executive Alex Gorsky said in a statement  The diversified healthcare company  which completed its  30 billion acquisition of Swiss biotech Actelion  S ATLN  last month  raised its 2017 profit forecast to a range of  7 12 to  7 22 per share  from  7 00 to  7 15  Excluding special items  the Band Aid maker earned  1 83 per share in the second quarter  beating analysts  estimates by 3 cents  J J is the first among major pharmaceutical companies to report its quarterly results  and the report comes a day after a second Republican effort to pass healthcare legislation in the Senate collapsed   While sales in J J s consumer and medical device divisions rose despite a negative currency impact  demand for pharmaceutical products   its largest business   fell marginally to  8 6 billion  Sales of Remicade  which is used to treat various autoimmune disorders  fell 14 percent to  1 53 billion in the second quarter  hurt by competition  This is the third quarter in a row that J J s pharmaceutical sales have fallen short of estimates  RBC Capital analysts said in a research note  However       there appears to be a light at the end of the tunnel   BMO Capital Markets analyst Joanne Wuensch said  citing Darzalex s expanded label and the U S  Food and Drug Administration s recent nod for J J s potential blockbuster psoriasis treatment  Tremfya  J J reported total sales of  18 84 billion for the second quarter  missing the average analyst estimate of  18 95 billion  according to Thomson Reuters I B E S  The company also raised the low end of its full year revenue forecast range to  75 8 billion from  75 4 billion  It  however  kept the top end of the range unchanged at  76 1 billion   
J J s shares were up 1 3 percent at  133 90 in premarket trading ",2017-07-18,Reuters,https://www.investing.com/news/stock-market-news/johnson--amp;-johnson-reports-dip-in-quarterly-profit-506706,506706
198402,419918,JNJ,Johnson   Johnson  JNJ  Outpaces Stock Market Gains  What You Should Know,opinion,"In the latest trading session  Johnson   Johnson  NYSE JNJ  closed at  130 42  marking a  0 99  move from the previous day  The stock outpaced the S P 500 s daily gain of 0 01   Elsewhere  the Dow gained 0 35   while the tech heavy Nasdaq added 0 45  
Coming into today  shares of the world s biggest maker of health care products had lost 12 58  in the past month  In that same time  the Medical sector lost 5 57   while the S P 500 lost 7 29  
Wall Street will be looking for positivity from JNJ as it approaches its next earnings report date  This is expected to be January 22  2019  In that report  analysts expect JNJ to post earnings of  1 95 per share  This would mark year over year growth of 12 07   Our most recent consensus estimate is calling for quarterly revenue of  20 11 billion  down 0 42  from the year ago period 
JNJ s full year Zacks Consensus Estimates are calling for earnings of  8 16 per share and revenue of  81 32 billion  These results would represent year over year changes of  11 78  and  6 37   respectively 
Investors should also note any recent changes to analyst estimates for JNJ  Recent revisions tend to reflect the latest near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  The Zacks Consensus EPS estimate remained stagnant within the past month  JNJ is currently a Zacks Rank  4  Sell  
Looking at its valuation  JNJ is holding a Forward P E ratio of 15 82  For comparison  its industry has an average Forward P E of 14 23  which means JNJ is trading at a premium to the group 
Meanwhile  JNJ s PEG ratio is currently 2 02  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  JNJ s industry had an average PEG ratio of 1 9 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 95  putting it in the top 37  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow JNJ in the coming trading sessions  be sure to utilize Zacks com ",2018-12-18,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-outpaces-stock-market-gains-what-you-should-know-200369302,200369302
198403,419919,JNJ,4 Worst ETF Areas Of Q4,opinion,"The fourth quarter of 2018 was horrible for Wall Street with the key indexes losing in double digits  A flattening yield curve causing recessionary fears in the United States led to this massacre  And why not  The return of global growth concerns pulled down long term treasury yields meaningfully while a hawkish Fed kept pushing short term rates higher 
While six out of the 11 sectors in the S P 500 have so far undergone double digit losses  per an article published on Wall Street Journal  below we highlight a few key ETF areas that have lost around 30  so far in the quarter  as of Dec 19  2018  
Energy
Concerns over rising output amid softer than expected U S  sanctions on Iran and falling demand from global growth worries have weighed on oil prices in the fourth quarter United States Oil  NYSE USO   haslost about 35 in the quarter  Even the fresh output cut decided by the OPEC and Russia in early December for the first six months of 2019 could not save the liquid commodity  read    
SPDR S P Oil   Gas Equipment   Services  NYSE XES  ETF   down 45 2    Invesco S P SmallCap Energy ETF  NYSE XLE    down 44 4    VanEck Vectors Oil Services ETF   CA OIH    down 41 4   and Invesco Dynamic Oil   Gas Services ETF  are of the worst performing energy ETFs of the fourth quarter 
Marijuana
Marijuana stocks and ETF were hot trades in 2018 due to growing efforts for legalization  both for medical and recreational usages  it saw a volatile phase in November on bubble fears and some downbeat earnings releases  ETFMG Alternative Harvest ETF   SNX MJ   is down 35 5  so far this year  as of Dec 19  2018   read   
Some industry experts are of the view that overvaluation is a threat to the space  It does have bright long term prospects  But things will probably shore up slower than anticipated  Probably this is why despite going through the roof in mid September  the fund succumbed to a steep slowdown in December  read    
Biotech
This fund follows an index  which is equal weighted and is designed to measure the equity market performance of the common stock of U S  exchange listed biotechnology companies with a primary product offering that is in a phase 1  phase 2 or phase 3 clinical trial stage of development 
Being a high beta and high growth sector  biotech has been beaten down badly on a broad market rout  Some sector specific news also played foul  The world s biggest maker of health care products Johnson   Johnson  NYSE JNJ  had a tumultuous ride in December on reports that its baby powder contained cancer causing asbestos 
Also  a federal judge in Texas ruled that President Barack Obama s signature health law   the Affordable Care Act  ACA  or Obamacare   is unconstitutional in December  Virtus LifeSci Biotech Clinical Trials ETF   MZ BBC   is off 33 2  this quarter  read    
Tech   Media
It is one of the prominent spaces which saw huge selloffs in 2018  Investors should note that tech stocks  particularly FAANGs  were once investors  darling this year  However  things took a turn  causing a steep slump in Wall Street  in the October November period  Rising rate worries  overvaluation and U S  China trade tensions led to the upheaval  read    
Per   technology and Internet based companies normally see high profit margins  In a rising rate environment  the profitability of such companies will be compromised as they will end up paying higher interests on borrowed money  As a result  AdvisorShares New Tech and Media ETF   BR FNG   is down 30 3  in the fourth quarter 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2018-12-21,Zacks Investment Research,https://www.investing.com/analysis/4-worst-etf-areas-of-q4-200370339,200370339
198404,419920,JNJ,AbbVie Partners Lupin To Boost Hematological Cancer Pipeline,opinion,"AbbVie Inc    NYSE ABBV   and India based Lupin Limited announced a partnership to develop and commercialize a novel cancer drug for the treatment of hematological cancer  The partnership grants AbbVie exclusive global rights to develop and commercialize Lupin s MALT1  Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1  inhibitor program MALT 1  a protein  is involved in T cell and B cell lymphocyte activation  AbbVie is planning to develop the MALT1 inhibitors across a range of hematological cancers  the majority of them with limited treatment options Per the terms of the agreement  AbbVie will pay  30 million to Lupin in upfront payment and will be liable to pay additional  947 million in future regulatory  development and commercial milestone payments  AbbVie will also pay double digit royalty on sales  upon successful commercialization  to Lupin  The commercial rights in India for the drug will be held by Lupin Shares of AbbVie have plunged 13  year to date against the  s increase of 1 2    AbbVie believes that oncology will be its major growth driver over the next decade  The company is continuously working on expanding and accelerating its presence in oncology  building upon its growing position in the  30 billion hematological oncology market Meanwhile  AbbVie has a few oncology drugs in its marketed portfolio  Imbruvica  which is approved for several indications  has multi billion dollar potential and AbbVie is exploring the potential to expand Imbruvica s label into solid tumors and autoimmune diseases  AbbVie expects Imbruvica peak sales of more than  7 billion and revenues of about  5 billion in 2020 Apart from Imbruvica  Venclexta is another cancer drug  which is approved for some lymphoma indications  AbbVie is developing it for other hematologic malignancies AbbVie has several collaborations for developing its cancer pipeline  which include one with Roche   OTC RHHBY   for Venclexta  Johnson   Johnson   NYSE JNJ   for Imbruvica and Bristol Myers   NYSE BMY   for Empliciti among others AbbVie Inc  Price
    Zacks RankAbbVie currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-25,Zacks Investment Research,https://www.investing.com/analysis/abbvie-partners-lupin-to-boost-hematological-cancer-pipeline-200371034,200371034
198409,419925,JNJ,FDA OKs Impax Labs  generic Concerta  shares ahead 6  premarket,news,Impax Laboratories  NASDAQ IPXL  is up 6  premarket  albeit on only 750 shares  on the heels of its announcement that the FDA has approved its  generic version of Johnson   Johnson  NYSE JNJ  s ADHD med Concerta  methylphenidate hydrochloride  Extended Release tablets Per IMS Health  the U S  market is   1 8B Now read ,2017-07-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-impax-labs'-generic-concerta;-shares-ahead-6-premarket-506321,506321
198410,419926,JNJ,Johnson   Johnson beats by  0 03  misses on revenue,news,"Johnson   Johnson  NYSE JNJ   Q2 EPS of  1 83 beats by  0 03 
Revenue of  18 84B   1 9  Y Y  misses by  110M 
Shares  1 01  PM 
Press Release
Now read ",2017-07-18,Seeking Alpha,"https://www.investing.com/news/stock-market-news/johnson--amp;-johnson-beats-by-$0.03,-misses-on-revenue-506701",506701
198411,419927,JNJ,Johnson   Johnson beats on Q2 EPS  misses on revenue,news,"Investing com   Johnson   Johnson  NYSE JNJ  reported mixed results on Tuesday that beat on the bottom line  but missed on revenue  sending its shares initially 1  higher in pre market trade 
The blue chip healthcare products firm said earnings per share  EPS  came in at  1 83 in the second quarter  compared to expectations of  1 80 a share and  1 74 in the same period last year 
The firm s revenue totaled  18 84 billion in the April to June quarter  coming out just under estimates for revenue of  18 93 billion  That compared to sales of  18 48 billion in the second quarter of 2016 
 Our second quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year   chairman and chief executive officer Alex Gorsky said in the press release  adding that the company s pharmaceutical pipeline  continued its strong momentum  
Traders will now turn their attention to the bank s conference call due to start at 8 30AM ET  12 30GMT  
Following the release of the report  shares in Johnson   Johnson rose 1 07  in pre market trade to  133 50 by 6 50AM ET  10 50GMT   Its shares closed down 0 34  on Monday at  132 15 
Meanwhile  U S  equity markets pointed to a flat open  The blue chip Dow futures advanced 0 06   the S P 500 futures edged down 0 02   while the tech heavy Nasdaq 100 futures slipped 0 02  ",2017-07-18,Investing.com,"https://www.investing.com/news/stock-market-news/johnson---johnson-beats-on-q2-eps,-misses-on-revenue-506692",506692
198412,419928,JNJ,Johnson   Johnson Q2 top line up 2   earning off 4   non GAAP EPS up 5   guidance raised  shares ahead 2  premarket,news,Johnson   Johnson  NYSE JNJ  Q2 results   M   Total Revenues  18 839   1 9    Consumer  3 478   1 7    Pharmaceutical  8 635   0 2    Medical Devices  6 726   4 9   Net Income  3 827   4 3    non GAAP EPS  5 017   3 1    1 40   2 1    non GAAP EPS  1 83   5 2   Company says sales growth will accelerate in H2  Global results negatively impacted by baby care products  but partially offset by domestic OTC products 2017 Guidance  Revenues   75 8B   76 1B from  75 4B   76 1B  Non GAAP EPS   7 12   7 22 from  7 00   7 15 Shares are up 2  premarket on light volume Now read ,2017-07-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/johnson---johnson-q2-top-line-up-2;-earning-off-4;-non-gaap-eps-up-5;-guidance-raised;-shares-ahead-2-premarket-506722,506722
198413,419929,JNJ,Sector ETF Week In Review For December 10 14,opinion,"Summary
Once again  the sector orientation is defensive on a 1 week  1 month  and 3 month basis
Defensive sectors are outperforming SPY  NYSE SPY 
Don t forget about other asset classes like bonds
Let s start where we always do   the weekly performance table 
It should surprise no one that most sectors were lower last week  Financials led the way  followed by energy and real estate  Two defensive sectors   utilities and consumer staples   held the first and third spot  respectively  While most of XLV s  NYSE XLV  largest members were down  JNJ  NYSE JNJ  disproportionately impacted the sector  which explains why this traditionally defensive sector was the fourth worst performer this week 
Next up  let s look at the performance of the sectors over the last month 

Four conservative sectors are at the top of the list  Utilities were up 4 26   Real estate was up marginally  The other two defensive sectors were modestly lower  At the bottom of the list are financials  industrials  and energy 
Finally  we have the three month performance table 

Again  we have a defensive orientation  Utilities were the only real gainer  rising 5 65  Staples were up fractionally  Real estate was off modestly  healthcare was down  again  remember the JNJ effect   Thanks to weak oil prices  energy is off the most  Industrials and financials rounded out the worst performers 
The relative performance continues to favor defensive sectors 

The defensive sectors continue to outperform SPY  While financials and basic materials are  improving   neither sector is poised for solid runs right now 

After selling off with the broader market this fall  the basic materials sector is now near a 52 week low  All the EMAs are moving lower with the shorter below the longer  Prices are below all the EMAs  which will keep pulling the averages down  Momentum is negative 

Financials are near a 52 week low  Like XLB  NYSE XLB   the chart technicals are bearish  shorter EMAs are below the longer with prices poised to pull them lower  broadening Bollinger Bands  signal higher volatility  and momentum is weak and moving lower 
So  the two industries that might show potential are only  improving  because they re doing less badly than SPY  But the daily charts of both sectors are very bearish 
But looking at the 6 month charts of all the sectors  we see a near universal bearishness 
Real estate  top row  far left  is in the top third of its chart and is in the middle of a 2 month rally  It s benefitting from high yields and a belief that we re nearing the end of the Fed s tightening cycle 
Basic materials  top row  second from left   see above for technical analysis   Fundamentally  this industry relies on international trade  which means increasing trade tensions are a key factor hurting the industry  In addition  a slowing global trade environment is also a net negative 
Energy  top row  second from right   Oil is now in a bear market  Adding to the problems  the IEA recently noted that global growth  and therefore oil demand  will be weaker in 2019  further hampering the industry 
Financials  top row  far right   a flattening yield curve is hurting the industry  In addition  weaker growth decreases loan demand 
Industrials  middle row  far left   This industry is comprised of large  multi national companies that rely on international trade and global growth  meaning they re on the negative receiving end of the global trade war 
Technology  middle row  second from left   The FAANG stocks   which drove this sector higher for the majority of this expansion   are now correcting for various reasons  The global trade war issues are also hurting as is the possibility of increased regulation 
Consumer staples  middle row  second from right   a defensive sector that is currently consolidating gains 
Utilities  middle row  right   a defensive sector that is currently in an upward sloping rally 
Healthcare  bottom left   Healthcare is comprised of truly conservative companies  drug companies   wholesalers  and financial companies  health insurers   The more conservative companies are doing well  the others are mixed 
Consumer discretionary  bottom right   assuming we re at the end of the expansion  we can expect consumers to start pulling back from spending 
So what s an investor to do in this environment  First  getting defensive is entirely appropriate  Stick with healthcare  utilities  and consumer staples  Also  don t forget other assets classes  At the end of an economic cycle  bonds typically outperform stocks  which we re seeing right now 
IEF  NASDAQ IEF  the 7 10 year Treasury  is leading SPY  Finally  don t forget cash  Remember that shorter dated bonds are now providing modestly decent yields  relatively speaking 







Disclosure  I we have no positions in any stocks mentioned  and no plans to initiate any positions within the next 72 hours  I wrote this article myself  and it expresses my own opinions  I am not receiving compensation for it  other than from Seeking Alpha   I have no business relationship with any company whose stock is mentioned in this article 
Original post",2018-12-17,Hale Stewart,https://www.investing.com/analysis/sector-etf-week-in-review-for-december-200368524,200368524
198414,419930,JNJ,Technically Speaking For December 17,opinion,"Summary
The high yield market s problems are continuing
Retail stocks are selling off
At a time when the bulls could really use some good news  they didn t get any
According to the Financial Times  the high yield market is  drying up  
Investment banks are having a difficult time finding buyers for leveraged loans  leading to the postponement of a number of deals until after the first of the year  Yields in the high yield market continue to move higher 

The CCC market rose over 200 basis points over the last few months  It looked like the market had crested in mid November  but rates continued to climb in early December  Overall  rates are now at their highest level since the oil price caused blow out of 2015 2016 

This is a standard  end of the economic cycle development 
Despite a positive retail sales report on Friday  the market is selling retail stocks  
The Consumer Discretionary  NYSE RXI  is trading near a 52 week low  Other retail stocks are also falling  The VanEck Vectors Retail ETF  NYSEARCA RTH     the ETF that tracks retail stocks    is in a clear downtrend 

The ETF peaked at 112 23 at the beginning of October  It has been moving consistently lower since printing a continuing series of lower lows and lower highs  Prices are now below all the EMAs  The 10 day EMA has moved below the 200 day EMA  the 20 day will soon follow  Department stores are also falling 

The six major stores are all technically weak  The timing of this sell off    at the height of the holiday shopping season    is particularly telling 
The market s underlying technicals are deteriorating  
Let s start with the percentage of Nasdaq  stocks above their respective 50 and 200 day EMAs 



Both are right above 20     a very low level  We see the same thing for the NYSE 

Both are also in the low 20  range  In other times during this  most hated rally in history   we d be in classic  buy the dip  territory  However  the current bearish state of the market means these are very worrying numbers 
Let s check in on today s performance table 

There s a lot of red in that table  The IWM  NYSE IWM  fell the most  it was off 2 3   The QQQ  NASDAQ QQQ  wasn t far behind  neither were the mid caps or the Dow  The long end of the Treasury curve continued to rally  which will send yields lower and further compress the curve 
The industry table wasn t any better 

Everybody was down today    even the defensive sectors  utilities were the second worst performer  staples were the fourth worst  Healthcare    which has the Johnson   Johnson  NYSE JNJ  handicap    actually performed modestly well  only dropping slightly more than 2  
Before looking at the charts  let s remember where we left off last week  A lot of indexes are at or near 52 week lows  All the charts have a number of bearish indicators such as declining EMAs  shorter EMAs below longer EMAs  and negative momentum  This is also the Fed week  it would not be unheard of for the markets to tread water until the Fed announcement Wednesday afternoon 
However  most of the charts continue to contain a number of very bearish indicators

The markets opened lower  They tried to rally in the morning  twice attempting to move through last week s closing price  After forming a double top  prices moved lower for the remainder of the session  printing a series of lower lows and lower highs 
The bearishness continues on the 5 day chart 

Prices are in a solid and continual three day downtrend 
The 30 day chart is also bearish 

Prices have moved through the last technical support level and are now near a 30 day low 
And  yes  the daily chart is also bearish 
Prices have broken the lower support line of the sideways consolidation pattern 
The next logical technical support level is the 52 week low  And that s never a good place to be 




Disclosure  I we have no positions in any stocks mentioned  and no plans to initiate any positions within the next 72 hours  I wrote this article myself  and it expresses my own opinions  I am not receiving compensation for it  other than from Seeking Alpha   I have no business relationship with any company whose stock is mentioned in this article 
Original post",2018-12-17,Hale Stewart,https://www.investing.com/analysis/technically-speaking-for-december-17-200368940,200368940
198418,419934,JNJ,FDA grants Priority Review status for lower dose of J J s Xarelto,news,The FDA accepts under Priority Review Johnson   Johnson  NYSE JNJ  unit Janssen Research   Development s  supplemental New Drug Application  sNDA  seeking approval of a 10 mg daily dose of blood thinner XARELTO  rivaroxaban   It is currently approved in a 20 mg strength The agency s action date  PDUFA  is October 28 Now read ,2017-06-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-grants-priority-review-status-for-lower-dose-of-j-j's-xarelto-500055,500055
198419,419935,JNJ,Nestle plan hailed as only the start of Schneider s shake up,news,"By Silke Koltrowitz and Maiya Keidan ZURICH LONDON  Reuters    Nestle s  S NESN  plan to shore up its capital structure  announced only days after being thrust into the spotlight by activist shareholder Third Point  was received by investors as a precursor to bigger changes under the company s new leadership  Shares in the world s largest foodmaker rose as much as 2 percent on Wednesday  close to the record high touched on Monday after the New York based hedge fund disclosed a  3 5 billion stake and urged Nestle to buy back shares  set a target for margin growth and shed non core assets including its stake in L Oreal  PA OREP   Investors did not have to wait long for a response  with Nestle announcing late on Tuesday that it would launch a 20 billion Swiss franc   20 8 billion  share buyback program while leaving room for near term acquisitions  Nestle also said it would continue adjusting its portfolio and assess opportunities to boost profit margins  stopping short of setting a firm target  It added that the measures were the result of a review instigated at the start of the year after Mark Schneider took over as chief executive   The moves were welcomed by stakeholders large and small   This is a new era for Nestle and I m extremely positive on the prospects for internal and external growth   said Carine Menache  who runs a Monaco investment firm that owns Nestle shares  She and UBS analysts said the buyback should lift earnings by 6 percent  while increased merger and acquisition  M A  activity could provide a further boost    Nestle may have a poor track record for M A  but the new CEO  Schneider  is now in charge and he has a great track record   she added   Reaching a 19 percent operating margin  the midpoint of Third Point s recommendation  would lift earnings by another 8 percent  according to UBS  which said Nestle shares now offered the greatest opportunity for growth of all the European packaged goods companies it covers  bolstering its  buy  rating  Of Nestle s plan  which they described as  responsive but not reactionary  to Third Point  UBS said   We think this sends a strong message to the markets   expect more to come    SECTOR CONVULSIONS The global packaged food sector is convulsing as its main players struggle with slowing growth  changing consumer habits and the growing influence of global investment firm 3G Capital  3G s Kraft Heinz  O KHC  launched a surprise  143 billion takeover bid for  Unilever   L ULVR  in February  sparking a deep review and new agenda at the target company  Many of the demands laid out in Third Point s letter echo the steps Unilever took in the wake of the Kraft bid   Investors said the biggest omission from Nestle s response was any reference to its 25 billion euro   28 4 billion  stake in L Oreal  which dates back to 1974  when the French heiress Liliane Bettencourt sold a large part of her holding to Nestle  That omission and lack of a margin target means the announcement may not completely satisfy Third Point  which is controlled by billionaire investor Daniel Loeb  Third Point has declined to comment on the announcement at this stage and Nestle is expected to say more at its investor day in September   It s only a start   said Mirabaud Asset Management s Nicolas Burki   It will not be enough   Nestle has long touted the L Oreal stake as value creating  and a source familiar with the company s thinking said there was no change to that view   The big question  however is what Nestle would do with the cash  besides buybacks  if it sold down the L Oreal stake  The company did say its capital spending would be focused on higher growth categories of coffee  pet food  baby food and water  It added consumer health to the list of priorities  potentially making it a competitor to the likes of Johnson   Johnson  N JNJ  and GlaxoSmithKline  L GSK   However  EFG Asset Management s Urs Beck cashed out of his Nestle position on Monday s price spike and is skeptical that it can find acquisitions big enough to move the needle for a company with  93 billion in sales   The ship is just too big to be steered into different waters through portfolio management   he said  VICTORY ON BOTH SIDES  Nestle is Europe s most valuable company  with a market value of  263 billion last week  before Loeb s position was made public  adding  10 billion in one day  The positive reaction most likely reflects the bullishness of long term investors rather than event driven hedge funds looking for quick turnarounds  says Michael Wegener at Case Equity Partners in Hong Kong   Wegener said he doubts that many arbitrageurs have moved into Nestle s stock yet  since the Loeb stake remains too soft a catalyst at this stage   But one London based manager of an event driven hedge fund with no involvement with Nestle described the situation as a victory for both sides    I suspect  Third Point s  presence actually helps Schneider with his change agenda   said the manager  who asked not to be named   I suspect the buyback is not enough  but Third Point is unlikely to feel the need to get shouty    Swiss activist shareholder Rudolf Bohli said that Loeb  known for campaigns against Yahoo  NASDAQ AABA   Sony Corp  T 6758  and the Dow DuPont merger  is on the right track   
 Loeb has set the right tone and his agenda is correct   said Bohli  who recently exited GAM Holding with a profit after failing to replace the financial company s chief executive ",2017-06-28,Reuters,https://www.investing.com/news/stock-market-news/nestle-plan-hailed-as-only-the-start-of-schneider's-shake-up-500218,500218
198420,419936,JNJ,Big pharma turns to AI to speed drug discovery  GSK signs deal,news,"By Ben Hirschler LONDON  Reuters    The world s leading drug companies are turning to artificial intelligence to improve the hit and miss business of finding new medicines  with GlaxoSmithKline unveiling a new  43 million deal in the field on Sunday  Other pharmaceutical giants including Merck  NYSE MRK    Co  Johnson   Johnson  NYSE JNJ  and Sanofi  PA SASY  are also exploring the potential of artificial intelligence  AI  to help streamline the drug discovery process   The aim is to harness modern supercomputers and machine learning systems to predict how molecules will behave and how likely they are to make a useful drug  thereby saving time and money on unnecessary tests   AI systems already play a central role in other high tech areas such as the development of driverless cars and facial recognition software   Many large pharma companies are starting to realize the potential of this approach and how it can help improve efficiencies   said Andrew Hopkins  chief executive of privately owned Exscientia  which announced the new tie up with GSK  Hopkins  who used to work at  Pfizer   NYSE PFE   said Exscientia s AI system could deliver drug candidates in roughly one quarter of the time and at one quarter of the cost of traditional approaches  The Scotland based company  which also signed a deal with Sanofi in May  is one of a growing number of start ups on both sides of the Atlantic that are applying AI to drug research  Others include U S  firms Berg  Numerate  twoXAR and Atomwise  as well as Britain s BenevolentAI   In pharma s eyes these companies are essentially digital biotechs that they can strike partnerships with and which help feed the pipeline   said Nooman Haque  head of life sciences at Silicon Valley Bank in London   If this technology really proves itself  you may start to see M A with pharma  and closer integration of these AI engines into pharma R D   STILL TO BE PROVEN It is not the first time drugmakers have turned to high tech solutions to boost R D productivity  The introduction of  high throughput screening   using robots to rapidly test millions of compounds  generated mountains of leads in the early 2000s but notably failed to solve inefficiencies in the research process  When it comes to AI  big pharma is treading cautiously  in the knowledge that the technology has yet to demonstrate it can successfully bring a new molecule from computer screen to lab to clinic and finally to market   It s still to be proven  but we definitely think we should do the experiment   said John Baldoni  GSK s head of platform technology and science  Baldoni is also ramping up in house AI investment at the drugmaker by hiring some unexpected staff with appropriate computing and data handling experience   including astrophysicists  His goal is to reduce the time it takes from identifying a target for disease intervention to finding a molecule that acts against it from an average 5 5 years today to just one year in future   That is a stretch  But as we ve learnt more about what modern supercomputers can do  we ve gained more confidence   Baldoni told Reuters   We have an obligation to reduce the cost of drugs and reduce the time it takes to get medicines to patients   Earlier this year GSK also entered a collaboration with the U S  Department of Energy and National Cancer Institute to accelerate pre clinical drug development through use of advanced computational technologies  
The new deal with Exscientia will allow GSK to search for drug candidates for up to 10 disease related targets  GSK will provide research funding and make payments of 33 million pounds   43 million   if pre clinical milestones are met ",2017-07-01,Reuters,"https://www.investing.com/news/technology-news/big-pharma-turns-to-ai-to-speed-drug-discovery,-gsk-signs-deal-501288",501288
198421,419937,JNJ,Mallinckrodt s Roxicodone Reformulation Gets CRL From FDA,opinion,"Mallinckrodt plc s   NYSE MNK   subsidiary  SpecGx LLC reported that the FDA has issued a complete response letter   CRL   for its new drug application   NDA   seeking approval of opioid analgesic candidate  MNK 812  The candidate is an abuse deterrent  immediate release reformulation of commonly abused opioid painkiller  Roxicodone  oxycodone hydrochloride tablets USP  The NDA sought approval of MNK 812 for management of pain severe enough to be treated with an opioid analgesic and where alternative treatments have inadequate effect  The company had been developing the reformulation with properties designed to deter intravenous and intranasal abuse under its 505 b 2 NDA However  last month  the FDA s Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted in favor of the candidate Mallinckrodt s stock has lost 7 6  in the year so far compared with the  s decline of 16 1  The letter provides guidance on areas of further evaluation for resubmitting the NDA  The letter from the FDA was unexpected  following the positive outcome at the Advisory Committee meeting held in November  The company is evaluating the agency s guidance and will request a meeting with the FDA in the coming weeks to discuss the path forward The news comes as a setback for the company  Acthar  Mallinckrodt s largest product  is being negatively impacted by the residual impact of the previously reported patient withdrawal issues  Two CRLs   for MNK 812 and stannsoporfin   have also impacted the company s future prospects unfavorably Meanwhile  Mallinckrodt is focused on streamlining its business to focus better on its innovative medicines and therapies  Earlier this month  it announced its intention to spin off its Specialty Generics Active Pharmaceutical Ingredients business and Amitiza into a new company The company expects to create two independent and publicly traded companies   one focused on innovative specialty pharmaceutical brands and the other primarily on niche specialty generic products and API manufacturing  The spin off is expected to be completed by the second half of 2019 Mallinckrodt public limited company Price
    Zacks Rank   Stocks to ConsiderMallinckrodt currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the same space are Bristol Myers Squibb Co    NYSE BMY    Johnson   Johnson   NYSE JNJ   and Merck   Co  Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   J J and Merck carry a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings per share estimates have increased from  3 64 to  3 87 for 2018 and from  3 94 to  4 08 for 2019 over the past 60 days J J s earnings per share estimates have increased from  8 14 to  8 16 for 2018 and from  8 62 to  8 66 for 2019 over the past 60 days Merck s earnings per share estimates have increased from  4 28 to  4 34 for 2018 and from  4 66 to  4 71 for 2019 over the past 60 days The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-12-12,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodts-roxicodone-reformulation-gets-crl-from-fda-200367803,200367803
198422,419938,JNJ,J J s Tremfya Beats Novartis  Cosentyx In Head to Head Study,opinion,Johnson   Johnson   NYSE JNJ   announced results from a head to head phase III ECLIPSE study  which compared its psoriasis drug  Tremfya  guselkumab   with Novartis    NYSE NVS   psoriasis drug  Cosentyx  secukinumab   The study evaluated the efficacy of the first in class IL 23 inhibitor  Tremfya  in comparison to IL 17 inhibitor Cosentyx The assessment showed that Tremfya was superior to Cosentyx for treating adult patients afflicted with moderate to severe plaque psoriasis at week 48 of treatment  indicative of the primary endpoint Findings from the study showed that 84 5  of patients  administered with Tremfya  achieved at least 90  improvement in psoriasis skin surface area  PASI 90  at week 48 compared with 70  patients  who received Cosentyx J J will present the study outcome at the Inflammatory Skin Disease Summit in Vienna  scheduled to be held between Dec 12 and Dec 15 Shares of J J have gained 5 3  so far this year  underperforming the  increase of 7 5    We would like to remind investors that Tremfya was first approved in the United States in July 2017 and subsequently  received the EU approval in November last year for plaque psoriasis Notably  Tremfya is also being evaluated for the treatment of psoriatic arthritis and Crohn s disease in several ongoing phase III studies  ECLIPSE is the fourth phase III program on Tremfya  conducted by J J Tremfya saw strong demand trends with more than 25 000 patients now on therapy and the drug capturing 5 8  share of the psoriasis market in the United States  The drug recorded sales of  171 million in third quarter 2018 compared with  126 million in the second Zacks Rank   Other Stocks to ConsiderJ J currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the large cap pharma sector include Bristol Myers Squibb Company   NYSE BMY   and Merck   Co   Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Merck carries a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings estimates have been revised 6 3  upward for 2018 and 3 6  for 2019 over the past 60 days Merck s earnings estimates have moved 1 4  north for 2018 and 1 1  for 2019 over the past 60 days  The stock has surged 38 6  year to date The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-12-12,Zacks Investment Research,https://www.investing.com/analysis/jjs-tremfya-beats-novartis-cosentyx-in-headtohead-study-200367855,200367855
198423,419939,JNJ,The Market Turns Risk Off After Disappointing Overseas Data,opinion," Friday Market Close  Weaker economic data from China were a mirror image to strong numbers from the United States  and as investors on Friday reflected on the two sets of figures it seems they focused more on the negative than the positive 
The losses on all three major U S  indices were around 2  after retail sales data from China showed slower than expected growth and the weakest reading in five years  Numbers also showed industrial output there grew the slowest in three years  a potential sign of the effects of the ongoing trade war with the United States  Meanwhile  private sector business activity in Europe also fell  news that came just one day after the European Central Bank sliced its growth and inflation forecasts  European and Asian shares fell across the board 
The data from China contrasted with retail sales and industrial figures from the United States  where November U S  retail sales growth of 0 2  that matched Wall Street analysts  expectations and U S  industrial production in November increased by 0 6   ahead of the 0 3  forecast in a Briefing com consensus 
That wasn t enough to outweigh the concerns about economic growth abroad  Perhaps that s because the overseas data come amid a backdrop of continued worry about global economic growth prospects as the trade war between the United States and China drags on 
JNJ Weighs on Healthcare Sector
Corporate news also weighed on the market  with Dow Jones Industrial Average   DJI  component Johnson   Johnson  NYSE JNJ  dropping more than 10  after a Reuters report said the company s Baby Powder product was sometimes tainted with carcinogenic asbestos and the company kept the information from regulators and the public  JNJ issued a statement saying the Reuters article is  one sided  false and inflammatory  
JNJ helped weigh on the S P 500  SPX  healthcare sector  which was the worst performer of the day  but other healthcare names were also markedly lower  Some of the other selling could be coming as traders look toward  quadruple witching hour  next Friday  which refers to the last hour of the trading day when market index futures and options expire along with stock options and stock futures  This can result in volatility as traders unwind positions 
The strength in the dollar might have been one sign that investors were flocking to perceived  safe haven  assets  though no investment is truly safe  Market participants were also buying up U S  government debt  pushing yields lower  Wall Street s main fear gauge  the Cboe Volatility Index  VIX  jumped after days of being on the decline 
Lots of Data Scheduled
Friday s ugly trading appeared to be data driven  and investors can expect the closely watched economic numbers to keep coming in the next few days  As the numbers come in  it could be interesting to see if investors continue to buy more bonds next week and continue exiting riskier positions 
Arguably the biggest bit of economic news would be the Fed s interest rate decision  expected Wednesday  Based on the futures market  most investors seem to be expecting the central bank to raise its key rate by another 25 basis points  but the odds have dropped  and it appears that there is a not insubstantial segment of the market thinking that monetary policy makers may stand pat on rates next week 
That could be because commentary from Fed officials in recent days has become seemingly more dovish  And the picture for rate moves into next year becomes more murky  Still  the futures market projects around a 75  chance of a hike next week  which would be the fourth this year 
Even with a Fed rate hike perhaps already baked into the proverbial cake  investors are still likely to comb through Fed comments accompanying the announcement to try to glean any fresh tidbits about where policymakers think the economy and inflation could be headed 
They ll get another clue about inflation later in the week when the government reports November personal consumption expenditure  PCE  data  According to the Fed  core PCE numbers are the central bank s preferred inflation gauge  A similar number  the core consumer price index  showed prices rose an as expected 0 2  in November even while headline consumer prices were flat month over month 
One economic uncertainty that s been percolating  perhaps a bit under the radar  is the state of the U S  housing market and its effect on the broader economy  Recent numbers have been mixed  but overall it seems that higher mortgage rates have been eating into home affordability even as input prices for steel and lumber also rise 
So investors may want to pay attention to reports on November building permits and housing starts on Tuesday and existing home sales for last month on Thursday 
Investors are also scheduled to see the government s third estimate for Q3 gross domestic product  arguably the mother of all economic reports because it includes the total value of the goods and services produced in the country 
Meanwhile  a fresh reading Friday from the Atlanta Fed s GDPNow model estimated that Q4 GDP would come in at a seasonally adjusted annual rate of 3   The estimate rose from 2 4  on Dec  7 after the U S  retail sales report helped boost Q4 PCE growth expectations along with a stronger than expected showing for U S  industrial production in November 
Other notable economic reports in coming days include November data on leading indicators  durable goods orders  and personal income and spending  As with the other report  a stronger than expected data point  while good for the economy  can spark worries on Wall Street that the Fed might tighten rates too quickly and put an artificial damper on economic and corporate growth  Weaker than forecast readings can boost the market  while as expected figures can be non events 

Figure 1  Health Stocks Take A Powder  The health sector  which had been  well  pretty healthy lately  took a dive Friday along with the S P 500 Index  purple line   hurt in part by shares of key component Johnson   Johnson  JNJ   which dived after a negative media report  Data Source  S P Dow Jones Indices  Chart source  The thinkorswim  platform from TD Ameritrade  For illustrative purposes only  Past performance does not guarantee future results 
Not an Immaterial Selloff in 2018   When looking at the various stock sectors  a few of them tend to grab a lot of the headlines  especially in 2018  Info tech  for example  has been the belle of the ball over the last few years  but lately has been dancing to a dismal tune  Crude oil s massive downturn has dragged energy shares down over 12  on the year  Financials  also down over 12  have been worth watching as a bellwether to not only the overall business climate  but also as sort of a proxy for the future of interest rates  But when you look at 2018 sector performance  it s Materials that has led the charge lower down about 15  on the year 
It seems the sector has been dragged down by some of the same fundamentals pressuring energy and financials  namely concerns of a global economic slowdown  But pressure at a few individual names have certainly added fuel to the flame  DowDuPont  DWDP   which at 19  has the highest weighting in the S P 500 materials sector index  has been the target of a number of analyst downgrades as it continues its plan to split into 3 companies  and likely loses its standing as a Dow component   according to media reports  Shares are down over 20  on the year  Other big names down over 20  include International Paper  IP   Vulcan Materials  VMC  and  the biggest laggard of all  mining giant Freeport McMoran  FCX   down over 40  since the start of the year 
Cheap for A Reason  There s a quote attributed to Thomas Jefferson that says   Never buy what you do not want  because it is cheap  it will be dear to you   He could have been talking about European equities  According to research firm CFRA  European stocks are cheaper when compared to historical averages  But just because something is cheap doesn t mean it s a good deal  In this column  we ve often touched on problems facing Europe and weighing on investor s minds  But with much of the geopolitical headlines these days dominated by news of the progress  or lack thereof  on the China U S  trade front  we thought it would be a good time to dig deeper into some of the headwinds that investors in Europe could face 
Various economic indicators have shown signs of slowing growth in Europe  according to the research firm  Even so  the European Central Bank announced recently that it will end its bond buying program  And  although it may be easy to forget with all the tariff issues surrounding the U S  and China  the United States still has tariffs on steel and aluminum from the European Union  Meanwhile  France is facing violent protests  and Italy s budget remains an overhang  Even as Britain is enmeshed in trying to work out a negotiated exit from the European Union  Spain continues to face separatist pressure from people who want Catalonia to secede  While it may be tempting to chase what seems like a bargain  caution is always in order   All told  a significant amount of uncertainty remains in Europe   CFRA said   Even though valuation is attractive with the S P Euro 350 trading at 6  discount to its long term average price to  earnings ratio  CFRA remains on the sideline  
TD Ameritrade  commentary for educational purposes only  Member SIPC  Options involve risks and are not suitable for all investors  Please read Characteristics and Risks of Standardized Options ",2018-12-16,JJ Kinahan,https://www.investing.com/analysis/flipping-a-switch-the-market-turns-risk-off-after-disappointing-overseas-data-200368438,200368438
198424,419940,JNJ,Weekend Update  Higher Volatility Is The New Normal ,opinion,"VIX eased down to challenge the weekly short term support at 20 48 on Thursday  On Friday it bounced to close above its Cycle Top support resistance at 21 25  Wall Street doesn t seem to be alarmed 
Wall Street is making peace with the new normal of higher volatility as stocks careen between agonizing sell offs and sudden rallies 
After the gut wrenching  2 5 trillion wipeout in the S P 500 since early October  traders are resting at relative ease as they prep for market bumps down the road 
A measure of expected changes in the CBOE Volatility Index is sitting near its lowest level since 2016 versus the underlying fear gauge  while demand to hedge tail risks is at multi year lows 
SPX bounced at the neckline  round trips back to where it started

SPX challenged the Head   Shoulders neckline at 2583 23 on Monday  then made a near 50  retracement before losing nearly all of its gains at the close of the week  The sentiment that this action is only a test of the low is fading fast  The Cycles Model still holds out for another week or more of decline 
U S  stocks closed at their lowest level since April  with Treasuries rising alongside the yen  as mounting concern over the health of the global economy overshadowed positive trade developments and signs of strength from the American consumer 
The S P 500 Index tumbled 1 9 percent Friday  after testing February lows  erasing the week s gains  Health care and technology stocks were among the biggest decliners  The Dow Jones Industrial Average sank almost 500 points  led by Johnson   Johnson s  NYSE JNJ  biggest rout in years amid mounting legal peril  Retailers retreated even after monthly data indicated U S  consumers are still spending  Oil and Gold fell ",2018-12-16,Anthony M. Cherniawski,https://www.investing.com/analysis/weekend-update-200368450,200368450
198428,419944,JNJ,Johnson   Johnson  JNJ  Stock Moves  0 08   What You Should Know,opinion,"In the latest trading session  Johnson   Johnson  NYSE JNJ  closed at  145 91  marking a  0 08  move from the previous day  This change was narrower than the S P 500 s 0 15  loss on the day  Elsewhere  the Dow lost 0 32   while the tech heavy Nasdaq added 0 42  
Prior to today s trading  shares of the world s biggest maker of health care products had gained 0 88  over the past month  This has lagged the Medical sector s gain of 1 8  and outpaced the S P 500 s loss of 1 1  in that time 
Investors will be hoping for strength from JNJ as it approaches its next earnings release  which is expected to be January 22  2019  In that report  analysts expect JNJ to post earnings of  1 95 per share  This would mark year over year growth of 12 07   Our most recent consensus estimate is calling for quarterly revenue of  20 11 billion  down 0 42  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  8 16 per share and revenue of  81 32 billion  These totals would mark changes of  11 78  and  6 37   respectively  from last year 
Any recent changes to analyst estimates for JNJ should also be noted by investors  Recent revisions tend to reflect the latest near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  The Zacks Consensus EPS estimate remained stagnant within the past month  JNJ is currently a Zacks Rank  2  Buy  
Digging into valuation  JNJ currently has a Forward P E ratio of 17 89  This valuation marks a premium compared to its industry s average Forward P E of 14 67 
It is also worth noting that JNJ currently has a PEG ratio of 2 28  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2 03 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 98  putting it in the top 38  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2018-12-06,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-stock-moves-008-what-you-should-know-200365860,200365860
198431,419947,JNJ,Janssen files suit in U S  to block sale of Samsung Bioepis  Remicade copy,news,"By Se Young Lee SEOUL  Reuters    A unit of healthcare conglomerate Johnson   Johnson  NYSE JNJ  filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea s Samsung  KS 005930  Bioepis Co Ltd from being sold in the United States  Janssen Biotech Inc  in a suit filed to the U S  District Court of New Jersey dated Wednesday  seeks a preliminary or permanent injunction to block Samsung Bioepis  biosimilar of Remicade from sale and argues the South Korean firm violated three of its patents   We have filed a lawsuit against Samsung to investigate whether their biosimilar infliximab infringes on our manufacturing process patents for Remicade   Janssen told Reuters in a statement on Friday   Remicade is Johnson   Johnson s biggest selling drug  with U S  sales of about  5 billion a year    We are confident we do not infringe Janssen s patents   Samsung Bioepis told Reuters in a statement  adding it believes Janssen is trying to delay the market entry of its Remicade copy    We will take all necessary measures against Janssen s attempts to violate patient rights and deny patient access to effective  lower cost treatment options    Janssen s lawsuit comes about a month after Samsung  an unlisted subsidiary of contract drug maker Samsung BioLogics Co Ltd  said it got U S  Food and Drug Administration approval to sell its biosimilar of Remicade  which is marketed as Renflexis in the United States  Analysts say biotech makers face increasing competition from firms such as Samsung Bioepis  which make biosimilar copies of Remicade and other drugs and sell them for cheaper  The IMS Institute for Healthcare Informatics say biosimilars could save healthcare systems in the United States and Europe s top 5 markets as much as 98 billion euros   108 79 billion  by 2020   Samsung Bioepis  part of South Korea s top conglomerate Samsung Group  SAGR UL   develops copies of complex biotech drugs and has found early success in beating rivals to market with its versions of some of the world s top selling drugs   Its Remicade biosimilar is already selling in the European Union  while its biosimilar of Amgen s rheumatoid arthritis drug Enbrel is also selling there   
  1   0 9008 euros ",2017-05-19,Reuters,https://www.investing.com/news/stock-market-news/janssen-files-suit-in-u.s.-to-block-sale-of-samsung-bioepis'-remicade-copy-486313,486313
198432,419948,JNJ,Sanofi and Regeneron s RA med Kevzara faces crowded market,news,The FDA approval of  Sanofi   PA SASY   SNY  0 1   and Regeneron Pharmaceuticals   REGN  Kevzara  sarilumab  to treat rheumatoid arthritis  RA  is just the first hurdle in its expected march to blockbuster status FiercePharma s Tracy Staton writes that the field is already hotly contested  led by AbbVie s Humira  Roche s Actemra and  shortly  GlaxoSmithKline and Johnson   Johnson  NYSE JNJ  s sirukumab  FDA decision expected next quarter  The entrenched nature of the leaders is the overriding reason that Kevzara is priced at  39K  lower than the two leading TNF alpha drugs Kevzara is an IL 6 inhibitor which bodes well for its long term fit in the treatment paradigm according to Sanofi s Jonathan Sadeh  He says RA is commonly diagnosed in the middle aged which means they need treatment over decades  First line therapy  typically a TNF  loses its effectiveness over time so the doctors should switch to a drug with a different mechanism of action The challenge for Sanofi and Regeneron is convincing physicians that Kevzara should be used as first line instead of second  third or fourth line  This was the motivation behind the head to head study with Humira which showed the superiority of Kevzara Sadeh adds that Kevzara has shown that it stalls the progression of joint damage as determined by radiographic imaging  a key selling point Now read ,2017-05-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/sanofi-and-regeneron's-ra-med-kevzara-faces-crowded-market-487704,487704
198433,419949,JNJ,Novartis has assets to sell  investors wary of what it might buy,news,"By John Miller ZURICH  Reuters    As  Novartis   S NOVN  considers asset sales that could raise  50 billion  investors are worried any cash raised may give the Swiss drugmaker firepower for another unsuccessful megadeal  Novartis s  52 billion takeover of U S  based eye care giant Alcon  completed in 2011  saddled it with a business whose sales and profit have faltered two years running   Now  Chief Executive Joe Jimenez is reviewing Alcon s surgical devices and contact lens businesses  suggesting they could be valued at  25  35 billion if he unloads them   The American CEO is also considering disposal of a roughly  14 billion stake in cross town rival Roche  as well as his over the counter  OTC  drugs venture with GlaxoSmithKline  L GSK   worth some  10 billion Given Alcon missteps  however  investors are wary about arming Novartis with a pile of cash  for fear managers eager to refocus on cancer drugs as they address a sales hit from patent expiries might blunder into a big takeover    We would applaud selling those stakes  generally   said Stephen Anness of Invesco Perpetual  Novartis s 23rd largest shareholder  according to Thomson Reuters data    But what do you do with that money   Anness said   I would be very cautious about selling stakes   in things to raise a war chest to go and do a massive deal  only for that deal to go and be another poor deal    To be sure  Jimenez has said Novartis s M A focus remains on smaller transactions  including lower risk drug licensing deals  ranging up to  5 billion   Still  Jimenez has not dismissed the notion of a larger transaction  He suggested last year the Roche stake   amassed during former chairman and CEO Daniel Vasella s unrequited merger aspirations two decades ago   could be sold once another  potentially more significant transaction is lined up to absorb the proceeds   We re always monitoring what s going on but have not changed our position regarding our M A strategy or potential disposals   Novartis spokesman Michael Willi told Reuters  PORTFOLIO HOLES  Novartis  which is holding a two day investor event in Boston on Tuesday and Wednesday  has portfolio holes a major deal could help fill   Where rivals including Roche  S ROG   Merck  N MRK  and Bristol Myers Squibb  N BMY  have immuno oncology drugs  I O  on the market for a range of cancers  Novartis has only investigational molecules in this hot new therapy area   Vas Narasimhan  Novartis s drug development chief  could be tempted to look outside the company  some analysts said  especially as competitors including AstraZeneca  L AZN  near approval for their own I O molecules    We believe that Novartis may be pushed to liquidate assets in order to finance acquisitions in pharma   said Michael Leuchten  a UBS analyst  Speculation that Novartis might buy AstraZeneca sparked a brief jump in the British company s stock last year  There has also been talk of its interest in Bristol Myers   PUT OPTION  For its OTC joint venture with GSK that emerged out of their2014 asset swap  Novartis faces a March 2018 deadline to exercise its put option for its 36 5 percent stake   People familiar with GSK s thinking confirmed the British group would be a willing buyer of the stake  which added  234 million to Novartis s profit last year   Alcon  whose eye drugs portfolio was moved into Novartis s main pharmaceuticals unit last year  has been trimmed to include surgical equipment for conditions like cataracts as well as contact lenses and solutions   When Jimenez began his strategic review this year  he said  all options were on the table   Sales have fallen nine quarters  necessitating a costly program to arrest the fall   Even Vasella  who bought Alcon as he sought to build up a European healthcare giant akin to Johnson   Johnson  N JNJ   now acknowledges the transaction was a mistake   Alcon s problems have coincided not only with the patent expiration of its blockbuster cancer drug Gleevec but also with the lackluster launch of Novartis s new heart failure medicine Entresto  which in 2016 missed sales expectations  Like Alcon  Entresto has forced the company to step up marketing investments   A fund manager among Novartis s top 60 investors said the Alcon and Entresto stumbles raise red flags about managers  ability to tackle business challenges like a big takeover   
 A big deal might solve some of their issues  but personally I would prefer to see them doing smaller acquisitions   the investor said   A cash mountain of  50 billion would definitely make me nervous  ",2017-05-30,Reuters,"https://www.investing.com/news/stock-market-news/novartis-has-assets-to-sell,-investors-wary-of-what-it-might-buy-489619",489619
198434,419950,JNJ,Recruitment suspended in mid stage study of TESARO s niraparib  shares down 9 ,news,TESARO  TSRO  9   slumps on increased volume in apparent response to the suspension of patient recruitment in a Phase 2 clinical trial assessing niraparib for the treatment of prostate cancer being conducted by collaboration partner Janssen Biotech  JNJ  0 5   Developing   Now read ,2017-06-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/recruitment-suspended-in-mid-stage-study-of-tesaro's-niraparib;-shares-down-9-493859,493859
198435,419951,JNJ,Johnson   Johnson expects to complete Actelion purchase on June 16,news,ZURICH  Reuters    Johnson   Johnson  N JNJ  said the approval of its proposed acquisition of Swiss biotech firm Actelion  S ATLN  by the European Commission on Friday meant all regulatory approvals required to complete the  30 billion deal had now been received  The U S  company said it expected settlement of the all cash public tender offer by its Swiss subsidiary  Janssen Holding  on June 16  EU antitrust regulators on Friday approved Johnson   Johnson s planned purchase of Actelion subject to conditions intended to ensure clinical development of insomnia drugs were unaffected  Separately  Actelion said on Friday it had published the prospectus relating to the listing of shares in Idorsia  the spin off company which will be led by current Actelion Chief Executive Jean Paul Clozel  Under the agreement all Actelion shareholders will receive one Idorsia share for each Actelion share held on June 13  2017 with the new company expected to start trading on the Swiss exchange on June 16  Idorsia will specialize in the discovery and development of small molecules in multiple therapeutic areas including central nervous system disorders  cardiovascular disorders  immunological disorders and orphan diseases  the company said ,2017-06-09,Reuters,https://www.investing.com/news/stock-market-news/eu-approves-j-amp;j-purchase-of-actelion-subject-to-conditions-493752,493752
198436,419952,JNJ,Johnson   Johnson  JNJ  Dips More Than Broader Markets  What You Should Know,opinion,"In the latest trading session  Johnson   Johnson  NYSE JNJ  closed at  145 85  marking a  0 4  move from the previous day  This move lagged the S P 500 s daily loss of 0 22   Meanwhile  the Dow lost 0 11   and the Nasdaq  a tech heavy index  lost 0 25  
Coming into today  shares of the world s biggest maker of health care products had gained 4 61  in the past month  In that same time  the Medical sector gained 6 05   while the S P 500 gained 3 57  
Wall Street will be looking for positivity from JNJ as it approaches its next earnings report date  This is expected to be January 22  2019  In that report  analysts expect JNJ to post earnings of  1 95 per share  This would mark year over year growth of 12 07   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  20 11 billion  down 0 42  from the year ago period 
JNJ s full year Zacks Consensus Estimates are calling for earnings of  8 16 per share and revenue of  81 32 billion  These results would represent year over year changes of  11 78  and  6 37   respectively 
Investors should also note any recent changes to analyst estimates for JNJ  Recent revisions tend to reflect the latest near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate remained stagnant within the past month  JNJ is holding a Zacks Rank of  2  Buy  right now 
Investors should also note JNJ s current valuation metrics  including its Forward P E ratio of 17 94  This valuation marks a premium compared to its industry s average Forward P E of 14 86 
Also  we should mention that JNJ has a PEG ratio of 2 29  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2 03 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 59  which puts it in the top 23  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
You can find more information on all of these metrics  and much more  on Zacks com ",2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-dips-more-than-broader-markets-what-you-should-know-200363744,200363744
198437,419953,JNJ,Key Pharma Players With HIV Focus Ahead Of World Aids Day ,opinion,"Acquired Immuno Deficiency Syndrome  popularly known as AIDS  is a pandemic caused due to the infection of human immunodeficiency virus   HIV    The virus weakens the immune system by destroying cells that fight diseases and infections  eventually leading to AIDS  Medicines for the treatment of HIV are called antiretroviral therapy   ART   that slow or put a check on the progression of the disease  The majority of them work either by blocking enzymes needed by HIV virus to multiply or inhibiting its entry into certain immune cells Like every year  World AIDS Day will be celebrated on Dec 1 in an effort to unite people in the fight against HIV  show support for HIV affected people and in memory of people who have lost their lives to AIDS related illness 
World AIDS Day is one of the eight official global public health campaigns carried out by the World Health Organization   WHO    According to WHO  globally  about 36 7 million people are living with the deadly virus  Per an estimate  the disease has taken more than 35 million lives since it was first identified in 1984 Per a UNAIDS report  more than 9 4 million people are unaware of their HIV infected status  Thus  the theme of the 30th anniversary of this campaign is  Know Your Status  Although there is no cure for the disease yet  there has been significant progress in the field of HIV treatment  which helps to slow disease progression and restrict secondary infections and complications  However  the huge number of HIV affected patients shows that it is a long road ahead before the disease can be eradicated completely  The lack of knowledge of HIV status is a significant roadblock as it prevents timely and accurate treatment Despite improved medical understanding of HIV and significant efforts made by leading government and medical bodies to prevent and treat HIV AIDS  this disease still has limited treatment options  Based on these statistics  it is not surprising that several healthcare companies are investing a significant amount of their R D expenditures on developing treatments and devices for HIV and AIDS  There are more than 40 FDA approved therapies available including 8 new regimens receiving approval this year  Several therapies are under development Stocks to Watch Out For Ahead of World AIDS Day  we present some key pharma companies developing treatments for HIV GlaxoSmithKline   NYSE GSK   has a long standing commitment to HIV and AIDS  The company had developed the widely used antibiotic amoxycillin around 40 years ago  which was the first medicine approved to treat HIV  Though sales of its older HIV products   Epzicom and Selzentry   have been declining due to generic competition  its new products  Triumeq and Tivicay  are among the major drivers of the company s top line  In 2017  it received approval for its first two drug regimen for HIV   Juluca   which is a combination of Johnson   Johnson s   NYSE JNJ   Edurant and Glaxo s Tivicay  It is also showing strong uptake  The company s HIV portfolio generated sales of  4 6 billion in first nine months of 2018  representing year over year growth of 12  at constant exchange rate On its third quarter conference call  the company stated that it expects the HIV franchise to be an important growth driver for its Pharma business going forward  There were some positive developments in its HIV pipeline recently  It has made regulatory filings in the United States and Europe to get its HIV drug  Tivicay approved as a two drug regimen  2DR  in combination with lamivudine on the back of the positive GEMINI study data  Glaxo anticipates U S  approval in the second quarter of 2019 Glaxo also announced positive data from both the FLAIR and ATLAS studies this year  evaluating cabotegravir plus rilpivirine in a long acting  once monthly HIV formulation  Glaxo believes that this long acting injectable HIV therapy will provide a highly differentiated treatment option for patients seeking a long lasting therapy for HIV  freeing them of the burden of daily oral therapy  It believes the positive data from these studies will allow it to file for approval in the first half of 2019 Glaxo currently carries a Zacks Rank  2  Buy   You can see  Gilead   NASDAQ GILD   is another dominant player in the HIV market with an impressive portfolio  In fact  Gilead s HIV franchise is a major contributor to sales with approved drugs like Genvoya  Truvada  Atripla  Stribild  Descovy  Odefsey and Complera  Sales at this franchise have grown 10  year over year to  10 6 billion in the first nine months of 2018  It also represents more than 65  of total product revenues for the period The company is the first to introduce single tablet regimen   STR   for treating HIV and has several STR regimens in its portfolio  Gilead s latest STR treatment for HIV is Biktarvy  which was approved earlier this year  The company is developing Biktarvy for treatment na ve adults in a late stage study  Meanwhile  Gilead is looking to transition the HIV market to drugs with improved long term safety profiles However  the older drugs are facing generic competition and their sales have slumped significantly year over year Gilead currently sports a Zacks Rank  1 Another company working toward developing HIV drugs is Johnson and Johnson  The company markets Juluca with Glaxo  Further  the company along with The Bill   Melinda Gates Foundation and National Institutes of Health is conducting a clinical study for an investigational mosaic HIV 1 preventive vaccine In July  J J s Symtuza  a darunavir based once daily single tablet regimen for the treatment of HIV  was approved in the United States J J is a Zacks Rank  2 company Other DrugsSome other popular marketed HIV drugs are AbbVie s   NYSE ABBV    Kaletra and Merck s   NYSE MRK   Isentress  In August 2018  Merck received approval for two new HIV drugs   Pifeltro and Delstrigo  These two were approved in EU this week 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/key-pharma-players-with-hiv-focus-ahead-of-world-aids-day-200363965,200363965
198438,419954,JNJ,Why Is AbbVie  ABBV  Up 17 5  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for AbbVie  ABBV   Shares have added about 17 5  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is AbbVie due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  AbbVie Q3 Earnings Beat Estimates  2018 EPS View UpThird quarter 2018 earnings of  2 14 per share beat the Zacks Consensus Estimate of  2 01  The figure surged 51 8  year over year  Earnings per share also exceeded the guided range of  2 00 and  2 02  Strong sales  operating margins and lower tax rate led to the bottom line beat Revenues of  8 24 billion marginally missed the Zacks Consensus Estimate of  8 26 billion  Sales rose 17 8  on a reported basis  Excluding a 0 7  unfavorable impact from foreign exchange rate fluctuations  operational revenues rose 18 5  backed by continued strong performances by Humira and Imbruvica  Operational revenue growth was better than the expectation of approximately 17  Currency tailwinds of 0 7  were in line with management expectation of a negative impact of approximately 1  Quarter in DetailsHumira sales rose 9   9 8  on an operational basis  to  5 1 billion  Sales in the United States increased 12 5  to  3 5 billion  better than expectation of 11  growth  The sales growth was driven by strong prescription volume growth and favorable pricing  Humira sales in the ex U S  markets were up 4 2  on an operational basis and 1 8  on reported basis to  1 58 billion  almost in line with the projected figure of  1 6 billion In the U S  market  Humira sales are expected to be approximately  13 7 billion in 2018  Internationally  Humira sales are expected to approach  6 3 billion in 2018  previously  6 4 billion   which includes the expected impact of biosimilar entrants in Europe in the fourth quarter  In 2019  international Humira sales are expected to decline in the range of 26 27  AbbVie s oncology hematology  including Imbruvica and Venclexta  sales rose 48 1  to  1 07 billion in the quarter  Third quarter net revenues from Imbruvica were  972 million  up 41 3  year over year primarily driven by market share gains across all lines of therapy in CLL as well as favorable pricing  U S  sales of Imbruvica grossed  812 million  up 41 5  from the year ago figure  AbbVie logged  160 million of international profit sharing with J J  NYSE JNJ   up 40 1  year over year In 2018  Imbruvica global revenues are expected to exceed  3 5 billion  previously  3 4 billion  with sales in the United States likely to cross  2 9 billion  previously  2 8 billion  Venclexta brought in revenues of  96 million  up more than 100  year over year driven by uptake in the second line plus setting following approval in the broad relapsed refractory CLL segment  MURANO study  in June HCV products  including Viekira and Mavyret  recorded sales of  862 million  up more than 100  year over year  on the back of strong demand for Mavyret  which was launched in the second half of 2017  Though global HCV sales were higher than management s expectation of  850 million  it declined sequentially from the second quarter due to lower international sales as a result of fewer warehoused patients in certain markets Mavyret alone accounted for nearly  839 million in the quarter  up more than 100  year over year driven by rapid uptake  On the call  the company said that Mavyret commands roughly 50  market share globally In 2018  global HCV sales are expected to be higher than  3 5 billion Other products that performed well include Lupron   214 million  up 7 5  year over year   Creon   239 million  up 11 3    Duodopa   106 million  up 13 3   and Kaletra   88 million  up 6   Margins RiseAdjusted gross margin rose 90 bps to 81 7  in the quarter  Adjusted SG A expenses increased 8 4  to  1 56 billion  However  as a percentage of sales  SG A expenses declined 170 bps to 19 1  in the quarter  reflecting sales leverage and operational efficiencies  R D expenses escalated 6  to  1 27 billion in the quarter due to greater investments in the pipeline  Adjusted operating margin was 47 2  of sales in the reported quarter  up 430 bps year over year AbbVie s board of directors announced 11 5  increase in its quarterly dividend from  0 96 per share to  1 07 per share  The first increased dividend will be paid on Feb 15  2019 to shareholders of record as of Jan 15  20192018 OutlookAbbVie raised its adjusted EPS guidance to the range of  7 90  7 92 for 2018 from  7 76  7 86 predicted earlier  The earnings guidance indicates a year over year surge of 41 3  at the mid point Revenues are expected to approach  32 7 billion  including currency impact   higher than the previous expectation of  32 5 billion  Total revenues are expected to grow 15  operationally  Currency impact is expected to benefit revenues by less than 1  in 2018 Adjusted gross margin is expected to be above 80 5  of sales in 2018 Operating margin is expected to be approximately 45   Previously  AbbVie expected operating margin to be above 44  of sales Fourth Quarter 2018 OutlookFourth quarter earnings are expected between  1 89 and  1 91 per share  indicating year over year growth of more than 28  at the midpoint  Revenues are estimated to grow above 7  on an operational basis  Foreign exchange is expected to have less than 1  unfavorable impact on sales in the fourth quarter Preliminary Outlook for 2019AbbVie said it is confident of delivering double digit earnings growth in 2019 despite negative impact from EU Humira biosimilar entry  a difficult comparison year  as HCV sales ramped up rapidly in 2018  and significant investments to support product launches  
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended downward during the past month 
VGM Scores
At this time  AbbVie has a great Growth Score of A  though it is lagging a bit on the Momentum Score front with a B  Following the exact same course  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  AbbVie has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-12-01,Zacks Investment Research,https://www.investing.com/analysis/why-is-abbvie-abbv-up-175-since-last-earnings-report-200364306,200364306
198439,419955,JNJ,J J s Blood Cancer Drugs Succeed In Label Expansion Studies ,opinion,Johnson   Johnson   NYSE JNJ   presented positive data from late stage label expansion studies evaluating its blood cancer drugs  Imbruvica and Darzalex  in previously untreated patients at the annual meeting of the American Society of Hematology  ASH  held in San Diego  CA New findings from a phase III study showed that its key cancer drug  Imbruvica  as a combination therapy  significantly improved survival compared to standard chemo immunotherapy regimen in previously untreated chronic lymphocytic leukemia small lymphocytic lymphoma  CLL SLL  patients  J J markets Imbruvica in partnership with AbbVie   NYSE ABBV   With nearly three years of follow up  interim data from the E1912 head to head study showed that Imbruvica in combination with Roche s   OTC RHHBY   Rituxan significantly prolonged progression free survival  PFS   the primary endpoint of the study  as a first line treatment for CLL SLL patients aged 70 or younger compared to fludarabine  cyclophosphamide and rituximab  FCR   The Imbruvica combination therapy resulted in a 65  reduction in the risk of progression or death  Moreover  the combination significantly improved overall survival  OS  compared to FCR  Note that FCR is the most commonly used treatment regimen for younger patients with CLL At ASH  J J also presented data from a phase III study  MAIA  evaluating Darzalex in combination with standard of care treatment regimen   Celgene s   NASDAQ CELG   Revlimid  lenalidomide  and dexamethasone  Rd    in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant  ASCT   At a median follow up of 28 months  the data showed that the addition of Darzalex to Rd significantly reduced the risk of disease progression or death by 44  in such patients compared to treatment with Rd alone  While PFS for patients who received Rd alone was 31 9 months  the median PFS for Darzalex plus Rd arm was not reached  The complete response rates and very good partial response  VGPR  rates were also higher in the patients receiving Darzalex plus Rd versus those receiving Rd alone Based on the data from the MAIA study  J J plans to file supplemental biologics license application  sBLA  for FDA approval of Darzalex in this patient population We remind investors that in May  Darzalex was approved in combination with bortezomib  melphalan and prednisone  VMP  for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for ASCT So far this year  J J s stock has risen 4 7  compared with an increase of 10 4  recorded by the    Both Darzalex and Imbruvica are key drugs in J J s oncology portfolio and contribute significantly to the drug giant s top line  Darzalex recorded sales of  1 4 billion in the first nine months of 2018  rising 65 4  on a year over year basis  Imbruvica sales in the same period were  1 9 billion  up almost 40  Imbruvica is currently approved for nine indications across six different cancer types and the drug is also being evaluated in a number of combination therapies  Darzalex  presently marketed for multiple myeloma in patients who have received at least three prior lines of therapy  is being evaluated in a comprehensive clinical development program across a range of treatment settings in multiple myeloma  such as in front line and relapsed settings J J currently has a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/jjs-blood-cancer-drugs-succeed-in-label-expansion-studies-200365310,200365310
198440,419956,JNJ,Why Is Theravance Bio  TBPH  Up 17 9  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Theravance Biopharma  TBPH   Shares have added about 17 9  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Theravance Bio due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Theravance Biopharma Beats on Q3 Earnings  Inks Deal for VibativTheravance Biopharma incurred third quarter 2018 loss of  1 10 per share  narrower than the Zacks Consensus Estimate of a loss of  1 18 and the year ago loss of  1 27 Total revenues in the quarter skyrocketed 200  year over year to  12 8 million  mainly on the back of an upfront payment received from J J  NYSE JNJ  in relation to a joint development agreement for Theravance s pan Janus kinase inhibitor  TD 1473  Moreover  the top line surpassed the Zacks Consensus Estimate of  10 8 million Quarterly DetailsVibativ g generated U S  revenues of  3 8 million in the third quarter  down 7 3  from the year ago period s figure  Revenues from collaborations were  8 9 million compared with  0 14 million in the year earlier quarter Research and development expenses were  52 7 million  up 34 1  from the year ago period  primarily due to higher cost related to employees and share based compensation 2018 Outlook ReiteratedTheravance persistently anticipates operating loss excluding non cash share based compensation for 2018 in the range of  180  200 million 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted 15 93  due to these changes 
VGM Scores
Currently  Theravance Bio has a subpar Growth Score of D  however its Momentum Score is doing a lot better with a B  However  the stock was allocated a grade of F on the value side  putting it in the fifth quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Notably  Theravance Bio has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-12-05,Zacks Investment Research,https://www.investing.com/analysis/why-is-theravance-bio-tbph-up-179-since-last-earnings-report-200365663,200365663
198443,419959,JNJ,J J ordered to pay  110 million in U S  talc powder trial,news,"By Nate Raymond  Reuters    Johnson   Johnson  NYSE JNJ  on Thursday was ordered by a Missouri jury to pay over  110 million to a Virginia woman who says she developed ovarian cancer after decades of using of its talc based products for feminine hygiene  The verdict in state court in St  Louis was the largest so far to arise out of about 2 400 lawsuits accusing J J of not adequately warning consumers about the cancer risks of talc based products including its well known Johnson s Baby Powder  Many of those lawsuits are pending in St  Louis  where the J J has faced four prior trials  three of which resulted in  197 million verdicts against J J and a talc supplier  Thursday s verdict came in a lawsuit against J J and talc supplier Imerys Talc by Lois Slemp  a resident of Virginia who is currently undergoing chemotherapy after her ovarian cancer initially diagnosed in 2012 returned and spread to her liver  Slemp claimed she developed cancer after four decades of using talc containing products produced by J J  including J J s Baby Powder and Shower to Shower Powder  The jury awarded  5 4 million in compensatory damages and said J J was 99 percent at fault while Imerys was just 1 percent  It awarded punitive damages of  105 million against J J and  50 000 against Imerys  Reuters watched the verdict through Courtroom View Network  which broadcast it online   Once again we ve shown that these companies ignored the scientific evidence and continue to deny their responsibilities to the women of America   Ted Meadows  a lawyer for Slemp and other plaintiffs  said in a statement  J J in a statement said it sympathized with women impacted by ovarian cancer but planned to appeal   We are preparing for additional trials this year and we continue to defend the safety of Johnson s Baby Powder   J J said  The verdict came after J J secured its first trial win in the Missouri litigation  when a jury in March sided with the company in a lawsuit by a Tennessee woman who said she developed cancer after using Baby Powder  That verdict broke a three trial winning streak by plaintiffs that began with a verdict in February 2016 in which a jury awarded  72 million to the family of a woman who died from ovarian cancer   In May 2016  another jury awarded  55 million to a woman who said J J s talc powder products caused her to develop cancer  A third jury hit J J and Imerys with a  70 million verdict in October   
The case is Slemp v  Johnson   Johnson  22nd Judicial Circuit of Missouri  No  1422 CC09326 01 ",2017-05-04,Reuters,https://www.investing.com/news/stock-market-news/j-amp;j-ordered-to-pay-$110-million-in-talc-product-liability-trial-480409,480409
198444,419960,JNJ,Johnson   Johnson to hold business review event,news,Wells Fargo   NYSE WFC  issues a preview on Johnson   Johnson s  JNJ  0 2   Pharmaceuticals Business Review Day event schedule for May 17  The company is expected to talk long term potential at the meeting  WF note   JNJ s 2017 sales guidance of 3 3 5  organic growth implies low single digit Pharma sales growth  mid single digit adjusted   below 9 10  adjusted growth in 2014 16  The last time that the Pharmaceuticals business grew in the low  to mid single digit was in 2012 when organic growth was estimated around 5   As such  we expect the analyst meeting to focus on the following key drivers to re accelerate Pharmaceuticals growth in 2018 and beyond  1  key in market products  2  the development pipeline  and 3  the ATLN acquisition  Specifically  we expect JNJ to highlight several key in market products with sustained growth opportunity beyond 2017  including Darzalex  Xarelto  Simponi  Imbruvica  Stelara  and the long acting atypical franchise   Johnson   Johnson event webcast Now read ,2017-05-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/johnson---johnson-to-hold-business-review-event-481188,481188
198445,419961,JNJ,J J discloses U S  probe related to arthritis drugs,news," Reuters    Healthcare conglomerate Johnson   Johnson  NYSE JNJ  said on Monday the U S  Justice Department has opened an investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that bought two of its drugs  The U S  healthcare company said its Janssen Biotech Inc unit received a civil investigative demand from the Justice Department regarding an investigation under the False Claims Act related to its arthritis drugs Remicade and Simponi Aria  J J also revealed in its quarterly filing that the U S  Attorney s Office in Massachusetts is seeking documents broadly relating to pharmaceutical co payment support programs for hepatitis C drug Olysiotm  Simponi and Crohn s disease drug Stelara   
That office s subpoena also seeks documents relating to average manufacturer price and best price reporting to the Center for Medicare and Medicaid services related to those products  as well as rebate payments to state Medicaid agencies  Johnson   Johnson said in the filing ",2017-05-08,Reuters,https://www.investing.com/news/stock-market-news/j-amp;j-discloses-u.s.-probe-related-to-arthritis-drugs-481424,481424
198446,419962,JNJ,New York county sues Purdue  J J over opioid marketing,news,"By Nate Raymond  Reuters    A county in New York state has sued Purdue Pharma LP  Johnson   Johnson  N JNJ  and other drugmakers  accusing them of engaging in fraudulent marketing that played down the risks of prescription opioid painkillers  leading to a drug epidemic  The lawsuit  which also named units of Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  and Endo International Plc  O ENDP  as defendants  was announced on Monday by Orange County  New York  which is located in the southeastern part of the state  The case  filed in a New York state court on Thursday  is the latest lawsuit by local and state governments seeking to hold drugmakers accountable for a national opioid epidemic  The lawsuit claims the drugmakers through deceptive marketing misrepresented the dangers of long term opioid use to doctors  pharmacists and patients  Those misrepresentations about drugs like Purdue s OxyContin and Endo s Opana ER led Orange County to incur health care  criminal justice and other costs related to addiction  the lawsuit said  Orange County  which has a population of about 379 000  said it recorded 943 opioid related emergency department admissions in 2014 and 44 deaths from overdoses involving opioid pain relievers in 2015  Orange County Executive Steven Neuhaus said in a statement the county has been working with non profits and doctors to increase awareness to opioid related problems   At the same time  we want those responsible to compensate the taxpayers for the public funds the county has had to pay to address opioid addiction   he said  The lawsuit also named four physicians as defendants  J J in a statement called the allegations  unfounded  and noted its drugs carry U S  Food and Drug Administration mandated warnings  Purdue said it shares officials  concerns about the opioid crisis and is  committed to working collaboratively to find solutions   Endo did not respond to a request for comment  Teva declined to comment  Opioid drugs  including prescription painkillers and heroin  killed over 33 000 people in the United States in 2015  more than any year on record  the U S  Centers for Disease Control and Prevention said  Orange County s lawsuit is the fourth since August by a New York county seeking to recover costs related to opioid addiction  Several other counties are also considering suing   Drugmakers also face lawsuits by Santa Clara and Orange counties in California  the city of Chicago and Mississippi over their marketing practices  
Some state attorneys general have started similar investigations  J J this month said New Jersey s attorney general had issued a subpoena related to opioid marketing ",2017-05-15,Reuters,"https://www.investing.com/news/stock-market-news/new-york-county-sues-purdue,-j-amp;j-over-opioid-marketing-484590",484590
198447,419963,JNJ,County in New York goes after J J  Teva and Endo for fraudulent marketing of opioids,news,Reuters reports that Orange County  New York has filed a lawsuit against Johnson   Johnson  NYSE JNJ   Teva Pharmaceutical Industries  NYSE TEVA   Endo International  NASDAQ ENDP  and other drug makers accusing them of fraudulent marketing that minimized the risk of prescription opioid pain medications which led to the epidemic of abuse In a statement  J J called the allegations  unfounded  noting the FDA required warning on the labeling  Teva and Endo declined comment Now read ,2017-05-16,Seeking Alpha,"https://www.investing.com/news/stock-market-news/county-in-new-york-goes-after-j-j,-teva-and-endo-for-fraudulent-marketing-of-opioids-484870",484870
198448,419964,JNJ,J J diabetes meds get boxed warnings on amputation risks,news,Based on data from two large clinical trials  the FDA is requiring Johnson   Johnson  JNJ  0 4   to add a boxed warning to the package inserts of diabetes meds Invokana  Invokamet and Invokamet XR about the risks of leg and foot amputations from taking canagliflozin  the active ingredient Source  BloombergNow read ,2017-05-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/j-j-diabetes-meds-get-boxed-warnings-on-amputation-risks-484926,484926
198449,419965,JNJ,The Zacks Analyst Blog Highlights  Pfizer  AbbVie  J J  Glaxo And AstraZeneca,opinion,For Immediate ReleaseChicago  IL  November 26  2018   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Pfizer   NYSE PFE    AbbVie   NYSE ABBV    J J   NYSE JNJ    Glaxo   NYSE GSK   and AstraZeneca   NYSE AZN   Here are highlights from Friday s Analyst Blog  Pharma Stock Roundup  PFE  ABBV   MoreThis week  the FDA granted approval to Pfizer s Daurismo  the drug giant s fourth new cancer drug in less than three months  It also approved the label expansion of AbbVie Roche s drug Venclexta  Both the drugs gained approval for the treatment of acute myeloid leukemia  AML   a rare blood cancer in newly diagnosed patients  The Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  gave positive recommendations for granting marketing approval to several drugs this week Recap of the Week s Most Important StoriesPfizer Gets FDA Nod for Rare Cancer Medicine   The FDA granted approval to Daurismo for a rare blood cancer  Pfizer s fourth cancer in less than three months  Daurismo  glasdegib   a once daily oral medicine is approved for use in combination with low dose cytarabine  LDAC    a kind of chemotherapy treatment   for the treatment of newly diagnosed acute myeloid leukemia  AML  in patients 75 years or older or who cannot take intensive chemotherapy  However  the approval comes with a boxed warning on the U S  label for embryo fetal toxicityPfizer s recent new cancer drug approvals include Lorbrena  lorlatinib  for second line non small cell lung cancer  Vizimpro  dacomitinib  for advanced NSCLC with EGFR activating mutations and Talzenna  talazoparib   an orally available PARP inhibitor for advanced breast cancer However  Pfizer s late stage study evaluating its PD L1 inhibitor Bavencio  avelumab   in patients with platinum resistant refractory ovarian cancer  of overall survival  OS  or progression free survival  PFS  In the study  both PFS and OS did not reach statistical significance  Bavencio is marketed for metastatic Merkel cell carcinoma in the United States  Europe and Japan and for the second line treatment of locally advanced or metastatic urothelial carcinoma in the United States Pfizer was also in news this week as a Wall Street report stated that it of 41 prescription drugs in 2019  The drug giant had put off such increases earlier this year as it faced criticism from President Trump AbbVie Roche Get FDA Nod for Venclexta in First Line AML  FDA also granted accelerated approval to AbbVie and partner Roche s supplemental new drug application  sNDA  looking for a label expansion of   AML   one of the most aggressive blood cancers Venclexta can now be prescribed in combination with azacitidine  or decitabine  or low dose cytarabine  LDAC  in AML patients who are ineligible for intensive chemotherapy  Venclexta is now approved for two different blood cancers in the United States   newly diagnosed AML and relapsed refractory  R R  chronic lymphocytic leukemia  CLL CHMP Gives Positive Opinion to Several Drugs  The CHMP gave a positive opinion  Erleada  apalutamide  for the treatment of adult patients with non metastatic castration resistant prostate cancer  nmCRPC  who are at high risk of developing metastatic disease  Erleada gained FDA approval in the United States in February  The CHMP also gave a nod to Glaxo s filing looking for EU approval of its HIV drug  Tivicay as a two drug regimen  2DR  in combination with lamivudine AstraZeneca Presents Final OS Data From MYSTIC Study  AstraZeneca announced final  from the pivotal phase III MYSTIC study  evaluating Imfinzi in first line lung cancer  The MYSTIC study evaluated Imfinzi  both as a monotherapy and in combination with tremelimumab  in treatment na ve non small cell lung cancer  NSCLC  patients whose tumors express PD L1 on 25  or more of their cancer cells The data from the primary analysis population of patients showed that Imfinzi monotherapy as well as in combination with tremelimumab failed to achieve statistical significance in the primary endpoint of overall survival compared to standard of care platinum based chemotherapy  Per data announced in July last year  the study failed to show improvement in progression free survival  thereby failing to meet the first primary endpoint Novartis Gets FDA Nod for Promacta in First Line Setting  Novartis gained FDA approval for label expansion of its anemia drug  Promacta as a for severe aplastic anemia  SAA  in combination with standard immunosuppressive therapy  IST   Promacta is already marketed for SAA for patients who have had an insufficient response to IST  A decision by the European Medicines Agency for a similar label expansion is expected in 2019  Promacta was also granted a Breakthrough Therapy designation by the FDA as a counter measure for hematopoietic sub syndrome of acute radiation syndrome  H ARS  Glaxo Files for Approval of Nucala in Pediatric Patients  Glaxo filed a supplemental Biologics License Application  sBLA  to the FDA  seeking label expansion of its severe eosinophilic asthma drug   aged six to 11 years  in the United States  The drug is already marketed in the United States and EU for patients aged 12 years or older  In the EU  it received approval for pediatric use  from aged six 17 years  in severe eosinophilic asthma in August  Nucala is a key drug in Galxo s respiratory portfolio  recording sales growth of 81  at constant exchange rate in the first nine months of 2018 FDA Accepts Allergan s sNDA for Avycaz  The FDA accepted Allergan s sNDA looking for approval of the latter s antibacterial medicine  Avycaz  for the pediatric patient population  The sNDA is seeking approval for Avycaz for the treatment of complicated urinary tract infections  cUTI  and complicated intra abdominal infections  cIAI   in combination with metronidazole  in pediatric patients  aged three months and above  Avycaz is already approved to treat these infections in adult patients The NYSE ARCA Pharmaceutical Index declined 0 9  in the last four trading sessions Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-11-25,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-pfizer-abbvie-jj-glaxo-and-astrazeneca-200362438,200362438
198450,419966,JNJ,Glaxo Inks Marketing Deal For Anaemia Candidate In Japan,opinion,GlaxoSmithKline plc   NYSE GSK   announced that it has signed a strategic collaboration deal with Japanese company Kyowa Hakko Kirin Co   Ltd for the future commercialization of its late stage candidate  daprodustat  in Japan  Daprodustat  an oral hypoxia inducible factor prolyl hydroxylase inhibitor  is currently being evaluated in phase III studies for the treatment of anaemia associated with chronic kidney disease  CKD  Per agreement  Glaxo will be responsible for completing the ongoing phase III studies on daprodustat and the subsequent regulatory submissions for its marketing authorization in Japan  While Kyowa Hakko Kirin will take care of the product s distribution marketing in Japan  On approval  both companies will jointly look after the commercialization and launch activities of the same  Financial details of the contract have been kept under the wraps though Glaxo expects to submit a regulatory application to the Japanese Ministry of Health  Labour and Welfare for daprodustat in 2019  The company believes that this will be a new oral treatment option for Japanese patients suffering anaemia associated with CKD Last month  Glaxo announced data from the second analysis of the three phase III studies evaluating daprodustat on Japanese patients afflicted with anaemia associated with CKD  The outcomes showed that oral daprodustat met its primary endpoint of non inferiority to darbepoetin alfa IV injection as measured by mean haemoglobin levels over weeks 40 to 52  Findings from the first phase III study were presented at the American Society of Nephrology s Kidney Week in the same month Results from the third phase III study on non dialysis dependent Japanese patients are awaited in the first half of 2019 Shares of Glaxo have rallied 14 6  year to date compared with the  increase of 6 7  Zacks Rank   Other Stocks to ConsiderGlaxo currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the large cap pharma sector include Bristol Myers Squibb Company   NYSE BMY    Johnson   Johnson   NYSE JNJ   and Merck   Co   Inc    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   J J and Merck carry a Zacks Rank of 2  You can see  Bristol Myers  earnings estimates have been revised 6 9  upward for 2018 and 6 8  for 2019 over the past 60 days J J s earnings estimates have moved 0 2  north for 2018 and 0 6  for 2019 over the past 60 days  The stock has inched up 1 8  so far this year Merck s earnings estimates have been raised 1 6  for 2018 and 1 7  for 2019 over the past 60 days  The stock has surged 32 7  year to date Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-25,Zacks Investment Research,https://www.investing.com/analysis/glaxo-inks-marketing-deal-for-anaemia-candidate-in-japan-200362403,200362403
198451,419967,JNJ,AMAG s Label Expansion Of Lead Products Raises Share Price,opinion,"Share price of AMAG Pharmaceuticals  Inc    NASDAQ AMAG   has increased 37 9  year to date  against the  s decline of 19 0  

AMAG has three marketed products  namely Feraheme  ferumoxytol   which is approved for intravenous  IV  as iron replacement therapy for the treatment of iron deficiency anemia  IDA  in adults with chronic kidney disease  CKD   Makena  hydroxyprogesterone caproate injection   which is a progestin approved to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth  and MuGard for the management of oral mucositis and stomatitis 
The company made efforts towards the label expansion of its marketed drugs  In February 2018  the company received FDA approval for the label expansion of Feraheme and Makena  The FDA approved label expansion of Feraheme  ferumoxytol injection  beyond the current CKD indication 
The new approval includes all eligible adult Iron Deficiency Anemia   IDA   patients who have intolerance to or have had unsatisfactory response to oral iron  The company launched Feraheme with broad IV IDA label during the first quarter of 2018 and the drug is already capturing additional market share In February 2018  the FDA also approved a new administration option for Makena  subcutaneous autoinjector drug device combination product to reduce the risk of preterm birth in certain at risk women  The company has developed an auto injector device for subcutaneous administration of Makena  Makena SQ   including chemistry  manufacturing and controls development  in partnership with Antares Pharma  AMAG also launched it in the first quarter of 2018 
Makena SQ auto injector will ensure easier administration by healthcare providers and less painful injections for patients  This might lead to better sales of the drug  Revenues for the Makena subcutaneous autoinjector grew three fold in the third quarter of 2018 versus that in the second quarter  and made up 57  of the total Makena brand revenues  The company is optimistic about the Makena subcutaneous autoinjector 
Further  AMAG bought exclusive U S  rights to develop and commercialize Palatin Technologies  Vyleesi  bremelanotide  this year  Vyleesi is designed for the on demand treatment of HSDD in pre menopausal women  In March 2018  AMAG submitted a new drug application  NDA  for bremelanotide to treat hypoactive sexual desire disorder  HSDD   which was accepted by the FDA in June 
Vyleesi is currently under review with the FDA and the company is preparing for the upcoming FDA advisory committee meeting in January 2019 and a PDUFA date of Mar 23  2019  A potential approval of this candidate will be a big boost for the company as it caters to a huge unmet medical need for women 
To further boost its maternal health portfolio  in September 2018  AMAG exercised its option to acquire the global rights to an orphan drug candidate  AMAG 423   The move was in accordance with an option agreement entered into in July 2015 with Velo Bio  LLC  a privately held life sciences company  the terms of which were amended at the time of exercise 
AMAG 423 is a polyclonal antibody  currently in clinical development for the treatment of severe preeclampsia in pregnant women  The candidate has been granted both orphan drug and fast track review designations by the FDA  AMAG will now complete the phase IIb IIIa study that Velo initiated in the second quarter of 2017  AMAG expects to report top line data from the study in the first half of 2020 and plans to submit a new drug application  NDA  to the FDA  soon 
Meanwhile  the company completed the divestiture of Cord Blood Registry  CBR  in August 2018 and this sale will allow AMAG to strengthen its balance sheet significantly by paying off its  475 million high yield notes  The deal also underscores the company s commitment to focus on the development and commercialization of medicines that address unmet medical needs 
However  we note that Feraheme currently competes with IV iron replacement therapies like Venofer  Injectafer  Ferrlecit and their generic versions  among others  Feraheme may also face competition from generic IV iron replacement products that could further limit sales AMAG Pharmaceuticals  Inc  Price

   Zacks Rank   Stocks to Consider
AMAG is a Zacks Rank  3  Hold  stock 
Some better ranked stocks worth considering are Bristol Myers Squibb Co    NYSE BMY    Johnson and Johnson   NYSE JNJ   and Merck   Co    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   J J and Merck carry a Zacks Rank  2  Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  3 62 to  3 87 for 2018 and from  3 82 to  4 08 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 11 99  
Merck s earnings per share estimates have increased from  4 27 to  4 34 for 2018 and from  4 63 to  4 71 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 3 96   Shares of the company have increased 35 8  year to date 
J J s earnings per share estimates have increased from  8 14 to  8 16 for 2018 and from  8 61 to  8 66 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 1 65   Shares of the company have increased 3 9  year to date 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-26,Zacks Investment Research,https://www.investing.com/analysis/amags-label-expansion-of-lead-products-raises-share-price-200362495,200362495
198455,419971,JNJ,J J first quarter revenue misses estimates  new forecast includes Actelion,news,"By Bill Berkrot and Natalie Grover  Reuters    Johnson   Johnson  NYSE JNJ  on Tuesday reported disappointing pharmaceutical and consumer product sales as revenue missed analyst estimates  sending its shares sharply lower   However  cost controls and lower taxes helped the healthcare conglomerate beat Wall Street profit forecasts  J J shares  part of the Dow Jones Industrial Average  fell 3 6 percent to  121 11 in the biggest one day percentage decline in more than eight years as the company said it expected a slower growth rate for pharmaceuticals this year  Overall sales of  17 77 billion in the quarter fell short of analysts  average estimate of  18 04 billion  according to Thomson Reuters I B E S   The company  which is on track to close its  30 billion acquisition of Actelion in the current quarter  issued a new full year forecast to include Europe s largest biotech  With Actelion  J J expects 2017 sales of  75 4 billion to  76 1 billion and adjusted earnings of  7 00 to  7 15 per share  It forecast Actelion will contribute 35 40 cents to earnings per share in 2018   The expected benefit from the Actelion acquisition this year came in lower than our estimates   said Edward Jones analyst Ashtyn Evans   Additionally  the company s total growth came in lower than we expected  which is disappointing   Without Actelion  J J maintained its prior forecast for sales of  74 1 billion to  74 8 billion and adjusted earnings of  6 93 to  7 08 per share    We remain on track for achieving our full year guidance   Chief Financial Officer Dominic Caruso said on a conference call  J J is the first major pharmaceutical company to report quarterly results since Republican attempts to overhaul the U S  healthcare system failed  While forecasts do not include expectations of tax reform  Caruso expressed confidence that Washington will come through with a lower U S  corporate tax rate at some point  Pharmaceutical sales rose just 0 8 percent to  8 25 billion  constrained by competition and pricing pressure  which hurt the diabetes drug Invokana and Xarelto blood thinner  Newer blood cancer drugs Darzalex and Imbruvica demonstrated very strong growth  while prostate cancer drug Zytiga struggled with U S  sales off 14 3 percent  Consumer products grew 1 percent to  3 23 billion  held back by a slowdown at retailers  inventory destocking and economic issues in Latin America  J J said it expects business to accelerate over the rest of the year  helped by the introduction of new products   You always worry that these things don t bounce back as quickly as you would like   said Guggenheim Securities analyst Tony Butler  adding that J J has become dependent on acquisitions for growth  Medical devices grew 3 percent to  6 29 billion  about in line with expectations  including sales from its purchase of Abbott Medical Optics  The company said it was continuing to evaluate its options for certain diabetes businesses  including possible partnerships or divestitures  That does not include its diabetes drugs   Excluding items  J J earned  1 83 per share  beating Wall Street expectations by 6 cents  
Net earnings in the first quarter were  4 42 billion  or  1 61 per share  compared with  4 46 billion  or  1 59 per share  in the year earlier period ",2017-04-18,Reuters,https://www.investing.com/news/stock-market-news/j-amp;j's-quarterly-sales-rise-1.6-percent-474922,474922
198456,419972,JNJ,BTG  Like A Butterfly  Set To Transform ,opinion,"B2Gold Corp  NYSE BTG  reported good H119 results headlined by 12  and 35  y o y growth in revenues and operating profit  respectively  The performance was driven by volume growth from the Interventional Medicine segment  royalties from Zytiga and cost control  Cash at the end of H119 was  285m and could be a powerful asset in redressing BTG s uncertainties 
H119 financials
A strong H1 performance saw total revenues grow 12  y o y to  496m comprising 18  growth in licensing revenues and 10  growth in product sales  to  156m and  340m respectively   Adjusted operating profit rose 39  y o y to  179m driven by the higher revenues but also c 30  lower SG A expenses  Together  these drove adjusted EPS up by 32   Net cash at the end of H119 was  285m  vs  295m at FY18   whereas net cash flow in H1 was reduced by  113m due to a one off litigation settlement of  73m and acquisitions 
A strong H1 makes for a challenging H2 comparison
The uncertainties surrounding BTG have been well flagged and we believe it has the capacity to address them  The 14  growth in interventional medicine sales in H1 was driven by volume  with flat pricing implying a commoditised market  Within the pharmaceutical business  CroFab antivenin sales grew 4   but it is encountering low cost competition  Prostate cancer drug Zytiga  abiraterone  remains patent protected  but BTG s partner J J  NYSE JNJ  recently had its sole unexpired US patent struck down and is appealing the judgement  Zytiga s exclusivity in Europe lasts until September 2022 but the inevitability of its genericisation casts a cloud over 28  of BTG s H1 revenues 
To read the entire report Please click on the pdf File Below  ",2018-11-19,Edison,https://www.investing.com/analysis/btg-like-a-butterfly-set-to-transform-200360472,200360472
198457,419973,JNJ,Glaxo Seeks Label Expansion Of Nucala In Pediatric Patients,opinion,"GlaxoSmithKline plc   NYSE GSK   announced the submission of a supplemental Biologics License Application  sBLA  for its asthma drug  Nucala  mepolizumab   to the FDA  The sBLA is seeking label expansion of Nucala as an add on treatment in pediatric patients with severe eosinophilic asthma  The drug is already approved for adolescent and adult patients for the same indication
The sBLA is supported by data from a pediatric open label study which evaluated Nucala for pharmacokinetics  pharmacodynamics and long term safety in patients aged six to 11 years 
Notably  Nucala received approval for similar indication in Europe in August 2018  In December 2017  Nucala was also approved for eosinophilic granulomatosis with polyangiitis in the United States 
Glaxo s shares have gained 13 7  so far this year  outperforming the  s rally of 8 2  

 
The company is also developing the drug in additional indications  A phase III is currently evaluating Nucala in patients with nasal polyps  A potential approval in pediatric asthma patients and successful development in other indications will further boost the prospects of the drug  driving the company s top line 
However in September  Glaxo suffered a regulatory setback related to Nucala when the FDA issued a complete response letter for a sBLA seeking label expansion of Nucala in eosinophilic chronic obstructive pulmonary disease 
Meanwhile  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and its partner Sanofi   NYSE SNY   received approval for Dupixent as an add on maintenance therapy for treating moderate to severe asthma with an eosinophilic phenotype last month  This is likely to intensify competitive pressures on Nucala  Notably  the companies are also developing Dupixent in pediatric patients 
Nucala is a key drug in Galxo s portfolio of new respiratory drugs  Sales of Nucala were more than  500 million in the first nine months of 2018  registering growth of around 80   However  Glaxo s older inhaled respiratory products  particularly Seretide Advair  are facing competitive and continued pricing pressure  consequently hurting sales 
Further  continued transition to newer products is affecting sales of Advair  The drug is expected to face generic competition in the United States this year  which will hurt sales further GlaxoSmithKline plc Price
 

   Zacks Rank   Stock to Consider
Glaxo currently carries a Zacks Rank  3  Hold   A better ranked large cap drug stock is Johnson   Johnson   NYSE JNJ    carrying a Zacks Rank  2  Buy   You can see  
J J s earnings estimates increased from  8 14 to  8 16 for 2018 and from  8 61 to  8 66 for 2019 over the last 60 days  The company delivered a positive earnings surprise in the trailing four quarters  recording average beat of 1 65  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-11-20,Zacks Investment Research,https://www.investing.com/analysis/glaxo-seeks-label-expansion-of-nucala-in-pediatric-patients-200361262,200361262
198458,419974,JNJ,Shire Takeda Deal Gets Phase I Conditional European Approval,opinion,Shire Plc   NASDAQ SHPG   announced that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co  Ltd  s  62 billion bid to acquire the former  The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment  called SHP647 that could compete with a Takeda marketed product Entyvio  vedolizumab if SHP647 gets approved and hits the market Takeda stated that the clearance from the European Commission was the final regulatory approval required to proceed with its acquisition of Shire  Takeda had announced the acquisition in May 2018 The acquisition is subject to certain other conditions  including receipt of approval from the shareholders of Shire and Takeda  the satisfaction or  where applicable  waiver of the other conditions set out in the Scheme Document  and the sanction of the Court  Assuming these conditions are met  Shire and Takeda confirmed that the acquisition will close on Jan 8  2019 Both the companies are leaders in their therapeutic areas and also have an attractive geographic footprint  Thus  the combined group will be better positioned to deliver highly innovative medicines and transformative care providing better health and a brighter future for patients around the worldShares of the company have increased 14 5  year to date  against the  s decline of 10 2   Shire plc Price     Zacks Rank   Stocks to ConsiderShire is a Zacks Rank  3  Hold  stock Some better ranked stocks worth considering are Bristol Myers Squibb Company   NYSE BMY    Johnson and Johnson   NYSE JNJ   and Merck   Co    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   J J and Merck carry a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings per share estimates have increased from  3 62 to  3 84 for 2018 and from  3 82 to  4 08 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 11 99  Merck s earnings per share estimates have increased from  4 27 to  4 34 for 2018 and from  4 63 to  4 71 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 3 96   Shares of the company have increased 36  year to date J J s earnings per share estimates have increased from  8 14 to  8 16 for 2018 and from  8 61 to  8 66 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 1 65   Shares of the company have increased 36  year to date Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-20,Zacks Investment Research,https://www.investing.com/analysis/shiretakeda-deal-gets-phase-i-conditional-european-approval-200361446,200361446
198459,419975,JNJ,Pharma Stock Roundup  Cancer Approvals For PFE   ABBV  CHMP Nod For Several Drugs,opinion,"This week  the FDA granted approval to Pfizer s   NYSE PFE   Daurismo  the drug giant s fourth new cancer drug in less than three months  It also approved the label expansion of AbbVie   NYSE ABBV   Roche s drug Venclexta  Both the drugs gained approval for the treatment of acute myeloid leukemia  AML   a rare blood cancer in newly diagnosed patients  The Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  gave positive recommendations for granting marketing approval to several drugs this week Recap of the Week s Most Important StoriesPfizer Gets FDA Nod for Rare Cancer Medicine   The FDA granted approval to Daurismo for a rare blood cancer  Pfizer s fourth cancer in less than three months  Daurismo  glasdegib   a once daily oral medicine is approved for use in combination with low dose cytarabine  LDAC    a kind of chemotherapy treatment   for the treatment of newly diagnosed acute myeloid leukemia  AML  in patients 75 years or older or who cannot take intensive chemotherapy  However  the approval comes with a boxed warning on the U S  label for embryo fetal toxicityPfizer s recent new cancer drug approvals include Lorbrena  lorlatinib  for second line non small cell lung cancer  Vizimpro  dacomitinib  for advanced NSCLC with EGFR activating mutations and Talzenna  talazoparib   an orally available PARP inhibitor for advanced breast cancer However  Pfizer s late stage study evaluating its PD L1 inhibitor Bavencio  avelumab   in patients with platinum resistant refractory ovarian cancer  of overall survival  OS  or progression free survival  PFS  In the study  both PFS and OS did not reach statistical significance  Bavencio is marketed for metastatic Merkel cell carcinoma in the United States  Europe and Japan and for the second line treatment of locally advanced or metastatic urothelial carcinoma in the United States Pfizer was also in news this week as a Wall Street report stated that it of 41 prescription drugs in 2019  The drug giant had put off such increases earlier this year as it faced criticism from President Trump AbbVie Roche Get FDA Nod for Venclexta in First Line AML  FDA also granted accelerated approval to AbbVie and partner Roche s supplemental new drug application  sNDA  looking for a label expansion of   AML   one of the most aggressive blood cancers Venclexta can now be prescribed in combination with azacitidine  or decitabine  or low dose cytarabine  LDAC  in AML patients who are ineligible for intensive chemotherapy  Venclexta is now approved for two different blood cancers in the United States   newly diagnosed AML and relapsed refractory  R R  chronic lymphocytic leukemia  CLL CHMP Gives Positive Opinion to Several Drugs  The CHMP gave a positive opinion    NYSE JNJ   Erleada  apalutamide  for the treatment of adult patients with non metastatic castration resistant prostate cancer  nmCRPC  who are at high risk of developing metastatic disease  Erleada gained FDA approval in the United States in February  The CHMP also gave a nod to Glaxo s   NYSE GSK   filing looking for EU approval of its HIV drug  Tivicay as a two drug regimen  2DR  in combination with lamivudine The regulatory submission for the update to the Tivicay EU label is based on data from phase III GEMINI 1   2 studies  Sanofi   NYSE SNY   also gained positive CHMP opinion for fexinidazole  an oral treatment for human African trypanosomiasis  HAT  or sleeping sickness  Novartis    NYSE NVS   filing looking for label expansion of its CDK4 6 inhibitor  Kisqali in combination with fulvestrant  as a first or second line treatment for HR  HER2  locally advanced or metastatic breast cancer  also received CHMP nod  The final decision by the European Union on these products is expected in the coming months AstraZeneca Presents Final OS Data From MYSTIC Study  AstraZeneca   NYSE AZN   announced final  from the pivotal phase III MYSTIC study  evaluating Imfinzi in first line lung cancer  The MYSTIC study evaluated Imfinzi  both as a monotherapy and in combination with tremelimumab  in treatment na ve non small cell lung cancer  NSCLC  patients whose tumors express PD L1 on 25  or more of their cancer cells The data from the primary analysis population of patients showed that Imfinzi monotherapy as well as in combination with tremelimumab failed to achieve statistical significance in the primary endpoint of overall survival compared to standard of care platinum based chemotherapy  Per data announced in July last year  the study failed to show improvement in progression free survival  thereby failing to meet the first primary endpoint Novartis Gets FDA Nod for Promacta in First Line Setting  Novartis gained FDA approval for label expansion of its anemia drug  Promacta as a for severe aplastic anemia  SAA  in combination with standard immunosuppressive therapy  IST   Promacta is already marketed for SAA for patients who have had an insufficient response to IST  A decision by the European Medicines Agency for a similar label expansion is expected in 2019  Promacta was also granted a Breakthrough Therapy designation by the FDA as a counter measure for hematopoietic sub syndrome of acute radiation syndrome  H ARS  Glaxo Files for Approval of Nucala in Pediatric Patients  Glaxo filed a supplemental Biologics License Application  sBLA  to the FDA  seeking label expansion of its severe eosinophilic asthma drug   aged six to 11 years  in the United States  The drug is already marketed in the United States and EU for patients aged 12 years or older  In the EU  it received approval for pediatric use  from aged six 17 years  in severe eosinophilic asthma in August  Nucala is a key drug in Galxo s respiratory portfolio  recording sales growth of 81  at constant exchange rate in the first nine months of 2018 FDA Accepts Allergan s sNDA for Avycaz  The FDA accepted Allergan s sNDA looking for approval of the latter s antibacterial medicine  Avycaz  for the pediatric patient population  The sNDA is seeking approval for Avycaz for the treatment of complicated urinary tract infections  cUTI  and complicated intra abdominal infections  cIAI   in combination with metronidazole  in pediatric patients  aged three months and above  Avycaz is already approved to treat these infections in adult patients The NYSE ARCA Pharmaceutical Index declined 0 9  in the last four trading sessions 
 Large Cap Pharmaceuticals Industry 5YR   Return
  

 Here is how the seven major stocks performed in the last four trading sessions   None of the stocks recorded any significant increase  Glaxo recorded the highest gain  0 3   while AstraZeneca declined the most  2 8   in the last four trading sessions In the past six months  Lilly has been the biggest gainer  35 7   while Glaxo recorded the lowest gain  1 2    See the last pharma stock roundup here   What s Next in the Pharma World Watch out for pipeline and regulatory updates next week Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-11-22,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-cancer-approvals-for-pfe--abbv-chmp-nod-for-several-drugs-200361965,200361965
198460,419976,JNJ,Bayer Hurts From Generic Competition   Pipeline Setbacks,opinion,"We issued an update report on Bayer AG  DE BAYGN    OTC BAYRY   on Nov 22  2018 
It is a life science company with core competencies in the areas of health care and agriculture 
Several pipeline and regulatory updates are expected from the company in the coming quarters Any adverse pipeline related news can impact the stock unfavorably 
In August 2018  Bayer and partner Johnson and Johnson   NYSE JNJ    announced data from two late stage studies  which demonstrated that blood thinner drug  Xarelto failed to show statistical benefits  These studies were being evaluated to expand the drug s eligible patient population 
Data from the two phase III studies   MARINER and COMMANDER HF   showed no significant difference between Xarelto and placebo for the primary efficacy endpoints  The studies are part of Xarelto s large clinical development program EXPLORER  which evaluates the potential of Xarelto in treating a wide range of critical medical conditions 
The company is currently facing generic competition for many of its products  including the Yaz franchise  oral contraceptives   This will negatively impact revenues of the company  Bayer s dependence on its pharmaceutical segment for growth is a concern 
The company s stock has declined 41 5  year to date  against the  s growth of 9 9  

 
However  Bayer has made several acquisitions and entered into a number of deals in the past few quarters to enhance its portfolio 
In June 2018  Bayer successfully completed the acquisition of Monsanto  NYSE MON  for  63 million  The combined business is expected to boost Bayer s Crop Science business and provide accretion to its core earnings from the first year of the closing of the transaction  followed by double digit percentage growth 
Bayer also expects annual earnings contribution of around  1 5 billion from synergies after three years of closing the transaction along with additional future benefits from integrated offerings  The Monsanto acquisition is a strategic move  which will offer Bayer a broad set of solutions to meet farmers  current and future needs 
The company also received approval for few drugs  which bode well 
In August 2018  the FDA approved Jivi  BAY94 9027  for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents aged 12 years or older in the United States  The FDA also approved Jivi for on demand treatment and perioperative management of bleeding in the same population  Jivi is a long acting PEGylated recombinant human Factor VIII  rFVIII  replacement therapy 
In September 2018  the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency recommended Jivi for marketing authorization for the treatment and prophylaxis of bleeding in previously treated patients aged 12 years or older with hemophilia A 
In August 2018  the European Commission approved a new treatment approach for Eylea  The approach enables clinicians to combine proactive treatment with early extension of the injection interval for patients with neovascular age related macular degeneration  nAMD   Bayer also has a robust pipeline  The company plans to launch at least 20 products by the end of 2023 and is already on track for the same  A potential approval of its pipeline candidates will boost sales of the company Bayer Aktiengesellschaft Price

   Zacks Rank   Stocks to Consider
Bayer is a Zacks Rank  5  Strong Sell  stock 
Some better ranked stocks worth considering are Bristol Myers Squibb Company   NYSE BMY   and Merck   Co    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   Merck carries a Zacks Rank  2  Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  3 62 to  3 87 for 2018 and from  3 82 to  4 08 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 11 99  
Merck s earnings per share estimates have increased from  4 27 to  4 34 for 2018 and from  4 63 to  4 71 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 3 96   Shares of the company have increased 36 1  year to date 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-11-23,Zacks Investment Research,https://www.investing.com/analysis/bayer-hurts-from-generic-competition--pipeline-setbacks-200362057,200362057
198461,419977,JNJ,BTG  The BTG Acquisition  Small Fly  Big Ointment ,opinion,"Following our note on BTG s interim results  the proposed  3 3bn all cash acquisition by Boston Scientific  NYSE BSX  was announced  Further  on 21 November  BTG and its partner Johnson   Johnson  NYSE JNJ   J J  failed to prevent the launch of generic competition to Zytiga  28  of BTG s H1 revenue   We examine the potential impact of generic Zytiga on the transaction 
Logical acquisition of interventional volume
US medical device company Boston Scientific announced the recommended offer for BTG of 840p in cash or  3 3bn  There are no break up fees for UK listed takeovers and further details on the terms of the transaction have not yet appeared in Boston s SEC filings  The 37  premium to BTG s 19 November share price should be warmly welcomed by at least the 75  of the shareholders required to approve the transaction 
Are imminent Zytiga generics a complication 
One of the bear points from our previous note was the potential for generic competition to Zytiga  abiraterone    a blockbuster oral drug to treat prostate cancer  The day after the proposed acquisition of BTG by Boston Scientific was announced  a US Appeals Court ruling allowed generic abiraterone launches while the invalidation of Zytiga s last valid US patent is being appealed 
To read the entire report Please click on the pdf File Below  ",2018-11-25,Edison,https://www.investing.com/analysis/btg-the-btg-acquisition-small-fly-big-ointment-200362141,200362141
198466,419982,JNJ,J J declares Actelion tender offer a success  sees closing in second quarter,news,"ZURICH  Reuters    Johnson   Johnson  N JNJ  declared its  30 billion tender offer for Swiss biotechnology company Actelion  S ATLN  successful on Friday  reporting it controlled 77 2 percent of the voting rights after the main offer period  The price of the offer  which J J announced on Jan  26  was  280 per share for Actelion  It said it expected the transaction to close in the second quarter  
J J has said it intends to delist Actelion  while a new research and development company being spun out of Actelion  to be called Idorsia and led by Actelion founder Jean Paul Clozel  will have a separate Swiss listing ",2017-03-31,Reuters,"https://www.investing.com/news/stock-market-news/j-amp;j-declares-actelion-tender-offer-a-success,-sees-closing-in-second-quarter-470158",470158
198467,419983,JNJ,J J reports higher Q1 EPS  revenues ,news,Investing com    NYSE Johnson   Johnson  Tuesday reported Q1 higher revenues and earnings J J said first quarter EPS came in at  1 61  up from  1 59 a year earlier The U S  pharmaceutical reported a 1 6  rise in revenues in the period to  17 77 bn J J shares were up 0 58  at  125 72 in pre market trade The U S  firm is in the process of acquiring Switzerland s Actelion for  30 bn ,2017-04-18,Investing.com,"https://www.investing.com/news/stock-market-news/j-j-reports-higher-q1-eps,-revenues-474944",474944
198468,419984,JNJ,This REIT Yields Over 7  And Will Profit From A Major Healthcare Trend ,opinion,"Investors looking to add healthcare stocks to their portfolio typically buy a pharmaceutical company like Johnson   Johnson  NYSE JNJ  or Pfizer  NYSE PFE   But investors can also gain exposure to the healthcare industry indirectly  through Real Estate Investment Trusts that invest in healthcare properties  The beauty of healthcare REITs is that they commonly offer significantly higher dividend yields than pharmaceutical stocks 
For example  Omega Healthcare Investors Inc  NYSE OHI  is one of the biggest healthcare REITs in the U S   and it has a 7 7  dividend yield  It has a very high dividend yield  compared with the S P 500 Index  which has an average dividend yield below 2  right now  Plus  Omega has potential for future growth  thanks to a huge healthcare trend set to unfold over the next several years  This makes Omega an attractive stock for income investors 
Business Overview   Recent Events
Omega Healthcare Investors is a REIT that owns healthcare properties  The company was founded in 1992  and today has a market capitalization above  6 billion  It utilizes long term triple net leases  The triple net structure is advantageous for Omega  as it provides fixed rent payments from tenants with annual escalators  And  property level expenses  such as labor  insurance  property taxes  and capital expenditures  are the operator s responsibility 
At the end of the third quarter  Omega s portfolio consisted of 923 healthcare facilities  located in 41 states and the United Kingdom  Its portfolio includes skilled nursing facilities  83  of revenue   senior housing  13  of revenue  as well as a small collection of other properties  4  of revenue  

Source  Investor Presentation  page 4
The past year has been difficult for Omega  due to some problems with two tenants  Orianna and Preferred Care  which entered bankruptcy  Preferred Care was a relatively small tenant with annual contractual revenues of just  3 million  but Orianna was Omega Healthcare s fifth largest tenant  with annual contractual revenues of  47 million 
Elevated costs related to the issues facing Orianna and Preferred Care weighed on Omega s cash flow  but the company is making progress reshaping its portfolio  Omega has transitioned the Mississippi based Orianna facilities and will generate contractual annual rent of  12 million from them  The company reaffirmed it expects  32 to  38 million in annual rent total from these assets once they are transitioned or sold 
Omega s strong third quarter earnings report showed that the steps taken to improve its property portfolio are having a positive impact  For the quarter  revenue of  222 million increased 1  year over year  and beat analyst estimates by  28 million  Funds from operation  FFO  per share of  0 77 also beat by  0 02 per share  and declined 2 5  from the same quarter last year  Higher tenant revenue was more than offset by higher restructuring and interest expenses 
Still  Omega generates more than enough cash flow to reward shareholders with a strong dividend  For 2018  the company expects FFO per share in a range of  3 03 to  3 06  Assuming the company reaches its FFO forecast  it will easily cover its  2 64 per share dividend  There could even be room for future dividend increases  as the company is set to grow FFO in the years ahead 
Profiting From The Aging Population
One of the advantages of investing in health care REITs is that the industry has a positive long term growth outlook  Healthcare REITs like Omega are ideally positioned to capitalize on a major trend  the aging population  Older generations of Americans such as the Baby Boomers are large in size  and growing  relative to other generational groups  To that end  Omega expects the 65  population to continue growing  as a share of the overall population 

Source  Investor Presentation  page 13
Continued growth of the 65  cohort means demand for healthcare real estate properties  such as skilled nursing facilities and senior housing facilities  is likely to grow for the foreseeable future  The number of elderly people in need of healthcare is expected to grow at a fast pace over the next decade  In addition  the trend is for the elderly to spend an increasing amount of money on healthcare  Healthcare spending is likely to rise at a faster rate than GDP growth in the United States going forward 
Omega s portfolio remains in good shape  It will see only a small portion of its leases expire over the next decade  Moreover  it has no material debt maturities until 2022  Therefore  the REIT is likely to enjoy reliable free cash flows in the upcoming years  without any shocks from debt maturities  Omega s FFO growth could be restrained while the company works through its tenant issues  but the company is well positioned for the long run 
Omega stock could generate strong returns for shareholders over the next five years  due to FFO growth  a low stock valuation  and dividends  During the last decade  the company grew FFO at a 4 5  average annual rate  As it is likely to complete its asset repositioning this year  it is reasonable to expect the REIT to grow its FFO at a 4 5  average annual rate over the next five years 
In addition  Omega shares appear to be undervalued today  Lingering concerns over its property portfolio caused Omega s stock valuation to decline in the past year  Now  Omega stock trades for a price to FFO ratio of 11 2  compared with a 10 year average ratio of 12 4  This means Omega is valued more cheaply than its long term historical average  which could signal a buying opportunity  The stock is expected to revert towards its average valuation level  since the company s turnaround efforts are likely to be successful  If this occurs  the stock will enjoy a 2 1  average annual gain thanks to expansion of the valuation multiple through 2023 
Lastly  dividends are a major component of REIT shareholder returns  In this case  Omega stock pays a current dividend yield of 7 7   This is a high and appealing dividend for investors searching for yield in a low interest rate environment  Adding it all up  the combination of valuation changes  FFO growth  and dividends cumulatively result in total expected returns of over 14  per year 
Final Thoughts
Stocks with high dividend yields should be approached with caution  It is important for investors to understand the unique risks of high yield stocks  and make sure the high yield is sustainable  In this case  Omega appears to be a safe high yield stock  with sufficient cash flow to maintain the dividend payout  And  Omega has positive growth potential for the future  thanks to the aging population and continued need for healthcare real estate  With a 7 7  yield and total expected returns of over 14  per year  Omega is an appealing stock for income investors 
Original post",2018-11-07,Modest Money,https://www.investing.com/analysis/this-reit-yields-over-7-and-will-profit-from-a-major-healthcare-trend-200356639,200356639
198469,419985,JNJ,Healthcare ETF  JHMH  Hits New 52 Week High,opinion,"For investors seeking momentum  the John Hancock Multifactor Healthcare ETF  is probably on radar  The fund just hit a 52 week high  and shares of JHMH are up roughly 22  from their 52 week low price of  29 91 share 
But could more gains be in store for this ETF  Let s take a quick look at the fund and the near term outlook to get a better idea on where it might be headed 
JHMH in Focus
The fundfocuses on the healthcare segment of the market and comprises 106 holdings  Johnson   Johnson   NYSE JNJ   occupies the top weight with 6 55  weight  It has a large cap bias  80    see    
Why the move 
Healthcare stocks are hot with Democrats taking the house in midterm elections as this is supposed to   Approval of Medicaid expansion referendums in Idaho  Nebraska and Utah were taken in positive light as it would allow thousands of poor Americans to gain access to healthcare coverage 
More Gains Ahead  
Currently  JHMH has a Zacks ETF Rank  2  Buy  with a Medium risk outlook  so there is definitely still some promise for those who want to try to ride this surging ETF a little further 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2018-11-09,Zacks Investment Research,https://www.investing.com/analysis/healthcare-etf-jhmh-hits-new-52week-high-200357328,200357328
198470,419986,JNJ,Johnson   Johnson  JNJ  Gains As Market Dips  What You Should Know,opinion,"In the latest trading session  Johnson   Johnson  NYSE JNJ  closed at  145 62  marking a  0 19  move from the previous day  The stock outpaced the S P 500 s daily loss of 1 97   Meanwhile  the Dow lost 2 32   and the Nasdaq  a tech heavy index  lost 2 78  
Heading into today  shares of the world s biggest maker of health care products had gained 8 59  over the past month  outpacing the Medical sector s loss of 1 15  and the S P 500 s loss of 3 33  in that time 
Wall Street will be looking for positivity from JNJ as it approaches its next earnings report date  This is expected to be January 22  2019  The company is expected to report EPS of  1 95  up 12 07  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  20 11 billion  down 0 42  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  8 16 per share and revenue of  81 32 billion  which would represent changes of  11 78  and  6 37   respectively  from the prior year 
Investors might also notice recent changes to analyst estimates for JNJ  These revisions typically reflect the latest short term business trends  which can change frequently  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Within the past 30 days  our consensus EPS projection has moved 0 29  higher  JNJ currently has a Zacks Rank of  2  Buy  
Valuation is also important  so investors should note that JNJ has a Forward P E ratio of 17 81 right now  This valuation marks a premium compared to its industry s average Forward P E of 14 76 
Also  we should mention that JNJ has a PEG ratio of 2 27  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 at yesterday s closing price 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 38  putting it in the top 15  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2018-11-12,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-gains-as-market-dips-what-you-should-know-200358437,200358437
198471,419987,JNJ,Johnson   Johnson  JNJ  Up 3 4  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Johnson   Johnson  NYSE JNJ   Shares have added about 3 4  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Johnson   Johnson due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  J J Tops on Third Quarter Earnings   Sales  Ups ViewJ J s third quarter 2018 earnings came in at  2 05 per share  beating the Zacks Consensus Estimate of  2 03 and increasing 7 9  from the year ago period driven by higher revenues and better operating margins Adjusted earnings excluded amortization expense and a charge for some after tax special items  Including these items  J J reported third quarter earnings of  1 44 per share  up 5 1  year over year Sales came in at  20 3 billion  beating the Zacks Consensus Estimate of  19 91 billion  Sales increased 3 6  from the year ago quarter  reflecting an operational increase of 5 5  and an unfavorable currency impact of 1 9  Organically  excluding the impact of acquisitions and divestitures  sales increased 6 1  on an operational basis  slightly less than 6 3  increase seen in the previous quarter  Continued above market growth in the Pharmaceutical segment and improved organic sales growth in the Medical Devices and the Consumer segments led to strong performance in the quarter Third quarter sales grew 3 6  in the domestic market to  10 66 billion and 3 5  in international markets to  9 68 billion  reflecting 7 5  operational growth and 4  negative currency impact Segment DetailsJ J s Pharma segment is performing better than the market in 2018 despite the impact of biosimilars on Remicade sales Pharmaceutical segment sales rose 6 7  year over year to  10 3 billion  reflecting 8 2  operational growth and 1 5  negative currency impact as sales rose in both domestic and international markets  Sales in the domestic market rose 4 8  to  6 1 billion  International sales grew 9 5  to  4 25 billion  operational increase of 13 2    The strong performance was led by the company s oncology portfolio  Worldwide sales of J J s cancer drugs rose 36 4  in the quarter  Acquisitions and divestitures had a negligible impact to sales growth in the quarter New products like Imbruvica  cancer  and Darzalex  multiple myeloma  continued to perform well  Core products like Stelara  Zytiga  Simponi Simponi Aria and Invega Sustenna also contributed to growth Imbruvica sales rose 37 7  to  705 million in the quarter driven largely by share gains across all lines of therapy Darzalex sales rose 57 1  to  498 million in the quarter  In United States  market growth and strong launch uptake in the first line setting  for which approval was received in May  drove sales  In outside U S  markets  increased penetration and share gains drove sales growth Zytiga sales rose 43 2  to  958 million in the quarter due to continued strong market growth and share gains  Zytiga was approved in the first line setting in February  which has been a key driver of Zytiga s strong performance in the past three quarters Stelara sales rose 16 5  to  1 31 billion in the quarter  Stelara has witnessed a strong uptake in its new indication for Crohn s disease  experiencing share gains in the third quarter  Simponi Simponi Aria sales rose 12 6  to  536 million in the quarter  Invega Sustenna sales rose 16 5  to  749 million in the quarter In the quarter  J J recorded pulmonary arterial hypertension  PAH  revenues of  656 million  up 3 8  year over year  Strong demand for Uptravi and Opsumit was partially offset by the expected decline of Tracleer outside the United States due to generic competition  The Actelion acquisition added 3 8  to sales growth in the third quarter compared with 6 6  in the second quarter Sales of Invokana Invokamet declined 28 3  to  190 million due to higher managed care discounting and market share decline due to competitive pressure Xarelto sales declined 3 6  in the quarter to  612 million with continued share gains being offset by increased rebates and a negative impact from prior quarter adjustments  Excluding these adjustments  the drug s underlying growth would have been approximately 2 5   The October FDA approval of Xarelto for a new 2 5 milligram vascular dose for the CAD PAD indication significantly expands the drug s eligible patient population  which can drive sales of the drug in future quarters Sales of Remicade were down 16 3  in the quarter to  1 38 billion due to competition from biosimilars   While U S  sales declined 18 2   U S  exports went down 35 9   Remicade sales rose 2 5  in international markets Regarding newly launched Tremfya  J J said that the product is seeing strong demand trends with more than 25 000 patients now on therapy and the drug capturing 5 8  share of the psoriasis market in the United States  Tremfya recorded sales of  171 million in the quarter compared with  126 million in the second quarter Medical Devices segment sales came in at  6 59 billion  down 0 2  from the year ago period  It included an operational increase of 1 7  and negative currency movement of 1 9  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 2 9   same as in the second quarter Operational growth was driven by continued strong performance in vision care and electrophysiology and improving performance in spine and keens and the orthopedics portfolio  which made up for a weaker sales performance in the diabetes care  Domestic market sales rose 0 3  year over year to  3 2 billion  International market sales decreased 0 6   operational increase of 3   year over year to  3 4 billion The Consumer segment recorded revenues of  3 4 billion in the reported quarter  up 1 8  year over year  Moreover  on an operational basis  Consumer segment sales increased 4 9   partially offset by unfavorable foreign currency movement of 3 1  Excluding the impact of acquisitions and divestitures  adjusted operational sales growth was 6 1  worldwide  a significant acceleration from the second quarter  The improved performance was driven by growth in beauty and over the counter products and the benefit of re stocking of retail inventory to support the re launch of the Johnson s baby care brand in August Regarding the baby care brand re launch  management informed that they launched in the United States  China and India during the third quarter  and plan to continue the full global rollout into 2019 Sales in the domestic market rose 6 6  from the year ago period to  1 4 billion  Meanwhile  the international segment recorded a decline of 1 3  to  2 04 billion  The operational increase of 3 7  was offset by negative currency impact of 5  in the quarter 2018 Outlook TrimmedJ J raised its previously issued earnings and sales guidance for 2018 J J expects 2018 adjusted earnings per share in the range of  8 13    8 18 compared with  8 07    8 17 expected previously  The guidance range reflects an operational growth rate between 9 3  and 10   previously 8 5  and 9 9    Currency fluctuations are expected to favorably impact EPS by approximately 15 cents  which remains unchanged from the prior guidance Revenues are expected in the range of  81 to  81 4 billion  higher than the previously expected  80 5 to  81 3 billion  reflecting operational constant currency sales growth rate in the range of 5 5  to 6   previously 4 5  to 5 5   Organic sales growth  excluding the impact of acquisitions and divestitures  is expected to be in the range of 4 5  higher than 3 5  4 5  previously  J J has raised its full year organic sales growth expectations thrice this yearCurrency fluctuations are expected to favorably impact sales by 50 basis points  lower than 80 basis points  previously In the fourth quarter  while the Consumer and Medical Device businesses should continue to improve  the Pharmaceuticals segment might see slower growth  The Pharmaceuticals segment is facing difficult comparisons in second half of 2018  which coupled with expected biosimilar and generic competition to Tracleer and Procrit later this year  may put pressure on the segment s growth in the fourth quarter  Adjusted pre tax operating margin is expected to increase at least 150 basis points in 2018  previously approximately150 basis points   Although a stronger than expected year to date performance would have resulted in higher margins  increased R D investments in the fourth quarter will offset some of the  benefit Adjusted tax rate is guided in the range of 17 5   18   17 previously  The company does not expect any biosimilar entrants for Zytiga  Prezista  Risperdal Consta  or Invega Sustenna in the United States in 2018  However  the company is confident that it can absorb the impact of any potential Zytiga headwind should there be an earlier than expected generics launch in 2018 However  the 2018 guidance includes the impact of generics for Procrit and Tracleer as well as Remicade biosimilars  
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates flatlined during the past month 
VGM Scores
At this time  Johnson   Johnson has a nice Growth Score of B  though it is lagging a lot on the Momentum Score front with an F  However  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Johnson   Johnson has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2018-11-14,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-up-34-since-last-earnings-report-can-it-continue-200359578,200359578
198477,419993,JNJ,Newer type 2 diabetes drugs show heart protective quality in study,news,By Bill Berkrot WASHINGTON  Reuters    A newer class of type 2 diabetes drugs significantly cut the risk of death and hospitalization for heart failure compared with other medicines for the disease  according to data released on Sunday from a so called real world study sponsored by AstraZeneca  The drugs  known as SGLT 2 inhibitors  work by removing blood sugar via the urine and include Astra s Farxiga  Jardiance from Eli Lilly and Co and Boehringer Ingelheim  and Invokana from Johnson   Johnson  NYSE JNJ   Jardiance caused a stir in 2015  when a clinical trial conducted to reassure it does not cause heart problems instead showed it reduced the combined risk of hospitalization for heart failure or death from heart failure by 39 percent in high risk patients  The heart benefit has since been incorporated into Jardiance s label  AstraZeneca is conducting its own large clinical trials to determine the heart effect of Farxiga with results expected in 2019   But the latest data presented by Dr  Mikhail Kosiborod at the American College of Cardiology scientific meeting in Washington appears to indicate that heart protection is not limited to Jardiance   The fact that the results are remarkably consistent from country to country regardless of which compound predominates  that certainly seems to suggest that it s a class effect   said Kosiborod  a cardiologist from Saint Luke s Mid America Heart Institute in Kansas City  He noted that most Americans in the data were taking Invokana  while Farxiga was dominant in Europe  The study  which analyzed data from more than 300 000 type 2 diabetes patients collected from six countries  found the SGLT 2 drugs slashed the combined risk of hospitalization for heart failure and death from any cause by 46 percent  The data was obtained from real world sources  such as medical records  claims databases and national registers   Most patients were taking Farxiga or Invokana with less than 10 percent on Jardiance  The comparator medicines included a wide variety of diabetes treatments  including metformin  DPP 4 inhibitors  such as Merck  NYSE MRK    Co s Januvia  and insulin  among others   The vast majority of patients had no history of heart disease  But heart disease is the number one killer of people with diabetes  and mounting evidence of heart protective qualities of SGLT 2 drugs could lead to greater use   This class has a real potential of improving patient outcomes   Kosiborod said  Given the observational nature of the study the possibility of unmeasured confounding factors exists  researchers noted  More than 400 million people worldwide have diabetes  of whom at least 90 percent have type 2   This story has been refiled to add word in last paragraph ,2017-03-19,Reuters,https://www.investing.com/news/general-news/newer-type-2-diabetes-drugs-show-heart-protective-quality-in-study-467278,467278
198478,419994,JNJ,Beaten Down Pharma ETFs To Buy Post Q3 Results ,opinion,"Total earnings for  of the total healthcare market capitalization are up 11  on revenue growth of 7 2   The growth rates seem unimpressive when compared with some of the other sectors  Earnings and revenue beat ratios of 82 9  and 57 1   respectively  are also not great either Among the most notable players  Johnson   Johnson   NYSE JNJ   was the first major drug company to report earnings on Oct 16  followed by Bristol Myers Squibb Company   NYSE BMY   and Merck   NYSE MRK    on Oct 25  Other major U S  drug company   Pfizer   NYSE PFE     reported Oct 30  These industry bigwigs came up with solid results either beating on earnings or revenue estimates or both  read    
Earnings in FocusJohnson and JohnsonThe world s biggest maker of healthcare products continued its long streak of earnings beat  Earnings per share came in at  2 05  couple of cents ahead of the Zacks Consensus Estimate and 7 9  higher than the year ago quarter  Revenues grew 3 6  year over year to  20 35 billion and edged past the Zacks Consensus Estimate of  19 92 billion  However  Johnson   Johnson raised its revenue guidance to  81  81 4 billion from  80 5  81 3 billion for 2018 and earnings per guidance range to  8 13  8 18 from  8 07  8 17 PfizerEarnings per share of 78 cents came in couple of cents above the Zacks Consensus Estimate and revenues of  13 3 billion were in line with the estimate  On an annual basis  earnings per share and revenues rose 16  and 1   respectively  For 2018  the U S  drug giant narrowed the revenue guidance range from  53  55 billion to  53  53 7 billion  and earnings per share guidance from  2 95  3 05 to  2 98  3 02 MerckEarnings per share came in at  1 19  surpassing the Zacks Consensus Estimate of  1 16 and improving 7 2  from the year ago quarter  Revenues inched up 5  year over year to  10 79 billion but missed the estimate of  10 87 billion  Merck raised its earnings guidance from  4 22  4 30 to  4 30  4 36 but slightly narrowed its revenue expectations from  42 0  42 8 billion to  42 1  42 7 billion  see    Bristol MyersBristol Myers reported earnings per share of  1 09  18 cents above the Zacks Consensus Estimate and higher than the year ago earnings of 75 cents  Revenues grew 8  to  5 69 billion but fell short of the Zacks Consensus Estimate of  5 72 billion  The company raised 2018 earnings per share guidance from  3 55  3 65 to  3 80  3 90 ETF AngleDespite strong results  the broad market sell off took the sheen from the pharma ETFs over the past month  Below we have highlighted them in detail  These funds have a Zacks ETF Rank  2  Buy   suggesting solid entry point on beaten down prices iShares U S  Pharmaceuticals ETF This ETF provides exposure to 47 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  The in focus firms are the top five holdings in the basket  accounting for a combined 34 8  of total assets  suggesting heavy concentration  The product has  420 4 million in AUM and charges 43 bps in fees and expense  Volume is light as it exchanges about 16 000 shares a day  The fund is down 5 4  in a month SPDR S P Pharmaceuticals ETF   HN XPH  This fund provides exposure to pharma companies by tracking the S P Pharmaceuticals Select Industry Index  With AUM of  319 7 million  it trades in good volume of around 96 000 shares a day and charges 35 bps in fees a year  In total  the product holds 44 securities with the in focus four firms making up for at least 4  share each  The product shed 3 5  in the same period  read    VanEck Vectors Pharmaceutical ETF   AX PPH  This ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 25 stocks in its basket  The in focus four firms account for more than 4  share each  The product has amassed  281 million in its asset base and trades in moderate volume of about 39 000 shares a day  Expense ratio comes in at 0 35   The fund has lost 3 6  in a month Invesco Dynamic Pharmaceuticals ETF   WA PJP  This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index  The product has AUM of about  524 2 million and sees lower volume of around 35 000 shares a day  The fund charges 57 bps in fees and expenses  Holding 30 stocks  the fund invests nearly 5  share each in these four firms  The ETF has lost 5 6  in a month First Trust Nasdaq Pharmaceuticals ETF This fund tracks the Nasdaq US Smart Pharmaceuticals Index  holding 30 securities in its basket  The in focus firms account for a combined 24  of assets  FTXH has a lower level of  4 5 million in AUM and 3 000 shares in average daily volume  It charges 60 bps in annual fees and shed 4 4  in the same time frame Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/beatendown-pharma-etfs-to-buy-post-q3-results-200355575,200355575
198479,419995,JNJ,Johnson   Johnson  JNJ  Gains But Lags Market  What You Should Know,opinion,"Johnson   Johnson  NYSE JNJ  closed the most recent trading day at  142 55  moving  0 25  from the previous trading session  This change lagged the S P 500 s 0 63  gain on the day  Meanwhile  the Dow gained 0 68   and the Nasdaq  a tech heavy index  added 0 64  
Prior to today s trading  shares of the world s biggest maker of health care products had gained 2 02  over the past month  This has outpaced the Medical sector s loss of 3 98  and the S P 500 s loss of 4 95  in that time 
JNJ will be looking to display strength as it nears its next earnings release  which is expected to be January 22  2019  The company is expected to report EPS of  1 95  up 12 07  from the prior year quarter  Meanwhile  our latest consensus estimate is calling for revenue of  20 11 billion  down 0 42  from the prior year quarter 
JNJ s full year Zacks Consensus Estimates are calling for earnings of  8 16 per share and revenue of  81 32 billion  These results would represent year over year changes of  11 78  and  6 37   respectively 
Investors should also note any recent changes to analyst estimates for JNJ  These revisions typically reflect the latest short term business trends  which can change frequently  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 29  higher  JNJ is holding a Zacks Rank of  2  Buy  right now 
Looking at its valuation  JNJ is holding a Forward P E ratio of 17 42  This represents a premium compared to its industry s average Forward P E of 14 5 
Investors should also note that JNJ has a PEG ratio of 2 22 right now  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Large Cap Pharmaceuticals was holding an average PEG ratio of 1 98 at yesterday s closing price 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 69  putting it in the top 27  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/johnson--johnson-jnj-gains-but-lags-market-what-you-should-know-200355794,200355794
198480,419996,JNJ,The Zacks Analyst Blog Highlights  HCA Healthcare  Molina Healthcare  Johnson   Johnson  Facebook And Twitter,opinion,For Immediate ReleaseChicago  IL   November 7  2018   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include HCA Healthcare  Inc    NYSE HCA    Molina Healthcare  Inc    NYSE MOH    Johnson   Johnson   NYSE JNJ    Facebook  Inc    NASDAQ FB   and Twitter  Inc    NYSE TWTR   Today  Zacks is promoting its   Buy   stock recommendations    Here are highlights from Tuesday s Analyst Blog Election Day 2018  Here Are the Stock Market Winners   LosersTuesday s mid term election will certainly change the tone of politics in the coming two years  if not the balance of power in Washington  The election is widely expected to see Democrats gaining control over the House of Representatives  while Republicans will probably retain control of the Senate  resulting in a divided Congress But state by state and district by district  the outcome will depend on voter turnout  enthusiasm and several other factors that polling may not take into account Thus  the results will not only have implications for the stock market but for the economy as a whole  After all  it will shape the outlook for the 2020 presidential election  Let us  thus  look into the sectors that are most likely to be impacted by the election results A Divided Congress Bodes Well for Healthcare StocksThe prospects of a divided Congress could be helpful for healthcare stocks  The Affordable Care Act  ACA  did come under tremendous assault by Republicans following Donald Trump s election in 2016  ACA was subjected to a series of legislative changes  Democrats  however  now are expected to take over the House of Representatives and that is a blessing in disguise for the ACA With not much legislative changes under Democrats  things are surely looking up for Medicaid health maintenance organization  HMOs  and hospitals  And why not  ACA has always encouraged the development of Medicaid HMOs and benefited hospitals by reducing the number of uninsured patients who cannot pay their bills Leading hospital company  HCA Healthcare  Inc  and Medicaid HMO provider  Molina Healthcare  Inc  are  thus  most likely to gain from the election outcome  While HCA Healthcare carries a Zacks Rank  2  Buy   Molina Healthcare sports a Zacks Rank  1  Strong Buy   You can see   By the way  a split Congress should also benefit pharma bigwigs  This is because legislative action on drug pricing will be put off  something that has haunted the drug manufacturers in recent times  Johnson   Johnson should breathe a sigh of relief as many of their drugs derive sales growth from price increases Democrats Increasing Clout Not Necessarily a Threat for BanksDemocrats taking over the House may exert some near term pressure on bank stocks  But Republicans are forecast to retain control of the Senate and that should help banks in the long term  Republicans have remained sympathetic to big banks and President Trump has taken enough steps to ease stringent banking rules  And  any how the current rising interest rate scenario bodes well for banks  Minutes from the U S  Federal Reserve s September meeting had already confirmed that the central bank is most likely to continue hiking benchmark lending rates at a gradual pace this year and beyond A Democratic House Could Affect Energy PlayersShares of integrated oil majors as well as exploration and production  refining and drilling companies could take a beating provided Democrats take the House  A Democratic House will surely try to reverse the easing of environmental regulations by the Trump administration And even if bills find it difficult to get through a Republican Senate  renewed focus on regulatory issues could become a potential headwind  Joe McMonigle  senior energy policy analyst at Hedgeye Risk Management said that  Democrats may bring a focus to other issues such as climate change   He added that  there could also be an oversight spotlight on the Environmental Protection Agency and Interior Department environmental regulations  Auto Makers   Big Tech Have Much Riding on Election ResultsStakes are also high for the American auto industry  In general  Democrats winning the House is not good news for automakers  They are widely expected to support the more stringent Obama era corporate average fuel economy standards currently in place  Thus  only if Republicans can control both the House and the Senate  a relief rally in auto stocks is possible Unlike automakers  no matter which party controls Congress  things aren t looking good for big Internet players  purely from a regulation standpoint  Both the parties have stuck a similar tone on online privacy policy through a series of hearings that roasted top executives from Facebook  Inc  and Twitter  Inc  as security and data related issues piled up Any Election Outcome Bodes Well for CannabisIf the Democrats gain ground  then the proposed federal laws like the SAFE Act will easily get implemented  This Act blocks the government from punishing banks that serve marijuana business in legal states GOP holding ground also does not necessarily mean that pot legalization is dead  As rightly pointed out by Cowen   Co analysts Jaret Seiberg and Chris Krueger that  given popular support for cannabis legislation and a preference by many Senate Republicans to respect states  rights  a GOP Senate could advance a cannabis bill  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter  Join us on Facebook  Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-hca-healthcare-molina-healthcare-johnson--johnson-facebook-and-twitter-200356102,200356102
198485,420001,JNJ,Exclusive  Cancer drugmaker Tesaro attracts takeover interest   sources,news,"By Carl O Donnell  Reuters    U S  biopharmaceutical company Tesaro Inc  O TSRO  is discussing its options with investment banks after receiving acquisition interest from several drugmakers  according to people familiar with the matter  The takeover interest in Tesaro underscores the pharmaceutical industry s strong appetite for the acquisition of biotechnology companies with promising medicines under development in lucrative sectors such as cancer treatment  Tesaro is not actively exploring a sale  the people said this week  noting that there is a significant gap over the company s valuation between Tesaro and potential acquirers   However  the Waltham  Massachussets based company is speaking to investment banks  including  Citigroup  Inc  N C   about its strategy and how to best respond to such overtures  the people added  Additional clinical trial data later this year on Tesaro s key drug  Niraparib  which targets advanced solid tumors in ovarian and breast cancers  could help narrow the valuation gap  the people said  The sources asked not to be identified because the deliberations are confidential   Tesaro and Citigroup declined to comment  Tesaro shares rose as much as 17 percent on the news and were up 11 percent at  180 50 in late morning trading in New York on Wednesday  giving the company a market capitalization of more than  9 billion  Tesaro went public in 2012 at  13 50 per share   Tesaro has been touted for months by analysts and investors as a likely acquisition target  in light of big deals in the biotechnology sector  such as  Pfizer  Inc s  N PFE   14 billion acquisition of cancer drugmaker Medivation Inc last September  and Johnson   Johnson s  N JNJ   30 billion announced acquisition last month of rare disease drugmaker Actelion Ltd  S ATLN   Tesaro has a coveted position as a leader in the so called immuno oncology sector  which harnesses the body s own immune system to combat cancer cells   Its drug Niraparib kills cancer cells by inhibiting the production of proteins called PARPs  which help repair damaged DNA strands  thereby hastening the death of some types of cancer cells   Effective PARP inhibitors are particularly sought after by drugmakers because of their potential to be used in combination with other types of cancer treatments to create new breakthroughs in treatments   Niraparib is closer than any other PARP inhibitor to receiving regulatory approval for ovarian cancer maintenance therapy  Analysts say its peak sales could exceed  3 billion   Last year  the U S  Food and Drug Administration agreed to  fast track  its Niraparib review process  raising the likelihood it could hit the market by 2018   That would give it a significant head start over its main rival   Clovis Oncology  Inc  O CLVS   whose similar treatment is in late stage trials  
Last year  Tesaro entered into a partnership with pharmaceutical company Merck   Co Inc  N MRK  to study the effects of using Niraparib in combination with Keytruda  Merck s immuno oncology treatment ",2017-02-08,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-cancer-drugmaker-tesaro-attracts-takeover-interest---sources-458715,458715
198486,420002,JNJ,Actelion  being bought by J J  says full year core net income rose 27 percent,news,"ZURICH  Reuters    Swiss drugmaker Actelion s  S ATLN  2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension  PAH   it said on Tuesday  Core net income rose to 881 million Swiss francs   877 8 million  from 693 million francs in the previous year  the company said in a statement   Sales rose 18 percent to 2 42 billion francs  in line with the 2 41 billion francs expected in a Reuters poll  Actelion reported that sales of its new drug Opsumit for PAH rose 57 percent to 831 million francs  while Uptravi booked 245 million francs in its first year after launch  more than making up for slumping sales of its once mainstay Tracleer after patent expiration   Europe s biggest biotech sold itself for  30 billion to U S  healthcare giant Johnson   Johnson  N JNJ  this year  in a deal that will also create a new research and development company to be overseen by Actelion Chief Executive Jean Paul Clozel  
 Our current PAH portfolio and our late stage pipeline will have expanded potential as part of Johnson   Johnson   Clozel said   With the creation of a new R D company we also have the opportunity to realize the value potential we have created with our discovery engine and early stage pipeline  ",2017-02-14,Reuters,"https://www.investing.com/news/stock-market-news/actelion,-being-bought-by-j-amp;j,-says-full-year-profit-rose-26-percent-459701",459701
198487,420003,JNJ,Novo Nordisk replaces head of North American operations,news,"By Jacob Gronholt Pedersen COPENHAGEN  Reuters     Novo Nordisk   CO NOVOb   the world s largest insulin maker  said on Wednesday the head of its North American operations Jakob Riis has resigned  casting doubt over its strategy in a market that accounts for more than half its sales  Riis joined the company in 1996 but was appointed to his current role only in September  The resignation comes after Novo Nordisk disappointed investors last month with a lower 2017 sales and profit growth forecast  citing price pressure and political uncertainty in the United States  Riis had previously been regarded as heir apparent to Lars Rebien Sorensen  who stepped down as long serving CEO in September last year  Instead  Sorensen was replaced by Lars Fruergaard  while Riis was put in charge of the North American operations after being in charge of marketing and head of the China and Pacific sales regions   Investors had confidence in Jakob Riis  so I think this will be received negatively by the market   said Jyske Bank analyst Frank Horning Andersen  Novo Nordisk shares were 1 5 percent lower at 245 60 Danish crowns at 0815 GMT  Doug Langa  who is currently senior vice president for market access and has been with the company since 2011  will assume the North America role  the company said   Given the evolving payer pressures faced by the company over insulin pricing in the United States  Jakob s departure after such a short period of time may raise some eyebrows   Jefferies analysts said in a note  Langa joined Novo Nordisk from GlaxoSmithKline and was previously at Johnson   Johnson  NYSE JNJ    Doug s experience in the U S  pharmaceutical market  his leadership skills and expertise in the area of market access make him the natural successor to Jakob Riis   Goran Ando  chairman of Novo Nordisk board  said in a statement  
U S  President Donald Trump has called on pharmaceuticals companies to make more of their drugs in the United States and to cut  astronomical  prices  while vowing to speed approval of new medicines and ease regulation ",2017-03-01,Reuters,https://www.investing.com/news/stock-market-news/novo-nordisk-replaces-head-of-north-american-operations-462932,462932
198488,420004,JNJ,Johnson   Johnson wins trial in talc product liability lawsuits,news,"By Nate Raymond  Reuters    Johnson   Johnson  NYSE JNJ  said on Friday that a state court jury in Missouri had returned a verdict in its favor in the latest trial to arise out of thousands of lawsuits alleging the company s talc based products can increase the risk of ovarian cancer  The jury sided with Johnson   Johnson and talc supplier Imerys Talc in a lawsuit by Tennessee resident Nora Daniels  who alleged that she used J J Baby Powder for 36 years and was diagnosed with ovarian cancer in 2013  The verdict came after three straight prior jury verdicts in St  Louis against J J awarding plaintiffs a combined  195 million  More than 2 500 lawsuits are pending in state court in St  Louis   The jury s decision is consistent with the science  research  clinical evidence and decades of studies by medical experts around the world that continue to support the safety of cosmetic talc   Johnson   Johnson said in a statement  Imerys in a statement thanked the jury  for following the science that establishes the safety of talc   Ted Meadows  a lawyer for Daniels  in a statement said he was disappointed by the verdict   We continue to maintain that the association between genital talc usage and ovarian cancer remains an issue of public health and demands that consumers be warned of the specific risks   he said in a statement   
Plaintiffs have accused J J of failing for years to warn that talc was linked to an increased risk for ovarian cancer  J J has said it acted properly in developing and marketing the products  In February 2016  a Missouri state jury ordered J J to pay  72 million to the family of a woman who died from ovarian cancer after years of using talc powder for feminine hygiene  In May  another jury in Missouri returned  55 million to a woman who said the company s talc powder products caused her to develop ovarian cancer  J J was subsequently hit with a third verdict in October for  67 5 million ",2017-03-03,Reuters,https://www.investing.com/news/stock-market-news/johnson--amp;-johnson-wins-trial-in-talc-product-liability-lawsuits-463762,463762
198489,420005,JNJ,Aduro  ADRO  Q3 Loss Narrower Than Expected  Revenues Lag,opinion,Aduro Biotech  Inc    NASDAQ ADRO   incurred third quarter 2018 loss of 29 cents per share  narrower than the Zacks Consensus Estimate of a loss of 31 cents and the year ago loss of 33 cents Revenues came in at  3 1 million  down 17 3  year over year due to changes in revenue recognition methodology  The top line also missed the Zacks Consensus Estimate of  4 59 million Shares of Aduro have plummeted 40 8  year to date  wider than the  decline of 19 9  Quarter in DetailResearch and development expenses declined 23 6  in the reported quarter to  18 7 million owing to lower expenses related to the company s pipeline candidates  namely ADU 1604 and BION 1301 General and administrative expenses were  9 1 million  up 8 2  year over year  primarily on higher stock based compensation expense and consulting costs Pipeline UpdateAduro s three distinct technology platforms  designed to harness the body s natural immune system  are being utilized to develop treatments for several cancer indications and show potential for label expansion into auto immune and infectious diseases  The three distinct platforms are the live  attenuated  double deleted  LADD  technology platform  STING pathway activator platform and the B select monoclonal antibody platform Aduro s LADD platform includes candidates like ADU 623  phase I   glioblastoma   ADU 741  phase I   metastatic castration resistant prostate cancer  and ADU 214  phase I   metastatic non small cell lung cancer   Aduro has a research and license agreement with Janssen  a subsidiary of Johnson   Johnson   NYSE JNJ    for developing ADU 214 and ADU 741 Aduro has a collaboration and license agreement with Novartis   NYSE NVS   for developing its lead STING Activator candidate  ADU S100  The same is being evaluated in a phase I program as a monotherapy on patients with cutaneously accessible metastatic solid tumors or lymphomas  Top line data from the program is expected soon Aduro is also performing a phase Ib study to assess ADU S100 in combination with Novartis  PD 1 checkpoint inhibitor  PDR001  for treating solid tumors as well as lymphomas Aduro s B select monoclonal antibody platform has a number of immune modulating assets  currently in research and pre clinical development stage  Agents from this platform  such as anti APRIL  anti CTLA4 and anti PD1  exhibit promises to generate novel immunotherapy combinations  Aduro is evaluating BION 1301  an anti APRIL antibody  in a phase I II study for treating adult patients with relapsed or refractory multiple myeloma Aduro Biotech  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stock to ConsiderAduro currently carries a Zacks Rank  3  Hold   A better ranked stock in the same sector is Gilead Sciences  Inc    NASDAQ GILD    which sports a Zacks Rank  1  Strong Buy   You can see  Gilead Sciences  earnings estimates have been revised 3 2  upward for 2018 and 2 3  for 2019 over the past 60 days  The stock has inched up 0 6  so far this year 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-10-30,Zacks Investment Research,https://www.investing.com/analysis/aduro-adro-q3-loss-narrower-than-expected-revenues-lag-200352475,200352475
198490,420006,JNJ,AbbVie s  ABBV  Q3 Earnings Beat Estimates  2018 EPS View Up,opinion,"AbbVie Inc    NYSE ABBV   posted better than expected third quarter 2018 earnings while its revenues missed estimates by a slight margin  Moreover  the company raised its expectations for 2018 bottom line  Shares rose almost 3 4  in pre market Shares of AbbVie have declined 17 1  in a year s time against the  s 5  rise The biopharmaceutical company reported earnings of  2 14 per share in the third quarter  beating the Zacks Consensus Estimate of  2 01  The figure surged 51 8  year over year  Earnings per share also exceeded the guided range of  2 00 and  2 02 The company posted revenues of  8 24 billion in the quarter under review  missing the Zacks Consensus Estimate of  8 26 billion  However  the top line increased 17 8  year over year  Excluding a 0 7  favorable impact from foreign exchange rate fluctuations  operational revenues rose 18 5   Revenues growth was higher than the projection of approximately 17  on an operational basis Quarter in DetailKey drug Humira recorded sales growth of 9 8  on an operational basis with revenues from the same coming in at  5 1 billion  Sales in the United States increased 12 5  to  3 5 billion  better than expectations  Humira sales in the ex U S  markets were up 4 2  on an operational basis and 1 8  on reported basis to  1 58 billion  almost in line with the projected figure of  1 6 billion Third quarter net revenues from Imbruvica were  972 million  up 41 3  year over year  U S  sales of Imbruvica grossed  812 million  up 41 5  from the year ago figure and also higher than the guided figure of  725 million  AbbVie logged  160 million of international profit sharing with Johnson   Johnson   NYSE JNJ   The company s leukemia drug  Venclexta  brought in revenues of  96 million  up more than 100  year over year Other products that delivered an impressive performance include Duodopa  It recorded revenue growth of 13 3  on operational basis and 12 1  on reported basis  Another product  Creon witnessed an increase of 11 3  in revenues on both operational and reported basis HCV  chronic hepatitis C virus  products recorded sales of  862 million  up more than 100  year over year  on the back of strong demand for Mavyret  which was launched in the second half of 2017  The company s expectation for HCV sales was  850 million However  sales of two key drugs  Androgel and Sevoflurane  fell 8 3  and 10 4   respectively  operationally  during the quarter Adjusted SG A expenses increased 8 4  to  1 56 billion while R D expenses escalated 6  to  1 27 billion in the third quarter  Adjusted operating margin was 47 2  of sales Other UpdatesIn October  a label expansion of cancer drug  Venclyxto  Venclexta   in combination with Roche s   OTC RHHBY   Rituxan  rituximab  for the treatment of patients with chronic lymphocytic leukemia   CLL   in second or later line setting was approved in Europe  Data from a phase III study showed that Venclexta in combination with Roche s Gazyva had superior progression free survival   PFS   in first line CLL compared to standard of care  A label expansion application for the drug is under review in the United States for treating acute myeloid leukemia in first line setting During the quarter  AbbVie entered into a license agreement with Sandoz  a generic arm of Novartis   NYSE NVS    which will grant non exclusive license relating to Humira in the United States and other countries  The agreement restricts Sandoz from launching a biosimilar version of the drug till Sep 30  2023 in the United States  The restriction on the launch of a biosimilar version in Europe expired on Oct 16  2018 2018 Outlook RaisedAbbVie raised its adjusted EPS guidance to the range of  7 90  7 92 for 2018 from  7 76  7 86 predicted earlier  The earnings guidance reflects a year over year surge of 41 3  at the mid point  The Zacks Consensus Estimate for current year earnings is pegged at  7 86 per share Price  Consensus and EPS Surprise
    Zacks Rank AbbVie currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/abbvies-abbv-q3-earnings-beat-estimates-2018-eps-view-up-200354117,200354117
198491,420007,JNJ,TESARO  TSRO  Q3 Earnings Beat  Revenues Miss  Shares Up,opinion,"TESARO  Inc    NASDAQ TSRO   incurred a loss of  2 49 per share in the third quarter of 2018  which was narrower than the Zacks Consensus Estimate of a loss of  2 62  The company had recorded a significantly lower loss of 47 cents in the year ago period due to recognition of an upfront payment  Please note that the loss included a gain of  17 6 million related to divestiture of Varubi rights 
TESARO s key marketed drug  Zejula is approved as maintenance treatment of recurrent ovarian cancer patients 
Total revenues  primarily from Zejula  were approximately  64 4 million in the quarter  up 12 6  sequentially  Revenues  however  missed the Zacks Consensus Estimate of  69 51 million  The company had recorded total revenues of  142 8 million in the year ago quarter  TESARO had recorded an upfront payment of  100 million from Takeda in the year ago period  which was missing this quarter 
Shares of the company rose almost 7 4  in pre market trading on Nov 2  presumably on the back of strong growth in Zejula sales and an improved guidance  However  TESARO has underperformed the  so far this year  While the stock has lost 61 5   the industry decreased 3 8  

 
Quarter in Detail
Product revenues during the quarter rose 52 3  year over year to  63 6 million  The significant increase was mainly driven by impressive growth in sales of Zejula  which increased almost 61  from the year ago period to  63 2 million  Zejula s sales were up 17 3  sequentially 
Importantly  the company registered more than 10 000 new patients on Zejula therapy since its launch  On its last quarter earnings call  the company stated that more than 6000 patients had been prescribed Zejula since launch  The drug showed strong uptake in Europe 
The company s other marketed drug  Varubi  generated sales of  0 4 million in the quarter  In late June  TESARO entered into an agreement with TerSera Therapeutics to divest the U S  and Canadian rights of the drug  During the third quarter  the company closed the deal and received an upfront payment of  35 million 
License  collaboration and other revenues were  0 8 million compared with  101 million in the year ago period 
During the third quarter  research   development expenses increased 28 3  year over year to  94 2 million  primarily due to increased expenses for clinical studies on Zejula  TSR 042 and TSR 022  Selling  general and administrative  SG A  expenses increased 11 3  year over year to  93 5 million  reflecting increased activities to support commercialization of Zejula in the United States as well as Europe 
TESARO ended the quarter with  476 8 million of cash and cash equivalents  down from  575 1 million on Jun 30  2018 
Pipeline Update
The company is actively working on expanding the label of Zejula in first line ovarian cancer as well as in other cancer indications  Zejula is being evaluated in several clinical studies as monotherapy or in combination for additional indications  Janssen  a subsidiary of Johnson   Johnson   NYSE JNJ    is developing Zejula in prostate cancer with regulatory applications to be filed next year 
A regulatory application seeking label expansion of Zejula in late line ovarian cancer beyond BRCA mutation patients is expected before year end  A phase III study and a phase II study are evaluating Zejula monotherapy and Zejula in combination with Roche s   OTC RHHBY   Avastin  bevacizumab   respectively  in first line ovarian cancer  Data is expected in late 2019 from both the studies 
Apart from Zejula  TESARO s pipeline also includes immunotherapies   anti PD 1 antibody  TSR 042  and anti LAG 3 antibody  TSR 022  The company is developing TSR 042 in the lucrative first line non small cell lung cancer among other indications  The company expects to file a Biologics License Application   BLA   for TSR 042 in the second half of 2019 for recurrent endometrial cancer 
2018 Outlook Raised
TESARO raised the lower end of its sales guidance for 2018  after lowering it significantly on the second quarter earnings call  It now expects it to be in the range of  258 to  265 million compared with  250 to  265 million expected previously  Expectations for Zejula sales were also higher in the range of  233 to  238 million  previously  225 to  235   Sales of the drug in the fourth quarter are expected to be  67 to  72 million 
The company expects other revenues  including licensing and Varuby oral  in Europe   to be in the range of  25 to  27 million  previously  25 to  30 million  
The company maintained its cash and cash equivalents guidance at  400 million at year end 
Our Take
Although Zejula continues to show strong adoption  competition is increasing in the stagnating PARP inhibitor segment  Approval of Clovis Oncology s   NASDAQ CLVS   Rubraca in earlier line setting and expansion in patient population without BRCA mutation has made the ovarian cancer space more competitive  AstraZeneca s Lynpraza is the third PARP inhibitor approved for ovarian cancer 
However  successful development of Zejula  earlier than Rubraca and Lynparza  in first line ovarian cancer may boost sales of the drug TESARO  Inc  Price  Consensus and EPS Surprise
 

   Zacks Rank 
TESARO currently has a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-02,Zacks Investment Research,https://www.investing.com/analysis/tesaro-tsro-q3-earnings-beat-revenues-miss-shares-up-200354260,200354260
198498,420014,JNJ,Wall St mixed after raft of earnings as Dow holds 20 000 ,news,Investing com   U S  stocks were mixed Thursday as investors waded through a stream of earnings reports The DJI was up 0 13  at 10 30 ET as it consolidated Wednesday s record close of over 20 000 The S P 500 shed 0 04  The tech heavy Nasdaq composite lost 0 04  Earnings so far have been positive with a majority of S P 500 companies beating estimates Initial jobless claims rose more than expected  New home sales fell more than forecast The dollar index bounced off seven week lows as oil rose over 2   NYSE J J  off 0 74  at  111 97 after agreeing to buy  SIX Actelion  for  30 bn ,2017-01-26,Investing.com,"https://www.investing.com/news/stock-market-news/wall-st-mixed-after-raft-of-earnings-as-dow-holds-20,000-455912",455912
198499,420015,JNJ,Merck reveals seven years of its U S  drug price increase history,news,"By Bill Berkrot
 Reuters    Merck   Co  N MRK  on Friday posted seven years of information showing a high single digit percentage annual average price hike across its portfolio of medicines in a move that provides new details on its pricing practices for the U S  market 
Politicians  health insurers and most recently President Donald Trump have criticized drug companies over high U S  prices for prescription drugs and repeated price hikes  Trump said pharmaceutical companies have been  getting away with murder  
Other pharmaceutical companies have also signaled intentions to address rising criticism over prescription drug cost 
In every year after 2010  Merck said its average list price hikes over its entire drug portfolio was more than 9 percent  peaking at 10 5 percent in 2014  The averages are near the 10 percent level that some pharmaceutical executives and lawmakers have targeted recently 
See graphic 
The pricing information  which can be found on Merck s website  provides data from 2010 through 2016 on average annual increases to list price  as well as net price after discounts and rebates to payers  including pharmaceutical benefit managers and insurers  It also lists the average discount for each year 
Merck s most important new revenue growth driver  the cancer drug Keytruda  lists for about  150 000 per year of treatment  The class of medicines that are transforming cancer treatment by helping the immune system to attack tumors command high prices but so far help only about 20 percent of patients who receive them 
Merck s chart shows that its annual net price increases ranged from a low of 3 4 percent in 2010 to a high of 6 2 percent in 2012  In 2013  2015 and 2016  they were 5 5 percent 
The average discount from list price climbed from 27 3 percent in 2010 to 40 9 percent in 2016  Merck said  Payers have been demanding increasing discounts and rebates in exchange for covering a drugmakers  medicines 
Johnson   Johnson  N JNJ  on Tuesday said it was planning to release a  pharmaceutical transparency report  with new disclosures on U S  pricing  research and development expenses  and programs to supply medicines to those who cannot afford them 
Earlier this month  AbbVie  N ABBV  became the third major drugmaker to pledge to keep U S  price increases under 10 percent in 2017  It also said it would raise prices only once this year  rather than the common industry standard of two  often double digit percentage  price increases ",2017-01-27,Reuters,https://www.investing.com/news/stock-market-news/merck-reveals-seven-years-of-its-u.s.-drug-price-increase-history-456249,456249
198500,420016,JNJ,J J loses venue fight for talc lawsuits in Missouri,news,"By Erica Teichert  Reuters    The Missouri Supreme Court has denied Johnson   Johnson s bid to move out of a St  Louis state court thousands of lawsuits alleging the company s talc based products can increase the risk of ovarian cancer  The state high court on Tuesday this week rejected an appeal by J J  N JNJ  seeking to transfer most of the 2 500 lawsuits pending in state court in St  Louis to courts across the country where the plaintiffs are located  The plaintiffs are women and their families who claim studies show J J s Baby Powder and Shower to Shower products increase the risk of ovarian cancer when used in the vaginal area  J J has said more comprehensive studies show no such link  St  Louis has become the main destination for talc lawsuits nationally  and J J has been hit with three straight jury verdicts there  totaling  195 million  The company had hoped to reverse that trend by changing the venues for the cases to potentially friendlier jurisdictions  In September  a state court judge in New Jersey  where J J is based  dismissed two talc lawsuits against the company  J J spokeswoman Carol Goodrich declined to comment on the Missouri Supreme Court s decision  The company had argued in court filings that plaintiffs  attorneys tainted the St  Louis jury pool by spending nearly  10 million on television commercials in the last year  with a disproportionate amount running in St  Louis  Plaintiffs  lawyers have denied the allegation  Ted Meadows  one of the plaintiffs  lawyers  said in a statement on Wednesday that the Missouri Supreme Court affirmed plaintiffs  right to file their claims in a single location  
The next trial is slated to start on Feb  6 in St  Louis  In that case  Nora Daniels of Columbia  Tennessee  alleges she used J J Baby Powder for 36 years and was diagnosed with ovarian cancer in 2013 ",2017-01-27,Reuters,https://www.investing.com/news/stock-market-news/j-amp;j-loses-venue-fight-for-talc-lawsuits-in-missouri-456271,456271
198501,420017,JNJ,Actelion  Syngenta takeovers set to shake up Swiss SMI index,news,"By Rupert Pretterklieber ZURICH  Reuters    The looming foreign takeovers of biotech group Actelion and agrichemicals firm  Syngenta  look set to trigger the biggest shake up in the Swiss blue chip SMI index  SSMI  in years just as passive investing makes membership increasingly important  Analysts say specialty chemicals group Lonza  S LONN  may be set to join the Swiss club of the 20 best capitalized and most liquid shares  whose ranks could be thinned even further by the time that the next review takes place in June  analysts say   It is pretty clear that under the current selection list by the Swiss exchange  Lonza could be taken into the SMI   said Thomas Kuehne  fund manager at Liechtensteinische Landesbank  He noted Lonza s market capitalization of around 10 billion Swiss francs   10 06 billion   which could increase thanks to its  5 5 billion acquisition of U S  group Capsugel   Lonza is now ranked 21st by market capitalization  SMI components have a combined market value above 1 trillion francs  Construction chemicals specialist Sika  S SIK  and hearing aid maker Sonova  S SOON  are also in the hunt for an SMI spot after boosting growth with acquisitions   Sika is in second place  after Lonza  said Eric Chassot  portfolio manager at Banque Cantonale Vaudoise  while Kuehne saw them battling for that role    Sonova has a bit more trading volume  while Sika has a higher free float market capitalization   he said  Joining the SMI is more than just a matter of prestige  Exchange traded funds that build portfolios mirroring the composition of stock indices    thus cutting costs for investors    have seen a massive boost in popularity  increasing the importance of belonging to a high profile index  U S  healthcare giant Johnson   Johnson  N JNJ  plans to buy Actelion  S ATLN  in a  30 billion all cash deal while state owned Chinese firm ChemChina has agreed a  43 billion offer for Syngenta  S SYNN   The SIX Swiss Exchange will decide in June on any modifications that would then take effect in September after Eurex derivatives contracts expire  But out of schedule changes are also possible in the wake of unusual events such as mergers or new listings  CHANGING FACE OF INDEX Market experts said the new share set to be created later this year by the spinoff of Credit Suisse s  S CSGN  Swiss banking unit had an outside chance of an SMI spot   Chassot said this hinged on details of the flotation  which  Credit Suisse  has said could list 20 to 30 percent of the unit  Kuehne thought the placement would be too small to heave the stock into the SMI  The SIX Exchange said having two shares from the same group in the SMI was not ruled out  In any event  more than two slots in the SMI may open up this year for the first time since 2009   Shares in private bank  Julius Baer   S BAER  and insurer  Swiss Life   S SLHN  are on the brink of dropping out of the index after Baer shares dipped to 21st on the volume criterion and Swiss Life s market value slipped to 23rd   We don t speculate about which share will join or drop out  of an index  said Serkan Batir of market leader BlackRock   We will await the official announcement from the exchange and then see what we need to do   
In many years there are no or only one change to the SMI  only half of whose constituents were among the founding members of 1988 and often with a new corporate name ",2017-01-31,Reuters,"https://www.investing.com/news/stock-market-news/actelion,-syngenta-takeovers-set-to-shake-up-swiss-smi-index-456874",456874
198504,420020,JNJ,Johnson   Johnson to buy Swiss pharma Actelion for  30 bn ,news,Investing com    NYSE Johnson   Johnson  is to buy Swiss pharma  SIX Actelion  for  30 bn in cash Actelion shareholders will receive  280 a share  equivalent to 280 08 Swiss francs Actelion shares closed Wednesday up 1 97  at 227 40 Swiss francsJohnson   Johnson will fund the deal with cash held outside of the U S In a statement  Actelion said as part of the deal it will spin off its R D unit which will be listed in Switzerland  Johnson   Johnson will hold a substantial minority interest in the new R D company Johnson   Johnson and Actelion will hold a conference call with investors at 08 00 ET to discuss the deal ,2017-01-26,Investing.com,https://www.investing.com/news/stock-market-news/johnson---johnson-to-buy-swiss-pharma-actelion-for-$30-bn-455779,455779
198505,420021,JNJ,Top 5 things to watch today ,news,Investing com   Global stock market rally continues after DJI tops 20 000 Another big day of U S  earnings ahead Dollar bounces back from 7 week lows U K  economy grew 0 6  in final quarter of 2016  NYSE Johnson   Johnson  to buy  SIX Actelion for  30 billion ,2017-01-26,Investing.com,https://www.investing.com/news/economy-news/top-5-things-to-watch-today-455826,455826
198506,420022,JNJ,4 Trade Ideas For Johnson   Johnson  Bonus Idea,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Johnson   Johnson  NYSE JNJ    JNJ  started to move to the downside in January  A fast drop brought it to a short term bottom in February and it bounced  It consolidated for 2 months and then drifted lower to a bottom in June  Since the start of July it has started moving higher  At the end of last week it was testing the April bounce high at the 200 day SMA 
The RSI is rising in the bullish zone with the MACD moving up and the price riding the Bollinger Bands  higher  There is resistance at 132 and 135 50 then 139 and 142 before 145 50 and 148  Support lower comes at 130 and 125  Short interest is low under 1   The company is expected to report earnings next on October 16th  The stock pays a 2 74  dividend and starts trading ex dividend on August 27th 
The August monthly options chain shows open interest the biggest at the 125 strike on the put side and then 120  On the call side it is big at 125 and 130  The September chain shows open interest spread from 135 down to 120 on the put side and bigger from 130 to 140 on the call side  The October chain  covering the earnings report  show the 120 strike the biggest open interest on the put side  On the call side it is biggest at 135 
Johnson   Johnson  Ticker   JNJ 
Trade Idea 1  Buy the stock on a move over 132 with a stop at 129 
Trade Idea 2  Buy the stock on a move over 132 and add an August 129 Put  86 cents  as protection  Sell a September 7 Expiry 136 Call  75 cents  to pay for most of the protection 
Trade Idea 3  Buy the August October 135 Call Calendar   1 77  and sell the September 120 put  47 cents  to lower the cost 
Trade Idea 4  Buy the October 120 135 140 Call Spread Risk Reversal  50 cents  
After reviewing over 1 000 charts  I have found some good setups for the week  This week s list contains the first five below to get you started early  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which as the last full week of July ended saw the equity markets looking tired on the shorter timeframe but remained solid on the longer one 
Elsewhere look for Gold to consolidate in the downtrend while Crude Oil shows signs of reversing higher at support  The US Dollar Index continues to mark time moving sideways while US Treasuries pullback in consolidation  The Shanghai Composite may be stalling in its bounce in the downtrend while Emerging Markets are building strength for a possible reversal higher 
Volatility looks to remain at very low levels keeping the bias higher for the equity index ETF s SPY  NYSE SPY   iShares Russell 2000  NYSE IWM  and PowerShares QQQ Trust Series 1  NASDAQ QQQ   Their charts are showing a lack of energy or maybe even some weakness in the short term  especially in the QQQ and IWM  All look stronger and remain in the uptrends on the longer timescale  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2018-07-30,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-for-johnson--johnson-bonus-idea-200334483,200334483
198507,420023,JNJ,4 Trade Ideas For Johnson   Johnson  Bonus Idea,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Johnson   Johnson  NYSE JNJ    JNJ  fell from a top in January  A quick bounce in February saw it consolidate and drop again  The bounce to a lower high in April resulted in another pullback to a low in late May  But since then it has done well  A move up first to the April high into the beginning of August  Then a pullback to a higher low at the 20 day SMA and reversal  completed an Inverse Head and Shoulders pattern  This gives a target to at least 147  or near the January high 
The price action at the end of last week saw it reversing out of a short term consolidation after it closed a small gap from February  The RSI is rising and bullish with the MACD flat but positive  The Bollinger Bands  are shifted to the upside  There is resistance at 137 and 139 then 141 25 and 143 75 then 146 80 and 148 25  Support lower comes at 134 and 132 75 before 129 75 and 126 50  Short interest is low under 1   The company is expected to report earnings next on October 16th  The stock pays a 2 65  dividend and it begins to trade ex dividend on Monday  the 27th 
The August 31 Expiry options chain shows the biggest open interest this week at the 135 strike on both the call and put side  The September options also show big open interest at 135 but bigger at 140 on the call side and 130 on the put side  The October chain  covering the earnings report  shows open interest focused from 130 to 140 on the call side  But on the put side it is big from 120 to 130 and then again at 90 
Johnson   Johnson  Ticker   JNJ
Trade Idea 1  Buy the stock on a move over 137 with a stop at 134 
Trade Idea 2  Buy the stock on a move over 137 and add a September 136 132 Put Spread   1 50  for protection  while selling the September 140 Calls  40 cents  to cover some of the cost 
Trade Idea 3  Buy the September October 140 Call Calendar  97 cents  and sell the September 130 Puts  45 cents  to lower the cost 
Trade Idea 4  Buy the October 130 140 bullish Risk Reversal  12 cents   
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which as the summer winds down with the last week of August coming up sees the equity markets waking up and moving higher 
Elsewhere look for Gold to possibly bounce around in its downtrend while Crude Oil moves higher  The US Dollar Index is stalling in its uptrend while US Treasuries may be on the verge of breaking their consolidation to the upside  The Shanghai Composite continues to look weak and with an easier path lower while Emerging Markets are bouncing in their downtrend 
Volatility looks to remain at very low levels keeping the bias higher for the equity index ETF s SPY  NYSE SPY   IWM and QQQ  Their charts are aligned with that view  The shorter daily timeframe shows all 3 back in uptrends  with the QQQ the only one short of its all time high level  The weekly charts all look fantastic as well and show lots of upside potential  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2018-08-27,Gregory W. Harmon,https://www.investing.com/analysis/4-trade-ideas-for-johnson--johnson-bonus-idea-200340788,200340788
198508,420024,JNJ,J J  Royal Bank of Canada Are Perfect For Your Forever Portfolio,opinion,"A general principle of investing is buy low and sell high  But many investors  who have made fortunes  rarely sell once they ve bought a cash producing asset 
The great investor Philip Fisher  in his book  Common Stocks and Uncommon Profits   famously argues that the best time to sell a stock is  almost never   Warren Buffett  the world s most successful value investor  wrote that his  favorite holding period is forever  in his 1988 letter to Berkshire Hathaway  NYSE BRKa  shareholders 
If your goal is to build a solid cash stream for your retirement  then keeping some Forever Stocks in your portfolio is a great idea  You can tap your dividend stocks for regular income when you need it  And when you don t need passive income  you can use these cash flows to re invest and unlock the power of compounding 
Forever Stocks are the companies that pay dividends no matter what s happening with the general economy  Their payouts survive peaks and troughs  wars  depressions and asset bubbles 
Their products and services are so crucial that we can t imagine a normal life without them  This quality has turned these companies into cash machines that never run out 
J J Makes The Cash And Doles It Out
Johnson   Johnson  NYSE JNJ  is not the kind of stock you hear people bragging about at dinner parties  It s an old economy stock that rarely gets space in the financial press  But the New Brunswick  N J   based healthcare giant is exactly the kind of investment that buy and hold investors prefer 

JNJ is one of the world s most powerful brands  Through its three business units  the company runs more than 260 companies across the world  JNJ generated leveraged free cash flow of more than  18 billion in the last four reported quarters 
When it comes to rewarding investors  few companies have done better than Johnson   Johnson  The company has increased its quarterly dividend rate every year for 56 consecutive years  This remarkable performance puts Johnson   Johnson among an elite group known as Dividend Kings  companies with at least five decades of annual dividend hikes 
Royal Bank of Canada Can Weather Any Storm
Since the 2008 financial crisis  banks haven t been on the radar screen of some income investors because of the inherent risk they carry in times of distress  But north of the border  banking stocks have proven a much better bet than at home 

In Canada  banks operate in an oligopoly  where their domestic businesses are well protected from competition  Canadian banking regulations are much tougher when compared to other advanced markets 
The latest example of this strong regulatory environment is the nation s successful handling of its real estate market  where rampant speculations in the past decade had many banks exposed  This alarming situation prompted the nation s banking watchdog to tighten the mortgage rules in a timely manner and avoid a disaster 
To get exposure to one of the best banking systems in the world  buy Royal Bank Of Canada  NYSE RY   the nation s largest lender  RBC also fits nicely in any Forever Stock portfolio  The Toronto based lender generates hefty cash flows and distributes about half of its income in dividends each year 
The lender has paid dividends to shareholders every year since 1870  Since 1998  the share price in US dollars has increased more than 1 400 percent  In that period  there were recessions  bank closures and the financial crisis  RBC was able to ride through all these crises because it had a wide economic moat to defend itself 
Bottom Line
Buying and holding Forever Stocks such as J J and RBC is a tested approach to build your wealth for your nest egg  You can use these two names to identify other long term opportunities in the market with the aim of holding those stocks for the next 30 to 40 years  Look for strong balance sheets  rising cash flows and a dominant market position ",2018-09-21,Haris Anwar/Investing.com,https://www.investing.com/analysis/jj-royal-bank-of-canada-are-perfect-for-your-forever-portfolio-200344854,200344854
198509,420025,JNJ,JNJ Stock Had A Nice Run Lately  Time To Sell ,opinion,"Less than four months ago  JNJ stock was trading below the  120 a share mark  down 20  from its all time high of  148 32  A 20  decline is a pretty serious thing for investors  especially when we talk about blue chip stocks  which are considered to be less volatile and therefore safer bets  In fact  many believe that once a security has fallen by 20  it is officially in a bear market and more weakness can be expected 
But instead of automatically jumping to a bearish conclusion simply because Johnson   Johnson  NYSE JNJ  was down 20   we decided to take a look at the Elliott Wave structure of this decline  The chart below  published on June 8th  revealed a much brighter picture 
The 20  drop from  148 32 to  118 62 looked like a textbook A B C zigzag correction with an ending diagonal pattern in the position of wave C  Ralph N  Elliott once discovered that ending diagonals are often followed by a  swift and sharp reversal   In other words  the structure of JNJ stock  s slump warned us not to join the bears near  123 a share in June and get ready for a major rally instead  Three and a half months later  here is an updated chart depicting JNJ s progress 
The bulls needed a little time to regroup at first  but they never allowed a new low to be reached   118 62 remained intact  so all investors had to do was stick to the analysis and stay long JNJ stock  Last Friday  Johnson and Johnson closed in the vicinity of  143 a share  up 15 9  since June 8th  Furthermore  it looks like a five wave impulse is in progress  If that is correct  we can expect JNJ to keep rising and eventually reach and exceed the  150 mark 
JNJ Stock  the Big Picture
Then what  No trend lasts forever and as the last 20  dip demonstrated  even blue chip stocks are not immune to sudden price declines  In order to decide if holding JNJ stock above  150 is worth the risk  let s take a look at its weekly chart  It reveals its entire uptrend since March  2009 
As visible  the recent selloff to  118 62 fits in the position of wave IV within a larger five wave advance from  46 25 in March  2009  A support cluster formed by the 38 2  Fibonacci level and the lower line of the trend channel helped JNJ stock recover in the second half of 2018  The problem is that every impulse is followed by a three wave correction in the opposite direction  Chances are good that the current rally is actually the fifth wave   V   of JNJ s post 2009 bull market  A major three wave decline can be expected as soon as it is over 
In conclusion  the Elliott Wave principle put us ahead of a strong and powerful recovery in a blue chip stock that was otherwise supposed to be in a bear market  The rally is not over as  150 is still there for the taking  but buying JNJ stock near all time highs is probably not a good idea 
Original post",2018-09-24,EWM Interactive,https://www.investing.com/analysis/jnj-stock-had-a-nice-run-lately-time-to-sell-200345169,200345169
198513,420029,JNJ,Exclusive  J J discussing breaking up Actelion in an acquisition   sources,news," Reuters    Johnson   Johnson  N JNJ  is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd  S ATLN  that would separate its commercialized portfolio from its research and development  R D  assets  people familiar with the matter said on Thursday  This deal structure would allow J J to acquire Actelion with a cash offer in the region of  260 per share  a little more than what it had offered when it walked away from negotiations earlier this month  while allowing Actelion shareholders to benefit further financially from Actelion s R D pipeline  the people said  Under the deal being discussed  Actelion s R D pipeline would be placed in a new publicly traded company  the people said  The exact ownership of this new company  and whether Actelion Chief Executive Jean Paul Clozel would head that new company  are among the details still being negotiated  the people said  A deal could be finalized by late January  the people said  cautioning that negotiations could still end without a deal and asking not to be identified because the details are confidential  
J J and Actelion declined to comment ",2016-12-29,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-j-amp;j-discussing-breaking-up-actelion-in-an-acquisition---sources-450357,450357
198514,420030,JNJ,Judge halves  1 billion award in J J hip implants case,news, Reuters    A U S  judge almost halved the award in a December jury verdict that ordered Johnson   Johnson  N JNJ  and its DePuy Orthopaedics unit to pay more than  1 billion to plaintiffs in six lawsuits who said they were injured by DePuy s Pinnacle hip implants  U S  District Judge Ed Kinkeade in Dallas cited  constitutional considerations  that limit how much plaintiffs may recover in punitive damages but upheld the jury s findings that the implants were defectively designed and that the companies failed to warn consumers about the risks  Around  500 million of punitive damages would be cut from the more than  1 billion awarded to the plaintiffs who are California residents that were implanted with the hip devices and experienced tissue death  bone erosion and other injuries they attributed to design flaws  The complainants claimed the companies promoted the implants as lasting longer than devices that include ceramic or plastic materials  DePuy ceased selling the metal on metal Pinnacle devices in 2013 after the U S  Food and Drug Administration strengthened its regulations on artificial hips  J J and DePuy paid  2 5 billion that year to settle more than 7 000 lawsuits over its ASR metal on metal hip devices ,2017-01-04,Reuters,https://www.investing.com/news/stock-market-news/judge-halves-$1-billion-award-in-j-amp;j-hip-implants-case-450974,450974
198515,420031,JNJ,Sanofi s M A misses frustrate some investors in drugmaker,news,"By Matthias Blamont  No lle Mennella and Ben Hirschler PARIS DAVOS  Switzerland  Reuters    For the last year  Sanofi s chief executive has made clear his quest for deals to help revive the fortunes of France s biggest drugmaker  The market is still waiting  Olivier Brandicourt s failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors   The company needs a growth driver and must make an acquisition  Time is running out   said Olivier David of Vega Investment Managers  who holds shares in the company  In an interview at the World Economic Forum in the Swiss resort of Davos this week Brandicourt defended his track record  citing an unwillingness to overpay for pricey assets and a paucity of good opportunities   We can grow without M A  However  it is a tool which we do continue to consider and which can help growth potentially  only if it makes sense strategically   he said   The reason why it is so competitive is that you don t have a very  very large number of potential targets    Sanofi s misses underscore the race for assets as the world s top drugmakers try to replenish their medicine cabinets  After entering exclusive talks  Johnson   Johnson  NYSE JNJ  appears to be closing in on a deal to buy Actelion for some  28 billion  edging out Sanofi  PA SASY   which also tried to buy the Swiss company  according to people familiar with the matter  It marks a second setback for Brandicourt s M A ambitions after he was beaten by Pfizer s  14 billion bid for U S  cancer specialist Medivation last August  Brandicourt said he had to tread a fine line between delivering and overpaying  arguing many shareholders appreciated the financial discipline needed to walk away from deals   Shareholders being frustrated after one year is not automatically what I m hearing  to be honest  because when I see investors they seem to be very happy for us not to have spent  14 billion on Medivation   he said   On Actelion  I m not making any comment but you will understand that a company like ours will continuously look at what s happening in the world of potential mergers and acquisitions   The global pharmaceutical industry has seen a flurry of acquisitions in recent years as leading players build their drug pipelines by snapping up young biotech firms   Sanofi has a particular need to do this because its core U S  diabetes business has stalled  Brandicourt   who joined the company in April 2015 after the ousting of former CEO Chris Viehbacher   insisted Sanofi was delivering effectively on a plan set out to 2020  The drugmaker posted better than expected quarterly earnings in October  helped by a surge in flu vaccine sales  but it stuck to its guidance for currency adjusted sales at its embattled diabetes business to shrink by 4 8 percent per year on average from 2015 to 2018  Despite a rally since October  over the last five years Sanofi shares have lagged the sector  rising around 37 percent  against a 61 percent gain for the STOXX Europe 600 Healthcare index   A lot of fund managers and historic shareholders are fed up with Sanofi and tired of seeing the stock in this  vegetative  state   said Frederic Rozier  a Sanofi investor and fund manager with Meeschaert   Cost cutting is not enough  we want to see growth in sales  that s where we need to see progress    CONSTANT SCREENING MODE   Sanofi is due to publish annual results on Feb  8 and its 2016 financial performance is expected to hinge on cost savings  The fear is that with few potential new blockbusters in development  with the notable exception of dupilumab for eczema and asthma  Sanofi may find itself stuck with no meaningful growth for a while   Sanofi is looking for a pipeline and for this very reason it must engage in external growth   said Rudi Van den Eynde  with asset management firm Candriam   At the moment  the company is being overtaken by other groups that are offering more money  One can applaud that Sanofi is financially disciplined but it is a pity that it misses its targets     it doesn t help in terms of credibility   Sanofi s failure to land either Medivation or Actelion has raised questions over its acquisition strategy  even as the group insists it is in  constant screening mode    Is Sanofi not too rigid when it comes to pricing  At the end  they lose to someone else   said a Paris based banker who asked not to be identified  Another banking source said Sanofi s hostile approach in the Medivation process had been a mistake  Weeks before losing out to  Pfizer   NYSE PFE   Sanofi tried to oust Medivation s board members to replace them with new directors   Everyone knows that 95 percent of hostile approaches go wrong   the source said  adding that in the final stage Pfizer and Sanofi were only a few hundred millions apart  Brandicourt said he simply stuck to his guns on price and he noted that Sanofi  with a relatively small oncology business  may have had fewer potential cost savings than competitors  IF YOU DON T LIKE IT  SWAP IT Sanofi has signaled its readiness to do deals of a similar size to its  20 billion purchase of Genzyme in 2011 but finding the right large biotech to fit is not that easy   Alternatively  Sanofi could purchase smaller companies  along the lines of the strategy pursued by Japan s Takeda  It would be more realistic   Van den Eynde said  Sanofi may also look at more asset swaps  after agreeing to hand its animal unit to Boehringer Ingelheim in exchange for the German firm s consumer healthcare operations  a business strand it is keen to grow  
 A number of healthcare companies are looking at Pfizer s consumer health unit  Sanofi is one of them   said one healthcare banker  A Sanofi spokesman declined to comment ",2017-01-20,Reuters,https://www.investing.com/news/stock-market-news/sanofi's-m-amp;a-misses-frustrate-some-investors-in-drugmaker-454529,454529
198516,420032,JNJ,Johnson   Johnson  Trouble On Lawsuits ,opinion,"Johnson   Johnson   Health Care   Pharmaceuticals   Reports Tuesday  July 17
Johnson   Johnson  NYSE JNJ  will release its FQ2 18 earnings report tomorrow  July 17  before the market opens  Estimize consensus projects an EPS of  2 08  a 14  YoY growth and 2 cents higher than Wall Street s prediction  Estimize has been more accurate than Wall Street in JNJ EPS predictions 96  of the time  We anticipate a revenue of  20 326B  an 8  growth  YoY   while Wall Street predicts a revenue of  20 245B 

Johnson   Johnson has been hit by a wave of lawsuits due to its perceived contribution to the opioid epidemic  In April  Kentucky sued the company for its deceptive advertisements stating the painkillers were  rarely addictive   and many similar suits are still in development  On Thursday  July 12  22 women were awarded  4 69B after stating that their ovarian cancer was caused by Johnson   Johnson s talcum powder  This will not be the last cancer related lawsuit against the pharmaceutical company  thousands of cases are making their way through court systems 
How do you expect JNJ to perform during this turbulent time 
Original Post",2018-07-16,Estimize,https://www.investing.com/analysis/johnson--johnson-trouble-on-lawsuits-200331163,200331163
198519,420035,JNJ,Johnson   Johnson shares could rally about 20 percent  Barron s,news,"NEW YORK  Reuters    Johnson   Johnson  N JNJ  shares could rally about 20 percent to the mid  130s as operating improvements spur earnings growth  Barron s said in a report  Healthcare stocks have taken a hit since U S  President elect Donald Trump vowed to bring down drug prices        It  SPXHC  remains one of the worst performing S P 500  SPX  sectors for 2016  and is down about 5 percent this year versus an S P 500 gain of about 10 percent  However  J J is less susceptible to changes in pricing than its peers  Barron s said in its report  adding that the company could in fact prosper from Trump s plans to lower corporate taxes   The company is also making substantial improvements in its consumer and medical devices businesses  according to the Barron s report  Reduced concern about competition for the company s blockbuster Remicade arthritis drug could also help bolster the stock  the report said   In the third quarter  J J s global medical device sales rose 1 1 percent to  6 16 billion  while consumer product sales fell 1 6 percent to  3 26 billion  
Shares of J J closed at  112 26 on the New York Stock Exchange on Friday ",2016-12-11,Reuters,https://www.investing.com/news/stock-market-news/johnson--amp;-johnson-shares-could-rally-about-20-percent:-barron's-447064,447064
198520,420036,JNJ,Actelion talks to new party  reported to be Sanofi  as J J drops bid,news,"By Greg Roumeliotis and John Miller NEW YORK ZURICH  Reuters    Switzerland s Actelion Ltd  S ATLN  confirmed it was in talks about a  strategic transaction   with a report that Sanofi  PA SASY  had filled the gap left after U S  healthcare group Johnson   Johnson  N JNJ  ended its takeover bid  Actelion s shares were indicated 3 7 percent lower on Wednesday after The Wall Street Journal  citing people familiar with the matter  said France s Sanofi was now in talks with Europe s largest biotechnology drug marker  The WSJ reported that it was not clear what price Sanofi was discussing or what structure might be involved  but said a deal could value Actelion at as much as  30 billion  The Swiss company  which was founded by its chief executive Jean Paul Clozel in 1997  did not name the party it was now in discussions with and a spokesman declined further comment   Analysts have previously identified Sanofi as a potential buyer for Actelion  whose portfolio would supplement the French drugmaker s Genzyme rare disease unit  Sanofi declined to comment on the WSJ report  Actelion informed Johnson   Johnson that it was confident it could attract an offer significantly higher than the approximately 250 Swiss francs per share that the U S  company had offered  according to a person familiar with the matter  There were also disagreements about the structure of the deal  the person added  Actelion shares closed at 208 50 Swiss francs on Tuesday before the company gave the update on the talks  giving it a market capitalization of 22 5 billion Swiss francs   22 2 billion   Acquiring lung disease specialist Actelion would have boosted J J s drug pipeline and given it more pricing power  at a time when its popular arthritis drug Remicade faces cheaper competition from  Pfizer  Inc  N PFE   Clozel and his wife  Chief Scientific Officer Martine Clozel  have built up a world leading drug portfolio at Actelion to treat pulmonary arterial hypertension  They aim to expand in drugs for multiple sclerosis and clostridium difficile  but regulatory approvals for those are years away  The company is also counting on its new pulmonary arterial hypertension treatments Opsumit and Uptravi  which combined are forecast to bring in nearly 4 5 billion francs in annual sales by 2020  
Clozel has faced pressure from some shareholders to do a deal  Five years ago  he successfully defended against an effort by activist hedge fund Elliott Management to put Actelion up for sale  questioning his strategy ",2016-12-14,Reuters,https://www.investing.com/news/stock-market-news/actelion-says-it-continues-deal-talks-as-j-amp;j-drops-out-447599,447599
198521,420037,JNJ,Actelion s shares jump on report of Sanofi deal nearing,news, Reuters    Shares in Swiss biopharmaceuticals company Actelion  S ATLN  surged more than 8 percent to a record high after Bloomberg reported that talks with French suitor Sanofi  PA SASY  were nearing an agreement that could be worth about  275 per share  The potential deal  which could come as soon as next week  would value Actelion at about  29 6 billion  Bloomberg said on Thursday  citing people with knowledge of the matter   Reuters reported on Wednesday that Actelion was in talks with Sanofi about a deal after U S  healthcare group Johnson   Johnson  N JNJ  abandoned efforts to buy the company  Actelion s share price was up 8 35 percent at 214 Swiss francs   208  by 1328 GMT  when Sanofi s was down 2 42 percent at 74 17 euros  underperforming a 0 6 percent gain in the STOXX Europe 600 Health Care index  0  SXDP   Sources familiar with the situation have said that Sanofi is likely to offer Actelion shareholders cash plus contingent value rights  a type of security that pays out only if experimental drugs reach certain commercial targets  keeping their owners exposed to some risk of failure  Several investors in Actelion told Reuters they would push for more information  Sanofi and Actelion declined to comment  A deal would mark Sanofi s largest transaction since 2011  when it bought rare disease specialist Genzyme for  20 1 billion  At the time Sanofi had also proposed cash plus payments tied to the success of the U S  biotech group s drugs  In recent years Genzyme has delivered a double digit percentage growth in sales thanks to robust demand for its multiple sclerosis treatments  Actelion makes drugs treating pulmonary arterial hypertension  PAH   a life threatening form of high blood pressure in arteries connecting the heart and lungs   It also plans to expand in drugs for multiple sclerosis and clostridium difficile   a condition which can lead to life threatening inflammation of the colon   but regulatory approvals are still some years away  However  Actelion has repeatedly maintained that it is better off staying independent and five years ago successfully fended off an attempt by activist hedge fund Elliott Management to put it up for sale  Meanwhile Sanofi has been attempting to diversify as it faces pressure on prices for its insulin products for treating diabetes in the United States and has repeatedly expressed an interest in making more acquisitions  Earlier this year it lost out to Pfizer s  N PFE   14 billion bid for cancer drug company Medivation ,2016-12-16,Reuters,https://www.investing.com/news/stock-market-news/sanofi-discusses-$275-per-actelion-share-for-potential-deal:-bloomberg-448204,448204
198522,420038,JNJ,Sanofi s takeover talks with Actelion progressing  source,news,"By Pamela Barbaglia and Maiya Keidan LONDON  Reuters    Talks between Actelion  S ATLN  and Sanofi  PA SASY  are making progress  despite investors  fears that the Swiss biotech firm s chief executive and founder might not want to sell  a person with direct knowledge of the situation said on Tuesday  The source said Actelion had now reached a point where the company needed to sign a deal and it could not call off negotiations with the French drugmaker without triggering an investor rebellion demanding the overthrow of its board  Actelion s share price has fallen more than 7 percent in the last two days as a hoped for takeover valuing the Swiss biotech firm at up to  30 billion has failed to emerge  frustrating hedge funds that have bought heavily into the stock   You can count us in to the growing camp of hedge fund discontent about this process   said Michael Wegener  managing partner at Hong Kong based Case Equity Partners   What is it that s wrong   Actelion s co founder and Chief Executive Jean Paul Clozel has fended off previous attempts to take over the Swiss firm  rejecting approaches by U S  and European rivals as well as resisting pressure from U S  activist hedge fund Elliott Advisors to find a buyer five years ago  The silence in recent days has unnerved investors who had been looking for a deal before the Christmas break  but the source said it would be  neither impossible nor unusual  to see a big transaction coming between Christmas and New Year s Eve  U S  healthcare group Johnson   Johnson  N JNJ  abandoned its efforts to buy Actelion last week but the source said it may still come back with a counter offer  depending on what terms are agreed with Sanofi  Other sources familiar with the situation said Sanofi had stepped in soon after J J made its initial approach with an all cash offer  The French firm tried to win over Actelion s board with a higher bid containing cash and a so called contingent value right  CVR   they said   The CVR   similar to one that Sanofi provided when it bought U S  rare diseases firm Genzyme for  20 billion in 2011   would pay out if certain Actelion drugs live up to commercial expectations  Investors said any offer where the CVR represented more than 20 percent of the overall value of the deal would not go down well with shareholders  Sanofi and Actelion declined to comment  After being trumped in August by Pfizer s  N PFE   14 billion bid for U S  cancer drug company Medivation  Sanofi remains hungry for deals to broaden its drug line up as its key diabetes business comes under pressure  Actelion s drugs for treating pulmonary arterial hypertension  a life threatening form of high blood pressure in arteries connecting the heart and lungs  would dovetail with its Genzyme rare diseases unit  analysts believe  
The Swiss group was co founded in 1997 by 61 year old Clozel and his wife  Chief Scientific Officer Martine Clozel ",2016-12-20,Reuters,https://www.investing.com/news/stock-market-news/sanofi-talks-with-actelion-progressing:-source-448969,448969
198523,420039,JNJ,Actelion shares gain on report of progress in Sanofi talks,news,"ZURICH  Reuters    Swiss biotech group Actelion s  S ATLN  shares rose by more than 3 percent on Wednesday following a report that talks with Sanofi  PA SASY  are making progress  increasing optimism that the two will strike a deal  Reuters reported late on Tuesday that discussions between the Swiss and French companies are progressing  despite investors  fears that the Swiss biotech firm s chief executive and founder might not want to sell  Analysts at Basler Kantonalbank and Thurguaer Kantonalbank cited the Reuters report as the reason for Actelion s share price rise  The shares were up 3 9 percent at 209 80 Swiss francs by 0914 GMT  while Sanofi stock edged up 0 1 percent  Actelion s share price had fallen more than 7 percent in the past two sessions as a hoped for takeover valuing the Swiss biotech firm at up to  30 billion has failed to emerge  frustrating hedge funds that have bought heavily into the stock  However  the source said Actelion had now reached a point where the company needed to sign a deal and it could not call off negotiations with the French drugmaker without triggering an investor rebellion demanding the overthrow of its board  Actelion s co founder and Chief Executive Jean Paul Clozel has fended off previous attempts to take over the Swiss firm  rejecting approaches by U S  and European rivals as well as resisting pressure from U S  activist hedge fund Elliott Advisors to find a buyer five years ago  The silence in recent days has unnerved investors who had been looking for a deal before the Christmas break  but the source said it would be  neither impossible nor unusual  to see a big transaction coming between Christmas and New Year s Eve  U S  healthcare group Johnson   Johnson  N JNJ  abandoned its efforts to buy Actelion last week but the source said it may still come back with a counter offer  depending on what terms are agreed with Sanofi  Other sources familiar with the situation said Sanofi had stepped in soon after J J made its initial approach with an all cash offer  The French firm tried to win over Actelion s board with a higher bid containing cash and a so called contingent value right  CVR   they said  The CVR   similar to one that Sanofi provided when it bought U S  rare diseases firm Genzyme for  20 billion in 2011   would pay out if certain Actelion drugs live up to commercial expectations  Investors said any offer where the CVR represented more than 20 percent of the overall value of the deal would not go down well with shareholders  
Sanofi and Actelion have declined to comment ",2016-12-21,Reuters,https://www.investing.com/news/stock-market-news/actelion-shares-gain-on-report-of-progress-in-sanofi-talks-449095,449095
198524,420040,JNJ,Johnson And Johnson  JNJ   Will Pipeline Drugs Offset Sales Erosion ,opinion,"Johnson   Johnson  NYSE JNJ  is a massive company with many products stretching across its three segments  Pharmaceutical  Consumer  and Medical Devices 
  The Pharmaceutical segment is the key to the bull and bear thesis  as it represents a majority of revenue and operating income  A number of drugs will face generic competition in 2019  and investors are watching to see if the pipeline is robust enough to fend off revenue erosion
  Consumer and Medical Devices have lagged Pharmaceuticals growth  but management outlined a robust plan to turn the businesses around over the next several years at a recent Investor Day on May 16  These segments may become a bigger part of the story should Pharmaceutical segment growth slow  and is essential for JNJ s multiple to recover
Pharmaceutical Segment to Likely Face Elevated Generic Competition in 2019
The Pharmaceutical segment represents  50  of sales and 66  of operating income  and therefore is key to the bull and bear thesis around Johnson and Johnson  The segment has seen high single to low double digits organic growth over the last several years 
However  investors fear that growth may begin to slow in 2019 as generics and biosimilars eat away at blockbuster drugs  In particular  investors are watching two drugs  Remicade and Zytiga 
Remicade is a drug that can be used to reduce signs and symptoms for a number of indications  including Colitis  Arthritis  and Crohn s Disease  Worldwide revenue began to decline in 2015 after the expiration of the EU patent  and then US revenue declined further in late 2016 after Inflectra  a Remicade biosimilar  launched  Today  many analysts believe current stock levels price in steep declines in Remicade revenue  Consensus estimates place Remicade revenues at  5 3 billion in 2018 and  4 6 billion in 2019 

Zytiga is used with Prednisone to treat mCRPC  an advanced form of metastatic prostate cancer  The drug faces generic competition that is thought to be 6 12 months away by most investors  Of note  Sun Pharma also recently received approval of its branded Yonsa drug  which is a new formulation of Zytiga  The approval was a surprise to many investors as Johnson and Johnson still holds onto a method of use patent on Zytiga  However  Yonsa is not a substitute for Zytiga  and is there expected to face an uphill battle in convincing doctors to write for Yonsa over Zytiga  As a result  investors remain focused on the expected generic competition in 2019  Consensus expects Zytiga revenue to drop from  3 1 billion in 2018 to  2 4 billion in 2019 

On the flip side  many of these same analysts also believe that not enough credit is being given to Johnson and Johnson s pipeline of drugs  They cite management s goal of filing 10 new products  each expected to drive  1B  in revenue  and 50 line extensions  11 with at least  500M potential  by 2021 as evidence of the company s efforts to offset potential blockbuster declines 
Within the pipeline  investors are particularly excited about Tremfya  Erleada  and Esketamine  Esketamine recently received strong top line phase 3 data for treatment resistant depression  TRD   which should support management s goal of a 2018 filing  Esketamine has received breakthrough therapy designations for TRD as well as for suicidal ideation  The addressable market is significant  as there are an estimated 6 million TRD patients in the US alone  Beyond the pipeline  investors are also watching for strength in Xarelto  Darzalex  and Imbruvica 
Key is whether the company s pipeline can offset erosion from competition
To summarize  investors are closely watching JNJ s Pharmaceutical segment for 1  Remicade and Zytiga sales erosion  especially as generics and biosimilars enter  and 2  the company s ability to offset erosion with new drugs and line extensions 
Consumer and Medical Devices are Show Me Stories
The Consumer and Medical Device segments represent the remainder of the 33  in operating income and have been a drag on overall growth at Johnson and Johnson  In mid May  Johnson and Johnson held an Investor Day to present the plan to turn around the businesses  These turnaround plans will be key in reviving JNJ s multiple and in de risking financials should the Pharmaceutical segment slow 
Consumer Segment Focused on Becoming More Nimble and Relevant
The Consumer segment saw solid  above market organic growth of about  3  between 2014 and 2016  However  the company experienced hiccups in 2017 as organic growth slowed to 1  driven by new entrants into the space 
Going forward  management expects the segment to grow at 1 2  above market growth between 2016 and 2020  They expect to achieve these goals through a number of organizational changes  including 
  Taking on more startup qualities while holding onto the benefits that come from a global brand with enormous scale
  Emphasis on e commerce channel  which they expect to grow significantly
  Tailored messaging that will be more local and consumer relevant
  The company continues to expect that the majority of revenue growth will be driven by its 12 megabrands  Specifically  watch for the relaunch of Baby and Oral Care  as these relaunches will be important indicators of whether the company s strategy will be effective 
Medical Devices Turnaround Expected to be Driven by Investments and New Product Launches
Medical Devices has underperformed for some time  but management believes the segment is now positioned to return to above market growth by 2020 driven by a number of factors 
  Management has invested heavily in the segment  with  5 billion in 2017 and  500 million year to date in 2018  Management believes the market outlook is bright as an aging population  increased urbanization  and growing access to healthcare globally drives market growth
  These investments will go towards 15 20 new product launches in 2018 and 20 25 product launches in 2019
  Robotic surgery  Verb Surgery  commercialization is expected in 2020
Turnaround Plan Encouraging  but Need to See Results
While analysts appear encouraged by the detailed plan put forth by management  the majority seem to be waiting for results to demonstrate traction within the Consumer and Medical Devices segments  As a result  investors will be watching in the coming quarters for signs that their strategy is bearing fruit ",2018-06-26,The Non-Consensus,https://www.investing.com/analysis/johnson-and-johnson-will-pipeline-drugs-offset-sales-erosion-to-upcoming-generics-200327720,200327720
198533,420049,JNJ,Actelion s ambitious independent minded CEO will drive up takeover price,news,"By John Miller ZURICH  Reuters    Actelion Chief Executive Jean Paul Clozel s desire to keep Europe s biggest biotech company independent after building it from scratch  means Johnson   Johnson  NYSE JNJ  will have to pay a steep premium if a takeover is to succeed  The U S  healthcare titan on Friday confirmed talks with the Swiss maker of medicines for deadly pulmonary arterial hypertension  PAH   While Actelion confirmed the courtship  it said there was no guarantee of a deal  Actelion s rare disease focus makes it an attractive target  since its drugs face less price pressure than other more widely used medicines   Analysts estimate a deal could be as high as 250 Swiss francs   247  per share  valuing Actelion at around  26 billion  or  6 billion more than its current price even after the share s 17 percent surge on Friday  Having fended off reported approaches by Shire in 2015 and hedge fund Elliott Advisors in 2011  Clozel  a French born cardiologist  has repeatedly asserted his desire to go it alone  with his three main PAH drugs and with pipeline medicines he hopes will create a broad based biotech company  This hard to get approach  coupled with the high value of recent deals in the sector  will drive up Actelion s takeover price  analysts said    Similar deals have been at a 40 plus percent premium and we view 240 Swiss francs as a possible floor takeout value   Jefferies analyst Peter Welford said  Analysts at Bryan Garnier suggested a bid price of up to 250 francs  In another recent biotech takeover   Pfizer   NYSE PFE  paid  14 billion for cancer specialist Medivation  or double its pre deal value  Switzerland s Roche in 2014 paid  8 3 billion for InterMune  a 63 percent premium   Clozel and his pediatrician wife  Martine Clozel  Actelion s chief science officer  own 5 percent of the company they founded in 1997  Close ties with Actelion s Swiss shareholder base suggest they can mobilize support  should an offer not live up to their expectations  Welford said  If J J fails to strike a deal  a rival like Sanofi  PA SASY  could well step in  analysts said  Actelion s PAH portfolio is a potentially nice fit for the French drugmaker s Genzyme rare disease unit  Sanofi  which lost out to Pfizer in the battle for Medivation  has said it is still looking for deals   A spokesman for Sanofi declined to comment on the company s possible interest in Actelion  NEW DRUGS While the patent for Actelion s PAH blockbuster Tracleer expired last year  Clozel s two newer PAH drugs  Opsumit and Uptravi  are expected to take up the slack   Opsumit s annual sales are set to hit 1 9 billion francs by 2020  according to Reuters data  Uptravi sales could top 2 5 billion francs  Clozel plans to use the cash to fund his late stage pipeline  which includes medicines for treating diarrhea causing clostridium difficile  as well as the multiple sclerosis drug ponesimod  Stefan Schneider  a Bank Vontobel analyst in Zurich  doubts a deal will go through and said any sign that a potential buyer will tinker with Clozel s prized pipeline to cut costs could be a deal killer    We don t see how the CEO would part from the pipeline where he sees the value for Actelion to transform into the first European large cap biotech company   Schneider said  Actelion s shares have risen six fold to nearly 190 francs since the start of 2012  just after Elliott tried to wrest control   on the grounds the company s stock should fetch 70 francs   As retirement edges closer  analysts said it is possible Clozel is more receptive to handing over the reins  especially if a buyer agrees to retain Actelion s presence in Basel where the company  however successful  still plays second fiddle to giants Roche and Novartis   Actelion s shares have risen 400 percent based on the strength of the PAH portfolio alone   Zuercher Kantonalbank analyst Michael Nawrath said    Even when Clozel has always made the case for independence  it s possible a stock price at its zenith  combined with his 61 years  could prompt a change of heart    
  1   1 0139 Swiss francs ",2016-11-28,Reuters,https://www.investing.com/news/stock-market-news/actelion's-ambitious-independent-minded-ceo-will-drive-up-takeover-price-443993,443993
198534,420050,JNJ,Actelion shares fall on report it rejects J J offer,news,"ZURICH  Reuters    Shares in Swiss biotech company Actelion fell more than 6 percent after news outlet streetinsider com reported on Wednesday the company had rejected a full takeover offer by U S  healthcare group Johnson   Johnson  NYSE JNJ  and may sell a unit   
Actelion declined to comment on the report  which cited an unidentified source  and referred to a statement the company had published on Friday  The companies had confirmed last week they were in talks about a possible transaction ",2016-11-30,Reuters,https://www.investing.com/news/stock-market-news/actelion-shares-fall-on-report-it-rejects-j-amp;j-offer-444669,444669
198535,420051,JNJ,Johnson   Johnson hit with over  1 billion verdict on hip implants,news,"By Erica Teichert  Reuters    A federal jury in Dallas on Thursday ordered Johnson   Johnson  N JNJ  and its DePuy Orthopaedics unit to pay more than  1 billion to six plaintiffs who said they were injured by Pinnacle hip implants  The jurors found that the metal on metal Pinnacle hip implants were defectively designed and that the companies failed to warn consumers about the risks  J J  which faces more than 8 000 lawsuits over the hip implants  said in a statement it would immediately appeal the verdict and was committed to defending itself and DePuy from further litigation over the Pinnacle devices  The six plaintiffs awarded more than  1 billion are California residents who were implanted with the hip devices and experienced tissue death  bone erosion and other injuries they attributed to design flaws  Plaintiffs claimed the companies promoted the devices as lasting longer than devices that include ceramic or plastic materials  Both companies denied any wrongdoing stemming from the development and marketing of the devices  According to plaintiff s lawyer Mark Lanier  the total verdict of  1 041 billion included  32 million in compensatory damages  The rest were punitive damages  Verdicts of such size are often scaled back by courts  In July  the judge presiding over this case  U S  District Judge Edward Kinkeade  reduced a  500 million verdict in an earlier Pinnacle implant case to  151 million  citing a Texas state law that limits punitive damages awards  J J and DePuy have been hit with nearly 8 400 lawsuits over the devices  which have been consolidated in Texas federal court  Test cases have been selected for trial  and their outcomes will help gauge the value of the remaining claims  The verdict on Thursday came in the third test case  with the second producing the earlier  500 million verdict  J J and DePuy were cleared of liability in the first test case in 2014  Lanier said Thursday s verdict was  a message loud and clear  that J J has  a really nasty part of their business they need to clean up    The company rejected a  1 8 million settlement offer from the plaintiffs before trial  Lanier said  The plaintiffs in the second test case have appealed Kinkeade s decision to cut the award  Johnson   Johnson and DePuy have also appealed the jury verdict in the case  In its statement  J J criticized the trial judge over certain rulings it claimed help the plaintiffs    Today s verdict provides no guidance on the merits of the overall Pinnacle litigation because the court s rulings precluded a fair presentation to the jury   said John Beisner  J J s attorney  He said the company will ask the appeals court to postpone any additional trials over the implant defects  
DePuy ceased selling the metal on metal Pinnacle devices in 2013 after the U S  Food and Drug Administration strengthened its artificial hip regulations   J J and DePuy also paid  2 5 billion that year to settle more than 7 000 lawsuits over its ASR metal on metal hip devices  The ASR devices were recalled in 2010 due to high failure rates   J J shares fell 38 cents to  111 in after hours trading  They had closed up 8 cents during the day ",2016-12-01,Reuters,https://www.investing.com/news/stock-market-news/johnson--amp;-johnson-hit-with-over-$1-billion-verdict-on-hip-implants-445081,445081
198536,420052,JNJ,Novartis CEO plays down prospects for Actelion bid  Blick,news,"VIENNA  Reuters    Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion  which is in talks with U S  healthcare group Johnson   Johnson  NYSE JNJ  about a transaction   Asked by Swiss Sunday newspaper SonntagsBlick whether Novartis could emerge as a white knight  he said   We have always said that we will concentrate on complementary acquisitions in the range of  2 billion to  5 billion   He did not elaborate  Actelion is worth nearly  20 billion at Friday s closing price  Jimenez said Novartis was still gauging what impact President elect Donald Trump could have on the U S  healthcare system and was watching what his priorities would be   Less has been invested in the United States in recent years  probably because of high corporate taxes  If these are now cut  as is being signaled  that is certainly positive   he said  He said Novartis should have intervened earlier and more decisively at its Alcon eyecare business  which Novartis bought in 2010 and had flourished until 2014  when innovation waned   
 We are disappointed that the turnaround is taking so long but I am convinced that the new management will get the job done  As far as the future of the business is concerned we are keeping all options open   he was quoted as saying ",2016-12-04,Reuters,https://www.investing.com/news/stock-market-news/novartis-ceo-plays-down-prospects-for-actelion-bid:-blick-445468,445468
198537,420053,JNJ,J J questions fairness of hip implant trial   1 billion verdict,news,"By Erica Teichert  Reuters    Johnson   Johnson  N JNJ  will challenge the fairness of a trial that produced a verdict of  1 billion in damages against the company last week over allegations of design flaws in its Pinnacle hip implant  Although legal experts think J J faces an uphill battle  both they and investors believe the Texas jury s penalty  the largest product liability verdict so far this year  is unlikely to stand  In the two month trial  five separate people from California argued that design flaws in the metal on metal implant made by J J subsidiary DePuy Orthopaedics caused tissue death  bone erosion and other injuries  It is the second large verdict against J J in the Pinnacle implant litigation  which has been consolidated before U S  District Court Judge Edward Kinkeade in Texas  In July  another jury awarded six Texas plaintiffs  500 million  Both cases were so called bellwethers  intended to gauge the value of claims for more than 9 000 other pending implant cases  J J said in a statement it was confident in its appeal prospects and would not settle  It also said it stood by the safety of its product  Last Thursday s verdict has had little impact on J J stock  Les Funtleyder  a portfolio manager with ESquared Asset Management  said investors assume large health products companies will occasionally be sued and lose and that the costs are ultimately manageable  J J said it will ask Kinkeade to reduce or throw out the jury award before appealing to the 5th U S  Circuit Court of Appeals in New Orleans  According to the company  the multi plaintiff format stacked the deck against it by parading a series of victims in front of the jury and exaggerating the number of complaints about the implant   The company won the first bellwether trial in a case involving a single plaintiff in 2014  The next is scheduled for September 2017  and Kinkeade has not decided how many plaintiffs will be involved in that trial  These results  perfectly illustrate the distortions and confusion inherent in multi plaintiff trials and underscore the extent of the legal errors that have been repeated   said J J defense lawyer John Beisner  But several legal experts said such a challenge faced long odds  Lynn Baker  a professor at the University of Texas School of Law  noted trial judges are normally given great leeway in managing their cases and multi plaintiff trials were a long established means of clearing dockets faster   I would not expect J J to succeed on a claim that they were prejudiced by the multi plaintiff bellwether format   she said  J J also said the judge allowed plaintiffs  lawyers to present inflammatory and prejudicial testimony to the juries  raising bribery accusations against the company and claims that the metal on metal implants could cause cancer   University of Richmond School of Law Professor Carl Tobias said an appeals court was unlikely to overturn the verdict on such grounds though   Unless there is clear prejudice on the part of the jury  you ve got to defer to the factfinder   he said  But even without showing its trial was unfair  the professors said J J s case was strong for having the  1 billion award reduced on the grounds that it is excessive   Kinkeade cut the  500 million July verdict to  151 million  Andrew Bradt  a professor at University of California Berkeley School of Law  noted the U S  Supreme Court has held punitive damages should be no more than 10 times compensatory damages  The  1 041 billion award was mainly punitive  with just  32 million in compensatory damages  
Bradt said the final award could be even lower than  320 million  since the high court has also said punitive damages awards should be closely tied to plaintiffs  injuries rather than as a broader deterrent ",2016-12-07,Reuters,"https://www.investing.com/news/stock-market-news/j-amp;j-questions-fairness-of-hip-implant-trial,-$1-billion-verdict-446168",446168
198538,420054,JNJ,JNJ Stock Preparing For A Bullish Breakout,opinion,"Johnson   Johnson  NYSE JNJ  stock did not start the year in the best way possible  The share price fell from an all time high of  148 32 on January 17th to as low as  118 62 on May 29th  erasing 20  of the company s market capitalization  Such declines come to remind us that even the best of blue chip stocks do not always rise  On the other hand  price drops often provide a great buying opportunity  Is JNJ stock s plunge a chance to buy the dip or the start of a bigger crash  The chart below looks encouraging 
The hourly chart of Johnson   Johnson allows us to put the recent plunge into Elliott Wave perspective  It looks like JNJ stock has drawn a textbook A B C simple zigzag correction with an ending diagonal in the position of wave C  It is also interesting to notice that wave B is a smaller simple zigzag  labeled  a   b   c   where wave  b  is a triangle 
According to the theory  once a correction is over  the larger trend resumes  In JNJ stock s case  the larger trend is clearly to the upside  so it makes sense to expect more strength from now on towards a new all time high near  150 per share  The proper way to take advantage of the anticipated recovery is to wait for a decisive breach of the upper line of the ending diagonal and then put a stop loss order right below the bottom of wave 5 of C at  118 60  As long as this level holds  the positive outlook remains valid  Given that JNJ stock has already slightly breached the 2 4 line of the diagonal  the situation currently provides an excellent risk reward ratio of 5 6  So to answer the question from the first paragraph  it definitely looks more like a buy the dip opportunity than the beginning of a bear market  The bulls are still alive and kicking 
Original post",2018-06-08,EWM Interactive,https://www.investing.com/analysis/jnj-stock-preparing-for-a-bullish-breakout-200323268,200323268
198543,420059,JNJ,Johnson   Johnson s Stelara approved in Europe for Crohn s disease,news,As expected  the European Commission approves the use of Janssen s  JNJ  0 9   STELARA  ustekinumab  for the treatment of adults with moderately to severely active Crohn s disease who fail to respond adequately to conventional therapy or a tumor necrosis factor alpha antagonist or are contraindicated for such therapies The European Medicines Agency s Committee for Medical Products for Human Use  CHMP  adopted a positive opinion backing approval in September The FDA approved the indication in late September STELARA s previously approved uses in the EU are plaque psoriasis and psoriatic arthritis ,2016-11-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/johnson---johnson's-stelara-approved-in-europe-for-crohn's-disease-440068,440068
198544,420060,JNJ,Merck s triple combo HCV candidate achieves cure rates as high as 100  in mid stage studies,news,Results from three Phase 2 clinical trials assessing Merck s  NYSE MRK  MK 3682B  MK 3682 grazoprevir ruzasvir  for the treatment of chronic hepatitis C virus  HCV  infection showed virologic cure  SVR12  rates as high as 100   The data were presented at The Liver Meeting 2016 in Boston  MA In patients with HCV genotypes 1a  1b  2 and 3 treated with MK 3682B with and without ribavirin  RBV  for eight weeks  the cure rates were 93   n 39 42   98   n 45 46   86   n 54 63  and 95   n 98 103   respectively The same categories of patients treated with MK 3682B with without RBV for 12 weeks showed cure rates of 98   n 47 48   100   n 40 40   97   n 60 62  and 97   n 155 159   respectively In HCV genotypes 2 and 3 treated with MK 3682B with without RBV for 16 weeks  the cure rates were 100   n 26 26  and 96   n 72 75   respectively In the HCV 3 cohorts  28   36  and 81  of the 8 week  12 week and 16 week groups  respectively  were previously treated with peginterferon RBV The most common adverse events  AEs  in patients receiving at least one dose of MK 3682B with without RBV were headache  22    fatigue  19   and nausea  13    There were two serious treatment related AEs  both attributed to RBV only  There were nine discontinuations due to AEs  four from RBV only  One patient died due to AEs unrelated to the study drug MK 3682B is a fixed dose combination of an NS5B polymerase inhibitor  MK 3682   an NS3 4A protease inhibitor  grazoprevir  and an NS5A inhibitor  ruzasvir  Clinical development of MK 3682B is ongoing Related tickers   NASDAQ GILD  NYSE ABBV  NYSE JNJ ,2016-11-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/merck's-triple-combo-hcv-candidate-achieves-cure-rates-as-high-as-100-in-mid-stage-studies-440318,440318
198545,420061,JNJ,Janssen s guselkumab shows positive results in mid stage psoriatic arthritis study,news,Results from a Phase 2 clinical trial assessing Janssen s  NYSE JNJ  anti interleukin 23  IL 23  monoclonal antibody guselkumab in patients with psoriatic arthritis  PA  showed a significant treatment benefit compared to placebo  The data were presented at the American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting in Washington  D C The study met its primary endpoint of a statistically valid proportion of patients treated with guselkumab achieving ACR20  20  improvement in PA symptoms  at week 24 versus placebo  58  vs  18 4   p 0 001   All secondary endpoints were also met At week 16  the proportion of subjects achieving ACR20 also favored guselkumab  60  vs  16 3   p 0 001   as did those achieving ACR50  34  vs  10 2   p 0 002  and PASI 75  78 6  vs  12 5   p 0 001  Patients receiving guselkumab experienced greater improvements in enthesitis  inflammation at the sites where tendons   ligaments attach to bone  and dactylitis  inflammation of the fingers or toes  The incidence of adverse events  AEs  was 36 0  for guselkumab and 32 7  for placebo  The most common AEs were infections The company announced positive results in a Phase 3 trial in plaque psoriasis last month Previously  Janssen s psoriasis candidate guselkumab tops Humira in late stage study  Oct  3 ,2016-11-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/janssen's-guselkumab-shows-positive-results-in-mid-stage-psoriatic-arthritis-study-440921,440921
198546,420062,JNJ,Janssen submits U S  marketing application for guselkumab,news,Johnson   Johnson s  NYSE JNJ  Janssen Biotech submits its Biologics License Application  BLA  to the FDA seeking approval of guselkumab for the treatment of adults with moderate to severe plaque psoriasis Guselkumab is a human monoclonal antibody that binds to interleukin 23  IL 23   a pro inflammatory cytokine  J J expects it to be a blockbuster and one of its major growth drivers ,2016-11-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/janssen-submits-u.s.-marketing-application-for-guselkumab-441760,441760
198547,420063,JNJ,ViiV Healthcare launches two late stage studies of long acting HIV treatment,news,ViiV Healthcare  the HIV focused company majority owned by GlaxoSmithKline  GSK  0 7   and  Pfizer   PFE  0 4    initiates two Phase 3 studies assessing an injectable regimen of cabotegravir and rilpivirine for the treatment of HIV 1 infection  The studies  FLAIR and ATLAS  will evaluate the safety and efficacy of the two drug combo  administered once per month  in both treatment naive and treatment experienced patients According to ClinicalTrials gov  the estimated final data collection date for the primary endpoint is July August 2018 for both studies  The estimated completion date for both is April May 2022 Cabotegravir  developed by ViiV  in an integrase strand transfer inhibitor  It is also being evaluated in a tablet formulation Rilpivirine  marketed as EDURANT by Janssen  JNJ  1 2    is a non nucleoside reverse transcriptase inhibitor ,2016-11-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/viiv-healthcare-launches-two-late-stage-studies-of-long-acting-hiv-treatment-442362,442362
198548,420064,JNJ,AbbVie  ABBV  Up 5 9  Since Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for AbbVie Inc    NYSE ABBV    Shares have added about 5 9  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is ABBV due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers AbbVie Tops Q1 Earnings   Revenue Estimates  Ups 2018 GuidanceAbbVie reported better than expected earnings and sales for the first quarter of 2018  Importantly  it raised its earnings expectations for 2018 based on strong Q1 performance and an optimistic outlook for future quarters AbbVie reported first quarter 2018 earnings of  1 87 per share  beating the Zacks Consensus Estimate of  1 80 by 3 9  and ahead of the guided range of  1 77 and  1 79  Earnings grew 46 1  year over year  Strong sales performance and higher operating profits led to the bottom line beat Revenues of  7 9 billion in the reported quarter marginally beat the Zacks Consensus Estimate of  7 7 billion  Sales increased 21 4  year over year  Excluding a 3 8  favorable impact from foreign exchange rate fluctuations  operational revenues rose 17 6  backed by continued strong performances by Humira and Imbruvica and solid uptake of new HCV medicine  Mavyret  Operational revenue growth was in line with management expectations of growth in a mid teen range  Currency tailwinds of 3 8  were also better than 3  expected by the company Quarter in DetailsHumira recorded sales growth of 14 4   10 7  on an operational basis  with revenues coming in at  4 7 billion  reflecting continued strong demand trends Sales in the United States increased 11 4  to  3 billion driven by strong prescription volume growth across all three major market categories  Humira sales in the ex U S  market were up 9 3  on an operational basis and 20  on a reported basis to  1 71 billion driven primarily by market growth across indications Humira holds the leading market position as a front line therapy in all three major market categories despite stiffer competition from new classes of drugs as well as an indirect biosimilar competition in the international marketsHowever  on the call  AbbVie said that retail specialty pharmacy destocking hurt sales of Humira somewhat in the quarter In 2018  Humira sales in the United States are expected to be approximately  13 7 billion  which is lower than the prior expectation of  14 0 billion  14 1 billion  Humira U S  sales expectations were softer than the previous outlook due to the impact of a retail specialty pharmacy destocking in the first quarter and a conservative stance on co pay costs associated with co pay accumulator programs Internationally  Humira sales are expected to approach  6 4 billion  up from  6 2 billion previously  which includes the expected impact of biosimilar entrants in Europe in the fourth quarter First quarter net revenues from Imbruvica were  762 million  up 38 5  year over year  This included U S  sales of  624 million  up 36 7   and  138 million  up 47 2   of international profit sharing with Johnson   Johnson  NYSE JNJ  Continued uptake in the front line CLL market and steady gains across other indications led to the strong performance of Imbruvica In 2018  Imbruvica global revenues are expected to exceed  3 3 billion with sales in the United States likely to cross  2 7 billion Other products that performed well include Lupron   219 million  up 13 3  year over year  Duodopa   103 million  up 28 9  year over year  and Creon   209 million  up 13   Despite competitive dynamics in the HCV market  AbbVie HCV sales  including Viekira and Mavyret  were  919 million in the quarter  up 80 2  on a sequential basis  Mavyret alone accounted for nearly  850 million in the quarter driven by better than expected launch uptake in the United States and international markets  Mavyret commands a market share of 45  in the United States with less than a year on the market  The medicine has also established a strong position in other major countries as well  such as Japan  Germany  Spain  and Italy  Viekira sales declined in the quarter In 2018  global HCV sales are expected to be approximately  3 5 billion  higher than  2 5 billion expected previously Adjusted gross margin rose 30 bps to 80 2  in the quarter  Adjusted SG A expenses increased 21 4  to  1 67 billion  As a percentage of sales  SG A expenses rose 20 bps to 21 0  in the quarter  reflecting new product launch costs  R D expenses escalated 7 2  to  1 19 billion in the quarter due to greater investments in the pipeline  Adjusted operating margin was 44 1  of sales in the reported quarter  up 200 bps year over year 2018 OutlookAbbVie raised its adjusted EPS guidance to a range of  7 66  7 76 for 2018 compared with  7 33  7 43 predicted earlier  A strong first quarter performance coupled with an optimistic outlook for stronger underlying business performance through the rest of the year and the benefit from the planned share buybacks through the  Dutch  tender offer propelled the increase in earnings guidance  The earnings guidance reflects a year over year surge of 38  at the mid point versus 32  previously Revenues are expected to approach  32 6 billion  up from the previous expectation of  32 billion  Currency impact is expected to benefit revenues by 2  in 2018 compared with 1 5  expected previously While R D expense is expected to be slightly more than 16  of revised sales outlook  SG A is expected to be about 20 5  of sales  Operating margin is expected to be above 43 5   roughly 100 basis points above 2017 levels  Previously  AbbVie expected operating margin to be approximately 44  of sales  AbbVie decreased the projected 2018 operating margin expectations as it plans to increase investments in upcoming product launches Adjusted tax rate is expected to be approximately 9  in 2018  The normalized tax rate expectation over the next five years is 13  Second Quarter 2018 OutlookSecond quarter earnings are expected between  1 94 and  1 96  Revenues are estimated to grow approximately 15  on an operational basis  Foreign exchange is expected to have approximately 3  favorable impact on sales in the second quarter U S  Humira sales are expected to grow at approximately 10  year over year  Internationally  sales are expected to be approximately  1 6 billion  Imbruvica U S  sales are expected to be approximately  700 million  Global HCV sales are expected to be approximately  950 million with approximately 40  of those sales coming from U S  sales 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  There have been six revisions higher for the current quarter AbbVie Inc  Price and Consensus
    VGM Scores
At this time  ABBV has a nice Growth Score of B  however its Momentum is doing a bit better with an A  The stock was also allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is more suitable for momentum investors than those looking for value and growth 
Outlook
Estimates have been trending upward for the stock and the magnitude of these revisions looks promising  Notably  ABBV has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-05-28,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-up-59-since-earnings-report-can-it-continue-200319751,200319751
198549,420065,JNJ,Pfizer s Arthritis Drug Gets FDA Nod For Ulcerative Colitis,opinion,"Pfizer Inc    NYSE PFE   announced that the FDA has approved the label expansion of its JAK inhibitor  Xeljanz  tofacitinib   to include a new indication   moderately to severely active ulcerative colitis   UC    The drug is approved for the treatment of adult patients with recommended a dose of 10 mg twice daily for at least eight weeks The approval was expected as the FDA Gastrointestinal Drugs Advisory Committee had adopted a positive vote in a meeting in March recommending the approval of the supplemental new drug application  sNDA  filed in July last year seeking label expansion of Xeljanz in UC Xeljanz is already marketed for the treatment of rheumatoid arthritis and active psoriatic arthritis  In the first quarter of 2018  Xeljanz sales were  326 million  up 30 4  from the year ago period  The label expansion in the UC indication is likely to boost its sales further Shares of Pfizer have lost 0 5  so far this year  compared with a 6  decrease for the  it belongs to The approval was based on data from three pivotal studies   OCTAVE Induction 1  OCTAVE Induction 2 and OCTAVE Sustain   which demonstrated that statistically significant and greater proportion of patients achieved remission when treated with Xeljanz compared to a placebo Pfizer is currently evaluating Xeljanz in an open label long term extension study  OCTAVE Open However  there are several blockbuster drugs in the inflammatory segment approved for UC  which includes Johnson   Johnson s   NYSE JNJ   Remicade and Simponi  AbbVie s   NYSE ABBV   Humira and Shire s   NASDAQ SHPG   Lialda  Moreover  many biotech companies are developing their candidates for the treatment for UC  Hence  competition is likely to increase in this segment Pfizer Inc  Price
    Pfizer currently has a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-05-30,Zacks Investment Research,https://www.investing.com/analysis/pfizers-arthritis-drug-gets-fda-nod-for-ulcerative-colitis-200320967,200320967
198550,420066,JNJ,Fortive Plans To Buy Johnson   Johnson s Sterilization Unit,opinion,"Fortive Corporation   NYSE FTV   has recently made a proposal to Johnson   Johnson   NYSE JNJ   to acquire its business unit of Advanced Sterilization Products   ASP   from its subsidiary  Ethicon  Inc  ASP offers infection prevention solutions that are used in disinfection and sterilization of reusable surgical instruments  The solutions are based on low temperature hydrogen peroxide sterilization technology and help in protecting patients from hospital infections  Last year  it generated  775 million of revenues Fortive has made a binding cash offer of  2 7 billion to purchase the business  which the company is likely to finance through available cash  equity and debt With the latest move  the company will be able to foray into the rapidly growing infection control market  Per the data from Markets and Markets  the market is expected to grow at a CAGR of 6 5  between 2017 and 2022 and reach 21 06 billion by 2022 from  15 35 billion in 2017 Coming to the price performance  shares of Fortive have returned 17 7  over a year  outperforming the  s rally of 12   Expanding Product PortfolioThe ASP deal will help the company to expand its product portfolio  The products of ASP are STERRAD  EVOTECH and ENDOCLENS  which have gained popularity in the global market We believe the company is well poised to gain from the acquisition and the market in which ASP operates along with its own products namely Gilbarco Veeder Root  Fluke  Sensing technologies  Tektronix  Qualitrol and Jacobs Vehicle Systems   Notably  all of these products performed well in the last reported quarter and are expected to sustain the performance of Fortive across its geographical regions Strategic Deals Continues to Aid GrowthStrategic acquisitions and other deals have significantly contributed to Fortive s growth trajectory by expanding its product portfolio  The company expects the buyout of ASP to be accretive like its other previous acquisitions Recently  the company signed a definitive agreement for combining four units of Automation   Specialty platform with Altra Industrial Motion  which will enhance its portfolio Additionally  the company s acquisitions of Orpak  Industrial Scientific  eMaint and Landauer  have been aiding the segmental and regional performance of the company in every quarter since then We note that these deals will continue to help the company in gaining momentum in the market by improving its customer base  This will aid Fortive s top line growth Fortive Corporation Revenue  TTM    Zacks Rank   Stocks to Consider
Currently  Fortive carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader technology sector are TE Connectivity   NYSE TEL   and AMETEK   NYSE AME    Both the stocks carry a Zacks Rank  2  Buy   You can see Long term earnings growth rate for TE Connectivity and AMETEK is pegged at 10 94  and 10   respectively Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-06-06,Zacks Investment Research,https://www.investing.com/analysis/fortive-plans-to-buy-johnson--johnsons-sterilization-unit-200323011,200323011
198553,420069,JNJ,European stocks move higher on strong German  French PMIs  DAX up 0 83 ,news,"Investing com   European stocks were higher on Monday  after the release of upbeat German and French data and as investors eyed the release of euro zone manufacturing and service sector activity data due later in the trading session 
During European morning trade  the EURO STOXX 50 jumped 0 94   France s CAC 40 climbed 0 81   while Germany s DAX 30 advanced 0 83  
Research group Markit said its German manufacturing purchasing managers  index rose to 55 1 in October from 54 3 the previous month  beating expectations for an unchanged reading 
The German services PMI climbed to 54 1 this month from 50 9  compared to expectations for an uptick to 51 5 
Markit also said its French manufacturing PMI rose to 51 3 in October from 49 7 the previous month  exceeding expectations for a reading of 50 0 
However  the French services PMI slipped to 52 1 this month from 53 3  compared to expectations for a fall to 53 0 
European equities also remained supported after European Central Bank President Mario Draghi indicated last week that the bank may extend its stimulus program in December 
Financial stocks were broadly higher  as French lenders  BNP Paribas   PA BNPP  and  Societe Generale   PA SOGN  jumped 1 39  and 2 29   while Germany s Commerzbank  DE CBKG  and  Deutsche Bank   DE DBKGn  gained 1 10  and 2 23  
Among peripheral lenders  Italy s  Intesa Sanpaolo   MI ISP  and Unicredit  MI CRDI  rallied 1 61  and 1 58  respectively  while Spanish banks  Banco Santander   MC SAN  and BBVA  MC BBVA  surged 2 10  and 2 66  
Elsewhere  E ON SE  DE EONGn  advanced 1 28  after the German company announced late last week that it has signed a major power purchase agreement with healthcare giant Johnson   Johnson  NYSE JNJ  to provide wind power from its 200MW wind farm at Colbeck s Corner in the Texas Panhandle 
 Mediaset   MI MS  shares climbed 0 84  even after saying last week that  Vivendi   PA VIV  had told it in a letter that an interim management accord over its pay TV unit no longer stood  prompting the Italian broadcaster to blame the French media group for paralyzing the unit s operations  Vivendi SA  PA VIV  shares were up 1 07  on Monday morning 
In London  commodity heavy FTSE 100 gained 0 66   helped by gains in the mining sector 
Shares in  Glencore   LON GLEN  rallied 1 85  and  Rio Tinto   LON RIO  advanced 2 15   while BHP Billiton  LON BLT  surged 2 17  
Financial stocks were also broadly higher  as  HSBC Holdings   LON HSBA  rose 0 37  and  Barclays   LON BARC  climbed 0 94   while Lloyds Banking  LON LLOY  rallied 1 22   The Royal Bank of Scotland  LON RBS  underperformed however  with shares sliding 0 24  
In the U S   equity markets pointed to a higher open  The Dow Jones Industrial Average futures pointed to a 0 49  increase  S P 500 futures showed a 0 53  climb  while the Nasdaq 100 futures indicated a 0 59  gain ",2016-10-24,Investing.com,"https://www.investing.com/news/stock-market-news/european-stocks-move-higher-on-strong-german,-french-pmis;-dax-up-0.83-434210",434210
198554,420070,JNJ,British artificial intelligence company nabs rights to certain Janssen drug candidates,news,British artificial intelligence firm BenevolentAI inks an exclusive license for a series of clinical stage drug candidates from Janssen Pharmaceutica NV  NYSE JNJ  with the aim of developing the small molecule compounds using artificial intelligence technology  Phase 2b clinical trials are on tap for mid 2017  Financial terms are not disclosed ,2016-11-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/british-artificial-intelligence-company-nabs-rights-to-certain-janssen-drug-candidates-438662,438662
198555,420071,JNJ,What Can I Expect to Make If I Invest In Johnson   Johnson Today  ,opinion,"Overview
AAA rated Johnson   Johnson  NYSE JNJ  has produced one of the most impeccable and consistent long term records of fundamental results and growth  No matter whether you are measuring earnings  cash flows or dividends  you will be hard pressed to find any company in any industry with a more consistent and complete record of operating excellence than Johnson   Johnson 
Consequently  in the minds of many investors  Johnson   Johnson is considered a forever stock  Personally  I can t disagree  However  even with forever stocks there are good and bad times to initiate an investment  For much of 2016 and most of 2017  Johnson   Johnson was a little pricey  However  in 2018 Johnson   Johnson s stock price has been steadily moving towards alignment with intrinsic value  Although I still don t consider it a screaming bargain  I do consider it a reasonable choice given its quality and above market dividend yield 
Johnson   Johnson  FAST Graphs Analyze out Loud Video
I never invest in a stock simply hoping that it might go up  Instead  I always endeavor to calculate reasonable but specific future return expectations  Therefore  in the following FAST Graphs Analyze out Loud Video  I will illustrate and calculate reasonable total return calculations and expectations on Johnson   Johnson through calendar year end fiscal year 2021  Although forecasting future returns will never be perfectly precise  I believe it s imperative that investors have a rational sense and forecast of what a given investment in a specific company might be capable of generating  Stated simply  investors would be wise to run the numbers out to their logical conclusion  In my mind  this represents a significant differentiation between investing versus speculating 

Disclosure  Long JNJ at the time of writing 
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2018-05-16,Chuck Carnevale,https://www.investing.com/analysis/what-can-i-expect-to-make-if-i-invest-in-johnson--johnson-today-200316495,200316495
198556,420072,JNJ,Why Is Johnson   Johnson  JNJ  Down 4 1  Since Its Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Johnson   Johnson   NYSE JNJ    Shares have lost about 4 1  in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is JNJ due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers J J Tops First Quarter Earnings Estimates  Raises Sales GuidanceJ J s first quarter 2018 earnings came in at  2 06 per share  beating the Zacks Consensus Estimate of  2 01 and increasing 12 6  from the year ago period Adjusted earnings excluded amortization expense and some special items  Including these items  J J reported first quarter earnings of  1 60 per share compared with earnings of  1 61 in the year ago period Sales came in at  20 billion  beating the Zacks Consensus Estimate of  19 48 billion  Sales also increased 12 6  from the year ago quarter  reflecting an operational increase of 8 4  and a positive currency impact of 4 2  Organically  excluding the impact of acquisitions and divestitures  sales increased 4 3  on an operational basis  better than 2 4  increase seen in 2017  This is because the Pharmaceutical segment continued the positive momentum seen in the second half of 2017 and the Consumer segment sales improved First quarter sales grew 6 1  in the domestic market to  9 95 billion and 19 9  in international markets to  10 billion  reflecting 10 9  operational growth and 9  positive currency impact Segment DetailsPharmaceutical segment sales rose 19 4  year over year to  9 84 billion  reflecting 15 1  operational growth and 4 3  positive currency impact as sales rose in both domestic and international markets Sales in the domestic market rose 9 9  to  5 35 billion while international sales grew 33 1  to  4 49 billion  operational increase of 22 5   New products like Imbruvica and Darzalex continued to perform well  Core products like Stelara  Zytiga  Simponi Simponi Aria and Invega Sustenna also contributed to growth Organically  excluding the impact of acquisitions and divestitures  sales increased 7 5  on an operational basis  slightly less than 7 6  growth seen in the previous quarter  The strong performance was led by the company s oncology portfolio Imbruvica sales rose 43 5  to  587 million in the quarter driven largely by higher market share across all lines of therapy and market growth in the Unites States Stelara sales rose 28 9  to  1 06 billion in the quarter  Stelara gained market share in the quarter driven by share gains in the psoriasis market as well as in the newer Crohn s disease market  Simponi   Simponi Aria sales rose 21  to  518 million in the quarterDarzalex sales rose 69 4  to  432 million in the quarter  Darzalex enjoyed increased penetration in outside U S  markets and market growth in the United States  With an approval in first line setting expected this year  it is expected to be a driver of Darzalex sales  going forward Xarelto sales rose 12 7  to  578 million in the quarter  Sales were softer than the previous quarter due to some inventory build and seasonality issues  However  the company said the drug continued to witness market share gains Zytiga sales rose 61 6  to  845 million in the quarter due to improved market share in a growing metastatic castration resistant prostate cancer market  Zytiga was approved in the first line setting in February  which was a key driver of Zytiga s strong performance in the first quarter  Invega Sustenna sales rose 15 2  to  696 million In the quarter  J J recorded pulmonary arterial hypertension  PAH  revenues of  585 million  less than  610 million in the previous quarter  Strong demand for Uptravi and Opsumit was partially offset by the expected decline of Tracleer outside the United States due to generic competition and the transition of patient assistance foundations  The Actelion acquisition added 7 6  to sales growth in the first quarter Invokana Invokamet sales declined 12 7  to  248 million due to higher managed care discounting Sales of Remicade declined 16 9  in the quarter to  1 4 billion with U S  sales declining 22 5  due to some rebate adjustment  However  international sales rose 1 8  despite biosimilar competition Regarding newly launched Tremfya  J J said that the uptake of the product has been strong  Tremfya recorded sales of  72 million in the first quarter compared with  47 million in the previous quarter J J is quite confident that its Pharma segment will continue to perform better than the market this year despite the impact of biosimilars on Remicade sales Medical Devices segment sales came in at  6 77 billion  up 7 5  from the year ago period  It included an operational increase of 3 2  and positive currency movement of 4 3  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 1 1  Operational growth was driven by continued strong performance in vision care  electrophysiology as well as the advanced surgery business  which made up for a weaker sales performance in the diabetes care and orthopedics  particularly US Hips  Knees  and Spine Domestic market sales rose 2 2  year over year to  3 16 billion  International market sales increased 12 7   operational increase of 4 2   year over year to  3 61 billion The Consumer segment recorded revenues of  3 4 billion in the reported quarter  up 5 3  year over year  operational increase of 1 3    Foreign currency movement positively impacted sales in the segment by 4   Excluding the impact of acquisitions and divestitures  adjusted operational sales growth was 2  worldwide  an acceleration from the fourth quarter of 2017  Slower growth in domestic baby care products due to competitive pressure was offset by growth in beauty and over the counter products Sales in the domestic market rose 1 6  from the year ago period to  1 44 billion Meanwhile  the international segment recorded an increase of 8 2  to 1 96 billion  reflecting an operational increase of 1 2  and a positive currency impact of 7  Margins DiscussionCost of goods sold  as a percentage of sales  declined 140 basis points mostly due to favorable product mix  Selling  marketing and administrative expenses were down 50 bps year over year to 26 3  of sales despite investment behind new products  This was due to lower cost relative to sales growth in the Pharmaceutical unit  Research and Development costs  as a percentage of sales  rose 30 bps over the prior year quarter to 12  2018 Sales Outlook RaisedJ J maintained the previously issued earnings guidance for 2018 while increasing the sales range J J still expects 2018 adjusted earnings per share in the range of  8 00    8 20  reflecting an operational growth rate between 6 8  and 9 6   Currency fluctuations are expected to favorably impact earnings per share by 20 cents  However  revenues are expected in the range of  81 0 to  81 8 billion  higher than  80 6 billion to  81 4 billion  reflecting operational constant currency sales growth rate in the range of 4  to 5   previously 3 5  to 4 5   Organic sales growth  excluding the impact of acquisitions and divestitures  is expected to be in the range of 3 versus 2 5  3 5  previously Currency fluctuations are expected to favorably impact sales by 200 basis points Adjusted pre tax operating margins are expected to increase by approximately 150 basis points  previously 100 bps  in 2018 despite expectations for increased R D investments Adjusted tax rate guidance is in the range of 16 5 The company does not expect any biosimilar entrants for Zytiga  Prezista  Risperdal Consta  or Invega Sustenna in the United States in 2018  However  the company is confident that it can absorb the impact of any potential Zytiga headwind should there be an earlier than expected generics launch in 2018 However  the 2018 guidance includes the impact of generics for Procrit and Tracleer as well as Remicade biosimilars New Cost Savings InitiativeJ J announced some global supply chain initiatives  which will annually save approximately  600 million to  800 million in pre tax costs that will be substantially delivered by 2022  Discussions regarding specific future actions are ongoing J J said that the company will invest more than  30 billion in R D and capital investments in the United States over the next four years  2018 2021   representing an increase over the prior four years of more than 15   The new tax laws will leave some extra cash in the hands of large pharma companies like J J  allowing them to invest in innovation and capital building 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended downward during the past month  There have been two revisions higher for the current quarter compared to four lower 
Johnson   Johnson Price and Consensus   VGM Scores
At this time  JNJ has a strong Growth Score of A  though it is lagging a bit on the momentum front with a B  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is primarily suitable for growth investors while also being suitable for those looking for momentum and to a lesser degree value 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Notably  JNJ has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-05-16,Zacks Investment Research,https://www.investing.com/analysis/why-is-johnson--johnson-jnj-down-41-since-its-last-earnings-report-200317224,200317224
198557,420073,JNJ,Weighing The Week Ahead  Will Higher Interest Rates Lead To Lower Stock Prices   ,opinion,"The economic calendar is light  and the market week will be shortened  There is no holiday this week  but expect many participants to take off early for a long weekend  If interest remain above 3  on the ten year note  that will be the focus  Pundits will be asking 
Will higher interest rates lead to lower stock prices  
Last Week Recap
In my  I suggested that the week lacked a dominant theme  That part was right  I took the occasion to discuss which stocks might benefit from Trump policy changes  While few pundits took up the topic  it was still a useful exercise for me  and I hope for my readers as well 
The Story in One Chart
I always start my personal review of the week by looking at a great chart  I especially like the version  She includes a lot of valuable information in a single visual  The full post has even more charts and analysis  including commentary on volume  Check it out 


The market declined about 0 6  with a trading range of only 1 5   This is the quietest week we have seen in a long time  I summarize actual and implied volatility each week in our Indicator Snapshot section below  As you can see  volatility has been moving lower  and is back into the long term range 
Personal Note
Mrs  OldProf and I will be enjoying an extended holiday next weekend  so there will not be the regular WTWA installment  I ll try to update indicators if possible  She is in withdrawal in the absence of football of any sort  She was watching some wedding on TV when I asked her for a comment 
Thanks to the Intelligent Economist for once again including me among the   Most readers know that my labor of love is fueled by the knowledge that people find the work useful 
Noteworthy

From the   where you can also see prior years for comparison 



And  some updated information on debt from the NY Fed     The report also has information about various types of debt levels over time along with related credit scores 

The News
Each week I break down events into good and bad  For our purposes   good  has two components  The news must be market friendly and better than expectations  I avoid using my personal preferences in evaluating news   and you should  too  
Feel free to add items that I have missed  Please keep in mind that we are looking for current news  especially from the last week or so  WTWA is not about long term concerns like debt  These are important  of course  but not our weekly subject unless there has been some major change 
The overall picture remains positive  Economic strength is reasonable  and inflation is low   analysis of high frequency indicators shows some deterioration but retains the overall outlook 

Both the nowcast remains and the short term forecast remain positive 


The long term forecast has deteriorated further  with interest rates and money supply now both generally negative  Only the continued strength in housing and credit are keeping me from switching this from positive to neutral or even negative 

The Good 

The rail traffic growth cycle continues  Steven Hansen    does the best deep dive into this series  using his  intuitive sector  approach  rolling averages  and year over year comparisons  Here is just one of his summary tables and charts 



Industrial production increased 0 7  in April slightly beating expectations and matching the upwardly revised report from March  See  for charts and analysis 
Initial jobless claims while rising somewhat to 222K  continued lower on the less noisy four week moving average   observes   With this week s reading of 222K  the four week moving average dropped to 213 25K  That s a new low for the cycle  the century  and all the way back to December 1969  




Leading indicators matched expectations of 0 4  and the upwardly revised 0 4  from March    



Port traffic improves on both imports and exports  Steven Hansen s    analysis suggests that the implications are stronger for global economic growth than for the U S 
Improvement in the US China trade talks   reports that China has dropped sanctions against U S  sorghum  China is the largest destination for U S  sorghum exports  It remains difficult to get an accurate read on the progress 
NAHB index registered 70  a slight gain over April and beating expectations of 69    


The Bad 

Oil and gasoline prices move higher  The  quotes Morgan Stanley  NYSE MS  estimates that gasoline at  2 96 would take an annualized  38 billion from spending elsewhere  That is about a third of the additional take home pay from the tax cuts 



Housing starts declined to a SAAR of 1287K  down 3 7  and missing expectations of 1325K  Building permits were in line with expectations   provides analysis and charts  Bill also notes the volatility in multi family and the continuing  wide bottom  in single family starts  This long standing prediction has been quite accurate 
Mortgage rates reached a seven year high    

The Ugly 
Santa Fe  Texas  I understand that more people die from other causes  including terrorism around the world  These high school massacres are different  Senseless  Innocent young people  A familiar environment that we all expect to be safe 
The Week Ahead 
We would all like to know the direction of the market in advance  Good luck with that  Second best is planning what to look for and how to react 
The Calendar 
The economic calendar is light  Home sales data are most important  and many will pay careful attention to the FOMC minutes  Many participants will be taking off early to extend their holiday weekend 
 has a good U S  economic calendar for the week  and many other good features which I monitor each day   Here are the main U S  releases 

Next Week s Theme 
Without much news and a quiet week on tap  it is an open field for the punditry  Home sales and the FOMC minutes will get some attention  If interest rates do not move any lower I expect many to be asking 
Do higher interest rates imply lower stock prices  
There are a few clear cut positions 

Interest rates have broken to new levels and may move much higher   covers this angle 



Don t fight the Fed 
Interest rates will lead to a  and lower earnings 
Three steps and a stumble 
It is just a return to normalcy    

As usual  I ll save my overall personal conclusions for today s Final Thought 
Quant Corner 
We follow some regular featured sources and the best other quant news from the week 
Risk Analysis 
I have a rule for my investment clients  Think first about your risk  Only then should you consider possible rewards  I monitor many quantitative reports and highlight the best methods in this weekly update 
The Indicator Snapshot 
 
Short term trading conditions improved dramatically  Despite the recent borderline ratings suggesting  bad weather  it was not quite enough to take us out of the market  A strength of our modeling approach  Thanks  Vince   is a touch more patience than shown by many technical systems  This has a mild cost  and can reap great rewards  as it has in the last few weeks 
A notable feature of the chart is that we recently increased the nine month recession odds to a chance of 25   While this is significantly higher than it has been during the long stock rally  it does not yet represent a real threat  Instead of thinking of the odds as higher than before  we must keep in mind the continuing evidence that a near term recession is unlikely  The odds are only slightly higher than the long term average 
That said  we watch this quite closely and plan to reduce position sizes if the risk grows much larger 
The Featured Sources  
  Business cycle analysis via the  C Score 
  Strong quantitative indicators for both economic and market analysis 
  All things earnings  for the overall market as well as many individual companies 
  Business cycle indicator and market timing tools  None of Georg s indicators signal recession 
 and Jill Mislinski  Regular updating of an array of indicators  Great charts and analysis  With some crucial updates on the most important indicators  it is time for an update of their extremely helpful  










The post January sea of green is impressive  If only we could highlight this for all the individual investors bombarded with the incessant flow of perma bear negativity  These are not forecasts  they are facts from an objective source 
Guests Like us   the market implied inflation expectation 
The Daily Shot takes note of consumer inflation expectations from the University of Michigan sentiment survey  a bit higher than the market verdict 

 the importance of seasonal adjustments for employment data 


The Dallas Fed    reports that consumers respond more to negative news than positive info  This is a nice analysis of the asymmetric reaction to shocks  with a discussion of policy implications 
When do recessions accompany stock market corrections   has both an interesting approach and some useful conclusions 
Insight for Traders 
Check out our weekly Stock Exchange post  We combine links to important posts about trading  themes of current interest  and ideas from our trading models   we asked fellow traders if their rules were too rigid 
As usual  we included varying expert opinions and a comparison with our trading models  We also discussed some stock ideas and updated the ratings lists for Felix and Oscar  this week featuring the Russell 2000  With  on a European jaunt  business  he insists  we were delighted that earnings expert and investment manager  was able to offer his view of the various ideas 
While I emphasize trading in the Stock Exchange series  it often has implications for long term investors  It is worth a visit 
Insight for Investors 
Investors should have a long term horizon  They can often exploit trading volatility 
Best of the Week 
If I had to pick a single most important source for investors to read this week it would be  of the current investment landscape  To get the setting  please consider some facts from this week s  about Jack Bogle  The story covers a lot of interesting and controversial ground  but I was drawn to this factual statement 

Bogle fears that ETFs are purely speculative  encouraging selling at the bottom and buying at the top  Bogle shared his analysis of dollar weighted investor returns  which accounts for money flows  with Barron s  The research shows that from 2005 to 2017  the average investor return from  Traditional Index Funds  was 8 4   For actively managed funds  it was 7 2   For ETFs  it was 5 5   even worse than actively managed funds  That contains the seeds of the category s demise   How long are investors going to be happy with that  Sure if you double your money  why would you complain  But you could have tripled it  I am glad we continue to be primarily on the TIF horse  and not the ETF horse   He also foresees that growth in ETFs will slow because  an awful lot of  market  niches have been populated   Next up   a lot of ETFs will go out of business along the way  

The key takeaway is that individual investors do worse than they would by merely holding some asset  How could this happen 
I cannot do justice to Lloyd s article with one quote  but here is a taste 

The media driven issue of the day is virtually always misleading  Ignore all of them  If you insist on watching CNBC  be sure to leave the sound off  Leave it off unless you actually know the person is worth listening to  Of course that usually requires years of experience   not just your emotional preferences  Leave the latter to your evening cable show watching  And leave it entirely out of your investment decision making 


There is no euphoria or even complacency in the U S  equity market today  Rather  it is clear to me that investors are scared  The VIX doesn t tell you what you might think it does  If it explodes over 40  it is worth looking at in conjunction with other psychological indicators  Recent public interpretations of it are preposterous  Bond funds have drawn ridiculous sums from individual investors  The Wall of Worry is huge 

As one who watches financial television with TIVO and mute  and who knows the players  I fully understand this description 
Please read the rest of the post for more valuable insights 
Stock Ideas 
Individual investors seeking high quality research on their stock holdings and ideas already use the many resources at Seeking Alpha  Just in case you are not following the  series  take a look  You will definitely find ideas that you would otherwise have missed 
 discusses blue chip Johnson   Johnson  NYSE JNJ   asking  What can I expect to make if I invest today   As usual  he combines a lesson about how to analyze a stock with a specific idea and conclusion  Take time to watch his video 
 has a good record trading Prospect Capital  PSEC  and he has a new call 
Energy stocks   has had some winning ideas in the sector and still sees room to run  He suggests a  New Golden Age  for oil stocks  Check out his post for the full discussion and some ideas for how to play possible strength 

Target  TGT  might be at an attractive value point   argues that the top line growth will be fine  although year over year comparisons will remain tough for a few quarters 
Consumer staples bargains   takes a look 

Airline stocks  Southwest or others   analyzes the choices  You probably cannot guess which is cheapest on a forward PE basis 
Chip stocks   applies his unique methods to consider the risk and reward for the entire sector  We own one of the stocks listed  and I was quite eager to see where it was in his chart 
Aerospace and defense stocks   takes on this sector as well  I am considering some candidates  and my own methods yield similar results 
Closed end funds   has a first rate method and covers this space carefully  Many buyers merely look for discounts without considering the risks  He provides an interesting list of choices  using various important criteria 
A high potential REIT   has a pick that has both yield and upside 
Stone Fox Capital makes the case for Baidu      
Market Outlook 
 covers earnings calls by reviewing transcripts and presentations  This is an excellent source for those of us wondering whether economic growth is reflected in corporate profits  This week s report highlights overall optimism  solid growth  a strong labor market  and a CEO expectation that the business cycle could continue for several more years  They love tax reform but are feeling pricing pressures from capacity limits and oil price increases 
Personal Finance 
Seeking Alpha Senior Editor Gil Weinreich has expanded his excellent series for financial advisors  and serious individual investors  to include some podcasts  This week I especially enjoyed his  on the last installment of WTWA  Gil adds his own valuable insights and points to some great posts from other contributors  He also continued his podcast series with  
Abnormal Returns is always worth reading  with many links on an array of interesting topics  Wednesday the focus is on   Among many good choices  I especially appreciated the  of an advisor who  botched her own RMD   There are plenty of lessons in this post  More important for most investors is the discussion from   Inc on why it so often right to  do nothing  
Watch out for 
Investments in direct general obligation bonds from the State of Illinois   of Cumberland Advisors explains the reasons  They are all familiar to those of us who call Illinois  home  
Non GAAP adjustments   analyzes Symantec  NASDAQ SYMC  with the earnings controversy in mind   Jeff   I understand the value of adjusting for one time effects in an effort to gauge a stock s future performance  This demonstrates why it is important to do solid research on individual stocks  with this question in mind  
Cisco Systems   CSCO   A good company with a valuation that is too high    
Legalized sports betting is an interesting news story  There was the typical rush to find stocks that might benefit   an interesting contrarian analysis  the reason to measure your optimism 
Zillow   has an interesting story explaining what might go wrong with the business model ",2018-05-20,Jeff Miller,https://www.investing.com/analysis/weighing-the-week-ahead-will-higher-interest-rates-lead-to-lower-stock-prices-200317589,200317589
198558,420074,JNJ,Glaxo And J J s Two Drug HIV Regimen Juluca Gets EU Approval,opinion,GlaxoSmithKline plc   NYSE GSK   and partner J J   NYSE JNJ   announced that the European Commission  EC  has granted marketing approval to Juluca  making it Europe s first two drug HIV treatment  Juluca combines two approved HIV drugs   Tivicay  50 mg  and Edurant  25 mg    into a single  once daily pill for the treatment of virologically suppressed HIV 1 infectionJuluca gained approval in the United States in November last year and generated sales  10 million in the first quarter of 2018 Tivicay  a novel investigational integrase strand transfer inhibitor  INSTI   is marketed by ViiV Healthcare  an HIV company majorly owned by Glaxo and Pfizer   NYSE PFE    Edurant is a non nucleoside reverse transcriptase inhibitor  NNRTI  marketed by Janssen  J J s pharma arm  Juluca has been developed under a partnership between ViiV Healthcare and Janssen The approval in the EU was expected as in March this year the Committee for Human Use of Medicinal Products  CHMP  of the European Medicines Agency  EMA  had given a positive opinion recommending approval of Juluca This year so far  J J s shares have declined 11 4  while that of Glaxo have gone up 13   In the said time frame  the  has witnessed a decline of 3 7  Juluca  the first two drug regimen to be approved  reduces the number of medicines HIV patients take without compromising on the efficacy of a conventional three drug regimen Juluca s approval was based on data from two phase III SWORD studies  Data from these studies showed that the combination of Tivicay and Edurant antiretroviral was as effective as a three  or four drug antiretroviral regimen as a maintenance therapy in HIV patients who have already achieved viral suppression We remind investors that Gilead   NASDAQ GILD   also gained FDA approval for a single tablet HIV regimen  triple therapy  this year   Biktarvy gained FDA approval in February this year while a regulatory application is under review in the EU  The STR is a fixed dose combination of three drugs bictegravir 50mg  emtricitabine 200mg and tenofovir alafenamide 25mg  BIC FTC TAF  Both Glaxo and J J carry a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-05-21,Zacks Investment Research,https://www.investing.com/analysis/glaxo-and-jjs-twodrug-hiv-regimen-juluca-gets-eu-approval-200318263,200318263
198562,420078,JNJ,J J warns diabetic patients  Insulin pump vulnerable to hacking,news,"By Jim Finkle  Reuters    Johnson   Johnson  NYSE JNJ  is telling patients that it has learned of a security vulnerability in one of its insulin pumps that a hacker could exploit to overdose diabetic patients with insulin  though it describes the risk as low  Medical device experts said they believe it was the first time a manufacturer had issued such a warning to patients about a cyber vulnerability  a hot topic in the industry following revelations last month about possible bugs in pacemakers and defibrillators  J J executives told Reuters they knew of no examples of attempted hacking attacks on the device  the J J Animas OneTouch Ping insulin pump  The company is nonetheless warning customers and providing advice on how to fix the problem    The probability of unauthorized access to the OneTouch Ping system is extremely low   the company said in letters sent on Monday to doctors and about 114 000 patients who use the device in the United States and Canada   It would require technical expertise  sophisticated equipment and proximity to the pump  as the OneTouch Ping system is not connected to the internet or to any external network    A copy of the text of the letter was made available to Reuters  Insulin pumps are medical devices that patients attach to their bodies that injects insulin through catheters   The Animas OneTouch Ping  which was launched in 2008  is sold with a wireless remote control that patients can use to order the pump to dose insulin so that they do not need access to the device itself  which is typically worn under clothing and can be awkward to reach   Jay Radcliffe  a diabetic and researcher with cyber security firm Rapid7 Inc  said he had identified ways for a hacker to spoof communications between the remote control and the OneTouch Ping insulin pump  potentially forcing it to deliver unauthorized insulin injections   The system is vulnerable because those communications are not encrypted  or scrambled  to prevent hackers from gaining access to the device  said Radcliffe  who reported vulnerabilities in the pump to J J in April and published them on the Rapid7 blog on Tuesday   J J executives said they worked on the security issues with Radcliffe  Dosing a patient with too much insulin could cause hypoglycemia  or low blood sugar  which in extreme cases can be life threatening  said Brian Levy  chief medical officer with J J s diabetes unit  Company technicians were able to replicate Radcliffe s findings  confirming that a hacker could order the pump to dose insulin from a distance of up to 25 feet  Levy said  He said such attacks are difficult to pull off because they require specialized technical expertise and sophisticated equipment    We believe the OneTouch Ping system is safe and reliable  We urge patients to stay on the product   Levy said   J J s letter said that if patients were concerned  they could take several steps to thwart potential attacks  They include discontinuing use of a wireless remote control and programming the pump to limit the maximum insulin dose  Radcliffe said he believed that OneTouch Ping users would be safe if they followed the steps outlined in the letters from J J   They can give peace of mind to the patient or parent of a child using the device   he said  FDA GUIDANCE ON MEDICAL DEVICES In August  a prominent short seller and a cyber security research firm went public with allegations of potentially life threatening cyber vulnerabilities in heart devices from St  Jude Medical Inc   As its shares tumbled  St  Jude said the allegations were false  and the U S  Food and Drug Administration began an investigation  J J said before it sent out the letters  it reviewed the matter with the FDA  which is preparing to issue formal guidance on how medical device makers should handle reports about cyber vulnerabilities   An early draft of that guidance  which was released in January for public comments  called for device makers to work with security researchers  identify steps to mitigate risks  and provide patients with information about bugs so they can  make informed decisions  about device use   The FDA on Tuesday praised J J and Rapid7 for their work in discovering  finding ways to mitigate and disclosing the vulnerability   This is the proactive behavior the FDA has been looking to see from the medical device manufacturer and research community and demonstrates the collaborative manner in which vulnerabilities can be addressed in a way that best protects patients   the agency said in a statement  J J Chief Information Security Officer Marene Allison said her team would make sure other J J products do not have similar bugs  Radcliffe said he found vulnerabilities in the Animas OneTouch Ping  but not the Animas Vibe line of insulin pumps  The FDA has said it knows of no cases where hackers have exploited cyber vulnerabilities to harm a patient  
The agency last year issued multiple warnings about cyber bugs in infusion pumps from Hospira  which has since been acquired by  Pfizer  Inc   NYSE PFE    ",2016-10-04,Reuters,"https://www.investing.com/news/stock-market-news/exclusive:-j-amp;j-warns-patients-of-insulin-pump-cyber-bug,-low-hacking-risk-430201",430201
198563,420079,JNJ,J J says pharma future bright  despite threat to Remicade,news,"By Ransdell Pierson  Reuters    Johnson   Johnson  N JNJ  on Tuesday reported a better than expected quarterly profit and said its phamaceutical business will keep prospering despite the threatened launch of a competitor for its blockbuster Remicade arthritis drug   Pfizer  Inc  N PFE  late on Monday said it would begin U S  shipments of Inflectra  its biosimilar form of Remicade  by late November at a 15 percent discount to J J s current wholesale prices  With annual U S  sales of about  5 billion  Remicade is J J s biggest product   Biosimilar drugs are close copies intended to provide savings compared with costly branded products  Inflectra is already available in Europe   We are confident our pharma business will go well with or without  the  biosimilar launch   J J Chief Financial Officer Dominic Caruso said Tuesday in an interview on CNBC  J J is appealing an August federal court decision that invalidated a U S  Remicade patent  setting the stage for a February court battle with Pfizer  Should Pfizer launch Inflectra and later lose the court fight  that could entitle J J to triple damages   We will continue the appeal process  and feel very good about it   Caruso told CNBC  In the third quarter  J J revenue rose to  17 82 billion from  17 10 billion a year earlier  Its pharmaceutical sales jumped 9 2 percent to  8 40 billion  with strong growth for its Imbruvica and Darzalex cancer drugs and its blood thinner Xarelto  U S  sales of Remicade jumped 9 4 percent to  1 22 billion  Global medical device sales rose 1 1 percent to  6 16 billion in the quarter  while consumer product sales fell 1 6 percent to  3 26 billion  J J raised the lower end of its full year 2016 profit forecast to  6 68 per share  from  6 63 a share  It retained the upper end at  6 73 per share  The company s net earnings rose to  4 27 billion  or  1 53 per share  in the third quarter  from  3 36 billion  or  1 20 per share  a year earlier   Excluding special items  J J earned  1 68 per share  Analysts on average had expected a profit of  1 66 per share and revenue of  17 74 billion  according to Thomson Reuters I B E S   
Up to Monday s close  J J s shares had gained about 15 percent since the start of the year  compared with the 3 7 percent decline in the S P 500 healthcare sector  SPXHC  ",2016-10-18,Reuters,https://www.investing.com/news/stock-market-news/j-amp;j-quarterly-sales-rise-4.2-percent-433065,433065
198564,420080,JNJ,Geron  GERN  Q1 Loss Narrows Y Y  Revenues Fall  Shares Down,opinion,"Geron Corporation   NASDAQ GERN   reported a loss of 4 cents per share for the first quarter of 2018  narrower than the year ago loss of 5 cents Quarterly revenues fell 40 8  from the year ago quarter to  0 32 million  Revenues comprised royalty and license fee revenues received under various non imetelstat license agreements  The company stated that active non imetelstat license agreements reduced in numbers and products sales from the licensees decreased Shares were down 5 5  in pre market trading on May 11  However  so far this year  Geron s shares have significantly outperformed the   rising 101 7   against the industry s decline of 11 3  Research and development  R D  expenses declined 27 7  to  2 4 million  The decline was due to decreased stock based compensation and lower costs for the proportionate share of clinical development costs for imetelstat under collaboration with Janssen  a subsidiary of Johnson   Johnson   NYSE JNJ   General and administrative  G A  expenses rose 14 1  to  5 3 million due to consulting costs and legal costs The company ended the quarter with  103 2 million in cash and investments compared with  109 2 million at the end of the fourth quarter Pipeline UpdateGeron s sole pipeline candidate  imetelstat  is being evaluated in two mid stage studies   IMerge and IMbark   in myelodysplastic syndromes   MDS   and myelofibrosis   MF    respectively  Geron is conducting the studies in collaboration with J J In December 2017  Geron presented preliminary data from part I of phase II III IMerge study  Data showed that imetelstat achieved RBC transfusion independence  RBC TI   reduced or no requirement of RBC transfusion over a certain interval  in 54  of the patient population  who have not received prior treatment with either lenalidomide or a hypomethylating agent  for at least eight weeks  RBC TI was achieved in 31  of the patients in the above subset for at least 24 weeks Based on this data  J J expanded part I of the study to include 20 more patients in a refined MDS indication to confirm the clinical benefit and safety observed earlier  In October 2017  the FDA granted fast track designation to imetelstat based on data from part 1 of IMerge Meanwhile  the clinical benefit and a potential overall survival benefit observed during the third internal review in March 2018 supported continuation of the phase II IMbark study without modifications However  J J is planning to amend the protocol of the study to allow long term treatment of patients  The amendment will be based on a primary analysis of data from the study  which is expected in the second quarter of 2018  J J will also notify Geron about continuation of the study based on this analysis  which is expected in the third quarter of 2018 Geron Corporation Price  Consensus and EPS Surprise
    Zacks Rank   Key PicksGeron currently carries a Zacks Rank  2  Buy  A couple of other stocks to consider in the biotech sector are Ligand Pharmaceuticals   NASDAQ LGND    and Enanta Pharmaceuticals  Inc    NASDAQ ENTA    While Ligand sports a Zacks Rank  1  Strong Buy   Enata carries a Zacks Rank  2  You can see  Ligand s earnings per share estimates moved up from  4 20 to  4 43 for 2018 and remained stable at  5 32 for 2019 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 31 79   The company s shares have rallied 25 4  year to date Enanta s earnings per share estimates significantly increased from 86 cents to  2 48 for 2018 over the last 30 days  The company came up with an average beat of 372   The stock has surged 68 2  so far this year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-05-10,Zacks Investment Research,https://www.investing.com/analysis/geron-gern-q1-loss-narrows-yy-revenues-fall-shares-down-200315459,200315459
198567,420083,JNJ,Bayer raises sales targets for top selling drugs after Monsanto deal,news,By Ludwig Burger FRANKFURT  Reuters    German drugmaker Bayer  DE BAYGn  said its two best selling drugs had a higher annual peak sales potential than previously targeted  after the agreed  66 billion takeover of  Monsanto   N MON  stirred criticism it might neglect its pharmaceuticals business  Bayer now expects annual peak sales of more than 5 billion euros   5 6 billion  for stroke prevention pill Xarelto  jointly sold with Johnson   Johnson  N JNJ   where it had previously seen about 3 5 billion  For the eye medicine Eylea  jointly developed with Regeneron  O REGN   it now sees peak sales potential of more than 2 5 billion euros  up from at least 1 5 billion previously  Also underpinned by cancer drug Xofigo and pulmonary hypertension treatment Adempas  the group s prescription drugs unit aims to increase earnings before interest  taxes  depreciation and amortisation  EBITDA   adjusted for special items  to 32 34 percent of sales in 2018  up from 30 1 percent last year  The smaller animal health unit could also slightly increase margins  Bayer said  In consumer health  previously boosted by the acquisition of brands from Merck   Co  N MRK   it now sees sales adjusted for currency swings growing by between 4 and 5 percent by the end of 2018 and an adjusted EBITDA margin of about 25 percent  up from 24 percent in 2015  Bayer has  underestimated the country risk from Emerging Markets volatility   the company said in presentation slides  It also cited  stronger business disruption than anticipated during the integration of Merck Consumer Care and Dihon in China   referring to a Chinese non prescription drugs unit it acquired in 2014   2018 EBITDA guidance for Pharma and Animal Health may     offer some upside against consensus  though the consumer margin guidance may disappoint slightly   Jefferies analysts said in a note to investors  Bayer shares were seen 1 5 percent higher in premarket trading at brokerage Lang   Schwarz  where the overall German market was seen little changed ahead of the official market open at 0700 GMT ,2016-09-20,Reuters,https://www.investing.com/news/stock-market-news/bayer-ups-sales-targets-for-top-selling-drugs-after-monsanto-deal-427203,427203
198570,420086,JNJ,Johnson   Johnson crushed earnings expectations and raised its guidance for the year  JNJ ,news,Johnson   Johnson  NYSE JNJ  on Tuesday reported second quarter profits that topped estimates  and raised its guidance for the rest of the year   The pharmaceutical giant posted revenue of  18 5 billion  up 3 9  year on year  and more than analysts  median forecast for  18 billion  according to Bloomberg  Adjusted earnings per share came in at  1 74   1 68 expected    We saw notable strength in our Pharmaceuticals business due to the continued success of new products  and also achieved significant clinical milestones  advancing our robust pipeline   said CEO Alex Gorsky in the earnings   The company raised its sales guidance for the full year to  72 2 billion from  71 5 billion  It also boosted its EPS expectation to between  6 63 and  6 73 per share   Global pharmaceutical sales rose 8 9  to  8 7 billion  driven by new products like Imbruvica  a lymph node cancer treatment  and Invokana  which treats type 2 diabetes   Johnson   Johnson shares rose as much as 3  in premarket trading ,2016-07-19,Business Insider,https://www.investing.com/news/economy-news/johnson---johnson-crushed-earnings-expectations-and-raised-its-guidance-for-the-year-(jnj)-415206,415206
198571,420087,JNJ,Johnson   Johnson raises 2016 forecast  shares touch record high,news,"By Natalie Grover and Susan Kelly  Reuters    Johnson   Johnson  N JNJ  on Tuesday raised its full year 2016 sales and earnings forecasts and reported quarterly results that beat estimates  helped by strength in its prescription drugs business  Shares of the diversified healthcare products maker rose 1 6 percent at  125 06 on the New York Stock Exchange after touching a new record high of  125 75  Analysts said the overall results bode well for J J shares       We expect today s results to drive further upside and  given investor preference for safer names with good dividend yields in the current market environment  we think it bodes well for the stock over the near term   said  Credit Suisse   SIX CSGN  analyst Vamil Divan  Strong demand for the company s Imbruvica cancer drug and Xarelto blood thinner boosted pharmaceutical sales  which jumped 8 9 percent to  8 7 billion in the quarter  Sales of autoimmune drug Remicade  J J s biggest product  rose 6 7 percent to  1 78 billion   The company  which is the first major U S  drugmaker to announce quarterly earnings  raised its 2016 sales forecast to a range of  71 5 billion to  72 2 billion  from  71 2 billion to  71 9 billion previously   J J expects sales to grow at a faster rate than the global healthcare market  which it sees increasing by 3 percent to 5 percent annually over the next five years  Chief Executive Officer Alex Gorsky said on a conference call  The maker of a variety of products from Tylenol to Band Aid bandages to Acuvue contact lenses also increased its adjusted profit range to  6 63 to  6 73 per share  from  6 53 to  6 68   Investors have been concerned about potential competition to Remicade in the United States  U S regulators earlier this year approved Inflectra  a cheaper version developed by  Celltrion Inc   KQ 068270  and  Pfizer  Inc  N PFE   but a patent battle between J J and Celltrion has delayed its introduction   J J said its sales outlook assumes no new U S  competition for Remicade in 2016  New Jersey based J J is also restructuring its medical device business to focus on areas such as artificial knees and devices for trauma surgery  Worldwide device sales inched up about 1 percent to  6 4 billion in the quarter  buoyed by higher demand for its advanced surgery products  Growth in its devices business was roughly in line with the market  the company said  Total revenue rose 3 9 percent to  18 5 billion   Net earnings fell to  3 997 billion  or  1 43 per share  from  4 516 billion  or  1 61 per share  Excluding special items  J J earned  1 74 per share  Analysts  on average  expected profit of  1 68 per share on revenue of  17 98 billion  according to Thomson Reuters I B E S  
Up to Monday s close  J J s stock had gained about 20 percent this year ",2016-07-19,Reuters,https://www.investing.com/news/stock-market-news/j-amp;j-quarterly-sales-rise-3.9-percent-415159,415159
198572,420088,JNJ,Acclarent pays  18 million to settle False Claims Act allegations,news,"Investing com    Acclarent  a California based medical device manufacturer and subsidiary of Johnson   Johnson  NYSE JNJ   agreed on Friday to pay an  18 million fine to settle charges that the company enabled health care providers to submit false claims to Medicare by distributing a sinus spacer product without receiving approval from U S  federal regulators 
For a period of several years  beginning in 2006  Acclarent received clearance from the U S  Food and Drug Administration to market a market device called the Relieva Stratus MicroFlow Spacer in cases when saline was required was to maintain sinus openings in post surgery periods  A year later  Acclarent allegedly continued to promote Stratus as a drug delivery device for a prescription corticosteroid without receiving clearance from the FDA for an expanded use clearance  By 2010  the company added a warning label to the Stratus  packaging warning of the use of active drug substances within the device  according to court filings  but still continued to market the device for drug delivery  the U S  Justice Department said in a statement  The company discontinued the sale of the Stratus device by May  2013 
 The FDA approval process serves an important role in ensuring that federal health care participants receive devices that are safe  effective and medically appropriate   said Principal Deputy Assistant Attorney General Benjamin C  Mizer  head of the Justice Department s Civil Division    We will not permit companies to circumvent that process and put profits over patient safety  
The settlement comes two days after Acclarent s former CEO William Facteau and former Vice President of Sales Patrick Fabian were convicted of 10 misdemeanor counts of introducing adulterated and misbranded medical devices into interstate commerce  A jury acquitted the former executives of 14 felony counts of fraud  Acclarent s civil settlement with the federal government resolves a lawsuit filed under the whistleblower provision of the False Claims Act 
 It is imperative that medical device companies adhere to FDA approval requirements so that patients are not subject to questionable medical treatments at taxpayer expense   said Special Agent in Charge Phillip Coyne of the Department of Health and Human Services Office of Inspector General  
Each charge of violating the Food  Drug and Cosmetics Act provides for a sentence of no greater than one year in prison on each count  the Justice Department said in a statement 
Shares in Johnson   Johnson inched down 0 03 or 0 02  to 125 00 in after hours trading ",2016-07-22,Investing.com,https://www.investing.com/news/stock-market-news/acclarent-pays-$18-million-to-settle-false-claims-act-allegations-416156,416156
198573,420089,JNJ,Here s Why Geron Stock Surged More Than 90  In 6 Months,opinion,"Geron Corporation   NASDAQ GERN   shares have soared 91 9  in the past six months  significantly outperforming the  s decline of 7 7   The stock saw a turnaround this year after it fell 13  in 2017 Geron is focused on developing anti cancer therapies based on telomerase inhibitors  The company s pipeline consists of only one candidate  imetelstat  It is being developed for the treatment of hematologic myeloid malignancies like myelofibrosis   MF   and myelodysplastic syndromes   MDS    Notably  Geron has collaborated with Johnson   Johnson s   NYSE JNJ   subsidiary  Janssen  for imetelstat Geron has no approved product in its portfolio and its top line solely comprises license fees and royalties Currently  Imetelstat is being evaluated for MF in a phase II IMbark study and for MDS in a phase II III IMerge study In December 2017  Geron presented preliminary data from part I of phase II III IMerge study  The data showed that imetelstat achieved RBC transfusion independence  RBC TI   reduced or no requirement of RBC transfusion over a certain interval  in 54  of the patient population  which have not received prior treatment with either lenalidomide or a hypomethylating agent  for at least 8 weeks Moreover  Geron expanded the Part I of IMerge and enrolled 20 additional patients in a refined MDS population to confirm the clinical benefit and safety observed earlier  The FDA granted fast track designation to imetelstat based on data from part 1 of IMerge in October 2017 Meanwhile  the clinical benefit and a potential overall survival benefit observed during the third internal review in March 2018 supported continuation of the phase II IMbark study without modifications  However  J J is planning to amend the protocol of the study to allow long term treatment of patients Investors are solely banking on the continuation and success of these two studies  Geron s price has started rallying before J J s earnings release next week in anticipation of positive updates on imetelstat Geron Corporation Price
    Zacks Rank   Key PicksGeron carries a Zacks Rank  3  Hold  A few better ranked stocks in the pharma sector include Protagonist Therapeutics  Inc    NASDAQ PTGX   and Catabasis Pharmaceuticals  Inc    NASDAQ CATB    While Protagonist sports a Zacks Rank  1  Strong Buy   Catabasis carries a Zacks Rank  2  Buy   You can see  Protagonist s loss estimates narrowed from  1 30 to 66 cents for 2018 and from  1 99 to  1 26 for 2019  over the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 24 95  Catabasis  loss estimates narrowed from  1 09 to 92 cents for 2018 and from  1 76 to  1 48 for 2019  in the last 30 days  The company came up with a positive earnings surprise in all the preceding four quarters  with an average beat of 14 56   The stock has rallied 22 2  so far this year Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-04-12,Zacks Investment Research,https://www.investing.com/analysis/heres-why-geron-stock-surged-more-than-90-in-6-months-200305440,200305440
198574,420090,JNJ,J J  JNJ  Beats On Q1 Earnings   Sales  Ups 2018 Sales View,opinion,"Johnson   Johnson   NYSE JNJ    the bellwether of healthcare companies  has a strong presence in the pharmaceutical  medical devices and consumer care markets across the world  This New Jersey based company is well known for its baby care products and brands like Tylenol in addition to drugs like Remicade and Concerta However  like many of its peers  JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment In this scenario  investor focus remains on late stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top and bottom line numbers JNJ has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters  with an average positive surprise of 3 09   Estimate movement has been stable over the past 7 days Currently  JNJ has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  JNJ beat on first quarter earnings   the company reported EPS of  2 06 while our consensus called for EPS of  2 01 Revenues Beat  Revenues also slightly beat expectations  Johnson   Johnson posted revenues of  20 0 billion  compared to our consensus estimate of  19 48 billion Key Statistics  Pharmaceutical segment sales rose 19 4  year over year to  9 84 billion  reflecting 15 1  operational growth and 4 3  positive currency impact as sales rose in both domestic and international markets Ups 2018 Sales Outlook  J J maintained the previously issued earnings guidance for 2018 while increasing the sales range J J still expects 2018 adjusted earnings per share in the range of  8 00    8 20  reflecting an operational growth rate between 6 8  and 9 6  However  it expects revenues in the range of  81 0 to  81 8 billion higher than  80 6 billion to  81 4 billion expected previously  reflecting operational constant currency sales growth rate in the range of 4 0  to 5 0   previously 3 5  to 4 5   The Zacks Consensus Estimate for earnings per share and revenues were  8 11 and  81 27 billion  respectively Stock Price Impact  Shares rose 1 3  in pre market trading Johnson   Johnson Price and EPS Surprise
    Check back later for our full write up on this JNJ earnings report later The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1   Strong Buys   free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5   Strong Sells    Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ",2018-04-17,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-beats-on-q1-earnings--sales-ups-2018-sales-view-200306188,200306188
198575,420091,JNJ,U S  stocks fall sharply  as U S  10 year yields fall to record lows,news,"Investing com    U S  stocks fell sharply on Tuesday erasing some of the gains from last week s post Brexit rally  as widespread concerns related to the viability of banking stocks in the euro area and a continued global bond yield rout served as a drag on equities on Wall Street 
The Dow Jones Industrial Average fell 108 75 or 0 61  to  while the S P 500 Composite index dropped 108 75 or 0 61  to 17 840 62  as declines among energy stocks and Dow transports weighed heavily on the major indices  For the session  crude futures plunged more than 4  dropping below  48 a barrel due to reports of an unexpected build at the Cushing Oil Hub in Oklahoma  On the S P 500  nine of 10 sectors closed lower  as stocks in the Energy  Financials and Basic Materials industries lagged  Stocks in the defensive minded Utilities sector led  gaining more than 0 60  on the session 
The NASDAQ Composite index  meanwhile  lost 39 67 or 0 82  to 4 822 90  amid a disappointing session among several top semiconductor stocks 
During Tuesday s session  yields on the U S  10 Year and U S  30 Year fell to intraday lows of 1 357  and 2 131  respectively  each dropping to their lowest levels on record  It came as investors continued to seek safety in safe haven assets  as bank stocks in Italy and England tumbled further  extending Brexit inspired losses  Investors also monitored political developments on Tuesday after FBI director James Comey said the bureau would not recommend charges against presumptive democratic presidential frontrunner Hillary Clinton upon the completion of a comprehensive e mail probe  White House spokesman Josh Earnest said U S  president Barack Obama would not comment on the issue at a campaign stop with Cllinton on Tuesday in Charlotte 
The top performer on the Dow was Johnson   Johnson  NYSE JNJ   which gained 0 98 or 0 81  to 122 27  Since the final results of the Brexit referendum were tallied on June 24  shares in Johnson   Johnson have surged approximately 7   Over the last two weeks  Johnson   Johnson and other high dividend plays have become attractive to investors during a broad risk off trade  The worst performer was JPMorgan Chase   Co  NYSE JPM   which fell 1 71 or 2 79  to 59 55  as the plunge in bond yields and the sell off in European banking stocks spilled over into the U S  financial sector  Shares in  Barclays   LON BARC  Bank PLC Pd ADR  NYSE BCS pd  and Royal Bank of Scotland Group PLC  LON RBS  Pl ADR  NYSE RBS pl   two global banks with deep exposure to economic activity in Britain  are both down more than 20  since the surprising Brexit decision 
The biggest gainer on the NASDAQ was NVIDIA Corporation  NASDAQ NVDA   which rose 0 69 or 1 48  to 47 35  Nvidia closed just above  Dollar Tree Inc   NASDAQ DLTR   which added 0 69 or 1 48  to 47 35  Shares in the Virginia based discount variety chain store are up approximately 16  since touching down to 52 week lows at 61 38 last October  The worst performer was  Skyworks Solutions Inc   NASDAQ SWKS   which fell 3 78 or 6 04  to 58 82 after analysts from Pacific Crest downgraded the Massachusetts based semiconductor company  amid heightened risks related to Apple Inc  NASDAQ AAPL  s rollout of the iPhone 7  As part of their analysis  Pacific Crest anticipates that initial iPhone 7 demand could slump by 15 20  in comparison with its iPhone 6 counterpart 
On the New York Stock Exchange  declining issues outnumbered advancing ones by a 2 227 799 margin ",2016-07-05,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-fall-sharply,-as-u.s.-10-year-yields-fall-to-record-lows-412588",412588
198576,420092,JNJ,Karyopharm s Myeloma Candidate Gets Fast Track Designation,opinion,Karyopharm Therapeutics Inc  s   NASDAQ KPTI   shares increased more than 6  on Apr 10 after the company announced that its oral selective inhibitor of nuclear export  SINE  compound  selinexor  KPT 330   has been granted a fast track designation by the FDA The company is looking to get the candidate approved for treatment of patients with penta refractory multiple myeloma  having received at least three prior lines of therapy The FDA grants a fast track designation to expedite a candidate s development as well as its faster review to treat serious and unmet medical conditions  With this designation  a candidate is expected to be granted a priority review once it files a new drug application This news is a huge positive for the company as it comes ahead of the data from a phase IIb STORM study on selinexor  expected by the end of this April  The study is evaluating selinexor with low dose dexamethasone on 122 penta refractory multiple myeloma patients Positive data from the trial will allow the company to submit a regulatory application to the FDA during the second half of 2018  It will also pave the way for selinexor s accelerated approval in the United States for the given indication Karyopharm s shares have rallied 29 6  year to date against the  s decrease of 2 2   We remind investors that Karyopharm is also evaluating selinexor in several mid  and later phase studies on multiple cancer indications  the most advanced being the phase III study of the candidate in combination with Johnson   Johnson s   NYSE JNJ   Velcade on multiple myeloma patients  The company is also planning to evaluate Selinexor on subjects with gynecological malignancies Notably  last October  Karyopharm entered into an exclusive license agreement with the Japanese company Ono Pharmaceutical for developing and commercializing selinexor for all human oncology indications in Japan  South Korea  Taiwan  Hong Kong and the 10 Southeast Asian countries Going forward  we expect investor s focus to remain on the company s further updates on selinexor Karyopharm Therapeutics Inc  Price    Zacks Rank   Key PicksKaryopharm carries a Zacks Rank  4  Sell  Two better ranked stocks in the health care sector are Ligand Pharmaceuticals Incorporated   NASDAQ LGND   and Infinity Pharmaceuticals  Inc    NASDAQ INFI    both sporting a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates have moved up from  3 78 to  4 20 for 2018 and from  4 75 to  5 32 for 2019 in the last 60 days  The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24 88   Share price of the company has soared 54 6  over a year Infinity s loss per share estimates narrowed from  1 07 to 74 cents for 2018 and from 83 cents to 66 cents for 2019 in the last 30 days  The company delivered a positive surprise in three of the trailing four quarters with an average beat of 7 87  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-04-10,Zacks Investment Research,https://www.investing.com/analysis/karyopharms-myeloma-candidate-gets-fast-track-designation-200304749,200304749
198577,420093,JNJ,Is J J s  JNJ  Pharma Segment Likely To Drive Q1 Earnings ,opinion,"Johnson   Johnson   NYSE JNJ   has one of the most diverse revenue streams in the industry within the pharmaceutical division that accounts for almost half of its revenues  The company has several multi million dollar drugs covering a broad range of areas such as neuroscience  cardiovascular and metabolism  immunology  oncology  pulmonary hypertension  and infectious diseases vaccines  However  several products in this segment are facing generic competition J J s stock has depreciated 6 1  this year so far  comparing unfavorably with a decline of 1 7  recorded by the  J J s domestic Pharma segment sales witnessed a positive trend in the second half of 2017 after being soft in the first half of the year  We are likely to see the positive impact of the trend in first quarter results The Zacks Consensus Estimate for the Pharmaceutical segment is  9 51 billion  Last quarter  the segment s sales beat the consensus estimate We believe that new products  continued share gains of some key products  label expansion of drugs like Imbruvica  Xarelto  Stelara and Darzalex  and meaningful contribution from Swiss biotech Actelion that J J bought in June  will support the top line Continued share gains should drive sales of Imbruvica  cancer indications   Xarelto  blood thinner   Zytiga  prostate cancer  and Stelara  psoriasis   Meanwhile  strong adoption for the newer indication of Crohn s disease should continue contributing to Stelara growth  J J also gained FDA approval for Zytiga in first line setting in February  which can drive sales of the drug higher in the first quarter  Please note that J J markets Imbruvica in partnership with AbbVie  Inc    NYSE ABBV   Also  strong adoption in outside U S  markets and accelerated adoption in the United States across all lines of therapy should drive sales of Darzalex  These positives will likely offset the loss of sales of some drugs like Invokana due to higher managed care discounting  Meanwhile  biosimilar competition is expected to continue hurting key arthritis drug Remicade s sales outside the United States  J J markets Remicade in partnership with Merck   NYSE MRK   Regarding newly launched Tremfya  J J said at the fourth quarter conference call that the uptake of the product has been decent  The drug recorded sales of  47 million in the last quarter  which are expected to be higher in the to be reported quarter  Also  J J should discuss the initial sales uptake of Juluca at the call   the first dual treatment for HIV developed in partnership with GlaxoSmithKline   NYSE GSK     that gained FDA approval in last November  Juluca is under review in the EU Meanwhile  we expect J J to discuss commercialization plans for Erleada  its newly approved prostate cancer drug  at the first quarter conference call Overall  in2018  J J expects the Pharmaceutical segment to remain strong while the Consumer and Medical Device segments will continue to improve   Read More   J J carries a Zacks Rank  2  Buy   You can see  Johnson   Johnson Price and EPS Surprise
    Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-04-12,Zacks Investment Research,https://www.investing.com/analysis/is-jjs-jnj-pharma-segment-likely-to-drive-q1-earnings-200305443,200305443
198580,420096,JNJ,New incentives needed to develop antibiotics to fight superbugs,news,"By Bill Berkrot
NEW YORK  Reuters    Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic resistant bacteria  but creating new classes of drugs on the scale needed is unlikely to happen without new financial incentives to make the effort worth the investment  companies and industry experts said 
American military researchers on Thursday announced the first U S  case of a patient with an infection found to be resistant to the antibiotic colistin  the drug often held in reserve for when all else fails 
That put a spotlight on the urgent need for new medicines that can combat what health officials have called  nightmare bacteria  
Drugmakers on Friday acknowledged that in the absence of a new way of compensating them  it simply does not make economic sense to pour serious resources into work on new antibiotics 
 The return on investment based on the current commercial model is not really commensurate with the amount of effort you have to put into it   said David Payne  who heads GlaxoSmithKline PLC s  L GSK  antibiotics drug group 
Other pharmaceutical companies expressed a similar sentiment 
In January  some 80 drugmakers and diagnostics companies  including  Pfizer  Inc  N PFE   Merck   Co  N MRK   Johnson   Johnson  N JNJ  and Glaxo  signed a declaration calling for cooperation among governments and companies to create incentives to revitalize research and development of new antibiotics 
It proposed a new business model in which profit would not be linked to higher sales  For example  governments and health organizations could offer lump sum rewards for development of a successful new antibiotic  A British government panel suggested this month that drug companies be offered up to  1 5 billion for successful development of a new antibiotic 
In the United States alone  antibiotic resistant bacteria causes 2 million serious infections and 23 000 deaths annually  according to U S  health officials 
Unrestrained overuse of current antibiotics by doctors and hospitals  often when they are not needed  and widespread antibiotic use in food livestock have contributed to the evolution of antibiotic resistant bacteria 
But in recent years  major drugmakers have poured most of their research dollars into highly profitable medicines to fight cancer  rare diseases and hepatitis C  These drugs not only command high prices  they also are typically used far longer than antibiotics 
And the companies  which have come under intense criticism in recent months for continually raising prices on popular drugs  say it costs about as much to develop a new antibiotic as it does to bring to market new cancer drugs that can command more than  100 000 a year per patient 
 Drug companies can t make an economic case for investing in superbug drugs   said Erik Gordon  a professor at the University of Michigan s Ross School of Business 
Gordon said governments and foundations need to get more involved in research and funding to spearhead efforts to combat the problem 
To critics who argue that U S  companies have enormous cash reserves that could be used to address a public health crisis  drugmakers say they have a fiduciary duty to shareholders to maximize profits 
ON THE R D FRONT LINES
One reason companies are calling for alternative compensation is that aggressive sales and use of new antibiotics could help create ever more dangerous bacteria that develop resistance to the new medicines 
Glaxo and Merck are among the large pharmaceutical companies developing new antibiotics they hope can beat back resistant bugs  while Pfizer is working on vaccines aimed at reducing the need for their use 
Industry experts said small  lesser known companies with promising approaches to tackling resistant superbugs included  Entasis Therapeutics  an AstraZeneca PLC spinoff   Tetraphase Pharmaceuticals Inc   O TTPH   and  Achaogen Inc   O AKAO  
 We believe plazomicin  our lead drug in late stage development  has the potential to play an important role in treating this dreaded superbug   Achaogen Chief Executive Kenneth Hillan said 
Allan Coukell  an antibiotics expert at the Pew Charitable Trusts nonprofit research and policy organization  said what is needed is a wave of new drugs based on new chemistry or that work in new ways 
 Most of what s being developed are variations on drugs that we ve had for decades   Coukell said 
Pew has outlined what its calls a scientific roadmap to create a body of work around new drug discovery that companies and academic researchers could draw upon to help jumpstart the process of finding new antibiotics 
Glaxo said its experimental antibiotic gepotidacin  in midstage testing  belongs to an entirely new class of antibacterials 
 Based on that  we re predicting it would work against infections that could be caused by bacteria that are resistant to available antibiotics   Payne said 
Other companies with late stage studies underway for antibiotics include   Cempra Inc   O CEMP   whose drug was recently validated in a Japanese trial  Medicines Co  O MDCO   and Paratek Pharmaceuticals Inc  O PRTK   J J is also putting money into battling antibiotic resistance 

 If there is a bright side  it is that the world policymakers and health leaders have focused on this issue like never before   Coukell said   But we ve got a long way to go  ",2016-05-27,Reuters,https://www.investing.com/news/stock-market-news/new-incentives-needed-to-develop-antibiotics-to-fight-superbugs-405104,405104
198581,420097,JNJ,New incentives needed to develop antibiotics to fight superbugs,news,"By Bill Berkrot
NEW YORK  Reuters    Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic resistant bacteria  but creating new classes of drugs on the scale needed is unlikely to happen without new financial incentives to make the effort worth the investment  companies and industry experts said 
American military researchers on Thursday announced the first U S  case of a patient with an infection found to be resistant to the antibiotic colistin  the drug often held in reserve for when all else fails 
That put a spotlight on the urgent need for new medicines that can combat what health officials have called  nightmare bacteria  
Drugmakers on Friday acknowledged that in the absence of a new way of compensating them  it simply does not make economic sense to pour serious resources into work on new antibiotics 
 The return on investment based on the current commercial model is not really commensurate with the amount of effort you have to put into it   said David Payne  who heads GlaxoSmithKline PLC s antibiotics drug group 
Other pharmaceutical companies expressed a similar sentiment 
In January  some 80 drugmakers and diagnostics companies  including  Pfizer  Inc  NYSE PFE   Merck  NYSE MRK    Co  Johnson   Johnson  NYSE JNJ  and Glaxo  signed a declaration calling for cooperation among governments and companies to create incentives to revitalize research and development of new antibiotics 
It proposed a new business model in which profit would not be linked to higher sales  For example  governments and health organizations could offer lump sum rewards for development of a successful new antibiotic  A British government panel suggested this month that drug companies be offered up to  1 5 billion for successful development of a new antibiotic 
In the United States alone  antibiotic resistant bacteria causes 2 million serious infections and 23 000 deaths annually  according to U S  health officials 
Unrestrained overuse of current antibiotics by doctors and hospitals  often when they are not needed  and widespread antibiotic use in food livestock have contributed to the evolution of antibiotic resistant bacteria 
But in recent years  major drugmakers have poured most of their research dollars into highly profitable medicines to fight cancer  rare diseases and hepatitis C  These drugs not only command high prices  they also are typically used far longer than antibiotics 
And the companies  which have come under intense criticism in recent months for continually raising prices on popular drugs  say it costs about as much to develop a new antibiotic as it does to bring to market new cancer drugs that can command more than  100 000 a year per patient 
 Drug companies can t make an economic case for investing in superbug drugs   said Erik Gordon  a professor at the University of Michigan s Ross School of Business 
Gordon said governments and foundations need to get more involved in research and funding to spearhead efforts to combat the problem 
To critics who argue that U S  companies have enormous cash reserves that could be used to address a public health crisis  drugmakers say they have a fiduciary duty to shareholders to maximize profits 
ON THE R D FRONT LINES
One reason companies are calling for alternative compensation is that aggressive sales and use of new antibiotics could help create ever more dangerous bacteria that develop resistance to the new medicines 
Glaxo and Merck are among the large pharmaceutical companies developing new antibiotics they hope can beat back resistant bugs  while Pfizer is working on vaccines aimed at reducing the need for their use 
Industry experts said small  lesser known companies with promising approaches to tackling resistant superbugs included  Entasis Therapeutics  an AstraZeneca PLC spinoff  Tetraphase Pharmaceuticals Inc  and Achaogen Inc 
 We believe plazomicin  our lead drug in late stage development  has the potential to play an important role in treating this dreaded superbug   Achaogen Chief Executive Kenneth Hillan said 
Allan Coukell  an antibiotics expert at the Pew Charitable Trusts nonprofit research and policy organization  said what is needed is a wave of new drugs based on new chemistry or that work in new ways 
 Most of what s being developed are variations on drugs that we ve had for decades   Coukell said 
Pew has outlined what its calls a scientific roadmap to create a body of work around new drug discovery that companies and academic researchers could draw upon to help jumpstart the process of finding new antibiotics 
Glaxo said its experimental antibiotic gepotidacin  in midstage testing  belongs to an entirely new class of antibacterials 
 Based on that  we re predicting it would work against infections that could be caused by bacteria that are resistant to available antibiotics   Payne said 
Other companies with late stage studies underway for antibiotics include  Cempra Inc  whose drug was recently validated in a Japanese trial  Medicines Co  and Paratek Pharmaceuticals Inc  J J is also putting money into battling antibiotic resistance 

 If there is a bright side  it is that the world policymakers and health leaders have focused on this issue like never before   Coukell said   But we ve got a long way to go  ",2016-05-29,Reuters,https://www.investing.com/news/general-news/new-incentives-needed-to-develop-antibiotics-to-fight-superbugs-405200,405200
198582,420098,JNJ,J J to buy hair care products maker Vogue for  3 3 billion,news," Reuters    Johnson   Johnson  N JNJ  said on Thursday it would acquire Vogue International for  3 3 billion  adding brands such as OGX shampoos and FX hair styling products to its consumer portfolio that includes Neutrogena and Clean   Clear  Vogue s hair care products have gained popularity  helped by colorful packaging that makes them stand out in drugstore aisles  The privately held company has focused on increasing its presence in drugstores and is spending more on buying shelf space than on consumer advertising  Buyout firm  Carlyle Group  LP  O CG  acquired a 49 percent stake in the company in 2014  Vogue s products are sold in the United States and 38 other countries  Johnson   Johnson said in a statement  The transaction  slated to close in the third quarter  is not expected to affect the company s 2016 sales or earnings forecasts  it said  
Unilever NV  AS UNc   Henkel   Co KgaA AG  DE HNKG p   L Or al SA  PA OREP  and other companies had submitted first round bids in an auction for Vogue  people familiar with the matter told Reuters in May ",2016-06-02,Reuters,https://www.investing.com/news/stock-market-news/j-amp;j-to-buy-hair-care-products-maker-vogue-for-$3.3-billion-406072,406072
198583,420099,JNJ,Industry weighs radical shake up of European drug pricing,news,"By Ben Hirschler
LONDON  Reuters    The pharmaceutical industry is considering a radical shift in the way it prices drugs in Europe so companies are rewarded for the clinical benefit of treatments rather than the number of pills sold  according to an internal report 
The high price of drugs is straining Europe s cash strapped health systems and depriving some patients of the latest products  to the concern of manufacturers who argue they can save costs in the long run by keeping people out of hospital 
As a result  companies are looking at a fundamentally different way of getting paid for their innovations  according to the internal report  a copy of which was seen by Reuters 
Its proposed  roadmap for change toward outcomes based reward systems  will be discussed by the board of the European Federation of Pharmaceutical Industries and Associations  Efpia  on June 16  which groups the world s top drugmakers and national trade associations 
The report is the clearest sign yet that the drug industry is ready to negotiate a new pricing framework with governments and insurers 
 This is not without risk   according to the paper by Efpia s director of market access Francois Bouvy   If a product does not deliver on its clinical promise  society should not continue to pay for it  Equally  if the product delivers more value than was ever expected  this extra value must be rewarded  
Officials at Efpia declined to comment on the internal report because of its confidential nature 
TOO EXPENSIVE
The concept of drug pricing based on clinical results has been gaining ground for some years and has the support of several leading industry figures  including Novartis Chief Executive Joe Jimenez  the current president of Efpia 
Europe already has some ad hoc results based pricing agreements 
Britain  for example  agreed a deal with Johnson   Johnson  NYSE JNJ  a decade ago whereby the health service only pays for multiple myeloma drug Velcade in patients who respond after four treatment cycles  Italy uses patient registries to pay for new cancer drugs based on actual patient response 
But the Efpia proposals go further by suggesting the wholesale adoption of the new approach 
The report said  affordability is a major issue for healthcare systems across Europe  and the need for a better system would only grow with the rollout of hard to price cancer drug combinations  new antibiotics and stem cell therapies 
Drug pricing is a hot topic worldwide  as advances in medical science come at an increasingly high cost 
A study of cancer drug prices in seven countries released on Monday highlighted cost obstacles in many markets and a report last month into antibiotic resistance also called for a rethink of market mechanisms 
There are likely to be plenty of battles ahead  especially as the industry is looking for a trade off in the form of relief from market mechanisms that weigh on drug prices in Europe 
In particular  the Efpia paper says external reference pricing  which allows governments to refer to prices in other countries when determining what they will pay   should be removed as new systems evolve  
The industry also wants an end to tenders for patented medicines and curbs on parallel trade  under which wholesalers buy drugs in low cost European markets and sell them for higher prices elsewhere ",2016-06-09,Reuters,https://www.investing.com/news/stock-market-news/industry-weighs-radical-shake-up-of-european-drug-pricing-407411,407411
198584,420100,JNJ,Pharma Stock Roundup  ABBV s Rova T Disappoints  J J Unit Gets Buyout Offer,opinion,"Discouraging results from a phase II study evaluating AbbVie s   NYSE ABBV   promising cancer candidate rovalpituzumab tesirine or Rova T in third line or later small cell lung cancer   SCLC   grabbed headlines this week  Other news included a purchase offer for J J s   NYSE JNJ   diabetes device unit and successful study results announced by Heron Therapeutics   NASDAQ HRTX   and Roche   OTC RHHBY   
Recap of the Week s Most Important Stories
AbbVie s Rova T Falls Short in Key Lung Cancer Study  AbbVie s promising cancer candidate  rovalpituzumab tesirine or Rova T fell short of expectations in a phase II TRINITY study evaluating it in third line or later small cell lung cancer  SCLC   AbbVie said it will not seek accelerated approval of Rova T in the third line setting after consulting with the FDA  Rova T was added to AbbVie s portfolio  following the  5 8 billion acquisition of Stemcentrx in June 2016  AbbVie had significant confidence in Rova T s potential  The failure of TRINITY has raised skepticism on Rova T s potential and has brought into question the viability of the Stemcentrx deal   Read More   
J J Gets  2 1B Offer for LifeScan Unit  J J said it has received a  2 1 billion binding offer from a private equity firm  Platinum Equity  for its LifeScan diabetes device unit  J J has time until Jun 15 to accept the offer  failing which it will expire  J J has been evaluating potential strategic options for its Diabetes Care units specifically  LifeScan  Animas Corporation  and Calibra Medical since early last year   Read More   
Pfizer Gets FDA s Priority Review to Expand Label of Xtandi  Pfizer   NYSE PFE   and its Japanese partner Astellas gained FDA s priority review for a regulatory filing  which was looking to expand the label of its prostate cancer drug Xtandi to include an early stage patient population  The regulatory applications to add the non metastatic Castration Resistant Prostate Cancer   CRPC   indication to the drug s label were based on the results of the PROSPER study on Xtandi  With the FDA granting priority review  a decision is expected in July   Read More    
Meanwhile  British company Reckitt Benckiser Group pulled out of the discussion with Pfizer to buy the latter s Consumer Health segment  Last October  Pfizer had said that it was exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin off  sale or other transaction  A decision regarding the same is expected to be made this year and it may ultimately opt to retain the business  Glaxo also said it has withdrawn from the race to buy Pfizer s unit 
Heron s HTX 011 Succeeds in Phase III  Heron Therapeutics  pipeline candidate  HTX 011 met the primary endpoint in two pivotal phase III studies  evaluating it in post operative pain control  following bunionectomy and hernia repair  respectively  Top line data from both the studies showed that treatment with HTX 011 led to statistically significant reductions in pain intensity and opoid use through 72 hours following surgery  The candidate was also superior to bupivacaine solution  which is the current standard of care local anesthetic for postoperative pain control   Read More  
Roche s Tecentriq Succeeds in Lung Cancer Combo Study  Roche s Tecentriq met the co primary endpoint of progression free survival in a phase III study  evaluating the PD L1 inhibitor in combination with chemotherapy  carboplatin and Abraxane  for the first line treatment of advanced squamous non small cell lung cancer  NSCLC   Tecentriq is already marketed for the treatment of second line metastatic NSCLC  Label expansion in the first line setting should boost the drug s sales further  However  Roche awaits overall survival data and the study will continue  Read More    
Novartis Tasigna Gets FDA Nod for Label Expansion  Novartis s   NYSE NVS   leukemia drug Tasigna was granted FDA approval for use in the pediatric  one year of age or older  population for the first  and the second line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase  Ph  CML CP  
Glaxo Begins New Combo Study on Benlysta  Glaxo   NYSE GSK   has initiated a late stage study   BLISS BELIEVE   which will evaluate its systemic lupus erythematosus medicine Benlysta in combination with Roche s Rituxan  Benlysta  in previous late stage studies  has demonstrated its consistent efficacy in reducing disease activity in SLE  The aim of the new combination study is to achieve clinical remission in SLE patients apart from demonstrating low disease activity   Read More  
The NYSE ARCA Pharmaceutical Index declined 3 9  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 

Here is how the seven major stocks performed this week 

AstraZeneca   NYSE AZN   was the only stock to record a gain  1 9   in the last five trading sessions  While J J declined 4 3   Bristol Myers   NYSE BMY   was down 3 5  
In the last six months  while AstraZeneca was the biggest gainer  4 2    Merck   NYSE MRK   was the biggest loser  declining 15 5  
 See the last pharma stock roundup here   
What s Next in the Pharma World 
Watch out for regulatory and pipeline news from pharma stocks 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-03-23,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-abbvs-rovat-disappoints-jj-unit-gets-buyout-offer-200300377,200300377
198585,420101,JNJ,Glaxo Drops Bid For Pfizer Unit  Shingrix Gains EU Japan Nod,opinion,GlaxoSmithKline plc   NYSE GSK   has withdrawn from the race to buy Pfizer s   NYSE PFE   Consumer Healthcare segment Last October  Pfizer had said that it was exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin off  sale or other transaction  A decision regarding the same is expected to be made this year and it may ultimately opt to retain the businessGlaxo s chief executive officer  Emma Walmsley said that management is interested in deals that will improve the company s returns and not  compromise on its priorities for capital allocation  Pfizer is having a tough time finding a buyer for its Consumer Healthcare segment  Last week  British company Reckitt Benckiser Group also pulled out of the discussion with Pfizer to buy the latter s Consumer Health segment  After  Reckitt Benckiser backed out  Glaxo was seen as the frontrunner to buy Pfizer s unit Shares of Glaxo were up around 3 5  on Friday in response to this positive news  Glaxo s stock has risen 7 3  this year so far  against a decline of 4 6  for the  In a separate press release  Pfizer announced that its shingles vaccine  Shingrix has gained regulatory approval in Japan and EU  Please note that Shingrix was approved in the United States and Canada in October last year  Also  Shingrix enjoys preferential recommendation from the US Centers for Disease Control and Prevention s Advisory Committee on Immunization Practices  ACIP   Last year  the ACIP recommended thepreferentialuse of Shingrix for prevention of shinglesover Merck s   NYSE MRK   Zostavax In yet another release  Glaxo announced that the Committee for Medicinal Products for Human Use  CHMP  of Europe has granted a positive opinion  recommending approval of Juluca a two drug regimen dolutegravir and rilpivirine   once daily  single pill for HIV Juluca becomes the first two drug pill to be approved in Europe  A final decision from the European Commission in the EU is expected toward the end of the second quarter Juluca was approved in the United States in November last year  Juluca has been developed by Glaxo and Pfizer s HIV focused company  ViiV Healthcare  in partnership with Johnson   Johnson   NYSE JNJ   Glaxo carries a Zacks Rank  2  Buy   You can see  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-03-25,Zacks Investment Research,https://www.investing.com/analysis/glaxo-drops-bid-for-pfizer-unit-shingrix-gains-eujapan-nod-200300851,200300851
198586,420102,JNJ,Protagonist Therapeutics Stalls Ulcerative Colitis Study,opinion,"Protagonist Therapeutics  Inc    NASDAQ PTGX   announced that it has discontinued phase IIb study   PROPEL   on its ulcerative colitis   UC   candidate  PTG 100 Protagonist is a small biotech company focused on developing treatment for inflammatory bowel diseases  Crohn s disease and thalassemia  PTG 100 was the most advanced candidate in the company s pipeline Shares of the company fell 57 2  following the news  In fact  Protagonist s shares are down 57 9  so far this year  underperforming the  s decline of 5 9  in that period The discontinuation decision was based on a planned interim analysis of PROPEL study by an independent Data Monitoring Committee  The committee deemed that the study will not be able to achieve its primary endpoint of clinical remission  The interim analysis was done on data from first 65 patients who had completed the 12 week treatment with PTG 100  The total patient population of the study was 240 However  the company is conducting an extensive review of the data from the study  It has notified that it will stop further treatment of patients currently in the study Protagonist has also postponed its decision to initiate a phase II III on PTG 100 in patients with chronic pouchitis  as it awaits full review of the interim data from the PROPEL study Apart from PTG 100  the company is developing two candidates   PTG 200 and PTG 300   in two separate phase I studies for the treatment of Crohn s disease and beta thalassemia  respectively The company has a worldwide license and collaboration agreement with Johnson   Johnson   NYSE JNJ   for the development of PTG 200  Moreover  PTG 300 enjoys orphan drug designation in the United States Protagonist Therapeutics  Inc  Price
    Zacks Rank   Other Stocks to ConsiderProtagonist currently sports a Zacks Rank  1  Strong Buy  Some other top ranked stocks in the health care sector include Horizon Pharma Public Limited Company   NASDAQ HZNP   and Ligand Pharmaceuticals Incorporated   NASDAQ LGND    Both the stocks carry a Zacks Rank  2  Buy   You can see  Horizon Pharma s earnings estimates increased 10  to  1 43 for 2018 and 15  to  1 77 for 2019 over the last 30 days  The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 68 92  Ligand s earnings per share estimates increased 11  to  4 20 for 2018 and 12  to  5 32 for 2019 over the last 30 days  The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 24 88   The company s shares have increased 23  so far this year Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-03-26,Zacks Investment Research,https://www.investing.com/analysis/protagonist-therapeutics-stalls-ulcerative-colitis-study-200301128,200301128
198587,420103,JNJ,Why Is Integra LifeSciences  IART  Up 3 6  Since Its Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Integra LifeSciences Holdings Corporation   NASDAQ IART    Shares have added about 3 6  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is IART due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts 
Recent EarningsIntegra LifeSciences Holdings reported adjusted earnings per share  EPS  of 64 cents in the fourth quarter of 2017  up 23 1  from the year ago figure Adjusted EPS surpassed the Zacks Consensus Estimate of 57 cents by 12 2  Full year adjusted earnings came in at  1 94  reflecting increase of 10 23  from the year ago quarter  Full year adjusted EPS also surpassed the Zacks Consensus Estimate of  1 86 by 4 3  Revenue DiscussionTotal revenues in the reported quarter increased 44 2  year over year to  368 6 million  which surpassed the Zacks Consensus Estimate of  364 9 million  Excluding revenues from acquisitions  discontinued products and the effect of currency exchange rates  organic revenues rose 5 8  year over year Full year revenues came in at  1 19 billion  reflecting an increase of 19 8   The figure also surpassed the Zacks Consensus Estimate of  1 17 billion The solid revenue growth was primarily driven by high organic revenues and better than expected performance by both the recently acquired businesses   Johnson   Johnson  NYSE JNJ  Codman Neurosurgery business and Derma Sciences Coming to product categories  revenues from the company s Codman Specialty Surgical segment increased 46 2  to  239 4 million Orthopedics and Tissue Technologies revenues came in at  129 2 million in the fourth quarter  up 40 6  year over year Margin TrendAdjusted gross margin contracted 679 basis points  bps  to 59 8  in the reported quarter  Selling  general and administrative expenses increased 70  to  190 6 million in the reported quarter  while research and development expenses rose 23 6  to  17 2 million  Accordingly  adjusted operating margin saw a 1388 bps contraction to 3 4  in the fourth quarter Financial PositionIntegra LifeSciences exited 2017 with cash and cash equivalents of  174 9 million  up from  102 1 million recorded at the end of 2016  Full year 2017 cash flow from operating activities was  114 5 million  down from  116 4 million in the year ago period 2018 OutlookThe company now expects full year 2018 revenue guidance at the high end of the range of  1 46  1 48 billion  on the back of more favorable foreign currency rates  The Zacks Consensus Estimate for full year 2018 revenues is  1 48 billion  at the high end of the guided range The company expects adjusted earnings per diluted share to be at the high end of its previously provided range of  2 25  2 35  The Zacks Consensus Estimate for 2018 adjusted earnings is pegged at  2 30  within the company s guided range For full year 2018  the company reiterated adjusted gross margin at the band of 68  to 69  For the first quarter of 2018  the company expects adjusted EPS in the range of 48   51 cents  representing about 25  growth year over year  The Zacks Consensus Estimate for first quarter 2018 adjusted EPS is pegged at 50 cents  within the company s guided range For the first quarter of 2018  the company expects total revenues in the range of  347  352 million  which includes about 2  organic growth  The Zacks Consensus Estimate is  351 4 million  within the guided range 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There has been one revision higher for the current quarter compared to two lower 
Integra LifeSciences Holdings Corporation Price and Consensus
    VGM Scores
At this time  IART has an average Growth Score of C  however its Momentum is doing a bit better with a B  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is more suitable for momentum investors than those looking for value and growth 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Notably  IART has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-03-28,Zacks Investment Research,https://www.investing.com/analysis/why-is-integra-lifesciences-iart-up-36-since-its-last-earnings-report-200301999,200301999
198588,420104,JNJ,AbbVie forges deeper into cancer  as clock ticks for Humira,news,"By Ransdell Pierson  Reuters     AbbVie Inc   NYSE ABBV  placed another big bet on new cancer drugs on Thursday with a  5 8 billion acquisition that could lessen its dependence on arthritis treatment Humira  the world s top selling drug  Shares of AbbVie rose 1 3 percent in afternoon trading   The suburban Chicago drugmaker said it would buy privately held Stemcentrx and its experimental treatment for small cell lung cancer  which accounts for about 10 percent to 15 percent of all lung cancers and is notoriously difficult to treat   It brings AbbVie into the broad and lucrative arena of solid tumors  such as lung cancer  breast cancer and colon cancer  AbbVie s current drugs  including leukemia treatment Imbruvica  focus on blood cancers  a smaller group of patients  Companies with innovative cancer drugs  especially ones that spur the immune system to attack tumors  are attractive takeover targets  These life extending new treatments can command extremely high prices that health insurers seem willing to pay for  unlike some other therapeutic categories where they are putting pressure on price   The mantra to reimbursement is innovation  and AbbVie is heading down the right path  by its widening focus on oncology  said John Boris  an analyst with Suntrust Robinson Humphrey  AbbVie last year bought Pharmacyclics Inc and its half ownership of Imbruvica for  21 billion  It sells the drug with Johnson   Johnson  NYSE JNJ    U S  rival Bristol Myers Squibb has been particularly successful with its oncology focus  It predicted on Thursday its earnings will jump as much as 29 percent this year  fueled by its new Opdivo treatment for melanoma and lung cancer  A similar new drug from Merck  NYSE MRK    Co also has a list price of  150 000  Also on Thursday  French drugmaker Sanofi  PA SASY  announced its  9 3 billion offer to buy Medivation  which makes prostate cancer treatment Xtandi  Stemcentrx s drug  called Rova T  is a toxic chemical that has been loaded onto an antibody  It targets a protein called DLL3 found in more than 80 percent of patients with the cancer  A biomarker is used to help select patients whose cancers express the protein  Late stage trials involving patients who have already failed to benefit from chemotherapy and radiation are under way and AbbVie expects the drug to be approved by 2018   Oncology is an important growth driver and an area we plan to build a leading portfolio   Michael Severino  AbbVie s chief scientific officer  said in an interview  But he said AbbVie will remain heavily involved in arthritis  psoriasis and other inflammatory diseases that are treated by Humira  which generates  14 billion in annual sales  AbbVie s quarterly earnings results on Thursday demonstrated its reliance on Humira  for which sales jumped 15 percent to  3 58 billion  accounting for 60 percent of company revenue  As sales of Humira rise by double digit percentages each year  investors are growing ever more fretful because its main U S  patent lapses in December  AbbVie says other patents will stave off introduction of cheaper biosimilar forms of Humira until at least 2022  AbbVie said it would pay about  2 billion in cash for Stemcentrx and fund the remainder with stock  Stemcentrx shareholders may also receive up to  4 billion in cash if certain performance milestones are achieved  AbbVie  which expects the deal to close in the second quarter  lowered its full year adjusted profit forecast to  4 62  4 82 per share  from its earlier view of  4 90  5 10  
It said the deal would be dilutive this year and for several years to come ",2016-04-28,Reuters,https://www.investing.com/news/stock-market-news/abbvie-to-buy-stemcentrx-in-$5.8-billion-deal-398562,398562
198589,420105,JNJ,Johnson   Johnson ordered to pay  55 million in talc powder trial,news,"By Jessica Dye NEW YORK  Reuters    Johnson   Johnson  N JNJ  was ordered by a U S  jury on Monday to pay  55 million to a woman who said that using the company s talc powder products for feminine hygiene caused her to develop ovarian cancer  The verdict is the second straight trial loss for the company  which is facing approximately 1 200 lawsuits accusing it of not adequately warning consumers about its talc based products  cancer risks  Following a three week trial in Missouri state court  jurors deliberated for about a day before returning a verdict in favor of plaintiff Gloria Ristesund   J J spokeswoman Carol Goodrich said the verdict contradicted 30 years of research supporting the safety of cosmetic talc  The company intends to appeal the jury s decision and will continue defending its products  safety  she said  Ristesund said she used J J s talc based powder products   which include the well known Baby Powder and Shower to Shower Powder   on her genitals for decades  According to her lawyers  she was diagnosed with ovarian cancer and had to undergo a hysterectomy and related surgeries   The verdict follows a  72 million jury award from the same court in February to the family of a woman who died from ovarian cancer after years of using talc powder for feminine hygiene   Plaintiffs in talc litigation  which is concentrated in Missouri and New Jersey state courts  have accused J J of failing for years to warn that talc was linked to an increased risk for ovarian cancer  J J has said that it acted properly in developing and marketing the products   
Reuters viewed the proceedings on Courtroom View Network ",2016-05-02,Reuters,https://www.investing.com/news/stock-market-news/johnson--amp;-johnson-hit-with-$55-million-verdict-in-talc-powder-trial-399393,399393
198590,420106,JNJ,Your Money  Money smart gifts for college grads,news,"By Caitlin Kelly NEW YORK  Reuters    For college graduates entering a challenging job market  some of whom are carrying tremendous student loan debt  any gift to help them better manage their money is both practical and welcome  The following are three ways to help recent graduates find their financial footing in the real world  1  Investing for the long haul When William Bauer  managing director of Royce  a New Jersey leather goods company  graduated from McGill University in 2014 and HEC Paris in 2015  his mother gave him 100 shares of Johnson   Johnson  NYSE JNJ  stock and 100 shares of Qualcomm  NASDAQ QCOM    It s nice to have money to fall back on for the inevitable rainy day   says Bauer  who liked the gift idea so much that he recently gave his brother stock upon college graduation  Jake Rheude s parents essentially gave him a forced savings plan  Rheude studied marketing at the University of Tennessee in Knoxville  driving a 2001 Audi A4 his parents loaned him  He paid the insurance on it to them every month  When Rheude graduated  his parents gave him access to a bank account where his monthly payments of  96 had been deposited and accumulating in a mutual fund account    Their gift to me was over  5 000  money that would have likely been spent on frivolous expenses had I not been required to make the payments   says Rheude  now director of business development and marketing for Red Stag Fulfillment  in Knoxville    It taught me an immense amount about the realities of living expenses  but also about the power of saving a relatively small amount   although some months it seemed like a huge amount   consistently  over the course of several years   he said  Cash gifts are another conduit to fiscal responsibility  For financial writer Scott Bowen  a gift of  1 000 from his father as he graduated from an MFA program was directed into a mutual fund account   That wasn t much money  but it got me focused on two essential habits  putting your own money away for the future and not thinking you can rely on a 401 k  or Social Security   Bowen says  adding that  you have to pay attention to the things that you invest in   you actually have to understand some things about the fund itself and its investment direction   2  Advice and guidance  On My Own Two Feet  A Modern Girl s Guide to Personal Finance   by personal finance experts Manisha Thakor and Sharon Kedar  tackles money basics like credit card debt and retirement planning  The lessons shared in the book are even more powerful when paired with frank  personal advice  Thakor says   Take the young person out to a restaurant of their choosing and share with them your best and worst financial decisions   advises Thakor  who is director of wealth strategies for women at The BAM Alliance   Answer their questions about money   Another book recommended by personal finance experts was written 90 years ago  but is still relevant today  Daniel L  Grote  a certified financial planner in Denver  received  The Richest Man in Babylon  by George S  Clason from his Uncle Jim    My mentor and the most financially successful person I know   notes Grote   It is an excellent  quick read  for anyone who wants to know how acquire solid personal finance skills  says Grote  who has since given the book as a gift many times  Booking a session with a financial planner or adviser is another smart move   When the advice comes from someone other than a parent  it tends to sink in more   says consumer credit expert and author Beverly Blair Harzog  Ask the planner to provide basic money advice  such as budgeting  avoiding debt and the importance of a healthy credit score  3  Launch a career Ashley Souza  associate director of relationship development for Centerpoint Advisors  LLC in Needham  Massachusetts  surprised and delighted her newly graduated cousin by giving her a boot camp with a career strategist   She found it priceless   receiving a professional resume  headshot  LinkedIn  NYSE LNKD  profile  mock interviews with professional contacts  and tips covering everything regarding meeting etiquette and wardrobe must haves  Souza also gave her cousin a  100 gift card to Banana Republic for some updated work clothes  
 The coaching really helped her gain confidence  and the interviewers were impressed with her updated resume when she arrived  as well as her poise   Souza says ",2016-05-09,Reuters,https://www.investing.com/news/stock-market-news/your-money:-money-smart-gifts-for-college-grads-400890,400890
198591,420107,JNJ,U S  sees first case of bacteria resistant to all antibiotics,news,"By Ransdell Pierson and Bill Berkrot  Reuters    U S  health officials on Thursday reported the first case in the country of a patient with an infection resistant to all known antibiotics  and expressed grave concern that the superbug could pose serious danger for routine infections if it spreads   We risk being in a post antibiotic world   said Thomas Frieden  director of the U S  Centers for Disease Control and Prevention  referring to the urinary tract infection of a 49 year old Pennsylvania woman who had not travelled within the prior five months  Frieden  speaking at a National Press Club luncheon in Washington  D C   said the infection was not controlled even by colistin  an antibiotic that is reserved for use against  nightmare bacteria   The infection was reported Thursday in a study appearing in Antimicrobial Agents and Chemotherapy  a publication of the American Society for Microbiology  It said the superbug itself had first been infected with a tiny piece of DNA called a plasmid  which passed along a gene called mcr 1 that confers resistance to colistin    This  heralds the emergence of truly pan drug resistant bacteria   said the study  which was conducted by the Walter Reed National Military Medical Center   To the best of our knowledge  this is the first report of mcr 1 in the USA   The patient visited a clinic on April 26 with symptoms of a urinary tract infection  according to the study  which did not describe her current condition  Authors of the study could not immediately be reached for comment  The study said continued surveillance to determine the true frequency of the gene in the United States is critical    It is dangerous and we would assume it can be spread quickly  even in a hospital environment if it is not well contained   said Dr  Gail Cassell  a microbiologist and senior lecturer at Harvard Medical School  But she said the potential speed of its spread will not be known until more is learned about how the Pennsylvania patient was infected  and how present the colistin resistant superbug is in the United States and globally   MEDICINE CABINET IS EMPTY FOR SOME  In the United States  antibiotic resistance has been blamed for at least 2 million illnesses and 23 000 deaths annually  The mcr 1 gene was found last year in people and pigs in China  raising alarm  The potential for the superbug to spread from animals to people is a major concern  Cassell said  For now  Cassell said people can best protect themselves from it and from other bacteria resistant to antibiotics by thoroughly washing their hands  washing fruits and vegetables thoroughly and preparing foods appropriately  Experts have warned since the 1990s that especially bad superbugs could be on the horizon  but few drugmakers have attempted to develop drugs against them   Frieden said the need for new antibiotics is one of the more urgent health problems  as bugs become more and more resistant to current treatments   The more we look at drug resistance  the more concerned we are   Frieden added   The medicine cabinet is empty for some patients  It is the end of the road for antibiotics unless we act urgently    Overprescribing of antibiotics by physicians and in hospitals and their extensive use in food livestock have contributed to the crisis  More than half of all hospitalized patients will get an antibiotic at some point during their stay  But studies have shown that 30 percent to 50 percent of antibiotics prescribed in hospitals are unnecessary or incorrect  contributing to antibiotic resistance   Many drugmakers have been reluctant to spend the money needed to develop new antibiotics  preferring to use their resources on medicines for cancer and rare diseases that command very high prices and lead to much larger profits   
In January  dozens of drugmakers and diagnostic companies  including  Pfizer   N PFE   Merck   Co  N MRK   Johnson   Johnson  N JNJ  and GlaxoSmithKline  L GSK   signed a declaration calling for new incentives from governments to support investment in development of medicines to fight drug resistant superbugs ",2016-05-26,Reuters,https://www.investing.com/news/world-news/u.s.-sees-first-case-of-bacteria-resistant-to-all-antibiotics-404835,404835
198592,420108,JNJ,G7 told to act on antibiotics as dreaded superbug hits U S ,news,"By Kylie MacLellan and Ben Hirschler ISE SHIMA  Japan LONDON  Reuters    Britain told the G7 industrial powers on Friday to do more to fight killer superbugs as the United States reported the first case in the country of a patient with bacteria resistant to a last resort antibiotic  U S  scientists said the infection in a 49 year old Pennsylvania woman  heralds the emergence of truly pan drug resistant bacteria  because it could not be controlled even by colistin  an antibiotic reserved for  nightmare  bugs  In Japan  British Prime Minister David Cameron said leading countries needed to tackle resistance by reducing the use of antibiotics and rewarding drug companies for developing new medicines   In too many cases antibiotics have stopped working  That means people are dying of simple infections or conditions like TB  tuberculosis   tetanus  sepsis  infections that should not mean a death sentence   he told a news conference at a summit in Japan   If we do nothing about this there will be a cumulative hit to the world economy of  100 trillion and it is potentially the end of modern medicine as we know it   A review commissioned by the British government and published last week said a reward of between  1 billion and  1 5 billion should be paid for any successful new antimicrobial medicine brought to market  If the problem is not brought under control  antimicrobial resistance could kill an extra 10 million people a year by 2050  the review warned  The U S  case is a further wake up call for the world  although it is not the first time that colistin resistance has appeared  Medics around were alarmed last year by the discovery in China of a new gene that makes bacteria highly resistant to the medicine  Since then  the deadly strain has also been detected in Europe and Canada  The development of colistin resistance is linked to the drug s widespread use in livestock and the European Medicines Agency on Thursday called for a 65 percent cut in the amount of the medicine used in farming   The more we look at drug resistance  the more concerned we are   Thomas Frieden  director of the U S  Centers for Disease Control and Prevention  told reporters in Washington   The medicine cabinet is empty for some patients  It is the end of the road for antibiotics unless we act urgently   The problem is aggravated by drugmakers  reluctance to invest in developing new antibiotics  preferring to focus on more profitable disease areas  although recently there has been some increase in investment  prompted by the superbug threat  
In January  83 companies  including  Pfizer   N PFE   Merck   Co  N MRK   Johnson   Johnson  N JNJ  and GlaxoSmithKline  L GSK   signed a declaration urging governments to support work on new antibiotics ",2016-05-27,Reuters,https://www.investing.com/news/stock-market-news/g7-told-to-act-on-antibiotics-as-dreaded-superbug-hits-u.s.-405031,405031
198593,420109,JNJ,Pharma Stock Roundup  ABBV s Elagolix Meets Study Goal  MRK s Keytruda In Focus,opinion,"This week was a relatively light one as far as developments in the pharma sector were concerned  The key highlights were priority review for Merck s   NYSE MRK   Keytruda for advanced cervical cancer  delay in final data from AstraZeneca s   NYSE AZN   key lung cancer study  success of AbbVie s   NYSE ABBV   another late stage study and breakthrough therapy designation for J J s   NYSE JNJ   cancer candidate Recap of the Week s Most Important StoriesAstraZeneca Delays Final Data from MYSTIC Study  The final overall survival data from AstraZeneca s pivotal phase III MYSTIC study on Imfinzi in the first line lung cancer indication has been delayed to the second half of this year  The data was previously expected to be presented in the first half of 2018  In July last year  the study failed to meet the primary endpoint of progression free survival   Read More   Merck s Keytruda Gets Priority Review for Another Indication  Merck s supplemental filing looking to expand the label of its anti PD 1 therapy  Keytruda  to treat advanced cervical cancer  has been accepted for priority review by the FDA  A decision is expected on Jun 28  This is the 14th regulatory submission for Keytruda accepted by the FDA   Read More   AbbVie Second Late Stage Study on Elagolix Meets Endpoints  AbbVie and Neurocrine Biosciences  second of the two pivotal phase III studies on pipeline candidate  elagolix met the primary endpoint  The ELARIS UF II study was evaluating elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids  Data from the study demonstrated that elagolix  in combination with low dose add back therapy  reduced heavy menstrual bleeding in 76 2  of women with uterine fibroids compared with 10 1  in placebo at month six   Read More   Top line data from the first study of elagolix in uterine fibroids was announced in February  This study also met the primary endpoint   Read More   J J s Cancer Candidate Gets Breakthrough Therapy Designation  J J s late stage pipeline candidate  erdafitinib gained breakthrough therapy designation from the FDA for the treatment of urothelial cancer  a type of bladder cancer   Read More   The NYSE ARCA Pharmaceutical Index was up a marginal 0 1  in the last five trading sessions Large Cap Pharmaceuticals Industry 5YR   Return
 Here is how the seven major stocks performed 
While Merck emerged as the biggest gainer  1 8   in the last five trading sessions  Glaxo s   NYSE GSK   shares declined the most  1 6   In the last six months  while AstraZeneca has gained 7 2   Merck declined 14 8   See the last pharma stock roundup here   What s Next in the Pharma World Watch out for regulatory and pipeline news from pharma stocks The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2018-03-15,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-abbvs-elagolix-meets-study-goal-mrks-keytruda-in-focus-200298714,200298714
198594,420110,JNJ,Trump s jobs homecoming a long shot even in manufacturing hot spots ,news,"By Howard Schneider JACKSONVILLE  Fla  Reuters    When U S  manufacturing employment peaked  Jimmy Carter was president  inflation was 11 percent  and craftsmen at Frontier Contact Lenses made the company s products one at a time on diamond tipped lathes  As presidential candidates promise to reclaim jobs lost in the intervening decades  they might want to visit the company now  Bought by Johnson   Johnson  N JNJ  in 1981  the fully automated factory allows four workers to produce in a 12 hour shift what more labor intensive methods produced in a year  The Jacksonville plant and one in Ireland make 4 billion soft contacts a year  and between the robots and lasers and computer algorithms no worker touches the product from the start of the process through final packaging   I don t think you could even make 4 billion lenses  using the old method  said David Turner  vice president of research and development for Johnson   Johnson Vision Care  Inc   You d need a guy with a lathe in every town   Since peaking at 19 5 million in 1979  the number of U S  manufacturing jobs has fallen 37 percent to around 12 2 million as of March  or just over 10 percent of the private sector workforce   Graphic    That may be as good as it gets  Despite the promises made on the campaign trail by Republican frontrunner Donald Trump and other candidates  the next president will find it hard to raise manufacturing s share of a U S  labor force that keeps shifting toward services  While much of the jobs debate has centered on trade pacts that Democrats and Republicans have backed over the last quarter century  both successful and struggling companies and sectors offer evidence of long term trends that neither sharp trade negotiators nor aggressive political leaders can easily reverse  Even critics of trade deals acknowledge that labor intensive industries  such as textiles  which once employed hundreds of thousands of less skilled workers  are probably gone for good  Technology continues to diminish the share of labor in production and its spread around the world has made other nations   notably China  but also Korea  Brazil  Mexico and former Soviet bloc countries   competitive both as exporters and in their own markets  Investment worldwide is drifting steadily toward services  according to the United Nations Conference on Trade and Development  and Americans are spending relatively less of their income on manufactured goods   A Reuters analysis of federal data for 1 267 categories of goods shows that the United States has been running a trade deficit in more than 500 of them since at least 1992   before the North American Free Trade Agreement came into force or China joined the World Trade Organization  events often cited as turning points for U S  manufacturing  Since the 2007 2009 recession manufacturing has added about 800 000 jobs  but that has lagged overall job growth  As a result manufacturing s share of private employment has continued to fall  from about 11 percent since the recession ended   The move toward a more global market hurts the marginal  low skilled worker  but it was inevitable and you cannot roll it back   said Brookings Institution senior fellow Barry Bosworth  At CareerSource Northeast Florida  a job development group  President Bruce Ferguson  Jr  said by necessity he focused on finding a  path  for entry level service sector employees to move up a career ladder  because services are where the growth is    The raw  manufacturing  numbers don t look anything like the service sector and they never will   he said   VOTER ANGST AND PROMISES  A majority of 6 500 Americans surveyed in March as part of Reuters Ipsos 2016 campaign polling acknowledged that free trade brings lower prices  but also saw it as a drag on wages and jobs and an  important  issue for the next president to confront  Tapping such concerns  Trump has promised punitive tariffs to  bring back  jobs for those left behind in the current recovery  particularly the roughly two thirds of Americans without a college degree   Former Secretary of State Hillary Clinton switched gears as a candidate to oppose a major Pacific trade deal and promises billions in public support for manufacturing  Her Democratic rival Bernie Sanders calls for worker protection against what he considers unfair trade  while Republican Ted Cruz has focused on trimming government red tape  However  playing tough on trade carries some risks and there are limits to what trade talks and tariffs can accomplish  The U S  steel industry is a case in point  The American Iron and Steel Institute estimates around 12 000 jobs were lost to a recent jump in imports  mainly from China  It reckons those jobs could be recovered with steps  such as the anti dumping duties imposed by Washington late last year  That pales  however  in comparison with more than 200 000 jobs that the sector has lost since the early 1980s  some because of imports  but some because the amount of labor needed to produce a ton of steel has fallen from 10 hours to less than two    There has been a short term loss that is definitely attributable to imports  while a longer term trend reflects technological innovation   said Kevin Dempsey  the institute s senior vice president   Such dynamic is not limited to old industries like steel  Florida is home to successful manufacturers big and small in a wide range of sectors  which export nearly half of their output   double the national average  Yet  as is the case nationally  the share of jobs available to those with a high school degree has been shrinking since 2000  according to federal data  and wages have been stagnant  Johnson   Johnson Vision Care s recent approval of a  300 million expansion  which added some 100 jobs  cements the company s U S  presence  but also shows how technology and innovation reshape the landscape  The company s local workforce has risen to around 1 700  but about 60 percent of that are white collar and non manufacturing jobs   from research positions for PhD scientists to those in sales and a highly automated shipping operation  Florida development officials say the trend is clear  manufacturers keep cutting the labor content of their products and each round of investment tends to drive up the skill levels that workers need  That may benefit the state s economy  but acts as a reality check for workers who hope that the November 8 presidential vote can reverse decades old trends  
 How do you evaluate a company that says we will spend a lot of money and make the workforce more qualified but not create many jobs   said Aaron Bowman  senior vice president for business development at JAXUSA Partnership  a regional economic development agency and division of the local chamber of commerce   Over time you see more projects that bring in fewer jobs but a bigger bang  ",2016-04-14,Reuters,https://www.investing.com/news/stock-market-news/trump's-jobs-homecoming-a-long-shot-even-in-manufacturing-hot-spots-395369,395369
198595,420111,JNJ,Investors find safety in J J shares  but run could stall ,news,"By Lewis Krauskopf NEW YORK  Reuters    After lagging a six year healthcare sector run fueled by fast growing biotech companies  Johnson   Johnson  N JNJ  shares have beaten the group in 2016 as investors turn to safety in rocky equity markets  But with the stock price now hovering near its  110 35 record high  that strategy may be in doubt  J J shares already have risen to the level that the average analyst has targeted for them  and sell at a healthy premium to large pharmaceutical companies such as  Pfizer   N PFE  and Merck  N MRK   Relative to their own future earnings  the shares are more expensive than they have been in more than a year   What I am more concerned at this juncture is  do we see more follow through or do we see profit taking   said Arthur Henderson  portfolio manager of the global healthcare equity fund at the Tennessee Consolidated Retirement System  where he has recently sold some J J shares so they account for a smaller part of the fund s holdings  J J shares could build on their gains if investors rekindle worries about the broader economy or continue to hide from concerns facing the pharmaceutical and biotech industries  and some analysts are optimistic about the company s pipeline of experimental medicines  But  ultimately  the company will have to produce enough earnings growth to justify the higher prices  On that front  the company faces a fresh competitive threat to its biggest drug franchise  U S  regulators earlier this month approved a rival version of the company s Remicade treatment for conditions such as rheumatoid arthritis  J J s first quarter report  due on April 19  is expected to show earnings up 6 percent over the same quarter a year ago  on a 0 6 percent increase in sales  according to Thomson Reuters data  Wall Street analysts are predicting fairly consistent annual earnings growth between 5 percent to 6 percent over the next few years  In January  the company projected that its calendar year 2016 profits would ultimately be up 5 percent to 8 percent over 2015 and it would aim to significantly increase its operating margins   Most pharmaceutical companies have cut fat over the past years and my sense is what it implies is they can cut some extra fat   said Tony Butler  analyst at Guggenheim Securities  J J s product diversity makes it more immune than other drug stocks to political pressures on the cost of medicines  The company s pharmaceutical unit accounted for 45 percent of its  70 billion in sales last year  with medical devices totaling more than a third and over the counter medicines and other consumer products making up the rest  The shares are up 7 percent in 2016 against a 3 percent decline for the S P healthcare sector  SPXHC   The company s shares had underperformed the sector every year dating back to 2009 as J J also grappled with a slew of product recalls and manufacturing setbacks for its consumer division  At 16 6 times estimated earnings over the next 12 months  the stock is still slightly cheaper than the valuation for the overall S P 500  SPX   Investors also are drawn to J J s 2 7 percent dividend yield  which nonetheless lags Merck and Pfizer  which both yield more than 3 percent  
 People right now are paying up quite a bit for that safety piece of it   said Morningstar analyst Damien Conover  who puts fair value for the shares at  102   I think it s overvalued  but I do think there are characteristics in the economy and political landscape that bode well for J J  ",2016-04-14,Reuters,"https://www.investing.com/news/stock-market-news/investors-find-safety-in-j-amp;j-shares,-but-run-could-stall-395498",395498
198596,420112,JNJ,J J shares hit new high on strong drug sales  weaker dollar,news,"By Ransdell Pierson  Reuters    Johnson   Johnson  N JNJ  beat quarterly earnings forecasts on strong prescription drug revenue and a weakening dollar  and it reassured investors that it did not expect its blockbuster Remicade arthritis drug to face U S  competition this year   The company also said on Tuesday that it remained on track to boost profit margins significantly this year  in part from cost cuts   In a possibly encouraging signal for other drugmakers that will be reporting results in coming weeks  J J said the strong dollar took a 3 3 percent bite out of global sales in the first quarter   half the impact in the prior period   as the currency s value eased somewhat  J J shares rose as much as 2 7 percent to an all time high of  113 95  The ARCA Pharmaceutical Index  DRG  of large drugmakers was up 0 6 percent  outpacing slight gains for the broad stock market   Until this year  J J shares had underperformed the healthcare sector every year since 2009 as the company grappled with patent expirations on important drugs and a slew of product recalls and manufacturing setbacks for its consumer division  But J J has recently introduced a number of fast growing medicines  Pharmaceutical sales rose 5 9 percent to  8 2 billion in the first quarter  with increased demand for the Imbruvica cancer drug and Invokana diabetes treatment  Sales of Remicade  J J s biggest product  jumped 11 2 percent to  1 78 billion  But investors have been concerned it could be hurt by Inflectra  a cheaper version developed by South Korea s Celltrion Inc  068270 KQ  in partnership with  Pfizer  Inc  N PFE   U S  regulators approved Inflectra earlier this month  but a continuing patent battle between J J and Celltrion has delayed its introduction   J J Chief Financial Officer Dominic Caruso said on Tuesday that strong patents should shield Remicade from biosimilar competition in 2016 and potentially for years to come  The company is upgrading plants that make its consumer medicines  including Tylenol  to address longstanding quality control problems   J J is also restructuring its struggling medical device business to focus on areas like artificial knees and devices for trauma surgery  Medical device sales slipped 2 4 percent to  6 1 billion in the quarter  while sales of consumer products fell 5 8 percent to  3 2 billion   Total sales rose 0 6 percent to  17 48 billion  matching the analysts  average estimate compiled by Thomson Reuters I B E S  Net earnings fell to  4 29 billion  or  1 54 per share  from  4 32 billion  or  1 53 per share  a year earlier  Excluding special items  J J earned  1 68 per share  topping Wall Street expectations of  1 65   Overall it was a pretty solid quarter  with J J beating earnings estimates and delivering on sales   said Edward Jones analyst Ashtyn Evans   
J J said that based on current exchange rates  it expected sales of  71 2 billion to  71 9 billion in 2016  up from its January forecast of  70 8 billion to  71 5 billion  It raised its earnings outlook to between  6 53 and  6 68 a share from a prior range of  6 43 to  6 58 ",2016-04-19,Reuters,https://www.investing.com/news/stock-market-news/j-amp;j-first-quarter-sales-rise-marginally-396384,396384
198597,420113,JNJ,Mexico explores regulating opium to fight drug violence,news,"By Gabriel Stargardter MEXICO CITY  Reuters    Mexico s government has explored regulating poppy production to make pharmaceutical opiates like morphine in an effort to weaken heroin smuggling gangs  according to two sources with knowledge of the government s thinking   Amid a government review of drugs policy  Interior Minister Miguel Angel Osorio Chong asked policy experts late last year whether Mexico could win authorization from the International Narcotics Control Board  INCB   a United Nations body  to grow and export opium poppies for painkillers   It s a legitimate question   said one of the sources with direct knowledge of the talks  who was not authorized to speak publicly   States have to ask themselves questions and have to discuss their policies   It is not clear how seriously the government is considering the regulation of poppy production and it has not yet approached the INCB directly but the discussion illustrates how concerned it is about heroin related violence  Mexico s interior ministry did not respond to a request for comment  On Thursday  Pena Nieto proposed legalizing marijuana based medicines  substantially raising the amount of pot that users can carry and freeing inmates on minor marijuana charges  With its shift  Mexico has joined a growing group of Latin American countries openly questioning the prohibitionist policies at the heart of the war on drugs   The terms of the drugs debate are changing in Mexico and the rest of the world   Pena Nieto said   Pena Nieto made no mention of poppy regulation on Thursday  but in a speech on drugs at the U N  General Assembly this week he said   we should create productive alternatives in those areas where drugs are grown    A heroin epidemic has killed tens of thousands of people in the United States in recent years and led to a surge in demand for Mexican heroin   Regulating poppy production would in theory make it more difficult for Mexico s drug gangs to produce heroin  although some drug experts say Mexico s unique mix of extreme gang violence and weak institutions render the idea a non starter   More than 100 000 people have died in drug related violence in Mexico in the last decade  Last month  Mexican news magazine Proceso reported on a government study examining the legalization of opium for medicinal uses as a way to lower violence  The governor of the southwestern state of Guerrero  which has been ravaged by drug violence  has also floated the idea  Click here for a graphic on opium poppy cultivation and murder rates in Mexico   Stefano Berterame  the INCB chief  said Mexico has not made contact over authorizing its opium crop for export  a prerequisite for major pharmaceutical buyers like Johnson   Johnson  NYSE JNJ   He said the INCB would likely refuse any request because there is a global surplus of pharmaceutical opiates  resulting in low prices  The INCB frowns on opiate gluts because they can easily be diverted into the illegal market   Mexico could proceed without the INCB s blessing  as Portugal has previously done  to produce painkillers for its domestic market but it would struggle to offer poppy growers higher prices for their crop than those offered by drug cartels  Peter Reuter  a drugs expert at the University of Maryland  said regulation would provide farmers with two markets  one legal and the other illegal  encouraging them to grow even more  There is one precedent that could support the idea  Under pressure from the United States  Turkey managed to destroy its illegal poppy trade in the 1970s by regulating production to make opium based medicines   Turkey is indeed the poster child for this kind of policy   said Reuter   It was a major producer for the illegal market and then converted entirely to the legal market   
However  he said Mexico s violent gangs  corrupt police forces and weak judicial system make it more comparable to Afghanistan  where attempts at poppy regulation never got off the ground  than Turkey ",2016-04-22,Reuters,https://www.investing.com/news/world-news/mexico-explores-regulating-opium-to-fight-drug-violence-397340,397340
198598,420114,JNJ,Why Is Johnson   Johnson  JNJ  Down 8 5  Since Its Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Johnson   Johnson   NYSE JNJ    Shares have lost about 8 5  in that time frame  underperforming the market 
Will the recent negative trend continue leading up to its next earnings release  or is JNJ due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers J J Beats on Q4 Earnings  Misses Sales  Issues 2018 OutlookJ J s fourth quarter 2017 earnings came in at  1 74 per share  beating the Zacks Consensus Estimate of  1 72 and increasing 10 1  from the year ago period  Higher sales  higher net other income and a lower tax rate made up for higher operating costs in the quarter Adjusted earnings excluded amortization expense and some special items  which included a charge of approximately  13 6 billion related to the recent tax law changes  Including these items  J J reported fourth quarter net loss of  3 99 per share versus earnings of  1 38 per share in the year ago period Sales came in at  20 20 billion  slightly missing the Zacks Consensus Estimate of  20 22 billion  Nonetheless  sales increased 11 5  from the year ago quarter  reflecting an operational increase of 9 4  and a positive currency impact of 2 1   Organically  excluding the impact of acquisitions and divestitures  sales increased 4 2  on an operational basis  better than 3 8  seen in the third quarter and 2 4  in the first half As expected  J J s sales growth accelerated in the second half backed by higher sales in the pharmaceutical segment and improving performance in Medical Devices Fourth quarter sales grew 9 8  in the United States to  10 47 billion and 13 5  in international markets to  9 73 billion  reflecting 9  operational growth as currency favorably impacted reported international sales growth by 4 5  Segment DetailsPharmaceutical segment sales rose 17 6  year over year to  9 7 billion  reflecting 15 5  operational growth and 2 1  positive currency impact as sales rose in both domestic and international markets Sales in the domestic market rose 15 5  to  5 78 billion while international sales grew 20 9  to  3 91 billion  operational increase of 15 5   New products like Imbruvica and Darzalex continued to perform well  Other growth drivers were core products like Xarelto  Stelara  Zytiga and Invega Sustenna Organically  excluding the impact of acquisitions and divestitures  sales increased 7 6  on an operational basis outperforming the 6 7  growth seen in the third quarter Imbruvica sales rose 50 9  to  522 million in the quarter driven largely by higher market share and market growth across several indications in the Unites States and strong uptake outside Unites States Stelara sales rose 23  to  1 08 billion in the quarter  Stelara gained market share in the quarter driven by share gains in the psoriasis market as well as in the newer Crohn s disease market  Simponi   Simponi Aria sales rose 15  to  490 million in the quarterDarzalex sales rose 85 5  to  371 million in the quarter  Darzalex enjoyed strong uptake in outside U S  markets and accelerated adoption in the United States across all lines of therapy Xarelto sales rose 18 7  to  710 million in the quarter backed by increasing market share Zytiga sales rose 45 5  to  755 million in the quarter due to improved market share in a growing metastatic castration resistant prostate cancer market  Invega Sustenna sales rose 18 5  to  693 million In the quarter  J J recorded pulmonary arterial hypertension  PAH  revenues of  610 million  less than  670 million in the third quarter  Strong demand for Uptravi and Opsumit was partially offset by the expected decline of Tracleer outside the United States due to generic competition and the transition of patient assistance foundations  The Actelion acquisition added 4 2  to sales growth in 2017 Invokana Invokamet sales declined 28  to  267 million due to increasing discounts for managed care contracting and loss of market share Sales of Remicade declined 9 7  to  1 47 billion in the quarter with U S  sales declining 8 5   Meanwhile  international sales declined 18 7  due to biosimilar competition Regarding newly launched Tremfya  J J said that the uptake of the product has been decent and it recorded sales of  47 million in the fourth quarter Medical Devices segment sales came in at  6 97 billion  up 8 3  from the year ago period  It included an operational increase of 6 5  and positive currency movement of 1 8  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 2  Operational growth was driven by continued strong performance in Vision Care and Cardiovascular as well as improving growth in surgery  which made up for a weaker sales performance in the Diabetes Care unit Domestic market sales rose 5 3  year over year to  3 31 billion  International market sales increased 11 1   operational increase of 7 5   year over year to  3 66 billion The Consumer segment recorded revenues of  3 54 billion in the reported quarter  up 3 1  year over year  operational increase of 0 4    Foreign currency movement positively impacted sales in the segment by 2 7   Excluding the impact of acquisitions and divestitures  adjusted operational sales growth was 0 2  worldwide  Slower growth in domestic baby care products due to competitive pressure was offset by growth in beauty and over the counter products Sales in the domestic market declined 0 6  from the year ago period to  1 38 billion Meanwhile  the international segment recorded an increase of 5 7  to  2 16 billion  reflecting an operational increase of 1 2  and a positive currency impact of 4 5  Margins DiscussionCost of goods sold  as a percentage of sales  declined 80 basis points mostly due to favorable product mix  Selling  marketing and administrative expenses were up 50 bps year over year to 29 8  of sales due to investment behind new products  Research and Development costs  as a percentage of sales  rose 340 bps over the prior year quarter to 18  2017 ResultsFull year 2017 sales rose 6 3  to  76 5 billion  falling slightly short of the Zacks Consensus Estimate of  76 8 billion  Operationally  sales rose 6  in the year  which was in line with the upper end of the guided range of 5 5 Adjusted earnings for 2017 were  7 30 per share  above the Zacks Consensus Estimate of  7 28 and up 8 5  year over year  Earnings were at the higher end of the guidance range of  7 25    7 30 per share 2018 Outlook IssuedJ J issued a mixed guidance for 2018 wherein the earnings range was above the consensus estimate while sales fell slightly short of the same J J expects 2018 adjusted earnings per share in the range of  8 00    8 20  reflecting an operational growth rate between 6 8  and 9 6   The company s guidance exceeded the then Zacks Consensus Estimate of  7 86 per share  Currency fluctuations are expected to favorably impact earnings per share by 20 cents It expects revenues in the range of  80 6 billion to  81 4 billion  reflecting operational constant currency sales growth rate in the range of 3 5  to 4 5   However  the sales guidance fell slightly short of the then Zacks Consensus Estimate of  81 55 billion  Organic sales growth  excluding the impact of acquisitions and divestitures  is expected to be in the range of 2 5  3 5  which  though slightly higher than 2 4  seen in 2017  fell short of 4 2  in the fourth quarter  Currency fluctuations are expected to favorably impact sales by 200 basis points In 2018  J J expects the Pharmaceutical segment to remain strong while the Consumer and Medical Device segments will continue to improve  We believe that new products in all segments  label expansion of drugs like Imbruvica and Darzalex and contribution from acquisitions  mainly Actelion  will support top line growth Adjusted pre tax operating margins are expected to increase by approximately 100 basis points in 2018 despite expectations for increased R D investments  The company said that since tax rates on U S  earnings will be lower in 2018  it will allow increased investment in R D Adjusted tax rate guidance is in the range of 16 5 The company does not expect any biosimilar entrants for Zytiga  Prezista  Risperdal Consta  or Invega Sustenna in the United States in 2018  However  the company is confident that it can absorb the impact of any potential Zytiga headwind should there be an earlier than expected generics launch in 2018 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  There have been two revisions higher for the current quarter  While looking back an additional 30 days  we can see even more upward momentum  There has been three moves up in the last two months Johnson   Johnson Price and Consensus   VGM Scores
At this time  JNJ has a nice Growth Score of B  however its Momentum is doing a bit better with an A  Charting a somewhat similar path  the stock was  allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is more suitable for momentum investors than those looking for value and growth 
Outlook
Estimates have been trending upward for the stock and the magnitude of these revisions looks promising  Interestingly  JNJ has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-02-21,Zacks Investment Research,https://www.investing.com/analysis/why-is-johnson--johnson-jnj-down-85-since-its-last-earnings-report-200293035,200293035
198599,420115,JNJ,S P 500 Makes Key Reversal  Yen Breaks Through The Neckline,opinion,"VIX expanded its retracement to 83 8  in the three week period since its high What seems to be missed is the daily key reversal that has put the VIX back on a buy signal  The next Cycle Top may occur in the next 2 3 weeks 
   wo months ago  we detailed what the current Fed Chair  then a mere mortal  Jay Powell said during the October 23 24  2012 FOMC meeting   just one month after the Fed announced QE3  as exposed by recently released FOMC transcripts 

  W hen it is time for us to sell  or even to stop buying  the response could be quite strong  there is every reason to expect a strong response  So there are a couple of ways to look at it  It is about  1 2 trillion in sales  you take 60 months  you get about  20 billion a month  That is a very doable thing  it sounds like  in a market where the norm by the middle of next year is  80 billion a month  Another way to look at it  though  is that it s not so much the sale  the duration  it s also unloading our short volatility position 

SPX also makes a weekly key reversal 

SPX made a wide ranging pattern known as a key reversal  It closed beneath the upper long term trendline at 2726 01andthe prior week low Should the lower short term trendline at 2675 00 be broken  Long term support at 2569 73 may be tested  The fractal model suggests that the first test of the lows may bounce at Long term support without breaking the low  but there may be multiple tests of that support 
   U S  stocks closed well off session lows on Friday  helped by a sharp rise in health care shares 
The S P 500 ended 0 5 percent higher at 2 691 25 after falling more than 1 percent  Health care sector was the best performing sector  gaining 1 percent  Shares of Universal Health Services and Perrigo were among the best performers in the index 
The Nasdaq composite rose 1 1 percent to 7 257 87 as the iShares Nasdaq Biotechnology  NASDAQ IBB advanced 2 4 percent  At its low  the Nasdaq fell as much as 1 3 percent 
The Dow Jones industrial average closed 70 92 points lower at 24 538 06 after falling as much as 391 points  Johnson   Johnson  NYSE JNJ  and Merck  NYSE MRK  were among one of the best performing stocks in the index  rising 1 2 percent each 
NDX also has a volatile week 

The NDXalso had a wide ranging week  but did not close beneath the prior week low  However  the test of the upper trendline of the two year channel failed This implies a retest of the February 9 low The Fractal Model also suggests that Long term support at 6280 96 may be tested again  
   As the recent swoon in the S P showed  the lasting pain from the February vol unwind has combined with multiple policy shocks to weigh on markets 
However  while the early Feb swoon was largely the result of the  Quant Quake   the transmission mechanism in this move lower is no longer systematic funds   vol target strategies  according to Morgan Stanley  NYSE MS  s Chris Metli  Instead  the MS executive director notes that this time selling has come from more fundamental discretionary investors   the MS PB Content team has noted that there were multiple large sell days from L S HFs this week  versus buying the week of Feb 5th     exacerbated by a lack of liquidity 
Here the lack of liquidity is important 
High Yield Bond Index swings between support and resistance 

The High Yield Bond Index rallied to Intermediate term resistance at 193 35  then sold off to the trendline at 184 00 The sell signal remains and the Cycles Model suggests that Long term support at 181 05 may be broken this week 
   There s something funny in the high yield bond market  and even Martin Fridson isn t quite sure what it means though he does believe the junk bond market has enjoyed a false tranquility for the past 30 years 
Fridson  whom Institutional Investor calls  the dean of high yield bond analysts   was combing through price data with his researchers  Kai Zhao and Yaxian Li  They were studying the magnitude of price movements in government bonds  investment grade corporate bonds  and high yield bonds  from 1987 to 2017 and something stood out 
Price swings should fall along a normal distribution  But it turns out the bell curve in high yield bonds is messed up 
UST closes beneath the Cycle Bottom resistance 

The 10 year Treasury Note Indexcontinued its bounce off the Master Cycle low  but may be running out of time to continue higher The normal  target for this bounce is usually a retest of the Head   Shoulders neckline near 122 75 However  the Model shows weakness that may turn into a rout for bonds within the next week  suggesting that Short term resistance at 121 27 may prove fatal to the rally 
   Investors sold Treasurys on Friday as anxiety about an international trade war percolated global markets 
The yield on the 10 year Treasury note rose to 2 855   from 2 802  on Thursday  Yields rise as bond prices fall 
Bond and stock prices remained volatile Friday as investors grappled with new uncertainty regarding trade policy  President Donald Trump s pledge to impose tariffs on steel and aluminum imports was met with threats and angry responses from U S  allies around the world 
The Euro tests the rising trendline 

The Eurotested the rising trendline then bounced back above its Cycle Top at 122 94  A violation of the trendline may issue a sell signal for the Euro  The Cycle Model suggests abject weakness over the next two weeks  implying that the trendline may be broken sooner than later 
 Reuters    Germany s 10 year government bond yield hit a five week low on Friday  as an Italian election and a milestone in German coalition politics this Sunday together with worries about a global trade war boosted demand for safe haven debt 
Italian bond yields fell to a three week low  pushing the gap over German peers to its tightest in two weeks and suggesting some confidence among investors heading into Sunday s election 
U S  President Donald Trump on Thursday announced plans for hefty tariffs on imported steel and aluminum to protect U S  producers  That stoked concerns about a trade war  rattling stock markets and pushing U S  and European bond yields down 
Euro Stoxx make a key reversal 

The Euro Stoxx 50 Indexmade a key reversal by rallying to a new weekly high  then declining and closing beneath the prior weekly low  European stocks remain on a sell signal The Cycles Model suggests the decline may continue through the third week of March 
   A global stock market slide triggered by President Trump s tariff announcements on Thursday has spread into Europe on Friday morning  with all the continent s major bourses dropping substantially after the president said that  trade wars are good 

 When a country  USA  is losing many billions of dollars on trade with virtually every country it does business with  trade wars are good  and easy to win  Example  when we are down  100 billion with a certain country and they get cute  don t trade anymore we win big  It s easy    he tweeted 

On Thursday  Trump promised new tariffs   taxes on imports   of 25  for steel and 10  for aluminum  The president did not specify whether any countries would be exempt  but the restrictions are expected to be wide ranging 
The Yen breaks through the neckline 

The Yen broke broke through the Head   Shoulders neckline  activating that chart formation This solidifies the rising trend through early to mid March  During that time  the Cycle Top resistance may be challenged 
   President Donald Trump is touting the virtues of a trade war  In the  5 1 trillion a day currency market  the yen has emerged as a clear winner from the escalating rhetoric 
The latest move pushes forward the administration s trade agenda  after it took similar actions on other goods this year and jawboned the dollar lower  The potential hit to U S  and global growth from protectionism has sent stocks lower  initially drove bonds higher and buoyed the yen  Investors and strategists are wagering there s more of the same to come 
The unfolding events remind Chris Turner  global head of currency strategy at IING Groep NV  of the early 1990s when the U S  took protectionist steps against Japan 
Nikkei makes a weekly key reversal 

The Nikkei made a weekly Key Reversal by testing Short and Intermediate term resistance at 22695 57  then dropping to test Long term support at 21192 88 Cyclical strength appears to have disappeared with a major low may be due in the next week or two  The two year trendline at 21750 00 has been violated and may be retested as the next decline is launched 
   The Nikkei 225 Stock Average s so called death cross    when the 25 day moving average drops below the 75 day moving average    suggests that the market s rebound from its 10 percent correction isn t going to extend  according to Toshio Sumitani  chief market analyst at Tokai Tokyo Research Institute Co  in Tokyo   The death cross is a bad signal for Japanese stocks   indicating that investors may be ready to sell at lower levels following any rebound  he said 
U S  Dollar falters

USDfaltered after rising above trendline and Cycle Bottom support at 89 29 TheCycles Model indicates a probable week of strength left in this rally  This suggests that the Broadening Top  Point 7  target near the weekly mid Cycle resistance at 96 11 may be in question 
     The U S  dollar could face headwinds if President Donald Trump s proposals to impose stiff tariffs on steel and aluminium imports are enacted  with the biggest risk stemming from the possible flight of capital flows needed to finance ballooning U S  deficits 
Currency markets  in general  dislike any form of trade intervention and previous protectionist efforts by the U S  government have resulted in dollar weakness 

 The U S  is now in a very precarious position because it s putting a risk premium on U S  assets by introducing tariffs and going down this protectionist route  which is negative for growth   said Mark McCormick  head of North American FX strategy at TD Securities in Toronto 

 Gold bounces on Intermediate term support 

Gold bounced on Intermediate term support at 1308 21 this week  The bounce may extend for another week  according to the Cycles Model However  the upside may be limited  while a larger decline appears to be waiting soon after 
 Reuters    Rising inflation has put gold back on the radar for investors looking to protect themselves from emerging price pressures  but history suggests its reputation has been overstated 
The experience of the last 50 years suggests gold performs better as a hedge against inflation shocks   like the spike caused by surging oil prices in the late 1970s and early 1980s   than the widely anticipated grind higher currently seen 

 If you strip out the 1970s  you find the relationship between gold and inflation is quite weak   Brian Lucey  professor of international finance at Trinity College Dublin  said  That is because you have a very different inflation regime in the late 1980s and 1990s than you had in the 1970s  

Crude rebuffed at Cycle Top resistance 

Crudechallenged its Broadening Wedge trendline and Cycle Top resistance at 63 81but was pushed back to Intermediate term support at 60 62 The Cycles Model suggests some volatile swings in crude over the next week  A break of the Intermediate term support  however  gives crude a sell signal 
   U S  oil production surged to an all time high in November  topping the previous record set nearly half a century ago  government data showed on Wednesday 
The nation s drillers pumped 10 057 million barrels a day in November  the U S  Energy Information Administration said in a monthly report  That edges out the previous record of 10 044 million barrels a day set in November 1970 
The record setting output comes after a revision to last month s report showing November s output leaped to 10 038 million barrels a day 
Shanghai Composite may have broken critical supports 

The Shanghai Index rallied Short and Intermediate term resistance at 3344 3355 70  but was rejected It has since declined beneath Long term support at 3286 53 and the two year trendline as well This may set up the Shanghai to retest the February low and possibly the Cycle Bottom at 2798 18 in the coming weeks ",2018-03-04,Anthony M. Cherniawski,https://www.investing.com/analysis/weekend-update-200295725,200295725
198601,420117,JNJ,Social media users concerned over J J talc powder after verdict,news,By Anjali Athavaley NEW YORK  Reuters    Consumers expressed concern on social media about a talc based baby powder made by Johnson   Johnson  N JNJ  on Wednesday after a Missouri jury ordered the company to pay  72 million in damages to the family of a woman who said her death from cancer was linked to use of the product   Johnson   Johnson  was a trending term on Twitter  N TWTR  on Wednesday morning  Social sentiment regarding the company declined on Wednesday to its lowest levels in the past year  according to a Thomson Reuters social media sentiment analysis index  J J shares were down 37 cents at  103 71 in early afternoon trading on the New York Stock Exchange  In a verdict announced late on Monday night  jurors in the circuit court of St  Louis awarded the family of Jacqueline Fox  10 million of actual damages and  62 million of punitive damages  according to the family s lawyers and court records  On Twitter  several users interpreted the verdict to mean there was a causal link between the talc used in J J s products and ovarian cancer  an argument made during the trial by the family s lawyers  Jenn   JennLA82  tweeted on Wednesday   So baby powder caused ovarian cancer   now Johnson   Johnson must pay 72 million  Congrats to those tireless lawyers  Also   scary   On Tuesday  a Johnson   Johnson spokeswoman  Carol Goodrich  said the company believes the safety of cosmetic talc is supported by decades of scientific evidence  Some Twitter users said they would stop using the product   DayZ   D Acevedo213  tweeted   If talc is dangerous why is it one of your main ingredients    JNJNews I m not using your baby powder in my son anymore   Not all were alarmed  Shivam M   Observer68   tweeted   After Johnson and Johnson s  I m waiting for all the women who eat pounds of lipsticks every year  to sue the respective cosmetics brands   Fox  who lived in Birmingham  Alabama  claimed she used the company s Baby Powder and Shower to Shower for feminine hygiene for more than 35 years before being diagnosed three years ago with ovarian cancer  She died in October at age 62  A J J spokesman did not respond immediately to a request for comment on Wednesday ,2016-02-24,Reuters,https://www.investing.com/news/technology-news/social-media-users-concerned-over-j-amp;j-talc-powder-after-verdict-386313,386313
198602,420118,JNJ,Big verdict doesn t assure more wins for plaintiffs in talc cancer cases,news,By Jessica Dye NEW YORK  Reuters    The  72 million verdict this week against Johnson   Johnson  N JNJ  in a U S  case alleging links between talc based powder and ovarian cancer has prompted global headlines  social media buzz and calls to lawyers from would be plaintiffs  But the attention grabbing judgment is no guarantee future plaintiffs will be able to convince juries the company s products caused their illnesses  About 1 200 similar cases are pending  primarily in Missouri and New Jersey state courts  but the facts are different in every one  And even in cases with similar evidence and expert testimony  juries in mass personal injury litigation can come to different conclusions   While the survivors of Jacqueline Fox were awarded  72 million by a St  Louis jury Monday  jurors in a federal court action in South Dakota   the only other talc case to go to trial   found in 2013 that J J had been negligent but declined to award damages to plaintiff Deane Berg  Like Fox  Berg alleged her ovarian cancer was caused by her decades long use of J J s talc powder products for feminine hygiene  and jurors in both cases heard testimony about studies linking talc to cancer risks   But  unlike Fox  who passed away several months before the trial began  Berg was in remission at the time of the trial  according to court documents  In addition to factual differences among cases  venue can affect outcomes  Some state courts are considered more plaintiff friendly than federal courts  which have stricter rules for the admission of evidence and expert testimony  said lawyers involved in the litigation   One juror in the Missouri case  Jerome Kendrick  said in an interview with Reuters that he and other jurors were especially swayed by testimony from plaintiffs  medical experts and documents showing J J employees discussing talc powder s possible cancer risk    The problem I had is that  according to inter office documents  J J was aware of the potential concerns   Kendrick said   And it really looked like instead of trying to investigate  they started talking about how to combat what would eventually be a court case   J J has said that  decades of sound science  prove that talc is safe  The company on Tuesday issued a statement expressing sympathy for Fox s family but disagreeing with the verdict  It also said it is exploring its post trial options   UNDER THE RADAR Talc litigation got its start in 2009  when Berg filed her lawsuit  The Fox lawsuit was selected by plaintiffs  lawyers as the first to go to trial in Missouri  to serve as an early bellwether of how similar cases in that venue might fare  The litigation flew largely under the public s radar until jurors returned the award for the family of Fox  who died in October at 62  The plaintiffs said Fox used J J Baby Powder and Shower to Shower Powder for feminine hygiene daily for 35 years before she was diagnosed three years ago with ovarian cancer   It has resonated with the public far more than the Berg case  which  didn t get headlines because they didn t award any damages   said R  Allen Smith  a Missouri based lawyer who represented both the Fox family and Berg   More cases may be filed soon  and lawyers at several plaintiffs  firms who worked on the Fox case said they are investigating thousands of additional claims   Still  the talc cases represent a relatively small portion of the tens of thousands of lawsuits J J is facing over its many products  For instance  it is the target of more than 44 000 cases from women who say they were harmed by pelvic mesh devices made by its Ethicon unit  and more than 8 000 against its DePuy subsidiary regarding Pinnacle metal on metal hip systems   The next J J talc trial is set for April in St  Louis  and additional trial dates have been set for later this year   To be successful  plaintiffs must make both a general link between talc and ovarian cancer and show that J J s products   as opposed to something else   are to blame for their cancer   In spite of the increased interest in the litigation following the Fox verdict  attorney Danielle Mason of Beasley Allen  who was part of the team representing the Fox family at trial  said she expected J J to fight hard to defend itself in upcoming trials   We re in this for the long haul   she said ,2016-02-25,Reuters,https://www.investing.com/news/stock-market-news/big-verdict-doesn't-assure-more-wins-for-plaintiffs-in-talc-cancer-cases-386611,386611
198603,420119,JNJ,FIFA paid Blatter  3 76 million in 2015,news,"By Brian Homewood ZURICH  Reuters    Soccer s ruling body FIFA said it paid disgraced former president Sepp Blatter 3 63 million Swiss francs   3 8 million  last year  publishing his salary for the first time under new governance regulations  FIFA also announced it lost  122 million in 2015  its first deficit since 2002  attributing that mainly to the costs of battling the worst graft scandal in its history   In particular  FIFA s legal fees rose from  31 29 million in 2014 to  61 49 million while its reserves dropped from  1 52 billion to  1 34 billion   The unprecedented events that occurred in 2015 have impacted upon FIFA s financial results  however the organization s healthy reserves have allowed it to weather the storm   the Swiss based federation said in a statement  Several dozen officials  including former members of FIFA s executive committee  have been indicted in the United States while Blatter has been banned for six years by the ruling body s ethics committee  FIFA said Blatter s former secretary general Jerome Valcke  banned for 12 years  was paid 2 12 million Swiss francs last year  The aggregate remuneration of key management personnel was  27 9 million  Blatter had been FIFA president since 1998 and his salary had long been the subject of speculation  It was finally published on Thursday under new rules which were passed in February in an attempt to make FIFA more transparent  FIFA said it calculated Blatter and Valcke s payments on the advice of an  independent  external company that specializes in HR and compensation issues   Despite the troubles  FIFA said it had revised its projected revenue for the 2015 2018 cycle upwards from  5 billion to  5 65 billion  with projected investments amounting to  5 55 billion   Last year  Valcke  while still secretary general  admitted that FIFA was having trouble in negotiating new sponsorship deals because of its battered reputation  New FIFA president Gianni Infantino  whose salary has not been revealed  made ambitious promises during his election campaign to increase spending on football development around the world   With the recently approved reforms  I believe that we have turned a corner and that FIFA is poised to emerge stronger than ever   said Infantino    During my presidency  I pledge to make this happen and to lead FIFA into a brighter and more sustainable future so that we can all return our full focus to football    We saw in 2015 that FIFA s competitions   such as the FIFA Women s World Cup   remain an incredible opportunity for us to promote the game and to raise the funds we need to fulfill our core mission of football development   During the electoral campaign  two of Infantino s rivals said that his plans were not financially viable and could wipe out FIFA s reserves  Revenue from World Cup sponsors dropped from  131 million to  44 5 million in 2015 after contracts with Johnson   Johnson  NYSE JNJ   Castrol and Continental expired at the end of 2014  However  revenue from FIFA s top tier partners increased from  177 1 million to  180 million   FIFA  which said it employed an average of 582 people throughout 2015  spent  92 1 million on personnel  compared to  115 28 million the year before  
  1   0 9663 Swiss francs ",2016-03-17,Reuters,https://www.investing.com/news/general-news/blatter-appeals-against-six-year-soccer-ban:-arbitration-court-390583,390583
198604,420120,JNJ,3 Top Large Cap Value Mutual Funds For Stupendous Returns,opinion,Large cap funds are considered prudent choices for risk averse investors when compared with small cap and mid cap funds  These funds have exposure to large cap stocks  with a long term performance history and more stability than what mid caps or small caps offer  Companies with market capitalization of more than  10 billion are generally considered large cap  However  due to their significant international exposure  large cap companies might be affected by a global downturn Meanwhile  investors looking for a bargain  i e   stocks trading at a discount  are mostly interested in value funds  which pick stocks that tend to trade at a price lower than their fundamentals  i e  earnings  book value  Debt Equity  and pay out dividends  In the long run  value stocks are expected to outperform the growth ones across all asset classes and are less vulnerable to trending markets  However  investors interested in choosing value funds for yield  should check the mutual fund yield as not all value funds comprise solely companies that primarily use their earnings to pay out dividends Below we share with you three top ranked  large cap value mutual funds  Each has earned a   Strong Buy  and is expected to outperform its peers in the future  Investors can  Principal LargeCap Value J  invests the majority of its assets in equity securities of large cap companies on the Russell 1000 Value Index  According to the index  large cap companies are those whose market cap ranges between  394 9 million and  634 4 billion  PVLJX seeks capital appreciation for the long run  Principal LargeCap Value J has returned 14 9  in the last one year As of December 2017  PVLJX held 82 issues  with 4 51  of its assets invested in Johnson   Johnson  NYSE JNJ  Vanguard US Value Investor  seeks growth of capital and income for the long run  VUVLX invests all of its assets in value companies having low price earnings  P E  ratios  The fund focuses on acquiring stocks of large and mid cap companies having impressive growth potential and favorable valuations  Vanguard US Value Investor has one year annualized returns of 9 9  Binbin Guo is one of the fund managers of VUVLX since 2016 DFA US Large Cap Value III  attains its investment objective by investing almost all its assets in its master fund  the U S  Large Cap Value Series  which in turn allocates its assets in securities of large cap U S  companies that are believed to be undervalued  DFUVX seeks growth of capital for the long run  DFA US Large Cap Value III returned 16 9  in the last one year DFUVX has an expense ratio of 0 13  compared with a category average of 1 05  To view the Zacks Rank and past performance of all large cap value mutual funds  investors can  Want key mutual fund info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/3-top-largecap-value-mutual-funds-for-stupendous-returns-200288390,200288390
198605,420121,JNJ,Theravance  J J Ink Deal For Inflammatory Intestinal Drug,opinion,Theravance Biopharma  Inc  s   NASDAQ TBPH   shares increased almost 15  on Feb 7 after it announced a global collaboration agreement with Janssen  a subsidiary of Johnson   Johnson   NYSE JNJ    to jointly develop and commercialize its pan Janus kinase  JAK  inhibitor  TD 1473  for treatment of inflammatory intestinal diseases Notably  TD 1473 is being evaluated in a phase Ib study for moderate to severe active ulcerative colitis  In August 2017  the company announced positive results from the trial It also plans to initiate a phase IIb III adaptive design induction and maintenance program on TD 1473 this year  for the given indication  Additionally  Theravance is planning to start a phase II study on the candidate for Crohn s Disease in 2018 Pursuant to the above mentioned agreement  Theravance will be entitled to receive an upfront payment of  100 million and be also eligible to get potential payments of  900 million if J J remains in the collaboration on completion of phase II activities  Moreover  while Janssen will be responsible for developing TD 1473 in Crohn s Disease after phase II  Theravance will lead the candidate s development in ulcerative colitis after the conclusion of phase IIb III program Both Janssen and Theravance will share profits in the respective ratios of 67  and 33  with potential sales in the United States and expenses related to a potential phase III program Theravance  shares have underperformed the  in a year s time  The stock has lost 8 6  versus the industry s 2 6  increase  Theravance is focused on using targeted JAK inhibitors for treatment of a range of inflammatory intestinal diseases  Around 900 000 and 700 000 patients in the United States are affected with ulcerative colitis and Crohn s Disease  respectively  Hence  successful development of the candidate will offer a huge boost to the company s top line Apart from TD 1473  Theravance s pipeline includes promising candidates like revefenacin  Revefenacin is under review in the United States for treatment of COPD Theravance Biopharma  Inc  Price    Zacks Rank   Key PicksTheravance carries a Zacks Rank  3  Hold   Two better ranked stocks in the health care sector are Exelixis  Inc    NASDAQ EXEL   and XOMA Corporation   NASDAQ XOMA    both carrying a Zacks Rank  2  Buy   You can see  Exelixis  earnings per share estimates have been revised upward from 72 cents to 77 cents for 2018 over the last 60 days  The company pulled off a positive surprise in all the trailing four quarters with an average beat of 572 92   Share price of the company has surged 37 6  in a year s time XOMA s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 over the last 60 days  The company came up with an average beat of 47 92   The stock has skyrocketed 556 9  in the last 12 months Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/theravance-jj-ink-deal-for-inflammatory-intestinal-drug-200288611,200288611
198606,420122,JNJ,Glaxo s  GSK  Begins Phase III HIV Two Drug Regimen Study,opinion,GlaxoSmithKline   NYSE GSK   along with partner Pfizer  Inc    NYSE PFE   announced that their HIV focused joint venture company  ViiV Healthcare  has initiated a phase III program to evaluate its two drug HIV regimen of dolutegravir  Tivicay  and lamivudine  Epivir  The study will evaluate the two drug regimen for maintenance of viral suppression achieved in HIV 1 infected patients on a three drug regimen   tenofovir alafenamide fumarate   TAF   based regimen We remind investors that Glaxo is also evaluating another two drug based regimen   cabotegravir and Johnson   Johnson s   NYSE JNJ   rilpivirine   in another phase III study for treating adults with virally suppressed HIV 1 infection  Moreover  the company is also evaluating cabotegravir monotherapy for the prevention of HIV infection in sexually active women HIV treatments generally are three drug based regimens  The latest entrant in the market is Gilead Sciences  Inc  s   NASDAQ GILD   once daily single tablet regimen  Biktarvy  bictegravir  emtricitabine  tenofovir alafenamide   approved earlier this month  However  Glaxo is trying to reduce the number of medicines in a HIC treatment regimen without compromising on the efficacy of a conventional three drug regimenShares of GlaxoSmithKline have underperformed the  so far this year  The stock has lost 9 6  against the industry s 10 1  rally during the period The phase III TANGO study will investigate a two drug regimen for the treatment of HIV  The phase III program is designed to evaluate non inferior antiviral activity of the combination regimen at 48 weeks compared to continuation of a TAF based regimen  The study will also evaluate long term antiviral activity  tolerability and safety of the combination therapy for up to 96 weeks Glaxo is also evaluating the combination regimen in GEMINI studies in patients with HIV 1 who have received no prior treatment  Data from the GEMINI and TANGO studies are anticipated in 2018 We note that Glaxo s newest HIV medicine   Juluca is a single tablet containing dolutegravir and J J s rilpivirine  Juluca is the first two drug regimen approved by the FDA Meanwhile  with several companies interested in developing drugs to treat this life threatening disease  competition has intensified manifold in the space GlaxoSmithKline PLC Price   Zacks RankGlaxoSmithKline carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/glaxos-gsk-begins-phase-iii-hiv-twodrug-regimen-study-200289004,200289004
198607,420123,JNJ,FDA Okays J J s Prostate Cancer Drug In First Line Setting,opinion,Johnson   Johnson s   NYSE JNJ   subsidiary  Janssen  announced that the FDA has granted approval to its prostate cancer drug  Zytiga   abiraterone acetate  in combination with prednisone to treat an early stage of prostate cancer Notably  Zytiga  was earlier approved in both the United States and the EU to treat metastatic castration resistant prostate cancer  mCRPC  in treatment experienced patients  whose chemotherapy contained docetaxel   With this latest nod from the regulatory body  the drug s label has been expanded to treat newly diagnosed patients with metastatic high risk castration sensitive prostate cancer  CSPC  Zytiga was approved for treatment of newly diagnosed CSPC patients in the EU in November 2017  The company also submitted regulatory filings for the combination therapy in Japan  Canada  Mexico  Switzerland  Singapore and Philippines for the given indication J J s shares have outperformed the in a year s time  The stock has increased 10 8   comparing favorably with the industry s 10 1  rally  The FDA approval for the expanded patient population was supported by encouraging data from a pivotal phase III LATITUDE study  evaluating Zytiga prednisone s combination on CSPC patients with no prior experience of cytotoxic chemotherapy  Data from the trial demonstrated a statistically significant and improvement in overall survival in the given patients  population  The combination regimen showed a reduction in death risk by 38  compared with placebos It is important to note that Zytiga is one of the most important and successful products in the company s oncology portfolio  The drug s sales surged 45 5  to  755 million in fourth quarter 2017 owing to an improved share in a growing metastatic castration resistant prostate cancer market  It was the highest prescribed oral medication in the United States for patients with metastatic CRPC in 2016 Approval for the combination therapy on CSPC patient population should increase Zytiga s sales in the future quarters Incidentally  another marketed drug for CSPC patients  having received docetaxel therapy  is Pfizer   NYSE PFE   and Japanese company  Astellas Pharma s  combined Xtandi  enzalutamide  Though Zytiga is facing patent challenges in the United States  the company anticipates no impact from generic competition for the drug this year  Also  J J is confident that it can absorb the effect of any potential Zytiga headwind  should there be an earlier than expected generic launch in 2018 Johnson   Johnson Price    Zacks Rank   Key PicksJ J carries a Zacks Rank  3  Hold   Two better ranked stocks in the health care sector are Exelixis  Inc    NASDAQ EXEL   and XOMA Corporation   NASDAQ XOMA    While XOMA sport a Zacks Rank  1  Strong Buy   Exelixis carries a Zacks Rank  2  Buy   You can see  Exelixis  earnings per share estimates have been revised upward from 72 cents to 77 cents for 2018 over the last 60 days  The company pulled off a positive surprise in all the trailing four quarters with an average beat of 572 92   Share price of the company has soared 22 6  in a year s time XOMA s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 over the last 60 days  The company came up with an average beat of 47 92   The stock has skyrocketed 541 0  in the last 12 months The Hottest Tech Mega Trend of All              Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-08,Zacks Investment Research,https://www.investing.com/analysis/fda-okays-jjs-prostate-cancer-drug-in-firstline-setting-200289102,200289102
198608,420124,JNJ,Old Economy  Buy And Hold Dividend Stock Perfect For This Downturn,opinion,"As the volatility in the markets increases and investors re price their risks  one proven strategy to survive in this environment is to focus on companies which have time tested products and services  Stock prices of these old economy companies are sure to bounce back once the dust has settled and normal trading patterns resume 
If you re a long term income investor with plenty of dry powder on the sideline and were looking for better entry points  this market pullback is a great news  Lower stock prices of some top quality dividend stocks mean their yields have become more attractive  Keeping this theme in mind  I m recommending Johnson   Johnson  NYSE JNJ   In this ongoing volatile trading  investors have seen J J s share value decline despite the fact that its business is growing and it s not facing any major threats to its future profitability 

Here s why this pharma behemoth might be a good pick for your portfolio 
Market Beating Returns 
Johnson   Johnson doesn t get too much financial press because it s an old  boring stock that rarely surprises investors  But if you analyze how much investors have benefited from having this stock in their portfolios you might be surprised  During the past two decades  this New Brunswick  New Jersey based healthcare giant delivered a total return of more than 489  to shareholders  To keep things in perspective  the benchmark S P 500 Index returned just under 288  over the same period 
The biggest advantage of having buy and hold stocks in your portfolio is that you don t need to worry about market ups and downs on a daily basis  You don t invest in J J to make a quick buck  All you care about is a consistent income stream that s beating the inflation beast and growing every year 
The dividend is your friend in both good and bad times  as long as the company is able to make their dividend payments during downturns as well as upturns  Increasing payouts make it easier for you to hold on to your investment even when the share price contracts  Investors who made about 500  in total returns while holding on to J J stock have successfully ridden through many market crashes and bubbles  including the Great Recession of 2008 and the dot com bubble of 2001 
When it comes to rewarding investors  few companies have done better than Johnson   Johnson  The company has increased its quarterly dividend rate every year for 56 consecutive years  This remarkable performance puts Johnson   Johnson among an elite group known as  dividend kings   companies with at least five decades of annual dividend hikes  And though its payout ratio of 57 04  could be considered a tad high by some  given the company s strength and stellar dividend history  it should be considered a healthy metric in this case 
Growth momentum 
The latest numbers suggest that J J s earning momentum is still going strong  and there is no reason for long term investors to panic  Last month  the company reported that its fourth quarter sales surged 11 5   while its net income jumped 9 5  as the company beat analysts expectations 
This strength came from the fact that J J has one of the biggest R D budgets in the industry  Since 2015 it has spent more than other large pharma firms on M A  And the company has done almost twice as many drug licensing deals as its nearest large pharma competitor over that same period  according to Bloomberg data 
For dividend investors  the current stock price it closed at  129 67 yesterday might be a good entry point  following the 7  dip this year  Trading with the forward price to earnings  P E  of just 15  J J stock is much cheaper now than it was a month ago 
The timing to make the entry seems perfect  especially when management plans to repatriate  12 billion in overseas cash  Analysts are expecting that most of this money will go toward higher dividends or share buybacks 
Over the last five years  J J has increased the dividend between 5  and 8 1   Given the new tax code and all that cash  I wouldn t be surprised if the company hits the top of the range when it s likely to announce its new dividend plan in April 
The bottom line  If your investment objective is to buy solid dividend stocks in order to earn a steady income  you can t go wrong with J J  It s one of the biggest dividend distributors in the pharma industry  With a strong balance sheet  cash flows and a dominant market position in consumer healthcare  pharmaceuticals and medical devices  you can rely on Johnson   Johnson s dividend for years to come ",2018-02-15,Haris Anwar/Investing.com,https://www.investing.com/analysis/an-oldeconomy-buyandhold-dividend-stock-perfect-for-this-downturn-200290658,200290658
198609,420125,JNJ,J J to cut 3 000 jobs in struggling device division,news, Reuters    Johnson   Johnson  N JNJ  said on Tuesday it would cut about 3 000 jobs within its medical devices unit over the next two years  or about 4 to 6 percent of the struggling division s global workforce  to generate annual cost savings of up to  1 billion and focus on more innovative products  The job cuts relate to J J s orthopedics  surgery and cardiovascular operations  although there are no immediate plans to pare back or eliminate specific products  said company spokesman Ernie Knewitz  He did not provide specific regions for the cuts   The savings will help us grow our  device  business   Knewitz said   That could involve acquisitions  but it will also involve investing in our own internal programs    The company s consumer medical devices  vision care and diabetes care will not be affected  J J said   J J s medical device sales reached almost  19 billion in the first nine months of 2015  but fell 10 4 percent  making the wide array of products the company s poorest performing segment  By contrast  sales of J J s prescription drugs fell 3 9 percent and sales of its consumer products fell 6 5 percent in the same period  also hurt by a stronger dollar which lowers sales in overseas markets  The company said it expected to record pretax restructuring charges of  2 0 billion to  2 4 billion in connection with these plans  of which about  600 million will be recorded in the fourth quarter of 2015  Leerink analysts said the announcement meant that an acquisition was still in the cards for J J  given that it had about  37 billion in cash as of the end of the third quarter   We continue to believe JNJ is an active acquirer with a focus likely heavily weighted toward it s lagging medical devices business     it s a matter of when  not if  J J does a deal   they wrote in a note  J J also reiterated its full year 2015 forecast  and said the restructuring in the devices business would not affect the  10 billion share repurchase program  The restructuring is expected to produce annualized pretax cost savings of  800 million to  1 billion  J J said  Most savings are expected by the end of 2018  including about  200 million in 2016  New Brunswick  New Jersey based J J employs about 60 000 within its medical devices unit  part of a global workforce of about 127 000  The Band Aid maker is expected to report fourth quarter results on Jan  26  J J shares were up 0 7 percent at  97 67 ,2016-01-19,Reuters,"https://www.investing.com/news/stock-market-news/johnson--amp;-johnson-to-cut-3,000-jobs-in-medical-devices-division-380671",380671
198610,420126,JNJ,Investor pressures J J to consider split up  sources,news,"By Carl O Donnell  Reuters    Artisan Partners  a major shareholder in Johnson   Johnson  N JNJ   has urged several activists to pressure the consumer products giant to consider major changes that include a potential split  according to sources and documents  Artisan has asked Johnson   Johnson s management to consider separating its three divisions   consumer products  pharmaceuticals and medical devices   into standalone companies in hopes of unlocking up to  90 billion in enterprise value  said sources familiar with the matter   Artisan  which manages nearly  100 billion  also suggested that Johnson   Johnson consider replacing board members  and reviewing standards for executive pay and financial reporting  documents seen by Reuters showed  In a presentation to Johnson   Johnson last year that was seen by Reuters  Artisan said the firm has significantly underperformed its peers across each of its major divisions  due partly to opaque financial reporting and flawed executive compensation   It also said the company s conglomerate structure has caused the it to trade at a substantial discount relative to more focused peers   The heightened pressure on Johnson   Johnson comes as rival healthcare companies increasingly focus on a handful of areas of competitive advantage  while exiting other areas through divestitures or spin offs  Johnson   Johnson posted fourth quarter earnings on Tuesday that beat forecasts  but gave a 2016 revenue outlook that was below analysts  estimates  The firm also said earlier in January that it was slashing 3 000 jobs in its struggling medical device division  A Johnson   Johnson spokesperson declined to comment  and referred to remarks that the firm made in an investor presentation on Tuesday    Because of our broad base across healthcare  we are uniquely positioned to be a partner of choice   Alex Gorsky  chairman and chief executive officer of Johnson   Johnson  had said on Tuesday    This broad based structure has helped us deliver strong  consistent and sustainable financial performance    
In 2006  rival pharmaceutical giant Pfizer sold its consumer products division to Johnson   Johnson for  17 billion  becoming a focused play on drugs  Pfizer is now considering separating its patented drugs from its generics division ",2016-01-27,Reuters,https://www.investing.com/news/stock-market-news/investor-pressures-j-amp;j-to-consider-split-up:-sources-382039,382039
198611,420127,JNJ,GSK and J J back  1 billion biotech spin off from Index Ventures,news,"By Ben Hirschler LONDON  Reuters    Index Ventures  an early investor in technology hits like Skype and Dropbox  is spinning off its biotech portfolio into a new  1 billion  695 million pounds  business  with backing from drug giants GlaxoSmithKline  L GSK  and Johnson   Johnson  N JNJ   The new Medicxi Ventures business will be led by the existing life sciences team from Index Ventures and includes all the current biotech portfolio companies  Medicxi said on Tuesday it had raised 210 million euros   229 million  for a new fund focused on early stage life sciences investments in Europe  with GSK and J J each contributing 25 percent  That takes funds under management at Medicxi to around  1 billion  making it one of the largest independent European life sciences focused investment firms   We are doubling down on life sciences and early stage investments across Europe   said general partner Francesco De Rubertis  who expects 80 to 90 percent of Medicxi investments to be in Europe  Although Europe plays second fiddle to the United States when it comes to developing successful biotech companies  the continent s universities carry out much of the cutting edge science behind new medicines   Every year  around 30 to 40 percent of the drugs approved by the FDA  U S  Food and Drug Administration  were actually discovered in European academic labs   De Rubertis said  The new financing marks a further vote of confidence by GSK and J J in Index s so called asset centric approach to biotech investing  Both pharmaceutical companies first linked with Index in a European biotech fund round in 2012  In contrast to the traditional idea of building fully integrated new businesses  Index invests in  virtual  companies with a single experimental medicine and minimal infrastructure  Last year  for example  it sold XO1  a British firm working on an early stage anti blood clotting drug with just two employees  That approach is increasingly at odds with the conventional tech approach to building a company   Index Ventures is best known for its investments in tech businesses but the company has also backed a number of successful biotech firms  including Denmark s  Genmab   CO GEN   The life sciences operations being carved out to form Medicxi account for about a third of Index s investments  The Index Ventures technology practice remains unchanged  De Rubertis will manage Medicxi along with three other ex Index general partners   David Grainger  Kevin Johnson and Michele Ollier  
  1   0 9175 euros ",2016-02-02,Reuters,https://www.investing.com/news/stock-market-news/gsk-and-j-amp;j-back-$1-billion-biotech-spin-off-from-index-ventures-382835,382835
198612,420128,JNJ,Can Pfizer Beat Analysts  Forecasts  ,opinion,"The all American pharmaceutical company  Pfizer  NYSE PFE   is looking to report its fourth quarter and full year 2017 results next week and here are the things that you can expect from the company  Looking at the company s previous quarter performance  they managed to hit positive figures with great dominating market performance 
Pfizer had a great 2017 run and a lot of analysts are expecting that the positive trend will continue with its coming fourth quarter and whole year results  The company s previous earnings were up by an incredible and surprising 3 08   they also managed to stay ahead of most analysts  expectations and forecasts from the same quarter 
Pfizer s Previous Quarter
Looking at the overall growth of the company in the previous year  Pfizer managed to score a total of 18 7  growth for their shares  For the anticipated results  analysts are looking to pay close attention to their new products such as Xeljanz and Ibrance to contribute to their results  older products such as the Lyrica  Chantix  and Eliquis are also looking to contribute greatly 
One thing that may hinder the company s 2017 performance is the reported supply shortage that they for their products from legacy Hospira portfolio  They announced that shortage on the same time their third quarter results were unveiled  According to Pfizer  the supply shortages stemmed from the capacity constraints and technical issues 
All in all  the pharmaceutical company also raised their full year adjusted earnings forecast by a total of 3 cents  putting the price range at  2 58 to  2 62 per share  They also updated their revenue forecast to  52 4 billion to  53 1 billion  from the latter  52 billion to  54 billion 
Future predictions and expectations for the company are as follows  analysts believe that Pfizer will update the commercialization plan for its upgraded oral SGLT 2 inhibitor 
Johnson   Johnson  NYSE JNJ   Pfizer Deal
The pharmaceutical company is also currently arranging an acquisition deal for its consumer health business  According to sources that are familiar with the matter  the current race has depleted to two bidders after J J pulled out  this leaves GlaxoSmithKline and Reckitt Benckiser on the acquisition deal  The bid will run until February 1  until then negotiations are still ongoing 
According to Johnson   Johnson s Vice President of media relations Ernie Knewitz  While we would normally not comment on market speculation or rumors  in this instance we refute assertions that we are in negotiation for Pfizer s consumer business  ",2018-01-29,Trade12,https://www.investing.com/analysis/can-pfizer-beat-analysts-forecasts-200284367,200284367
198614,420130,JNJ,AstraZeneca chases Acerta to secure next cancer drug winner,news,"By Ben Hirschler LONDON  Reuters    AstraZeneca said on Monday it was in talks that might lead to the acquisition of privately held biotech firm Acerta Pharma  a potential  5 billion plus deal designed to build up its cancer drug portfolio   AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV  There can be no certainty that any transaction will ultimately be entered into  or as to the terms of any transaction   it said in a brief statement   Credit Suisse   VX CSGN  analysts said acalabrutinib s considerable potential could also encourage other potential buyers   If Acerta is open to a transaction  we would expect significant interest from multiple other bidders   they said in a note  The Wall Street Journal had reported on Friday that the British drugmaker was looking to buy Acerta for more than  5 billion to gain access to its experimental blood cancer drug acalabrutinib  Acalabrutinib works in a similar way to Imbruvica  which was developed by Pharmacyclics but is now controlled by AbbVie after the U S  drugmaker bought Pharmacyclics for  21 billion earlier this year  Johnson   Johnson  N JNJ  jointly markets Imbruvica  Both drugs are so called Burton s tyrosine kinase inhibitors that target an array of blood cancers and have the potential to become multibillion dollar a year sellers  according to industry analysts  They may also help in autoimmune diseases like lupus  Given pharmaceutical companies  current heated interest in oncology  Bernstein analyst Tim Anderson said it was not surprising that Acerta  based in California and the Netherlands  was an acquisition candidate  PIPELINE BOOST Acerta does not yet have a partner to help develop its leading drug  although it has agreed to test acalabrutinib in combination with Merck s Keytruda  Acerta is running a wide range of cancer clinical trials  including two final stage Phase III studies  Last week it reported positive results in leukemia  The decision to chase after Acerta reflects a determination by AstraZeneca Chief Executive Pascal Soriot to use deals to boost his company s pipeline as sales of older blockbusters  including cholesterol fighter Crestor  lose patent protection  Last month he agreed to buy ZS Pharma  a specialist in treating high potassium levels  for  2 7 billion   The biggest hopes are pinned on oncology  however  where AstraZeneca already has a goal of bringing six new cancer treatments to market by 2020  Its new lung cancer pill Tagrisso  which it believes could sell  3 billion a year  was approved last month and the company also recently launched Lynparza for ovarian cancer  Buying Acerta would take AstraZeneca into the less familiar territory of blood cancers and some analysts said the move suggested a bigger commitment to this area of oncology than initially expected  
Earlier this year AstraZeneca signed a deal to co develop another cancer drug  durvalumab  in blood cancers with Celgene  O CELG  because it said at the time it had limited experience in the field ",2015-12-14,Reuters,https://www.investing.com/news/stock-market-news/astrazeneca-chases-acerta-to-secure-next-cancer-drug-winner-375928,375928
198615,420131,JNJ,AstraZeneca buys most of Acerta for  4 billion to add cancer drug,news,"By Ben Hirschler LONDON  Reuters    AstraZeneca  L AZN  said on Thursday it had agreed to buy 55 percent stake of privately held biotech firm Acerta Pharma for  4 billion to give it access to a new kind of drug for fighting blood cancers  AstraZeneca will pay  2 5 billion upfront  with a further  1 5 billion paid either on receipt of the first regulatory approval for the medicine acalabrutinib or at the end of 2018  depending on which comes first   Acalabrutinib works in a similar way to AbbVie  N ABBV  and Johnson   Johnson s  N JNJ  product Imbruvica  AstraZeneca believes the new medicine  which is now in final stage testing  could sell more than  5 billion a year  Chief Executive Pascal Soriot said the deal was consistent with the British drugmaker s drive to build up its cancer business through targeted deals and would give the company a  potential best in class medicine that could transform treatment for patients across a range of blood cancers   Acerta shareholders will have the option to sell the remaining 45 percent of shares in the biotech company to AstraZeneca for approximately  3 billion  once acalabrutinib has been approved in both the United States and Europe  Acalabrutinib is expected to be submitted for regulatory approval in the second half of 2016  The medicine is a so called Burton s tyrosine kinase inhibitor that targets an array of blood cancers  It may also help in autoimmune diseases like lupus   The decision to snap up Acerta reflects Soriot s determination to boost his company s pipeline as sales of older blockbuster products  including cholesterol fighter Crestor and heartburn pill Nexium  lose patent protection  Last month he agreed to buy ZS Pharma  O ZSPH   a specialist in treating high potassium levels  for  2 7 billion  
The agreement with Acerta was not unexpected  since AstraZeneca announced on Monday that it was  exploring potential strategic options  with the unlisted firm  which is based in California and the Netherlands ",2015-12-17,Reuters,https://www.investing.com/news/stock-market-news/astrazeneca-to-buy-55-percent-of-cancer-firm-acerta-for-$4-billion-376513,376513
198616,420132,JNJ,Democrat Clinton announces plan to battle Alzheimer s,news,"By Luciana Lopez NEW YORK  Reuters    Democratic presidential candidate Hillary Clinton on Tuesday announced a slate of proposals to battle Alzheimer s disease and seek a cure by 2025  including an increase in funding for research on the disease and related disorders  Clinton called for a decade long investment of  2 billion per year for research  which her campaign called a fourfold increase over last year s  586 million  The proposal could help boost research into an illness that has not only pressured the middle class families Clinton has made a centerpiece of her campaign  but is expected to weigh substantially on public spending as the U S  population ages    We owe it to the millions of families who stay up at night worrying about their loved ones afflicted by this terrible disease and facing the hard reality of the long goodbye to make research investments that will prevent  effectively treat and make a cure possible by 2025   Clinton said in a statement  Alzheimer s is an irreversible  progressive brain disorder that eventually destroys the ability to carry out the simplest tasks  More than 5 million Americans are estimated to have the disease  which the National Institute on Aging said is the sixth leading cause of death in the United States  On a conference call with reporters  the Clinton campaign pointed to the expected growth in spending on Alzheimer s by government health insurance programs Medicare and Medicaid  A researcher on the call  Rudolph Tanzi of Harvard Medical School  also detailed the recent progress in medical research that has improved the chances for finding treatment or even a cure   Our single bottleneck has been funding   he said  calling his area of research a  budget constrained  not a knowledge constrained field   The  2 billion also could include research on related dementias and pathologies  Tanzi said  Clinton s proposed level of funding  would be a tremendous boost for our nationwide efforts to overcome Alzheimer s disease   said Robert Egge  executive director of the advocacy organization Alzheimer s Impact Movement   Egge  who is also an executive with the Alzheimer s Association  talked to Reuters after speaking on the Clinton campaign conference call  While neither the association nor AIM advised the campaign on this proposal  Egge said  the association did provide the campaign with an educational briefing on Alzheimer s disease   Clinton s proposal also comes as researchers have made recent progress in drug development for the disease   Recent trial data on solanezumab from Eli Lilly and Co and Biogen s aducanumab have shown hints of genuine benefits  Other companies aggressively working on Alzheimer s treatments include Roche and Johnson   Johnson  N JNJ   Clinton  the front runner for her party s nomination for the November 2016 presidential election  was to discuss her plan on Tuesday in an appearance in Fairfield  Iowa  A cure for Alzheimer s would also help caregivers  including the so called sandwich generation   people providing care for their children and their parents at the same time   About 15 percent of middle aged people are helping financially support both an aging parent and a child  according to the Pew Research Center  Older parents are likelier to need caregiving of some kind  Clinton has often spoken on the campaign trail about meeting supporters who are struggling to care for family members with Alzheimer s  
For more on the 2016 presidential race  see the Reuters blog   Tales from the Trail     ",2015-12-22,Reuters,https://www.investing.com/news/politics-news/clinton-announces-plan-to-battle-alzheimer's-377189,377189
198617,420133,JNJ,Healthcare ETFs In Focus Post JNJ Q4 Results,opinion,The Q4 earnings season has commenced and Johnson   Johnson   NYSE JNJ   was the first drug company to report on Jan 23  before the opening bell  The world s biggest maker of health care products continued its long streak of earnings beat and offered a decent outlook for 2018 Earnings per share came in at  1 74  a couple of cents ahead of the Zacks Consensus Estimate and 10 1  higher than the year ago quarter  Revenues grew 11 5  year over year to  20 2 billion but fell shy of the Zacks Consensus Estimate of  20 22 billion  The company lagged the revenue estimate despite robust sales of blood cancer treatments Darzalex and Imbruvica as well as plaque psoriasis treatment Tremfya Johnson   Johnson issued its 2018 outlook  It expects earnings per share to come in at  8 00  8 20  well ahead of the Zacks Consensus Estimate of  7 86  Revenues are expected in the range of  80 60  81 40 billion  the high end is well below the Zacks Consensus Estimate of  81 55 billion  see    Market ImpactDespite the strong results  shares of JNJ dropped as much as 4 3  on the day  marking the biggest intraday decline since August 2015  The drop came as the U S  Circuit Court of Appeals for the Federal Circuit upheld the ruling that the company s patent on its top selling arthritis drug Remicade is invalid  The blow came just a week after JNJ lost a patent on another blockbuster prostate cancer drug  Zytiga Currently  the stock has a Zacks Rank  3  Hold  with a VGM Score of B  Further  Johnson   Johnson belongs to a solid industry with a Zacks Rank in the  As a result  investors should closely watch the movement of the stock and keep a close eye on ETFs having double digit allocation to this diversified drug maker  Below  we have highlighted those Health Care Select Sector SPDR Fund The most popular healthcare ETF  XLV follows the Health Care Select Sector Index  This fund manages nearly  17 9 billion in its asset base and trades in heavy volume of around 6 6 million shares  Expense ratio comes in at 0 14  annually  In total  the fund holds 61 securities in its basket with JNJ taking the top spot at 11 7  of the assets  Pharma accounts for 32 8  share from a sector look while healthcare providers and services  biotech  and healthcare equipment and supplies make up for a double digit exposure each  It has a Zacks ETF Rank  3  Hold  with a Medium risk outlook  read    iShares U S  Healthcare ETF This fund offers exposure to 118 securities by tracking the Dow Jones U S  Health Care Index  Here again  Johnson   Johnson dominates the fund s returns with 11 2  of total assets  In terms of industrial exposure  pharma takes the top spot at 32 4   followed by biotech  23    and healthcare equipment  18 9    The product has amassed nearly  2 1 billion in its asset base while charges 44 bps in annual fees  It trades in a good volume of around 78 000 shares a day and has a Zacks ETF Rank  3 with a Medium risk outlook iShares Edge MSCI Multifactor Healthcare ETF This ETF follows the MSCI USA Health Care Diversified Multiple Factor Capped Index and targets companies with the potential to outperform the broad U S  healthcare sector  Holding 38 stocks in its basket  JNJ is the top firm with 11 1  allocation  From an industrial look  managed health care  pharmaceuticals  health care equipment and biotechnology takes the double digit exposure each  The product has accumulated  11 9 million in its asset base and trades in a paltry volume of 7 000 shares per day on average  It charges 35 bps in annual fees and has a Zacks ETF Rank  3 iShares U S  Pharmaceuticals ETF This ETF provides exposure to 43 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  Here too  Johnson and Johnson takes the top spot  accounting for 10 2  share  The product has  580 9 million in AUM and charges 44 bps in fees and expenses  Volume is lower as it exchanges about 20 000 shares a day  The fund has a Zacks ETF Rank  3 with a High risk outlook  read    Vanguard Health Care ETF   AX VHT  This ETF tracks the MSCI US Investable Market Health Care 25 50 Index and holds 372 stocks in its basket  Of these  Johnson   Johnson occupies the top position with 10 2  allocation  Pharma takes the largest share at 30 4  while biotech and healthcare equipment round off the top three spots  VHT is also one of the popular and liquid ETFs with AUM of  7 6 billion and average daily volume of about 188 000 shares  It charges 10 bps in annual fees and has a Zacks ETF Rank  3 with a Medium risk outlook Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2018-01-23,Zacks Investment Research,https://www.investing.com/analysis/healthcare-etfs-in-focus-post-jnj-q4-results-200283016,200283016
198618,420134,JNJ,Johnson   Johnson  Key Day Trading And Swing Trading Levels ,opinion,"Key Day Trading And Swing Trading Levels On Johnson   Johnson  NYSE JNJ 
Below you find the video  ",2018-01-23,Gareth Soloway,https://www.investing.com/analysis/key-day-trading-and-swing-trading-levels-on-johnson--johnson-jnj-200282879,200282879
198619,420135,JNJ,Pfizer s Rituxan Biosimilar Meets Endpoint In Phase III,opinion,Pfizer Inc    NYSE PFE   announced positive top line results from a phase III comparative study  evaluating PF 05280586  the company s biosimilar version of Roche s   OTC RHHBY   blockbuster leukemia drug Rituxan Mabthera  rituximab  Notably  Rituxan is approved for treating blood cancers including non Hodgkin s lymphoma  follicular lymphoma and diffuse large B cell lymphoma  and chronic lymphocytic leukemia as well as immunological diseases like rheumatoid arthritis Shares of Pfizer have gained 18 5  in a year s time  underperforming the  s rally of 23 5  The phase III REFLECTION B3281006 study was designed to compare the efficacy  safety  pharmacokinetics and immunogenicity of PF 05280586 compared with Rituxan  The study met its primary endpoint demonstrating equivalence in overall response rate for the first line treatment of patients with CD20 positive  low tumor burden and follicular lymphoma This marks Pfizer s fifth proposed biosimilar monoclonal antibody  mAb   showing positive trial results Significantly  Pfizer s biosimilar capabilities were substantially boosted by the acquisition of Hospira in 2015  In December 2017  the company launched Ixifi  the second biosimilar version of Johnson   Johnson   NYSE JNJ   Merck   Co   Inc  s   NYSE MRK   blockbuster drug  Remicade  in the United States We remind investors that Pfizer is evaluating 14 biosimilar molecules in various developmental stages  Incidentally  biosimilar products in late stage development include the biosimilar versions of Roche s Avastin and AbbVie s Humira  Also  Herceptin s biosimilar version is under review in the United States as well as the EU Importantly  Novartis and Teva filed regulatory applications last year in the United States for the biosimilar version of Rituxan in September and June respectively Pfizer  Inc  Price    Zacks RankPfizer carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-01-24,Zacks Investment Research,https://www.investing.com/analysis/pfizers-rituxan-biosimilar-meets-endpoint-in-phase-iii-200283565,200283565
198620,420136,JNJ,Will Pfizer  PFE  Surpass Estimates This Earnings Season ,opinion,"We expect Pfizer  Inc    NYSE PFE   to beat expectations when it reports fourth quarter and full year 2017 results on Jan 30  before the market opens  Last quarter  the company delivered a positive earnings surprise of 3 08  
The pharma giant has a fairly decent record of earnings surprises  The company s earnings surpassed expectations in three of the last four quarters while missing in one  resulting in an average positive surprise of 0 79  
Pfizer s shares have risen 18 7  in the past year  comparing unfavorably with an increase of 24 7  for the  

Factors at Play
New products like Xeljanz  rheumatoid arthritis  and Ibrance  breast cancer  as well as older products like Lyrica  neuropathic pain   Chantix  smoking cessation  and Eliquis  blood thinner  are likely to contribute meaningfully to the top line 
However  the loss of exclusivity and associated generic competition for some products  primarily Pristiq in the United States and Vfend and Lyrica in developed Europe   supply shortages in legacy Hospira products  and divesture of the Hospira Infusion Systems unit will continue to hamper top line growth 
Blockbuster drug Enbrel s sales will continue to decline in the quarter due to biosimilar competition  The Prevnar Prevenar 13 vaccines franchise is likely to see lower sales while lower demand is expected to hurt sales of Viagra 
On the third quarter call  Pfizer said that it is facing supply shortages for products from legacy Hospira portfolio mainly due to capacity constraints and technical issues  At the time of acquiring Hospira in September 2015  Pfizer had estimated that it would take a couple of years to integrate the manufacturing plants and resolve the majority of the supply chain issues  The company also stated that the remediation of the business has taken longer than expected  We expect the supply shortages to hurt sales in the fourth quarter 
Meanwhile  the bottom line is likely to be driven by cost savings and share buybacks 
Two leukemia treatments   Besponsa inotuzumab ozogamicin  approved in EU in June 2017 and in the United States in August 2017  for relapsed refractory acute lymphoblastic leukemia  ALL  and Mylotarg for newly diagnosed CD33 positive acute myeloid leukemia  AML  were approved in third quarter 2017 
Xeljanz  Sutent and Bosulif were approved for line extensions in the fourth quarter while Ixifi  Pfizer s second biosimilar version of Johnson   Johnson s   NYSE JNJ   blockbuster drug Remicade  was also launched in December 
All these new products and line extensions should bring in some additional sales in the fourth quarter 
We also expect management to update on the commercialization plans for new approved oral SGLT 2 inhibitor  Steglatro  ertugliflozin  tablets on the conference call  Apart from being approved as a monotherapy to treat type II diabetes  Steglatro has also been approved for use in combination with metformin under the brand name  Segluromet and with Januvia  under the brand name Steglujan 
What Our Model Indicates
Our proven model shows that Pfizer is likely to beat on earnings because it has the right combination of two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen 
Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate is  0 45   This is a meaningful indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our 
Zacks Rank  Pfizer has a Zacks Rank  2  The combination of Pfizer s Zacks Rank  2 and positive ESP makes us confident of an earnings beat in the upcoming release 
Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions 
Other Stocks to Consider
Here are some other health care stocks worth considering per our model  These have the right combination of elements to beat on earnings this time around 
AbbVie Inc    NYSE ABBV   is scheduled to release results on Jan 26  The company has an Earnings ESP of  1 30  and a Zacks Rank  3  You can see  
Merck   Co   Inc    NYSE MRK   has an Earnings ESP of  1 06  and a Zacks Rank of 3  The company is scheduled to report earnings on Feb 2 Pfizer  Inc  Price  Consensus and EPS Surprise
 

   Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-01-25,Zacks Investment Research,https://www.investing.com/analysis/will-pfizer-pfe-surpass-estimates-this-earnings-season-200283767,200283767
198622,420138,JNJ,Johnson   Johnson beats on Q3 earnings  guides higher,news,"Investing com   Health care conglomerate Johnson   Johnson  N JNJ  reported better than expected third quarter earnings and provided upbeat guidance for the year ahead  sending its shares higher in pre market trade 
J J said adjusted earnings per share came in at  1 49 in the quarter ended September 30  beating expectations for earnings of  1 45 per share and down from adjusted earnings of  1 61 in the same period a year earlier 
The company s third quarter revenue totaled  17 1 billion  a decrease of 7 4  as compared to the third quarter of 2014 and below expectations for revenue of  17 46 billion 
Operational sales results increased 0 8  and the negative impact of currency was 8 2  
Domestic sales decreased 0 6   International sales decreased 13 7   reflecting operational growth of 2 1  and a negative currency impact of 15 8  
Excluding the net impact of acquisitions  divestitures and hepatitis C sales  on an operational basis  worldwide sales increased 5 6   domestic sales increased 7 7  and international sales increased 3 8  
Prior to its earnings announcement  the health care and consumer products company said it approved a  10 billion share repurchase program  The buyback  which J J said will be financed by issuing debt  has no time limit 
 New and core products drove solid underlying growth for Johnson   Johnson in the quarter   said Alex Gorsky  Chairman and Chief Executive Officer 
The firm now sees full year adjusted earnings per share in a range between  6 15 and  6 20  up from a previous estimate for adjusted earnings between  6 10 and  6 20 per share 
Immediately after the earnings announcement  Johnson   Johnson shares tacked on 0 95   or 91 cents  in trading prior to the opening bell to  96 90 compared to Monday s closing price of  95 98 
Meanwhile  U S  equity markets pointed to a weaker open  The Dow futures pointed to a drop of 0 4   the S P 500 futures shed 0 4   while the Nasdaq 100 futures declined 0 5  ",2015-10-13,Investing.com,"https://www.investing.com/news/stock-market-news/johnson---johnson-beats-on-q3-earnings,-guides-higher-365855",365855
198623,420139,JNJ,J J third quarter sales miss mark  hurt by strong dollar,news,"By Ransdell Pierson  Reuters    Johnson   Johnson  N JNJ  reported third quarter sales well below Wall Street estimates  hurt by the stronger dollar and disappointing demand for its Remicade arthritis drug and its Xarelto blood clot preventer  J J shares fell 0 7 percent  even though the company also said on Tuesday it planned to buy back up to  10 billion worth of its common stock   The repurchases  to be financed with debt and to have no time limit  would remove about 3 8 percent of the company s outstanding shares   The company had already bought back  5 billion of shares in a program it announced in July last year   Global company revenue fell 7 4 percent to  17 1 billion in the quarter  Analysts  on average  expected  17 45 billion  Revenue would have risen 0 8 percent if not for the stronger dollar  which hurts the value of sales outside the United States   where J J receives nearly half its revenue  Jefferies analyst Jeffrey Holford said revenue for each of the company s three divisions  including its largest segment of prescription drugs  were about 2 percent below forecasts   The news of a  10 billion share repurchase program is welcome  but it doesn t address the underlying issues in pharmaceuticals   Holford said  and may lessen the likelihood of J J making big acquisitions in the company s biggest segment  J J s net profit fell to  3 36 billion  or  1 20 per share  from  4 75 billion  or  1 66 per share  a year earlier  Excluding special items  the company said it earned  1 49 per share  topping Wall Street expectations of  1 45 per share   Wells Fargo   N WFC  analyst Lawrence Biegelsen said the company was able to top earnings forecasts largely due to an unexpectedly low tax rate   
J J said it now expects full year earnings  excluding special items  of  6 15 to  6 20 per share  It had previously forecast  6 10 to  6 20 per share ",2015-10-13,Reuters,https://www.investing.com/news/stock-market-news/strong-dollar-eats-into-j-j-quarterly-sales-365858,365858
198624,420140,JNJ,Johnson   Johnson Q3 earnings hit by strong dollar ,news,"Investing com   Johnson   Johnson  N JNJ  reported a 7 4  fall in quarterly sales as the impact of a strong dollar more than offset higher sales of its older drugs 
Revenue fell to  17 10 billion in the third quarter from  18 47 billion a year earlier 
International sales fell nearly 14  to  8 31 billion in the quarter  including a currency impact of 15 8   the company said  The company receives nearly half of its revenue from outside the U S 
Net profit fell to  3 36 billion  or  1 20 per share  from  4 75 billion  or  1 66 per share  a year earlier 
The company said its adjusted profit was  1 49 per share 
The company also said it planned to buy back up to  10 billion worth of shares  Shares rose 1 3  after the buyback announcement but pared some of the gains to trade near its Monday close of  95 80 in premarket trading ",2015-10-13,Investing.com,https://www.investing.com/news/stock-market-news/johnson---johnson-q3-earnings-hit-by-strong-dollar-365905,365905
198625,420141,JNJ,Stair climbing wheelchair offers alternative to lifts and ramps,news,By Jim Drury An electric wheelchair that can climb most stairs  including spiral staircases  has been developed by Zurich based students  The Scalevo Wheelchair can mount one stair per second and was designed by 10 students at the Swiss Federal Institute of Technology  ETH Zurich  and the Zurich University of the Arts  When being used on normal flat ground it balances on two wheels like a Segway and allows users to turn on the spot in order to quickly change direction  Two rubber tracks mounted to the bottom of the chair can be summoned at the press of a button to allow the user to climb stairs   According to Carlos Gomes  of ETH Zurich   we have two main wheels  two large wheels to drive around on the flat ground in a balancing mode like a Segway  And then we have two rubber tracks which we can extend to the angle of the stairs and let the wheelchair be always upright on every angle on the stairs   Colleague Miro Voellmy said the rubber tracks make the system entirely safe  even if stairs are uneven or cracked   Tracks are excellent for this use case because they have a very large footprint  which makes it near impossible to tilt  and they are also very smooth so it doesn t feel like you re driving up stairs  so it just feels like you re driving up a ramp because they re so flat and they adapt to the stair profile  So it doesn t matter if the stair is wooden or metal or glass  the tracks they grip and there s no danger of slipping   said Voellmy  Scalevo ascends the stairs backwards  When it reaches a set of stairs  the user presses a button to lower the tracks to the ground and its rubber grips hook onto the steps above to propel the chair and its occupant upwards  As it reaches the top a smaller pair of support wheels descend to prevent the wheelchair from toppling over   By traveling backwards the user can see what is below them  while a small video device similar to those used as reverse parking cameras in cars is fitted on Scalevo s arm  allowing them to see where they are going   The great thing is that everything on this wheelchair is automated   said Voellmy   If I want to climb the stairs I can just drive up to them  turn around  press one button and all I have to do is control the velocity I want to drive at  The alignment on the stairs  the leveling of the wheelchair driver  is automated and he can control it  he can view the back with a back facing camera  and have a full  safe  driving experience    The designers believe that  if adopted widely  their technology could negate the necessity for access ramps and in house stair lifts  while wheelchair users could have the option of avoiding out of the way lifts   It was built very compact  so it s not much wider than a classic manual wheelchair and it can still go under tables  you can go through narrow doors and use it indoors without any hassle  so it s extremely compact in comparison to different wheelchairs and it s very easy to use   said Voellmy  Their prototype was built in ten months and has been subjected to a series of tests  According to Gomes   we tested the wheelchair on several staircases  even on a spiral staircase  because we can move the tracks independently and all kinds of staircases we are able to drive  on  like from 34 to 17  I think  degrees  And this is almost every stair  You can drive everywhere   Previous stair climbing wheelchairs have failed to make the grade  Six years ago the iBot  devised by Johnson   Johnson  N JNJ  product was discontinued  regarded as expensive  and requiring users to have use of at least one arm and some upper body control  according to the Huffington Post  Scalevo s makers believe that when it eventually comes to market  their stair climbing wheelchair will not be much more expensive than traditional wheelchairs   Scalevo is also taking part in the 2016 Cybathlon  an ETH organized championship for pilots with disabilities using advanced assistive devices    OLUSSCIENCE Reuters US Online Report Science News 20151016T111940 0000,2015-10-16,Reuters,https://www.investing.com/news/general-news/stair-climbing-wheelchair-offers-alternative-to-lifts-and-ramps-366511,366511
198626,420142,JNJ,Will J J s  JNJ  Pharma Segment Pull Up Its Q4 Earnings ,opinion,"Johnson   Johnson   NYSE JNJ   has one of the most diverse revenue streams in the industry within the pharmaceutical division  which accounts for almost half of its revenues  The company has several multi million dollar drugs covering a broad range of areas such as neuroscience  cardiovascular and metabolism  immunology  oncology  pulmonary hypertension  and infectious diseases vaccines  However  several products in this segment are facing generic competition 
J J s shares have gained 28 7  in the past year  outperforming the 23 3  increase witnessed by the  it belongs to 
J J s domestic Pharma segment sales decelerated in the first half of 2017   However  sales growth accelerated in the third quarter and we are likely to see  a continuation of the positive trend in the fourth quarter and probably in 2018  The Zacks Consensus Estimate for the Pharmaceutical segment is  9 61 billion  Last quarter  segment sales beat the consensus estimate We believe that new products in all segments  label expansion of drugs like Imbruvica  Xarelto  Stelara and Darzalex and meaningful contribution from Swiss biotech  Actelion which J J bought in June  will support the top line  The Pharma segment will also continue to benefit from easier comps in the second half of 2017 compared with the first  Continued share gains are likely to drive sales of Imbruvica  cancer indications  and Stelara  psoriasis   Strong adoption for the newer indication of Crohn s disease is expected to contribute to Stelara growth  Also  strong adoption in outside U S  markets and accelerated adoption in the United States across all lines of therapy are likely to drive sales of multiple myeloma product  Darzalex  These positives will offset the loss of sales of some drugs like Invokana due to higher managed care discounting J J also gained FDA approval for several line extensions in  the second and third quarters of 2017    a lower dose of Xarelto  two new indications of Simponi Aria  use in adolescents for Stelara  combination use of Darzalex with Celgene s   NASDAQ CELG   multiple myeloma drug Pomalyst and the sixth indication for Imbruvica  among others  The line extensions can expand the eligible patient population of these drugs and drive their sales in the fourth quarter Two new drugs were approved last year  These include Tremfya  guselkumab  in the United States  July  as well as in the EU  November  for plaque psoriasis and the first dual treatment for HIV  Juluca  dolutegravir   rilpivirine  in partnership with GlaxoSmithKline   NYSE GSK   in the United States  November   Juluca is under review in the EU Regarding Tremfya  J J said on the third quarter conference call that it has been well received by physicians and patients  The drug is likely to contribute to sales in the soon to be reported quarter  We expect an update on the commercialization plans of Juluca on the fourth quarter conference call However  biosimilar competition is expected to hurt sales of key arthritis drug  Remicade outside the United States  Please note that J J markets Remicade in partnership with Merck   NYSE MRK   Overall  strong performance of the pharmaceutical segment as well as positive contribution from acquisitions like Actelion and Abbott Medical Optics should pull up the top line in the quarter  Meanwhile  higher investments for product launches will continue to hurt profits as had been the case in the third quarter   Read More  J J carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-01-18,Zacks Investment Research,https://www.investing.com/analysis/will-jjs-jnj-pharma-segment-pull-up-its-q4-earnings-200281912,200281912
198633,420149,JNJ,China s Li Ning says vice chairman Kim resigns  names new director ,news,"HONG KONG  Reuters    Chinese sportswear maker  Li Ning  Co Ltd  HK 2331  said on Friday that Jin Goon Kim  formerly interim CEO  had resigned as executive director and executive vice chairman with effect from July 4 to pursue other business commitments  Li Ning said Wu Jen Wei  chairman of Johnson   Johnson China  N JNJ   had been appointed a non executive director effective Aug  12  Wu has been nominated as a company director by TPG Stallion  a substantial shareholder  In March  Li Ning said its namesake founder was returning to lead a turnaround drive after China s best known sports brand posted a third consecutive year of losses  squeezed by global brands and cheap local rivals   The former Olympic champion gymnast returned as interim chief executive to replace Kim  who ran daily operations as interim chief executive from July 2012 until last November  Kim is an executive of U S  private equity fund and Li Ning backer TPG Capital  
The Chinese sportswear maker said Kim had no disagreement with the board  It gave no further details ",2015-07-03,Reuters,"https://www.investing.com/news/stock-market-news/china's-li-ning-says-vice-chairman-kim-resigns,-names-new-director-349530",349530
198634,420150,JNJ,Johnson   Johnson beats on Q2 earnings  guides higher,news,"Investing com   Health care conglomerate Johnson   Johnson  NYSE JNJ  reported better than expected second quarter earnings and provided upbeat guidance for the year ahead  sending its shares higher in pre market trade 
J J said earnings per share came in at  1 71 in the quarter ended June 30  beating expectations for earnings of  1 68 per share 
The company s second quarter revenue totaled  17 79 billion  a decrease of 8 8  as compared to the second quarter of 2014 but above expectations for revenue of  17 49 billion 
Operational results decreased 0 9  and the negative impact of currency was 7 9  
Domestic sales decreased 2 4   while international sales decreased 14 3   reflecting operational growth of 0 5  and a negative currency impact of 14 8  
Excluding the net impact of acquisitions and divestitures  on an operational basis  worldwide sales increased 1 7   domestic sales increased 0 6  and international sales increased 2 7  
 Our solid sales and earnings results in the quarter reflect the strong underlying growth we re seeing across the enterprise   said Alex Gorsky  Chairman and Chief Executive Officer 
The firm now sees full year adjusted earnings per share in a range between  6 10 and  6 20  up from a previous estimate for adjusted earnings between  6 04 and  6 19 per share 
Immediately after the earnings announcement  Johnson   Johnson shares eased up 0 76  in trading prior to the opening bell to  101 00 compared to Monday s closing price of  100 24 
Meanwhile  U S  equity markets pointed to a flat open  The Dow futures pointed to a drop of 0 1   the S P 500 futures shed 0 05   while the Nasdaq 100 futures inched up 0 05  ",2015-07-14,Investing.com,"https://www.investing.com/news/stock-market-news/johnson---johnson-beats-on-q2-earnings,-guides-higher-351090",351090
198635,420151,JNJ,Johnson   Johnson second quarter sales wilt on strong dollar  weak device sales,news,"By Ransdell Pierson  Reuters    Johnson   Johnson  NYSE JNJ  on Tuesday reported sharply lower sales in the second quarter  and cited a stronger U S  dollar  disappointing sales of its medical devices and plunging demand for a hepatitis C drug faced with strong competition  But the company  whose shares were down 0 8 percent in early afternoon trading on the New York Stock Exchange  raised its full year profit forecast  reflecting better than expected earnings in the quarter related to divestiture related gains and lower taxes  J J Chief Executive Alex Gorsky acknowledged that sales of medical devices  one of the company s big three product lines  have disappointed in recent quarters  but in a conference call  he urged industry analysts to remain patient   We are absolutely committed to accelerating our growth in medical devices through innovation  and research  Gorsky said   We don t think these are commodity businesses   J J said medical device sales fell 12 2 percent in the quarter to  6 36 billion  following the recent sale of the company s Ortho Clinical Diagnostics business  which had generated annual sales of almost  2 billion   Investors would like to see the medical device business do better  but the company doesn t have enough products in development that are differentiated  from rival brands  said RBC Capital Markets analyst Glenn Novarro  Novarro said J J needs to buy cutting edge medical devices and prescription drugs  whose revenue will be sorely needed to offset expected competition by 2018 from biosimilar forms of J J s blockbuster Remicade arthritis drug  Remicade  already facing cheaper generics in some overseas markets  saw sales fall 7 5 percent to  1 67 billion in the quarter  The New Brunswick  New Jersey based company s array of consumer healthcare products also struggled in the second quarter  with sales falling 7 percent to  3 48 billion  Global sales of company prescription drugs fell 6 6 percent to  7 95 billion  but would have grown 1 percent if not for foreign exchange factors  it said   Ashtyn Evans  an analyst with Edward Jones  cited strong sales of leukemia treatment Imbruvica and Invokana for diabetes  but disappointment with two older products   psoriasis treatment Stelera and blood clot preventer Xarelto  Sales of hepatitis C treatment Olysio plunged 68 percent to  264 million  as it became overshadowed by newer drugs  but Evans said it came in about  100 million above expectations  J J earned  4 52 billion  or  1 61 per share  in the second quarter  from  4 33 billion  or  1 51 per share  a year earlier  Excluding special items  it earned  1 71 per share  or 4 cents above Wall Street expectations  Revenue fell almost 9 percent to  17 8 billion  in line with Wall Street forecasts  as the strong dollar crimped global sales by 7 9 percent  The company reported a currency drag of 7 2 percent in the prior quarter  
The healthcare conglomerate raised its full year profit forecast to  6 10  6 20 per share  from an earlier view of  6 04  6 19  It had cut its profit forecast in April blaming the strong dollar  which lowers the value of sales in overseas markets ",2015-07-14,Reuters,https://www.investing.com/news/stock-market-news/johnson--amp;-johnson-profit-beats-street;-raises-full-year-forecast-351113,351113
198636,420152,JNJ,Can Merck Regain Its Mojo In 2018 After An Unimpressive  17 ,opinion,Shares of Merck   NYSE MRK   declined 4 4  in 2017 against the industry s surge of 16 3  The industry s rally was backed by strong quarterly results  new product sales ramp up with rising demand  successful innovation and product line expansion  strong clinical study results  more frequent FDA approvals and continued strong performance of legacy products  All these played a pivotal role in bringing the large cap drug sector back on track last year  Pharma giants AstraZeneca   NYSE AZN    Novo Nordisk   NYSE NVO   and Johnson   Johnson   NYSE JNJ   led from the front and outperformed the industry However  Merck missed out on the opportunity as it suffered some notable pipeline setbacks in 2017  In October  Merck decided not to seek approval for its CETP inhibitor anacetrapib for cholesterol management as its clinical profile was not strong enough to support regulatory filings In October  the company also announced a delay in the readout from an important lung cancer study to 2019  This was due to the inclusion of overall survival as a co primary endpoint in the KEYNOTE 189 phase III study of Keytruda in first line lung cancer  This raised investor concern  as the delay in the readout can give competitors a chance to gain strength in the lung cancer market In October  Merck also withdrew a regulatory application in Europe  which was looking to get Keytruda approved as first line combination therapy for lung cancer In September  Merck discontinued the development of two of its HCV combination programs   MK 3682B and MK 3682C   saying that the HCV market is becoming extremely crowded  Also  three combination studies of Keytruda for multiple myeloma were placed on clinical hold  following reports of death in Keytruda groups in July  Keytruda is seen as a key long term growth driver at Merck and such setbacks do not bode well for the company It remains to be seen if the strong performance of its new drugs  particularly Keytruda  its strong vaccines and animal health business and cost saving efforts can help Merck pick up in 2018 Keytruda  the second largest product in the Merck portfolio  is gaining strong momentum from new indication of first line lung cancer  In fact  Keytruda is continuously growing and expanding into new indications and markets globally  The Keytruda development program also significantly advanced in 2017 with several key regulatory approvals which should further drive sales in 2018 Merck s global restructuring program aims at reducing the cost structure and increasing efficiency  It intends to reduce the number of manufacturing sites  including animal health sites  and consolidate other facilities  The company expects annual savings of about  4 0  4 6 billion once the restructuring program is completed Merck carries a Zacks Rank  3  Hold   You can see    Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2018-01-02,Zacks Investment Research,https://www.investing.com/analysis/can-merck-regain-its-mojo-in-2018-after-an-unimpressive-17-200277408,200277408
198637,420153,JNJ,Will J J  JNJ  Continue To Tread Growth Path This Year ,opinion,Johnson   Johnson s   NYSE JNJ   stock was up 21 3  in 2017  which compared favorably with a gain of 16 3  recorded by the  Last year s share price surge was supported by a series of positive news including promising data from several pivotal studies and rapid progress with its pipeline and line extensions  The positive trend is likely to continue this year as well What Drove the Stock in 2017 Two new drugs were approved last year   Guselkumab Tremfya in the United States as well as in the EU for plaque psoriasis and the first dual treatment for HIV  Juluca  dolutegravir   rilpivirine  in partnership with GlaxoSmithKline   NYSE GSK   in the United States  Juluca is under review in the EU J J also gained FDA approval for several line extensions    a lower dose of Xarelto  two new indications of Simponi Aria  use in adolescents for Stelara  combination use of Darzalex with Celgene s   NASDAQ CELG   multiple myeloma drug Pomalyst and the sixth indication for Imbruvica  among others  Please note that J J markets Imbruvica in partnership with AbbVie  Inc    NYSE ABBV   The line extensions can expand the eligible patient populations of these drugs and drive their sales higher in future quarters In 2017  J J also submitted regulatory applications for label expansion of key drugs including Darzalex  in first line setting for multiple myeloma   Xarelto  for chronic coronary artery disease and or peripheral artery disease   Invokana  to include the cardiovascular indication   Zytiga  for earlier stages of metastatic prostate cancer   It might get FDA nod for these line extensions this year Factors Likely to Support the Rally in 2018With several pivotal data readouts and regulatory milestones expected in 2018  the bullish run of the stock is likely to continue in 2018 This year J J expects to file for approval of depression candidate  esketamine while apalutamide for pre metastatic prostate cancer and Symtuza  a darunavir based once daily single tablet regimen for HIV could be approved by the FDA J J s domestic Pharma segment sales decelerated in the first half of 2017 as a number of key growth drivers like Remicade and Concerta faced competition  However  sales growth accelerated in the third quarter and we are likely to see the positive impact of the trend in fourth quarter results and probably in 2018  We believe that new products in all segments  label expansion of drugs like Imbruvica  Xarelto  Stelara and Darzalex and contribution from recent acquisitions   mainly Actelion   will support top line growth  All these factors bode well for the stock  J J carries a Zacks Rank  3  Hold   You can see  Zacks Editor in Chief Goes   All In   on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2018-01-04,Zacks Investment Research,https://www.investing.com/analysis/will-jj-jnj-continue-to-tread-growth-path-this-year-200277904,200277904
198638,420154,JNJ,Celsion s Phase I II Cancer Study Initiation Gets FDA Nod,opinion,"Celsion Corporation   NASDAQ CLSN   announced that the FDA has accepted the design of its phase I II study   Ovation II   in ovarian cancer and cleared it for initiation  The study will evaluate its DNA based immunotherapy  GEN 1  as localized treatment for stage III IV ovarian cancer in newly diagnosed patients Shares of the company opened 13  higher on Jan 5  following the announcement   In fact  Celsion s shares are up 44 8  in the past six months  significantly outperforming the  s gain of 1 6  during the period The FDA has cleared the study based on compelling data from a dose escalating phase Ib OVATION study evaluating GEN 1 in ovarian cancer  The candidate achieved comparable progression free survival  PFS  in patients versus neoadjuvant chemotherapy The OVATION II study is also a dose escalation study whose phase I part is designed to find suitable dose of GEN 1 while evaluating doses up to 100 mg m2  The selected dose will be evaluated in the phase II part of the study  The primary endpoint of the study is to achieve at least 33  improvement in PFS in patients treated with GEN 1 in combination with neoadjuvant chemotherapy compared to neoadjuvant chemotherapy alone The company expects to initiate the study in the first half of 2018 Celsion is also developing the candidate in combination with Johnson   Johnson s   NYSE JNJ   Doxil and Roche Holding  SIX ROG  AG s   OTC RHHBY   Avastin for patients with platinum resistant ovarian cancer Apart from GEN 1 immunotherapy  another cancer program in Celsion s portfolio is ThermoDox  its lead pipeline candidate  It is currently being investigated in a phase III study for primary liver cancer and a phase II study for recurrent chest wall breast cancer The company has no approved product in its portfolio  Thus  investors remain focused on its pipeline progress Celsion Corporation Price
    Zacks Rank   Key PickCelsion carries a Zacks Rank  2  Buy  Sucampo Pharmaceuticals  Inc    NASDAQ SCMP   is another top ranked health care stock  carrying  Zacks Rank  2  You can see  Sucampo s earnings per share estimates have increased from 3 cents to  1 12 for 2017 and from  1 15 to  1 19 for 2018 over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15 63   The company s stock is up 72 7  in the past six months Zacks Editor in Chief Goes  All In  on This StockFull disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ",2018-01-04,Zacks Investment Research,https://www.investing.com/analysis/celsions-phase-iii-cancer-study-initiation-gets-fda-nod-200277899,200277899
198641,420157,JNJ,Dollar slides on data  U S  growth forecast  oil up,news,"By Rodrigo Campos NEW YORK  Reuters    The U S  dollar fell sharply on Tuesday  weighed by mixed retail sales data and economic growth predictions  while crude rose after a surprise drop in forecasts for U S  shale oil production  Energy shares buoyed stocks on Wall Street  with investors also focused on U S  corporate earnings and the data miss  A lower full year earnings forecast from Johnson   Johnson  NYSE JNJ  due to the impact of dollar strength kept gains in check  Angst over the stronger dollar added to a list of concerns throughout the first quarter that have lowered estimates on corporate earnings   Expectations are low  primarily because of economic weakness during the first quarter related to weather  the strong dollar  the West Coast dock strike and oil prices   said Tim Ghriskey  chief investment officer of Solaris Group in Bedford Hills  New York  The Dow Jones industrial average rose 59 66 points  or 0 33 percent  to 18 036 7  the S P 500 gained 3 41 points  or 0 16 percent  to 2 095 84 and the Nasdaq Composite fell 10 96 points  or 0 22 percent  to 4 977 29  The S P energy sector jumped 1 8 percent  The FTSEurofirst 300 index of top European shares ended down 0 45 percent after touching its highest since November 2000  Nikkei futures edged up 0 2 percent  DOLLAR STUMBLES Despite its recent strength  the U S  dollar fell on Tuesday after U S  retail sales rose in March for the first time since last year but at a slower pace than expected  The greenback was also hit by the International Monetary Fund s lowered forecasts for U S  growth  to 3 1 percent for this year and next  from January s expectations of 3 6 percent and 3 3 percent  respectively   I wouldn t be surprised if people bring down Q1 GDP forecasts on the data   said Marc Chandler  global head of currency strategy at Brown Brothers Harriman in New York   Couple that with the IMF  forecasts   and I think you have reason to trim  dollar  positions   he said  The euro strengthened 0 8 percent against the greenback at  1 0649 following six consecutive sessions of losses  The dollar index fell 0 7 percent   Crude oil rose after a forecast that U S  shale oil output would record its first monthly decline in more than four years and on tensions in Yemen  where neighboring top oil exporter Saudi Arabia is embroiled in a civil war   O R  Brent gained 1 7 percent to  58 93 a barrel while U S  crude added 3 3 percent to  53 61  U S  Treasury yields fell after the retail sales data  though prices pared some gains towards the end of the session   It s lower than consensus   said Sean Murphy  a Treasuries trader at  Societe Generale   PARIS SOGN  in New York about the retail sales number   This is slightly helping to confirm that June might be a little bit too early  for a rate hike from the Federal Reserve   The benchmark 10 year Treasury note rose 11 32 in price to yield 1 9002 percent  down from 1 939 percent late on Monday  The yield fell low as 1 855 percent earlier on Tuesday  
Spot gold dropped for a fifth session in six  down 0 5 percent at  1 192 16 an ounce ",2015-04-14,Reuters,"https://www.investing.com/news/stock-market-news/china-shares-pause-for-gdp-test,-euro-pressured-336911",336911
198642,420158,JNJ,Pfizer s Second Biosimilar Of Remicade Receives FDA Approval,opinion,"Pfizer Inc    NYSE PFE   announced that the FDA has approved Ixifi its second biosimilar version of Johnson   Johnson s   NYSE JNJ   blockbuster rheumatoid arthritis   RA   drug  Remicade  infliximab   Notably  Ixifi is a chimeric human murine monoclonal antibody against tumor necrosis factor 
Ixifi received the nod for all approved indications of Remicade including RA  ulcerative colitis  plaque psoriasis  psoriatic arthritis  ankylosing spondylitis and Crohn s disease 
Shares of Pfizer have risen 12 8  so far this year  underperforming the  s rally of 17 7  

The approval was based on an encouraging data from phase III study  REFLECTIONS B537 02  A biologics license application was filed with the FDA in April 
Notably  in February 2016  Pfizer had divested the rights to development  commercialization and manufacturing of Ixifi in the European Economic Area   EEA   to Novartis  generic arm  Sandoz  However  Pfizer retains the commercialization and manufacturing rights to Ixifi in all countries outside the EEA 
We remind investors that Pfizer s first biosimilar product to Remicade  Inflectra  was launched last November in the United States  The company has exclusive commercialization rights to Inflectra in the United States and on certain other territories 
In September  Pfizer filed a lawsuit in a U S  district court alleging that J J is resorting to unfair practices to prevent the sale of Inflectra  available at a Wholesale Acquisition Cost  which is 19  lower than J J s referenced product 
Pfizer alleged in a complaint filed in the U S  District Court for the Eastern District of Pennsylvania that J J has entered into biosimilar exclusion contracts with U S  insurers  These contracts boost insurers not to cover Inflectra  thus making it difficult to access by patients and protecting its referenced product 
Pfizer also claimed that anticompetitive contracts with discounts were offered to hospitals on purchase of Remicade on condition that they do not buy the biosimilar versions  Pfizer claims that these unfair practices benefit sales of J J s referenced product  a key revenue generator for the latter 
Pfizer is evaluating 13 biosimilar molecules in various stages of development  Biosimilar products in late stage development include biosimilar versions of Roche s   OTC RHHBY   Rituxan and Avastin and AbbVie s   NYSE ABBV   Humira  A biosimilar version of Herceptin is under review in the United States and the EU  In Europe  Pfizer markets Nivestim  biosimilar versions of Amgen s Neupogen and Retacrit as well as biosimilar versions of Amgen s Epogen Pfizer  Inc  Price

   Zacks Rank
Pfizer carries a Zacks Rank  3  Hold   You can see  
Zacks Editor in Chief Goes  All In  on This Stock 
Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ",2017-12-14,Zacks Investment Research,https://www.investing.com/analysis/pfizers-second-biosimilar-of-remicade-receives-fda-approval-200273349,200273349
198644,420160,JNJ,Johnson   Johnson beats on Q1 earnings  guides lower,news,"Investing com   Health care conglomerate Johnson   Johnson  NYSE JNJ  reported better than expected first quarter earnings  but provided weak guidance for the year ahead  reflecting further negative foreign currency movements 
J J said earnings per share came in at  1 56 in the first quarter ended March 31  beating expectations for earnings of  1 54 per share 
The company s first quarter revenue totaled  17 37 billion  above expectations for revenue of  17 31 billion 
Operational results increased 3 1  and the negative impact of currency was 7 2  
Domestic sales increased 5 9   while international sales decreased 12 4   reflecting operational growth of 0 8  and a negative currency impact of 13 2  
Excluding the net impact of acquisitions and divestitures  on an operational basis  worldwide sales increased 5 7   domestic sales increased 9 1  and international sales increased 3 0  
 The company delivered strong underlying growth in the first quarter driven by new products and the strength of the core business  Of note is the continued robust growth of the Pharmaceutical business and the solid performance of our Consumer brands   said Alex Gorsky  Chairman and Chief Executive Officer 
The firm now sees full year adjusted earnings per share in a range between  6 04 and  6 19  down from a previous estimate for adjusted earnings between  6 12 and  6 27 per share 
Immediately after the earnings announcement  Johnson   Johnson shares eased up 0 2  in trading prior to the opening bell 
Meanwhile  the outlook for U S  equity markets was downbeat  The Dow futures pointed to a drop of 0 15   the S P 500 futures shed 0 15   while the Nasdaq 100 futures slumped 0 15  ",2015-04-14,Investing.com,"https://www.investing.com/news/stock-market-news/johnson---johnson-beats-on-q1-earnings,-guides-lower-336964",336964
198645,420161,JNJ,Retail sales rebound signals thaw in economic activity,news,"By Lucia Mutikani WASHINGTON  Reuters    Retail sales rose in March for the first time since November as consumers stepped up purchases of automobiles and other goods  suggesting a sharp slowdown in economic growth in the first quarter was temporary   The Commerce Department s fairly sturdy report on Tuesday together with other data showing that producer inflation crept up last month should keep the Federal Reserve on track to start raising interest rates later this year  An unusually snowy winter undercut activity early in 2015  Labor disruptions at normally busy West Coast ports  a stronger dollar and softer global demand also have hurt growth   A rebound in retail sales in March provides evidence that the U S  economy is pulling out of a soft patch seen at the start of the year  The improvement in retail sales     adds to the likelihood of policymakers voting to hike rates this year   said Chris Williamson  chief economist at Markit in London  Retail sales increased 0 9 percent in March  broadly in line with expectations  That was the largest gain since the same month last year and snapped three straight months of declines that had been blamed on harsh winter weather  The sales rebound  which was mainly driven by automobiles  furniture  clothing  building materials  restaurants and bars  was even more encouraging because of the big step back in job growth last month  But retail sales excluding automobiles  gasoline  building materials and food services rose 0 3 percent after dropping 0 2 percent in February  The so called core retail sales correspond most closely with the consumer spending component of gross domestic product   U S  stocks traded marginally higher  with banking giants JPMorgan Chase   Co  N JPM  and  Wells Fargo    Co  N WFC  reporting unexpectedly strong earnings but Johnson   Johnson  N JNJ  announcing that it was cutting its full year earnings forecast due to the impact of the buoyant dollar  Prices for U S  government debt rose  while the dollar was weaker against a basket of currencies  TEPID CONSUMER SPENDING Last month s mild rebound in core retail sales and February s decline pointed to a slower pace of consumer spending in the first quarter   That  however  was offset by a second report from the Commerce Department showing a relatively solid increase in retail inventories excluding autos in February  Data including for retail sales  housing starts  inventories  trade and manufacturing suggest the economy grew at a sub 1 5 percent annual rate in the first quarter after a 2 2 percent pace in the October December quarter  But with household savings at their highest level in just over two years  thanks to a tightening labor market and cheaper gasoline  there is great potential for consumers to boost spending in the months ahead and cushion the economy against the strong dollar   Given the fading headwinds and the considerable war chest that consumers have accumulated in recent months     we look for GDP growth to re accelerate in the second quarter   said Millan Mulraine  deputy chief economist at TD Securities in New York  In a separate report  the Labor Department said its producer price index for final demand rose 0 2 percent last month  with rising prices for goods accounting for more than half of the increase  The PPI had declined 0 5 percent in February  In the 12 months through March  producer prices fell 0 8 percent  the biggest year on year decline since the revamped series started in 2009  A key measure of underlying producer price pressures that excludes food  energy and trade services rose 0 2 percent after being unchanged in February  Core PPI was up 0 8 percent in the 12 months through March   From the Fed s perspective there may be a little reassurance here that the spillover from lower energy prices has been limited thus far   said John Ryding  chief economist at RDQ Economics in New York  Low inflation and signs of a sharp slowdown in economic growth in the first quarter have prompted most economists to push back their expectations for the first Fed rate hike to either September or October from June  Others believe the U S  central bank will only tighten monetary policy in 2016  
The Fed  which has a 2 percent inflation target  has kept its key short term interest rate near zero since December 2008 ",2015-04-14,Reuters,"https://www.investing.com/news/economic-indicators/retail-sales-rebound,-post-largest-gain-in-a-year-336991",336991
198646,420162,JNJ,Incyte  INCY  Reports Phase III Follow Up Data For Jakafi  ,opinion,Incyte Corporation   NASDAQ INCY   announced a new 208 week  4 year  follow up data from the phase III RESPONSE study of Jakafi  The study compared the efficacy and safety of Jakafi with best available therapy  BAT  LON BATS   in patients with polycythemia vera  PV   who are resistant to or intolerant of hydroxyurea  HU  The primary response was a composite endpoint of the proportion of patients  who achieved both hematocrit  Hct  control  defined as no phlebotomy eligibility from week 8 through week 32  and a spleen volume reduction of at least 35  from baseline at week 32  The study met the primary endpoint showing that Jakafi was superior to BAT at controlling hematocrit  Hct  and reducing spleen volume at week 32 The data from this study showed that durable primary response to Jakafi in patients with PV who are resistant to or intolerant of HU and overall safety profile for Jafaki remained consistent with the 80 week RESPONSE data published earlier  In fact  the 80 week follow up from the RESPONSE study confirmed that among patients who initially responded to Jakafi treatment have probability of maintaining primary and hematocrit  Hct  responses for greater than 80 weeks was 92  and 89   respectively  Thus confirming that Jakafi could be an effective long term treatment option for patients with PV who are HU resistant or intolerant So far this year  Incyte s shares have declined 3 7   as against the  s growth of 2 6  Jakafi is Incyte s sole marketed product and is a first in class JAK1 JAK2 inhibitor  It is approved in the United States for the treatment of patients with polycythemia vera  PV   who have had an inadequate response to or are intolerant to hydroxyurea  Also  Jakafi is approved for the treatment of patients with intermediate or high risk myelofibrosis  MF  including primary MF  post PV MF  and post essential thrombocythemia MF While Incyte markets the drug in the United States  it is marketed by Novartis   NYSE NVS   as Jakavi outside the country  Its label has been updated several times since approval  In March 2016  the FDA approved supplemental labeling for Jakafi to include additional safety data as well as efficacy analyses from the RESPONSE study that assessed the durability of response in Jakafi treated patients after 80 weeks Incyte Corporation Price   Zacks Rank   Stocks to ConsiderIncyte has a Zacks Rank  3  Hold   Some better ranked health care stocks in the same space are Sucampo Pharmaceuticals   NASDAQ SCMP   and Johnson and Johnson   NYSE JNJ    Both the companies hold a Zacks Rank  2  Buy   You can see  Sucampo s earnings per share estimates have moved up from 3 cents to  1 12 for 2017 and from  1 15 to  1 19 for 2018  over the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with an average beat of 15 63   The share price of the company has increased 18   year to date Johnson and Johnson s earnings per share estimates have moved up from  7 19 to  7 28 for 2017 and from  7 75 to  7 85 for 2018  over the last 60 days  The company pulled off a positive earnings surprise in all of the trailing four quarters  with an average beat of 3 12   The share price of the company has increased 22   year to date Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-12-10,Zacks Investment Research,https://www.investing.com/analysis/incyte-incy-reports-phase-iii-followup-data-for-jakafi-200272122,200272122
198647,420163,JNJ,Johnson   Johnson Opens Bay Area Biotech Incubator ,news,"By    

Johnson   Johnson  NYSE JNJ  announced the grand opening of a biotech incubator in South San Francisco on Tuesday and unveiled the first 10 businesses that will reside there  The 30 000 square foot facility can house up to 50 startups at a time  and its members will focus on developing healthcare solutions in the highly competitive industries of pharmaceuticals  medical devices and digital health  The inaugural members of the incubator  called a JLab  will include start ups focused on chronic pain  rare diseases and skin cancer  Employees of a firm called Goleini Inc  who are developing a gene therapy for glaucoma will work there along with the team at Corexyme  which is trying to stave off Alzheimer s disease   You ve got young scientists with first time startups  but we also decided to have some seriously experienced serial founders and heavyweights come in  so that we have this great mix of dynamic new talent and experienced wisdom   Melinda Richter  head of the innovation for Johnson   Johnson  told FierceBiotech   And that s really what the community is about   One member company called Applied Molecular Transport has already announced a partnership with Janssen Biotech Inc   a division of Johnson   Johnson  for a treatment of inflammatory bowel disease  Another called EpiBiome Inc  earned its place in the incubator by winning a competition hosted earlier this year and is attempting to treat diseases in livestock by tapping the microbiome  the term for the many microorganisms that reside within humans and other large animals  California is already home to 2 490 companies that focus on biomedicine  which is more than any other state  Its lawmakers have offered startup friendly policies including a sales tax exemption for companies to use when purchasing equipment related to research and development  Even during the recession  which hit California particularly hard  this homegrown industry continued to grow at a faster clip than in any state except North Carolina  according to a report by PricewaterhouseCoopers   The addition of JLabs to the Bay Area is a welcome and needed resource that will help advance innovative products and further support the formation of additional life science companies   Richard Garbarino  mayor of South San Francisco  said in a statement  Johnson   Johnson runs similar incubators in San Francisco  San Diego and Boston and plans to open a fifth in Houston next year  Members of each incubator rent space and gain access to laboratory equipment  business services  educational programs and offices as part of a  no strings attached  arrangement  according to the company s website  However  it s clear that Johnson and Johnson sees the 70 companies housed in its JLabs throughout the country as a loosely held extension of the company s own innovation arm  Over the years  Johnson and Johnson has struck 20 deals with member companies for products or medicines created at its incubators and is currently in negotiations for 20 more  as reported by San Francisco Business Times ",2015-03-03,International Business Times,https://www.investing.com/news/stock-market-news/johnson---johnson-opens-bay-area-biotech-incubator-330676,330676
198648,420164,JNJ,AbbVie To Acquire Cancer Drugmaker Pharmacyclics For  21B ,news,"By   

 AbbVie Inc   NYSE ABBV   has agreed to acquire Pharmacyclics Inc  in a transaction valued at  21 billion  according to a statement released by the two companies on Wednesday  The deal would give AbbVie control over Pharmacyclics  flagship Imbruvica drug  which is used to treat blood cancer 
Chicago based AbbVie will acquire all of the outstanding shares of Pharmacyclics through a tender offer  Under the terms of the deal  AbbVie will pay  261 25 per share comprised of a mix of cash and AbbVie equity  the two companies said  in the statement  The deal values the smaller drugmaker at a premium to its current market value of  16 5 billion  AbbVie reportedly outbid rivals also looking to acquire the Sunnyvale  California  drugmaker 
 Its flagship product  Imbruvica  is not only complementary to AbbVie s oncology pipeline  it has demonstrated strong clinical efficacy across a broad range of hematologic malignancies and raised the standard of care for patients   Richard A  Gonzalez  chairman and CEO of AbbVie  said  in the statement 
The drug  whose sales are reportedly expected to grow to  3 56 billion over the next three years  has already been approved for use in treating several different types 0f blood cancer 
The joint announcement comes just hours after the Financial Times reported  citing people familiar with the matter  that Johnson   Johnson  NYSE JNJ  was nearing a deal to acquire Pharmacyclics  According to a Forbes report  AbbVie apparently outbid several other companies that were interested in the biotech company 
Shares in Pharmacyclics closed at  230 48  up 6 3 percent  in U S  trading on Wednesday ",2015-03-05,International Business Times,https://www.investing.com/news/stock-market-news/abbvie-to-acquire-cancer-drugmaker-pharmacyclics-for-$21b-330939,330939
198649,420165,JNJ,How Will U S  Tax Reform Impact Pharma Biotech Industry ,opinion,"Tax reform has been grabbing headlines since the election campaign last year  However  the plan has been modified quite a few times  With a Congressional vote expected this week to move the tax reform bill forward  let s revisit some aspects of the bill and their impact on the biotech pharma industry 
Corporate Tax Cut
The bill in its current form proposes to cut the tax rate for corporates from 35  to 20   Although it is higher than the originally proposed 15   a 15 point cut will also help companies to save a considerable amount in tax payment in the United States The bill also proposes a full exemption on future dividend income from a company s foreign subsidiaries 
Currently  if foreign income is repatriated  it is taxed at 35  with a full credit of the local levies  However  the change will allow foreign subsidiaries to send the cash back to the parent company after just paying local taxes 
This will leave some extra cash in the hands of these companies to fund their capital expenditures  acquisitions and share buybacks among others  The lower tax rate and inflow of foreign income may lead to a rise in mergers   acquisitions  M A   which have been relatively low so far in 2017  Pharma sector acquisitions so far this year include Johnson   Johnson s   NYSE JNJ   buyout of Actellion and Gilead Sciences  Inc  s   NASDAQ GILD   takeover of Kite Pharma 
Minimum Tax on Foreign Earnings
While the bill cuts tax rates and removes tax on dividends from foreign subsidiaries  it proposes to implement  minimum tax  on foreign incomes  Under the current tax plan  the companies can defer tax payment by parking its foreign profits in the host country  However  if minimum tax is imposed  there will be no deferral route to skip taxes  The companies will have to pay taxes  difference of minimum tax   local taxes  every year  which will increase the tax bill of U S  based companies 
This proposed tax may improve the competitiveness of foreign pharma companies like Swiss giants AstraZeneca   NYSE AZN   and Novartis   NYSE NVS   against their U S  based counterparts 
However  the rate of this tax has yet to be decided 
Cash Repatriation Window
The current tax plan allows multinational companies to keep their foreign cash in the host country and thereby defer tax liability in the United States  However  the proposed minimum tax will stop the deferral system  The companies that have hoarded cash in low tax countries will be allowed to repatriate at a much lower rate 
This move will also increase domestic cash for the companies  The biotech companies may utilize the extra cash to fund their clinical studies or make a strategic acquisition to strengthen their portfolio 
Deductions
The tax reform proposes to expense capital expenditure excluding costs for structures like plants and warehouses in the current year rather than deferring it over 5 15 years as allowed currently  The large pharma companies areexpected to have a huge pile of cash available with them upon a potential tax reform 
Any acquisition or setting up of a manufacturing facility will help the companies to lower the tax bill in the near term  However  the reform will partially limit the deduction of interest on debt in tax calculation  The deduction limit is yet to be set 
Moreover  presently the companies can claim a tax credit for half of the research cost related to development of drugs for rare diseases  This credit may get eliminated if the reform passes  This will hurt the small biotech companies  which could have recouped some of their development costs 
Although the Senate budget committee has voted the bill for a full vote of the house  many are still sceptical about the tax reform  Many still believe that this will add to the country s fiscal deficit  Some also argue that lower federal revenues  a result of lower taxes will strain healthcare funds 
Moreover  healthcare costs are expected to increase in the future as the United States will see an increase in the number of aged people  which will further dent healthcare funds  Congress is still divided on the impact of the tax reform over the long term 
Investor Alert  Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline 
Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ",2017-11-29,Zacks Investment Research,https://www.investing.com/analysis/how-will-us-tax-reform-impact-pharmabiotech-industry-200269275,200269275
198650,420166,JNJ,Glaxo Begins Phase III Study On Injection To Prevent HIV ,opinion,GlaxoSmithKline plc   NYSE GSK   has announced the start of a large late stage African study on an experimental long acting injection for the prevention of HIV  ViiV Healthcare  an HIV company majorly owned by Glaxo and Pfizer   NYSE PFE    said that the phase III study  HPTN 084  will evaluate long acting cabotegravir monotherapy for the prevention of HIV infection in sexually active women ViiV Healthcare is conducting the study under a public private funding collaboration with the National Institute of Allergy and Infectious Diseases  NIAID  and the Bill   Melinda Gates Foundation  While NIAID  part of the National Institutes of Health  NIH   is sponsoring the study  ViiV Healthcare and Gilead   NASDAQ GILD   are providing the medicines  The study will enrol more than 3 000 women between the age of 18 and 45 from sub Saharan African countries In order to prevent HIV infection  uninfected people  at present  use oral anti retroviral medication  which needs to be taken every day  Compared to these  cabotegravir injections will be administered every two months  if approvedGlaxo s shares have declined 9  this year so far  underperforming the 16 2  increase witnessed by the  ViiV Healthcare is already conducting a HPTN 083 study on cabotegravir in HIV uninfected men and transgender women who have sex with men  also under co funding with NIAID  Meanwhile  cabotegravir is also being evaluated in three late stage studies as a two drug regimen with Johnson   Johnson s   NYSE JNJ   Edurant rilpivirine  with the third study initiation announced earlier this week Last week Glaxo and partner J J announced FDA approval of the first dual treatment for HIV  Juluca  Tivicay dolutegravir   Edurant rilpivirine   Juluca has been developed under a partnership between ViiV Healthcare and Janssen HIV has been a key therapeutic area for Glaxo  Its two new HIV drugs  Tivicay and Triumeq have been recording consistently strong sales while gaining market share  Glaxo s HIV sales rose 16  at constant exchange rate in the first nine months of 2017  Meanwhile  a significant portion of its R D expenditures goes toward developing HIV medicines to treat prevent HIV Glaxohas a Zacks Rank  3  Hold   You can see  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2017-11-30,Zacks Investment Research,https://www.investing.com/analysis/glaxo-begins-phase-iii-study-on-injection-to-prevent-hiv-200269793,200269793
198651,420167,JNJ,Gilead   3 Other Drug Stocks In Focus This World AIDS Day,opinion,"World AIDS Day takes place every year on December 1 with people across the world coming together to fight against HIV  to support those living with HIV and to commemorate those who have died from an AIDS related disease Everybody CountsThe slogan for this World AIDS Day is  Everybody Counts   The goal is to ensure access to affordable and high quality care and services for people with HIV  a strong health care system  as well as the integration of HIV  tuberculosis and hepatitis services According to information provided by the World Health Organization   WHO    more than 35 million people have lost their lives due to HIV so far while one million people died last year from HIV related causes  At the end of 2016  approximately 36 7 million people were living with HIV  Number of newly infected HIV patients was 1 8 million in 2016 Currently Available TreatmentsWhile there is no cure for HIV at present  the virus can be controlled through the use of effective antiretroviral   ARV   drugs  According to WHO  54  of adults and 43  of children with HIV are currently on lifelong ARV   19 5 million people living with HIV were receiving antiretroviral therapy   ART   in 2016  Combination ART  combining 3 or more ATV drugs  has been found to be effective in suppressing viral replication within a person s body thereby allowing the immune system to strengthen and regain the capacity to fight off infections The HIV drug landscape has evolved over the years with drugs with varying mechanisms of action being approved over the years  These include multi class combination products  Atripla  Complera  Stribild   nucleoside reverse transcriptase inhibitors  NRTIs   Combivir  Epivir  Truvada  Viread   non nucleoside reverse transcriptase inhibitors  NNRTIs   Edurant  Sustiva   protease inhibitors  PIs   Prezista  Reyataz  Norvir   HIV integrase strand transfer inhibitors  INSTI   Isentress  Tivicay  as well as fusion inhibitors and entry inhibitors  CCR5 co receptor antagonist  According to WHO  new HIV infections fell by 39  between 2000 and 2016 while HIV related deaths declined by one third with ART saving 13 1 million lives  However  with only 70  of HIV infected people being aware of their status  there remains significant need to spread awareness about the disease and the availability of rapid diagnostic tests  RDTs   which detect the presence or absence of HIV antibodies   According to GlobalData  the HIV market across the United States  France  Germany  Italy  Spain  the UK  Japan  Brazil  and China  is expected to grow from  16 3 billion in 2015 to  22 5 billion by 2025 There is significant need for new alternative ARV treatment options that come with better tolerability  higher efficacy  and lower rates of treatment discontinuation  Here is a look at a few key players in the HIV market 4 Drug Stocks in FocusJohnson   Johnson   NYSE JNJ    J J is a key player in the HIV market with the company introducing several transformational medicines in this therapeutic area over the last 25 years  The company and its partner GlaxoSmithKline plc   NYSE GSK   recently gained FDA approval for  Juluca  the first  complete  single pill  two drug regimen for the treatment of HIV 1 infection in certain adults living with the disease who are virologically suppressed The once daily  antiretroviral is a combination of Tivicay  INSTI  and Edurant  NNRTI  which maintains the safety and efficacy of a traditional three drug regimen without an NRTI  Simpler treatment regimens will make compliance easier for HIV patients who need to stay on a consistent treatment regimen in order to keep their viral counts low The company is currently seeking FDA approval with partner Gilead Sciences  Inc    NASDAQ GILD   for a darunavir based single tablet regimen   STR    The once daily regimen comprises darunavir 800mg cobicistat 150mg emtricitabine 200mg tenofovir alafenamide 10mg  D C F TAF  J J is also working on an HIV vaccine  The company along with The Bill   Melinda Gates Foundation and National Institutes of Health is conducting an efficacy study for an investigational mosaic HIV 1 preventive vaccine  There is significant unmet need for a vaccine for HIV   although a lot of progress has been made in treating and managing the disease  almost two million people become infected every year  Developing a vaccine for HIV has proved to be challenging due to the unique properties of the virus including its ability to mutate rapidly  Moreover  genetic diversity with multiple strains and subtypes prevalent in different parts of the world are additional hurdles J J is a Zacks Rank  2  Buy  stock   you can see   The stock has gained 20 9  year to date  compared to the 16 3  rally of the  it belongs to 
Gilead Sciences  Inc   HIV is one of the primary areas of focus at Gilead  The company s HIV portfolio includes drugs like Genvoya  Truvada  Atripla  Descovy  Odefsey  Complera and Stribild which contributed approximately  9 5 billion to total sales in the first nine months of 2017  Gilead s TAF based products like Genvoya  Descovy and Odefsey remain key growth drivers  Gilead is currently seeking FDA approval for an investigational  fixed dose combination of BIC FTC TAF with the FDA expected to respond on Feb 12  2018  Meanwhile  the company expects to complete a 6mg cohort phase I study on GS 9620  TLR 7 agonist  HIV cure  by year end  A late stage study evaluating Descovy for pre exposure prophylaxis  PrEP  is scheduled to complete in the third quarter of 2018 With the company s hepatitis C virus   HCV   franchise seeing declining sales  Gilead is focusing on its HIV franchise for growth  The company s non HCV products are expected to generate sales of  16    16 5 billion in 2017  However  competition in this market is intense  Moreover  the company is facing competition from generic products as well Gilead is a Zacks Rank  3  Hold  stock  The stock has gained 4 4  year to date  compared to the 2 6  rally of the  it belongs to 
GlaxoSmithKline  Glaxo is a majority stakeholder in ViiV Healthcare  a global specialist HIV company  which was set up in partnership with Pfizer Inc    NYSE PFE   in 2009 and now has Shionogi as a shareholder as well  Key products in the HIV portfolio include Triumeq and Tivicay  Glaxo is working on bringing new growth drivers into the HIV business with Juluca being a recent addition  Glaxo is exploring new treatment paradigms  two drug regimens   new modalities  long acting injectables  and new mechanisms of actions  including maturation inhibitors and broadly neutralising antibodies   The company is working on a dolutegravir   lamivudine combination which will also be for naive patients and a long acting cabotegravir plus rilpivirine combination ViiV has commenced a late stage study on long acting cabotegravir for the prevention of HIV infection in sexually active women  The study will compare cabotegravir injections given every two months to daily oral pre exposure prophylaxis  PrEP  with emtricitabine tenofovir disoproxil fumarate Glaxo  a Zacks Rank  3 stock  has declined 8 9  year to date  compared to the 16 3  rally of the  it belongs to 
Merck   NYSE MRK    Merck has a presence in the HIV market in the form of Isentress Isentress HD  HIV integrase inhibitors for use in combination with other antiretroviral agents  The company s HIV franchise brought in sales of  896 million in the first nine months of 2017  down 15  from the year ago period mainly due to lower demand in the United States due to competitive pressures Merck s HIV pipeline has a couple of late stage candidates   MK 1439  doravirine  NNRTI  and MK 1439A  doravirine lamivudine tenofovir disoproxil fumarate   DOR 3TC TDF   The company expects to file for regulatory approval of doravirine both as a single entity tablet and as a fixed dose combination tablet  DOR 3TC TDF  by year end Merck  a Zacks Rank  3 stock  has declined 6 1  year to date  compared to the 16 3  rally of the  it belongs to 
5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2017-11-30,Zacks Investment Research,https://www.investing.com/analysis/gilead--3-other-drug-stocks-in-focus-this-world-aids-day-200269772,200269772
198652,420168,JNJ,Sanofi s Toujeo Meets Key Objective In Head to Head Study ,opinion,Sanofi  PA SASY   Inc    NYSE SNY   announced that a head to head study comparing Toujeo  insulin glargine   a long acting insulin to Novo Nordisk s   NYSE NVO   Tresiba long acting insulin  insulin degludec  has met the main objective  The study showed that the extent to which Toujeo lowered blood glucose levels in adult patients with diabetes was similar to Tresiba Other than assessing the similarity and difference in efficacy  the secondary objective of the BRIGHT study involves the evaluation of an important safety aspect such as the total number of participants with low blood sugar events  Full results from the study are expected to be presented next year Sanofi s shares have risen 9 2  so far this year  comparing unfavorably with a gain of 16 5  recorded by the  Toujeo is already marketed in the United States and EU  The injection recorded sales growth of 45  in the first nine months of 2017 and is a key new product in Sanofi s portfolio  Please note that Sanofi s Diabetes franchise is under significant pressure with key product  Lantus  facing increasing competitive pressure at the payor level and biosimilar competition in several European markets and Japan  Moreover  a biosimilar version of Lantus hit the U S  markets in December last year In 2017 so far  Lantus sales have declined 24 9  in the United States due to lower average net price and due to exclusion from the CVS Health Corporation   NYSE CVS   and United Health formulary plans  U S  diabetes sales have declined 20 2  so far in 2017 In fact  U S  diabetes franchise sales are expected to decline at an accelerated rate in the fourth quarter due to CVS United Health formulary exclusion plans  continued lower average pricing and difficult comparisons with the last year Sanofi carries a Zacks Rank  4  Sell  You can see A better ranked large cap pharma stock is Johnson   Johnson   NYSE JNJ    carrying a Zacks Rank  2  Buy  Shares of J J have risen 20 7  this year so far while 2018 earnings estimates have gone up 1 3  in the past 60 days Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-12-04,Zacks Investment Research,https://www.investing.com/analysis/sanofis-toujeo-meets-key-objective-in-headtohead-study-200270632,200270632
198653,420169,JNJ,New sponsors ready to replace old say beleaguered FIFA,news,"By Mike Collett LONDON  Reuters    FIFA have rejected suggestions that major sponsors were cutting their ties with the organization because it was a  toxic brand   saying on Friday that they were in advanced negotiations with new sponsors eager to replace the old  Britain s Daily Telegraph revealed on Friday that three major sponsors  Continental  Castrol and Johnson   Johnson  were not renewing their contracts with world soccer s governing body  Emirates Airlines and Sony announced last year that they were also severing their ties with FIFA  But FIFA s marketing director Thierry Weil told Reuters on Friday that those companies contracts with FIFA were always due to expire at the end of last year and new ones were negotiating to take their place   Rotations at the end of a sponsorship cycle are commonplace in the sports industry and have continuously occurred since the commercialisation of the FIFA World Cup began   Weil said   It is natural that as brands  strategies evolve they reassess their sponsorship properties  The contracts were always planned to run until the end of 2014   As in previous FIFA World Cup cycles  we are now in advanced negotiations with a number of companies related to sponsorship agreements in all three of our categories  TOXIC BRAND  But not everyone is convinced that FIFA  who have been buffeted by one crisis after another over the last few years  is still a name sponsors want to be associated with  Damian Collins  the British MP and the guiding light behind the pressure group New FIFA Now which was launched in Brussels on Wednesday  said he believed sponsors were cutting ties as a result of the scandals and controversies that continually surround FIFA   FIFA is a toxic brand   Collins was quoted as saying in the Daily Telegraph   I think that s why companies who care about their reputation don t want to be considered with it   Sponsors bring in at least  1 5 billion in revenue over each four year cycle   Castrol had been a World Cup sponsor since 2008  Continental Tyres since 2010 and Johnson   Johnson signed a deal for a single cycle in 2011   Meanwhile the sportswear company SKINS  whose chairman Jamie Fuller was a delegate at the launch of New FIFA Now  launched a light hearted  non sponsorship  relationship with the governing body  In a statement on Friday the company said   The non multi million pound  announcement allows the company to highlight unshared brand values and confirms SKINS  contempt for an organisation which has been constantly shrouded in allegations of corruption and controversy  yet is potentially preparing to re elect its President Sepp Blatter for an unprecedented fifth term in office   This anti FIFA stance is intended to be fun and engaging but it carries a very serious message in support of newfifanow org   
 Refile to fix lit in third last par  light hearted sted heated  ",2015-01-23,Reuters,https://www.investing.com/news/general-news/new-sponsors-ready-to-replace-old-say-beleaguered-fifa-324796,324796
198654,420170,JNJ, Slower Than Expected ,news,"By    

The U S  Food   Drug Administration is on track to approve a new drug by Sandoz  marking the first time a so called biosimilar has made it through the agency s accelerated approval process  The drug compound  known as filgrastim  is meant to boost the immune systems of cancer patients by helping to make white blood cells  Its imminent government consent represents a promising step for drugmakers that have long been banned from selling biosimilars in the U S  while marketing them freely in Europe    The FDA approval of a filgrastim biosimilar represents a milestone   says Joshua Cohen  a researcher who specializes in drug development at Tufts University  Getting the FDA s go ahead  however  may be the easy part for Sandoz  The company s next big test will be to push doctors to prescribe its drug  patients to take it  and insurance companies to pay for it  a task that hasn t proven easy in Europe  While certain remedies have found success in specific countries   and the drug Sandoz is pushing has achieved a 30 percent market share in Europe  according to the company   overall adoption has been  slower than expected   as Cohen states in a recent study on biosimilars in the U S  Cohen says that s partly because European doctors and patients have been largely reluctant to switch due to unfamiliarity and safety concerns  Nearly a quarter of doctors there could not describe or have never heard of biosimilars  according to a 2014 survey of 470 doctors across Europe  Pharmaceutical companies with plans to bring their own biosimiliars to market are watching closely  Biosimilars are so named for their similarity to biologics  which are derived directly from living organisms as modified proteins  sugars or nucleic acids  The drugs include treatments for cancer and autoimmune diseases as well as vaccines  blood  allergy shots and gene therapies  Worldwide  biologics made up a  170 billion industry in 2013 and rank among some of the top selling drugs in America  But many are coming up on their due date  IMS Health estimates that  64 billion worth of drugs classified as biologics will be off patent by 2015 in the U S  and Europe  leaving them open to competition if other companies can make a fair approximation of the original    By mimicking biologics at a lower price  biosimilars should bring financial relief for patients and insurance companies  Last year  the RAND Corporation estimated that biosimilars could save patients and insurance companies in the U S   44 2 billion by 2024   The biosimilar  because it s a very close copy of the original  is a very good substitute for patents to take if the patient is in a setting where the cost might matter   says Fiona Scott Morton  an economist at Yale University  In addition to Sandoz  at least three other companies have filed drug applications for biosimilars through the FDA  Celltrion has applied for approval of a monoclonal antibody  which treats rheumatoid arthritis and could rival Remicade  a product of Johnson   Johnson s Janssen Biotech with a patent set to expire in September 2018  Earlier this month  an advisory committee unanimously recommended Sandoz s drug  which would be marketed as Zarxio  for FDA approval  A final decision is still pending and expected by May if the FDA is to meet its goal for speedy approvals of biosimilars  Just because a drug is approved  however  does not mean it will be endorsed by insurance companies  stored on site by hospitals or prescribed to patients by their doctors  Cohen says that the uptake of biosimilars in Europe has been  a bit disappointing  since countries there began approving them in 2006  There are now 17 such medicines available in European markets  several of which are expected to make their way to the U S  in the coming years  Dr  Phillip Cole  head of the pharmacology department at Johns Hopkins University  says it may take time for doctors to feel completely comfortable with the safety of biosimilars  The complexity and size of the molecules in biologics cannot be replicated exactly  so biosimilars vary slightly from the original drugs on which they are based    I think that it will be important  once we start having these used in large numbers of patients  to continue to follow them in post market surveillance where we ensure that there isn t really a differential in the level of side effect   he says   Another reason doctors and patients may not have been so eager to switch is that cost savings for biosimilars are not quite as significant as for generics because that complexity also drives up manufacturing costs   Standard generics are typically 80 to 90 percent cheaper than the major brands   Scott Morton says  Cost savings in Europe have averaged about 25 percent but Cohen expects savings to be even greater in the U S  In Europe  state run health systems have largely failed to provide incentives to entice doctors and hospitals to prescribe biosimilars according to Cohen  Scott Morton suggests there may still be logistical hurdles since biologics can sometimes require delicate handling   It s not clear that a doctor who treats people on several different insurance plans wants to hold several different biosimilars in his or her fridge   she says  Still  Cohen is more optimistic about the industry s promise in the U S  Sales of biosimilars doubled worldwide from  6 4 billion in 2006 to  12 4 billion in 2012  I expect payers to push harder than their European counterparts for biosimilar uptake   he says  by perhaps instating a lower cost for patients to pay as compared with a biologic  In a review of survey results from 277 physicians who attended a cancer conference in 2011  Cohen also learned that 62 percent of U S  physicians had at least moderate interest in prescribing a biosimilar to their patients  He also thinks professional organizations will revise their clinical guidelines to recommend biosimilars to doctors  Cohen expects to see more U S  applications for biosimilars in the near future   I expect other filgrastim products  such as the pegfilgrastim  originator is Neulasta  to be approved soon   in 2015 or 2016   he says ",2015-01-23,International Business Times,https://www.investing.com/news/stock-market-news/'slower-than-expected'-324862,324862
198655,420171,JNJ,2 Large Cap Drug Stocks Missing Out On Industry Rally In  17,opinion,After the drug pricing issue crippled its performance last year  the drug biotech industry  except for a small correction recently  has witnessed a turnaround this year  Stocks with large market cap have done particularly well  After declining 5 2  last year  the industry has risen 15 3  this year so far with a number of things going in its favor Strong quarterly results  new product sales ramp up with rising demand  successful innovation and product line expansion  strong clinical study results  more frequent FDA approvals and continued strong performance of legacy products played a pivotal role in bringing the large cap drug sector back on track this year Most drug companies with a larger market cap have seen their share price rising this year  AstraZeneca   NYSE AZN    Novo Nordisk   NYSE NVO    Novartis   NYSE NVS    and Johnson   Johnson   NYSE JNJ   have even outperformed the industry  However  a couple of large cap pharma companies have witnessed a downside this year  We discuss them below Merck   Co   Inc    NYSE MRK  While Merck was one of the very few companies whose shares were up last year notwithstanding the industry s decline  it s the other way round this year  Shares of Merck have declined 7 3  this year so far Merck has suffered some notable pipeline setbacks this year  In October  Merck decided not to seek approval for its CETP inhibitor anacetrapib for cholesterol management as its clinical profile was not strong enough to support regulatory filings Last month  the company also announced a delay in the readout from an important lung cancer study to 2019  This was due to the inclusion of overall survival as a co primary endpoint in the KEYNOTE 189 phase III study of Keytruda in first line lung cancer  This raised investor concern  as the delay in the readout can give competitors a chance to gain strength in the lung cancer market In October  Merck also withdrew a regulatory application in Europe  which was looking to get Keytruda approved as first line combination therapy for lung cancer In September  Merck discontinued the development of two of its HCV combination programs   MK 3682B and MK 3682C   saying that the HCV market is becoming extremely crowded  Also  three combination studies of Keytruda for multiple myeloma were placed on clinical hold following reports of death in Keytruda groups in July  Keytruda is seen as a key long term growth driver at Merck and such setbacks do not bode well for the company It remains to be seen if the strong performance of its new drugs  particularly Keytruda  its strong vaccines and animal health business and cost saving efforts can help Merck pick up from here GlaxoSmithKline plc   NYSE GSK  Shares of Glaxo are down 7 7  this year so far The stock was on a rising trajectory till the announcement of third quarter resultson Oct 25  On the third quarter conference call  Glaxo expressed its interest to purchase Pfizer s   NYSE PFE   consumer healthcare business  which the latter plans to put up for sale  However  Glaxo s interest in buying Pfizer s unit raised investor concerns about the acquirer possibly sacrificing a portion of its dividend payment due to the potential buyout  Shares declined sharply thereafter Meanwhile  persistent challenges like stiff competition  genericization  pricing pressure and slowing growth in emerging markets have been hurting sales  Pricing pressure and competitive dynamics are hurting sales in Glaxo s respiratory franchise  particularly the older products  Meanwhile  its top selling product  Advair is also expected to face generic competition in the United States next year  which will further hurt sales  The slowdown in sales of the Consumer Healthcare segment this year is also a concern We would like to see if Glaxo s strong pipeline  consistent outperformance of new HIV drugs and vaccines  three new products   Trelegy Ellipta  Shingrix and Juluca   that have boosted its portfolio lately  and cost cuts can bring it back on track next year Both Merck and Glaxo have a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-11-27,Zacks Investment Research,https://www.investing.com/analysis/2-largecap-drug-stocks-missing-out-on-industry-rally-in-17-200268745,200268745
198656,420172,JNJ,Pfizer Merck KGaA s Bavencio Fails In Gastric Cancer Study,opinion,Pfizer  Inc    NYSE PFE   and its Germany based partner Merck  NYSE MRK  KGaA  announced that a phase III study evaluating their key pipeline candidate  avelumab  for the treatment of gastric cancer in the third line setting  failed to meet the primary endpoint The JAVELIN Gastric 300 trial study evaluated avelumab monotherapy for the treatment of unresectable  recurrent or metastatic gastric or gastroesophageal junction  GEJ  adenocarcinoma in patients whose disease progressed following two prior therapeutic regimens  regardless of PD L1 expression  The study failed to demonstrate superior overall survival   the primary endpoint   of avelumab treatment over chemotherapy Though this study evaluating avelumab use in a hard to treat patient population failed  the other gastric cancer study   JAVELIN Gastric 100   continues  It is evaluating avelumab in the first line switch maintenance setting Shares of Pfizer have risen 10 4  this year compared with a 15 3  increase for the industry  Avelumub  a human anti PD L1 antibody  received FDA approval for metastatic Merkel cell carcinoma  MCC   a rare form of skin cancer  in March and for advanced bladder cancer in May  to be marketed by the trade name of Bavencio  Bavencio was also approved in EU and Japan in September for MCC Meanwhile  avelumab is being evaluated for different types of cancers both as monotherapy and in combination with other portfolio assets  Pfizer has also initiated avelumab double triple combination studies for chemotherapy and targeted therapies and has eleven avelumab combination therapies with immuno oncology agents under development Currently  avelumab is being developed for more than 15 types of tumors including gastric gastroesophageal junction  head and neck  Hodgkin s lymphoma  non small cell lung  ovarian  renal cell carcinoma and others  These studies are part of the JAVELIN development program  Bavencio is considered to be a key long term growth driver for Pfizer Pfizer carries a Zacks Rank  3  Hold   You can see Some better ranked large cap pharma stocks include Johnson   Johnson   NYSE JNJ   and H  Lundbeck A S   OTC HLUYY    both carrying a Zacks Rank  2  Buy  Shares of J J have risen 21 5  this year so far while 2018 earnings estimates have gone up 1 8  in the past 60 days Shares of Lundbeck have risen 26 1  so far this year while 2018 earnings estimates have gone up 3 2  in the past 30 days Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2017-11-28,Zacks Investment Research,https://www.investing.com/analysis/pfizermerck-kgaas-bavencio-fails-in-gastric-cancer-study-200269222,200269222
198657,420173,JNJ,Merck Announces  10 Billion Buyback  Hikes Dividend By 2 1 ,opinion,In an effort to enhance its shareholders  value  Merck   NYSE MRK   declared a 2 1  hike in quarterly dividend to 48 cents from 47 cents per share paid last quarter The increased dividend will be paid on Jan 8  2018 to shareholders of record as of Dec 15  2017 The raised dividend rate brings Merck s annual dividend to  1 89 per share  implying a yield of 3 5   which is better than the industry average of 2 6  Concurrently  the board of directors of Merck also sanctioned a new  10 billion stock buyback plan  Notably  during the first nine months of 2017  the company completed the purchase of  2 3 billion of its equity Merck s financial strength enables it to continue with its repurchase program and initiate dividend payouts  As of Sep 30  2017  the company s cash and cash equivalents were  7 9 billion  The increased repurchase authorization and new dividend payouts are expected to boost investors  confidence in the stock  Merck s strategy to return wealth to the shareholders demonstrates its growth potential and a stable liquidity position Meanwhile  Merck has a global restructuring program in progress  aimed at reducing the cost structure and increasing the company s efficiency  It intends to decrease the number of manufacturing sites including the animal health one and consolidate other facilities instead  The company expects annual savings of about  4 0  4 6 billion  once the restructuring program is completed Merck has also divested segments like the Consumer Care business so that it can focus on its core areas of expertise However  Merck s shares have declined 6 2  this year so far  underperforming the  s16 2  rally  The company has also suffered some notable pipeline setbacks this year  hurting the share price performance  In October  Merck decided not to seek an approval for its CETP inhibitor  anacetrapib  for cholesterol management as its clinical profile was not strong enough to support the regulatory filings Last month  the company also postponed the readout from an important lung cancer study to 2019  This was due to the inclusion of overall survival as a co primary endpoint in the KEYNOTE 189 phase III study on Keytruda in first line lung cancer  This raised investors  concern as the delay in the readout can give competitors a chance to gain strength in the lung cancer market In October  Merck also withdrew a regulatory application in Europe  which was looking to get Keytruda approved as a first line combination therapy for lung cancer In September  Merck discontinued the development of two of its HCV combination programs   MK 3682B and MK 3682C   citing the HCV market to be extremely crowded  Also  three combination studies on Keytruda for multiple myeloma were placed on clinical hold following reports of death in Keytruda groups in July  The drug is seen as a key long term growth driver at Merck and such setbacks do not bode well for the company It remains to be seen if the strong performance of the company s new drugs  particularly Keytruda  its strong vaccines  animal health business and cost saving efforts can help Merck pick up from here Merck   Company  Inc  Price   Zacks Rank   Key PicksMerck carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector are Johnson   Johnson   NYSE JNJ    Ligand Pharmaceuticals Inc    NASDAQ LGND   and Achillion Pharmaceuticals  Inc    NASDAQ ACHN    each carrying a Zacks Rank  2  Buy   You can see  Johnson   Johnson s earnings per share estimates have moved up from  7 18 to  7 28 for 2017 and from  7 71 to  7 85 for 2018 over the last 60 days  The company came up with positive earnings surprises in each of the trailing four quarters with an average beat of 3 21   Share price of the company has surged 21 9  year to date Ligand s earnings per share estimates have moved up from  3 68 to  3 70 for 2018 over the last 30 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 8 22   Share price of the company has surged 29 6  year to date Achillion s loss per share estimates has narrowed from 65 cents to 63 cents for 2017 and from 74 cents to 67 cents for 2018 over the last 30 days  The company came up with positive earnings surprises in two of the trailing four quarters with an average beat of 4 51  Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2017-11-28,Zacks Investment Research,https://www.investing.com/analysis/merck-announces-10-billion-buyback-hikes-dividend-by-21-200269214,200269214
198659,420175,JNJ,Johnson   Johnson s Ebola Research Gets  115M ,news,"By    
Johnson   Johnson will receive  115 million to support its Ebola vaccine research through a private public partnership  the company said on Friday   The money comes from Europe s Innovative Medicines Initiative  IMI   and is meant to speed up development and testing of J J s drug through a newly created consortium that includes the London School of Hygiene and Tropical Medicine  the University of Oxford and La Centre Muraz    In the face of the global challenge of Ebola  bringing together the expertise and capabilities of the pharmaceutical industry  academic centers and NGOs will be critical to help solve this crisis   Paul Stoffels  Johnson   Johnson s worldwide chairman of pharmaceuticals  said in a Friday statement   The European Commission s support through IMI bolsters collaboration that should significantly accelerate efforts to help address this human crisis   The worst Ebola outbreak in history has killed more than 8 200 people and infected more than 20 000 in Guinea  Liberia and Sierra Leone since it started last year  Despite the fact that Ebola outbreaks have been occurring for decades  the commercial incentive for large companies to research it didn t exist  because of the low number of patients    A profit driven industry does not invest in products for markets that cannot pay   World Health Organization Director General Dr  Margaret Chan said in November   Because Ebola has historically been confined to poor African nations  the R D incentive is virtually nonexistent     But in recent months  some of the world s largest pharmaceutical companies have become big players in the fight against Ebola   In October  J J committed  200 million to Ebola research and began testing its drug in humans on Jan  6 after producing more than 400 000 doses last year   The vaccine regimen is made up of two different parts injections    one from Crucell Holland B V  and Denmark s Bavarian Nordic  Johnson   Johnson isn t the only company working on Ebola  GlaxoSmithKline is planning to begin human trials in five countries this February and Merck started its own trials in December  though recently lowered its dosage after volunteers experienced joint pain  Chimerix started testing its Ebola drug on patients in Liberia earlier this month  in partnership with Oxford University and Doctors Without Borders ",2015-01-16,International Business Times,https://www.investing.com/news/stock-market-news/johnson---johnsons-ebola-research-gets-$115m-323840,323840
198660,420176,JNJ,Stronger dollar hurts J J s quarterly sales,news," Reuters    Johnson   Johnson reported lower than expected quarterly sales as a stronger dollar offset higher sales of the Band Aid maker s new drugs and older treatments 
The company s international sales fell about 7 percent to  9 65 billion in the fourth quarter  accounting for about half of its total sales 
The dollar gained nearly 13 percent against a basket of major currencies in 2014  its strongest performance since 1997 
Revenue in J J s pharmaceuticals business rose 9 6 percent in the quarter  driven by higher sales of new drugs such as hepatitis C drug Olysio and older treatments such as psoriasis drug Stelara  The business accounts for about 44 percent of the company s total sales 
However  sales in J J s medical devices business  its second largest  fell 9 percent 
The company s net profit fell about 28 percent to  2 52 billion  or 89 cents per share  including a  1 1 billion charge related to its acquisition of Synthes Inc 
Excluding items  J J earned  1 27 per share 
Total sales fell 0 6 percent to  18 25 billion 
Analysts on average had expected a profit of  1 26 per share and revenue of  18 55 billion  according to Thomson Reuters I B E S 
J J forecast a profit of  6 12  6 27 per share for 2015 
Chief Financial Officer Dominic Caruso warned in October that a strong dollar could hurt the company s 2015 earnings by 15 20 cents per share 

J J s shares were down 1 percent at  102 45 in premarket trading on Tuesday ",2015-01-20,Reuters,https://www.investing.com/news/stock-market-news/stronger-dollar-hurts-j-amp;j's-quarterly-sales-324246,324246
198661,420177,JNJ,Glaxo s Triple Therapy COPD Inhaler Gets Marketing Nod In EU,opinion,"GlaxoSmithKline plc   NYSE GSK   and partner Innoviva  Inc    NASDAQ INVA   announced that their triple combination therapy was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with chronic obstructive pulmonary disease  COPD  
The once daily single inhaler triple therapy will be marketed by the trade name of Trelegy Ellipta  It is approved for the treatment of moderate to severe COPD in patients who are already being treated with a combination of inhaled corticosteroid  ICS  and a long acting beta2 adrenergic agonist  LABA  but require additional bronchodilation 
Trelegy Ellipta was approved in the United States in September this year  The EU approval was expected  This is because the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  had granted a positive opinion recommending marketing approval of Trelegy Ellipta in September 
Trelegy Ellipta  a combination of fluticasone furoate   an ICS  umeclidinium     a long acting muscarinic antagonist  LAMA  and vilanterol   a LABA therapy  will provide patients with a convenient dosing option by removing the need for multiple inhalers  The product is expected to bring in blockbuster sales  Trelegy Ellipta will be delivered in Glaxo s Ellipta dry powder inhaler 
Glaxo s shares have declined 8 6  this year so far  underperforming the 14 7  increase witnessed by the  

Please note that shares of Theravance Biopharma  Inc    NASDAQ TBPH   were up more than 6  on Thursday as the biotech has an economic interest on the royalties that Glaxo will pay to Innoviva on global sales of Trelegy Ellipta 
Glaxo has a Zacks Rank  3  Hold  
A better ranked stock in the large cap pharma sector is Johnson   Johnson   NYSE JNJ   with a Zacks Rank  2  Buy   You can see  
Shares of J J are up 20 5  so far this year while earnings estimates for 2018 have gone up by almost 1  over the past 30 days 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-11-17,Zacks Investment Research,https://www.investing.com/analysis/glaxos-triple-therapy-copd-inhaler-gets-marketing-nod-in-eu-200266385,200266385
198665,420181,JNJ,Johnson   Johnson Q3 earnings  revenue beat expectations,news,"Investing com   Health care conglomerate Johnson   Johnson  NYSE JNJ  reported better than expected third quarter earnings on the back of strong revenue figures  it announced early Tuesday 

J J said earnings per share came in at  1 50 in the three months ending September 30  beating expectations for earnings of  1 44 per share 

The company s third quarter revenue totaled  18 47 billion  above expectations for revenue of  17 57 billion 

Domestic sales increased 11 6   while international sales decreased 0 3   reflecting operational growth of 1 0  and a negative currency impact of 1 3  

Worldwide  domestic and international operational sales growth  excluding the impact of this divestiture  was 8 4   14 8  and 3 1  respectively 

 Our strong third quarter performance reflects the continued success of our new products and the strength of our core business  We are making deliberate portfolio choices  positioning us well for achieving our near term priorities and our long term growth drivers   said Alex Gorsky  Chairman and Chief Executive Officer 
The firm now sees full year adjusted earnings per share in a range between  5 92 and  5 97  up from a previous estimate for adjusted earnings between  5 85 and  5 92 per share 

Immediately after the earnings announcement  JNJ shares rose 1 4  in trading prior to the opening bell 

Meanwhile  the outlook for U S  equity markets was modestly higher  The Dow 30 futures indicated a gain of 0 2   the S P 500 pointed to a rise of 0 3   while the tech heavy NASDAQ 100 indicated an increase of 0 3  ",2014-10-14,Investing.com,"https://www.investing.com/news/stock-market-news/johnson---johnson-q3-earnings,-revenue-beat-expectations-312922",312922
198666,420182,JNJ,J J beats forecasts  helped by hepatitis drug,news,"By Ransdell Pierson   Reuters    Johnson   Johnson reported strong quarterly earnings on surging sales of a new treatment for hepatitis C  but the company said it had sharply reduced prices for its artificial hips and warned that profits could be hurt next year by the stronger dollar   Sales of the J J  N JNJ  drug  called Olysio and approved in November  reached  796 million in the third quarter  As with other hepatitis C drugs that began with rapid ascents  however  its commercial success is expected to be short lived   Morningstar analyst Damien Conover predicted 2015 sales of Olysio will plunge more than 50 percent due to the approval on Friday of a new pill called Harvoni from Gilead Sciences Inc  O GILD  that can rid patients of the liver destroying viral infection within as little as 8 weeks   Conover said strong quarterly sales of other relatively new J J drugs  including its Zytiga treatment for prostate cancer and blood clot preventer Xarelto  bode well for J J and the drug industry over the long term    The core drugs are doing well  with a lot of strength from newer brands  and that signifies a healthy environment for pharmaceutical stocks   Conover said   J J s global drug sales jumped 18 percent to  8 3 billion  a slowdown from 21 percent growth in the second quarter   But sales of J J s medical devices fell 5 2 percent to  6 6 billion  after the recent divestiture of the company s Ortho Clinical Diagnostics unit and a 5 percent price cut for its artificial hips   J J Chief Financial Officer Dominic Caruso told analysts on a conference call that J J cut prices of the hip implants as it attempted to renew contracts with hospitals and other customers   On another cautionary note  Caruso said the strengthening dollar could hurt 2015 earnings by 15 to 20 cents per share   Sales of company consumer products  including Tylenol  slipped 0 6 percent to  3 6 billion in the quarter   The company earned  4 75 billion  or  1 66 per share  That compared with  2 98 billion  or  1 04 per share  in the year earlier period  when J J took special charges for legal expenses and merger related costs   Excluding special items  J J earned  1 50 per share  Analysts on average had expected  1 45 per share  according to Thomson Reuters I B E S  A net gain from after tax items of about  500 million was seen  mostly due to tax benefits from the Ortho Clinical Diagnostics divestiture   Company sales rose 5 1 percent to  18 47 billion  topping the average analyst estimate of  18 38 billion   J J said it now expects 2014 earnings  excluding special items  of  5 92 to  5 97 per share  In July  it forecast  5 85 to  5 92 per share   
J J shares slipped 0 6 percent to  98 52 shortly after midday  amid moderate gains for the drug sector     Reporting by Ransdell Pierson  Editing by Chizu Nomiyama  Meredith Mazzilli and Richard Chang ",2014-10-14,Reuters,"https://www.investing.com/news/stock-market-news/j-amp;j-sales-top-forecast,-helped-by-drug-for-hepatitis-c-312923",312923
198667,420183,JNJ,U S  tightens Ebola monitoring for West African visitors,news,"By Bill Berkrot NEW YORK  Reuters    The United States imposed new constraints on Wednesday on people entering the country from three nations at the center of West Africa s Ebola epidemic  mandating that they report their temperature daily and stay in touch with health authorities 
President Barack Obama expressed cautious optimism about the situation in the United States after meeting with his Ebola response coordinator  Ron Klain  and other top officials on Klain s first day on the job since being named on Friday 
The U S  Centers for Disease Control and Prevention s new restrictions on travelers arriving from Liberia  Sierra Leone and Guinea marked the latest precautions put in place by the Obama administration to stop the spread of the virus  The steps stopped short of a ban on travelers from those countries demanded by some lawmakers 
Health authorities and the public have been on alert for Ebola since late September when a Liberian visiting Dallas  Texas became the first person diagnosed with the virus in the United States  Two nurses who cared for him were also infected 
The CDC said that  beginning on Monday  travelers from the three countries will be told to check in with health officials every day and report their temperatures and any Ebola symptoms for 21 days  the period of incubation for the virus 
The travelers will be required to provide emails  phone numbers and addresses for themselves and for a friend or relative in the United States covering the 21 days  and the information will be shared with local health authorities 
The travelers also will be required to coordinate with local public health officials if they intend to travel within the United States  If a traveler does not report in  local health officials will take immediate steps to find the person 
CDC Director Dr  Tom Frieden told reporters the active monitoring program will remain in place until the outbreak in West Africa is over  The U N  World Health Organization s latest figures on Wednesday showed at least 4 877 people out of 9 936 confirmed  probable and suspected cases have died in the outbreak  the worst on record 
 These new measures I m announcing today will give additional levels of safety so that people who develop symptoms of Ebola are isolated early in the course of their illness   Frieden said   That will reduce the chance that Ebola will spread from an ill person through close contact and to healthcare workers  
Beginning Wednesday  travelers from Liberia  Sierra Leone or Guinea were being funneled through one of five major U S  airports conducting increased screening for the virus 
Six states account for nearly 70 percent of all travelers arriving from the affected countries  New York  Pennsylvania  Maryland  Virginia  New Jersey and Georgia  The new monitoring will begin in those states first and will be expanded to other states 
The CDC said the monitoring program affects anyone coming back from the region  including CDC employees and journalists  It said when affected travelers enter one of the five airports they will receive a care kit that contains a tracking log  a pictorial description of symptoms  a thermometer  instructions on how to monitor their temperature and information on what to do if they experience symptoms 
Liberian Thomas Eric Duncan  who died on Oct  8 and nurses Nina Pham and Amber Vinson of Texas Health Presbyterian Hospital  are the only cases detected in the country  Pham s condition was last upgraded on Tuesday to good from fair at a hospital in Bethesda  Maryland 
Vinson s family said in a statement Wednesday that officials at the CDC and Emory University Hospital in Atlanta  where she is being treated   are no longer able to detect virus in her body  
OBAMA SEES PROGRESS
Speaking in the White House Oval Office with Klain sitting on a couch beside him  Obama said the CDC would continue to put in place further measures to prevent the spread of Ebola as needed 
 A number of things make us cautiously more optimistic about the situation here in the United States   Obama said  noting that dozens of people who interacted with Duncan did not get Ebola 
Obama said officials were working to ensure that problems that arose with Ebola protocols at the Dallas hospital do not occur again  He expressed confidence that any further Ebola patients would get first class treatment and said officials would make sure hospitals are prepared and would take the right precautions 
The White House said Obama spoke by phone with staff at Texas Presbyterian Hospital  to thank them for their courage and perseverance in dealing with the first cases of Ebola to appear in the United States  
Human testing of a second  investigational  Ebola vaccine has begun at the U S  National Institutes of Health s Clinical Center in Maryland  officials said 
The vaccine was developed at the Public Health Agency of Canada s National Microbiology Laboratory and licensed to NewLink Genetics Corp through its wholly owned subsidiary BioProtection Systems  both based in Ames  Iowa  the NIH said 
Testing on a first potential vaccine began last month  and initial results were expected by year s end 
NBC freelance cameraman Ashoka Mukpo  an American who contracted Ebola while working in West Africa  is free of the virus and was discharged on Wednesday from a special unit at Nebraska Medical Center in Omaha  the hospital said 
 I feel profoundly blessed to be alive  and in the same breath aware of the global inequalities that allowed me to be flown to an American hospital when so many Liberians die alone with minimal care   Mukpo said in a statement 

The 1 year old King Charles Spaniel belonging to Pham has tested free of the virus  the city of Dallas said 
 Additional reporting by Ben Hirschler in London  Will Dunham and Susan Heavey in Washington  Barbara Goldberg in New York  Julie Steenhuysen in Chicago and David Bailey in Minneapolis  Writing by Will Dunham  Editing by Michele Gershberg  Grant McCool and Jonathan Oatis ",2014-10-22,Reuters,https://www.investing.com/news/stock-market-news/u.s.-tightens-ebola-monitoring-for-west-african-visitors-313920,313920
198668,420184,JNJ,Drugmakers may need indemnity for fast tracked Ebola vaccines,news,"By Ben Hirschler and Stephanie Nebehay LONDON GENEVA  Reuters    Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or claims arising from the widespread emergency use of new Ebola vaccines in Africa 
While the issue will not delay the industry s work to accelerate production and clinical testing of three experimental vaccines  it is likely to be discussed at a high level meeting in Geneva on Thursday 
World Health Organization  WHO  Director General Margaret Chan will chair the meeting  which includes industry executives  representatives from countries including those affected by Ebola  drug regulators and funders 
GlaxoSmithKline  L GSK  Chief Executive Andrew Witty said a system of indemnity made sense given the unique situation in which companies are being urged by the WHO to fast track the supply of novel vaccines in a matter of months rather than years 
There is currently no proven vaccine against Ebola and drug companies have been wary in the past of investing in the area  since the commercial opportunity is small  Potential losses or claims arising from the use of new vaccines would represent an additional hurdle 
Many drug companies are now discussing ways to help out with production  including some like Pfizer  N PFE  that are not directly involved in Ebola vaccine development 
Witty said indemnity was not a concern for the early phase of testing  when thousands of doses are expected to be given to frontline healthcare workers as part of a clinical trial program in January  but it would be needed when vaccines were rushed into much more widespread use 
 I think it is reasonable that there should be some level of indemnification because the vaccine is essentially being used in an emergency situation before we ve all had the chance to confirm its absolute profile   he told BBC radio 
 That s a situation where we would look for some kind of indemnification  either from governments or from multilateral agencies  
Brian Greenwood  a professor of clinical tropical medicine at the London School of Hygiene and Tropical Medicine  agrees that drug companies should not have to shoulder all the risk   There would have to be some sort of guarantee   he told Reuters 
MANUFACTURING CAPACITY
Leading drugmakers say they are ready to work together to speed up the supply of Ebola vaccines 
Johnson   Johnson  N JNJ  research head Paul Stoffels  who hopes to produce more than 1 million doses of an Ebola vaccine next year  said he was discussing collaboration with both GSK and other companies such as Pfizer  which has significant capacity to make a variety of biotech drugs and vaccines 
 We are looking at capabilities for biological production to upscale further   Stoffels said in Geneva 
The meeting is set to discuss ways to streamline the vaccine supply process and ensure there are adequate financial resources 
 WHO is organizing this meeting to discuss how to access vaccines when they are proven safe and how to finance them   a spokesman for the United Nations agency said 
Europe is also set to provide 200 million euros   250 million  of funding to develop new Ebola vaccines  as well as drugs and diagnostic tests  sources said  An announcement on the European move is now expected for next week 
 We are now in a situation where we are desperate and we are looking for solutions   Yvette Stevens  Sierra Leone ambassador to the U N  in Geneva  told Reuters 
GSK currently has the most advanced vaccine  the first doses of which are expected to be ready for use late this year  while clinical trials on a second vaccine from NewLink Genetics  O NLNK  have just started and J J will begin testing a third one in January 

 This is an unprecedented pace of development  We are literally doing in maybe five or six months what would normally take five or six years   Witty said   I ve already ordered five production lines to allow us to expand production  
 Additional reporting by Kate Kelland and Marina Depetris  Editing by Giles Elgood and David Stamp ",2014-10-23,Reuters,https://www.investing.com/news/stock-market-news/drugmakers-may-need-indemnity-for-fast-tracked-ebola-vaccines-314005,314005
198669,420185,JNJ,Exclusive  Scientists tell U S    find recipe for Ebola cure in survivors  blood,news,"By Sharon Begley
NEW YORK  Reuters    A group of scientists including three Nobel laureates in medicine has proposed that U S  health officials chart a new path to developing Ebola drugs and vaccines by harnessing antibodies produced by survivors of the deadly outbreak     
The proposal builds on the use of  convalescent serum   or survivors  blood  which has been given to at least four U S  Ebola patients who then recovered from the virus  It is based on an approach called passive immunization  which has been used since the 19th century to treat diseases such as diphtheria but has been largely surpassed by vaccination 
The scientists propose using new genetic and other technologies to find hundreds or thousands of different Ebola antibodies  determine their genetic recipe  grow them in commercial quantities and combine them into a single treatment analogous to the multi drug cocktails that treat HIV AIDS 
That contrasts with current drug development  which focuses on finding one molecule  or a small number  to defeat the Ebola virus that has killed nearly 5 000 people in West Africa and infected thousands more since March 
Nobel laureates David Baltimore  an expert in the molecular biology of the immune system  James Watson  co discoverer of the double helix that is DNA  and Jim Simons  who founded hedge fund Renaissance Technologies and was a pioneer in the quant revolution on Wall Street  are among the advocates of the idea  It was outlined in a letter that was reviewed by Reuters 
The proposal was sent to officials at the Department of Health and Human Services  including the Food and Drug Administration  to lawmakers and to biotech companies  They have not responded  said geneticist Michael Wigler of Cold Spring Harbor Lab  who wrote and gathered signatures for the position paper  The recipients did not respond to Reuters  requests for comment or said they had no comment 
The scientists urged government leadership without offering a specific development or production plan  and it is not clear whether the idea would offer a faster track to success than current efforts 
 Government agencies  commercial manufacturers and perhaps philanthropy  must work together to form a research and development infrastructure capable of producing therapeutic antibodies  Wigler said in an interview 
Although there is no proof that blood from survivors helps Ebola patients survive  it is known that patients recover when their own blood produces enough antibodies to stop the virus 
 
OLD PROCESS
Antibodies are proteins produced by the immune system to fight bacteria  viruses  and other invaders  from colds to measles  Giving antibodies to infected people would offer their immune systems a head start in fighting Ebola  the theory goes 
If the antibodies in survivors  blood is genetically sequenced  they would provide a recipe for treatments  which could be produced with technologies already used to manufacture antibodies that target cancer or rheumatoid arthritis  the scientists said 
 It would cost less than  1 million to get the genetic sequences of the antibodies from people who have recovered  and then we would have an armamentarium of hundreds or even thousands of antibodies   Wigler said 
He speculated that the idea has not gained traction before because  academics are trained to overlook the obvious   The approach would be difficult  and  many people in this day and age are afraid to risk failure   he said 
Ebola experts were cautious about the possibility that hundreds of anti Ebola antibodies would prevent or cure infections 
Studies have shown that some antibodies that neutralize Ebola virus in test tubes don t protect infected lab animals  said Dr  Thomas Geisbert of the University of Texas Medical Branch  who is working on Ebola vaccines  He also questioned whether the proposal would save time  given the need to test any antibody cocktail in both lab animals and human volunteers 
One of the most promising experimental treatments  Mapp Biopharmaceutical s ZMapp  consists of three different antibodies produced by mice infected with Ebola  Initial research was published in 2000  but it took until this summer for a study to show that ZMapp cured Ebola infected lab monkeys 
GlaxoSmithKline Plc  L GSK  and Johnson   Johnson  N JNJ  are among the drugmakers working on an Ebola vaccine  Both declined to comment on whether the antibodies proposal might be effective against Ebola 
Wigler acknowledges that none of those who have signed on to the proposal are experts on Ebola  Nor do they know how long it might take to develop a production line  get regulatory approval  and test the antibodies        
LESSON FROM DIPHTHERIA
European researchers separately are planning to test whether Ebola survivors  serum can cure patients  starting this month 
By Sharon Begley
NEW YORK  Reuters    A group of scientists including three Nobel laureates in medicine has proposed that U S  health officials chart a new path to developing Ebola drugs and vaccines by harnessing antibodies produced by survivors of the deadly outbreak     
The proposal builds on the use of  convalescent serum   or survivors  blood  which has been given to at least four U S  Ebola patients who then recovered from the virus  It is based on an approach called passive immunization  which has been used since the 19th century to treat diseases such as diphtheria but has been largely surpassed by vaccination 
The scientists propose using new genetic and other technologies to find hundreds or thousands of different Ebola antibodies  determine their genetic recipe  grow them in commercial quantities and combine them into a single treatment analogous to the multi drug cocktails that treat HIV AIDS 
That contrasts with current drug development  which focuses on finding one molecule  or a small number  to defeat the Ebola virus that has killed nearly 5 000 people in West Africa and infected thousands more since March 
Nobel laureates David Baltimore  an expert in the molecular biology of the immune system  James Watson  co discoverer of the double helix that is DNA  and Jim Simons  who founded hedge fund Renaissance Technologies and was a pioneer in the quant revolution on Wall Street  are among the advocates of the idea  It was outlined in a letter that was reviewed by Reuters 
The proposal was sent to officials at the Department of Health and Human Services  including the Food and Drug Administration  to lawmakers and to biotech companies  They have not responded  said geneticist Michael Wigler of Cold Spring Harbor Lab  who wrote and gathered signatures for the position paper  The recipients did not respond to Reuters  requests for comment or said they had no comment 
The scientists urged government leadership without offering a specific development or production plan  and it is not clear whether the idea would offer a faster track to success than current efforts 
 Government agencies  commercial manufacturers and perhaps philanthropy  must work together to form a research and development infrastructure capable of producing therapeutic antibodies  Wigler said in an interview 
Although there is no proof that blood from survivors helps Ebola patients survive  it is known that patients recover when their own blood produces enough antibodies to stop the virus 
 
OLD PROCESS
Antibodies are proteins produced by the immune system to fight bacteria  viruses  and other invaders  from colds to measles  Giving antibodies to infected people would offer their immune systems a head start in fighting Ebola  the theory goes 
If the antibodies in survivors  blood is genetically sequenced  they would provide a recipe for treatments  which could be produced with technologies already used to manufacture antibodies that target cancer or rheumatoid arthritis  the scientists said 
 It would cost less than  1 million to get the genetic sequences of the antibodies from people who have recovered  and then we would have an armamentarium of hundreds or even thousands of antibodies   Wigler said 
He speculated that the idea has not gained traction before because  academics are trained to overlook the obvious   The approach would be difficult  and  many people in this day and age are afraid to risk failure   he said 
Ebola experts were cautious about the possibility that hundreds of anti Ebola antibodies would prevent or cure infections 
Studies have shown that some antibodies that neutralize Ebola virus in test tubes don t protect infected lab animals  said Dr  Thomas Geisbert of the University of Texas Medical Branch  who is working on Ebola vaccines  He also questioned whether the proposal would save time  given the need to test any antibody cocktail in both lab animals and human volunteers 
One of the most promising experimental treatments  Mapp Biopharmaceutical s ZMapp  consists of three different antibodies produced by mice infected with Ebola  Initial research was published in 2000  but it took until this summer for a study to show that ZMapp cured Ebola infected lab monkeys 
GlaxoSmithKline Plc  L GSK  and Johnson   Johnson  N JNJ  are among the drugmakers working on an Ebola vaccine  Both declined to comment on whether the antibodies proposal might be effective against Ebola 
Wigler acknowledges that none of those who have signed on to the proposal are experts on Ebola  Nor do they know how long it might take to develop a production line  get regulatory approval  and test the antibodies        
LESSON FROM DIPHTHERIA
European researchers separately are planning to test whether Ebola survivors  serum can cure patients  starting this month  But relying on transfusions of survivors  blood for those antibodies is a daunting task in West Africa  given the need to screen it for other diseases and ensure health workers aren t exposed during the collection or infusion process 
By contrast   it takes a very short time  to produce countless copies of antibody genes  said molecular biologist Michel Nussenzweig of the Rockefeller University  an expert on the immune system who was not involved in the Ebola proposal   Hundreds are not a problem  this has been automated   he said  However  he questioned whether hundreds would be necessary to fight Ebola 
Wigler s answer  the Ebola virus is mutating  That might thwart an three antibody cocktail like ZMapp  he said  but it is highly unlikely that the targets of hundreds of antibodies would all mutate  A diversity of antibodies  mimics the body s own defenses and could overcome mutations in the virus that may develop   he said 
Multiple antibodies is what finally worked against HIV  which causes AIDS and  like the Ebola virus  mutates rapidly 

 We should make sure we learn from HIV to take our best shot at Ebola   Nobelist Baltimore said in an interview 
 Reporting By Sharon Begley  Editing by Michele Gershberg and Peter Henderson ",2014-11-07,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-scientists-tell-u.s.---find-recipe-for-ebola-cure-in-survivors'-blood-315896,315896
198670,420186,JNJ,What Lies In Store For Pharma ETFs ,opinion,"As we head toward the end of 2017  the pharma sector continues to perform well  representing a contrast to 2016 when the sector was under immense pressure due to the drug pricing issue  The sector was also weighed down by a significantly lower number of FDA approvals last year and was hit by some high profile R D failures as well as mixed results  slower than expected new product launches and increasing competition 
Pharma stocks have fared better this year with the NYSE ARCA Pharmaceutical Index gaining 16  year to date  Factors like new product sales ramp up  R D success and innovation  strong results  a higher number of FDA approvals and continued strong performance from legacy products should help sustain the recovery  Importantly  investors are now more comfortable with the drug pricing issue and are now focusing more on the fundamentals of the sector  Tax reforms and cash repatriation are other factors that should support the sector s performance   Read   
M As Yet to Pick Pace
The year started off with expectations that M A activity would pick up  but this did not happen  Although several small deals were announced  big ticket M A activity was more or less limited  Major M A news this year in the pharma sector was Johnson   Johnson s acquisition of Actelion for  30 billion  Apart from this  a few bolt on deals were announced by other companies 
Although several big companies remain interested in striking M A deals  high valuations remain a major deterrent with companies remaining wary of bidding wars leading to over priced deals 
Meanwhile  in licensing deals continue to be popular with several big companies tying up with smaller and mid sized players with promising mid to late stage pipeline candidates or interesting technology  Companies developing immunotherapies are highly sought after   Read 
Divestment  Streamlining   Restructuring
Several pharma companies are also streamlining operations by divesting non core business segments and restructuring  Companies like UCB  Novartis  Teva  Sanofi  PA SASY   Valeant  Glaxo and AstraZeneca have all been a part of this trend  Meanwhile  Pfizer  which has already divested several of its business segments  is currently looking at strategic options for its Consumer Healthcare business  The monetization of non core assets allows these companies to focus on their key areas of expertise  Moreover  the sale proceeds are utilized for reinvestment in the pipeline  debt repayment and for returning value to shareholders in the form of share buybacks and dividends 
Restructuring activities are also gaining momentum as large companies look to cut costs and streamline operations  Most of these companies are re evaluating their pipelines and discontinuing programs with an unfavorable risk benefit profile 
New Product Sales Should Ramp Up
Sales of products that gained approval over the last two years  as well as line and label extensions  should ramp up and boost growth  Recent entrants like Novartis  psoriasis treatment Cosentyx and Pfizer s cancer treatment Ibrance have already achieved blockbuster status and are key contributors to the top line 
Meanwhile  things are looking up on the regulatory front with the FDA already approving a higher number of drugs so far in 2017 compared to the whole of 2016  Moreover  with the passing of the 21st Century Cures Act  expectations are that there will be more innovation in the sector followed by a surge in new drug approvals 
Pharma companies continue to work on bringing innovative new treatments to market  and there could be significant catalysts in the coming quarters in the form of important new product approvals as well as major data read outs especially in key therapeutic areas like immuno oncology  Alzheimer s  central nervous system disorders  and immunology inflammation   Read   
Key approvals this year include Novartis s Kymriah  the first gene therapy in the United States   Lilly s Verzenio  advanced or metastatic breast cancer   J J s Tremfya  moderate to severe plaque psoriasis   Regeneron Sanofi s Kevzara  rheumatoid arthritis   Roche s multiple sclerosis treatment  Ocrevus  and Regeneron and Sanofi s eczema treatment  Dupixent  among others  Quite a few of these drugs have blockbuster potential 
Pricing Pressure   Competition Remain Headwinds
While the drug pricing issue no longer remains a major headwind  it will nevertheless remain a headline risk until the administration comes out with a policy for controlling drug prices  Moreover  with increasing competition in the market and the entry of innovative treatments  pricing pressure is expected to hit sales 
Another challenge being faced by the sector is the recent entry of biosimilar competition in the United States  While a relatively new area  the market for biosimilars is huge and highly lucrative with several blockbuster biologics including Humira and Lantus slated to lose patent protection by 2020 
Many companies are also facing a slowdown in sales of mature products in their portfolios  At the same time  new product sales are yet to pick up significantly  Many of these companies are also facing loss of patent protection  which means generics or biosimilars  as the case may be  could enter the market soon and lead to price erosion 
Pharma ETFs in Focus
Highlighted below are some pharma ETFs   ETFs present a low cost and convenient way to get a diversified exposure to the sector 
Powershares Dynamic Pharmaceuticals ETF   
PJP  launched in June 2005 by Invesco PowerShares  tracks the Dynamic Pharmaceuticals Intellidex Index  The fund covers healthcare stocks  The top 3 holdings include AbbVie  6 13    Bristol Myers Squibb Company  NYSE BMY   5 13   and Gilead Sciences  NASDAQ GILD   Inc   5 12    The total assets of the fund as of Oct 23  2017 were  700 2 million representing 30 holdings  The fund s expense ratio is 0 56  while dividend yield is 0 8   The trading volume is roughly 41 788 shares per day 
SPDR S P Pharmaceuticals  NYSE XPH  ETF   
XPH  launched in June 2006  tracks the S P Pharmaceuticals Select Industry Index  This ETF primarily covers pharma stocks with the top 3 holdings being Horizon Pharma plc  5 12    Perrigo Company plc  5 1    and Bristol Myers Squibb  5   
Total assets as of Oct 22  2017 were  429 6 million representing 39 holdings  The fund s expense ratio is 0 35  and dividend yield is 0 65   The trading volume is roughly 66 745 shares per day 
iShares U S  Pharmaceuticals   
IHE  launched in May 2006  seeks investment results that correspond generally to the price and yield performance of the Dow Jones U S  Select Pharmaceuticals Index  The fund mainly consists of pharma companies  90 2    Biotech companies account for about 9 7  of the fund 
The top 3 holdings of this fund are Johnson   Johnson  NYSE JNJ   10 83    Pfizer Inc   NYSE PFE   8 7   and Merck  NYSE MRK   7 67    The total assets of the fund as of Oct 23  2017 were  621 4 million representing 42 holdings  The fund s expense ratio is 0 44  with the dividend yield being 1 31   The trading volume is roughly 7 632 shares per day 
Market Vectors Pharmaceutical   
PPH was launched in December 2011 and tracks the Market Vectors U S  Listed Pharmaceutical 25 Index  This ETF covers healthcare stocks  While the expense ratio is 0 35   dividend yield is 1 96   The trading volume is roughly 7 820 shares per day  The total assets of the fund as of Oct 22  2017 were  273 6 million representing 25 holdings  The top 3 holdings of this fund are Johnson   Johnson  8 66    Novartis  6 67   and AbbVie  6 26   
Conclusion
Although pricing pressure and increasing competition will remain headwinds for pharma stocks  increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector 
 Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-11-07,Zacks Investment Research,https://www.investing.com/analysis/what-lies-in-store-for-pharma-etfs-200263397,200263397
198671,420187,JNJ,AstraZeneca  AZN  Misses Q3 Earnings  Tweaks 2017 EPS View,opinion,"AstraZeneca plc   NYSE AZN   reported third quarter 2017 core earnings of 56 cents per American Depositary Share  ADS   which missed the Zacks Consensus Estimate of 57 cents  Core earnings declined 17  year over year at constant exchange rates  CER   Lower product sales and gross margins and higher SG A costs hurt profits in the quarter Total revenue rose 10  at CER to  6 23 billion in the reported quarter  Revenues also beat the Zacks Consensus Estimate of  5 75 billion  Revenues  however  gained mainly from the  997 million payment from Merck   NYSE MRK   for the oncology collaboration the companies announced in July to jointly commercialize and develop Lynparza selumetinib Meanwhile  product sales declined in the quarter due to generic competition facing some legacy products Key growth platforms  representing 66  of total revenues  were up 6  in the quarter at CER  Among the key growth platforms  Emerging Markets  New Cardiovascular   Metabolic Diseases  CVMD   New Oncology and Japan performed well in the quarter  However  Respiratory sales declined 2  in the reported quarter All growth rates mentioned below are on a year over year basis and at CER Product Sales DeclineProduct sales declined 2  in the quarter to  4 88 billion due to lower sales in the United States as well as Europe  which offset strong performance in emerging markets and in China Crestor sales declined 14  to  580 million with sales in the United States and Europe down due to the entry of multiple generic versions of the drug in the market Seroquel XR sales declined 68  to  62 million due to competition from generic launches In the quarter  Onglyza sales declined 25  to  127 million due to competitive pressure in the DPP 4 class Symbicort sales were down 4  in the quarter to  668 million due to lower sales in the United States and Europe  U S  sales declined in the due to continued pricing pressure from managed care access within the ICS LABA class and also competition from other class like LAMA LABA combination medicines Nexium recorded sales of  469 million  down 7   However  some legacy products that recorded growth in the quarter include Farxiga Forxiga  up 29  to  285 million   Daliresp Daxas  up 26  to  53 million   Faslodex  up 16  to  241 million   Iressa  up 10  to  137 million   Pulmicort  up 9  to  242 million  and Atacand  up 11  to  80 million  Among the newer medicines  Lynparza sales rose 36  to  81 million  While sales in the United States gained from the label expansion approval in August for the treatment of second line ovarian cancer  in Europe  sales were pushed higher by a number of successful launches Brilinta Brilique sales were  284 million in the reported quarter  up 36  year over year and 4 4  sequentially  Brilinta maintained its leadership position in the U S  branded oral anti platelet market  In the United States   Europe and China  Brilinta continued to display an impressive performance Tagrisso  launched in 2015  recorded sales of  248 million  up 7  sequentially  Another new medicine  Movantik Moventig recorded sales of  30 million in the quarter  less than  32 million in the previous quarter Bevespi  a LAMA LABA in a pressurized metered dose inhaler launched commercially in the United States in January 2017  recorded sales of  4 million in the quarter  less than  3 million in the second quarter as the LAMA LABA class grew more slowly than anticipated PD L1 inhibitor Imfinzi  launched for second line bladder cancer in the United States in May  did not generate any sales in the third quarter against  1 million in the second quarter  A regulatory application seeking label expansion of Imfinzi to treat an earlier stage of lung cancer was granted priority review by the FDA last month Imfinzi is a key candidate in the company s immuno oncology pipeline which is beingevaluated for multiple cancers  either alone or in combination with other regimens  Last month  AstraZeneca expanded its clinical trial collaboration with Incyte   NASDAQ INCY   to evaluate Incyte s investigational selective IDO1 enzyme inhibitor  epacadostat  in combination with Imfinzi  compared to Imfinzi alone in early lung cancer Regional PerformanceProduct sales declined 10  to  1 39 billion  primarily due to generic competition for Crestor and Seroquel XR and pricing pressure for Symbicort in the United States  European markets witnessed an 8  decline in sales to  1 19 billion  Revenues from Emerging Markets were up 10  to  1 52 billion primarily on the back of strong growth in China  up 14  to  723 million   In Established ROW market  sales were flat at  793 million Other DetailsAstraZeneca s core gross margin declined 400 basis points  bps  to 79 6   Core selling  general and administrative  SG A  expenses rose 4  to  1 95 billion In the quarter  core research and development  R D  expenses were flat at  1 34 billion 2017 OutlookWhile AstraZeneca retained its previously issued sales outlook for 2017  it slightly refined the core earnings guidance AstraZeneca continues to expect total revenue to decline in the low to mid single digit percentage range in 2017  However core earnings in 2017 are expected toward the favorable end of the previously issued guidance of a decline in low to mid teen percentage  Based on the average exchange rates in the first half  currency movements are still expected to adversely impact the top line by a low single digit percentage but minimally impact core EPS Our TakeThough AstraZeneca s third quarter performance was mixed  shares rose around 1 4  in pre market trading on Thursday as the company brightened its 2017 earnings outlook  Moreover  the company has announced quite a few positive developments on the regulatory and pipeline front so far this year  The latest such development is the accelerated approval of Calquence for the treatment of mantle cell lymphoma  an aggressive form of blood cancer  last month Backed by the positive news flow  so far this year  AstraZeneca s shares have gained 22   comparing favorably with the  s growth of 14 8   Astrazeneca  LON AZN  PLC Price  Consensus and EPS Surprise
    AstraZeneca currently carries a Zacks Rank  3  Hold   You can see  A better ranked company in the large cap pharma industry is Johnson   Johnson   NYSE JNJ    carrying a Zacks Rank  2  Buy  Shares of J J are up 22 7  while earnings estimates for 2018 have gone up 1 6  over the past 30 days Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-11-08,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-azn-misses-q3-earnings-tweaks-2017-eps-view-200263805,200263805
198672,420188,JNJ,AstraZeneca Gets Positive CHMP Opinion For Asthma Candidate,opinion,AstraZeneca  plc   NYSE AZN   announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has given a positive opinion recommending marketing approval of its respiratory disease candidate  benralizumab  AstraZeneca is looking to get benralizumab approved as an add on maintenance treatment for severe eosinophilic asthma in adults The candidate is also under review in the United States with a response from the FDA expected this year  Meanwhile  benralizumab is also being evaluated for the treatment of chronic obstructive pulmonary disease  COPD  in late stage studies The CHMP opinion was based on positive data from pivotal studies  SIROCCO and CALIMA  which showed significant reductions in exacerbations and improvements in lung function on treatment with benralizumab  Meanwhile  another phase III study  ZONDA  showed that adding benralizumab to standard of care led to statistically significant and clinically relevant reduction in daily maintenance oral corticosteroid  OCS  use with two benralizumab dosing regimens compared with placebo So far this year  AstraZeneca s shares have gained 20 4  comparing favorably with the  s growth of 14 5  AstraZeneca s respiratory products on the market include Symbicort  Pulmicort Tudorza  Duaklir and others  Sales of its respiratory portfolio have declined 5  so far this year Other than benralizumab  promising respiratory treatments in the pipeline include tralokinumab in phase III studies for severe asthma  and PT010  also in phase III studies for the treatment of COPD  It remains to be seen if these candidates can improve AstraZeneca s respiratory sales upon approval AstraZeneca carries a Zacks Rank  3  Hold   You can see  Some better ranked stocks in the industry are Johnson   Johnson   NYSE JNJ    PDL BioPharma  Inc    NASDAQ PDLI   and Ligand Pharmaceuticals Incorporated   NASDAQ LGND    all with a Zacks Rank  2  Buy  Shares of J J are up 21 1   while earnings estimates for 2018 have gone up by 1 2  over the past 30 days Shares of PDL BioPharma have increased 43 4  this year so far while earnings estimates for 2018 have increased 3 2  in the past 30 days Shares of Ligand Pharmaceuticals have risen 37 6  this year so far while earnings estimates for 2018 have increased 0 5  in the past 60 days Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-11-12,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-gets-positive-chmp-opinion-for-asthma-candidate-200264531,200264531
198673,420189,JNJ,Merck  MRK  Gets CHMP Nod For Infection Candidate Prevymis,opinion,Merck   Co   Inc    NYSE MRK   announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has given a positive opinion recommending marketing approval of Prevymis  letermovir  Merck is looking to get Prevymis approved in the EU for the prevention of cytomegalovirus  CMV  reactivation and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant  HSCT   Merck expects a decision from the European Commission within two months We remind investors that only last week  Prevymis received approval from the FDA for the prevention of CMV infection  A common and potentially serious viral infection in allogeneic HSCT recipients  CMV infection is associated with increased mortality in HSCT patients Merck said that Prevymis is the first new CMV medicine to be approved in the United States in 15 years  Merck intends to launch the drug in the United States next month at a list price of  195 per day for the tablets and  270 for the injection Merck s shares have declined 6 4  this year against a 14 5  increase for the  Some other key pipeline candidates of Merck include doravirine for HIV with a new drug application  NDA  filing expected before the end of the year  and MK 7264  which is being developed in phase II studies for refractory  chronic cough and idiopathic pulmonary fibrosis  IPF  with cough Merck and Pfizer   NYSE PFE   have developed diabetes candidate ertugliflozin for which regulatory applications are under review in the United States and the EU  The companies have filed three separate NDAs for ertugliflozin  one for monotherapy and twoforfixed dose combinations with metformin and with Januvia sitagliptin  respectively   A decision from the FDA is expected next month Merck carries a Zacks Rank  3  Hold   You can see  Some better ranked stocks in the industry are Johnson   Johnson   NYSE JNJ   and Ligand Pharmaceuticals Incorporated   NASDAQ LGND    both with a Zacks Rank  2  Buy  Shares of J J are up 21 3  while earnings estimates for 2018 have gone up by 1 2  over the past 30 days Shares of Ligand Pharmaceuticals have risen 40 5  this year so far while earnings estimates for 2018 have increased 0 5  in the past 60 days Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-11-13,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-gets-chmp-nod-for-infection-candidate-prevymis-200264922,200264922
198675,420191,JNJ,Corporate America s  ABC  policy   Anything But Capex,news,"By Jamie McGeever  LONDON  Reuters    The U S  economy continues to recover from the depths of the Great Recession  although its speed  trajectory and cruising altitude remain the subject of fierce debate   What s indisputable  however  is that one of the economy s engines has persistently failed to ignite  despite record fuel levels in the tank   Corporate America has never been more flush with cash  But business investment or capital expenditure    capex    has remained depressed  puzzling economists and strategists who have long predicted its resurgence and attendant impact on growth   Instead  companies have chosen to dip into their collective  1 8 trillion pile of cash to re hire workers  fund merger and acquisitions activity or buy back their own shares  Boosting growth and returns through long term investment in their business hasn t registered nearly as highly   This suggests underlying demand for goods and services is weak   certainly weaker than it should be  given that the economy is five years into a recovery   and not strong enough to sustain a potential growth rate of around 2 5 3 percent   The problem then becomes circular  weak demand holds back capex  which drags on growth  which depresses demand    Waiting for business investment to accelerate has been a painful and thankless exercise   wrote Morgan Stanley in a recent 14 page report on capex   A close examination of this underinvestment paints a grim picture of productivity rates and the economy s trend growth potential    Since the 2008 09 economic and financial meltdown  U S  capex has fallen short of the trend seen over 1990 2007 by more than 15 percent  That s an annual  400 billion gap today  never mind the shortfall accumulated over the previous five years   On some levels  this reluctance from firms to invest is puzzling   Productivity growth in the United States   the rate of growth in the level of output per worker   is near its lowest in 30 years  according to Bridgewater Associates  Spending on research  development and technology  would surely improve this trend   The need for capex spending is also pressing because firms are reaching the point where they simply have to replace aging equipment  According to Morgan Stanley  the average age of industrial equipment is now almost 10 5 years  the highest since 1938   M A BOOM  But just replacing old equipment will not be enough to have a notable impact on economic growth  That will require businesses to spend over and above simple replacement rates  and so far that hasn t happened   If company executives can be convinced demand can hold up  the conditions for splashing the capex cash are certainly there  Firms have nearly  2 trillion cash  they ve reduced their leverage and indebtedness  and funding remains cheap and easy   The positive impact of capex spending would be felt both in the long  and short term  according to Bridgewater   The effect of boosting productivity helps the economy s longer term growth potential  while corporate profits and margins are  front loaded  because outlays are amortized over time  yet related sales are booked instantly   But executives have instead preferred to hoard cash in record amounts  And even when it has been spent it has been diverted to pretty much anywhere but capex   The global year to date dollar volume of M A deals stands at  2 5 trillion  or an increase of 70 percent on the previous year  led by North America   1 2 trillion  up 83 percent  and Europe   773 billion  up 85 percent   according to Deutsche Bank   This year is almost certain to be the best year for M A since the crisis   There has also been a drive to increase dividend payments to shareholders and a resurgence of high profile share buybacks   Oil services company Halliburton  N HAL  has just increased its buyback authorization to  6 billion  oil major Exxon Mobil  N XOM  spent  3 billion in the second quarter alone  and consumer goods giant Johnson   Johnson  N JNJ  announced a  5 billion repurchase program last month   Buybacks and dividends may not be giving the U S  economy any discernible boost  but they ve done the stock market no harm at all  as Wall Street roared to a record high late last month   Despite the numerous false dawns since the Great Recession  analysts still expect capex to pick up  If it does  then the broader economy should benefit   
Morgan Stanley is confident it will  and predicts growth of around 5 percent  Bridgewater also expects a  gradual acceleration   which could strengthen the economic recovery   But the danger is that it fails to pick up enough   A more historically normal cyclical pickup  something in excess of 8 percent annually  simply looks unrealistic   Morgan Stanley said     Editing by Will Waterman ",2014-08-06,Reuters,https://www.investing.com/news/stock-market-news/corporate-america's-'abc'-policy---anything-but-capex-301236,301236
198676,420192,JNJ,Scientists grapple with ethics in rush to release Ebola vaccines,news,"By Kate Kelland LONDON  Reuters    Normally it takes years to prove a new vaccine is both safe and effective before it can be used in the field  But with hundreds of people dying a day in the worst ever outbreak of Ebola  there is no time to wait 
In an effort to save lives  health authorities are determined to roll out potential vaccines within months  dispensing with some of the usual testing  and raising unprecedented ethical and practical questions 
 Nobody knows yet how we will do it  There are lots of tough real world deployment issues and nobody has the full answers yet   said Adrian Hill  who is conducting safety trials on healthy volunteers of an experimental Ebola shot developed by GlaxoSmithKline 
Hill  a professor and director at the Jenner Institute at Britain s University of Oxford  says that if his results show no adverse side effects  GSK s new shot could used in people in West Africa by the end of this year 
Even if a drug is shown to be safe  it takes longer to prove it is effective   time that is simply not available when cases of Ebola infection are doubling every few weeks and projected by the World Health Organization to reach 20 000 by November 
Among questions that scientists are grappling with  should an unproven vaccine be given to everybody  or just a few  Should it be offered to healthcare workers first  The young before the old  Should it be used first in Liberia where Ebola is spreading fastest  or Guinea where it is closer to being under control 
Should people be told to assume it will protect them from Ebola  Or should they take all the protective measures they would if they hadn t been vaccinated  And if so  how will anyone know whether the vaccine works 
GSK is one of several drug firms that have either started or announced plans for human trials of candidate Ebola vaccines  Others include Johnson   Johnson  NewLink  Inovio Pharmaceuticals and Profectus Biosciences 
The WHO says it hopes to see small scale use of the first experimental Ebola vaccines in the West Africa outbreak by January next year 
It has convened vaccine specialists  epidemiologists  pharmaceutical companies and ethicists  for a meeting on Monday and Tuesday to discuss the moral and practical issues 
 Normally safety is the absolutely paramount thing when you re developing a new vaccine  but this time we re going to have to take more risks   said Brian Greenwood  a professor at the London School of Hygiene and Tropical Medicine who will take part in the WHO led meeting 
 Quite how we do that  and what risks we take  hasn t really been thought through yet  That s what people are trying to figure out  
TWO THINGS AT THE SAME TIME
The chaos caused by the epidemic itself makes it even more difficult to deploy and track use of a new vaccine  said Hill 
 You re trying to do two things at the same time  you re trying to evaluate a vaccine and deploy it   when normally you would evaluate the vaccine first  by doing a randomized double blind controlled trial  and then you d deploy it if it was shown to be safe and effective  
Because Ebola virus is so deadly  those who receive a trial vaccine must be told to take all other precautions and protect themselves fully  This could make it harder for researchers to decipher whether the protective clothing and safety protocols  or the new vaccine  is what kept them safe 
Normally researchers testing a vaccine would give some volunteers a placebo  or dummy  to create a  control  group to compare against those who get the real drug  That seems unthinkable in a situation where disease with a death rate of up to 90 percent is raging through villages 
 Would it be ethical to do a trial where some people don t get the vaccine because they are in the control group  Most people think it wouldn t be   especially if you have reasonable evidence that the vaccine might work   said Hill 
Jeremy Farrar  an infectious diseases expert and director of the Wellcome Trust medical charity  said limited supplies of any candidate vaccine could result in a form of natural control group being formed anyway  Researchers can compare populations where the vaccine is available with those where it isn t 
GSK has said it is aiming to have 10 000 doses of its experimental shot by the end of the year  while Canada has given 800 vials of the NewLink candidate vaccine to the WHO  expected to yield at least 1 500 doses 
Most experts interviewed by Reuters favor the idea of the first doses going to frontline healthcare workers  since their exposure to risk is so high  Researchers could then compare infection rates among health workers who receive the vaccine to those working in regions still waiting for it 
Peter Piot  a co discoverer of the Ebola virus in 1976 and now director of the London School of Hygiene and Tropical Medicine said that however complicated the ethics  reverting to the traditional years long process of testing vaccines  and withholding them from West Africa until then  is not an option 

 It may be that without a vaccine  we can t really stop this epidemic   he said 
 Reporting by Kate Kelland  Editing by Peter Graff ",2014-09-28,Reuters,https://www.investing.com/news/stock-market-news/scientists-grapple-with-ethics-in-rush-to-release-ebola-vaccines-311045,311045
198677,420193,JNJ,Geron  GERN  Q3 Loss Narrower Than Expected  Sales Miss,opinion,"Geron Corporation   NASDAQ GERN   reported a loss of 4 cents per share in the third quarter of 2017  which was narrower than the Zacks Consensus Estimate of a loss of 5 cents  In the year ago quarter  the company had recorded a loss of 2 cents Quarterly revenues were significantly down to  0 16 million from  5 11 million in the year ago quarter  However  revenues in the year ago quarter included a  5 million upfront payment from Johnson   Johnson s   NYSE JNJ   subsidiary Janssen related to a licensing agreement  Revenues also missed the Zacks Consensus Estimate of  0 59 million  Revenues comprised royalty and license fee revenues received under various non imetelstat license agreements Shares fell 1 8  in after hours trading on Wednesday  However  so far this year  Geron s shares have outperformed the   rising 4 9  during the period compared with the industry gain of 2 7  Research and development  R D  expenses declined 39 5  to  2 6 million due to lower costs for the proportionate share of clinical development costs for imetelstat  General and administrative expenses rose 2 1  to  4 7 million due to increased stock based compensation The company ended the quarter with  112 7 million in cash and investments compared with  117 2 million at the end of the second quarter Pipeline UpdateGeron develops anti cancer therapies based on telomerase inhibitors  The company s sole pipeline candidate  imetelstat  is in mid stage studies and is being evaluated in hematologic myeloid malignancies like myelofibrosis  MF  and myelodysplastic syndromes  MDS   Geron is conducting the studies in collaboration with J J Last year  Janssen announced unfavorable findings from the planned internal reviews of initial data from two studies of imetelstat   IMbark  phase II  for the treatment of MF and IMerge  phase II III  for the treatment of MDS Following an internal review in April this year by J J  the two studies  IMbark  phase II  on MF and IMerge  phase II III  on MDS  evaluating imetelstat were continued unmodified In the fourth quarter  20 more patients will be enrolled in part 1 of IMerge in refined MDS indication to confirm the clinical benefit and safety observed earlier  Discussions are currently on with the FDA on data package and proposed refinements to the trial design for part 2 of IMerge  If J J decides to proceed to Part 2 of IMerge  a larger  170 patient  phase III study   patient enrollment is expected to begin in the fourth quarter Last month the FDA granted fast track designation to imetelstat based on data from part 1 of IMerge Meanwhile  for the IMbark study  the clinical benefit and a potential overall survival benefit observed during internal review  supported continuation of thestudy without modifications  Data from the study is expected in the third quarter of 2018 Geron Corporation Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderGeron currently carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the pharma sector includes Agenus Inc    NASDAQ AGEN   and Exelixis  Inc    NASDAQ EXEL    Both the stocks carry a Zacks Rank  2  Buy   You can see  Agenus  loss estimates remained stable at  1 17 for 2017 and narrowed from  1 40 to  1 36 for 2018 over the last 30 days  The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 4 27  Exelixis  earnings per share estimates remained stable at 26 cents for 2017 and increased from 63 cents to 64 cents for 2018 over the last 30 days  The company delivered positive earnings surprises in all the four trailing quarters with an average beat of 543 59   The company s shares are up 62 5  so far this year Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/geron-gern-q3-loss-narrower-than-expected-sales-miss-200257922,200257922
198678,420194,JNJ,Roche to buy U S  biotech firm Seragon for up to  1 7 billion,news,"ZURICH  Reuters    Roche Holding AG  VX ROG  said it would pay up to  1 725 billion to buy Seragon Pharmaceuticals  a privately held U S  biotech company that researches breast cancer treatments   Roche has long dominated the field of breast cancer with drugs such as Herceptin and recently won approval for Kadcyla and Perjeta  two treatments for patients whose cancer cells contain increased amounts of the protein known as HER2   San Diego based Seragon was spun out from Aragon Pharmaceuticals last year when that company was bought by Johnson   Johnson  N JNJ   Seragon is focused on developing a new generation of oral medicines that it believes offer an improved way of tackling hormone receptor positive breast cancer  and potentially other cancers   Its most advanced experimental drug  ARN 810  is currently in initial Phase I clinical trials for breast cancer patients who have not responded to current hormonal agents   Roche said Seragon s so called oral selective estrogen receptor degraders  or SERDs  would complement existing research and development programmes in breast cancer under way at the Swiss group s Genentech unit   The Basel based drugmaker will pay  725 million in cash and may hand over as much as  1 billion more if Seragon achieves drug development milestones    HIGH PRICE SEEN AS JUSTIFIED  The price Roche is paying for Seragon looks relatively high for a firm with only one treatment in a Phase I study  but can be justified because Roche is filling a huge gap for future breast cancer treatments with the purchase  analysts at Zuercher Kantonalbank said    We assume that Genentech s scientists see considerable potential in SERDs  because otherwise they would not have accepted this relatively high price   ZKB said   Roche shares were up 0 5 percent rose at 0821 GMT  outpacing a 0 3 percent rise in a wider index of European drugmakers    Since acquiring Genentech for  46 8 billion in 2009  Roche has earned a reputation as a disciplined acquirer  prepared to walk away from potential deals rather than overpay   Chief Executive Severin Schwan abandoned a  6 8 billion deal to buy U S gene sequencing company Illumina in 2012 and has snapped up a couple of smaller diagnostic companies this year instead of pursuing multi billion deals   Roche has also partnered with various companies to develop antibiotics and said last week it would work with Inception Sciences Inc and Versant Ventures on a new company to develop therapies for patients with multiple sclerosis   Seragon is the second notable acquisition in as many months for Roche  which bought privately held U S  gene sequencing firm Genia Technologies for up to  350 million in June  securing access to a technology that should allow it to decipher human genes more quickly at a cheaper cost   
The acquisition represents a response to investors who wondered how Roche might use its cash now that its ratio of net debt to assets is back within its target band of zero to 15 percent after paying down debt from acquiring Genentech   The transaction is expected to close in the third quarter of 2014      Reporting By Katharina Bart  Caroline Copley and Ben Hirschler  editing by Tom Pfeiffer ",2014-07-02,Reuters,https://www.investing.com/news/stock-market-news/roche-to-buy-u.s.-biotech-firm-seragon-for-$725-million-292655,292655
198679,420195,JNJ,Johnson   Johnson Q2 earnings  revenue beat expectations,news,"Investing com   Health care conglomerate Johnson   Johnson  NYSE JNJ  reported better than expected second quarter earnings on the back of strong revenue figures  it announced early Tuesday 
J J said earnings per share came in at  1 66 in the second quarter  beating expectations for earnings of  1 55 per share  The company s second quarter revenue totaled  19 5 billion  above expectations for revenue of  18 98 billion 
Domestic sales increased 14 9  in the second quarter  while international sales increased 4 4   reflecting operational growth of 5  and a negative currency impact of 0 6  
The firm now sees full year adjusted earnings per share in a range between  5 85 and  5 92  compared to expectations for adjusted earnings of  5 90 per share 
 Our strong second quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near term priorities   said Alex Gorsky  Chairman and Chief Executive Officer 
Immediately after the earnings announcement  J J  NYSE JNJ shares rose 0 6  in trading prior to the opening bell 
Meanwhile  the outlook for U S  equity markets was modestly higher  The Dow futures indicated a gain of 0 15   the S P 500 pointed to a rise of 0 1   while the Nasdaq 100 indicated an increase of 0 1  ",2014-07-15,Investing.com,"https://www.investing.com/news/stock-market-news/johnson---johnson-q2-earnings,-revenue-beat-expectations-294939",294939
198680,420196,JNJ,J J beats forecasts  helped by new hepatitis C drug,news," Reuters    Johnson   Johnson  N JNJ  reported sharply better than expected quarterly revenue and earnings  fueled by strong sales of newer prescription drugs  including its Olysio treatment for hepatitis C 
The diversified healthcare company on Tuesday said it earned  4 33 billion  or  1 51 per share  in the second quarter  That compared with  3 83 billion  or  1 33 per share  in the year earlier period  when the company took charges for litigation and an acquisition 
Excluding special items  J J earned  1 66 per share  Analysts  on average  were expecting  1 55 per share  according to Thomson Reuters I B E S 

Company sales jumped 9 1 percent to  19 5 billion  well above Wall Street expectations of  18 99 billion 
 Reporting by Ransdell Pierson  Editing by Franklin Paul ",2014-07-15,Reuters,"https://www.investing.com/news/stock-market-news/j-j-beats-forecasts,-helped-by-new-hepatitis-c-drug-294969",294969
198683,420199,JNJ,UPDATE 1 Crucell gets Johnson Johnson 302 mln euros investment,news," Corrects headline to euros from   
   Collaboration to focus on universal flu vaccine
   Crucell share issue equal to 18 percent of share capital
   Deal dilutive to Johnson   Johnson EPS of up to  0 04
 
  Adds details  company comments 
 AMSTERDAM  Sept 28  Reuters    Dutch biotechnology firm
Crucell said on Monday Johnson   Johnson had bought 14 6 million
new Crucell shares for 302 million euros   443 5 million  as
part of a flu vaccine development deal 
 Crucell said the collaboration will focus on developing a
universal  flu mAb  product targeting all influenza A strains 
including H1N1 strains which cause seasonal flu and the current
pandemic flu along with the H5N1 or avian strain 
 The newly issued shares represent about 18 percent of
Crucell s outstanding ordinary shares  Both companies also
agreed to development milestones and royalty payments based on
the successful development and commercialisation of products 
  A universal antibody or vaccine that protects against a
broad range of strains would be an important advance in helping
    control acute epidemic and pandemic outbreaks   said Paul
Stoffels  global head of pharmaceuticals R D at Johnson  
Johnson 
 The collaboration will also focus on development and
commercialization of non flu vaccines for the treatment and
prevention of other infectious and non infectious diseases 
 As part of the deal Crucell and Johnson   Johnson affiliate
JHC Nederland agreed to a three year standstill requiring
Crucell s consent for an increase of in JHC Nederland s interest
in Crucell and a three month lock up on transfers of the shares 
 The transaction will have an estimated dilutive impact of
 0 02 to  0 04 on Johnson   Johnson s 2009 adjusted earnings per
share 
  Reporting by Aaron Gray Block  Editing by David Holmes 
   1  6810 Euro ",2009-09-28,Reuters,https://www.investing.com/news/equities-news/update-1-crucell-gets-johnson-johnson-302-mln-euros-investment-90293,90293
198684,420200,JNJ,Johnson   Johnson Q4 earnings  revenue beat expectations,news,Investing com   Health care conglomerate Johnson   Johnson reported better than expected fourth quarter earnings on the back of strong revenue figures  it announced early Tuesday Earlier in the day  in its fourth quarter earnings report  J J said earnings per share came in at USD1 24  beating expectations for earnings of USD1 20 per share The company s fourth quarter revenue totaled USD18 36 billion  up 4 5  from the same period a year earlier and above expectations for revenue of USD17 91 billion Domestic sales increased 7 4   while international sales increased 2 4   reflecting operational growth of 5 6  and a negative currency impact of 3 2  Worldwide sales for the full year 2013 were USD71 3 billion  an increase of 6 1  versus 2012 The firm now sees full year adjusted earnings per share in a range between USD5 75 and USD5 85  compared to expectations for adjusted earnings of USD5 86 per share Alex Gorsky  Chairman and Chief Executive Officer  said   Johnson   Johnson delivered strong results in 2013 led by the outstanding performance in our Pharmaceutical business  the strength of key brands in our US OTC and other Consumer businesses and continued progress in integrating Synthes into our Medical Devices and Diagnostics business   Immediately after the earnings announcement  Johnson   Johnson shares rose 0 65  in trading prior to the opening bell Meanwhile  U S  stock futures pointed to a higher open  The Dow Jones Industrial Average futures indicated a gain of 0 45  at the open  S P 500 futures added 0 4   while the Nasdaq 100 futures indicated a rise of 0 55  ,2014-01-21,Investing.com,"https://www.investing.com/news/stock-market-news/johnson---johnson-q4-earnings,-revenue-beat-expectations-261306",261306
198685,420201,JNJ,J J  JNJ  Beats On Q3 Earnings  Actelion Buyout Drives Sales,opinion,Johnson   Johnson   NYSE JNJ   reported better than expected third quarter 2017 results  beating the Zacks Consensus Estimate for both earnings and sales  The drug and consumer products giant raised its 2017 sales and profit outlook  which sent shares up 1 5  in pre market trading In fact  this year so far  J J s share price is up 18 1   This is almost in line with the 18 2  increase witnessed by the  Earnings BeatJ J s third quarter 2017 earnings came in at  1 90 per share  beating the Zacks Consensus Estimate of  1 80 and increasing 13 1  from the year ago period Including amortization expense and special items  J J reported third quarter earnings of  1 37 per share  down 10 5  from the year ago period Sales BeatSales came in at  19 65 billion  beating the Zacks Consensus Estimate of  19 28 billion by 1 9   Sales increased 10 3  from the year ago quarter  reflecting an operational increase of 9 5  and a positive currency impact of 0 8   Organically  excluding the impact of acquisitions and divestitures  sales increased 3 8  on an operational basis Third quarter sales grew 9 7  in the domestic market to  10 29 billion and 10 9  in international markets to  9 36 billion  reflecting 9 3  operational growth and 1 6  positive currency impact Sales in DetailsPharmaceutical segment sales rose 15 4  year over year to  9 7 billion  reflecting 14 6  operational growth and 0 8  positive currency impact as sales rose in both the domestic and international markets  Sales in the domestic market rose 15 4  to  5 82 billion  while international sales grew 15 5  to  3 88 billion  Organically  excluding the impact of acquisitions and divestitures  sales increased 6 7  on an operational basis New products like Imbruvica  cancer  and Darzalex  multiple myeloma  continued to perform well  Other growth drivers were core products like Xarelto  Stelara and Invega Sustenna  Sales of Concerta and Zytiga improved in the quarter In the quarter  J J recorded pulmonary arterial hypertension  PAH  revenues of  670 million  The  30 billion acquisition of Swiss biotech Actelion in June diversified J J s revenues to the PAH category However  sales of Invokana Invokamet declined 19 2  due to higher managed care discounting  Importantly  sales of the blockbuster rheumatoid arthritis drug Remicade  marketed in partnership with Merck   Co   Inc    NYSE MRK    declined 7 6  in the quarter with U S  sales declining 1 3  and international sales declining 6 9  due to biosimilar competition  In this regard  we would like to mention that Pfizer  Inc    NYSE PFE   filed a lawsuit in a U S  district court recently  In the lawsuit  Pfizer alleged J J of resorting to unfair practices to prevent sale of Inflectra   Pfizer s biosimilar version of Remicade   that was launched in the United States in November last year J J s Pharma segment achieved some clinical milestones during the quarter including label expansions in the United States for pulmonary arterial hypertension  PAH  drug  Tracleer for pediatric use and Imbruvica for chronic graft versus host disease  GVHD    the drug s first indication outside of cancer  J J markets Imbruvica in partnership with AbbVie  Inc    NYSE ABBV   At the call  the company also mentioned that it will not file global regulatory applications for rheumatoid arthritis candidate  sirukumab  We remind investors that last month  J J received a complete response letter  CRL  from the FDA for sirukumab for want of additional safety data   Medical Devices segment sales came in at  6 6 billion  up 7 1  from the year ago period  It included an operational increase of 6 6  and positive currency movement of 0 5   Sales gained mainly from the inclusion of Abbott Medical Optics acquisition  which added 5 2  to operational sales growth  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 1 2  Domestic market sales rose 4 6  year over year to  3 19 billion  International market sales increased 9 6   operational increase of 8 6   year over year to  3 41 billion Operational growth was driven by wound closure products in the General Surgery business  electrophysiology products in the Cardiovascular business and Acuvue contact lenses in the Vision Care business  which made up for a weaker sales performance in the Diabetes Care unitThe Consumer segment recorded revenues of  3 36 billion in the reported quarter  up 2 9  year over year operational increase of 1 6    Foreign currency movement positively impacted sales in the segment by 1 3   Sales in the domestic market declined 0 5  from the year ago period to  1 29 billion Slower growth in baby care products due to competitive pressure was partially offset by growth in beauty and over the counter products and international smoking cessation aids Meanwhile  the international segment recorded an increase of 5 1  to  2 07 billion  reflecting an operational increase of 3  and a positive currency impact of 2 1  2017 Guidance RaisedJ J raised its adjusted earnings and sales outlook for the year J J expects 2017 adjusted earnings per share in the range of  7 25    7 30 compared with  7 12    7 22 expected previously The revenue guidance was raised to a range of  76 1 billion to  76 5 billion compared with  75 8 billion to  76 1 billion expected previouslyOur TakeAs indicated last quarter  J J s sales growth accelerated in the third quarter leading the company to post its first positive sales surprise after almost a year  Higher sales in the pharmaceutical segment as well as positive contribution from the Actelion deal pulled up the top line in the quarter  The Actelion acquisition added an impressive 7 9  to operational sales growth in the quarter Though quite a few key products in J J s portfolio like Remicade and Concerta are facing generic competition  we believe that new products in all segments  label expansion of drugs like Imbruvica and Darzalex and contribution from Actelion could lead to better sales trends  going forward J J carries a Zacks Rank  3  Hold   You can see  Johnson   Johnson Price  Consensus and EPS Surprise   Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-10-16,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-beats-on-q3-earnings-actelion-buyout-drives-sales-200219323,200219323
198686,420202,JNJ,J J  JNJ  Beats On Q3 Earnings   Sales  Ups 2017 View,opinion,"Johnson   Johnson   NYSE JNJ    the bellwether of healthcare companies  has a strong presence in the pharmaceutical  medical devices and consumer care markets across the world  This New Jersey based company is well known for its baby care products and brands like Tylenol in addition to drugs like Remicade and Concerta However  like many of its peers  JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment In this scenario  investor focus remains on late stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top and bottom line numbers JNJ has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 2 18   Estimates have gone up slightly over the past 7 days Currently  JNJ has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  JNJ beat on third quarter earnings   the company reported EPS of  1 90 while our consensus called for EPS of  1 80 Revenues Beat  Revenues were also above expectations  Johnson   Johnson posted revenues of  19 65 billion  compared to our consensus estimate of  19 28 billion Higher sales from new products as well as the positive contribution from recent acquisitions like Actelion pulled up the top line in the quarter Key Statistics  Pharmaceutical segment sales rose 15 4  year over year to  9 7 billion  reflecting 14 6  operational growth and 0 8  positive currency impact as sales rose in both the domestic and international markets Ups 2017 View  J J raised its adjusted earnings and sales outlook for the year J J expects 2017 adjusted earnings per share in the range of  7 25    7 30 compared with  7 12    7 22 expected previously The revenue guidance was raised to a range of  76 1 billion to  76 5 billion compared with  75 8 billion to  76 1 billion expected previously Stock Price Impact  Shares rose 1 6  in pre market trading  Johnson   Johnson Price and Consensus   Check back later for our full write up on this JNJ earnings report later 
 Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-17,Zacks Investment Research,https://www.investing.com/analysis/jj-jnj-beats-on-q3-earnings--sales-ups-2017-view-200219308,200219308
198691,420207,JNJ,J J s Psoriasis Drug Stelara Gets FDA Nod For Adolescent Use,opinion,"Janssen  a subsidiary of Johnson   Johnson   NYSE JNJ    announced that the FDA has approved the label expansion of its plaque psoriasis drug  Stelara for use in adolescents  12 years of age or older   The drug is approved for adults in this indication since 2009 The company believes that the label expansion is a significant achievement as plaque psoriasis develops before the age of 20 years in approximately one third of the patients  Moreover  the number of treatments available for adolescents is limited Patients are administered only four doses a year after two starter doses of Stelara  which has become a leading therapeutic option Shares of the company are up 18 4  so far this year  almost in line with the  s performance  The industry has gained 18 3  in the same time frame The latest approval for Stelara is based on data from a phase III study  which evaluated the subcutaneous administration of the drug in adolescent patients  The data showed that the drug achieved minimal psoriasis or clear skin in at least two thirds of the patients  The safety data was also consistent with what was achieved in adult patients There are almost 7 5 million people suffering from psoriasis in the United States per the American Academy of Dermatology  Moreover  the National Center for Biotechnology Information stated that the majority of psoriasis patients suffer from plaque psoriasis  The numbers represent a huge opportunity for the drug following its label expansion  Moreover  with this approval Stelara has gained an edge over competing drugs like AbbVie Inc  s   NYSE ABBV   Humira  Novartis AG s Cosentyx and Celgene Corporation s   NASDAQ CELG   Otezla  which are only approved for adult plaque psoriasis patients  However  Pfizer Inc  s   NYSE PFE   Enbrel will compete with Stelara in the adolescent segment Johnson   Johnson Price and Consensus
    Johnson   Johnson carries a Zacks Rank  3  Hold   You can see  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-10-15,Zacks Investment Research,https://www.investing.com/analysis/jjs-psoriasis-drug-stelara-gets-fda-nod-for-adolescent-use-200218970,200218970
198698,420214,JNJ,Merck Drops Two HCV Combination Programs Amid Competition,opinion,Merck   Co   Inc    NYSE MRK   announced that it is discontinuing further development of two of its next generation hepatitis C  HCV  programs   MK 3682B and MK 3682C   as the market is becoming extremely crowded MK 3682B was an all oral  triple combination regimen  3682 uprifosbuvir  in combination with grazoprevir and ruzasvir1  developed for the treatment of chronic HCV infection  MK 3682C was a combination of ruzasvir uprifosbuvir Merck s shares have risen 9 2  this year so far compared with a 16 4  increase for the  The company will now focus on growing sales of its key HCV drug in the market  Zeptier  which is approved for use with ribavirin to treat chronic HCV genotype 1 or 4 infection  Zepatier  a once daily  fixed dose combination tablet containing the NS5A inhibitor elbasvir and the NS3 4A protease inhibitor grazoprevir  is gradually becoming a key top line driver for Merck along with cancer drug Keytruda The medicine recorded sales of  517 million in the second quarter of 2017  much higher than  378 million in the first quarter  attributable to strong underlying demand trends in the United States  Europe and Japan as the company continues to launch Zepatier globally  However  we remind investors that at the second quarter conference call  management had warned that Zepatier uptake  going forward  may be impacted by the ongoing decline in overall patient volumes in many markets and increased competition The HCV market is getting crowded and is thus seeing increased pricing pressure  Gilead Sciences Inc    NASDAQ GILD   markets blockbuster HCV drugs  Sovaldi and Harvoni  while other well known names in this market are AbbVie Inc  s   NYSE ABBV   Viekira Pak  Bristol Myers  Daklinza and Johnson   Johnson s   NYSE JNJ   Olysio Moreover  other companies are also looking to bring new  improved  shorter duration HCV treatments to market AbbVie s pan genotypic shorter duration HCV regimen of glecaprevir pibrentasvir  G P   Mavyret  received approval in the United States   Canada and the EU in July August  Meanwhile  Gilead already markets Epclusa  an all oral  pan genotypic  single tablet HCV regimen since 2016  Meanwhile  Gilead s single tablet regimen  STR  of Sovaldi  velpatasvir and voxilaprevir  Vosevi received approval in the United States  EU and Canada in July August  Vosevi became the first once daily STR available as a salvage therapy for patients infected with HCV genotype 1 6 who have failed prior treatment with DAA regimens including NS5A inhibitors Merck carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-02,Zacks Investment Research,https://www.investing.com/analysis/merck-drops-two-hcv-combination-programs-amid-competition-200216523,200216523
198699,420215,JNJ,Will Gilead   AbbVie Benefit From Merck s Decision To Drop Two HCV Programs ,opinion,Late last week  Merck   NYSE MRK   announced its decision to discontinue the development of a couple of candidates in its hepatitis C virus   HCV   program   MK 3682B  grazoprevir ruzasvir  uprifosbuvir  and MK 3682C  ruzasvir uprifosbuvir   The company s decision was based on a review of available phase II efficacy data and the growing competition in the HCV market  Merck itself has a marketed product in the HCV market in the form of Zepatier  elbasvir and grazoprevir  which brought in sales of  895 million in the first six months of 2017  including a  40 million favorable adjustment to rebate accruals due to mix of business   While Merck will continue to work on expanding Zepatier s utilization across the world  uptake will be impacted by the ongoing decline in overall patient volumes in many markets and increased competition Gilead and AbbVie in HCV SpotlightMerck s announcement has now put the spotlight firmly on Gilead Sciences   NASDAQ GILD   and AbbVie   NYSE ABBV    two key players in this market Gilead is the undisputed leader in the HCV market with its HCV products bringing in sales of  5 4 billion in the first half of 2017  The company revolutionized the treatment paradigm in the HCV market with the introduction of Sovaldi by cutting down the duration of treatment to as few as 12 weeks instead of the prior standard of care of up to 48 weeks  Moreover  the need for peg interferon injections  which come with several side effects  was reduced or eliminated completely Gilead launched Harvoni next  the first once daily single tablet regimen for the treatment of the most prevalent HCV genotype in the United States  This was followed by the launch of Epclusa  the first all oral  pan genotypic  single tablet regimen for the treatment of adults with genotype 1 6 chronic HCV infection  This year  Gilead gained approval for yet another HCV treatment  Vosevi Although Gilead ruled the HCV market for quite a few years  sales are declining given intense pricing pressure  growing competition  pricing scrutiny and a declining patient population  The approval of newer HCV products has resulted in a rapid increase in the number of patients who were treated and cured followed by a decline in the number of patients seeking care and being able to access HCV treatment  Gilead expects HCV net product sales in the range of  8 5 billion to  9 5 billion in 2017  announced with Q2 results   representing quite a drop from last year s HCV product sales of  14 8 billion Meanwhile  AbbVie s HCV products include Mavyret  glecaprevir pibrentasivr   Viekira Pak  ombitasvir  paritaprevir and ritonavir tablets co packaged with dasabuvir tablets  and Viekira XR  dasabuvir  ombitasvir  paritaprevir and ritonavir   While Mavyret was approved recently  Viekira sales were  488 million in the first half of 2017  Mavyret  the company s next generation HCV offering  should be a meaningful contributor to sales from 2018 Other HCV drugs include Bristol Myers Squibb Company s   NYSE BMY   Daklinza  daclastavir  and Janssen Therapeutics s Olysio  simeprevir  We remind investors that Merck is not the only company to have taken the decision to halt the development of HCV candidates  Last month  Johnson   Johnson   NYSE JNJ   had announced its decision to terminate a collaboration agreement with Achillion Pharmaceuticals   NASDAQ ACHN   for HCV J J s Janssen Pharmaceuticals said that it would be discontinuing the development of the investigational HCV treatment regimen JNJ 4178  a combination of three direct acting antivirals  AL 335  odalasvir and simeprevir With both Merck and J J dropping their investigational HCV treatments  Gilead and AbbVie should benefit from the lack of additional competition entering the market  at least in the near term  While the companies will continue to face challenges like declining patient volume and intense pricing pressure  the lack of additional entrants in the market should slow down the rate of decline in sales Gilead has been working on expanding the HCV market by encouraging baby boomers to get tested  According to the company  there has been an 80  increase in HCV antibody screening by baby boomers since the start of this initiative  Increased testing has led to an increase in diagnosis with about 190 000 people being newly diagnosed with HCV in 2016  up 32  from 2015  This represents a significant opportunity for the existing players in the HCV market Both Gilead and AbbVie are Zacks Rank  3  Hold  stocks   you can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-10-02,Zacks Investment Research,https://www.investing.com/analysis/will-gilead--abbvie-benefit-from-mercks-decision-to-drop-two-hcv-programs-200216697,200216697
198700,420216,JNJ,Here s What s Has Happened In The HCV Space Lately,opinion,"Hepatitis C is an infectious disease caused by the hepatitis C virus  HCV  that primarily affects the liver  Gilead Sciences Inc    NASDAQ GILD   markets blockbuster HCV drugs  Sovaldi and Harvoni  while other well known names in this market are AbbVie Inc  s   NYSE ABBV   Viekira Pak  Bristol Myers    NYSE BMY   Daklinza and Johnson   Johnson s   NYSE JNJ   Olysio 
According to the Centers for Disease Control and Prevention  CDC   about 3 2 million people in the United States are living with chronic hepatitis C infection while many remain unaware of being infected  There are about 17 000 new hepatitis C cases each year in the United States  many of which go unreported Considering these numbers  it is not a surprise that quite a few pharma and biotech companies are working on bringing new  improved  shorter duration HCV treatments to the market  The market is thus getting crowded and seeing increased pricing pressure   
A lot has happened in the HCV space of late   
In September 2017  Gilead Sciences  Sovaldi received approval in China  as a component of a combination antiviral treatment regimen  It is the first Gilead HCV drug to be approved in China   
Meanwhile  Gilead s single tablet regimen  STR  of Sovaldi  velpatasvir and voxilaprevir  Vosevi received approval in the United States  EU and Canada in July August  Vosevi became the first once daily STR available as a salvage therapy for patients infected with HCV genotype 1 6 who have failed prior treatment with DAA regimens including NS5A inhibitors 
Gilead s shares have outperformed the industry year to date  The stock has rallied 16 6  compared with the s gain of 14 5  in the same time frame  The stock carries a Zacks Rank  3  Hold   You can see  
 

Meanwhile  AbbVie s 8 week  pan genotypic  ribavirin free  once daily HCV treatment  Mavyret Maviret  gained approval in the United States  EU and Canada in the past couple of months  Mavyret  AbbVie s next generation HCV program  is a combination of glecaprevir  a potent protease inhibitor and pibrentasvir  a NS5A inhibitor  Maviret has the potential to rejuvenate growth in the HCV franchise  According to AbbVie  Mavyret may be used in up to 95  of HCV patients  depending on the stage of liver disease and prior treatment history 
Abbvie s shares have outperformed the industry year to date  The stock has rallied 44  compared with the  s gain of 17 9  in the same time frame  The stock carries a Zacks Rank  3 

However  last week  pharmaceutical giant Merck   NYSE MRK   announced that it is discontinuing further development of two of its next generation hepatitis C  HCV  programs   MK 3682B  grazoprevir ruzasvir  uprifosbuvir  and MK 3682C  ruzasvir uprifosbuvir   The company made this decision based on review of available phase II efficacy data and a heavily crowded HCV market 
Merck s shares have underperformed the industry year to date  The stock has gained 9 7  compared with the  s gain of 17 9  in the same time frame  The stock carries a Zacks Rank  3 

Besides Merck  another giant Johnson   Johnson also discontinued the development of its investigational HCV treatment regimen JNJ 4178  a combination of three direct acting antivirals  AL 335  odalasvir and simeprevir  The company took this decision considering that there are several highly effective therapies available for this indication 
Johnson   Johnson s shares have underperformed the industry year to date  The stock has gained 15 6  compared with the  s gain of 17 9  in the same time frame  The stock carries a Zacks Rank  3 

It is believed that the discontinuation of Merck and J J s combination HCV regimens should act in favor of Gilead and AbbVie  Gilead and AbbVie should benefit from the lack of additional competition entering the market  at least in the near term  However  the companies will continue to face challenges in the form of declining patient volume and intense pricing pressure  The lack of additional entrants in the market should also slow down the rate of decline in sales 
Where Do Zacks  Investment Ideas Come From 
You are welcome to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buy  stocks free of charge  There is no better place to start your own stock search  Plus you can access the full list of must avoid Zacks Rank  5  Strong Sells  and other private research ",2017-10-06,Zacks Investment Research,https://www.investing.com/analysis/heres-whats-has-happened-in-the-hcv-space-lately-200217501,200217501
198706,420222,JNJ,Here s Why These 3 Biotech Stocks Might Stop Rallying  Revised ,opinion,Biotech stocks have bounced back strongly this year after a poor show last year despite challenges like rising competition  slowdown in growth of mature products and generic competition for certain key drugs  Strong clinical results  faster FDA approvals  success of new products and significant contributions from established drugs have led to the rally in the biotech sector The NASDAQ Biotechnology Index gained 24 6  so far this year  This is in sharp contrast to last year s performance when the index was down 22  However  despite the strong performance  investors are keen to know whether the rally will continue and what factors will drive the same These companies are likely to see continued demand for their products  given an accelerated increase in aging population and the proportionate increase in diseases Moreover  the FDA has approved far more drugs so far in 2017 than it did in the whole of 2016  Hence  a faster drug approval process along with strong pipelines  innovative treatments  impressive results  and increased health care spending should support further growth in the sector Though the momentum in the biotech sector is likely to continue  it s a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant year to date gains 3 Small Biotech Stocks to Avoid Avoiding stocks that have represented significant share price gain could be a bit tricky  However  we have taken the help of the  to identify stocks  which may stop rallying in the near term  To shortlist the stocks from the vast universe of biotech sector  we have picked stocks that carry a Zacks Rank  4  Sell  or 5  Strong Sell  Moreover  we have also taken into consideration stocks that witnessed negative estimate revisions for the current year over the last 60 days as these are likely to plunge further and should be dumped Keryx Biopharmaceuticals Inc    NASDAQ KERX    This Boston based biopharmaceutical company focuses on treating patients suffering from renal disease  The company s shares have risen 20 1  so far this year  However  it currently carries a Zacks Rank  4  Further  over the last 60 days  the loss per share estimates widened by 33  for 2017  Though the company s label expansion efforts for its only marketed drug  Auryxia bode well for growth  the company s sole dependence on the product for revenue is concerning Keryx Biopharmaceuticals  Inc  Price   Juno Therapeutics  Inc    NASDAQ JUNO    This Washington based biopharmaceutical company focuses on the development of immuno oncology treatments  The company s shares have gained a significant 139 5  so far this year  Shares of the company mainly rose in September this year on the speculation that it will be acquired soon after the acquisition of Kite Pharma by Gilead  However  it currently carries a Zacks Rank  4 and has a of D  Further  over the last 60 days  its loss per share estimates widened almost 3  for 2017 Although Juno is among the major players in the field of T cell based immunotherapy  there are several other companies that are looking to develop and bring immunotherapy treatments to market  The CAR space has many companies including Novartis  Kite Pharma  bluebird bio  Intrexon  and Johnson   Johnson   NYSE JNJ   working on treatments  We note that Juno lags Kite Pharma and Novartis in the race to bring a CAR T product to the market  Hence  competition in the immunotherapy space may weigh heavily on the stock in the near term Juno Therapeutics  Inc  Price   Abeona Therapeutics Inc    NASDAQ ABEO    This Delaware based biopharmaceutical company focuses on developing gene therapies for life threatening rare genetic diseases  The company s shares showed a significant gain of 245 3  so far this year  However  it currently carries a Zacks Rank  4 and has a VGM Score of F Further  over the last 60 days  its loss per share estimates widened by 24 5  for 2017  The company s lead gene therapies EB 101 and ABO 201 recently received breakthrough therapy and orphan drug designation  respectively from the FDA  Abeona s share significantly rose in July 2017 after the company announced that it has received guidance from the FDA to commence pivotal phase III for EB 101  However  many companies are working on bringing gene therapies to the market  Therefore  these candidates may face intense competition in the targeted space  if approved Abeona Therapeutics Inc  Price    We are reissuing this article to correct a mistake  The original article  issued on Sep 20  should no longer be relied upon  ,2017-09-25,Zacks Investment Research,https://www.investing.com/analysis/heres-why-these-3-biotech-stocks-might-stop-rallying-revised-200215237,200215237
198712,420228,JNJ,Catalyst  CPRX  Focused On Two Lead Pipeline Candidates,opinion,We issued an updated report on Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   on Sep 15 Catalyst Pharma is a development stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders such as Lambert Eaton myasthenic syndrome  LEMS   epilepsy  initially infantile spasms  and Tourette syndrome At present  this Coral Gables  FL based company has two candidates under development  Firdapse and CPP 115 Catalyst Pharma s shares have outperformed the industry year to date  The stock has surged 129 6  compared with the  s gain of 2 9  in the same time frame The company expects to report top line results from its second phase III study of Firdapse for the treatment of Lambert Eaton myasthenic syndrome  LEMS  in the second half of 2017 and resubmit a new drug application  NDA  before the end of 2017  Earlier in 2016  it received a refusal to file letter from the FDA in connection with the NDA for Firdapse Notably  the agency determined that the company s NDA was insufficient after a preliminary review  Consequently  Catalyst Pharma was required to conduct additional studies as per the agency s requirements  in addition to the results of its previously submitted phase III data In October 2016  it reached an agreement with the FDA under a Special Protocol Assessment  SPA  for the protocol design  clinical endpoints  and statistical analysis approach to be taken in its second phase III study evaluating Firdapse Meanwhile  the company is working on developing Firdapse for additional indications  In February 2016  Catalyst initiated an investigator sponsored phase II III study on Firdapse for the symptomatic treatment of MuSK antibody positive MG   In March 2017  the company reported top line data from the phase II III trial The potential approval of Firdapse  along with its label expansion  will help in generating revenues for the company Additionally  Catalyst Pharma is exploring the possibility of developing CPP 115  a GABA aminotransferase inhibitor  for the treatment of epilepsy  initially infantile spasms  and the treatment of other selected neurological indications such as complex partial seizures and Tourette s disorder However  the market for epilepsy treatments is highly competitive and crowded given the presence of products like Pfizer s   NYSE PFE   Neurontin and Lyrica  Johnson   Johnson s   NYSE JNJ   Topamax  and Novartis    NYSE NVS   Trileptal Catalyst Pharmaceuticals  Inc  Price and Consensus   Zacks RankCatalyst Pharma currently carries a Zacks Rank  3  Hold   You can see  New Report  An Investor s Guide to CybersecurityCyberattacks have become more frequent and destructive than ever  In fact  they re expected to cause  6 trillion per year in damage by 2020 The cybersecurity industry is expanding quickly in response to these threats  In fact  a projected  170 billion per year will be spent to protect consumer and corporate assets  Zacks has just released Cybersecurity  An Investor s Guide to Locking Down Profits which reveals 4 promising investment candidates ,2017-09-17,Zacks Investment Research,https://www.investing.com/analysis/catalyst-cprx-focused-on-two-lead-pipeline-candidates-200213876,200213876
198713,420229,JNJ,Pharma Stock Roundup  Pfizer Files Suit Against J J  Supernus Hit By Study Update,opinion,"Key highlights this week include a lawsuit filed by Pfizer   NYSE PFE   accusing Johnson   Johnson   NYSE JNJ   of adopting exclusionary contracts and other anticompetitive practices to prevent biosimilar uptake  Meanwhile  companies like GlaxoSmithKline   NYSE GSK   and Supernus Pharmaceuticals   NASDAQ SUPN   were in the news for regulatory pipeline updates Recap of the Week s Most Important StoriesSupernus Down on Study Update  Supernus provided an update on the first phase III study on SPN 810 which is being evaluated for the treatment of impulsive aggression   IA   in patients aged 6 to 12 years who have attention deficit hyperactivity disorder   ADHD    Based on a planned interim analysis  the company has decided to drop the lower dose of 18 mg from the study and patients will be randomized to receive either the 36 mg dose or placebo  Investors were disappointed by the update and shares were down 23 4   Read more      CHMP Positive on J J Psoriasis Drug  J J s Tremfya  guselkumab  got a positive opinion in the EU with the Committee for Medicinal Products for Human Use   CHMP   recommending marketing authorization for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy Timely approval would make Tremfya the first biologic that selectively blocks interleukin  IL  23  a cytokine that plays a key role in plaque psoriasis  According to information in the press release  about 14 million people across Europe are estimated to suffer from psoriasis Tremfya gained FDA approval earlier this year in July Pfizer Files Suit against J J for Biosimilars  Pfizer has filed a lawsuit against J J in the U S  District Court for the Eastern District of Pennsylvania related to providing patient and physician access to lower cost biosimilars  According to the lawsuit  J J has adopted exclusionary contracts and other anticompetitive practices to deny access to and undermine the benefits of price competition in the biologics market  In order to maintain its monopoly in connection with Remicade  infliximab   J J was accused in the lawsuit of inappropriately excluding biosimilar competitors  Pfizer had launched Inflectra  its biosimilar version of Remicade  in late 2016  Biosimilars  while available in the EU for many years  are a relatively recent entrant in the United States and are yet to have a significant impact on reference product sales  Read more    Glaxo Innoviva COPD Treatment Gets FDA Nod  Glaxo and partner Innoviva got a boost with the FDA approval of their once daily  single inhaler triple therapy  Trelegy Ellipta  for the treatment of appropriate patients with chronic obstructive pulmonary disease   COPD   A combination of an inhaled corticosteroid   ICS    a long acting muscarinic antagonist   LAMA    and a long acting beta2 adrenergic agonist   LABA    Trelegy Ellipta will provide patients with a convenient dosing option and is expected to bring in blockbuster sales  Read more     Glaxo stock has gained 4 7  year to date  compared to the 16 6  rally of the  it belongs to 
Teva Divests Women s Health Business  Teva   NYSE TEVA    which recently got a new Chief Executive Officer   CEO    is taking steps to get its performance back on track  The company announced the sale of the remaining assets in its specialty global women s health portfolio  The planned divestiture of this segment will bring in total proceeds of  2 48 billion which will be used by Teva to pay down debt  The decision to sell the women s health business is part of Teva s efforts to divest its non core segments and focus on its key strategic areas  The company also announced amendments to its USD and JPY term loan and revolving credit facilities  Teva is currently going through tough times with the company being hit by generic pricing erosion  The company needs to work on paying down debt  divesting non core businesses to increase focus on core areas and generate cash  delivering on the pipeline and getting the U S  generics business back on track Roche AbbVie Cancer Drug Positive in Late Stage Study  Roche   OTC RHHBY   and partner AbbVie are looking to expand the label of their cancer therapy  Venclexta Venclyxto  Results from a late stage study  MURANO  showed that Venclexta plus Rituxan met the primary endpoint of prolonged progression free survival compared with Treanda  bendamustine  plus Rituxan in patients with relapsed refractory chronic lymphocytic leukemia   CLL    An independent data monitoring committee has recommended the unblinding of the study based on the positive results  Label expansion for this indication will expand the patient population for Venclexta significantly and boost its commercial potential  Read more    Roche is a Zacks Rank  3  Hold  stock  You can see  Performance
Large Cap Pharmaceuticals Industry 5YR   ReturnThe NYSE ARCA Pharmaceutical Index slipped 0 8  over the last five trading sessions  Among major stocks  Bristol Myers Squibb   NYSE BMY   gained 1  while J J slipped 1 8   Over the last six months  Bristol Myers was up 15 3  while Glaxo declined 2 4   See the last pharma stock roundup here    
What s Next in the Pharma World Watch out for the usual pipeline and regulatory updates  Bristol Myers s PD 1 inhibitor  Opdivo  is under priority review for use in patients with hepatocellular carcinoma   HCC   after prior treatment with Nexavar  sorafenib   The FDA is expected to give a response on Sep 24  2017  Meanwhile  J J is expecting a response from the FDA for its investigational rheumatoid arthritis   RA   treatment  Plivensia  sirukumab   an IL 6 inhibitor  However  with Plivensia failing to get the support of the FDA s Arthritis Advisory Committee on safety concerns  it s quite likely that the agency will ask for additional information before granting approval 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-09-22,Zacks Investment Research,https://www.investing.com/analysis/pharma-stock-roundup-pfizer-files-suit-against-jj-supernus-hit-by-study-update-200214888,200214888
198723,420239,JNJ,Novartis Announces Long Term Data On Psoriasis Drug Cosentyx,opinion,Novartis AG   NYSE NVS   announced long lasting skin clearance rates of Cosentyx in plaque psoriasis patients from a phase III study  which evaluated the drug for five years  Cosentyx is the first and only fully human IL 17A inhibitor to achieve sustained skin clearance rates over five years  reinforcing its long term favorable impact Data from the study showed that Cosentyx maintained 100  Psoriasis Area and Severity Index  PASI  90 and PASI 100  a measure of skin clearance  from year one to year five in patients with moderate to severe plaque psoriasis Data from this study were presented at the 26th European Academy of Dermatology and Venereology  EADV  Congress in Geneva  Switzerland Shares of the company have outperformed the   having surged 17 4  so far this year  while the industry increased 16  The drug is approved in the United Sates for the treatment of adults with active ankylosing spondylitis  active psoriatic arthritis  PsA  and moderate to severe plaque psoriasis  Since its launch  the drug has been prescribed to more than 100 000 patients  Cosentyx achieved blockbuster status in 2016  recording  1 1 billion in sales  In first half 2017  it generated solid sales of  900 million The long term safety and efficacy data of the drug is expected to further boost its growth Meanwhile  in the second quarter  the drug was granted approval in Europe for a label update to include 52 week data from the CLEAR study  It demonstrated the long term superiority of Cosentyx compared to Johnson   Johnson s   NYSE JNJ   Stelara in psoriasis  Also  patient recruitment is underway for the new head to head clinical trial  EXCEED  to evaluate the superiority of Cosentyx versus AbbVie s   NYSE ABBV   Humira in PsA Novartis expects the next growth phase to begin in 2018 driven by Cosentyx  in psoriasis  psoriatic arthritis and ankylosing spondylitis indications   Entresto  Kisqali and a deep pipeline with candidates like BAF312  AMG 334  RTH258  Moreover  the approval of Kymriah  CTL019  in August made Novartis the first company to bring CAR T cell therapy to treat cancer  Going forward  we expect that the approval of new drugs and label expansion of existing ones to bode well for Novartis Novartis AG Price and Consensus   Zacks Rank   Stock to ConsiderNovartis has a Zacks Rank  3  Hold   Aduro Biotech  Inc    NASDAQ ADRO   is a better ranked biomedical company with a Zacks Rank  2  Buy   You can see  Aduro s loss estimates narrowed 9 6  to  1 32 for 2017 and 20  to  1 24 for 2018 over the last 60 days  The company delivered an average earnings beat of 2 53  for the four trailing quarters 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-09-13,Zacks Investment Research,https://www.investing.com/analysis/novartis-announces-longterm-data-on-psoriasis-drug-cosentyx-200213321,200213321
198724,420240,JNJ,Neos Therapeutics ADHD Drug Adzenys Receives Approval In US,opinion,"Neos Therapeutics  Inc    NASDAQ NEOS   announced that the FDA has approved its third attention deficit hyperactivity disorder   ADHD   drug  Adzenys ER extended release oral suspension in patients six years and older  The drug is approved as a once daily treatment The company s shares were up 2 2  on Friday after the announcement of the news  The stock has outperformed the  so far this year  Neos Therapeutics  shares have risen 57 3  whereas the industry rose 2 9  in the same period The FDA approval will give ADHD patients an option of different dosage form  The other products in the ADHD portfolio include Adzenys XR ODT  Orally Disintegrating Tablets  and Cotempla XR ODT Both Adzenys XR ODT and Adzenys ER are prescription drugs  which stimulate the central nervous system   CNS   for treating ADHD in patients six years and older  Cotempla XR ODT is also a CNS stimulant  which treats ADHS in pediatric patients  6 17 years  The company said that Adzenys XR ODT  which was approved in January 2016  is the fastest growing alternative dosage form product for the treatment of ADHD The company expects to launch the drug in the first half of 2018 We note that both dosage forms of Adzenys are a bioequivalent form of Shire plc s   NASDAQ SHPG   Adderall XR  We remind investors that Shire is a market leader in the ADHD segment and received approval for its new ADHD drug  Mydayis in June Adzenys XR ODT recorded sales of  7 3 million in the first half of 2017  registering sequential growth of 35 5  in the second quarter of 2017 The ADHD space is one of the largest and fastest growing segments of the market  There are many drugs available for the indication including Johnson   Johnson s   NYSE JNJ   Concerta and Pfizer Inc  s   NYSE PFE   Quillivant Neos Therapeutics  Inc  Price and Consensus
    Neos Therapeutics has a Zacks Rank  3  Hold   You can see  New Report  An Investor s Guide to CybersecurityCyberattacks have become more frequent and destructive than ever  In fact  they re expected to cause  6 trillion per year in damage by 2020 The cybersecurity industry is expanding quickly in response to these threats  In fact  a projected  170 billion per year will be spent to protect consumer and corporate assets  Zacks has just released Cybersecurity  An Investor s Guide to Locking Down Profits which reveals 4 promising investment candidates ",2017-09-17,Zacks Investment Research,https://www.investing.com/analysis/neos-therapeutics-adhd-drug-adzenys-receives-approval-in-us-200213892,200213892
198728,420244,JNJ,Pfizer Presents Encouraging Eliquis Results In NVAF Patients,opinion,"Pfizer Inc   NYSE PFE   and partner Bristol Myers Squibb Company   NYSE BMY   presented findings from a phase IV study on Eliquis  which demonstrated the oral anticoagulation s potential in achieving and maintaining normal heart rhythm  cardioversion  The study  EMANATE  compared Eliquis with standard of care  Heparin  for reducing the occurrence of acute stroke  systemic embolism  major bleeding  clinically relevant non major bleeding and all cause death in non valvular atrial fibrillation  NVAF  patients undergoing cardioversion We remind investors that Eliquis is already approved for the reduction of the risk of stroke and systemic embolism in patients with NVAF  treatment of deep vein thrombosis  DVT  and pulmonary embolism  PE  and reduction in the risk of recurrent DVT and PE following initial therapy  and prophylaxis of DVT  which may lead to PE  in patients who have undergone hip or knee replacement surgery  However  the drug is not approved for the reduction of stroke in NVAF patients undergoing cardioversion Pfizer has underperformed the  so far this year  The stock has gained 3  during this period  while the industry gained 11 3  Coming back to the latest news  cardioversion procedure is associated with a concern for clotting of blood in the heart while travelling to brain  stroke  or other body parts  systemic embolism   The EMANATE study showed that there was no stroke in Eliquis group compared to six strokes in the Heparin arm  However  no systemic embolism was observed for both the drug groups  Eliquis also reduced the number of major bleeding events and clinically relevant non major bleeding events compared to Heparin The current standard of care   Heparin and Coumadin   requires monitoring and potential dose adjustment while administered for reducing the risk of stroke  However  Eliquis can be administered at a fixed dose of 5mg twice daily We note that Eliquis  being an anticoagulant  increases the risk of bleeding  which can become serious and potentially fatal The company also announced data from a real world analysis of Eliquis in NVAF patients in a separate press release  Per the analysis  Eliquis showed lower risk of stroke SE and lower rates of major bleeding compared to Coumadin in NVAF patients as well as for each of the selected high risk patient sub populations Eliquis faces competition in the anticoagulant segment from Johnson   Johnson s   NYSE JNJ   Xarelto and Boehringer Ingelheim s Pradaxa  With the approval of Portola Pharmaceuticals  Inc  s   NASDAQ PTLA   Bevyxxa in June 2017competition is expected to intensify Stroke events are a major concern for NVAF patient  The above findings show that Eliquis may become a preferred treatment for the same which may boost the potential of the drug  If Pfizer and Bristol Myers try to get the label of Eliquis expanded to include the findings  it will give the drug an edge over other marketed blood thinners Pfizer  Inc  Price and Consensus
    Currently  Pfizer carries a Zacks Rank  3  Hold   You can see  Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-08-28,Zacks Investment Research,https://www.investing.com/analysis/pfizer-presents-encouraging-eliquis-results-in-nvaf-patients-200210254,200210254
198729,420245,JNJ,JNJ Stock Bulls To Call A 15  Timeout  ,opinion,"Johnson   Johnson  NYSE JNJ  is a global medical  pharmaceutical and consumer goods manufacturer  founded in 1886  The company s stock  listed on the New York Stock Exchange under the symbol JNJ  is a component in the S P 500 as well as in the Dow Jones Industrial Average index 
This is a blue chip company with a long and profitable history  so hardly anyone is surprised when JNJ stock is rising  The price jumped from  81 79 a share on August 24th  2015  to as high as  137 08 in July  2017 
On the other hand  when JNJ stock plunges  it often comes as a shock to shareholders  Unfortunately  even the strongest of businesses cannot escape the market s vagaries 

The daily price chart of JNJ shows the stock s entire progress since the low in August  2015  As visible  it took the shape of a perfect five wave impulse  The sub waves of wave  5  are also clearly recognizable  According to the   a three wave correction in the other direction follows every impulse  erasing most or all of the fifth wave  This means that instead of loading up on JNJ stock near  130 a share  investors would be better off staying away for now  because a notable three wave decline could drag the price down to the support of wave  4  near  111 
Johnson   Johnson is one of the biggest enterprises in the world with annual sales exceeding  70 billion  The anticipated 15  decline in its capitalization would hardly matter in the long term  but it would create a much better buying entry than the market is currently offering ",2017-09-07,EWM Interactive,https://www.investing.com/analysis/jnj-stock-bulls-to-call-a-15-timeout-200211814,200211814
198737,420253,JNJ,Pacira Pharmaceuticals Focuses On Exparel s Label Expansion,opinion,We issued an updated report on Pacira Pharmaceuticals  Inc    NASDAQ PCRX   on Aug 11 In fact  shares of the company have rallied 12 7  against the Zacks classified i fall 3 4  on a year to date basis Pacira Pharmaceuticals  Inc  is a specialty pharmaceutical company focused on the development  commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers Notably  the company s flagship product  Exparel  was launched in 2012  This product is a liposome injection of bupivacaine  which is indicated for single dose administration into the surgical site to produce postsurgical analgesia  In January 2017  Pacira inked a co promotion agreement with DePuy Synthes Sales Inc  to market and promote the use of Exparel for orthopedic procedures in the U S  market  We expect this collaboration to significantly expand use of Exparel across a broad range of surgical procedures In fact  this Parsippany  NJ based company s efforts to expand Exparel s label to boost sales in oral surgery and chronic pain are encouraging In September 2016  the company had launched Exparel to the oral surgeon community to treat pain following oral and maxillofacial procedures Currently  it expects that a label expansion of this injection into oral surgery might benefit oral and maxillofacial surgeons  prosthodontists and endodontists by giving them the ability to produce analgesia with a single dose administration during the days following surgery Prior to this  in April 2016  the company had initiated a randomized controlled study on Exparel for total knee arthroplasty  TKA   In March 2017  the company announced positive topline data from this study Additionally  Pacira is conducting a phase IV study of Exparel in spinal fusion surgery with results expected in the fourth quarter of 2017  Also  it is launching a series of phase IV studies in soft tissue procedures  These studies will assess the company s flagship product as part of its multimodal protocol for C section  colon cancer and breast reconstruction surgery Meanwhile  Pacira remains on track to resubmit its supplemental new drug application  sNDA   to the FDA later in 2017  This  in turn  will seek expansion of the Exparel label to include the indication of administration via nerve block  The sNDA will be based on two pivotal efficacy studies Furthermore  the company announced positive top line data from these studies in July 2017  The company believes that the data from these two studies will meet the requirements of the FDA as stated in the complete response letter  issued in March 2015  In January  Pacira signed an agreement with DePuy Synthes Sales Inc   a subsidiary of Johnson   Johnson   NYSE JNJ    to market and promote the use of Exparelfor orthopedic procedures in the U S  market However  Pacira s drug  DepoCyt e  s sales have been declining  The downturn was almost 59 4  in the first half of 2017 compared with the year ago quarter  The company also announced that it will discontinue the production of DepoCyt e  due to persistent technical issues specific to DepoCyt Hence  it is heavily dependent on Exparel for growth  which accounts for a significant chunk of its revenues  Hence  a decline in Exparel sales will adversely impact the company s top line  Pacira Pharmaceuticals  Inc  Price and Consensus   Zacks Rank   Stocks to ConsiderPacira currently carries a Zacks Rank  3  Hold   Better ranked stocks in health care sector include Enzo Biochem  Inc    NYSE ENZ   and Sanofi   NYSE SNY    While Enzo Biochem sports a Zacks Rank  1  Strong Buy   Sanofi holds a Zacks Rank  2  Buy   You can see  Enzo Biochem s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018 over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 55 83   The share price of the company has increased 59 3  year to date Sanofi s earnings per share estimates increased from  3 21 to  3 31 for 2017 and from  3 36 to  3 38 for 2018 over last 30 days  The company pulled off positive earnings surprises in three of the trailing four quarters  with an average beat of 5 10   The share price of the company has increased 17 6  year to date 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course  Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-08-13,Zacks Investment Research,https://www.investing.com/analysis/pacira-pharmaceuticals-focuses-on-exparels-label-expansion-200207128,200207128
198738,420254,JNJ,Catalyst  CPRX  Focused On Development Of Pipeline Candidates ,opinion,We issued an updated report on Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   on Aug 14 In fact  Catalyst Pharma is a development stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders such as Lambert Eaton myasthenic syndrome  LEMS   epilepsy  initially infantile spasms  and Tourette syndrome At present  this Coral Gables  FL based company has two candidates under development   Firdapse and CPP 115 The company expects to report top line results from its second phase III study of Firdapse for the treatment of Lambert Eaton myasthenic syndrome  LEMS  in the second half of 2017 and resubmit a new drug application  NDA  before the end of 2017  Earlier in 2016  it received a refusal to file letter from the FDA in connection with the NDA for Firdapse Notably  the agency had determined that the company s NDA was insufficient after a preliminary review  Consequently  Catalyst Pharma was required to conduct additional studies as per the agency s requirements  in addition to the results of its previously submitted phase III data In Oct 2016  it reached an agreement with the FDA under a Special Protocol Assessment  SPA  for the protocol design  clinical endpoints  and statistical analysis approach to be taken in its second phase III study evaluating Firdapse Meanwhile  the company is working on developing Firdapse for additional indications  Catalyst initiated an investigator sponsored phase II III study on Firdapse for the symptomatic treatment of MuSK antibody positive MG in Feb 2016   In Mar 2017  the company reported top line data from the phase II III trial The potential approval of Firdapse  along with its label expansion will help in generating revenues for the company Additionally  Catalyst Pharma is exploring the possibility of developing CPP 115  a GABA aminotransferase inhibitor  for the treatment of epilepsy  initially infantile spasms  and the treatment of other selected neurological indications such as complex partial seizures and Tourette s disorder However  the market for epilepsy treatments is highly competitive and crowded given the presence of products like Pfizer s   NYSE PFE   Neurontin and Lyrica  Johnson   Johnson s   NYSE JNJ   Topamax  Novartis    NYSE NVS   Trileptal Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars  But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-08-14,Zacks Investment Research,https://www.investing.com/analysis/catalyst-cprx-focused-on-development-of-pipeline-candidates-200207302,200207302
198739,420255,JNJ,JNJ Bulls Be Warned,opinion,"One of our stocks in focus is JNJ US  Johnson   Johnson  NYSE JNJ   
 
Share price is testing important short term support trend line  Breaking below 132 50  will be an important bearish signal  Price has entered the Ichimoku cloud and is in a neutral trend  Breaking below the trend line will increase the chances of breaking below the Kumo  cloud  and providing a bearish signal according to Ichimoku terms 

According to my elliott wave view there are high chances 5 waves from 109  area are complete  So a pull back towards 128 122  is justified 

Zooming out we get an even worrisome picture as a bigger 5 wave pattern could already be complete as well  

With bearish divergence signs from the RSI and a 5 wave pattern most probably complete  we might be standing at a major top with a major reversal coming  So bulls should be very careful this is not an opportunity to take profits for bulls but an opportunity in the short side  I will be opening short positions once we break my support levels with stops at the highs 
Conclusion
 JNJ US could be at the very early stages of a big decline as an impulse wave pattern since the lows of 2015 might be complete  Bulls need to be very cautious  Could the negative verdict from the Talc cancer case be the first among the 5 500 cases the company faces and loses    This would be a terrible blow for the company and the stock market price will soon reflect the worries  fears and the concern this result creates 
Disclosure  None of the information or opinions expressed in this blog constitutes a solicitation for the purchase or sale of any security or other instrument  Nothing in this article constitutes investment advice and any recommendations that June be contained herein have not been based upon a consideration of the investment objectives  financial situation or particular needs of any specific recipient  Any purchase or sale activity in any securities or other instrument should be based upon your own analysis and conclusions ",2017-08-24,Alexandros Yfantis,https://www.investing.com/analysis/jnj-bulls-be-warnedan-elliot-wave-approach-200209218,200209218
198746,420262,JNJ,Achillion  ACHN  Q2 Loss In Line  Gains On Pipeline Update,opinion,"Achillion Pharmaceuticals  Inc    NASDAQ ACHN   reported a loss of 16 cents per share in the second quarter of 2017  in line with the Zacks Consensus Estimate  In the year ago quarter  the company had reported a loss of 14 cents per share The company generated no revenues in the reported quarter as had been the case in the year ago quarter Shares of Achillion surged almost 28  in after hours trading on Aug 8  as the company announced positive interim results on its most advanced factor D inhibitor pipeline candidate  ACH 4471  However  the stock has underperformed the  year to date  The company s shares lost 2 9  whereas the industry registered an increase of 8 7  Research and development expenses increased nearly 29  from the year ago period to  18 3 million due to increased clinical trial costs related to pipeline candidate  ACH 4471  The increase in expenses also included higher manufacturing costs related to ACH 5528 and cost related to ophthalmic factor D inhibitor compounds in development  However  the increase was partially offset by a decrease in cost related to manufacturing of ACH 4471 General and administrative expenses were up 4  to  5 4 million due to an increase in corporate legal fees and consulting fees  partially offset by a decrease in corporate taxes Pipeline UpdateIn April  Achillion initiated patient dosing in a phase II study  evaluating its key pipeline candidate  a factor D inhibitor  ACH 4471 for the treatment of patients with paroxysmal nocturnal hemoglobinuria  PNH   The company completed three months of dosing during the quarter and entered a long term extension trial The interim results from the study  announced together with the earnings release  showed clinically meaningful complement inhibition and a favorable tolerability profile for ACH 4471  The candidate has shown improvement in LDH  hemoglobin  fatigue score and other markers of response Moreover  the company plans to initiate a phase II study later this year on ACH 4471 in patients with C3G  a rare renal disorder  which includes dense deposit disease  DDD  and C3 glomerulonephritis  C3GN  Meanwhile  Achillion is planning to advance a number of next generation factor D inhibitors in preclinical or clinical studies by 2017 end Also  Achillion is evaluating a triple combination of simeprevir  odalasvir and AL 335 in a phase II OMEGA 1 study in patients with HCV genotype 1  2  4  5  and 6 infection  with and without cirrhosis  The study is being conducted by Johnson   Johnson s   NYSE JNJ   subsidiary Janssen with data expected in the second half of 2017 Achillion Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to ConsiderAchillion Pharma carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the pharma sector include Summit Therapeutics PLC   NASDAQ SMMT   and Enzo Biochem  Inc    NYSE ENZ    Both stocks carry a Zacks Rank  2  Buy   You can see  Summit s loss estimates narrowed from  2 59 to 32 cents for 2017 over the last 60 days  The company delivered positive earnings surprise in each of the four trailing quarters with an average beat of 25 55   Its share price is up 66 6  so far this year Enzo Biochem s loss estimates narrowed from 12 cents to 7 cents for 2017 over the last 60 days  The company came up with a positive earnings surprise in all the four trailing quarters with an average beat of 55 83   The stock is up 62 7  so far this year More Stock News  Tech Opportunity Worth  386 Billion in 2017From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-08-08,Zacks Investment Research,https://www.investing.com/analysis/achillion-achn-q2-loss-in-line-gains-on-pipeline-update-200206347,200206347
198748,420264,JNJ,Is A Beat In The Cards For Pfizer  PFE  In Q2 Earnings ,opinion,We expect Pfizer  Inc    NYSE PFE   to beat expectations when it reports second quarter 2017 results on Aug 1  before the market opens  Last quarter  the company delivered a positive earnings surprise of 2 99  The pharma giant has a mixed record of earnings surprises  The company s earnings surpassed expectations in two of the last four quarters while missing in the other two  resulting in an average negative surprise of 0 35  Pfizer s shares rose 1 9  this year so far  comparing unfavorably with an increase of 11 8  for the Zacks classified  Factors at PlayNew products like Xeljanz  rheumatoid arthritis  and Ibrance  breast cancer  as well as older products like Lyrica  neuropathic pain  and Eliquis  blood thinner  are likely to contribute to the top line meaningfully  Xeljanz  5 mg taken twice daily  was approved in the EU in Mar 2017  which may boost the drug s sales in the to be reported quarter Also  revenues from the blockbuster prostate cancer drug Xtandi  added to Pfizer s portfolio following the Sep 2016 Medivation acquisition  are likely to propel U S  revenues The Hospira acquisition is expected to be an important growth driver as well Also  Pfizer launched Inflectra  a biosimilar version of Johnson   Johnson   NYSE JNJ   blockbuster drug Remicade in Nov 2016  Inflectra recorded sales of  17 million in the U S  and  78 million globally in the first quarter  The biosimilar may generate more sales in the soon to be reported quarter However  Pfizer will continue to face headwinds in the form of loss of exclusivity on key products like Pristiq  Zyvox and Celebrex and the expiration of a few co promotion agreements  which will continue to hamper top line growth  Blockbuster drug Enbrel sales will continue to decline in the quarter due to biosimilar competition  The Prevnar Prevenar 13 vaccines franchise is expected to continue to see lower sales while lower demand should continue to hurt sales of Viagra Meanwhile  the bottom line should be driven by cost savings and share buybacks  However  new product launch expenses and R D investments are expected to hurt profits On the second quarter call  investor focus is expected to remain on the performance of new products and pipeline progress including biosimilars and immuno oncology  Importantly  key cancer candidate  Bavencio avelumab received FDA approval for metastatic Merkel cell carcinoma  MCC  in Mar 2017 and for advanced bladder cancer in May  The drug may bring in some revenues in the second quarter  Management is expected to shed light on how the launch is progressing at the conference call Acute lymphoblastic leukemia  ALL  candidate  Besponsa  was also approved in the EU in late Jun 2017  We expect management to comment on the commercialization plans at the conference call What Our Model IndicatesOur proven model shows that Pfizer is likely to beat on earnings because it has the right combination of the two key ingredients  A stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP  The   which represents the difference between the Most Accurate estimate  66 cents per share  and the Zacks Consensus Estimate  65 cents per share   is  1 54   This is a meaningful indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Pfizer has a Zacks Rank  3  The combination of Pfizer s Zacks Rank  3 and positive ESP makes us confident of an earnings beat in the upcoming release Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks to ConsiderA couple of stocks in the pharmaceuticals sector that also have a positive Earnings ESP and a favorable Zacks Rank are Novo Nordisk  CO NOVOb  A S   NYSE NVO    scheduled to release results on Aug 9  has an Earnings ESP of  3 57  and a Zacks Rank  3  You can see  Celgene Corporation   NASDAQ CELG   with an Earnings ESP of  0 62  and a Zacks Rank  3  The company is scheduled to release results on Jul 27 The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires     but that should still leave plenty of money for regular investors who make the right trades early ,2017-07-25,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-pfizer-(pfe)-in-q2-earnings-200203658,200203658
198757,420273,JNJ,J J Brightens Outlook  Healthcare ETFs In Focus,opinion,The Q2 earnings season has commenced and Johnson   Johnson   NYSE JNJ   was the first drug company to report earnings on July 18 before the opening bell  The world s biggest maker of health care products continued its long streak of earnings beat and offered an upbeat outlook for the full year  However  it lagged our revenue estimate again on sluggish drug sales Q2 Results in DetailEarnings per share came in at  1 83  4 cents ahead of the Zacks Consensus Estimate and 5 2  higher than the year ago quarter  Revenues grew 1 9  year over year to  18 84 billion but fell shy of the Zacks Consensus Estimate of  18 89 billion  Weak drug sales of arthritis treatment Remicade  diabetes medicine Invokana and cancer drug Zytiga   which are among the company s 10 top selling treatments   were responsible for the revenue miss Johnson   Johnson raised its full year earnings per share guidance to  7 12  7 22 from  7 00  7 15 and revenue guidance to  75 8  76 1 billion from  75 4  76 1 billion  It expects sales and profitability to pick up in the second half of this year on strong demand for newer  pricey treatments such as cancer drugs Darzalex and Imbruvica  The Zacks Consensus Estimate are currently pegged at  7 10 for earnings per share and  75 71 billion for revenues  see    Market ImpactFollowing the results  shares of JNJ rose 1 7  at the close on July 18  Currently  the stock has a Zacks Rank  2  Buy  with a VGM Score of B  Further  Johnson   Johnson belongs to a solid industry with a Zacks Rank in the  As a result  investors should closely watch the movement of the stock and keep a close eye on ETFs having the largest allocation to this diversified drug maker  Below  we have highlighted those Health Care Select Sector SPDR Fund The most popular healthcare ETF  XLV follows the Health Care Select Sector Index  This fund manages nearly  17 7 billion in its asset base and trades in heavy volume of around 7 8 million shares  Expense ratio comes in at 0 14  annually  In total  the fund holds 63 securities in its basket with JNJ taking the top spot at 11 7  of the assets  Pharma accounts for 34 5  share from a sector look while biotech  healthcare providers and services  and healthcare equipment and supplies make up for a double digit exposure each  It has a Zacks ETF Rank of 1 or  Strong Buy  rating with a Medium risk outlook  read    iShares U S  Healthcare ETF This fund offers exposure to 118 securities by tracking the Dow Jones U S  Health Care Index  Here again  Johnson   Johnson dominates the fund s return at 11 2  of total assets  In terms of industrial exposure  pharma takes the top spot at 33 9   followed by biotech  22 8    and healthcare equipment  19 2    The product has amassed nearly  2 billion in its asset base while charges 44 bps in annual fees  It trades in a good volume of around 99 000 shares a day and has a Zacks ETF Rank of 1 with a Medium risk outlook Vanguard Health Care ETF   AX VHT  This ETF tracks the MSCI US Investable Market Health Care 25 50 Index and holds 364 stocks in its basket  Out of these  Johnson   Johnson takes the top spot with 10 2  allocation  Pharma takes the largest share at 31 3  while biotech and healthcare equipment round off the top three spots  VHT is also one of the popular and liquid ETFs with AUM of  6 8 billion and average daily volume of about 199 000 shares  It charges 10 bps in annual fees and has a Zacks ETF Rank of 1 with a Medium risk outlook Fidelity MSCI Health Care Index ETF This fund provides exposure to 346 healthcare stocks with AUM of  813 million  This is done by tracking the MSCI USA IMI  LON IMI  Health Care Index  Here too  JNJ is the top firm with nearly 10 2  allocation  Pharma accounts for 30 9  share while biotech  healthcare equipment and supplies  and healthcare providers and services round off the top three spots with a double digit exposure each  The ETF has 0 08  in expense ratio while volume is good at 141 000 shares a day  FHLC has a Zacks ETF Rank of 3 or  Hold  rating with a Medium risk outlook iShares U S  Pharmaceuticals ETF This ETF provides exposure to 41 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  Of these  Johnson and Johnson is the top firm accounting for 9 9  share  The product has  703 1 million in AUM and charges 44 bps in fees and expenses  Volume is lower as it exchanges about 20 000 shares a day  The fund has a Zacks ETF Rank of 2 or  Buy  rating with a High risk outlook  read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2017-07-18,Zacks Investment Research,https://www.investing.com/analysis/j-j-brightens-outlook:-healthcare-etfs-in-focus-200202153,200202153
198758,420274,JNJ,AbbVie Inc s   ABBV  Q2 Earnings  Disappointment In Store ,opinion,"AbbVie Inc    NYSE ABBV   is scheduled to release second quarter 2017 earnings  before the opening bell on Jul 28 
AbbVie s shares have rallied 18 2  so far this year  while the  has recorded an increase of 13 2  

Last quarter  the company delivered a positive surprise of 1 59   We note that AbbVie s earnings history is a mixed bag as the pharmaceuticals company delivered positive surprises in the two of the last four quarters but recorded in line earnings in the other two  The average earnings beat for the last four quarters is 1 65  AbbVie Inc  Price and EPS Surprise

   Let s see how things are shaping up for the company this quarter 
Factors to Consider
At the first quarter 2017 conference call  management revealed that it expects second quarter 2017 earnings in the range of  1 39  1 41 per share  Revenues are expected to grow between 7  and 8  on a reported basis  Currency headwinds are expected to hurt revenues by 1  
The company s key drug  Humira  is likely to remain the main growth driver in the second quarter  Increasing awareness  favorable clinical data  additional indications and expansion into new markets are expected to help the product continue making significant contributions to the top line  This quarter  AbbVie also expects Humira sales growth in the U S  in the mid to high teens range while internationally  Humira sales are expected to rise in a mid single digit range on an operational basis 
Though Humira is doing well  the company is concerned about the product s long term prospects owing to the potential biosimilar competition 
Another area of focus is the performance of Imbruvica  added to AbbVie s portfolio following its May 2015 acquisition of Pharmacyclics  The drug recorded strong sales since past few quarters  a trend that we expect to continue  Imbruvica has multi billion dollar potential and the company is looking to expand the drug s label for solid tumors and autoimmune diseases 
The company expects the Imbruvica sales growth in the U S  to approach 35  in the second quarter 
Although Imbruvica has huge commercial potential  investors should know that revenues from it will be shared with Johnson   Johnson   NYSE JNJ    which has a collaboration agreement with Pharmacyclics 
Other drugs like Duopa and Creon are also expected to continue to perform well in the soon to be reported quarter 
However  Abbvie s Hepatitis C virus  HCV  treatment  Viekira  will continue to be adversely impacted by an intense pricing and competitive pressure in the HCV market 
Notably  last month  the company announced that the Committee for Medicinal Products for Human Use  CHMP  recommended a marketing approval of its investigational  hepatitis C virus  HCV  combo regimen of glecaprevir pibrentasvir  G P   The candidate will be marketed by the trade name of Maviret 
A decision from the European Commission is expected in the third quarter of 2017  An approval will definitely provide the company with a stronger presence against the competitive dynamics in the HCV market 
Earnings Whispers
Our proven model does not conclusively show that AbbVie is likely to beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below 
Zacks ESP  The Earnings ESP for AbbVie is  0 71  as the Most Accurate estimate is pegged at  1 39 per share and the Zacks Consensus Estimate stands higher at  1 40  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Though AbbVie s Zacks Rank  3 increases the predictive power of the ESP  its  0 71  Earnings ESP makes the surprise prediction difficult 
We caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks That Warrant a Look
Here are some better ranked health care stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Novo Nordisk  CO NOVOb  A S   NYSE NVO   is scheduled to release its results on Aug 9  The company has an Earnings ESP of  3 57  and a Zacks Rank  2  You can see  
Pfizer Inc    NYSE PFE    scheduled to release its results on Aug 1  has an Earnings ESP of  1 54  and a Zacks Rank  3 
Will You Make a Fortune on the Shift to Electric Cars  
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-07-21,Zacks Investment Research,https://www.investing.com/analysis/abbvie-inc's.-(abbv)-q2-earnings:-disappointment-in-store-200202747,200202747
198769,420285,JNJ,J J  JNJ  Beats On Q2 Earnings  Lags Sales  Ups 2017 View,opinion,"Johnson   Johnson   NYSE JNJ   reported mixed second quarter 2017 results  While earnings beat expectations  sales missed the same  However  the drug and consumer products giant raised its 2017 sales and profit outlook  which sent shares up more than 1  in pre market trading This year so far  J J s share price is up 14 7   This compares favorably with the 11 3  increase witnessed by the Zacks classified industry Earnings BeatJ J s second quarter 2017 earnings came in at  1 83 per share  beating the Zacks Consensus Estimate of  1 79 and increasing 5 2  from the year ago period Including one time items  J J reported second quarter earnings of  1 40 per share  down 2 1  from the year ago period Sales Miss AgainSales came in at  18 84 billion  missing the Zacks Consensus Estimate of  18 89 billion by 0 3   Sales increased 1 9  from the year ago quarter  reflecting an operational increase of 2 9  and a negative currency impact of 1   Organically  excluding the impact of acquisitions and divestitures  sales increased 0 5  on an operational basis Second quarter sales grew 1 6  in the domestic market to  9 73 billion and 2 3  in international markets to  9 11 billion  reflecting 4 4  operational growth  partially offset by a 2 1  negative currency impact Sales in DetailsPharmaceutical segment sales declined 0 2  year over year to  8 64 billion  reflecting 1  operational growth and 1 2  negative currency impact  Higher sales in international markets offset a weaker performance in the U S Sales in the domestic market declined 2 6  to  5 01 billion  while international sales grew 3 3  to  3 63 billion New products like Imbruvica  cancer  and Darzalex  multiple myeloma  continued to perform well  Other growth drivers were Xarelto  Stelara and Invega Sustenna However  sales of Invokana Invokamet declined 23   Also  Concerta declined 23 9  while Zytiga sales fell 7 2  Importantly  sales of the blockbuster rheumatoid arthritis drug Remicade  marketed in partnership with Merck   Co   Inc    NYSE MRK    declined 14  in the quarter with U S  sales declining 13 9  and international sales declining 5 6  due to biosimilar competition  In this regard  we would like to mention that Pfizer Inc    NYSE PFE   launched its Inflectra injection  a biosimilar version of Remicade in the U S  late last November  This did not have any significant impact on Remicade sales in the past two quarters  Management is expected to comment on the impact of the biosimilar on second quarter sales at the conference call J J s Pharma segment achieved some clinical milestones during the quarter  These included the FDA approval for Darzalex to be used in combination with Celgene Corporation s   NASDAQ CELG   Pomalyst  pomalidomide  and dexamethasone for the third line treatment of multiple myeloma  Importantly  last week  J J announced FDA approval for its pipeline candidate guselkumab for the treatment of moderate to severe plaque psoriasis  The drug will be marketed by the trade name of Tremfya Meanwhile  last month J J completed its previously announced  30 billion acquisition of Swiss biotech Actelion  which will diversify its revenuesto the pulmonary arterial hypertension  PAH  category  Actelion s PAH drugs added  91 million to the top line in the quarter Medical Devices segment sales came in at  6 73 billion  up 4 9  from the year ago period  It included an operational increase of 5 9  and negative currency movement of 1   Sales gained mainly from the inclusion of Abbott Medical Optics acquisition  Excluding the impact of all acquisitions and divestitures  on an operational basis  worldwide sales increased 1 1  Sales in the domestic market rose 6 1  year over year to  3 23 billion  International market sales increased 3 9   operational increase of 5 8   year over year to  3 5 billion Operational growth was driven by the Advanced Surgery business  electrophysiology products in the Cardiovascular business and Acuvue contact lenses in the Vision Care business  which made up for a weaker sales performance in the Diabetes Care unitThe Consumer segment recorded revenues of  3 48 billion in the reported quarter  up 1 7  year over year operational increase of 2 3    Foreign currency movement negatively impacted sales in the segment by 0 6   Sales in the domestic market grew 7 4  from the year ago period to  1 49 billion Slower growth in baby care products was partially offset by growth in over the counter products Meanwhile  the international segment recorded a decline of 2 2  to  1 99 billion  reflecting an operational decline of 1 1  and a negative currency impact of 1 1  2017 Guidance RaisedJ J raised its earnings guidance for 2017 and increased the lower end of its sales outlook J J expects 2017 adjusted earnings per share in the range of  7 12    7 22  including currency impact  compared with  7 00    7 15 expected previously The revenue guidance is in the range of  75 8 billion to  76 1 billion compared with  75 4 billion to  76 1 billion expected previouslyOur TakeDespite the third consecutive sales miss  J J looks optimistic about a better sales performance in the second half  Chief executive officer  Alex Gorsky said that J J s sales growth will accelerate in the second half of the year Importantly  sales in the Medical Device segment are picking up  which made up for lower sales in the international Consumer and U S  Pharmaceutical segments in the quarter  Sales in J J s domestic Pharma segment have decelerated this year as key growth drivers have slowed down due to competition  Quite a few products in its portfolio like Remicade and Concerta are facing generic competition  However  we believe that new products like Tremfya  label expansion of drugs like Imbruvica and Darzalex and contribution from Actelion could lead to better sales trends in the remaining half of the year J J carries a Zacks Rank  3  Hold   You can see  Johnson   Johnson Price  Consensus and EPS Surprise
    5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-07-17,Zacks Investment Research,"https://www.investing.com/analysis/j-j-(jnj)-beats-on-q2-earnings,-lags-sales,-ups-2017-view-200201899",200201899
198770,420286,JNJ,Gilead s HCV Portfolio Receives A Boost With Vosevi Approval,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced that the FDA has approved Vosevi  Sovaldi  velpatasvir 100 mg voxilaprevir 100 mg  tablets  The drug is a single tablet regimen  STR  for the re treatment of chronic hepatitis C virus  HCV  infection in adults with genotype 1  2  3  4  5 or 6  previously treated with an NS5A inhibitor containing regimen  or with genotype 1a or 3 previously treated with a Sovaldi containing regimen without an NS5A inhibitor The approval came on the back of positive data from the phase III studies   POLARIS 1 and POLARIS 4 studies  The studies evaluated 12 weeks of Vosevi in direct acting antiviral experienced chronic HCV infected patients without cirrhosis or with compensated cirrhosis However  Vosevi has been warned for its product label regarding the risk of hepatitis B virus  HBV  reactivation in HCV HBV co infected patients Nevertheless  the approval makes Vosevi the first once daily STR available as a salvage therapy for patients infected with HCV genotype 1 6 who have failed prior treatment with DAA regimens including NS5A inhibitors  The approval is expected to boost Gilead s strong HCV portfolio Gilead has a strong presence in the HCV market due to its blockbuster HCV drugs  Sovaldi and Harvoni  While Sovaldi continues to be a very important product for the company  Harvoni s label has been expanded twice in the U S  since approval and is now approved for use in a broader range of patient population  The HCV portfolio got a huge a boost when Epclusa gained approval in both the U S   Jun 2016  and the EU  Jul 2016  to become the first and only all oral  pan genotypic  STR consisting of Sovaldi and velpatasvir  an NS5A inhibitor   for the treatment of adults with genotype 1 6 chronic HCV infection  Initial uptake of Epclusa has been encouraging while formulary reviews are on track  Gilead expects to launch Epclusa in other large EU markets once pricing and reimbursement is in place by the second half of 2017  which should boost sales further Last month  the Committee for Medicinal Products for Human Use  CHMP  adopted a positive opinion on the company s Marketing Authorization Application  MAA  for Vosevi following an accelerated assessment procedure Gilead s HCV franchise is under pressure due to intense competition and pricing issues  HCV product sales were weaker than expected mainly due to fewer new patient starts for Harvoni and lower revenues per patient  Harvoni  Sovaldi and Epclusa has being facing competition from AbbVie s   NYSE ABBV   Viekira Pak and Viekira XR  Bristol Myers    NYSE BMY   Daklinza and Johnson   Johnson s   NYSE JNJ   Olysio The company expects that the persistent decline in HCV patient starts will be the primary factor behind the year over year decrease in revenues in 2017 along with increased competition which will impact patient share and pricing Shares of Gilead have underperformed the Zacks classified  industry in the year so far  with the stock losing 0 1  during this period  against the industry s gain of 8 8   Nevertheless  the HIV franchise of Gilead is performing well and is expected to help the company combat the persistent decline in HCV franchise 
Zacks Rank 
Gilead currently carries a Zacks Rank  3  Hold  
You can see  
Looking for Stocks with Skyrocketing UpsiZacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-07-18,Zacks Investment Research,https://www.investing.com/analysis/gilead's-hcv-portfolio-receives-a-boost-with-vosevi-approval-200202109,200202109
198778,420294,JNJ,Should You Buy Johnson   Johnson Stock Before Earnings ,opinion,"Johnson   Johnson  NYSE  NYSE JNJ  is a  358 billion company today  Investors that bought shares one year ago are sitting on a 10 56  total return  That s below the S P 500 s return of 16 05  
Johnson   Johnson stock is underperforming the market  It s beaten down  but it reports earnings next week  So is it a good time to buy  To answer this question  we ve turned to the Investment U Stock Grader  Our Research Team built this system to diagnose the financial health of a company 
Our system looks at six key metrics   
  Earnings per Share   EPS  Growth  Johnson   Johnson reported a recent EPS growth rate of 0 62   That s below the pharmaceuticals industry average of 242 54   That s not a good sign  We like to see companies that have higher earnings growth 
  Price to Earnings 
Price to Earnings
 P E is a valuation ratio of a company s EPS compared to its current share price  Generally speaking  a high P E means the market is bullish on a stock  but it can also signal that a stock is overpriced  What we look for is a stock trading below its industry average  This means we can get a better deal on a stock compared to its peers   P E   The average price to earnings ratio of the pharmaceuticals industry is 113 93  And Johnson   Johnson s ratio comes in at 20 92  It s trading at a better value than many of its competitors 
  Debt to Equity 
Debt to Equity
Debt to equity measures a company s liabilities compared to its stockholders  equity  The ratio measures a company s financial leverage  In general  a high debt to equity ratio means a company has been aggressively financing its growth with debt  As with P E  we want to see where a company stands compared to its peers since some industries are more capital intensive than others   The debt to equity ratio for Johnson   Johnson stock is 46 02   That s below the pharmaceuticals industry average of 57 48   The company is less leveraged 
  Free Cash Flow per Share Growth 
Free cash flow  FCF  per share growth helps determine a company s financial flexibility  It compares free cash flow to the total number of shares outstanding  At IU  we look for companies that are growing their cash flow year over year  In general  if a company is growing its FCF  it will be able to pay down debt  buy back stock  pay out more in dividends and or invest money back into the business to help boost growth   Johnson   Johnson s FCF has been lower than that of its competitors over the last year  That s not good for investors  In general  if a company is growing its FCF  it will be able to pay down debt  buy back stock  pay out more in dividends and or invest money back into the business to help boost growth  It s one of our most important fundamental factors 
  Profit Margins   The profit margin of Johnson   Johnson comes in at 24 89  today  And generally  the higher  the better  We also like to see this margin above that of its competitors  Johnson   Johnson s profit margin is above the pharmaceuticals average of 11 75   So that s a positive indicator for investors 
  Return on Equity   Return on equity tells us how much profit a company produces with the money shareholders invest  The ROE for Johnson   Johnson is 23 09   and that s above its industry average ROE of 17 77  
Johnson   Johnson stock passes four of our six key metrics today  That s why our Investment U Stock Grader rates it as a Buy With Caution ",2017-07-16,Investment U,https://www.investing.com/analysis/should-you-buy-johnson---johnson-stock-before-earnings-200201337,200201337
198787,420303,JNJ,Here s Where You Want To Short JJ,opinion,"Shares of Johnson   Johnson  NYSE JNJ  have risen sharply in 2017  The maker of band aids and other household products is up 23 5  this year  Using a technique called a  measured move   I have calculated J J s maximum upside   the spot where every investor should short it for an easy money  swing trade profit as it falls 
To calculate this  you simply take the first move up  which is  28  then add it to the beginning of the second move  Each move should be a total of  28  thus putting the maximum upside at  139  That s where you want to short the stock  The target on the swing trade short is  130  which will probably hit within weeks of the maximum upside  139 level  Note the chart below for a visual representation of the measured move ",2017-06-26,Gareth Soloway,https://www.investing.com/analysis/here's-where-you-want-to-short-j-j-200197565,200197565
198788,420304,JNJ,Gilead s  GILD  HCV Drug Application Accepted In The EU ,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced that the Committee for Medicinal Products for Human Use  CHMP  has adopted a positive opinion on the company s Marketing Authorization Application  MAA  for Vosevi following an accelerated assessment procedure Vosevi is an experimental once daily  single tablet regimen of Sovaldi  velpatasvir 100 mg  and voxilaprevir 100 mg  SOF VEL VOX  which is being evaluated for the treatment of chronic hepatitis C virus  HCV  infected patients The data included in the application support the use of SOF VEL VOX in patients with or without compensated cirrhosis  with all genotypes  GT1 6  of HCV infection regardless of prior therapy  It includes eight weeks of treatment for HCV direct acting antiviral  DAA  na ve patients without cirrhosis  as well as 12 weeks of treatment for patients who have previously failed therapy with a DAA containing regimen The recommendation will now be reviewed by the European Commission  The EMA generally takes into account CHMP s opinion while reviewing a drug but is not bound by it The MAA was filed based on positive data from four phase III studies  We remind investors that Sovaldi was approved in the EU in Jan 2014 for use in combination with other agents while the single tablet regimen of Sovaldi and ledipasvir  90 mg  received marketing authorization in the European Union in Nov 2014 under the trade name Harvoni  On the other hand  the single tablet regimen of Sovaldi and velpatasvir  100 mg  received marketing authorization in the EU in Jul 2016  under the trade name Epclusa  Meanwhile  Gilead has also submitted a regulatory application for SOF VEL VOX in the U S  as well  The FDA has set a target action date under the Prescription Drug User Fee Act of Aug 8  2017 If approved  the combination would be the first once daily STR available as a salvage therapy for patients infected with HCV genotype 1 6 who have failed prior treatment with DAA regimens including NS5A inhibitors Gilead s HCV franchise is under pressure due to intense competition and pricing issues  HCV product sales were weaker than expected mainly due to fewer new patient starts for Harvoni and lower revenues per patient  Harvoni  Sovaldi and Epclusa has being facing competition from AbbVie s   NYSE ABBV   Viekira Pak and Viekira XR  Bristol Myers    NYSE BMY   Daklinza and Johnson   Johnson s   NYSE JNJ   Olysio The company expects that the persistent decline in HCV patient starts will be the primary factor behind the year over year decrease in revenues in 2017 along with increased competition which will impact patient share and pricing Shares of Gilead have underperformed the Zacks classified  industry in the last one year  with the stock losing 13 4  during this period  against the industry s gain of 8 2  
Nevertheless  the HIV franchise of Gilead is performing well and is expected to help the company combat the persistent decline in HCV franchise  
Gilead currently carries a Zacks Rank  3  Hold   You can see  
Sell These Stocks  Now 
Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-06-26,Zacks Investment Research,https://www.investing.com/analysis/gilead's-(gild)-hcv-drug-application-accepted-in-the-eu-200197796,200197796
198789,420305,JNJ,Aduro Starts Phase II Combo Study With CRS 207   Keytruda ,opinion,Aduro Biotech  Inc    NASDAQ ADRO   has announced initiation of a phase II study to evaluate a combination therapy of its lead LADD  live  attenuated double deleted  based candidate  CRS 207  in combination with Merck   Co   Inc  s   NYSE MRK   anti PD 1 therapy  Keytruda  pembrolizumab   for treatment of patients previously nursed for malignant pleural mesothelioma  MPM   Note that  this combination therapy is also being evaluated for treatment of gastric cancer Aduro is developing the LADD platform for treating multiple cancer indications  including pancreatic  ovarian  lung and prostate cancers  mesothelioma and glioblastoma  In addition  a personalized form of LADD is being developed utilizing tumor neoantigens  specific to an individual patient s tumor We remind investors that in Oct 2016  the FDA had placed a partial clinical hold on studies evaluating Aduro s LADD based agents  thus bringing patient enrollment to a halt  The decision came after a blood culture sample taken from an indwelling port of a metastatic pancreatic cancer patient tested positive for Listeria  a serious infection usually caused by eating contaminated food  Subsequently in Nov 2016  the FDA had lifted the partial clinical hold on studies However  the company had to revise and implement study protocols in accordance with the FDA s guideline in order to recommence enrollment Shares of Aduro increased almost 2  after the company announced initiation of the combination trial   Moreover  the company s shares have outperformed the Zacks classified  industry in the last three months  The stock rose 2 8  compared with the broader industry s advance of 2 2  The phase II study is designed to evaluate the safety and efficacy of the combination of CRS 207 with Keytruda in adult patients  n 35   previously treated for MPM  The primary efficacy endpoint of the study is objective response rate  to be based on the proportion of patients with either complete or partial responses It is important to remind investors that in June last year  Aduro had presented data from a phase Ib study  evaluating CRS 207 alone and in combination with standard chemotherapy in patients with newly diagnosed MPM at the American Society of Clinical Oncology  Data from the study has demonstrated encouraging anti tumor responses Note that  several studies utilizing this platform are being conducted  including a phase I II study on CRS 207 in combination with Incyte Corporation s   NASDAQ INCY   selective IDO1 inhibitor epacadostat  for healing ovarian cancer  and a phase I lung cancer study on ADU 214 in collaboration with Johnson   Johnson s   NYSE JNJ   Janssen Biotech  among others Aduro continues to progress with its other two platform technologies   the STING pathway activator and the B select antibody programs Aduro Biotech  Inc  Price   Zacks RankAduro currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-06-28,Zacks Investment Research,https://www.investing.com/analysis/aduro-starts-phase-ii-combo-study-with-crs-207---keytruda-200198340,200198340
198794,420310,JNJ,J J Immunotherapy Darzalex Ok d For Expanded Combination Use,opinion,Johnson   Johnson   NYSE JNJ   announced that its immunotherapy  Darzalex has been approved for use in combination with Celgene Corporation s   NASDAQ CELG   multiple myeloma drug Pomalyst  pomalidomide  and dexamethasone  The combination has been approved for the treatment of patients with multiple myeloma who have received at least two prior therapies including Revlimid  an immunomodulatory agent  and a proteasome inhibitor  PI  The approval was based on data from the phase Ib EQUULEUS study  which showed an overall response rate  ORR  of 59 2  with Darzalex in combination with Pomalyst and dexamethasone in the abovementioned patients Darzalex is already approved in the U S  as well as EU for use in combination with Revlimid and dexamethasone  or Velcade  a proteasome inhibitor PI  and dexamethasone  for the treatment of adult patients with relapsed multiple myeloma patients who have received at least one prior therapy  Darzalex was approved in Nov 2015 as a monotherapy for multiple myeloma in patients who had received at least three prior lines of therapy  including PI and an immunomodulatory agent J J s shares have outperformed the Zacks classified  industry so far this year  The company s shares have gained 16 6  compared with the industry s gain of 11 4  Coming back to Darzalex  the drug has been generating strong sales and is a key contributor to J J s top line  It is enjoying strong adoption in outside U S  markets following launches last year as well as accelerated adoption in the U S Darzalex is also being evaluated in a comprehensive clinical development program that includes five phase III studies across a range of treatment settings in multiple myeloma  such as in frontline and relapsed settings These include combination studies with other cancer drugs like Roche Holding  SIX ROG  AG s   OTC RHHBY   atezolizumab  Bristol Myers Squibb Company   NYSE BMY   Opdivo  and Amgen s Kyprolis J J carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-06-19,Zacks Investment Research,https://www.investing.com/analysis/j-j-immunotherapy-darzalex-ok'd-for-expanded-combination-use-200196021,200196021
198795,420311,JNJ,J J AbbVie s Imbruvica Positive In Follow up Lymphoma Study ,opinion,Johnson   Johnson   NYSE JNJ   announced a three year follow up data from a late stage study  evaluating its cancer drug Imbruvica  ibrutinib  against Pfizer Inc  s   NYSE PFE   Torisel  temsirolimus  for treatment of patients with relapsed or refractory mantle cell lymphoma  MCL   Notably  Imbruvica is jointly developed and marketed by J J subsidiary Janssen Biotech and Pharmacyclics LLC  a subsidiary of AbbVie Inc    NYSE ABBV   Imbruvica is currently approved in the U S  for treating patients with mantle cell lymphoma or MCL  who have received at least one therapy earlier and for CLL patients with deletion 17p  It is also approved in the EU for treatment of MCL  Significantly in Jan 2017  Imbruvica was approved for patients with marginal zone lymphoma  MZL   requiring a systemic therapy and having received at least one prior anti CD20 based therapy Shares of J J have outperformed the Zacks classified  industry so far this year  The stock has climbed 16 4  with the broader industry s increase of 12 1  during the period Data from the phase III RAY study showed that the progression free survival  PFS  of patients when treated with Imbruvica is four times more  25 4 months  compared with Torisel  6 2 months  at first relapse after one prior line of therapy  Patients who had received over one prior line of therapy  their median PFS significantly increased when treated with Imbruvica in comparison to Torisel  15 6 months vs 6 2 months   The study was conducted on a total of 280 patients  Data showed a median overall survival  OS  with Imbruvica after one prior line of therapy of 42 1 months against 27 0 months with Torisel Data from the study was presented at the International Conference on Malignant Lymphoma  ICML  J J is presently exploring the potential to expand Imbruvica s label into solid tumors and autoimmune diseases Importantly  Imbruvica has one of the most robust clinical oncology development programs in the industry with nearly 30 company sponsored trials underway  Of these  14 are in phase III development  The drug is being evaluated in a number of cancer indications and has a multi billion dollar potential  Another 100 investigator sponsored trials and external collaborations for Imbruvica are underway around the world Per the company s press release  MCL is a rare disease that accounts for 5 10  of all non Hodgkin s lymphomas  Besides  one in two lakh people in Europe suffer from the disease  Thus  there is a huge market potential for the drug to cater to the unmet needs of patients affected with the disease Johnson   Johnson Price   Zacks Rank   Key PicksJ J currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Regeneron Pharmaceuticals  Inc    NASDAQ REGN    which carries a Zacks Rank  2  Buy   You can see  Regeneron s earnings per share estimates increased from  10 16 to  10 52 for 2017 and from  10 90 to  12 10  over the last 60 days  The company has delivered positive earnings surprises in two of the four trailing quarters with an average beat of 0 45  Looking for Stocks with Skyrocketing Upside  Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-06-19,Zacks Investment Research,https://www.investing.com/analysis/j-j-abbvie's-imbruvica-positive-in-follow-up-lymphoma-study-200196395,200196395
198796,420312,JNJ,Shire s  SHPG  ADHD Drug Mydayis Receives Approval In US,opinion,Shire Plc  LON SHP    NASDAQ SHPG   announced that the FDA has approved its new attention deficit hyperactivity disorder  ADHD  drug  Mydayis  mixed salts of a single entity amphetamine product  in patients 13 years and older  The drug is approved as a once daily treatment consisting of three different types of drug releasing beads for patients The company s shares were up 1 34  after the announcement of the news  However  the stock has underperformed the Zacks classified  industry so far this year  Shire s shares have fallen 1 9  whereas the industry rose 5 5  in the same period The approval from the FDA is based on data from 16 studies evaluating Mydayis in adolescents and adults with ADHD in comparison to a placebo  The results showed that the drug achieved statistically significant improvement beginning after 2 or 4 hours of dosing and lasting up to 16 hours post dose The company is planning to launch Mydayis commercially in the third quarter Shire is a leader in the ADHD market with drugs like Intuniv  Adderall XR and Vyvanse  Vyvanse  the growth engine for the company  generated sales of  563 7 million in the first quarter of 2017  up 11  from the year ago period  The sales for the drug were  2 0 billion for 2016  up 16 9  year over year The adult ADHD space is one of the largest and fastest growing segments of the market and approval of new drugs will further strengthen Shire s dominant position in that market  However  Shire faces competition from branded stimulants in the ADHD segment in the U S  from Johnson   Johnson s   NYSE JNJ   Concerta and Pfizer Inc  s   NYSE PFE   Quillivant Shire PLC Price and Consensus   Zacks Rank  Stock to ConsiderShire currently carries a Zacks Rank  3  Hold  A better ranked stock in the healthcare sector is VIVUS  Inc    NASDAQ VVUS   sporting a Zacks Rank  1  Strong Buy   You can see  VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017 in the last 60 days  The company delivered positive earnings surprises in all four trailing quarters with an average beat of 233 69  Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-06-20,Zacks Investment Research,https://www.investing.com/analysis/shire's-(shpg)-adhd-drug-mydayis-receives-approval-in-us-200196671,200196671
198797,420313,JNJ,Here s Why Geron  GERN  Is A Good Stock To Invest In Now,opinion,"Geron Corporation   NASDAQ GERN   is developing anti cancer therapies based on telomerase inhibitors  The company s telomerase technology platform represents significant commercial opportunity  The successful development of products that target telomeres could change the treatment paradigm for several diseases  including oncology  which exhibits huge commercial potential The small biotech currently has one candidate in its pipeline  imetelstat  It is being developed for the treatment of hematologic myeloid malignancies like myelofibrosis  MF  and myelodysplastic syndromes  MDS   Geron enjoys a strong collaboration with Johnson   Johnson s   NYSE JNJ   subsidiary Janssen for imetelstat  We remind investors that imetelstat has orphan drug status in the U S  for the MF and MDS indications  In 2016  J J announced unfavorable findings from the planned internal reviews of initial data from the two studies of imetelstat   IMbark  phase II  for MF and IMerge  phase II III  for MDS However  in Apr 2017  Geron informed that Janssen has completed the second internal data review of the two studies to inform on further development plans  As a result of the review  both trials are continuing unmodified For IMerge  the company believes that the benefit risk profile supports continued development  If Janssen decides to proceed to Part 2 of IMerge  a larger  170 patient  phase III study   patient enrollment will begin in the fourth quarter of this year For IMbark  the results suggested that the clinical benefit and potential overall survival benefit observed supports continuation of the trial without modifications  However  Janssen will evaluate maturing data from the IMbark study during next year  including an assessment of overall survival Geron has a Zacks Rank  2  Buy   Loss estimates have narrowed 80  for 2017  For 2018  estimates have gone up from breakeven to 2 cents per share over the past 60 days  The average earnings surprise over the past four quarters is 27 98   Shares of the company have risen 37 7  this year so far  outperforming the Zacks classified industry which rose 10 6  The favorable numbers and the rapid advances in imetelstat development suggest that the stock could be a good investment 
Other stocks worth considering in the sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and VIVUS  Inc    NASDAQ VVUS    both sporting a Zacks Rank  1  Strong Buy      You can see  
VIVUS  loss per share estimates narrowed 22  cents for 2017 in the last 60 days  The company delivered positive earnings surprises in all four trailing quarters with an average beat of 233 69  
Regeneron s earnings estimates have risen almost 10  for 2017 over the last 60 days  Shares of the company have risen 42 2  so far this year Looking for Ideas with Even Greater Upside  Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-06-21,Zacks Investment Research,https://www.investing.com/analysis/here's-why-geron-(gern)-is-a-good-stock-to-invest-in-now-200196939,200196939
198798,420314,JNJ,Healthcare ETF  IYH  Hits New 52 Week High,opinion,For investors seeking momentum  iShares U S  Healthcare ETF  is probably on radar now  The fund hit a 52 week high  and is up about 23 5  from its 52 week low price of  137 30 share But are more gains in store for this ETF  Let s take a quick look at the fund and the near term outlook on it to get a better idea on where it might be headed IYH in Focus    This ETF offers broad exposure to the healthcare sector with key holdings in pharma  biotech  healthcare equipment and managed healthcare  Holding 118 stocks in its basket  Johnson   Johnson   NYSE JNJ   dominates the fund s returns with double digit exposure while other firms account for less than 6 4  share  The product has amassed nearly  1 9 billion in its asset base while charges 44 bps in annual fees  see    Why the Move Healthcare has been an area to watch lately given the strong momentum building in the space  This is especially true as the release of Senate Republicans  healthcare bill to replace Obamacare  investor s defensive tilt to the portfolio amid low growth and uncertainty  and the surge in Clovis Oncology   NASDAQ CLVS   shares following its positive cancer drug data renewed optimism in the sector More Gains Ahead Currently  IYH has a Zacks ETF Rank of 1 or  Strong Buy  rating with a Medium risk outlook  suggesting that the outperformance could continue in the months ahead  Further  many of the segments that make up this ETF have a strong Zacks Industry Rank  so there is definitely still some promise for those who want to ride on this surging ETF a little longer Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2017-06-22,Zacks Investment Research,https://www.investing.com/analysis/healthcare-etf-(iyh)-hits-new-52-week-high-200197171,200197171
198799,420315,JNJ,Top Ranked Health Care ETFs To Buy Now,opinion,After many twists and turns  the healthcare sector is once again hogging investors  attention  This is especially true as strong momentum has started to build up in the space  pushing many stocks to multi year highs The optimism comes especially from the shift in investors  sentiment to defensive sectors like healthcare  which generally outperform during periods of low growth and high uncertainty  The latest spate of disappointing data points to slow and steady economic growth while geopolitical tensions are still looming Added to the strength is the release of Senate Republicans  healthcare bill to replace Obamacare  The legislation aims to eliminate taxes on the industry  curb Medicaid funding  reshape subsidies to cover low income people under private insurance  and offer provisions to stabilize insurance exchanges set up under former president Barack Obama s 2010 healthcare law  Additionally  the surge in Clovis Oncology   NASDAQ CLVS   following its positive cancer drug data for Rubraca spread bullishness in the overall sector  read    Further  the efforts of Trump s administration to ease the drug pricing issue  expedite new drug approvals and enact reforms to free cash held overseas for tax reason by large U S  pharmaceutical companies are driving the rally in the stocks  Moreover  the sector is poised to benefit from other encouraging industry trends including hopes of increased M A activity  an accelerated pace of innovation  promising drug launches  growing importance of biosimilars  cost cutting efforts  an aging population  expanding insurance coverage  growing middle class  an insatiable demand for new drugs  and ever increasing health care spending Given the encouraging fundamentals  investors should look at some of the top ranked  Zacks Rank  1 or  Strong Buy  rating  ETFs that target the broad health care segment and are expected to outperform in the months to come  These funds have enjoyed a strong momentum in the year to date period and potentially superior weighting methodologies  which could allow these to continue leading the health care space going forward  see    Health Care Select Sector SPDR Fund The most popular healthcare ETF  XLV follows the Health Care Select Sector Index  This fund manages nearly  16 9 billion in its asset base and trades in heavy volume of around 7 9 million shares  Expense ratio comes in at 0 14  annually  In total  the fund holds 63 stocks with heavy concentration on the top firm Johnson   Johnson  NYSE JNJ  at 11 9  of the assets while other firms hold less than 6 7  share  Pharma accounts for 35 1  share from a sector look while biotech  healthcare providers and services  and healthcare equipment and supplies make up for a double digit exposure each  The ETF has gained 17 8  in the year to date time frame  read    Vanguard Health Care ETF   AX VHT  This ETF tracks the MSCI US Investable Market Health Care 25 50 Index and holds 365 stocks in its basket with a double digit allocation to JNJ  Other firms hold less than 6  share  Pharma takes the largest share at 32  while biotech and healthcare equipment round off the top three spots  VHT has AUM of  6 5 billion and average daily volume of about 208 000 shares  It charges 10 bps in annual fees and expenses and has returned 19  so far this year iShares U S  Healthcare ETF This fund provides exposure to 118 securities by tracking the Dow Jones U S  Health Care Index  Here again  Johnson   Johnson dominates the fund s returns at 11 5  of total assets while other firms account for less than 6 4  share  In terms of industrial exposure  pharma takes the top spot at 34 5   followed by biotech  22 6    healthcare equipment  19 2   and managed healthcare  12 1    The product has amassed nearly  1 9 billion in its asset base while charges 44 bps in annual fees  It trades in a solid volume of about 208 000 shares a day and is up 18  since the start of the year Guggenheim S P 500 Equal Weight Health Care ETF This fund provides equal weight exposure of less than 2  to 61 stocks and tracks the S P 500 Equal Weight Health Care Index  In terms of industries  healthcare providers and services  and healthcare equipment and supplies takes the top two spots at 29 3  and 27 3  respectively  The fund has accumulated  611 1 8 million in its asset base while it trades in a light volume of around 22 000 shares daily  It charges 40 bps in annual fees and has gained 20 9  in the year to date time frame  read    iShares U S  Healthcare Providers ETF This ETF offers exposure to companies that provide health insurance  diagnostics and specialized treatment by tracking the Dow Jones U S  Select Healthcare Providers Index  It holds 45 securities in its basket with heavy concentration on the top firm United Health  UNH  holding 13 7   The other firms hold no more than 6 81  of assets  About half of the portfolio is dominated by managed healthcare while healthcare services and healthcare facilities round off the next two spots with a double digit allocation each  The fund has amassed  570 3 million in its asset base while volume is light at around 22 000 shares per day on average  It charges 44 bps in annual fees and has gained 19  so far in the year Bottom LineInvestors should note that healthcare is the second top performing sector so far this year  trailing technology Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2017-06-22,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-health-care-etfs-to-buy-now-200197216,200197216
198811,420327,JNJ,J J  JNJ  Plans To Seek Approval For 10 New Drugs By 2021,opinion,Johnson   Johnson  Inc   NYSE JNJ   discussed its future plans and showcased a strong pipeline of transformational medicines at a meeting held yesterday with industry analysts J J intends to seek approval for 10 new products between 2017 and 2021  The company said that each of these products have blockbuster potential  Also  the company is targeting more than 50 line extensions of existing and new drugs as well Shares of Johnson   Johnson closed at  126 67 on Wednesday  down 0 86   amid a broader decline in the stock market  Moreover  the company s shares are up 10  so far this year  outperforming the Zacks Classified  industry  which has increased 8 2  in the same time frame Meanwhile  Johnson   Johnson also said it expects approval and launch of its two pipeline candidates this year   guselkumab for psoriasis and sirukumab for rheumatoid arthritis  Both the candidates are under review in the U S  and EU The acquisition of Swiss based biotech company Actelion  which is expected to be closed this quarter  will diversify Johnson   Johnson s revenue stream to include pulmonary arterial hypertension  PAH  category The drugmaker has a record of making blockbuster drugs  The company s immunology drugs like Remicade generated  1 7 billion in sales in the first quarter of 2017 while Stelara recorded  823 million  Blood thinner Xarelto recorded sales of  513 million in the same period  The company recorded total drug sales of  8 2 billion in the quarter However  the company is facing a slowdown in its pharmaceutical product sales  The Pharma segment is expected to see slower growth in 2017 as a number of key growth drivers like Remicade  rheumatoid arthritis  and Concerta  attention deficit hyperactivity disorder  are facing competition Remicade is facing biosimilar competition in Europe since Feb 2015 while Pfizer Inc    NYSE PFE   launched a biosimilar in the U S  in Nov 2016 Johnson   Johnson Price and Consensus   Zacks Rank   Key PicksJohnson   Johnson currently has a Zacks Rank  3  Hold   A couple of better ranked medical stocks are VIVUS  Inc    NASDAQ VVUS   and Catabasis Pharmaceuticals  Inc    NASDAQ CATB    Vivus sports a Zacks Rank  1  Strong Buy  while Catabasis carries a Zacks Rank  2  Buy   You can see  Vivus  loss per share estimates narrowed 22  to 39 cents for 2017 over the last 60 days  The company posted positive surprises in all the four trailing quarters with an average beat of 233 69  Catabasis  loss per share estimates narrowed 13  to  1 61 for 2017 over the last 60 days  The company posted positive earnings surprises in all the four trailing quarters  with an average beat of 8 65  Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-05-17,Zacks Investment Research,https://www.investing.com/analysis/j-j-(jnj)-plans-to-seek-approval-for-10-new-drugs-by-2021-200190041,200190041
198812,420328,JNJ,Protagonist Therapeutics Soars On Janssen Biotech Deal,opinion,"Protagonist Therapeutics  Inc   NASDAQ PTGX 
Protagonist Therapeutics  a clinical stage biopharmaceutical company yesterday before the market opened announced a worldwide agreement with Janssen Biotech Inc 
The agreement with Janssen was to co develop and commercialize PTG 200 for inflammatory bowel disease  The agreement pays Protagonist  50 million in upfront payment and the possibility of an additional  940 million in development and sales milestones 
Protagonist Therapeutics  Inc  CEO s Comments

We are very pleased to partner with Janssen  a world leader in the development of innovative therapies for patients suffering with chronic inflammatory and immunomodulatory diseases  As an oral IL 23 receptor antagonist  PTG 200 nicely complements Janssen s current IBD portfolio   said Dinesh V  Patel  Ph D   Protagonist s President and Chief Executive Officer   The funding provided by this transaction enables us to advance our platform and clinical pipeline of innovative peptide drugs  including our lead oral peptide alpha 4 beta 7 integrin antagonist  PTG 100  which is currently in a Phase 2b clinical trial as a potential treatment for ulcerative colitis   PR Newswire

PTGX Technical Analysis

PTGX opened trading yesterday at  12 28 which was up from the previous day s trading close of  9 22  equivalent to a 49  increase  PTGX closed trading yesterday at  11 82  Taking a look at the daily chart we can see the last time PTGX traded above these levels we have to go back to April 5th when it traded at  12 38 
Taking a closer look at the daily chart we can see that before the spike up PTGX had been in an overall downward trend dating back to December 5  2016 when it traded at  26 24  PTGX has a float of 7 03 million shares and traded 124 38 times the normal daily trading volume on Tuesday 
For day trading purposes  I would like to see PTGX open trading on Wednesday above  11 25 and if it does I would be looking to take a long position at the bell  My stop loss would be  0 30 from my entry position fearing anything more than that and the stock would start to fill in the gap up 
Company Profile
Protagonist Therapeutics  Inc   incorporated on August 22  2006  is a clinical stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities  NECs  to address significant unmet medical needs  The Company s product pipeline includes PTG 100  PTG 200 and PTG 300  Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs 
PTG 100
PTG 100 is an oral  alpha 4 beta 7  a4b7  integrin specific antagonist peptide product candidate  which has completed a Phase I clinical trial in normal healthy volunteers  NHVs   PTG 100 is being developed for treatment of moderate to severe ulcerative colitis  UC  
PTG 200
The Company s PTG 200 is an oral Interleukin 23 receptor  IL 23R  antagonist being developed for moderate to severe Crohn s disease  CD   PTG 200 is in investigational new drug  IND  enabling studies 
PTG 300
The Company s PTG 300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases  Its peptides have applicability in a range of therapeutic areas in addition to gastrointestinal  GI  diseases  PTG 300 is in pre clinical development  PTG 300 has utility for the treatment of iron overload disorders  such as transfusion dependent b Thalassemia  hereditary hemochromatosis  HH  and sickle cell disease  SCD  
The Company competes with Takeda Pharmaceutical Company  Johnson   Johnson  NYSE JNJ  Services  Abbvie  Roche and UCB S A ",2017-05-31,Ticker.tv News,"https://www.investing.com/analysis/protagonist-therapeutics,-inc.-$ptgx-stock-|-shares-soar-as-company-an-200192321",200192321
198817,420333,JNJ,Achillion  ACHN  Reports Wider than Expected Loss In Q1,opinion,"Achillion Pharmaceuticals  Inc    NASDAQ ACHN   reported a loss of 15 cents per share in the first quarter  wider than the Zacks Consensus Estimate of a loss of 8 cents  In the year ago quarter  the company had reported a loss of 13 cents per share 

The company generated no revenues in the reported quarter  The company also had no revenues in the year ago quarter 
Shares of Achillion gained almost 7 8  on May 5  in spite of the company reporting wider than expected loss for the first quarter of 2017 a day before  However  the stock has underperformed the Zacks classified  industry year to date  The company s shares lost 10 2  whereas the industry registered an increase of 3 9  

Research and development expenses increased 16 5  from the year ago period to  15 5 million due to increased clinical trial and consulting costs related to pipeline candidate ACH 4471  The increase in expenses also included preclinical and manufacturing costs related to next generation factor D inhibitor compounds in development 
General and administrative expenses were up 5 56  to  5 7 million due to an increase in corporate legal fees and consulting fees 
Pipeline Update
During the quarter  Achillion was granted a patent to compositions of matter for compounds that inhibit complement factor D activity  Also  U S  Patent and Trademark Office  USPTO  issued notices of allowance of four additional U S  patent applications owned by Achillion  which are expected to be issued as patents over the next few months 
The company initiated a phase II study evaluating its key pipeline candidate  a factor D inhibitor  ACH 4471 for the treatment of patients with paroxysmal nocturnal hemoglobinuria  PNH   Subsequent to the quarter  in April  Achillion initiated patient dosing in the phase II study of ACH 4471 and recently completed 28 days of dosing  The patients will receive up to two additional months of therapy  The company plans to present interim results in a future medical conference
Also  Achillion announced additional results from Johnson   Johnson s   NYSE JNJ   Janssen sponsored phase II study  The data demonstrated that the triple combination of simeprevir  odalasvir and AL 335 has the ability to shorten treatment duration in patients whose disease is caused by hepatitis C virus  HCV  genotype 1  GT1  Achillion Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
   Zacks Rank   Key Picks
Achillion currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector include BioTime  Inc    NYSE BTX   and Celsion Corp    NASDAQ CLSN    Each of these stock carries a Zacks Rank  2  Buy   You can see  
BioTime s loss estimates narrowed 60 9  over the last 60 days to 18 cents for 2017  The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 12 32   Its shares have increased 10 3  in the last one year 
Celsion s loss estimates narrowed 42 9  to 28 cents for 2017 over the last 60 days  The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 0 24  
Zacks  2017 IPO Watch List 
Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time 
One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-05-08,Zacks Investment Research,https://www.investing.com/analysis/achillion-(achn)-reports-wider-than-expected-loss-in-q1-200187842,200187842
198818,420334,JNJ,AbbVie And J J Present Positive Imbruvica Leukemia Data ,opinion,AbbVie Inc    NYSE ABBV   recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug  Imbruvica  ibrutinib   The drug is to be used for the treatment of patients with high risk chronic lymphocytic leukemia small lymphocytic lymphoma  CLL SLL  Imbruvica is currently approved in the U S  for the treatment of patients with mantle cell lymphoma or CLL  who have received at least one therapy earlier and for CLL patients with deletion 17p  It is also approved for the treatment of Waldenstrom s macroglobulinemia  Please note that in Jan 2017  Imbruvica was approved for patients with marginal zone lymphoma  MZL  who require systemic therapy and have received at least one prior anti CD20 based therapy Analysis of the data from the three phase III studies  RESONATE  RESONATE 2 and HELIOS  showed that CLL SLL patients with genomic abnormalities  when treated with Imbruvica  achieved higher complete response  CR  rates and overall response rates  ORR  as well as longer progression free survival  PFS  at 24 months and overall survival  OS  at 30 months versus patients treated with comparator treated patients  CLL SLL patients with genomic abnormalities are usually the ones who are at high risk for poor outcomes Data were presented at the International Workshop on Chronic Lymphocytic Leukemia  iwCLL  We note that Imbruvica became part of AbbVie s portfolio following its acquisition of Pharmacyclics in May 2015  Imbruvica is jointly marketed by AbbVie and Janssen Biotech  a subsidiary of Johnson   Johnson   NYSE JNJ   Shares of AbbVie have underperformed the Zacks classified  industry so far this year  The stock has gained 5 5  during the period  while the broader industry witnessed an increase of 8 6  AbbVie is presently exploring the potential to expand Imbruvica s label into solid tumors  in phase III for diffuse large B cell lymphoma and follicular lymphoma  and autoimmune diseases Notably  Imbruvica has one of the most robust clinical oncology development programs in the industry with nearly 30 company sponsored trials underway  Of these  14 are in phase III  The drug is approved for a number of indications and has multi billion dollar potential  Moreover  another 100 investigator sponsored trials and external collaborations for Imbruvica are underway around the world According to the company  more than 25 000 CLL patients have been treated in the U S  alone with Imbruvica since approval in 2014  Per the company s press release  nearly 19 000 patients are diagnosed with CLL every year in the U S  Thus  there is a huge market potential for the drug to cater the unmet needs of patients in the nation AbbVie Inc  Price    Zacks Rank   Key PicksAbbVie currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector are Galena Biopharma  Inc    NASDAQ GALE   and VIVUS  Inc    NASDAQ VVUS    While Galena carries a Zacks Rank  2  Buy   VIVUS sport a Zacks Rank  1  Strong Buy   You can see  Galena s loss per share estimates narrowed from  2 03 to 58 cents for 2017  over the last 60 days  The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 53 83  VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017  over the last 30 days  The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233 69  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-05-14,Zacks Investment Research,https://www.investing.com/analysis/abbvie-and-j-j-present-positive-imbruvica-leukemia-data-200189216,200189216
198820,420336,JNJ,AbbVie  ABBV  Q1 Earnings Beat Estimates  Revenues Up Y Y,opinion,"AbbVie Inc    NYSE ABBV   reported better than expected results in the first quarter of 2017  The company surpassed both earnings and sales expectations 

In the past one year  AbbVie s shares gained 3 9   while the Zacks classified  industry witnessed an increase of 5 9  The biopharmaceutical company reported first quarter 2017 earnings of  1 28 per share that beat the Zacks Consensus Estimate of  1 26 per share by 1 6   Earnings grew 11  year over year The company posted revenues of  6 54 billion in the reported quarter  which surpassed the Zacks Consensus Estimate of  6 51 billion  Revenues also jumped 9 7  year over year  On operational basis revenue increased 10 1  Quarter in DetailHumira sales on an operational basis  excluding currency impact  rose 15 8  year over year to  4 1 billion First quarter net revenue from Imbruvica was  551 million  up 44 7  year over year   U S  sales of Imbruvica were  457 million  AbbVie recorded  94 million of international profit sharing with Johnson   Johnson   NYSE JNJ   Other products that delivered an impressive performance include Duodopa which showed revenue of  80 million up 22 8  on both operational and reported basis  Another product Creon reported revenue of  185 million up 19 8  and 17  on an operational and reported basis respectively HCV product Viekira recorded sales of  263 million  down 15 4  sequentially Adjusted SG A expenses rose 0 7   while R D expenses increased 23 3  in the quarter  Adjusted operating margin was 42 3  of sales in the reported quarter 
2017 Outlook
AbbVie reiterated its previously issued outlook for 2017  The company maintains its adjusted EPS in the range of  5 44  5 54 reflecting growth of 13 9  at the mid point AbbVie Inc  Price  Consensus and EPS Surprise

   Zacks Rank   Key Picks
AbbVie currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector are Heska Corporation   NASDAQ HSKA   and Galena Biopharma  Inc    NASDAQ GALE   which sports a Zacks Rank  1  Strong Buy   You can see  
Heska s earnings per share estimates increased from  1 53 to  1 65 for 2017 and from  1 80 to  2 01 for 2018  over the last 60 days  The company posted positive surprises in three of the four trailing quarters with an average beat of 291 54  
Galena s loss per share estimates narrowed from  2 03 to 58 cents for 2017  over the last 60 days  The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 53 83  
The Best   Worst of Zacks
Today you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ",2017-04-27,Zacks Investment Research,"https://www.investing.com/analysis/abbvie-(abbv)-q1-earnings-beat-estimates,-revenues-up-y-y-200185789",200185789
198821,420337,JNJ,Geron  GERN  Q1 Earnings  What s In Store For The Stock ,opinion,Geron Corporation   NASDAQ GERN   is expected to report first quarter 2017 results on May 4 In the last reported quarter  the company recorded a positive earnings surprise of 16 67   Let s see how things are shaping up for the upcoming announcement Geron s shares outperformed the Zacks classified  industry by adding 23 7  so far this year  while the industry witnessed a gain of 5 0  Imetelstat Remains in FocusWith no approved product in its portfolio  Geron s top line solely comprises license fees and royalties  In such a scenario  investor focus will remain on the company s pipeline  Geron currently has one candidate in its pipeline  imetelstat  It is being developed in collaboration with Johnson   Johnson s   NYSE JNJ   Janssen Biotech for the treatment of hematologic myeloid malignancies like myelofibrosis  MF   myelodysplastic syndromes  MDS  and acute myelogenous leukemia  AML  Last month  Geron provided a positive update on two late stage studies for imetelstat  its lead pipeline   IMbark  phase II  for the treatment of myelofibrosis  and IMerge  phase II III  for the treatment of myelodysplastic syndromes Geron informed that Janssen has completed the second internal data review of two studies  IMbark  phase II for the treatment of MF  and IMerge  phase II III for the treatment of MDS   on imetelstat  Janssen said that the benefit risk profile of imetelstat in the treated patients supports continued development in lower risk MDS indication For IMbark  the recent results suggest that the clinical benefit and a potential overall survival benefit observed supports continuation of the trial without modifications  The trial that assesses the safety and efficacy of imetelstat treatment in relapsed or refractory MDS will also include an assessment of overall survival  Also  the data suggest that 9 4 mg kg is an appropriate starting dose in the study Janssen will take a decision regarding the commencement of the phase III stage of the IMerge study later this year and a decision regarding the continued development of imetelstat for the relapsed or refractory MF indication next year We expect the company to shed light on the path forward for imetelstat development program at the first quarter conference call Surprise HistoryGeron s performance over the last four quarters has been mixed  with the company surpassing expectations thrice and meeting the same once  The average positive surprise over the last four quarters is 27 98  Geron Corporation Price and EPS Surprise   Earnings WhispersOur proven model does not conclusively show that Geron is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 5 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Although Geron s Zacks Rank  2 increases the predictive power of ESP  its 0 00  ESP makes surprise prediction difficult this quarter Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into an earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are a couple of health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Proteostasis Therapeutics  Inc    NASDAQ PTI   is expected to release results on May 12  The company has an Earnings ESP of  5 17  and a Zacks Rank  2  You can see  Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  2 77  and a Zacks Rank  3  The company is scheduled to release results on May 2 Sell These Stocks  Now Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500  ,2017-04-30,Zacks Investment Research,https://www.investing.com/analysis/geron-(gern)-q1-earnings:-what's-in-store-for-the-stock-200186281,200186281
198826,420342,JNJ,AbbVie s  ABBV  Cancer Candidate Fails In Phase III Studies,opinion,AbbVie Inc    NYSE ABBV   recently announced disappointing top line results from two phase III studies evaluating its PARP inhibitor  veliparib in combination with chemotherapy  such as carboplatin and paclitaxel  for treatment of patients with squamous non small cell lung cancer  NSCLC  and triple negative breast cancer  TNBC  AbbVie s shares underperformed the Zacks classified  industry so far this year  Shares of the company gained 1 3  while the industry registered an increase of 4 2  Coming back to the latest news  the two randomized  double blind  multicenter  phase III studies failed to meet their primary endpoints  In the first study  the combination treatment failed to improve the overall survival of NSCLC patients  who had smoked within the past 12 months and had more than 100 smoking events in their lifetime  In the second study  which evaluated the treatment on patients with early stage triple negative breast cancer  the drug did not achieve the primary endpoint of complete pathologic response  The studies were conducted in a total number of 970 and 312 patients for the NSCLC and TNBC study  respectively We note that another phase III study is being conducted on veliparib  evaluating it for treatment of patients suffering from ovarian cancer Presently  Pfizer   NYSE PFE   has an approved drug for NSCLC  Xalkori  This apart  AstraZeneca Plc s   NYSE AZN   Lynparza  also known as olaparib  is approved for ovarian cancer AbbVie has been actively pursuing partnership deals and collaborations to enhance its oncology portfolio  In May 2015  AbbVie acquired Pharmacyclics in a deal worth approximately  21 billion  The acquisition added Imbruvica to AbbVie s portfolio  diversifying the acquirer s revenue base  Investors should know that Pharmacyclics has a partnership agreement with Johnson   Johnson   NYSE JNJ   for Imbruvica Moreover  in Jun 2016  AbbVie acquired cancer drugmaker Stemcentrx  Post buyout  the company gained a late stage candidate  rovalpituzumab tesirine or Rova T   four additional early stage compounds in solid tumor indications and a significant portfolio of pre clinical assets  Rova T is currently in registration studies for small cell lung cancer  SCLC  AbbVie Inc  Price    Zacks RankAbbVie currently carries a Zacks Rank  3  Hold   You can see  Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-04-19,Zacks Investment Research,https://www.investing.com/analysis/abbvie's-(abbv)-cancer-candidate-fails-in-phase-iii-studies-200184004,200184004
198827,420343,JNJ,JNJ Has To Find A Low,opinion,"A few days ago the leading health care stock Johnson   Johnson  NYSE JNJ  dropped sharply after reporting earnings  The stock lost about 3 percent on Tuesday  Many traders and investors are now wondering where this stock will finally find a low and then rebound 
The daily 200 day moving average is sitting around the  119 level  This will be a decent support area for a bounce  but if JNJ consolidates above the  119 level for another week or so  traders will have to look lower  The next major support level for the stock will be around  116 83  an area where the stock broke out from in February  Often  stocks will retrace back down to the break out level before moving higher 
Either way  JNJ stock should be on your radar ",2017-04-20,Nicholas Santiago,https://www.investing.com/analysis/jnj-has-to-find-a-low-200184065,200184065
198828,420344,JNJ,JNJ Drops After Earnings  Where Will This Stock Rebound ,opinion,"A few days ago the leading healthcare stock Johnson   Johnson  NYSE JNJ  dropped sharply lower after reporting earnings  The stock lost about 3 0 percent on April 18th  2017  Many traders and investors are now wondering where this stock will finally find a low and rebound 
The daily chart 200 day moving average is sitting around the  119 00 level  This will be a decent chart support area for a bounce  but if the stock consolidates above the  119 00 level for another week or so traders will have to look lower 
The next major support level for JNJ stock will be around the  116 83 level  This is an area where the stock broke out in February 2017  Often  stocks will retrace back down to the break out level before moving higher  Either way  JNJ stock should be on traders radar ",2017-04-21,Nicholas Santiago,"https://www.investing.com/analysis/johnson---johnson-(nyse:jnj)-drops-after-earnings,-where-are-the-trade-200184123",200184123
198832,420348,JNJ,J J  JNJ  Q1 Earnings Beat Estimates  Pharma Sales Slow Down,opinion,Johnson   Johnson   NYSE JNJ   reported mixed first quarter 2017 results  While earnings beat expectations  sales missed the same due to a slowdown in pharmaceutical product sales  The drug and consumer products giant raised its 2017 sales and earnings outlook though only to include the impact of the pending  30 billion acquisition of Swiss biotechnology company Actelion Ltd    OTC ALIOF   Shares declined 1 4  in pre market trading This year so far  J J s share price is up 9 8   This compares favorably with the 6 8  increase witnessed by the Zacks classified industry Earnings BeatJ J s first quarter 2017 earnings came in at  1 83 per share  beating the Zacks Consensus Estimate of  1 77 and increasing 5 8  from the year ago period Including one time items  J J reported first quarter earnings of  1 61 per share  up 1 3  from the year ago period Sales MissSales came in at  17 77 billion  missing the Zacks Consensus Estimate of  18 0 billion by 1 3   Sales increased 1 6  from the year ago quarter  reflecting an operational increase of 2  and a negative currency impact of 0 4  First quarter sales grew 0 6  in the domestic market to  9 38 billion and 2 8  in international markets to  8 39 billion  reflecting 3 6  operational growth  partially offset by a 0 8  negative currency impact Sales in DetailsPharmaceutical segment sales grew 0 8  year over year to  8 25 billion  reflecting 1 4  operational growth and a 0 6  negative currency impact Sales in the domestic market declined 1 3  to  4 87 billion  while international sales grew 4 1  to  3 37 billion New products like Imbruvica  cancer  and Darzalex  multiple myeloma  continued to perform well  Other growth drivers were Stelara  Invega Sustenna and Simponi However  sales of Xarelto declined 9 5  in the quarter  Invokana Invokamet sales declined 12 6   Concerta declined 9 5  while Zytiga sales fell 6 3  Importantly  sales of the blockbuster rheumatoid arthritis drug Remicade  marketed in partnership with Merck   Co   Inc    NYSE MRK    declined 6  in the quarter with U S  sales declining 2 4  and international sales declining 3  due to biosimilar competition  In this regard  we would like to mention that Pfizer Inc    NYSE PFE   launched its Inflectra injection  a biosimilar version of Remicade in the U S  late last November  which did not have any significant impact on Remicade sales in the fourth quarter of 2016  Management is expected to comment on the impact of the biosimilar on first quarter sales at the conference call J J s Pharma segment achieved some clinical milestones during the quarter including label expansion for Imbruvica and positive late stage data for psoriasis candidate guselkumab  Meanwhile  J J announced the deal to buy Actelion in January this year with the transaction expected to close in the second quarter Medical Devices segment sales came in at  6 29 billion  up 3  from the year ago period  It included an operational increase of 3 4  and negative currency movement of 0 4  Sales in the domestic market rose 2 2  year over year to  3 09 billion  International market sales inched up 3 8   operational increase of 4 7   year over year to  3 2 billion Operational growth was driven by endocutters in the Advanced Surgery business  electrophysiology products in the Cardiovascular business and Acuvue contact lenses in the Vision Care business  which made up for a weaker sales performance in the Diabetes Care unitThe Consumer segment recorded revenues of  3 23 billion in the reported quarter  up 1  year over year  operational increase of 0 8    Foreign currency movement positively impacted sales in the segment by 0 2   Sales in the domestic market grew 4 1  from the year ago period to  1 41 billion Slower growth in Listerine oral care  baby care and wound care products was partially offset by growth in over the counter products Meanwhile  the international segment recorded a decline of 1 3  to  1 81 billion  reflecting an operational decline of 1 6  and a positive currency impact of 0 3  2017 Guidance RaisedJ J raised its sales and earnings guidance for 2017 to include the impact of the Actelion deal J J expects adjusted earnings per share in the range of  7 00    7 15 for 2017 compared with  6 93 to  7 08 expected previously The revenue guidance is in the range of  75 4 billion to  76 1 billion compared with  74 1 billion to  74 8 billion expected previously The Zacks Consensus Estimate for sales and earnings are pegged at  75 02 billion and  7 03 per share  respectively for 2017 The company carries a Zacks Rank  3  Hold   You can see  Our TakeThis was the second consecutive sales miss for J J  While sales in the Medical Device segment are picking up  as expected  the Pharma segment saw softer growth in the quarter  In 2017  growth in J J s Pharma segment is expected to be slower as key growth drivers have slowed down due to competition  Quite a few products in its portfolio like Remicade and Concerta are facing generic competition  However  the deal with Actelion  though expensive  will diversify J J s revenues to the pulmonary arterial hypertension  PAH  category and bolster its long term growth Johnson   Johnson Price  Consensus and EPS Surprise   5 Trades Could Profit  Big League  from Trump Policies If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-04-17,Zacks Investment Research,"https://www.investing.com/analysis/j-j-(jnj)-q1-earnings-beat-estimates,-pharma-sales-slow-down-200183403",200183403
198833,420349,JNJ,After Johnson   Johnson Earnings  Buy These Pharma Stocks,opinion,"Shares of Johnson   Johnson   NYSE JNJ   slid nearly 3 5  in morning trading Tuesday after the pharma giant s first quarter earnings results were met with mixed reactions from investors  As the sell off continues  investors focused on large cap pharma companies may want to move their money into stronger options this earnings season 
JNJ Earnings
For the first quarter  Johnson   Johnson posted earnings of  1 83 per share  beating the Zacks Consensus Estimate of  1 77  Revenues  on the other hand  came in below expectations  Johnson   Johnson posted quarterly revenues of  17 8 billion  which missed our consensus estimate of  18 0 billion 
The company s Worldwide Pharmaceutical segment grew 0 8  year over year  with domestic pharma sales slipping 1 3  and international pharma sales growing 4 1   Johnson   Johnson also said that its recent purchase of Actelion   OTC ALIOF   should close in the second quarter 
Like many of its peers  Johnson   Johnson is facing generic competition and pricing pressure for some its pharma products  especially in the United States  Today s price action most likely reflects investors  hesitation towards the company s slumping domestic sales figures 
Other Pharma Stocks to Buy
Johnson   Johnson is often considered a bellwether for the large cap pharma industry  and while its earnings beat is hopefully a sign of things to come  there appear to other companies that are better positioned to post strong results this quarter 
One company to consider is Roche Holding  SIX ROG  AG   OTC RHHBY    This Swiss healthcare giant has a strong presence in the cancer  immunology  infectious diseases  and ophthalmology markets  The company has a deep pipeline and is working to build up its offerings in immuno oncology market 
Roche has key data readouts lined up for 2017 and has already gained FDA approval for an important drug Ocrevus  MS  this year  The stock has outperformed its industry peers so far this year  and its Zacks Rank  1  Strong Buy  pairs well with its  B  grades for Growth and Momentum headed into its earnings announcement 
Another stock to look at is Sanofi  PA SASY    NYSE SNY    Sanofi has averaged an earnings beat of 4 77  over the last four quarters  and its fundamental metrics make it appealing for value minded investments  Its Forward P E ratio of 14 44 outpaces the industry average of 15 5  and its P S ratio of 3 0 comes in better than the industry s 4 1  Moreover  the P B ratio for Sanofi is 1 8  less than 4 3 for the industry  These metrics have helped the stock earn an  A  grade for Value 
Sell These Stocks  Now 
Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-04-18,Zacks Investment Research,"https://www.investing.com/analysis/after-johnson---johnson-earnings,-buy-these-pharma-stocks-200183516",200183516
198834,420350,JNJ,Lackluster J J Q1 Pushes Healthcare ETFs Down,opinion,The Q1 earnings season has kicked in and Johnson   Johnson   NYSE JNJ   was the first drug company to report earnings on April 18 before the opening bell  The world s biggest maker of health care products continued its long streak of earnings beat but lagged our revenue estimate again on sluggish drug sales Q1 Results in DetailEarnings per share came in at  1 83  six cents ahead of the Zacks Consensus Estimate and 5 8  higher than the year ago quarter  Revenues grew 1 6  year over year to  17 77 billion but fell shy of the Zacks Consensus Estimate of  18 billion  read    Weak drug sales of blood thinner Xarelto  diabetes medicine Invokana and cancer drug Zytiga   which are among the company s 10 top selling treatments   were responsible for revenue miss  Additionally  J J s blockbuster arthritis treatment Remicade lost its momentum due to stiff competition from the biosimilar version of the drug in the U S  late last November by Pfizer   NYSE PFE   Johnson   Johnson is on track to close its biggest ever  30 billion acquisition of Swiss drugmaker Actelion in the ongoing quarter  As such  it raised its earnings per share guidance to  7 00  7 15 from  6 93  7 08 and revenue guidance to  75 4  76 1 billion from  74 1  74 8 billion to include the impact of the Actelion deal  The Zacks Consensus Estimate is currently pegged at  7 03 for earnings per share and  75 02 billion for revenues Further  the company expects Actelion to contribute 35 40 cents to earnings per share in 2018  see    Market ImpactFollowing the results  shares of JNJ fell as much as 3 8   representing the biggest one day drop in more than eight years  Currently  the stock has a Zacks Rank  3  Hold  with a VGM Score of C  However  Johnson   Johnson belongs to a solid industry with a Zacks Rank in the  As a result  investors should closely watch the movement of the stock and keep a close eye on ETFs having double digit allocation to this diversified drug maker  Below  we have listed the five funds that have a Zacks ETF Rank of 3 Health Care Select Sector SPDR Fund The most popular healthcare ETF  XLV follows the Health Care Select Sector Index  This fund manages nearly  15 9 billion in its asset base and trades in heavy volume of around 9 8 million shares  Expense ratio comes in at 0 14  annually  In total  the fund holds 63 securities in its basket with JNJ taking the top spot at 12 1  of the assets  Pharma accounts for 36 3  share from a sector look while biotech  healthcare providers and services  and healthcare equipment and supplies make up for a double digit exposure each  The ETF shed 1 1  following lackluster JNJ result  read    iShares U S  Healthcare ETF This fund provides exposure to 118 securities by tracking the Dow Jones U S  Health Care Index  Here again  Johnson   Johnson dominates the fund s return at 11 6  of total assets  In terms of industrial exposure  pharma takes the top spot at 35 7   followed by biotech  22 4    and healthcare equipment  18 6    The product has amassed nearly  1 8 billion in its asset base while charges 44 bps in annual fees  It trades in a solid volume of more than 135 000 shares a day and lost 0 8  on the day Vanguard Health Care ETF   AX VHT  This ETF tracks the MSCI US Investable Market Health Care 25 50 Index and holds 358 stocks in its basket  Out of these  Johnson   Johnson takes the top spot with 10 2  allocation  Pharma takes the largest share at 32 9  while biotech and healthcare equipment round off the top three spots  VHT is also one of the popular and liquid ETFs with AUM of  6 1 billion and average daily volume of about 273 000 shares  It charges 10 bps in annual fees and expenses and shed 1  post JNJ result Fidelity MSCI Health Care Index ETF This fund provides exposure to 344 healthcare stocks with AUM of  691 6 million  This is done by tracking the MSCI USA IMI  LON IMI  Health Care Index  Here too  JNJ is the top firm with nearly 10 3  allocation  Pharma accounts for 32 7  share while biotech  healthcare equipment and supplies  and healthcare providers and services round off the top three spots with a double digit exposure each  The ETF has 0 08  in expense ratio while volume is good at 184 000 shares a day  FHLC was down 0 9  on the day iShares U S  Pharmaceuticals ETF This ETF provides exposure to 40 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  Out of these  Johnson and Johnson is the top firm accounting for 10 1  share  The product has  708 3 million in AUM and charges 44 bps in fees and expense  Volume is lower as it exchanges about 47 000 shares a day  The fund has shed 1 3  following JNJ earnings  read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2017-04-18,Zacks Investment Research,https://www.investing.com/analysis/lackluster-j-j-q1-pushes-healthcare-etfs-down-200183784,200183784
198839,420355,JNJ,Integra LifeSciences  IART  Q1 Earnings  A Beat In Store ,opinion,We expect Integra LifeSciences Holdings Corporation   NASDAQ IART   to beat expectations when it reports its first quarter 2017 results  after market close on Apr 26 Last quarter  the company s earnings met the Zacks Consensus Estimate  In fact  in the last four quarters  Integra s earnings outpaced the Zacks Consensus Estimate at an average of 3 02   Let s see how things are shaping up prior to this announcement Why a Likely Positive Surprise Our proven model shows that Integra is likely to beat earnings because it has the perfect combination of two key ingredients Integra LifeSciences Holdings Corporation Price and EPS Surprise    Zacks ESP   Integra has an  of  7 50  as the Most Accurate estimate is pegged at 43 cents while the Zacks Consensus Estimate is at 40 cents  A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Integra currently carries a Zacks Rank  3  Hold   Note that stocks with Zacks Rank  1  Strong Buy   2  Buy  or 3 have a significantly higher chance of beating earnings estimates Conversely  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions The combination of Integra s Zacks Rank  3 and  7 50  ESP makes us reasonably confident of an earnings beat What is Driving the Better Than Expected Earnings Management has adopted a 3 pillar strategy to optimize  execute and accelerate growth  Integra aims to expand economies of scale in the wake of escalating operating expenses  Also  the company aims to expand through inorganic means through profitable integration of new products and businesses and also organically In line with the core growth strategy  Integra is on a buyout spree  Also  post the fourth quarter of 2016  the company launched several regenerative products such as CUSA Clarity ultrasonic tissue ablation platform and Titan Press Fit Reverse Shoulder for Fracture  The company also announced full commercial availability of its Cadence Total Ankle System  a new ankle prosthesis developed in partnership with four world leading foot and ankle surgeons  Management is hopeful that synergies from these new products will be reflected in the first quarter s top line results We are also encouraged by Integra s consistent growth at its Specialty Surgical Solution segment on account of its core expertise in neurosurgery  The segment experienced strong 7  revenue growth in the previously reported fourth quarter 2016  Management is also investing substantially in the segment to drive growth  We expect the strong top line uptrend to continue in the upcoming first quarter as well The company s decision to acquire Codman Neurosurgery  from Johnson   Johnson  NYSE JNJ   and Derma Sciences have already boosted the market sentiment  We believe  post completion  these strategic buyouts should bolster Integra s business further within Specialty Surgical space Meanwhile  Integra issued a fiscal 2017 guidance  The company currently projects 2017 revenues in the range of  1 12 billion to  1 14 billion  representing growth of 12 5  to 15 5  and organic sales growth between 7  and 8 5   For the first quarter of 2017  revenues are expected in the band of  252 million to  256 million  representing 5  to 6  organic growth On the flip side  in the last three months  Integra has been trading below the Zacks categorized  sub industry  The stock lost 3 5   wider than the 1 2  decline of the broader industry  Factors such as rising operating expenses and pre closing costs related to the Codman Neurosurgery acquisition are believed to have had a negative impact on Integra s share price  Also  currency fluctuation and intense competition are major headwinds that are likely to linger Other Stocks to ConsiderHere are some other companies you may consider as our model shows that they also have the right combination of elements to post an earnings beat in the upcoming quarter Galectin Therapautics  Inc    NASDAQ GALT   has an Earnings ESP of  13 33  and a Zacks Rank  2  You can see Hill Rom Holdings Inc   NYSE HRC   has an Earnings ESP of  1 27  and a Zacks Rank  2 Syros Pharmaceuticals  Inc    NASDAQ SYRS   has an Earnings ESP of  3 85  and a Zacks Rank  2 The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ,2017-04-12,Zacks Investment Research,https://www.investing.com/analysis/integra-lifesciences-(iart)-q1-earnings:-a-beat-in-store-200182768,200182768
198840,420356,JNJ,Why Juno Therapeutics  Stock Tumbled In The Past One Year,opinion,Seattle  WA based Juno Therapeutics  Inc    NASDAQ JUNO   remains focused on the development of immuno oncology treatments  The company is looking to revolutionize cancer treatments by engaging the body s immune system to treat the disease  Juno is developing cell based cancer immunotherapies using CAR and high affinity TCR technologies in order to activate a patient s own T cells to recognize and kill cancer cells  However  the stock has significantly underperformed Zacks classified  industry in the past one year  To be precise  the stock lost 45 3  during this period compared with the industry s decrease of 12 3  Let s delve deeper to understand the reasons for the underperformance Leukemia Candidate DiscontinuedLast July  Juno suffered a huge setback with the FDA placing a clinical hold on the company s phase II study  ROCKET  on JCAR015 in adult patients with Relapsed Refractory  R R  B Cell Acute Lymphocytic Leukemia  ALL   The hold was placed after two patients died within a week due to severe neurotoxicity following the addition of fludarabine to the pre conditioning regimen  Though the hold was lifted a week later and the study was resumed under a revised protocol  the company voluntarily placed the study on hold again in Nov 2016 after two patients suffered from cerebral edema  Finally  this March  Juno announced that it is discontinuing the development of JCAR015 for r r ALL due to the toxicity witnessed in the ROCKET trial Negative SurprisesJuno  performance has been far from encouraging as the company missed estimates thrice in the trailing four quarters  Overall  Juno has an average negative surprise of 10 19   In the last reported quarter  the company posted a negative surprise of 4 76  In fact  the company s loss widened on a year over year basis in all the quarters of 2016 CompetitionAlthough Juno is among the major players in the field of T cell based immunotherapy  there are several other companies that are looking to develop and bring immunotherapy treatments to market  The CAR space has companies like Novartis   NYSE NVS    Kite Pharma  bluebird bio  Intrexon  and Johnson   Johnson   NYSE JNJ   working on treatments  We note that Juno is well behind Kite Pharma and Novartis in the race to bring a CAR T product to the market The company also faces stiff competition in the TCR space from players like Glaxo Pharma   NYSE GSK   and Kite Pharma You can see  The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ,2017-04-12,Zacks Investment Research,https://www.investing.com/analysis/why-juno-therapeutics'-stock-tumbled-in-the-past-one-year-200182861,200182861
198841,420357,JNJ,Should You Sell Johnson   Johnson  JNJ  Before Earnings ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Johnson   Johnson   NYSE JNJ   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Johnson   Johnson is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings with the most up to date information possible is a pretty good indicator of some favorable trends underneath the surface for JNJ in this report In fact  the Most Accurate Estimate for the current quarter is currently at  1 78 per share for JNJ  compared to a broader Zacks Consensus Estimate of  1 77 per share  This suggests that analysts have very recently bumped up their estimates for JNJ  giving the stock a Zacks Earnings ESP of 0 57  heading into earnings season Johnson   Johnson Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that JNJ has a Zacks Rank  3  Hold  and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Johnson   Johnson  and that a beat might be in the cards for the upcoming report Zacks  Hidden TradesWhile we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ,2017-04-13,Zacks Investment Research,https://www.investing.com/analysis/should-you-sell-johnson---johnson-(jnj)-before-earnings-200182815,200182815
198847,420363,JNJ,JNJ  Double Top Resistance Level Approaching Quickly,opinion,Healthcare products maker Johnson   Johnson  NYSE JNJ  is nearing a double top resistance point on the stock chart  The level is  126 and is the former all time high on the stock from July 2016  A double top on the stock chart is a technical term that tells investors there will be heavy selling at that point  It likely will be tough for Johnson   Johnson to go higher in the near term  Often  investors and traders will sell double tops short  profiting when the stock pulls back  That is what I will be looking to do if Johnson   Johnson hits double top this week  The stock has run too far  too fast in the last few weeks  In the last month  Johnson   Johnson is up from  111 to  124  For this historically slow moving stock  that is insane ,2017-03-06,Jenny Rebekka,https://www.investing.com/analysis/$jnj-double-top-resistance-level-approaching-quickly...-200177929,200177929
198848,420364,JNJ,Geron Stock Rises After Positive Interim Update On Imetelstat,opinion,Shares of Geron Corporation   NASDAQ GERN   increased almost 20  on Monday after it provided a positive update on two late stage studies for imetelstat  its lead pipeline candidate So far this year  Geron s shares have outperformed the Zacks classified industry  The stock rose 23 7  during the period while the industry witnessed a gain of 2 9  Telomerase inhibitor  imetelstat  is being developed for the treatment of hematologic myeloid malignancies like myelofibrosis  MF  and myelodysplastic syndromes  MDS  Geron informed that partner Johnson   Johnson s   NYSE JNJ   subsidiary Janssen has completed the second internal data review of two studies  IMbark  phase II for the treatment of MF  and IMerge  phase II III for the treatment of MDS   on imetelstat We remind investors that in September last year  Janssen had announced unfavorable findings from the planned internal reviews of initial data from IMbark and IMerge  As a result of the analysis  Janssen had then said that clinical activity of imetelstat  in the 4 7 mg kg dosing arm  in the IMbark study did not warrant any further investigation and that it will no longer enrol new patients In March this year  Geron informed that the treatment of patients remaining on study in IMbark and IMerge is ongoing to obtain additional and more mature data  However  new patient enrollment in both trials was suspended until completion of the second internal data reviews by Janssen Following the second internal review  for IMerge  Janssen said that the benefit risk profile of imetelstat in the treated patients supports continued development in lower risk MDS indication  The companies plan to provide a data package and proposed trial design refinements to the FDA  Geron mentioned that if Janssen decides to proceed to Part 2 of IMerge  a larger  170 patient  Phase III portion   patient enrollment will begin in the fourth quarter of this year For IMbark  the recent results suggest that the clinical benefit and a potential overall survival benefit observed supports continuation of the trial without modifications  The trial that assesses the safety and efficacy of imetelstat treatment in relapsed or refractory MDS will also include an assessment of overall survival  Also  the data suggest that 9 4 mg kg is an appropriate starting dose in the study We remind investors that in Nov 2014 Geron entered into a license and collaboration agreement with Janssen  granting the latter exclusive worldwide rights to develop and commercialize imetelstat for all human therapeutic uses  including hematologic myeloid malignancies Geron currently carries a Zacks Rank  2  Buy   You can see  Other stocks in the health care sector worth considering include Sanofi   NYSE SNY   and Roche Holding  SIX ROG  AG   OTC RHHBY    While Roche sports a Zacks Rank  1  Sanofi has a Zacks Rank  2 Shares of Roche have risen 11  this year so far while earnings estimates for 2017 went up almost 12  in the past 30 days Shares of Sanofi have risen 10 2  this year so far while earnings estimates for 2017 went up almost 2  in the past 60 days Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ,2017-04-10,Zacks Investment Research,https://www.investing.com/analysis/geron-stock-rises-after-positive-interim-update-on-imetelstat-200182304,200182304
198849,420365,JNJ,Inovio s Ebola Vaccine Positive In Expanded Phase I Study,opinion,Inovio Pharmaceuticals  Inc    NASDAQ INO   recently reported positive preliminary results from the expanded stage of its phase I study  EBOV 001  The study was conducted to evaluate the company s Ebola DNA vaccine  INO 4212  The company has enrolled an additional 125 patients in the study The decision to expand the enrollment came after positive initial safety and immune response data was received from the first set of 75 healthy volunteers  The initial 75 patient stage of the study evaluated INO 4212 in muscle and skin in five study arms in two and three doses  of which one included Inovio s DNA based IL 12 immune activator Inovio s share price movement shows that the stock has underperformed the Zacks classified industry so far this year  To be precise  the stock lost 11 3  during this period compared with the industry s increase of 2 6  Coming back to the latest news  the EBOV 001 study demonstrated robust immune responses with favorable safety profile in expanded clinical study  It showed that 95  of the subjects generated an Ebola specific antibody immune response with the mean antibody titer superior to those reported from viral vector based Ebola vaccines Inovio plans to meet with regulators to discuss the next step for INO 4212 in 2017  The company s decision is supported by encouraging data from the EBOV 001 study and positive preliminary preclinical data from several animal species We remind investors that the company was awarded a  45 million grant by the Defense Advanced Research Projects Agency in 2015 to lead a collaborative team for the development of multiple treatment and prevention approaches for Ebola  The Inovio led consortium is taking a multi faceted approach to develop treatments for the prevention of Ebola We note that Inovio is not the only company taking steps to curb this lethal disease in the absence of an approved vaccine or treatment  Peers like GlaxoSmithKline plc   NYSE GSK    Johnson   Johnson   NYSE JNJ   and Merck   Co   Inc    NYSE MRK   are also developing Ebola vaccines In fact  Merck s Ebola Zaire vaccine candidate  V920  received Breakthrough Therapy status from the FDA  The European Medicines Agency provided the candidate PRIME  PRIority MEdicines  status in Jul 2016 Apart from Ebola vaccines  the company is working on the development of Middle East respiratory syndrome MERS  GLS 5300  virus Inovio Pharmaceuticals  Inc  Price   Zacks RankInovio currently carries a Zacks Rank  3  Hold   You can see  Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-04-11,Zacks Investment Research,https://www.investing.com/analysis/inovio's-ebola-vaccine-positive-in-expanded-phase-i-study-200182526,200182526
198857,420373,JNJ,S P 500 Weekly Earnings Update  The Treasury Market Was Busy This Week ,opinion,"The big news this week was the Treasury market and the rise in yields  but more on that in a minute 
With 488 companies having reported Q4  16 earnings already  there is little left to know  and instead we look forward 
Thomson Reuters data by the numbers  Source  This Week in Earnings dated 3 3 17   

Forward 4 Quarter estimate   131 22 vs last week s  131 43
P E ratio  18 x 
PEG ratio  2 1 x 
S P 500 earnings yield  5 51  vs last week s 5 55 
Year over year growth of the forward estimate   8 49  vs last week s  8 41 

It is always welcome to see the  forward growth rate   last bullet  tick higher each week  and this week the forward growth rate increased again 
However  the big news this week was the rise in Treasury yields  as the 10 year Treasury jumped 17 basis points from 2 32  last Friday to 2 49  as of Friday  March 3  17 
17 bp s is a sizable increase in yield and it came as the probability on a fed funds rate increase from 50 to 75 bp s rose from 33 early last week  pre Dudley s speech  to 90  as of Friday 
No surprise that the sharpest increase in the 10 Year Treasury occurred the week of the Presidential election as it rose from 1 78  to 2 12  or a whopping 34 basis points 
The high for this move since November 8th is 2 60   which occurred mid December  16 
All the technicians are watching 2 60    2 62  and then 3 02  which was the 2013 high tick and the highest 10 year yield in the last 9 years 
Both the 1 Year and 2 Year Treasuries traded to 7   8 years highs this week  highs not seen since November  2008 
Analysis   Conclusion  Higher interest rates have a habit of putting a wet blanket on rising stock prices  however  that wasn t true in 2013  when the S P 500 rose 32  and the 10 year Treasury yield rose from 2  to 3   The momentum trade might see some heavy sledding if rates rise rapidly  but rising interest rates are also a sign that the US economy is returning to a more  normal  environment 
There hasn t been any fear of inflation for many  many years  or even heightened  inflationary expectations   Most of the Treasury curve is trading underwater with negative real returns 
2013 was all about the Bernanke  Taper Tantrum   i e  faster growth and therefore Ben was going to start withdrawing liquidity  but he got the boot before the end of the year 
While many expect higher interest rates down the road  it s the  rate of change  in yields that matter  Actually the long end seems to be remaining fairly stable 
Client bond allocations within the 60    40  portfolio remain in a lot of cash  some global bond funds  and a position in the TBF  unlevered inverse Treasury  
Client s healthcare exposure has increased since January 1  17  mainly with biotech ETF s like the iShares Nasdaq Biotechnology  NASDAQ IBB   The SPDR S P Biotech  NYSE XBI  is smaller cap focused and that hasn t added  yet  nor has the VanEck Vectors Biotech  NASDAQ BBH   Health Care was the worst performing sector in 2016  down 3  on the year  versus the 11 96  2016 return on the S P 500   Pfizer  NYSE PFE  has been client s largest Health Care position for years  and the only single stock risk  outside of a few positions in Merck  NYSE MRK  and Johnson   Johnson  NYSE JNJ   The Health Care weighting has been lifted from 3    5  to close to 10  depending on the client account and the overall objective 
Readers are owed a separate post on Health Care  There has been a lot on the plate 
Client positions continue to reflect the view of  stocks over bonds  in the normal 60    40  asset allocation portfolio  and Technology and Financial s are the two biggest sector weights and overweights  with Technology being the largest overweight 
 Positions can change at any time  and there may or may not be an update on this blog  ",2017-03-05,Brian Gilmartin,https://www.investing.com/analysis/sp-500-weekly-earnings-update:-the-treasury-market-was-busy-this-week-200177719,200177719
198876,420392,JNJ,Achillion  J J To Initiate Phase IIb Study On HCV Combo,opinion,Achillion Pharmaceuticals  Inc    NASDAQ ACHN   announced the initiation of patient dosing in a global phase IIb study by its partner Janssen  a company of Johnson   Johnson   NYSE JNJ    on JNJ 4178   a triple combination of AL 335  odalasvir  also known as ACH 3102  and J J s Olysio  simeprevir   The all oral combination regimen is being developed for the treatment of genotype 1 chronic hepatitis C virus  HCV  infection However  shares of Achillion lost 31 5  in the past one month compared to a 9 6  increase in the Zacks classified Biomed Genetics industry In Jun 2015  Achillion out licensed its HCV portfolio to J J  Under the agreement  J J has the global rights to develop and commercialize one or more of Achillion s lead HCV candidates  including ACH 3102  ACH 3422 and sovaprevir The phase IIb  open label  multi center OMEGA 1 study is expected to enroll approximately 300 treatment naive and treatment experienced patients with chronic HCV without cirrhosis  The study aims to investigate the efficacy  safety and pharmacokinetics of JNJ 4178  Patients in the study will receive the triple combination once daily for either 6 or 8 weeks  The primary efficacy endpoint is the percentage of patients with a sustained virological response 12 weeks after the end of treatment  SVR12  Presently  JNJ 4178 is being evaluated in a phase IIa study in HCV patients with or without compensated cirrhosis  Interim results from the phase IIa study  presented in Sep 2016  showed that all the patients in cohort 1 remained HCV RNA undetectable at 24 weeks after completing therapy  The phase IIa study also confirmed the required dose for each component as well as the treatment duration Per the company s press release  more than 150 million people are infected with HCV worldwide including approximately 3 million people in the U S  Therefore  successful development of the combination drug will allow the company to tap huge unmet patient needs in the U S The collaboration with J J could see Achillion receiving up to  1 1 billion in the form of development  regulatory and sales milestone payments  apart from a separate equity investment  Achillion is also entitled to receive tiered royalties in the mid teens to low twenties on future worldwide sales  All development and commercialization costs will be borne by J J ACHILLION PHARM Price    Zacks Rank   Key PicksAchillion currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector include Heska Corporation   NASDAQ HSKA   and Cambrex Corporation   NYSE CBM    Each of these stocks sports a Zacks Rank  1  Strong Buy   You can see  Heska s earnings estimates have increased from  1 13 to  1 35 for 2016 and from  1 38 to  1 53 for 2017 over the last 60 days  The company has posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301 64   Its share price has increased 70 9  year to date Cambrex s earnings estimates increased from  2 46 to  2 55 for 2016 and from  2 91 to  3 06 for 2017 over the last 60 days  The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19 78   Its share price has increased 6 4  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-30,Zacks Investment Research,"https://www.investing.com/analysis/achillion,-j-j-to-initiate-phase-iib-study-on-hcv-combo-200167709",200167709
198877,420393,JNJ,Is Federated Muni And Stock Advantage A Fund  FMUAX  Worth Another Look  ,opinion,"Federated Muni and Stock Advantage A     a Zacks Rank  2  Buy  was incepted in September 2003  FMUAX seeks income with tax advantage and growth of capital  FMUAX maintains a diversified portfolio by investing in both equity securities and fixed income securities  FMUAX invest a minimum of half of its assets in securities that are expected to pay interest income exempted from taxes 

	This fund  as of the last filing  allocates their fund in five major groups  Large Value  Foreign Bond  Intermediate Bond  Large Growth and Small Value  Further  as of the last filing  Altria Group  NYSE MO   GlaxoSmithKline and Johnson   Johnson  NYSE JNJ  were the top holdings for FMUAX 

	Federated Muni and Stock Advantage A  managed by   carries an expense ratio of 0 08   Moreover  FMUAX requires a minimal initial investment of  1 500 

	FMUAX has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 1  3  5 year benchmarks  1 year 4 02   3 year 3 77  and 5 year 6 36   To see how this fund performed compared in its category and other  1 and  2 Ranked Mutual Funds   

	FMUAX s performance  as of the last filing  when compared to funds in its category was in the top 15  in 1 year  top 31  over the past 3 years  and in the 51  over the past 5 years 

About Zacks Mutual Fund Rank

	By applying the Zacks Rank to mutual funds  investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward  Pick the  with the Zacks Rank 

Want key mutual fund info delivered straight to your inbox  

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2016-12-01,Zacks Investment Research,https://www.investing.com/analysis/is-federated-muni-and-stock-advantage-a-fund-(fmuax)-worth-another-look-200167893,200167893
198884,420400,JNJ,Aduro Reports Partial Hold Lift On LADD Studies In U S ,opinion,Aduro Biotech  Inc    NASDAQ ADRO   received encouraging news when the FDA lifted the partial clinical hold on studies evaluating investigational agents based on its LADD  live  attenuated double deleted  immunotherapy platform  With the partial hold lift  the company has now been able to resume patient enrollment in all Aduro sponsored studies However  the company has had to revise and implement study protocols in accordance with the FDA s guideline in order to recommence enrollment  These guidelines include extended patient surveillance  exclusion of patients with certain prosthetic devices that are not easily removed  and guidance in the administration of prophylactic antibiotics following LADD based treatment in patients who may receive immune suppressive treatments In its press release  Aduro stated that it is on track to initiate a phase II study utilizing the LADD based therapy CRS 207  in combination with an anti PD 1 compound  for the treatment of mesothelioma in the first half of 2017 We remind investors that last month  the FDA had placed a partial clinical hold on studies evaluating Aduro s LADD based agents  bringing patient enrollment to a halt  The decision came after a blood culture sample taken from an indwelling port of a metastatic pancreatic cancer patient tested positive for Listeria ADURO BIOTECH Price    Note that Aduro is developing the LADD platform for the treatment of multiple indications  including pancreatic  ovarian  lung and prostate cancers  mesothelioma and glioblastoma  In addition  a personalized form of LADD is being developed utilizing tumor neoantigens that are specific to an individual patient s tumor Several studies utilizing this platform are being conducted  which include a phase I II study on CRS 207  in combination with Incyte Corporation s   NASDAQ INCY   selective IDO1 inhibitor epacadostat  for the treatment of ovarian cancer  and a phase I lung cancer study on ADU 214  in collaboration with Johnson   Johnson s   NYSE JNJ   Janssen Biotech among others Meanwhile  Aduro continues to progress with its two other platform technologies   the STING pathway activator and the B select antibody programs Aduro currently has a Zacks Rank  2  Buy  Another Stock to ConsiderVanda Pharmaceuticals  Inc    NASDAQ VNDA   is another favorably placed stock in the health care sector  sporting a Zacks Rank  1  Strong Buy   You can see  Vanda s loss estimates narrowed from 68 cents to 56 cents for 2016 while earnings estimates increased from 16 cents to 17 cents for 2017 over the last 60 days  The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56 65   Its share price has surged 85  year to date The Best Place to Start Your Stock SearchToday  you are invited to download the full list of 220 Zacks Rank  1  Strong Buy  stocks   absolutely free of charge  Since 1988  Zacks Rank  1 stocks have nearly tripled the market  with average gains of  26  per year  Plus  you can access the list of portfolio killing Zacks Rank  5  Strong Sells  and other private research ,2016-11-21,Zacks Investment Research,https://www.investing.com/analysis/aduro-reports-partial-hold-lift-on-ladd-studies-in-u.s.-200166058,200166058
198885,420401,JNJ,Overview Of Fidelity Stock Selector Large Cap Value Fund  FSLVX ,opinion,"Fidelity Stock Selector Large Cap Value     a Zacks Rank  2  Buy  was incepted in November 2001 and is managed by Fidelity Management   Research Inc  FSLVX seeks long term growth of capital  FSLVX primarily invests its assets in common stocks  FSLVX normally invests at least 80  of its assets in securities of companies with large market capitalizations  FSLVX usually invests in securities of companies that it believes are undervalued in the marketplace in relation to factors such as assets  sales  earnings  growth potential  or cash flow or in relation to securities of other companies in the same industry  FSLVX may invest its assets in securities of foreign and domestic issuers 

	This fund  as of the last filing  allocates their fund in three major groups  Large Value  Large Growth and Precious Metal  Further  as of the last filing  Berkshire Hathaway  NYSE BRKa   Procter   Gamble and Johnson   Johnson  NYSE JNJ  were the top holdings for FSLVX 

	Fidelity Stock Selector Large Cap Value  managed by   carries an expense ratio of 0 78   Moreover  FSLVX requires a minimal initial investment of  2 500 

	FSLVX has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 1  3  5 year benchmarks  1 year 5 48   3 year 6 95  and 5 year 12 92   To see how this fund performed compared in its category and other  1 and  2 Ranked Mutual Funds   

	FSLVX s performance  as of the last filing  when compared to funds in its category was in the top 9  in 1 year  top 33  over the past 3 years  and in the 21  over the past 5 years 

About Zacks Mutual Fund Rank

	By applying the Zacks Rank to mutual funds  investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward  Pick the  with the Zacks Rank 

Want key mutual fund info delivered straight to your inbox  

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2016-11-24,Zacks Investment Research,https://www.investing.com/analysis/overview-of-fidelity-stock-selector-large-cap-value-fund-(fslvx)-200166595,200166595
198886,420402,JNJ,S P 500 Rallies To Its Cycle Top,opinion,"VIX declined to its lowest point in 2 months on Monday  while the VIX ETFs appear to have bottomed on Tuesday If this is correct  then we may see the VIX and its ETFs rally for the next three weeks  The next important milestones are the Flag trendline near 22 50 and Cycle Top resistance at 24 27 where a long term breakout may occur and the Cyclical uptrend may begin in earnest The media is panning VIX  claiming it no longer signals danger in the markets 
 Bloomberg  Rest in peace  VIX  You re no longer the fear gauge for global markets 
The Bank for International Settlements has found a better barometer to capture the nervousness that starts as a slight reduction in global banks  leverage  is magnified by European lenders as a dollar squeeze in Asian supply chains  and reverberates around the world as a financial tightness felt by everyone 
Everyone  except the Chicago Board Options Exchange s Volatility Index 
S P 500 rallies to its Cycle Top 

SPX rallied to challenge its Cycle Top Resistance at 2215 55 and slightly exceeded its Fibonacci 61 8  measure of Wave  3  at 2208 67  It may venture higher next week  but either the Cycle Top resistance or trendline resistance at 2225 00 may prevail  Point 5 of the Broadening Topmay be complete or nearly so 
 WSJ  U S  stocks notched fresh records  capping a week when the Dow Jones Industrial Average breached 19000 for the first time 
It is the third consecutive week of gains for stocks as investors have bet on expectations for reduced corporate taxation and regulation and greater infrastructure spending  Thanks to these past three weeks  the Dow Jones Industrials are on track to end the year with 9 9  gains  which would mark their best annual finish since 2013 

 Nothing is stopping the market at this point   said Jonathan Corpina  senior managing partner at Meridian Equity Partners 

The NDX rally is blocked by its Cycle Top 

NDX has been unable to better its October 25 high at 4911 76  causing a non confirmation among the major indices  A decline beneath Intermediate term support at 4810 74 confirms a new sell signal  It may be imprudent to be long beyond this point 
 ZeroHedge  Another month  and the pain for the hedge fund industry just keeps getting more intense 
According to the latest Evestment report  investors redeemed an estimated net  14 2 billion from hedge funds in October  Year to date  there has been a net  77 0 billion removed from the industry  October s outflow was the fourth month of redemptions in the last five and seventh in 2016  Due to the breadth of products experiencing outflows  and the persistence of redemptions outweighing new allocations  it is clear the industry is experiencing a crisis  like wave of negative investor sentiment 
One almost wonders how much higher the market can keep rising with redemption requests flooding countless back offices  We hope to find out soon 
High Yield Bond Index also falls short of its Cycle Top 

The High Yield Bond Index used its weekly Intermediate term support at 159 83 as a springboard to challenge its prior high at 162 79  Should it succeed  it may then rally to its Cycle Top resistance at 164 03 A failure at either level may produce a sharp decline to mid Cycle support at 145 72 
 WSJ  Count the junk bond market among those sending relatively optimistic signs about a Donald Trump administration 
Prices are dropping  and money has been flowing out of high yield bond funds  But risk premiums haven t risen  and companies are still issuing bonds suggesting that a market renowned for picking up early signs of economic stress retains a benign outlook on the U S  economy 
On Tuesday  Weatherford International PLC sold  540 million of bonds  40 million more than initially expected  The same day  the oil field services company was assigned a lowly triple C rating by Fitch Ratings  a four notch downgrade from its previous rating 
USB finally ready to bounce 

The Long Bond took a breather from its decline this week  There is a high probability of a rally that may last the next three weeks that may challenge weekly mid Cycle resistance at 158 23 However critical supports have been broken and there is room for more downside to come  A panic may propel USB to its 35 year trendline at 137 30 
 ZeroHedge  The long end of the US Treasury curve rallied on the week  for the first time since Trump s win  with 30 Year yields ending down almost 3bps  as a last minute panic bid hit stocks and bonds at the early market close  and despite the exuberance in US bank stocks  the yield curve continues to collapse   
At the cash equity close today  bonds and stocks were suddenly both bid    with 30Y back at 3 00 
The Euro retests the Cup with Handle 

The Euro has been challenging the Lip of its inverted Cup with Handle formation this week  It achieved a probable Master Cycle low on Wednesday and may be due for a three week retracement  Since the Broadening Wedge trendline has already been broken we should expect to see its target coming into view early next year 
 ZeroHedge  A reasonable question that many Europeans might ask would be whether it is not perhaps time to review priorities 
Perhaps the time has come to look at whether it remains worth it  in terms of the potential loss of human life  to remain party to the 1961 Convention  which would prohibit a country from stripping a returning ISIS fighter of his citizenship in order to prevent him from entering the country 
The terrorist as poor  traumatized victim who needs help seems to be a recurring theme among European politicians  But what about the rights of the poor  traumatized citizens who elected these politicians 
Euro Stoxx 50 has another inside week 

The Euro Stoxx 50 Index bounced from its Intermediate term support at 3019 79  but only managed to make another inside week The Cycles Model suggests the period of relative strength may end next week  The Index may have been able to resist making a sell signal so far  but that may change should that support be violated with new lows 
 Bloomberg  European shares closed at a one month high  capping their longest streak of weekly gains since July 
The Stoxx Europe 600 Index rose 0 2 percent at the close  taking its advance for the week to 0 9 percent  The number of its shares changing hands was about 40 percent lower than the 30 day average  with U S  markets closing early following yesterday s Thanksgiving holiday  Actelion Ltd  SIX ATLN   led a rally in health care shares  surging 18 percent after confirming that Johnson   Johnson  NYSE JNJ  has approached the Swiss drug maker about a potential takeover 
European shares have rebounded 4 2 percent from a low on Nov  4 on bets that Donald Trump s administration will lead to increased infrastructure spending  A related rally in copper prices pushed European miners to their highest prices since June 2015 on Thursday  While the Stoxx 600 has been trading in a tight range  its longer term average level is getting close to crossing above its shorter term mean 
The Yen completes a long retracement 

The Yen may have completed its longest decline in two years after three weeks of solid declines  The expected turn in the Yen may have finally arrived today  about two weeks later than indicated by the Model  We may see up to four weeks of Cyclical strength ahead The decline does not negate the Cup with Handle formation 
 Bloomberg  The dollar posted its biggest three week gain versus the yen since 1995 as traders view a U S  interest rate increase next month as a certainty 
The greenback has surged about 10 percent since Nov  4 to an eight month high against the Japanese currency  Expectations that President elect Donald Trump will implement policies to spur inflation and growth drove U S  Treasury yields to their highest in a year  underpinning demand for the dollar and strengthening the case for the Federal Reserve to raise interest rates  Minutes of the central bank s November meeting this week showed officials said the labor market has tightened  with some indicating a rate hike should happen in December 
The Nikkei 225 rallies to new retracement highs 

The Nikkei rallied to a new retracement high after breaking through mid cycle resistance last week nearly reaching a 60  retracement of the 2015 decline It appears to have a few more days of Cyclical strength in which it may meet its 61 8  Fibonacci retracement  However  the reversal may be sharp and without warning  Should the Head   Shoulders neckline be broken  a panic decline may ensue 
 Reuters  Japan s Nikkei share average rose for a seventh straight session on Friday after U S  shares soared and the dollar jumped further against the yen  lifting prospects for better corporate earnings 
The Nikkei rose 0 6 percent to 18 438 97 points by mid morning  extending its longest winning streak since November 2015 
For the week  the benchmark index is poised to rise 2 8 percent 
US Dollar Index reaches its Cycle Top 

USD rallied toward its cycle Top resistance at 102 00  reaching 101 97 before reversing today  Current support is at 100 60  A decline beneath that level may cause a rapid move from bullish to bearish as traders find themselves wrong footed 
 ZeroHedge  Having soared to fresh 13 year highs in a quiet overnight session on thin liquidity due to the US Thanksgiving holiday  which sent the USD JPY just shy of 114 and the Yuan to 6 96  the dollar pared back its weekly advance with modest profit taking after traders wondered if the rally has gotten  too stretched  
 Expectations of rises in U S  inflation and interest rates have driven the greenback to a gain of more than 6 percent in October and November combined  its strongest performance over a similar period since its rally in early 2015  Most investors expect those gains to continue  but a combination of the Thanksgiving break in the United States  market participants  need to process corporate flows at the end of the month and a raft of risks in the first half of December all speak for cashing in some of those gains now 
Gold declines to its Broadening Top trendline 

Gold declined to the lower trendline of its Orthodox Broadening Top formation  However  the decline may not be over  yet The Cycles Model suggests possibly another two weeks of decline  which agrees with the Broadening Top pattern which calls for a continued decline to the vicinity of 1150 00 Nonetheless  it may be time to be on guard for a reversal pattern
 Bloomberg  Gold pared a third weekly drop as the dollar halted a rally that sent bullion prices to a nine month low and pushed silver into a bear market 
Bullion s first gain in four days cut this week s loss to 2 percent  Prices have tumbled as strong economic data and the prospect of more spending after Donald Trump s U S  election win boosted bets for higher interest rates  Investors are selling out of gold backed funds at the fastest pace in three years 
The metal rebounded on Friday as the Bloomberg Dollar Spot Index retreated from a recent high  Gold s decline earlier stalled at  1 171 18 an ounce  which is near a 61 8 percent retracement of the rally from December to July  The Fibonacci figure is used by some traders and analysts to determine support levels 
Crude Oil retraces to mid Cycle resistance 

Crude bounced from its Intermediate term support at 46 06 to challenge mid Cycle resistance at 48 81  where it peaked on Wednesday The cycles Model suggests a decline may be imminent  while a significant low may be reached in approximately 3 weeks There is now the probability of a decline that may test the February low  After 6 months of being range bound  traders may not have seen this decline coming 
 Reuters  U S  crude fell nearly 4 percent on Friday  dragged down by uncertainty over whether the Organization of the Petroleum Exporting Countries will reach an output deal  after Saudi Arabia said it will not attend talks on Monday with non OPEC producers to discuss supply cuts 
Brent crude futures settled at  47 24 a barrel  down  1 76 or 3 59 percent  U S  crude futures settled down  1 90 a barrel at  46 06  a 3 96 percent decline  Prices continued to decline in post settlement trading  dropping as low as  45 88 a barrel 
Shanghai Composite challenges mid Cycle resistance 

The Shanghai Index challenged mid Cycle resistance at 3269 00 today  making nearly a 60  retracement of its early 2016 decline Its cyclical strength is waning and a reversal from this resistance may lead to an inevitable breakdown The fractal Model suggests the Shanghai is due for another 1 000 point drop  possibly starting next week  The next Master Cycle low may be due in early January 
 ZeroHedge  Over the weekend we reported that as Obama was speaking at the APEC summit in Peru  hoping to salvage his global trade legacy  the TPP  China s President Xi Jinping officially called for the launch of the Free Trade Area of Asia Pacific for  institutional guarantee of open economy   a move many had expected would take place as China was eager to fill in the void left by the US in any trans Pacific trade treaty As we previously reported  in his speech in Lima  Xi Jinping sought to position himself as a leader in global commerce  vowing to support trade  The attendees signaled  deepening economic integration and opposing trade protectionism   the Foreign Ministry spokesman said on Tuesday Then  overnight  China got a present when Trump announced in a brief video statement that his first executive order upon becoming president would be to remove the US from the TPP  That s all Beijing needed to hear and this morning China said it hoped to conclude an Asia wide trade pact as soon as possible  in what the WSJ dubbed was  a sign of Beijing s intent to broaden its regional influence amid the apparent collapse of the U S  backed Trans Pacific Partnership  
The Banking Index reaches the trendline of its Orthodox Broadening Top 

BKX surged to the upper trendline of its Orthodox Broadening Top at 87 00 today This may well be the terminal push as the Cycles Model suggests the period of strength ends on Monday  Once broken  we may expect this three year pattern to unwind very quickly 
   Shares in US banks have surged since Donald Trump won the US election  It is in expectation of the president elect s proposed bonfire of what he believes are rules and regulations that hamper business 
But in banking  many of those rules were put in place after the last financial crisis in the hope of preventing a future meltdown 
Now Neel Kashkari  president of the Federal Reserve Bank of Minneapolis is proposing an alternative that may be more in line with Donald Trump s way of thinking 
He believes that banks should be forced to massively increase their capital reserves   the amount of cash they are obliged to keep in hand for the day when everything goes wrong at once 
   The long end of the US Treasury curve rallied on the week  for the first time since Trump s win  with 30Y yields ending down almost 3bps  as a last minute panic bid hit stocks and bonds at the early market close  and despite the exuberance in US bank stocks  the yield curve continues to collapse   
At the cash equity close today  bonds and stocks were suddenly both bid    with 30Y back at 3 00 
   Back in the summer we wrote about an IMF report that flagged Deutsche Bank  DE DBKGn  as the  most important net contributor to systemic risks    Those who read our site frequently were likely not terribly surprised by the IMF s conclusion 
Among the G SIBs  Deutsche Bank appears to be the most important net contributor to systemic risks  followed by HSBC and Credit Suisse  SIX CSGN   In turn  Commerzbank  DE CBKG   while an important player in Germany  does not appear to be a contributor to systemic risks globally  In general  Commerzbank tends to be the recipient of inward spillover from U S  and European G SIBs  The relative importance of Deutsche Bank underscores the importance of risk management  intense supervision of G SIBs and the close monitoring of their cross border exposures  as well as rapidly completing capacity to implement the new resolution regime 
That said  we suspect the latest ranking of global systemically important banks  G SIBs  by the Financial Stability Board may be a bit more surprising to our readers  among others  as it features two of America s largest banks right at the very top 
   If everything is so awesome  with a growth inflation miracle just around the corner  then why is the US treasury yield curve collapsing in a dismal growth outlook implying manner 
Following the knee jerk spike on the election  5s30s have crashed to 6 week lows   
Nowhere is this decoupling from reality narrative more obvious than in the banks as NIM is a spread not an absolute   
And  as we asked last night  if bank stocks are so great and bank business looks so shiny    why is bank credit risk now at its highest in a month ",2016-11-27,Anthony M. Cherniawski,"https://www.investing.com/analysis/weekend-update-november-25,-2016-200166724",200166724
198887,420403,JNJ,J J  JNJ  Confirms It Approached Actelion For Possible Deal,opinion,"Johnson   Johnson   NYSE JNJ   confirmed that it approached Swiss biotechnology company  Actelion Ltd    OTC ALIOF    with a takeover offer  J J stated in a press release that it is  engaged in preliminary discussions  with Actelion regarding a possible transaction  However  both J J and Actelion warned that there is no certainty that the discussions will culminate into any transaction  J J said it will make additional comments on the topic only when a formal agreement is reached or when it is appropriate to do so Actelion s shares surged nearly 20  on Friday  while J J s shares rose 1  on the news  In fact  while the Zacks classified Drugs industry declined 15 8  over the past one year period  the stock of J J s climbed 12 7  while that of Actelion shot up almost 32  Last week  Bloomberg reported that the companies were holding initial talks   Read More    Actelion is a leader in the pulmonary arterial hypertension  PAH  market with key drugs like Opsumit  Tracleer  Ventavis  Veletri and Uptravi  The newer drugs   Opsumit and Uptravi  have been well received and are poised to become blockbuster drugs  These should make up for the lost revenues from Actelion s older PAH medicine  Tracleer  which is facing competitive pressure Tracleer lost patent protection in the U S  last year and will also lose exclusivity in the EU in early 2017   Sales of Tracleer declined 18  in constant exchange rates in the first nine months of 2016  while that of Opsumit surged 63   Uptravi  which was launched earlier this year  recorded sales of CHF 160 million in the first nine months of 2016  Actelion s strong sales performance enabled it to increase its 2016 guidance A deal with Actelion will diversify J J s revenues and can pull up its top line as its largest product  the arthritis drug Remicade  partner  Merck   Co   Inc    NYSE MRK     is facing biosimilar competition in EU  Also  Pfizer  Inc    NYSE PFE   will soon launch a biosimilar version of Remicade in the U S On the third quarter conference call  when asked about its acquisition plans  J J mentioned that as far as pharmaceuticals are concerned  it will most likely use an  acquisition type  strategy instead of a licensing strategy if it decides to add another major therapeutic area to its existing five major therapeutic areas J J also said it has specific areas of focus in the Consumer segment  mainly international growth in emerging markets  over the counter medications and the beauty space in Asia  Within the Medical Devices segment  J J continues to look for bolt on acquisitions in orthopedics and general surgery  Although certain areas like structural heart look attractive in the cardiovascular segment  the company was pretty clear about being disciplined from a valuation aspect While J J has a Zacks Rank  3  Hold   Actelion has a Zacks Rank  4  Sell  JOHNSON   JOHNS Price and Consensus
    You can see  Zacks  Best Private Investment Ideas In addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ",2016-11-28,Zacks Investment Research,https://www.investing.com/analysis/j-j-(jnj)-confirms-it-approached-actelion-for-possible-deal-200166887,200166887
198894,420410,JNJ,Is Eaton Vance Dividend Builder A Fund  EVTMX  Worth Another Look ,opinion,"Eaton Vance Dividend Builder A     a Zacks Rank  2  Buy  was incepted in December 1981 and is managed by Boston Management and Research  The objective of EVTMX is to provide a high level of total return  consisting of capital appreciation and relatively predictable income  EVTMX pursues its objective by investing in utilities portfolio  EVTMX seeks high total return consistent with prudent management and preservation of capital  investing principally in dividend paying common stocks and dividend paying or interest bearing securities that are convertible into common stock  EVTMX normally invests at least 80  of its net assets in equity securities of utilities companies  EVTMX also invests 20  of its net assets in fixed income securities  including up to 10  of net assets in lower rated fixed income securities  

	This fund  as of the last filing  allocates their fund in three major groups  Large Growth  Large Value and Intermediate Bond  Further  as of the last filing  Verizon  Johnson   Johnson  NYSE JNJ  and Pfizer  NYSE PFE  were the top holdings for EVTMX 

	Eaton Vance Dividend Builder A  managed by   carries an expense ratio of 1 05   Moreover  EVTMX requires a minimal initial investment of  1 000 

	EVTMX has a history of positive total returns for over 10 years  Specifically  the fund s returns over the 1  3  5 year benchmarks  1 year 3 19   3 year 8 09  and 5 year 11 64   To see how this fund performed compared in its category and other  1 and  2 Ranked Mutual Funds   

	EVTMX s performance  as of the last filing  when compared to funds in its category was in the top 62  in 1 year  top 6  over the past 3 years  and in the 15  over the past 5 years 

About Zacks Mutual Fund Rank

	By applying the Zacks Rank to mutual funds  investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward  Pick the  with the Zacks Rank 

Want key mutual fund info delivered straight to your inbox  

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ",2016-11-15,Zacks Investment Research,https://www.investing.com/analysis/is-eaton-vance-dividend-builder-a-fund-(evtmx)-worth-another-look-200165006,200165006
198895,420411,JNJ,J J  JNJ  Stelara Gets Approval In EU For Label Expansion  ,opinion,"Johnson   Johnson s   NYSE JNJ   subsidiary  Janssen Therapeutics  announced that the European Commission  EC  has approved its prescription drug Stelara for the treatment of moderate to severely active Crohn s disease in adults Stelara is presently marked in the EU and U S  for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis The approval was not surprising as the European Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  had granted a positive opinion to Stelara  recommending approval for the indication in September  Also  in the same month  Stelara received the FDA approval for the same indication  J J is also evaluating Stelara as a subcutaneous treatment for ulcerative colitis  phase III ongoing  and axial spondylytis  phase III    Sales of Stelara in the upcoming quarters should receive a boost with this label expansion  According to the company s press release  more than five million people worldwide suffer from Crohn s disease and ulcerative colitis which are collectively referred to as inflammatory bowel disease  IBD  JOHNSON   JOHNS Price and Consensus
    Apart from Stelara  J J is also working actively on expanding the label of other new marketed products like Simponi  Xarelto and Imbruvica  For Imbruvica  partner  AbbVie  Inc    NYSE ABBV     six additional indications have been approved since its launch and the drug is also being evaluated in a number of combination therapies  For Xarelto  there are eight new indications seeking trials as part of the EXPLORER clinical development program  While Johnson   Johnson has exclusive U S  marketing rights of Xarelto  the drug is being marketed by Bayer  DE BAYGN  AG   OTC BAYRY   outside the U S Simponi  partner  Merck   Co   Inc    NYSE MRK    received approval this year in the EU for the treatment of polyarticular juvenile idiopathic arthritis in combination with methotrexate  Also  the company plans to file two line extensions for Simponi Aria  the intravenous formulation of Simponi  in psoriatic arthritis and ankylosing spondylitis  We believe that in the forthcoming period  these drugs will contribute significantly to the company s top line J J carries a Zacks Rank  3  Hold   You can see the  Zacks  Top Investment Ideas for Long Term Profit How would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ",2016-11-16,Zacks Investment Research,https://www.investing.com/analysis/j-j-(jnj)-stelara-gets-approval-in-eu-for-label-expansion-200165279,200165279
198896,420412,JNJ,New Oriental Education   Technology Group  BJ s Restaurants  ARIAD Pharmaceuticals  Incyte And Exelixis Highlighted As Zacks Bull And Bear Of The Day ,opinion,"For Immediate Release

	Chicago  IL   November 18  2016    highlights New Oriental Education   Technology Group  NYSE      as the Bull of the Day and BJ s Restaurants  NASDAQ      as the Bear of the Day  In addition  Zacks Equity Research provides analysis on ARIAD Pharmaceuticals Inc   NASDAQ     Incyte Corporation  NASDAQ     and Exelixis  Inc   NASDAQ      

	Here is a synopsis of all five stocks 

  

	China s largest private education provider delivered another strong quarter  Analysts have been raising their price and earnings estimates after solid results  sending the stock back to a Zacks rank  1  Strong Buy  About the Company
	Founded in 1993  New Oriental Education   Technology Group  NYSE      is the largest provider of private educational services in China with over 26 6 million student enrollments  The company IPO d on the NYSE in September 2006 
	Headquartered in Beijing  New Oriental group currently has a network of 771 schools learning centers and over 19 700 teachers in 56 cities  Additionally  it has a large online network with over 14 2 million users 
	They provide a comprehensive range of educational products for students of all ages  including POP kids programs  summer camps  private schools  after school tutoring  adult English as well as domestic and overseas entrance tests preparation Excellent Quarterly Results
	The company reported its Q1 FY 2017  ended August 31  results on October 25  Revenue for the quarter increased 16 5  year over year to  534 1 million  Net income increased 9 7  year over year to  141 1 million 
	Strong growth was mainly attributable to 31 2  increase in total enrollments  Their K 12 all subjects after school tutoring business continued to perform well  with revenue up 28  year over year and enrollment up 46  year over year Strong Guidance
	The management expects net revenues in the second quarter of fiscal year 2017  ending November 31  2016  to be in the range of  324 6 million to  335 1 million  representing year over year growth in the range of 17  to 21  Rising Estimates  
	After strong results  analysts have been raising their estimates for the company  Zacks Consensus Estimates for current and the next fiscal year have gone up to  1 76 per share and  2 29 per share respectively  from  1 75 and  2 18  before the results  Rising estimates sent the stock to a Zacks Rank   1  Strong Buy  

  

	Founded in 1978 and headquartered in Orange County  CA  BJ s Restaurants  NASDAQ      owns and operates a chain of 186 high end casual dining restaurants in 24 states  Their signature menu items include deep dish pizza  craft beer and  pizookie  dessert  They call their positioning  contemporary  high quality  casual plus  Results Disappoint
	The company reported lackluster Q3 results  missing both on the top and bottom lines  Adjusted earnings of  0 30 per share fell short of the Zacks Consensus Estimate of  0 32 by 6 3  
	Revenues increased 1 9  year over year to  233 7 million but were below the Zacks Consensus Estimate of  239 million by 2 2  Did the Presidential Election Impact Results 
	According to the management   businesses dependent on consumer discretionary spending were challenged by a variety of macro factors including the timing of the Summer Olympics as well as the current economic uncertainty arising from the political elections  
	The CEO Greg Trojan  the election had created  a nearly unprecedented level of negativity and doubt in the minds of everyday American citizens  Falling Estimates
	Analysts have slashed their estimates for the company after disappointing results  Zacks Consensus Estimates for the current and the next fiscal year have fallen to  1 75 per share and  1 95 per share respectively  from  1 82 and  2 10  30 days ago  Declining estimates sent the stock to a Zacks Rank  5  Strong Sell  

Additional content 

3 Biotech Stocks to Add as M A Hopes Rise

	2016 has not been a great year for mergers and acquisitions  M As  in the pharma and biotech sector although some headline deals like the Pfizer Medivation and the Teva Actavis Generics acquisitions were completed this year  While expectations were high that this year too  the pharma and biotech sector would see lots of M A activity that did not happen  with the focus being mostly on small bolt on acquisitions and licensing deals and agreements 

Will a Trump Presidency Trigger More M A Deals for Biotechs 
	Although it may be too early to speculate  there is a lot of chatter about a possible increase in M As in the pharma and biotech sector now that Donald Trump is President elect 
	Basically  the Trump victory is being viewed as a positive for the biotech and pharma sector  There are several reasons for this  the foremost being the drug pricing issue  The general view is that a Hillary Clinton win would have been a negative for pharma and biotech stocks given her stand on rising drug prices and her plans to address the excessive price hikes of treatments that have been available for years and to lower drug prices for all Americans  With Clinton s frequent rhetoric regarding drug prices  biotech and pharma stocks have been under intense pressure for more than a year 
	Trump  on the other hand  has not been so vocal about drug pricing though he did call for price transparency from all healthcare providers and drug re importation  Not just that  his pro business stand is also expected to benefit the sector  Major biotech and pharma companies should gain from Trump s proposed tax plan and proposal to repatriate corporate profits held offshore at a one time tax rate of 10  
	With focus on drug pricing expected to subside and given the possibility of repatriation of funds  hopes are up that M A activity will pick up with companies like Pfizer  NYSE PFE   Merck  NYSE MRK   Johnson   Johnson  NYSE JNJ  expected to take the lead  Big companies with deep pockets often look to replenish and boost their pipelines as well as portfolios by acquiring companies with innovative pipelines and technology Stock Picks
	Here we highlight 3 companies that have often been considered attractive take over targets and have a Zacks Rank of  1  Strong Buy  or  2  Buy  ARIAD Pharmaceuticals Inc    NASDAQ          Cambridge  MA based ARIAD focuses on bringing innovative treatments for rare cancers to market  ARIAD  which already has a marketed product  Iclusig  in its portfolio  could well become a two product firm as early as 2017 if it gains FDA approval for brigatinib in April  Meanwhile  Iclusig s growth should be driven by new patient starts  extended treatment duration and label expansion  ARIAD s product portfolio  potential brigatinib approval and its next wave of discovery and development programs such as AP32788 and the immuno oncology program make it an attractive acquisition target  The Zacks Rank  2 stock has a solid earnings track record having surpassed expectations in each of the last three quarters 

ARIAD PHARMA Price and Consensus

   

Incyte Corporation   NASDAQ          Wilmington  DE based Incyte has two marketed products in its portfolio and a strong pipeline  Flagship product  Jakafi   a JAK1 JAK2 inhibitor   looks well positioned for growth and is expected to bring in sales of  850    855 million in 2016  Moreover  with Gilead presenting mixed results on its experimental JAK inhibitor  momelotinib  the competitive threat for Jakafi seems to have gone down considerably  Incyte  a Zacks Rank  2 stock  has a robust pipeline as well with a focus on the highly sought after immuno oncology space  Jakafi s strong performance along with the company s pipeline makes Incyte an attractive acquisition target 

INCYTE CORP Price and Consensus

   

Exelixis  Inc    NASDAQ          South San Francisco  CA based Exelixis is also focused on bringing cancer treatments to market  Approved products include Cabometyx  advanced kidney cancer   Cometriq  certain forms of thyroid cancer  and Cotellic  advanced melanoma   Exelixis  earnings track record is good having surpassed expectations in three of the last four quarters  Cabometyx is experiencing rapid and broad uptake in the market with label expansion opportunities leaving room for upside  The Zacks Rank  2 stock has quite a few pipeline catalysts lined up for the coming quarters  You can see   

EXELIXIS INC Price and Consensus

   

	The three companies discussed above are not the only ones with acquisition potential  Several other companies are often viewed as acquisition targets  The bottom line is that companies with innovative technologies and pipelines are highly sought after with niche disease areas like nonalcoholic steatohepatitis  NASH   immuno oncology  multiple sclerosis and hepatitis C virus  HCV  in demand  Treatments for orphan diseases are also in demand Zacks  Best Investment Ideas for Long Term Profit
	Today you can gain access to long term trades with double and triple digit profit potential rarely available to the public  Starting now  you can look inside our stocks under  10  home run and value stock portfolios  plus more  Want a peek at this private information  

	Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  



About the Bull and Bear of the Day

	Every day  the analysts at Zacks Equity Research select two stocks that are likely to outperform  Bull  or underperform  Bear  the markets over the next 3 6 months 

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous analyst coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research

	800 767 3771 ext  9339





	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-11-17,Zacks Investment Research,"https://www.investing.com/analysis/new-oriental-education---technology-group,-bj's-restaurants,-ariad-pharmaceuticals,-incyte-and-exelixis-highlighted-as-zacks-bull-and-bear-of-the-day-200165428",200165428
198897,420413,JNJ,J J  JNJ  Files For Psoriasis Candidate Guselkumab In U S ,opinion,"Johnson   Johnson s   NYSE JNJ   subsidiary  Janssen announced the submission of a Biologics License Application  BLA  to the FDA for its pipeline candidate guselkumab for the treatment of adults with moderate to severe plaque psoriasis The application is served on the basis of four studies   phase III VOYAGE 1  VOYAGE 2 and NAVIGATE  and phase II X PLORE   evaluating the efficacy and safety of guselkumab administered by subcutaneous injection for the treatment of adults with moderate to severe plaque psoriasis Results of the VOYAGE 1 study were recently presented at the European Academy of Dermatology and Venereology congress in Austria  while VOYAGE 2 and NAVIGATE data are expected to be presented at upcoming scientific congresses Data from the VOYAGE 1 trial  n 837  showed that significantly higher proportions of patients with moderate to severe plaque psoriasis treated with guselkumab achieved high rates of skin clearance compared to those receiving placebo  73  of the patients receiving guselkumab achieved near complete skin clearance versus 2 9  on placebo The active comparator arm of the VOYAGE trial evaluated guselkumab in comparison with AbbVie Inc  s   NYSE ABBV   top selling product  Humira  The study demonstrated statistically significant efficacy of guselkumab compared to Humira after week 16  which was maintained through 48 weeks of treatment  Almost 50  of the patients treated with Humira achieved near complete skin clearance compared with 73  receiving guselkumab A phase II trial evaluating guselkumab in moderate to severely active psoriatic arthritis is also ongoing  Per the company s press release  around 125 million people worldwide suffer from psoriasis  including 7 5 million Americans with their disease ranging from mild to severe and disabling  Hence  an approval of guselkumab would give the company access to a wide patient population in the U S JOHNSON   JOHNS Price

   Zacks Rank   Key Picks
Johnson   Johnson currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector include Cambrex Corp    NYSE CBM   and Vanda Pharmaceuticals  Inc    NASDAQ VNDA    Each of these stocks sports a Zacks Rank  1  Strong Buy   You can see  
Cambrex s earnings estimates increased from  2 46 to  2 55 for 2016 and from  2 91 to  3 06 for 2017 over the last 60 days  The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19 78   Its share price has increased 9 7  year to date 
Vanda s loss estimates narrowed from 68 cents to 56 cents for 2016  while its earnings estimates have increased from 16 cents to 17 cents for 2017 over the last 60 days  The company posted a positive earnings surprise in three of the four trailing quarters with an average positive surprise of 56 65   Its share price has surged 83 1  year to date 
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-18,Zacks Investment Research,https://www.investing.com/analysis/j-j-(jnj)-files-for-psoriasis-candidate-guselkumab-in-u.s.-200165566,200165566
198898,420414,JNJ,Trump Rotation Stocks To Buy Right Now ,opinion,"Boy am I glad that the election is finally over  I don t know about you  but frankly I was sick and tired of hearing about Hillary s emails and Trump s grabby little hands  While most of my liberal friends are absolutely beside themselves  my unapologetic capitalist friends are ecstatic  There s nothing that takes your mind off a rough week in politics like getting filthy rich 
Some serious head scratching took place as the Trump rotation began  The VIX had spiked following the reopening of Clinton s email probe  implying the market was upset about the prospects of a Trump Presidency  However  since then  we ve been in a rip your face off rally  And surprisingly it s not in the stocks you d think 
For example  Rogaine maker Johnson and Johnson   NYSE JNJ   has struggled to push above  120  selling off into the  115s over the last couple of days  There s been virtually no improvement in tanning salons or hair dye either  Out of nowhere Pant suits have rallied  Lane Bryant parent company Ascena Retail   NASDAQ ASNA   is up big since the election  Rallying up from  5 to  6 44 
Big money has been rotating into the Financial Sector   Industrials  and Health care   The recent interest in health care is very surprising as you d think Trump s decision to repeal and replace Obamacare would hurt those stocks  However  don t forget the witch hunt on Capitol Hill targeting drug companies that were hiking up prices  Under a Clinton regime  those stocks would have come under serious pressure to change their pricing policies  The election of Trump has caused a relief rally in drug stocks and given a shot in the arm to the entire sector 
Fund flows have been seen coming out of consumer discretionary which is exactly why I m looking at stocks like Foot Locker  NYSE FL  which just reported an earnings beat earlier today  Foot Locker is a Zacks Rank  2  Buy  stock right now  A big reason why is 4 analysts increasing their estimates of how much money they thing Foot Locker is going to make next year  The bullish attitude has pushed up our Zacks Consensus Estimate or the average of all these earnings guesses  up to  5 25 per share 
Every time you share this video  somebody who didn t vote for Trump dries their tears with  100 bills  Chime in the comments section below  let me know what stocks you re looking to buy as part of the Trump rotation  Subscribe to the YouTube channel  Twitter and come back here for all the Trending Stocks with Zacks com  I m Dave Bartosiak ",2016-11-18,Zacks Investment Research,https://www.investing.com/analysis/trump-rotation-stocks-to-buy-right-now-200165561,200165561
198899,420415,JNJ,The Zacks Analyst Blog Highlights  Johnson   Johnson  Ascena Retail  Financial Sector  Industrials And Health Care,opinion,"For Immediate Release

	Chicago  IL   November 21  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Johnson   Johnson  NYSE JNJ   NYSE     Ascena Retail  Nasdaq     Financial Sector  AMEX      Industrials  AMEX    and Health care  AMEX     

	Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Friday s Analyst Blog  

Trump Rotation Stocks to Buy Now

	Boy am I glad that the election is finally over  I don t know about you  but frankly I was sick and tired of hearing about Hillary s emails and Trump s grabby little hands  While most of my liberal friends are absolutely beside themselves  my unapologetic capitalist friends are ecstatic  There s nothing that takes your mind off a rough week in politics like getting filthy rich 

	Some serious head scratching took place as the Trump rotation began  The VIX had spiked following the reopening of Clinton s email probe  implying the market was upset about the prospects of a Trump Presidency  However  since then  we ve been in a rip your face off rally  And surprisingly it s not in the stocks you d think 

	For example  Rogaine maker Johnson   Johnson  NYSE     has struggled to push above  120  selling off into the  115s over the last couple of days  There s been virtually no improvement in tanning salons or hair dye either  Out of nowhere Pant suits have rallied  Lane Bryant parent company Ascena Retail  Nasdaq     is up big since the election  Rallying up from  5 to  6 44 

	Big money has been rotating into the Financial Sector  AMEX      Industrials  AMEX    and Health care  AMEX       The recent interest in health care is very surprising as you d think Trump s decision to repeal and replace Obamacare would hurt those stocks  However  don t forget the witch hunt on Capitol Hill targeting drug companies that were hiking up prices  Under a Clinton regime  those stocks would have come under serious pressure to change their pricing policies  The election of Trump has caused a relief rally in drug stocks and given a shot in the arm to the entire sector 

	Fund flows have been seen coming out of consumer discretionary which is exactly why I m looking at stocks like Foot Locker  NYSE FL  which just reported an earnings beat earlier today  Foot Locker is a Zacks Rank  2  Buy  stock right now  A big reason why is 4 analysts increasing their estimates of how much money they thing Foot Locker is going to make next year  The bullish attitude has pushed up our Zacks Consensus Estimate or the average of all these earnings guesses  up to  5 25 per share 

	Every time you share this video  somebody who didn t vote for Trump dries their tears with  100 bills  Chime in the comments section below  let me know what stocks you re looking to buy as part of the Trump rotation  Subscribe to the YouTube channel  Twitter  and come back here for all the Trending Stocks with Zacks com  I m Dave Bartosiak 

	Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research
	800 767 3771 ext  9339

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ",2016-11-20,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-johnson---johnson,-ascena-retail,-financial-sector,-industrials-and-health-care-200165907",200165907
198905,420421,JNJ,Geron  GERN  Reports Narrower than Expected Loss In Q3,opinion,"Geron Corporation   NASDAQ GERN   reported a loss of 2 cents per share in the third quarter of 2016 narrower than the Zacks Consensus Estimate of a loss of 6 cents  The company had reported earnings of 17 cents in the year ago quarter Quarterly revenues came in at  5 1 million  compared with  35 4 million in the year ago quarter  which included an upfront payment from Johnson   Johnson s   NYSE JNJ   Janssen Biotech related to its collaboration agreement for imetelstat  Revenues  however  surpassed the Zacks Consensus Estimate of  0 2 million Revenues included royalty and license fees under various non imetelstat agreements Research and development  R D  expenses increased 4 9  to  4 3 million  reflecting higher costs for the company s proportionate share of development expenses under the imetelstat collaboration with Janssen Biotech  partially offset by lower personnel related costs due to the Mar 2015 organizational resizing and lower costs of manufacturing imetelstat General and administrative expenses increased 9 3  to  4 7 million  reflecting higher non cash stock based compensation expense  and increased allocation of facilities and other overhead costs to general and administrative activities Pipeline UpdateIn the third quarter  the company announced unfavorable findings from the planned internal reviews of initial data from the two studies   IMbark  phase II  for the treatment of myelofibrosis  and IMerge  phase II III  for the treatment of myelodysplastic syndromes Findings concluded that clinical activity of imetelstat in the 4 7 mg kg dosing arm in the IMbark study did not warrant any further investigation and the study will thus be closed to new patient enrollment  The company  however  is still evaluating imetelstat in the 9 4 mg kg dosing arm On the other hand  an internal review of the part I of the IMerge study on imetelstat showed similar safety and efficacy data as the pilot study conducted on the candidate at the Mayo Clinic Further assessment of data from both the studies is expected by the end of second quarter 2017 Meanwhile  Geron is working on expanding its pipeline and is simultaneously working to add oncology candidates  programs or companies to its portfolio GERON CORP Price  Consensus and EPS Surprise
    We are positive on Geron s agreement with Johnson   Johnson which provides it with a strong partner as well as funds  The company s growth prospects currently depend entirely on the successful development of imetelstat  which is its sole pipeline candidate  Investors are expected to focus on further updates related to imetelstat and business development  going forward Zacks Rank   Key PicksGeron is a Zacks Rank  2  Buy  stock  A couple of other favorably placed ranked stocks in the healthcare sector are Infinity Pharmaceuticals  Inc    NASDAQ INFI   and Exelixis  Inc    NASDAQ EXEL    Both the stocks sport a Zacks Rank  1  Strong Buy   You can see  Infinity s loss estimates narrowed from  3 84 to  3 79 for 2016 but remained unchanged for 2017 over the last 60 days  The company has posted a positive surprise in all of the four trailing quarters with an average beat of 67 62  Exelixis  loss estimates narrowed from 71 cents to 61 cents for 2016 and from 16 cents to earnings of 4 cents for 2017 over the last 60 days  The company has posted a positive surprise twice in the four trailing quarters with an average beat of 9 1  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-03,Zacks Investment Research,https://www.investing.com/analysis/geron-(gern)-reports-narrower-than-expected-loss-in-q3-200162885,200162885
198906,420422,JNJ,Aduro  ADRO  Stock Down On Wider than Expected Q3 Loss,opinion,"Aduro BioTech  Inc    NASDAQ ADRO   reported third quarter 2016 loss of 54 cents per share  wider than the Zacks Consensus Estimate of a loss of 49 cents  The company had reported earnings of a penny in the year ago quarter  Aduro s shares were down almost 8  since the release of its third quarter 2016 results Since Aduro does not have any approved product in its portfolio yet  the company s top line solely comprises collaboration  license and grant revenues Quarterly revenues plunged 80 2  year over year to  3 79 million  The top line deterioration was mainly due to the full recognition of upfront license fee from Johnson   Johnson s   NYSE JNJ   Janssen Biotech  Inc  in 2015  Revenues were also below the Zacks Consensus Estimate of  3 94 million 
We note that Aduro has exclusive research and license agreements with Janssen for the development and commercialization of candidates in the LADD platform  including ADU 741  GVAX for prostate cancer  and ADU 214  Under these agreements  Aduro has granted Janssen exclusive rights to develop and commercialize the LADD candidates for the treatment of prostate and lung cancers 
Research and development expenses escalated 61 2  to  19 million mainly due to licensing fees related to the company s STING technology platform and additional personnel related costs including stock based compensation  partially offset by a decline in contract manufacturing and clinical trial expenses for the pancreatic cancer program 
General and administrative expenses were  8 6 million  up approximately 24  year over year  The increase was primarily due to higher personnel related costs  including stock based compensation  and the expansion of its office and laboratory facilities 
In Oct 2016  Aduro announced that studies evaluating its LADD based agents have been placed on a partial clinical hold and new patient enrollment has been halted  The hold was placed after a blood culture sample taken from an indwelling port of a metastatic pancreatic cancer patient tested positive for Listeria 
Aduro is currently working with the FDA to lift the partial hold so that new patient enrollment in the LADD studies can resume 
We expect investor focus to remain on further updates by the company 
ADURO BIOTECH Price  Consensus and EPS Surprise
    Zacks Rank   Stocks to Consider
Aduro is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the health care sector are Exelixis  Inc    NASDAQ EXEL   and Infinity Pharmaceuticals  Inc    NASDAQ INFI    Both the stocks sport a Zacks Rank  1  Strong Buy   You can see  
Infinity s loss per share estimates narrowed from  3 84 to  3 79 for 2016 but has remained unchanged for 2017 over the last 60 days  The company has posted a positive surprise in all of the four trailing quarters with an average beat of 67 62  
Exelixis  loss per share estimates narrowed from 71 cents to 61 cents for 2016 and from a loss of 16 cents to earnings of 4 cents for 2017 over the last 60 days  The company has posted an average positive surprise of 9 10  over the trailing four quarters  Its share price has surged over 80  year to date 
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-03,Zacks Investment Research,https://www.investing.com/analysis/aduro-(adro)-stock-down-on-wider-than-expected-q3-loss-200162871,200162871
198907,420423,JNJ,The Zacks Analyst Blog Highlights  Johnson   Johnson  Wells Fargo  Facebook And Qualcomm,opinion,"For Immediate Release

	Chicago  IL   November 07  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Johnson   Johnson  NYSE JNJ   NYSE     Wells Fargo  NYSE WFC   NYSE     Facebook  NASDAQ FB   NASDAQ     and Qualcomm  NASDAQ QCOM   NASDAQ      

	Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Friday s Analyst Blog  

Top Research Reports for Monday

	Today s Research Daily features new research reports on 17 major stocks  including Johnson   Johnson  NYSE      Wells Fargo  NYSE      Facebook  NASDAQ     and Qualcomm  NASDAQ      

Johnson   Johnson   shares have bucked the broader healthcare slump this year and are up almost 12  year to date  While the company is faced with a number of headwinds like unfavorable currency movements  increased competition from generics  pricing pressures and an uncertain global macroeconomic backdrop  the analyst believes that JNJ s diversified business model  deep product pipeline  lack of cyclicality and financial strength position it for continued momentum going forward  We saw this in the company s Q3 earnings report when it beat on the top  and bottom lines and provided favorable outlook  The analyst expects these trends to continue in the coming periods as well   You can     

Wells Fargo   has long maintained a reputation for disciplined and reliable operations and an attractive retail banking franchise  Recent quarterly results showing strong growth in loans and deposits reconfirm the bank s inherent strengths  but they have been totally offset lately by the sales practices controversy that has already cost the well regarded CEO his position  The new management team is making all the right moves and further downside risks in the stock may be low at this stage  the stock is already down more than  16  year to date vs  a roughly 2  decline for the peer banks   but it will likely take a while for clouds to fully lifted   You can  

Facebook shares have lagged following the company s quarterly report when it came out with blowout numbers for the September period  but appeared cautious on future growth prospects  These near term challenges notwithstanding  Facebook s status as a Technology powerhouse with an enviable future earnings potential remains unchanged  Driving this is the company s huge user and advertiser base  higher engagement levels along with monetization opportunities presented by the Instagram  Oculus  Messenger and WhatsApp properties   You can  

Qualcomm   shares have surged nearly 34  year to date  Qualcomm  which reported strong fourth quarter fiscal 2016 results  has entered into an agreement to buy Netherlands based chipset giant NXP Semiconductors  The analyst likes this deal since the combined entity is likely to generate annual revenues of over  30 billion position itself as a strong player in the next generation mobile chipset segment  However  regulatory proceedings against Qualcomm are a major headwind   You can  

Free Access  All Zacks Research Reports
	Starting today  you are invited to download in depth analysis reports covering more than 1 000 of the most widely followed stocks  Valued at  25 each  they are yours to consult over the next 30 days absolutely free  They feature sensitive Zacks Rank information on each stock that you won t find anywhere else    

	Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  









	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  

	This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-11-06,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-johnson---johnson,-wells-fargo,-facebook-and-qualcomm-200163138",200163138
198908,420424,JNJ,Merck s Triple Combination HCV Therapy Positive In Phase III,opinion,"Merck   Co   Inc    NYSE MRK   announced positive data from three phase II trials evaluating its pipeline candidate  MK 3682  in combination with grazoprevir and ruzasvir1 for the treatment of chronic hepatitis C  HCV  infection Results from two studies showed that treatment with the all oral  triple combination regimen  MK 3682B  resulted in high rates of sustained virologic response 12 weeks after the completion of the therapy  SVR12  in patients  with chronic HCV genotype  GT  1 or GT3 infection  who received eight weeks of treatment with combination medicine  Findings from these studies also demonstrated high rates of SVR12 in GT1  GT2 and GT3 infected patients  who received the combination therapy for 12 or 16 weeks Merck s key HCV drug in the market is Zepatier which was launched in the U S  in February  Zepatier  brought in sales of  164 million  up from  112 million in the second quarter of 2016  Zepatier is expected to be launched in the fourth quarter in Japan where it was recently approved  It is expected to be a key top line driver for Merck MERCK   CO INC Price and Consensus
    The HCV market is getting crowded and could thus see more pricing pressure   Gilead Sciences Inc    NASDAQ GILD   markets blockbuster HCV drugs  Sovaldi and Harvoni  while other well known names in this market are AbbVie Inc  s   NYSE ABBV   Viekira Pak  Bristol Myers  Daklinza and Johnson   Johnson s   NYSE JNJ   Olysio  Moreover  other companies are also looking to bring new  improved  shorter duration HCV treatments to market Merck currently carries a Zacks Rank  2  Buy   You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-13,Zacks Investment Research,https://www.investing.com/analysis/merck's-triple-combination-hcv-therapy-positive-in-phase-iii-200164465,200164465
198917,420433,JNJ,Geron  GERN  Q3 Earnings  Will The Store Pull A Surprise ,opinion,"Geron Corporation   NASDAQ GERN   is scheduled to report third quarter 2016 results on Nov 3 after the market closes In the last reported quarter  the company recorded a positive surprise of 28 57   Let s see how things are shaping up for the upcoming announcement Imetelstat Remains in FocusWith no approved product in its portfolio  Geron s top line solely comprises license fees and royalties  In such a scenario  investor focus will remain on the company s pipeline  Geron currently has one candidate in its pipeline  imetelstat  which is being developed in collaboration with Johnson   Johnson s   NYSE JNJ   Janssen Biotech The company s shares took a hit this September when the company announced unfavorable findings from planned internal reviews of initial data from the two studies   IMbark  phase II  for the treatment of myelofibrosis  and IMerge  phase II III  for the treatment of myelodysplastic syndromes Findings concluded that clinical activity of imetelstat in the 4 7 mg kg dosing arm in the IMbark study did not warrant any further investigation and it will be closed to new patient enrollment  The company  however  is still evaluating imetelstat in the 9 4 mg kg dosing arm  which was on hold  In the upcoming conference call  we expect the company to shed more light on the candidate In addition to updates on imetelstat  investors will also be interested to know if Geron has made any progress in expanding its pipeline  The company is seeking to add new oncology candidates  programs or companies to its portfolio with focus on the hematology oncology space Like all development stage companies  Geron too will to see a rise in research and development expenses Surprise HistoryGeron s performance over the last four quarters has been mixed  with the company surpassing expectations twice and meeting the same twice  The average positive surprise over the last four quarters is 20 78  GERON CORP Price and EPS Surprise
    What Our Model IndicatesOur proven model does not conclusively show that Geron is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat estimates  But that is not the case here  as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate Estimate and the current Zacks Consensus Estimate stand at a loss of 6 cents  Please check our  that enables you find stocks that are expected to come out with earnings surprises Zacks Rank  Although Geron s Zacks Rank  1 increases the predictive power of ESP  its 0 00  ESP makes surprise prediction difficult this quarter Note that we caution against stocks with Zacks Ranks  4 or  5  Sell rated stocks  going into an earnings announcement  especially when the company is seeing a negative estimate revision momentum Stocks to ConsiderHere are some health care stocks that you may want to consider  as our model shows that they too have the right combination of elements to post an earnings beat this quarter Infinity Pharmaceuticals  Inc    NASDAQ INFI   is scheduled to release third quarter results on Nov 3 after market closes  The company has an Earnings ESP of is  5 81  and it sports a Zacks Rank  1  You can see  The Earnings ESP for Zoetis Inc    NYSE ZTS   is  2 17  and it carries a Zacks Rank  3  The company is slated to release third quarter results on Nov 2 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-01,Zacks Investment Research,https://www.investing.com/analysis/geron-(gern)-q3-earnings:-will-the-store-pull-a-surprise-200161926,200161926
198927,420443,JNJ,3 Amazing Earnings Charts ,opinion,"Earnings season is now in full swing 
This week s best earnings charts include companies who have perfect earnings surprise track records  
Despite what you might think  it s not easy for companies to beat every quarter for years on end  Only a couple dozen companies are able to do it  
Here are three doing it this week 
1  Johnson   Johnson  NYSE JNJ  has a solid track record  It might not have big earnings beats but it s consistent  
2  Unitedhealth Group  UNH  has one of the best earnings surprise charts on Wall Street  Shares have tripled over the last few years 
3  Omnicom  OMC  is a hidden gem  This marketing and advertising giant has quietly gone about its own business  beating the Zacks Consensus Estimate every quarter for the last 5 years  Impressive  
All three of these companies should be on your short list if you re trading the earnings report 
What else should you know about these earnings charts  Tune into the short video to find out 
Want to Know More about Johnson   Johnson s Upcoming Earnings  
Eric Dutram gives you the low down in this two minute video ",2016-10-17,Zacks Investment Research,https://www.investing.com/analysis/3-amazing-earnings-charts-200159230,200159230
198928,420444,JNJ,J J Beats On Q3 Earnings  Should You Buy Healthcare ETFs ,opinion,The Q3 earnings season has kicked in and Johnson   Johnson   NYSE JNJ   is the first drug company to have reported earnings on October 18 before the opening bell  The world s biggest maker of health care products continued its long streak of earnings beat and topped our revenue estimate on strong prescription drug sales  The company also raised its full year earnings outlook  reflecting confidence in its future growth Q3 Results in DetailEarnings per share came in at  1 68  three cents ahead of the Zacks Consensus Estimate and 12 8  higher than the year ago quarter  Revenues grew 4 2  year over year to  17 82 billion and edged past the Zacks Consensus Estimate of  17 72 billion  Better than expected results came from healthy sales of new drugs like Darzalex  Imbruvica and Xarelto and the strength of established drugs such as Stelara  Remicade  Simponi and Invega Sustenna  read    For fiscal 2016  Johnson   Johnson lifted its earnings per share guidance to  6 68  6 73 from  6 63  6 73 while kept its revenue forecast stable at  71 5  72 2 billion  The Zacks Consensus Estimate is currently pegged at  6 69 for earnings per share and  72 1 billion for revenues  These are far above the mid point of the company s current projection Going forward  management is confident of filing 10 new pharmaceutical products between 2015 and 2019  each with a revenue potential over  1 billion given a number of regulatory approvals  several new drug application submissions  and new breakthrough therapy designations from the FDA Market ImpactFollowing the results  shares of JNJ initially rose 0 9  in the pre market session but pulled back thereafter by 1   Currently  the stock has a Zacks Rank  3  Hold  with a VGM Score of C  However  Johnson   Johnson belongs to a lackluster industry with a Zacks Rank in the bottom 22   suggesting that rough trading might be in store As a result  investors should closely watch the movement of the stock and keep a close eye on ETFs having double digit allocation to this diversified drug maker  Below  we have listed four funds that have a top Zacks ETF Rank of 1  Strong Buy  or 2  Buy  with a Medium risk outlook  see    Health Care Select Sector SPDR Fund The most popular healthcare ETF  XLV follows the Health Care Select Sector Index  This fund manages nearly  12 billion in its asset base and trades in heavy volume of around 9 2 million shares  Expense ratio comes in at 0 14  annually  In total  the fund holds 61 securities in its basket with JNJ taking the top spot at 12 2  of the assets  Pharma accounts for 37 9  share from a sector look while biotech  healthcare equipment and supplies  and healthcare providers and services make up for a double digit exposure each  The fund has a Zacks ETF Rank of 1 iShares U S  Healthcare ETF This fund provides exposure to 119 securities by tracking the Dow Jones U S  Health Care Index  Here again  Johnson   Johnson dominates the fund s return at 11 5  of total assets  In terms of industrial exposure  pharma takes the top spot at 36 9   followed by biotech  22 2    and healthcare equipment  19 1    The product has amassed nearly  1 8 billion in its asset base while charges 44 bps in annual fees  It trades in a solid volume of more than 113 000 shares a day and has a Zacks ETF Rank of 1  read    Vanguard Health Care ETF This ETF tracks the MSCI US Investable Market Health Care 25 50 Index and holds 348 stocks in its basket  Out of these  Johnson   Johnson takes the top spot with 10 1  allocation  Pharma takes the largest share at 33 3  while biotech and healthcare equipment round off the top three spots  VHT is also one of the popular and liquid ETFs with AUM of  5 4 billion and average daily volume of about 177 000 shares  It charges 9 bps in annual fees and expenses and has a Zacks ETF Rank of 1 Fidelity MSCI Health Care Index ETF This fund provides exposure to 348 healthcare stocks with AUM of  488 8 million  This is done by tracking the MSCI USA IMI  LON IMI  Health Care Index  Here too  JNJ is the top firm with nearly 10 5  allocation  Pharma accounts for 33 7  share while biotech  healthcare equipment and supplies  and healthcare providers and services round off the top three spots with a double digit exposure each  The ETF has 0 08  in expense ratio while volume is good at 110 000 shares a day  FHLC has a Zacks ETF Rank of 2  read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2016-10-17,Zacks Investment Research,https://www.investing.com/analysis/j-j-beats-on-q3-earnings:-should-you-buy-healthcare-etfs-200159371,200159371
198940,420456,JNJ,The Zacks Analyst Blog Highlights  GW Pharmaceuticals  Shire  Johnson   Johnson And Supernus Pharmaceuticals,opinion,"For Immediate Release

Chicago  IL   October 10  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include GW Pharmaceuticals plc  NASDAQ     Shire plc  NASDAQ      Johnson   Johnson  NYSE JNJ   NYSE    and Supernus Pharmaceuticals  Inc   NASDAQ     

Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Friday s Analyst Blog  

5 Stocks for World Mental Health Day

World Mental Health Day is observed every year on Oct 10    this year  the theme is  psychological first aid   which covers both psychological and social support  According to information provided by the National Alliance on Mental Illness  about one in five adults in the U S  or 43 8 million people experience mental illness in a given year and approximately 1 in 25 adults in the U S  or 10 million people experience a serious mental illness in a given year that substantially interferes with or limits one or more major life activities 

Given these statistics  it is not surprising that several pharma and biotech companies are involved in developing and selling drugs that target mental health disorders which include a wide range of conditions like attention deficit hyperactivity disorder  ADHD   anxiety disorders  bipolar disorder  depression  eating disorders and schizophrenia among others 
	The market potential for drugs targeting mental health disorders is huge  In fact  due to the social stigma and ignorance associated with such conditions  a large part of the market remains untapped as people don t seek treatment or are unaware of their symptoms 

5 Stocks to Consider
	Ahead of World Mental Health Day  let us look at some of the companies which are actively pursuing the development of treatments for various types of mental illnesses 
	To guide investors to the right picks  we highlight 5 stocks that carry a favorable Zacks Rank   Zacks Rank  1  Strong Buy  or  2  Buy  or  3  Hold   You can see   
	The Zacks Rank is a reliable tool that helps you to trade with confidence regardless of your trading style and risk tolerance  To learn more about how you can use this proven system for market beating gains  visit  
	First on our list is Zacks Rank  1 stock GW Pharmaceuticals plc  NASDAQ      which is working on the development of plant derived cannabinoid therapeutics  The company s proprietary cannabinoid product platform targets a broad range of disease areas including schizophrenia which affects about 1 1  of the adult population in the U S   as per the National Institute of Mental Health  While GW Pharma has been more in the news for its progress with the development of Epidiolex  childhood onset epilepsy   the company has an experimental schizophrenia treatment in its pipeline   GWP42003  GW Pharma has completed a mid stage study on the candidate which demonstrated positive proof of concept  The candidate showed notable anti psychotic effects as well as demonstrated the ability to reduce the characteristic movement disorders induced by currently available anti psychotic agents  Shares of this UK based stock  which has been witnessing positive estimate revisions  are up 94 4  year to date  YTD  

Shire plc   NASDAQ      is well known for its ADHD offerings including Vyvanse  Adderall XR and Intuniv even though some of these products are facing generic competition  The company s neuroscience division delivered sales of  2 5 billion in 2015 and continues to perform well driven by its strong presence in the ADHD market  Shire is working on developing new treatment options for the growing adult ADHD market  The company expects to re submit its regulatory filing for SHP465 in the U S  and is hoping to gain approval in the second quarter of 2017 followed by product launch in the second half of 2017  The company believes that SHP465 has the potential to address a segment of the adult ADHD market that still has unmet needs for non residual control  Shire s share of the U S  ADHD prescription market in Dec 2015 was 16 7   compared to 16 2  in Dec 2014  
	Shire also has a presence in the binge eating disorder  BED  market with Vyvanse being approved for the treatment of moderate to severe BED in adults  According to information provided by Shire  BED is the most common eating disorder in the U S   affecting about 2 8 million adults  Shire  a Zacks Rank  3 stock  has a strong earnings track record with the company beating expectations in each of the last four quarters with an average surprise of 8 41  

Healthcare giant  Johnson   Johnson  NYSE      also has a strong presence in the neuroscience segment  which is one of its core therapeutic areas  In addition to Concerta for ADHD  the company has products like Risperdal Consta  schizophrenia and bipolar I disorder  and Invega Sustenna Trinza  schizophrenia  in its portfolio 
	Meanwhile  one of the most promising candidates in J J s pipeline is esketamine  an investigational antidepressant medication with blockbuster potential  Esketamine recently got breakthrough therapy designation from the FDA for major depressive disorder with imminent risk for suicide  According to the National Institute of Mental Health  in 2015 about 16 1 million adults in the U S  had at least one major depressive episode in the past year  FDA approval would make esketamine one of the first new approaches to treat major depressive disorder in the last 50 years  Esketamine has breakthrough therapy designation for treatment resistant depression as well 
	J J  a Zacks Rank  3 stock  has a good earnings track record having surpassed expectations in each of the last four quarters  The company s shares are up 18 2  YTD 

Specialty pharma company  Supernus Pharmaceuticals  Inc   NASDAQ       is developing several candidates in psychiatry to address large unmet medical needs and market opportunities  SPN 810 is currently in a couple of late stage studies for impulsive aggression in ADHD patients in the 6 12 years age group  If all goes well  the company expects to launch the product in 2019  SPN 810 has the potential to be developed for other indications like autism and bipolar disorder 
	Supernus has another experimental ADHD treatment in its portfolio  SPN 812  for the 6 12 years age group  Data from an ongoing phase IIb study are expected by early 2017  According to research and consulting firm GlobalData  the ADHD market across the U S   France  Germany  Italy  Spain  the UK  and Japan  is set to grow at a CAGR of 8 5  from approximately  6 1 billion in 2014 to  13 9 billion by 2024  Growth will be driven by the launch of new products with convenient oral formulations or less frequent dosing  growing awareness and higher treatment rates 
	Supernus  a Zacks Rank  2 stock has an impressive earnings track record with an average surprise of 117 95  over the last four quarters 

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   









Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact
	Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-10-09,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-gw-pharmaceuticals,-shire,-johnson---johnson-and-supernus-pharmaceuticals-200157985",200157985
198941,420457,JNJ,Merck s New Products And Solid Pipeline As Growth Drivers,opinion,"We issued an updated research report on Merck   Co   Inc    NYSE MRK   on Oct 7 The leading pharmaceutical company has made significant progress with its pipeline and is working on bringing new products to market  Merck has more than 10 candidates in phase III development  The company has prioritized its pipeline so that candidates with the highest potential get the required support  Some of its important pipeline candidates include MK 0859  anacetrapib   cholesterol management   verubecestat  Alzheimer s disease   Zinplava  bezlotoxumab  and MK 8835  ertugliflozin  type II diabetes  Meanwhile  Merck s new products are performing well  Products that should contribute significantly to revenues include cancer drug Keytruda  fertility drug Elonva  Simponi  treatment of certain inflammatory diseases   Dulera  asthma   and Daxas  chronic obstructive pulmonary disease   Keytruda is the first anti PD 1 therapy to gain FDA approval and is being studied for more than 30 types of cancer  Keytruda sales should receive a boost with approval for additional indications especially in the first line lung cancer setting  Failure of Bristol Myers Squibb Company s   Opdivo in the first line lung cancer setting should give an advantage to Keytruda  if and when it is approved in this indication MERCK   CO INC Price
    Merck has also been pursuing acquisitions and business development deals to boost its pipeline  Other than that  Merck is aiming to increase its presence in emerging markets  To fulfill its objective  the company plans to launch new products  successfully market its current portfolio of drugs and vaccines  and leverage the market for branded generics It is also looking at biosimilars to drive long term growth  The biosimilar market represents huge commercial opportunity with more than  60 billion of biologic sales slated to lose patent protection through 2017  Merck has an agreement with Samsung  KS 005930  Bioepis Co   Ltd  for the development and commercialization of several pre specified and undisclosed biosimilar candidates  The companies are seeking U S  and EU approval for their insulin glargine biosimilar  MK 1293   while the Remicade biosimilar  SB2  is currently under FDA review Merck will also undertake cost cutting initiatives to drive the bottom line  The company has a global restructuring program in place aimed at trimming the cost structure and increasing efficiency  Merck intends to reduce the number of manufacturing sites  including animal health sites  and consolidate other facilities  The company expects annual savings of about  4 0 billion to  4 6 billion once the restructuring program is completed However  the top line will remain under pressure mainly due to increased competition and generic threats  Merck is facing generic threat for several drugs including Singulair  Maxalt  Propecia  Temodar  Cozaar Hyzaar  Zocor and Fosamax  All these drugs have recorded rapid and steep declines in revenues due to generic entry  Earlier than expected entry of Nasonex generics will impact 2016 sales In addition to generic threats  its HIV drug Isentress  a key growth driver  is facing competitive pressure  hurt by sluggish growth of the integrase class  Isentress faces competition from Gilead Sciences Inc  s   NASDAQ GILD   once daily combination pill  Stribild Meanwhile  biosimilar competition for its rheumatoid arthritis drug Remicade in the EU has intensified  leading to pricing pressure  and sales are expected to continue declining rapidly in the coming quarters  Merck s partner for Remicade is Johnson   Johnson   NYSE JNJ   which is solely responsible for marketing Remicade in markets such as Canada  Central and South America  the Middle East  Africa and Asia Pacific Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-10,Zacks Investment Research,https://www.investing.com/analysis/merck's-new-products-and-solid-pipeline-as-growth-drivers-200158224,200158224
198942,420458,JNJ,Time To Buy More Johnson   Johnson Stock,opinion,"There are plenty of investors that are afraid right now  Whether they fear the impact of the election or a Fed move on interest rates or something else it has led to a lot of money sitting on the sidelines  As a market technician this bearish sentiment with prices at all time highs is a very bullish signal  Yes I said BULLISH 
So with all that dry powder lying around what should investors do  Well one could buy more powder  like Johnson s Baby powder  Or better yet  buy Johnson   Johnson  NYSE JNJ   stock  The chart is compelling for this 
After a long shallow pullback from June 2014 until October 2015  Johnson   Johnson started to move higher  Not a sharp steep move up but a slow steady run higher  That lasted until July this year when it started to digest its move up  Now it looks like the digestion is done and it is ready for the next leg higher 
The chart above shows weekly movement to the upside  It also shows the RSI reversing back higher  That is a bullish sign  And the stock has gone from selling to accumulation again  How far will it go  One view would be to place an AB CD pattern on the chart which gives a target to about 148 over the next 6 months  A move over 125 would give strong confirmation  Keep a tight stop or small size until then 
DISCLAIMER  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer ",2016-10-11,Gregory W. Harmon,https://www.investing.com/analysis/put-some-dry-powder-to-work-in-johnson---johnson-200158070,200158070
198943,420459,JNJ,Celgene To Present Phase Ib Data On Crohn s Disease Drug,opinion,Celgene Corporation s   NASDAQ CELG   wholly owned subsidiary  Celgene International S rl  announced encouraging data from a phase Ib study on its pipeline candidate  GED 0301  mongersen   Data will be presented at the United European Gastroenterology Week The randomized  double blind  multi center  exploratory study evaluated the effects of oral GED 0301 on both endoscopic response and clinical remission in patients with active Crohn s disease  Patients in the study were given one of the three active treatment regimens in a 12 week treatment phase   GED 0301 160 mg once daily for 12 weeks  GED 0301 160 mg once daily for eight weeks followed by four weeks of placebo  or GED 0301 160 mg once daily for four weeks followed by eight weeks of placebo Data showed that clinical improvement was observed as early as week 2  while the clinical response and remission rates were the highest in the 12 week treatment group at 67  and 48   respectively  at week 12  Endoscopic improvement was seen across all treatment groups at 12 weeks  On the safety front  rates of adverse events and serious adverse events were found to be low and similar across the treatment groups  There were no new safety signals for oral GED 0301 160 mg daily reported in the study Meanwhile  the study is ongoing until all patients complete the observation phase  Data from the observation portion of the study are anticipated in 2017  The phase III program on the candidate is currently underway CELGENE CORP Price    The latest study results are encouraging  Considering that a significant number of Crohn s disease patients do not witness remission with current therapies or suffer relapses over time  a regulatory approval for GED 0301 is expected to provide patients with a new treatment option Per Celgene s press release  Crohn s disease  an immune mediated  chronic inflammatory condition of the gastrointestinal tract  is estimated to affect three out of every 1 000 people in Europe and North America Currently approved treatments for Crohn s disease include AbbVie Inc  s   NYSE ABBV   Humira and Johnson   Johnson s   NYSE JNJ   Remicade among others Zacks Rank   a Stock to ConsiderCelgene currently carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Incyte Corporation   NASDAQ INCY    sporting a Zacks Rank  1  Strong Buy   You can see  Incyte s earnings estimates for 2016 and 2017 were up a respective 22 2  and 6 6  over the last 60 days  The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335 16  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-10-16,Zacks Investment Research,https://www.investing.com/analysis/celgene-to-present-phase-ib-data-on-crohn's-disease-drug-200159174,200159174
198952,420468,JNJ,Johnson   Johnson On Track Ror Rally,opinion,"Johnson   Johnson  NYSE JNJ  started a downward trend just as the month of August started  This significant stock price movement pushed shares lower over the past 6 weeks  The multinational company started to regain its strength earlier in the month of September after retracing almost all of the gains in the aftermath of Britain s exit from the European Union 
After the last two days of positive price movement  the decline may have finally come to an end  placing Johnson   Johnson on track for a new bullish trend 
During the Brexit selling wave  the JNJ stock incurred very little damage  In fact  on the 27th of June when the Dow Jones Industrial Average ended the session with a loss of 260 points  the company s stock closed in 0 8 percent higher  In the following day  the JNJ stock hit fresh 2016 highs as a buying wave which spanned 4 days resulted in an exceptional breakout  The shares of the multinational firm moved steadily to the upside until the middle of July as the  126 level was hit 
Johnson   Johnson stalled at this area and after hovering just below this strong resistance for 2 and a half weeks  a significant decline started  Now that this phase seems to have ended  market players will be rewarded with very low risk entry opportunity 
The narrow basing action which took place over the previous two weeks has confirmed the  117 level as a strong support level  This region includes the June 28 breakout and the low for September 
In the near term  bulls should regard JNJ stock as a low risk buy between the  117 and  119 levels  We believe that a close below the  116 mark would signal that more basing will be required before the decline from the July high has run its course 
The  121 region will offer a significant hurdle  but once this area is completely broken out  the JNJ stock should have sufficient momentum to surpass its 50 day moving average ",2016-09-26,TradingBanks,https://www.investing.com/analysis/johnson---johnson-on-track-ror-rally-200155575,200155575
198963,420479,JNJ,Sanofi  SNY  Presents Positive Diabetes Data On IGlarLixi  revised ,opinion,"Sanofi   NYSE SNY   announced positive results of a new post hoc analysis of data from a phase III trial that evaluated its investigational candidate  iGlarLixi  a titratable fixed ratio combination of insulin glargine and lixisenatide iGlarLixi was tested for mealtime blood sugar  post prandial glucose  PPG   control in adults with type 2 diabetes in the LixiLan L Trial  The post hoc analysis of the trial data showed that iGlarLixi led to greater PPG control compared to insulin glargine 100 Units mL The analysis showed that a significantly higher proportion of participants attained the PPG target after 30 weeks  The percentage of patients achieving the PPG target at week 30 was 16 4  higher in the fixed ratio combination group than the insulin glargine 100 Units mL arm at 0 5 hour  At one hour and two hours  the proportions of patients achieving the PPG target in the fixed ratio combination group were 22 4  and 28 2  higher  respectively  compared to the insulin glargine 100 Units mL arm This data was presented at the European Association for the Study of Diabetes   EASD  52nd Annual Meeting in Munich  Germany Presently  iGlarLixi is under review in the U S  and Europe  Sanofi also presented new patient level meta analysis data from the EDITION phase III trials in type 2 diabetes at the EASD  Results showed that patients treated with its diabetes drug  Toujeo  demonstrated a consistently lower rate of hypoglycemia compared to its other diabetes drug Lantus R  at all levels of hba1c  average blood glucose over the previous three months  control Zacks Rank   Key PicksSanofi currently carries a Zacks Rank  4  Sell   Some better ranked stocks in health care sector include ANI Pharmaceuticals  Inc    NASDAQ ANIP    Cambrex Corp    NYSE CBM   and Johnson   Johnson   NYSE JNJ    While both ANI Pharma and Cambrex  sport a Zacks Rank  1  Strong Buy   Johnson   Johnson carries a Zacks Rank  2  Buy  
 We are reissuing this article to correct a mistake  The original article  issued yesterday  September 14  2016  should no longer be relied upon  ",2016-09-15,Zacks Investment Research,https://www.investing.com/analysis/sanofi-(sny)-presents-positive-diabetes-data-on-iglarlixi-(revised)-200153830,200153830
198964,420480,JNJ,Merck Pfizer Diabetes Drug Ertugliflozin Positive In Phase III,opinion,"Merck   Co   Inc    NYSE MRK    in partnership with Pfizer Inc    NYSE PFE    announced that their diabetes pipeline candidate  ertugliflozin  MK 8835   has met the primary endpoint in a phase III study  The double blind  randomized  placebo controlled study  VERTIS SITA2  showed that ertugliflozin  both 5 mg and 15 mg daily doses   when added to sitagliptin and metformin  led to A1C reduction in patients with type 2 diabetes  While the 5 mg dose reduced A1C by 0 69   the 15 mg dose led to a 0 76  decline in A1C  Ertugliflozin is an investigational oral sodium glucose cotransporter  SGLT2  inhibitor  The drug met the key secondary end points of the trial as well  Overall adverse event  AE  rates were also low in both the dosage arms of ertugliflozin compared to placebo  These results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes  EASD  in Munich  Germany  Pfizer and Merck plan to submit an NDA in the U S  for ertugliflozin and the two fixed dose combination tablets  ertugliflozin Januvia and ertugliflozin metformin  by 2016 end  Merck has several late stage candidates in its pipeline targeting multiple disease areas such as atherosclerosis  cancer  diabetes and cardiovascular diseases  The company has more than 10 candidates in phase III development  Some of the important candidates include MK 0859  anacetrapib   cholesterol management   phase III   verubecestat  Alzheimer s disease   phase III  and Zinplava  bezlotoxumab  MERCK   CO INC Price
     Zacks Rank   Key PicksBoth Merck and Pfizer currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in health care sector are ANI Pharmaceuticals   NASDAQ ANIP   and Johnson   Johnson   NYSE JNJ    While ANI Pharmaceuticals sports a Zacks Rank  1  Strong Buy   Johnson   Johnson carries a Zacks Rank  2  Buy   You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-15,Zacks Investment Research,https://www.investing.com/analysis/merck-pfizer-diabetes-drug-ertugliflozin-positive-in-phase-iii-200153994,200153994
198965,420481,JNJ,AstraZeneca Diabetes Drug Combination Positive In Phase III,opinion,"AstraZeneca plc   NYSE AZN   announced positive results from a phase III combination trial evaluating the combination of its diabetes drugs Bydureon  exenatide extended release  and Farxiga  dapagliflozin  for the treatment of patients with type II diabetes Anti diabetes medicine Bydureon is a GLP 1 receptor agonist  whereas Farxiga is an SGLT 2 inhibitor The study achieved the primary endpoint  showing significant blood sugar reduction from baseline  as measured by HbA1c  in patients with type II diabetes  when treated with the combination of once weekly exenatide and dapagliflozin  compared with the drugs alone in patients  who are inadequately controlled on metformin Duration 8 is a phase III  randomized  multi center  double blind  active controlled trial  It was conducted over a 28 week treatment period  with an extension of two years  and enrolled approximately 700 patients from six countries  Eligible participants in the trial included adults with type II diabetes  who had uncontrolled HbA1c  The trial achieved the secondary endpoints as well  leading to a significant reduction in bodyweight and systolic blood pressure for the combination drug The combination of exenatide and dapagliflozin demonstrated similar rates of adverse events and serious events as the individual medicine treatment groups The results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes in Munich  Germany  and were also published in The Lancet Diabetes   Endocrinology AstraZeneca has been making significant progress with its pipeline  Promising pipeline candidates at the company include brodalumab  moderate to severe psoriasis   benralizumab  asthma and chronic obstructive pulmonary disease   tralokinumab  asthma   anifrolumab  systemic lupus erythematosus   roxadustat  anemia in patients with chronic kidney disease  and AZD3293  Alzheimer s disease  phase III  ASTRAZENECA PLC Price
    Zacks Rank   Key PicksAstraZeneca currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include ANI Pharmaceuticals  Inc    NASDAQ ANIP    Cambrex Corporation   NYSE CBM   and Johnson   Johnson   NYSE JNJ    While both ANI Pharmaceuticals and Cambrex Corporation sport a Zacks Rank  1  Strong Buy   Johnson   Johnson carries a Zacks Rank  2  Buy   You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-18,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-diabetes-drug-combination-positive-in-phase-iii-200154243,200154243
198966,420482,JNJ,Pfizer  PFE  Breast Cancer Drug Ibrance Wins CHMP Backing ,opinion,"Pfizer Inc    NYSE PFE   came up with a couple of announcements related to its breast cancer drug  Ibrance and PF 06438179  a biosimilar version of Johnson   Johnson s   NYSE JNJ   blockbuster drug  Remicade  infliximab  
Ibrance a Step Closer to EU Approval
Pfizer announced that the European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  has rendered a positive opinion in favor of the approval of the company s marketing authorization for Ibrance  Ibrance is under review in the EU for the treatment of women with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   locally advanced or metastatic breast cancer  The CHMP has indicated that Ibrance is to be used in combination with an aromatase inhibitor as well as in combination with Faslodex  fulvestrant  in women who have received prior endocrine therapy 
The favorable opinion of the CHMP will now be reviewed by the European Commission  EC   With the CHMP in favor of approving Ibrance  we believe chances of gaining EU approval are high  A decision should be out by year end 
Approval would make Ibrance the first CDK 4 6 inhibitor to be approved by the EC 
We note that Ibrance is already approved in the U S  for the treatment of HR  HER2  advanced or metastatic breast cancer in combination with Novartis AG s   NYSE NVS   Femara  letrozole  as initial endocrine based therapy in postmenopausal women or Faslodex in women with disease progression following endocrine therapy  The indication in combination with Femara was cleared in the U S  under accelerated approval 
Ibrance has received broad patient and physician acceptance with an encouraging feedback  and the company plans to continue to build momentum in the U S  by penetrating all lines of therapy  The drug has recorded sales of  942 million in the first half of 2016 since its launch in Feb 2015 
Approval in the EU would boost the commercial potential of the drug significantly  Meanwhile  Pfizer is also working on expanding Ibrance s label by targeting different segments of breast cancer patients 
Biosimilar Remicade Hits Phase III Primary Endpoint
Pfizer announced positive top line data from a phase III confirmatory study   REFLECTIONS B537 02 on PF 06438179  infliximab Pfizer   The multi national  randomized  double blind  two arm  parallel group phase III study evaluated the efficacy  safety  and immunogenicity of PF 06438179  against Remicade in combination with methotrexate when administered intravenously for the treatment of patients with moderate to severely active rheumatoid arthritis  RA  who have had an inadequate response to methotrexate therapy 
The study hit the primary endpoint and showed that PF 06438179 demonstrated similar efficacy to Remicade as measured by the American College of Rheumatology 20 response at Week 14 of study treatment 
PF 06438179 is presently in development for all currently approved indications of Remicade  We note that Pfizer had divested in Feb 2016 the rights to the development  commercialization and manufacture of PF 06438179 in the European Economic Area  EEA  to Novartis  generic arm  Sandoz  Pfizer  on the other hand  retains the commercialization and manufacturing rights to PF 06438179 in all countries outside the EEA 
We remind investors that Celltrion Inc  s biosimilar version of Remicade  Inflectra  infliximab dyyb   had gained FDA approval earlier this year in April  Pfizer has exclusive commercialization rights to Inflectra in the U S  and certain other territories 
PFIZER INC Price   Pfizer carries a Zacks Rank  3  Hold   Geron Corporation   NASDAQ GERN   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy   You can see  
Confidential from Zacks 
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-20,Zacks Investment Research,https://www.investing.com/analysis/pfizer-(pfe)-breast-cancer-drug-ibrance-wins-chmp-backing-200154449,200154449
198972,420488,JNJ,Sanofi  SNY  Presents Positive Diabetes Data On IGlarLixi,opinion,"Sanofi  PA SASY    NYSE SNY   announced positive results of a new post hoc analysis of data from a phase III trial that evaluated its investigational candidate  iGlarLixi  a titratable fixed ratio combination of insulin glargine and lixisenatide iGlarLixi was tested for mealtime blood sugar  post prandial glucose  PPG   control in adults with type 2 diabetes in the LixiLan L Trial  The post hoc analysis of the trial data showed that iGlarLixi led to greater PPG control compared to insulin glargine 100 Units mL The analysis showed that a significantly higher proportion of participants attained the PPG target after 30 weeks  The percentage of patients achieving the PPG target at week 30 was 16 4  higher in the fixed ratio combination group than the insulin glargine 100 Units mL arm at 0 5 hour  At one hour and two hours  the proportions of patients achieving the PPG target in the fixed ratio combination group were 22 4  and 28 2  higher  respectively  compared to the insulin glargine 100 Units mL arm This data was presented at the European Association for the Study of Diabetes   EASD  52nd Annual Meeting in Munich  Germany Presently  iGlarLixi is under review in the U S  and Europe  Sanofi also presented new patient level meta analysis data from the EDITION phase III trials in type 2 diabetes at the EASD  Results showed that patients treated with its diabetes drug  Toujeo  demonstrated a consistently lower rate of hypoglycemia compared to its other diabetes drug Lntus R  at all levels of hba1c  average blood glucose over the previous three months  control SANOFI AVENTIS Price
    Zacks Rank   Key PicksSanofi currently carries a Zacks Rank  4  Sell   Some better ranked stocks in health care sector include ANI Pharmaceuticals  Inc    NASDAQ ANIP    Cambrex Corporation   NYSE CBM   and Johnson   Johnson   NYSE JNJ    While both ANI Pharmaceuticals and Cambrex Corporation sport a Zacks Rank  1  Strong Buy   Johnson   Johnson carries a Zacks Rank  2  Buy   You can see Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-13,Zacks Investment Research,https://www.investing.com/analysis/sanofi-(sny)-presents-positive-diabetes-data-on-iglarlixi-200153529,200153529
198973,420489,JNJ,Novo Nordisk  NVO  Presents Data On Obesity Drug Saxenda,opinion,"Novo Nordisk  CO NOVOb  A S   NYSE NVO   announced data from a post hoc analysis of the three year part of the phase IIIa SCALE  Satiety and Clinical Adiposity   Liraglutide Evidence  Obesity and Prediabetes study on Saxenda  liraglutide 3 mg  glucagon like peptide 1 receptor agonist   Data were presented at the annual meeting of the European Association for the Study of Diabetes  Data showed that people treated with Saxenda experienced consistent weight loss and improvement in blood glucose control across body mass index  BMI  categories over a period of three years in comparison to placebo  On the safety front  Saxenda was found to be well tolerated  with side effects in line with the previous studies  Novo Nordisk s phase III development program  SCALE  comprises four placebo controlled multinational studies   SCALE Obesity and Prediabetes  SCALE Diabetes  SCALE Sleep Apnea  and SCALE Maintenance  All these studies involve a reduced calorie diet and increased physical activity  While key results of all the studies in the SCALE program have been published  additional data will be presented and published through the rest of 2016 We note that Saxenda is approved in both the U S  and the EU for weight management  The drug has been off to an encouraging start following its launch in 2015  While promotional activities are progressing as planned  feedback from patients and prescribers have been encouraging too  The drug is expected to contribute meaningfully to the company s top line  going forward NOVO NORDISK AS Price
    Zacks Rank   Key PicksNovo Nordisk currently carries a Zacks Rank  3  Hold   Some better ranked stocks in health care sector include ANI Pharmaceuticals  Inc    NASDAQ ANIP    Cambrex Corporation   NYSE CBM   and Johnson   Johnson   NYSE JNJ    While both ANI Pharmaceuticals and Cambrex Corporation sport a Zacks Rank  1  Strong Buy   Johnson   Johnson carries a Zacks Rank  2  Buy   You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-14,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisk-(nvo)-presents-data-on-obesity-drug-saxenda-200153713,200153713
198974,420490,JNJ,FDA Panel Suggests Removing Warning From Pfizer s Chantix,opinion,"Pfizer  Inc    NYSE PFE   announced that the FDA advisory panels have recommended removing a serious warning about neuropsychiatric side effects on the label of its smoking cessation therapy Chantix We remind investors that Chantix s label includes a boxed warning regarding serious neuropsychiatric adverse events  reported in some patients attempting to quit smoking while taking the drug in the post marketing experience The recommendation given at a joint meeting of the FDA s Psychopharmacologic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee was based on data from the EAGLES  Evaluating Adverse Events in a Global Smoking Cessation Study  study This randomized  double blind  active and placebo controlled study evaluated the neuropsychiatric safety of Chantix Champix  Chantix s trade name in the EU and other countries  and bupropion  in comparison to placebo and nicotine replacement therapy patch  NRT   in patients with and without a history of psychiatric disorder Per data published in The Lancet in April this year  the study did not show a significant increase in the incidence of the composite primary safety endpoint of serious neuropsychiatric adverse events in the Chantix arm  compared to placebo and nicotine patch  It also found that smokers treated with Chantix had significantly higher quit rates compared to those treated with bupropion  nicotine patch  or placebo The Committees recommended  by a majority vote  to remove the boxed warning from Chantix s label  Pfizer had submitted a supplemental New Drug Application  sNDA  to the FDA earlier this year  requesting updates to the label to include safety and efficacy data from the EAGLES study and removal of the boxed warning In May this year  the EU label of Champix was updated to include safety and efficacy data from the EAGLES study  Also  the black triangle symbol  which indicated that additional safety monitoring for Champix in the EU was required  was removed We note that the EAGLES study was conducted by Pfizer in collaboration with GlaxoSmithKline plc   NYSE GSK    in consultation with the FDA as well as the European Medicines Agency The FDA is not obligated to follow the recommendations of its panel  but usually it does Stocks to Consider
Currently  Pfizer carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Johnson   Johnson   NYSE JNJ   and Geron Corporation   NASDAQ GERN    While Geron sports a Zacks Rank  1  Strong Buy   J J has a Zacks Rank  2  Buy   You can see  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-14,Zacks Investment Research,https://www.investing.com/analysis/fda-panel-suggests-removing-warning-from-pfizer's-chantix-200153784,200153784
198984,420500,JNJ,Merck Offers Value and Steady Dividend Growth,opinion,"Merck  NYSE MRK  is a  that has paid a consistent dividend since 1970 and has grown its dividend at a 1 8  annual rate over the last 10 years 
They have been able to continually pay a dividend during difficult times thanks to a   attractive operating margins  and reliable free cash flow generation 
This is the type of consistency I like to see for investments I consider for our Conservative Retirees dividend portfolio 
Currently  the business looks attractive with a nearly 3  dividend yield and optionality for additional dividend increases  however  with many large pharmaceutical companies struggling with billion dollar revenue drugs  patent protection expiring  should investors continue to count on Merck s dividend stability Business OverviewMerck has an extremely long company history which dates back to a German apothecary shop in the 17th century  However  they trace their roots in the United States only back to the late 1800s where they were established to be a chemical supplier for their German parent  Today  they operate the business primarily through two main categories  Pharmaceuticals  88  of sales  and Animal Health  8 4  of sales  
The Pharmaceuticals business discovers  develops  and produces therapeutic and preventive agents for the treatment of human disorders  Merck s target markets include cardiovascular  diabetes  general medicine and women s health  hepatitis  HIV  acute care  immunology  oncology  respiratory  and vaccines 
In 2015  their top 10 therapeutics accounted for around 47  of total sales and included 9 different billion dollar drugs  The largest therapeutics include Januvia  treatment of type 2 diabetes   Zetia  cholesterol   Janumet  type 2 diabetes   Gardasil Gardasil 9  HPV   and Remicade  inflammatory diseases  
The Animal Health business discovers  develops  and produces products for livestock  poultry  companion animals  and aquaculture  Their products range from antibiotics for use in cattle and swine to a chewable tablet that kills fleas and ticks in dogs to vaccines against bacterial diseases in fish 
Overall  Merck is one of the largest pharmaceutical companies in the world by market capitalization  only behind Johnson   Johnson  NYSE JNJ   Novartis AG  NYSE NVS   and Pfizer  NYSE PFE   Compared to these competitors  Merck had sales of over  39 billion in 2015 versus  70 1 billion at Johnson   Johnson   49 4B at Novartis  and  48 9B at Pfizer Business AnalysisThe business model for a multinational pharmaceutical company comes down to investing in R D  patenting new therapeutics  and then using manufacturing and distribution scale to get the products to market 
The cost to bring a drug to market after years of research  development  and clinical trials is astronomical  Some estimates now put the total cost at over  2 billion dollars  However  once a company gets a new product to market  they enjoy years of monopoly status with a recession resistant product 
This leads to a relatively stable margin and revenue structure over time  which is exactly what individuals living off dividends in retirement like to see in their investments 
Source  Simply Safe Dividends
These industry characteristics illustrate that Merck isn t going anywhere anytime soon  However  conditions aren t always stable for drug producers Key RisksMerck has gone through a very difficult period of time as they have faced patent expirations in many of their blockbuster drugs and settled a multibillion dollar lawsuit over the painkiller Vioxx 
Merck s sales peaked in 2011 at over  48 billion and have declined to  39 5 billion in 2015  The company has executed a couple of divestitures over this time that have contributed to the sales decline 
However  even if these transactions are adjusted out  organic growth has still been negative  This is further illustrated by total employee count decreasing over this period from 86 000 to 68 000 
The declining sales are a result of the well publicized  patent cliff  that many of the major pharmaceutical giants recently faced 
Also  Merck has had some major setbacks in their pipeline over the last few years  They dropped plans for approval of cardiovascular drug Tredaptive in the U S  and pulled out of markets where it had already been approved 
Another example is Odanacatib  which was an osteoporosis drug that underwent many delays over safety questions  Neither of these once promising drugs is meaningful to Merck today 
Furthermore  a number of their current billion dollar revenue drugs  including Januvia  Isentress  Gardasil  Remicade  Zetia  Vytorin  and Nasonex  have either recently come off patent or have patents expiring over the next few years 
Clearly  the pipeline setbacks and outlook for many of their key drugs should be a cause of concern for investors 
However  even with all of its challenges  not everything is going wrong at Merck  They appear to be through the worst of their patent cliff and still are able to spend nearly  7 billion per year on research and development  which has led to some promising new products 
Also  the company has improved the effectiveness of their R D spend by targeting unmet areas of specialty care such as diabetes and cancer  rather than primary care 
In addition  Merck has a few levers to pull that can extend the patent window of some of their key drugs  They can work to hold later granted patents on processes and intermediates related to the most efficient manufacturing method of the active ingredient  Additionally  they can generate unique compositions and formulations that could push out expiration dates for some treatment options 
With all that said  the most promising new therapeutic is Keytruda  According to Merck  Keytruda can treat different cancers including melanoma or lung cancer or head and neck cancer by working with the immune system 
The share of these markets Keytruda can capture got a boost when Bristol Myers Squibb s Opdivo failed in a lung cancer trial earlier this month  which sent Bristol Myers Squibb s stock price down 18  
Kaytruda is addressing huge markets  and it is widely expected for the drug to increase sales from the current annualized rate of roughly  1 billion to be a multibillion dollar therapeutic Dividend Analysis  MerckWe analyze 25  years of dividend data and 10  years of fundamental data to understand the safety and growth prospects of a dividend 
Dividend Safety ScoreOur Safety Score answers the question   Is the current dividend payment safe   We look at factors such as current and historical EPS and FCF payout ratios  debt levels  free cash flow generation  industry cyclicality  ROIC trends  and more  Scores of 50 are average  75 or higher is very good  and 25 or lower is considered weak 
Merck s dividend is very safe with a Dividend Safety Score of 69  The company s strong score is driven by Merck s stable business model and relatively modest free cash flow payout ratio of 46  
Analysts are projecting future diluted earnings per share of  3 75   4 05  and  4 43 in 2017  2018  and 2019  respectively  This forecast implies low  to mid single digit earnings growth and a safe payout ratio below 50  
Merck s dividend safety is also helped by the company s consistent free cash flow generation  which is needed to sustainably pay and grow dividends 
As seen below  Merck has generated positive free cash flow for more than a decade Source  Simply Safe Dividends
Most of Merck s products are non discretionary purchases as well  Pharmaceuticals are needed regardless of how the economy is doing  which helped Merck report a sales decline of just 1  in 2008 
The company s balance sheet is also very supportive of the dividend  Merck maintains investment grade credit ratings from the major agencies  reflecting the company s strong market position  diverse revenue mix  healthy profit margins  and consistent cash flow generation 
Merck has  11 8 billion in cash compared to  23 6 billion in debt  The company could retire all of its debt using cash on hand and just 1 5 years of earnings before interest and taxes  EBIT  
Overall  Merck s dividend payment is very safe  The company s payout ratio is healthy  cash flow generation is excellent  the balance sheet is reasonably flexible  and earnings are expected to continue growing at a moderate pace 
Dividend Growth ScoreOur Growth Score answers the question   How fast is the dividend likely to grow   It considers many of the same fundamental factors as the Safety Score but places more weight on growth centric metrics like sales and earnings growth and payout ratios  Scores of 50 are average  75 or higher is very good  and 25 or lower is considered weak 
Merck s Dividend Growth Score is only 35  This low score shouldn t be a surprise considering the patent cliff the company faced and hiccups with the product pipeline 
Merck has paid a consistent dividend since initiating it in 1970  Nonetheless  the company is not adividend aristocrat because they have not been a consistent dividend grower 
In fact  Merck held its quarterly dividend constant at 38 cents per share from September 2004 through September 2011  Furthermore  they do not have as good of a dividend growth track record as some of the other global pharmaceutical giants 
Merck has grown their dividend at a 10 year CAGR of only 1 8   5 year CAGR of 3 6   and 3 year CAGR of 2 3  

This is well below Johnson   Johnson  which has grown their dividend at an 8 7  10 year CAGR  5 year CAGR of 6 9   and 3 year CAGR of 7 1   During the same time periods Pfizer has grown their dividend at 4   9 2   and 8 4  per year  respectively 
During the first quarter of 2016  the board of directors at Merck elected to maintain the same quarterly dividend of 46 cents per share that they paid in the fourth quarter of 2015 
Historically  the fourth quarter is when the company decides whether or not to increase the dividend  In the fourth quarter of 2015  they elected to increase the dividend by roughly 2  
Overall  we would expect Merck to continue to increase the dividend at a low single digit rate  which should keep up with inflation  I don t expect any significant increases in the free cash flow payout ratio  which has consistently been around 50  for the last decade Source  Simply Safe Dividends
Thus  future increases in the dividend will have to come from earnings and cash flow growth  which is a function of introducing new therapeutics and managing the decline of off patent drugs 
As of now  major risks to the dividend are more likely to come from lawsuits  recalls  and lack of successful new product introductions than anything to do with the economy or business model ValuationMerck s stock currently trades at 17x forward earnings estimates and offers a dividend yield of 3   which is somewhat below the stock s five year average dividend yield of 3 65  
Assuming the company the company continues growing earnings at a low  to mid single digit rate  the stock appears to offer total annual return potential of 7 10  and looks reasonably priced today ConclusionMerck is a large cap dividend stock that appears to be a good investment to consider for investors looking to add more yield to their portfolio 
The company has a solid balance sheet  a recession resistant business model  generates consistent free cash flow  a reasonable forward P E ratio of 17x  and has paid a consistent dividend since 1970 
However  outside of introducing a number of major blockbuster drugs to the market  Merck is unlikely to grow it dividend much in excess of inflation over the next few years 
Investors looking for a true dividend growth name that could grow to have a high yield on cost someday should pass on the company ",2016-08-24,Brian Bollinger,https://www.investing.com/analysis/merck-offers-value-and-steady-dividend-growth-200149760,200149760
198999,420515,JNJ,3 Best Ranked Fidelity Mutual Funds To Buy Now,opinion,Fidelity Investments is one of the largest and oldest mutual fund companies in the world  The company serves more than 24 million individual customers  As of Dec 31  2015  Fidelity had total assets of  5 2 trillion with  2 1 trillion under management  Fidelity Investments carries out operations in the U S  through 10 regional offices and over 180 Investor Centers  It also has its presence in eight other countries of North America  Europe  Asia and Australia The company provides investment advice  discount brokerage services  retirement services  wealth management services  securities execution and clearance and life insurance products to its clients  At Fidelity  a large group of investment professionals carry out extensive and in depth research on potential investment avenues worldwide Below we share with you three top ranked Fidelity mutual funds  Each has earned a  and is expected to outperform its peers in the future  Investors can   their Zacks Rank and past performance Fidelity Select Software   IT Services Portfolio  invests a major portion of its assets in companies whose primary operations are related to software or information based services  FSCSX primarily focuses on acquiring common stocks of both domestic and foreign companies  FSCSX uses fundamental analysis to select companies for investment purposes  Fidelity Select Software   IT Services Portfolio has a three year annualized return of 15 9  FSCSX has an expense ratio of 0 76  as compared to a category average of 1 51  Fidelity Strategic Dividend   Income  seeks reasonable income  FSDIX invests a large portion of its assets in equity securities  FSDIX invests half of its assets in common stocks  15  in REITs  15  in convertible securities and the rest in preferred stocks  FSDIX invests in both domestic and foreign issuers  Fidelity Strategic Dividend   Income has a three year annualized return of 8 8  As of June 2016  FSDIX held 301 issues with 3 32  of its assets invested in Johnson   Johnson  NYSE JNJ  Fidelity Select Gold  invests heavily in companies whose principal operations are related to gold as well as in bullion or coins  A maximum of 25  of FSAGX s assets are invested in precious metals via a wholly owned subsidiary  FSAGX focuses on acquiring common stocks of firms involved in exploration  mining  processing  or dealing in gold  or to a lesser degree  in silver and other precious metals  Fidelity Select Gold has a three year annualized return of 11 1  Joe Wickwire is the fund manager of FSAGX since 2007 To view the Zacks Rank and past performance of all Fidelity mutual funds  investors can  About Zacks Mutual Fund RankBy applying the Zacks Rank to mutual funds  investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward  Pick the  with the Zacks Rank ,2016-08-07,Zacks Investment Research,https://www.investing.com/analysis/3-best-ranked-fidelity-mutual-funds-to-buy-now-200146684,200146684
199000,420516,JNJ,Inovio Expands Enrollment In Ebola Vaccine Phase I Study,opinion,"Late last week  Inovio Pharmaceuticals  Inc    NASDAQ INO   announced that it is expanding the enrollment in a phase I study evaluating its Ebola DNA vaccine  INO 4212  The company is enrolling 125 patients in the second stage of a phase I study on INO 4212 and will evaluate immune response characteristics generated with fewer intradermal administrations  lower doses  and with or without its DNA based IL 12 immune activator 
The study will also help characterize and identify in humans the most optimal immunization regimen using intradermal  skin  delivery of its preventive Ebola DNA vaccine 
The decision to expand study enrollment came after positive initial safety and immune response data was received from the first set of 75 healthy volunteers  The initial 75 patient stage of the study evaluated INO 4212 in muscle and skin in five study arms in two and three doses  one including Inovio s DNA based IL 12 immune activator 
Inovio plans to meet with regulators regarding the path forward for INO 4212 following the close of this study  which it anticipates early next year INOVIO PHARMAC Price   We note that the company was awarded a  45 million grant by the Defense Advanced Research Projects Agency in 2015 to lead a collaborative team for the development of multiple treatment and prevention approaches against Ebola  The Inovio led consortium is taking a multi faceted approach to develop treatments for the prevention of Ebola 
And it s not just Inovio taking action to curb this lethal disease in the absence of an approved vaccine or treatment  Companies like GlaxoSmithKline plc   NYSE GSK    Johnson   Johnson   NYSE JNJ   and Merck   Co   Inc    NYSE MRK   among others are also developing Ebola vaccines 
In fact  Merck s Ebola Zaire vaccine candidate known as V920 received Breakthrough Therapy status from the FDA while the European Medicines Agency provided the candidate PRIME  PRIority MEdicines  status last month ",2016-08-14,Zacks Investment Research,https://www.investing.com/analysis/inovio-expands-enrollment-in-ebola-vaccine-phase-i-study-200148037,200148037
199001,420517,JNJ,J J s  JNJ  Depression Treatment Esketamine Gets BTD ,opinion,"Johnson   Johnson s   NYSE JNJ   Janssen Research   Development  LLC announced that the FDA has granted Breakthrough Therapy Designation  BTD  to esketamine  an experimental antidepressant treatment  The designation was granted for major depressive disorder with imminent risk for suicide This is the second indication for which esketamine got BTD in the U S  Esketamine had previously got this designation in Nov 2013 for treatment resistant depression  Esketamine is currently in phase III development for treatment resistant depression 
According to information provided by the Centers for Disease Control and Prevention  there are more than 41 000 suicides each year in the U S  with many resulting from untreated or poorly treated major depression We note that J J recently got BTD for two other drugs as well  In Jul 2016  the company s cancer treatment  Darzalex  daratumumab  got the designation for use in combination with standard of care regimens for multiple myeloma patients Earlier in Jun 2016  the company and its partner AbbVie Inc    NYSE ABBV   got a fourth BTD for Imbruvica  The FDA granted BTD to Imbruvica for the treatment of chronic graft versus host disease  cGVHD  after one or more lines of systemic therapy have failed  Imbruvica was also granted Orphan Drug Designation for the indication BTD  helps fasten the development and review of drugs which are being evaluated for the treatment of serious or life threatening conditions and where preliminary clinical evidence indicates that the drug may be substantially better than existing treatments on clinically significant endpoint s  JOHNSON   JOHNS Price   J J is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the health care sector include Actelion Ltd    OTC ALIOF   and Geron Corporation   NASDAQ GERN     both are Zacks Rank  1  Strong Buy  stocks Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-17,Zacks Investment Research,https://www.investing.com/analysis/j-j's-(jnj)-depression-treatment-esketamine-gets-btd-200148412,200148412
199006,420522,JNJ,Geron  GERN  Posts Narrower Than Expected Loss In Q2,opinion,Geron Corporation   NASDAQ GERN   reported a loss of 5 cents per share in the second quarter of 2016  in line with the year ago loss but narrower than the Zacks Consensus Estimate of a loss of 7 cents per share Total revenues declined 15 9  from the year ago period to  211 000 in the second quarter of 2016  The Zacks Consensus Estimate forecasted no revenues for the second quarter Revenues included royalty and license fee revenues under various non imetelstat agreements Research and development  R D  expenses declined 4 2  from the year ago period to  4 6 million reflecting the impact of lower personnel related costs following the Mar 2015 organizational resizing as well as lower costs for the manufacturing of imetelstat  partially offset by higher costs for the company s share of development expenses under the imetelstat collaboration with Johnson   Johnson s   NYSE JNJ   Janssen Biotech R D expenses are expected to increase during the remainder of the year as the development of imetelstat continues Imetelstat is currently in a phase II study  IMbark  in patients with DIPSS intermediate 2 or high risk myelofibrosis who have relapsed after or are refractory to a JAK inhibitor  An internal review to determine the adequacy of one or both of the initial dosing arms is slated to take place by the end of the third quarter  Based on this review  a decision will be taken regarding the continuation halting modification of the dosing arms or the selection of alternative doses  Meanwhile  another internal review including longer follow up with patients in the study for at least 24 weeks  is expected by year end Imetelstat is in a phase II III study  IMerge  as well for myelodysplastic syndrome  MDS   An internal review of this study  to support advancement into Part 2  is also expected in the second half of the year General and administrative expenses increased 12 5  to  4 5 million reflecting higher non cash stock based compensation expense and increased allocation of facilities and other overhead costs to general and administrative activities Geron is currently working on expanding its pipeline   the company is seeking to add new oncology candidates  programs or companies to its portfolio Geron is a Zacks Rank  3  Hold  stock  We are positive on the company s agreement with Johnson   Johnson which provides it with a strong partner as well as funds  The company s growth prospects currently depend entirely on the successful development of imetelstat which is its sole pipeline candidate We expect investor focus to remain on imetelstat and business development updates GERON CORP Price  Consensus and EPS Surprise   Some better ranked stocks in the health care sector include Agenus Inc    NASDAQ AGEN   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    Both are Zacks Rank  1  Strong Buy  stocks Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-08-03,Zacks Investment Research,https://www.investing.com/analysis/geron-(gern)-posts-narrower-than-expected-loss-in-q2-200146084,200146084
199019,420535,JNJ,Roche  RHHBY  Misses On Q2 Revenues  New Launches In Focus ,opinion,"Roche Holding  SIX ROG    OTC RHHBY   reported sales of  12 1 billion  CHF11 7 billion  in the second quarter of 2016  missing the Zacks Consensus Estimate of  12 9 billion 
In the first half of 2016  however  sales were up 6  year over year in local currency  Growth was primarily driven by pharmaceutical sales in the U S  and strong demand for immunodiagnostic products 
The company reports results under two divisions  Pharmaceuticals and Diagnostics  All growth rates mentioned below are on a year over year basis and at constant exchange rates 
First Half 2016 Results in Detail 
Sales at the Pharmaceuticals division increased 4  to CHF19 5 billion on the back of strong demand for oncology and immunology medicines  Sales of the HER2 breast cancer franchise   10   were driven by robust demand for Herceptin  Perjeta and Kadcyla  Herceptin sales grew 5  on the back of higher demand due to a longer duration of treatment in combination with Perjeta 
Sales of Perjeta were strong in both Europe and the U S  driven mainly by uptake in the neoadjuvant setting and continually strong growth in the metastatic setting  Kadcyla sales increased on account of demand in the international region and Europe 
Sales of Avastin were up 4  due to increased demand in international markets  especially China where sales grew on improved access in the lung cancer setting  Robust sales of Rituxan MabThera   4   also contributed significantly to the top line 
Sales of the immunology franchise were driven by strong uptake of Esbriet   51   and increased sales of Actemra RoActemra   17   and Xolair   19   The new subcutaneous formulation of Actemra  along with its use as a single agent  fueled sales  Demand was strong for Alecensa which was recently launched in the U S  for a specific type of lung cancer 
However  sales of Pegasys   49   were hurt by competition from a new generation of treatments  while Valcyte Cymevene   14   and Xeloda   12   suffered due to generic competition 
Revenues at the Diagnostics division were CHF5 6 billion  up 6  driven by solid performance of the professional diagnostics   9   unit  which was in turn  propelled by the immunodiagnostics business   14    Tissue diagnostics   12   and Molecular Diagnostics   8   also performed impressively  However  sales of diabetes care decreased due to pricing pressure in the U S 
2016 Outlook
Roche continues to expect sales to increase in the low to mid single digits  The company expects core earnings to grow at a higher rate than sales  Roche intends to increase its dividend further in 2016 
 ROCHE HLDG LTD Price and EPS Surprise
   Pipeline Update
Roche made strong pipeline progress in the first half of 2016  The FDA granted accelerated approval to Venclexta for a specific form of leukemia in the U S  The drug was developed in collaboration with AbbVie   NYSE ABBV    The FDA also granted accelerated approval to immunotherapy drug  Tecentriq  for bladder cancer 
The subcutaneous formulation of MabThera Rituxan received approval in the EU for chronic lymphocytic leukemia in May  In Jun 2016  the European Commission approved Gazyva for the second line treatment of follicular lymphoma  Meanwhile  the combination of Avastin and Tarceva received approval in Europe for the treatment of patients with a specific type of lung cancer 
Also  the marketing applications for Ocrevus for both relapsing and progressive multiple sclerosis is under review in the U S  and EU  The PDUFA date in the U S  is Dec 28  2016  Results from the largest trial in giant cell arteritis  GCA  showed that Actemra RoActemra effectively sustained remission through one year as compared to a 6  or 12 month steroid only regimen in patients with newly diagnosed and relapsing GCA 
Roche also presented positive data on Tecentriq in the treatment of previously treated lung cancer  Moreover  the company revealed encouraging results on the drug in combination with chemotherapy  targeted anti cancer medicines and other cancer immunotherapy agents in several tumor types from various trials 
However  Roche suffered a setback when the phase III study on Gazyva in previously untreated diffuse large B cell lymphoma did not meet its primary goal of extending the time patients live without disease progression 
Our Take
Roche currently carries a Zacks Rank  3  Hold   Sales in the second quarter fell short of estimates  The company is making efforts to broaden its portfolio outside the oncology space into immunology  New drug approvals such as those of Tecentriq  Cotellic and Alecensa also boosted sales 
However  headwinds in the form of generic competition for Xeloda and Valcyte may continue to hurt sales  Going forward  we expect investors to focus on new drug approvals  as the top line could be marred by the entry of biosimilars  expected in the second half of 2017 in Europe  for key drugs like MabThera and Herceptin 
Investors interested in the health care sector may consider Gilead Sciences   NASDAQ GILD   and Johnson   Johnson   NYSE JNJ    Both the stocks carry a Zacks Rank  2  Buy  ",2016-07-25,Zacks Investment Research,"https://www.investing.com/analysis/roche-(rhhby)-misses-on-q2-revenues,-new-launches-in-focus-200144021",200144021
199028,420544,JNJ,3 Healthcare ETFs To Buy As JNJ Beats Q2 Earnings,opinion,With the Q2 earnings season under way  Johnson   Johnson   NYSE JNJ   is one of the first to report results in the health care space  The world s biggest maker of health care products continued its long streak of earnings and revenue beat  Further  the company lifted its full year outlook  reflecting confidence in its future growth  read    Johnson and Johnson Q2 Results in FocusEarnings per share came in at  1 74  seven cents ahead of the Zacks Consensus Estimate and 1 8  higher than the year ago earnings  Revenues were up 3 9  year over year to  18 5 billion and edged past the Zacks Consensus Estimate of  17 9 billion Healthy sales of new drugs like Darzalex  Invokana  Imbruvica and Xarelto and the strength of established drugs such as Stelara  Remicade  Imbruvica  Simponi and Invega Sustenna partially offset a steep decline in sales of the hepatitis C medicine   Olysio   which lost its competitive position in the U S  to its rivals Gilead   NASDAQ GILD   and AbbVie   NYSE ABBV   Johnson   Johnson raised its guidance for 2016  The company now expects revenues in the range of  71 5  72 2 billion compared with the previous forecast of  71 2  71 9 billion  Additionally  the earnings per share guidance has been raised from  6 53  6 68 to  6 63  6 73  The Zacks Consensus Estimate is currently pegged at  71 73 billion for revenues and  6 65 for earnings per share Market ImpactDespite the earnings beat and encouraging guidance  shares of JNJ gained a nominal 1 7  on the day  This could be an attractive entry point for momentum investors given that Johnson   Johnson has a solid Momentum Style Score of  B   Further  the stock has a favorable Zacks Rank  2  Buy  ETFs to BuyBased on impressive results and solid growth prospects  investors should definitely focus on ETFs that have a double digit allocation to this diversified drug maker and grab any opportunity from a surge in the JNJ price  For those investors  we have highlighted three ETFs that are poised to outperform following Q2 results and have a top Zacks ETF Rank of 1 or  Strong Buy  rating with a Medium risk outlook  see    Health Care Select Sector SPDR Fund The most popular healthcare ETF  XLV follows the Health Care Select Sector Index  This fund manages nearly  13 6 billion in its asset base and trades in heavy volume of around 12 million shares  Expense ratio came in at 0 14  annually  In total  the fund holds 59 securities in its basket with JNJ taking the top spot at 12 2  of assets  Pharma accounts for 39  share from a sector look while biotech  healthcare providers and services  and equipment and supplies make up for a double digit exposure each iShares U S  Healthcare ETF This fund provides exposure to 122 securities by tracking the Dow Jones U S  Health Care Index  Here again  Johnson   Johnson dominates the fund s return at 11 7  of total assets  In terms of industrial exposure  pharma takes the top spot at 37 8   followed by biotech  22 1    and healthcare equipment  18 5    The product has amassed nearly  2 billion in its asset base and charges 45 bps in annual fees  It trades in solid volume of around 134 000 shares a day  read    Vanguard Health Care ETF This ETF tracks the MSCI US Investable Market Health Care 25 50 Index and holds 356 stocks in its basket  Out of these  Johnson   Johnson takes the top spot with 10 7  allocation  Pharma takes the largest share at 35 3  while biotech and healthcare equipment round off the top three spots  VHT is also one of the popular and liquid ETFs with AUM of  5 7 billion and average daily volume of about 227 000 shares  It charges 9 bps in annual fees and expenses Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-21,Zacks Investment Research,https://www.investing.com/analysis/3-healthcare-etfs-to-buy-as-jnj-beats-q2-earnings-200143361,200143361
199041,420557,JNJ,Novartis  NVS  Tops Q2 Earnings   Sales  Expenses To Grow,opinion,Novartis AG   NYSE NVS   reported second quarter 2016 core earnings of  1 23 per share  On an adjusted basis  earnings were  1 22 per share beating the Zacks Consensus Estimate of  1 18 Revenues also declined 2  to  12 5 billion but were above the Zacks Consensus Estimate of  12 1 billion All growth rates mentioned below are on a year over year basis and at constant exchange rates The Quarter in DetailNovartis operates under three divisions  Innovative Medicines  Pharmaceuticals   Alcon and Generics  Sandoz  The Innovative Medicines  pharmaceuticals  division recorded sales of  8 4 billion  down 1   Generic competition for Gleevec and pricing negatively impacted sales  Growth Products  Gilenya  Tasigna  Tafinlar   Mekinist  Jakavi and Promacta Revolade  increased 23  to  3 8 billion  and comprised 45  of net division sales The Alcon division recorded sales of  1 5 billion  down 1   Surgical sales were down as the strong performance of cataract consumables was more than offset by weak sales of intraocular lenses  IOLs   Vision care sales were flat as growth in contact lenses offset the decline in contact lens care In a bid to revamp its beleaguered Alcon business  Novartis has moved its ophthalmic pharmaceuticals business to the pharmaceuticals division Sales at the Sandoz division  Novartis  generic arm  were  2 6 billion  as volume growth was offset by price erosion  Sales of Biopharmaceuticals surged 11  to  249 million 2016 Outlook ReiteratedNovartis expects net sales to be broadly in line with the 2015 levels  Growth products are expected to offset the impact of generic competition  primarily Gleevec   In a bid to boost Entresto sales  Novartis decided to significantly increase spending in the second half of 2016 to create a primary care field force in the U S  and improve medical support for the drug  Consequently  additional spending on Entresto and generic erosion of Gleevec will lead to a decline in operating income  Moreover  unfavorable currency movement will hurt sales by 3  in 2016  For the third quarter  sales and earnings will be down 1  and 2   respectively  due to foreign exchange fluctuations   Pipeline UpdateNovartis  pipeline progress in the reported quarter was encouraging  Afinitor was approved in the EU for the treatment of unresectable or metastatic  well differentiated nonfunctional neuroendocrine tumors of gastrointestinal or lung origin in adults with progressive disease  The FDA approved an expanded label for Xolair to include children aged 6 to 11 years with moderate to severely persistent asthma Additionally  Entresto obtained a strong Class I recommendation in both the U S  and the EU as per the heart failure treatment guidelines  These guidelines establish Entresto as the standard of care for symptomatic patients with heart failure with reduced ejection fraction  HFrEF   Novartis has also entered into collaboration and licensing agreement with Xencor  Inc    NASDAQ XNCR   to add bispecific antibodies to its growing immuno oncology portfolio Moreover  an independent Data Monitoring Committee recommended stopping the phase III trial on LEE011 early as a pre planned interim analysis showed that the candidate was able to meet the primary endpoint in postmenopausal women who had received no prior therapy for their HR  HER2  advanced breast cancer  Novartis also presented  encouraging data on Cosentyx  while the three year follow up results of a phase III study on the Tafinlar Mekinist combination showed a survival benefit in patients with BRAF V600E K  advanced melanoma on combination therapy versus Tafinlar monotherapy On the other hand  the ENESTfreedom trial on Tasigna for the treatment of Ph CML patients did not meet the primary endpoint Meanwhile  Sandoz continues to strengthen its biosimilars portfolio and pipeline  The biosimilar versions of Enbrel and MabThera showed pharmacokinetic bioequivalence to their reference products  The FDA advisory committee has recommended the approval of biosimilar of Enbrel for five indications of the reference product  However  Sandoz received a complete response letter from the FDA for Neulasta biosimilar and the company is working with the agency to resolve the issues  The company is planning to file for two more biosimilars in 2016 NOVARTIS AG ADR Price and EPS Surprise   Our TakeNovartis  second quarter 2016 results were encouraging with the company beating both top  and bottom line estimates  Novartis has been facing challenging conditions for the past few quarters  Nevertheless  uptake of newly launched products  Cosentyx  should be able to offset the impact of entry of generics for Gleevec as well as weakness in Alcon  Moreover  the company is working to boost Entresto sales  We are also impressed by the company s efforts to strengthen its biosimilars portfolio Novartis currently carries a Zacks Rank  3  Hold   Investors interested in the health care sector may consider Johnson   Johnson  NYSE JNJ   and Gilead Sciences  NASDAQ GILD     Both the stocks carry a Zacks Rank  2  Buy  ,2016-07-19,Zacks Investment Research,"https://www.investing.com/analysis/novartis-(nvs)-tops-q2-earnings---sales,-expenses-to-grow-200142981",200142981
199048,420564,JNJ,Geron  GERN  Gets Three Patents For Imetelstat In The U S ,opinion,Geron Corporation   NASDAQ GERN   announced the issuance of three U S  patents related to its telomerase inhibitor  imetelstat The first patent  U S  Patent No  9 375 485  covers imetelstat s use for alleviating at least one symptom of myelofibrosis or myelodysplastic syndromes  including chronic myelomonocytic leukemia The other two patents  U S  Patent No  9 388 415 and U S  Patent No  9 388 416  are related to the methods of using imetelstat to inhibit the activity of telomerase as well as to inhibit cancer cell proliferation  They also include methods for using imetelstat to treat cancer The first patent is expected to be valid till at least Mar 2033  while the other two will run through at least Sept 2024 GERON CORP Price   These patents relate to Geron s existing patent  U S  Patent No  7 494 982  on imetelstat s composition of matter  which was issued in 2009 and is expected to be valid until at least Dec 2025 Geron has licensed its portfolio of patents related to imetelstat to Janssen Biotech  a Johnson   Johnson   NYSE JNJ   company  In Nov 2014  Geron entered into a license and collaboration agreement under which Janssen was granted exclusive worldwide rights to develop and commercialize imetelstat for all human therapeutic uses  including hematologic myeloid malignancies Currently  Janssen is conducting two studies on imetelstat   IMbark  phase II  for the treatment of myelofibrosis and IMerge  phase II III  for the treatment of myelodysplastic syndromes Currently  Geron carries a Zacks Rank  3  Hold   Johnson   Johnson is a better ranked stock with a Zacks Rank  2  Buy   Other favorably ranked stocks in the health care sector include GW Pharmaceuticals plc   NASDAQ GWPH   and Innoviva  Inc    NASDAQ INVA    Both the stocks sport a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-14,Zacks Investment Research,https://www.investing.com/analysis/geron-(gern)-gets-three-patents-for-imetelstat-in-the-u.s.-200141925,200141925
199049,420565,JNJ,Novartis  NVS  Likely To Beat Q2 Earnings  Stock To Gain ,opinion,Novartis AG   NYSE NVS   is scheduled to report second quarter 2016 results on Jul 19 Novartis  track record has been quite bleak  with the company beating estimates in only one of the last four quarters  In the last reported quarter  it recorded a negative earnings surprise of 0 85   Overall  Novartis has posted an average negative earnings surprise of 1 98  for the four trailing quarters  Let s see how things are shaping up for this announcement Factors to Impact the Quarter 2016 is expected to be a transformational year for Novartis  The company s ophthalmologic division  Alcon  was facing challenging conditions due to a decline in surgical equipment sales in the U S  and emerging markets as well as intensifying generic competition in the country for ophthalmic pharmaceuticals In a bid to revamp its beleaguered Alcon business  Novartis decided to move its ophthalmic pharmaceuticals business to the pharmaceuticals division  Consequently  the Alcon division will focus solely on the surgical and vision care businesses  The restructuring plan is expected to result in savings of  1 billion through 2020  The company also transferred approximately  1 billion of mature products from Pharma to Sandoz  Novartis is also expected to face headwinds in the form of generic competition for Gleevec  additional spending related to the launch of Entresto and Cosentyx  as well as expenditure on Alcon On the other hand  unfavorable movement in foreign exchange rates is estimated to impact sales by 3  in the second quarter of 2016 and earnings by 4   In terms of sales growth  the second quarter is expected to be the worst as the company is integrating products from GlaxoSmithKline plc   NYSE GSK   and expects to realize the full quarter impact of generic competition for Gleevec  Loss of patent protection for some key drugs  including Diovan and Exforge  in Novartis  portfolio will also impact results On a positive note  Sandoz  Novartis  generic arm  continues to strengthen its biosimilars portfolio and pipeline  which should offset weakness in the Alcon segment  Meanwhile  investor focus should remain on the sales ramp up of newly launched drugs  20 approvals in 2015   Entresto  Glatopa and Cosentyx  Main growth drivers at the oncology segment are Tasigna  Jakavi and Jadenu  the improved formulation of Exjade  Gilenya for the treatment of multiple sclerosis should also do well Earnings WhispersOur proven model conclusively shows that Novartis is likely to beat estimates in the quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  This is the case here  as elaborated below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  0 85  Zacks Rank  The combination of Novartis  Zacks Rank  3 and positive ESP indicates a likely earnings beat this quarter On the other hand  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderNOVARTIS AG ADR Price and EPS Surprise   Here are a couple of health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter Johnson  Johnson   NYSE JNJ   has an Earnings ESP of  0 60  and a Zacks Rank  2  The company is scheduled to report second quarter results on Jul 19 Gilead Sciences Inc    NASDAQ GILD   has an Earnings ESP of  6 91  and a Zacks Rank  2  The company will report results on Jul 25 ,2016-07-15,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-likely-to-beat-q2-earnings:-stock-to-gain-200142154,200142154
199050,420566,JNJ,Roche s Gazyva Fails In Phase III B cell Lymphoma Study,opinion,"Roche Holding  SIX ROG  AG   OTC RHHBY   announced disappointing results from the phase III study  GOYA  on Gazyva for previously untreated diffuse large B cell lymphoma  DLBCL  
The global phase III  open label  multicenter  randomized  two arm study examined the efficacy and safety of the combination of Gazyva and CHOP chemotherapy  G CHOP  against Rituxan plus CHOP chemotherapy  R CHOP  
The trial failed to meet the primary endpoint of a reduction in the risk of disease worsening or death  progression free survival  compared to Rituxan plus R CHOP  Adverse events were consistent in both arms ROCHE HLDG LTD Price and EPS Surprise
   The results were a setback for the company as previous trials had showed that Gazyva helped people with previously untreated follicular lymphoma or chronic lymphocytic leukemia live longer without their disease worsening  compared to Rituxan  when combined with chemotherapy 
Results were disappointing also because DLBCL is the most common subtype of non Hodgkin lymphoma  NHL  
Gazyva is already approved in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia  In Feb 2016  the FDA expanded the label of Gazyva in combination with bendamustine followed by Gazyva alone to include the treatment of follicular lymphoma in patients who did not respond to a Rituxan containing regimen  or whose follicular lymphoma returned after such a treatment  Last month  it was approved as Gazyvaro in the EU for the same indication 
Roche s hematology portfolio boasts approved drugs like MabThera Rituxan  Gazyva Gazyvaro  Tecentriq  atezolizumab  and Venclexta  as well as an encouraging pipeline comprising candidates like polatuzumab vedotin RG7596 and a small molecule antagonist of MDM2  idasanutlin RG7388  
Roche currently carries a Zacks Rank  2  Buy   Other favorably placed stocks in the healthcare sector include Pfizer  Inc    NYSE PFE    Johnson   Johnson   NYSE JNJ   and Gilead Sciences   NASDAQ GILD    Each of these stocks carries the same rank as Roche ",2016-07-18,Zacks Investment Research,https://www.investing.com/analysis/roche's-gazyva-fails-in-phase-iii-b-cell-lymphoma-study-200142547,200142547
199056,420572,JNJ,JNJ VS  PFE  Which Is The Better Large Cap Pharma Stock  ,opinion,"With market caps in the triple digit billions  Johnson   Johnson   NYSE JNJ   and Pfizer Inc    NYSE PFE   are two large cap pharmaceutical stocks that many investors like to keep in their portfolio for their relative stability  Large cap stocks tend to be go to picks for investors  as they tend to be less volatile than most other stocks  They also tend to offer solid dividend payments that help to limit downside risk  in addition to providing income to investors 
JNJ and PFE are both Zacks Rank  2  Buy  stocks  and the Large Cap Pharmaceutical Industry is currently ranked 26th out of 265 industries by Zacks  placing it in the top 10  of all industries  While they share the same Zacks Rank and operate in the same strong industry  the stocks differ from each other in what they can offer to investors 
Johnson   Johnson  JNJ 
Johnson   Johnson is engaged in the research and development  manufacture  and sale of a range of products in the healthcare field  The company operates in three segments  Consumer  Pharmaceuticals  and Medical Devices and Diagnostics  JNJ is a long term  proven winner  as the company raised its dividend every year since 1961  a 54 year streak  and has produced a return of 175  just since 2005 
As mentioned the company is a Zacks Rank  2  Buy  stock currently  and also has a Momentum Style Score of an A for the recent success the stock has seen  The company is up nearly 20  thus far in 2016  and dating back 52 weeks JNJ has a price change of nearly 23   The trend upwards could continue too with JNJ s growth projections 
JNJ is projected to see its sales hit  71 64 billion this year  which would represent year over year growth of 2 23   and sales in 2017 are projected to grow another 4 53   The company s earnings are also projected for solid growth  with projected EPS growth of 6 40  this year  and another 6 08  of growth projected for next year 
Johnson   Johnson has long been a well performing blue chip stock  and is likely to continue to do so moving forward  With a forward PE ratio of 18 63 and a dividend yield of 2 60  that is likely to grow given the company s history  JNJ offers solid value to income and value investors  as well as being attractive to momentum investors given its run of success 
Pfizer Inc   PFE 
Pfizer Inc  is a research based  global pharmaceutical company that discovers  develops  manufactures  and markets medicines for humans and animals  The company s diversified global healthcare portfolio includes human  biologic and small molecule medicines and vaccines  as well as nutritional products and healthcare products 
Pfizer too is a Zacks Rank  2  Buy  stock currently  and offers investors good bang for their buck with a B Value Style Score  This Style Score can be attributed to a low PE ratio of 14 72  an earnings yield of 6 85   and a cash to price ratio of 10 81  The company also offers a solid dividend yield of 3 32   making it attractive as an income and value investment 
Shares of PFE are up more than 12  year to date  and could be poised to finish the year even higher thanks to its projected growth in sales and earnings  The company has current year projected sales growth of 7 74   in addition to projected EPS growth of 11 57   PFE s current year earnings estimate has soared from recent analyst revision activity  jumping from  2 28 90 days ago to the current estimate of  2 45 
With a solid dividend yield  PFE offers income for investors and some protection against downside risk in the recent volatile market  The company has a positive growth outlook too  and its solid value provides investors with an interesting investment opportunity 
Bottom Line
Armed with a high Zacks Rank  investors should consider both stocks  Both offer a solid dividend payment  though PFE s is higher  for those looking for income  and each stock has other positives behind it  JNJ is a strong performer thus far this year and has proven over a long period of time that is a stable  growing stock  both in regards to its share price and its dividend payment 
PFE is more of an income and value play for investors  with a higher dividend yield and lower PE ratio  Both stocks look strong at the moment  and it is really up to investors to choose between the two on which attributes they tend to look for when making their stock picks ",2016-07-11,Zacks Investment Research,https://www.investing.com/analysis/jnj-vs.-pfe:-which-is-the-better-large-cap-pharma-stock-200141087,200141087
199057,420573,JNJ,Shire s  SHPG  Dry Eye Disease Drug Xiidra Gets FDA Nod,opinion,"Shire plc   NASDAQ SHPG   received a major boost when the FDA approved its ophthalmology drug Xiidra  lifitegrast ophthalmic solution  5   a twice daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease  DED  in adults 
Per the company  Xiidra is the only prescription eye drop indicated for the treatment of both signs and symptoms of this condition  Approximately 16 million adults in the U S  are diagnosed with dry eye disease  underscoring significant need for treatments in this field  Shire expects to launch the drug in the third quarter of 2016 
However  the road to Xiidra s approval has been bumpy  In Oct 2015  the FDA issued a complete response letter to the company s new drug application  NDA  for the drug  The agency had requested for an additional clinical study to support the company s NDA SHIRE PLC ADR Price
   Thereafter  Shire announced positive top line results from a phase III study  OPUS 3  The study met both the primary and secondary endpoints  It compared Xiidra to placebo administered twice daily for 84 days in patients suffering from DED  who have a recent history of artificial tear use within 30 days of study entry and an eye dryness score of 40 
The study also evaluated the safety and tolerability of the drug based on the occurrence of treatment emergent adverse events  The safety and tolerability profile of the drug was consistent with results from previous studies  Consequently  Shire resubmitted the NDA with the new data in Jan 2016 
Our Take
We note that Shire has a solid presence in the rare disease markets  The approval of Xiidra will enable the company to build a strong ophthalmology franchise as well  The DED market represents significant potential 
The company has a deep pipeline in ophthalmology comprising early   mid  and late stage candidates gained through organic growth and strategic acquisitions  Over the last three years  the company has made several acquisitions  including those of Foresight Biotherapeutics  SARcode Bioscience  Premacure AB and Bikam Pharmaceuticals  These transactions added key early   mid  and late stage candidates to Shire s ophthalmic pipeline  
We remind investors that Shire s ophthalmic pipeline currently includes candidates for infectious conjunctivitis  retinopathy of prematurity  autosomal dominant retinitis pigmentosa and glaucoma 
Shire currently carries a Zacks Rank  2  Buy   Other favorably placed stocks in the healthcare sector include Pfizer  Inc    NYSE PFE    Roche Holding  SIX ROG  AG   OTC RHHBY   and Johnson   Johnson   NYSE JNJ    While Pfizer sports a Zacks Rank  1  Strong Buy   Roche and Johnson   Johnson carry the same rank as Shire ",2016-07-13,Zacks Investment Research,https://www.investing.com/analysis/shire's-(shpg)-dry-eye-disease-drug-xiidra-gets-fda-nod-200141434,200141434
199058,420574,JNJ,Sucampo To Stop Developing Cobiprostone For Oral Mucositis,opinion,"Sucampo Pharmaceuticals  Inc    NASDAQ SCMP   announced that it will discontinue the development of its pipeline candidate  cobiprostone 
The candidate was being developed for the prevention of oral mucositis  The decision to discontinue was taken on the basis of the results of a prespecified futility analysis of a phase II study  The study evaluated an oral spray formulation of cobiprostone for the prevention of oral mucositis in patients who are undergoing radio chemotherapy for head and neck cancers 
The futility analysis showed that the clinical benefit of cobiprostone was insufficient to support the continuation of the study  However  there were no safety concerns and the safety profile was consistent with the previous studies 
In Apr 2016  Sucampo announced disappointing top line data from a phase IIa study on cobiprostone in patients with proton pump inhibitor  PPI  refractory non erosive reflux disease  NERD  or symptomatic gastroesophageal reflux disease  sGERD   Consequently  the company had to discontinue the development of cobiprostone for PPI refractory NERD sGERD 
Meanwhile  Sucampo will focus on other candidates in its pipeline   label expansion of Amitiza and its partnership with Cancer Prevention Pharmaceuticals for the phase III candidate for familial adenomatous polyposis  FAP   We remind investors that the company entered into an option and collaboration agreement with Cancer Prevention Pharmaceuticals in Jan 2016  whereby the company was granted the sole option to acquire an exclusive license to commercialize CPP 1X sulindac combination product in North America  The product is currently in a phase III trial for the treatment of familial adenomatous polyposis  FAP  
We note that Amitiza is approved in the U S  for three gastrointestinal indications   chronic idiopathic constipation  CIC  in adults  irritable bowel syndrome with constipation  IBS C  in adult women and opioid induced constipation  OIC  in adults suffering from chronic non cancer related pain 
However  Sucampo is heavily dependent on Amitiza for growth and the company needs to deliver on its pipeline in order to reduce its dependence on a single product  Hence  any further delay in the development programs for candidates in its pipeline will adversely impact the prospects of the company 
Sucampo carries a Zack Rank  3  Hold   Some better ranked stocks in the healthcare sector include Pfizer  Inc    NYSE PFE    Roche Holding  SIX ROG  AG   OTC RHHBY   and Johnson   Johnson   NYSE JNJ    While Pfizer sports a Zacks Rank  1  Strong Buy   both Roche and Johnson   Johnson are Zacks Rank  2  Buy  stocks ",2016-07-13,Zacks Investment Research,https://www.investing.com/analysis/sucampo-to-stop-developing-cobiprostone-for-oral-mucositis-200141431,200141431
199064,420580,JNJ,Novartis  Systemic Mastocytosis Drug Positive In Phase II,opinion,"Novartis AG   NYSE NVS   announced that data from its phase II study  CPKC412D2201  on PKC412  midostaurin  was published in The New England Journal of Medicine 
The open label study enrolled adults  aged 18 years and above  who had the following subtypes of advanced systemic mastocytosis  SM  in the primary efficacy population   aggressive systemic mastocytosis  mast cell leukemia  and SM with an associated hematologic neoplasm  Patients enrolled in the trial received single agent oral administration of PKC412 until disease progression or unacceptable toxicity 
Data demonstrated an overall response rate of 60  in patients suffering from SM  Results showed a median overall survival of 28 7 months  along with improvements in both bone marrow mast cell burden and serum tryptase levels 
We note that the FDA has recently granted Breakthrough Therapy designation to PKC412 for the treatment of adults with newly diagnosed FLT3 mutated acute myeloid leukemia  AML   The candidate also enjoys Orphan Drug status in the EU and the U S  for both AML and mastocytosis 
Advanced SM is rare and has a poor prognosis  As per the European Journal of Hematology  there is currently no approved treatment for the majority of patients suffering from the disease  Hence  the successful development and commercialization of PKC412 will bode well for Novartis NOVARTIS AG ADR Price
   We believe investors should look out for approval of new drugs and label expansion of existing ones at Novartis as the company has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec  This apart  its oncology drugs are facing competition from immuno oncology therapies  Moreover  its Alcon segment is witnessing a decline in surgical equipment sales in the U S  and emerging markets 
Novartis currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Pfizer  Inc    NYSE PFE    Bristol Myers Squibb Co    NYSE BMY   and Johnson   Johnson   NYSE JNJ    While Pfizer and Bristol Myers sport a Zacks Rank  1  Strong Buy   Johnson   Johnson is a Zacks Rank  2  Buy  stock ",2016-07-01,Zacks Investment Research,https://www.investing.com/analysis/novartis'-systemic-mastocytosis-drug-positive-in-phase-ii-200139637,200139637
199065,420581,JNJ,UCB s Vimpat Approved In Japan For Partial Onset Seizures,opinion,UCB S A   and partner Daiichi Sankyo Company Limited  announced that the Japanese Ministry of Health  Labor and Welfare  MHLW  has approved its anti epileptic drug  Vimpat  as an adjunctive therapy in the treatment of partial onset seizures  with or without secondary generalization  in adults with epilepsy who have not obtained sufficient response to other anti epileptic drugs The recommended dose starts at 100mg day  which can be increased to an initial therapeutic dose of 200mg day at intervals of at least 1 week  each given orally in 2 divided doses UCB and Daiichi Sankyo will jointly commercialize Vimpat in Japan  While UCB manufactures and supplies the product  Daiichi Sankyo will manage distribution and book sales We note that Vimpat is approved in the U S   both as an adjunct therapy and monotherapy  for the treatment of partial onset seizures in people with epilepsy who are 17 years and older  The drug is also approved in the EU as an adjunct therapy in the treatment of partial onset seizures with or without secondary generalization in patients aged 16 years and older with epilepsy  A Marketing Authorisation Application for Vimpat  as monotherapy in the treatment of partial onset seizures  is currently under review in the EU Meanwhile  Vimpat is being evaluated as an adjunct therapy in two phase III studies   for the treatment of partial onset seizures in pediatrics and for the treatment of primary generalized tonic clonic seizures  Results from the former study are expected in 2017  while that from the latter study are expected in 2019 According to information provided by the company  epilepsy affects approximately 65 million people worldwide  Approximately 1 in every 26 people is expected to suffer from epilepsy in their lifetime  In Japan  approximately 1 million individuals are estimated to be affected by the disease Drugs currently approved to treat epilepsy include Novartis AG s   NYSE NVS   Tegretol  AbbVie Inc  s   NYSE ABBV   Depakote and Johnson   Johnson s   NYSE JNJ   Topamax Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-05,Zacks Investment Research,https://www.investing.com/analysis/ucb's-vimpat-approved-in-japan-for-partial-onset-seizures-200140323,200140323
199066,420582,JNJ,Roche Asthma Drug Xolair Gets FDA Nod For Label Expansion,opinion,"Roche Holding  SIX ROG  AG   OTC RHHBY   announced that the FDA has approved a label expansion of respiratory drug  Xolair 
The drug is now approved for the treatment of moderate to severely persistent asthma in children aged 6 to 11 years  who have had a positive skin test or in vitro reactivity to an airborne allergen  along with symptoms that are inadequately controlled with inhaled corticosteroids 
We note that the drug is already approved for the treatment of allergic asthma patients aged 12 years and older  Xolair is also approved for the treatment of chronic idiopathic urticaria  CIU  in patients aged 12 years and older  who continue to have hives that are not controlled by an H1 antihistamine treatment 
The latest label expansion to include the treatment of a younger group of children should further boost sales of the drug  As per the U S  Centers for Disease Control and Prevention  asthma affects 6 3 million people under 18  or one in every 12 children in the U S  Out of this  approximately 60  have allergic asthma  As per estimates from the American Academy of Pediatrics  70  to 80  of school aged children with asthma also have allergies  This reflects significant need for treatments in this indication ROCHE HLDG LTD Price
   Roche has a collaboration agreement with Novartis AG   NYSE NVS   for Xolair  under which Novartis is responsible for the commercialization of Xolair outside the U S   while Roche markets the product in the U S 
We are impressed by the company s efforts to grow its portfolio beyond oncology and foray into new avenues such as multiple sclerosis and asthma  Roche currently has more than a dozen candidates in its pipeline for diseases like Alzheimer s disease  spinal muscular atrophy and Parkinson s disease among others 
The company currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Pfizer  Inc    NYSE PFE   and Johnson   Johnson   NYSE JNJ    Both the stocks carry a Zacks Rank  2  Buy  ",2016-07-08,Zacks Investment Research,https://www.investing.com/analysis/roche-asthma-drug-xolair-gets-fda-nod-for-label-expansion-200140857,200140857
199075,420591,JNJ,AbbVie  J J s Imbruvica Gets Breakthrough Therapy Status,opinion,AbbVie Inc    NYSE ABBV   and Johnson   Johnson s   NYSE JNJ   Imbruvica got a fourth Breakthrough Therapy Designation  BTD   this time for a non cancer indication  The FDA granted BTD to Imbruvica for the treatment of chronic graft versus host disease  cGVHD  after one or more lines of systemic therapy have failed  Imbruvica was also granted Orphan Drug Designation  ODD  for the indication Breakthrough Therapy Designation helps fasten the development and review of drugs which are being evaluated for the treatment of serious conditions and where preliminary clinical evidence indicates that the drug may be substantially better than existing treatments on clinically significant endpoint s  Currently  no treatments are available specifically for cGVHD with most patients being prescribed glucocorticoids  a systemic steroid treatment  However  according to the Fred Hutchinson Cancer Research Center  research shows that serious health complications can arise from the long term use of steroids Earlier BTDs for Oncology IndicationsImbruvica has previously received BTD for oncology indications including for the treatment of patients with relapsed or refractory mantle cell lymphoma  MCL   the treatment of Waldenstr m s macroglobulinemia  WM  and the treatment of patients with chronic lymphocytic leukemia  CLL  or small lymphocytic lymphoma  SLL  with a deletion of the short arm of chromosome 17  del 17p  Pipeline in a MoleculeImbruvica became a part of AbbVie s portfolio following its acquisition of Pharmacyclics  Currently approved for certain types of blood cancer  Imbruvica has multi billion dollar potential and AbbVie is exploring the potential to expand Imbruvica s label into solid tumors and autoimmune diseases  AbbVie is positioning Imbruvica as a  pipeline in a molecule    the treatment is in several studies including 14 phase III studies AbbVie is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the healthcare sector include Pfizer Inc    NYSE PFE   and Bristol Myers Squibb Company   NYSE BMY     both are Zacks Rank  1  Strong Buy  stocks  Johnson   Johnson carries a Zacks Rank  2  Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-29,Zacks Investment Research,"https://www.investing.com/analysis/abbvie,-j-j's-imbruvica-gets-breakthrough-therapy-status-200139277",200139277
199076,420592,JNJ,Tesaro Stock Up On Successful Phase III Ovarian Cancer Trial,opinion,"Shares of Tesaro  Inc    NASDAQ TSRO   surged 108  after the company announced that its phase III trial  NOVA  on oncology drug niraparib successfully achieved the primary endpoint of progression free survival  PFS  
The double blind  placebo controlled  international trial  n 500  was designed to define those patients who are most likely to benefit from niraparib  The trial evaluated niraparib in patients suffering from recurrent ovarian cancer who were in response to their most recent platinum based chemotherapy  The trial showed that niraparib significantly prolonged PFS compared to placebo among various cohorts   patients who are germline BRCA mutation carriers  patients who are not germline BRCA mutation  non gBRCAmut  carriers but who have homologous recombination deficient  HRD  tumors as determined by the Myriad myChoice HRD test  and overall in patients who are not germline BRCA mutation carriers  Hence  the trial demonstrates that a single  daily  oral dose of niraparib is much superior in prolonging PFS in women with recurrent ovarian cancer 
The company will present full results from the trial at the European Society for Medical Oncology  ESMO  congress in Oct 2016  The company also plans to submit its New Drug Application  NDA  and Marketing Authorization Application  MAA  on niraparib in the fourth quarter of 2016 
Nearly 22 000 women are diagnosed with ovarian cancer in the U S  every year  while 80  are diagnosed after the disease has become symptomatic and has progressed to a late stage  Moreover  majority of the women who are diagnosed with advanced ovarian cancer are likely to experience a relapse of their disease 
This underscores the need for new treatment options to extend the time between the cycles of platinum based chemotherapy for these patients  As per the company  there is currently no approved therapy in the U S  for the maintenance treatment of patients with recurrent ovarian cancer following response to platinum  Hence  the successful phase III trial results bode well for Tesaro as a potential approval of niraparib will boost its portfolio TESARO INC Price and Consensus
   We note that the FDA approved Tesaro s first commercial product  Varubi  for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy in Sep 2015 
Tesaro currently carries a Zacks Rank  4  Sell   Investors interested in the healthcare sector may consider stocks like Pfizer  Inc    NYSE PFE    Bristol Myers Squibb Co    NYSE BMY   and Johnson   Johnson   NYSE JNJ    While Pfizer and Bristol Myers sport a Zacks Rank  1  Strong Buy   Johnson   Johnson is a Zacks Rank  2  Buy  stock ",2016-06-30,Zacks Investment Research,https://www.investing.com/analysis/tesaro-stock-up-on-successful-phase-iii-ovarian-cancer-trial-200139377,200139377
199077,420593,JNJ,AbbVie Humira Gains FDA Approval For Yet Another Indication,opinion,"AbbVie Inc    NYSE ABBV   announced a label expansion for its anti inflammatory drug  Humira  in the U S  With the label expansion  Humira can now be used for the treatment of adults suffering from non infectious intermediate  posterior and panuveitis  Approval makes Humira the first and only FDA approved non corticosteroid treatment for this indication 
We note that this is the tenth FDA approval for Humira in the U S  This approval comes after Humira gained approval in the EU last month for the treatment of non infectious intermediate  posterior and panuveitis in adults who have had an inadequate response to corticosteroids  in patients in need of corticosteroid sparing  or in whom corticosteroid treatment is inappropriate 
Humira is currently approved in the U S  for several indications including psoriatic arthritis  ankylosing spondylitis  moderate to severe rheumatoid arthritis  polyarticular juvenile idiopathic arthritis  Crohn s disease  CD   hidradenitis suppurativa  ulcerative colitis  and chronic plaque psoriasis  It is also approved for the treatment of moderate to severe CD in children six years of age and older 
We note that Humira enjoys orphan drug status in the U S  for the treatment of certain forms of uveitis  which affect a population of fewer than 200 000 patients  The orphan drug status should now make Humira eligible for seven years of market exclusivity for the treatment of adults with non infectious intermediate  posterior and panuveitis 
We note that Humira is the key growth driver at AbbVie  The drug recorded total sales of  14 billion in 2015  reflecting an 11 7  surge  Label expansion should boost the commercial potential of the drug 
AbbVie is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the healthcare sector include Pfizer Inc    NYSE PFE    Bristol Myers Squibb Company   NYSE BMY   and Johnson   Johnson   NYSE JNJ    While Pfizer and Bristol Myers are Zacks Rank  1  Strong Buy  stocks  Johnson   Johnson carries a Zacks Rank  2  Buy  ",2016-06-30,Zacks Investment Research,https://www.investing.com/analysis/abbvie-humira-gains-fda-approval-for-yet-another-indication-200139578,200139578
199078,420594,JNJ,Shire Stock Up Despite Mixed Data On Pipeline Candidate,opinion,"Shire plc   NASDAQ SHPG   announced disappointing results from a phase II study on pipeline candidate SHP607 
The multicenter  randomized  controlled study  ROPP 2008 01  compared experimental protein replacement  SHP607  to the standard neonatal care in 121 premature infants who were born at a gestational age of 23 weeks to 27 weeks plus 6 days  These patients were randomized at birth to receive either SHP607 or the standard neonatal care  and were treated until an equivalent gestational age of 30 weeks 
The study did not meet its primary endpoint of reducing the severity of retinopathy of prematurity  ROP   However  it demonstrated clinically relevant effects in the secondary endpoints related to the development of severe bronchopulmonary dysplasia  BPD   a chronic lung disease  and severe intraventricular hemorrhage  IVH    a type of brain injury 
Top line data from the study showed a 53  reduction in the incidence of severe BPD in all patients who received SHP607  as compared to untreated infants  The data also showed an 89  reduction in those who achieved the prespecified target drug exposure  The secondary endpoint of time to discharge from neonatal intensive care was  however  not met 
As per the data provided by the company  approximately 28 000 infants are born extremely premature  before 28 weeks of gestation  in the U S  According to research  60  of extremely premature infants experience one or more severe complications related to prematurity  which include  IVH  grade  3   BPD  or ROP thereby underscoring the need for treatments for the same 
Consequently  Shire expects to initiate discussions with regulatory authorities about a phase III clinical program focusing on clinically relevant complications of prematurity  Meanwhile  Shire is enrolling patients from the phase II study into a five year observational long term outcomes study SHIRE PLC ADR Price
   Share price was up on mixed results  Shire has built a deep pipeline in ophthalmology comprising early   mid  and late stage candidates gained through organic growth and strategic acquisitions  We remind investors that Shire s ophthalmic pipeline currently includes candidates for the potential treatment of dry eye disease  lifitegrast   infectious conjunctivitis  SHP640   ROP  SHP607   autosomal dominant retinitis pigmentosa and glaucoma 
Shire currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Pfizer  Inc    NYSE PFE    Bristol Myers Squibb Co    NYSE BMY   and Johnson   Johnson   NYSE JNJ    While Pfizer and Bristol Myers sport a Zacks Rank  1  Strong Buy   Johnson   Johnson is a Zacks Rank  2  Buy  stock ",2016-07-01,Zacks Investment Research,https://www.investing.com/analysis/shire-stock-up-despite-mixed-data-on-pipeline-candidate-200139612,200139612
199088,420604,JNJ,Identifying Opportunities In International Dividend ETFs,opinion,"When sorting through the list of available ETFs that offer high dividend yields  it s very obvious that investors favor U S  stocks  The overwhelming majority of assets are parked in funds with similar holdings such as AT T  NYSE T  and Johnson   Johnson  NYSE JNJ   They also have low expenses  a high degree of daily liquidity  and have performed admirably when viewed over 3  5  and even 10 year time horizons 
There is not much to complain about in U S  focused high dividend ETFs other than the lofty valuations and slowly deteriorating yields  This has many investors becoming concerned that the current pace of income and capital appreciation will be unsustainable when viewed through a long term lens 
Those who have ridden through these cycles in the past may be ready to expand the scope of their investment focus in the months and years ahead  One option to consider are dividend ETFs with an international income emphasis  Many of these funds offer greater yields  more attractive valuations  or simply  
iShares International Select Dividend ETF  IDV 
IDV has one of the longest tenures and largest size in this category with over  2 7 billion in total assets  This exchange traded fund tracks 100 foreign stocks with an emphasis on high dividend yields  Top country allocations include the United Kingdom  Australia  and Canada  Developed markets make up the majority of this fund  which charges a net expense ratio of 0 50  and offers a 30 day SEC yield of 5 25  
For comparison purposes  the iShares Select Dividend ETF  DVY  sports a yield of 3 27   That means IDV offers a 60  higher dividend rate versus its U S  focused peer  Income from this ETF is paid on a quarterly basis as well 
Probably of greater importance to this discussion is the performance of IDV  which Barclays  LON BARC  lists on their website as  0 71  annualized  total return  over the last 5 years through May 31  2016  DVY has returned 12 68  annualized during that same time frame 

This gaping performance differential also helps explain why the P E ratio of the underlying stocks in DVY is 19 47 versus 13 74 for IDV  Put simply  international stocks are much cheaper than their domestic counterparts because they have lagged on the way higher 
SPDR S P International Dividend ETF  DWX 
Another comparable option to consider is DWX  which invests in a basket of 119 high dividend paying stocks outside the United States  This ETF has  944 million in total assets and charges an expense ratio of 0 45   The current 30 day SEC yield is 5 85  and dividends are also paid quarterly 
Some notable remarks about the DWX index is that included companies are screened for liquidity and market capitalization requirements  Constituents must also demonstrate positive 3 year earnings growth and profitability  Emerging market exposure is also capped at 15  during each annual rebalancing cycle 
It may appear from a casual glance that DWX and IDV have a similar number of holdings  yield  and expense ratio  However  these two funds do have noticeable variances in country exposure and stock selection criteria  This will likely lead to differing returns over various market cycles as their  
Vanguard International High Dividend Yield ETF  VYMI 
A relatively new fund in this category that I m excited about is VYMI  Not surprisingly  this ETF has one of the lowest expense ratios in the group at 0 30  and is supported by a broader index of 890 stocks  This means that VYMI is a much more suitable option for those looking to achieve extensive diversification in a single investment vehicle 
VYMI also has more exposure to Asia Pacific stocks with 20  of its portfolio and 16  dedicated to emerging markets  This makes for a highly differentiated portfolio offering versus the traditional model of more tightly grouped dividend paying indexes 
Vanguard has yet to post yield statistics for VYMI and the two initial dividends have been lumpy  It will be interesting to compare this offering versus its peers after a full year of distributions have been paid  My instinct is that this fund will have a modestly lower yield than IDV or DWX in conjunction with its larger number of holdings 
The Bottom Line
For   this gap in performance and fundamental valuations should not go unnoticed  The hard part is being able to determine when it will eventually narrow and having the patience or fortitude to capture that opportunity 
Further complicating the waters is the practical fear that international stocks have recently shown greater volatility and undiscernible trends versus U S  markets  There is no way to know whether international stocks will just gradually drift higher as U S  stocks stagnate or if it will take a more pronounced shock to global markets in order to induce a new momentum trade 
In my opinion  this opportunity is one that will likely offer forward looking investors a sizeable advantage in the years ahead 
Disclosure   FMD Capital Management  its executives  and or its clients June hold positions in the ETFs  mutual funds or any investment asset mentioned in this article  The commentary does not constitute individualized investment advice  The opinions offered herein are not personalized recommendations to buy  sell or hold securities ",2016-06-23,David Fabian,https://www.investing.com/analysis/identifying-opportunities-in-international-dividend-etfs-200137741,200137741
199089,420605,JNJ,Gilead s  GILD  HIV Treatment Odefsey Gains Approval In EU,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced that its once daily single tablet regimen  STR  Odefsey gained approval in the EU for the treatment of HIV 1 infection in certain patients  Odefsey comprises Gilead s Descovy  Emtriva v 200 mg and tenofovir alafenamide TAF  25 mg  and Johnson   Johnson s   NYSE JNJ   Edurant  25 mg  
Odefsey is approved for the treatment of adults and adolescents  aged 12 years and older with body weight of at least 35 kg  without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor class  tenofovir or Emtriva  and with a viral load less than 100 000 HIV 1 RNA copies ml 
Following the approval of Genvoya in Nov 2015  Odefsey is the company s second STR containing Descovy and the third product to be added to Gilead s new TAF portfolio to receive approval in the EU  Moreover  Odefsey is the smallest STR pill for the treatment of HIV 
Earlier this year  Odefsey gained approval in the U S  for the treatment of HIV 1 infection 
We note that Odefsey approval is part of the ongoing development and commercialization agreement between Gilead and Johnson   Johnson s Janssen  which was struck in 2009  While Gilead is responsible for the manufacturing  registration  distribution and commercialization of Odefsey in most countries  Janssen will distribute it in about 18 markets and have co detailing rights in several key markets including the U S   
The original agreement was signed for the development and commercialization of Complera Eviplera and was expanded in 2014 to include Odefsey 
HIV is Gilead s one of the primary areas of focus and the company is working to bring new HIV treatments to market to boost sales of the franchise  Currently  an STR of bictegravir is being evaluated in phase III studies in combination with TAF and Emtriva for the treatment of HIV 1 infection 
Gilead is a Zacks Rank  5  Strong Sell  stock  A couple of better ranked stocks in the health care sector are ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Retrophin  Inc    NASDAQ RTRX    each sporting a Zacks Rank  1  Strong Buy  ",2016-06-23,Zacks Investment Research,https://www.investing.com/analysis/gilead's-(gild)-hiv-treatment-odefsey-gains-approval-in-eu-200138045,200138045
199090,420606,JNJ,Genmab Novartis  Arzerra Gets Unfavorable CHMP Opinion,opinion,Genmab A S  announced that the European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  rendered a negative opinion for Arzerra as a maintenance therapy for patients suffering from relapsed chronic lymphatic leukemia  CLL  Currently  Arzerra is approved in the EU in combination with Leukeran or Levact for the treatment of patients with CLL who have not received prior therapy and are not eligible for Fludara based therapy Additionally  the drug is approved in the U S  in combination with Leukeran for the treatment of previously untreated patients with CLL for whom Fludara based therapy is considered inappropriate as well as for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL We note that Arzerra is marketed under a collaboration agreement between Genmab and Novartis AG   NYSE NVS    wherein Novartis holds the rights to develop Arzerra for autoimmune indications  including multiple sclerosis Genmab also has a collaboration agreement with Johnson   Johnson s   NYSE JNJ   Janssen Biotech  Inc  for the development  manufacture and commercialization of Darzalex  Darzalex is currently in several phase III studies in relapsed and frontline settings while additional studies are ongoing or being planed for other malignant and pre malignant diseases on which CD38 is expressed  like smoldering myeloma  non Hodgkin s lymphoma and a solid tumor Last year  Darzalex got accelerated FDA approval for the treatment of multiple myeloma patients who have received at least three prior lines of therapy  including a proteasome inhibitor  PI  and an immunomodulatory agent  or who are double refractory to a PI and an immunomodulatory agent Meanwhile  Darzalex gained conditional approval in the EU in May 2016 for use as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma  whose prior therapy included a PI and an immunotherapy agent and who have demonstrated disease progression on the last therapy Genmab is a Zacks Rank  2  Buy  stock  Another favorably ranked stock in the health care sector is ANI Pharmaceuticals  Inc    NASDAQ ANIP    sporting a Zacks Rank  1  Strong Buy  ,2016-06-24,Zacks Investment Research,https://www.investing.com/analysis/genmab-novartis'-arzerra-gets-unfavorable-chmp-opinion-200138135,200138135
199091,420607,JNJ,Pfizer Investing  350M In China  Setting Up Biotech Center,opinion,Pfizer Inc    NYSE PFE   is boosting its presence in China by setting up a state of the art Global Biotechnology Center in the Hangzhou Economic Development Area  HEDA   The company will be investing about  350 million in the facility which will be Pfizer s third biotechnology center globally and the first in Asia Pfizer intends to manufacture high quality  affordable biosimilar medicines at the Center to cater to patients in China as well as across the world  The Center is scheduled to be completed in 2018  China remains an attractive investment area for several companies given the rising incidence of non communicable diseases and an aging population We remind investors that Pfizer s biosimilar portfolio was significantly enhanced with the acquisition of Hospira last year  Earlier this year  the company s biosimilar version of Remicade gained FDA approval while key programs include biosimilar versions of Herceptin  Rituxan  Avastin  and Humira The biosimilars market represents huge commercial potential  On its first quarter call  Pfizer had mentioned that approximately  100 billion of currently patented branded biologics are expected to lose patent protection in the next 5   10 years  Moreover  the company said that the global market for biosimilars is expected to grow from around  1 billion annually in 2013 to  17 billion    20 billion in 2020 Pfizer is a Zacks Rank  1  Strong Buy  stock  Other well ranked large cap pharma stocks include Bristol Myers Squibb Company   NYSE BMY    Johnson   Johnson   NYSE JNJ   and Bayer  DE BAYGN  AG   OTC BAYRY   Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-27,Zacks Investment Research,"https://www.investing.com/analysis/pfizer-investing-$350m-in-china,-setting-up-biotech-center-200138782",200138782
199092,420608,JNJ,Roche s Multiple Sclerosis Drug Under Review By FDA  EMA,opinion,"Roche Holding  SIX ROG    OTC RHHBY   announced that the FDA has accepted its Biologics License Application  BLA  for Ocrevus  ocrelizumab  for review as the treatment of relapsing multiple sclerosis  RMS  and primary progressive multiple sclerosis  PPMS  
The BLA was also granted Priority Review Designation with a targeted action date of Dec 28  2016 
Additionally  the EMA has validated Roche s Marketing Authorization Application  MAA  for Ocrevus 
We note that Priority Review Designation is granted to medicines that the FDA believes to have the potential for significant improvements in safety and effectiveness of a treatment of a serious disease 
Earlier in 2016  the FDA had granted Breakthrough Therapy designation to Ocrevus for the treatment of PPMS 
We note that Roche is evaluating Ocrevus in a phase III development program   OPERA I  OPERA II and ORATORIO  While OPERA I and OPERA II are identical phase III  randomized  global multi center studies that are evaluating the efficacy and safety of Ocrevus  600 mg administered by intravenous infusion every six months  versus interferon beta 1a  44 mcg administered by subcutaneous injection three times per week  for the treatment of relapsing forms of MS  relapsing remitting MS and secondary progressive MS with relapses  
Meanwhile  the randomized phase III study  ORATORIO  is evaluating the efficacy and safety of Ocrevus  600 mg administered by intravenous infusion every six months  as compared to placebo in patients with PPMS ROCHE HLDG LTD Price and Consensus
   We are impressed by the company s efforts to grow its portfolio beyond oncology and foray into new avenues such as MS and asthma  Roche currently has more than a dozen pipeline candidates for diseases that include MS  Alzheimer s disease  spinal muscular atrophy  Parkinson s disease  Down syndrome and autism 
The company currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Pfizer  Inc    NYSE PFE    Bristol Myers Squibb Co    NYSE BMY   and Johnson   Johnson   NYSE JNJ    While Pfizer and Bristol Myers sport a Zacks Rank  1  Strong Buy   Johnson   Johnson is a Zacks Rank  2  Buy  stock ",2016-06-29,Zacks Investment Research,"https://www.investing.com/analysis/roche's-multiple-sclerosis-drug-under-review-by-fda,-ema-200139046",200139046
199099,420615,JNJ,Kura  KURA  Begins Dosing In Phase II Study On Cancer Drug,opinion,"Kura Oncology  Inc    NASDAQ KURA   announced the dosing of the first patient in a phase II study on its farnesyl transferase inhibitor  tipifarnib  being developed for the treatment of patients suffering from lower risk myelodysplastic syndromes  MDS  
The study will enroll about 58 patients and patient samples will be analyzed for the presence or absence of various biomarkers possibly relevant to the activity of tipifarnib 
We are encouraged by the company s progress with tipifarnib  Per information provided by Kura in its press release  MDS is estimated to have an annual incidence of roughly 13 000 patients in the U S  and is usually associated with poor prognosis due to the low response rate to available treatment options 
We note that Kura in licensed tipifarnib from Johnson   Johnson s   NYSE JNJ   Janssen in Dec 2014 
In addition to the MDS study  tipifarnib is being evaluated in several other phase II studies in patients with locally advanced solid tumors that carry HRAS mutations and in patients with peripheral T cell lymphomas  The candidate is also currently being evaluated in an investigator sponsored phase II study in patients with advanced  previously treated urothelial carcinomas that carry HRAS mutations 
The company also plans to initiate a phase II study on tipifarnib for the treatment of chronic myelomonocytic leukemia in the second half of 2016  Considering that Kura has no approved product in its portfolio at the moment with tipifarnib being the company s lead pipeline candidate  we expect investor focus to remain on updates pertaining to its development 
Kura is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the health care sector are Retrophin  Inc    NASDAQ RTRX   and Bristol Myers Squibb Company   NYSE BMY    each sporting a Zacks Rank  1  Strong Buy  ",2016-06-17,Zacks Investment Research,https://www.investing.com/analysis/kura-(kura)-begins-dosing-in-phase-ii-study-on-cancer-drug-200136705,200136705
199100,420616,JNJ,Top Stock PIcks For The Week Of June 20th ,opinion,"Johnson   Johnson  NYSE JNJ   is engaged in the research and development  manufacture and sale of a range of products in the healthcare field  The Company operates in three segments  Consumer  Pharmaceutical  and Medical Devices and Diagnostics  Its Consumer segment offers products for use in the baby care  skin care  oral care  wound care  and women s health fields  nutritional and over the counter pharmaceutical products  The company s Pharmaceutical segment provides various products in the areas of anti infective  antipsychotic  contraceptive  dermatology  gastrointestinal  hematology  immunology  neurology  oncology  pain management  thrombosis  vaccines  and infectious diseases  Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products  orthopedic joint reconstruction  spinal care  neurological  and sports medicine products  surgical care  aesthetics  and women s health products  Johnson   Johnson is based in New Brunswick  New Jersey 
 
Canadian Imperial Bank of Commerce  CM   is a leading North American financial institution that offers a full range of products and services through its comprehensive electronic banking network  branches and offices across Canada  in the United States and around the world  It offers these services through two distinct business lines  CIBC Retail Markets and CIBC World Markets  The former comprises CIBC s personal  business banking and wealth businesses  It provides a full range of financial products and services to personal  business and wealth management clients  as well as investment management services globally to retail and institutional clients  CIBC is headquartered in Toronto  Canada ",2016-06-20,Zacks Investment Research,https://www.investing.com/analysis/top-stock-picks-for-the-week-of-june-20th-200137064,200137064
199101,420617,JNJ,Commercial Vehicle Group  Houlihan Lokey  Johnson   Johnson And Canadian Imperial Bank Of Commerce Highlighted As Zacks Bull And Bear Of The Day ,opinion,"For Immediate Release

Chicago  IL   June 21  2016    highlights Commercial Vehicle Group    as the Bull of the Day and  Houlihan Lokey    as the Bear of the Day  In addition  Zacks Equity Research provides analysis on Johnson   Johnson  NYSE JNJ     and  Canadian Imperial Bank of Commerce    

Here is a synopsis of all four stocks  

  

Commercial Vehicle Group    absolutely crushed the Zacks Consensus Estimate and is now benefiting from the  post earnings drift  higher  The stock is a Zacks Rank  1  Strong Buy  and today it is the Bull of the Day 

The Numbers

CVGI beat the Zacks Consensus Estimate of a loss of  0 09 by  0 19 for a 211  positive earnings surprise  The topline was equally as strong with the company reporting revenues of  180M and that was  15M more than expected for a 9  positive revenue surprise 

As a result of the great performance Wall Street sent shares of CVGI higher by more than 19  in the session following the release 

Description

Commercial Vehicle Group sells various cab related products and systems for Trucks and busses Commercial Vehicle Group  Inc  was founded in 2000 and is headquartered in New Albany  Ohio 

Earnings History

The most recent beat was nice  not just because of its size but also because it ended a streak of three straight misses  The company had not topped the Zacks Consensus Estimate since the March 2015 quarter when an eight cent beat was good for a positive earnings surprise of 160  

Estimates

The thing about a huge beat like the most recent one is that it can really change the outlook  The Zacks Consensus Estimate was calling for a loss of  0 16 in April  but following the beat the number flipped to a gain  and a big one at that  We are now looking for a  0 13 gain and that is a huge  0 29 move 

The 2017 Zacks Consensus Estimate flipped from a loss of   011 to a gain of  0 15  Again  another big move there too  and that comes with even less visibility 

Valuation

The valuation is a little stiff for CVGI  37x forward PE is sort of big especially when the industry average is only 9 5x  The price to book multiple of 2 1x is just a little ahead of the 1 7x industry average  The price to sales multiple is the only stat that I tend to look at that shows this stock trading at a discount  CVGI trades at 0 2x price to sales multiple  while the industry average is 0 6x 

 

Houlihan Lokey    posted back to back misses of the Zacks Consensus Estimate  That alone will not make a stock the Bear of the Day  so let s figure out why the stock is now a Zacks Rank  5  Strong Sell  and the Bear of the Day 

The Numbers

HLI missed the Zacks Consensus Estimate of  0 45 by  0 02 for a 4 4  negative earnings surprise in the most recent quarter 

Description

Houlihan Lokey is an independent investment bank with focus on mergers and acquisitions  financings  financial restructurings and financial advisory services 

Earnings History

Usually when a stock is the Bear of the Day  the earnings history is filled with misses  This is also the case for HLI  as there are two misses in the only three quarters that have been reported 

Estimates

Here is the real reason the stock is a Zacks Rank  5  Strong Sell  and the Bear of the Day  The Zacks Consensus Estimate has fallen steadily over the last few months  The FY16 estimate stood at  1 84 in April but fell to  1 75 in May and has remained there throughout the month of June 

Next year has not seen any movement in the estimate that started as  2 02 in September of last year 

Additional content 

Top Stock Picks for the Week of June 20th

Johnson   Johnson    is engaged in the research and development  manufacture and sale of a range of products in the healthcare field  The Company operates in three segments  Consumer  Pharmaceutical  and Medical Devices and Diagnostics  Its Consumer segment offers products for use in the baby care  skin care  oral care  wound care  and women s health fields  nutritional and over the counter pharmaceutical products  The company s Pharmaceutical segment provides various products in the areas of anti infective  antipsychotic  contraceptive  dermatology  gastrointestinal  hematology  immunology  neurology  oncology  pain management  thrombosis  vaccines  and infectious diseases  Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products  orthopedic joint reconstruction  spinal care  neurological  and sports medicine products  surgical care  aesthetics  and women s health products  Johnson   Johnson is based in New Brunswick  New Jersey 

Canadian Imperial Bank of Commerce    is a leading North American financial institution that offers a full range of products and services through its comprehensive electronic banking network  branches and offices across Canada  in the United States and around the world  It offers these services through two distinct business lines  CIBC Retail Markets and CIBC World Markets  The former comprises CIBC s personal  business banking and wealth businesses  It provides a full range of financial products and services to personal  business and wealth management clients  as well as investment management services globally to retail and institutional clients  CIBC is headquartered in Toronto  Canada 

Want the latest recommendations from Zacks Investment Research  Today  you can download7 Best Stocks for the Next 30 Days   



About the Bull and Bear of the Day

Every day  the analysts at Zacks Equity Research select two stocks that are likely to outperform  Bull  or underperform  Bear  the markets over the next 3 6 months 

About the Analyst Blog

Updated throughout every trading day  the  provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets 

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous analyst coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact

Zacks Investment Research

800 767 3771 ext  9339





Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-06-20,Zacks Investment Research,"https://www.investing.com/analysis/commercial-vehicle-group,-houlihan-lokey,-johnson---johnson-and-canadian-imperial-bank-of-commerce-highlighted-as-zacks-bull-and-bear-of-the-day-200137284",200137284
199102,420618,JNJ,7 Profitable Medical Stocks Ranked As Buys Now,opinion,"It s been a tough few quarters for the medical sector with the NASDAQ Biotechnology Index and the NYSE ARCA Pharmaceutical Index declining 26 7  and 4 1  year to date  YTD   respectively  Several factors are weighing on the performance of the sector including increasing political and media focus on high price tags for new drugs  the changing competitive scenario  pipeline setbacks and mixed earnings reports among others However  is it all bad news for the sector  Not really   fundamentals remain strong with several companies continuing to generate robust revenues from key drugs and working on bringing innovative treatments to market Moreover  with valuations approaching reasonable levels  we could see several merger and acquisition  M As  agreements being announced as the year progresses  Quite a few of the major pharma and biotech companies are rumored to be on the look out for suitable deals  Sanofi  PA SASY  is currently looking to acquire cancer focused Medivation  Inc  while Shire recently acquired Baxalta While the drug pricing issue is not likely to die down easily    at least not until election is over   the medical sector could bounce back on the back of positive pipeline news  new product approvals  label expansions and sales ramp up of newly launched products and continued strong performance of existing products  So far in 2016  the FDA has approved 13 drugs and has expanded the label of cancer treatments like Kyprolis  Imbruvica and Xalkori Medical Sector Price Index7 Profitable Medical Stocks With Favorable Zacks RankFor investors averse to putting their money in high risk biotech and pharma stocks that bank on single products for growth or just have one major candidate in their pipeline  we have zeroed in on seven medical companies that have favorable Zacks Ranks    Zacks Rank  1  Strong Buy  and Zacks Rank  2  Buy    and are expected to be profitable this year New York based Pfizer  Inc    NYSE PFE   focuses on the development and commercialization of a wide range of products including human and animal biologic and small molecule medicines and vaccines  as well as consumer health care products  Pfizer s first quarter results surpassed expectations by a huge margin and the company s raised outlook was also above expectations 
This Zacks Rank  1 stock has seen its 2016 earnings estimate being raised by 6 9  over the past 60 days to  2 45 per share  representing year over year growth of 11 5   Cost cutting efforts and share buybacks should help Pfizer achieve its earnings guidance  Core products and new products like Ibrance should drive revenues  Moreover  the Hospira acquisition has significantly expanded Pfizer s sterile injectable and biosimilar capabilities 
Bristol Myers Squibb Company   NYSE BMY    another New York based stock  also performed well in the first quarter of 2016 and raised its earnings outlook for the year  This Zacks Rank  1 stock is focused on the development of innovative treatments for serious diseases and has a strong presence in the cancer market  The 2016 Zacks Consensus Estimate for this company is up 7 9  to  2 60 per share over the last 60 days  Earnings are expected to grow 29 5  in 2016 New Brunswick  NJ based Johnson   Johnson  Inc    NYSE JNJ   has started the year on a strong note with the company beating on all fronts and raising its outlook for the year  The 2016 Zacks Consensus Estimate for this Zacks Rank  2 stock is up 1 2  over the last 60 days with 6 4  earnings growth expected this year  A diversified business model  lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations  New as well as core products should continue performing well and share buybacks should help boost the bottom line La Jolla  CA based Ligand Pharmaceuticals Inc    NASDAQ LGND   is a biotechnology company with a focus on drug discovery  reformulation and partnering  The company s Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties  This Zacks Rank  2 stock s 2016 Zacks Consensus Estimate is up 0 7  over the past 60 days 
Ligand s earnings history is pretty impressive  with the company delivering positive earnings surprises over the last four quarters  Ligand s raised outlook for 2016 is encouraging  Geographical and label expansion of its key partnered assets  Promacta and Kyprolis  the anticipated approval and launch of up to five new partnered products  and continued development of the partnership portfolio are likely to boost the top line throughout 2016 Florham Park  NJ based Zoetis Inc    NYSE ZTS   is another company with rising earnings estimates and an impressive earnings history  The company  which came into existence following Pfizer s decision to spin off its animal health business  focuses on the discovery  development  manufacture and commercialization of animal health medicines and vaccines The 2016 Zacks Consensus Estimate for this Zacks Rank  2 stock is up 3 9  over the past 60 days with earnings expected to grow 5 2  Copenhagen  Denmark based Genmab A S  is a biotechnology company focused on the development of differentiated antibody therapeutics for the treatment of cancer  The company has two approved antibodies in its portfolio    Arzerra and Darzalex  Genmab has a licensing agreement with J J s Janssen Biotech for Darzalex  Efforts are ongoing to expand Darzalex s label  The 2016 Zacks Consensus Estimate for this Zacks Rank  2 stock is up 45 2  over the last 60 days Rancho Cucamonga  CA based specialty pharmaceutical company Amphastar Pharmaceuticals  Inc    NASDAQ AMPH   is a Zacks Rank  1 stock focused on developing  manufacturing  marketing  and selling technically challenging generic and proprietary injectable  inhalation  and intranasal products  The company also sells insulin active pharmaceutical ingredient products  Amphastar has a strong earnings track record and the Zacks Consensus Estimate for 2016 has improved considerably over the last 60 days from a loss of 6 cents per share to the current estimate of 5 cents per share  Earnings are expected to grow 183 3  this year Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-06-21,Zacks Investment Research,https://www.investing.com/analysis/7-profitable-medical-stocks-ranked-as-buys-now-200137356,200137356
199103,420619,JNJ,AstraZeneca Nasal Spray Flu Vaccine To Be Hit By ACIP Vote,opinion,AstraZeneca plc   NYSE AZN   confirmed that the Advisory Committee on Immunization Practices  ACIP  of the Centers for Disease Control and Prevention  CDC  has provided its interim recommendation related to the use of the company s  nasal spray  flu vaccine   FluMist Quadrivalent Live Attenuated Influenza Vaccine  LAIV  The ACIP voted that the vaccine should not be used during the 2016 2017 flu season in the U S  The vote was based on data showing poor or relatively lower effectiveness of FluMist Quadrivalent from 2013 through 2016  The data indicated that the vaccine did not show statistically significant effectiveness in children  2 17 years  Although AstraZeneca is working with the CDC to understand its data and ensure that eligible patients continue to receive the vaccine  the compact expects limited demand for its vaccine in the U S  in the second half of the year  FluMist Quadrivalent had brought in sales of  290 million last year  including sales of  206 million in the U S AstraZeneca said that it will be taking an inventory write down of about  80 million in the second quarter of 2016  However  2016 guidance remains unchanged  At the time of reporting first quarter results  the company had reiterated its guidance of a low to mid single digit percentage decline in both revenues and earnings  at constant exchange rates  The guidance takes into account the recent entry of generic competition for one of AstraZeneca s key branded drugs  Crestor  in the U S  Crestor had brought in worldwide sales of  5 billion in 2015 including U S  sales of  2 8 billion AstraZeneca is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the large cap pharma sector include Pfizer Inc    NYSE PFE    GlaxoSmithKline plc   NYSE GSK   and Johnson   Johnson   NYSE JNJ    While Pfizer is a Zacks Rank  1  Strong Buy  stock  Glaxo and Johnson   Johnson are Zacks Rank  2  Buy  stocks Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-22,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-nasal-spray-flu-vaccine-to-be-hit-by-acip-vote-200137815,200137815
199109,420625,JNJ,Glaxo J J Sirukumab Positive In Rheumatoid Arthritis Study,opinion,"GlaxoSmithKline plc   NYSE GSK   and Johnson   Johnson s   NYSE JNJ   Janssen Biologics announced encouraging new data from a pivotal phase III study  SIRROUND D  evaluating subcutaneous sirukumab for the treatment of patients suffering from moderately to severely active rheumatoid arthritis  RA  
The multi center  randomized  double blind  placebo controlled  parallel group study is in progress in patients with moderately to severely active RA who had an inadequate response to disease modifying antirheumatic drugs  Results demonstrated that patients when treated with sirukumab  50 mg and 100 mg  witnessed significant inhibition of radiographic progression or joint destruction from baseline to week 52 and improvement in signs and symptoms of RA at week 16 compared to the placebo group  thereby meeting both the co primary endpoints of the study 
Moreover  sirukumab also achieved all major secondary endpoints with statistical significance for both doses of sirukumab compared to placebo  The study is expected to be complete by Jan 2017 
Data from the SIRROUND D study will be presented at the annual European Congress of Rheumatology conference later this week  Currently  long term safety and efficacy data are being collected from ongoing extensions of phase III studies  Regulatory applications for sirukumab for RA have been planned in the third quarter of 2016 
We note that Glaxo is developing sirukumab under a licensing and co development agreement with Janssen  The agreement also gives both companies the option to evaluate sirukumab for additional indications beyond RA  In Nov 2015  Glaxo announced the initiation of a phase III study on sirukumab for the treatment of patients with giant cell arteritis and also plans to start a study for asthma 
In a separate press release  Glaxo announced new phase III data from a pivotal study  BLISS SC   which showed that patients with highly active systemic lupus erythematosus  SLE  experienced a significantly greater response when treated with Benlysta  200 mg  given through subcutaneous injection plus standard of care  SoC  compared to placebo plus SoC  Data was presented at the annual European Congress of Rheumatology 
Currently  an intravenous formulation of Benlysta is approved for the treatment of patients with SLE 
Glaxo is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the health care sector are Retrophin  Inc    NASDAQ RTRX   and Bristol Myers Squibb Company   NYSE BMY    both sporting a Zacks Rank  1  Strong Buy  ",2016-06-08,Zacks Investment Research,https://www.investing.com/analysis/glaxo-j-j-sirukumab-positive-in-rheumatoid-arthritis-study-200135075,200135075
199110,420626,JNJ,Merck  MRK  To Acquire Afferent In Deal Worth Up To  1 25B,opinion,Merck   Co  Inc    NYSE MRK   announced its intention to acquire privately held biotech company Afferent Pharmaceuticals in a deal which could see the company paying up to  1 25 billion Deal to Add Chronic Cough Treatment to PipelineWith the completion of this acquisition  Merck will add Afferent s lead pipeline candidate  AF 219  to its pipeline  AF 219 is in a phase IIb study for the treatment of refractory  chronic cough as well as a phase II study in idiopathic pulmonary fibrosis  IPF  with cough Afferent had presented data on AF 219 last month at the American Thoracic Society  ATS  International Conference  Results from the first cohort of a two cohort phase IIb dose escalation study showed that AF 219 significantly reduced cough frequency  Data from the second cohort  which is evaluating lower doses  will be presented at a future congress According to information provided by the company in its press release  chronic cough is estimated to affect about 10  of adults in the U S  With no approved therapies for the treatment of chronic cough  there is significant unmet need in this area Afferent has another candidate in its pipeline   AF 130   which completed phase I development and is slated to move into phase II studies for non respiratory conditions Merck Could Pay Up To  1 25 BillionWhile Merck will be making an upfront payment of  500 million  the company could make additional payments of up to  750 million on the achievement of development and commercial milestones for multiple indications and candidates including AF 219  The acquisition is scheduled to close in the third quarter of the year The deal is in line with Merck s efforts to boost its pipeline and bring new products to market  Earlier this year  Merck had acquired IOmet  a privately held UK based drug discovery company focused on the development of cancer treatments  with an emphasis on cancer immunotherapy and cancer metabolism Merck has more than 10 candidates in phase III development and recently got a favorable FDA panel recommendation  10 5 with one abstention  for Zinplava  bezlotoxumab  for the prevention of Clostridium difficile  C  difficile  infection recurrence in patients aged 18 years and older  A final response from the FDA should be out by Jul 23 Merck is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the large cap pharma sector include Bristol Myers Squibb Company   NYSE BMY    Pfizer Inc    NYSE PFE   and Johnson   Johnson   NYSE JNJ    While Bristol Myers and Pfizer are Zacks Rank  1  Strong Buy  stocks  Johnson   Johnson is a Zacks Rank  2  Buy  stock Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-10,Zacks Investment Research,https://www.investing.com/analysis/merck-(mrk)-to-acquire-afferent-in-deal-worth-up-to-$1.25b-200135297,200135297
199114,420630,JNJ,Zacks Investment Ideas Feature Highlights  Boston Scientific  Johnson   Johnson  Facebook  Lumber Liquidators And Chipotle,opinion,"For Immediate Release 

Chicago  IL   May 31  2016   Today  Zacks Investment Ideas feature highlights Features   Boston Scientific  NYSE BSX      Johnson   Johnson  NYSE JNJ      Facebook  NASDAQ FB      Lumber Liquidators      and Chipotle    

How to Buy Momentum  Trade Options   Short Stocks

Over the years  maybe you ve bought some individual stocks and some ETFs  You may own some mutual funds in a retirement account 

But now  you want to get out of your comfort zone and take your investing to the next level 

But how 

I ve recently explored 3 popular trading strategies on the Market Edge Podcast with Zacks stock strategists who use these strategies every day 

How to Buy Momentum Stocks

Perhaps momentum stocks interest you  You like buying stocks that have upward velocity and enjoy the adrenalin rush of getting in when everyone else is getting in too 

But you re unsure of how to pick momentum stocks 

Zacks Stock Strategist David Bartosiak  who also manages the  portfolio  shares his tips for finding the best momentum stocks including 

1  Buying when there is relative strength versus the market

2  Using the chart to find resistance  52 week highs and trend lines

3  How to use the Zacks Rank to increase your odds of finding the best momentum stocks

He talks about the momentum in Boston Scientific     and how some regional banks are also popping up on his momentum screen 

How to Trade Options

What about trading options 

If you ve been on Stocktwits enough times  you ll come across a lot of people talking about options and  calls  and  puts  and being  in the money  

Ever wonder what it all means 

Zacks Kevin Matras  who manages the  portfolio  breaks it all down for beginners 

He sets up the options trade on Johnson   Johnson    and Facebook     among a few others 

How to Short a Stock

Maybe you don t want to be a long only trader anymore  You have some ideas on shorting some stocks 

But how do you get started 

Jeremy Mullin  the manager of  portfolio  which is both long and short on individual stocks  describes two main scenarios that traders should watch for when deciding to short a stock 

1  When an  event  of some kind happens  Recent examples of this were with Lumber Liquidators     when it was the focus of a 60 Minutes segment about its Chinese laminate flooring and Chipotle    which had to shut restaurants after a health scare 

2  When there are disappointing fundamentals  This usually happens when a company reports earnings or pre announces disappointing sales or guidance  Recent examples of this scenario were with LinkedIn  NYSE LNKD  and Michael Kors  Both stocks plunged on earnings fears  and rebounded 

Be sure to check out these three strategies and the Market Edge Podcast every week for even more trading ideas  

About Zacks

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact

Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-05-30,Zacks Investment Research,"https://www.investing.com/analysis/zacks-investment-ideas-feature-highlights:-boston-scientific,-johnson---johnson,-facebook,-lumber-liquidators-and-chipotle-200133106",200133106
199115,420631,JNJ,J J To Buy Vogue For   3 3B  Boost Hair Care Portfolio,opinion,"Johnson   Johnson   NYSE JNJ   announced that Johnson   Johnson Consumer Inc  has entered into a definitive agreement under which it will acquire a privately held company Vogue International in a deal worth about  3 3 billion in cash  Based in Florida  Vogue is focused on the marketing  development and distribution of salon influenced and nature inspired hair care and other personal care products 
The proposed acquisition will give Johnson   Johnson a full line of leading advanced hair care products including the OGX collection of shampoos  conditioners  treatments  styling products  body care and bath products  the FX line of hair styling products  and the Proganix and Maui Moisture hair care lines 
The acquisition is slated to close in the third quarter of 2016 and is not expected to impact Johnson   Johnson s sales or earnings guidance for 2016 that was announced with first quarter 2016 results 
We are positive on the deal  The Vogue acquisition is in line with Johnson   Johnson s strategy of strengthening its global presence in the hair care category and will also complement the company s existing Consumer portfolio 
Johnson   Johnson s Consumer business currently has three  1 billion brands  The company expects to expand that to five  1 billion brands by 2020  The company has been working on prioritizing and investing in key Consumer areas including baby care  skin care and over the counter products and has been striking deals to augment the segment further 
This April  it announced its intention to acquire a privately held company NeoStrata  in a bid to boost its skin care portfolio  Financial terms of the agreement were undisclosed and the transaction is expected to close in the first half of 2016 
Johnson   Johnson is a Zacks Rank  2  Buy  stock  Some favorably ranked stocks in the health care sector include Pfizer Inc    NYSE PFE    Bristol Myers Squibb Company   NYSE BMY   and Retrophin  Inc    NASDAQ RTRX    All three stocks sport a Zacks Rank  1  Strong Buy  ",2016-06-02,Zacks Investment Research,"https://www.investing.com/analysis/j-j-to-buy-vogue-for-~$3.3b,-boost-hair-care-portfolio-200133864",200133864
199116,420632,JNJ,AbbVie At ASCO  Early Stage Data On ABT 414 And Rova T,opinion,AbbVie Inc    NYSE ABBV   was present at the ongoing annual meeting of the American Society of Clinical Oncology  ASCO  with early stage data on a couple of its pipeline candidates   ABT 414 and rovalpituzumab tesirine  Rova T   Both are antibody drug conjugates  ADC    while ABT 414 is being investigated for epidermal growth factor receptor  EGFR  amplified  recurrent glioblastoma  GBM   Rova T is being evaluated in patients with recurrent or refractory small cell lung cancer  SCLC   identified with high expression of delta like protein 3  DLL3  Safety and preliminary efficacy results from an expansion cohort of one arm  Arm C  of a three arm open label phase I study on ABT 414 showed no dose limiting toxicities and frequent  reversible ocular toxicities  Moreover  about 30  of patients treated with ABT 414 as monotherapy were progression free at six months According to information provided by AbbVie in its press release  amplified EGFR is the most common genetic mutation associated with malignant GBM  an aggressive brain cancer  Given the median survival of 15 months after diagnosis and two year survival rate of 30   there remains significant unmet need for a new treatment option for this type of brain cancer ABT 414 is currently in a randomized phase II study in patients with EGFR amplified GBM Meanwhile  there was a lot of interest in the Rova T data  considering AbbVie shelled out  5 8 billion and could pay up to an additional  4 billion  on the achievement of milestones  to Stemcentrx under an acquisition agreement New data on Rova T from a phase Ia Ib  multicenter  open label  dose escalation study showed a confirmed overall response rate  ORR  of 39  and clinical benefit rate  stable disease or better  of 89  in patients with recurrent or refractory SCLC  identified with high expression of DLL3 Median overall survival was 5 8 months and a one year overall survival  OS  rate of 32  was also observed in the recurrent refractory second  and third line patient population 18  of evaluable patients experienced tumor shrinkage  while 68  achieved clinical benefit  having at least stable disease   Almost all the patients who responded to the treatment had elevated levels of DLL3 in their tumor According to information provided by AbbVie in its press release  SCLC is an aggressive  difficult to treat form of cancer that accounts for roughly 13 15  of all lung cancers  The 5 year survival rate for extensive stage SCLC is less than 5  with limited treatment options available for the more than 234 000 people diagnosed every year with SCLC Rova T is currently in a single arm phase II pivotal study in patients with DLL3 positive SCLC that has worsened despite at least two prior therapies   according to AbbVie  Rova T has blockbuster potential and could be launched in 2018 AbbVie is a Zacks Rank  5  Strong Sell  stock  Some better ranked stocks in the health care sector include Pfizer Inc    NYSE PFE    Bristol Myers Squibb Company   NYSE BMY   and Johnson   Johnson   NYSE JNJ    While Pfizer and Bristol Myers are Zacks Rank  1  Strong Buy  stocks  Johnson   Johnson is a Zacks Rank  2  Buy  stock Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-05,Zacks Investment Research,https://www.investing.com/analysis/abbvie-at-asco:-early-stage-data-on-abt-414-and-rova-t-200134274,200134274
199121,420637,JNJ,Hedge Funds Are Buying These Stocks  Should You  ,opinion,"Hedge funds move markets more then you and I could ever dream  The actions that they take in the purchase and sales of equities make the notable headlines you see on a day to day basis  These moves are important to follow and can give investors clues on the future direction of a stock 
According to Barclayhedge com hedge funds managed over 2 7 trillion of capital in the first quarter of 2016  Approximately  866 Billion of that number is focused on equities and equity strategies  both long and short 
In chart below you can see the top ten new positions from the first quarter 2016 according to Factset  This data allows you to visualize where hedge fund money has been flowing so far this year  These funds aren t doing this for fun  they expect these stocks to go higher and are putting their money where their mouth is 

 
The stocks listed below are among the top 50 holdings among the top 50 hedge funds and are Zacks Rank  1 Strong Buy  or  2  Buy   These stocks are favorites in the hedge fund industry and have plenty of buying power behind them 
Canadian Pacific Railway  CP  is a Zacks Rank  1  Strong Buy  that operates a transcontinental railway in Canada and the United States and is the only transcontinental carrier with direct service to the Eastern Seaboard  It transports bulk commodities  including grain  coal  potash  fertilizers  and sulphur  and merchandise freight comprising finished vehicles and automotive parts  chemicals and plastics  crude oil  as well as petroleum  forest  industrial  metals  minerals  and consumer products  The Calgary based company has over 12 000 employees and was founded it 1881 
Canadian Pacific has a market cap of almost  20 Billion  a forward PE of 15 and pays a dividend of 0 80   The stock sports a Zacks Style Score of  C  in Value and has expected 3 5 year EPS growth of 12 19   The company reports earnings for Q2 on July 19th  where investors will look for an EPS beat after a 0 55  miss last quarter 
CEO E  Hunter Harrison made some comments yesterday at the Wolfe Research Conference in which he expected the second half of the year to be stronger then the first half  and is hopeful that the company can achieve fiscal year 2016 guidance  These comments are a relief to an industry that has seen carloads down  8 5  year over year according to the Association of American Railroads weekly traffic report on May 21st 
The stock is down 40  from all time highs  since EPS in late April the stock is down around 13   There is a lot of negativity priced in and investors should look at the company as a good way to enter the hated transportation rail space that is due for a bounce  This space is ranked 184 265  Bottom 31   of the Zacks Industry Rank and stock sentiment will quickly turn positive on the first sign of good news 
Hedge funds agree with that notion  with 13 different funds allocating over 2 6 Billion of capital into the stock 

Facebook  NASDAQ FB   FB  is a Zacks Rank  1  Strong Buy  that operates a popular social networking website worldwide  The Menlo Park  California based company has over 13 000 employees and was founded in 2004 
The company has a market cap of almost  337 Billion and a forward PE of 42  The stock sports a Zacks Style Score of  B  in Growth and Momentum  Growth is the key for Facebook as it has an expected 3 5 year EPS growth rate of 30 58   The next earnings report is on august 8th which follows a 29 55  EPS beat last quarter  which caused the stock to surge over 10  
Hedge funds love Facebook  with over  3 Billion of new money added last quarter  bringing the total amount to  8 Billion invested in Facebook  Looking at the chart below you can see why  The company has been on a steady rise since its IPO and is currently on a streak of three EPS surprises to the upside  Continued earnings momentum should continue to fuel the price higher and bring more funds in on the bid 

Johnson   Johnson  NYSE JNJ   JNJ  is a Zacks Rank  2  Buy  that is engaged in the research and development  manufacture and sale of a range of products in the healthcare field  The company operates in three segments  Consumer  Pharmaceutical  and Medical Devices and Diagnostics  The New Jersey based company has over 127 000 empoyees and was founded in 1885 
J J has a market cap of almost  311 Billion and a forward PE of 17  The stock sports a Zacks Style Score of  B  in Momentum and pays a dividend of 2 82   Over the next 3 5 years the J J sees expected growth at 5 73   Earnings for Q2 are on July 12th where the company will try to beat last quarter s upside surprise of 2 44   It hasn t missed on earnings in over four years  which helped the stock almost double since early 2012 
J J is a top ten new holding for hedge funds with over  728 Million allocated last quarter  The company s industry also has a rank of 42 out of 265  top 16   in the Zacks Industry Rank 

In Summary 
Hedge funds have underperformed the S P 500 so far this year  but following the stocks the big boys collectively buy can lead to big gains  As long as these stocks continue to attract the smart money  they typically will outperform  Investors should monitor quarterly filings in order to keep up with what stocks hedge funds are buying and selling and adjust their portfolios accordingly 
Note  Want more articles from this author  Scroll up to the top of this article and click the FOLLOW AUTHOR button to get an email each time a new article is published ",2016-05-26,Zacks Investment Research,"https://www.investing.com/analysis/hedge-funds-are-buying-these-stocks,-should-you-200132597",200132597
199122,420638,JNJ,How To Buy Momentum  Trade Options And Short Stocks,opinion,"Over the years  maybe you ve bought some individual stocks and some ETFs  You may own some mutual funds in a retirement account 

But now  you want to get out of your comfort zone and take your investing to the next level   

But how 

I ve recently explored 3 popular trading strategies on the Market Edge Podcast with Zacks stock strategists who use these strategies every day 
How to Buy Momentum Stocks

Perhaps momentum stocks interest you  You like buying stocks that have upward velocity and enjoy the adrenalin rush of getting in when everyone else is getting in too 

But you re unsure of how to pick momentum stocks  

Zacks Stock Strategist David Bartosiak  who also manages the  portfolio  shares his tips in this podcast for finding the best momentum stocks including 

1  Buying when there is relative strength versus the market
2  Using the chart to find resistance  52 week highs and trend lines
3  How to use the Zacks Rank to increase your odds of finding the best momentum stocks

He talks about the momentum in Boston Scientific  NYSE BSX     and how some regional banks are also popping up on his momentum screen  

How to Trade Options

What about trading options  

If you ve been on Stocktwits enough times  you ll come across a lot of people talking about options and  calls  and  puts  and being  in the money  

Ever wonder what it all means  

Zacks Kevin Matras  who manages the  portfolio  breaks it all down for beginners in this podcast  

He sets up the options trade on Johnson   Johnson  NYSE JNJ     and Facebook  NASDAQ FB     among a few others  

How to Short a Stock

Maybe you don t want to be a long only trader anymore  You have some ideas on shorting some stocks 

But how do you get started 

Jeremy Mullin  the manager of  portfolio  which is both long and short on individual stocks  describes two main scenarios that traders should watch for when deciding to short a stock 

1  When an  event  of some kind happens  Recent examples of this were with Lumber Liquidators    when it was the focus of a 60 Minutes segment about its Chinese laminate flooring and Chipotle    which had to shut restaurants after a health scare 

2  When there are disappointing fundamentals  This usually happens when a company reports earnings or pre announces disappointing sales or guidance  Recent examples of this scenario were with LinkedIn  NYSE LNKD  and Michael Kors  Both stocks plunged on earnings fears  and rebounded  


Be sure to check out these three strategies and the Market Edge Podcast every week for even more trading ideas  


Tracey Ryniec is the Value Stock Strategist for Zacks com  She is also the Editor of the  and  services  You can follow her on twitter at  and she also hosts the  on iTunes ",2016-05-26,Zacks Investment Research,"https://www.investing.com/analysis/how-to-buy-momentum,-trade-options-and-short-stocks-200132595",200132595
199123,420639,JNJ,Zacks Investment Ideas Feature Highlights  Canadian Pacific Railway  Facebook And Johnson   Johnson,opinion,"For Immediate Release 

Chicago  IL   May 27  2016   Today  Zacks Investment Ideas feature highlights Features  Canadian Pacific Railway     Facebook  NASDAQ FB     and Johnson   Johnson  NYSE JNJ     

Hedge Funds Are Buying These Stocks    Should You 

Hedge funds move markets more then you and I could ever dream  The actions that they take in the purchase and sales of equities make the notable headlines you see on a day to day basis  These moves are important to follow and can give investors clues on the future direction of a stock 

According to Barclayhedge com hedge funds managed over 2 7 trillion of capital in the first quarter of 2016  Approximately  866 Billion of that number is focused on equities and equity strategies  both long and short 

In chart below you can see the top ten new positions from the first quarter 2016 according to Factset  This data allows you to visualize where hedge fund money has been flowing so far this year  These funds aren t doing this for fun  they expect these stocks to go higher and are putting their money where their mouth is 

The stocks listed below are among the top 50 holdings among the top 50 hedge funds and are Zacks Rank  1 Strong Buy  or  2  Buy   These stocks are favorites in the hedge fund industry and have plenty of buying power behind them 

Canadian Pacific Railway     is a Zacks Rank  1  Strong Buy  that operates a transcontinental railway in Canada and the United States and is the only transcontinental carrier with direct service to the Eastern Seaboard  It transports bulk commodities  including grain  coal  potash  fertilizers  and sulphur  and merchandise freight comprising finished vehicles and automotive parts  chemicals and plastics  crude oil  as well as petroleum  forest  industrial  metals  minerals  and consumer products  The Calgary based company has over 12 000 employees and was founded it 1881 

Canadian Pacific has a market cap of almost  20 Billion  a forward PE of 15 and pays a dividend of 0 80   The stock sports a Zacks Style Score of  C  in Value and has expected 3 5 year EPS growth of 12 19   The company reports earnings for Q2 on July 19th  where investors will look for an EPS beat after a 0 55  miss last quarter 

CEO E  Hunter Harrison made some comments yesterday at the Wolfe Research Conference in which he expected the second half of the year to be stronger then the first half  and is hopeful that the company can achieve fiscal year 2016 guidance  These comments are a relief to an industry that has seen carloads down  8 5  year over year according to the Association of American Railroads weekly traffic report on May 21st 

The stock is down 40  from all time highs  since EPS in late April the stock is down around 13   There is a lot of negativity priced in and investors should look at the company as a good way to enter the hated transportation rail space that is due for a bounce  This space is ranked 184 265  Bottom 31   of the Zacks Industry Rank and stock sentiment will quickly turn positive on the first sign of good news 

Hedge funds agree with that notion  with 13 different funds allocating over 2 6 Billion of capital into the stock 

Facebook     is a Zacks Rank  1  Strong Buy  that operates a popular social networking website worldwide  The Menlo Park  California based company has over 13 000 employees and was founded in 2004 

The company has a market cap of almost  337 Billion and a forward PE of 42  The stock sports a Zacks Style Score of  B  in Growth and Momentum  Growth is the key for Facebook as it has an expected 3 5 year EPS growth rate of 30 58   The next earnings report is on august 8th which follows a 29 55  EPS beat last quarter  which caused the stock to surge over 10  

Hedge funds love Facebook  with over  3 Billion of new money added last quarter  bringing the total amount to  8 Billion invested in Facebook  Looking at the chart below you can see why  The company has been on a steady rise since its IPO and is currently on a streak of three EPS surprises to the upside  Continued earnings momentum should continue to fuel the price higher and bring more funds in on the bid 

Johnson   Johnson     is a Zacks Rank  2  Buy  that is engaged in the research and development  manufacture and sale of a range of products in the healthcare field  The company operates in three segments  Consumer  Pharmaceutical  and Medical Devices and Diagnostics  The New Jersey based company has over 127 000 employees and was founded in 1885 

J J has a market cap of almost  311 Billion and a forward PE of 17  The stock sports a Zacks Style Score of  B  in Momentum and pays a dividend of 2 82   Over the next 3 5 years the J J sees expected growth at 5 73   Earnings for Q2 are on July 12th where the company will try to beat last quarter s upside surprise of 2 44   It hasn t missed on earnings in over four years  which helped the stock almost double since early 2012 

J J is a top ten new holding for hedge funds with over  728 Million allocated last quarter  The company s industry also has a rank of 42 out of 265  top 16   in the Zacks Industry Rank 

In Summary 

Hedge funds have underperformed the S P 500 so far this year  but following the stocks the big boys collectively buy can lead to big gains  As long as these stocks continue to attract the smart money  they typically will outperform  Investors should monitor quarterly filings in order to keep up with what stocks hedge funds are buying and selling and adjust their portfolios accordingly 

About Zacks

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact
	Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-05-26,Zacks Investment Research,"https://www.investing.com/analysis/zacks-investment-ideas-feature-highlights:-canadian-pacific-railway,-facebook-and-johnson---johnson-200132652",200132652
199124,420640,JNJ,Minerva Surges On Positive Results On Depression Candidate,opinion,Shares of Minerva Neurosciences  Inc    NASDAQ NERV   soared 233 3  after the company announced positive top line results from a phase IIa trial on antidepressant drug candidate  MIN 117 The candidate is being evaluated for major depressive disorder  MDD   The objective of the trial is to test efficacy  safety and tolerability of MIN 117 over six weeks of treatment  The randomized double blind trial  n 84  tested two daily administered doses of MIN 117  0 5 mg and 2 5 mg  in moderate to severe MDD patients in four European countries The results of the trial showed dose dependent superiority of MIN 117 over placebo as measured by a change in the Montgomery Asberg Depression Rating Scale  MADRS   The results of the trial also demonstrated that MIN 117 at the 0 5 milligrams  mg  daily dose had an effect size  magnitude of difference  as compared to the placebo group of 0 23  while the 2 5 mg daily dose had an effect size of 0 33  Consequently  MIN 117 met both the primary and secondary endpoints The candidate showed a favourable safety and tolerability profile Per the World Health Organization  MDD is the leading cause of disability worldwide and a significant contributor to the overall global disease burden  thereby emphasizing the need for therapies to treat it The successful results of the trial bode well for Minerva Neurosciences which does not have any approved products in its portfolio  Other candidates in the company s pipeline include MIN 101   currently in phase IIb for schizophrenia   MIN 202  insomnia and the adjunctive MDD  among others We note that MIN 202 is being developed by Minerva in collaboration with Janssen Pharmaceutical NV  a Johnson   Johnson   NYSE JNJ   undertaking Minerva Neurosciences presently carries a Zacks Rank  2  Buy   A couple of other well placed stocks in the health care sector are Pfizer Inc    NYSE PFE   and Bristol Myers Squibb Company   NYSE BMY    Both companies sport a Zacks Rank  1  Strong Buy  ,2016-05-27,Zacks Investment Research,https://www.investing.com/analysis/minerva-surges-on-positive-results-on-depression-candidate-200132589,200132589
199129,420645,JNJ,Weekly Credit Update   17 May 2016 ,opinion,"Overall  European credit indices have been trading range bound over the past week  with the European main and crossover indices being broadly unchanged compared with last week  In government bond markets  Greek bonds outperformed  with the country s 10 year bond yield dropping by more than 50bp  on optimism about a potential forthcoming agreement for a new rescue package for the country after a meeting with eurozone finance ministers last Monday 
Last week was otherwise extremely busy in terms of new issuance activity in the euro corporate bond market  Total euro issuance came in well above EUR30bn  with some EUR20bn stemming from the corporate segment  which is the second highest volume in one single week so far this year  Among last week s issuers were Suez  Johnson   Johnson  NYSE JNJ   Total  General Motors  NYSE GM  and Kraft Heinz 
Last Friday  the ECB presented more details regarding its forthcoming corporate bond buying programme  According to the ECB  the purchases will be done by six national central banks with coordination from the ECB  Also  it was made clear that car companies will be part of the purchase programme  even though many of them have their own in house banks and as banks are excluded from the programme  Also  while the ECB can acquire up to 70  of a single bond  it said it will be mindful of the potential impact of its purchases on market liquidity 
To read the entire report Please click on the pdf File Below",2016-05-17,Danske Markets,https://www.investing.com/analysis/weekly-credit-update---17-may-2016-200130358,200130358
199130,420646,JNJ,Bear Of The Day  AbbVie  ABBV ,opinion,"AbbVie  ABBV  was big in the news this week after Federal regulators agreed to review a key patent for the anti inflammatory drug Humira  knocking the stock down 3 5  on over three times the average volume of 9 million shares 

According to a story from Dow Jones on Tuesday by Anne Steele  the US Patent and Trademark Office s Patent Trial and Appeal Board took up a petition by hopeful rival Coherus BioSciences  CHRS  to look at AbbVie s patent on a Humira dosing regimen to treat rheumatoid arthritis 

But ABBV shares were already pushed into the cellar of the Zacks Rank before this news because of a slide in earnings estimates over the past 30 days  Full year 2106 profit projections fell from  5 00 to  4 77 and the 2017 consensus EPS estimate dropped from  5 99 to  5 73   

And that loss of earnings momentum is what makes ABBV today s Bear of the Day by virtue of its Zacks  5 Rank  Strong Sell   This simply means that relative to over 4 000 other stocks across all sectors  ABBV has poor prospects for a price advance because of the magnitude and agreement of negative EPS revisions from analysts 

The Coherus Challenge

Part of this action by analysts in the past month may have been in anticipation of the move by Federal patent authorities  Coherus management revealed at an investor conference in January that the company planned to file an application this year to market a biosimilar  generic  version of Humira 

On Tuesday  Coherus Chief Executive Denny Lanfear said they are  confident that this will lead to a final decision nullifying  the patent 

Shares Coherus shot up nearly 16  to  18 83 on very strong volume of 1 6 million shares  over five times their daily average 

AbbVie responded  we are confident in the validity of our patents and will vigorously defend them  

 Humira is protected by many patents covering all aspects of its manufacture  formulation and indications  and the patents are the result of AbbVie s investment in biologic innovation and the unique attributes of Humira   a spokesperson said 

According to the Dow Jones article by Anne Steele  Humira was the second best selling drug in the U S  in 2015 and is AbbVie s largest source of revenue 

AbbVie has also been preparing for this competitive battle by taking out about 70 patents for Humira  one of the largest patent portfolios ever assembled for a single drug  

Again from Steele   The drug s primary U S  patent is due to expire in December  but AbbVie says the additional patents should keep copycat versions of Humira off the U S  market until at least 2022  and possibly longer  

Bottom Line for ABBV  Watch the Zacks Rank

While this patent battle could actually become a multi year war  after today s big news the analysts may continue to revise ABBV estimates downward  And that could keep it in the basement of the Zacks Rank for a while 

So if you are looking at big Biopharma stocks right now  check out Johnson   Johnson  NYSE JNJ   Pfizer  NYSE PFE   or Abbott Labs ABT   all with a Zacks  2 Rank  Buy  

Kevin Cook is a Senior Stock Strategist for Zacks where he runs the  portfolio ",2016-05-17,Zacks Investment Research,https://www.investing.com/analysis/bear-of-the-day:-abbvie-(abbv)-200130775,200130775
199142,420658,JNJ,Bonus Stock To Watch  Johnson   Johnson,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Johnson   Johnson  NYSE JNJ  pulled back the first two weeks of the year and found a bottom when the price fell below the 200 day SMA  A quick run higher led to a pullback to a higher low  In mid February it started higher again and did not look back  Over the next two months it would rise 11  to a high at 114 in April  The last two days of that run saw a gap higher and some topping tails 
It has pulled back since then  ending Friday above that gap and printing a Hammer candle  a possible reversal  The pullback also has brought the price back into the Bollinger Bands   On close inspection the trend line that was resistance as it was rising before the gap up is now acting as support  a retest  The price is also close to the rising 20 day SMA that has acted as support since February 
The RSI is pulling back but in the bullish zone while the MACD is crossed down  These look for short term downside but can flip quickly  There is support lower at 111 50 and 111 followed by 109 50 and 108 before 105  Resistance above stands at 114  Short interest is low under 1   The company is expected to report earnings next on July 19th and the stock goes ex dividend May 20th 
The chart has clear levels to look for a reversal higher against and to confirm a continuation lower  Perhaps you have owned it for that run  or missed it and are lamenting it  Well time to dry up those tears and look for a way in 
Looking at the options chains this week sees the biggest open interest above at 113 on the Put side  The May options have very large open interest at the 110 strike  suggesting a possible pullback  June has a very large open interest at the 115 strike on the call side  This reads for a possible short term pullback to continue and then a move higher 
Johnson   Johnson
Trade Idea 1  Buy the stock on a move over 112 75 with a stop at the rising trend line or the 20 day SMA 
Trade Idea 2  Buy the stock with a May 112 110 Put Spread and selling a June 115 Covered Call  30 cents for the collar  
Trade Idea 3  Buy the May 112 110 1 2 Put Spread for 12 cents 
Trade Idea 4  Sell the May 110 112 Strangle for a  2 10 credit 
Trade 1 is a straight buy following a confirmed reversal  Trade 2 adds a collar for protection for a pullback to that large open interest in May at 110 and selling the covered call at the large open interest in June  Trade 3 is a way to buy the stock at 108 should it pullback to 110 at may Expiry  Trade 4 looks for the large open interest to draw the stock to 110 at Expiry  a pin  and possibly give an entry at 108 
After reviewing over 1 000 charts  I have found some good setups for the week  This week s list contains the first five below to get you started early  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which as the calendar turns to May sees the equity markets are looking worn out and in general better to the downside 
Elsewhere look for gold to continue its uptrend while crude oil moves higher as well  The US Dollar Index is on the cusp of a major breakdown while US Treasuries churn with a bias to break to the upside  The Shanghai Composite looks to continue to consolidate along with Emerging Markets but look for the latter to be biased to eventually break that consolidation higher 
Volatility looks to remain subdued but not at the lows keeping the bias higher for the equity index ETFs NYSE SPY  NYSE IWM and NASDAQ QQQ  despite the moves lower  Their charts are more mixed with the QQQ firmly heading lower  the SPY pulling back in its uptrend and the IWM stalling  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  Please see my Disclaimer page for my full disclaimer",2016-05-02,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-may-2,-2016:-bonus-idea-200127162",200127162
199143,420659,JNJ,Aduro  ADRO  Q1 Loss Wider Than Expected  Revenues Fall,opinion,Aduro BioTech  Inc    NASDAQ ADRO   reported a loss of 45 cents per share in the first quarter of 2016  wider than the Zacks Consensus Estimate of a loss of 30 cents but narrower than the year ago loss of  39 97 Since Aduro does not have any approved product in its portfolio yet  the company s top line solely comprises collaboration  license and grant revenues Quarter in DetailQuarterly revenues were down 58 3  year over year to  4 million  primarily due to deferred revenues from the company s collaboration agreement with Johnson   Johnson s   NYSE JNJ   Janssen Biotech  Inc  Revenues were also below the Zacks Consensus Estimate of  13 5 million Research and development  R D  expenses escalated 97 2  to  20 9 million  primarily due to manufacturing costs related to the ongoing studies and personnel expenses General and administrative  G A  expenses were  9 million  up 45 2  year over year Pipeline UpdateMeanwhile  Aduro is progressing with the candidates in its pipeline  Currently  the company is evaluating CRS 207  in combination with GVAX Pancreas  in two phase IIb studies   ECLIPSE and STELLAR   in patients with metastatic pancreatic cancer  The company expects to present top line data from the ECLIPSE study in the second quarter of 2016 and interim data from the STELLAR study in the second half of the year Our TakeAduro s first quarter results were disappointing with the company reporting a wider than expected loss and revenues lagging estimates  However  we are positive on the company s collaboration with Janssen Biotech  which should drive revenues in the form of milestone payment  With a number of data readouts lined up for the coming quarters  we expect investors to focus on the company s pipeline updates  going forward Aduro currently has a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector are Aegerion Pharmaceuticals  Inc    NASDAQ AEGR   and Gilead Sciences Inc    NASDAQ GILD    both  sporting a Zacks Rank  1  Strong Buy  ,2016-05-03,Zacks Investment Research,"https://www.investing.com/analysis/aduro-(adro)-q1-loss-wider-than-expected,-revenues-fall-200127607",200127607
199144,420660,JNJ,SPX  Peaked Earnings And Weak Price Trends,opinion,"I recently talked about the S P 500 s ongoing trading range 

First of all  it is worth noting that despite all of the recent excitement of the markets advance  it remains extremely confined in a sideways trading range  This can either be good or bad news 
The Good  Sideways consolidations during bullishly biased markets provides the ability to work off excesses built up during the previous advance to provide the  fuel  necessary for the next leg higher 
The Bad  However  sideways consolidations can also mark the end of the previous bullish advance and the beginning of a bearish decline 



How do we know the difference  Normally  fundamentals tell the story  When earnings are still rising  market consolidations tend to resume to the upside  However  declining earnings have historically marked market topping processes much as we see today 


Despite the roller coaster ride over the last 16 months  most of the major markets have made little or no progress  That is with the exception of the recent explosion in large cap  dividend paying companies  This  yield chase  puts investors into a tremendous amount of risk as historically such  investment crowding  tends to end badly 

The real problem is the mentality behind the crowding of investors into  yield stocks   
The Fed s zero interest policy has driven investors from normally more secure forms of income  bonds and money market funds  into equities in a quest to generate income  Furthermore  it is currently believed that dividend paying companies are  safer  than other areas of the market 
The problem for investors  as shown below  is that such beliefs tend to be wrong at the worst possible time  During the last recessionary driven sell off  dividend yielding stocks lost 51 4  of their value  It took two rounds of quantitative easing and three and one half years to get back to even  The problem is many investors dumped their stocks in 2008 and 2009 and failed to get back in until much later  In either case  years of an individual s saving and investment time horizon was lost 

During the next recessionary drag  several things will again happen  The first is that companies will cut dividends  as they are doing now  driving yields lower  This is shown in the chart below courtesy of Political Calculations 


For the first time since October 2015  the number of U S  firms that announced dividend cuts during a calendar month dropped below the level where we can be reasonably certain that at least part of the U S  economy is experiencing significant contraction 
But the bad news is that at 24 firms  the still elevated number of dividend cutting firms who communicated that they are experiencing economic distress during April 2016 indicates that the U S  economy is pretty far from being out of the woods 

Secondly  companies will cease  buying back shares  to boost bottom line EPS  which will take away a level of support for stock prices  Furthermore  the majority of these repurchases have been through debt accumulation  which is now back at peak levels  What could go wrong 

Finally  the lack of support will lead to falling stock prices  which will destroy years of dividend accumulation for investors  Ultimately  the  yield chase  will end  as it always does  with investors giving up on the idea of  owning stocks for the long run  in exchange for  I need to keep what bit of value I have left in my portfolio   
I agree with Jeff Gundlach s recent statement 

The riskiest things are now stocks and other investments perceived to be safe  One of the most popular categories in US investing are low volatility stock funds  But there is no such thing  If you think that a stock like Johnson   Johnson  NYSE JNJ  can t go down  you re wrong  And if people own funds that invest in stocks which they think are immune from decline and they start to decline  all hell breaks loose 

Market To Nowhere
Let s get back to the current market  As we enter May and the end of the seasonally strong period of the year  it is worth noting that the markets are still trading lower  However  during that time frame  the market has certainly experienced a sharp rise in volatility  which has left investors questioning the efficacy of their preferred investment strategies 
As you are well aware  I increased equity exposure in portfolios when the markets broke above 2080 moving above the downtrend resistance from the May highs  As I stated then  by the time that such a move occurs the market is overbought and requires some consolidation before attempting a push higher 
In the chart below  you will see the extreme overbought condition of the market currently and the current process of reduction  Importantly  the last time such extremes existed was in November of 2015 heading into the Fed rate hike  That hike led to a critical unwinding of positions at the beginning of this year  

Currently  I DO NOT BELIEVE the Fed will hike rates further at any point prior to the November election  With employment and inflation data now hitting the Fed s  targets  for  normalizing rates  the new  perma excuse   as coined by Danielle DiMartino Booth  for not hiking rates is now    global weakness   
As long as the Fed signals ongoing  accommodation  by not hiking rates  the markets will continue to hold on to the belief that  stocks are the only game in town  
This is a risky proposition at best as earnings and profits continue their normal reversion process which  just to remind you  is driven by  real  economic activity  Eventually  the current  fantasy  of stock prices will have to meet the  reality  of economic underpinnings 
The question is whether the Fed can successfully convince investors to remain in stocks  keeping prices elevated  long enough for the economy to complete a recessionary cycle and return to growth 
While it is has never happened before in history  could this be the first time that the Fed is able to  engineer  a  soft landing  scenario in the economy 
Anything is certainly possible  however  the probability is more akin to a 2000 or 2008 scenario as the decoupling of the markets from the economy is corrected 

As shown in the long term chart above  the ongoing current topping process is very similar to what has been seen previously  Earnings have peaked  price trends are weak and the  market to nowhere  has existed for 16 months  
Eventually  the sideways trading market will end  The only question will be the catalyst that pushes stock prices higher or sends investors panicking to the sidelines  
I suspect we will find out that answer much sooner than most expect 

The stock market is like a carousel  you can get on and off horses at any time    Ron Miller",2016-05-03,Lance Roberts,https://www.investing.com/analysis/spx:-peaked-earnings-and-weak-price-trends-200127604,200127604
199145,420661,JNJ, Pharma ETFs Outlook    Drug Pricing Issues Remain In Focus,opinion,"The pharma sector remains in the limelight thanks to the drug pricing controversy  The sector has been under a lot of pressure since Sep 2015 when Democratic presidential frontrunner Hillary Clinton s  price gouging  tweet triggered a slide in healthcare stocks 

	While there have always been concerns regarding the pricing and affordability of prescription drugs  the issue is back in focus following a 5000  price hike implemented by Turing Pharmaceuticals for Daraprim  pyrimethamine  that was approved by the FDA way back in 1953 

	Other companies like Valeant are also under review for significantly hiking the prices of acquired drugs  According to the Oct 2015 Kaiser Health Tracking poll  affordability of prescription drugs remains at the top of the public s priority list for the President and Congress   focus should be on ensuring the affordability of high cost drugs to people who need them and taking steps to lower prescription drug prices 

	So drug companies may find it a bit difficult to justify their high prices by citing the years and funds that go into bringing new treatments to market and the need to invest in R D to bring additional treatments to market 

	In addition to the impact of the increasing political and media focus on high price tags for new drugs  other factors like oil prices  global terrorism and China are also weighing on the performance of the sector   Read   
M As to Continue  

	With the major price correction that has resulted in reasonable valuations  we could see several merger and acquisition  M As  agreements being announced as the year progresses  Meanwhile  small bolt on acquisitions will continue 

	However  with the Treasury Department coming out with new guidelines  tax inversion deals are once again losing popularity  The termination of the Pfizer Allergan merger agreement will act as a deterrent for deals of a similar nature 

	In licensing activities and collaborations for the development of pipeline candidates have also increased significantly  Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time  Small biotech companies are open to such deals    most of them find it challenging to raise cash  thereby making it difficult to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense to seek deals with pharma companies sitting on huge piles of cash   Read   

	Therapeutic areas attracting a lot of interest include central nervous system disorders  hepatitis C virus  HCV  and immunology inflammation  Another highly lucrative area is immuno oncology  Major players in this field include Bristol Myers  AstraZeneca  Merck  NYSE MRK  and Roche 

	Another trend being witnessed is the divestment of non core business segments  Companies like Pfizer  UCB  Novartis  Glaxo and AstraZeneca have all been a part of this trend  The monetization of non core assets allows these companies to focus on their areas of expertise 

	Restructuring activities are also gaining momentum as large pharma companies are looking to cut costs and streamline their operations  Most of these companies are re evaluating their pipelines and discontinuing programs which do not have a favorable risk benefit profile  Swapping of businesses is another activity that could pick pace in 2016 
New Products Should Gain Traction

	Highly awaited new products that gained approval last year should contribute significantly to revenues  While 45 new molecular entities  NMEs  and Biologics License Applications  BLAs  were approved by the FDA last year  so far in 2016  the FDA has approved 5 NMEs and BLAs 

	Biosimilars are also a focus area  Pfizer s acquisition of Hospira  NYSE HSP  gives it a strong position in the biosimilars market  Companies like Merck and Novartis are involved in the development of biosimilars as well   in fact  Novartis  Sandoz was the first company to launch a biosimilar in the U S  
Pharma ETFs in Focus

	Highlighted below are some pharma ETFs   ETFs present a low cost and convenient way to get a diversified exposure to the sector 
Powershares Dynamic Pharmaceuticals ETF   

	PJP  launched in Jun 2005 by Invesco PowerShares  tracks the Dynamic Pharmaceuticals Intellidex Index  The fund covers health care stocks  The top 3 holdings include Merck   Co  Inc   5 29    Gilead Sciences Inc  NASDAQ GILD    5 28   and Pfizer Inc   NYSE PFE   5 21    The total assets of the fund as of Apr 8  2016 were  1 177 6 million representing 23 holdings  The fund s expense ratio is 0 56  while dividend yield is 4 31   The trading volume is roughly 142 657 shares per day 
SPDR S P Pharmaceuticals ETF   

	XPH  launched in Jun 2006  tracks the S P Pharmaceuticals Select Industry Index  This ETF primarily covers pharma stocks  99 9   with the top 3 holdings being Relypsa  Inc   7 11    Pacira Pharmaceuticals  Inc   5 02    and Zoetis Inc  NYSE ZTS    4 87   

	Total assets as of Apr 8  2016 were  563 9 million representing 38 holdings  The fund s expense ratio is 0 35  and dividend yield is 0 60   The trading volume is roughly 117 304 shares per day 
iShares U S  Pharmaceuticals   

	IHE  launched in May 2006  seeks investment results that correspond generally to the price and yield performance of the Dow Jones U S  Select Pharmaceuticals Index  The fund mainly consists of pharma companies  86 6    Biotech companies account for about 13 3  of the fund 

	The top 3 holdings of this fund are Johnson   Johnson  NYSE JNJ   9 52    Pfizer  8 53   and Merck   Co  Inc   7 64    The total assets of the fund as of Apr 11  2016 were  659 million representing 42 holdings  The fund s expense ratio is 0 45  with the dividend yield being 1 06   The trading volume is roughly 48 947 shares per day 
Market Vectors Pharmaceutical   

	PPH was launched in Dec 2011 and tracks the Market Vectors U S  Listed Pharmaceutical 25 Index  While the expense ratio is 0 35   dividend yield is 2 31   The trading volume is roughly 32 886 shares per day 
Conclusion

	While negative currency impact and pricing pressure remain headwinds  cost cutting  downsizing and new products should support growth  Increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector 

	Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-05-04,Zacks Investment Research,https://www.investing.com/analysis/pharma-etfs-outlook----drug-pricing-issues-remain-in-focus-200128029,200128029
199146,420662,JNJ,Merck  MRK  Raises Outlook Following Q1 Earnings Beat,opinion,Merck   Co    NYSE MRK   reported first quarter 2016 earnings of 89 cents per share  surpassing the Zacks Consensus Estimate of 85 cents and increasing 4 7  from the year ago period Revenues for the quarter declined 1 2  to  9 3 billion  missing the Zacks Consensus Estimate of  9 5 billion  Currency movement negatively impacted revenues by 4  The Quarter in DetailMerck s Pharmaceutical segment posted revenues of  8 1 billion  down 2   Currency movement negatively impacted revenues by 4   Reduced operations in Venezuela also impacted sales Products like Remicade  loss of exclusivity in Europe and increasing biosimilar competition in this region   Nasonex  generic version launched in the U S  in Mar 2016   Zostavax  Isentress and Vytorin all recorded a decline in sales Meanwhile  Gardasil 9  Keytruda  Cubicin and ProQuad performed well  New product  Keytruda  brought in sales of  249 million in the first quarter of 2016  up from  214 million in the fourth quarter of 2015  Sales continue to be driven by new indications and geographical expansion Recently launched HCV product Zepatier brought in sales of  50 million Januvia Janumet sales grew 1  reflecting strong growth in the U S  and Europe  partially offset by lower sales in emerging markets Cubicin sales came in at  292 million  Cubicin will be losing patent protection in Jun 2016 following which sales are expected to fall significantly Merck s animal health segment posted revenues of  829 million  unchanged from the year ago quarter Marketing and administrative expenses declined 1 1  to  2 3 billion in the first quarter of 2016  R D spend declined 6  to  1 6 billion in the first quarter of 2016 reflecting lower licensing expenses Updates GuidanceMerck narrowed and raised its 2016 earnings guidance to  3 65    3 77 per share  including an approximately 2  negative impact from foreign exchange at mid April exchange rates  The company had previously guided towards 2016 earnings of  3 60    3 75 per share  including negative currency impact of approximately 4  The revised outlook reflects recent favorability in foreign exchange rates  partially offset by the earlier than expected entry of a generic version of Nasonex in the U S Revenues are now expected in the range of  39 0 billion    40 2 billion  including an approximately 2  negative impact from foreign exchange  The company had earlier guided towards revenues of  38 7 billion    40 2 billion  including a negative currency impact of about 3   The Zacks Consensus Estimate for earnings and revenues is currently  3 71 per share and  40 1 billion  respectively Meanwhile  Merck continues to expect marketing and administrative spend to decline from 2015 levels and R D spend to be slightly above 2015 levels  The company spent  6 6 billion and  9 8 billion on R D and marketing and administrative matters  respectively  in 2015 Our TakeWhile Merck s first quarter earnings were better than expected  revenues once again fell short of estimates  The top line will remain under pressure mainly due to increased competition as well as generic competition  Merck will continue to look toward cost cutting initiatives to drive the bottom line  We are also positive on Merck s efforts to expand its pipeline and focus on core areas of expertise  Investor focus will remain on the performance of new products like Keytruda and Zepatier Merck is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the large cap pharma sector include Bristol Myers Squibb Company   NYSE BMY    Johnson   Johnson   NYSE JNJ   and Novo Nordisk  CO NOVOb  A S   NYSE NVO    While Bristol Myers is a Zacks Rank  1  Strong Buy  stock  Johnson   Johnson and Novo Nordisk are Zacks Rank  2  Buy  stocks Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-05-04,Zacks Investment Research,https://www.investing.com/analysis/merck-(mrk)-raises-outlook-following-q1-earnings-beat-200128231,200128231
199156,420672,JNJ,Strong Earnings May Not Help Stocks,opinion,"Earnings Are Beating Estimates Like Crazy
In a not so surprising outcome  the number of companies beating earnings estimates currently is above the 12 quarter average  Via Zacks Research 

While growth remains problematic  actual results are turning out to be less bad relative to the low levels to which estimates had fallen ahead of this reporting cycle  More companies are coming out with positive surprises for both earnings as well as revenues 



Total earnings for the 209 S P 500 members that have reported results are down  5 5  from the same period last year on  1 6  lower revenues  with 75 6  beating EPS estimates and 56  coming ahead of top line expectations 

So  this is all good news and a reason to buy stocks  right  Not so fast 
The problem  as shown in the chart above  is that the pace of growth in earnings is far weaker than previous averages  Furthermore  while Wall Street will point to the  beat rate  as a reason why the current  bull market  is still intact  it has been a function of excessively low expectations 
The problem is that expectations for the second half of the year are still overly optimistic 


Many see the Q1 earnings season as the inflection point for corporate earnings  with the growth picture starting to improve from Q2 onwards and turning positive in the back half of the year  The relative more numerous positive surprises and the fewer negative revisions to current period estimates would support that view 

For profits to improve to such a degree in the second half of the year  such would suggest a resumption of economic growth both domestically and internationally  However  there is scant evidence currently that such is going to be the case given the ongoing drive to suppress interest rates and flood the financial system with liquidity  
As shown by the Economic Output Composite Index  Chasing Return But Still In Cash   economic growth is currently at levels more normally associated with recessions  The only previous anomaly was in 2012 as the combination of Central Bank interventions  a Japanese earthquake tsunami  a warm winter and falling energy prices all collided to drag forward consumption 

 The indicator uses a 6 month average to smooth out the month to month volatility caused by seasonal adjustment anomalies as we are currently witnessing  


Will the recent exceptionally warm winter  low energy prices  and Central Bank interventions once again be enough to stave off further economic weakness  We will have to wait and see 
Secondly  stock buybacks have been a major support of earnings reports over the last several quarters 
As top line revenue growth has remained mired in a slow growth state  along with the economy  bottom line earnings per share have skyrocketed due to ongoing cost cutting  wage suppression and share buybacks  Q1 is currently estimated to show the largest differential in Operating EPS  as compared non buyback adjusted Operating EPS  of  1 08 

What is interesting is when we take a look at the estimated Operating EPS for Q1 currently and compare that to the estimates for Q1 of 2016 in January of this year  Currently  Operating EPS for Q1 is expected to be  25 35 when in January it was estimated to be  28 05  If we back out  2 70 over estimation error  the current beat rate for earnings is actually ZERO 
But  of course  that takes all the fun out of the  beat the earnings estimates  game  doesn t it 
Warning In Today s GDP
Contributing Editor Michael Lebowitz  via 720 Global Research  penned the following Thursday morning 

In today s GDP release the Bureau of Economic Analysis  BEA  reported 0 50   annualized economic growth  a sharp departure from the 1 40  annualized growth of the prior quarter  
Economic growth is now running below a 1 00  annualized rate for the last two quarters and has been by and large trending lower for the last two years as graphed below 


Economists consider this quarter an anomaly as judged by their forecasts for a rebound in the second quarter  The current consensus projection for the second quarter ending June 30  2016  is 2 50   Despite a secular trend of slowing domestic economic growth and global economic weakness  few economists are predicting a recession this year  Then again  few have ever correctly forecast a recession   The graph below highlights the slowing secular trend in GDP growth and the series of cycles through which the U S  economy tends to move  Note that five of the last seven economic cycles have progressively peaked at lower levels  If the current cycle peaked in mid 2015  labeled  peak     a multi year decline in GDP growth is likely  The average decline in economic growth from peak to trough for the seven cycles has been  4 3   with  3 0  being the smallest decline  A 3 0  decrease from the current level of 2 3   implies that the U S  economy will have a three year period averaging  0 7  growth 

If economists are correct and economic growth in the second quarter remains true to forecasts  the economy will avoid a recession in the first half of the year  That said  we must consider that while economists foresee a pickup in economic activity  relying on their forecasts is dangerous   On February 14  2016  the Atlanta Federal Reserve was forecasting first quarter economic growth of 2 7   and a consensus of economists expected 2 1  growth  Based on today s GDP data  those forecasts were grossly off the mark  leaving one to question the integrity of second quarter forecasts 
Michael is correct  Importantly  however  will be the annual backward revisions to the data which will likely show that 2015 and 2016 economic growth was substantially weaker than current reports currently suggest  This was what was seen when 2012 growth rates were marked sharply downward as well  Of course  there is one main driver of recessions that we must now review 
Recessions Are Driven By The Market
As I penned previously 

Recessions don t cause bear markets  bear markets cause recessions 

George Soros once discussed the idea of  reflexivity  suggesting that 

Reflexivity sets up a feedback loop between market valuations and the so called fundamentals which are being valued  The feedback can be either positive or negative  Negative feedback brings market prices and the underlying reality closer together  In other words  negative feedback is self correcting  It can go on forever  and if the underlying reality remains unchanged  it may eventually lead to an equilibrium in which market prices accurately reflect the fundamentals 
By contrast  a positive feedback is self reinforcing  It cannot go on forever because eventually  market prices would become so far removed from reality that market participants would have to recognize them as unrealistic When that tipping point is reached  the process becomes self reinforcing in the opposite direction  That is how financial markets produce boom bust phenomena or bubbles  Bubbles are not the only manifestations of reflexivity  but they are the most spectacular 

This idea of reflexivity is important in understanding the relationship between market psychology and the ultimate outcome of the markets themselves  While the vast majority of the media and analysts continue to assert the markets are fine because there is currently  no signs of recession   it ignores the impact of the psychology of the participants 
Bear markets are a result of the switch of market psychology from  greed  to  fear  driven by an event that leads to a broad market  selling panic  that triggers a negative feedback loop in the market   reflexivity 
Recessions are coincident with market declines ONLY IN HINDSIGHT  The reason is due to the annual revisions to past economic data that only reveal the start and end of the recession after the fact   The chart below shows this effect  

Jeffrey Gundlach  head of Doubleline  recently made the same observation  stating 

We will be on watch for that  a recession  in the coming months  But it doesn t really matter  Recessions don t drive financial markets  It s the other way around  People are so focused on this  recession yes or no question   What really matters is that we are in a low nominal growth environment and global growth keeps getting marked down  It is going to be slower in 2016 than in 2015 

Here is the important point 

In a number of cases over the past century  a bear market in U S  stocks was well underway long before a recession had taken hold of the U S  economy  If you are waiting for the confirmation of a recession before taking actions to protect your investment portfolio  it will likely be far too late 

With valuations pushing extreme levels  economic growth extremely weak and markets now grossly exuberant based solely on  future hopes   such has been a toxic brew that has left investors wondering what went wrong 
As Gundlach summed up 

In the financial markets  80  of the time it s a coin flip  But the other 20  of the time you have very high confidence and it s not a coin flip  For instance  I don t think the stock market is a coin flip  Especially in the United States stocks are very expensive  particularly low volatility stocks 
The riskiest things are now stocks and other investments perceived to be safe  One of the most popular categories in US investing are low volatility stock funds  But there is no such thing  If you think that a stock like Johnson   Johnson  NYSE JNJ  can t go down  you re wrong  And if people own funds that invest in stocks which they think are immune from decline and they start to decline  all hell breaks loose 

Just some things to think about ",2016-04-28,Lance Roberts,https://www.investing.com/analysis/strong-earnings-may-not-help-stocks-200126794,200126794
199165,420681,JNJ,The Last 16 Times This Happened There Was A Recession,opinion,"Something has just happened that has signaled a recession every single time that it has occurred since World War I  16 times since 1919 there have been at least 8 month over month declines in industrial production during the preceding 12 month period  and in each of those 16 instances the U S  economy has plunged into recession  Now that it has happened again  will the U S  economy beat the odds and avoid a major economic downturn  I certainly wouldn t count on it  As I have written about   there are a whole host of other numbers that are screaming that a new recession is here  and global financial markets   It would take a miracle of epic proportions to pull us out of this tailspin  and yet there are many people out there that are absolutely convinced that it will happen 
John Hussman is not one of them  In his most recent weekly comment  he examined this stunning correlation between month over month declines in industrial production and recessions  To me  what Hussman has presented is  

Last week  following a long period of poor internals and weakening order surplus  we observed fresh declines in industrial production and retail sales  Industrial production has now also declined on a year over year basis  The weakness we presently observe is strongly associated with recession  The chart below  h t Jeff Wilson  plots the cumulative number of month over month declines in Industrial Production during the preceding 12 month period  in data since 1919  Recessions are shaded  The current total of 10  of a possible 12  month over month declines in Industrial Production has never been observed except in the context of a U S  recession  Historically  as Dick Van Patten would say  eight is enough 


After looking at that chart  is there anyone out there that still doubts that the U S  economy is in significant trouble 
Many estimates of U S  GDP growth for the fourth quarter of 2015 are already just a small fraction of one percent  It would not be a surprise at all to see a negative number posted once it is all said and done 
And of course more bad news for the economy just keeps pouring in  So far this week we have learned that the growth rate of federal withholding taxes   Johnson   Johnson  N JNJ  plans has announced that it is eliminating 3 000 jobs  and BP  L BP  has announced that it is eliminating 4 000 jobs 
Of course it is not exactly a surprise that BP is cutting jobs  At this point the entire energy industry is absolutely hemorrhaging workers  As I wrote about yesterday  130 000 good paying energy jobs have been lost in the United States since the beginning of last year 
But now we are seeing major firms outside the energy industry cutting payrolls  Even financial giants such as Morgan Stanley  N MS  are looking for ways to cut costs 

Morgan Stanley just announced fourth quarter earnings  and it is providing detail to investors on a cost saving plan called Project Streamline 
During a conference call  CEO James Gorman uttered a sentence that will most likely make the bank s staff shudder 
 Too many employees based in high cost centers are doing work that can sensibly be done in lower cost centers   he said 

The whole environment is changing 
When things start to get tough  big corporations start to get rid of people  We saw this back in 2008  and it is starting to happen again right now 
And just like last time around  we are going to see millions of Americans lose their jobs during the hard years that are ahead of us 
But thankfully for the moment there is a brief lull in the action  The  that has gripped the planet was calmed on Tuesday when China announced that their economy grew at a rate of 6 8 percent during the fourth quarter of 2015  This was right in line with expectations  and markets around the world responded positively to the news 
There is just one huge problem  Everyone knows that GDP figures coming out of China are essentially meaningless  If you believe that the Chinese economy actually grew at a 6 8 percent rate during the fourth quarter of 2015  then I have a bridge to sell you  Virtually every other number coming out of China over the past several months tells us that the Chinese economy is shrinking  and so that 6 8 percent figure is extremely questionable at best 
Do you want to know the last time the communist Chinese admitted to having a recession 
It was in 1976 
Over the past four decades  economic growth figures have become a source of great national pride for China  To admit that the economy is now imploding would bring great shame on the Chinese government and the nation as a whole  and so that must be avoided at all costs 
Yes  the numbers are fraudulent in the U S  too  According to John Williams of shadowstats com  if the U S  was actually using honest numbers the last recession  
But in China they take this to ridiculous extremes  The Chinese economy is fueled by exports  and Chinese exports have been down on a year over year basis for six months in a row  And the primary reason why commodity prices have been absolutely collapsing is because of the economic contraction in China 
Of course if China had released a GDP number that was honest  global markets would have crashed hard  So their lies are making everyone else feel a bit better for the moment  and every day of relative stability that we can enjoy from here on out is something to be thankful for 
As you read this article  markets all over Asia  Europe  South America and the Middle East   More than 30 percent of the market has been wiped out in Brazil and Hong Kong  more than 40 percent of the market has been wiped out in China and Italy  and about 50 percent of the market has been wiped out in Saudi Arabia 
We are already experiencing a major global financial crisis 
The only question remaining is how bad it will eventually become 
Let us hope for more days like this one that are relatively calm  But I wouldn t count on things turning around significantly any time soon  because the economic fundamentals are telling us that big trouble is ahead ",2016-01-20,Michael T. Snyder,https://www.investing.com/analysis/the-last-16-times-this-happened-there-was-a-recession-380741,380741
199166,420682,JNJ,Johnson   Johnson  Earnings In Focus,opinion,"Johnson   Johnson  N JNJ  is one of the largest healthcare companies out there  Recently  the company reported earnings  and I have to say it was a bit of a mixed report  Nonetheless  I still have faith in the company  Today  we ll talk about what we saw from JNJ earnings  how the market reacted to the news  and what we can expect to see from Johnson   Johnson moving forward 
What We Saw From JNJ Earnings
As mentioned above  Johnson   Johnson recently released its earnings report  Unfortunately  the report sent a bit of a mixed signal  While earnings slightly beat expectations  revenue missed the mark  Here s what we saw from the report   
Earnings   For the quarter  it was expected that Johnson   Johnson would produce earnings per share in the amount of  1 42  However  the company actually reported earnings per share in the amount of  1 44  While earnings came in above expectations  the results were still a bit bitter  After all  this is the second quarter in a row that we saw earnings decline  Nonetheless  coming in ahead of expectations is always positive 
Revenue   While earnings came in ahead of expectations  top line revenue was unfortunately a miss  For the quarter  analysts expected to see JNJ generate revenue in the amount of  17 9 billion  However  the company actually produced slightly lower  reproting revenue in the amount of  17 8 billion 
Guidance   With earnings slightly beating expectations and revenue slightly missing  JNJ needed some positivity  Guidance is where this positivity was found  Analysts are currently expecting for Johnson   Johnson to produce full year earnings in the amount of  6 35 per share  However  the company released guidance  stating that it is expecting to generate between  6 43 and  6 58 in earnings per share throughout the year 2016 
How The Market Reacted To The News
When it comes to market movers  there are few that are as effective as earnings reports  However  in this particular case  earnings were a bit mixed  as a result  we ve seen mixed activity in the market  In fact  since JNJ reported its earnings  we ve seen relatively flat movement on the stock  Currently  9 42   JNJ is trading at  103 66 after a minor loss of 0 68  thus far today 
What We Can Expect To See Moving Forward
In all reality  I m not too concerned about the revenue miss  After all  earnings came in ahead of expectations and guidance proved to be positive  Not to mention  JNJ has a strong history of producing incredibly positive earnings reports  In fact  over the past 4 consecutive quarters  the company hasn t missed expectations once  Another thing worth mentioning here is the sheer size of the product offering at Johnson   Johnson  With an incredible list of products  great management  a strong team  and a history of strong earnings  I m expecting to see long run gains from JNJ ",2016-02-02,Joshua Rodriguez,https://www.investing.com/analysis/johnson---johnson:-earnings-in-focus-382899,382899
199169,420685,JNJ,No More Tears For Johnson   Johnson,opinion,"Johnson   Johnson  N JNJ  makes all sorts of products for consumers  but one line that stick with me from the 90s is their baby shampoo  They would market it with the slogan  No more tears   From the promotional picture above  that is still the slogan  Only now it is time to apply it to their stock too 
Johnson   Johnson  JNJ  stock price had a long run higher from June 2012 until topping in November 2014  Since then it pulled back slightly  but could not move away from 100  This is a common phenomenon  stocks or indexes holding for a long time around round numbers  Well it finally did move away  but not how investors had hoped  in August when it fell with the market  If you bought then  congratulations 

Since the bottom throughout September  it rose back to the 100 level  But it has been stuck there again  Or has it  Looking closely  the stock has formed a rising channel since the beginning of November  A third higher high following a second higher low  defining an uptrend  So what to do 
With the price at the top of the channel  there are two things for a future holder to look for  First  a break above the channel should be bought as it indicates a change of character and a move to the upside out of the long consolidation  Second  a failure to break the channel and move lower is an opportunity for a current investor to sell covered calls  and a future investor to sell Puts on the 100 Strike  at the bottom of the channel  for a potential entry 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  Please see my Disclaimer page for my full disclaimer ",2015-12-08,Gregory W. Harmon,https://www.investing.com/analysis/no-more-tears-for-johnson---johnson-374866,374866
199170,420686,JNJ,The Tycoon Secret  Patience And Value,opinion,"There are numerous strategies tycoons use to build tremendous wealth  such as investing in emerging blue chips  But today  I m going to focus on a broader characteristic tycoons possess that any investor can use to expand their wealth 
And that characteristic is a patient and persistent attention to the price  Tycoons will wait as long as necessary for an attractive entry price point for high quality assets  whether it s a stock  bond  or property 
Now  the sharp pullback in a stock s price that would draw a tycoon s attention could be due to any of the following three reasons 
There could be a broad market blowout  as occurred during the 2008 2009 global financial crisis  Great names like Johnson   Johnson  N JNJ  fell 60  or more  giving investors a once in a lifetime opportunity 
A stock could be off due to company specific issue such as missing a critical earnings report  launching a new product that flops  or suffering a credit downgrade after missing an interest payment 
A country or region could be out of favor  pulling down all stocks irrespective of quality and performance 
No  3 is the case with a tycoon blue chip idea that I m covering today 
Opportunity in Southeast Asia
 is off about 20  across the board in 2015 
Why  The slowdown in China  a sharp pullback in commodity prices  fear that U S  interest rates will rise  all these factors are negatively affecting sentiment and crowding out the many positives that these countries offer 
Positives such as growth rates that are four times America s  geographic advantage at the heart of Asian trade and investment flows  a young and growing consumer middle class  and manufacturing wage rates below China s 
As the financial capital of Southeast Asia  my pick is Singapore s leading blue chip bank   the Development Bank of Singapore  DBSDY   better known as DBS 
DBS is the leading consumer bank in both Hong Kong and Singapore  with influence throughout the region through 200 branches in 50 cities 
Investing in strong banks to tap economic growth in a country or region is a simple and time tested strategy that can lower your risks  especially in emerging markets 
One of Sir John Templeton s favorite strategies in difficult markets  banks as proxies for gaining exposure to undervalued markets around the world is both conservative and smart 
Banks have exposure to a national or regional economy through their loans and services to both companies and individuals 
A pick up in economic growth leads to an increase in loan demand  higher levels of interest income  and lower levels of non performing loans  Assuming capable management and ample cash flow  this should lead to a jump in profitability and stock price 
DBS is trading at just 10 times trailing and forward earnings and right at book value  while the industry average is around 2 3 times book value  This is in spite of DBS  steady earnings growth of 10  and its impressive 40  net earnings margin  Moody s also recently upgraded the credit rating of Singapore s banking sector 
What s most important is that DBS is rapidly building up its low risk private banking and wealth management business just as wealthy Chinese assets are moving their capital offshore  Management is targeting a 40  increase in wealth management fees by 2020  and that may be conservative given the opportunities sitting right in front of the bank 
Indeed  wealth is piling up in Singapore faster than anywhere else in the world 
Investment assets in Singapore have surged an incredible 1 110  since 2000  If this rate continues  this city state will overtake Switzerland by 2020 
Could tiny Singapore truly beat powerhouses such as London  New York  and Zurich 
Despite these strengths  DBS has pulled back 24  so far this year  It also sports a rich 3 6  dividend yield 
Blend some tycoon blue chips like DBS with the old standbys  and watch your global portfolio grow in 2016 
Good investing ",2015-12-31,Wall Street Daily,https://www.investing.com/analysis/the-tycoon-secret:-patience-and-value-378259,378259
199191,420707,JNJ,iFOREX Daily Analysis   September 30  2015,opinion,"The dollar moved higher against the other major currencies on Tuesday  amid growing concerns over China s economy and despite uncertainty over a potential U S  rate hike this year as investors eyed upcoming U S  consumer sentiment data 
The Conference Board reported said its index of consumer confidence rose to an eight year high of 103 0 this month  from a reading of 101 3 in August  whose figure was revised from a previously reported 101 5  Analysts expected the index to fall to 96 1 in September 
Now investors await today release of September inflation data in the euro zone and non farm payrolls data on Friday  for further indications on the strength of the global economy 
EUR USD
The euro remained relatively flat on Tuesday  as investors showed hesitancy to make any major moves ahead of Wednesday s monthly report on inflation throughout the euro zone 
The single currency came under pressure after data showed that Germany s annual rate of inflation slowed to zero in September  worse than forecasts of 0 1  
The German consumer price index fell 0 2  from a month earlier  compared to expectations for a decline of 0 1  
Currency traders today await the release of critical inflation data from the euro zone for further indications on the strength of the global economy  Analysts expect to see a 0 1  gain for the month  following a 0 1  increase in August 
Pivot 1 119
Support 1 1191 11451 1115
Resistance 1 12951 1331 1365
Scenario 1 Long positions above 1 119 with targets   1 1295   1 133 in extension 
Scenario 2 Below 1 119 look for further downside with 1 1145   1 1115 as targets 
Comment The RSI is mixed to bullish 
Gold
Gold futures were relatively flat on Tuesday amid a steady dollar  as the timing of an interest rate hike by the Federal Reserve and continuing fears of a recession in China remained in focus 
Gold was mostly steady also in Asia Wednesday  ahead of a holiday starting in China tomorrow expected to trim trading activity 
Today s focus will be on the U S  monthly ADP nonfarm payrolls report  as well as on manufacturing activity data in the Chicago region  While later in the day  Fed Chair Janet Yellen  speech in St  Louis will be closely watched 
Pivot 1135
Support 112111161110
Resistance 11351140 51148
Scenario 1 Short positions below 1135 with targets   1121   1116 in extension 
Scenario 2 Above 1135 look for further upside with 1140 5   1148 as targets 
Comment As long as 1135 is resistance  likely decline to 1121 
WTI Oil
WTI fell sharply in early Asian trade on Wednesday  after U S  inventories showed a weekly buildup that far exceeded analyst expectations 
The American Petroleum Institute said late on Tuesday that U S  crude oil stockpiles rose by 4 6 million barrels to 457 8 million barrels in the week to September 25  Analysts polled by Reuters had expected an increase of only 102 000 barrels 
U S  crude is heading for a 9  decline this month  as the slump in commodities continues  amid deepening concerns over China s slowdown in economic growth 
Investors  focus today will be on the U S  government s Energy Information Administration official weekly inventory data  According to some analysts  today s session may be more volatile due to the close of September and third quarter trading 
Pivot 44 35
Support 44 3543 743 2
Resistance 45 7546 447 1
Scenario 1 Long positions above 44 35 with targets   45 75   46 4 in extension 
Scenario 2 Below 44 35 look for further downside with 43 7   43 2 as targets 
Comment A support base at 44 35 has formed and has allowed for a temporary stabilisation 
S P 500
U S  stocks ended higher after a volatile session on Tuesday  as concerns about the health of the global economy kept investors cautious after more than a month of turbulence 
The S P 500 recovered after falling earlier to within 0 26  of lows it touched in August  when fears of a slowdown in China shocked global markets 
Seven of the ten S P sectors rose  with the healthcare index up 0 9   ending a seven day losing streak  thanks in part to gains in Johnson   Johnson  NYSE JNJ  and Gilead Sciences  NASDAQ GILD  
Although the market s recent rout has forced many strategists to slash their year end expectations  a new Reuters poll shows the S P 500 ending 2015 roughly 11  above current levels 
Investors are awaiting data scheduled to be released this week  culminating in nonfarm payrolls numbers on Friday 
 Pivot  2044
Support  1867 1820 1798
Resistance  2044 2135 2180
Scenario 1  Short positions below 2044 with targets   1867   1820 in extension 
Scenario 2  Above 2044 look for further upside with 2135   2180 as targets 
Comment  The RSI has just struck against its neutrality area at 50  and is reversing down  The rising wedge pattern calls for 1867 ",2015-09-30,iFOREX,"https://www.investing.com/analysis/iforex-daily-analysis-:-september-30,-2015-266638",266638
199192,420708,JNJ,Zeltia FDA Approval ,opinion,"FDA approves Yondelis in soft tissue sarcomaThe US FDA has approved Zeltia s Yondelis  trabectedin  for the treatment of soft tissue sarcomas  STS  liposarcoma and leiomyosarcoma  This is positive news for Zeltia  MC ZEL  and closely follows the approval of Yondelis in all types of STS in Japan late last month  Yondelis will be marketed in the US by Janssen  N JNJ  and in Japan by Taiho  T 6470   and the approvals will trigger approx   20m in milestone payments  The approvals are in line with our expectations and justify the recent strong share price  which is likely to continue to be buoyed by this positive news 

The FDA approved Yondelis as a second line treatment of metastatic or unresectable liposarcoma and leiomyosarcoma for patients who have previously been treated with chemotherapy that contained anthracycline  eg doxorubicin   The approval is in line with our expectations  with no unexpected conditions 
The Yondelis approvals will trigger milestone payments totalling approx   20m   10m US   10m Japan   Approximately 12 000 cases of STS are diagnosed in the US each year and we forecast peak US sales of  130m for Yondelis in STS  Zeltia will receive a royalty on Yondelis sales in the US  we assume 15   and a margin on sales of raw material to Janssen  The company s trabectedin manufacturing facility in Madrid passed an FDA inspection in July and Janssen has purchased  5 5m of Yondelis active ingredient over the past two quarters  which could enable Yondelis to be launched in the US market before the end of November 
To Read the Entire Report Please Click on the pdf File Below",2015-10-28,Edison,https://www.investing.com/analysis/zeltia-fda-approval-269496,269496
199227,420743,JNJ,Johnson   Johnson To Rebound  What To Expect From Tomorrow s Report,opinion,"Johnson   Johnson  NYSE JNJ  reports its FQ2  15 results before the market opens tomorrow and both Estimize and Wall Street are predicting a quarter on quarter  QoQ  uplift in EPS and revenues  Despite the positive outlook for this quarter s result  Johnson   Johnson s stock year to date  YTD  has not performed well falling 4 42  relative to the S P 500 index which has appreciated 1 71  
Johnson   Johnson researches and develops  manufacturers  and sells a wide range of products in the healthcare industry globally  The company operates under three different fields  Consumer  Pharmaceutical  and Medical Devices 
Estimize and Wall Street predict an EPS figure of  1 72  The Estimize community  however  is looking for a slightly lower revenue figure of  17 640B compared to Wall Street s forecast of  17 652 

In the previous quarter  Johnson   Johnson reported a third consecutive fall in revenues QoQ  In addition to falling revenues  Johnson   Johnson has reported volatile EPS figures over the past twenty four months causing the share price to fluctuate quite substantially 
Despite the falling revenues and volatility  Johnson   Johnson still maintains many solid fundamentals  In particular  the stock is trading at an attractive multiple of 17 79X earnings  TTM  and pays an attractive dividend yield of 2 85   In addition  Johnson   Johnson s profit margins are increasing and its return on equity is above the industry average 

Although Johnson   Johnson has lagged both the index and the healthcare industry year to date  the stock price has very recently experienced a bounce leading into its result  Last week  Johnson   Johnson announced to the market that a recent self funded study indicates that its experimental psoriasis medicine works better than the key rival drug  The drug being tested is known as  Guselkumab  and is currently in the final stage of patent testing  If approved  Johnson   Johnson will be competing in a market in which tens of billions of sales are shared among a handful of different biotech and pharmaceutical companies 
The result tomorrow will be important  Investors are hoping for a positive reversal in revenues and a strong EPS number  If achieved  Johnson   Johnson may rebound and begin to move upwards again  However  if the results disappoint  the share price may continue in its downward trend ",2015-07-14,Estimize,https://www.investing.com/analysis/johnson---johnson-to-rebound-what-to-expect-from-tomorrows-report.-258184,258184
199245,420761,JNJ,Johnson   Johnson  Price Forming Diamond Top Formation,opinion,Johnson   Johnson  NYSE JNJ  share price forming a diamond top formation  Usually this increases the chance of a bearish reversal JNJ  1 5 years  ,2015-04-22,Petros Steriotis,"https://www.investing.com/analysis/johnson---johnson-(jnj)-april-22,-2015-preview-249229",249229
199246,420762,JNJ,Johnson   Johnson  Neutral Outlook ,opinion,"Johnson   Johnson  NYSE JNJ  shares moving trendlessly in the last couple of months  Neutral outlook 
JNJ   9 months",2015-05-10,Petros Steriotis,"https://www.investing.com/analysis/johnson---johnson-(jnj)-weekly-preview-may-11,-2015-251145",251145
199247,420763,JNJ,Johnson   Johnson  Bullish With A Tight Stop ,opinion,"Breaking our above the horizontal channel resistance at  103 50 will make  108 50 the new target  Bullish with a tight stop 
Johnson   Johnson  NYSE JNJ    9 months",2015-05-20,Petros Steriotis,"https://www.investing.com/analysis/johnson---johnson-(jnj)-may-19,-2015-252333",252333
199259,420775,JNJ,Gold Trades Above  1300 As Central Banks Turn Dovish,opinion,"Gold traded above the  1300 in early trading  establishing a new 5 month high at 1305 34  before correcting modestly  The yellow metal continues to garner support from a global shift toward easier monetary policy that seems to be gaining momentum 
Word leaked today that the ECB is contemplating QE of  50 bln a month for at least a year  That  600 bln minimum total is 20  more than the market consensus of  500 bln  But as a Wall Street Journal article on the topic suggests  it could be  much more  
The Bank of Canada announced a surprise 25 bps rate cut this morning  dropping their benchmark overnight lending rate to 0 75   The plunge in oil prices is already negatively impacting the Canadian economy  reducing export revenue and energy sector investment  which is resulting in layoffs   The drop in oil prices is unambiguously negative for the Canadian economy   said BoC governor Stephen Poloz 
Today s release of the minutes from the Bank of England s January MPC meeting reveal a decidedly more dovish tone  The vote to hold rates steady at 0 5  was unanimous  meaning that hawks  McCafferty and Weale  had dropped their dissent and calls for tightening 
Last week  the Reserve Bank of India did a surprise rate cut  in advance of their February policy meeting  The RBI is attempting to reinvigorate a flagging economy and believes the drop in energy prices has reduced the inflation risk  giving them the leeway to ease 
Of course the big policy news from last week was the SNB s abandonment of the franc s ceiling against the euro  They also cut rates  deeper into negative territory in an effort to staunch inflows into the franc 
On Monday  the Danish central bank cut its deposit rate to  0 2   from  0 05   Nationalbank also reaffirmed its commitment to the krone s peg against the euro  Your safe haven flows are not welcome in Denmark either 
Meanwhile  we are to believe that the Fed is moving toward a rate hike  The Treasury market doesn t seem to believe it  as we ve seen yields come down sharply in recent weeks 
Typically  the prospects of ever easier monetary policy and liquidity  would hearten stock market investors  However  I think they may finally be catching on that the swing away from policy normalization is reflective of mounting growth and price risks 
U S  stock market belwether Johnson   Johnson reported this week that they were basically getting killed by the stronger dollar  The company s international sales fell about 7  in Q4 as the dollar rose 

 Currency headwinds have increased quite substantially   Chief Financial Officer Dominic Caruso said in a conference call  Last year  he said  the dollar grew stronger  to a greater extent than we had anticipated   He said the company expects another 3 5  to 4 5  of negative foreign exchange impact this year if the dollar remains at its current high levels    via 
A big multinational like J J hedges their currency exposure  so things could have been much worse  given that the greenback rose more than 14  against a basket of currencies last year  However  there are certainly companies that sell overseas and don t hedge at all 
It seems terribly unlikely that the Fed will tighten  when the rest of the world s central banks are moving in the absolute opposite direction  The most hawkish scenario in my mind is that they hold pat  However  one has to wonder if the Fed might launch a counter offensive in the global currency war in order to provide some relief to U S  exporters 
If that were to happen  it would mark a severe escalation of the currency wars with everyone debasing their currencies in a beggar thy neigbor race to the bottom  The implications for the gold market would be very bullish indeed ",2015-01-21,Peter Grant,https://www.investing.com/analysis/gold-trades-above-$1300-as-central-banks-turn-dovish-239269,239269
199265,420781,JNJ,Try This One On The Dip,opinion,"With the market  crashing  down    nearly 3 points on the S P 500 ETF  ARCA SPY     the rhetoric from the bearish side is heating up  They may have their way finally  but I m not yet convinced  So as the modest pullback continues I am looking for candidates to buy on the dip 
One that stuck out Wednesday was Johnson   Johnson  NYSE JNJ   which was hammered down more than 2 3  as the S P 500 shed just over 1 3   That s a lot for a company of its size to outperform to the downside 
Play The Pullback
Technically  I see two triangles that have traced out a bearish shark harmonic  which completed about a week ago  The trigger for the bearish break came on September 25 and it has moved lower since  The shark pattern targets a retracement of the pattern by 61 8   That is  to 102 56  which is just below the 50  and 100 day SMA s  There may be a good area between 102 56 and 103 60 to start a position for the long term in the stock  As it falls  the RSI is at the edge of the bullish zone  If that area fails  the pattern calls for a full retracement to the 98 80 area at the 200 day SMA 
Keep in mind that some of the pain from the 102 50 to 98 80 area can also be buffeted by the 2 80  dividend yield  Perhaps a half position at 102 5 and then add October 102 100 1 2 Put Spreads for a credit to both protect the position and possibly add to it at 98 
The Upside 
The Point and Figure Price Objective is to at least 125 ",2014-10-01,Gregory W. Harmon,https://www.investing.com/analysis/try-this-one-on-the-dip-227690,227690
199266,420782,JNJ,Bavarian Nordic s Strategic JNJ Deal To Fill 2015 Revenue Gap ,opinion,"Strategic Ebola deal fills 2015 revenue gap
Bavarian Nordic s  COP BAVA   187m exclusive global licensing and supply deal for its development Ebola vaccine MVA BN Filovirus with Janssen  part of Johnson   Johnson  NYSE JNJ   secures its financial position and provides large pharma validation for the core MVA BN vaccine platform  Deal terms include a  43m  DKK251m  equity investment  giving J J a 4 9  stake  and various licence supply payments that will boost FY15 revenues  easing the company through an anticipated gap in US government Imvamune orders  End FY14 cash preparedness guidance is raised to DKK1 000m from DKK600m  revenue guidance is maintained  recognition will occur in 2015   Factoring deal economics into our company valuation increases it to DKK5 3bn 

Janssen deal terms  Forging ahead to combat Ebola
The three part deal includes a  43m  DKK251m  equity investment  an exclusive licensing agreement for MVA BN Filovirus   25m upfront   20m in development and regulatory milestones and undisclosed royalties on ex Africa sales   and a  99 3m supply agreement for up to one million doses of vaccine  covering full development and scale up funding   These doses will be used for clinical trials of a prime boost vaccine in combination with J J s AdVac technology  Phase I to start in 2015  and emergency use for the current West Africa Ebola outbreak  In a deal extension  J J also has an exclusive collaboration option to evaluate MVA BN for another three undisclosed infectious disease targets 
Financials  Deal results in P L   cash upgrade
9m14 revenue of DKK676m predominantly relates to US Imvamune deliveries  Delivery of the remaining doses under the  118m US Imvamune option exercised in September will be completed in Q414 enabling revenue guidance  DKK1 200m  to be met  The FY14 cash preparedness expectation is increased to DKK1 000m  vs DKK600m  reflecting the impact of the Janssen deal  and including a c DKK150m reduction in debt and credit facilities  Recognition of already received anticipated cash flows from Janssen substantially upgrades our FY15 P L forecasts 
Valuation   703m or  32 ADR
Including deal economics for MVA BN Filovirus in our sum of the parts model increases our valuation to  703m or  32 ADR  previously  620m or  24 ADR   We now include receipt of the  25m upfront and impact of the J J equity investment in our FY14e cash forecasts  as well as un risk weighted supply and licensing payments and risk weighted future milestones in our DCF 
To Read the Entire Report Please Click on the pdf File Below",2014-12-05,Edison,https://www.investing.com/analysis/bavarian-nordic's-strategic-jnj-deal-to-fill-2015-revenue-gap-234766,234766
199267,420783,JNJ,Stop Waiting For Johnson   Johnson To Break Up Or Down,opinion,"We all have seen the  V  bottom in the market and in stocks that we either own or have been following  One that sticks out to me is Johnson   Johnson  NYSE JNJ   It is in that large cap slice of the market that has been doing so well  And it is healthcare related  also a plus  It was also at all time highs as the market sold off  The recovery brought it back to that all time high quickly  And it has done nothing for over a month since  Forget no more tears  it is keeping your baby powder dry  Both disappointing and uncharacteristic for it over the last year 

The chart above shows that price action  As it sits in a tight range between 106 50 and 109 50 the Bollinger bands have been tightening  The momentum indicators are drifting lower  with the MACD pointing to more downside while the RSI is holding over the mid line for now  remaining in the bullish zone 
So which way is it going to break  I do not know  But I have a plan to trade it now anyway  When you see a tight consolidation in a stock for a long time with tightening Bollinger bands  it often foretells a move  This type of action can be played with options using a Straddle or Strangle  This is just a combination of a long put and a long call to participate in a move in either direction 
For Johnson   Johnson I like a January 23 Expiry 107 108 Strangle  offered at about  3 75 as i write   To make money the stock needs to move beyond either strike by the premium paid   3 75  by Expiry  so either lower that 103 25 or above 111 75  That maybe a comfortable range for you  But if it is too wide then look at selling shorted dated Strangles to recoup some cost and narrow the range where the trade becomes profitable  For example  selling a December 105 110 Strangle narrows the range by 40 cents  Even better  if the stock does not break that December Strangle range by Expiry  you can sell another Strangle in early January 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-12-10,Gregory W. Harmon,https://www.investing.com/analysis/stop-waiting-for-johnson---johnson-to-break-up-or-down-235204,235204
199276,420792,JNJ,Johnson   Johnson  Becoming More Attractive Each Day,opinion,"Johnson   Johnson  NYSE JNJ   which is one of my favorite long term stocks for income and dividend reinvesting investors  just dropped below the  100 00 per share level and is becoming more attractive each day 
This stock has been doing extremely well over the last few years and should continue to do so  The position has been a worthy buy when it s down and according to its recent trading history  it typically isn t down for long 
If you re a shareholder in this company or are considering a long term position  you ll want to take a look at the company s recently filed Securities and Exchange Commission  SEC  Form 10 Q  which was submitted August 1 
This quarterly SEC filing reveals much more information over and above a company s regular earnings press release  It gives a much better snapshot of a company s financial position  where the sales are  which divisions are the most profitable  and where the company sees its operations in the near future 
In Johnson   Johnson s recently filed Form 10 Q  the company s overall profitability  that is its net earnings as a percentage of total sales  leapt higher from 20 7  to 24 1  in the first half of this year compared to last 
This is a huge accomplishment for a company this large and a major reason why stockholders should feel so confident about increasing dividends in the future  along with more share buybacks 
The company s average common shares outstanding in the first half of 2014 dropped by approximately 3 3 million shares on a diluted basis compared to the same period last year 
Johnson   Johnson s two year stock chart is featured below 

Johnson   Johnson s most recent quarter was a standout  Within the numbers  U S  total sales charged ahead by 15  compared to the second quarter of 2013  sales to Europe advanced 8 2   This was led by a whopping 37  increase in U S  pharmaceutical sales  International pharmaceutical sales grew 6 8  comparatively 
The company s pharmaceutical segment produced a sea of double digit comparative gains  From oncology to immunology  Johnson   Johnson s pharmaceutical business is booming  and it s a big reason why earnings as a percentage of total sales are growing 
While all corporate disclosure is to be taken with a grain of salt  the company s management said that between 2003 and 2013  in the U S  market  the weighted average compound annual price increase for its prescription and over the counter drugs  as well as its hospital and professional products was actually below that of the Consumer Price Index  CPI  
Regardless  pharmaceuticals are the biggest contributor to sales and earnings and the company is on track to have another very good year  
Johnson   Johnson is a very good candidate for those investors able to participate in dividend reinvestment  Those dividends really add up over time  and there s nothing like owning more shares in a company at no additional cost to you as a shareholder 
If you bought Johnson   Johnson s shares in November of 2011  your simple rate of return to date would be approximately 59   But if you reinvested the dividends Johnson   Johnson paid over the same period  your return improves to approximately 74  and naturally  you own more shares over your original investment 
For a company with a long track record of increasing dividend payments to shareholders  a dividend reinvestment strategy with a stock like Johnson   Johnson should continue to produce excellent returns 
Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ",2014-08-07,Mitchell Clark,https://www.investing.com/analysis/johnson---johnson:-becoming-more-attractive-each-day-221944,221944
199277,420793,JNJ,Is Johnson   Johnson s 2 Year Run Over ,opinion,"Johnson   Johnson  NYSE JNJ  had been consolidating in a box for over 2 years when it hit my radar in late 2011 here  It took a little longer to move out of that box but since then has had a spectacular run higher from the mid sixties to over 100  But  the run does not seem to be over  In fact there are signs that it may be going through another short term consolidation phase before the next leg higher 

The chart above shows that the move to 105 in June pulled back and retested the 100 level in July  The price held and is moving back higher  Will it get caught at the falling trend resistance  Maybe  It went ex dividend Friday though without much of a pullback  The momentum indicators are supportive of upside with a RSI rising and bullish and the MACD leveling after a pullback  and in positive territory  But a longer term trader or investor can deal with that by selling covered call options as it reverses to collect some premium  There is a natural stop just under 100  making the risk  3 less any premium sold  And how far can it go  The Measured Move out of the triangle it is making now would target 110 but the Point and Figure chart is carrying a price objective to at least 125  Who knew selling Band Aids  Listerine and Baby Powder could be so lucrative 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-08-26,Gregory W. Harmon,https://www.investing.com/analysis/is-johnson---johnson's-2-year-run-over-223739,223739
199278,420794,JNJ,HQLA And Munis    The New Rules And Regulations,opinion,"High Quality Liquid Assets  HQLA  is a term that now applies to the implementation of the Liquidity Coverage Ratio  LCR  in the Basel III Rule  This highly technical mouthful of acronyms and rules specifically applies to banks  their liquidity requirements and the rules governing the securities in their investment portfolios  The targets of the new rules are the big banks 
According to an analysis by BMO Capital Markets   In general it will require banks with more than  250 billion in assets to hold enough HQLA to cover 100  of a projected 30 day cash outflow in a stressed scenario   BMO notes that banks holding over  50 billion will have to meet a  lighter version  of the requirements than will banks with over  250 billion  Small banks with under  50 billion are in a different category and are not considered by regulators to be systemically risky institutions  so the new rules do not apply to them 
What does all this have to do with municipal bonds 
The HQLA rules as defined by the Federal Reserve  Fed  for US banks have excluded municipal bonds from this category of securities that must meet the LCR  Corporate bonds  certain equities  conventional mortgages  federal agency securities  and U S  and other OECD sovereign debt are included 
Multiple issues arise for investors in the wake of the new rules  though readers must note that this is a fluid rulemaking determination and things may change  We will address some issues as we see them in this current and evolving regulatory structure 
It is important to note that investment grade corporate bonds have a default rate that is 36 times higher than the default rate on investment grade municipal bonds  This determination is based on information from Moody s and compiled on investment grade defaults from 1970 to 2013  In other words  the Fed has defined into the rule those corporate securities that have 36 times the default rate  historically speaking  of investment grade municipal bonds that the Fed has excluded from the rule 
To give an example  the bond of Johnson   Johnson  NYSE JNJ   a corporation headquartered at Exit 9 of the NJ turnpike is included  but NJ Turnpike Authority debt is not  Both bonds are quite liquid and easily traded  and both are high grade ratings  Why the Fed made this decision  which would include JNJ and exclude NJ TPKE  is still not completely clear  There is discussion underway among market professionals who are attempting to get the Fed to change its view 
What the rule means for municipal bonds is that a support mechanism in the marketplace that would have facilitated the issuance of municipal debt is weakened by a new rule  As a result  it will cost municipal bond issuers more to achieve their financing  There are various estimates of how much more it will cost   these issuers are all guessing  The fact is that it will take time to determine exactly how banks will hold municipal debt in the future  after the market has adjusted the price or yield to make up for the difference made by the rule 
There is an area in which municipal bonds will be surely impacted  That is in the  bank qualified  smaller issues  BQ was an exception made in the Tax Reform Act of 1986 to facilitate the issuance of municipal debt by smaller issuers  Those bonds are not highly liquid and it would have made sense for the Fed to exclude them in a liquidity calculation  In most cases  the banks holding BQ debt are servicing local customers that are municipal entities and assisting them with financing  That is why the Tax Reform Act of 1986 provided special incentives for banks 
We now have a situation resulting from a change in a tax law incentive that had been in place for decades  The Fed has issued a rule that has offset or reduced that incentive  A tension between incentive and disincentive is at work in the small bank qualified issuer municipal bond market  In the United States  a large number of the 90 000 municipal bond issuers fall into in this BQ category  Their cost of financing will certainly rise by some amount 
Let s get to what the new HQLA rules mean for investors  In one way  this is good news  We are taking bond buyers  large banks  for instance  who traditionally participated in parts of a bond market  and removing some of those buyers or imposing a new cost on them  The impact raises tax free yields to offset the change 
Individual municipal bond investors will like this new rule because it results in a higher tax free interest rate for them  There is more prospective tax free income for owning municipal bonds  As attractive as municipal bonds may have been in the past  they will be even more attractive because a competing buyer  the larger banks  is being removed or reduced 
How this ultimately plays out in a  3 7 trillion US municipal bond market remains to be seen  We know the rule currently impacts municipal bond issuers in a negative way  At the present time  there is no indication that the rule is going to be changed 
In the US  at intermediate and long maturities  the tax arbitrage available in the income tax code for tax free bonds is minimally applicable  Market forces are pricing municipal bonds of long maturities at relative bargain rates  We see that today when we compare a long term  true AAA  highest grade  tax free bond with an equivalent long term US Treasury taxable obligation  When we do that  we find the interest rate paid on those tax free bonds in current market conditions is approximately the same as that paid on the taxable bond  In other words  market agents and forces are pricing the municipal bonds as if there is no income tax code  That makes no sense 
We also know that when we get to the shorter maturity end of the yield curve  we see the yield on tax free way below the taxable yield  In the shorter end the tax arbitrage is almost fully applied  In the middle of the yield curve  the tax arbitrage of the US income tax code is somewhat fully applied  while at the longest maturities it is virtually nonexistent in market pricing  So  as one goes from shorter to longer maturity  the tax arbitrage component diminishes  We think HQLA will only exacerbate this anomaly 
The bottom line of HQLA is that a change has occurred that will alter market pricing references by some amount  We do not know how much  HQLA rules will benefit the individual investor who selectively manages municipal bonds and chooses them skillfully  The individual investor will gain at the expense of the large banks  which will be adversely affected to some degree  Small banks are not affected  The details will be revealed as markets adjust to this new paradigm 
Meanwhile  there are still relative bargains in the tax free bond space  Investors who worry about rising rates can use hedging devices to dampen the volatility they would experience if and when rates eventually rise 
David R  Kotok  Chairman and Chief Investment Officer",2014-09-08,David Kotok,https://www.investing.com/analysis/hqla-and-munis----the-new-rules-and-regulations-225114,225114
199279,420795,JNJ,Merck  Chasing Down The  1 Billion Specialty Drug,opinion,"Pharmaceuticals Sector   Merck   Co   Inc 
Yesterday  Merck  NYSE MRK  closed just off the 52 week high  61 33  at 59 99  but it was not for lack of effort or headlines  Merck has been active in 2014 and seems to grab either a positive or negative headline every other day  Headlines go with the territory of being a major pharmaceutical provider in the 21st century  Between the FDA approval process and the numerous lawsuits facing the industry  it can be difficult to determine  
With Merck shares gaining 1 55 percent in the last 30 days and 24 54 percent this year  investors seem to be warming to MRK  The keys to pharmaceutical success remain research and the development of specialty pharmaceuticals  The challenges to release these new drugs is slowed by the FDA process but shares usually receive significant lifts when the FDA announces progress 
Challenges faced by Merck   Co   Inc  
Kenneth Frazier  Merck CEO since 2011  is the last in a long line of executives at Merck who mentored under former CEO and industry magnate P  Roy Vagelos  Before Vagelos retired in 1994  Merck achieved its greatest successes  The company was the biggest pharmaceutical on the planet  Before Frazier  an attorney by trade  took the reins  he met with his former boss and was charged to restore the company to greatness    Some of the mountains Merck has faced include the reality that since 2007  no single Merck drug has generated annual sales of more than  1 billion  Share prices have floundered and with the exception of a boost from the  41 billion acquisition of Schering Plough  performance has been stagnant  But  there is reason for optimism with a few positive releases from the FDA regarding new drugs from MRK 
Merck  which over the last 60 years has brought more new drugs to market than any of its competitors has slipped to fifth place with new approvals over the last 10 years  Once the biggest fish in the pharmaceutical pond  Merck has begun to look like a floundering provider  If research and new specialty drugs drive the truck  Merck has been losing ground and fast  On April 29  2014  Merck s 1st quarter results showed a year over year decline of 3 8 percent as sales slumped to  10 3 billion  The downturn was  to patent expirations and an unfavorable foreign exchange rate 
In early May  Merck  the sale of its consumer care business to Bayer for  14 2 billion in cash  This transaction took place at a time when pharmaceuticals were scurrying to stay ahead of expiring patents and seemed to solidify Merck 
Of late  the news has been more favorable for Merck and investors are responding in kind  Despite a September 9 report that a judge in Pennsylvania refused to dismiss two lawsuits regarding the  of the company s proprietary vaccine for mumps prevention  new announcements from the FDA appear promising 
On September 2  2014  a new survey from Axxiom Consulting reported that more than half of global sales for animal health products  feed and diagnostics were generated in the Kansas City Animal Health Corridor  where Merck is a major player   The corridor generated more than  88 2 billion in sales last year and Merck has benefited from this market 
Reasons for Optimism on Merck
Capital Cube s news releases include an important announcement made September 4th when the FDA announced  as the first cancer drug in the US to treat melanoma  The drug is to be taken in 2 mg hg does every three weeks as a treatment for unresectable or metastatic melanoma  The drug is hailed as a major breakthrough in the fight against cancer and should be a big winner for Merck  On September 5th  the news broke that the cost of Keytruda will be  12 500 per patient per month  At  150 000 per year per patient  Merck may have some  but cost has a way of responding to market conditions 
Also on September 4th  Merck received more good news from the FDA when the company s  as a Qualified Infectious Disease Product  QIDP  on the FDA s Fast Track Status  Under the Generating Antibiotic Incentives Now Act  GAIN   this urinary tract drug could get to market and be in use on an expedited basis  Phase 3 research will commence in 2015  Relebactam has passed Phase 2 testing with outstanding results and is sure to be a huge seller when coming to market  One of these drugs could be the  1 billion specialty drug Merck s recent portfolio has lacked 
On September 8  2014   of 61 33 or 37 percent above the 52 week low of 44 62  The Capital Cube news trail also points out that on September 10th Merck had made  resolving the manufacturing problem that disrupted the flow of the BCG vaccine  Merck received a request from the FDA to step up shipments of the drug after a manufacturing slowdown at the Sanofi  NYSE SNY  Pasteur facility  Over the last two years  Merck manufacture of BCG has increased by 100 percent 
On the development side  Merck is positioned to rebound and investors seem to be responding to the recent good news  However  Merck s inconsistent performance from dividends to sales to weaker than expected margins might dim enthusiasm  As Capital Cube notes  over the last five years  the dividend quality trend has been solid for 4 years but subpar for one year  This does not compare favorably with Johnson   Johnson  NYSE JNJ   a company with much stronger growth expectations than Merck 
But  one of MRK s biggest challenges is in restoring investor confidence in its products and its business operations  If we compare Capital Cube s assessment of MRK s sustainability of returns to JNJ  we can see that MRK has a long way to go 
CEO Frazier has strengthened company reserves over the last 12 months and MRK is in a good position with leverage and liquidity  The company appears not to be entertaining any mergers or acquisitions at this time so growth will be dependent on the new releases  a stronger position in the animal health industry and continued production of BCG  When the two new specialty drugs come to market  investors would like to be holding MRK 
by Hiland Doolittle
Disclosure  The views and opinions expressed above are those of the author and do not necessarily reflect the views of  CapitalCube com  AnalytixInsight  Inc   its affiliates  or its employees ",2014-09-17,CapitalCube,https://www.investing.com/analysis/merck:-chasing-down-the-$1-billion-specialty-drug-226184,226184
199280,420796,JNJ,Viking Therapeutics IPO  BioPharm Gets A Neutral Rating,opinion,"Viking Therapeutics  VKTX   New IPO going public Thursday  September 18  2014   Overview VKTX is a clinical stage biopharmaceutical company focused on the development of novel  first in class or best in class therapies for metabolic and endocrine disorders  Clinical trials have shown that VK0612 is safe  well tolerated and leads to significant glucose lowering effects in patients with type 2 diabetes  The P E ratio is  3 6  which indicates a very high cash burn rate relative to the market cap    Based in San Diego  CA  Viking Therapeutics  VKTX  scheduled a  55 million IPO on the NASDAQ with a market capitalization of  167 million at a price range midpoint of  11 for Thursday September 18  2014 
   Manager  Co Managers  Oppenheimer   Co   Roth Capital
Joint Managers  Craig Hallum Capital Group  MLV   Co  Summer Street Research Partners 
Conclusion The rating is neutral  Clinical trials have shown that VK0612 is safe  well tolerated and leads to significant glucose lowering effects in patients with type 2 diabetes  VKTX is an intellectual property carve out spin off of Ligand Pharmaceuticals  NASDAQ LGND    1 billion market cap  which owns 25  pre IPO  Ligand  the  parent  indicated an interest in purchasing  5 million on the IPO  To put the conclusions and observations in context  the following is reorganized  edited and summarized from the full S 1 referenced above    Valuation    Business VKTX is a clinical stage biopharmaceutical company focused on the development of novel  first in class or best in class therapies for metabolic and endocrine disorders    VKTX has exclusive worldwide rights to a portfolio of five drug candidates in clinical trials or preclinical studies  which are based on small molecules licensed from Ligand Pharmaceuticals   1 billion market cap    Clinical programs VKTX s lead clinical program is VK0612  a first in class  orally available drug candidate entering a Phase 2b clinical trial for type 2 diabetes  one of the largest global healthcare challenges today  Preliminary clinical data suggest VK0612 has the potential to provide substantial glucose lowering effects  with an attractive safety and convenience profile compared with existing type 2 diabetes therapies    VKTX s second clinical program is VK5211  an orally available drug candidate entering a Phase 2 clinical trial for the treatment of cancer cachexia  a complex disease characterized by an uncontrolled decline in muscle mass    VK5211 is a non steroidal selective androgen receptor modulator  or SARM  A SARM is designed to selectively interact with a subset of receptors that have a normal physiologic role of interacting with naturally occurring hormones called androgens    Broad activation of androgen receptors with drugs  such as exogenous testosterone  can stimulate muscle growth but often results in unwanted side effects  such as prostate growth  hair growth and acne    VK5211 is expected to selectively produce the therapeutic benefits of testosterone in muscle tissue  with improved safety  tolerability and patient acceptance  VKTX expects to commence Phase 2 clinical trials for both VK0612 and VK5211 in early 2015 and to complete the clinical trials in 2016    Three pre clinical programs VKTX is also developing three preclinical programs targeting metabolic diseases and anemia  VKTX s most advanced preclinical program is VK0214  a novel liver selective thyroid hormone receptor beta  or TR   agonist for lipid disorders such as dyslipidemia and nonalcoholic steatohepatitis  or NASH  VKTX expects to file an investigational new drug application  or IND  and commence clinical trials for this program in 2015    VK0612 is a potent  selective inhibitor of fructose 1 6 bisphosphatase  or FBPase  an enzyme that plays an important role in endogenous glucose production  or the synthesis of glucose by the body  VKTX believes the inhibition of FBPase provides an attractive approach to controlling blood glucose levels in patients with diabetes  VK0612 has demonstrated potent glucose lowering effects in diabetic animal models    Clinical trials have shown that VK0612 is safe  well tolerated and leads to significant glucose lowering effects in patients with type 2 diabetes  VKTX intends to commence a Phase 2b clinical trial of VK0612 in approximately 500 patients with poorly controlled type 2 diabetes  defined as having baseline fasting plasma glucose  or FPG  levels greater than or equal to 180 mg dL  VKTX expects to commence the clinical trial in early 2015 and to complete the clinical trial in 2016    Dividend Policy No dividends are planned    Intellectual Property VKTX s portfolio of drug candidates is protected by a number of U S  composition of matter patents  foreign patents and U S  and foreign patent applications  all of which VKTX in licenses from Ligand    VKTX plans to file additional patent applications in the U S   E U  and other foreign jurisdictions on its clinical and preclinical programs    Competition The key competitive factors affecting the success of VK0612  if approved  are likely to be its efficacy  safety  tolerability  frequency and route of administration  convenience and price  and the level of branded and generic competition and the availability of coverage and reimbursement from government and other third party payors    In the U S   there are a variety of currently marketed oral type 2 diabetes therapies  including metformin  generic   pioglitazone  generic   glimepiride  generic   sitagliptin  Merck   Company Inc  NYSE MRK  and canagliflozin  Johnson   Johnson  NYSE JNJ      These therapies are well established and are widely accepted by physicians  patients  caregivers and third party payors as the standard of care for the treatment of type 2 diabetes    Physicians  patients and third party payors may not accept the addition of VK0612 to their current treatment regimens for a variety of potential reasons  including           if they do not wish to incur any potential additional costs related to VK0612  or           if they perceive the use of VK0612 to be of limited additional benefit to patients     In addition to the currently approved and marketed type 2 diabetes therapies  there are a number of experimental drugs that are in various stages of clinical development by companies such as Eli Lilly and Company  Takeda Pharmaceutical Company Limited and TransTech Pharma  Inc    VK5211 The key competitive factors affecting the success of VK5211  if approved  are likely to be its efficacy  safety  tolerability  frequency and route of administration  convenience and price  the level of branded and generic competition and the availability of coverage and reimbursement from government and other third party payors    In the U S   there are currently no marketed therapies for the treatment of cancer cachexia  though steroids such as nandrolone  generic   oxandrolone  generic  and testosterone  generic  are sometimes prescribed for the treatment of weight loss in cancer patients    There are several experimental therapies that are in various stages of clinical development by companies including GTx  Inc   Helsinn Group and Morphosys AG  In addition  nutritional and growth hormone based therapies are sometimes used in patients experiencing muscle wasting    5  stockholders Ligand Pharmaceuticals Incorporated 24 8  Brian Lian  Ph D  24 8  Michael Dinerman  M D  11 1                                      Use of proceeds VKTX intends to use the  49 million in proceeds from its IPO as follows     23 0 million to fund the continued clinical development of its lead drug candidate  VK0612  including a randomized  double blind  placebo controlled  multicenter Phase 2b clinical trial to evaluate various doses of VK0612  as well as a Phase 1 drug drug interaction clinical trial and a Phase 1 clinical trial to evaluate the effect of renal impairment on VK0612 pharmacokinetics and lactate clearance       10 million to fund the continued clinical development of VK5211  including a randomized  double blind  placebo controlled  multicenter Phase 2 proof of concept clinical trial in patients with cancer cachexia      8 0 million to fund the continued development of its three preclinical drug candidates  including VK0214  a novel liver selective thyroid hormone receptor beta agonist for lipid disorders such as dyslipidemia and NASH  and    The remainder for working capital and other general corporate purposes    Disclaimer  This VKTX IPO report is based on a reading and analysis of VKTX s S 1 filing  which can be found   and a separate  independent analysis by   There are no unattributed direct quotes in this article ",2014-09-18,Francis Gaskins,https://www.investing.com/analysis/viking-therapeutics-ipo:-biopharm-gets-a-neutral-rating-226223,226223
199305,420821,JNJ,J J  Buy Side Sees More Growth,opinion,"Johnson   Johnson  NYSE JNJ  is set to report FQ1 2014 earnings before the market opens on Tuesday  April 15th   Johnson   Johnson is one of the largest medical device  pharmaceutical  and packaged consumer goods companies in the world  Over the past year JNJ has beaten expectations from both Wall Street and the buy side 4 quarters in a row  This quarter Wall Street is expecting JNJ to keep expanding and report 3  year over year EPS growth as well as a 2 6  increase in yoy sales  Here s what investors expect JNJ to report on Tuesday 
The information below is derived from data submitted to the Estimize com platform by a set of Buy Side and Independent analyst contributors 

The current Wall Street consensus expectation is for Johnson   Johnson to report  1 48 EPS and  17 955B revenue while the current Estimize com consensus from 22 Buy Side and Independent contributing analysts is  1 49 EPS and  18 051B in revenue  This quarter the buy side as represented by the Estimize com community is expecting Johnson   Johnson to beat the Wall Street consensus on both EPS and revenue by a small margin 
Over the past 6 quarters the consensus from Estimize com has been more accurate than Wall Street in forecasting JNJ s EPS every time and has been more accurate in forecasting revenue 5 times  By tapping into a wider range of contributors including hedge fund analysts  asset managers  independent research shops  students  and non professional investors Estimize has created a data set that is more accurate than Wall Street up to 69 5  of the time  but more importantly it does a better job of representing the market s actual expectations  It has been confirmed by Deutsche Bank Quant  Research and an independent academic study from Rice University that stock prices tend to react with a more strongly associated degree to the expectation benchmark from Estimize than from the Wall Street consensus 
The magnitude of the difference between the Wall Street and Estimize consensus numbers often identifies opportunities to take advantage of expectations that may not have been priced into the market  In this case we are seeing a small to moderate differential between the two groups  EPS expectations 

The distribution of estimates published by analysts on the Estimize com platform range from  1 45 to  1 53 EPS and from  17 900B to  18 594B in revenues  This quarter we re seeing a wider distribution of estimates on Johnson   Johnson  especially on revenue 
The size of the distribution of estimates relative to previous quarters often signals whether or not the market is confident that it has priced in the expected earnings already  A wider distribution of estimates signaling less agreement in the market  which could mean greater volatility post earnings 
 
Over the past 4 months the Wall Street EPS consensus both started and ended the period at  1 48 while the Estimize consensus also remained flat at  1 49  Meanwhile the Wall Street revenue consensus declined from  18 039B to  17 955B while the Estimize forecast rose to a high of  18 179B before falling to  18 051B  Timeliness is correlated with accuracy and downward analyst revenue revisions at the end of the quarter are often a bearish indicator  Although the Estimize revenue consensus was falling going into the report  there is still a moderate differential between the two groups  sales projections 
The analyst with the highest estimate confidence rating this quarter is bonefishr who projects  1 50 EPS and  18 112B in revenue  bonefishr is ranked v among over 4 000 contributing analysts  Over the past 2 years bonefishr has been more accurate than Wall Street in forecasting EPS and revenue 75  and 50  of the time respectively throughout only 4 estimates  Estimate confidence ratings are calculated through algorithms developed by deep quantitative research which looks at correlations between analyst track records and tendencies as they relate to future accuracy  In this case bonefishr is making a bullish call expecting JNJ to beat the Street s expectations on both EPS and revenue 
In 2013 JNJ beat analyst expectations in each quarter and the stock rose 29 1  on the year  This quarter contributing analysts on the Estimize com platform expect Johnson   Johnson to continue the trend and beat the Wall Street consensus by 1c per share on earnings and  96 million in sales 
Get access to estimates for Johnson   Johnson published by your Buy Side and Independent analyst peers and follow the rest of earnings season by heading over to Estimize com  Register for free to create your own estimates and see how you stack up to Wall Street ",2014-04-15,Estimize,https://www.investing.com/analysis/j-j:-buy-side-sees-more-growth-209680,209680
199314,420830,JNJ,Dow Jones Declines  Other Major Indices Advance,opinion,"On Tuesday  the Dow Jones Industrial Average declined while the other major stock indices advanced 
Tuesday brought us the inverse of the situation which we saw on Friday  when the Dow Jones Industrial Average was the only major stock index to stay out of the red   On Tuesday  the Dow was the only index in the red  while the other major stock indices advanced   Setting the Dow back on Tuesday were earnings misses by Verizon  VZ  and Johnson   Johnson  JNJ   each of which declined by more than one percent   Another big decliner was Travelers  TRV   which sank 1 70 percent  despite an earnings beat   The positive statement released by CEO Jay Fishman was overruled by analysts who saw the company s profits sinking next quarter 
The Dow Jones Industrial Average  DIA  lost 44 points to finish Tuesday s trading session at 16 414 for a 0 27 percent decline   The S P 500  SPY  advanced 0 28 percent to close at 1 843 
The Nasdaq 100  QQQ  surged 0 74 percent to finish at 3 617   The Russell 2000  IWM  climbed 0 62 percent to end the day at 1 175 
In other major markets  oil  USO  soared 0 89 percent to close at  33 99 
On London s ICE Futures Europe Exchange  March futures for Brent crude oil advanced 50 cents  0 47 percent  to  106 85 bbl   BNO  
February gold futures declined 20 cents  0 02 percent  to  1 240 00 per ounce  GLD  
Transports dodged the polar front on Tuesday  as the Dow Jones Transportation Average climbed 0 57 percent  IYT  
In Japan  stocks advanced as the Bank of Japan began its two day monetary policy meeting   The exchange rate for the yen continues to be the dominant factor in stock market activity   There is a good deal of speculation that the nation s central bank will weaken the yen to 110 per dollar   Japanese stocks soared as the yen weakened to 104 68 per dollar during Tuesday s trading session in Tokyo   A weaker yen causes Japanese exports to be more competitively priced in foreign markets  FXY    The Nikkei 225 Stock Average surged 0 99 percent to 15 428  EWJ  
Stocks made a huge advance in mainland China and that can only mean one thing   that the People s Bank of China pumped another liquidity injection into the money market   This time  the amount was the equivalent of  42 billion   The Shanghai Composite Index climbed 0 86 percent to 2 008  FXI    Hong Kong s Hang Seng Index advanced 0 45 percent to 23 033  EWH  
In Europe  stocks made an almost immeasurable decline after the  in Germany retreated from 62 0 to 61 7   The indicator for the current economic situation in the Eurozone increased by 6 2 points to negative 48 2   The Euro STOXX 50 Index dipped microscopically from 3 153 17 to 3 153 08   remaining above its 50 day moving average of 3 055   Its Relative Strength Index is 63 54  FEZ  
Technical indicators revealed that the S P 500 climbed further above its 50 day moving average of 1 809 after advancing 0 28 percent to finish Tuesday s trading session at 1 843   Its Relative Strength Index rose from 56 49 to 58 51   The MACD is now on a level trajectory  just below the signal line  which would suggest that the S P could remain in the 1 840   1 849 range during the immediate future  
On Tuesday  all sectors advanced except for the consumer discretionary sector  which dipped 0 09 percent  
Consumer Discretionary  XLY     0 09 
Technology    XLK     0 50 
Industrials  XLI     0 10 
Materials   XLB     0 61 
Energy  XLE     0 83 
Financials   XLF     0 09 
Utilities  XLU     1 10 
Health Care   XLV     0 58 
Consumer Staples  XLP     0 38 
Bottom line   Tuesday s trading session brought us the inverse of the situation we saw on Friday   This time  the Dow was in the red  while the other indices advanced 
Disclaimer  The content included herein is for educational and informational purposes only  and readers agree to Wall Street Sector Selector s     and  before accessing or using this or any other publication by Wall Street Sector Selector or Ridgeline Media Group  LLC ",2014-01-21,John Nyaradi,"https://www.investing.com/analysis/dow-jones-declines,-other-major-indices-advance-199573",199573
199315,420831,JNJ,Is Dividend Machine Johnson   Johnson Still A Buy ,opinion,"Medical and consumer products giant Johnson   Johnson  NYSE JNJ  made a big splash this week by agreeing to sell its Ortho Clinical Diagnostics business to The Carlyle Group  NASDAQ CG   The diagnostics business  which JNJ founded in 1937  makes blood tests that screen for disease and contributed about 2 6  of JNJ s revenue last year 
Carlyle was certainly enthusiastic about the deal     We have been focused on the diagnostics industry for many years given its attractive growth prospects  driven by the crucial role it plays in health care decision making  
I understand Carlyle s rationale for the acquisition  The aging of America gives massive tailwinds to virtually the entire medical sector  and blood testing would seem far safer and less subject to political meddling or Medicare and insurance cuts than  say  cutting edge medical devices or prescription pharmaceuticals 
But I m left scratching my head as to why Johnson   Johnson would want to part with this business 
It s not like Johnson   Johnson needs the money  The company has no net debt  and about 10  of the market cap of JNJ stock is cash in the bank 
J J didn t release much in the way of details as to its motivation for selling  My best guess is that  as a relatively small unit responsible for a tiny sliver of JNJ s revenues  management thought it would make sense to focus its energies on the business lines that have the biggest impact on the income statement  pharmaceuticals  medical devices and consumer products 
To put these product lines in perspective  JNJ operates the eighth largest pharmaceuticals business and the sixth largest biotechnology business in the world  Its medical devices and diagnostics business is the largest in the world  and its consumer health products business   which sells everything from Band Aid bandages to Neutrogena skin care products   is the sixth largest consumer healthcare business in the world 
Suffice it to say  JNJ is a big player in every business line it chooses to enter 
What to Do With JNJ Stock
With Johnson   Johnson in the news   and with JNJ stock continuing its march to  100 per share   is JNJ stock a buy 
Johnson   Johnson is a 128 year old company that has raised its dividend for 51 consecutive years and counting  It s also one of only four American companies that sports a AAA rated credit rating  JNJ is the very definition of a high quality  blue chip stock 
Let s take a look at the numbers 
JNJ stock isn t particularly cheap  trading at 20 times trailing earnings and 16 times expected forward earnings  But then  given JNJ s quality and stability  this is a stock that should and generally does trade at a slight premium to the broader market  JNJ stock sported a much higher multiple for most of the past 15 years  Figure 1  

And while its dividend yield  at 2 7   is lower than the average of recent years  Figure 2   it s still high by the company s standards and significantly higher than the market average  It s also about in line with the current 10 year Treasury yield 

So  is JNJ a buy  I think it is  but only with the right expectations going into it 
For instance  I own JNJ shares in a handful of dividend focused portfolios  and I continue to reinvest my dividends  I consider Johnson   Johnson a great core dividend stock 
But I wouldn t buy JNJ expecting it to massively outperform the market at current prices  At JNJ s current price  you re paying a premium for quality  and that s OK  But I would probably wait for a modest 10  15  pullback before making any major new purchases 
Disclosure  Charles Lewis Sizemore  CFA  is the editor of  and chief investment officer of the investment firm Sizemore Capital Management ",2014-04-03,Charles Sizemore,https://www.investing.com/analysis/is-dividend-machine-johnson---johnson-still-a-buy-208386,208386
199329,420845,JNJ,Fed Speakers Calm Taper Nerves,opinion,"Several US central bankers spoke late on Monday about the US Federal Reserve s taper plans   The speakers  which included the Boston Fed s Eric Rosengren  St  Louis Fed President James Bullard and Fed Board Governor Jerome Powell  all reiterated that the bank s stimulus program will continue until data indicates that the US can stand on its own and unemployment has fallen   Top News In other news around the markets  

As investor demand picked up ahead of Twitter s highly anticipated IPO  the company decided to raise the higher end of its price range by 25 percent  making the shares  23 to  25 per share  Reuters reported that final pricing could increase further due to the strong demand among institutional investors 
BlackBerry shares plummeted on Monday afternoon following an announcement that the company was no longer up for sale and that its CEO was stepping down  Instead  Blackberry is planning to issue convertible notes to long term investors in order to raise  1 billion 
In what many are considering to be a historic settlement  SAC Capital Advisors LP agreed to pay  1 8 billion and plead guilty to an insider trading indictment  The settlement marks the largest ever financial penalty for an insider trading offense 
The US and the EU are planning to move forward with free trade negotiations over the next two months despite rising tension over US NSA spying revelations  If followed through  a pact between the two sides could help both regions boost economic growth by cutting tariffs and creating common regulations  all of which would lower the cost of doing international business 

Asian Markets Asian markets were mixed this morning  the Japanese NIKKEI was up 0 17 percent  China s Shanghai composite was up 0 35 percent and the Shenzhen composite gained 0 95 percent  However the Hang Seng index fell 0 65 percent and Indonesia s JSX composite was down 0 21 percent   European Markets European markets were down across the board  the UK s FTSE lost 0 62 percent and the eurozone s STOXX 600 lost 0 30 percent  The German DAX lost 0 40 percent and France s CAC 40 was down by 0 43 percent   Commodities Energy futures were quiet with Brent futures up 0 03 percent and WTI futures down 0 18 percent  Precious metals were also down with gold falling 0 24 percent and silver down 0 23 percent  Industrial metals followed suit with aluminum posting the largest loss  down 1 14 percent   Currencies The euro continued to lose ground against the dollar ahead of the ECB meeting  down 0 14 percent  The pound gained 0 55 percent against the dollar and the yen gained 0 32 percent against the greenback  Earnings Notable earnings released on Monday included  

Plains All American Pipeline  L P   PAA  reported third quarter EPS of  0 53 on revenue of  10 70 billion  compared to last year s EPS of  0 73 per share on revenue of  9 35 billion 
Hill International  Inc   HIL  reported EPS of  0 06 on revenue of  142 00 million  compared to last year s EPS of  0 03 on revenue of  103 56 million 
CME Group Inc   CME  reported third quarter EPS of  0 75 on revenue of  714 60 million  compared to last year s EPS of  0 70 on revenue of  683 20 million 
Kellogg Company  K  reported third quarter EPS of  0 95 on revenue of  3 72 billion  compared to last year s EPS of  0 82 on revenue of  3 72 billion 

Pre Market Movers Stocks moving in the Premarket included  

Johnson   Johnson  JNJ  gained 0 18 percent in premarket trade after a week of choppy trading 
General Motors Co   GM  lost 1 25 percent in premarket trade following a 4 66 percent rise over the past week 
Alcoa Inc   AA  lost 1 01 percent in premarket trade after jumping 7 01 percent on Monday 
Exxon Mobil Corp  XOM  lost 0 21 percent in premarket trade after climbing 4 39 percent over the past week 

Earnings Earnings reports expected on Tuesday include 

Tesla Motors  Inc   TSLA  is expected to report EPS of  0 11 on revenue of  50 10 million  compared to last year s loss of  0 92 per share on revenue of  535 41 million 
Health Net Inc   HNT  is expected to report EPS of  0 60 on revenue of  2 72 billion  compared to last year s EPS of  0 38 on revenue of  2 78 billion 
DIRECTV  DTV  is expected to report third quarter EPS of  1 03 on revenue of  7 85 billion  compared to last year s EPS of  0 90 on revenue of  7 42 billion 
Sandridge Energy Inc   SD  is expected to report third quarter EPS of  0 00 on revenue of  448 62 million  compared to last year s EPS of  0 05 on revenue of  532 80 million 

Economics More PMI data will be out on Tuesday including British and Indian services PMI  Other notable releases include the US ISM non manufacturing index  Canada s trade balance and eurozone PPI BY Laura Brodbeck",2013-11-05,Benzinga ,https://www.investing.com/analysis/fed-speakers-calm-taper-nerves-190717,190717
199330,420846,JNJ,Top Trade Idea   Week Of November 18  Johnson   Johnson,opinion,Here is your Bonus Idea with links to the full Top Ten  Johnson   Johnson  Ticker  JNJJohnson   Johnson   JNJ   has completed a  W  pattern and is back at the all time highs at 94 40  It has been slowly moving sideways into this area  consolidating the move higher  A break over 94 40 would carry a target for another leg higher to 101 50  The RSI is hovering at the 70 level   bullish and the MACD is level  These continue to support the upside until they roll lower  If they do then a move back to the middle of the  W  at 90 or lower to the 61 8  retracement at 89 is in order  There is no resistance higher over 94 40 and support lower is found at 90 and 88 50 before 87 50 and 85 75  Trade Idea 1  Buy the stock on a move over 94 40 with a stop at 93 Trade Idea 2  Buy the December 95 Calls  offered at 76 cents late Friday  on the same trigger Trade Idea 3  Buy the November 22 weekly December 95 Call Calendars  53 cents  Trade Idea 4  Sell the stock short on a move under 92 50 with a stop at 93 50 Trade Idea 5  Buy the November 29 weekly 92 Puts  27 cents  on the same trigger Trade Idea 6  Buy the December 92 5 90 Put Spread  52 cents  on the same trigger After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which  heading into the last week before the Holiday Season begins sees the markets continuing to look strong  Next week look for Gold to consolidate in the longer downtrend while Crude Oil also holds in the downward move  The US Dollar Index looks better lower in the current short uptrend while US Treasuries look to consolidate their move  The Shanghai Composite and Emerging Markets are biased to the upside in the very short term with Chinese markets still lower long term and Emerging Markets in a rut  Volatility looks to remain subdued keeping the bias higher for the equity index ETF s SPY  IWM and QQQ  despite the moves higher this past week  Their charts show the possibility for the next rotation  into IWM and out of QQQ  Use this information as you prepare for the coming week and trad em well Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2013-11-19,Gregory W. Harmon,https://www.investing.com/analysis/top-trade-idea---week-of-november-18:-johnson---johnson-192393,192393
199331,420847,JNJ,What Investors Should Know About The Coming Retrenchment,opinion,There are lots of companies but very few stocks I like in this stock market  because stocks have already gone up in value so tremendously    Countless large caps provided excellent returns this year  and many of them are old brands that still offer meaningful dividend yields  What s transpired with the equity market this year has been truly amazing and practically  I don t think the run is over just yet    Cracker Barrel Old Country Store  Inc   CBRL  has a 52 week trading range of  60 07 to  118 44 and a forward price to earnings  P E  ratio of 18 46  according to Thomson Reuters  And guess where the stock is now right at its all time record high  up approximately 84   not including dividends  since this time last year  All this from a mature restaurant brand    Johnson   Johnson  JNJ   one of my key benchmark stocks and the kind of company that s welcome in any long term equity market portfolio  has had a really good year  Its capital appreciation is reminiscent of its performance in the late 90s    Many blue chips trade similarly to Cracker Barrel and Johnson   Johnson  they go through long periods of consolidation providing minimal capital gains  and then they explode in trading action  typically associated with technology stocks  So with the huge price moves  the case for a major retrenchment correction consolidation in the equity market is very solid  But there needs to be a catalyst for this to happen  The equity market is overbought and looking tired  but there is still a strong willingness on the part of institutional investors to buy on the right news I don t think the catalyst for a correction will be corporate led  Balance sheets continue to grow stronger and  generally speaking  the sense that I got from the last couple of earnings seasons is that business conditions and corporate outlooks are improving going into 2014 A geopolitical event could certainly be a catalyst for an equity market correction  but this can t be predicted Equity markets have a tendency to require a big reason for a change in trend  The most powerful force in stocks is monetary policy  but the Street already expects quantitative easing to be tapered  While there will be pressure on interest rates by the marketplace  the central bank continues to chime that the Fed funds rate will be staying put for the foreseeable future So what s left is the potential for non central bank policymakers to act  or not to act  in a manner that wreaks havoc with equity market confidence once again  The political stalemate regarding the debt ceiling is a perfect example  Given current information  I think the next major retrenchment in the equity market will be a buying opportunity  and I m still of the view that investors can stick to the market s existing winners in large caps  The big  brand name companies have the pricing power and economies of scale to accelerate earnings and dividend payments quickly on any uptick in business conditions Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ,2013-11-29,Mitchell Clark,https://www.investing.com/analysis/what-investors-should-know-about-the-coming-retrenchment-193782,193782
199332,420848,JNJ, Pharma And Biotech Stock Outlook  December 2013,opinion,With 2013 coming to an end  the worst of the patent cliff faced by the pharmaceutical sector is over  Major blockbuster drugs like Merck s  MRK  Singulair  Pfizer s  PFE  Lipitor  Forest Laboratories   FRX  Lexapro  Sanofi Bristol Myers Squibbs   SNY   BMY  Plavix and Eli Lilly s  LLY  Zyprexa representing combined branded sales worth more than  15 billion in lost patent protection over the last couple of years  However  the effect of the genericization of these products was felt mostly in 2012  While the industry won t be completely free from genericization  the major patent expiries are over and done with    Several companies which had been struggling to post growth in the face of genericization over the past few years should see accelerated growth in 2014  New products should start contributing significantly to results and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector  Some products that are slated to lose patent protection later this year and next year include AstraZeneca s  AZN  Nexium could also start facing generics from 2014 in the U S   where sales were  2 2 billion in 2012 Collaborations  Acquisitions and Restructuring The pharma sector witnessed major merger and acquisitions  M A  activity over the last couple of years  The trend continued this year and going forward  we expect small bolt on acquisitions to continue  In licensing activities and collaborations for the development of pipeline candidates have also increased significantly  Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time  Small biotech companies are open to in licensing activities and collaborations  Most of these companies find it challenging to raise cash  thereby making it difficult for them to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense for them to seek deals with pharma companies that are sitting on huge piles of cash  We recommend biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics  Therapeutic areas which could see a lot of in licensing activity include oncology  central nervous system disorders  diabetes and immunology inflammation  The hepatitis C virus  HCV  market is also attracting a lot of attention  Some recent acquisitions deals include Shire s  SHPG  upcoming acquisition of ViroPharma  VPHMt   Salix s upcoming acquisition of Santarus  SNTS  as well as the acquisition of Optimer Pharmaceuticals and Trius Therapeutics by Cubist Pharmaceuticals  CBST   Elan  ELN  is also on track to be acquired by Perrigo Company  PRGO  by year s end  Another trend that we are seeing in recent months is the divestment of non core business segments  Pfizer sold its Capsugel unit and its Nutrition business in Aug 2011 and Nov 2012  respectively  Pfizer then spun off its animal health business into a new company  Zoetis  ZTS   Meanwhile  GlaxoSmithKline  GSK  divested certain non core brands from its Consumer Healthcare segment  In Aug 2011  AstraZeneca sold its Astra Tech business to DENTSPLY  XRAY     The monetization of non core assets will allow the pharma biotech companies to focus on their areas of expertise  Abbott Labs  ABT  split into two separate publicly traded companies  while one company deals in diversified medical products  the other  AbbVie  ABBV   is focusing on research based pharmaceuticals  Johnson   Johnson  JNJ  also announced its plans to explore strategic alternatives for its ortho clinical diagnostics business  including a possible divestiture  Vertex  VRTX  monetized its Incivo related royalties    Vertex can use the cash generated from this deal for its cystic fibrosis program  Restructuring activities are also gaining momentum as large pharma companies are looking to cut costs and streamline their operations  Most of these companies are re evaluating their pipelines and discontinuing programs which do not have a favorable risk benefit profile  Some of the companies that announced restructuring plans include Merck  Novartis  NVS   Eli Lilly  Shire and Sanofi Emerging Markets and Biosimilars Another trend seen in the pharmaceutical sector is a focus on emerging markets  Companies like Mylan  MYL   Pfizer  Merck  Eli Lilly  Glaxo and Sanofi are all looking to expand their presence in India  China  Brazil and other emerging markets  Until recently  most of the commercialization efforts were focused on the U S  market    the largest pharmaceutical market    along with Europe and Japan  Emerging markets are slowly and steadily gaining more importance  and several companies are now shifting their focus to these areas  However  while higher demand for medicines  government initiatives for healthcare  new patient population and increasing use of generics should help drive demand  we point out that emerging markets are also not immune from genericization  Moreover  investigations into bribery charges in China could put a lid on near term growth  Meanwhile  growth in Europe will continue to be pressurized by austerity and cost containment measures  We are also seeing several companies entering into deals for the development of biosimilars  generic versions of biologics  Companies like Merck  Amgen  Biogen  BIIB   and Actavis  ACT  are all targeting the highly lucrative biosimilars market 3Q Earnings All companies falling under the Medical sector have reported third quarter 2013 results  While earnings beat and revenue beat ratios  percentage of companies coming out with positive surprises  were pretty impressive  growth ratios were modest  Third quarter results were characterized by currency headwinds especially in Japan as well as a slowdown in China where bribery investigations remained in the headlines  Third quarter 2013 earnings  beat ratio  was 74 5  while the revenue  beat ratio  was 51 0   Total earnings for this sector were up 0 2   compared to the 1 5  decline recorded in the second quarter of 2013  Total revenues moved up 5 8  in the quarter versus 2 4  growth in the second quarter of 2013  Looking at the consensus earnings expectations for the fourth quarter  earnings are expected to decline 3 5   Tough challenges for some companies  negative currency movement and a few patent expiries will affect fourth quarter growth  With the year coming to an end  several companies maintained or narrowed their guidance ranges  Overall  2013 earnings are expected to grow 0 6  Focus on New Products 2012 saw the FDA approving 35 novel medicines including the following  Most of these products have been performing well so far in 2013  Stivarga  Kalydeco  Xtandi and Kyprolis  especially  represent strong commercial potential  So far in 2013  quite a few important products have gained approval including Biogen s oral multiple sclerosis drug Tecfidera  Johnson   Johnson s type II diabetes drug Invokana  Merck s Liptruzet  cholesterol   Forest s Fetzima  major depressive disorder   Pharmacyclics  PCYC  Johnson   Johnson s Imbruvica  mantle cell lymphoma  and Roche s  RHHBY  Gazyva  chronic lymphocytic leukemia   Biogen s Tecfidera is off to a strong start with sales surpassing expectations by a wide margin  Upcoming events include FDA advisory panel reviews of the biologic licensing application  BLA  for Bristol Myers Squibbs  metreleptin  rare forms of lipodystrophy  and dapagliflozin  type II diabetes   and Merck s Grastek  a Timothy grass pollen extract tablet for sublingual use   All these reviews are scheduled to take place in the Dec 11   12 timeframe  A response on the approval status of Auxilium Pharma s  AUXL  Xiaflex for Peyronie s and Gilead s sofosbuvir  chronic HCV infection  in the U S  should also be out in December Zacks Industry Rank Within the Zacks Industry classification  pharma and biotech are broadly grouped into the Medical sector  one of 16 Zacks sectors  and further sub divided into four industries at the expanded level  large cap pharma  med biomed gene  med drugs and med generic drugs  We rank all the 260 plus industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry  To learn more  visit  About Zacks Industry Rank  As a point of reference  the outlook for industries with Zacks Industry Rank  88 and lower is  Positive   between  89 and  176 is  Neutral  and  177 and higher is  Negative   The Zacks Industry Rank for large cap pharma is  95  med biomed gene is  77  med drugs is  66  while the med generic drugs is  40  Analyzing the Zacks Industry Rank for different medical segments  it is obvious that the outlook is Positive for med drugs  med biomed gene and med generic drugs and Neutral for large cap pharma stocks OPPORTUNITIES The outlook for the pharma sector has improved significantly with the Zacks Industry Rank moving up from  195 to  95 over the past few months  While several companies will continue to face challenges like EU austerity measures and genericization  the pharma industry is out of the worst of the genericization phase    Many companies which had faced generic headwinds in the last couple of years should continue to see a sustained improvement in results as we move into 2014  Cost cutting  downsizing  streamlining of the pipeline  growth in emerging markets and new product launches should support growth  Among large cap pharma stocks  Bayer  BAYRY   a Zacks Rank  2  Buy  stock  looks well positioned with several new products    Eylea  Stivarga and Xarelto    in its portfolio  These products represent significant commercial potential Forest Labs  FRX   another Zacks Rank  2 stock  is doing well with first half fiscal 2014 results beating expectations  The company has launched several new products over the past few quarters and continues to work on expanding its pipeline  This company also raised its earning guidance for fiscal 2014 Shire  SHPG   Analyst Report   a Zacks Rank  1  Strong Buy  stock  looks well positioned for growth with the company expanding its product portfolio and pipeline through the upcoming acquisition of ViroPharma  We are positive on Johnson   Johnson  JNJ  even though the company currently holds a Zacks Rank  3  Hold   The company has performed well so far this year and the momentum should continue  Johnson   Johnson upped its 2013 earnings guidance again after announcing third quarter results    The company has been trying to offset the declining sales of some of its important products by bringing in new products through in licensing deals and acquisitions  We believe the diversity and strength of the company s underlying businesses will continue to provide strong growth in future  In the biotech space  we are positive on Biogen  BIIB   Tecfidera  the company s recently launched oral multiple sclerosis drug  is off to a strong start with the product delivering sales of  478 million since its launch in early April  While Tecfidera has gained the top spot in the oral multiple sclerosis market in the U S   Avonex and Tysabri should continue contributing significantly to sales  Tecfidera should gain EU approval shortly  Biogen is also progressing with its hemophilia pipeline  Biogen is another company that raised its 2013 guidance again this year  We are also positive on Amgen  AMGN   Amgen should be able to deliver on its long term strategy based on expansion in key markets  launch of new manufacturing technologies  and pipeline development  Enbrel should continue performing well  Amgen s late stage pipeline is also moving along  While Amgen is a Zacks Rank  2 stock  Biogen is a Zacks Rank  3  Hold  stock  Gilead  a Zacks Rank  3 stock  continues to do well in the HIV segment and is also progressing with its HCV pipeline Medivation  MDVN   a Zacks Rank  2 company  should continue delivering with its prostate cancer therapy  Xtandi  performing well  Based on the data we have seen so far  we believe Xtandi has blockbuster potential  It is currently in several studies including for the pre chemo setting  Expansion into the pre chemo setting would be a major positive for Medivation Vanda Pharmaceuticals  Inc   VNDA   Snapshot Report  also looks well positioned with the company receiving a positive feedback from the FDA regarding insomnia candidate  tasimelteon  The FDA s advisory panel voted resoundingly in favor of approving the candidate for the treatment of Non 24 Hour Disorder in the totally blind  While the FDA is not required to follow the advice of its advisory panel  it usually does so  A response from the agency should be out by Jan 31  2014  Vanda is a Zacks Rank  1 stock  Among generic companies  Actavis  ACT  looks well positioned  We view the acquisition of Actavis Group as a smart strategic move and we believe the company will be able to achieve its guidance easily  We are also positive on the recent acquisition of Warner Chilcott  which makes strategic and financial sense  With fewer major patent expiries slated to occur in the next few years  we are encouraged by Actavis  focus on building its branded and biosimilars pipeline  The company carries a Zacks Rank  2 WEAKNESSES We recommend avoiding names that offer little growth or opportunity for a take out  These include companies which are developing drugs that are likely to face regulatory hurdles  The FDA has been exercising more caution in granting approval to new products and several candidates are facing delays in receiving final approval  Among large cap pharma companies  Eli Lilly  LLY  is gearing up for another round of patent expiries  Cymbalta in Dec 2013 and Evista next year  We prefer waiting on the sidelines until the company is able to emerge from the impact of genericization  Companies that currently carry a Zacks Rank  4  Sell  include Alkermes  ALKS   BioLineRx  Ltd   BLRX  and XOMA Corporation  XOMA   Snapshot Report  among others ,2013-12-04,Zacks Investment Research,https://www.investing.com/analysis/pharma-and-biotech-stock-outlook:-december-2013-194339,194339
199333,420849,JNJ,Core Investment Portfolio Holdings  My First Pick,opinion,Over the coming weeks  I d like to highlight a number of companies that I think might make for some attractive core holdings in a long term equity market portfolio    With this in mind  there is absolutely no reason to chase this market at all  Some of the best blue chip  dividend paying stocks are already fully priced  given current expectations for earnings  But there are a number of really good businesses out there that I think are worth putting on a wish list in anticipation of a more attractive entry point  The companies I m referring to are the long term  bedrock businesses that equity investors can buy and hold for long periods of time    To start  I d like to feature one of my favorite benchmark stocks  Johnson   Johnson  JNJ   which is worthy of serious consideration when it s down   See  My Favorite Picks for After the Market Corrects      In an economy where health care and pharmaceuticals are such a large component of economic activity  equity investors really should have some exposure to this sector  What I like about Johnson   Johnson is its diversified business model that covers the gamut of healthcare related needs  The company has a great  long term track record of wealth creation and increasing dividends to stockholders  It s the kind of company that could be a key component in a long term equity market portfolio    Johnson   Johnson is a member of the Dow Jones Industrial Average  So far  the company has produced 29 consecutive years of increased adjusted earnings and 51 consecutive years of increased dividends  The company was founded by three brothers whose first commercial success was the development of the first commercial first aid kits  originally sold to railroad workers Johnson   Johnson can be broken down into three main operating divisions The first is consumer healthcare  which includes baby care  skin care  and oral healthcare products  over the counter medicines  and nutritionals  sweeteners and supplements  The company also has a large medical device and diagnostics division  This business segment has countless subsidiary companies in catheters  diabetes management  sterilization products  vascular products  aesthetics  and vision care Finally  the company s pharmaceutical business would be the world s eighth largest drug company if it was its own entity  This division makes pharmaceuticals that cover a vast range of treatments for oncology  immunology  cardiovascular  neurological  and metabolic diseases Just under half of the company s total sales come from the U S  market  of which pharmaceuticals and medical devices represent about 80  of the total business Last year  Johnson   Johnson spent  5 3 billion on research and development for pharmaceuticals  Even with this expenditure  this division is by far the company s most profitable What s most impressive about this company is its track record of increasing dividends to stockholders  This year  Johnson   Johnson will pay out  2 59 per share in dividends  In 2009  this figure was  1 93  in 2005  it was  1 28  and in 2000  it was  0 62 With the reasonable expectation that this diversified healthcare company will continue to grow its revenues  earnings  and dividends over the next several years  I think this stock is a worthwhile addition to a long term investment portfolio Naturally  it s already gone up tremendously this year  as institutional investors bid the relative safety of this enterprise Healthcare should be a key component in any long term equity market portfolio  and Johnson   Johnson is one of the best in the business  Investors should consider adding this worthwhile investment to their wish  and watch  lists Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ,2013-12-11,Mitchell Clark,https://www.investing.com/analysis/core-investment-portfolio-holdings:-my-first-pick-195290,195290
199334,420850,JNJ,MedTech Industry Update  Restructuring  Mergers And Market Expansion,opinion,We are on the verge of the Q4 earnings season and it is once again time to review the players in the worldwide medical devices market  For the U S  medical device industry  spending cuts and higher taxes have been a big issue lately  The industry faced sequestration related spending cuts to the U S  federal budget and the 2 3  medical device excise tax  Unfortunately  this is not the end of the story  This year  more spending cuts are scheduled to take place which will last through 2021  The sequestration which resulted in a 5 5  cut in the National Institutes of Health s  NIH  fiscal 2013 budget resulted in 640 fewer grants in 2013    The NIH was not the sole victim of federal budget austerities  In 2013  under the sequester  there was a 5  cut in the Centers for Disease Control and Prevention s budget  another 5  cut to the U S  Food and Drug Administration s fund and a 2  cut in Medicare funding that included cut in payments to hospitals  physicians  other medical providers  Medicare Advantage insurance companies and Part D prescription drug plans  Unless repealed or replaced  NIH apprehends sequestration to take a worse shape in 2014 leading to serious consequences like delaying progress in medical breakthroughs  deterioration in job creation and tempering of economic growth  An NBC news article recently noted that many new researchers  who were trained with the U S  taxpayer s money  may have to move to Europe and Asia where government funding for medical research is on the rise  On top of these  the Obamacare s medical device excise tax is taking a heavy toll on the MedTech sector  hurting pricing decisions of companies and subjecting them to tremendous margin pressure  The small and the medium sized players in the sector  comprising about 80  of the industry  are the worst hit by this public policy  The devastating 2 3  excise tax  effective Jan 2013   which is imposed on the sale price instead of net profit  amounts to a stupendous sum  wiping out almost a quarter of the profit at the med instrument owners  Conversely  the big players are trying every means to change their business model and cost structure to accommodate the excise tax  They are undertaking various restructuring initiatives to counter costs incurred from the implementation of the new tax  Restructuring especially to offset the effect of the excise tax has already been adopted by key players  such as  Boston Scientific Corporation  BSX   Medtronic Inc   MDT   St  Jude Medical  Inc   STJ   Stryker Corporation  SYK   Zimmer Holdings  ZMH  and Quest Diagnostics  DGX   The companies are also trying to focus on strategic mergers and acquisitions  M A   emerging market expansion or are reducing operations in order to weather the tax burden   M A Activities As mentioned above  MedTech M A is expected to continue unabated in 2014  Wary of an uncertain economy  MedTech giants have resorted to the acquisition route to harness their strength and diversify offerings  The most noteworthy move in recent times was the Irish medical device maker Covidien plc  s  COV   860 million deal in December to acquire Israel based diagnostic products maker Given Imaging  GIVN  in order to get a share of the  3 billion gastrointestinal  GI  market  The acquisition is expected to be completed by Mar 31  2014  Stryker Corporation was also in the headlines last month with its  1 65 billion acquisition of robotic assisted surgery developer MAKO Surgical Corp  Stryker is excited about inheriting MAKO s robotic technology as the company believes it has long term potential for human joint reconstruction  Last month  HeartWare International  HTWR  acquired CircuLite  Inc     developer of the SYNERGY Circulatory Support System for a cash and stock deal amounting to  350 million  This accentuates the company s focus on advanced heart failure treatment    In November  Wright Medical Group  Inc   WMGI  succeeded in its efforts to expand its direct sales and international distribution network in France by completing the acquisition of French orthopedic extremities company Biotech International  The acquisition has added Biotech s extremity product portfolio that will boost WMGI s global Extremities business growth  In continuity of its strategic investment plans  Henry Schein  Inc   HSIC  acquired a 60  stake in BioHorizons  a U S  based manufacturer of advanced dental implants with sales of  115 million  The acquisition of BioHorizons marks Henry Schein s foray into the global implant market  which is estimated to touch  4 2 billion by 2016  Combined together  the U S and Canadian markets alone have a potential of  1 5 billion in 2016  up from  1 billion in 2012 CareFusion Corp   CFN  announced in November that it has signed a  500 million agreement to acquire Vital Signs  a division of GE Healthcare  for  500 million  The acquisition will not only expand its Specialty Disposables business under the Procedural Solutions segment internationally but establish it as a leader in the  3 billion market for respiratory and anesthesia consumables  There have been many more M As in the MedTech space  Boston Scientific Corporation recently closed the acquisition of Bard EP  the electrophysiology business of C R  Bard  Inc   BCR   The deal  valued at  275 million  is a step forward to strengthening the company s foothold in the  2 5 billion global electrophysiology market  In October  St  Jude Medical acquired world s first and only leadless pacemaker manufacturer Nanostim  Inc  for  123 5 million  St  Jude utilized an exclusive option  obtained on May 3  2011  when it had entered into a partnership agreement with the then privately held company  In September  Kinetic Concepts formed a trinity with LifeCell Corp  and Systagenix to develop a diversified wound care  biologics and regenerative medicine company with more than  2 billion in sales  At the end of September  Baxter International    closed its  3 9 billion deal to acquire Gambro AB  a Sweden based privately owned renal products company  The deal is expected to strengthen the company s role in the hemodialysis market  A notable move made in recent times was the MedTech giant Medtronic Inc  s strategic shift from being a device manufacturer to a provider of broader healthcare services and solutions with meaningful clinical and economic value for hospitals  physicians  patients and payers  As an opening move  in August  the company acquired privately held Cardiocom  a provider of integrated telehealth and patient services for chronic disease management  for  200 million  Also worth mentioning is the mega  13 6 billion takeover agreement by Thermo Fisher Scientific  TMO  to acquire its major peer Life Technologies Corporation  LIFE   This is the biggest ever deal for Thermo Fisher which will inevitably strengthen the company s global foothold and commercial reach  With the approval of LIFE s stockholders and the European Commission in favor of the deal  the acquisition is expected to close in early 2014    In August  C  R  Bard entered into a  200 million definitive acquisition deal to purchase a leading developer and supplier of plant based hemostatic agents  Medafor  Inc  The acquisition will help Bard gain access to a proprietary technology platform and expand its global footprint  It will boost the company s surgical specialties portfolio  particularly surgical hemostats  in its Davol subsidiary  Also  Quest Diagnostics  acquisition of ConVerge Diagnostic Services  LLC from Water Street Healthcare Partners in October was part of the five point strategy announced by the company in 2012  ConVerge Diagnostic was the fourth laboratory acquisition of Quest Diagnostics in 2013 following the acquisitions of UMass Memorial Medical Center s clinical and anatomic pathology outreach laboratory businesses  Jan 2013   the toxicology and clinical laboratory business from Concentra  a subsidiary of Humana  Inc  HUM   May 2013  and the acquisition of lab related clinical outreach service operations of California based Dignity Health  Jun 2013   In June  to strengthen its contraceptive portfolio  drug and pesticide maker Bayer    acquired the contraceptive device maker Conceptus Inc  for approximately  1 1 billion in cash  This acquisition has added the Essure permanent  non surgical  birth control system to Bayer s product portfolio   In the light of the discussion above  we see no slowing down of M A deals in the MedTech space in the first half of 2014    We also expect a significant pickup in in licensing activities and collaborations for the development of pipeline candidates  Several MedTech majors struggling in their core businesses are looking to explore potential emerging therapies through collaborations and alliances  Divestments With the medical device excise tax in force  leading to further contraction in profit margins  we have been observing a lot of divestments of late  particularly of non core business segments  Divestment  specifically to offset the tax  has already been announced by key players like Johnson   Johnson  JNJ   Medtronic and Quest Diagnostics  We expect this trend to continue into 2014  MedTech giant Johnson   Johnson  after its  1 billion acquisition of privately held  pharmaceutical discovery and development company  Aragon Pharmaceuticals  Inc  is currently looking for opportunities to sell or spin off its Ortho Clinical Diagnostics business  Last August  Medtronic handed over its interventional device Pioneer Plus re entry catheter product line to Volcano Corporation  VOLC   Quest Diagnostics has also been focusing on areas with high potential  such as  gene based esoteric testing for cancer  cardiovascular disease  infectious disease and neurological disorders  As a part of this strategy  in November  it divested the Enterix colorectal cancer screening test business to Clinical Genomics Technologies Pty Ltd    In July  the company sold its rights to royalties from the commercialization of the Imbruvica to Royalty Pharma  the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products  for  485 million in cash  Earlier  in April  the company completed the divestiture of the HemoCue diagnostics products business Kimberly Clark Corporation  KMB  on the other hand is working on a potential tax free spin off of the company s health care business   This spin off would create a stand alone  publicly traded health care company with  1 6 billion in annual net sales with a significant presence in both surgical and infection prevention products and in the medical devices market  Wright Medical expects to close the sale of its OrthoRecon unit to MicroPort Medical B V   a subsidiary of MicroPort Scientific Corporation  by the end of January this year  Novartis  NVS  has also entered into a definitive agreement to divest its blood transfusion diagnostics unit to Spain based Grifols for  1 675 billion  The divestment is expected to be completed by the first half of 2014  Last October  GE Healthcare sold off its Centricity Laboratory Division to Cirdan Ultra  a subsidiary of Ireland based Cirdan Imaging Limited  In 2013  to focus on its high margin Medical Devices and Medical Supplies businesses  healthcare products maker Covidien  COV  divested its pharmaceuticals business Mallinckrodt plc  MNK   Last January  Abbott Laboratories separated its research based pharmaceuticals business by creating a new company  AbbVie  ABBV   to allow the two separate entities to focus on their core areas of expertise Emerging Markets Although the U S  still holds the leading position with almost one third of the global market share  a gradual slowing down of the established markets due to several prevailing headwinds are forcing MedTech companies to move beyond their comfort zone  Currently with the growth rate remaining at low single digits in developed markets like the U S   Europe and Japan  large cap medical device makers are looking to invest more in the high growth emerging markets  Accordingly  emerging economies like Brazil  Russia  India and China   collectively known as BRICs   as well as Turkey  Mexico  Malaysia  South Africa  South Korea and the Czech Republic are fast coming up in the medical devices space  These emerging economies are seeing an increasing uptake in medical devices due largely to growing medical awareness and economic prosperity  Urbanization is taking place at a massive rate in most of these regions with people entering the middle class and demanding better health care  An aging population  increasing wealth  government focus on healthcare infrastructure and expansion of medical insurance coverage make these markets a happy hunting ground for global medical device players  Expansion in emerging markets  especially those with double digit annual growth rates  represents one of the best potential avenues for growth in 2014 and beyond  Companies like Abbott  Medtronic  Boston Scientific  Edwards Lifescience  EW   Thermo Fisher Scientific  Life Technologies  Smith and Nephew  SNN  and many more are all vying to expand their presence in BRIC and other emerging markets  These companies are also looking to establish their manufacturing facilities abroad  Abbott continues to lead the trend with about 40  of sales coming from emerging markets  The company expects this contribution to increase to 50  by 2015  Johnson   Johnson with almost 25  of sales derived from the emerging markets is currently working to increase its presence in this region    The company has already set up manufacturing and R D centers in Brazil  China and India  The Guangzhou Bioseal Biotech deal marked the company s first MedTech acquisition in China  The company is expected to expand further in China on the back of the Synthes acquisition Becton  Dickinson and Company  BDX  with about 23  of revenues coming from the emerging markets is currently promoting its product lines in HIV monitoring  Diabetes Care and TB Diagnostics  Baxter on the other hand  given the possibilities rife in these regions  is working hard at expansion  20  of the company s worldwide sales came from this segment in the third quarter of 2013  Medtronic  with emerging market exposure of 12   continues to record double digit growth in emerging markets  accounting for half of its overall growth  The adoption of its implantable cardioverter defibrillators  ICDs  and pacers in the emerging markets continues to improve  Moreover  commercialization of new products should accelerate sales growth in these regions  Management is targeting 20  of its revenues from emerging markets over the long term with mid teens growth for the current fiscal  According to the company  the premium segments in China and India alone include a population of more than 380 million  leading to  5 billion of annual sales opportunity  Boston Scientific is also aiming to increase its below average market share in the  700 million combined drug eluting stent market in China and India  which is growing sharply at 20   The company plans to invest  150 million in China over the next five years to build a local manufacturing operation  Stryker  with its acquisition of China based Trauson Medical  is expected to grow market share in the value oriented orthopedic segment in the developing nations  In November  orthopedic major  Smith   Nephew acquired the assets of its Brazilian distributor  Pr  Cirurgia Especializada  PCE   PCE has been associated with the company for the last 30 years and has distributed its sports medicine  orthopedic reconstruction and trauma offerings in Brazil    The company is also venturing into India and Turkey  In May 2013  the company announced an agreement to take over Adler Mediequip Private Limited and with it  the brands and assets of Sushrut Surgicals Private Limited  a leader in mid tier  orthopedic trauma products for the Indian market  Last July  the company decided to acquire certain assets of its Turkish distributor Plato Grup  The acquisition will promote distribution of Smith   Nephew s orthopedic reconstruction  trauma and sports medicine products in Turkey  Thermo Fisher is also expanding its presence in the emerging markets  It expects to garner 25  of total revenues from the high growth Asia Pacific region and emerging markets by 2016  up from 19  in 2011  According to the company  China with its rapid industrialization  increasing focus on healthcare  new BioPharma R D centers and government sponsored research has robust growth potential  Brazil is also gaining momentum with growth rate of more than 20   On the other hand  key growth drivers in India include outsourcing of clinical packaging and logistics by Pharma and Biotech companies  growing Biotech and food   beverage industries  and introduction of environmental regulations to address air quality issues in the wake of rapid industrialization  Among the BRIC members  Brazil is currently the largest healthcare market in Latin America  covering almost one fourth of the population  Though India has one of the largest and fastest growing healthcare markets in the world  it is considered to have the least developed healthcare infrastructure and spends relatively little in this area  In order to reverse the trend  during the 12th Plan  2012 2017   the Indian government planned to spend 2 5  of its GDP  up from 1 2  earlier  on health care and raise it to at least 3  by 2022    Other Issues at Work Apart from the medical device excise tax and sequestration  other issues faced by the MedTech industry include pricing concerns  hospital admission and procedural volume pressure  Medicare reimbursement issues and regulatory overhang  While the debt crisis in Europe remains unresolved  economies throughout the world are trying to come to terms with myriad challenges  Consequently  procedural volumes in the U S  have been hit by a high unemployment rate  which has resulted in the expiry of health insurance as well as a decline in enrollment in private health plans  Governments across several European countries have taken up measures to curb spending on devices  which is taking a toll on utilization  Volume headwind is likely to linger as unemployment continues to influence procedure deferrals  Last but not least  the highly regulated U S  medical device industry is constrained by stringent and complex procedures  leading to approval delays  This sometimes demotivates companies  deterring them from investing in product development  According to a report based on a survey of over 200 medical technology companies  FDA Impact on U S  Medical Technology Innovation   the FDA takes a significantly longer time to review compared to its European counterpart Zacks Industry Rank Within the Zacks Industry classification  MedTech is broadly grouped into the Medical sector  one of 16 Zacks sectors  and further sub divided into four industries at the expanded level  med instruments  med products  med dental supp and medical info systems  We rank all the 260 plus industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry   As a guideline  the outlook for industries with Zacks Industry Rank of  88 and lower is  Positive   between  89 and  176 is  Neutral  and  177 and higher is  Negative   The Zacks Industry Rank for med instruments is  141  med products is  93  med dental supp is  161  while the medical info systems is  246  Analyzing the Zacks Industry Rank for different MedTech segments  it is obvious that while the outlook for medical info systems stocks is negative  that for med instruments  med products and med dental supp is neutral Earnings Trend of the Sector Overall fourth quarter earnings guidance for the medical majors looks not so impressive  However  third quarter results have been fairly good with respect to beat ratios  percentage of companies coming out with positive surprises   We note that  the results were not impressive in terms of year over year growth  The earnings  beat ratio  was 74 5   while the revenue  beat ratio  was 51 0  in the third quarter  Total earnings for the companies in this sector increased marginally 0 2  year over year despite revenue growth of 5 8   In fact  earnings and revenues showed a slight increase from the second quarter 2013 performance  The earnings is expected to decline by 3 5  in the fourth quarter 2013  However  the sector is expected to register a nominal growth of 0 6  for the full year 2013 and an impressive 8 3  in the full year 2014  In terms of revenue expectation  the sector is expected to register 3 1  year over year growth in the fourth quarter of the year  resulting in an annual growth rate of 5 1   For more information about earnings for this sector and others  please read our  Earnings Trends  report OPPORTUNITIES In spite of several core market challenges  the big three medical device players   Medtronic  Boston Scientific and St  Jude   are striving to gain share in the ICD market through new product launches  The companies are also exploring fresh avenues of growth beyond the mature pacemaker and ICD markets    With gradual stability in the ICD market  these players should be able to revive their top line  Also  better pipeline visibility and appropriate utilization of cash should increase confidence in the medical device sector  The better than expected ICD performance from the trio indicates a revival in the worldwide ICD market The Cooper Companies Inc     represents a value proposition based on factors such as margin expansion  acquisitions  product line expansion and geographical reach as well as share buybacks  On the other hand  we are positive about multiple initiatives taken by Boston Scientific to expand electrophysiology  EP  division  St  Jude is also doing well with its growing Atrial Fibrillation products portfolio that witnessed a major boost with the acquisition of Endosense and the regulatory approval of its Mediguide catheters  Beyond the MedTech majors  we are also optimistic about the Zacks Ranked  3 orthopedic device players  Zimmer Holdings and Stryker Corporation  The percentage of population over 65 in the U S   Europe  Japan and other regions is expected to nearly double by the year 2030  In the U S   the oldest baby boomers are now approaching retirement age  We believe the orthopedic giants stand to benefit from this aging demography  Among scientific instrument makers  Thermo Fisher Scientific has been successfully expanding operating margins over the past few quarters on the back of operational efficiency  Thermo Fisher s market leading portfolio of analytical technologies and specialty diagnostic will be complemented by the upcoming buyout of Life Technologies  The latter has an expansive line of consumables for genomic  molecular and cell biology  Among mid cap MedTech stocks  Align Technology  ALGN  and Symmetry Medical  Inc   SMA  carrying a Zacks Rank  2  Buy  also look attractive   CHALLENGES AND WEAKNESSES Coming to the weakest link in the MedTech sector  we advise investors against names that offer little growth opportunity over the near term  These include companies for which estimate revision trends for 2014 reflect a bearish sentiment  After posting dismal third quarter results and lowering its fiscal guidance  Intuitive Surgical  ISRG  currently retains a Zacks Rank  4  Sell   Other stocks which do not look inspiring are Allscripts Healthcare Solutions  Inc   MDRX   Laboratory Corporation of America Holdings  LH  and Edward Lifesciences  While MDRX holds a Zacks Rank  4  Sell   EW and LabCorp fall under the Zacks Rank  5  Strong Sell  category  Pricing compression on hips  knees and spine products  which impaired the performances of several orthopedic companies  remains a key concern  at the macro level  We remain skeptical about the prospects of Zimmer and Wright Medical Group  WMGI   each with a current Zacks Rank  4  Sell  ,2014-01-08,Zacks Investment Research,"https://www.investing.com/analysis/medtech-industry-update:-restructuring,-mergers-and-market-expansion-197967",197967
199335,420851,JNJ,The Stocks Investors Should Be Monitoring Now,opinion,Any investment portfolio is always well served with some exposure to healthcare  medical devices  and or pharmaceutical stocks  You can own the sector for income  capital gains  or a combination of both  Regardless  it is an industry sector that is consistently good at making money for stockholders You can invest or speculate in large cap  mid cap or small cap healthcare companies  the opportunities run the gamut and it s not too difficult to find the right stocks to fit a particular risk tolerance level In the large cap space  we previously looked at Becton  Dickinson and Company  BDX   which is a New Jersey based medical instrument and supply company  This healthcare company has been a powerhouse wealth creator and one of many large cap healthcare stocks that also pay dividends  Its current dividend yield is approximately two percent BDX has been soaring  especially since the beginning of last year  due to a solid financial performance and outlook for 2014 According to the company  its revenues for the fourth fiscal quarter  ended September 30  2013  were  2 1 billion for a 7 2  currency neutral gain  Fiscal 2014 should see sales grow by four to five percent  and diluted earnings per share from continuing operations should grow between six and seven percent over fiscal 2013 These aren t growth stock type gains  but we re talking about a very mature enterprise Ten times larger than BDX is Johnson   Johnson  JNJ   This is one of my favorite blue chip healthcare stocks for long term investors The company has a great  consistent track record of increasing its dividends over time  as well as revenues and earnings Johnson   Johnson also experienced substantial capital gains  breaking out of its traditional price action at the beginning of 2013  The Street expects a lot from this company  but it typically delivers  illustrating how lucrative business can be in pharmaceuticals and medical devices Johnson   Johnson is a member of the Dow Jones Industrial Average and is highly likely to see another quarterly dividend increase this year  Among a large universe of healthcare stocks  this one is a portfolio benchmark But not to be excluded are the countless small cap stocks in this industry sector that offer good potential for capital gains in any kind of market   Biotechnology stocks have been the hottest over the last 24 months  One small cap company that I ve liked for quite some time is Cerus Corporation  CERS   which is a small  but developing biomedical company focused on commercializing its  INTERCEPT Blood System   This product is designed to improve blood safety by rendering pathogens  such as viruses  bacteria  and parasites  inactive in donated blood Third quarter sales for Cerus in 2013 were approximately  10 5 million  for a comparative gain of 28   The company is still operating at a substantial loss  but it s developing in a very diligent and responsible manner  which is what I like to see in an early stage technology play Healthcare stocks can be just as volatile as any growth industry sector  But institutional investors rally behind the sector on a consistent basis  because the earnings growth is there and it offers relative stability in the large caps Any equity portfolio is well served by some exposure to healthcare stocks  It s an industry sector requiring constant monitoring as trading opportunities are plentiful Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ,2014-01-09,Mitchell Clark,https://www.investing.com/analysis/the-stocks-investors-should-be-monitoring-now-198135,198135
199351,420867,JNJ,With Q3 Earnings Expectations Falling  Where To Invest Now ,opinion,"Investment risk for the very near term stock market is going up  There s been pressure on interest rates  investor sentiment was hit by the lack of tapering to quantitative easing  and finally  the third quarter earnings outlook is mediocre at best  Everything related to the stock market has been exceptional this year  While earnings growth was completely and totally lackluster  with several exceptions  the main stock market indices proceeded to rise tremendously  based on continued monetary expansion and the fact that there really is nowhere else for investors to go but stocks  Second quarter earnings season was unimpressive  and I think it will be the same for the third quarter reporting season  Financial results very well could be the catalyst for a major market retrenchment in October  I think that all investors need to prepare for such an eventuality  Generally speaking I do think that stocks will can continue to rise in 2014  however  corporations will have to provide genuine earnings growth and top line growth to keep valuations from pushing the envelope 
I would say that given current earnings and expectations for 2014  the stock market is at least slightly if not fully overvalued at present  With the expectation of very modest earnings growth in the third quarter and little in the way of sales growth  especially among large cap companies   recent stock market strength has been an expansion of valuations only  This is why I m so cautious near term and why October could be a wild ride for share prices  It is quite likely that market leaders that did well in the first two quarters of this year will continue to do so  These are the Johnson   Johnson s  JNJ  of the equity market universe these are the companies that have been well bid by institutional investors 
The health of large corporations continues to be robust  But if their earnings can t outperform or sales growth is nonexistent  then the last carrot attracting shareholders is increased dividends I think we re going to get a lot of news related to new share buyback programs and increasing dividends for the simple reason that companies won t be able to beat consensus earnings in the third quarter Or at best  they will produce results similar to the second quarter  when most corporations were not able to beat consensus on both revenues and adjusted earnings These are the makings of the next recession in 2014  Rising interest rates  continued lackluster revenue and earnings growth from companies  and mediocrity in other mature economies can certainly tip the GDP scale I am therefore very cautious on the near term outlook for stocks  and I do believe that the marketplace will continue to stick with its existing winners  These are the companies that can deliver on revenue and earnings expectations with rising dividends  It s a blue chip market  and in a slow growth environment  the big brand name companies are what you want to stick with Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ",2013-09-25,Mitchell Clark,"https://www.investing.com/analysis/with-q3-earnings-expectations-falling,-where-to-invest-now-185190",185190
199352,420868,JNJ,Looking For Rising Dividend Income  Stick With Existing Winners,opinion,Third quarter earnings season continues this week  with a number of companies set to report in the next few days  the stock market s attention should finally be on corporate earnings  And while earnings expectations are being reduced  the positive disposition to the Dow Jones Transportation Average remains  The index has trended higher compared to many blue chips  which have been in consolidation for some time now  Many component companies of the index are trading at or near their 52 week highs  With this trend  there is still some resilience to this stock market  even with a backdrop of reduced earnings outlooks  What is noteworthy in this regard is the NASDAQ Composite Index  which remains right at its 52 week high and is creeping closer to its all time record high set in 2000  Countless technology and biotechnology stocks continue to push to new highs  It s a near term bullish stock market indicator in an environment of declining expectations  And declining expectations are why the action in the NASDAQ is so worrisome  The stock market s been stretched for some time now  with previous leadership from blue chips and small cap companies  The recent outperformance in the NASDAQ Composite the component companies of which are far more risky than blue chips is itself a telling indicator  But while the stock market has been due for a correction for months now  the action in the Dow Jones transportation stocks  as well as the technology sector  is evidence of the continued resilience in equities  Recognizing that there are very few instances of optimal buying opportunities in this stock market  I m still very reticent to be a buyer in a market that s nearing its all time high on what is looking to be anemic earnings growth  There s nothing wrong with building cash positions at this time  Of course  secure dividend paying securities are still going to be in demand in a stock market that s actually starved of genuine economic growth  For investors considering new positions in this stock market  I m a fan of sticking with existing winners  These are blue chip dividend paying stocks like Johnson   Johnson  JNJ   The Procter   Gamble Company  PG   PepsiCo  Inc   PEP   and The Walt Disney Company   DIS  all large  brand name companies that have meaningful dividend yields and aren t overly stretched in terms of valuation I m also a fan of domestic energy and storage stocks  select restaurant stocks  and select transportation companies  But the reality is that economic conditions slowed in the third quarter and financial results should reflect this  There s no urgency to buy this stock market  I expect the market to sell off shortly ,2013-10-17,Mitchell Clark,https://www.investing.com/analysis/looking-for-rising-dividend-income-stick-with-existing-winners-188464,188464
199353,420869,JNJ,My Six Favorite Growing Dividend Payers,opinion,"The stock market typically reacts quite positively when a company beats Wall Street consensus  But in a considerable number of cases  a company s share price after earnings bounce isn t really warranted  considering the run up in anticipation Many stocks go up in value after beating expectations  but many numbers this quarter actually reveal a contraction in business conditions Western Digital Corporation  WDC  is the Irvine  California based maker of hard drives and solid state hybrid drives for desktops and personal computers  PCs   The company beat the Street on earnings  but the company s numbers actually represented a decline from the comparable quarter last year The company said that in its most recent quarter  fiscal 2014 first quarter   sales dropped six percent to  3 8 billion  earnings fell to  495 million  or  2 05 per share  compared to  519 million  or  2 06 per share  in the same period a year ago  and adjusted earnings came in at  2 12  while Wall Street was looking for a consensus of  2 05 Naturally  the position moved higher on the stock market  The company did experience an improved gross margin  but it wasn t a good quarter  The stock is up about 70  so far this year to an all time record high There are countless other stories similar to Western s  and investors have to be very careful with this so called outperformance by Wall Street standards  Business conditions are not improving for a lot of companies  Earnings are slightly improving  but only through continued pressure on costs and a slight improvement in pricing Of course  the monetary backdrop continues to be very supportive for stocks as we know  The S P 500 Index has broken out of what looked like the perfect head and shoulders pattern  It s still an ominous looking chart  but the breakout pattern is significant  It s as if the index is returning to its modern era mean  The S P 500 s 35 year chart is featured below 
Investment risk is always high with equities  but there are very few alternative investment classes with interest rates sitting so low  especially for those investors who rely on dividend income  Given the monetary situation and the expectation that the Federal Reserve will continue to be highly supportive to equities  this is very much a market that can still tick higher  But there is absolutely no need to chase stocks  or play the momentum gain  especially with companies that aren t actually growing  Wall Street s expectations for a company are both useful and irrelevant at the same time  Stocks didn t advance this year on the expectation of better growth rates of revenues and earnings  the marketplace just went all in with the Federal Reserve s grand attempt at reflation  For investors  I like existing winners that pay growing dividends in an era of very slow real corporate growth  Companies like NIKE  Inc   NKE   Johnson   Johnson  JNJ   PepsiCo  Inc   PEP   Canadian National Railway Company  CNI   E  I  du Pont de Nemours and Company  DD   and Colgate Palmolive Company  CL  are just a few examples of growing dividend payers with excellent long term track records of wealth creation   See  Equity Market Super Stock Adding Up to Solid Returns    And energy is not to be excluded as a great income provider  It s one of the economic bright spots with staying power for the rest of this decade  If a company beats the Street  that s great  But when it beats the Street without actually growing comparatively  it s not worth chasing  
Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ",2013-10-30,Mitchell Clark,https://www.investing.com/analysis/my-six-favorite-growing-dividend-payers-189805,189805
199359,420875,JNJ,Johnson   Johnson  Delivers The Goods  Again,opinion,In what can only be described as another excellent quarter of performance and growth  Johnson   Johnson  JNJ  once again beat Wall Street consensus with its earnings  The company defied the odds and posted genuine business growth not just domestically  but abroad as well  Similar to its first quarter performance  the company seems to be on a bit of a roll Johnson   Johnson reported revenues of  17 9 billion for the second quarter of 2013  a solid increase of 8 5  over the comparable quarter in 2012  Domestic sales grew eight percent  which was expected  the surprise was in the company s international sales  which grew 11 8  in total  with a negative currency impact of 2 8  for a net growth of nine percent  This growth measure includes acquisitions and divestitures  excluding those  global operational sales growth was 5 6  Global pharmaceutical revenues were  7 0 billion in the second quarter for a net gain of 11 7  comparatively  Domestic pharmaceutical sales grew 9 1  Johnson   Johnson s operational top line growth really is solid  considering today s economically challenged global economy  The company appears to be in the right businesses at the right time  at least according to the numbers On the stock market  Johnson   Johnson s shares have soared as the marketplace chases the safest  dividend paying stocks that are actually able to generate real economic growth The company s stock chart is featured below  Earnings were  3 8 billion  including a gain on sale and an after tax gain   and diluted earnings per share  EPS  were  1 33  handedly beating Wall Street estimates  Not only did Johnson   Johnson s numbers beat consensus  but the company also increased its full year 2013 guidance  The company raised its earnings forecast to a range of  5 40  5 47 a share excluding items  At the beginning of the year  Johnson   Johnson forecast earnings between  5 35 and  5 45 a share  Speaking of beginnings  Johnson   Johnson s share price is up a whopping  20 00 a share  not including dividends  since the beginning of the year  The company is now worth a quarter of a trillion dollars  which is truly amazing for such a mature brand  Johnson   Johnson exemplifies the kind of stock that institutional investors want to own in this kind of market  The company has diversified operations  so there are good prospects for dividend increases going forward  and there s a lot of safety in what this company is selling  Revenues and earnings growth  while not robust  were still very impressive for a company of this size The company really hasn t done much on the stock market over the last seven years until recently  when all of a sudden it did  But that is how so many large cap  blue chip companies trade  periods of nonperformance are met with increasing dividends followed by a comparatively short breakout representing the majority of the position s capital gains over a period of time  The opportunity cost of not being in the position while it is experiencing its breakout capital gains is significant  Johnson   Johnson serves to illustrate that great businesses tend to remain just that great and that long term ownership with dividend reinvestment is an excellent way to generate meaningful investment returns  Without question  this company is due for a stock market correction  Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ,2013-07-19,Mitchell Clark,"https://www.investing.com/analysis/johnson---johnson:-delivers-the-goods,-again-176130",176130
199360,420876,JNJ,S P 500 Lapping Weakest 2012 Earnings Growth In Q3  13 ,opinion,Q3  12  earnings growth for the S P 500 was just 0 1   the lowest year over year growth for the S P 500 since the 2nd quarter of 2009  In my opinion  Q3  12 really marked the end of the huge productivity boom off the 2008   2009 recession  and was the transition quarter  as the S P 500 started to shift from productivity driven earnings growth to organic and revenue generated earnings growth  According to ThomsonReuters   This Week in Earnings  the forward 4 quarter estimate for the S P 500 slipped this past week to  115 96  from last week s  116 14  The P E ratio on the forward estimate is 14 7 x  as of the market close on Friday  August 2nd  The S P 500 earnings yield is 6 78   The year over year growth rate of the forward estimate has risen to 7 14   the highest growth rate in the last year  and about even with what Factset thinks is the  average  4 year growth rate of S P 500 earnings at 7   In fact  it was the first week of August in 2012  that saw the slowest year over year growth rate for the forward estimate at just 1 08  on August 3rd  2012  With 384 S P 500 companies having reported Q2  13 earnings  the y y growth rate has risen to 4 3   versus the 2 9  as of July 1  and revenue growth has ticked up to 2 1   So far there is nothing unusual about Q2  13 s earnings save for the gigantic contribution of the Financial sector   28 5  y y earnings growth when a still robust but far lower 17 5  was expected on July 1  Basic Materials as a sector is still getting crushed  Metals and Mining stocks are the worst subsector of the sector  Per FactSet  Metals and Mining earnings growth is down 59  year over year  One interesting technical item to note  despite horrid 2nd quarters by Alcoa  AA   Freeport  FCX   and US Steel  X   the stocks have NOT made new lows below their June  early July prints  At just 3  of the S P 500 by market cap  Basic Materials are not a big influence on the index  but I do like to watch these heavily pessimistic  very cheap valuations  for opportunity  How do Q3  13 and Q4  13 look from an earnings perspective    The expected Q3  13 earnings growth rate has fallen 2 5  from July 1 to 6 0  y y growth from 8 5   Part of that sharp drop is Telecom  which is down from an expected 17 3  to 9 1   ThomsonReuters told me that Sprint  S  has been removed from the S P 500  At the rate analyst s are cutting estimates  Q3  13 should come in at  1    2  expected growth by early October  which is how the last 4 quarters have tracked  The expected Q4  13 earnings growth has fallen 13  on July 1 to 11 6   Again  Telecom is down from an expected earnings growth rate in Q4  13 of 47 8  to 20 8   Financial sector estimates continue to be a Rock of Gibraltar for both quarters  with slightly upward revisions  Basic Materials  Telecom and Utilities stocks each represent about 3  of the S P 500  by market cap  Owning Financial s  18  of S P 500 by market cap   Technology  18  of S P 500   and Industrial s  10  of S P 500  gets you about 46  exposure to the S P 500  Healthcare was the best performing sector in both July  13 and year to date  with the sector being 7 09  and 27 90  per Bespoke s data  Interesting that Pfizer  PFE   Merck  MRK  and Amgen  AMGN  haven t made new highs in a while  AMGN hit its  115 high in the 3rd week of April  MRK hit  50 in early June  and PFE s  31 high was all the way back in the 3rd week of April  Only Johnson   Johnson  JNJ  keeps chugging along  JNJ s chart looks a lot like Home Depot s  HD  did in 2012  JNJ is up 36  year to date as of Friday  which is just capital gain  Healthcare is 13  of the S P 500 and we are probably underweight the sector  with closer to a 10  weight in client accounts  The fact is  long term average earnings growth is just now returning to  average  and is actually a little below average currently  S P 500 earnings growth SHOULD continue to improve  Municipal closed end funds  we will be out with charts on Sunday and Monday  with technical commentary on a few positions from Gary Morrow  but we ve added the Nuveen Municipal Value  NUV  closed end fund to client accounts in the last week  as well as the Blackrock Muni Enhanced  MEN  closed end fund to get both yield and technical support for clients taxable bond portfolios  We will save the fundamental write up for the blog specific post  but we are finding a whole lot of muni closed end funds at weekly oversold readings on our charts  What I do worry about is meaningful tax reform  which reduces or eliminates the favored tax exemption of municipal bonds for individual investors  given Congress  and the President s penchant for screwing the wealthy investor AND trying to boost tax revenue  BUT the catch is that current muni yields on some of these funds  rival the current investment grade bond yield  which if you ve followed muni s for a while  means muni yields are trading at 100  of investment grade corporates  which is truly cheap  If we used taxable equivalent yields on the muni CEF s  the muni market is approaching yields closer to taxable high yield or 7  8   even as high as 10   These tax exempt yields discount a lot of potential trouble with an 8  to 10  taxable equivalent yield  Some of these closed end funds could start to see  cross over buying   which means that they could get bought in IRA and tax deferred accounts simply for absolute yield purposes  I know I ve thought about it for some large IRA and Foundation accounts we manage  which are tax advantaged already  Selling mutual bond and fixed income funds  part of the above interest in closed end funds is that we are in the process of selling all of our taxable and municipal bond funds and moving more towards individual bonds  closed end fund s and ETF s  Part of the strategy or methodology is that with the undefined maturity  mutual funds could very likely struggle with redemptions in the next few years  and we are looking more to trade for shorter time period  s and to generate  absolute return  within client fixed income and balanced accounts to minimize loss  and maximize total return  I think the bond markets of the next few years will be very different from the 2010   2013 market  where you simply bought mutual funds of various duration and credit spectrums and then sat on them for a while  We sold some more Friday  August 2nd  as we tried to catch a Treasury rally  Treasuries saw a little rally on Friday on the weaker jobs report  I thought Rick Santelli  the CME CNBC reported that covers Treasuries  currencies and such from Chicago  made a very astute point  The June payroll report in realy July  which was stronger than expcected  saw 10 year Treasury yields spike 24 bp s  or 3 4ths of a point  The rally Friday  August 2nd on the weaker July jobs report was just a 1 2 point  Per Rick  the Treasury risk reward remains skewed toward higher rates  It is only a matter of time before technical levels get trashed in my opinion  We are still long a little iShares Barclays 7 10 Year Treasury ETF  IEF  and iShares Barclays 20  Year Treasury Bond ETF  TLT  for an off season trade in August  We could end up selling at a loss  too  Facebook  FB  was our best July  13 performer  So glad we stayed with the stock  afterit on the blog a few times  Stock was up 48  in July  13 and jumped to our  2 position on appreciation alone  My budy  Ryan Detrick out of Schaeffer s in Cincinnati   how the Russell 2000  RUT  needs to take out 1 060  Key level   Closed Friday at 1059 86  We are keeping it short and sweet this week  The S P 500 remains overbought and August is typically a weak period for stock returns  but we could have seen our correction in June  We are still overweight Financials in client equity accounts   3 of top 5 positions  which has been the case for a while   with Consumer Discretionary and Retail in the Top 10 too  The inverse Treasury is a large position in balanced  and fixed income accounts  We are long Japan ETF s and like the Treasury ETF s IEF and TLT for a counter trade in what could be a blah and slow August  13  We have a found a couple of oversold stocks due for a trading bounce  so check back on the blog Monday or Tuesday ,2013-08-04,Brian Gilmartin,https://www.investing.com/analysis/s-p-500-lapping-weakest-2012-earnings-growth-in-q3-13-178184,178184
199361,420877,JNJ,Deferred Tax Assets and Liabilities,opinion,This report is one of a series on the adjustments we make to convert GAAP data to economic earnings  Reported earnings don t tell the whole story of a company s profits  They are based on  rules designed for debt investors  not equity investors  and are manipulated by companies to manage earnings  Only economic earnings provide a complete and unadulterated measure of profitability  Converting GAAP data into economic earnings should be part of every investor s diligence process  Performing detailed analysis of footnotes and the MD A is part of fulfilling fiduciary responsibilities  We ve performed unrivalled due diligence on 5 500 10 Ks every year for the past decade  Deferred tax assets  DTAs  arise when reported income on a financial statement is less than taxable income  DTAs are  in a sense  like pre paid taxes and represent expected reductions of future reported taxes  Deferred tax liabilities  DTLs   on the other hand  arise when reported income is greater than taxable income  DTLs represent the expected amount of additional reported taxes to be paid  These items are a result of differences between GAAP accrual accounting and tax policy  Examples of DTAs include  product warranty reserves  tax loss carry forwards  and future pension and postretirement benefit payments  Examples of DTLs include  accelerated depreciation payments and nondeductible intangibles  DTAs artificially raise reported assets and do not help generate operating profit while DTLs are like a source of interest free financing  We remove the impact of DTAs and DTLs from our calculation of invested capital to ensure the more accurate measure of a firm s return on invested capital  ROIC   We subtract all DTAs from invested capital  We include all DTLs in invested capital  When we calculate a firm s implied value in our DCF model  we subtract any net DTLs  DTLs minus DTAs  as they are real cash obligations on future cash flows  DTAs and DTLs are disclosed in two ways  They are either explicitly presented as DTAs and DTLs or hidden in other line items on the balance sheet  in which case investors have to dig through the footnotes to find them  Johnson   Johnson  JNJ  had over  7 6 billion in deferred tax assets adjusted out of invested capital for 2012  This deferred tax asset is mostly due to future employee benefit obligations that have been recorded but not paid  and that have not yet been taxed  Without this adjustment  JNJ s invested capital would have been over  108 billion  but taking this adjustment into account brings JNJ s invested capital down to  100 billion  Figure 1 shows the five companies with the largest gross value of deferred tax assets and liabilities adjusted out of invested capital for 2012 Figure 1  Companies Most Affected By Deferred Tax Assets and LiabilitiesSources  New Constructs  LLC and company filings However  these companies are far from the only ones affected by deferred tax assets and liabilities  In the last fiscal year  DTA and DTL adjustments occurred 3075 times for 1980 different companies  Our database contains over 28460 DTA and DTL adjustments for a total adjustment value of  2 6 trillion out of invested capital and  4 9 billion back into invested capital  Though the removal of DTAs DTLs can lower raise invested capital and boost depress ROIC  this does not always mean the company s stock will earn a favorable rating  For instance  Ford  F  still has only a 3 star or Neutral rating despite its  15 billion in adjustments out of invested capital  Likewise  PartnerRe  PRE  still earns a 5 star Very Attractive rating despite having  300 million adjusted back into invested capital  In other cases  however  DTAs DTLs can artificially depress boost invested capital and make a stock look over undervalued  Case in point  General Motors  GM  had a total of  37 billion in deferred tax liabilities in 2012  or 25  of its total assets  This huge sum was primarily due to operating loss and tax credit carry forwards from the years of losses GM racked up before its bankruptcy  Now that GM expects to make money again  it is expecting to realize these losses as tax benefits on its new income  GM s net DTAs were disclosed on its balance sheet  but investors would need to go to   deep in the financial footnotes  to uncover the value and details of the company s short and long term DTLs  On GM s balance sheet  these hidden DTLs are simply lumped in with  other liabilities   Including GM s net DTAs in its invested capital would have raised the company s average invested capital from  69 billion to over  106 billion  However  removing the value of these assets gives a truer representation of the capital GM currently has on hand to generate a profit  Without the adjustments  GM s ROIC would be under 4   but adding back the amount of the DTAs gives GM an ROIC of 6   While this boost in ROIC elevates GM above the bottom quintile of all companies I cover  GM s high share price of   36 makes the stock too risky to receive above a 2 star Dangerous rating  Still  this example shows how due diligence can make a substantial difference when calculating a firm s invested capital  Andr  Rouillard contributed to this report Disclosure  David Trainer and Andr  Rouillard receive no compensation to write about any specific stock  sector  or theme ,2013-08-04,David Trainer,https://www.investing.com/analysis/deferred-tax-assets-and-liabilities-178228,178228
199362,420878,JNJ,Economic Data Support Taking Some Profits Off the Table,opinion,A stock market strategist who I trust and respect is advocating that investors take some money off the table and book profits from U S  equities  His view is that  with declining earnings expectations for the bottom half of the year combined with mostly zero top line growth  the likelihood of reduced monetary stimulus and lackluster global growth do not warrant a rising stock market  The market s expectation for an improving U S  economy is already priced into share prices  But while this market strategist makes a very good case for taking profits in U S  blue chips  there still isn t anywhere else for most investors to go other than the stock market  This gentleman thinks that a rising cash position is warranted and that the cash can then be put to work in the next correction and or recession  Cash in the bank is always a good thing  but there is an  opportunity cost  to not being in the stock market s best positions  From my own perspective  I find it difficult taking profits in blue chips like Johnson   Johnson  JNJ  with a current price to earnings ratio of around 20 and a 2 9  dividend yield  With an earnings plus dividend growth rate of approximately 10  over the next 12 months  JNJ to me is a big  Hold   And there are many other blue chips that I wouldn t sell either  even though they have done extremely well on the stock market recently Realistically  I come back to the old adage that it usually doesn t pay to fight the Fed  With a change in monetary policy somewhat likely this September  the Fed s actions will be the catalyst for correction  even though the stock market s been due for a correction for months now The perception of certainty is a Wall Street staple  and that s what the central bank has provided to date  Monetary policy  at least in the near term trading action  always overrides the marketplace s real financial metrics  Second quarter earnings and revenue growth among blue chips was mediocre  at best There has been  however  a continued resiliency in the stock market this entire year  and the market s strength  even in the face of weak news  is difficult to trade against I m certainly an advocate for creating lists of good companies that would be worth accumulating when they are down  Given the current information  however  I wouldn t be selling the market s best performing blue chips in anticipation of the future With investor sentiment interwoven with the next Fed meeting in a little over a month  I expect stocks to basically move sideways  save for a shock  The argument for lightening up on U S  equities makes total sense with declining earnings expectations  yet the one thing that the market strategist I mentioned above is not quantifying is investor sentiment itself This is still a market that wants to bid stocks  regardless of a mediocre outlook  There is also some asset rotation taking place  as some investors move out of bonds  The resiliency continues Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ,2013-08-14,Mitchell Clark,https://www.investing.com/analysis/economic-data-support-taking-some-profits-off-the-table-179568,179568
199363,420879,JNJ,Why Corporate Earnings Are Taking A Back Seat To The Fed,opinion,The second quarter earnings season is considered over  but there are still a number of companies reporting  And the same trend continues the numbers are anemic  Making the case for a rising stock market in the face of little sales growth and earnings results that are basically just meeting expectations is difficult  The stock market s performance for the last few years has been very much due to the monetary expansion  followed by a slight improvement in general business conditions  What is clear is that corporate balance sheets continue to be extremely healthy  However  the lack of investment in new plants  equipment  and employees remains a big problem  There is more certainty in the marketplace  but corporations just aren t making much in the way of bold new investments  Despite the mediocrity  there are still a number of blue chips whose earnings estimates are being increased by Wall Street  In a lot of the earnings results from blue chips over the last several quarters  sales increases have mostly been due to rising prices  not necessarily rising volumes  This is emblematic of the very slow growth environment the U S  economy continues to experience  as well as the economic misnomer that price inflation is tame The velocity of money  which is the willingness of both corporations and individuals to spend cash  continues to be faint  Improving balance sheets is an excellent development for the long run  but cash hoarding means no growth near term  It s a trend that s likely to continue  While not much of an advocate for buying in the stock market today  I do think that it s wise for investors to stick with the safest names to keep holding those blue chips who have been the market s leaders to date  Some of these names include  The Procter   Gamble Company  PG   Johnson   Johnson  JNJ   Pepsico  Inc   PEP   The Walt Disney Company  DIS   Nike Inc   NKE   The Home Depot  Inc   HD   and Union Pacific Corporation  UNP   to name a few  These are the proven blue chips  with increasing dividends providing the earnings certainty that institutional investors will continue to pay for The way the stock market finishes this year is highly dependent on the Federal Reserve and the amount of monetary stimulus stirring the system  This is a market about the perception of certainty  not the reality of it  Economic news of late shows the U S  economy to be very tame in its recovery  with regional  and industry specific fractions very much a reality As things go in capital markets  good news in the form of positive economic statistics or earnings produces a falling stock market  Good news also increases the probability of a reduction in monetary stimulus This is the reality of the extreme short term focus of capital markets  For equities  the market  extremely focused on the Fed  corporate earnings are secondary Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ,2013-08-20,Mitchell Clark,https://www.investing.com/analysis/why-corporate-earnings-are-taking-a-back-seat-to-the-fed-180302,180302
199364,420880,JNJ,Will A Return To Normalized Interest Rates Halt Economic Growth ,opinion,I really don t expect the stock market to come apart unless there s some sort of shock  Why  Because many blue chips are trading right around their historical valuations at this time  And with equities in consolidation mode until the next meeting of the Federal Reserve in September  there is not a lot of new action to take  I have to admit that the stock market is holding up extremely well in the face of declining earnings expectations  Given the anemic rate of growth in the U S  economy  the next recession is a real possibility within the next 18 months  The catalyst for a technical recession could be rising interest rates that  as we know  have been artificially low for a long time now  But there are other pressures in the marketplace  too  The spot price of oil is surprisingly strong  given the economic outlook  Some precious metals have also been ticking higher recently  But while there is price inflation in the general economy  it doesn t show in the headline numbers and it isn t translating into new spending by corporations   Many companies experienced revenue growth in the second quarter solely due to increased prices for their products  not increased volume   Corporations and individuals continue to be highly conservative with their spending  This is a positive development as corporate and individual balance sheets improve  but it doesn t help a consumption based economy  I continue to believe that this year s stock market winners will remain that way  Institutional investors want reliability in earnings results  and they want the dividends that blue chips provide  There is not a lot of reliable growth out there  so when a company like Johnson   Johnson  JNJ  generates eight percent top line growth in one quarter  the stock market loads up  You can tell by the most recent numbers that corporations have pretty much exhausted their abilities to grow their bottom lines on cost control alone  Meaningful revenue growth is a must if earnings are to grow at a rate greater than inflation going forward  So all in all  the stock market is a big hold  but there are clouds on the horizon  Dividend income remains a top priority as far as I m concerned  it s probably the greatest certainty that a stock market investor has in the current environment  Interest rates are too low and the marketplace is chomping at the bit to see the entire yield curve move upward  And while it s correct to have the Federal Reserve out of the bond market  a return to a more normal interest rate environment may turn out to be the catalyst for even slower growth The cycle will play itself out  and there s no reason to be in a rush to consider new positions in this stock market  I wouldn t be adding to existing blue chips  rather  I d be keeping any new monies in cash for the time being  I really don t expect anything significant from the stock market until the next Fed meeting Disclaimer  There is no magic formula to getting rich  Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis  The opinions in this e newsletter are just that  opinions of the authors  Information contained herein  while believed to be correct  is not guaranteed as accurate  Warning  Investing often involves high risks and you can lose a lot of money  Please do not invest with money you cannot afford to lose ,2013-08-22,Mitchell Clark,https://www.investing.com/analysis/will-a-return-to-normalized-interest-rates-halt-economic-growth-180624,180624
199388,420904,JNJ,Whic Is The Larger Bubble  The S P 500 Index Or U S  Treasuries ,opinion,Over the past week  we ve had a plethora of companies reporting earnings and are moving through the 1st Quarter earnings season at a rapid pace  Thus far  earnings have been far from exciting and have made the previous 2013 forward earnings estimates laughable The only way we get to the proposed valuations is through multiple expansion which is simply going to require the Federal Reserve to continue to pump  85 billion into Treasury s and MBS securities each month  I am confident they will comply There are a few analysts out there who are discussing the potential bubble forming in equities and other risk assets as Bernanke s plan is working to the extent that asset prices are rising  However  even fewer analysts are pointing out that both retail and institutional money is constantly chasing yield at this point Simply take a look at the 2013 price action in high yield dividend paying stocks  high yield bonds  preferred stocks  and master limited partnerships  It is safe to say that a bubble has formed not just in equities  but in various fixed investments as well  Consider the following chart of the S P 500 Index  SPX  shown as the dotted trendline and Johnson   Johnson  JNJ  shown as the solid black line Obviously from looking at the chart above  JNJ has outperformed the S P 500 Index year to date  Has JNJ suddenly become a growth giant  Is it all about earnings growth and or forward earnings potential or anticipated growth  Or is the rally in JNJ really about the fact that Johnson   Johnson has a long history of paying strong  rising dividends  I am sure there are plenty of sell side analysts who will tell you that JNJ is going to  100   share in the future for a variety of macro or quantitative reasons  The sell side analysts will tell you the economy is strengthening or that large cap multinational companies are seeing strengthening fundamentals and earnings growth  They are called the sell side for a reason  they want to sell you stock  Furthermore  my favorite recent discussion is about future earnings projections and the new strength that we are going to see in earnings  The following chart was posted at  and originally came from Standard   Poors  The chart below illustrates the trailing 12 month operating earnings per share of S P 500 companies  Based on the above data  how is the stock market fundamentally sound when earnings are collapsing  I guess the Federal Reserve is going to print profits for the S P 500 companies  Actually earnings are irrelevant when central banks all over the world including the Federal Reserve are juicing the markets with a sea of liquidity and where multiple expansion trumps real earnings or value Furthermore  these same central banks are openly purchasing equities and allocating sizable portions of their balance sheets to stocks  Several central banks around the world have more than 10  of their reserves allocated to stocks at this point in time  The world is long risk and money is still flowing into bonds at the same time  Simply look at the recent price action in Treasury s for the past few weeks or note the strength in municipal bonds in aggregate since mid March This brings me to my final point  For the past several years  bonds and stocks in the United States have rallied together  U S  Treasuries and domestic equities have been trending higher for more than three years as shown below  The S P 500 is shown as the dotted line and the 30 Year Treasury Bond Price Index is the black solid line It is without question that both the S P 500 Index and the 30 Year Treasury Bond have been trending higher for the past 3 years overall  Both underlying assets have produced strong gains during the same period of time  Now this brings me to my final question for readers to ponder  If both the S P 500 Index and the 30 Year Treasury Bond can rally together  what happens if they sell off together The answer to that question is the real problem  Many sell side analysts and economists ignore the bubble that the Federal Reserve has created in equity valuations  The bubble continues to be fueled by the monstrous liquidity injections that they have conducted beginning with the original quantitative easing  However  what is even less acknowledged by the sell side is the massive artificial bullish valuations that have been created in the bond market Long dated Treasuries are being purchased by the Federal Reserve to artificially hold down interest rates  This ongoing practice is causing a separate bubble to form in fixed income investments  So now we have a bubble in equities and long dated treasuries forming and the sell side continues to trumpet that higher prices are likely  Ultimately the sell side may be right in short to intermediate time frame  but the end game has a finality that few want to consider When these bubbles finally pop as all excessively valued assets do  the result is going to devastate financial markets  It may be in 6 months or it may be in 10 years  but history will not be thwarted  The central banks can try to outsmart history  but they will ultimately fail Disclaimer  This material should not be considered investment advice  J W  Jones is not a registered investment advisor  Under no circumstances should any content from this article or the OptionsTradingSignals com website be used or interpreted as a recommendation to buy or sell any type of security or commodity contract  This material is not a solicitation for a trading approach to financial markets  Any investment decisions must in all cases be made by the reader or by his or her registered investment advisor  This information is for educational purposes only ,2013-04-28,J.W. Jones,"https://www.investing.com/analysis/whic-is-the-larger-bubble,-the-s-p-500-index-or-u.s.-treasuries-164748",164748
199389,420905,JNJ,Tired Bull Market,opinion,Not much seems able to restrain the strength of the bull market in U S  equities  On a year to date basis the S P 500 Index is up 15 43   The advance has finally drawn investors into equity mutual funds as reflected in positive equity mutual fund flows the first three months of the year The positive market results continue to keep the S P 500 Index in a positive uptrend channel that began in the middle of November of last year  Aside from the fact that company fundamentals and valuations look reasonable  or at least not overvalued  higher equity prices could continue to unfold  However  we have noted in several recent posts the rotation that has occurred of late out of the more defensive sectors into the more cyclical ones Because of the significant amount of artificial stimulus being pumped into the global economy by most central banks around the world  we believe investors need to have a heightened focus on the underlying technical aspects of the market in order to gain insight into potential market turning points  No one technical indicator is the panacea that will predict the market s future direction  One indicator useful to evaluate for the market and or individual stocks is the   This index is a variation of the Relative Strength Index  RSI   The  website provides the following definition of MFI   The Money Flow Index  MFI  is an oscillator that uses both price and volume to measure buying and selling pressure  Created by Gene Quong and Avrum Soudack  MFI is also known as volume weighted RSI  MFI starts with the typical price for each period  Money flow is positive when the typical price rises  buying pressure  and negative when the typical price declines  selling pressure   A ratio of positive and negative money flow is then plugged into an RSI formula to create an oscillator that moves between zero and one hundred  As a momentum oscillator tied to volume  the Money Flow Index  MFI  is best suited to identify reversals and price extremes with a variety of signals   The Money Flow Index is a rather unique indicator that combines momentum and volume with an RSI formula  RSI momentum generally favors the bulls when the indicator is above 50 and the bears when below 50  Even though MFI is considered a volume weighted RSI  using the centerline to determine a bullish or bearish bias does not work as well  Instead  MFI is better suited to identify potential reversals with overbought oversold levels  bullish bearish divergences and bullish bearish failure swings  emphasis added   As with all indicators  MFI should not be used by itself  A pure momentum oscillator  such as RSI  or pattern analysis can be combined with MFI to increase signal robustness   As the below charts display  the weekly chart of the market and the MFI are showing divergence  A weekly time period is used in order to smooth out the potential day to day market variations  On the daily chart  the MFI trend is positive  however  the index recently rose above the overbought area of 80 on the chart  Also  market volume has been in a steady decline since late 2011 and has not picked up in spite of positive equity fund flows as noted in the first chart in this post  As with any indicator  no single one is the perfect market predictor  As an example  the  and is based on the money flow concept as well  As the   this indicator has given off false signals as well  At HORAN  we do remain positive on the market  but believe some consolidation could occur and would be healthy for the performance potential through the balance of the year  Our focus has been to reduce or sell some of the holdings in the defensive sectors and build or add to positions in the more cyclically exposed sectors that have underperformed this year  and over the last year for that matter  One stock we trimmed recently was Johnson   Johnson  JNJ   We trimmed the holding for more than technical reasons  but   it does show some potential stock weakness ahead when looking at just the MFI ,2013-05-13,Blog of HORAN Capital Advisors,https://www.investing.com/analysis/tired-bull-market-166603,166603
199390,420906,JNJ,Effective Johnson   Johnson Put Strategy ,opinion,The climax of yesterday s bullish stampede exceeded an in our wildest dreams target by 56 cents  see inset   but when the dust had settled  short positions initiated by subscribers near an 89 43 Hidden Pivot were well in the black  For tracking purposes I ll use 24 May 87 50 weekly Johnson   Johnson  JNJ  puts that  Dave  reported buying for 0 11 in the chat room  They had tripled by the close  and so half should have been exited at some point along the way  However  I ll assume none were sold and recommend that you close out half at the market on the opening  Of the 12 that would remain  offer six for 0 50 and hold the rest for a potential home run on Friday  when the puts are due to expire  The 0 50 offer should be entered before Thursday s opening  since traders could conceivably close out a total of 18 at that price or higher on a gap down at the bell ,2013-05-23,Rick Ackerman,https://www.investing.com/analysis/effective-johnson---johnson-put-strategy-168138,168138
199397,420913,JNJ,A Pill For Every Ill  Big Pharma SWOT Analysis ,opinion,Every industry has its ups and downs  and many have been riding on the crest of the success wave for so many years that they ve all but forgotten what it means to take stock of the situation and regroup their efforts to address the future  The housing industry was forced to go through that phase over the last few years  Will it be pharmaceuticals that face the next big crisis  Is there a crisis in the first place  or is it exaggerated  And more importantly  what are the opportunities for big pharma to recoup the billions of dollars lost over the patent cliff  Exploring the Strengths  Weaknesses  Opportunities and Threats  SWOT  of a particular situation has always helped put things in perspective  The ship may still be afloat but it s taking on water at a tremendous rate  hopefully  we can derive a clear picture of major pharma companies struggling to keep their bodies out of the water StrengthsMarket Dominance   Market dominance is probably their key global advantage  Big pharma has so many millions of doctors all over the world eating out of their hands that they won t think twice about crushing the competition any way they can  This isn t a colorful description of their dominant position   it s merely calling it a spade  Why have so many flagship drugs been doing so well the past few years  Could it be that the  incentive  programs offered to doctors to prescribe one brand over another competitor has something to do with it  While it wouldn t be proper to make accusations  everyone is free to have an opinion  But unlike opinions  doctors don t help pharma companies achieve their targets for free  There s the first spade Eradicate  They drive the medical profession in whatever direction they want  Treatment is more profitable than curing  so that s the direction they ve always taken doctors in  Insider after insider will tell you that this is true  Most doctors know this  but because it s profitable for them too  the majority won t squeal on big pharma  Theoretically  there should be fewer diseases today than there were 200 years ago because disease can t possibly proliferate faster than the speed of research  Or can it  Consider this statistic  There have been eight attempts at eradicating diseases in the last 200 or so years  Only one has been successful   Smallpox   in terms of human diseases  Why  Could it be because pharma hasn t driven their research in that direction  Of course  there is government intervention required to implement eradication programs  but where are the drugs for it  But credit is due where credit is due   there are zero cases of polio in the U S   Europe and China  Merck and GlaxoSmithKline have done their part in donating medicines  ivermectin and albendazole  respectively  for treating lymphatic filariasis  Pfizer  Eli Lilly and Johnson and Johnson have all spent millions pursuing treatments for Alzheimer s   until investor pressure made them back down  There s your second spade Its Money Honey   Their third strength lies in their monetary power  The amount of money they have for research  acquisitions and everything else has come from their first strength of dominance  With that money  they rule the pharma roost  They may not be able to control drug legislation or regulation  but they can certainly decide what they send for approval   and that decision is primarily made to improve their bottom line  this strength is not derived from their altruistic motives to cure the world of disease  but to profit from it   and handsomely  At the end of the day  money is what matters to a company  and this is something they have managed to accrue brilliantly  This is the reason there are fewer new drugs coming out of their labs   variations on existing  approved  ones are much cheaper to produce and put on the market  as are same drugs profiled for new indications  called drug repositioning  With the use of monetary muscle  they are also able to fill gaps in their drug portfolios by acquiring smaller companies  this is something that smaller companies are also looking at now as an investment avenue The Brand   The fourth pillar of the major players in this industry is their reputation  While this may be an intangible quality  for a drug company it s a matter of patient confidence in the efficacy of their medicines  This is something that has withstood erosion for the most part despite controversy with drug trials and product roll backs  But reputation isn t as intangible as most people think  A 2012 study by APCO Worldwide showed that a single percentage point increase in an average company s reputation could account for a 3 33  growth in sales  Naturally  for a large pharma brand that might be considerably less  but it still equates to millions of dollars  if not billions  Though big pharma s reputation has come under the scanner many times over the last few decades  there has never been any doubt as to the efficacy of the drugs they put out regularly  Their practices may be subject to criticism  but their financial performance is a direct measure of the success of their products WeaknessesThis is where we explore the nerve points of big pharma  the areas where they need more focus  essentially  the things they haven t accomplished with their strengths  or the conditions that have come about despite them Complacency  The first weak point of any big corporation is complacency  While this is not by far a universal phenomenon  the trend in the drug industry that has led to weakened drug pipelines in recent years shows that many top pharma companies have been riding the crest of waves generated by their top selling patented formulations  Pfizer s Lipitor may have made headlines  but several other drugs have and will come under the patent axe in the years between 2010 and 2015  The fact remains that these patent losses have left them in compromising positions  specifically but not limited to the issue of neuroscience research in European markets  Despite their monetary clout and resource rich culture  they have not been able to address this adequately  However  as we will see later in this piece  this opens up several opportunities for filling the revenue gaps left by the patent cliff You Really Know the FDA  The second weak point is their lack of control over regulatory approvals  especially in the United States  It takes about 15 years and  1 1 7 billion  2002 data  to conduct research  test and then submit a New Molecular Entity  NME  for approval as a branded drug  even at that stage  only 3 out of 10 drugs ever make it to the market and cover their cost of development and marketing  With stats like this  it is no wonder that the pipelines are running on fumes  The high risk undertaking of drug development is one of the main reasons that new and revolutionary drugs are few and far between  There are currently 1002 prescription drugs that have FDA approval  Pfizer has 30 FDA approved drugs  Merck has 24  Abbot Labs  17  AstraZeneca  19  Many of them have approved drugs that were developed in collaboration with each other or other third party pharma companies  But the weakness lies in the fact that phase 3 clinical trials have much fewer drugs than before  as far as big pharma is concerned  Here is where another opportunity will present itself down the road   acquisition of smaller companies such as Spectrum Pharmaceuticals  SPPI   which has two successful cancer drugs on the market  Zevalin and Fusilev  and 10 in the pipeline  The poor performance of drugs in phases 2 and 3 have also contributed to considerable losses  Briston Myers Squibb reported a pretax impairment charge of  1 8 billion on BMS 986094  a Hepatitis C drug  Eli Lilly announced the halt of phase 3 trials for mGlu2 3  a schizophrenia drug  and solanezumab for Alzheimer s  Such losses weigh heavily on their bottom line  leading to a reticence on the part of big pharma to undertake R D on innovative drugs Niche or Diverse  The third weakness stems from too much diversity  Big pharma s firepower  as defined by Ernst   Young in its recent report  has been used to diversify extensively in previous years  and big pharma is now in a state of dilution that is affecting its core operations  Luckily  most of them have realized this and have started divesting their interests in these other entities   not only to create cash but to make sure that their focus goes back to their R D capabilities  Pfizer has already made two major divestitures  and is considering two more   infant nutrition and animal health  However  this is still a weak point with many companies who  like Pfizer  are now looking for buyers for various non core units Ratings by Companies that didn t have a clue about the great financial crisis  The fourth weak point is the threat from ratings companies like Moody  AstraZeneca and other European pharma companies are already facing possible credit downgrades for their massive share buyback exercises  and Moody pegged the repurchase over cash flow excess for the Anglo Swedish company at  2 billion for 2012  A credit rating downgrade would impact their  cost of capital   making it harder for them to boost investor confidence despite promises of future profits ,2013-01-28,Pharma lifeline,https://www.investing.com/analysis/a-pill-for-every-ill:-big-pharma-swot-analysis-152755,152755
199398,420914,JNJ,Pfizer Could Be Just What The Doctor Ordered ,opinion,The recent stock market rally is getting long in the tooth  Major stock indexes will only go so far in one direction before pulling back or staging a 7 0 to 10 percent correction  When stock indexes have run as far as they have recently  it makes it very difficult to pick stocks that can have further upside in the short term  However  in the stock market there is always opportunity around the corner Pfizer Inc  PFE  is one of the world s largest pharmaceutical companies  The PFE stock is one of the few leading stocks that is still signaling possible upside on the charts  Traders and investors can still look for another  3 00 points to the upside in this leading name  Currently  the stock is trading at  27 39 a share as of the close on March 1  2013  Traders and investors can easily take note of the sideways basing pattern that the stock has been making on the charts since January 29  2013  The pattern in place tells us that the stock should face a lot of daily and weekly chart resistance around the  30 00 level  Therefore  the stock still has some further upside in the cards  Should the stock reverse the current trend there should be some daily chart support around the  26 00 level Pfizer Inc is one of three leading pharmaceutical stocks that is part of the Dow Jones Industrial Average DJIA   The other two leading pharmaceutical stocks in the DJIA are Merck   Co Inc  MRK   and Johnson   Johnson  JNJ   PFE stock still looks better than these other two leading pharmaceutical stocks  MRK  JNJ  on the charts at this time ,2013-03-04,Nicholas Santiago,https://www.investing.com/analysis/pfizer-could-be-just-what-the-doctor-ordered-157469,157469
199399,420915,JNJ,Johnson   Johnson  No More Tears  Eh ,opinion,Last Thursday  I took a strong liking to Johnson   Johnson  JNJ  based on its absolutely ridiculous hockey stick rise  I bought puts as well as got short  The puts were up over 50  yesterday morning  and unless shampoo suddenly makes people breakfast and drives their car for them  I really don t see the logic in a cleaning products and shampoo maker garnering these kind of valuations  My positions stand ,2013-04-09,Tim Knight,"https://www.investing.com/analysis/johnson---johnson:-no-more-tears,-eh-162148",162148
199410,420926,JNJ,Ampio Stays Calm Ahead Of Further Developments,opinion,The last year has been very volatile for the diversified drug developer  Ampio Pharmaceuticals  AMPE   AMPE was trading as low as  2 54 in May 2012 due to extreme weakness in the broader market brought about by macroeconomic concerns  Soon after  specifically in early July 2012   the stock was trading as high as  6 25 after an overly optimistic article about the company was published on the financial site Seeking Alpha While that rally was brought down by a public stock offering  what can infer from that price action is that the market doesn t really have a well defined opinion on Ampio s prospects  At least for now  AMPE has found a comfortable medium just above  4 00 per share as investors await further developments Currently  Ampio has four pharmaceutical products in development for various indications and three diagnostic products on the side  Their furthest developed product is Zertane  which is an oral tablet that is designed to prevent premature ejaculation  PE   Surveys indicated that this is the most common sexual dysfunction in men  occurring in about 1 3 of the global male population  While there is no question that the PE market is enormous and lucrative  Zertane has some major hurdles One of the biggest issues for Zertane is its path to US approval  The phase III studies done in Europe will not be valid for an NDA  so two additional phase III trials will have to be performed  as described in the June 20  2012 meeting with the FDA   After all that work  Ampio will also have to compete with the current leading in PE in the United States   Priligy  dapoxetine   which is commercialized by Johnson   Johnson  JNJ   On the bright side  Zertane is a 505 b  2  submission which allows the drug to use clinical data from other formulations of tramadol  its active ingredient  for its approval process  This would make Zertane s approval very rapid given the right conditions Investors should also note that Zertane will have better luck with approval abroad  The company is hoping to have the drug approved in Australia this year  based on trials conducted there  It should also be a smoother process to reach the European market  as well as other nations  Sexual health drugs have generally been disastrous investments in the past  Biosante Pharmaceuticals  BPAX  comes to mind  as does the infamous  female Viagra  developed by Boehringer Ingelheim  Still  Ampio does have two other products also being submitted under 505 b  2  which could result in surprisingly rapid approval Optina is an interesting drug being developed for diabetic retinopathy and diabetic macular edema  which targets a common side effect of diabetes  Diabetes  as you may know  has enormous prevalence in the United States  recent estimates come in at 25 8 million Americans   The size of the market for diabetes treatment is estimated to be close to  92 billion  so Optina s potential is certainly there since there are no good daily medications for diabetic retinopathy at this point  Vasaloc is another 505 b  2  drug that will target diabetic nephropathy  another problem induced by diabetes The one treatment that is being developed as a new molecule rather than a reformulation of sorts is Ampion   a non steroidal treatment for diseases that induce inflammation  Arthritis is one example that would be could be highly profitable for the company Note that while Ampion is produced by humans naturally the company was able to obtain commercial rights due to the molecule s discovery and patent protection by Ampio s Chief Scientific Officer Dr  David Bar Or Since Ampio s pipeline contains compounds that have already been extensively tested for safety in the past  barring Ampion  which is produced in the body naturally anyway   the focus should be on the efficacy demonstrated in future clinical trials as measured by endpoints  Expectations regarding future clinical trials and a degree of optimism over Zertane s eventual launch should keep the stock stable for the time being  I d imagine that those who are long the stock are in it  or should be in it  for the long run ,2013-01-09,Myriad Equity,https://www.investing.com/analysis/ampio-stays-calm-ahead-of-further-developments-150160,150160
199420,420936,JNJ,Think Corporates Are A Safe Haven  Think Again,opinion,Yields on some corporate bonds are trading below their U S  Treasury counterparts suggesting dwindling credit risk in the bond market according to the Wall Street Journal  In the article     the authors wrote that it is a sign that  investors perceive them as a safer bet   Furthermore  they wrote that some market observers think that this could be the  beginning of a new era for debt markets  which means that companies will have lower rates than their home country  In all of my years as an institutional fixed income portfolio manager  nothing surprises me  What we are seeing is not a signal of a  new era  for the corporate bond market but a case of too many people chasing too few assets  Companies rated  AAA  like Johnson   Johnson  JNJ  and Exxon Mobil  XOM  are without a doubt  safe companies  From what I can see  they are worthy of their ratings or at the very least  show a low probability of default  That probability drops even further when you account for the maturity of the bonds  To borrow part of a phrase made popular by our friends at   if given a long enough time frame  a company s survival rate drops to zero and the default probability increases  Shrink that time frame by way of the bond s maturity  and the default probability falls with it  As we all know  this should lead to a drop in the yield or more precisely the credit spread or yield differential between the two short maturity bonds  Having said this  it is not surprising that yields on these highly rated companies converge with their U S  Treasury counterparts on this part of the yield curve  If I had to quantify it  I would say that their default probability given their rating is just a tad above zero  For most people and in the grand scheme of things  it is pretty close to nil which partly explains the low level of yields  But to infer that a company is  safer  over a sovereign is just plain wrong  When it comes down to it  default risk is determined by the borrower s ability to pay off that debt  A corporation s ability is determined by revenues and profits which is completely contingent on demand from its client base  If a client likes a company s product  they will buy more which means increasing revenue and cash flow where they can service their debt with ease  Hence  a company s solvency and likelihood of default is at the mercy of its client base s wills and desires for their product  In other words  they are price takers in determining their likelihood of default  For the U S  government  their ability to pay off that debt is determined by their ability to tax  While higher taxes may upset some people  their ability to do so is ultimately up to the government  This includes taxing individuals and corporations like Johnson   Johnson and Exxon  Furthermore  the U S  Government is not a country like Greece that is facing a debt problem since the U S  controls its own currency  This suggests that for the U S   the  printing press  is a means to service its debt  So  if you rule out a complete collapse of the country s way of life  the conditions for a true default are completely left to the U S  Government  In this context  they are price makers  Does that mean that the U S  cannot have a technical default where the timely repayment of principal and interest on their debt is compromised  The answer is no  Does that mean that if there is a technical default on the U S   is debt on U S  corporations a better bet  The answer to this is an even bigger NO  If there is a technical default  the markets would see equities tank  and that would lead to wider corporate spreads  Of course spreads would widen more than others depending on the credit quality  In any case  most corporate bond would be negatively affected by rising risks and volatility spurred by a U S  Treasury default  In the case of these short dated corporates trading on top of Treasuries  it is difficult to determine exactly what is driving this  Let s face it  The markets are driven by people who in turn  are motivated by a variety of factors  To be able to accurately determine the cause of the convergence of these corporate bonds with Treasuries is to intimately know the objectives of bond investors that focus in this space  A great example of the variety of factors is that you can have bond managers who both believe that yields will head higher but position their portfolio differently  A total return manager of a hedge fund or ETF will sell their holdings and go to cash  Here they are maximizing return and taking on risk  Another manager who manages both equities and bonds may do the opposite and buy bonds after the initial selloff since their current positions fell in market value  This discipline in rebalancing to maintain a fixed allocation to bonds takes precedence over a portfolio manager s view on higher interest rates  The process over price gain determines their actions  A portfolio manager of an insurance company may not even flinch despite their bearish outlook simply because their liabilities dictate their portfolio positioning  Here  risk control over price gain dictates their actions  That said  my guess is that money market bond investors who are flush with cash are driving up the price of these corporates simply because they have nowhere else to go  As we mentioned before in our post  The Federal Reserve Does Not Care If Treasury Rates are Higher   the Federal Reserve s latest Quantitative Easing program is a huge driver of demand  The Fed s purchases of Mortgage Backed Securities  after all is said and done  will undoubtedly overwhelm the amount of new issuance for most taxable bonds which may result in a net supply of zero or perhaps even negative  A money market bond investor who needs to buy but is having a hard time finding bonds will pay up so he can stay fully invested  In addition  the European Debt Crisis and the potential of contagion to the financial sector may drive away money market players from investing in European banks  commercial paper programs  This may lead investors to seek their returns elsewhere and drive up the price in limited supply securities like the aforementioned short dated corporate bonds  Whatever the case may be  what we are seeing should look familiar since long time bond investors will know that we have traveled down this path before where the incremental yield between safer and riskier bonds compresses  Prior to the Long Term Capital Market debacle back in the late 1990s  an investor could own Merrill Lynch 5 Year bonds with a  AA  rating at 60 basis points over Treasuries while pick up an additional  miniscule 5 basis points to go to the bottom end of the investment grade scale by buying Lehman Brothers 5 Year bonds  Back in 2006  bond investors could buy so called  AAA  subprime bonds for 25 to 30 basis points over LIBOR  Credit spreads were tight simply because investors were desperate for return and needed bonds  Carry was king  and the objective of remaining fully invested over risk control determined their actions  As we all know from the financial crisis  the spread on these instruments did not stay at that level for very long  Common sense and experience tells me to not read into short dated corporates trading below U S  Treasuries  Corporate issuers are not safer than U S  Treasuries and the market is not about to embark on a  new era   Also  this isn t a sign that the default probability of U S  Treasuries is increasing because of the country s budget problems  In fact  I would look to a falling dollar if that is indeed the case  Furthermore  if I were an owner of said corporate bonds  I would sell JNJ and XOM bonds and buy U S  Treasuries  Yields may trade below Treasuries and this may continue going forward given the Fed s influence on demand  However  the upside should be limited while it is just a matter of time before corporate spreads widen  As illustrated by the two examples  it has happened before and will happen again and is far from anything new  The fact that history repeats itself in some form or another where corporate spreads widen is probably the safest of bet of them all Disclaimer  The above content is provided for educational and informational purposes only  does not constitute a recommendation to enter in any securities transactions or to engage in any of the investment strategies presented in such content  and does not represent the opinions of Bondsquawk or its employees ,2012-11-08,Bondsquawk,https://www.investing.com/analysis/think-corporates-are-a-safe-haven-think-again-142721,142721
199437,420953,JNJ,Medivation Building Value On Prostate Cancer Prospects And Takeover Spec,opinion,Medivation  MDVN  is a single drug drug developer that has been on an absolute tear since it released extremely positive results for its prostate cancer drug Enzalutamide  formerly known as MDV3100  in November 2011  Since the data was released  Medivation is up over 430  and continues to make new highs with a very stable uptrend  For the most part  investors are more focused on estimating the market potential for Enzalutamide rather than the efficacy of its mechanism of action  which has been demonstrated quite well in the phase III AFFIRM trials   Competing drugs that have already hit the prostate cancer market are being watched closely to determine the actual revenue potential for Enzalutamide  Denderon s  DNDN  PROVENGE  an FDA approved drug that was poised to be a blockbuster  is generating roughly  82 million per quarter in sales  Johnson   Johnson s  JNJ  ZYTIGA is generating about  232 million per quarter in sales  Judging by the market cap of Medivation of about  3 5 billion  investors are really expecting Enzalutamide to not only dominate the prostate cancer drug market but penetrate the breast cancer drug market later on as well  which is something the company is working on with its phase I trial    Although Medivation has become a lot more expensive as more and more investors pile into this very promising play on the prostate cancer drug market  Enzalutamide MDV3100 could bring MDVN to a higher market cap based solely on takeover speculation which is attracting attention from the big players  Even if Enzalutamide s greatness in prostate cancer has been priced in at this point  the drug and company might be worth a lot more than the market cap suggests  Checking the   one can note that a potential catalyst for the stock is on the horizon  specifically on July 23rd  2012   This is the date that the FDA will respond to the NDA submitted for Enzalutamide  and either grant it a standard 10 month review or priority review of 6 months  which is what we are expecting   Expect Medivation to draw additional attention after a likely priority review by the FDA  leading up to the final decision which will most likely end up being on November 21st 2012  Traders who are interested in MDVN might try riding the sheer excitement over this drug and the takeover speculation  which has been supported by an extremely nice chart  Things are likely to pick up as summer ends and market activity picks up too ,2012-07-20,Myriad Equity,https://www.investing.com/analysis/medivation-building-value-on-prostate-cancer-prospects-and-takeover-spec-130252,130252
199438,420954,JNJ,Dendreon s Provenge Needs To Pull Itself Together Soon,opinion,Dendreon  DNDN   a big name in the prostate cancer world  is struggling to heavily market the drug PROVENGE   much to the dismay of its shareholders  DNDN was trading around  38 share a year ago  but have fallen more than 80  as a double whammy of underwhelming sales data and very narrow profit margins brought the company into negative EPS territory  For the most part  this is not something that is expected by the market after a company with a highly anticipated game changing drug gets an FDA approval  which happened in April 2010  The bulk of the  80  drop occurred on August 3rd 2011  when Dendreon unveiled second quarter results  It wasn t only the underwhelming revenue and weak earnings that upset the shareholders  but the company s guidance on PROVENGE   Included in the report is an explanation for the dynamics of the PROVENGE launch  with major blame being put on knowledge of the problems regarding the reimbursement program  Physicians would be required to keep enormous lines of credit  not surprising given the  93 000 cost of PROVENGE  per full patient treatment  This is a very annoying problem that has kept smaller oncology centers away from the drug To fight the problem  Dendreon has begun to issue Q codes that expedite the process immensely  Almost a year later  we are still seeing revenue growth  The bigger problem is that it s simply not enough to bring the company into profitability  and Dendreon s  seemingly  permanent drop in outlook is causing major negativity amongst the analysts Last quarter we saw PROVENGE  sales of approximately  82 million  Although this is set to grow into the future  the earnings generated from the drug are underwhelming  At a profit margin of approximately 27   PROVENGE is not nearly as profitable to distribute as we may have originally thought  It s true that the manufacturing process is extreme complex  and will require time to refine  in terms of cost reduction   but the bottom line is that improvements are necessary to the company s survive In a financially based analysis of Dendreon  I found that PROVENGE s quarterly sales would have to reach approximately  340 000 000  with a much higher 40  profit margin  just for Dendreon to break even in terms of revenue versus total expenses  This far exceeds the sales of Johnson   Johnson s  JNJ  Zytiga  which enjoys a far better marketing environment The takeaway is that Dendreon is in a very difficult situation as a company  Even if roughly  5 billion was blown off the market cap of DNDN since mid 2011  this is not so much a value play as it is a very long bet on an improvement in the drug s marketing prospects  We will see in future quarters whether or not PROVENGE can ever bring Dendreon into profitability though  so this is a company you might want to keep your eye on in the event that we see a miracle ,2012-07-25,Myriad Equity,https://www.investing.com/analysis/dendreons-provenge-needs-to-pull-itself-together-soon-130733,130733
